Dossier zur Nutzenbewertung gemäß § 35a SGB V

Sparsentan (Filspari™)

Vifor Pharma Deutschland GmbH

Separater Anhang 4-G

Erwachsene Patienten mit primärer Immunglobulin-A-Nephropathie (IgAN) mit einer Ausscheidung von Eiweiß im Urin von ≥ 1,0 g/Tag (oder einem Protein/Kreatinin-Quotienten im Urin von ≥ 0,75 g/g)

Medizinischer Nutzen und
medizinischer Zusatznutzen,
Patientengruppen mit therapeutisch
bedeutsamem Zusatznutzen

Stand: 31.07.2024

Inhaltsverzeichnis

Tabellenverzeichnis

Table PT1BTS_FMA0: Treatment status double-blind period
Full analysis Set

Parameter	Study	Treatment	Category	N	n (%)
Treatment status	PROTECT	Sparsentan	Treatment completed	202	18 (8.9)
			Treatment discontinued	202	19 (9.4)
			Treatment ongoing	202	165 (81.7)
			Untreated patients	202	0 (0.0)
		Irbesartan	Treatment completed	202	15 (7.4)
			Treatment discontinued	202	29 (14.4)
			Treatment ongoing	202	158 (78.2)
			Untreated patients	202	0 (0.0)

N = total number of patients in analysis set. n = number of patients in category.
Source Data: asl, created on: 26JAN2024

Table PT1BSX_FMA0: Sex
Full analysis Set

Parameter	Study	Treatment	Category	N	n (%)
Sex	PROTECT	Sparsentan	Male	202	139 (68.8)
			Female	202	63 (31.2)
			Missing	202	0 (0.0)
		Irbesartan	Male	202	143 (70.8)
			Female	202	59 (29.2)
			Missing	202	0 (0.0)

N = total number of patients in analysis set. n = number of patients in category.
Source Data: asl, created on: 26JAN2024

Table PT1BRC_FMA0: Race
Full analysis Set

Parameter	Study	Treatment	Category	N	n (%)
Race	PROTECT	Sparsentan	White	202	130 (64.4)
			Black	202	1 (0.5)
			Asian	202	67 (33.2)
			Others	202	4 (2.0)
			Missing	202	0 (0.0)
		Irbesartan	White	202	142 (70.3)
			Black	202	3 (1.5)
			Asian	202	48 (23.8)
			Others	202	9 (4.5)
			Missing	202	0 (0.0)

N = total number of patients in analysis set. n = number of patients in category.
Source Data: asl, created on: 26JAN2024

Table PT1BRG_FMA0: Geographic region
Full analysis Set

Parameter	Study	Treatment	Category	N	n (%)
Geographic region	PROTECT	Sparsentan	North America	202	35 (17.3)
			Europe	202	98 (48.5)
			Asia Pacific	202	69 (34.2)
			Missing	202	0 (0.0)
		Irbesartan	North America	202	46 (22.8)
			Europe	202	115 (56.9)
			Asia Pacific	202	41 (20.3)
			Missing	202	0 (0.0)

N = total number of patients in analysis set. n = number of patients in category.
Source Data: asl, created on: 26JAN2024

Table PT1BCO_FMA0: Country
Full analysis Set

Parameter	Study	Treatment	Category	N	n (%)
Country	PROTECT	Sparsentan	Australia	202	19 (9.4)
			Belgium	202	9 (4.5)
			Croatia	202	3 (1.5)
			Czech Republic	202	4 (2.0)
			Estonia	202	1 (0.5)
			France	202	3 (1.5)
			Germany	202	9 (4.5)
			Hong Kong	202	14 (6.9)
			Italy	202	11 (5.4)
			Lithuania	202	7 (3.5)
			New Zealand	202	3 (1.5)
			Poland	202	7 (3.5)
			Portugal	202	8 (4.0)
			South Korea	202	24 (11.9)
			Spain	202	16 (7.9)
			Taiwan	202	9 (4.5)
			USA	202	35 (17.3)
			United Kingdom	202	20 (9.9)
		Irbesartan	Australia	202	12 (5.9)
			Belgium	202	3 (1.5)
			Croatia	202	8 (4.0)
			Czech Republic	202	9 (4.5)
			Estonia	202	6 (3.0)
			France	202	10 (5.0)
			Germany	202	7 (3.5)
			Hong Kong	202	9 (4.5)
			Italy	202	15 (7.4)
			Lithuania	202	4 (2.0)
			New Zealand	202	2 (1.0)
			Poland	202	6 (3.0)
			Portugal	202	4 (2.0)
			South Korea	202	14 (6.9)
			Spain	202	14 (6.9)
			Taiwan	202	4 (2.0)
			USA	202	46 (22.8)
			United Kingdom	202	29 (14.4)

N = total number of patients in analysis set. n = number of patients in category.
Source Data: asl, created on: 26JAN2024

Table PT1BE1_FMA0: Baseline eGFR – Group 1
Full analysis Set

Parameter	Study	Treatment	Category	N	n (%)
Baseline eGFR - Group 1	PROTECT	Sparsentan	< 60 mL/min/1.73 m**2	202	127 (62.9)
			60 to < 90 mL/min/1.73 m**2	202	49 (24.3)
			>= 90 mL/min/1.73 m**2	202	26 (12.9)
			Missing	202	0 (0.0)
		Irbesartan	< 60 mL/min/1.73 m**2	202	129 (63.9)
			60 to < 90 mL/min/1.73 m**2	202	48 (23.8)
			>= 90 mL/min/1.73 m**2	202	25 (12.4)
			Missing	202	0 (0.0)

N = total number of patients in analysis set. n = number of patients in category.
Results are presented in mL/min/1.73 m**2. eGFR = estimated glomerular filtration rate.
Source Data: asl, created on: 26JAN2024

Table PT1BE2_FMA0: Baseline eGFR – Group 2
Full analysis Set

Parameter	Study	Treatment	Category	N	n (%)
Baseline eGFR - Group 2	PROTECT	Sparsentan	< 45 mL/min/1.73 m**2	202	82 (40.6)
			45 to < 60 mL/min/1.73 m**2	202	45 (22.3)
			60 to < 90 mL/min/1.73 m**2	202	49 (24.3)
			>= 90 mL/min/1.73 m**2	202	26 (12.9)
			Missing	202	0 (0.0)
		Irbesartan	< 45 mL/min/1.73 m**2	202	80 (39.6)
			45 to < 60 mL/min/1.73 m**2	202	49 (24.3)
			60 to < 90 mL/min/1.73 m**2	202	48 (23.8)
			>= 90 mL/min/1.73 m**2	202	25 (12.4)
			Missing	202	0 (0.0)

N = total number of patients in analysis set. n = number of patients in category.
Results are presented in mL/min/1.73 m**2. eGFR = estimated glomerular filtration rate.
Source Data: asl, created on: 26JAN2024

Table PT1BUR_FMA0: Baseline UP/C
Full analysis Set

Parameter	Study	Treatment	Category	N	n (%)
Baseline UP/C	PROTECT	Sparsentan	<= 1.25 g/g	202	101 (50.0)
			> 1.25 g/g	202	101 (50.0)
			Missing	202	0 (0.0)
		Irbesartan	<= 1.25 g/g	202	104 (51.5)
			> 1.25 g/g	202	98 (48.5)
			Missing	202	0 (0.0)

N = total number of patients in analysis set. n = number of patients in category.
Results are presented in g/g. UP/C = Urine protein/creatinine ratio.
Source Data: asl, created on: 26JAN2024

Table PT1BPE_FMA0: Baseline urine protein excretion
Full analysis Set

Parameter	Study	Treatment	Category	N	n (%)
Baseline urine protein excretion	PROTECT	Sparsentan	<= 1.75 g/day	202	98 (48.5)
			> 1.75 g/day	202	104 (51.5)
			Missing	202	0 (0.0)
		Irbesartan	<= 1.75 g/day	202	94 (46.5)
			> 1.75 g/day	202	108 (53.5)
			Missing	202	0 (0.0)

N = total number of patients in analysis set. n = number of patients in category.
Results are presented in g/day.
Source Data: asl, created on: 26JAN2024

Table PT1BAG_FMB0: Age at informed consent
Full analysis Set

Variable	Study	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Age at informed consent	PROTECT	Sparsentan	202	202	46.56 (12.76)	18.0	37.00	47.00	57.00	73.0
		Irbesartan	202	202	45.43 (12.12)	19.0	36.00	46.00	55.00	76.0

N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in years.
Source Data: asl, created on: 26JAN2024

Table PT1BWI_FMB0: Baseline BMI
Full analysis Set

Variable	Study	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Baseline BMI	PROTECT	Sparsentan	202	202	28.52 (5.21)	18.3	25.10	27.85	31.40	47.2
		Irbesartan	202	201	28.34 (5.66)	17.7	24.60	27.50	31.00	49.4

N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in kg/m**2.
BMI = Body mass index.
Source Data: asl, created on: 26JAN2024

Table PT1BHA_FMB0: Baseline HbA1c
Full analysis Set

Variable	Study	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Baseline HbA1c	PROTECT	Sparsentan	202	202	5.51 (0.57)	3.9	5.20	5.50	5.80	9.7
		Irbesartan	202	202	5.52 (0.59)	4.3	5.20	5.40	5.70	8.9

N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in %.
HbA1c = Hemoglobin A1c.
Source Data: asl, created on: 26JAN2024

Table PT1BE_FMB0: Baseline eGFR
Full Analysis Set

Variable	Study	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Baseline eGFR	PROTECT	Sparsentan	202	202	56.86 (24.38)	24.0	38.00	50.00	71.00	128.0
		Irbesartan	202	202	57.08 (23.58)	26.0	39.00	50.00	70.00	123.0

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in mL/min/1.73 m**2. eGFR = estimated glomerular filtration rate.
Source Data: asl, created on: 26JAN2024

Table PT1BAD_FMA0: Age at IgAN diagnosis - Group 1
Full analysis Set

Parameter	Study	Treatment	Category	N	n (%)
Age at IgAN diagnosis	PROTECT	Sparsentan	<= 18 years	202	9 (4.5)
			>18 to 40 years	202	102 (50.5)
			> 40 years	202	91 (45.0)
			Missing	202	0 (0.0)
		Irbesartan	<= 18 years	202	5 (2.5)
			>18 to 40 years	202	109 (54.0)
			> 40 years	202	88 (43.6)
			Missing	202	0 (0.0)

N = total number of patients in analysis set. n = number of patients in category.
Results are presented in years. IgAN = immunoglobulin A nephropathy
Source Data: asl, created on: 26JAN2024

Table PT1BRP_FMA0: Time since renal biopsy - Group 1
Full analysis Set

Parameter	Study	Treatment	Category	N	n (%)
Time since renal biopsy	PROTECT	Sparsentan	<= 5 years	202	113 (55.9)
			> 5 years	202	89 (44.1)
			Missing	202	0 (0.0)
		Irbesartan	<= 5 years	202	127 (62.9)
			> 5 years	202	75 (37.1)
			Missing	202	0 (0.0)

N = total number of patients in analysis set. n = number of patients in category.
Results are presented in years.
Source Data: asl, created on: 26JAN2024

Table PT1BMI_FMA0: Previous renal immunosuppressives
Full analysis Set

Parameter	Study	Treatment	Category	N	n (%)
Previous renal immunosuppressives	PROTECT	Sparsentan	Yes	202	10 (5.0)
			No	202	192 (95.0)
			Missing	202	0 (0.0)
		Irbesartan	Yes	202	11 (5.4)
			No	202	191 (94.6)
			Missing	202	0 (0.0)

N = total number of patients in analysis set. n = number of patients in category.
Source Data: asl, created on: 26JAN2024

Table PT1BMR_FMA0: RAAS inhibitors at Screening
Full analysis Set

Parameter	Study	Treatment	Category	N	n (%)
RAAS inhibitors at Screening	PROTECT	Sparsentan	Yes	202	201 (99.5)
			No	202	1 (0.5)
			Missing	202	0 (0.0)
		Irbesartan	Yes	202	202 (100.0)
			No	202	0 (0.0)
			Missing	202	0 (0.0)

N = total number of patients in analysis set. n = number of patients in category.
RAAS = Renin-angiotensin-aldosterone system.
Source Data: asl, created on: 26JAN2024

Table PT1BMRE_FMA0: ACEI at MLD at Screening
Full analysis Set

Parameter	Study	Treatment	Category	N	n (%)
ACEI at MLD at Screening	PROTECT	Sparsentan	Yes	202	51 (25.2)
			No	202	151 (74.8)
			Missing	202	0 (0.0)
		Irbesartan	Yes	202	53 (26.2)
			No	202	149 (73.8)
			Missing	202	0 (0.0)

N = total number of patients in analysis set. n = number of patients in category.
ACEI = Angiotensin converting enzyme inhibitor. MLD = Maximum labeled dose.
Source Data: asl, created on: 26JAN2024

Table PT1BMRR_FMA0: ARB at MLD at Screening
Full analysis Set

Parameter	Study	Treatment	Category	N	n (%)
ARB at MLD at Screening	PROTECT	Sparsentan	Yes	202	85 (42.1)
			No	202	117 (57.9)
			Missing	202	0 (0.0)
		Irbesartan	Yes	202	76 (37.6)
			No	202	126 (62.4)
			Missing	202	0 (0.0)

N = total number of patients in analysis set. n = number of patients in category.
ARB = Angiotensin II receptor blocker. MLD = Maximum labeled dose.
Source Data: asl, created on: 26JAN2024

Table PT1BMRB_FMA0: ACEI and ARB at MLD at Screening
Full analysis Set

Parameter	Study	Treatment	Category	N	n (%)
ACEI and ARB at MLD at Screening	PROTECT	Sparsentan	Yes	202	5 (2.5)
			No	202	197 (97.5)
			Missing	202	0 (0.0)
		Irbesartan	Yes	202	4 (2.0)
			No	202	198 (98.0)
			Missing	202	0 (0.0)

N = total number of patients in analysis set. n = number of patients in category.
ACEI = Angiotensin converting enzyme inhibitor. ARB = Angiotensin II receptor blocker. MLD = Maximum labeled dose.
Source Data: asl, created on: 26JAN2024

Table PT1BMA_FMA0: Antihypertensive medications at Baseline
Full analysis Set

Parameter	Study	Treatment	Category	N	n (%)
Antihypertensive medications at Baseline	PROTECT	Sparsentan	Yes	202	88 (43.6)
			No	202	114 (56.4)
			Missing	202	0 (0.0)
		Irbesartan	Yes	202	83 (41.1)
			No	202	119 (58.9)
			Missing	202	0 (0.0)

N = total number of patients in analysis set. n = number of patients in category.
Source Data: asl, created on: 26JAN2024

Table PT1BML_FMA0: Lipid-lowering medications at Baseline
Full analysis Set

Parameter	Study	Treatment	Category	N	n (%)
Lipid-lowering medications at Baseline	PROTECT	Sparsentan	Yes	202	112 (55.4)
			No	202	90 (44.6)
			Missing	202	0 (0.0)
		Irbesartan	Yes	202	111 (55.0)
			No	202	91 (45.0)
			Missing	202	0 (0.0)

N = total number of patients in analysis set. n = number of patients in category.
Source Data: asl, created on: 26JAN2024

Table PT1BA_FMB0: Age at IgAN diagnosis
Full Analysis Set

Variable	Study	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Age at IgAN diagnosis	PROTECT	Sparsentan	202	202	40.19 (13.35)	10.0	30.00	39.00	51.00	72.0
		Irbesartan	202	202	38.96 (12.38)	8.0	31.00	38.00	48.00	75.0

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in years. IgAN = immunoglobulin A nephropathy
Source Data: asl, created on: 26JAN2024

Table PT1BR_FMB0: Time since renal biopsy
Full Analysis Set

Variable	Study	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Times since renal biopsy	PROTECT	Sparsentan	202	202	6.41 (6.48)	0.0	1.00	4.00	10.00	33.0
		Irbesartan	202	202	6.37 (7.10)	0.0	1.00	4.00	10.00	36.0

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in years.
Source Data: asl, created on: 26JAN2024

Table PT1BSS_FMA0: Study status double-blind period
Full analysis Set

Parameter	Study	Treatment	Category	N	n (%)
Study status	PROTECT	Sparsentan	Completed	202	18 (8.9)
			Premature discontinuation	202	3 (1.5)
			Ongoing	202	181 (89.6)
		Irbesartan	Completed	202	14 (6.9)
			Premature discontinuation	202	11 (5.4)
			Ongoing	202	177 (87.6)

N = total number of patients in analysis set. n = number of patients in category.
Source Data: asl, created on: 26JAN2024

Table PT1BSR_FMA0: Reason for premature study discontinuation during double-blind period
Full analysis Set

Parameter	Study	Treatment	Category	N	n (%)
Reason premature study discontinuation	PROTECT	Sparsentan	No discontinuation	202	199 (98.5)
			Deaths	202	0 (0.0)
			Lost to follow-up	202	0 (0.0)
			PI decision	202	0 (0.0)
			Study terminated by sponsor	202	0 (0.0)
			Withdrawal of consent	202	3 (1.5)
		Irbesartan	No discontinuation	202	191 (94.6)
			Deaths	202	0 (0.0)
			Lost to follow-up	202	1 (0.5)
			PI decision	202	3 (1.5)
			Study terminated by sponsor	202	0 (0.0)
			Withdrawal of consent	202	7 (3.5)

N = total number of patients in analysis set. n = number of patients in category.
Source Data: asl, created on: 26JAN2024

Table PT1BTR_FMA0: Reason for premature treatment discontinuation during double-blind period
Full Analysis Set

Parameter	Study	Treatment	Category	N	n (%)
Reason premature treatment discontinuation	PROTECT	Sparsentan	No discontinuation	202	183 (90.6)
			Adverse event/adverse event of interest	202	14 (6.9)
			Death	202	0 (0.0)
			Diagnosis of class II-IV CHF	202	0 (0.0)
			Hyperkalemia resistant to treatment	202	0 (0.0)
			Lost to follow-up	202	0 (0.0)
			Subject decision	202	3 (1.5)
			Physician decision	202	0 (0.0)
			Pregnancy	202	0 (0.0)
			Protocol deviation	202	1 (0.5)
			Receipt of kidney transplant or initiation of chronic dialysis	202	1 (0.5)
			Site terminated by sponsor	202	0 (0.0)
			Study terminated by sponsor	202	0 (0.0)
			Other	202	0 (0.0)
		Irbesartan	No discontinuation	202	173 (85.6)
			Adverse event/adverse event of interest	202	8 (4.0)
			Death	202	0 (0.0)
			Diagnosis of class II-IV CHF	202	0 (0.0)
			Hyperkalemia resistant to treatment	202	0 (0.0)
			Lost to follow-up	202	0 (0.0)
			Subject decision	202	12 (5.9)
			Physician decision	202	5 (2.5)
			Pregnancy	202	1 (0.5)
			Protocol deviation	202	1 (0.5)
			Receipt of kidney transplant or initiation of chronic dialysis	202	0 (0.0)
			Site terminated by sponsor	202	0 (0.0)
			Study terminated by sponsor	202	0 (0.0)
			Other	202	2 (1.0)

N = total number of patients in analysis set. n = number of patients in category.
Source Data: asl, created on: 26JAN2024

Table PT1BDS_FMB0: Study duration of double-blind period
Full analysis Set

Variable	Study	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Study duration	PROTECT	Sparsentan	202	202	68.66 (35.36)	9.9	34.71	77.07	99.57	119.1
		Irbesartan	202	202	67.90 (35.24)	0.6	34.43	75.79	97.00	122.9

N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in weeks.
Duration is defined as time from study day 1 to end of double-blind treatment (regular Week 114).
Source Data: asl, created on: 26JAN2024

Table PT1BDT_FMB0: Treatment duration of double-blind period
Full analysis Set

Variable	Study	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Treatment duration	PROTECT	Sparsentan	202	202	64.29 (35.04)	0.1	32.57	73.43	95.71	115.9
		Irbesartan	202	202	61.27 (35.58)	0.1	27.00	60.86	93.57	114.9

N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in weeks.
Duration is defined as time from study day 1 to last study dose during double-blind period (regular Week 110).
Source Data: asl, created on: 26JAN2024

Table PT1RPR_FML0: Percent change from baseline in UP/C
Full Analysis Set

Percent change from baseline in UP/C				Repeated measures analysis					
				Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)			
Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value	
Week 6	Sparsentan	202	191 (94.6)	-39.47	(-44.52, -33.97)	0.652	(0.576, 0.737)	<0.001	*
	Irbesartan	202	191 (94.6)	-7.15	(-14.89, 1.29)				
Week 36	Sparsentan	202	139 (68.8)	-48.18	(-53.00, -42.88)	0.613	(0.534, 0.705)	<0.001	*
	Irbesartan	202	132 (65.3)	-15.52	(-23.46, -6.76)				
Week 58	Sparsentan	202	113 (55.9)	-46.34	(-51.83, -40.22)	0.632	(0.541, 0.739)	<0.001	*
	Irbesartan	202	99 (49.0)	-15.16	(-24.20, -5.03)				

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale.
LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. Only key visits up to Week 58 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate.
All observed values up to Week 58 are included in the model.
An increase reflects a worsening of the status of the patient. Results are presented in g/g. UP/C = urine protein/creatinine ratio.
A first order autoregressive covariance structure was used.
Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as a other common summarizing ratios (e.g. RR).
Source Data: alb, created on: 19FEB2024

Table PT1RPR_FMH0: Course of UP/C (percentage change)
Full Analysis Set

Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
UP/C	Baseline	Sparsentan	202	202 (100.0)	1.43 (0.90)	0.1	0.78	1.25	1.82	7.0
		Irbesartan	202	202 (100.0)	1.44 (0.89)	0.2	0.88	1.23	1.72	6.9
	Week 6	Sparsentan	202	191 (94.6)	0.97 (0.80)	0.1	0.41	0.79	1.27	5.6
		Irbesartan	202	191 (94.6)	1.41 (0.93)	0.1	0.75	1.14	1.78	6.2
	Week 36	Sparsentan	202	139 (68.8)	0.97 (0.84)	0.1	0.36	0.70	1.37	4.4
		Irbesartan	202	132 (65.3)	1.34 (1.04)	0.1	0.63	1.03	1.73	6.6
	Week 58	Sparsentan	202	113 (55.9)	0.96 (0.79)	0.1	0.32	0.77	1.29	3.5
		Irbesartan	202	99 (49.0)	1.40 (1.08)	0.1	0.67	1.10	1.76	5.6
Percent change from baseline in UP/C	Week 6	Sparsentan	202	191 (94.6)	-28.26 (46.40)	-88.7	-60.81	-40.80	-7.96	256.2
		Irbesartan	202	191 (94.6)	5.28 (67.89)	-74.5	-29.48	-8.32	26.69	696.4
	Week 36	Sparsentan	202	139 (68.8)	-27.96 (54.16)	-92.4	-64.65	-43.61	-7.46	168.2
		Irbesartan	202	132 (65.3)	2.91 (80.60)	-83.9	-42.91	-9.96	27.88	581.8
	Week 58	Sparsentan	202	113 (55.9)	-26.68 (54.90)	-94.1	-67.15	-36.52	1.70	166.7
		Irbesartan	202	99 (49.0)	1.58 (79.68)	-93.2	-40.51	-10.95	17.70	451.6

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/g. UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Figure PF1RPR_FMG0: Percent change from baseline in UP/C
Full Analysis Set
Study: PROTECT



Sparsentan	191	139	113
Irbesartan	191	132	99

An increase reflects a worsening of the status of the patient. Results are presented in g/g. Analysis was performed on log-transformed data but original units are displayed. Number of available records are presented for key visits up to Week 58 only. UP/C = urine protein/creatinine ratio. Reference table: PT1RPR_FML0

Table PT1UEC_FMH0: Course of urine protein excretion
Full Analysis Set

Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Urine protein excretion	Baseline	Sparsentan	202	202 (100.0)	2.22 (1.65)	0.1	1.18	1.76	2.83	14.7	
		Irbesartan	202	202 (100.0)	2.16 (1.24)	0.5	1.33	1.81	2.60	7.5	
	Week 6	Sparsentan	202	192 (95.0)	1.49 (1.21)	0.2	0.67	1.09	1.98	6.5	
		Irbesartan	202	191 (94.6)	2.18 (1.59)	0.4	1.08	1.77	2.70	10.3	
	Week 36	Sparsentan	202	139 (68.8)	1.47 (1.54)	0.1	0.56	0.91	1.92	9.4	
		Irbesartan	202	133 (65.8)	2.12 (1.66)	0.2	1.01	1.67	2.68	9.2	
	Week 58	Sparsentan	202	113 (55.9)	1.45 (1.43)	0.1	0.57	1.03	1.73	7.5	
		Irbesartan	202	98 (48.5)	2.14 (1.71)	0.1	0.90	1.72	2.88	8.6	
Change from baseline in urine protein excretion	Week 6	Sparsentan	202	192 (95.0)	-0.72 (1.42)	-13.0	-1.21	-0.67	-0.10	5.2	-0.54 [-0.75, -0.34]
		Irbesartan	202	191 (94.6)	0.01 (1.27)	-3.7	-0.63	-0.15	0.51	8.4	
	Week 36	Sparsentan	202	139 (68.8)	-0.65 (1.26)	-4.2	-1.23	-0.67	-0.07	4.6	-0.43 [-0.67, -0.19]
		Irbesartan	202	133 (65.8)	-0.07 (1.45)	-3.3	-0.92	-0.26	0.53	6.5	
	Week 58	Sparsentan	202	113 (55.9)	-0.63 (1.29)	-4.4	-1.27	-0.62	0.02	3.3	-0.34 [-0.61, -0.06]
		Irbesartan	202	98 (48.5)	-0.17 (1.41)	-2.7	-0.93	-0.38	0.25	6.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FMC0: Change from baseline in urine protein excretion
Full Analysis Set

Change from baseline in urine protein excretion				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Week 6	Sparsentan	202	192 (95.0)	-0.69 (0.09)	(-0.86, -0.51)	-0.67 (0.12)	(-0.91, -0.42)	<0.001 *
	Irbesartan	202	191 (94.6)	-0.02 (0.09)	(-0.19, 0.15)			
Week 36	Sparsentan	202	139 (68.8)	-0.76 (0.10)	(-0.96, -0.56)	-0.70 (0.14)	(-0.98, -0.42)	<0.001 *
	Irbesartan	202	133 (65.8)	-0.06 (0.10)	(-0.26, 0.14)			
Week 58	Sparsentan	202	113 (55.9)	-0.66 (0.11)	(-0.88, -0.44)	-0.57 (0.16)	(-0.89, -0.25)	<0.001 *
	Irbesartan	202	98 (48.5)	-0.09 (0.12)	(-0.32, 0.14)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. Only key visits up to Week 58 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate.
All observed values up to Week 58 are included in the model following a treatment policy approach.
An increase reflects a worsening of the status of the patient. Results are presented in g/day. A first order regressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Figure PF1UEC_FMG0: Change from baseline in urine protein excretion
Full Analysis Set
Study: PROTECT



Sparsentan	192	139	113
Irbesartan	191	133	98

Number of available records are presented for key visits up to Week 58 only. MMRM = Mixed model Repeated Measures. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. All observed values up to Week 58 are included in the model following a treatment policy approach.
An increase reflects a worsening of the status of the patient. Results are presented in g/day. Reference table: PT1UEC_FMC0

Table PT1URP_FMP0: Patients with partial remission
Full Analysis Set

Variable	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Partial remission	Week 6	Sparsentan	202	192 (95.0)	86 (44.8)	2.251 [1.627, 3.116]	3.267 [2.072, 5.149]	24.9 [15.3, 34.4]	<0.001	*
		Irbesartan	202	191 (94.6)	38 (19.9)					
	Week 36	Sparsentan	202	139 (68.8)	76 (54.7)	2.272 [1.621, 3.186]	3.808 [2.265, 6.399]	30.6 [18.9, 42.4]	<0.001	*
		Irbesartan	202	133 (65.8)	32 (24.1)					
	Week 58	Sparsentan	202	113 (55.9)	55 (48.7)	1.645 [1.148, 2.356]	2.256 [1.277, 3.987]	19.1 [5.2, 32.9]	0.005	*
		Irbesartan	202	98 (48.5)	29 (29.6)					

N = number of patients in analysis set. n = number of patients with event. nval = number of evaluable values.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Partial remission means an urinary protein excretion of <1.0 g/day.
Source Data: alb, created on: 19FEB2024

Table PT1URPT_FMT0: Time to partial remission
Full Analysis Set

Time to partial remission			Kaplan-Meier analysis		Cox regression			
Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Sparsentan	202	145 (71.8)	6.9	(6.0, 12.3)	2.513	(1.929, 3.273)	<0.001	*
Irbesartan	202	94 (46.5)	59.6	(36.1, 114.1)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable. * = significant treatment effect.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
Partial remission means an urinary protein excretion of <1.0 g/day.
Source Data: alb_tte, created on: 31MAY2024

Figure PF1URPT_FMK0: Time to partial remission - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	62	42	25	11	6
Irbesartan	202	106	69	45	20	8

_____
Partial remission means an urinary protein excretion of <1.0 g/day. No event means no partial remission.
Reference table: PT1URPT_FMT0

Table PT1URF_FMP0: Patients with complete remission
Full Analysis Set

Variable	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Complete remission	Week 6	Sparsentan	202	192 (95.0)	9 (4.7)	18.902 + [1.108, 322.477]	19.828 + [1.146, 343.135]	4.7 [1.2, 8.2]	0.004	*
		Irbesartan	202	191 (94.6)	0 (0.0)					
	Week 36	Sparsentan	202	139 (68.8)	14 (10.1)	2.679 [0.992, 7.232]	2.867 [1.003, 8.197]	6.3 [-0.4, 13.0]	0.056	
		Irbesartan	202	133 (65.8)	5 (3.8)					
	Week 58	Sparsentan	202	113 (55.9)	19 (16.8)	2.746 [1.142, 6.602]	3.099 [1.185, 8.109]	10.7 [1.4, 20.0]	0.019	*
		Irbesartan	202	98 (48.5)	6 (6.1)					

N = number of patients in analysis set. n = number of patients with event. nval = number of evaluable values.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Complete remission means an urinary protein excretion of <0.3 g/day.
Source Data: alb, created on: 19FEB2024

Table PT1URFT_FMT0: Time to complete remission
Full Analysis Set

Time to complete remission			Kaplan-Meier analysis		Cox regression			
Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Sparsentan	202	43 (21.3)	NE		2.672	(1.522, 4.692)	<0.001	*
Irbesartan	202	17 (8.4)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable. * = significant treatment effect.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
Complete remission means an urinary protein excretion of <0.3 g/day.
Source Data: alb_tte, created on: 31MAY2024

Figure PF1URFT_FMK0: Time to complete remission - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	134	110	78	36	16
Irbesartan	202	152	113	78	32	12

_____
Complete remission means an urinary protein excretion of <0.3 g/day. No event means no complete remission.
Reference table: PT1URFT_FMT0

Table PT1GGC_FMH0: Course of eGFR
Full Analysis Set

Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR	Baseline	Sparsentan	202	202 (100.0)	56.86 (24.38)	24.0	38.00	50.00	71.00	128.0	
		Irbesartan	202	202 (100.0)	57.08 (23.58)	26.0	39.00	50.00	70.00	123.0	
	Week 6	Sparsentan	202	193 (95.5)	55.92 (23.65)	21.0	36.00	52.00	70.00	121.0	
		Irbesartan	202	195 (96.5)	55.58 (23.39)	19.0	38.00	48.00	69.00	120.0	
	Week 36	Sparsentan	202	136 (67.3)	54.24 (23.12)	18.0	36.00	48.50	67.50	123.0	
		Irbesartan	202	133 (65.8)	50.59 (22.84)	7.0	34.00	44.00	62.00	125.0	
	Week 58	Sparsentan	202	110 (54.5)	53.73 (24.31)	13.0	36.00	47.00	69.00	133.0	
		Irbesartan	202	95 (47.0)	48.57 (22.12)	13.0	33.00	41.00	60.00	122.0	
Change from baseline in eGFR	Week 6	Sparsentan	202	193 (95.5)	-1.13 (7.69)	-43.0	-4.00	-1.00	2.00	20.0	0.06 [-0.14, 0.25]
		Irbesartan	202	195 (96.5)	-1.53 (6.56)	-31.0	-5.00	-2.00	2.00	20.0	
	Week 36	Sparsentan	202	136 (67.3)	-3.84 (8.69)	-39.0	-8.00	-3.00	1.00	26.0	0.08 [-0.16, 0.32]
		Irbesartan	202	133 (65.8)	-4.49 (7.70)	-32.0	-8.00	-4.00	0.00	15.0	
	Week 58	Sparsentan	202	110 (54.5)	-4.89 (8.95)	-34.0	-9.00	-4.00	0.00	24.0	0.16 [-0.11, 0.44]
		Irbesartan	202	95 (47.0)	-6.27 (7.88)	-24.0	-12.00	-7.00	0.00	12.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FMC0: Change from baseline in eGFR
Full Analysis Set

Change from baseline in eGFR				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Week 6	Sparsentan	202	193 (95.5)	-1.12 (0.52)	(-2.13, -0.11)	0.38 (0.73)	(-1.04, 1.81)	0.598
	Irbesartan	202	195 (96.5)	-1.50 (0.51)	(-2.51, -0.50)			
Week 36	Sparsentan	202	136 (67.3)	-3.70 (0.59)	(-4.87, -2.53)	0.85 (0.85)	(-0.81, 2.51)	0.315
	Irbesartan	202	133 (65.8)	-4.55 (0.60)	(-5.73, -3.37)			
Week 58	Sparsentan	202	110 (54.5)	-4.61 (0.66)	(-5.91, -3.31)	1.55 (0.97)	(-0.35, 3.45)	0.110
	Irbesartan	202	95 (47.0)	-6.16 (0.70)	(-7.54, -4.78)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. Only key visits up to Week 58 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate.
All observed values up to Week 58 are included in the model following a treatment policy approach.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order regressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Figure PF1GGC_FMG0: Change from baseline in eGFR
Full Analysis Set
Study: PROTECT



Sparsentan	193	136	110
Irbesartan	195	133	95

Number of available records are presented for key visits up to Week 58 only. MMRM = Mixed model Repeated Measures. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. All observed values up to Week 58 are included in the model . A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. Reference table: PT1GGC_FMC0

Table PT1GGA_FMR0: Rate of change in eGFR (total slope) - Year 1
Full Analysis Set

Rate of change in eGFR (total slope) - year 1			Mixed Random Coefficient Model				
			Annualized Slope		Slope Difference		
Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline to Week 58	Sparsentan	202	-4.26 (0.89)	(-6.01, -2.52)	0.62 (1.27)	(-1.88, 3.11)	0.629
	Irbesartan	202	-4.88 (0.91)	(-6.67, -3.09)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject.
All observed post-baseline values up to Week 58 are included in the model. A first order autoregressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate.
Source Data: alb, created on: 19FEB2024

Table PT1GGLA_FMR0: Rate of change in eGFR (chronic slope) - Year 1
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 1			Mixed Random Coefficient Model				
			Annualized Slope		Slope Difference		
Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Week 6 to Week 58	Sparsentan	202	-3.92 (0.94)	(-5.76, -2.08)	1.00 (1.34)	(-1.64, 3.63)	0.457
	Irbesartan	202	-4.92 (0.96)	(-6.80, -3.03)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject.
All observed values up from Week 6 to Week 58 are included in the model. A first order autoregressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate.
Source Data: alb, created on: 19FEB2024

Table PT1MIS_FMI0: Patients with systemic immunosuppressive medication
Full Analysis Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Systemic immunosuppressive medication	Double-blind period	Sparsentan	202	14 (6.9)	0.700 [0.364, 1.347]	0.678 [0.332, 1.382]	-3.0 [-8.9, 2.9]	0.370
		Irbesartan	202	20 (9.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aeff, created on: 28FEB2024

Table PT1MIST_FMT0: Time to systemic immunosuppressive medication
Full Analysis Set

Time to systemic Immunosuppressive medication			Kaplan-Meier analysis		Cox regression		
Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sparsentan	202	14 (6.9)	NE		0.661	(0.334, 1.309)	0.235
Irbesartan	202	20 (9.9)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable. * = significant treatment effect.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
Source Data: aeff_tte, created on: 28FEB2024

Figure PF1MIST_FMK0: Time to systemic immunosuppressive medication - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	156	121	97	50	16
Irbesartan	202	149	110	88	46	17

Reference table: PT1MIST_FMT0

Table PT1MIK_FMI0: Patients with systemic immunosuppressive renal medication
Full Analysis Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Systemic immunosuppressive renal medication (renal indication)	Double-blind period	Sparsentan	202	2 (1.0)	0.222 [0.049, 1.016]	0.214 [0.046, 1.005]	-3.5 [-7.1, 0.2]	0.062
		Irbesartan	202	9 (4.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aeff, created on: 28FEB2024

Table PT1MIKT_FMT0: Time to systemic immunosuppressive renal medication
Full Analysis Set

Time to systemic Immunosuppressive renal medication			Kaplan-Meier analysis		Cox regression			
Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Sparsentan	202	2 (1.0)	NE		0.202	(0.044, 0.937)	0.041	*
Irbesartan	202	9 (4.5)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable. * = significant treatment effect.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
Source Data: aeff_tte, created on: 28FEB2024

Figure PF1MIKT_FMK0: Time to systemic immunosuppressive renal medication - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	161	127	105	54	18
Irbesartan	202	154	114	92	48	19

Reference table: PT1MIKT_FMT0

Table PT1HOS_FMI0: Patients with hospitalizations
Full Analysis Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Hospitalizations	Double-blind period	Sparsentan	202	22 (10.9)	1.000 [0.572, 1.747]	1.000 [0.535, 1.870]	0.0 [-6.6, 6.6]	1.000
		Irbesartan	202	22 (10.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aeff, created on: 28FEB2024

Table PT1HNS_FMN0: Number of hospitalizations
Full Analysis Set

Number of hospitalizations						Negative binomial model		
Treatment	N	nval (%)	Time at risk (years)	Number of events	Crude rate	Rate ratio	95% CI	p-value
Sparsentan	202	202 (100.0)	265.8	24	0.09	0.924	(0.520, 1.639)	0.786
Irbesartan	202	202 (100.0)	262.9	26	0.10			

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. nval (%) = number of patients included in the analysis (i.e., with post-baseline data).
NE = not evaluable.
Number of events = number of considered hospitalizations. 95% CI = 95% confidence interval for rate ratio.
A negative binomial model was applied with factors treatment, randomisation strata, and log of offset. The study duration of double blind period was used as offset.
* = significant treatment effect.
Source Data: aeff, created on: 28FEB2024

Table PT1HDS_FMN0: Duration of hospitalizations
Full Analysis Set

Duration of hospitalizations						Negative binomial model		
Treatment	N	nval (%)	Time at risk (years)	Number of events	Crude rate	Rate ratio	95% CI	p-value
Sparsentan	202	202 (100.0)	265.8	105	0.40	0.799	(0.307, 2.082)	0.647
Irbesartan	202	202 (100.0)	262.9	178	0.68			

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. nval (%) = number of patients included in the analysis (i.e., with post-baseline data).
NE = not evaluable.
Number of events = number of days with considered hospitalizations. 95% CI = 95% confidence interval for rate ratio.
A negative binomial model was applied with factors treatment, randomisation strata, and log of offset. The study duration of double blind period was used as offset.
* = significant treatment effect.
Source Data: aeff, created on: 28FEB2024

Table PT1HDS_FMB0: Duration of hospitalizations
Full Analysis Set

Variable	Study	Treatment	N	n	Mean (SD)	Min	Q25	Q50	Q75	Max
Duration of hospitalizations	PROTECT	Sparsentan	202	202	0.52 (2.01)	0.0	0.00	0.00	0.00	18.0
		Irbesartan	202	202	0.88 (3.32)	0.0	0.00	0.00	0.00	30.0

N = total number of patients in analysis set. n = number evaluable values. SD = standard deviation. Q = quantile.
Results are presented in days.
Source Data: aeff, created on: 28FEB2024

Table PT1VSC_FMH0: Course of EQ-5D VAS
Full Analysis Set

Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
EQ-5D VAS	Baseline	Sparsentan	202	191 (94.6)	80.48 (14.24)	7.0	75.00	81.00	90.00	100.0	
		Irbesartan	202	184 (91.1)	80.36 (14.21)	19.0	75.00	80.00	90.00	100.0	
	Week 24	Sparsentan	202	132 (65.3)	83.20 (10.84)	50.0	76.00	83.50	91.00	100.0	
		Irbesartan	202	115 (56.9)	80.93 (16.23)	4.0	77.00	81.00	91.00	100.0	
	Week 48	Sparsentan	202	113 (55.9)	82.11 (10.59)	49.0	79.00	82.00	90.00	100.0	
		Irbesartan	202	83 (41.1)	82.77 (12.72)	40.0	80.00	83.00	90.00	100.0	
Change from baseline in EQ-5D VAS	Week 24	Sparsentan	202	132 (65.3)	3.20 (15.02)	-31.0	-4.50	1.00	10.00	75.0	0.16 [-0.09, 0.41]
		Irbesartan	202	115 (56.9)	0.57 (17.19)	-90.0	-5.00	0.00	10.00	52.0	
	Week 48	Sparsentan	202	113 (55.9)	2.84 (15.56)	-30.0	-4.00	1.00	9.00	87.0	0.06 [-0.23, 0.34]
		Irbesartan	202	83 (41.1)	2.07 (10.72)	-35.0	-1.00	2.00	9.00	27.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FMC0: Change from baseline in EQ-5D VAS
Full Analysis Set

Change from baseline in EQ-5D VAS				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Week 24	Sparsentan	202	132 (65.3)	3.19 (1.03)	(1.16, 5.21)	2.41 (1.51)	(-0.56, 5.38)	0.112
	Irbesartan	202	115 (56.9)	0.78 (1.11)	(-1.40, 2.95)			
Week 48	Sparsentan	202	113 (55.9)	2.20 (1.11)	(0.02, 4.38)	-0.30 (1.70)	(-3.65, 3.04)	0.859
	Irbesartan	202	83 (41.1)	2.50 (1.29)	(-0.03, 5.04)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate.
A decrease reflects a worsening of the status of the patient.
A first order regressive covariance structure was used.
Source Data: aqs, created on: 04APR2024

Figure PF1VSC_FMG0: Change from baseline in EQ-5D VAS
Full Analysis Set
Study: PROTECT



Sparsentan	132	113
Irbesartan	115	83

Number of available records are presented per time-point. LS-Mean = Least square mean. 95% CI = 95% confidence interval.
A decrease reflects a worsening of the status of the patient.
Reference table: PT1VSC_FMC0

Table PT1VSIT_FMT0: Time to increase in EQ-5D VAS by at least 15 points
Full Analysis Set

Time to increase in EQ-5D VAS by at least 15			Kaplan-Meier analysis		Cox regression		
Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sparsentan	202	29 (14.4)	NE		0.936	(0.539, 1.625)	0.813
Irbesartan	202	26 (12.9)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable. * = significant treatment effect.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
Source Data: aqs_tte, created on: 04APR2024

Figure PF1VSIT_FMK0: Time to increase in EQ-5D VAS by at least 15 points - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	133	98	69	29	8
Irbesartan	202	118	80	50	20	7

An increase reflects an improvement of the status of the patient.
Reference table: PT1VSIT_FMT0

Table PT1VSDT_FMT0: Time to decrease in EQ-5D VAS by at least 15 points
Full Analysis Set

Time to decrease in EQ-5D VAS by at least 15			Kaplan-Meier analysis		Cox regression		
Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sparsentan	202	26 (12.9)	112.1	(111.0, NE)	1.242	(0.660, 2.338)	0.502
Irbesartan	202	16 (7.9)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable. * = significant treatment effect.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
Source Data: aqs_tte, created on: 04APR2024

Figure PF1VSDT_FMK0: Time to decrease in EQ-5D VAS by at least 15 points - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	137	109	79	35	13
Irbesartan	202	119	82	55	21	8

_____
A decrease reflects a worsening of the status of the patient.
Reference table: PT1VSDT_FMT0

Table PT1KBUC_FMH0: KDQOL: Course of burden of kidney disease
Full Analysis Set

Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
KDQOL: burden of kidney disease	Baseline	Sparsentan	202	186 (92.1)	69.52 (25.46)	0.0	50.00	75.00	87.50	100.0	
		Irbesartan	202	179 (88.6)	76.85 (22.80)	6.3	62.50	81.25	93.75	100.0	
	Week 24	Sparsentan	202	125 (61.9)	75.55 (22.00)	12.5	68.75	81.25	93.75	100.0	
		Irbesartan	202	104 (51.5)	78.85 (22.14)	0.0	68.75	81.25	100.00	100.0	
	Week 48	Sparsentan	202	110 (54.5)	77.33 (20.92)	6.3	68.75	81.25	93.75	100.0	
		Irbesartan	202	77 (38.1)	80.76 (20.27)	6.3	75.00	81.25	100.00	100.0	
KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	202	125 (61.9)	7.75 (22.94)	-81.3	0.00	6.25	18.75	75.0	0.38 [0.11, 0.64]
		Irbesartan	202	104 (51.5)	-0.06 (17.73)	-50.0	-12.50	0.00	6.25	56.3	
	Week 48	Sparsentan	202	110 (54.5)	9.26 (20.44)	-62.5	0.00	6.25	25.00	62.5	0.34 [0.04, 0.63]
		Irbesartan	202	77 (38.1)	2.84 (17.10)	-50.0	-6.25	0.00	12.50	56.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FMC0: KDQOL: Change from baseline in burden of kidney disease
Full Analysis Set

				Repeated measures analysis				
KDQOL: Change from baseline in burden of kidney disease				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Week 24	Sparsentan	202	125 (61.9)	5.48 (1.50)	(2.54, 8.42)	2.79 (2.24)	(-1.62, 7.21)	0.214
	Irbesartan	202	104 (51.5)	2.69 (1.65)	(-0.56, 5.93)			
Week 48	Sparsentan	202	110 (54.5)	7.31 (1.58)	(4.20, 10.42)	2.86 (2.48)	(-2.00, 7.73)	0.248
	Irbesartan	202	77 (38.1)	4.45 (1.89)	(0.74, 8.16)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate.
A decrease reflects a worsening of the status of the patient.
A first order regressive covariance structure was used.
Source Data: aqs, created on: 04APR2024

Figure PF1KBUC_FMG0: KDQOL: Change from baseline in burden of kidney disease
Full Analysis Set
Study: PROTECT



Sparsentan	125	110
Irbesartan	104	77

Number of available records are presented per time-point. LS-Mean = Least square mean. 95% CI = 95% confidence interval.
A decrease reflects a worsening of the status of the patient.
KD = kidney disease. Reference table: PT1KBUC_FMC0

Table PT1KBUIT_FMT0: KDQOL: Time to increase in burden of kidney disease by at least 15 points
Full Analysis Set

KDQOL: Time to increase in burden of kidney disease by at least 15			Kaplan-Meier analysis		Cox regression			
Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Sparsentan	202	61 (30.2)	75.3	(50.1, NE)	1.594	(1.013, 2.508)	0.044	*
Irbesartan	202	29 (14.4)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable. * = significant treatment effect.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
Source Data: aqs_tte, created on: 04APR2024

Figure PF1KBUIT_FMK0: KDQOL: Time to increase in burden of kidney disease by at least 15 points - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	127	81	56	21	10
Irbesartan	202	111	75	43	15	5

An increase reflects an improvement of the status of the patient.
Reference table: PT1KBUIT_FMT0

Table PT1KBUDT_FMT0: KDQOL: Time to decrease in burden of kidney disease by at least 15 points
Full Analysis Set

KDQOL: Time to decrease in burden of kidney disease by at least 15			Kaplan-Meier analysis		Cox regression		
Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sparsentan	202	25 (12.4)	112.1	(112.1, NE)	0.651	(0.382, 1.109)	0.115
Irbesartan	202	33 (16.3)	96.1	(94.6, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable. * = significant treatment effect.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
Source Data: aqs_tte, created on: 04APR2024

Figure PF1KBUDT_FMK0: KDQOL: Time to decrease in burden of kidney disease by at least 15 points - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	135	104	73	32	11
Irbesartan	202	114	82	47	20	7

_____
A decrease reflects a worsening of the status of the patient.
Reference table: PT1KBUDT_FMT0

Table PT1KEFC_FMH0: KDQOL: Course of effect of kidney disease
Full Analysis Set

Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
KDQOL: effect of kidney disease	Baseline	Sparsentan	202	186 (92.1)	88.21 (13.70)	28.1	84.38	93.75	96.88	100.0	
		Irbesartan	202	179 (88.6)	88.88 (13.03)	37.5	84.38	93.75	100.00	100.0	
	Week 24	Sparsentan	202	125 (61.9)	89.68 (13.42)	9.4	87.50	93.75	100.00	100.0	
		Irbesartan	202	104 (51.5)	88.67 (16.94)	0.0	84.38	93.75	100.00	100.0	
	Week 48	Sparsentan	202	110 (54.5)	90.23 (13.12)	0.0	87.50	93.75	100.00	100.0	
		Irbesartan	202	77 (38.1)	92.78 (10.80)	40.6	90.63	96.88	100.00	100.0	
KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	202	125 (61.9)	1.58 (13.88)	-75.0	-3.13	0.00	6.25	34.4	0.23 [-0.03, 0.50]
		Irbesartan	202	104 (51.5)	-1.77 (14.75)	-100.0	-3.13	0.00	4.69	31.3	
	Week 48	Sparsentan	202	110 (54.5)	2.07 (15.78)	-100.0	-3.13	3.13	6.25	56.3	0.05 [-0.24, 0.35]
		Irbesartan	202	77 (38.1)	1.34 (9.17)	-25.0	0.00	0.00	3.13	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FMC0: KDQOL: Change from baseline in effect of kidney disease
Full Analysis Set

				Repeated measures analysis				
KDQOL: Change from baseline in effect of kidney disease				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Week 24	Sparsentan	202	125 (61.9)	1.15 (1.13)	(-1.08, 3.37)	2.29 (1.68)	(-1.02, 5.61)	0.175
	Irbesartan	202	104 (51.5)	-1.15 (1.25)	(-3.59, 1.30)			
Week 48	Sparsentan	202	110 (54.5)	0.99 (1.20)	(-1.36, 3.34)	0.02 (1.86)	(-3.64, 3.68)	0.991
	Irbesartan	202	77 (38.1)	0.97 (1.42)	(-1.83, 3.77)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate.
A decrease reflects a worsening of the status of the patient.
A first order regressive covariance structure was used.
Source Data: aqs, created on: 04APR2024

Figure PF1KEFC_FMG0: KDQOL: Change from baseline in effect of kidney disease
Full Analysis Set
Study: PROTECT



Sparsentan	125	110
Irbesartan	104	77

Number of available records are presented per time-point. LS-Mean = Least square mean. 95% CI = 95% confidence interval.
A decrease reflects a worsening of the status of the patient.
KD = kidney disease. Reference table: PT1KEFC_FMC0

Table PT1KEFIT_FMT0: KDQOL: Time to increase in effect of kidney disease by at least 15 points
Full Analysis Set

KDQOL: Time to increase in effect of kidney disease by at least 15			Kaplan-Meier analysis		Cox regression		
Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sparsentan	202	23 (11.4)	NE		1.192	(0.589, 2.413)	0.625
Irbesartan	202	14 (6.9)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable. * = significant treatment effect.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
Source Data: aqs_tte, created on: 04APR2024

Figure PF1KEFIT_FMK0: KDQOL: Time to increase in effect of kidney disease by at least 15 points - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	131	99	70	29	12
Irbesartan	202	115	85	51	21	9

An increase reflects an improvement of the status of the patient.
Reference table: PT1KEFIT_FMT0

Table PT1KEFDT_FMT0: KDQOL: Time to decrease in effect of kidney disease by at least 15 points
Full Analysis Set

KDQOL: Time to decrease in effect of kidney disease by at least 15			Kaplan-Meier analysis		Cox regression		
Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sparsentan	202	18 (8.9)	NE		0.628	(0.329, 1.196)	0.157
Irbesartan	202	20 (9.9)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable. * = significant treatment effect.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
Source Data: aqs_tte, created on: 04APR2024

Figure PF1KEFDT_FMK0: KDQOL: Time to decrease in effect of kidney disease by at least 15 points - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	133	109	81	34	11
Irbesartan	202	114	82	51	21	8

A decrease reflects a worsening of the status of the patient.
Reference table: PT1KEFDT_FMT0

Table PT1KSYC_FMH0: KDQOL: Course of symptom/problems of kidney disease
Full Analysis Set

Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
KDQOL: symptom/problems of kidney disease	Baseline	Sparsentan	202	186 (92.1)	88.84 (11.24)	31.8	84.09	90.91	97.73	100.0	
		Irbesartan	202	179 (88.6)	89.36 (11.04)	38.6	86.36	93.18	97.73	100.0	
	Week 24	Sparsentan	202	125 (61.9)	88.53 (12.87)	4.5	84.09	93.18	97.73	100.0	
		Irbesartan	202	104 (51.5)	87.22 (17.74)	4.5	84.09	93.18	97.73	100.0	
	Week 48	Sparsentan	202	110 (54.5)	88.02 (15.92)	0.0	81.82	93.18	97.73	100.0	
		Irbesartan	202	77 (38.1)	89.64 (12.52)	47.7	86.36	93.18	100.00	100.0	
KDQOL: Change from baseline in symptom/problems of kidney disease	Week 24	Sparsentan	202	125 (61.9)	0.16 (12.59)	-72.7	-4.55	0.00	4.55	63.6	0.17 [-0.09, 0.44]
		Irbesartan	202	104 (51.5)	-2.43 (17.14)	-90.9	-4.55	0.00	2.27	52.3	
	Week 48	Sparsentan	202	110 (54.5)	0.04 (17.54)	-100.0	-4.55	0.00	6.82	59.1	0.04 [-0.25, 0.33]
		Irbesartan	202	77 (38.1)	-0.53 (9.48)	-27.3	-4.55	0.00	2.27	34.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FMC0: KDQOL: Change from baseline in symptom/problems of kidney disease
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Week 24	Sparsentan	202	125 (61.9)	-0.25 (1.23)	(-2.67, 2.17)	1.80 (1.83)	(-1.80, 5.39)	0.326
	Irbesartan	202	104 (51.5)	-2.05 (1.35)	(-4.71, 0.61)			
Week 48	Sparsentan	202	110 (54.5)	-0.50 (1.31)	(-3.08, 2.07)	0.02 (2.05)	(-4.00, 4.04)	0.993
	Irbesartan	202	77 (38.1)	-0.52 (1.57)	(-3.60, 2.56)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate.
A decrease reflects a worsening of the status of the patient.
A first order regressive covariance structure was used.
Source Data: aqs, created on: 04APR2024

Figure PF1KSYC_FMG0: KDQOL: Change from baseline in symptom/problems of kidney disease
Full Analysis Set
Study: PROTECT



Sparsentan	125	110
Irbesartan	104	77

Number of available records are presented per time-point. LS-Mean = Least square mean. 95% CI = 95% confidence interval.
A decrease reflects a worsening of the status of the patient.
KD = kidney disease. Reference table: PT1KSYC_FMC0

Table PT1KSYIT_FMT0: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points
Full Analysis Set

KDQOL: Time to increase in symptom/problems of kidney disease by at least 15			Kaplan-Meier analysis		Cox regression		
Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sparsentan	202	15 (7.4)	NE		1.237	(0.504, 3.037)	0.643
Irbesartan	202	9 (4.5)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable. * = significant treatment effect.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
Source Data: aqs_tte, created on: 04APR2024

Figure PF1KSYIT_FMK0: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	135	106	74	31	12
Irbesartan	202	114	85	54	23	8

An increase reflects an improvement of the status of the patient.
Reference table: PT1KSYIT_FMT0

Table PT1KSYDT_FMT0: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points
Full Analysis Set

KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15			Kaplan-Meier analysis		Cox regression		
Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sparsentan	202	23 (11.4)	NE		0.967	(0.519, 1.804)	0.916
Irbesartan	202	18 (8.9)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable. * = significant treatment effect.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
Source Data: aqs_tte, created on: 04APR2024

Figure PF1KSYDT_FMK0: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	135	107	75	29	10
Irbesartan	202	115	83	53	24	10

A decrease reflects a worsening of the status of the patient.
Reference table: PT1KSYDT_FMT0

Table PT1KPSC_FMH0: KDQOL-SF12: Course of PCS
Full Analysis Set

Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
KDQOL-SF12: PCS	Baseline	Sparsentan	202	187 (92.6)	51.05 (8.10)	12.4	46.73	53.18	56.71	63.5	
		Irbesartan	202	184 (91.1)	51.70 (7.02)	21.6	49.37	53.46	56.15	64.3	
	Week 24	Sparsentan	202	128 (63.4)	51.04 (7.48)	16.3	47.08	52.67	56.36	62.9	
		Irbesartan	202	112 (55.4)	51.32 (7.20)	20.8	46.64	53.46	56.15	64.3	
	Week 48	Sparsentan	202	112 (55.4)	51.01 (6.96)	29.8	46.60	53.17	55.96	66.1	
		Irbesartan	202	80 (39.6)	51.58 (7.19)	32.8	46.78	54.53	56.59	64.5	
KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	202	128 (63.4)	0.38 (6.78)	-24.8	-3.59	0.07	3.92	20.4	0.09 [-0.16, 0.34]
		Irbesartan	202	112 (55.4)	-0.20 (5.70)	-20.0	-2.27	0.00	2.37	16.9	
	Week 48	Sparsentan	202	112 (55.4)	0.53 (7.31)	-22.3	-3.19	0.00	4.34	24.7	0.09 [-0.19, 0.38]
		Irbesartan	202	80 (39.6)	-0.17 (7.71)	-24.7	-4.06	0.14	3.01	20.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FMC0: KDQOL-SF12: Change from baseline in PCS
Full Analysis Set

KDQOL-SF12: change from baseline in PCS				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Week 24	Sparsentan	202	128 (63.4)	0.35 (0.52)	(-0.68, 1.37)	0.29 (0.77)	(-1.22, 1.80)	0.704
	Irbesartan	202	112 (55.4)	0.06 (0.56)	(-1.05, 1.16)			
Week 48	Sparsentan	202	112 (55.4)	0.16 (0.55)	(-0.92, 1.24)	0.24 (0.85)	(-1.43, 1.91)	0.781
	Irbesartan	202	80 (39.6)	-0.08 (0.65)	(-1.35, 1.19)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate.
A decrease reflects a worsening of the status of the patient.
A first order regressive covariance structure was used.
Source Data: aqs, created on: 04APR2024

Figure PF1KPSC_FMG0: KDQOL-SF12: Change from baseline in PCS
Full Analysis Set
Study: PROTECT



Sparsentan	128	112
Irbesartan	112	80

Number of available records are presented per time-point. LS-Mean = Least square mean. 95% CI = 95% confidence interval.
A decrease reflects a worsening of the status of the patient.
Reference table: PT1KPSC_FMC0

Table PT1KPSIT_FMT0: KDQOL-SF12: Time to increase in PCS by at least 8.4 points
Full Analysis Set

KDQOL-SF12: time to increase in PCS by at least 8.4			Kaplan-Meier analysis		Cox regression		
Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sparsentan	202	22 (10.9)	NE		1.067	(0.537, 2.119)	0.853
Irbesartan	202	15 (7.4)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable. * = significant treatment effect.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
Source Data: aqs_tte, created on: 04APR2024

Figure PF1KPSIT_FMK0: KDQOL-SF12: Time to increase in PCS by at least 8.4 points - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	136	101	72	32	15
Irbesartan	202	119	83	51	17	5

An increase reflects an improvement of the status of the patient.
Reference table: PT1KPSIT_FMT0

Table PT1KPSDT_FMT0: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points
Full Analysis Set

KDQOL-SF12: time to decrease in PCS by at least 8.4			Kaplan-Meier analysis		Cox regression		
Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sparsentan	202	25 (12.4)	NE		1.068	(0.578, 1.973)	0.833
Irbesartan	202	18 (8.9)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable. * = significant treatment effect.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
Source Data: aqs_tte, created on: 04APR2024

Figure PF1KPSDT_FMK0: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	135	107	76	32	10
Irbesartan	202	119	82	54	22	9

A decrease reflects a worsening of the status of the patient.
Reference table: PT1KPSDT_FMT0

Table PT1KMSC_FMH0: KDQOL-SF12: Course of MCS
Full Analysis Set

Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
KDQOL-SF12: MCS	Baseline	Sparsentan	202	187 (92.6)	50.39 (8.31)	16.2	44.98	51.55	56.68	66.5	
		Irbesartan	202	184 (91.1)	51.37 (8.63)	24.3	47.20	52.88	57.16	66.6	
	Week 24	Sparsentan	202	128 (63.4)	51.58 (7.68)	20.8	47.69	52.83	57.27	66.8	
		Irbesartan	202	112 (55.4)	52.71 (8.31)	24.2	48.87	55.37	57.95	64.2	
	Week 48	Sparsentan	202	112 (55.4)	50.72 (8.35)	27.5	44.95	51.89	57.25	63.4	
		Irbesartan	202	80 (39.6)	51.28 (9.92)	19.6	47.43	54.20	57.66	64.6	
KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	202	128 (63.4)	0.73 (8.28)	-23.6	-3.61	0.49	4.82	26.4	0.03 [-0.23, 0.28]
		Irbesartan	202	112 (55.4)	0.54 (6.77)	-15.4	-4.23	0.00	3.83	28.7	
	Week 48	Sparsentan	202	112 (55.4)	0.64 (9.02)	-23.7	-4.53	0.21	6.18	28.1	0.21 [-0.08, 0.50]
		Irbesartan	202	80 (39.6)	-1.20 (8.39)	-33.9	-3.72	0.00	4.07	17.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FMC0: KDQOL-SF12: Change from baseline in MCS
Full Analysis Set

				Repeated measures analysis				
KDQOL-SF12: change from baseline in MCS				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Week 24	Sparsentan	202	128 (63.4)	0.54 (0.63)	(-0.71, 1.78)	-0.42 (0.93)	(-2.25, 1.41)	0.654
	Irbesartan	202	112 (55.4)	0.95 (0.68)	(-0.38, 2.29)			
Week 48	Sparsentan	202	112 (55.4)	0.05 (0.68)	(-1.28, 1.38)	0.69 (1.05)	(-1.37, 2.75)	0.510
	Irbesartan	202	80 (39.6)	-0.64 (0.80)	(-2.21, 0.93)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate.
A decrease reflects a worsening of the status of the patient.
A first order regressive covariance structure was used.
Source Data: aqs, created on: 04APR2024

Figure PF1KMSC_FMG0: KDQOL-SF12: Change from baseline in MCS
Full Analysis Set
Study: PROTECT



Sparsentan	128	112
Irbesartan	112	80

Number of available records are presented per time-point. LS-Mean = Least square mean. 95% CI = 95% confidence interval.
A decrease reflects a worsening of the status of the patient.
Reference table: PT1KMSC_FMC0

Table PT1KMSIT_FMT0: KDQOL-SF12: Time to increase in MCS by at least 9.0 points
Full Analysis Set

KDQOL-SF12: time to increase in MCS by at least 9.0			Kaplan-Meier analysis		Cox regression		
Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sparsentan	202	33 (16.3)	NE		1.821	(0.968, 3.426)	0.063
Irbesartan	202	15 (7.4)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable. * = significant treatment effect.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
Source Data: aqs_tte, created on: 04APR2024

Figure PF1KMSIT_FMK0: KDQOL-SF12: Time to increase in MCS by at least 9.0 points - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	133	97	67	32	13
Irbesartan	202	117	85	55	19	7

An increase reflects an improvement of the status of the patient.
Reference table: PT1KMSIT_FMT0

Table PT1KMSDT_FMT0: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points
Full Analysis Set

KDQOL-SF12: time to decrease in MCS by at least 9.0			Kaplan-Meier analysis		Cox regression		
Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sparsentan	202	34 (16.8)	111.1	(96.1, 114.3)	1.409	(0.808, 2.455)	0.227
Irbesartan	202	22 (10.9)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable. * = significant treatment effect.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
Source Data: aqs_tte, created on: 04APR2024

Figure PF1KMSDT_FMK0: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	136	102	71	31	11
Irbesartan	202	118	84	52	19	7

A decrease reflects a worsening of the status of the patient.
Reference table: PT1KMSDT_FMT0

Table PT1A_SMI0: Incidence of TEAEs during double-blind period
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
TEAEs	Double-blind period	Sparsentan	202	166 (82.2)	1.122 [1.010, 1.246]	1.682 [1.045, 2.709]	8.9 [0.3, 17.5]	0.042	*
		Irbesartan	202	148 (73.3)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AN_SMI0: Incidence of non-severe TEAEs during double-blind period
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Non-severe TEAEs	Double-blind period	Sparsentan	202	49 (24.3)	1.195 [0.829, 1.724]	1.258 [0.786, 2.013]	4.0 [-4.6, 12.6]	0.403
		Irbesartan	202	41 (20.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AC_SMI0: Incidence of severe TEAEs during double-blind period
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Severe TEAEs	Double-blind period	Sparsentan	202	14 (6.9)	0.933 [0.463, 1.883]	0.928 [0.436, 1.977]	-0.5 [-6.0, 5.0]	1.000
		Irbesartan	202	15 (7.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AS_SMI0: Incidence of serious TEAEs during double-blind period
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Serious TEAEs	Double-blind period	Sparsentan	202	28 (13.9)	0.903 [0.563, 1.449]	0.888 [0.511, 1.543]	-1.5 [-8.9, 5.9]	0.778
		Irbesartan	202	31 (15.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AT_SMI0: Incidence of TEAEs leading to study drug discontinuation during double-blind period
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
TEAEs leading to study drug discontinuation	Double-blind period	Sparsentan	202	16 (7.9)	1.778 [0.804, 3.929]	1.845 [0.795, 4.278]	3.5 [-1.7, 8.6]	0.215
		Irbesartan	202	9 (4.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AD_SMI0: Incidence of fatal TEAEs during double-blind period
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Fatal TEAEs	Double-blind period	Sparsentan	202	0 (0.0)				NE
		Irbesartan	202	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AA_SMI0: Incidence of non-disease related TEAEs during double-blind period
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Non-disease related TEAEs	Double-blind period	Sparsentan	202	162 (80.2)	1.117 [1.001, 1.248]	1.592 [1.003, 2.528]	8.4 [-0.4, 17.2]	0.062
		Irbesartan	202	145 (71.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AAN_SMI0: Incidence of non-disease related non-severe TEAEs during double-blind period
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Non-disease related non-severe TEAEs	Double-blind period	Sparsentan	202	162 (80.2)	1.125 [1.007, 1.257]	1.631 [1.029, 2.587]	8.9 [0.1, 17.7]	0.048	*
		Irbesartan	202	144 (71.3)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AAC_SMI0: Incidence of non-disease related severe TEAEs during double-blind period
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Non-disease related severe TEAEs	Double-blind period	Sparsentan	202	11 (5.4)	1.000 [0.444, 2.254]	1.000 [0.423, 2.362]	0.0 [-4.9, 4.9]	1.000
		Irbesartan	202	11 (5.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AAS_SMI0: Incidence of non-disease related serious TEAEs during double-blind period
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Non-disease related serious TEAEs	Double-blind period	Sparsentan	202	25 (12.4)	0.893 [0.540, 1.476]	0.878 [0.492, 1.565]	-1.5 [-8.6, 5.6]	0.768
		Irbesartan	202	28 (13.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1A_SMS0: Incidence of TEAEs during double-blind period by SOC/PT
Safety Set

TEAEs

SOC/PT	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
SOC: Blood and lymphatic system disorders	Double-blind period	Sparsentan	202	13 (6.4)	1.625 [0.688, 3.836]	1.668 [0.676, 4.116]	2.5 [-2.3, 7.3]	0.370	
		Irbesartan	202	8 (4.0)					
SOC: Cardiac disorders	Double-blind period	Sparsentan	202	6 (3.0)	0.462 [0.179, 1.190]	0.445 [0.166, 1.195]	-3.5 [-8.1, 1.1]	0.157	
		Irbesartan	202	13 (6.4)					
SOC: Eye disorders	Double-blind period	Sparsentan	202	10 (5.0)	2.000 [0.696, 5.748]	2.052 [0.689, 6.114]	2.5 [-1.7, 6.6]	0.293	
		Irbesartan	202	5 (2.5)					
SOC: Gastrointestinal disorders	Double-blind period	Sparsentan	202	47 (23.3)	1.175 [0.809, 1.708]	1.228 [0.763, 1.976]	3.5 [-5.0, 12.0]	0.468	$
		Irbesartan	202	40 (19.8)					$
PT: Diarrhoea	Double-blind period	Sparsentan	202	7 (3.5)	0.500 [0.206, 1.213]	0.482 [0.190, 1.221]	-3.5 [-8.3, 1.3]	0.178	
		Irbesartan	202	14 (6.9)					
SOC: General disorders and administration site conditions	Double-blind period	Sparsentan	202	50 (24.8)	1.316 [0.905, 1.913]	1.420 [0.882, 2.285]	5.9 [-2.6, 14.5]	0.185	$
		Irbesartan	202	38 (18.8)					$
PT: Fatigue	Double-blind period	Sparsentan	202	16 (7.9)	2.667 [1.065, 6.677]	2.810 [1.077, 7.335]	5.0 [0.1, 9.8]	0.046	*
		Irbesartan	202	6 (3.0)					
PT: Oedema peripheral	Double-blind period	Sparsentan	202	25 (12.4)	1.563 [0.861, 2.837]	1.642 [0.848, 3.178]	4.5 [-1.9, 10.8]	0.187	$
		Irbesartan	202	16 (7.9)					$

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Only events are reported with at least 1% of affected patients and 10 affected patients in at least 1 treatment arm. § = events with at least 10% affected patients in at least 1 treatment arm.
Source Data: aae, created on: 30JAN2024

Table PT1A_SMS0: Incidence of TEAEs during double-blind period by SOC/PT
Safety Set

TEAEs

SOC/PT	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
SOC: Infections and infestations	Double-blind period	Sparsentan	202	56 (27.7)	0.918 [0.676, 1.246]	0.887 [0.577, 1.363]	-2.5 [-11.8, 6.9]	0.661	$
		Irbesartan	202	61 (30.2)					$
PT: Upper respiratory tract infection	Double-blind period	Sparsentan	202	12 (5.9)	1.000 [0.460, 2.173]	1.000 [0.438, 2.282]	0.0 [-5.1, 5.1]	1.000	
		Irbesartan	202	12 (5.9)					
SOC: Injury, poisoning and procedural complications	Double-blind period	Sparsentan	202	11 (5.4)	0.611 [0.296, 1.261]	0.589 [0.271, 1.280]	-3.5 [-9.0, 2.1]	0.247	
		Irbesartan	202	18 (8.9)					
SOC: Investigations	Double-blind period	Sparsentan	202	47 (23.3)	1.516 [1.007, 2.283]	1.673 [1.012, 2.766]	7.9 [-0.2, 16.1]	0.058	$
		Irbesartan	202	31 (15.3)					$
PT: Lipase increased	Double-blind period	Sparsentan	202	10 (5.0)	2.000 [0.696, 5.748]	2.052 [0.689, 6.114]	2.5 [-1.7, 6.6]	0.293	
		Irbesartan	202	5 (2.5)					
SOC: Metabolism and nutrition disorders	Double-blind period	Sparsentan	202	44 (21.8)	0.880 [0.617, 1.255]	0.847 [0.533, 1.344]	-3.0 [-11.7, 5.8]	0.556	$
		Irbesartan	202	50 (24.8)					$
PT: Hyperkalaemia	Double-blind period	Sparsentan	202	21 (10.4)	1.167 [0.641, 2.123]	1.186 [0.612, 2.300]	1.5 [-4.8, 7.7]	0.737	$
		Irbesartan	202	18 (8.9)					$
SOC: Musculoskeletal and connective tissue disorders	Double-blind period	Sparsentan	202	46 (22.8)	1.000 [0.698, 1.432]	1.000 [0.628, 1.592]	0.0 [-8.7, 8.7]	1.000	$
		Irbesartan	202	46 (22.8)					$

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Only events are reported with at least 1% of affected patients and 10 affected patients in at least 1 treatment arm. § = events with at least 10% affected patients in at least 1 treatment arm.
Source Data: aae, created on: 30JAN2024

Table PT1A_SMS0: Incidence of TEAEs during double-blind period by SOC/PT
Safety Set

TEAEs

SOC/PT	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Back pain	Double-blind period	Sparsentan	202	8 (4.0)	0.615 [0.261, 1.453]	0.600 [0.243, 1.479]	-2.5 [-7.3, 2.3]	0.370	
		Irbesartan	202	13 (6.4)					
PT: Muscle spasms	Double-blind period	Sparsentan	202	8 (4.0)	0.727 [0.299, 1.770]	0.716 [0.282, 1.819]	-1.5 [-6.1, 3.1]	0.639	
		Irbesartan	202	11 (5.4)					
SOC: Nervous system disorders	Double-blind period	Sparsentan	202	53 (26.2)	1.262 [0.885, 1.799]	1.355 [0.853, 2.151]	5.4 [-3.3, 14.2]	0.241	$
		Irbesartan	202	42 (20.8)					$
PT: Dizziness	Double-blind period	Sparsentan	202	26 (12.9)	2.889 [1.389, 6.010]	3.168 [1.445, 6.946]	8.4 [2.5, 14.3]	0.004 *	$
		Irbesartan	202	9 (4.5)					$
PT: Headache	Double-blind period	Sparsentan	202	20 (9.9)	0.952 [0.533, 1.702]	0.947 [0.496, 1.807]	-0.5 [-6.9, 5.9]	1.000	$
		Irbesartan	202	21 (10.4)					$
SOC: Psychiatric disorders	Double-blind period	Sparsentan	202	12 (5.9)	1.000 [0.460, 2.173]	1.000 [0.438, 2.282]	0.0 [-5.1, 5.1]	1.000	
		Irbesartan	202	12 (5.9)					
SOC: Renal and urinary disorders	Double-blind period	Sparsentan	202	29 (14.4)	1.115 [0.682, 1.825]	1.135 [0.642, 2.005]	1.5 [-5.7, 8.7]	0.772	$
		Irbesartan	202	26 (12.9)					$
SOC: Respiratory, thoracic and mediastinal disorders	Double-blind period	Sparsentan	202	25 (12.4)	1.471 [0.820, 2.638]	1.537 [0.803, 2.943]	4.0 [-2.5, 10.4]	0.254	$
		Irbesartan	202	17 (8.4)					$

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Only events are reported with at least 1% of affected patients and 10 affected patients in at least 1 treatment arm. § = events with at least 10% affected patients in at least 1 treatment arm.
Source Data: aae, created on: 30JAN2024

Table PT1A_SMS0: Incidence of TEAEs during double-blind period by SOC/PT
Safety Set

TEAEs

SOC/PT	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
SOC: Skin and subcutaneous tissue disorders	Double-blind period	Sparsentan	202	22 (10.9)	0.917 [0.532, 1.580]	0.906 [0.490, 1.676]	-1.0 [-7.7, 5.7]	0.876	$
		Irbesartan	202	24 (11.9)					$
SOC: Vascular disorders	Double-blind period	Sparsentan	202	47 (23.3)	1.679 [1.097, 2.568]	1.884 [1.125, 3.155]	9.4 [1.4, 17.4]	0.021 *	$
		Irbesartan	202	28 (13.9)					$
PT: Hypertension	Double-blind period	Sparsentan	202	16 (7.9)	0.941 [0.489, 1.811]	0.936 [0.459, 1.909]	-0.5 [-6.3, 5.3]	1.000	
		Irbesartan	202	17 (8.4)					
PT: Hypotension	Double-blind period	Sparsentan	202	20 (9.9)	3.333 [1.367, 8.127]	3.590 [1.410, 9.138]	6.9 [1.7, 12.2]	0.007 *	
		Irbesartan	202	6 (3.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Only events are reported with at least 1% of affected patients and 10 affected patients in at least 1 treatment arm. § = events with at least 10% affected patients in at least 1 treatment arm.
Source Data: aae, created on: 30JAN2024

Table PT1AC_SMS0: Incidence of severe TEAEs during double-blind period by SOC/PT
Safety Set

Not done. No valid soc/pt combination with sufficient high incidence found.

_____
Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Only events are reported with at least 5% of affected patients in at least 1 treatment arm.
Source Data: aae, created on: 30JAN2024

Table PT1AS_SMS0: Incidence of serious TEAEs during double-blind period by SOC/PT
Safety Set

Serious TEAEs

SOC/PT	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
SOC: Infections and infestations	Double-blind period	Sparsentan	202	7 (3.5)	0.636 [0.252, 1.609]	0.623 [0.237, 1.642]	-2.0 [-6.5, 2.5]	0.470
		Irbesartan	202	11 (5.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Only events are reported with at least 5% of affected patients in at least 1 treatment arm.
Source Data: aae, created on: 30JAN2024

Table PT1AT_SMSD: Incidence of TEAEs leading to study drug discontinuation during double-blind period by SOC/PT
Safety Set

TEAEs leading to study drug discontinuation				
SOC/PT	Time	Treatment	N	n (%)
SOC: Gastrointestinal disorders	Double-blind period	Sparsentan	202	1 (0.5)
		Irbesartan	202	1 (0.5)
PT: Abdominal pain	Double-blind period	Sparsentan	202	1 (0.5)
		Irbesartan	202	0 (0.0)
PT: Frequent bowel movements	Double-blind period	Sparsentan	202	0 (0.0)
		Irbesartan	202	1 (0.5)
PT: Nausea	Double-blind period	Sparsentan	202	0 (0.0)
		Irbesartan	202	1 (0.5)
PT: Rectal haemorrhage	Double-blind period	Sparsentan	202	1 (0.5)
		Irbesartan	202	0 (0.0)
PT: Vomiting	Double-blind period	Sparsentan	202	1 (0.5)
		Irbesartan	202	0 (0.0)
SOC: Infections and infestations	Double-blind period	Sparsentan	202	0 (0.0)
		Irbesartan	202	1 (0.5)
PT: COVID-19	Double-blind period	Sparsentan	202	0 (0.0)
		Irbesartan	202	1 (0.5)

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Source Data: aae, created on: 30JAN2024

Table PT1AT_SMSD: Incidence of TEAEs leading to study drug discontinuation during double-blind period by SOC/PT
Safety Set

TEAEs leading to study drug discontinuation				
SOC/PT	Time	Treatment	N	n (%)
SOC: Injury, poisoning and procedural complications	Double-blind period	Sparsentan	202	0 (0.0)
		Irbesartan	202	1 (0.5)
PT: Foetal exposure during pregnancy	Double-blind period	Sparsentan	202	0 (0.0)
		Irbesartan	202	1 (0.5)
SOC: Investigations	Double-blind period	Sparsentan	202	4 (2.0)
		Irbesartan	202	1 (0.5)
PT: Alanine aminotransferase increased	Double-blind period	Sparsentan	202	2 (1.0)
		Irbesartan	202	0 (0.0)
PT: Aspartate aminotransferase increased	Double-blind period	Sparsentan	202	1 (0.5)
		Irbesartan	202	0 (0.0)
PT: Blood creatinine increased	Double-blind period	Sparsentan	202	1 (0.5)
		Irbesartan	202	0 (0.0)
PT: Lipase increased	Double-blind period	Sparsentan	202	1 (0.5)
		Irbesartan	202	0 (0.0)
PT: Pregnancy test urine positive	Double-blind period	Sparsentan	202	0 (0.0)
		Irbesartan	202	1 (0.5)

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Source Data: aae, created on: 30JAN2024

Table PT1AT_SMSD: Incidence of TEAEs leading to study drug discontinuation during double-blind period by SOC/PT
Safety Set

TEAEs leading to study drug discontinuation				
SOC/PT	Time	Treatment	N	n (%)
SOC: Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Double-blind period	Sparsentan	202	1 (0.5)
		Irbesartan	202	0 (0.0)
PT: Diffuse large B-cell lymphoma	Double-blind period	Sparsentan	202	1 (0.5)
		Irbesartan	202	0 (0.0)
SOC: Nervous system disorders	Double-blind period	Sparsentan	202	1 (0.5)
		Irbesartan	202	0 (0.0)
PT: Dizziness	Double-blind period	Sparsentan	202	1 (0.5)
		Irbesartan	202	0 (0.0)
SOC: Pregnancy, puerperium and perinatal conditions	Double-blind period	Sparsentan	202	1 (0.5)
		Irbesartan	202	1 (0.5)
PT: Pregnancy	Double-blind period	Sparsentan	202	1 (0.5)
		Irbesartan	202	1 (0.5)
SOC: Psychiatric disorders	Double-blind period	Sparsentan	202	1 (0.5)
		Irbesartan	202	0 (0.0)
PT: Depressed mood	Double-blind period	Sparsentan	202	1 (0.5)
		Irbesartan	202	0 (0.0)

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Source Data: aae, created on: 30JAN2024

Table PT1AT_SMSD: Incidence of TEAEs leading to study drug discontinuation during double-blind period by SOC/PT
Safety Set

TEAEs leading to study drug discontinuation				
SOC/PT	Time	Treatment	N	n (%)
SOC: Renal and urinary disorders	Double-blind period	Sparsentan	202	6 (3.0)
		Irbesartan	202	4 (2.0)
PT: Acute kidney injury	Double-blind period	Sparsentan	202	3 (1.5)
		Irbesartan	202	0 (0.0)
PT: Chronic kidney disease	Double-blind period	Sparsentan	202	2 (1.0)
		Irbesartan	202	0 (0.0)
PT: Glomerulonephritis rapidly progressive	Double-blind period	Sparsentan	202	0 (0.0)
		Irbesartan	202	1 (0.5)
PT: IgA nephropathy	Double-blind period	Sparsentan	202	0 (0.0)
		Irbesartan	202	1 (0.5)
PT: Nephrotic syndrome	Double-blind period	Sparsentan	202	0 (0.0)
		Irbesartan	202	1 (0.5)
PT: Renal impairment	Double-blind period	Sparsentan	202	1 (0.5)
		Irbesartan	202	2 (1.0)
SOC: Skin and subcutaneous tissue disorders	Double-blind period	Sparsentan	202	1 (0.5)
		Irbesartan	202	1 (0.5)

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Source Data: aae, created on: 30JAN2024

Table PT1AT_SMSD: Incidence of TEAEs leading to study drug discontinuation during double-blind period by SOC/PT
Safety Set

TEAEs leading to study drug discontinuation				
SOC/PT	Time	Treatment	N	n (%)
PT: Rash	Double-blind period	Sparsentan	202	1 (0.5)
		Irbesartan	202	1 (0.5)
SOC: Vascular disorders	Double-blind period	Sparsentan	202	2 (1.0)
		Irbesartan	202	0 (0.0)
PT: Hypotension	Double-blind period	Sparsentan	202	1 (0.5)
		Irbesartan	202	0 (0.0)
PT: Orthostatic hypotension	Double-blind period	Sparsentan	202	1 (0.5)
		Irbesartan	202	0 (0.0)

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Source Data: aae, created on: 30JAN2024

Table PT1AD_SMSD: Incidence of fatal TEAEs during double-blind period by SOC/PT
Safety Set

No deaths observed.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Source Data: aae, created on: 30JAN2024

Table PT1AEF_SMI0: Incidence of AESI abnormal liver function during double-blind period
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI abnormal liver function	Double-blind period	Sparsentan	202	4 (2.0)	1.000 [0.254, 3.944]	1.000 [0.247, 4.055]	0.0 [-3.2, 3.2]	1.000
		Irbesartan	202	4 (2.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEFN_SMI0: Incidence of AESI abnormal liver function during double-blind period – non-severe
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI abnormal liver function - non-severe	Double-blind period	Sparsentan	202	4 (2.0)	1.000 [0.254, 3.944]	1.000 [0.247, 4.055]	0.0 [-3.2, 3.2]	1.000
		Irbesartan	202	4 (2.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEFC_SMI0: Incidence of AESI abnormal liver function during double-blind period – severe
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI abnormal liver function - severe	Double-blind period	Sparsentan	202	1 (0.5)	3.000 + [0.123, 73.208]	3.015 + [0.122, 74.448]	0.5 [-1.0, 2.0]	1.000
		Irbesartan	202	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEFS_SMI0: Incidence of AESI abnormal liver function during double-blind period – serious
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI abnormal liver function - serious	Double-blind period	Sparsentan	202	0 (0.0)	0.333 + [0.014, 8.134]	0.332 + [0.013, 8.191]	-0.5 [-2.0, 1.0]	1.000
		Irbesartan	202	1 (0.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEV_SMI0: Incidence of AESI COVID-19 during double-blind period
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI COVID-19	Double-blind period	Sparsentan	202	5 (2.5)	0.625 [0.208, 1.878]	0.615 [0.198, 1.914]	-1.5 [-5.4, 2.4]	0.575
		Irbesartan	202	8 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEVN_SMI0: Incidence of AESI COVID-19 during double-blind period – non-severe
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI COVID-19 - non-severe	Double-blind period	Sparsentan	202	3 (1.5)	0.429 [0.112, 1.634]	0.420 [0.107, 1.647]	-2.0 [-5.5, 1.5]	0.338
		Irbesartan	202	7 (3.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEVC_SMI0: Incidence of AESI COVID-19 during double-blind period – severe
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI COVID-19 - severe	Double-blind period	Sparsentan	202	2 (1.0)	2.000 [0.183, 21.882]	2.010 [0.181, 22.344]	0.5 [-1.7, 2.7]	1.000
		Irbesartan	202	1 (0.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEVS_SMI0: Incidence of AESI COVID-19 during double-blind period – serious
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI COVID-19 - serious	Double-blind period	Sparsentan	202	3 (1.5)	0.500 [0.127, 1.972]	0.492 [0.121, 1.997]	-1.5 [-4.9, 1.9]	0.503
		Irbesartan	202	6 (3.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEC_SMI0: Incidence of AESI cardiovascular system during double-blind period
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI cardiovascular system	Double-blind period	Sparsentan	202	51 (25.2)	1.244 [0.866, 1.786]	1.326 [0.831, 2.116]	5.0 [-3.7, 13.6]	0.286
		Irbesartan	202	41 (20.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AECN_SMI0: Incidence of AESI cardiovascular system during double-blind period – non-severe
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI cardiovascular system - non-severe	Double-blind period	Sparsentan	202	50 (24.8)	1.250 [0.866, 1.805]	1.332 [0.832, 2.134]	5.0 [-3.6, 13.5]	0.282
		Irbesartan	202	40 (19.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AECC_SMI0: Incidence of AESI cardiovascular system during double-blind period – severe
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI cardiovascular system - severe	Double-blind period	Sparsentan	202	1 (0.5)	1.000 [0.063, 15.878]	1.000 [0.062, 16.098]	0.0 [-1.9, 1.9]	1.000
		Irbesartan	202	1 (0.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AECS_SMI0: Incidence of AESI cardiovascular system during double-blind period – serious
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI cardiovascular system - serious	Double-blind period	Sparsentan	202	1 (0.5)	0.500 [0.046, 5.471]	0.498 [0.045, 5.531]	-0.5 [-2.7, 1.7]	1.000
		Irbesartan	202	2 (1.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEH_SMI0: Incidence of AESI hypotension during double-blind period
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
AESI hypotension	Double-blind period	Sparsentan	202	50 (24.8)	2.381 [1.487, 3.813]	2.835 [1.630, 4.931]	14.4 [6.6, 22.1]	<0.001	*
		Irbesartan	202	21 (10.4)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEHN_SMI0: Incidence of AESI hypotension during double-blind period – non-severe
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
AESI hypotension - non-severe	Double-blind period	Sparsentan	202	49 (24.3)	2.333 [1.455, 3.743]	2.760 [1.585, 4.807]	13.9 [6.1, 21.6]	<0.001	*
		Irbesartan	202	21 (10.4)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEHC_SMI0: Incidence of AESI hypotension during double-blind period – severe
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI hypotension - severe	Double-blind period	Sparsentan	202	1 (0.5)	3.000 + [0.123, 73.208]	3.015 + [0.122, 74.448]	0.5 [-1.0, 2.0]	1.000
		Irbesartan	202	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEHS_SMI0: Incidence of AESI hypotension during double-blind period – serious
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI hypotension - serious	Double-blind period	Sparsentan	202	3 (1.5)	3.000 [0.315, 28.599]	3.030 [0.313, 29.378]	1.0 [-1.4, 3.4]	0.623
		Irbesartan	202	1 (0.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEL_SMI0: Incidence of AESI hepatic disorders during double-blind period
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI hepatic disorders	Double-blind period	Sparsentan	202	13 (6.4)	1.857 [0.757, 4.558]	1.916 [0.748, 4.907]	3.0 [-1.7, 7.7]	0.251
		Irbesartan	202	7 (3.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AELN_SMI0: Incidence of AESI hepatic disorders during double-blind period – non-severe
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI hepatic disorders - non-severe	Double-blind period	Sparsentan	202	13 (6.4)	1.857 [0.757, 4.558]	1.916 [0.748, 4.907]	3.0 [-1.7, 7.7]	0.251
		Irbesartan	202	7 (3.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AELC_SMI0: Incidence of AESI hepatic disorders during double-blind period – severe
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI hepatic disorders - severe	Double-blind period	Sparsentan	202	1 (0.5)	3.000 + [0.123, 73.208]	3.015 + [0.122, 74.448]	0.5 [-1.0, 2.0]	1.000
		Irbesartan	202	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AELS_SMI0: Incidence of AESI hepatic disorders during double-blind period – serious
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI hepatic disorders - serious	Double-blind period	Sparsentan	202	0 (0.0)	0.333 + [0.014, 8.134]	0.332 + [0.013, 8.191]	-0.5 [-2.0, 1.0]	1.000
		Irbesartan	202	1 (0.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEP_SMI0: Incidence of AESI acute pancreatitis during double-blind period
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI acute pancreatitis	Double-blind period	Sparsentan	202	13 (6.4)	1.625 [0.688, 3.836]	1.668 [0.676, 4.116]	2.5 [-2.3, 7.3]	0.370
		Irbesartan	202	8 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEPN_SMI0: Incidence of AESI acute pancreatitis during double-blind period – non-severe
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI acute pancreatitis - non-severe	Double-blind period	Sparsentan	202	13 (6.4)	1.625 [0.688, 3.836]	1.668 [0.676, 4.116]	2.5 [-2.3, 7.3]	0.370
		Irbesartan	202	8 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEPC_SMI0: Incidence of AESI acute pancreatitis during double-blind period – severe
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI acute pancreatitis - severe	Double-blind period	Sparsentan	202	0 (0.0)				NE
		Irbesartan	202	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEPS_SMI0: Incidence of AESI acute pancreatitis during double-blind period – serious
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI acute pancreatitis - serious	Double-blind period	Sparsentan	202	0 (0.0)				NE
		Irbesartan	202	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEO_SMI0: Incidence of AESI fluid retention during double-blind period
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI fluid retention	Double-blind period	Sparsentan	202	28 (13.9)	1.556 [0.889, 2.721]	1.645 [0.878, 3.080]	5.0 [-1.7, 11.6]	0.158
		Irbesartan	202	18 (8.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEON_SMI0: Incidence of AESI fluid retention during double-blind period – non-severe
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI fluid retention - non-severe	Double-blind period	Sparsentan	202	28 (13.9)	1.556 [0.889, 2.721]	1.645 [0.878, 3.080]	5.0 [-1.7, 11.6]	0.158
		Irbesartan	202	18 (8.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEOC_SMI0: Incidence of AESI fluid retention during double-blind period – severe
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI fluid retention - severe	Double-blind period	Sparsentan	202	0 (0.0)				NE
		Irbesartan	202	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEOS_SMI0: Incidence of AESI fluid retention during double-blind period – serious
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI fluid retention - serious	Double-blind period	Sparsentan	202	1 (0.5)	3.000 + [0.123, 73.208]	3.015 + [0.122, 74.448]	0.5 [-1.0, 2.0]	1.000
		Irbesartan	202	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEA_SMI0: Incidence of AESI anemia during double-blind period
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI anemia	Double-blind period	Sparsentan	202	13 (6.4)	1.857 [0.757, 4.558]	1.916 [0.748, 4.907]	3.0 [-1.7, 7.7]	0.251
		Irbesartan	202	7 (3.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEAN_SMI0: Incidence of AESI anemia during double-blind period – non-severe
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI anemia - non-severe	Double-blind period	Sparsentan	202	13 (6.4)	1.857 [0.757, 4.558]	1.916 [0.748, 4.907]	3.0 [-1.7, 7.7]	0.251
		Irbesartan	202	7 (3.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEAC_SMI0: Incidence of AESI anemia during double-blind period – severe
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI anemia - severe	Double-blind period	Sparsentan	202	0 (0.0)				NE
		Irbesartan	202	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEAS_SMI0: Incidence of AESI anemia during double-blind period – serious
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI anemia - serious	Double-blind period	Sparsentan	202	1 (0.5)	3.000 + [0.123, 73.208]	3.015 + [0.122, 74.448]	0.5 [-1.0, 2.0]	1.000
		Irbesartan	202	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEU_SMI0: Incidence of AESI hyperkalemia during double-blind period
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI hyperkalemia	Double-blind period	Sparsentan	202	23 (11.4)	1.211 [0.681, 2.152]	1.238 [0.652, 2.351]	2.0 [-4.5, 8.4]	0.625
		Irbesartan	202	19 (9.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEUN_SMI0: Incidence of AESI hyperkalemia during double-blind period – non-severe
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI hyperkalemia - non-severe	Double-blind period	Sparsentan	202	23 (11.4)	1.211 [0.681, 2.152]	1.238 [0.652, 2.351]	2.0 [-4.5, 8.4]	0.625
		Irbesartan	202	19 (9.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEUC_SMI0: Incidence of AESI hyperkalemia during double-blind period – severe
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI hyperkalemia - severe	Double-blind period	Sparsentan	202	0 (0.0)				NE
		Irbesartan	202	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEUS_SMI0: Incidence of AESI hyperkalemia during double-blind period – serious
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI hyperkalemia - serious	Double-blind period	Sparsentan	202	0 (0.0)				NE
		Irbesartan	202	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEY_SMI0: Incidence of AESI cardiac arrhythmias during double-blind period
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI cardiac arrhythmias	Double-blind period	Sparsentan	202	9 (4.5)	0.600 [0.269, 1.339]	0.581 [0.248, 1.361]	-3.0 [-8.1, 2.1]	0.293
		Irbesartan	202	15 (7.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEYN_SMI0: Incidence of AESI cardiac arrhythmias during double-blind period – non-severe
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI cardiac arrhythmias - non-severe	Double-blind period	Sparsentan	202	9 (4.5)	0.600 [0.269, 1.339]	0.581 [0.248, 1.361]	-3.0 [-8.1, 2.1]	0.293
		Irbesartan	202	15 (7.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEYC_SMI0: Incidence of AESI cardiac arrhythmias during double-blind period – severe
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI cardiac arrhythmias - severe	Double-blind period	Sparsentan	202	0 (0.0)				NE
		Irbesartan	202	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEYS_SMI0: Incidence of AESI cardiac arrhythmias during double-blind period – serious
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI cardiac arrhythmias - serious	Double-blind period	Sparsentan	202	0 (0.0)				NE
		Irbesartan	202	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEI_SMI0: Incidence of AESI acute kidney injury during double-blind period
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI acute kidney injury	Double-blind period	Sparsentan	202	8 (4.0)	2.667 [0.718, 9.908]	2.735 [0.715, 10.463]	2.5 [-1.2, 6.1]	0.220
		Irbesartan	202	3 (1.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEIN_SMI0: Incidence of AESI acute kidney injury during double-blind period – non-severe
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI acute kidney injury - non-severe	Double-blind period	Sparsentan	202	5 (2.5)	1.667 [0.404, 6.881]	1.684 [0.397, 7.140]	1.0 [-2.2, 4.2]	0.724
		Irbesartan	202	3 (1.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEIC_SMI0: Incidence of AESI acute kidney injury during double-blind period – severe
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI acute kidney injury - severe	Double-blind period	Sparsentan	202	3 (1.5)	7.000 + [0.364, 134.653]	7.105 + [0.365, 138.444]	1.5 [-0.7, 3.6]	0.248
		Irbesartan	202	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1AEIS_SMI0: Incidence of AESI acute kidney injury during double-blind period – serious
Safety Set

Variable	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
AESI acute kidney injury - serious	Double-blind period	Sparsentan	202	4 (2.0)	4.000 [0.451, 35.478]	4.061 [0.450, 36.650]	1.5 [-1.2, 4.1]	0.372
		Irbesartan	202	1 (0.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Source Data: aae, created on: 30JAN2024

Table PT1RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis					
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)			
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value	
Sex	Overall	Sparsentan						Interaction:	0.007	#
Male	Week 6	Sparsentan	139	132 (95.0)	-41.52	(-47.37, -35.02)	0.596	(0.514, 0.691)	<0.001	*
		Irbesartan	143	137 (95.8)	-1.91	(-11.56, 8.79)				
	Week 36	Sparsentan	139	92 (66.2)	-47.16	(-53.12, -40.44)	0.584	(0.494, 0.691)	<0.001	*
		Irbesartan	143	97 (67.8)	-9.58	(-19.51, 1.57)				
	Week 58	Sparsentan	139	69 (49.6)	-46.10	(-52.99, -38.20)	0.583	(0.482, 0.706)	<0.001	*
		Irbesartan	143	73 (51.0)	-7.58	(-19.06, 5.52)				
Female	Week 6	Sparsentan	63	59 (93.7)	-34.05	(-43.52, -22.99)	0.813	(0.650, 1.017)	0.070	
		Irbesartan	59	54 (91.5)	-18.86	(-30.90, -4.71)				
	Week 36	Sparsentan	63	47 (74.6)	-49.63	(-57.44, -40.38)	0.709	(0.551, 0.913)	0.008	*
		Irbesartan	59	35 (59.3)	-28.97	(-41.10, -14.34)				
	Week 58	Sparsentan	63	44 (69.8)	-46.91	(-55.50, -36.66)	0.788	(0.596, 1.042)	0.094	
		Irbesartan	59	26 (44.1)	-32.61	(-45.67, -16.41)				

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 56 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 58 are included in the model.
An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT1RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis				
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)		
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value
Age	Overall	Sparsentan						Interaction:	0.591
<= 45 years	Week 6	Sparsentan	96	91 (94.8)	-44.39	(-51.02, -36.86)	0.613	(0.513, 0.732)	<0.001 *
		Irbesartan	99	95 (96.0)	-9.23	(-19.88, 2.84)			
	Week 36	Sparsentan	96	66 (68.8)	-50.03	(-56.62, -42.44)	0.658	(0.539, 0.804)	<0.001 *
		Irbesartan	99	64 (64.6)	-24.09	(-34.09, -12.57)			
	Week 58	Sparsentan	96	51 (53.1)	-47.04	(-54.84, -37.90)	0.672	(0.534, 0.845)	<0.001 *
		Irbesartan	99	45 (45.5)	-21.20	(-33.16, -7.11)			
> 45 years	Week 6	Sparsentan	106	100 (94.3)	-34.61	(-41.96, -26.32)	0.691	(0.583, 0.819)	<0.001 *
		Irbesartan	103	96 (93.2)	-5.36	(-16.16, 6.84)			
	Week 36	Sparsentan	106	73 (68.9)	-46.28	(-53.04, -38.54)	0.576	(0.475, 0.699)	<0.001 *
		Irbesartan	103	68 (66.0)	-6.79	(-18.79, 6.99)			
	Week 58	Sparsentan	106	62 (58.5)	-45.60	(-53.02, -37.00)	0.599	(0.484, 0.742)	<0.001 *
		Irbesartan	103	54 (52.4)	-9.21	(-22.22, 5.97)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 56 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 58 are included in the model.
An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT1RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis				
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)		
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value
Age at IgAN diagnosis	Overall	Sparsentan						Interaction:	0.490
<= 18 years	Week 6	Sparsentan	9	8 (88.9)	-48.45	(-70.11, -11.09)	0.554	(0.210, 1.461)	0.212
		Irbesartan	5	5 (100.0)	-6.98	(-55.78, 95.70)			
	Week 36	Sparsentan	9	6 (66.7)	-35.09	(-64.13, 17.45)	0.921	(0.296, 2.868)	0.882
		Irbesartan	5	2 (40.0)	-29.55	(-72.79, 82.41)			
	Week 58	Sparsentan	9	4 (44.4)	-52.57	(-75.56, -7.94)	1.441	(0.369, 5.630)	0.587
		Irbesartan	5	1 (20.0)	-67.08	(-89.97, 8.07)			
> 18 to 40 years	Week 6	Sparsentan	102	98 (96.1)	-43.71	(-49.93, -36.71)	0.628	(0.534, 0.740)	<0.001 *
		Irbesartan	109	104 (95.4)	-10.42	(-20.04, 0.36)			
	Week 36	Sparsentan	102	69 (67.6)	-50.14	(-56.34, -43.07)	0.627	(0.521, 0.754)	<0.001 *
		Irbesartan	109	72 (66.1)	-20.47	(-30.05, -9.57)			
	Week 58	Sparsentan	102	58 (56.9)	-48.71	(-55.67, -40.65)	0.623	(0.506, 0.768)	<0.001 *
		Irbesartan	109	52 (47.7)	-17.73	(-29.08, -4.55)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 56 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 58 are included in the model.
An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT1RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis					
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)			
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value	
> 40 years	Week 6	Sparsentan	91	85 (93.4)	-32.26	(-40.74, -22.56)	0.711	(0.587, 0.860)	<0.001	*
		Irbesartan	88	82 (93.2)	-4.67	(-16.75, 9.18)				
	Week 36	Sparsentan	91	64 (70.3)	-46.19	(-53.61, -37.59)	0.599	(0.484, 0.741)	<0.001	*
		Irbesartan	88	58 (65.9)	-10.13	(-22.92, 4.79)				
	Week 58	Sparsentan	91	51 (56.0)	-42.02	(-50.84, -31.62)	0.655	(0.516, 0.832)	<0.001	*
		Irbesartan	88	46 (52.3)	-11.53	(-25.55, 5.14)				

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 56 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 58 are included in the model.
An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT1RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis					
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)			
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value	
Geographic region	Overall	Sparsentan						Interaction:	0.597	
North America	Week 6	Sparsentan	35	32 (91.4)	-29.17	(-41.34, -14.47)	0.688	(0.536, 0.884)	0.004	*
		Irbesartan	46	43 (93.5)	2.89	(-12.62, 21.15)				
	Week 36	Sparsentan	35	18 (51.4)	-47.67	(-58.60, -33.87)	0.465	(0.341, 0.633)	<0.001	*
		Irbesartan	46	25 (54.3)	12.60	(-7.81, 37.52)				
	Week 58	Sparsentan	35	12 (34.3)	-37.97	(-53.27, -17.67)	0.588	(0.407, 0.850)	0.005	*
		Irbesartan	46	18 (39.1)	5.52	(-16.53, 33.39)				
Europe	Week 6	Sparsentan	98	91 (92.9)	-43.23	(-49.90, -35.68)	0.626	(0.528, 0.742)	<0.001	*
		Irbesartan	115	108 (93.9)	-9.26	(-19.15, 1.83)				
	Week 36	Sparsentan	98	60 (61.2)	-47.91	(-54.96, -39.77)	0.642	(0.529, 0.780)	<0.001	*
		Irbesartan	115	78 (67.8)	-18.92	(-28.75, -7.73)				
	Week 58	Sparsentan	98	48 (49.0)	-44.23	(-52.68, -34.27)	0.657	(0.527, 0.820)	<0.001	*
		Irbesartan	115	57 (49.6)	-15.11	(-26.78, -1.59)				

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 56 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 58 are included in the model.
An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT1RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis					
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)			
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value	
Asia Pacific	Week 6	Sparsentan	69	68 (98.6)	-39.98	(-48.57, -29.96)	0.656	(0.509, 0.845)	0.001	*
		Irbesartan	41	40 (97.6)	-8.54	(-25.13, 11.73)				
	Week 36	Sparsentan	69	61 (88.4)	-48.71	(-56.29, -39.82)	0.684	(0.521, 0.897)	0.006	*
		Irbesartan	41	29 (70.7)	-24.97	(-39.74, -6.58)				
	Week 58	Sparsentan	69	53 (76.8)	-50.99	(-58.60, -41.97)	0.676	(0.502, 0.910)	0.010	*
		Irbesartan	41	24 (58.5)	-27.50	(-43.21, -7.43)				

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 56 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 58 are included in the model.
An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT1RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis				
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)		
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value
Baseline BMI	Overall	Sparsentan						Interaction:	0.714
< 27 kg/m**2	Week 6	Sparsentan	84	77 (91.7)	-43.64	(-50.72, -35.54)	0.644	(0.536, 0.775)	<0.001 *
		Irbesartan	94	90 (95.7)	-12.52	(-22.83, -0.83)			
	Week 36	Sparsentan	84	59 (70.2)	-52.39	(-58.95, -44.78)	0.672	(0.547, 0.827)	<0.001 *
		Irbesartan	94	59 (62.8)	-29.19	(-38.65, -18.28)			
	Week 58	Sparsentan	84	46 (54.8)	-57.42	(-63.86, -49.84)	0.595	(0.470, 0.753)	<0.001 *
		Irbesartan	94	41 (43.6)	-28.44	(-39.51, -15.34)			
>= 27 kg/m**2	Week 6	Sparsentan	118	114 (96.6)	-35.51	(-42.38, -27.81)	0.661	(0.561, 0.779)	<0.001 *
		Irbesartan	107	100 (93.5)	-2.46	(-13.42, 9.89)			
	Week 36	Sparsentan	118	80 (67.8)	-44.50	(-51.16, -36.94)	0.568	(0.472, 0.684)	<0.001 *
		Irbesartan	107	72 (67.3)	-2.31	(-14.60, 11.75)			
	Week 58	Sparsentan	118	67 (56.8)	-36.42	(-44.80, -26.76)	0.661	(0.538, 0.813)	<0.001 *
		Irbesartan	107	58 (54.2)	-3.84	(-17.23, 11.71)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 56 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 58 are included in the model.
An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT1RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis				
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)		
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value
Randomization strata	Overall	Sparsentan						Interaction:	0.549
eGFR Low and UP High	Week 6	Sparsentan	71	67 (94.4)	-33.04	(-41.81, -22.94)	0.673	(0.553, 0.819)	<0.001 *
		Irbesartan	74	70 (94.6)	-0.46	(-13.26, 14.24)			
	Week 36	Sparsentan	71	49 (69.0)	-41.33	(-49.90, -31.30)	0.640	(0.512, 0.799)	<0.001 *
		Irbesartan	74	48 (64.9)	-8.27	(-21.63, 7.36)			
	Week 58	Sparsentan	71	42 (59.2)	-44.06	(-52.90, -33.56)	0.591	(0.461, 0.757)	<0.001 *
		Irbesartan	74	37 (50.0)	-5.37	(-20.82, 13.09)			
eGFR Low and UP Low	Week 6	Sparsentan	55	51 (92.7)	-37.53	(-47.44, -25.76)	0.713	(0.559, 0.910)	0.007 *
		Irbesartan	55	53 (96.4)	-12.42	(-26.22, 3.96)			
	Week 36	Sparsentan	55	37 (67.3)	-42.23	(-52.27, -30.08)	0.654	(0.500, 0.854)	0.002 *
		Irbesartan	55	39 (70.9)	-11.61	(-26.72, 6.61)			
	Week 58	Sparsentan	55	29 (52.7)	-41.89	(-53.12, -27.98)	0.766	(0.567, 1.036)	0.083
		Irbesartan	55	30 (54.5)	-24.18	(-38.60, -6.38)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 56 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 58 are included in the model.
An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT1RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis				
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)		
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value
eGFR High and UP High	Week 6	Sparsentan	37	34 (91.9)	-46.21	(-56.95, -32.78)	0.574	(0.417, 0.789)	<0.001 *
		Irbesartan	36	32 (88.9)	-6.25	(-25.31, 17.68)			
	Week 36	Sparsentan	37	26 (70.3)	-57.31	(-66.64, -45.37)	0.544	(0.379, 0.782)	0.001 *
		Irbesartan	36	20 (55.6)	-21.57	(-39.86, 2.28)			
	Week 58	Sparsentan	37	19 (51.4)	-56.06	(-66.78, -41.87)	0.530	(0.349, 0.804)	0.003 *
		Irbesartan	36	15 (41.7)	-17.06	(-39.10, 12.95)			
eGFR High and UP Low	Week 6	Sparsentan	39	39 (100.0)	-46.90	(-56.32, -35.46)	0.604	(0.457, 0.799)	<0.001 *
		Irbesartan	37	36 (97.3)	-12.08	(-28.03, 7.41)			
	Week 36	Sparsentan	39	27 (69.2)	-58.69	(-66.98, -48.31)	0.581	(0.421, 0.801)	0.001 *
		Irbesartan	37	25 (67.6)	-28.87	(-43.53, -10.42)			
	Week 58	Sparsentan	39	23 (59.0)	-48.85	(-59.91, -34.75)	0.611	(0.425, 0.880)	0.008 *
		Irbesartan	37	17 (45.9)	-16.32	(-36.14, 9.67)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 56 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 58 are included in the model.
An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT1RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis				
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)		
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value
Baseline eGFR Group 1	Overall	Sparsentan						Interaction:	0.020 #
< 60 mL/min/1.73 m**2	Week 6	Sparsentan	127	119 (93.7)	-35.57	(-42.18, -28.21)	0.679	(0.583, 0.791)	<0.001 *
		Irbesartan	129	124 (96.1)	-5.13	(-14.76, 5.58)			
	Week 36	Sparsentan	127	88 (69.3)	-40.53	(-47.26, -32.93)	0.666	(0.562, 0.789)	<0.001 *
		Irbesartan	129	88 (68.2)	-10.70	(-20.75, 0.64)			
	Week 58	Sparsentan	127	71 (55.9)	-42.52	(-49.71, -34.29)	0.674	(0.558, 0.815)	<0.001 *
		Irbesartan	129	70 (54.3)	-14.72	(-25.39, -2.52)			
60 to < 90 mL/min/1.73 m**2	Week 6	Sparsentan	49	48 (98.0)	-46.47	(-55.50, -35.61)	0.520	(0.399, 0.679)	<0.001 *
		Irbesartan	48	44 (91.7)	2.89	(-14.85, 24.33)			
	Week 36	Sparsentan	49	31 (63.3)	-58.39	(-66.51, -48.30)	0.439	(0.323, 0.596)	<0.001 *
		Irbesartan	48	32 (66.7)	-5.14	(-23.44, 17.54)			
	Week 58	Sparsentan	49	24 (49.0)	-51.34	(-61.92, -37.82)	0.478	(0.334, 0.685)	<0.001 *
		Irbesartan	48	19 (39.6)	1.73	(-21.80, 32.33)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 56 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 58 are included in the model.
An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT1RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis				
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)		
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value
>= 90 mL/min/1.73 m**2	Week 6	Sparsentan	26	24 (92.3)	-44.00	(-55.69, -29.24)	0.785	(0.561, 1.099)	0.157
		Irbesartan	25	23 (92.0)	-28.68	(-43.87, -9.36)			
	Week 36	Sparsentan	26	20 (76.9)	-61.41	(-70.12, -50.18)	0.802	(0.540, 1.192)	0.273
		Irbesartan	25	12 (48.0)	-51.89	(-64.37, -35.02)			
	Week 58	Sparsentan	26	18 (69.2)	-56.32	(-66.65, -42.79)	0.723	(0.467, 1.121)	0.146
		Irbesartan	25	10 (40.0)	-39.62	(-57.15, -14.92)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 56 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 58 are included in the model.
An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT1RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis					
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)			
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value	
Baseline eGFR Group 2	Overall	Sparsentan						Interaction:	0.008	#
< 45 mL/min/1.73 m**2	Week 6	Sparsentan	82	77 (93.9)	-30.54	(-39.74, -19.94)	0.756	(0.618, 0.924)	0.007	*
		Irbesartan	80	78 (97.5)	-8.07	(-20.30, 6.04)				
	Week 36	Sparsentan	82	55 (67.1)	-36.00	(-45.40, -24.99)	0.729	(0.584, 0.911)	0.006	*
		Irbesartan	80	57 (71.3)	-12.24	(-24.94, 2.60)				
	Week 58	Sparsentan	82	45 (54.9)	-41.80	(-51.19, -30.61)	0.728	(0.568, 0.932)	0.012	*
		Irbesartan	80	45 (56.3)	-20.07	(-32.82, -4.89)				
45 to < 60 mL/min/1.73 m**2	Week 6	Sparsentan	45	42 (93.3)	-43.85	(-52.20, -34.05)	0.562	(0.449, 0.703)	<0.001	*
		Irbesartan	49	46 (93.9)	-0.04	(-14.38, 16.69)				
	Week 36	Sparsentan	45	33 (73.3)	-47.50	(-56.01, -37.34)	0.567	(0.439, 0.731)	<0.001	*
		Irbesartan	49	31 (63.3)	-7.34	(-22.66, 11.02)				
	Week 58	Sparsentan	45	26 (57.8)	-43.16	(-53.42, -30.65)	0.583	(0.438, 0.777)	<0.001	*
		Irbesartan	49	25 (51.0)	-2.53	(-20.53, 19.55)				

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 56 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 58 are included in the model.
An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT1RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis				
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)		
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value
60 to < 90 mL/min/1.73 m**2	Week 6	Sparsentan	49	48 (98.0)	-46.47	(-55.50, -35.61)	0.520	(0.399, 0.679)	<0.001 *
		Irbesartan	48	44 (91.7)	2.89	(-14.85, 24.33)			
	Week 36	Sparsentan	49	31 (63.3)	-58.39	(-66.51, -48.30)	0.439	(0.323, 0.596)	<0.001 *
		Irbesartan	48	32 (66.7)	-5.14	(-23.44, 17.54)			
	Week 58	Sparsentan	49	24 (49.0)	-51.34	(-61.92, -37.82)	0.478	(0.334, 0.685)	<0.001 *
		Irbesartan	48	19 (39.6)	1.73	(-21.80, 32.33)			
>= 90 mL/min/1.73 m**2	Week 6	Sparsentan	26	24 (92.3)	-44.00	(-55.69, -29.24)	0.785	(0.561, 1.099)	0.157
		Irbesartan	25	23 (92.0)	-28.68	(-43.87, -9.36)			
	Week 36	Sparsentan	26	20 (76.9)	-61.41	(-70.12, -50.18)	0.802	(0.540, 1.192)	0.273
		Irbesartan	25	12 (48.0)	-51.89	(-64.37, -35.02)			
	Week 58	Sparsentan	26	18 (69.2)	-56.32	(-66.65, -42.79)	0.723	(0.467, 1.121)	0.146
		Irbesartan	25	10 (40.0)	-39.62	(-57.15, -14.92)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 56 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 58 are included in the model.
An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT1RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis					
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)			
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value	
Baseline urine protein excretion	Overall	Sparsentan						Interaction:	0.252	
<= 1.75 g/day	Week 6	Sparsentan	98	93 (94.9)	-34.02	(-42.13, -24.78)	0.694	(0.575, 0.837)	<0.001	*
		Irbesartan	94	89 (94.7)	-4.91	(-16.79, 8.66)				
	Week 36	Sparsentan	98	73 (74.5)	-43.10	(-50.70, -34.33)	0.634	(0.514, 0.783)	<0.001	*
		Irbesartan	94	61 (64.9)	-10.31	(-23.04, 4.51)				
	Week 58	Sparsentan	98	61 (62.2)	-39.64	(-48.34, -29.48)	0.711	(0.558, 0.905)	0.006	*
		Irbesartan	94	38 (40.4)	-15.08	(-29.45, 2.22)				
> 1.75 g/day	Week 6	Sparsentan	104	98 (94.2)	-44.08	(-50.18, -37.23)	0.618	(0.526, 0.727)	<0.001	*
		Irbesartan	108	102 (94.4)	-9.50	(-19.20, 1.36)				
	Week 36	Sparsentan	104	66 (63.5)	-53.13	(-58.95, -46.48)	0.585	(0.486, 0.703)	<0.001	*
		Irbesartan	108	71 (65.7)	-19.84	(-29.44, -8.94)				
	Week 58	Sparsentan	104	52 (50.0)	-53.14	(-59.68, -45.54)	0.559	(0.455, 0.686)	<0.001	*
		Irbesartan	108	61 (56.5)	-16.12	(-27.07, -3.52)				

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 56 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 58 are included in the model.
An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT1RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis				
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)		
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value
Baseline use of antihypertensives	Overall	Sparsentan						Interaction:	0.576
Yes	Week 6	Sparsentan	88	82 (93.2)	-40.00	(-47.34, -31.64)	0.648	(0.537, 0.782)	<0.001 *
		Irbesartan	83	76 (91.6)	-7.36	(-19.08, 6.06)			
	Week 36	Sparsentan	88	57 (64.8)	-46.36	(-53.89, -37.61)	0.602	(0.486, 0.745)	<0.001 *
		Irbesartan	83	58 (69.9)	-10.91	(-23.33, 3.53)			
	Week 58	Sparsentan	88	46 (52.3)	-40.65	(-49.91, -29.68)	0.748	(0.589, 0.950)	0.017 *
		Irbesartan	83	46 (55.4)	-20.64	(-32.97, -6.05)			
No	Week 6	Sparsentan	114	109 (95.6)	-38.54	(-45.32, -30.92)	0.666	(0.565, 0.784)	<0.001 *
		Irbesartan	119	115 (96.6)	-7.65	(-17.57, 3.46)			
	Week 36	Sparsentan	114	82 (71.9)	-49.10	(-55.21, -42.15)	0.635	(0.529, 0.762)	<0.001 *
		Irbesartan	119	74 (62.2)	-19.80	(-29.60, -8.63)			
	Week 58	Sparsentan	114	67 (58.8)	-49.88	(-56.43, -42.36)	0.565	(0.460, 0.694)	<0.001 *
		Irbesartan	119	53 (44.5)	-11.33	(-23.72, 3.08)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 56 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 58 are included in the model.
An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT1RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis				
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)		
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value
Time since renal biopsy	Overall	Sparsentan						Interaction:	0.210
<= 5 years	Week 6	Sparsentan	113	104 (92.0)	-40.96	(-47.69, -33.37)	0.659	(0.558, 0.777)	<0.001 *
		Irbesartan	127	121 (95.3)	-10.38	(-19.95, 0.35)			
	Week 36	Sparsentan	113	73 (64.6)	-50.87	(-57.13, -43.69)	0.642	(0.531, 0.775)	<0.001 *
		Irbesartan	127	79 (62.2)	-23.43	(-32.78, -12.78)			
	Week 58	Sparsentan	113	58 (51.3)	-43.60	(-51.64, -34.22)	0.755	(0.610, 0.936)	0.010 *
		Irbesartan	127	60 (47.2)	-25.33	(-35.69, -13.31)			
> 5 years	Week 6	Sparsentan	89	87 (97.8)	-37.40	(-44.70, -29.12)	0.637	(0.529, 0.766)	<0.001 *
		Irbesartan	75	70 (93.3)	-1.71	(-14.28, 12.71)			
	Week 36	Sparsentan	89	66 (74.2)	-44.36	(-51.53, -36.12)	0.566	(0.461, 0.694)	<0.001 *
		Irbesartan	75	53 (70.7)	-1.63	(-15.44, 14.43)			
	Week 58	Sparsentan	89	55 (61.8)	-48.75	(-55.89, -40.46)	0.496	(0.395, 0.623)	<0.001 *
		Irbesartan	75	39 (52.0)	3.35	(-12.99, 22.76)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 56 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 58 are included in the model.
An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT1RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis					
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)			
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value	
History of hypertension	Overall	Sparsentan						Interaction:	0.196	
Yes	Week 6	Sparsentan	153	143 (93.5)	-37.84	(-43.71, -31.35)	0.679	(0.591, 0.781)	<0.001	*
		Irbesartan	157	146 (93.0)	-8.46	(-17.00, 0.96)				
	Week 36	Sparsentan	153	104 (68.0)	-45.14	(-50.92, -38.68)	0.644	(0.551, 0.753)	<0.001	*
		Irbesartan	157	105 (66.9)	-14.80	(-23.68, -4.88)				
	Week 58	Sparsentan	153	83 (54.2)	-42.85	(-49.52, -35.30)	0.679	(0.569, 0.809)	<0.001	*
		Irbesartan	157	80 (51.0)	-15.78	(-25.68, -4.57)				
No	Week 6	Sparsentan	49	48 (98.0)	-43.42	(-52.90, -32.03)	0.595	(0.456, 0.777)	<0.001	*
		Irbesartan	45	45 (100.0)	-4.89	(-21.43, 15.12)				
	Week 36	Sparsentan	49	35 (71.4)	-55.69	(-63.88, -45.64)	0.556	(0.410, 0.755)	<0.001	*
		Irbesartan	45	27 (60.0)	-20.36	(-36.33, -0.38)				
	Week 58	Sparsentan	49	30 (61.2)	-54.60	(-63.63, -43.31)	0.538	(0.381, 0.760)	<0.001	*
		Irbesartan	45	19 (42.2)	-15.67	(-35.12, 9.60)				

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 56 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 58 are included in the model.
An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Figure PF1RPR_FSGM: Percent change from baseline in UP/C by subgroup
Full Analysis Set
Study: PROTECT
Sex: Male



Sparsentan	132	92	69
Irbesartan	137	97	73

An increase reflects a worsening of the status of the patient. Results are presented in g/g. Analysis was performed on log-transformed data. Number of available records are presented for key visits up to Week 58 only.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. Reference table: PT1RPR_FSLM

Figure PF1RPR_FSGM: Percent change from baseline in UP/C by subgroup
Full Analysis Set
Study: PROTECT
Sex: Female



Sparsentan	59	47	44
Irbesartan	54	35	26

An increase reflects a worsening of the status of the patient. Results are presented in g/g. Analysis was performed on log-transformed data. Number of available records are presented for key visits up to Week 58 only.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. Reference table: PT1RPR_FSLM

Figure PF1RPR_FSGM: Percent change from baseline in UP/C by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 1: < 60 mL/min/1.73 m**2



Sparsentan	119	88	71
Irbesartan	124	88	70

An increase reflects a worsening of the status of the patient. Results are presented in g/g. Analysis was performed on log-transformed data. Number of available records are presented for key visits up to Week 58 only.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. Reference table: PT1RPR_FSLM

Figure PF1RPR_FSGM: Percent change from baseline in UP/C by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 1: 60 to < 90 mL/min/1.73 m**2



Sparsentan	48	31	24
Irbesartan	44	32	19

An increase reflects a worsening of the status of the patient. Results are presented in g/g. Analysis was performed on log-transformed data. Number of available records are presented for key visits up to Week 58 only.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. Reference table: PT1RPR_FSLM

Figure PF1RPR_FSGM: Percent change from baseline in UP/C by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 1: >= 90 mL/min/1.73 m**2



Sparsentan	24	20	18
Irbesartan	23	12	10

An increase reflects a worsening of the status of the patient. Results are presented in g/g. Analysis was performed on log-transformed data. Number of available records are presented for key visits up to Week 58 only.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. Reference table: PT1RPR_FSLM

Figure PF1RPR_FSGM: Percent change from baseline in UP/C by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 2: < 45 mL/min/1.73 m**2



Sparsentan	77	55	45
Irbesartan	78	57	45

An increase reflects a worsening of the status of the patient. Results are presented in g/g. Analysis was performed on log-transformed data. Number of available records are presented for key visits up to Week 58 only.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. Reference table: PT1RPR_FSLM

Figure PF1RPR_FSGM: Percent change from baseline in UP/C by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 2: 45 to < 60 mL/min/1.73 m**2



Sparsentan	42	33	26
Irbesartan	46	31	25

An increase reflects a worsening of the status of the patient. Results are presented in g/g. Analysis was performed on log-transformed data. Number of available records are presented for key visits up to Week 58 only.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. Reference table: PT1RPR_FSLM

Figure PF1RPR_FSGM: Percent change from baseline in UP/C by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 2: 60 to < 90 mL/min/1.73 m**2



Sparsentan	48	31	24
Irbesartan	44	32	19

An increase reflects a worsening of the status of the patient. Results are presented in g/g. Analysis was performed on log-transformed data. Number of available records are presented for key visits up to Week 58 only.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. Reference table: PT1RPR_FSLM

Figure PF1RPR_FSGM: Percent change from baseline in UP/C by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 2: >= 90 mL/min/1.73 m**2



Sparsentan	24	20	18
Irbesartan	23	12	10

An increase reflects a worsening of the status of the patient. Results are presented in g/g. Analysis was performed on log-transformed data. Number of available records are presented for key visits up to Week 58 only.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. Reference table: PT1RPR_FSLM

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Urine protein excretion	Baseline	Sparsentan	139	139 (100.0)	2.28 (1.37)	0.1	1.21	1.96	3.12	7.2	
			Irbesartan	143	143 (100.0)	2.25 (1.33)	0.5	1.34	1.85	2.85	7.5	
		Week 6	Sparsentan	139	132 (95.0)	1.59 (1.34)	0.2	0.63	1.17	2.08	6.5	
			Irbesartan	143	137 (95.8)	2.38 (1.69)	0.4	1.28	1.89	3.07	10.3	
		Week 36	Sparsentan	139	92 (66.2)	1.71 (1.78)	0.1	0.57	0.99	2.30	9.4	
			Irbesartan	143	98 (68.5)	2.26 (1.73)	0.2	1.02	1.87	2.84	9.2	
		Week 58	Sparsentan	139	69 (49.6)	1.70 (1.70)	0.1	0.49	1.21	2.11	7.5	
			Irbesartan	143	73 (51.0)	2.39 (1.77)	0.1	1.08	2.06	3.06	8.6	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	139	132 (95.0)	-0.75 (1.19)	-4.2	-1.41	-0.72	-0.11	5.2	-0.66 [-0.91, -0.41]
			Irbesartan	143	137 (95.8)	0.11 (1.39)	-3.7	-0.54	-0.11	0.72	8.4	
		Week 36	Sparsentan	139	92 (66.2)	-0.61 (1.36)	-4.1	-1.36	-0.67	-0.07	4.6	-0.40 [-0.69, -0.11]
			Irbesartan	143	98 (68.5)	-0.03 (1.55)	-3.3	-0.92	-0.21	0.65	6.5	
		Week 58	Sparsentan	139	69 (49.6)	-0.60 (1.43)	-4.4	-1.30	-0.62	0.07	3.3	-0.36 [-0.70, -0.03]
			Irbesartan	143	73 (51.0)	-0.06 (1.53)	-2.7	-0.89	-0.34	0.46	6.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Female	Urine protein excretion	Baseline	Sparsentan	63	63 (100.0)	2.09 (2.14)	0.5	1.15	1.45	2.32	14.7	
			Irbesartan	59	59 (100.0)	1.94 (0.97)	0.6	1.33	1.77	2.33	5.7	
		Week 6	Sparsentan	63	60 (95.2)	1.28 (0.83)	0.2	0.69	1.03	1.72	3.9	
			Irbesartan	59	54 (91.5)	1.67 (1.15)	0.4	0.93	1.36	2.24	7.6	
		Week 36	Sparsentan	63	47 (74.6)	1.02 (0.74)	0.1	0.56	0.80	1.32	3.5	
			Irbesartan	59	35 (59.3)	1.73 (1.43)	0.2	0.80	1.20	2.44	7.1	
		Week 58	Sparsentan	63	44 (69.8)	1.05 (0.70)	0.1	0.63	0.92	1.35	3.4	
			Irbesartan	59	25 (42.4)	1.42 (1.34)	0.2	0.65	1.03	1.94	6.8	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	63	60 (95.2)	-0.67 (1.84)	-13.0	-0.89	-0.45	-0.01	1.8	-0.29 [-0.66, 0.08]
			Irbesartan	59	54 (91.5)	-0.24 (0.86)	-1.8	-0.81	-0.19	0.12	3.0	
		Week 36	Sparsentan	63	47 (74.6)	-0.71 (1.04)	-4.2	-1.06	-0.66	-0.20	1.7	-0.50 [-0.95, -0.06]
			Irbesartan	59	35 (59.3)	-0.17 (1.12)	-2.0	-0.91	-0.29	0.18	2.6	
		Week 58	Sparsentan	63	44 (69.8)	-0.66 (1.04)	-3.7	-1.04	-0.59	-0.02	1.2	-0.16 [-0.65, 0.33]
			Irbesartan	59	25 (42.4)	-0.50 (0.89)	-2.1	-0.99	-0.55	-0.18	2.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
<= 45 years	Urine protein excretion	Baseline	Sparsentan	96	96 (100.0)	2.39 (2.00)	0.4	1.23	1.81	2.91	14.7	
			Irbesartan	99	99 (100.0)	2.18 (1.06)	0.5	1.41	1.92	2.70	5.9	
		Week 6	Sparsentan	96	91 (94.8)	1.45 (1.18)	0.2	0.60	1.07	1.95	6.2	
			Irbesartan	99	95 (96.0)	2.19 (1.63)	0.4	1.08	1.84	2.67	10.3	
		Week 36	Sparsentan	96	66 (68.8)	1.52 (1.49)	0.1	0.55	0.92	2.26	8.3	
			Irbesartan	99	65 (65.7)	2.08 (1.81)	0.2	0.81	1.45	2.74	9.2	
		Week 58	Sparsentan	96	51 (53.1)	1.56 (1.61)	0.1	0.57	0.96	2.11	7.5	
			Irbesartan	99	44 (44.4)	2.06 (1.94)	0.1	0.66	1.42	2.47	8.6	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	96	91 (94.8)	-0.90 (1.69)	-13.0	-1.29	-0.71	-0.03	2.1	-0.57 [-0.86, -0.27]
			Irbesartan	99	95 (96.0)	-0.02 (1.40)	-3.2	-0.70	-0.25	0.46	8.4	
		Week 36	Sparsentan	96	66 (68.8)	-0.62 (1.19)	-4.1	-1.09	-0.66	0.15	2.6	-0.33 [-0.67, 0.02]
			Irbesartan	99	65 (65.7)	-0.16 (1.61)	-3.3	-1.10	-0.32	0.49	6.5	
		Week 58	Sparsentan	96	51 (53.1)	-0.59 (1.42)	-4.2	-1.29	-0.46	0.17	3.3	-0.21 [-0.61, 0.20]
			Irbesartan	99	44 (44.4)	-0.26 (1.69)	-2.7	-1.07	-0.58	0.12	6.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 45 years	Urine protein excretion	Baseline	Sparsentan	106	106 (100.0)	2.08 (1.24)	0.1	1.12	1.76	2.81	6.3	
			Irbesartan	103	103 (100.0)	2.15 (1.40)	0.6	1.25	1.77	2.43	7.5	
		Week 6	Sparsentan	106	101 (95.3)	1.53 (1.24)	0.2	0.73	1.09	2.01	6.5	
			Irbesartan	103	96 (93.2)	2.17 (1.56)	0.4	1.09	1.65	2.74	9.5	
		Week 36	Sparsentan	106	73 (68.9)	1.43 (1.59)	0.1	0.60	0.91	1.59	9.4	
			Irbesartan	103	68 (66.0)	2.16 (1.52)	0.2	1.12	1.78	2.64	7.7	
		Week 58	Sparsentan	106	62 (58.5)	1.35 (1.26)	0.1	0.57	1.14	1.62	6.8	
			Irbesartan	103	54 (52.4)	2.20 (1.52)	0.1	1.05	1.99	2.94	7.2	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	106	101 (95.3)	-0.56 (1.12)	-3.8	-1.05	-0.57	-0.10	5.2	-0.54 [-0.82, -0.25]
			Irbesartan	103	96 (93.2)	0.04 (1.14)	-3.7	-0.54	-0.05	0.62	4.2	
		Week 36	Sparsentan	106	73 (68.9)	-0.67 (1.32)	-4.2	-1.27	-0.68	-0.27	4.6	-0.53 [-0.87, -0.19]
			Irbesartan	103	68 (66.0)	0.02 (1.28)	-2.5	-0.77	-0.13	0.59	4.2	
		Week 58	Sparsentan	106	62 (58.5)	-0.66 (1.17)	-4.4	-1.27	-0.65	-0.02	2.4	-0.48 [-0.85, -0.11]
			Irbesartan	103	54 (52.4)	-0.10 (1.14)	-2.1	-0.83	-0.27	0.39	3.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age at IgAN diagnosis												
<= 18 years	Urine protein excretion	Baseline	Sparsentan	9	9 (100.0)	3.85 (2.41)	1.2	2.78	3.07	4.00	9.7	
			Irbesartan	5	5 (100.0)	1.91 (1.00)	0.6	1.22	2.14	2.56	3.1	
		Week 6	Sparsentan	9	8 (88.9)	2.24 (1.77)	0.4	0.81	1.66	3.84	4.9	
			Irbesartan	5	5 (100.0)	2.01 (1.42)	0.6	1.18	1.73	2.27	4.3	
		Week 36	Sparsentan	9	6 (66.7)	2.63 (1.60)	0.6	1.50	2.62	3.82	4.6	
			Irbesartan	5	2 (40.0)	2.02 (1.30)	1.1	1.11	2.02	2.94	2.9	
		Week 58	Sparsentan	9	4 (44.4)	2.17 (2.17)	0.1	0.49	1.78	3.84	5.0	
			Irbesartan	5	1 (20.0)	0.57	0.6	0.57	0.57	0.57	0.6	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	9	8 (88.9)	-0.87 (1.57)	-2.5	-2.18	-1.03	-0.11	2.1	-0.66 [-1.80, 0.49]
			Irbesartan	5	5 (100.0)	0.09 (1.30)	-1.9	-0.02	0.13	0.51	1.7	
		Week 36	Sparsentan	9	6 (66.7)	-0.61 (1.48)	-3.1	-1.42	-0.32	0.60	0.9	-0.03 [-1.63, 1.57]
			Irbesartan	5	2 (40.0)	-0.57 (1.94)	-1.9	-1.95	-0.57	0.80	0.8	
		Week 58	Sparsentan	9	4 (44.4)	-1.04 (2.00)	-3.7	-2.42	-0.70	0.35	1.0	NE
			Irbesartan	5	1 (20.0)	-2.49	-2.5	-2.49	-2.49	-2.49	-2.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 18 to 40 years	Urine protein excretion	Baseline	Sparsentan	102	102 (100.0)	2.26 (1.79)	0.4	1.21	1.81	2.81	14.7	
			Irbesartan	109	109 (100.0)	2.21 (1.08)	0.5	1.42	1.96	2.70	5.9	
		Week 6	Sparsentan	102	98 (96.1)	1.40 (1.13)	0.2	0.60	1.06	1.80	6.2	
			Irbesartan	109	105 (96.3)	2.16 (1.48)	0.4	1.18	1.82	2.61	7.7	
		Week 36	Sparsentan	102	69 (67.6)	1.52 (1.68)	0.1	0.55	0.90	2.14	9.4	
			Irbesartan	109	73 (67.0)	2.00 (1.58)	0.2	1.01	1.68	2.52	9.2	
		Week 58	Sparsentan	102	58 (56.9)	1.48 (1.62)	0.1	0.57	0.92	1.86	7.5	
			Irbesartan	109	51 (46.8)	1.99 (1.54)	0.1	0.80	1.69	2.50	6.8	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	102	98 (96.1)	-0.90 (1.60)	-13.0	-1.22	-0.69	-0.22	1.8	-0.59 [-0.87, -0.31]
			Irbesartan	109	105 (96.3)	-0.07 (1.16)	-3.2	-0.68	-0.25	0.44	4.2	
		Week 36	Sparsentan	102	69 (67.6)	-0.61 (1.31)	-4.1	-1.28	-0.72	-0.03	4.6	-0.22 [-0.55, 0.11]
			Irbesartan	109	73 (67.0)	-0.30 (1.48)	-3.3	-1.17	-0.36	0.31	6.5	
		Week 58	Sparsentan	102	58 (56.9)	-0.66 (1.35)	-4.2	-1.34	-0.73	-0.03	3.3	-0.16 [-0.54, 0.21]
			Irbesartan	109	51 (46.8)	-0.45 (1.25)	-2.7	-1.44	-0.58	0.02	3.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 40 years	Urine protein excretion	Baseline	Sparsentan	91	91 (100.0)	2.02 (1.29)	0.1	1.06	1.54	2.70	6.3	
			Irbesartan	88	88 (100.0)	2.11 (1.43)	0.6	1.27	1.66	2.37	7.5	
		Week 6	Sparsentan	91	86 (94.5)	1.53 (1.23)	0.2	0.72	1.13	2.12	6.5	
			Irbesartan	88	81 (92.0)	2.22 (1.75)	0.4	1.03	1.66	2.78	10.3	
		Week 36	Sparsentan	91	64 (70.3)	1.32 (1.34)	0.1	0.59	0.87	1.46	6.4	
			Irbesartan	88	58 (65.9)	2.27 (1.78)	0.2	0.88	1.63	3.30	7.7	
		Week 58	Sparsentan	91	51 (56.0)	1.35 (1.10)	0.1	0.57	1.23	1.67	4.8	
			Irbesartan	88	46 (52.3)	2.34 (1.89)	0.1	0.98	2.02	3.08	8.6	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	91	86 (94.5)	-0.51 (1.15)	-3.8	-1.03	-0.51	-0.03	5.2	-0.49 [-0.80, -0.18]
			Irbesartan	88	81 (92.0)	0.12 (1.40)	-3.7	-0.54	0.02	0.62	8.4	
		Week 36	Sparsentan	91	64 (70.3)	-0.69 (1.20)	-4.2	-1.17	-0.66	-0.27	2.6	-0.72 [-1.09, -0.36]
			Irbesartan	88	58 (65.9)	0.23 (1.37)	-2.1	-0.62	-0.11	0.98	5.1	
		Week 58	Sparsentan	91	51 (56.0)	-0.55 (1.17)	-4.4	-1.23	-0.58	0.12	2.4	-0.55 [-0.96, -0.15]
			Irbesartan	88	46 (52.3)	0.18 (1.49)	-2.1	-0.58	-0.11	0.58	6.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Geographic region												
North America	Urine protein excretion	Baseline	Sparsentan	35	35 (100.0)	2.73 (2.53)	0.1	1.18	2.19	3.14	14.7	
			Irbesartan	46	46 (100.0)	2.53 (1.47)	0.6	1.67	2.14	3.00	7.5	
		Week 6	Sparsentan	35	33 (94.3)	1.99 (1.37)	0.3	1.09	1.71	2.64	6.5	
			Irbesartan	46	43 (93.5)	2.69 (1.73)	0.5	1.41	2.45	3.78	7.7	
		Week 36	Sparsentan	35	18 (51.4)	1.55 (1.23)	0.3	0.69	1.00	2.50	4.0	
			Irbesartan	46	25 (54.3)	2.87 (1.71)	0.5	1.84	2.68	4.02	7.1	
		Week 58	Sparsentan	35	12 (34.3)	1.57 (1.28)	0.5	0.66	1.14	1.90	4.7	
			Irbesartan	46	18 (39.1)	3.18 (2.02)	0.5	1.46	2.87	4.61	7.2	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	35	33 (94.3)	-0.88 (2.75)	-13.0	-1.65	-0.47	0.20	5.2	-0.46 [-0.92, -0.01]
			Irbesartan	46	43 (93.5)	0.13 (1.57)	-3.7	-0.54	-0.13	0.96	4.2	
		Week 36	Sparsentan	35	18 (51.4)	-0.80 (1.51)	-4.2	-1.54	-0.53	-0.11	2.6	-0.62 [-1.24, -0.00]
			Irbesartan	46	25 (54.3)	0.20 (1.66)	-2.5	-0.50	-0.06	0.93	4.2	
		Week 58	Sparsentan	35	12 (34.3)	-0.42 (1.76)	-3.7	-1.21	-0.11	0.39	3.3	-0.35 [-1.08, 0.39]
			Irbesartan	46	18 (39.1)	0.21 (1.83)	-2.7	-0.88	-0.29	1.24	3.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Europe	Urine protein excretion	Baseline	Sparsentan	98	98 (100.0)	2.17 (1.40)	0.4	1.21	1.86	2.86	9.7	
			Irbesartan	115	115 (100.0)	2.12 (1.17)	0.5	1.32	1.82	2.60	5.9	
		Week 6	Sparsentan	98	91 (92.9)	1.36 (1.03)	0.2	0.66	1.08	1.95	5.5	
			Irbesartan	115	109 (94.8)	2.06 (1.51)	0.5	1.09	1.65	2.56	10.3	
		Week 36	Sparsentan	98	60 (61.2)	1.53 (1.47)	0.1	0.60	1.01	2.07	6.4	
			Irbesartan	115	78 (67.8)	1.93 (1.42)	0.2	0.81	1.55	2.52	7.0	
		Week 58	Sparsentan	98	48 (49.0)	1.50 (1.43)	0.1	0.49	1.10	1.96	7.5	
			Irbesartan	115	56 (48.7)	1.99 (1.54)	0.1	0.88	1.72	2.75	8.6	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	98	91 (92.9)	-0.74 (1.07)	-4.2	-1.21	-0.70	-0.12	2.7	-0.60 [-0.88, -0.31]
			Irbesartan	115	109 (94.8)	-0.03 (1.26)	-2.4	-0.77	-0.12	0.44	8.4	
		Week 36	Sparsentan	98	60 (61.2)	-0.56 (1.25)	-4.1	-1.18	-0.70	0.10	2.6	-0.28 [-0.62, 0.05]
			Irbesartan	115	78 (67.8)	-0.19 (1.36)	-3.3	-1.10	-0.29	0.63	5.1	
		Week 58	Sparsentan	98	48 (49.0)	-0.49 (1.27)	-4.2	-1.14	-0.75	0.14	2.5	-0.17 [-0.55, 0.22]
			Irbesartan	115	56 (48.7)	-0.26 (1.40)	-2.5	-0.99	-0.39	0.14	6.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asia Pacific	Urine protein excretion	Baseline	Sparsentan	69	69 (100.0)	2.04 (1.36)	0.4	1.15	1.49	2.51	7.2	
			Irbesartan	41	41 (100.0)	1.87 (1.08)	0.6	1.25	1.59	2.29	6.8	
		Week 6	Sparsentan	69	68 (98.6)	1.43 (1.32)	0.2	0.61	0.95	1.79	6.2	
			Irbesartan	41	39 (95.1)	1.93 (1.56)	0.4	0.93	1.55	2.64	9.5	
		Week 36	Sparsentan	69	61 (88.4)	1.39 (1.70)	0.1	0.50	0.83	1.74	9.4	
			Irbesartan	41	30 (73.2)	1.99 (2.06)	0.2	0.73	1.23	2.48	9.2	
		Week 58	Sparsentan	69	53 (76.8)	1.37 (1.48)	0.1	0.57	0.88	1.53	6.8	
			Irbesartan	41	24 (58.5)	1.73 (1.62)	0.1	0.68	1.08	2.27	6.6	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	69	68 (98.6)	-0.62 (0.78)	-2.4	-1.01	-0.61	-0.10	0.9	-0.78 [-1.18, -0.37]
			Irbesartan	41	39 (95.1)	0.02 (0.88)	-1.7	-0.50	-0.20	0.42	2.8	
		Week 36	Sparsentan	69	61 (88.4)	-0.69 (1.19)	-3.1	-1.23	-0.71	-0.27	4.6	-0.54 [-0.99, -0.10]
			Irbesartan	41	30 (73.2)	0.02 (1.50)	-2.0	-0.75	-0.28	0.02	6.5	
		Week 58	Sparsentan	69	53 (76.8)	-0.79 (1.19)	-4.4	-1.44	-0.59	-0.04	2.0	-0.48 [-0.97, 0.01]
			Irbesartan	41	24 (58.5)	-0.25 (1.01)	-1.7	-0.91	-0.42	0.06	2.2	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline BMI												
< 27 kg/m**2	Urine protein excretion	Baseline	Sparsentan	84	84 (100.0)	1.88 (1.02)	0.4	1.15	1.58	2.40	5.0	
			Irbesartan	94	94 (100.0)	2.13 (1.13)	0.6	1.37	1.81	2.56	6.8	
		Week 6	Sparsentan	84	77 (91.7)	1.33 (1.19)	0.2	0.64	0.95	1.60	6.5	
			Irbesartan	94	90 (95.7)	2.07 (1.57)	0.5	1.06	1.56	2.43	9.5	
		Week 36	Sparsentan	84	59 (70.2)	1.20 (1.20)	0.1	0.50	0.79	1.47	6.3	
			Irbesartan	94	59 (62.8)	1.79 (1.39)	0.2	0.81	1.43	2.52	7.7	
		Week 58	Sparsentan	84	46 (54.8)	0.96 (0.90)	0.1	0.30	0.74	1.30	5.0	
			Irbesartan	94	40 (42.6)	1.70 (1.40)	0.1	0.78	1.22	2.37	6.6	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	84	77 (91.7)	-0.56 (1.12)	-2.4	-1.19	-0.65	-0.10	5.2	-0.43 [-0.74, -0.12]
			Irbesartan	94	90 (95.7)	-0.10 (1.04)	-2.4	-0.73	-0.29	0.42	2.9	
		Week 36	Sparsentan	84	59 (70.2)	-0.65 (1.06)	-3.1	-1.23	-0.65	-0.07	2.2	-0.18 [-0.54, 0.18]
			Irbesartan	94	59 (62.8)	-0.47 (0.99)	-3.3	-1.07	-0.44	0.26	1.2	
		Week 58	Sparsentan	84	46 (54.8)	-0.93 (1.01)	-3.7	-1.36	-0.80	-0.30	1.0	-0.30 [-0.73, 0.13]
			Irbesartan	94	40 (42.6)	-0.64 (0.87)	-2.5	-1.29	-0.53	-0.17	1.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 27 kg/m**2	Urine protein excretion	Baseline	Sparsentan	118	118 (100.0)	2.47 (1.95)	0.1	1.18	1.92	3.16	14.7	
			Irbesartan	107	107 (100.0)	2.20 (1.33)	0.6	1.33	1.82	2.78	7.5	
		Week 6	Sparsentan	118	115 (97.5)	1.60 (1.22)	0.2	0.69	1.20	2.32	6.2	
			Irbesartan	107	100 (93.5)	2.29 (1.61)	0.4	1.18	1.92	2.80	10.3	
		Week 36	Sparsentan	118	80 (67.8)	1.67 (1.73)	0.1	0.60	1.04	2.21	9.4	
			Irbesartan	107	73 (68.2)	2.41 (1.82)	0.2	1.12	1.96	3.35	9.2	
		Week 58	Sparsentan	118	67 (56.8)	1.78 (1.62)	0.1	0.65	1.21	2.18	7.5	
			Irbesartan	107	58 (54.2)	2.44 (1.85)	0.1	0.95	2.03	3.13	8.6	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	118	115 (97.5)	-0.83 (1.59)	-13.0	-1.28	-0.67	-0.09	2.7	-0.61 [-0.89, -0.34]
			Irbesartan	107	100 (93.5)	0.11 (1.45)	-3.7	-0.54	-0.05	0.62	8.4	
		Week 36	Sparsentan	118	80 (67.8)	-0.64 (1.39)	-4.2	-1.22	-0.70	-0.08	4.6	-0.58 [-0.91, -0.26]
			Irbesartan	107	73 (68.2)	0.25 (1.68)	-2.5	-0.78	-0.12	1.00	6.5	
		Week 58	Sparsentan	118	67 (56.8)	-0.42 (1.42)	-4.4	-1.19	-0.45	0.26	3.3	-0.38 [-0.73, -0.02]
			Irbesartan	107	58 (54.2)	0.15 (1.61)	-2.7	-0.74	-0.22	1.01	6.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Randomization strata												
eGFR Low and UP High	Urine protein excretion	Baseline	Sparsentan	71	71 (100.0)	3.07 (1.58)	0.1	1.96	2.81	3.74	9.7	
			Irbesartan	74	74 (100.0)	2.96 (1.43)	0.5	1.86	2.59	3.77	7.5	
		Week 6	Sparsentan	71	67 (94.4)	2.10 (1.20)	0.5	1.24	1.88	2.51	5.7	
			Irbesartan	74	70 (94.6)	2.98 (1.63)	0.8	1.89	2.66	3.75	7.7	
		Week 36	Sparsentan	71	49 (69.0)	2.20 (1.87)	0.3	0.87	1.49	2.89	9.4	
			Irbesartan	74	48 (64.9)	2.84 (1.63)	0.2	1.81	2.56	3.56	7.1	
		Week 58	Sparsentan	71	42 (59.2)	1.98 (1.67)	0.2	0.81	1.49	2.47	7.5	
			Irbesartan	74	36 (48.6)	2.93 (1.68)	0.1	1.97	2.73	3.43	7.2	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	71	67 (94.4)	-0.92 (1.29)	-4.2	-1.65	-0.85	0.09	1.9	-0.68 [-1.03, -0.34]
			Irbesartan	74	70 (94.6)	0.03 (1.47)	-3.7	-0.84	-0.08	0.73	4.2	
		Week 36	Sparsentan	71	49 (69.0)	-0.80 (1.68)	-4.2	-1.64	-0.96	0.21	4.6	-0.41 [-0.81, -0.01]
			Irbesartan	74	48 (64.9)	-0.13 (1.60)	-3.3	-1.32	-0.09	1.00	4.2	
		Week 58	Sparsentan	71	42 (59.2)	-0.82 (1.61)	-4.4	-1.80	-0.83	-0.01	2.5	-0.43 [-0.88, 0.02]
			Irbesartan	74	36 (48.6)	-0.16 (1.41)	-2.7	-1.30	-0.09	0.73	3.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR Low and UP Low	Urine protein excretion	Baseline	Sparsentan	55	55 (100.0)	1.56 (1.91)	0.4	0.97	1.19	1.51	14.7	
			Irbesartan	55	55 (100.0)	1.42 (0.44)	0.6	1.10	1.33	1.68	3.1	
		Week 6	Sparsentan	55	51 (92.7)	1.06 (0.97)	0.2	0.60	0.86	1.36	6.5	
			Irbesartan	55	53 (96.4)	1.32 (0.61)	0.6	0.89	1.29	1.64	4.0	
		Week 36	Sparsentan	55	37 (67.3)	1.02 (0.92)	0.1	0.52	0.62	1.31	4.0	
			Irbesartan	55	39 (70.9)	1.38 (1.02)	0.3	0.73	1.03	1.54	4.4	
		Week 58	Sparsentan	55	29 (52.7)	0.95 (0.88)	0.1	0.46	0.78	1.03	4.7	
			Irbesartan	55	30 (54.5)	1.22 (1.11)	0.1	0.65	0.97	1.35	5.0	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	55	51 (92.7)	-0.55 (2.08)	-13.0	-0.80	-0.41	0.08	5.2	-0.29 [-0.68, 0.10]
			Irbesartan	55	53 (96.4)	-0.11 (0.70)	-1.5	-0.48	-0.19	0.31	2.9	
		Week 36	Sparsentan	55	37 (67.3)	-0.17 (0.96)	-2.1	-0.79	-0.28	0.18	2.6	-0.08 [-0.53, 0.37]
			Irbesartan	55	39 (70.9)	-0.09 (1.04)	-1.3	-0.75	-0.35	-0.08	3.6	
		Week 58	Sparsentan	55	29 (52.7)	-0.22 (0.90)	-1.5	-0.82	-0.36	0.12	3.3	0.10 [-0.41, 0.61]
			Irbesartan	55	30 (54.5)	-0.32 (1.02)	-1.5	-0.74	-0.46	-0.18	3.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP High	Urine protein excretion	Baseline	Sparsentan	37	37 (100.0)	2.60 (1.20)	1.0	1.96	2.42	2.99	7.2	
			Irbesartan	36	36 (100.0)	2.47 (1.05)	0.6	1.95	2.32	2.84	6.8	
		Week 6	Sparsentan	37	35 (94.6)	1.82 (1.45)	0.2	0.76	1.20	2.47	6.2	
			Irbesartan	36	33 (91.7)	2.69 (2.11)	0.6	1.47	2.27	3.11	10.3	
		Week 36	Sparsentan	37	26 (70.3)	1.62 (1.69)	0.1	0.65	1.16	1.74	8.3	
			Irbesartan	36	21 (58.3)	2.86 (2.33)	0.6	1.52	1.96	2.83	9.2	
		Week 58	Sparsentan	37	19 (51.4)	1.66 (1.70)	0.1	0.23	1.21	1.90	5.4	
			Irbesartan	36	15 (41.7)	2.70 (2.32)	0.7	0.90	1.98	2.98	8.6	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	37	35 (94.6)	-0.79 (1.16)	-2.4	-1.47	-0.97	-0.31	2.7	-0.62 [-1.11, -0.13]
			Irbesartan	36	33 (91.7)	0.18 (1.89)	-3.2	-0.78	-0.04	0.72	8.4	
		Week 36	Sparsentan	37	26 (70.3)	-0.96 (1.05)	-3.1	-1.42	-0.66	-0.48	1.0	-0.70 [-1.29, -0.11]
			Irbesartan	36	21 (58.3)	0.23 (2.25)	-2.5	-1.34	-0.15	0.80	6.5	
		Week 58	Sparsentan	37	19 (51.4)	-1.01 (1.27)	-3.7	-1.83	-1.02	-0.16	1.7	-0.50 [-1.19, 0.19]
			Irbesartan	36	15 (41.7)	-0.11 (2.28)	-2.7	-1.62	-0.79	1.01	6.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP Low	Urine protein excretion	Baseline	Sparsentan	39	39 (100.0)	1.26 (0.48)	0.4	0.96	1.18	1.51	3.3	
			Irbesartan	37	37 (100.0)	1.37 (0.44)	0.6	1.11	1.41	1.60	2.9	
		Week 6	Sparsentan	39	39 (100.0)	0.72 (0.38)	0.2	0.46	0.64	0.90	1.8	
			Irbesartan	37	35 (94.6)	1.39 (0.80)	0.4	0.87	1.19	1.91	3.6	
		Week 36	Sparsentan	39	27 (69.2)	0.64 (0.47)	0.1	0.30	0.56	0.88	2.3	
			Irbesartan	37	25 (67.6)	1.28 (0.84)	0.2	0.78	1.13	1.58	3.6	
		Week 58	Sparsentan	39	23 (59.0)	0.91 (0.78)	0.1	0.30	0.59	1.21	3.1	
			Irbesartan	37	17 (45.9)	1.59 (1.07)	0.2	0.90	1.21	2.41	3.6	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	39	39 (100.0)	-0.54 (0.53)	-2.6	-0.79	-0.51	-0.19	0.6	-0.91 [-1.39, -0.43]
			Irbesartan	37	35 (94.6)	0.01 (0.67)	-1.1	-0.52	-0.25	0.72	1.4	
		Week 36	Sparsentan	39	27 (69.2)	-0.72 (0.60)	-2.4	-1.06	-0.73	-0.51	0.7	-0.83 [-1.40, -0.26]
			Irbesartan	37	25 (67.6)	-0.17 (0.73)	-1.5	-0.67	-0.24	0.36	1.0	
		Week 58	Sparsentan	39	23 (59.0)	-0.45 (0.88)	-2.7	-1.05	-0.51	0.11	1.4	-0.48 [-1.12, 0.15]
			Irbesartan	37	17 (45.9)	0.01 (1.06)	-1.5	-0.52	-0.34	0.25	2.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 1												
< 60 mL/min/1.73 m**2	Urine protein excretion	Baseline	Sparsentan	127	127 (100.0)	2.27 (1.52)	0.1	1.19	1.85	3.10	9.7	
			Irbesartan	129	129 (100.0)	2.28 (1.34)	0.5	1.33	1.82	2.80	7.5	
		Week 6	Sparsentan	127	119 (93.7)	1.60 (1.22)	0.2	0.72	1.25	2.12	6.5	
			Irbesartan	129	124 (96.1)	2.20 (1.46)	0.5	1.15	1.83	2.71	7.7	
		Week 36	Sparsentan	127	88 (69.3)	1.66 (1.63)	0.1	0.60	1.04	2.21	9.4	
			Irbesartan	129	88 (68.2)	2.10 (1.52)	0.2	0.98	1.74	2.79	7.1	
		Week 58	Sparsentan	127	71 (55.9)	1.53 (1.48)	0.1	0.59	1.13	1.92	7.5	
			Irbesartan	129	69 (53.5)	2.09 (1.63)	0.1	0.87	1.69	2.80	7.2	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	127	119 (93.7)	-0.67 (1.23)	-4.2	-1.36	-0.67	0.03	5.2	-0.51 [-0.76, -0.25]
			Irbesartan	129	124 (96.1)	-0.06 (1.18)	-3.7	-0.68	-0.19	0.43	4.2	
		Week 36	Sparsentan	127	88 (69.3)	-0.51 (1.42)	-4.2	-1.21	-0.64	0.19	4.6	-0.25 [-0.55, 0.05]
			Irbesartan	129	88 (68.2)	-0.17 (1.32)	-3.3	-1.01	-0.27	0.39	4.2	
		Week 58	Sparsentan	127	71 (55.9)	-0.56 (1.39)	-4.4	-1.29	-0.48	0.12	3.3	-0.22 [-0.56, 0.11]
			Irbesartan	129	69 (53.5)	-0.27 (1.19)	-2.7	-0.88	-0.40	0.21	3.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	Urine protein excretion	Baseline	Sparsentan	49	49 (100.0)	2.14 (2.03)	0.6	1.12	1.62	2.62	14.7	
			Irbesartan	48	48 (100.0)	1.97 (0.91)	0.6	1.36	1.84	2.45	4.6	
		Week 6	Sparsentan	49	48 (98.0)	1.33 (1.16)	0.2	0.56	0.86	1.84	5.5	
			Irbesartan	48	43 (89.6)	2.33 (1.76)	0.4	1.28	1.93	3.01	10.3	
		Week 36	Sparsentan	49	31 (63.3)	1.07 (0.90)	0.1	0.60	0.86	1.32	3.8	
			Irbesartan	48	33 (68.8)	2.37 (1.87)	0.2	1.24	1.77	2.60	9.2	
		Week 58	Sparsentan	49	24 (49.0)	1.16 (1.06)	0.1	0.25	1.17	1.56	4.6	
			Irbesartan	48	19 (39.6)	2.58 (1.92)	0.2	1.21	2.27	3.06	8.6	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	49	48 (98.0)	-0.80 (2.04)	-13.0	-1.09	-0.67	-0.15	2.7	-0.59 [-1.01, -0.17]
			Irbesartan	48	43 (89.6)	0.29 (1.61)	-3.2	-0.50	0.05	0.80	8.4	
		Week 36	Sparsentan	49	31 (63.3)	-0.79 (0.69)	-2.5	-1.32	-0.67	-0.52	0.9	-0.91 [-1.42, -0.39]
			Irbesartan	48	33 (68.8)	0.44 (1.76)	-2.2	-0.52	0.15	0.90	6.5	
		Week 58	Sparsentan	49	24 (49.0)	-0.62 (0.91)	-2.7	-1.07	-0.75	-0.16	1.7	-0.68 [-1.30, -0.06]
			Irbesartan	48	19 (39.6)	0.41 (2.06)	-2.7	-1.05	-0.08	1.46	6.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	Urine protein excretion	Baseline	Sparsentan	26	26 (100.0)	2.15 (1.51)	0.7	1.18	1.64	2.48	7.2	
			Irbesartan	25	25 (100.0)	1.94 (1.21)	0.6	1.30	1.63	2.10	6.8	
		Week 6	Sparsentan	26	25 (96.2)	1.31 (1.26)	0.4	0.57	0.90	1.51	6.2	
			Irbesartan	25	24 (96.0)	1.80 (1.91)	0.4	0.84	1.22	1.95	9.5	
		Week 36	Sparsentan	26	20 (76.9)	1.30 (1.84)	0.1	0.35	0.63	1.61	8.3	
			Irbesartan	25	12 (48.0)	1.57 (2.09)	0.2	0.43	0.78	1.96	7.7	
		Week 58	Sparsentan	26	18 (69.2)	1.49 (1.64)	0.2	0.34	0.85	1.81	5.4	
			Irbesartan	25	10 (40.0)	1.66 (1.90)	0.3	0.55	0.99	2.06	6.6	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	26	25 (96.2)	-0.83 (0.73)	-2.4	-1.20	-0.65	-0.44	0.4	-0.83 [-1.41, -0.25]
			Irbesartan	25	24 (96.0)	-0.13 (0.95)	-1.9	-0.63	-0.33	0.35	2.8	
		Week 36	Sparsentan	26	20 (76.9)	-1.02 (1.08)	-3.1	-1.50	-0.89	-0.45	1.0	-0.28 [-1.00, 0.43]
			Irbesartan	25	12 (48.0)	-0.72 (1.01)	-2.5	-1.46	-0.58	-0.13	1.0	
		Week 58	Sparsentan	26	18 (69.2)	-0.89 (1.30)	-3.7	-1.36	-0.83	0.07	1.4	-0.21 [-0.99, 0.56]
			Irbesartan	25	10 (40.0)	-0.63 (1.04)	-2.3	-1.55	-0.43	-0.12	1.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 2												
< 45 mL/min/1.73 m**2	Urine protein excretion	Baseline	Sparsentan	82	82 (100.0)	2.37 (1.59)	0.1	1.28	1.94	3.14	9.7	
			Irbesartan	80	80 (100.0)	2.32 (1.40)	0.5	1.33	1.95	2.94	7.5	
		Week 6	Sparsentan	82	77 (93.9)	1.75 (1.35)	0.2	0.92	1.28	2.15	6.5	
			Irbesartan	80	78 (97.5)	2.18 (1.37)	0.6	1.04	1.84	2.70	7.0	
		Week 36	Sparsentan	82	55 (67.1)	1.87 (1.78)	0.1	0.61	1.27	2.66	9.4	
			Irbesartan	80	57 (71.3)	2.21 (1.52)	0.2	1.00	2.05	2.85	6.7	
		Week 58	Sparsentan	82	45 (54.9)	1.67 (1.73)	0.1	0.59	1.01	1.99	7.5	
			Irbesartan	80	44 (55.0)	1.99 (1.56)	0.1	0.70	1.74	2.79	7.2	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	82	77 (93.9)	-0.59 (1.32)	-4.2	-1.36	-0.67	0.10	5.2	-0.36 [-0.67, -0.04]
			Irbesartan	80	78 (97.5)	-0.14 (1.22)	-3.7	-0.78	-0.21	0.38	3.2	
		Week 36	Sparsentan	82	55 (67.1)	-0.44 (1.57)	-4.2	-1.27	-0.60	0.51	4.6	-0.22 [-0.59, 0.15]
			Irbesartan	80	57 (71.3)	-0.12 (1.38)	-2.5	-0.99	-0.29	0.63	4.2	
		Week 58	Sparsentan	82	45 (54.9)	-0.53 (1.51)	-4.4	-1.45	-0.55	0.42	3.3	-0.09 [-0.50, 0.33]
			Irbesartan	80	44 (55.0)	-0.41 (1.11)	-2.7	-1.15	-0.38	0.18	3.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
45 to < 60 mL/min/1.73 m**2	Urine protein excretion	Baseline	Sparsentan	45	45 (100.0)	2.08 (1.39)	0.4	1.18	1.76	2.75	6.4	
			Irbesartan	49	49 (100.0)	2.20 (1.26)	0.6	1.34	1.76	2.64	5.7	
		Week 6	Sparsentan	45	42 (93.3)	1.32 (0.90)	0.2	0.60	1.09	2.01	3.5	
			Irbesartan	49	46 (93.9)	2.23 (1.62)	0.5	1.19	1.83	2.74	7.7	
		Week 36	Sparsentan	45	33 (73.3)	1.29 (1.28)	0.1	0.59	0.83	1.47	6.4	
			Irbesartan	49	31 (63.3)	1.90 (1.52)	0.3	0.88	1.22	2.34	7.1	
		Week 58	Sparsentan	45	26 (57.8)	1.30 (0.90)	0.1	0.69	1.19	1.60	4.5	
			Irbesartan	49	25 (51.0)	2.26 (1.76)	0.3	0.98	1.69	2.91	6.8	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	45	42 (93.3)	-0.80 (1.04)	-4.0	-1.28	-0.70	-0.10	0.9	-0.82 [-1.26, -0.39]
			Irbesartan	49	46 (93.9)	0.08 (1.10)	-1.9	-0.56	0.03	0.44	4.2	
		Week 36	Sparsentan	45	33 (73.3)	-0.62 (1.16)	-4.1	-1.18	-0.76	-0.07	2.6	-0.31 [-0.80, 0.19]
			Irbesartan	49	31 (63.3)	-0.26 (1.24)	-3.3	-1.10	-0.15	0.25	2.8	
		Week 58	Sparsentan	45	26 (57.8)	-0.61 (1.20)	-4.2	-1.25	-0.44	-0.02	2.4	-0.47 [-1.03, 0.08]
			Irbesartan	49	25 (51.0)	-0.02 (1.31)	-1.9	-0.74	-0.42	0.31	3.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	Urine protein excretion	Baseline	Sparsentan	49	49 (100.0)	2.14 (2.03)	0.6	1.12	1.62	2.62	14.7	
			Irbesartan	48	48 (100.0)	1.97 (0.91)	0.6	1.36	1.84	2.45	4.6	
		Week 6	Sparsentan	49	48 (98.0)	1.33 (1.16)	0.2	0.56	0.86	1.84	5.5	
			Irbesartan	48	43 (89.6)	2.33 (1.76)	0.4	1.28	1.93	3.01	10.3	
		Week 36	Sparsentan	49	31 (63.3)	1.07 (0.90)	0.1	0.60	0.86	1.32	3.8	
			Irbesartan	48	33 (68.8)	2.37 (1.87)	0.2	1.24	1.77	2.60	9.2	
		Week 58	Sparsentan	49	24 (49.0)	1.16 (1.06)	0.1	0.25	1.17	1.56	4.6	
			Irbesartan	48	19 (39.6)	2.58 (1.92)	0.2	1.21	2.27	3.06	8.6	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	49	48 (98.0)	-0.80 (2.04)	-13.0	-1.09	-0.67	-0.15	2.7	-0.59 [-1.01, -0.17]
			Irbesartan	48	43 (89.6)	0.29 (1.61)	-3.2	-0.50	0.05	0.80	8.4	
		Week 36	Sparsentan	49	31 (63.3)	-0.79 (0.69)	-2.5	-1.32	-0.67	-0.52	0.9	-0.91 [-1.42, -0.39]
			Irbesartan	48	33 (68.8)	0.44 (1.76)	-2.2	-0.52	0.15	0.90	6.5	
		Week 58	Sparsentan	49	24 (49.0)	-0.62 (0.91)	-2.7	-1.07	-0.75	-0.16	1.7	-0.68 [-1.30, -0.06]
			Irbesartan	48	19 (39.6)	0.41 (2.06)	-2.7	-1.05	-0.08	1.46	6.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	Urine protein excretion	Baseline	Sparsentan	26	26 (100.0)	2.15 (1.51)	0.7	1.18	1.64	2.48	7.2	
			Irbesartan	25	25 (100.0)	1.94 (1.21)	0.6	1.30	1.63	2.10	6.8	
		Week 6	Sparsentan	26	25 (96.2)	1.31 (1.26)	0.4	0.57	0.90	1.51	6.2	
			Irbesartan	25	24 (96.0)	1.80 (1.91)	0.4	0.84	1.22	1.95	9.5	
		Week 36	Sparsentan	26	20 (76.9)	1.30 (1.84)	0.1	0.35	0.63	1.61	8.3	
			Irbesartan	25	12 (48.0)	1.57 (2.09)	0.2	0.43	0.78	1.96	7.7	
		Week 58	Sparsentan	26	18 (69.2)	1.49 (1.64)	0.2	0.34	0.85	1.81	5.4	
			Irbesartan	25	10 (40.0)	1.66 (1.90)	0.3	0.55	0.99	2.06	6.6	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	26	25 (96.2)	-0.83 (0.73)	-2.4	-1.20	-0.65	-0.44	0.4	-0.83 [-1.41, -0.25]
			Irbesartan	25	24 (96.0)	-0.13 (0.95)	-1.9	-0.63	-0.33	0.35	2.8	
		Week 36	Sparsentan	26	20 (76.9)	-1.02 (1.08)	-3.1	-1.50	-0.89	-0.45	1.0	-0.28 [-1.00, 0.43]
			Irbesartan	25	12 (48.0)	-0.72 (1.01)	-2.5	-1.46	-0.58	-0.13	1.0	
		Week 58	Sparsentan	26	18 (69.2)	-0.89 (1.30)	-3.7	-1.36	-0.83	0.07	1.4	-0.21 [-0.99, 0.56]
			Irbesartan	25	10 (40.0)	-0.63 (1.04)	-2.3	-1.55	-0.43	-0.12	1.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline urine protein excretion												
<= 1.75 g/day	Urine protein excretion	Baseline	Sparsentan	98	98 (100.0)	1.14 (0.33)	0.1	0.97	1.16	1.40	1.7	
			Irbesartan	94	94 (100.0)	1.26 (0.31)	0.5	1.07	1.33	1.50	1.7	
		Week 6	Sparsentan	98	93 (94.9)	0.96 (0.80)	0.2	0.48	0.76	1.17	6.5	
			Irbesartan	94	88 (93.6)	1.46 (0.89)	0.4	0.89	1.27	1.83	4.8	
		Week 36	Sparsentan	98	73 (74.5)	0.97 (0.85)	0.1	0.40	0.70	1.27	4.0	
			Irbesartan	94	61 (64.9)	1.47 (1.11)	0.2	0.75	1.11	1.89	5.8	
		Week 58	Sparsentan	98	61 (62.2)	1.00 (0.85)	0.1	0.34	0.79	1.40	4.7	
			Irbesartan	94	38 (40.4)	1.30 (1.07)	0.1	0.65	1.04	1.56	5.0	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	98	93 (94.9)	-0.21 (0.80)	-1.2	-0.67	-0.40	0.02	5.2	-0.49 [-0.79, -0.20]
			Irbesartan	94	88 (93.6)	0.20 (0.84)	-1.1	-0.35	0.03	0.53	3.2	
		Week 36	Sparsentan	98	73 (74.5)	-0.22 (0.83)	-1.4	-0.79	-0.48	0.15	2.6	-0.42 [-0.76, -0.08]
			Irbesartan	94	61 (64.9)	0.18 (1.06)	-1.4	-0.44	-0.13	0.53	4.2	
		Week 58	Sparsentan	98	61 (62.2)	-0.20 (0.80)	-1.4	-0.76	-0.30	0.23	3.3	-0.18 [-0.59, 0.22]
			Irbesartan	94	38 (40.4)	-0.04 (1.03)	-1.5	-0.63	-0.35	0.10	3.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 1.75 g/day	Urine protein excretion	Baseline	Sparsentan	104	104 (100.0)	3.24 (1.75)	1.8	2.22	2.81	3.50	14.7	
			Irbesartan	108	108 (100.0)	2.95 (1.21)	1.8	2.05	2.54	3.39	7.5	
		Week 6	Sparsentan	104	99 (95.2)	1.99 (1.32)	0.3	1.03	1.62	2.51	6.2	
			Irbesartan	108	103 (95.4)	2.79 (1.79)	0.7	1.56	2.38	3.31	10.3	
		Week 36	Sparsentan	104	66 (63.5)	2.03 (1.90)	0.1	0.79	1.42	2.54	9.4	
			Irbesartan	108	72 (66.7)	2.67 (1.85)	0.2	1.42	2.43	3.40	9.2	
		Week 58	Sparsentan	104	52 (50.0)	1.97 (1.76)	0.2	0.73	1.33	2.58	7.5	
			Irbesartan	108	60 (55.6)	2.67 (1.84)	0.1	1.48	2.27	3.14	8.6	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	104	99 (95.2)	-1.20 (1.69)	-13.0	-1.82	-1.20	-0.54	2.7	-0.66 [-0.94, -0.37]
			Irbesartan	108	103 (95.4)	-0.14 (1.53)	-3.7	-1.00	-0.32	0.43	8.4	
		Week 36	Sparsentan	104	66 (63.5)	-1.12 (1.47)	-4.2	-2.05	-1.21	-0.53	4.6	-0.53 [-0.87, -0.19]
			Irbesartan	108	72 (66.7)	-0.28 (1.69)	-3.3	-1.34	-0.54	0.58	6.5	
		Week 58	Sparsentan	104	52 (50.0)	-1.12 (1.56)	-4.4	-2.12	-1.26	-0.54	2.5	-0.54 [-0.92, -0.17]
			Irbesartan	108	60 (55.6)	-0.26 (1.60)	-2.7	-1.45	-0.41	0.35	6.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline use of antihypertensives												
Yes	Urine protein excretion	Baseline	Sparsentan	88	88 (100.0)	2.57 (2.07)	0.4	1.30	2.13	3.15	14.7	
			Irbesartan	83	83 (100.0)	2.16 (1.42)	0.5	1.22	1.70	2.55	7.5	
		Week 6	Sparsentan	88	83 (94.3)	1.62 (1.31)	0.2	0.72	1.11	2.16	6.5	
			Irbesartan	83	77 (92.8)	2.22 (1.84)	0.4	1.05	1.64	2.70	10.3	
		Week 36	Sparsentan	88	57 (64.8)	1.56 (1.51)	0.3	0.67	0.97	1.72	8.3	
			Irbesartan	83	59 (71.1)	2.31 (1.93)	0.2	1.03	1.78	2.74	9.2	
		Week 58	Sparsentan	88	46 (52.3)	1.68 (1.58)	0.1	0.59	1.24	1.94	7.5	
			Irbesartan	83	46 (55.4)	2.14 (1.94)	0.1	0.86	1.62	2.80	8.6	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	88	83 (94.3)	-0.92 (1.86)	-13.0	-1.45	-0.77	-0.12	5.2	-0.60 [-0.92, -0.29]
			Irbesartan	83	77 (92.8)	0.09 (1.45)	-3.7	-0.56	-0.06	0.55	8.4	
		Week 36	Sparsentan	88	57 (64.8)	-0.80 (1.27)	-4.2	-1.36	-0.72	-0.29	2.6	-0.64 [-1.02, -0.27]
			Irbesartan	83	59 (71.1)	0.13 (1.58)	-3.3	-0.62	-0.11	0.63	6.5	
		Week 58	Sparsentan	88	46 (52.3)	-0.52 (1.42)	-4.4	-1.30	-0.53	0.11	3.3	-0.23 [-0.64, 0.18]
			Irbesartan	83	46 (55.4)	-0.18 (1.50)	-2.7	-1.08	-0.35	0.21	6.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Urine protein excretion	Baseline	Sparsentan	114	114 (100.0)	1.95 (1.17)	0.1	1.10	1.56	2.58	6.4	
			Irbesartan	119	119 (100.0)	2.17 (1.11)	0.6	1.40	1.92	2.64	6.9	
		Week 6	Sparsentan	114	109 (95.6)	1.40 (1.13)	0.2	0.60	1.06	1.78	5.7	
			Irbesartan	119	114 (95.8)	2.15 (1.41)	0.4	1.09	1.84	2.69	7.7	
		Week 36	Sparsentan	114	82 (71.9)	1.41 (1.56)	0.1	0.50	0.83	2.00	9.4	
			Irbesartan	119	74 (62.2)	1.97 (1.42)	0.2	1.00	1.50	2.68	7.1	
		Week 58	Sparsentan	114	67 (58.8)	1.28 (1.30)	0.1	0.42	0.88	1.58	6.8	
			Irbesartan	119	52 (43.7)	2.14 (1.51)	0.3	0.90	1.84	2.90	6.8	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	114	109 (95.6)	-0.57 (0.95)	-4.0	-1.00	-0.58	0.02	2.1	-0.50 [-0.77, -0.24]
			Irbesartan	119	114 (95.8)	-0.04 (1.14)	-3.2	-0.66	-0.19	0.44	4.2	
		Week 36	Sparsentan	114	82 (71.9)	-0.54 (1.24)	-4.1	-1.18	-0.65	0.15	4.6	-0.25 [-0.56, 0.07]
			Irbesartan	119	74 (62.2)	-0.22 (1.32)	-2.5	-1.07	-0.40	0.48	4.2	
		Week 58	Sparsentan	114	67 (58.8)	-0.69 (1.19)	-4.2	-1.25	-0.71	0.02	2.0	-0.42 [-0.79, -0.05]
			Irbesartan	119	52 (43.7)	-0.17 (1.33)	-2.7	-0.86	-0.40	0.39	3.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Time since renal biopsy												
<= 5 years	Urine protein excretion	Baseline	Sparsentan	113	113 (100.0)	2.28 (1.84)	0.1	1.17	1.67	2.95	14.7	
			Irbesartan	127	127 (100.0)	2.18 (1.33)	0.5	1.34	1.77	2.63	7.5	
		Week 6	Sparsentan	113	105 (92.9)	1.54 (1.32)	0.2	0.64	1.05	2.02	6.5	
			Irbesartan	127	120 (94.5)	2.10 (1.55)	0.4	1.05	1.56	2.68	9.5	
		Week 36	Sparsentan	113	73 (64.6)	1.45 (1.50)	0.1	0.56	0.88	1.77	8.3	
			Irbesartan	127	80 (63.0)	2.07 (1.84)	0.2	0.79	1.42	2.64	9.2	
		Week 58	Sparsentan	113	58 (51.3)	1.64 (1.59)	0.1	0.59	1.14	1.94	7.5	
			Irbesartan	127	59 (46.5)	2.01 (1.80)	0.1	0.69	1.35	2.75	7.2	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	113	105 (92.9)	-0.79 (1.70)	-13.0	-1.22	-0.71	-0.03	5.2	-0.51 [-0.78, -0.25]
			Irbesartan	127	120 (94.5)	-0.07 (1.09)	-3.7	-0.66	-0.18	0.48	3.2	
		Week 36	Sparsentan	113	73 (64.6)	-0.74 (1.21)	-4.2	-1.26	-0.68	-0.11	2.6	-0.45 [-0.77, -0.13]
			Irbesartan	127	80 (63.0)	-0.12 (1.50)	-3.3	-0.95	-0.30	0.58	6.5	
		Week 58	Sparsentan	113	58 (51.3)	-0.46 (1.36)	-4.4	-1.27	-0.55	0.39	3.3	-0.13 [-0.49, 0.23]
			Irbesartan	127	59 (46.5)	-0.29 (1.31)	-2.7	-1.05	-0.43	0.21	3.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 5 years	Urine protein excretion	Baseline	Sparsentan	89	89 (100.0)	2.15 (1.38)	0.4	1.18	1.77	2.78	9.7	
			Irbesartan	75	75 (100.0)	2.13 (1.09)	0.6	1.20	1.96	2.60	5.9	
		Week 6	Sparsentan	89	87 (97.8)	1.43 (1.07)	0.2	0.72	1.09	1.95	5.7	
			Irbesartan	75	71 (94.7)	2.30 (1.65)	0.5	1.20	1.89	2.74	10.3	
		Week 36	Sparsentan	89	66 (74.2)	1.50 (1.59)	0.1	0.60	0.96	1.92	9.4	
			Irbesartan	75	53 (70.7)	2.20 (1.37)	0.2	1.18	1.89	2.74	7.0	
		Week 58	Sparsentan	89	55 (61.8)	1.24 (1.22)	0.1	0.46	0.87	1.53	6.8	
			Irbesartan	75	39 (52.0)	2.33 (1.58)	0.3	1.12	2.06	2.98	8.6	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	89	87 (97.8)	-0.63 (0.99)	-4.0	-1.00	-0.59	-0.12	2.1	-0.62 [-0.95, -0.30]
			Irbesartan	75	71 (94.7)	0.15 (1.52)	-2.4	-0.54	-0.15	0.61	8.4	
		Week 36	Sparsentan	89	66 (74.2)	-0.54 (1.31)	-4.1	-1.16	-0.66	-0.07	4.6	-0.42 [-0.78, -0.05]
			Irbesartan	75	53 (70.7)	0.01 (1.38)	-2.5	-0.76	-0.17	0.53	5.1	
		Week 58	Sparsentan	89	55 (61.8)	-0.80 (1.19)	-4.2	-1.29	-0.76	-0.16	2.0	-0.59 [-1.01, -0.17]
			Irbesartan	75	39 (52.0)	-0.01 (1.54)	-2.5	-0.83	-0.30	0.46	6.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: History of hypertension												
Yes	Urine protein excretion	Baseline	Sparsentan	153	153 (100.0)	2.25 (1.67)	0.1	1.18	1.77	3.00	14.7	
			Irbesartan	157	157 (100.0)	2.20 (1.31)	0.5	1.34	1.78	2.64	7.5	
		Week 6	Sparsentan	153	144 (94.1)	1.54 (1.23)	0.2	0.70	1.09	2.07	6.5	
			Irbesartan	157	147 (93.6)	2.16 (1.59)	0.4	1.13	1.71	2.70	10.3	
		Week 36	Sparsentan	153	104 (68.0)	1.53 (1.48)	0.1	0.60	0.99	1.89	8.3	
			Irbesartan	157	106 (67.5)	2.21 (1.77)	0.2	1.01	1.72	2.74	9.2	
		Week 58	Sparsentan	153	83 (54.2)	1.56 (1.45)	0.1	0.59	1.13	1.92	7.5	
			Irbesartan	157	80 (51.0)	2.24 (1.82)	0.1	0.88	1.82	2.97	8.6	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	153	144 (94.1)	-0.74 (1.55)	-13.0	-1.29	-0.69	-0.03	5.2	-0.49 [-0.73, -0.26]
			Irbesartan	157	147 (93.6)	-0.04 (1.28)	-3.7	-0.63	-0.19	0.41	8.4	
		Week 36	Sparsentan	153	104 (68.0)	-0.63 (1.21)	-4.2	-1.25	-0.66	-0.05	2.6	-0.43 [-0.71, -0.16]
			Irbesartan	157	106 (67.5)	-0.04 (1.53)	-3.3	-0.92	-0.29	0.53	6.5	
		Week 58	Sparsentan	153	83 (54.2)	-0.53 (1.29)	-4.4	-1.18	-0.55	0.11	3.3	-0.29 [-0.60, 0.01]
			Irbesartan	157	80 (51.0)	-0.12 (1.48)	-2.7	-0.99	-0.34	0.39	6.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Urine protein excretion	Baseline	Sparsentan	49	49 (100.0)	2.14 (1.58)	0.4	1.18	1.62	2.63	9.7	
			Irbesartan	45	45 (100.0)	2.04 (0.96)	0.6	1.33	1.96	2.54	4.6	
		Week 6	Sparsentan	49	48 (98.0)	1.33 (1.16)	0.2	0.59	0.92	1.57	5.7	
			Irbesartan	45	44 (97.8)	2.25 (1.59)	0.5	1.00	1.85	2.66	7.7	
		Week 36	Sparsentan	49	35 (71.4)	1.30 (1.71)	0.1	0.40	0.71	1.92	9.4	
			Irbesartan	45	27 (60.0)	1.75 (1.12)	0.2	0.96	1.48	2.52	4.4	
		Week 58	Sparsentan	49	30 (61.2)	1.14 (1.32)	0.1	0.34	0.81	1.31	6.8	
			Irbesartan	45	18 (40.0)	1.71 (1.08)	0.3	0.90	1.56	2.41	4.6	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	49	48 (98.0)	-0.65 (0.96)	-4.0	-1.09	-0.57	-0.23	2.1	-0.77 [-1.20, -0.35]
			Irbesartan	45	44 (97.8)	0.19 (1.22)	-2.4	-0.57	0.12	0.73	4.2	
		Week 36	Sparsentan	49	35 (71.4)	-0.69 (1.39)	-4.1	-1.18	-0.77	-0.29	4.6	-0.39 [-0.89, 0.12]
			Irbesartan	45	27 (60.0)	-0.19 (1.09)	-2.5	-0.76	-0.14	0.79	1.6	
		Week 58	Sparsentan	49	30 (61.2)	-0.90 (1.27)	-4.2	-1.44	-0.80	-0.09	2.0	-0.40 [-0.99, 0.19]
			Irbesartan	45	18 (40.0)	-0.42 (0.99)	-2.1	-0.84	-0.42	-0.18	2.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Sex	Overall	Sparsentan						Interaction:	0.151
Male	Week 6	Sparsentan	139	132 (95.0)	-0.73 (0.11)	(-0.94, -0.52)	-0.81 (0.15)	(-1.11, -0.51)	<0.001 *
		Irbesartan	143	137 (95.8)	0.08 (0.11)	(-0.13, 0.29)			
	Week 36	Sparsentan	139	92 (66.2)	-0.71 (0.13)	(-0.95, -0.46)	-0.72 (0.17)	(-1.06, -0.37)	<0.001 *
		Irbesartan	143	98 (68.5)	0.01 (0.12)	(-0.23, 0.25)			
	Week 58	Sparsentan	139	69 (49.6)	-0.58 (0.14)	(-0.86, -0.30)	-0.59 (0.20)	(-0.98, -0.19)	0.003 *
		Irbesartan	143	73 (51.0)	0.01 (0.14)	(-0.26, 0.28)			
Female	Week 6	Sparsentan	63	60 (95.2)	-0.52 (0.14)	(-0.80, -0.23)	-0.25 (0.21)	(-0.66, 0.17)	0.240
		Irbesartan	59	54 (91.5)	-0.27 (0.15)	(-0.57, 0.03)			
	Week 36	Sparsentan	63	47 (74.6)	-0.83 (0.16)	(-1.14, -0.52)	-0.56 (0.24)	(-1.03, -0.10)	0.018 *
		Irbesartan	59	35 (59.3)	-0.27 (0.18)	(-0.62, 0.08)			
	Week 58	Sparsentan	63	44 (69.8)	-0.76 (0.17)	(-1.09, -0.43)	-0.35 (0.27)	(-0.87, 0.17)	0.189
		Irbesartan	59	25 (42.4)	-0.41 (0.21)	(-0.82, -0.00)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age	Overall	Sparsentan						Interaction:	0.972
<= 45 years	Week 6	Sparsentan	96	91 (94.8)	-0.81 (0.14)	(-1.09, -0.53)	-0.73 (0.20)	(-1.12, -0.34)	<0.001 *
		Irbesartan	99	95 (96.0)	-0.08 (0.14)	(-0.35, 0.19)			
	Week 36	Sparsentan	96	66 (68.8)	-0.78 (0.16)	(-1.09, -0.47)	-0.55 (0.22)	(-0.99, -0.11)	0.014 *
		Irbesartan	99	65 (65.7)	-0.23 (0.16)	(-0.54, 0.08)			
	Week 58	Sparsentan	96	51 (53.1)	-0.60 (0.18)	(-0.95, -0.25)	-0.42 (0.26)	(-0.93, 0.09)	0.107
		Irbesartan	99	44 (44.4)	-0.18 (0.19)	(-0.55, 0.19)			
> 45 years	Week 6	Sparsentan	106	101 (95.3)	-0.55 (0.11)	(-0.76, -0.35)	-0.57 (0.15)	(-0.87, -0.28)	<0.001 *
		Irbesartan	103	96 (93.2)	0.02 (0.11)	(-0.19, 0.23)			
	Week 36	Sparsentan	106	73 (68.9)	-0.72 (0.12)	(-0.96, -0.48)	-0.81 (0.17)	(-1.15, -0.46)	<0.001 *
		Irbesartan	103	68 (66.0)	0.09 (0.13)	(-0.16, 0.33)			
	Week 58	Sparsentan	106	62 (58.5)	-0.68 (0.13)	(-0.94, -0.42)	-0.67 (0.19)	(-1.05, -0.29)	<0.001 *
		Irbesartan	103	54 (52.4)	-0.01 (0.14)	(-0.28, 0.27)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age at IgAN diagnosis	Overall	Sparsentan						Interaction:	0.461
<= 18 years	Week 6	Sparsentan	9	8 (88.9)	-0.76 (0.57)	(-1.95, 0.43)	-0.44 (1.02)	(-2.60, 1.73)	0.676
		Irbesartan	5	5 (100.0)	-0.32 (0.77)	(-1.96, 1.31)			
	Week 36	Sparsentan	9	6 (66.7)	-0.79 (0.64)	(-2.10, 0.53)	-0.48 (1.24)	(-3.06, 2.09)	0.701
		Irbesartan	5	2 (40.0)	-0.30 (1.06)	(-2.47, 1.86)			
	Week 58	Sparsentan	9	4 (44.4)	-0.62 (0.72)	(-2.10, 0.87)	0.88 (1.53)	(-2.24, 4.00)	0.569
		Irbesartan	5	1 (20.0)	-1.50 (1.35)	(-4.24, 1.24)			
> 18 to 40 years	Week 6	Sparsentan	102	98 (96.1)	-0.86 (0.13)	(-1.11, -0.61)	-0.77 (0.18)	(-1.12, -0.42)	<0.001 *
		Irbesartan	109	105 (96.3)	-0.09 (0.12)	(-0.33, 0.15)			
	Week 36	Sparsentan	102	69 (67.6)	-0.76 (0.15)	(-1.05, -0.48)	-0.51 (0.20)	(-0.91, -0.11)	0.012 *
		Irbesartan	109	73 (67.0)	-0.26 (0.14)	(-0.53, 0.02)			
	Week 58	Sparsentan	102	58 (56.9)	-0.72 (0.16)	(-1.03, -0.41)	-0.46 (0.23)	(-0.92, -0.01)	0.045 *
		Irbesartan	109	51 (46.8)	-0.26 (0.17)	(-0.58, 0.07)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 40 years	Week 6	Sparsentan	91	86 (94.5)	-0.48 (0.12)	(-0.71, -0.24)	-0.56 (0.17)	(-0.90, -0.22)	0.001 *
		Irbesartan	88	81 (92.0)	0.08 (0.12)	(-0.16, 0.32)			
	Week 36	Sparsentan	91	64 (70.3)	-0.75 (0.14)	(-1.02, -0.48)	-0.95 (0.20)	(-1.34, -0.57)	<0.001 *
		Irbesartan	88	58 (65.9)	0.20 (0.14)	(-0.08, 0.48)			
	Week 58	Sparsentan	91	51 (56.0)	-0.58 (0.15)	(-0.88, -0.28)	-0.75 (0.22)	(-1.18, -0.31)	<0.001 *
		Irbesartan	88	46 (52.3)	0.17 (0.16)	(-0.15, 0.48)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Geographic region	Overall	Sparsentan						Interaction:	0.026 #
North America	Week 6	Sparsentan	35	33 (94.3)	-0.64 (0.29)	(-1.21, -0.08)	-0.65 (0.38)	(-1.40, 0.09)	0.086
		Irbesartan	46	43 (93.5)	0.01 (0.25)	(-0.48, 0.50)			
	Week 36	Sparsentan	35	18 (51.4)	-1.02 (0.37)	(-1.74, -0.30)	-1.22 (0.48)	(-2.17, -0.28)	0.012 *
		Irbesartan	46	25 (54.3)	0.21 (0.31)	(-0.41, 0.82)			
	Week 58	Sparsentan	35	12 (34.3)	-0.78 (0.44)	(-1.66, 0.09)	-0.99 (0.58)	(-2.13, 0.15)	0.087
		Irbesartan	46	18 (39.1)	0.21 (0.37)	(-0.51, 0.93)			
Europe	Week 6	Sparsentan	98	91 (92.9)	-0.75 (0.12)	(-0.97, -0.52)	-0.69 (0.16)	(-1.00, -0.38)	<0.001 *
		Irbesartan	115	109 (94.8)	-0.06 (0.11)	(-0.27, 0.15)			
	Week 36	Sparsentan	98	60 (61.2)	-0.69 (0.14)	(-0.96, -0.41)	-0.52 (0.19)	(-0.88, -0.16)	0.005 *
		Irbesartan	115	78 (67.8)	-0.17 (0.12)	(-0.41, 0.08)			
	Week 58	Sparsentan	98	48 (49.0)	-0.51 (0.16)	(-0.82, -0.20)	-0.39 (0.21)	(-0.80, 0.03)	0.069
		Irbesartan	115	56 (48.7)	-0.13 (0.14)	(-0.41, 0.15)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Asia Pacific	Week 6	Sparsentan	69	68 (98.6)	-0.62 (0.12)	(-0.86, -0.37)	-0.60 (0.20)	(-1.00, -0.20)	0.003 *
		Irbesartan	41	39 (95.1)	-0.01 (0.16)	(-0.33, 0.30)			
	Week 36	Sparsentan	69	61 (88.4)	-0.70 (0.13)	(-0.95, -0.45)	-0.65 (0.22)	(-1.08, -0.23)	0.003 *
		Irbesartan	41	30 (73.2)	-0.05 (0.17)	(-0.39, 0.30)			
	Week 58	Sparsentan	69	53 (76.8)	-0.73 (0.14)	(-0.99, -0.46)	-0.45 (0.24)	(-0.92, 0.02)	0.060
		Irbesartan	41	24 (58.5)	-0.27 (0.20)	(-0.66, 0.11)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline BMI	Overall	Sparsentan						Interaction:	0.174
< 27 kg/m**2	Week 6	Sparsentan	84	77 (91.7)	-0.57 (0.11)	(-0.79, -0.36)	-0.49 (0.15)	(-0.79, -0.20)	0.001 *
		Irbesartan	94	90 (95.7)	-0.08 (0.10)	(-0.28, 0.12)			
	Week 36	Sparsentan	84	59 (70.2)	-0.75 (0.12)	(-0.99, -0.51)	-0.36 (0.17)	(-0.70, -0.01)	0.041 *
		Irbesartan	94	59 (62.8)	-0.39 (0.12)	(-0.63, -0.15)			
	Week 58	Sparsentan	84	46 (54.8)	-0.85 (0.14)	(-1.12, -0.58)	-0.36 (0.20)	(-0.76, 0.04)	0.075
		Irbesartan	94	40 (42.6)	-0.49 (0.15)	(-0.77, -0.20)			
>= 27 kg/m**2	Week 6	Sparsentan	118	115 (97.5)	-0.72 (0.13)	(-0.97, -0.48)	-0.72 (0.19)	(-1.09, -0.36)	<0.001 *
		Irbesartan	107	100 (93.5)	-0.00 (0.13)	(-0.27, 0.26)			
	Week 36	Sparsentan	118	80 (67.8)	-0.73 (0.14)	(-1.02, -0.45)	-0.91 (0.21)	(-1.32, -0.50)	<0.001 *
		Irbesartan	107	73 (68.2)	0.18 (0.15)	(-0.12, 0.48)			
	Week 58	Sparsentan	118	67 (56.8)	-0.51 (0.16)	(-0.83, -0.20)	-0.66 (0.23)	(-1.12, -0.20)	0.005 *
		Irbesartan	107	58 (54.2)	0.15 (0.17)	(-0.19, 0.48)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Randomization strata	Overall	Sparsentan						Interaction:	0.039 #
eGFR Low and UP High	Week 6	Sparsentan	71	67 (94.4)	-0.87 (0.18)	(-1.22, -0.52)	-0.85 (0.25)	(-1.34, -0.37)	<0.001 *
		Irbesartan	74	70 (94.6)	-0.02 (0.17)	(-0.36, 0.32)			
	Week 36	Sparsentan	71	49 (69.0)	-0.88 (0.20)	(-1.28, -0.48)	-0.77 (0.29)	(-1.33, -0.21)	0.007 *
		Irbesartan	74	48 (64.9)	-0.11 (0.20)	(-0.51, 0.29)			
	Week 58	Sparsentan	71	42 (59.2)	-0.90 (0.22)	(-1.34, -0.47)	-0.81 (0.32)	(-1.45, -0.18)	0.011 *
		Irbesartan	74	36 (48.6)	-0.09 (0.23)	(-0.55, 0.37)			
eGFR Low and UP Low	Week 6	Sparsentan	55	51 (92.7)	-0.40 (0.11)	(-0.62, -0.18)	-0.28 (0.15)	(-0.59, 0.02)	0.068
		Irbesartan	55	53 (96.4)	-0.12 (0.11)	(-0.33, 0.10)			
	Week 36	Sparsentan	55	37 (67.3)	-0.41 (0.12)	(-0.66, -0.17)	-0.44 (0.17)	(-0.78, -0.09)	0.013 *
		Irbesartan	55	39 (70.9)	0.02 (0.12)	(-0.22, 0.26)			
	Week 58	Sparsentan	55	29 (52.7)	-0.41 (0.14)	(-0.69, -0.13)	-0.26 (0.20)	(-0.65, 0.13)	0.184
		Irbesartan	55	30 (54.5)	-0.15 (0.14)	(-0.42, 0.12)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
eGFR High and UP High	Week 6	Sparsentan	37	35 (94.6)	-0.82 (0.26)	(-1.33, -0.32)	-0.90 (0.37)	(-1.62, -0.18)	0.015 *
		Irbesartan	36	33 (91.7)	0.08 (0.26)	(-0.44, 0.59)			
	Week 36	Sparsentan	37	26 (70.3)	-1.16 (0.29)	(-1.72, -0.59)	-1.17 (0.42)	(-2.00, -0.34)	0.006 *
		Irbesartan	36	21 (58.3)	0.01 (0.31)	(-0.59, 0.62)			
	Week 58	Sparsentan	37	19 (51.4)	-0.92 (0.33)	(-1.56, -0.28)	-0.72 (0.49)	(-1.68, 0.23)	0.138
		Irbesartan	36	15 (41.7)	-0.20 (0.36)	(-0.91, 0.51)			
eGFR High and UP Low	Week 6	Sparsentan	39	39 (100.0)	-0.59 (0.10)	(-0.80, -0.39)	-0.61 (0.15)	(-0.90, -0.32)	<0.001 *
		Irbesartan	37	35 (94.6)	0.02 (0.11)	(-0.19, 0.23)			
	Week 36	Sparsentan	39	27 (69.2)	-0.72 (0.12)	(-0.95, -0.49)	-0.53 (0.17)	(-0.87, -0.20)	0.002 *
		Irbesartan	37	25 (67.6)	-0.19 (0.12)	(-0.43, 0.05)			
	Week 58	Sparsentan	39	23 (59.0)	-0.42 (0.13)	(-0.67, -0.16)	-0.51 (0.19)	(-0.89, -0.13)	0.009 *
		Irbesartan	37	17 (45.9)	0.09 (0.14)	(-0.19, 0.38)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 1	Overall	Sparsentan						Interaction:	0.189
< 60 mL/min/1.73 m**2	Week 6	Sparsentan	127	119 (93.7)	-0.63 (0.11)	(-0.85, -0.42)	-0.57 (0.15)	(-0.87, -0.27)	<0.001 *
		Irbesartan	129	124 (96.1)	-0.06 (0.11)	(-0.28, 0.15)			
	Week 36	Sparsentan	127	88 (69.3)	-0.60 (0.12)	(-0.85, -0.36)	-0.51 (0.18)	(-0.86, -0.17)	0.004 *
		Irbesartan	129	88 (68.2)	-0.09 (0.12)	(-0.33, 0.16)			
	Week 58	Sparsentan	127	71 (55.9)	-0.63 (0.14)	(-0.90, -0.35)	-0.49 (0.20)	(-0.88, -0.10)	0.013 *
		Irbesartan	129	69 (53.5)	-0.14 (0.14)	(-0.41, 0.14)			
60 to < 90 mL/min/1.73 m**2	Week 6	Sparsentan	49	48 (98.0)	-0.71 (0.19)	(-1.08, -0.33)	-0.91 (0.27)	(-1.45, -0.37)	<0.001 *
		Irbesartan	48	43 (89.6)	0.20 (0.19)	(-0.18, 0.58)			
	Week 36	Sparsentan	49	31 (63.3)	-1.10 (0.22)	(-1.53, -0.66)	-1.39 (0.31)	(-2.00, -0.78)	<0.001 *
		Irbesartan	48	33 (68.8)	0.30 (0.22)	(-0.13, 0.72)			
	Week 58	Sparsentan	49	24 (49.0)	-0.67 (0.25)	(-1.16, -0.18)	-0.97 (0.36)	(-1.68, -0.25)	0.009 *
		Irbesartan	48	19 (39.6)	0.30 (0.27)	(-0.23, 0.82)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
>= 90 mL/min/1.73 m**2	Week 6	Sparsentan	26	25 (96.2)	-0.84 (0.19)	(-1.22, -0.46)	-0.67 (0.27)	(-1.21, -0.13)	0.015 *
		Irbesartan	25	24 (96.0)	-0.17 (0.20)	(-0.55, 0.22)			
	Week 36	Sparsentan	26	20 (76.9)	-0.97 (0.21)	(-1.39, -0.55)	-0.23 (0.33)	(-0.89, 0.43)	0.484
		Irbesartan	25	12 (48.0)	-0.74 (0.26)	(-1.25, -0.23)			
	Week 58	Sparsentan	26	18 (69.2)	-0.86 (0.22)	(-1.30, -0.42)	-0.22 (0.37)	(-0.94, 0.51)	0.551
		Irbesartan	25	10 (40.0)	-0.64 (0.29)	(-1.22, -0.07)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 2	Overall	Sparsentan						Interaction:	0.171
< 45 mL/min/1.73 m**2	Week 6	Sparsentan	82	77 (93.9)	-0.56 (0.14)	(-0.83, -0.29)	-0.41 (0.20)	(-0.79, -0.02)	0.040 *
		Irbesartan	80	78 (97.5)	-0.15 (0.14)	(-0.43, 0.12)			
	Week 36	Sparsentan	82	55 (67.1)	-0.52 (0.16)	(-0.84, -0.21)	-0.51 (0.22)	(-0.95, -0.07)	0.023 *
		Irbesartan	80	57 (71.3)	-0.02 (0.16)	(-0.32, 0.29)			
	Week 58	Sparsentan	82	45 (54.9)	-0.56 (0.18)	(-0.91, -0.21)	-0.34 (0.25)	(-0.83, 0.15)	0.179
		Irbesartan	80	44 (55.0)	-0.23 (0.18)	(-0.57, 0.12)			
45 to < 60 mL/min/1.73 m**2	Week 6	Sparsentan	45	42 (93.3)	-0.78 (0.18)	(-1.14, -0.43)	-0.89 (0.25)	(-1.38, -0.39)	<0.001 *
		Irbesartan	49	46 (93.9)	0.10 (0.17)	(-0.24, 0.45)			
	Week 36	Sparsentan	45	33 (73.3)	-0.75 (0.20)	(-1.15, -0.36)	-0.56 (0.29)	(-1.13, 0.01)	0.053
		Irbesartan	49	31 (63.3)	-0.19 (0.21)	(-0.60, 0.21)			
	Week 58	Sparsentan	45	26 (57.8)	-0.76 (0.23)	(-1.20, -0.31)	-0.82 (0.33)	(-1.47, -0.18)	0.013 *
		Irbesartan	49	25 (51.0)	0.06 (0.23)	(-0.39, 0.52)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
60 to < 90 mL/min/1.73 m**2	Week 6	Sparsentan	49	48 (98.0)	-0.71 (0.19)	(-1.08, -0.33)	-0.91 (0.27)	(-1.45, -0.37)	<0.001 *
		Irbesartan	48	43 (89.6)	0.20 (0.19)	(-0.18, 0.58)			
	Week 36	Sparsentan	49	31 (63.3)	-1.10 (0.22)	(-1.53, -0.66)	-1.39 (0.31)	(-2.00, -0.78)	<0.001 *
		Irbesartan	48	33 (68.8)	0.30 (0.22)	(-0.13, 0.72)			
	Week 58	Sparsentan	49	24 (49.0)	-0.67 (0.25)	(-1.16, -0.18)	-0.97 (0.36)	(-1.68, -0.25)	0.009 *
		Irbesartan	48	19 (39.6)	0.30 (0.27)	(-0.23, 0.82)			
>= 90 mL/min/1.73 m**2	Week 6	Sparsentan	26	25 (96.2)	-0.84 (0.19)	(-1.22, -0.46)	-0.67 (0.27)	(-1.21, -0.13)	0.015 *
		Irbesartan	25	24 (96.0)	-0.17 (0.20)	(-0.55, 0.22)			
	Week 36	Sparsentan	26	20 (76.9)	-0.97 (0.21)	(-1.39, -0.55)	-0.23 (0.33)	(-0.89, 0.43)	0.484
		Irbesartan	25	12 (48.0)	-0.74 (0.26)	(-1.25, -0.23)			
	Week 58	Sparsentan	26	18 (69.2)	-0.86 (0.22)	(-1.30, -0.42)	-0.22 (0.37)	(-0.94, 0.51)	0.551
		Irbesartan	25	10 (40.0)	-0.64 (0.29)	(-1.22, -0.07)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline urine protein excretion	Overall	Sparsentan						Interaction:	<0.001 #
<= 1.75 g/day	Week 6	Sparsentan	98	93 (94.9)	-0.18 (0.08)	(-0.33, -0.02)	-0.35 (0.11)	(-0.58, -0.13)	0.002 *
		Irbesartan	94	88 (93.6)	0.18 (0.08)	(0.02, 0.33)			
	Week 36	Sparsentan	98	73 (74.5)	-0.23 (0.09)	(-0.41, -0.06)	-0.41 (0.13)	(-0.66, -0.16)	0.002 *
		Irbesartan	94	61 (64.9)	0.18 (0.09)	(-0.01, 0.36)			
	Week 58	Sparsentan	98	61 (62.2)	-0.14 (0.10)	(-0.33, 0.05)	-0.17 (0.15)	(-0.46, 0.12)	0.258
		Irbesartan	94	38 (40.4)	0.03 (0.12)	(-0.20, 0.26)			
> 1.75 g/day	Week 6	Sparsentan	104	99 (95.2)	-1.21 (0.16)	(-1.53, -0.89)	-1.04 (0.23)	(-1.49, -0.60)	<0.001 *
		Irbesartan	108	103 (95.4)	-0.17 (0.16)	(-0.48, 0.14)			
	Week 36	Sparsentan	104	66 (63.5)	-1.33 (0.19)	(-1.70, -0.96)	-1.07 (0.26)	(-1.58, -0.56)	<0.001 *
		Irbesartan	108	72 (66.7)	-0.26 (0.18)	(-0.61, 0.10)			
	Week 58	Sparsentan	104	52 (50.0)	-1.21 (0.21)	(-1.63, -0.79)	-0.99 (0.29)	(-1.57, -0.42)	<0.001 *
		Irbesartan	108	60 (55.6)	-0.22 (0.20)	(-0.61, 0.17)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline use of antihypertensives	Overall	Sparsentan						Interaction:	0.533
Yes	Week 6	Sparsentan	88	83 (94.3)	-0.79 (0.14)	(-1.07, -0.52)	-0.77 (0.21)	(-1.17, -0.36)	<0.001 *
		Irbesartan	83	77 (92.8)	-0.03 (0.15)	(-0.32, 0.26)			
	Week 36	Sparsentan	88	57 (64.8)	-0.91 (0.17)	(-1.23, -0.58)	-0.91 (0.23)	(-1.37, -0.46)	<0.001 *
		Irbesartan	83	59 (71.1)	0.01 (0.16)	(-0.32, 0.33)			
	Week 58	Sparsentan	88	46 (52.3)	-0.62 (0.19)	(-0.99, -0.26)	-0.43 (0.26)	(-0.95, 0.09)	0.103
		Irbesartan	83	46 (55.4)	-0.19 (0.19)	(-0.56, 0.17)			
No	Week 6	Sparsentan	114	109 (95.6)	-0.58 (0.11)	(-0.79, -0.36)	-0.54 (0.15)	(-0.84, -0.24)	<0.001 *
		Irbesartan	119	114 (95.8)	-0.04 (0.11)	(-0.24, 0.17)			
	Week 36	Sparsentan	114	82 (71.9)	-0.63 (0.12)	(-0.87, -0.39)	-0.48 (0.18)	(-0.83, -0.14)	0.006 *
		Irbesartan	119	74 (62.2)	-0.15 (0.13)	(-0.39, 0.10)			
	Week 58	Sparsentan	114	67 (58.8)	-0.67 (0.13)	(-0.93, -0.40)	-0.63 (0.20)	(-1.02, -0.24)	0.002 *
		Irbesartan	119	52 (43.7)	-0.04 (0.15)	(-0.33, 0.25)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Time since renal biopsy	Overall	Sparsentan						Interaction:	0.529
<= 5 years	Week 6	Sparsentan	113	105 (92.9)	-0.73 (0.12)	(-0.97, -0.48)	-0.61 (0.17)	(-0.95, -0.28)	<0.001 *
		Irbesartan	127	120 (94.5)	-0.11 (0.12)	(-0.34, 0.11)			
	Week 36	Sparsentan	113	73 (64.6)	-0.88 (0.14)	(-1.15, -0.60)	-0.71 (0.20)	(-1.10, -0.33)	<0.001 *
		Irbesartan	127	80 (63.0)	-0.16 (0.14)	(-0.43, 0.10)			
	Week 58	Sparsentan	113	58 (51.3)	-0.57 (0.16)	(-0.88, -0.25)	-0.35 (0.22)	(-0.79, 0.09)	0.115
		Irbesartan	127	59 (46.5)	-0.21 (0.16)	(-0.52, 0.09)			
> 5 years	Week 6	Sparsentan	89	87 (97.8)	-0.63 (0.12)	(-0.88, -0.39)	-0.76 (0.18)	(-1.13, -0.40)	<0.001 *
		Irbesartan	75	71 (94.7)	0.13 (0.14)	(-0.14, 0.40)			
	Week 36	Sparsentan	89	66 (74.2)	-0.60 (0.14)	(-0.88, -0.33)	-0.70 (0.21)	(-1.10, -0.29)	<0.001 *
		Irbesartan	75	53 (70.7)	0.10 (0.15)	(-0.20, 0.40)			
	Week 58	Sparsentan	89	55 (61.8)	-0.72 (0.15)	(-1.01, -0.42)	-0.83 (0.23)	(-1.28, -0.37)	<0.001 *
		Irbesartan	75	39 (52.0)	0.11 (0.17)	(-0.23, 0.45)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
History of hypertension	Overall	Sparsentan						Interaction:	0.861
Yes	Week 6	Sparsentan	153	144 (94.1)	-0.70 (0.11)	(-0.91, -0.49)	-0.61 (0.15)	(-0.90, -0.31)	<0.001 *
		Irbesartan	157	147 (93.6)	-0.09 (0.10)	(-0.30, 0.11)			
	Week 36	Sparsentan	153	104 (68.0)	-0.76 (0.12)	(-1.00, -0.53)	-0.73 (0.17)	(-1.06, -0.40)	<0.001 *
		Irbesartan	157	106 (67.5)	-0.03 (0.12)	(-0.27, 0.20)			
	Week 58	Sparsentan	153	83 (54.2)	-0.59 (0.13)	(-0.86, -0.33)	-0.52 (0.19)	(-0.89, -0.14)	0.007 *
		Irbesartan	157	80 (51.0)	-0.08 (0.14)	(-0.34, 0.19)			
No	Week 6	Sparsentan	49	48 (98.0)	-0.64 (0.15)	(-0.93, -0.34)	-0.82 (0.22)	(-1.25, -0.40)	<0.001 *
		Irbesartan	45	44 (97.8)	0.19 (0.16)	(-0.12, 0.49)			
	Week 36	Sparsentan	49	35 (71.4)	-0.73 (0.17)	(-1.06, -0.40)	-0.54 (0.25)	(-1.04, -0.05)	0.031 *
		Irbesartan	45	27 (60.0)	-0.19 (0.18)	(-0.55, 0.17)			
	Week 58	Sparsentan	49	30 (61.2)	-0.81 (0.18)	(-1.17, -0.45)	-0.64 (0.29)	(-1.21, -0.08)	0.026 *
		Irbesartan	45	18 (40.0)	-0.17 (0.22)	(-0.60, 0.27)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Figure PF1UEC_FSGM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set
Study: PROTECT
Geographic region: North America



Sparsentan	33	18	12
Irbesartan	43	25	18

Number of available records are presented for key visits up to Week 58 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT1UEC_FSCM.

Figure PF1UEC_FSGM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set
Study: PROTECT
Geographic region: Europe



Sparsentan	91	60	48
Irbesartan	109	78	56

Number of available records are presented for key visits up to Week 58 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT1UEC_FSCM.

Figure PF1UEC_FSGM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set
Study: PROTECT
Geographic region: Asia Pacific



Sparsentan	68	61	53
Irbesartan	39	30	24

Number of available records are presented for key visits up to Week 58 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT1UEC_FSCM.

Figure PF1UEC_FSGM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set
Study: PROTECT
Randomization strata: eGFR Low and UP High



Sparsentan	67	49	42
Irbesartan	70	48	36

Number of available records are presented for key visits up to Week 58 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT1UEC_FSCM.

Figure PF1UEC_FSGM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set
Study: PROTECT
Randomization strata: eGFR Low and UP Low



Sparsentan	51	37	29
Irbesartan	53	39	30

Number of available records are presented for key visits up to Week 58 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT1UEC_FSCM.

Figure PF1UEC_FSGM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set
Study: PROTECT
Randomization strata: eGFR High and UP High



Sparsentan	35	26	19
Irbesartan	33	21	15

Number of available records are presented for key visits up to Week 58 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT1UEC_FSCM.

Figure PF1UEC_FSGM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set
Study: PROTECT
Randomization strata: eGFR High and UP Low



Sparsentan	39	27	23
Irbesartan	35	25	17

Number of available records are presented for key visits up to Week 58 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT1UEC_FSCM.

Figure PF1UEC_FSGM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set
Study: PROTECT
Baseline urine protein excretion: <= 1.75 g/day



Sparsentan	93	73	61
Irbesartan	88	61	38

Number of available records are presented for key visits up to Week 58 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT1UEC_FSCM.

Figure PF1UEC_FSGM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set
Study: PROTECT
Baseline urine protein excretion: > 1.75 g/day



Sparsentan	99	66	52
Irbesartan	103	72	60

Number of available records are presented for key visits up to Week 58 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT1UEC_FSCM.

Table PT1URP_FSPM: Patients with partial remission by subgroup
Full Analysis Set

Partial remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Sex	Week 58	Sparsentan						Interaction test:	0.135	
Male	Week 58	Sparsentan	139	69 (49.6)	31 (44.9)	1.929 [1.180, 3.154]	2.687 [1.307, 5.525]	21.6 [5.0, 38.3]	0.008	*
		Irbesartan	143	73 (51.0)	17 (23.3)					
Female	Week 58	Sparsentan	63	44 (69.8)	24 (54.5)	1.136 [0.697, 1.853]	1.300 [0.486, 3.477]	6.5 [-21.1, 34.2]	0.625	
		Irbesartan	59	25 (42.4)	12 (48.0)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Partial remission means an urinary protein excretion of <1.0 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1URP_FSPM: Patients with partial remission by subgroup
Full Analysis Set

Partial remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Age	Week 58	Sparsentan						Interaction test:	0.209	
<= 45 years	Week 58	Sparsentan	96	51 (53.1)	26 (51.0)	1.319 [0.833, 2.089]	1.652 [0.729, 3.744]	12.3 [-9.7, 34.3]	0.302	
		Irbesartan	99	44 (44.4)	17 (38.6)					
> 45 years	Week 58	Sparsentan	106	62 (58.5)	29 (46.8)	2.105 [1.196, 3.704]	3.076 [1.365, 6.933]	24.6 [6.2, 42.9]	0.007	*
		Irbesartan	103	54 (52.4)	12 (22.2)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Partial remission means an urinary protein excretion of <1.0 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1URP_FSPM: Patients with partial remission by subgroup
Full Analysis Set

Partial remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Age at IgAN diagnosis	Week 58	Sparsentan						Interaction test:	0.072	
<= 18 years	Week 58	Sparsentan	9	4 (44.4)	2 (50.0)	0.500 [0.188, 1.332]	0.333 + [0.009, 12.815]	-50.0 [-100.0, 61.5]	1.000	
		Irbesartan	5	1 (20.0)	1 (100.0)					
> 18 to 40 years	Week 58	Sparsentan	102	58 (56.9)	32 (55.2)	1.759 [1.102, 2.807]	2.692 [1.227, 5.908]	23.8 [3.9, 43.7]	0.020	*
		Irbesartan	109	51 (46.8)	16 (31.4)					
> 40 years	Week 58	Sparsentan	91	51 (56.0)	21 (41.2)	1.578 [0.878, 2.838]	1.983 [0.837, 4.699]	15.1 [-5.5, 35.7]	0.137	
		Irbesartan	88	46 (52.3)	12 (26.1)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Partial remission means an urinary protein excretion of <1.0 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1URP_FSPM: Patients with partial remission by subgroup
Full Analysis Set

Partial remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Week 58	Sparsentan						Interaction test:	0.329
North America	Week 58	Sparsentan	35	12 (34.3)	5 (41.7)	3.750 [0.864, 16.280]	5.714 [0.885, 36.888]	30.6 [-7.8, 68.9]	0.084
		Irbesartan	46	18 (39.1)	2 (11.1)				
Europe	Week 58	Sparsentan	98	48 (49.0)	21 (43.8)	1.531 [0.907, 2.585]	1.944 [0.862, 4.385]	15.2 [-5.1, 35.5]	0.150
		Irbesartan	115	56 (48.7)	16 (28.6)				
Asia Pacific	Week 58	Sparsentan	69	53 (76.8)	29 (54.7)	1.194 [0.725, 1.967]	1.428 [0.542, 3.760]	8.9 [-18.2, 35.9]	0.623
		Irbesartan	41	24 (58.5)	11 (45.8)				

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Partial remission means an urinary protein excretion of <1.0 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1URP_FSPM: Patients with partial remission by subgroup
Full Analysis Set

Partial remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline BMI	Week 58	Sparsentan						Interaction test:	0.615	
< 27 kg/m**2	Week 58	Sparsentan	84	46 (54.8)	29 (63.0)	1.801 [1.118, 2.902]	3.168 [1.309, 7.665]	28.0 [5.4, 50.7]	0.017	*
		Irbesartan	94	40 (42.6)	14 (35.0)					
>= 27 kg/m**2	Week 58	Sparsentan	118	67 (56.8)	26 (38.8)	1.500 [0.884, 2.548]	1.818 [0.845, 3.911]	12.9 [-4.9, 30.8]	0.132	
		Irbesartan	107	58 (54.2)	15 (25.9)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Partial remission means an urinary protein excretion of <1.0 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1URP_FSPM: Patients with partial remission by subgroup
Full Analysis Set

Partial remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Week 58	Sparsentan						Interaction test:	0.532
eGFR Low and UP High	Week 58	Sparsentan	71	42 (59.2)	11 (26.2)	2.357 [0.821, 6.764]	2.839 [0.816, 9.873]	15.1 [-4.3, 34.5]	0.149
		Irbesartan	74	36 (48.6)	4 (11.1)				
eGFR Low and UP Low	Week 58	Sparsentan	55	29 (52.7)	20 (69.0)	1.293 [0.854, 1.957]	1.944 [0.671, 5.638]	15.6 [-12.3, 43.6]	0.288
		Irbesartan	55	30 (54.5)	16 (53.3)				
eGFR High and UP High	Week 58	Sparsentan	37	19 (51.4)	9 (47.4)	1.776 [0.678, 4.657]	2.475 [0.577, 10.617]	20.7 [-17.0, 58.4]	0.296
		Irbesartan	36	15 (41.7)	4 (26.7)				
eGFR High and UP Low	Week 58	Sparsentan	39	23 (59.0)	15 (65.2)	2.217 [1.002, 4.908]	4.500 [1.166, 17.373]	35.8 [1.6, 70.0]	0.054
		Irbesartan	37	17 (45.9)	5 (29.4)				

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Partial remission means an urinary protein excretion of <1.0 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1URP_FSPM: Patients with partial remission by subgroup
Full Analysis Set

Partial remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Week 58	Sparsentan						Interaction test:	0.494
< 60 mL/min/1.73 m**2	Week 58	Sparsentan	127	71 (55.9)	32 (45.1)	1.481 [0.954, 2.298]	1.875 [0.937, 3.754]	14.6 [-2.7, 31.9]	0.084
		Irbesartan	129	69 (53.5)	21 (30.4)				
60 to < 90 mL/min/1.73 m**2	Week 58	Sparsentan	49	24 (49.0)	11 (45.8)	2.903 [0.942, 8.949]	4.513 [1.036, 19.657]	30.0 [-0.5, 60.6]	0.052
		Irbesartan	48	19 (39.6)	3 (15.8)				
>= 90 mL/min/1.73 m**2	Week 58	Sparsentan	26	18 (69.2)	12 (66.7)	1.333 [0.662, 2.687]	2.000 [0.412, 9.712]	16.7 [-29.0, 62.3]	0.444
		Irbesartan	25	10 (40.0)	5 (50.0)				

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Partial remission means an urinary protein excretion of <1.0 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1URP_FSPM: Patients with partial remission by subgroup
Full Analysis Set

Partial remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Week 58	Sparsentan						Interaction test:	0.692
< 45 mL/min/1.73 m**2	Week 58	Sparsentan	82	45 (54.9)	22 (48.9)	1.537 [0.908, 2.599]	2.050 [0.865, 4.856]	17.1 [-5.2, 39.4]	0.132
		Irbesartan	80	44 (55.0)	14 (31.8)				
45 to < 60 mL/min/1.73 m**2	Week 58	Sparsentan	45	26 (57.8)	10 (38.5)	1.374 [0.621, 3.041]	1.607 [0.495, 5.217]	10.5 [-19.1, 40.1]	0.555
		Irbesartan	49	25 (51.0)	7 (28.0)				
60 to < 90 mL/min/1.73 m**2	Week 58	Sparsentan	49	24 (49.0)	11 (45.8)	2.903 [0.942, 8.949]	4.513 [1.036, 19.657]	30.0 [-0.5, 60.6]	0.052
		Irbesartan	48	19 (39.6)	3 (15.8)				
>= 90 mL/min/1.73 m**2	Week 58	Sparsentan	26	18 (69.2)	12 (66.7)	1.333 [0.662, 2.687]	2.000 [0.412, 9.712]	16.7 [-29.0, 62.3]	0.444
		Irbesartan	25	10 (40.0)	5 (50.0)				

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Partial remission means an urinary protein excretion of <1.0 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1URP_FSPM: Patients with partial remission by subgroup
Full Analysis Set

Partial remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Week 58	Sparsentan						Interaction test:	0.317
<= 1.75 g/day	Week 58	Sparsentan	98	61 (62.2)	37 (60.7)	1.281 [0.866, 1.894]	1.713 [0.756, 3.882]	13.3 [-8.9, 35.5]	0.218
		Irbesartan	94	38 (40.4)	18 (47.4)				
> 1.75 g/day	Week 58	Sparsentan	104	52 (50.0)	18 (34.6)	1.888 [0.984, 3.623]	2.358 [0.990, 5.620]	16.3 [-1.7, 34.3]	0.055
		Irbesartan	108	60 (55.6)	11 (18.3)				

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Partial remission means an urinary protein excretion of <1.0 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1URP_FSPM: Patients with partial remission by subgroup
Full Analysis Set

Partial remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline use of antihypertensives	Week 58	Sparsentan						Interaction test:	0.293	
Yes	Week 58	Sparsentan	88	46 (52.3)	18 (39.1)	1.286 [0.730, 2.265]	1.469 [0.620, 3.483]	8.7 [-12.9, 30.3]	0.512	
		Irbesartan	83	46 (55.4)	14 (30.4)					
No	Week 58	Sparsentan	114	67 (58.8)	37 (55.2)	1.914 [1.187, 3.088]	3.042 [1.410, 6.566]	26.4 [7.5, 45.2]	0.005	*
		Irbesartan	119	52 (43.7)	15 (28.8)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Partial remission means an urinary protein excretion of <1.0 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1URP_FSPM: Patients with partial remission by subgroup
Full Analysis Set

Partial remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Time since renal biopsy	Week 58	Sparsentan						Interaction test:	0.015	#
<= 5 years	Week 58	Sparsentan	113	58 (51.3)	24 (41.4)	1.110 [0.707, 1.742]	1.187 [0.565, 2.495]	4.1 [-15.3, 23.5]	0.707	
		Irbesartan	127	59 (46.5)	22 (37.3)					
> 5 years	Week 58	Sparsentan	89	55 (61.8)	31 (56.4)	3.140 [1.544, 6.388]	5.905 [2.225, 15.672]	38.4 [18.4, 58.4]	<0.001	*
		Irbesartan	75	39 (52.0)	7 (17.9)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Partial remission means an urinary protein excretion of <1.0 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1URP_FSPM: Patients with partial remission by subgroup
Full Analysis Set

Partial remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Week 58	Sparsentan						Interaction test:	0.725
Yes	Week 58	Sparsentan	153	83 (54.2)	37 (44.6)	1.551 [1.019, 2.360]	1.993 [1.041, 3.816]	15.8 [0.0, 31.6]	0.051
		Irbesartan	157	80 (51.0)	23 (28.8)				
No	Week 58	Sparsentan	49	30 (61.2)	18 (60.0)	1.800 [0.880, 3.682]	3.000 [0.884, 10.184]	26.7 [-5.7, 59.1]	0.135
		Irbesartan	45	18 (40.0)	6 (33.3)				

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Partial remission means an urinary protein excretion of <1.0 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1URPT_FSTM: Time to partial remission by subgroup
Full Analysis Set

Time to partial remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Sex	Sparsentan						Interaction test:	0.167	
Male	Sparsentan	139	91 (65.5)	7.1	(6.0, 24.1)	2.811	(2.006, 3.940)	<0.001	*
	Irbesartan	143	59 (41.3)	105.3	(50.3, NE)				
Female	Sparsentan	63	54 (85.7)	6.1	(4.1, 12.7)	2.178	(1.395, 3.400)	<0.001	*
	Irbesartan	59	35 (59.3)	12.4	(6.7, 59.6)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 31MAY2024

Table PT1URPT_FSTM: Time to partial remission by subgroup
Full Analysis Set

Time to partial remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Age	Sparsentan						Interaction test:	0.110	
<= 45 years	Sparsentan	96	66 (68.8)	7.1	(4.7, 24.0)	2.121	(1.463, 3.077)	<0.001	*
	Irbesartan	99	51 (51.5)	46.1	(25.1, 94.0)				
> 45 years	Sparsentan	106	79 (74.5)	6.1	(4.9, 13.3)	3.026	(2.067, 4.431)	<0.001	*
	Irbesartan	103	43 (41.7)	105.3	(37.3, NE)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 31MAY2024

Table PT1URPT_FSTM: Time to partial remission by subgroup
Full Analysis Set

Time to partial remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Age at IgAN diagnosis	Sparsentan						Interaction test:	0.889	
<= 18 years	Sparsentan	9	4 (44.4)	NE		2.263	(0.207, 24.756)	0.503	
	Irbesartan	5	2 (40.0)	24.0	(6.0, NE)				
> 18 to 40 years	Sparsentan	102	72 (70.6)	6.3	(4.7, 13.1)	2.437	(1.681, 3.532)	<0.001	*
	Irbesartan	109	51 (46.8)	59.6	(36.0, 105.3)				
> 40 years	Sparsentan	91	69 (75.8)	6.1	(4.9, 13.3)	2.530	(1.700, 3.767)	<0.001	*
	Irbesartan	88	41 (46.6)	57.4	(24.7, NE)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 31MAY2024

Table PT1URPT_FSTM: Time to partial remission by subgroup
Full Analysis Set

Time to partial remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Geographic region	Sparsentan						Interaction test:	0.645	
North America	Sparsentan	35	23 (65.7)	13.3	(4.7, 48.6)	3.514	(1.718, 7.188)	<0.001	*
	Irbesartan	46	13 (28.3)	NE					
Europe	Sparsentan	98	66 (67.3)	7.6	(5.0, 24.1)	2.543	(1.757, 3.680)	<0.001	*
	Irbesartan	115	55 (47.8)	58.1	(36.0, NE)				
Asia Pacific	Sparsentan	69	56 (81.2)	4.9	(4.1, 6.9)	2.040	(1.268, 3.283)	0.003	*
	Irbesartan	41	26 (63.4)	24.7	(6.9, 70.6)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 31MAY2024

Table PT1URPT_FSTM: Time to partial remission by subgroup
Full Analysis Set

Time to partial remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline BMI	Sparsentan						Interaction test:	0.599	
< 27 kg/m**2	Sparsentan	84	67 (79.8)	4.6	(4.1, 9.1)	2.199	(1.494, 3.235)	<0.001	*
	Irbesartan	94	48 (51.1)	38.0	(24.0, 114.1)				
>= 27 kg/m**2	Sparsentan	118	78 (66.1)	12.0	(6.1, 34.6)	2.859	(1.962, 4.166)	<0.001	*
	Irbesartan	107	45 (42.1)	82.9	(37.3, NE)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 31MAY2024

Table PT1URPT_FSTM: Time to partial remission by subgroup
Full Analysis Set

Time to partial remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Randomization strata	Sparsentan						Interaction test:	0.961	
eGFR Low and UP High	Sparsentan	71	36 (50.7)	51.1	(25.1, 112.1)	2.635	(1.494, 4.647)	<0.001	*
	Irbesartan	74	18 (24.3)	114.1	(94.0, NE)				
eGFR Low and UP Low	Sparsentan	55	50 (90.9)	4.3	(4.1, 4.7)	2.245	(1.458, 3.457)	<0.001	*
	Irbesartan	55	37 (67.3)	12.1	(4.9, 25.1)				
eGFR High and UP High	Sparsentan	37	22 (59.5)	24.7	(6.9, 81.9)	2.712	(1.308, 5.624)	0.007	*
	Irbesartan	36	11 (30.6)	82.9	(51.9, NE)				
eGFR High and UP Low	Sparsentan	39	37 (94.9)	4.1	(4.1, 4.4)	2.540	(1.522, 4.240)	<0.001	*
	Irbesartan	37	28 (75.7)	12.1	(6.1, 26.1)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 31MAY2024

Table PT1URPT_FSTM: Time to partial remission by subgroup
Full Analysis Set

Time to partial remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.368	
< 60 mL/min/1.73 m**2	Sparsentan	127	88 (69.3)	12.0	(6.0, 23.7)	2.393	(1.695, 3.378)	<0.001	*
	Irbesartan	129	58 (45.0)	70.6	(36.0, NE)				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	37 (75.5)	6.1	(4.6, 24.1)	3.705	(2.032, 6.753)	<0.001	*
	Irbesartan	48	19 (39.6)	82.9	(36.0, NE)				
>= 90 mL/min/1.73 m**2	Sparsentan	26	20 (76.9)	4.1	(4.1, 24.7)	1.652	(0.834, 3.271)	0.150	
	Irbesartan	25	17 (68.0)	24.7	(6.1, 36.3)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 31MAY2024

Table PT1URPT_FSTM: Time to partial remission by subgroup
Full Analysis Set

Time to partial remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eGFR Group 2	Sparsentan						Interaction test:	0.400	
< 45 mL/min/1.73 m**2	Sparsentan	82	54 (65.9)	12.4	(6.1, 38.0)	2.170	(1.413, 3.331)	<0.001	*
	Irbesartan	80	35 (43.8)	105.3	(25.6, NE)				
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	34 (75.6)	6.0	(4.1, 12.7)	3.054	(1.660, 5.618)	<0.001	*
	Irbesartan	49	23 (46.9)	70.6	(24.1, NE)				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	37 (75.5)	6.1	(4.6, 24.1)	3.705	(2.032, 6.753)	<0.001	*
	Irbesartan	48	19 (39.6)	82.9	(36.0, NE)				
>= 90 mL/min/1.73 m**2	Sparsentan	26	20 (76.9)	4.1	(4.1, 24.7)	1.652	(0.834, 3.271)	0.150	
	Irbesartan	25	17 (68.0)	24.7	(6.1, 36.3)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 31MAY2024

Table PT1URPT_FSTM: Time to partial remission by subgroup
Full Analysis Set

Time to partial remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline urine protein excretion	Sparsentan						Interaction test:	0.210	
<= 1.75 g/day	Sparsentan	98	88 (89.8)	4.3	(4.1, 4.7)	2.068	(1.494, 2.864)	<0.001	*
	Irbesartan	94	65 (69.1)	12.1	(6.1, 25.1)				
> 1.75 g/day	Sparsentan	104	57 (54.8)	37.3	(23.7, 69.3)	3.479	(2.175, 5.565)	<0.001	*
	Irbesartan	108	29 (26.9)	114.1	(94.0, NE)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 31MAY2024

Table PT1URPT_FSTM: Time to partial remission by subgroup
Full Analysis Set

Time to partial remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.042	#
Yes	Sparsentan	88	64 (72.7)	7.1	(6.0, 24.1)	3.658	(2.370, 5.645)	<0.001	*
	Irbesartan	83	36 (43.4)	70.6	(37.3, NE)				
No	Sparsentan	114	81 (71.1)	6.1	(4.7, 12.7)	1.909	(1.353, 2.692)	<0.001	*
	Irbesartan	119	58 (48.7)	46.1	(25.3, 114.1)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 31MAY2024

Table PT1URPT_FSTM: Time to partial remission by subgroup
Full Analysis Set

Time to partial remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Time since renal biopsy	Sparsentan						Interaction test:	0.102	
<= 5 years	Sparsentan	113	81 (71.7)	6.9	(4.9, 22.1)	2.161	(1.554, 3.004)	<0.001	*
	Irbesartan	127	66 (52.0)	36.1	(25.1, 82.9)				
> 5 years	Sparsentan	89	64 (71.9)	6.9	(4.7, 24.0)	3.446	(2.169, 5.475)	<0.001	*
	Irbesartan	75	28 (37.3)	105.3	(57.4, NE)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 31MAY2024

Table PT1URPT_FSTM: Time to partial remission by subgroup
Full Analysis Set

Time to partial remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
History of hypertension	Sparsentan						Interaction test:	0.647	
Yes	Sparsentan	153	110 (71.9)	7.6	(6.0, 22.1)	2.712	(1.998, 3.681)	<0.001	*
	Irbesartan	157	70 (44.6)	70.6	(36.3, NE)				
No	Sparsentan	49	35 (71.4)	4.4	(4.1, 12.7)	2.040	(1.186, 3.507)	0.010	*
	Irbesartan	45	24 (53.3)	26.1	(8.1, NE)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 31MAY2024

Figure PF1URPT_FSKM: Time to partial remission by subgroup
Full Analysis Set

Study: PROTECT
Baseline use of antihypertensives: Yes



Sparsentan	88	26	17	9	3	3
Irbesartan	83	47	31	22	9	4

Partial remission means an urinary protein excretion of <1.0 g/day. No event means no partial remission.
eGFR = estimated glomerular filtration rate.
Reference table: PT1URPT_FSTM

Figure PF1URPT_FSKM: Time to partial remission by subgroup
Full Analysis Set

Study: PROTECT
Baseline use of antihypertensives: No



Sparsentan	114	36	25	16	8	3
Irbesartan	119	59	38	23	11	4

_____
Partial remission means an urinary protein excretion of <1.0 g/day. No event means no partial remission.
eGFR = estimated glomerular filtration rate.
Reference table: PT1URPT_FSTM

Table PT1URF_FSPM: Patients with complete remission by subgroup
Full Analysis Set

Complete remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Week 58	Sparsentan						Interaction test:	0.792
Male	Week 58	Sparsentan	139	69 (49.6)	11 (15.9)	2.909 [0.972, 8.706]	3.272 [0.989, 10.823]	10.5 [-1.0, 22.0]	0.056
		Irbesartan	143	73 (51.0)	4 (5.5)				
Female	Week 58	Sparsentan	63	44 (69.8)	8 (18.2)	2.273 [0.523, 9.881]	2.556 [0.498, 13.114]	10.2 [-8.5, 28.9]	0.308
		Irbesartan	59	25 (42.4)	2 (8.0)				

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Complete remission means an urinary protein excretion of <0.3 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1URF_FSPM: Patients with complete remission by subgroup
Full Analysis Set

Complete remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Week 58	Sparsentan						Interaction test:	0.539
<= 45 years	Week 58	Sparsentan	96	51 (53.1)	9 (17.6)	3.882 [0.885, 17.023]	4.500 [0.917, 22.083]	13.1 [-1.2, 27.4]	0.058
		Irbesartan	99	44 (44.4)	2 (4.5)				
> 45 years	Week 58	Sparsentan	106	62 (58.5)	10 (16.1)	2.177 [0.724, 6.546]	2.404 [0.708, 8.165]	8.7 [-4.5, 22.0]	0.168
		Irbesartan	103	54 (52.4)	4 (7.4)				

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Complete remission means an urinary protein excretion of <0.3 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1URF_FSPM: Patients with complete remission by subgroup
Full Analysis Set

Complete remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Week 58	Sparsentan						Interaction test:	0.681
<= 18 years	Week 58	Sparsentan	9	4 (44.4)	1 (25.0)	1.200 + [0.077, 18.745]	1.286 + [0.031, 53.512]	25.0 [-79.9, 100.0]	1.000
		Irbesartan	5	1 (20.0)	0 (0.0)				
> 18 to 40 years	Week 58	Sparsentan	102	58 (56.9)	9 (15.5)	3.957 [0.896, 17.474]	4.500 [0.925, 21.902]	11.6 [-1.0, 24.2]	0.058
		Irbesartan	109	51 (46.8)	2 (3.9)				
> 40 years	Week 58	Sparsentan	91	51 (56.0)	9 (17.6)	2.029 [0.670, 6.148]	2.250 [0.643, 7.877]	9.0 [-6.4, 24.3]	0.242
		Irbesartan	88	46 (52.3)	4 (8.7)				

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Complete remission means an urinary protein excretion of <0.3 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1URF_FSPM: Patients with complete remission by subgroup
Full Analysis Set

Complete remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Week 58	Sparsentan						Interaction test:	0.761
North America	Week 58	Sparsentan	35	12 (34.3)	0 (0.0)	NE	NE	0.0 [NE, NE]	NE
		Irbesartan	46	18 (39.1)	0 (0.0)				
Europe	Week 58	Sparsentan	98	48 (49.0)	8 (16.7)	3.111 [0.874, 11.074]	3.533 [0.881, 14.171]	11.3 [-2.7, 25.3]	0.107
		Irbesartan	115	56 (48.7)	3 (5.4)				
Asia Pacific	Week 58	Sparsentan	69	53 (76.8)	11 (20.8)	1.660 [0.509, 5.414]	1.833 [0.461, 7.287]	8.3 [-11.9, 28.4]	0.529
		Irbesartan	41	24 (58.5)	3 (12.5)				

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Complete remission means an urinary protein excretion of <0.3 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1URF_FSPM: Patients with complete remission by subgroup
Full Analysis Set

Complete remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline BMI	Week 58	Sparsentan						Interaction test:	0.064	
< 27 kg/m**2	Week 58	Sparsentan	84	46 (54.8)	12 (26.1)	10.435 [1.419, 76.757]	13.765 [1.700, 111.419]	23.6 [7.7, 39.5]	0.002	*
		Irbesartan	94	40 (42.6)	1 (2.5)					
>= 27 kg/m**2	Week 58	Sparsentan	118	67 (56.8)	7 (10.4)	1.212 [0.406, 3.614]	1.237 [0.370, 4.129]	1.8 [-10.1, 13.7]	0.771	
		Irbesartan	107	58 (54.2)	5 (8.6)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Complete remission means an urinary protein excretion of <0.3 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1URF_FSPM: Patients with complete remission by subgroup
Full Analysis Set

Complete remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Week 58	Sparsentan						Interaction test:	NE
eGFR Low and UP High	Week 58	Sparsentan	71	42 (59.2)	2 (4.8)	all n<10			NE
		Irbesartan	74	36 (48.6)	1 (2.8)				
eGFR Low and UP Low	Week 58	Sparsentan	55	29 (52.7)	6 (20.7)	all n<10			NE
		Irbesartan	55	30 (54.5)	3 (10.0)				
eGFR High and UP High	Week 58	Sparsentan	37	19 (51.4)	5 (26.3)	all n<10			NE
		Irbesartan	36	15 (41.7)	0 (0.0)				
eGFR High and UP Low	Week 58	Sparsentan	39	23 (59.0)	6 (26.1)	all n<10			NE
		Irbesartan	37	17 (45.9)	2 (11.8)				

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Complete remission means an urinary protein excretion of <0.3 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1URF_FSPM: Patients with complete remission by subgroup
Full Analysis Set

Complete remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Week 58	Sparsentan						Interaction test:	0.671
< 60 mL/min/1.73 m**2	Week 58	Sparsentan	127	71 (55.9)	8 (11.3)	1.944 [0.613, 6.161]	2.063 [0.592, 7.197]	5.5 [-5.2, 16.1]	0.367
		Irbesartan	129	69 (53.5)	4 (5.8)				
60 to < 90 mL/min/1.73 m**2	Week 58	Sparsentan	49	24 (49.0)	7 (29.2)	5.542 [0.745, 41.235]	7.412 [0.823, 66.734]	23.9 [-1.6, 49.4]	0.059
		Irbesartan	48	19 (39.6)	1 (5.3)				
>= 90 mL/min/1.73 m**2	Week 58	Sparsentan	26	18 (69.2)	4 (22.2)	2.222 [0.286, 17.269]	2.571 [0.246, 26.851]	12.2 [-22.3, 46.7]	0.626
		Irbesartan	25	10 (40.0)	1 (10.0)				

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Complete remission means an urinary protein excretion of <0.3 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1URF_FSPM: Patients with complete remission by subgroup
Full Analysis Set

Complete remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Week 58	Sparsentan						Interaction test:	NE
< 45 mL/min/1.73 m**2	Week 58	Sparsentan	82	45 (54.9)	6 (13.3)	all n<10			NE
		Irbesartan	80	44 (55.0)	3 (6.8)				
45 to < 60 mL/min/1.73 m**2	Week 58	Sparsentan	45	26 (57.8)	2 (7.7)	all n<10			NE
		Irbesartan	49	25 (51.0)	1 (4.0)				
60 to < 90 mL/min/1.73 m**2	Week 58	Sparsentan	49	24 (49.0)	7 (29.2)	all n<10			NE
		Irbesartan	48	19 (39.6)	1 (5.3)				
>= 90 mL/min/1.73 m**2	Week 58	Sparsentan	26	18 (69.2)	4 (22.2)	all n<10			NE
		Irbesartan	25	10 (40.0)	1 (10.0)				

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Complete remission means an urinary protein excretion of <0.3 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1URF_FSPM: Patients with complete remission by subgroup
Full Analysis Set

Complete remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Week 58	Sparsentan						Interaction test:	0.311
<= 1.75 g/day	Week 58	Sparsentan	98	61 (62.2)	14 (23.0)	1.744 [0.683, 4.453]	1.966 [0.645, 5.989]	9.8 [-7.4, 27.0]	0.298
		Irbesartan	94	38 (40.4)	5 (13.2)				
> 1.75 g/day	Week 58	Sparsentan	104	52 (50.0)	5 (9.6)	5.769 [0.696, 47.809]	6.277 [0.709, 55.578]	7.9 [-2.5, 18.4]	0.095
		Irbesartan	108	60 (55.6)	1 (1.7)				

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Complete remission means an urinary protein excretion of <0.3 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1URF_FSPM: Patients with complete remission by subgroup
Full Analysis Set

Complete remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline use of antihypertensives	Week 58	Sparsentan						Interaction test:	0.026	#
Yes	Week 58	Sparsentan	88	46 (52.3)	4 (8.7)	0.800 [0.229, 2.791]	0.781 [0.196, 3.115]	-2.2 [-16.5, 12.1]	1.000	
		Irbesartan	83	46 (55.4)	5 (10.9)					
No	Week 58	Sparsentan	114	67 (58.8)	15 (22.4)	11.642 [1.589, 85.300]	14.712 [1.874, 115.515]	20.5 [8.1, 32.8]	<0.001	*
		Irbesartan	119	52 (43.7)	1 (1.9)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Complete remission means an urinary protein excretion of <0.3 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1URF_FSPM: Patients with complete remission by subgroup
Full Analysis Set

Complete remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Time since renal biopsy	Week 58	Sparsentan						Interaction test:	0.322	
<= 5 years	Week 58	Sparsentan	113	58 (51.3)	10 (17.2)	2.034 [0.741, 5.589]	2.250 [0.718, 7.048]	8.8 [-5.0, 22.5]	0.178	
		Irbesartan	127	59 (46.5)	5 (8.5)					
> 5 years	Week 58	Sparsentan	89	55 (61.8)	9 (16.4)	6.382 [0.843, 48.341]	7.435 [0.901, 61.335]	13.8 [0.6, 27.0]	0.042	*
		Irbesartan	75	39 (52.0)	1 (2.6)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Complete remission means an urinary protein excretion of <0.3 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1URF_FSPM: Patients with complete remission by subgroup
Full Analysis Set

Subgroup	Time	Treatment	N	Complete remission nval (%)	Complete remission n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
History of hypertension	Week 58	Sparsentan						Interaction test:	0.300	
Yes	Week 58	Sparsentan	153	83 (54.2)	12 (14.5)	1.928 [0.760, 4.889]	2.085 [0.742, 5.854]	7.0 [-3.8, 17.7]	0.212	
		Irbesartan	157	80 (51.0)	6 (7.5)					
No	Week 58	Sparsentan	49	30 (61.2)	7 (23.3)	9.194 + [0.556, 151.969]	11.809 + [0.633, 220.441]	23.3 [3.8, 42.9]	0.036	*
		Irbesartan	45	18 (40.0)	0 (0.0)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Complete remission means an urinary protein excretion of <0.3 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1URFT_FSTM: Time to complete remission by subgroup
Full Analysis Set

Time to complete remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Sex	Sparsentan						Interaction test:	0.632	
Male	Sparsentan	139	30 (21.6)	NE		2.906	(1.507, 5.602)	0.001	*
	Irbesartan	143	13 (9.1)	NE					
Female	Sparsentan	63	13 (20.6)	NE		2.086	(0.647, 6.724)	0.218	
	Irbesartan	59	4 (6.8)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 31MAY2024

Table PT1URFT_FSTM: Time to complete remission by subgroup
Full Analysis Set

Time to complete remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Age	Sparsentan						Interaction test:	0.872	
<= 45 years	Sparsentan	96	26 (27.1)	NE		2.750	(1.319, 5.730)	0.007	*
	Irbesartan	99	10 (10.1)	NE					
> 45 years	Sparsentan	106	17 (16.0)	NE		2.458	(1.011, 5.977)	0.047	*
	Irbesartan	103	7 (6.8)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 31MAY2024

Table PT1URFT_FSTM: Time to complete remission by subgroup
Full Analysis Set

Time to complete remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Age at IgAN diagnosis	Sparsentan						Interaction test:	NE	
<= 18 years	Sparsentan	9	1 (11.1) No events in 1 group	NE		NE		NE	
	Irbesartan	5	0 (0.0)	NE					
> 18 to 40 years	Sparsentan	102	26 (25.5)	NE		2.731	(1.303, 5.726)	0.008	*
	Irbesartan	109	10 (9.2)	NE					
> 40 years	Sparsentan	91	16 (17.6)	NE		2.203	(0.899, 5.398)	0.084	
	Irbesartan	88	7 (8.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 31MAY2024

Table PT1URFT_FSTM: Time to complete remission by subgroup
Full Analysis Set

Time to complete remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Geographic region	Sparsentan						Interaction test:	0.118	
North America	Sparsentan	35	4 (11.4)	NE		1.218	(0.244, 6.078)	0.810	
	Irbesartan	46	3 (6.5)	NE					
Europe	Sparsentan	98	21 (21.4)	NE		4.370	(1.847, 10.336)	<0.001	*
	Irbesartan	115	7 (6.1)	NE					
Asia Pacific	Sparsentan	69	18 (26.1)	NE		1.430	(0.585, 3.496)	0.433	
	Irbesartan	41	7 (17.1)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 31MAY2024

Table PT1URFT_FSTM: Time to complete remission by subgroup
Full Analysis Set

Time to complete remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline BMI	Sparsentan						Interaction test:	0.528	
< 27 kg/m**2	Sparsentan	84	22 (26.2)	NE		3.107	(1.362, 7.087)	0.007	*
	Irbesartan	94	8 (8.5)	NE					
>= 27 kg/m**2	Sparsentan	118	21 (17.8)	NE		2.509	(1.102, 5.712)	0.028	*
	Irbesartan	107	8 (7.5)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 31MAY2024

Table PT1URFT_FSTM: Time to complete remission by subgroup
Full Analysis Set

Time to complete remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Randomization strata	Sparsentan						Interaction test:	0.808	
eGFR Low and UP High	Sparsentan	71	5 (7.0)	NE		1.591	(0.378, 6.684)	0.526	
	Irbesartan	74	3 (4.1)	NE					
eGFR Low and UP Low	Sparsentan	55	18 (32.7)	94.3	(59.0, NE)	3.475	(1.376, 8.777)	0.008	*
	Irbesartan	55	6 (10.9)	NE					
eGFR High and UP High	Sparsentan	37	6 (16.2)	NE		2.831	(0.570, 14.070)	0.203	
	Irbesartan	36	2 (5.6)	NE					
eGFR High and UP Low	Sparsentan	39	14 (35.9)	NE		2.115	(0.802, 5.573)	0.130	
	Irbesartan	37	6 (16.2)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 31MAY2024

Table PT1URFT_FSTM: Time to complete remission by subgroup
Full Analysis Set

Time to complete remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.058	
< 60 mL/min/1.73 m**2	Sparsentan	127	23 (18.1)	NE		2.641	(1.207, 5.780)	0.015	*
	Irbesartan	129	9 (7.0)	NE					
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	14 (28.6)	NE		4.870	(1.334, 17.774)	0.017	*
	Irbesartan	48	3 (6.3)	NE					
>= 90 mL/min/1.73 m**2	Sparsentan	26	6 (23.1)	NE		0.780	(0.232, 2.618)	0.688	
	Irbesartan	25	5 (20.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 31MAY2024

Table PT1URFT_FSTM: Time to complete remission by subgroup
Full Analysis Set

Time to complete remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eGFR Group 2	Sparsentan						Interaction test:	0.011	#
< 45 mL/min/1.73 m**2	Sparsentan	82	12 (14.6)	NE		1.274	(0.507, 3.202)	0.606	
	Irbesartan	80	8 (10.0)	NE					
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	11 (24.4)	NE		13.639	(1.734, 107.307)	0.013	*
	Irbesartan	49	1 (2.0)	NE					
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	14 (28.6)	NE		4.870	(1.334, 17.774)	0.017	*
	Irbesartan	48	3 (6.3)	NE					
>= 90 mL/min/1.73 m**2	Sparsentan	26	6 (23.1)	NE		0.780	(0.232, 2.618)	0.688	
	Irbesartan	25	5 (20.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 31MAY2024

Table PT1URFT_FSTM: Time to complete remission by subgroup
Full Analysis Set

Time to complete remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline urine protein excretion	Sparsentan						Interaction test:	0.426	
<= 1.75 g/day	Sparsentan	98	31 (31.6)	NE		2.220	(1.160, 4.250)	0.016	*
	Irbesartan	94	13 (13.8)	NE					
> 1.75 g/day	Sparsentan	104	12 (11.5)	NE		4.243	(1.296, 13.891)	0.017	*
	Irbesartan	108	4 (3.7)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 31MAY2024

Table PT1URFT_FSTM: Time to complete remission by subgroup
Full Analysis Set

Time to complete remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.034	#
Yes	Sparsentan	88	11 (12.5)	NE		1.294	(0.542, 3.090)	0.562	
	Irbesartan	83	10 (12.0)	NE					
No	Sparsentan	114	32 (28.1)	NE		4.035	(1.761, 9.247)	<0.001	*
	Irbesartan	119	7 (5.9)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 31MAY2024

Table PT1URFT_FSTM: Time to complete remission by subgroup
Full Analysis Set

Time to complete remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Time since renal biopsy	Sparsentan						Interaction test:	0.210	
<= 5 years	Sparsentan	113	25 (22.1)	NE		2.232	(1.156, 4.308)	0.017	*
	Irbesartan	127	14 (11.0)	NE					
> 5 years	Sparsentan	89	18 (20.2)	NE		5.140	(1.496, 17.657)	0.009	*
	Irbesartan	75	3 (4.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 31MAY2024

Table PT1URFT_FSTM: Time to complete remission by subgroup
Full Analysis Set

Time to complete remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
History of hypertension	Sparsentan						Interaction test:	0.366	
Yes	Sparsentan	153	31 (20.3)	NE		3.082	(1.547, 6.138)	0.001	*
	Irbesartan	157	11 (7.0)	NE					
No	Sparsentan	49	12 (24.5)	NE		1.401	(0.494, 3.970)	0.526	
	Irbesartan	45	6 (13.3)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 31MAY2024

Figure PF1URFT_FSKM: Time to complete remission by subgroup
Full Analysis Set

Study: PROTECT
Baseline eGFR Group 2: < 45 mL/min/1.73 m**2



Sparsentan	82	59	47	35	18	8
Irbesartan	80	67	51	35	11	2

_____
Complete remission means an urinary protein excretion of <0.3 g/day. No event means no complete remission.
eGFR = estimated glomerular filtration rate.
Reference table: PT1URFT_FSTM

Figure PF1URFT_FSKM: Time to complete remission by subgroup
Full Analysis Set

Study: PROTECT
Baseline eGFR Group 2: 45 to < 60 mL/min/1.73 m**2



Sparsentan	45	30	23	18	8	4
Irbesartan	49	35	28	22	13	6

_____
Complete remission means an urinary protein excretion of <0.3 g/day. No event means no complete remission.
eGFR = estimated glomerular filtration rate.
Reference table: PT1URFT_FSTM

Figure PF1URFT_FSKM: Time to complete remission by subgroup
Full Analysis Set

Study: PROTECT
Baseline eGFR Group 2: 60 to < 90 mL/min/1.73 m**2



Sparsentan	49	27	23	15	6	2
Irbesartan	48	34	27	15	5	2

_____
Complete remission means an urinary protein excretion of <0.3 g/day. No event means no complete remission.
eGFR = estimated glomerular filtration rate.
Reference table: PT1URFT_FSTM

Figure PF1URFT_FSKM: Time to complete remission by subgroup
Full Analysis Set

Study: PROTECT
Baseline eGFR Group 2: >= 90 mL/min/1.73 m**2



Sparsentan	26	18	17	10	4	2
Irbesartan	25	16	7	6	3	2

_____
Complete remission means an urinary protein excretion of <0.3 g/day. No event means no complete remission.
eGFR = estimated glomerular filtration rate.
Reference table: PT1URFT_FSTM

Figure PF1URFT_FSKM: Time to complete remission by subgroup
Full Analysis Set

Study: PROTECT
Baseline use of antihypertensives: Yes



Sparsentan	88	60	48	34	12	7
Irbesartan	83	66	47	36	15	5

_____
Complete remission means an urinary protein excretion of <0.3 g/day. No event means no complete remission.
eGFR = estimated glomerular filtration rate.
Reference table: PT1URFT_FSTM

Figure PF1URFT_FSKM: Time to complete remission by subgroup
Full Analysis Set

Study: PROTECT
Baseline use of antihypertensives: No



Sparsentan	114	74	62	44	24	9
Irbesartan	119	86	66	42	17	7

_____
Complete remission means an urinary protein excretion of <0.3 g/day. No event means no complete remission.
eGFR = estimated glomerular filtration rate.
Reference table: PT1URFT_FSTM

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	eGFR	Baseline	Sparsentan	139	139 (100.0)	53.52 (22.58)	25.0	36.00	45.00	66.00	126.0	
			Irbesartan	143	143 (100.0)	57.03 (23.53)	26.0	38.00	50.00	70.00	123.0	
		Week 6	Sparsentan	139	133 (95.7)	52.58 (22.55)	21.0	35.00	48.00	65.00	121.0	
			Irbesartan	143	139 (97.2)	55.73 (23.29)	21.0	37.00	50.00	70.00	120.0	
		Week 36	Sparsentan	139	92 (66.2)	50.26 (22.05)	18.0	34.00	46.00	62.00	123.0	
			Irbesartan	143	97 (67.8)	51.90 (23.55)	7.0	34.00	48.00	64.00	125.0	
		Week 58	Sparsentan	139	64 (46.0)	47.86 (21.45)	13.0	33.00	42.00	59.50	121.0	
			Irbesartan	143	70 (49.0)	50.09 (22.58)	18.0	33.00	44.50	66.00	122.0	
	Change from baseline in eGFR	Week 6	Sparsentan	139	133 (95.7)	-0.89 (6.70)	-27.0	-4.00	-1.00	2.00	20.0	0.04 [-0.19, 0.28]
			Irbesartan	143	139 (97.2)	-1.18 (6.63)	-31.0	-5.00	-1.00	2.00	20.0	
		Week 36	Sparsentan	139	92 (66.2)	-3.24 (7.63)	-26.0	-8.00	-2.00	1.00	26.0	0.11 [-0.18, 0.39]
			Irbesartan	143	97 (67.8)	-4.07 (8.14)	-32.0	-7.00	-4.00	0.00	15.0	
		Week 58	Sparsentan	139	64 (46.0)	-4.83 (7.63)	-33.0	-8.00	-4.00	0.00	13.0	0.17 [-0.16, 0.51]
			Irbesartan	143	70 (49.0)	-6.19 (7.88)	-24.0	-12.00	-7.00	-1.00	12.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Female	eGFR	Baseline	Sparsentan	63	63 (100.0)	64.22 (26.67)	24.0	41.00	59.00	86.00	128.0	
			Irbesartan	59	59 (100.0)	57.19 (23.89)	27.0	39.00	50.00	70.00	123.0	
		Week 6	Sparsentan	63	60 (95.2)	63.32 (24.52)	26.0	44.00	60.00	82.00	120.0	
			Irbesartan	59	56 (94.9)	55.20 (23.83)	19.0	39.00	47.00	68.00	116.0	
		Week 36	Sparsentan	63	44 (69.8)	62.57 (23.33)	25.0	45.00	60.00	81.50	114.0	
			Irbesartan	59	36 (61.0)	47.08 (20.70)	15.0	33.50	42.00	55.50	109.0	
		Week 58	Sparsentan	63	46 (73.0)	61.89 (25.89)	23.0	43.00	56.50	85.00	133.0	
			Irbesartan	59	25 (42.4)	44.32 (20.63)	13.0	32.00	38.00	54.00	116.0	
	Change from baseline in eGFR	Week 6	Sparsentan	63	60 (95.2)	-1.67 (9.58)	-43.0	-4.00	-0.50	3.00	14.0	0.09 [-0.28, 0.45]
			Irbesartan	59	56 (94.9)	-2.39 (6.34)	-19.0	-6.50	-2.50	3.50	9.0	
		Week 36	Sparsentan	63	44 (69.8)	-5.09 (10.56)	-39.0	-9.50	-4.00	1.00	17.0	0.06 [-0.38, 0.50]
			Irbesartan	59	36 (61.0)	-5.61 (6.34)	-24.0	-9.00	-5.00	-1.00	3.0	
		Week 58	Sparsentan	63	46 (73.0)	-4.98 (10.62)	-34.0	-10.00	-5.00	2.00	24.0	0.16 [-0.33, 0.65]
			Irbesartan	59	25 (42.4)	-6.52 (8.05)	-24.0	-12.00	-6.00	0.00	8.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
<= 45 years	eGFR	Baseline	Sparsentan	96	96 (100.0)	63.16 (27.44)	25.0	41.00	55.50	83.00	128.0	
			Irbesartan	99	99 (100.0)	65.52 (26.04)	26.0	42.00	63.00	80.00	123.0	
		Week 6	Sparsentan	96	93 (96.9)	61.13 (26.48)	23.0	38.00	56.00	82.00	121.0	
			Irbesartan	99	97 (98.0)	63.19 (25.41)	23.0	43.00	57.00	80.00	120.0	
		Week 36	Sparsentan	96	65 (67.7)	61.75 (26.47)	18.0	42.00	56.00	84.00	123.0	
			Irbesartan	99	65 (65.7)	55.91 (26.42)	7.0	37.00	53.00	65.00	125.0	
		Week 58	Sparsentan	96	49 (51.0)	63.96 (27.96)	13.0	42.00	58.00	85.00	133.0	
			Irbesartan	99	43 (43.4)	53.70 (26.09)	13.0	34.00	45.00	69.00	122.0	
	Change from baseline in eGFR	Week 6	Sparsentan	96	93 (96.9)	-2.28 (8.84)	-43.0	-5.00	-1.00	1.00	15.0	0.01 [-0.28, 0.29]
			Irbesartan	99	97 (98.0)	-2.35 (6.22)	-17.0	-6.00	-2.00	2.00	14.0	
		Week 36	Sparsentan	96	65 (67.7)	-5.72 (9.89)	-39.0	-12.00	-3.00	1.00	12.0	-0.01 [-0.35, 0.34]
			Irbesartan	99	65 (65.7)	-5.66 (8.94)	-32.0	-12.00	-5.00	1.00	15.0	
		Week 58	Sparsentan	96	49 (51.0)	-6.14 (11.23)	-34.0	-15.00	-5.00	0.00	24.0	0.13 [-0.28, 0.54]
			Irbesartan	99	43 (43.4)	-7.40 (8.35)	-24.0	-13.00	-7.00	0.00	10.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 45 years	eGFR	Baseline	Sparsentan	106	106 (100.0)	51.15 (19.68)	24.0	36.00	45.00	64.00	103.0	
			Irbesartan	103	103 (100.0)	48.97 (17.56)	27.0	36.00	44.00	56.00	104.0	
		Week 6	Sparsentan	106	100 (94.3)	51.07 (19.59)	21.0	35.00	49.00	64.50	104.0	
			Irbesartan	103	98 (95.1)	48.05 (18.43)	19.0	35.00	43.00	59.00	102.0	
		Week 36	Sparsentan	106	71 (67.0)	47.37 (17.02)	24.0	34.00	45.00	62.00	97.0	
			Irbesartan	103	68 (66.0)	45.51 (17.53)	23.0	32.00	39.50	56.00	98.0	
		Week 58	Sparsentan	106	61 (57.5)	45.51 (17.14)	21.0	32.00	43.00	56.00	94.0	
			Irbesartan	103	52 (50.5)	44.33 (17.35)	18.0	31.00	38.00	55.00	88.0	
	Change from baseline in eGFR	Week 6	Sparsentan	106	100 (94.3)	-0.06 (6.30)	-21.0	-3.00	0.00	3.00	20.0	0.10 [-0.18, 0.38]
			Irbesartan	103	98 (95.1)	-0.71 (6.81)	-31.0	-4.00	0.00	3.00	20.0	
		Week 36	Sparsentan	106	71 (67.0)	-2.11 (7.06)	-22.0	-7.00	-2.00	1.00	26.0	0.19 [-0.14, 0.52]
			Irbesartan	103	68 (66.0)	-3.37 (6.15)	-25.0	-6.00	-3.00	-1.00	13.0	
		Week 58	Sparsentan	106	61 (57.5)	-3.89 (6.51)	-19.0	-8.00	-4.00	0.00	14.0	0.21 [-0.16, 0.58]
			Irbesartan	103	52 (50.5)	-5.35 (7.43)	-24.0	-10.00	-6.00	-0.50	12.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age at IgAN diagnosis												
<= 18 years	eGFR	Baseline	Sparsentan	9	9 (100.0)	57.33 (29.45)	32.0	35.00	41.00	70.00	119.0	
			Irbesartan	5	5 (100.0)	66.60 (34.46)	35.0	39.00	66.00	72.00	121.0	
		Week 6	Sparsentan	9	9 (100.0)	50.00 (20.99)	26.0	36.00	38.00	62.00	86.0	
			Irbesartan	5	5 (100.0)	64.80 (32.64)	34.0	37.00	61.00	79.00	113.0	
		Week 36	Sparsentan	9	6 (66.7)	56.50 (22.13)	34.0	36.00	51.00	82.00	85.0	
			Irbesartan	5	2 (40.0)	45.00 (19.80)	31.0	31.00	45.00	59.00	59.0	
		Week 58	Sparsentan	9	4 (44.4)	58.50 (29.85)	33.0	34.50	52.50	82.50	96.0	
			Irbesartan	5	1 (20.0)	26.00	26.0	26.00	26.00	26.00	26.0	
	Change from baseline in eGFR	Week 6	Sparsentan	9	9 (100.0)	-7.33 (10.75)	-33.0	-8.00	-4.00	-1.00	1.0	-0.59 [-1.71, 0.52]
			Irbesartan	5	5 (100.0)	-1.80 (5.63)	-8.0	-5.00	-2.00	-1.00	7.0	
		Week 36	Sparsentan	9	6 (66.7)	-11.67 (12.82)	-34.0	-19.00	-7.00	-2.00	-1.0	-0.36 [-1.97, 1.25]
			Irbesartan	5	2 (40.0)	-7.50 (0.71)	-8.0	-8.00	-7.50	-7.00	-7.0	
		Week 58	Sparsentan	9	4 (44.4)	-11.00 (9.83)	-23.0	-19.00	-9.50	-3.00	-2.0	NE
			Irbesartan	5	1 (20.0)	-13.00	-13.0	-13.00	-13.00	-13.00	-13.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 18 to 40 years	eGFR	Baseline	Sparsentan	102	102 (100.0)	63.27 (26.69)	25.0	42.00	56.50	85.00	128.0	
			Irbesartan	109	109 (100.0)	60.08 (25.53)	26.0	40.00	52.00	71.00	123.0	
		Week 6	Sparsentan	102	98 (96.1)	61.86 (26.08)	23.0	40.00	57.00	82.00	121.0	
			Irbesartan	109	105 (96.3)	58.53 (24.53)	23.0	40.00	54.00	72.00	120.0	
		Week 36	Sparsentan	102	68 (66.7)	60.79 (26.00)	18.0	40.50	54.50	82.50	123.0	
			Irbesartan	109	74 (67.9)	51.97 (24.73)	7.0	34.00	47.50	64.00	125.0	
		Week 58	Sparsentan	102	56 (54.9)	61.07 (26.96)	13.0	41.50	53.50	84.50	133.0	
			Irbesartan	109	51 (46.8)	51.37 (25.06)	13.0	34.00	42.00	66.00	122.0	
	Change from baseline in eGFR	Week 6	Sparsentan	102	98 (96.1)	-1.44 (8.29)	-43.0	-4.00	-1.00	2.00	15.0	0.07 [-0.21, 0.34]
			Irbesartan	109	105 (96.3)	-1.92 (5.95)	-17.0	-5.00	-1.00	2.00	14.0	
		Week 36	Sparsentan	102	68 (66.7)	-4.68 (9.02)	-39.0	-10.00	-3.00	1.50	10.0	0.04 [-0.29, 0.37]
			Irbesartan	109	74 (67.9)	-5.03 (8.18)	-32.0	-10.00	-4.50	0.00	15.0	
		Week 58	Sparsentan	102	56 (54.9)	-5.48 (10.46)	-34.0	-9.50	-5.00	1.00	24.0	0.08 [-0.30, 0.46]
			Irbesartan	109	51 (46.8)	-6.22 (7.43)	-24.0	-10.00	-7.00	0.00	10.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 40 years	eGFR	Baseline	Sparsentan	91	91 (100.0)	49.62 (18.73)	24.0	35.00	45.00	64.00	101.0	
			Irbesartan	88	88 (100.0)	52.82 (19.64)	27.0	38.00	48.00	65.50	106.0	
		Week 6	Sparsentan	91	86 (94.5)	49.77 (19.05)	21.0	34.00	46.00	62.00	99.0	
			Irbesartan	88	85 (96.6)	51.39 (20.82)	19.0	36.00	46.00	69.00	108.0	
		Week 36	Sparsentan	91	62 (68.1)	46.84 (17.21)	22.0	33.00	45.00	62.00	97.0	
			Irbesartan	88	57 (64.8)	49.00 (20.47)	15.0	33.00	42.00	61.00	109.0	
		Week 58	Sparsentan	91	50 (54.9)	45.12 (17.47)	21.0	30.00	43.00	57.00	94.0	
			Irbesartan	88	43 (48.9)	45.77 (17.83)	18.0	33.00	41.00	56.00	88.0	
	Change from baseline in eGFR	Week 6	Sparsentan	91	86 (94.5)	-0.13 (6.25)	-21.0	-3.00	0.00	3.00	20.0	0.13 [-0.17, 0.43]
			Irbesartan	88	85 (96.6)	-1.02 (7.31)	-31.0	-5.00	-2.00	3.00	20.0	
		Week 36	Sparsentan	91	62 (68.1)	-2.16 (7.39)	-22.0	-7.00	-2.50	1.00	26.0	0.21 [-0.15, 0.57]
			Irbesartan	88	57 (64.8)	-3.68 (7.15)	-25.0	-6.00	-4.00	0.00	13.0	
		Week 58	Sparsentan	91	50 (54.9)	-3.74 (6.68)	-19.0	-8.00	-3.50	0.00	14.0	0.32 [-0.09, 0.73]
			Irbesartan	88	43 (48.9)	-6.19 (8.49)	-24.0	-13.00	-7.00	0.00	12.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Geographic region												
North America	eGFR	Baseline	Sparsentan	35	35 (100.0)	56.54 (25.93)	25.0	38.00	50.00	67.00	121.0	
			Irbesartan	46	46 (100.0)	55.93 (23.44)	26.0	36.00	50.50	71.00	123.0	
		Week 6	Sparsentan	35	34 (97.1)	54.41 (25.54)	21.0	33.00	51.00	67.00	120.0	
			Irbesartan	46	44 (95.7)	53.43 (22.83)	21.0	35.00	46.00	71.00	107.0	
		Week 36	Sparsentan	35	19 (54.3)	57.68 (24.72)	27.0	36.00	51.00	78.00	104.0	
			Irbesartan	46	26 (56.5)	46.23 (21.24)	23.0	32.00	39.00	60.00	123.0	
		Week 58	Sparsentan	35	14 (40.0)	60.93 (28.04)	23.0	41.00	55.50	85.00	119.0	
			Irbesartan	46	18 (39.1)	44.83 (16.47)	21.0	34.00	39.00	60.00	72.0	
	Change from baseline in eGFR	Week 6	Sparsentan	35	34 (97.1)	-2.47 (8.28)	-33.0	-4.00	-1.00	1.00	9.0	-0.08 [-0.53, 0.37]
			Irbesartan	46	44 (95.7)	-1.84 (7.80)	-17.0	-6.50	-3.00	3.50	20.0	
		Week 36	Sparsentan	35	19 (54.3)	-4.68 (9.85)	-34.0	-10.00	-2.00	3.00	8.0	-0.10 [-0.69, 0.49]
			Irbesartan	46	26 (56.5)	-3.77 (8.81)	-19.0	-8.00	-3.00	1.00	14.0	
		Week 58	Sparsentan	35	14 (40.0)	-6.86 (13.34)	-33.0	-14.00	-5.50	-1.00	24.0	-0.16 [-0.86, 0.54]
			Irbesartan	46	18 (39.1)	-5.06 (8.94)	-20.0	-10.00	-7.00	1.00	12.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Europe	eGFR	Baseline	Sparsentan	98	98 (100.0)	56.00 (24.15)	24.0	36.00	48.00	71.00	128.0	
			Irbesartan	115	115 (100.0)	56.89 (24.29)	27.0	38.00	50.00	69.00	123.0	
		Week 6	Sparsentan	98	92 (93.9)	55.46 (24.07)	25.0	34.50	50.00	70.00	117.0	
			Irbesartan	115	111 (96.5)	55.81 (24.15)	19.0	37.00	48.00	69.00	120.0	
		Week 36	Sparsentan	98	57 (58.2)	54.18 (24.65)	18.0	37.00	47.00	65.00	123.0	
			Irbesartan	115	77 (67.0)	51.42 (23.72)	7.0	34.00	46.00	63.00	125.0	
		Week 58	Sparsentan	98	47 (48.0)	51.98 (23.92)	13.0	36.00	45.00	66.00	133.0	
			Irbesartan	115	54 (47.0)	49.57 (23.91)	18.0	33.00	43.00	59.00	122.0	
	Change from baseline in eGFR	Week 6	Sparsentan	98	92 (93.9)	-0.49 (6.30)	-17.0	-4.00	0.00	2.50	15.0	0.15 [-0.12, 0.43]
			Irbesartan	115	111 (96.5)	-1.47 (6.36)	-31.0	-5.00	-1.00	2.00	14.0	
		Week 36	Sparsentan	98	57 (58.2)	-2.54 (7.68)	-26.0	-5.00	-2.00	2.00	17.0	0.17 [-0.18, 0.51]
			Irbesartan	115	77 (67.0)	-3.78 (7.22)	-32.0	-6.00	-4.00	0.00	15.0	
		Week 58	Sparsentan	98	47 (48.0)	-2.96 (7.68)	-19.0	-8.00	-1.00	2.00	14.0	0.35 [-0.04, 0.74]
			Irbesartan	115	54 (47.0)	-5.54 (7.08)	-24.0	-10.00	-6.50	-1.00	10.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asia Pacific	eGFR	Baseline	Sparsentan	69	69 (100.0)	58.23 (24.20)	26.0	40.00	51.00	74.00	121.0	
			Irbesartan	41	41 (100.0)	58.90 (22.11)	31.0	41.00	52.00	69.00	112.0	
		Week 6	Sparsentan	69	67 (97.1)	57.31 (22.32)	26.0	38.00	54.00	70.00	121.0	
			Irbesartan	41	40 (97.6)	57.30 (22.20)	23.0	41.50	53.50	70.00	119.0	
		Week 36	Sparsentan	69	60 (87.0)	53.22 (21.33)	19.0	34.00	50.00	66.00	108.0	
			Irbesartan	41	30 (73.2)	52.27 (22.10)	15.0	38.00	44.50	70.00	101.0	
		Week 58	Sparsentan	69	49 (71.0)	53.35 (23.71)	21.0	33.00	48.00	64.00	121.0	
			Irbesartan	41	23 (56.1)	49.13 (22.13)	13.0	33.00	42.00	65.00	98.0	
	Change from baseline in eGFR	Week 6	Sparsentan	69	67 (97.1)	-1.33 (9.03)	-43.0	-4.00	-1.00	3.00	20.0	0.00 [-0.39, 0.39]
			Irbesartan	41	40 (97.6)	-1.35 (5.71)	-19.0	-4.00	-1.50	2.00	9.0	
		Week 36	Sparsentan	69	60 (87.0)	-4.80 (9.19)	-39.0	-8.50	-4.00	-1.00	26.0	0.24 [-0.19, 0.68]
			Irbesartan	41	30 (73.2)	-6.93 (7.64)	-24.0	-12.00	-5.50	-2.00	5.0	
		Week 58	Sparsentan	69	49 (71.0)	-6.18 (8.42)	-34.0	-9.00	-6.00	-1.00	13.0	0.33 [-0.17, 0.83]
			Irbesartan	41	23 (56.1)	-8.96 (8.53)	-24.0	-15.00	-9.00	-2.00	8.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline BMI												
< 27 kg/m**2	eGFR	Baseline	Sparsentan	84	84 (100.0)	58.71 (24.55)	24.0	39.00	52.50	72.00	126.0	
			Irbesartan	94	94 (100.0)	58.86 (26.11)	26.0	39.00	50.00	70.00	123.0	
		Week 6	Sparsentan	84	78 (92.9)	58.27 (23.19)	23.0	37.00	55.00	74.00	117.0	
			Irbesartan	94	91 (96.8)	56.64 (25.44)	19.0	37.00	50.00	71.00	120.0	
		Week 36	Sparsentan	84	56 (66.7)	55.96 (24.60)	19.0	34.00	50.50	72.50	123.0	
			Irbesartan	94	60 (63.8)	51.20 (27.21)	7.0	33.00	41.50	60.50	125.0	
		Week 58	Sparsentan	84	46 (54.8)	53.35 (21.52)	21.0	36.00	47.00	71.00	96.0	
			Irbesartan	94	38 (40.4)	50.89 (26.65)	13.0	33.00	41.50	60.00	122.0	
	Change from baseline in eGFR	Week 6	Sparsentan	84	78 (92.9)	-1.46 (9.46)	-43.0	-4.00	0.00	3.00	20.0	0.10 [-0.20, 0.41]
			Irbesartan	94	91 (96.8)	-2.24 (5.58)	-16.0	-5.00	-2.00	2.00	12.0	
		Week 36	Sparsentan	84	56 (66.7)	-4.18 (10.24)	-39.0	-8.00	-3.00	0.00	26.0	0.21 [-0.15, 0.58]
			Irbesartan	94	60 (63.8)	-6.10 (7.91)	-32.0	-11.00	-5.00	-2.00	15.0	
		Week 58	Sparsentan	84	46 (54.8)	-5.41 (10.04)	-34.0	-10.00	-5.50	0.00	24.0	0.28 [-0.15, 0.71]
			Irbesartan	94	38 (40.4)	-7.79 (6.39)	-24.0	-12.00	-7.00	-5.00	7.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 27 kg/m**2	eGFR	Baseline	Sparsentan	118	118 (100.0)	55.53 (24.28)	25.0	38.00	48.00	69.00	128.0	
			Irbesartan	107	107 (100.0)	55.66 (21.19)	27.0	38.00	50.00	70.00	114.0	
		Week 6	Sparsentan	118	115 (97.5)	54.32 (23.92)	21.0	35.00	50.00	67.00	121.0	
			Irbesartan	107	103 (96.3)	54.81 (21.56)	21.0	39.00	48.00	69.00	119.0	
		Week 36	Sparsentan	118	80 (67.8)	53.04 (22.10)	18.0	36.00	47.00	64.00	114.0	
			Irbesartan	107	73 (68.2)	50.10 (18.68)	20.0	34.00	45.00	64.00	101.0	
		Week 58	Sparsentan	118	64 (54.2)	54.00 (26.29)	13.0	35.00	47.00	60.50	133.0	
			Irbesartan	107	57 (53.3)	47.02 (18.61)	21.0	32.00	41.00	59.00	96.0	
	Change from baseline in eGFR	Week 6	Sparsentan	118	115 (97.5)	-0.90 (6.25)	-20.0	-4.00	-1.00	2.00	15.0	-0.00 [-0.27, 0.26]
			Irbesartan	107	103 (96.3)	-0.89 (7.31)	-31.0	-4.00	0.00	3.00	20.0	
		Week 36	Sparsentan	118	80 (67.8)	-3.60 (7.47)	-26.0	-8.00	-2.50	1.50	12.0	-0.06 [-0.38, 0.26]
			Irbesartan	107	73 (68.2)	-3.16 (7.31)	-25.0	-6.00	-3.00	1.00	13.0	
		Week 58	Sparsentan	118	64 (54.2)	-4.52 (8.15)	-33.0	-8.50	-4.00	1.00	13.0	0.09 [-0.27, 0.45]
			Irbesartan	107	57 (53.3)	-5.26 (8.64)	-24.0	-12.00	-4.00	1.00	12.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Randomization strata												
eGFR Low and UP High	eGFR	Baseline	Sparsentan	71	71 (100.0)	40.34 (9.83)	25.0	31.00	39.00	48.00	67.0	
			Irbesartan	74	74 (100.0)	41.78 (9.97)	26.0	34.00	39.00	50.00	66.0	
		Week 6	Sparsentan	71	69 (97.2)	39.59 (10.79)	21.0	32.00	38.00	49.00	65.0	
			Irbesartan	74	70 (94.6)	39.64 (10.00)	21.0	32.00	38.50	46.00	64.0	
		Week 36	Sparsentan	71	49 (69.0)	38.76 (11.13)	18.0	32.00	39.00	46.00	65.0	
			Irbesartan	74	47 (63.5)	34.83 (10.69)	7.0	28.00	33.00	41.00	58.0	
		Week 58	Sparsentan	71	42 (59.2)	37.93 (10.71)	13.0	30.00	36.50	45.00	61.0	
			Irbesartan	74	34 (45.9)	33.53 (9.57)	13.0	28.00	33.50	38.00	55.0	
	Change from baseline in eGFR	Week 6	Sparsentan	71	69 (97.2)	-0.55 (5.71)	-27.0	-3.00	-1.00	1.00	15.0	0.20 [-0.14, 0.53]
			Irbesartan	74	70 (94.6)	-1.57 (4.60)	-12.0	-5.00	-2.00	2.00	9.0	
		Week 36	Sparsentan	71	49 (69.0)	-2.00 (5.48)	-13.0	-5.00	-2.00	1.00	10.0	0.59 [0.18, 1.00]
			Irbesartan	74	47 (63.5)	-5.87 (7.49)	-32.0	-8.00	-5.00	-2.00	5.0	
		Week 58	Sparsentan	71	42 (59.2)	-3.79 (5.70)	-18.0	-7.00	-3.50	0.00	7.0	0.47 [0.02, 0.93]
			Irbesartan	74	34 (45.9)	-6.68 (6.56)	-20.0	-10.00	-7.00	-2.00	7.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR Low and UP Low	eGFR	Baseline	Sparsentan	55	55 (100.0)	42.11 (9.25)	24.0	35.00	42.00	50.00	62.0	
			Irbesartan	55	55 (100.0)	44.27 (9.37)	27.0	38.00	43.00	50.00	71.0	
		Week 6	Sparsentan	55	50 (90.9)	42.20 (10.15)	26.0	34.00	39.50	50.00	70.0	
			Irbesartan	55	54 (98.2)	43.26 (9.91)	19.0	36.00	43.00	48.00	68.0	
		Week 36	Sparsentan	55	35 (63.6)	42.23 (11.93)	25.0	34.00	41.00	48.00	76.0	
			Irbesartan	55	40 (72.7)	41.28 (8.99)	28.0	34.50	40.00	47.50	66.0	
		Week 58	Sparsentan	55	28 (50.9)	40.89 (10.81)	24.0	32.50	41.50	47.50	73.0	
			Irbesartan	55	29 (52.7)	39.76 (9.36)	25.0	33.00	39.00	45.00	59.0	
	Change from baseline in eGFR	Week 6	Sparsentan	55	50 (90.9)	0.44 (6.74)	-17.0	-3.00	0.00	3.00	20.0	0.23 [-0.16, 0.61]
			Irbesartan	55	54 (98.2)	-1.09 (6.81)	-31.0	-4.00	0.00	3.00	16.0	
		Week 36	Sparsentan	55	35 (63.6)	-0.20 (7.33)	-11.0	-4.00	-1.00	3.00	26.0	0.38 [-0.08, 0.84]
			Irbesartan	55	40 (72.7)	-2.45 (4.29)	-11.0	-5.00	-3.00	0.50	13.0	
		Week 58	Sparsentan	55	28 (50.9)	-1.75 (5.31)	-11.0	-5.50	-1.50	2.00	14.0	0.28 [-0.24, 0.80]
			Irbesartan	55	29 (52.7)	-3.41 (6.51)	-19.0	-7.00	-3.00	1.00	10.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP High	eGFR	Baseline	Sparsentan	37	37 (100.0)	82.76 (20.47)	51.0	66.00	77.00	91.00	128.0	
			Irbesartan	36	36 (100.0)	79.83 (14.94)	57.0	69.00	74.00	91.50	109.0	
		Week 6	Sparsentan	37	35 (94.6)	79.23 (18.78)	56.0	62.00	74.00	90.00	121.0	
			Irbesartan	36	34 (94.4)	77.12 (14.73)	56.0	63.00	76.00	85.00	108.0	
		Week 36	Sparsentan	37	26 (70.3)	76.31 (19.95)	51.0	62.00	71.50	86.00	118.0	
			Irbesartan	36	22 (61.1)	73.91 (19.24)	40.0	60.00	67.00	87.00	123.0	
		Week 58	Sparsentan	37	20 (54.1)	81.40 (23.66)	54.0	60.00	75.50	93.50	133.0	
			Irbesartan	36	15 (41.7)	69.67 (16.59)	37.0	55.00	72.00	78.00	98.0	
	Change from baseline in eGFR	Week 6	Sparsentan	37	35 (94.6)	-3.89 (11.57)	-43.0	-8.00	-1.00	4.00	12.0	-0.08 [-0.56, 0.39]
			Irbesartan	36	34 (94.4)	-3.09 (6.45)	-17.0	-6.00	-3.00	2.00	12.0	
		Week 36	Sparsentan	37	26 (70.3)	-9.46 (12.24)	-39.0	-17.00	-9.00	1.00	7.0	-0.26 [-0.83, 0.31]
			Irbesartan	36	22 (61.1)	-6.55 (10.24)	-25.0	-15.00	-6.50	0.00	14.0	
		Week 58	Sparsentan	37	20 (54.1)	-7.40 (14.33)	-34.0	-15.00	-10.50	3.00	24.0	0.23 [-0.44, 0.90]
			Irbesartan	36	15 (41.7)	-10.20 (8.54)	-23.0	-15.00	-12.00	-5.00	10.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP Low	eGFR	Baseline	Sparsentan	39	39 (100.0)	83.15 (16.11)	57.0	70.00	80.00	96.00	126.0	
			Irbesartan	37	37 (100.0)	84.57 (22.97)	50.0	66.00	79.00	104.00	123.0	
		Week 6	Sparsentan	39	39 (100.0)	81.46 (16.34)	53.0	67.00	78.00	98.00	113.0	
			Irbesartan	37	37 (100.0)	83.92 (20.66)	43.0	69.00	76.00	101.00	120.0	
		Week 36	Sparsentan	39	26 (66.7)	77.54 (17.72)	47.0	65.00	75.50	90.00	123.0	
			Irbesartan	37	24 (64.9)	75.63 (21.39)	41.0	61.50	68.50	87.50	125.0	
		Week 58	Sparsentan	39	20 (51.3)	77.20 (15.38)	58.0	62.50	74.50	88.50	106.0	
			Irbesartan	37	17 (45.9)	75.06 (22.55)	37.0	60.00	71.00	88.00	122.0	
	Change from baseline in eGFR	Week 6	Sparsentan	39	39 (100.0)	-1.69 (7.14)	-20.0	-7.00	-1.00	3.00	14.0	-0.13 [-0.58, 0.32]
			Irbesartan	37	37 (100.0)	-0.65 (9.02)	-19.0	-6.00	0.00	6.00	20.0	
		Week 36	Sparsentan	39	26 (66.7)	-6.58 (7.83)	-26.0	-12.00	-5.50	-2.00	12.0	-0.39 [-0.95, 0.17]
			Irbesartan	37	24 (64.9)	-3.29 (9.20)	-24.0	-10.00	-3.50	4.00	15.0	
		Week 58	Sparsentan	39	20 (51.3)	-9.10 (10.09)	-33.0	-16.00	-7.50	-4.00	13.0	-0.22 [-0.87, 0.43]
			Irbesartan	37	17 (45.9)	-6.88 (10.40)	-24.0	-14.00	-7.00	0.00	12.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 1												
< 60 mL/min/1.73 m**2	eGFR	Baseline	Sparsentan	127	127 (100.0)	41.08 (9.35)	24.0	33.00	41.00	49.00	59.0	
			Irbesartan	129	129 (100.0)	42.28 (8.61)	26.0	35.00	41.00	50.00	59.0	
		Week 6	Sparsentan	127	120 (94.5)	40.94 (10.91)	21.0	33.00	38.00	50.00	73.0	
			Irbesartan	129	126 (97.7)	41.75 (10.91)	19.0	34.00	41.00	47.00	76.0	
		Week 36	Sparsentan	127	86 (67.7)	40.59 (11.63)	18.0	33.00	39.50	48.00	76.0	
			Irbesartan	129	88 (68.2)	38.16 (10.97)	7.0	31.50	37.00	44.50	67.0	
		Week 58	Sparsentan	127	69 (54.3)	38.91 (10.70)	13.0	32.00	39.00	45.00	73.0	
			Irbesartan	129	66 (51.2)	37.79 (11.87)	13.0	31.00	36.00	44.00	71.0	
	Change from baseline in eGFR	Week 6	Sparsentan	127	120 (94.5)	0.15 (6.29)	-27.0	-3.00	0.00	2.00	20.0	0.12 [-0.13, 0.37]
			Irbesartan	129	126 (97.7)	-0.60 (6.14)	-31.0	-4.00	0.00	3.00	20.0	
		Week 36	Sparsentan	127	86 (67.7)	-1.05 (6.24)	-13.0	-4.00	-1.50	2.00	26.0	0.40 [0.10, 0.70]
			Irbesartan	129	88 (68.2)	-3.60 (6.61)	-32.0	-6.00	-3.00	0.00	13.0	
		Week 58	Sparsentan	127	69 (54.3)	-2.68 (5.58)	-18.0	-6.00	-2.00	1.00	14.0	0.25 [-0.09, 0.59]
			Irbesartan	129	66 (51.2)	-4.29 (7.16)	-20.0	-9.00	-5.50	1.00	12.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	eGFR	Baseline	Sparsentan	49	49 (100.0)	72.71 (8.32)	60.0	66.00	71.00	79.00	89.0	
			Irbesartan	48	48 (100.0)	71.60 (7.60)	60.0	66.50	70.00	76.00	89.0	
		Week 6	Sparsentan	49	47 (95.9)	69.87 (9.06)	56.0	62.00	69.00	76.00	90.0	
			Irbesartan	48	44 (91.7)	69.11 (9.14)	54.0	61.50	69.50	75.00	85.0	
		Week 36	Sparsentan	49	30 (61.2)	66.13 (10.46)	47.0	57.00	65.00	72.00	86.0	
			Irbesartan	48	32 (66.7)	64.59 (10.63)	40.0	58.50	63.50	70.00	87.0	
		Week 58	Sparsentan	49	23 (46.9)	66.22 (10.67)	51.0	58.00	64.00	74.00	91.0	
			Irbesartan	48	19 (39.6)	61.42 (11.45)	37.0	54.00	60.00	73.00	78.0	
	Change from baseline in eGFR	Week 6	Sparsentan	49	47 (95.9)	-2.68 (7.30)	-21.0	-7.00	-2.00	3.00	12.0	0.01 [-0.40, 0.42]
			Irbesartan	48	44 (91.7)	-2.73 (7.52)	-19.0	-7.00	-3.00	3.00	14.0	
		Week 36	Sparsentan	49	30 (61.2)	-7.30 (8.27)	-26.0	-12.00	-8.50	-2.00	12.0	-0.03 [-0.53, 0.47]
			Irbesartan	48	32 (66.7)	-7.06 (8.22)	-25.0	-13.00	-6.50	-2.00	12.0	
		Week 58	Sparsentan	49	23 (46.9)	-7.70 (9.50)	-19.0	-15.00	-10.00	-4.00	24.0	0.48 [-0.14, 1.09]
			Irbesartan	48	19 (39.6)	-11.95 (8.07)	-24.0	-18.00	-14.00	-5.00	1.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	eGFR	Baseline	Sparsentan	26	26 (100.0)	104.04 (11.51)	90.0	95.00	102.00	111.00	128.0	
			Irbesartan	25	25 (100.0)	105.56 (9.98)	91.0	98.00	105.00	112.00	123.0	
		Week 6	Sparsentan	26	26 (100.0)	99.81 (11.47)	77.0	92.00	99.00	104.00	121.0	
			Irbesartan	25	25 (100.0)	101.48 (10.76)	80.0	95.00	101.00	108.00	120.0	
		Week 36	Sparsentan	26	20 (76.9)	95.10 (14.20)	63.0	86.00	93.50	103.00	123.0	
			Irbesartan	25	13 (52.0)	100.31 (15.45)	80.0	89.00	98.00	109.00	125.0	
		Week 58	Sparsentan	26	18 (69.2)	94.56 (17.79)	61.0	85.00	90.00	105.00	133.0	
			Irbesartan	25	10 (40.0)	95.30 (14.34)	77.0	84.00	94.50	98.00	122.0	
	Change from baseline in eGFR	Week 6	Sparsentan	26	26 (100.0)	-4.23 (12.06)	-43.0	-5.00	-1.00	1.00	13.0	-0.02 [-0.56, 0.53]
			Irbesartan	25	25 (100.0)	-4.08 (6.00)	-16.0	-8.00	-3.00	0.00	7.0	
		Week 36	Sparsentan	26	20 (76.9)	-10.65 (12.44)	-39.0	-16.50	-10.50	-2.50	7.0	-0.53 [-1.24, 0.18]
			Irbesartan	25	13 (52.0)	-4.15 (11.72)	-24.0	-12.00	-4.00	3.00	15.0	
		Week 58	Sparsentan	26	18 (69.2)	-9.78 (14.72)	-34.0	-20.00	-9.50	2.00	13.0	-0.09 [-0.87, 0.68]
			Irbesartan	25	10 (40.0)	-8.60 (6.74)	-21.0	-12.00	-9.50	-1.00	0.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 2												
< 45 mL/min/1.73 m**2	eGFR	Baseline	Sparsentan	82	82 (100.0)	35.37 (5.60)	24.0	31.00	35.00	41.00	44.0	
			Irbesartan	80	80 (100.0)	36.58 (4.61)	26.0	33.00	37.00	40.00	44.0	
		Week 6	Sparsentan	82	79 (96.3)	36.10 (8.12)	21.0	31.00	35.00	40.00	58.0	
			Irbesartan	80	78 (97.5)	35.71 (6.41)	19.0	31.00	36.50	40.00	50.0	
		Week 36	Sparsentan	82	54 (65.9)	34.41 (7.94)	18.0	30.00	34.00	38.00	54.0	
			Irbesartan	80	56 (70.0)	32.38 (7.27)	7.0	28.50	33.00	37.00	47.0	
		Week 58	Sparsentan	82	44 (53.7)	33.05 (7.28)	13.0	29.00	33.00	37.50	48.0	
			Irbesartan	80	42 (52.5)	31.98 (7.50)	13.0	28.00	33.00	36.00	52.0	
	Change from baseline in eGFR	Week 6	Sparsentan	82	79 (96.3)	0.87 (4.98)	-10.0	-2.00	0.00	3.00	15.0	0.37 [0.05, 0.69]
			Irbesartan	80	78 (97.5)	-0.88 (4.50)	-16.0	-4.00	-0.50	2.00	10.0	
		Week 36	Sparsentan	82	54 (65.9)	-1.09 (5.34)	-13.0	-4.00	-1.00	2.00	10.0	0.51 [0.13, 0.89]
			Irbesartan	80	56 (70.0)	-4.11 (6.37)	-32.0	-6.00	-3.00	0.00	5.0	
		Week 58	Sparsentan	82	44 (53.7)	-2.77 (5.12)	-18.0	-6.00	-2.50	1.00	6.0	0.41 [-0.01, 0.84]
			Irbesartan	80	42 (52.5)	-5.05 (5.87)	-18.0	-9.00	-6.00	-1.00	8.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
45 to < 60 mL/min/1.73 m**2	eGFR	Baseline	Sparsentan	45	45 (100.0)	51.49 (4.57)	45.0	48.00	51.00	55.00	59.0	
			Irbesartan	49	49 (100.0)	51.59 (4.45)	45.0	48.00	51.00	55.00	59.0	
		Week 6	Sparsentan	45	41 (91.1)	50.27 (9.48)	23.0	46.00	50.00	54.00	73.0	
			Irbesartan	49	48 (98.0)	51.56 (9.50)	21.0	46.00	51.00	57.50	76.0	
		Week 36	Sparsentan	45	32 (71.1)	51.03 (9.16)	39.0	45.00	49.00	56.00	76.0	
			Irbesartan	49	32 (65.3)	48.28 (8.83)	33.0	41.50	48.00	54.00	67.0	
		Week 58	Sparsentan	45	25 (55.6)	49.24 (7.46)	42.0	44.00	47.00	52.00	73.0	
			Irbesartan	49	24 (49.0)	47.96 (11.31)	31.0	40.00	45.00	54.50	71.0	
	Change from baseline in eGFR	Week 6	Sparsentan	45	41 (91.1)	-1.24 (8.15)	-27.0	-4.00	-1.00	1.00	20.0	-0.13 [-0.55, 0.28]
			Irbesartan	49	48 (98.0)	-0.15 (8.17)	-31.0	-4.00	0.50	4.00	20.0	
		Week 36	Sparsentan	45	32 (71.1)	-0.97 (7.63)	-12.0	-5.00	-2.00	2.00	26.0	0.24 [-0.25, 0.73]
			Irbesartan	49	32 (65.3)	-2.72 (7.03)	-19.0	-6.00	-2.50	1.50	13.0	
		Week 58	Sparsentan	45	25 (55.6)	-2.52 (6.43)	-15.0	-7.00	-2.00	1.00	14.0	0.06 [-0.50, 0.62]
			Irbesartan	49	24 (49.0)	-2.96 (8.98)	-20.0	-9.00	-2.00	3.50	12.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	eGFR	Baseline	Sparsentan	49	49 (100.0)	72.71 (8.32)	60.0	66.00	71.00	79.00	89.0	
			Irbesartan	48	48 (100.0)	71.60 (7.60)	60.0	66.50	70.00	76.00	89.0	
		Week 6	Sparsentan	49	47 (95.9)	69.87 (9.06)	56.0	62.00	69.00	76.00	90.0	
			Irbesartan	48	44 (91.7)	69.11 (9.14)	54.0	61.50	69.50	75.00	85.0	
		Week 36	Sparsentan	49	30 (61.2)	66.13 (10.46)	47.0	57.00	65.00	72.00	86.0	
			Irbesartan	48	32 (66.7)	64.59 (10.63)	40.0	58.50	63.50	70.00	87.0	
		Week 58	Sparsentan	49	23 (46.9)	66.22 (10.67)	51.0	58.00	64.00	74.00	91.0	
			Irbesartan	48	19 (39.6)	61.42 (11.45)	37.0	54.00	60.00	73.00	78.0	
	Change from baseline in eGFR	Week 6	Sparsentan	49	47 (95.9)	-2.68 (7.30)	-21.0	-7.00	-2.00	3.00	12.0	0.01 [-0.40, 0.42]
			Irbesartan	48	44 (91.7)	-2.73 (7.52)	-19.0	-7.00	-3.00	3.00	14.0	
		Week 36	Sparsentan	49	30 (61.2)	-7.30 (8.27)	-26.0	-12.00	-8.50	-2.00	12.0	-0.03 [-0.53, 0.47]
			Irbesartan	48	32 (66.7)	-7.06 (8.22)	-25.0	-13.00	-6.50	-2.00	12.0	
		Week 58	Sparsentan	49	23 (46.9)	-7.70 (9.50)	-19.0	-15.00	-10.00	-4.00	24.0	0.48 [-0.14, 1.09]
			Irbesartan	48	19 (39.6)	-11.95 (8.07)	-24.0	-18.00	-14.00	-5.00	1.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	eGFR	Baseline	Sparsentan	26	26 (100.0)	104.04 (11.51)	90.0	95.00	102.00	111.00	128.0	
			Irbesartan	25	25 (100.0)	105.56 (9.98)	91.0	98.00	105.00	112.00	123.0	
		Week 6	Sparsentan	26	26 (100.0)	99.81 (11.47)	77.0	92.00	99.00	104.00	121.0	
			Irbesartan	25	25 (100.0)	101.48 (10.76)	80.0	95.00	101.00	108.00	120.0	
		Week 36	Sparsentan	26	20 (76.9)	95.10 (14.20)	63.0	86.00	93.50	103.00	123.0	
			Irbesartan	25	13 (52.0)	100.31 (15.45)	80.0	89.00	98.00	109.00	125.0	
		Week 58	Sparsentan	26	18 (69.2)	94.56 (17.79)	61.0	85.00	90.00	105.00	133.0	
			Irbesartan	25	10 (40.0)	95.30 (14.34)	77.0	84.00	94.50	98.00	122.0	
	Change from baseline in eGFR	Week 6	Sparsentan	26	26 (100.0)	-4.23 (12.06)	-43.0	-5.00	-1.00	1.00	13.0	-0.02 [-0.56, 0.53]
			Irbesartan	25	25 (100.0)	-4.08 (6.00)	-16.0	-8.00	-3.00	0.00	7.0	
		Week 36	Sparsentan	26	20 (76.9)	-10.65 (12.44)	-39.0	-16.50	-10.50	-2.50	7.0	-0.53 [-1.24, 0.18]
			Irbesartan	25	13 (52.0)	-4.15 (11.72)	-24.0	-12.00	-4.00	3.00	15.0	
		Week 58	Sparsentan	26	18 (69.2)	-9.78 (14.72)	-34.0	-20.00	-9.50	2.00	13.0	-0.09 [-0.87, 0.68]
			Irbesartan	25	10 (40.0)	-8.60 (6.74)	-21.0	-12.00	-9.50	-1.00	0.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline urine protein excretion												
<= 1.75 g/day	eGFR	Baseline	Sparsentan	98	98 (100.0)	59.05 (24.14)	24.0	40.00	53.50	77.00	126.0	
			Irbesartan	94	94 (100.0)	59.67 (25.13)	27.0	40.00	52.00	71.00	123.0	
		Week 6	Sparsentan	98	93 (94.9)	59.52 (23.68)	21.0	38.00	54.00	73.00	113.0	
			Irbesartan	94	91 (96.8)	59.05 (24.72)	19.0	41.00	54.00	72.00	120.0	
		Week 36	Sparsentan	98	70 (71.4)	57.37 (22.51)	25.0	38.00	51.00	73.00	123.0	
			Irbesartan	94	61 (64.9)	53.26 (22.50)	20.0	37.00	46.00	65.00	125.0	
		Week 58	Sparsentan	98	58 (59.2)	55.84 (22.10)	24.0	38.00	50.00	73.00	106.0	
			Irbesartan	94	36 (38.3)	53.44 (22.33)	25.0	36.50	52.50	65.00	122.0	
	Change from baseline in eGFR	Week 6	Sparsentan	98	93 (94.9)	-0.26 (6.82)	-17.0	-4.00	0.00	3.00	20.0	0.06 [-0.23, 0.35]
			Irbesartan	94	91 (96.8)	-0.69 (7.88)	-31.0	-5.00	0.00	4.00	20.0	
		Week 36	Sparsentan	98	70 (71.4)	-1.76 (7.35)	-18.0	-6.00	-2.00	2.00	26.0	0.08 [-0.26, 0.42]
			Irbesartan	94	61 (64.9)	-2.33 (7.10)	-24.0	-6.00	-3.00	2.00	15.0	
		Week 58	Sparsentan	98	58 (59.2)	-3.83 (8.91)	-33.0	-7.00	-3.00	2.00	24.0	0.02 [-0.40, 0.43]
			Irbesartan	94	36 (38.3)	-3.97 (8.37)	-24.0	-10.00	-2.00	1.50	12.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 1.75 g/day	eGFR	Baseline	Sparsentan	104	104 (100.0)	54.79 (24.54)	25.0	37.00	48.50	66.00	128.0	
			Irbesartan	108	108 (100.0)	54.82 (22.00)	26.0	37.50	48.00	68.00	116.0	
		Week 6	Sparsentan	104	100 (96.2)	52.57 (23.24)	23.0	35.00	47.50	63.50	121.0	
			Irbesartan	108	104 (96.3)	52.54 (21.82)	21.0	36.50	46.00	65.50	116.0	
		Week 36	Sparsentan	104	66 (63.5)	50.92 (23.46)	18.0	34.00	46.50	63.00	118.0	
			Irbesartan	108	72 (66.7)	48.33 (23.04)	7.0	32.00	40.00	60.00	123.0	
		Week 58	Sparsentan	104	52 (50.0)	51.37 (26.57)	13.0	33.00	44.50	59.50	133.0	
			Irbesartan	108	59 (54.6)	45.59 (21.65)	13.0	31.00	38.00	55.00	116.0	
	Change from baseline in eGFR	Week 6	Sparsentan	104	100 (96.2)	-1.94 (8.37)	-43.0	-4.00	-1.00	1.50	15.0	0.05 [-0.23, 0.32]
			Irbesartan	108	104 (96.3)	-2.26 (5.06)	-17.0	-5.00	-2.00	1.00	12.0	
		Week 36	Sparsentan	104	66 (63.5)	-6.05 (9.48)	-39.0	-10.00	-4.00	-1.00	10.0	0.03 [-0.30, 0.37]
			Irbesartan	108	72 (66.7)	-6.32 (7.76)	-32.0	-10.00	-5.00	-2.00	14.0	
		Week 58	Sparsentan	104	52 (50.0)	-6.08 (8.94)	-34.0	-10.50	-6.00	0.00	13.0	0.20 [-0.18, 0.57]
			Irbesartan	108	59 (54.6)	-7.68 (7.29)	-24.0	-12.00	-8.00	-2.00	10.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline use of antihypertensives												
Yes	eGFR	Baseline	Sparsentan	88	88 (100.0)	51.08 (21.98)	25.0	35.00	44.00	65.50	128.0	
			Irbesartan	83	83 (100.0)	50.61 (18.68)	26.0	36.00	45.00	62.00	108.0	
		Week 6	Sparsentan	88	83 (94.3)	50.78 (21.91)	25.0	33.00	44.00	60.00	121.0	
			Irbesartan	83	77 (92.8)	48.83 (18.85)	19.0	34.00	44.00	58.00	108.0	
		Week 36	Sparsentan	88	55 (62.5)	48.29 (21.94)	18.0	33.00	44.00	56.00	114.0	
			Irbesartan	83	59 (71.1)	45.69 (20.79)	7.0	32.00	38.00	54.00	109.0	
		Week 58	Sparsentan	88	44 (50.0)	48.57 (24.99)	13.0	32.50	43.00	55.00	133.0	
			Irbesartan	83	44 (53.0)	44.68 (17.82)	21.0	31.50	37.50	54.00	97.0	
	Change from baseline in eGFR	Week 6	Sparsentan	88	83 (94.3)	-0.49 (6.38)	-21.0	-3.00	-1.00	3.00	13.0	0.17 [-0.14, 0.48]
			Irbesartan	83	77 (92.8)	-1.62 (7.07)	-31.0	-4.00	0.00	2.00	13.0	
		Week 36	Sparsentan	88	55 (62.5)	-3.62 (6.28)	-22.0	-8.00	-3.00	1.00	10.0	0.03 [-0.34, 0.39]
			Irbesartan	83	59 (71.1)	-3.80 (7.01)	-32.0	-6.00	-4.00	0.00	12.0	
		Week 58	Sparsentan	88	44 (50.0)	-4.34 (5.88)	-18.0	-7.50	-4.50	0.00	6.0	0.20 [-0.22, 0.62]
			Irbesartan	83	44 (53.0)	-5.75 (8.04)	-24.0	-10.50	-6.00	1.00	12.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	eGFR	Baseline	Sparsentan	114	114 (100.0)	61.32 (25.28)	24.0	41.00	56.00	80.00	126.0	
			Irbesartan	119	119 (100.0)	61.59 (25.58)	28.0	41.00	55.00	76.00	123.0	
		Week 6	Sparsentan	114	110 (96.5)	59.79 (24.26)	21.0	38.00	56.50	74.00	120.0	
			Irbesartan	119	118 (99.2)	59.98 (25.03)	23.0	40.00	54.00	76.00	120.0	
		Week 36	Sparsentan	114	81 (71.1)	58.28 (23.16)	19.0	40.00	51.00	76.00	123.0	
			Irbesartan	119	74 (62.2)	54.50 (23.77)	15.0	38.00	49.50	64.00	125.0	
		Week 58	Sparsentan	114	66 (57.9)	57.17 (23.41)	21.0	41.00	52.50	73.00	119.0	
			Irbesartan	119	51 (42.9)	51.92 (24.95)	13.0	34.00	45.00	66.00	122.0	
	Change from baseline in eGFR	Week 6	Sparsentan	114	110 (96.5)	-1.61 (8.55)	-43.0	-4.00	-1.00	2.00	20.0	-0.02 [-0.28, 0.24]
			Irbesartan	119	118 (99.2)	-1.47 (6.23)	-17.0	-5.00	-2.00	3.00	20.0	
		Week 36	Sparsentan	114	81 (71.1)	-3.99 (10.03)	-39.0	-8.00	-3.00	2.00	26.0	0.11 [-0.20, 0.43]
			Irbesartan	119	74 (62.2)	-5.04 (8.22)	-25.0	-10.00	-4.00	0.00	15.0	
		Week 58	Sparsentan	114	66 (57.9)	-5.26 (10.55)	-34.0	-11.00	-4.00	1.00	24.0	0.16 [-0.21, 0.52]
			Irbesartan	119	51 (42.9)	-6.73 (7.79)	-24.0	-12.00	-7.00	-2.00	10.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Time since renal biopsy												
<= 5 years	eGFR	Baseline	Sparsentan	113	113 (100.0)	59.19 (25.65)	24.0	39.00	52.00	74.00	126.0	
			Irbesartan	127	127 (100.0)	61.37 (24.93)	28.0	41.00	56.00	73.00	123.0	
		Week 6	Sparsentan	113	106 (93.8)	58.44 (25.73)	21.0	37.00	53.50	76.00	121.0	
			Irbesartan	127	122 (96.1)	59.78 (25.18)	21.0	40.00	55.00	74.00	120.0	
		Week 36	Sparsentan	113	72 (63.7)	58.81 (25.96)	18.0	40.00	52.50	77.00	123.0	
			Irbesartan	127	80 (63.0)	54.80 (25.15)	7.0	37.50	48.00	66.00	125.0	
		Week 58	Sparsentan	113	56 (49.6)	57.84 (25.76)	13.0	41.50	54.00	72.50	121.0	
			Irbesartan	127	56 (44.1)	52.95 (23.72)	13.0	36.00	45.50	69.00	122.0	
	Change from baseline in eGFR	Week 6	Sparsentan	113	106 (93.8)	-1.31 (8.41)	-43.0	-4.00	-1.00	2.00	20.0	0.02 [-0.24, 0.28]
			Irbesartan	127	122 (96.1)	-1.47 (7.17)	-31.0	-5.00	-1.50	3.00	20.0	
		Week 36	Sparsentan	113	72 (63.7)	-4.17 (9.37)	-39.0	-9.50	-3.00	0.50	26.0	0.05 [-0.26, 0.37]
			Irbesartan	127	80 (63.0)	-4.66 (8.95)	-32.0	-9.50	-4.00	1.00	15.0	
		Week 58	Sparsentan	113	56 (49.6)	-6.32 (9.16)	-34.0	-11.50	-6.00	-1.00	14.0	-0.03 [-0.40, 0.34]
			Irbesartan	127	56 (44.1)	-6.02 (9.12)	-24.0	-12.50	-7.00	0.50	12.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 5 years	eGFR	Baseline	Sparsentan	89	89 (100.0)	53.90 (22.45)	28.0	36.00	44.00	66.00	128.0	
			Irbesartan	75	75 (100.0)	49.81 (19.15)	26.0	36.00	43.00	64.00	108.0	
		Week 6	Sparsentan	89	87 (97.8)	52.84 (20.55)	26.0	36.00	46.00	65.00	115.0	
			Irbesartan	75	73 (97.3)	48.56 (18.12)	19.0	35.00	43.00	59.00	95.0	
		Week 36	Sparsentan	89	64 (71.9)	49.11 (18.31)	25.0	34.50	45.00	59.50	114.0	
			Irbesartan	75	53 (70.7)	44.25 (17.18)	23.0	32.00	38.00	55.00	90.0	
		Week 58	Sparsentan	89	54 (60.7)	49.46 (22.14)	23.0	33.00	42.50	57.00	133.0	
			Irbesartan	75	39 (52.0)	42.28 (18.11)	18.0	29.00	36.00	53.00	97.0	
	Change from baseline in eGFR	Week 6	Sparsentan	89	87 (97.8)	-0.91 (6.76)	-33.0	-4.00	0.00	2.00	14.0	0.12 [-0.19, 0.43]
			Irbesartan	75	73 (97.3)	-1.63 (5.41)	-16.0	-5.00	-2.00	2.00	13.0	
		Week 36	Sparsentan	89	64 (71.9)	-3.47 (7.91)	-34.0	-7.50	-3.00	1.50	10.0	0.11 [-0.25, 0.47]
			Irbesartan	75	53 (70.7)	-4.23 (5.37)	-18.0	-6.00	-4.00	-1.00	10.0	
		Week 58	Sparsentan	89	54 (60.7)	-3.41 (8.56)	-29.0	-8.00	-2.50	2.00	24.0	0.43 [0.01, 0.85]
			Irbesartan	75	39 (52.0)	-6.64 (5.74)	-18.0	-10.00	-7.00	-2.00	6.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: History of hypertension												
Yes	eGFR	Baseline	Sparsentan	153	153 (100.0)	53.08 (22.63)	24.0	36.00	45.00	66.00	128.0	
			Irbesartan	157	157 (100.0)	54.81 (21.78)	26.0	38.00	50.00	68.00	123.0	
		Week 6	Sparsentan	153	144 (94.1)	52.47 (22.59)	21.0	35.00	47.50	66.00	121.0	
			Irbesartan	157	151 (96.2)	53.49 (22.08)	19.0	37.00	47.00	68.00	120.0	
		Week 36	Sparsentan	153	101 (66.0)	50.85 (22.30)	18.0	34.00	46.00	63.00	118.0	
			Irbesartan	157	105 (66.9)	50.17 (23.79)	7.0	33.00	42.00	61.00	125.0	
		Week 58	Sparsentan	153	82 (53.6)	50.68 (23.80)	13.0	33.00	45.00	59.00	133.0	
			Irbesartan	157	76 (48.4)	48.14 (22.34)	18.0	33.00	39.50	57.50	122.0	
	Change from baseline in eGFR	Week 6	Sparsentan	153	144 (94.1)	-0.63 (6.96)	-33.0	-3.50	-0.50	2.50	20.0	0.10 [-0.13, 0.33]
			Irbesartan	157	151 (96.2)	-1.32 (6.86)	-31.0	-5.00	-1.00	3.00	20.0	
		Week 36	Sparsentan	153	101 (66.0)	-2.91 (8.05)	-34.0	-7.00	-2.00	1.00	26.0	0.11 [-0.17, 0.38]
			Irbesartan	157	105 (66.9)	-3.74 (7.61)	-32.0	-7.00	-4.00	1.00	15.0	
		Week 58	Sparsentan	153	82 (53.6)	-3.73 (7.64)	-23.0	-8.00	-4.00	1.00	24.0	0.27 [-0.04, 0.59]
			Irbesartan	157	76 (48.4)	-5.87 (8.07)	-24.0	-12.00	-6.00	0.00	12.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	eGFR	Baseline	Sparsentan	49	49 (100.0)	68.65 (26.08)	29.0	46.00	69.00	89.00	126.0	
			Irbesartan	45	45 (100.0)	65.00 (27.83)	31.0	41.00	52.00	86.00	123.0	
		Week 6	Sparsentan	49	49 (100.0)	66.06 (23.98)	26.0	48.00	62.00	83.00	120.0	
			Irbesartan	45	44 (97.8)	62.75 (26.43)	23.0	42.50	51.00	81.00	119.0	
		Week 36	Sparsentan	49	35 (71.4)	64.03 (22.95)	32.0	46.00	63.00	82.00	123.0	
			Irbesartan	45	28 (62.2)	52.18 (19.17)	17.0	37.00	49.50	62.50	95.0	
		Week 58	Sparsentan	49	28 (57.1)	62.64 (24.00)	29.0	42.00	61.00	85.00	119.0	
			Irbesartan	45	19 (42.2)	50.26 (21.76)	13.0	33.00	48.00	69.00	98.0	
	Change from baseline in eGFR	Week 6	Sparsentan	49	49 (100.0)	-2.59 (9.46)	-43.0	-5.00	-1.00	1.00	12.0	-0.05 [-0.45, 0.36]
			Irbesartan	45	44 (97.8)	-2.23 (5.37)	-16.0	-5.50	-2.00	1.50	7.0	
		Week 36	Sparsentan	49	35 (71.4)	-6.51 (9.96)	-39.0	-12.00	-5.00	0.00	10.0	0.09 [-0.41, 0.58]
			Irbesartan	45	28 (62.2)	-7.29 (7.50)	-25.0	-12.50	-4.50	-2.50	4.0	
		Week 58	Sparsentan	49	28 (57.1)	-8.29 (11.51)	-34.0	-16.00	-6.50	-0.50	13.0	-0.04 [-0.62, 0.54]
			Irbesartan	45	19 (42.2)	-7.89 (7.05)	-24.0	-10.00	-8.00	-5.00	8.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Sex	Overall	Sparsentan						Interaction:	0.135
Male	Week 6	Sparsentan	139	133 (95.7)	-0.95 (0.61)	(-2.15, 0.24)	0.15 (0.85)	(-1.53, 1.82)	0.864
		Irbesartan	143	139 (97.2)	-1.10 (0.60)	(-2.27, 0.07)			
	Week 36	Sparsentan	139	92 (66.2)	-3.27 (0.71)	(-4.67, -1.88)	0.68 (0.99)	(-1.27, 2.63)	0.494
		Irbesartan	143	97 (67.8)	-3.95 (0.69)	(-5.31, -2.60)			
	Week 58	Sparsentan	139	64 (46.0)	-4.67 (0.84)	(-6.32, -3.02)	1.13 (1.17)	(-1.16, 3.42)	0.332
		Irbesartan	143	70 (49.0)	-5.80 (0.81)	(-7.39, -4.22)			
Female	Week 6	Sparsentan	63	60 (95.2)	-1.49 (0.97)	(-3.40, 0.41)	1.01 (1.40)	(-1.74, 3.77)	0.469
		Irbesartan	59	56 (94.9)	-2.51 (1.00)	(-4.48, -0.53)			
	Week 36	Sparsentan	63	44 (69.8)	-4.63 (1.09)	(-6.77, -2.48)	1.50 (1.63)	(-1.71, 4.71)	0.358
		Irbesartan	59	36 (61.0)	-6.13 (1.21)	(-8.50, -3.76)			
	Week 58	Sparsentan	63	46 (73.0)	-4.61 (1.11)	(-6.79, -2.43)	2.53 (1.82)	(-1.04, 6.10)	0.164
		Irbesartan	59	25 (42.4)	-7.14 (1.43)	(-9.95, -4.33)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age	Overall	Sparsentan						Interaction:	0.723
<= 45 years	Week 6	Sparsentan	96	93 (96.9)	-2.40 (0.85)	(-4.07, -0.73)	-0.05 (1.19)	(-2.40, 2.29)	0.963
		Irbesartan	99	97 (98.0)	-2.35 (0.84)	(-3.99, -0.70)			
	Week 36	Sparsentan	96	65 (67.7)	-5.58 (0.98)	(-7.50, -3.65)	0.06 (1.39)	(-2.67, 2.78)	0.968
		Irbesartan	99	65 (65.7)	-5.63 (0.98)	(-7.55, -3.71)			
	Week 58	Sparsentan	96	49 (51.0)	-5.67 (1.13)	(-7.88, -3.45)	1.26 (1.64)	(-1.95, 4.47)	0.442
		Irbesartan	99	43 (43.4)	-6.93 (1.19)	(-9.25, -4.60)			
> 45 years	Week 6	Sparsentan	106	100 (94.3)	0.12 (0.61)	(-1.07, 1.31)	0.83 (0.86)	(-0.86, 2.52)	0.334
		Irbesartan	103	98 (95.1)	-0.71 (0.61)	(-1.91, 0.49)			
	Week 36	Sparsentan	106	71 (67.0)	-1.98 (0.70)	(-3.35, -0.61)	1.52 (1.00)	(-0.44, 3.48)	0.128
		Irbesartan	103	68 (66.0)	-3.50 (0.71)	(-4.90, -2.10)			
	Week 58	Sparsentan	106	61 (57.5)	-3.69 (0.76)	(-5.19, -2.20)	1.68 (1.11)	(-0.50, 3.87)	0.131
		Irbesartan	103	52 (50.5)	-5.37 (0.81)	(-6.97, -3.78)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age at IgAN diagnosis	Overall	Sparsentan						Interaction:	0.172
<= 18 years	Week 6	Sparsentan	9	9 (100.0)	-7.25 (3.26)	(-13.77, -0.72)	-5.36 (5.58)	(-16.52, 5.80)	0.340
		Irbesartan	5	5 (100.0)	-1.88 (4.42)	(-10.72, 6.95)			
	Week 36	Sparsentan	9	6 (66.7)	-9.57 (4.03)	(-17.62, -1.51)	-1.50 (7.92)	(-17.35, 14.35)	0.851
		Irbesartan	5	2 (40.0)	-8.07 (6.86)	(-21.79, 5.65)			
	Week 58	Sparsentan	9	4 (44.4)	-8.67 (4.99)	(-18.66, 1.31)	7.30 (10.96)	(-14.62, 29.23)	0.508
		Irbesartan	5	1 (20.0)	-15.98 (9.83)	(-35.63, 3.68)			
> 18 to 40 years	Week 6	Sparsentan	102	98 (96.1)	-1.40 (0.76)	(-2.89, 0.09)	0.66 (1.06)	(-1.41, 2.74)	0.531
		Irbesartan	109	105 (96.3)	-2.06 (0.74)	(-3.51, -0.62)			
	Week 36	Sparsentan	102	68 (66.7)	-4.33 (0.88)	(-6.05, -2.60)	0.90 (1.22)	(-1.49, 3.29)	0.460
		Irbesartan	109	74 (67.9)	-5.23 (0.84)	(-6.88, -3.57)			
	Week 58	Sparsentan	102	56 (54.9)	-4.78 (0.97)	(-6.69, -2.87)	1.23 (1.40)	(-1.51, 3.97)	0.378
		Irbesartan	109	51 (46.8)	-6.02 (1.00)	(-7.97, -4.06)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 40 years	Week 6	Sparsentan	91	86 (94.5)	-0.17 (0.69)	(-1.53, 1.19)	0.60 (0.98)	(-1.33, 2.53)	0.542
		Irbesartan	88	85 (96.6)	-0.77 (0.70)	(-2.14, 0.60)			
	Week 36	Sparsentan	91	62 (68.1)	-2.25 (0.79)	(-3.80, -0.70)	1.26 (1.14)	(-0.97, 3.50)	0.266
		Irbesartan	88	57 (64.8)	-3.52 (0.82)	(-5.12, -1.91)			
	Week 58	Sparsentan	91	50 (54.9)	-3.81 (0.88)	(-5.54, -2.08)	2.20 (1.29)	(-0.33, 4.73)	0.089
		Irbesartan	88	43 (48.9)	-6.01 (0.94)	(-7.85, -4.16)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Geographic region	Overall	Sparsentan						Interaction:	0.424
North America	Week 6	Sparsentan	35	34 (97.1)	-2.52 (1.28)	(-5.03, -0.01)	-0.86 (1.70)	(-4.20, 2.48)	0.612
		Irbesartan	46	44 (95.7)	-1.66 (1.12)	(-3.86, 0.54)			
	Week 36	Sparsentan	35	19 (54.3)	-4.36 (1.65)	(-7.61, -1.10)	-0.66 (2.19)	(-4.96, 3.64)	0.763
		Irbesartan	46	26 (56.5)	-3.70 (1.42)	(-6.49, -0.90)			
	Week 58	Sparsentan	35	14 (40.0)	-5.87 (1.94)	(-9.69, -2.05)	-0.31 (2.59)	(-5.40, 4.77)	0.903
		Irbesartan	46	18 (39.1)	-5.56 (1.69)	(-8.88, -2.23)			
Europe	Week 6	Sparsentan	98	92 (93.9)	-0.50 (0.71)	(-1.89, 0.90)	0.94 (0.97)	(-0.95, 2.84)	0.329
		Irbesartan	115	111 (96.5)	-1.44 (0.65)	(-2.72, -0.16)			
	Week 36	Sparsentan	98	57 (58.2)	-2.48 (0.87)	(-4.19, -0.78)	1.61 (1.15)	(-0.65, 3.88)	0.162
		Irbesartan	115	77 (67.0)	-4.10 (0.76)	(-5.59, -2.61)			
	Week 58	Sparsentan	98	47 (48.0)	-2.89 (0.98)	(-4.81, -0.98)	2.36 (1.33)	(-0.24, 4.97)	0.075
		Irbesartan	115	54 (47.0)	-5.26 (0.90)	(-7.02, -3.50)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Asia Pacific	Week 6	Sparsentan	69	67 (97.1)	-1.23 (0.92)	(-3.04, 0.57)	0.24 (1.50)	(-2.71, 3.19)	0.874
		Irbesartan	41	40 (97.6)	-1.47 (1.18)	(-3.80, 0.86)			
	Week 36	Sparsentan	69	60 (87.0)	-4.66 (0.95)	(-6.54, -2.78)	1.81 (1.62)	(-1.38, 5.00)	0.266
		Irbesartan	41	30 (73.2)	-6.47 (1.31)	(-9.05, -3.89)			
	Week 58	Sparsentan	69	49 (71.0)	-5.84 (1.03)	(-7.87, -3.82)	3.18 (1.82)	(-0.39, 6.76)	0.080
		Irbesartan	41	23 (56.1)	-9.03 (1.49)	(-11.96, -6.09)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline BMI	Overall	Sparsentan						Interaction:	0.106
< 27 kg/m**2	Week 6	Sparsentan	84	78 (92.9)	-1.49 (0.85)	(-3.15, 0.18)	0.80 (1.16)	(-1.49, 3.08)	0.495
		Irbesartan	94	91 (96.8)	-2.28 (0.79)	(-3.84, -0.73)			
	Week 36	Sparsentan	84	56 (66.7)	-3.78 (0.98)	(-5.70, -1.87)	2.60 (1.36)	(-0.07, 5.26)	0.056
		Irbesartan	94	60 (63.8)	-6.38 (0.94)	(-8.23, -4.54)			
	Week 58	Sparsentan	84	46 (54.8)	-5.04 (1.08)	(-7.16, -2.92)	2.72 (1.58)	(-0.39, 5.83)	0.086
		Irbesartan	94	38 (40.4)	-7.76 (1.16)	(-10.04, -5.49)			
>= 27 kg/m**2	Week 6	Sparsentan	118	115 (97.5)	-0.78 (0.64)	(-2.04, 0.48)	0.13 (0.94)	(-1.71, 1.96)	0.893
		Irbesartan	107	103 (96.3)	-0.91 (0.68)	(-2.24, 0.43)			
	Week 36	Sparsentan	118	80 (67.8)	-3.59 (0.74)	(-5.05, -2.13)	-0.52 (1.08)	(-2.64, 1.59)	0.627
		Irbesartan	107	73 (68.2)	-3.07 (0.78)	(-4.60, -1.53)			
	Week 58	Sparsentan	118	64 (54.2)	-4.25 (0.84)	(-5.89, -2.61)	0.71 (1.22)	(-1.68, 3.10)	0.561
		Irbesartan	107	57 (53.3)	-4.96 (0.88)	(-6.69, -3.23)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Randomization strata	Overall	Sparsentan						Interaction:	0.137
eGFR Low and UP High	Week 6	Sparsentan	71	69 (97.2)	-0.58 (0.68)	(-1.93, 0.76)	1.09 (0.96)	(-0.80, 2.98)	0.258
		Irbesartan	74	70 (94.6)	-1.67 (0.67)	(-3.00, -0.34)			
	Week 36	Sparsentan	71	49 (69.0)	-2.30 (0.78)	(-3.83, -0.77)	4.07 (1.10)	(1.90, 6.24)	<0.001 *
		Irbesartan	74	47 (63.5)	-6.36 (0.78)	(-7.90, -4.83)			
	Week 58	Sparsentan	71	42 (59.2)	-3.91 (0.85)	(-5.58, -2.24)	3.11 (1.25)	(0.67, 5.56)	0.013 *
		Irbesartan	74	34 (45.9)	-7.02 (0.91)	(-8.81, -5.23)			
eGFR Low and UP Low	Week 6	Sparsentan	55	50 (90.9)	0.27 (0.80)	(-1.31, 1.85)	1.27 (1.13)	(-0.95, 3.50)	0.262
		Irbesartan	55	54 (98.2)	-1.00 (0.79)	(-2.56, 0.56)			
	Week 36	Sparsentan	55	35 (63.6)	-0.62 (0.91)	(-2.41, 1.18)	1.76 (1.27)	(-0.74, 4.26)	0.167
		Irbesartan	55	40 (72.7)	-2.38 (0.88)	(-4.11, -0.65)			
	Week 58	Sparsentan	55	28 (50.9)	-1.93 (1.03)	(-3.96, 0.10)	2.01 (1.45)	(-0.84, 4.86)	0.166
		Irbesartan	55	29 (52.7)	-3.94 (1.01)	(-5.93, -1.94)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
eGFR High and UP High	Week 6	Sparsentan	37	35 (94.6)	-3.64 (1.69)	(-6.97, -0.30)	-0.41 (2.42)	(-5.16, 4.35)	0.867
		Irbesartan	36	34 (94.4)	-3.23 (1.72)	(-6.62, 0.16)			
	Week 36	Sparsentan	37	26 (70.3)	-8.73 (1.94)	(-12.56, -4.91)	-2.71 (2.86)	(-8.33, 2.91)	0.344
		Irbesartan	36	22 (61.1)	-6.02 (2.09)	(-10.14, -1.91)			
	Week 58	Sparsentan	37	20 (54.1)	-6.85 (2.21)	(-11.20, -2.50)	1.60 (3.35)	(-4.99, 8.19)	0.633
		Irbesartan	36	15 (41.7)	-8.45 (2.51)	(-13.39, -3.52)			
eGFR High and UP Low	Week 6	Sparsentan	39	39 (100.0)	-1.69 (1.31)	(-4.28, 0.90)	-1.22 (1.88)	(-4.93, 2.48)	0.516
		Irbesartan	37	37 (100.0)	-0.47 (1.35)	(-3.13, 2.19)			
	Week 36	Sparsentan	39	26 (66.7)	-5.96 (1.56)	(-9.03, -2.89)	-2.65 (2.25)	(-7.08, 1.78)	0.240
		Irbesartan	37	24 (64.9)	-3.31 (1.62)	(-6.50, -0.12)			
	Week 58	Sparsentan	39	20 (51.3)	-7.97 (1.76)	(-11.43, -4.50)	-1.61 (2.59)	(-6.71, 3.49)	0.535
		Irbesartan	37	17 (45.9)	-6.36 (1.90)	(-10.10, -2.62)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 1	Overall	Sparsentan						Interaction:	0.207
< 60 mL/min/1.73 m**2	Week 6	Sparsentan	127	120 (94.5)	0.21 (0.53)	(-0.82, 1.24)	0.89 (0.74)	(-0.56, 2.34)	0.227
		Irbesartan	129	126 (97.7)	-0.68 (0.52)	(-1.69, 0.34)			
	Week 36	Sparsentan	127	86 (67.7)	-1.33 (0.60)	(-2.50, -0.16)	2.64 (0.84)	(0.99, 4.28)	0.002 *
		Irbesartan	129	88 (68.2)	-3.97 (0.59)	(-5.12, -2.81)			
	Week 58	Sparsentan	127	69 (54.3)	-2.72 (0.67)	(-4.03, -1.41)	2.13 (0.95)	(0.26, 4.00)	0.025 *
		Irbesartan	129	66 (51.2)	-4.85 (0.68)	(-6.18, -3.52)			
60 to < 90 mL/min/1.73 m**2	Week 6	Sparsentan	49	47 (95.9)	-2.78 (1.25)	(-5.23, -0.33)	-0.07 (1.79)	(-3.59, 3.46)	0.970
		Irbesartan	48	44 (91.7)	-2.72 (1.28)	(-5.23, -0.20)			
	Week 36	Sparsentan	49	30 (61.2)	-6.84 (1.52)	(-9.82, -3.85)	-0.39 (2.13)	(-4.57, 3.79)	0.854
		Irbesartan	48	32 (66.7)	-6.45 (1.48)	(-9.36, -3.53)			
	Week 58	Sparsentan	49	23 (46.9)	-7.96 (1.73)	(-11.36, -4.56)	2.04 (2.55)	(-2.98, 7.05)	0.425
		Irbesartan	48	19 (39.6)	-10.00 (1.88)	(-13.69, -6.31)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
>= 90 mL/min/1.73 m**2	Week 6	Sparsentan	26	26 (100.0)	-4.22 (1.97)	(-8.10, -0.34)	-0.13 (2.81)	(-5.68, 5.42)	0.963
		Irbesartan	25	25 (100.0)	-4.09 (2.01)	(-8.05, -0.13)			
	Week 36	Sparsentan	26	20 (76.9)	-10.49 (2.22)	(-14.86, -6.12)	-6.21 (3.44)	(-13.00, 0.58)	0.073
		Irbesartan	25	13 (52.0)	-4.28 (2.64)	(-9.47, 0.91)			
	Week 58	Sparsentan	26	18 (69.2)	-8.95 (2.33)	(-13.55, -4.35)	-0.79 (3.84)	(-8.36, 6.77)	0.836
		Irbesartan	25	10 (40.0)	-8.15 (3.05)	(-14.16, -2.15)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 2	Overall	Sparsentan						Interaction:	0.228
< 45 mL/min/1.73 m**2	Week 6	Sparsentan	82	79 (96.3)	0.84 (0.58)	(-0.29, 1.98)	1.71 (0.82)	(0.10, 3.33)	0.038 *
		Irbesartan	80	78 (97.5)	-0.87 (0.58)	(-2.02, 0.28)			
	Week 36	Sparsentan	82	54 (65.9)	-1.44 (0.66)	(-2.74, -0.15)	3.20 (0.92)	(1.38, 5.01)	<0.001 *
		Irbesartan	80	56 (70.0)	-4.64 (0.65)	(-5.92, -3.37)			
	Week 58	Sparsentan	82	44 (53.7)	-3.01 (0.73)	(-4.45, -1.57)	2.84 (1.04)	(0.79, 4.89)	0.007 *
		Irbesartan	80	42 (52.5)	-5.85 (0.74)	(-7.30, -4.40)			
45 to < 60 mL/min/1.73 m**2	Week 6	Sparsentan	45	41 (91.1)	-1.01 (1.06)	(-3.09, 1.06)	-0.66 (1.45)	(-3.51, 2.19)	0.649
		Irbesartan	49	48 (98.0)	-0.35 (0.99)	(-2.30, 1.60)			
	Week 36	Sparsentan	45	32 (71.1)	-1.20 (1.17)	(-3.49, 1.10)	1.62 (1.66)	(-1.64, 4.89)	0.328
		Irbesartan	49	32 (65.3)	-2.82 (1.17)	(-5.13, -0.51)			
	Week 58	Sparsentan	45	25 (55.6)	-2.26 (1.33)	(-4.87, 0.35)	1.01 (1.90)	(-2.73, 4.75)	0.596
		Irbesartan	49	24 (49.0)	-3.27 (1.35)	(-5.93, -0.61)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
60 to < 90 mL/min/1.73 m**2	Week 6	Sparsentan	49	47 (95.9)	-2.78 (1.25)	(-5.23, -0.33)	-0.07 (1.79)	(-3.59, 3.46)	0.970
		Irbesartan	48	44 (91.7)	-2.72 (1.28)	(-5.23, -0.20)			
	Week 36	Sparsentan	49	30 (61.2)	-6.84 (1.52)	(-9.82, -3.85)	-0.39 (2.13)	(-4.57, 3.79)	0.854
		Irbesartan	48	32 (66.7)	-6.45 (1.48)	(-9.36, -3.53)			
	Week 58	Sparsentan	49	23 (46.9)	-7.96 (1.73)	(-11.36, -4.56)	2.04 (2.55)	(-2.98, 7.05)	0.425
		Irbesartan	48	19 (39.6)	-10.00 (1.88)	(-13.69, -6.31)			
>= 90 mL/min/1.73 m**2	Week 6	Sparsentan	26	26 (100.0)	-4.22 (1.97)	(-8.10, -0.34)	-0.13 (2.81)	(-5.68, 5.42)	0.963
		Irbesartan	25	25 (100.0)	-4.09 (2.01)	(-8.05, -0.13)			
	Week 36	Sparsentan	26	20 (76.9)	-10.49 (2.22)	(-14.86, -6.12)	-6.21 (3.44)	(-13.00, 0.58)	0.073
		Irbesartan	25	13 (52.0)	-4.28 (2.64)	(-9.47, 0.91)			
	Week 58	Sparsentan	26	18 (69.2)	-8.95 (2.33)	(-13.55, -4.35)	-0.79 (3.84)	(-8.36, 6.77)	0.836
		Irbesartan	25	10 (40.0)	-8.15 (3.05)	(-14.16, -2.15)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline urine protein excretion	Overall	Sparsentan						Interaction:	0.825
<= 1.75 g/day	Week 6	Sparsentan	98	93 (94.9)	-0.26 (0.77)	(-1.77, 1.24)	0.33 (1.09)	(-1.82, 2.47)	0.765
		Irbesartan	94	91 (96.8)	-0.59 (0.78)	(-2.12, 0.94)			
	Week 36	Sparsentan	98	70 (71.4)	-1.73 (0.86)	(-3.42, -0.03)	0.67 (1.26)	(-1.82, 3.15)	0.598
		Irbesartan	94	61 (64.9)	-2.39 (0.92)	(-4.20, -0.58)			
	Week 58	Sparsentan	98	58 (59.2)	-3.69 (0.95)	(-5.56, -1.83)	0.41 (1.51)	(-2.55, 3.37)	0.785
		Irbesartan	94	36 (38.3)	-4.11 (1.17)	(-6.40, -1.81)			
> 1.75 g/day	Week 6	Sparsentan	104	100 (96.2)	-1.90 (0.68)	(-3.23, -0.56)	0.40 (0.96)	(-1.48, 2.27)	0.679
		Irbesartan	108	104 (96.3)	-2.29 (0.67)	(-3.61, -0.98)			
	Week 36	Sparsentan	104	66 (63.5)	-5.65 (0.81)	(-7.23, -4.06)	0.70 (1.12)	(-1.50, 2.90)	0.532
		Irbesartan	108	72 (66.7)	-6.35 (0.77)	(-7.87, -4.83)			
	Week 58	Sparsentan	104	52 (50.0)	-5.55 (0.92)	(-7.36, -3.75)	2.06 (1.26)	(-0.42, 4.54)	0.103
		Irbesartan	108	59 (54.6)	-7.61 (0.86)	(-9.31, -5.92)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline use of antihypertensives	Overall	Sparsentan						Interaction:	0.970
Yes	Week 6	Sparsentan	88	83 (94.3)	-0.36 (0.73)	(-1.79, 1.06)	1.49 (1.05)	(-0.56, 3.55)	0.154
		Irbesartan	83	77 (92.8)	-1.86 (0.75)	(-3.34, -0.38)			
	Week 36	Sparsentan	88	55 (62.5)	-3.26 (0.87)	(-4.97, -1.56)	0.74 (1.21)	(-1.64, 3.13)	0.541
		Irbesartan	83	59 (71.1)	-4.00 (0.85)	(-5.67, -2.34)			
	Week 58	Sparsentan	88	44 (50.0)	-4.17 (0.98)	(-6.10, -2.25)	1.64 (1.39)	(-1.08, 4.36)	0.237
		Irbesartan	83	44 (53.0)	-5.81 (0.98)	(-7.73, -3.90)			
No	Week 6	Sparsentan	114	110 (96.5)	-1.69 (0.72)	(-3.10, -0.28)	-0.41 (1.00)	(-2.38, 1.56)	0.680
		Irbesartan	119	118 (99.2)	-1.27 (0.70)	(-2.64, 0.10)			
	Week 36	Sparsentan	114	81 (71.1)	-4.06 (0.81)	(-5.65, -2.46)	0.91 (1.17)	(-1.39, 3.20)	0.438
		Irbesartan	119	74 (62.2)	-4.96 (0.84)	(-6.61, -3.32)			
	Week 58	Sparsentan	114	66 (57.9)	-4.98 (0.90)	(-6.74, -3.22)	1.41 (1.34)	(-1.22, 4.05)	0.293
		Irbesartan	119	51 (42.9)	-6.39 (1.00)	(-8.35, -4.44)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Time since renal biopsy	Overall	Sparsentan						Interaction:	0.289
<= 5 years	Week 6	Sparsentan	113	106 (93.8)	-1.38 (0.75)	(-2.87, 0.10)	0.07 (1.03)	(-1.96, 2.10)	0.945
		Irbesartan	127	122 (96.1)	-1.46 (0.71)	(-2.84, -0.07)			
	Week 36	Sparsentan	113	72 (63.7)	-3.90 (0.88)	(-5.62, -2.17)	0.77 (1.21)	(-1.62, 3.15)	0.528
		Irbesartan	127	80 (63.0)	-4.67 (0.84)	(-6.31, -3.02)			
	Week 58	Sparsentan	113	56 (49.6)	-5.79 (1.00)	(-7.75, -3.82)	0.11 (1.41)	(-2.66, 2.88)	0.941
		Irbesartan	127	56 (44.1)	-5.89 (0.99)	(-7.84, -3.94)			
> 5 years	Week 6	Sparsentan	89	87 (97.8)	-0.72 (0.66)	(-2.02, 0.58)	0.96 (0.98)	(-0.96, 2.89)	0.327
		Irbesartan	75	73 (97.3)	-1.68 (0.72)	(-3.10, -0.26)			
	Week 36	Sparsentan	89	64 (71.9)	-3.37 (0.76)	(-4.86, -1.89)	1.06 (1.12)	(-1.14, 3.26)	0.346
		Irbesartan	75	53 (70.7)	-4.43 (0.83)	(-6.05, -2.81)			
	Week 58	Sparsentan	89	54 (60.7)	-3.27 (0.83)	(-4.89, -1.65)	3.45 (1.26)	(0.98, 5.93)	0.006 *
		Irbesartan	75	39 (52.0)	-6.72 (0.95)	(-8.59, -4.85)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
History of hypertension	Overall	Sparsentan						Interaction:	0.848
Yes	Week 6	Sparsentan	153	144 (94.1)	-0.63 (0.57)	(-1.76, 0.49)	0.64 (0.80)	(-0.94, 2.22)	0.427
		Irbesartan	157	151 (96.2)	-1.27 (0.56)	(-2.38, -0.17)			
	Week 36	Sparsentan	153	101 (66.0)	-2.87 (0.67)	(-4.18, -1.57)	0.79 (0.93)	(-1.04, 2.62)	0.396
		Irbesartan	157	105 (66.9)	-3.67 (0.65)	(-4.95, -2.38)			
	Week 58	Sparsentan	153	82 (53.6)	-3.73 (0.74)	(-5.19, -2.28)	1.94 (1.07)	(-0.15, 4.03)	0.069
		Irbesartan	157	76 (48.4)	-5.67 (0.76)	(-7.17, -4.17)			
No	Week 6	Sparsentan	49	49 (100.0)	-2.39 (1.13)	(-4.61, -0.18)	0.11 (1.65)	(-3.13, 3.36)	0.945
		Irbesartan	45	44 (97.8)	-2.51 (1.19)	(-4.84, -0.17)			
	Week 36	Sparsentan	49	35 (71.4)	-6.00 (1.29)	(-8.53, -3.47)	2.11 (1.92)	(-1.68, 5.89)	0.274
		Irbesartan	45	28 (62.2)	-8.10 (1.42)	(-10.90, -5.31)			
	Week 58	Sparsentan	49	28 (57.1)	-7.08 (1.43)	(-9.90, -4.26)	1.27 (2.23)	(-3.12, 5.65)	0.570
		Irbesartan	45	19 (42.2)	-8.35 (1.70)	(-11.69, -5.01)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model. Only key visits up to Week 58 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Figure PF1GGC_FSGM: Change from baseline in eGFR by subgroup
Full Analysis Set

Not done: No significant subgroup found.

_____
Number of available records are presented for key visits up to Week 58 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT1GGC_FSCM.

Table PT1GGA_FSRM: Rate of change in eGFR (total slope) - Year 1 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Sex	Overall	Sparsentan					Interaction:	0.033 #
Male	Baseline to Week 58	Sparsentan	139	-4.00 (1.08)	(-6.12, -1.87)	0.37 (1.50)	(-2.58, 3.33)	0.804
		Irbesartan	143	-4.37 (1.05)	(-6.43, -2.31)			
Female	Baseline to Week 58	Sparsentan	63	-4.76 (1.57)	(-7.87, -1.66)	1.55 (2.39)	(-3.17, 6.28)	0.517
		Irbesartan	59	-6.32 (1.80)	(-9.88, -2.75)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGA_FSRM: Rate of change in eGFR (total slope) - Year 1 - by subgroup
Full Analysis Set

				Mixed Random Coefficient Model				
Rate of change in eGFR (total slope) - year 1				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age	Overall	Sparsentan					Interaction:	0.529
<= 45 years	Baseline to Week 58	Sparsentan	96	-4.74 (1.51)	(-7.71, -1.76)	0.93 (2.14)	(-3.29, 5.15)	0.663
		Irbesartan	99	-5.67 (1.52)	(-8.66, -2.68)			
> 45 years	Baseline to Week 58	Sparsentan	106	-3.77 (0.99)	(-5.72, -1.82)	0.38 (1.43)	(-2.43, 3.19)	0.790
		Irbesartan	103	-4.15 (1.03)	(-6.17, -2.12)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGA_FSRM: Rate of change in eGFR (total slope) - Year 1 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age at IgAN diagnosis	Overall	Sparsentan					Interaction:	0.008 #
<= 18 years	Baseline to Week 58	Sparsentan	9	-5.09 (3.62)	(-12.30, 2.12)	6.62 (7.00)	(-7.34, 20.58)	0.348
		Irbesartan	5	-11.71 (5.99)	(-23.65, 0.22)			
> 18 to 40 years	Baseline to Week 58	Sparsentan	102	-4.27 (1.35)	(-6.94, -1.60)	0.42 (1.89)	(-3.31, 4.14)	0.826
		Irbesartan	109	-4.68 (1.32)	(-7.28, -2.08)			
> 40 years	Baseline to Week 58	Sparsentan	91	-3.77 (1.15)	(-6.03, -1.50)	1.22 (1.66)	(-2.06, 4.50)	0.464
		Irbesartan	88	-4.99 (1.20)	(-7.36, -2.62)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGA_FSRM: Rate of change in eGFR (total slope) - Year 1 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Geographic region	Overall	Sparsentan					Interaction:	0.177
North America	Baseline to Week 58	Sparsentan	35	-4.65 (2.54)	(-9.72, 0.43)	-0.93 (3.35)	(-7.62, 5.76)	0.782
		Irbesartan	46	-3.72 (2.18)	(-8.07, 0.64)			
Europe	Baseline to Week 58	Sparsentan	98	-3.21 (1.31)	(-5.79, -0.62)	1.21 (1.75)	(-2.25, 4.66)	0.493
		Irbesartan	115	-4.41 (1.17)	(-6.71, -2.11)			
Asia Pacific	Baseline to Week 58	Sparsentan	69	-5.30 (1.36)	(-7.99, -2.60)	1.59 (2.35)	(-3.05, 6.24)	0.498
		Irbesartan	41	-6.89 (1.91)	(-10.67, -3.11)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGA_FSRM: Rate of change in eGFR (total slope) - Year 1 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline BMI	Overall	Sparsentan					Interaction:	0.161
< 27 kg/m**2	Baseline to Week 58	Sparsentan	84	-3.76 (1.50)	(-6.72, -0.80)	2.87 (2.11)	(-1.29, 7.03)	0.175
		Irbesartan	94	-6.63 (1.48)	(-9.55, -3.70)			
>= 27 kg/m**2	Baseline to Week 58	Sparsentan	118	-4.56 (1.07)	(-6.68, -2.45)	-1.03 (1.56)	(-4.10, 2.05)	0.511
		Irbesartan	107	-3.54 (1.13)	(-5.77, -1.31)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGA_FSRM: Rate of change in eGFR (total slope) - Year 1 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Randomization strata	Overall	Sparsentan					Interaction:	0.037 #
eGFR Low and UP High	Baseline to Week 58	Sparsentan	71	-4.60 (1.40)	(-7.38, -1.82)	2.41 (1.98)	(-1.52, 6.35)	0.227
		Irbesartan	74	-7.01 (1.41)	(-9.80, -4.22)			
eGFR Low and UP Low	Baseline to Week 58	Sparsentan	55	-2.51 (1.30)	(-5.09, 0.07)	0.02 (1.82)	(-3.59, 3.64)	0.991
		Irbesartan	55	-2.53 (1.28)	(-5.06, -0.00)			
eGFR High and UP High	Baseline to Week 58	Sparsentan	37	-3.57 (2.90)	(-9.36, 2.22)	1.64 (4.28)	(-6.88, 10.16)	0.702
		Irbesartan	36	-5.21 (3.14)	(-11.46, 1.04)			
eGFR High and UP Low	Baseline to Week 58	Sparsentan	39	-7.49 (2.16)	(-11.80, -3.18)	-2.98 (3.14)	(-9.24, 3.28)	0.345
		Irbesartan	37	-4.51 (2.28)	(-9.05, 0.03)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGA_FSRM: Rate of change in eGFR (total slope) - Year 1 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 1	Overall	Sparsentan					Interaction:	0.154
< 60 mL/min/1.73 m**2	Baseline to Week 58	Sparsentan	127	-3.62 (0.93)	(-5.45, -1.79)	1.02 (1.31)	(-1.56, 3.60)	0.438
		Irbesartan	129	-4.64 (0.93)	(-6.47, -2.82)			
60 to < 90 mL/min/1.73 m**2	Baseline to Week 58	Sparsentan	49	-5.11 (2.10)	(-9.28, -0.93)	1.39 (3.00)	(-4.56, 7.35)	0.643
		Irbesartan	48	-6.50 (2.14)	(-10.75, -2.25)			
>= 90 mL/min/1.73 m**2	Baseline to Week 58	Sparsentan	26	-6.59 (3.36)	(-13.38, 0.19)	-3.84 (5.23)	(-14.35, 6.68)	0.467
		Irbesartan	25	-2.76 (4.00)	(-10.80, 5.28)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGA_FSRM: Rate of change in eGFR (total slope) - Year 1 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 2	Overall	Sparsentan					Interaction:	0.097
< 45 mL/min/1.73 m**2	Baseline to Week 58	Sparsentan	82	-4.19 (1.16)	(-6.49, -1.89)	1.87 (1.63)	(-1.37, 5.11)	0.255
		Irbesartan	80	-6.06 (1.15)	(-8.34, -3.79)			
45 to < 60 mL/min/1.73 m**2	Baseline to Week 58	Sparsentan	45	-2.56 (1.70)	(-5.93, 0.81)	-0.04 (2.41)	(-4.82, 4.74)	0.987
		Irbesartan	49	-2.52 (1.71)	(-5.91, 0.87)			
60 to < 90 mL/min/1.73 m**2	Baseline to Week 58	Sparsentan	49	-5.11 (2.10)	(-9.28, -0.93)	1.39 (3.00)	(-4.56, 7.35)	0.643
		Irbesartan	48	-6.50 (2.14)	(-10.75, -2.25)			
>= 90 mL/min/1.73 m**2	Baseline to Week 58	Sparsentan	26	-6.59 (3.36)	(-13.38, 0.19)	-3.84 (5.23)	(-14.35, 6.68)	0.467
		Irbesartan	25	-2.76 (4.00)	(-10.80, 5.28)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGA_FSRM: Rate of change in eGFR (total slope) - Year 1 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline urine protein excretion	Overall	Sparsentan					Interaction:	0.606
<= 1.75 g/day	Baseline to Week 58	Sparsentan	98	-3.48 (1.19)	(-5.83, -1.13)	-0.18 (1.79)	(-3.70, 3.34)	0.920
		Irbesartan	94	-3.30 (1.33)	(-5.92, -0.68)			
> 1.75 g/day	Baseline to Week 58	Sparsentan	104	-4.98 (1.30)	(-7.54, -2.42)	1.18 (1.79)	(-2.36, 4.72)	0.511
		Irbesartan	108	-6.16 (1.24)	(-8.60, -3.71)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGA_FSRM: Rate of change in eGFR (total slope) - Year 1 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline use of antihypertensives	Overall	Sparsentan					Interaction:	0.764
Yes	Baseline to Week 58	Sparsentan	88	-3.69 (1.22)	(-6.10, -1.29)	0.79 (1.72)	(-2.61, 4.18)	0.648
		Irbesartan	83	-4.48 (1.21)	(-6.87, -2.09)			
No	Baseline to Week 58	Sparsentan	114	-4.73 (1.24)	(-7.18, -2.29)	0.37 (1.79)	(-3.17, 3.90)	0.838
		Irbesartan	119	-5.10 (1.30)	(-7.65, -2.55)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGA_FSRM: Rate of change in eGFR (total slope) - Year 1 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Time since renal biopsy	Overall	Sparsentan					Interaction:	0.388
<= 5 years	Baseline to Week 58	Sparsentan	113	-4.51 (1.33)	(-7.14, -1.88)	-0.02 (1.85)	(-3.67, 3.63)	0.993
		Irbesartan	127	-4.49 (1.29)	(-7.03, -1.96)			
> 5 years	Baseline to Week 58	Sparsentan	89	-3.96 (1.09)	(-6.12, -1.80)	1.49 (1.63)	(-1.73, 4.71)	0.363
		Irbesartan	75	-5.45 (1.21)	(-7.84, -3.06)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGA_FSRM: Rate of change in eGFR (total slope) - Year 1 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
History of hypertension	Overall	Sparsentan					Interaction:	0.727
Yes	Baseline to Week 58	Sparsentan	153	-3.56 (0.97)	(-5.47, -1.64)	0.84 (1.38)	(-1.87, 3.55)	0.540
		Irbesartan	157	-4.40 (0.97)	(-6.32, -2.49)			
No	Baseline to Week 58	Sparsentan	49	-6.22 (1.98)	(-10.16, -2.28)	0.36 (2.94)	(-5.50, 6.22)	0.903
		Irbesartan	45	-6.58 (2.18)	(-10.92, -2.25)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGLA_FSRM: Rate of change in eGFR (chronic slope) - Year 1 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Sex	Overall	Sparsentan					Interaction:	0.026 #
Male	Week 6 to Week 58	Sparsentan	139	-3.83 (1.13)	(-6.06, -1.61)	0.93 (1.57)	(-2.17, 4.02)	0.556
		Irbesartan	143	-4.76 (1.10)	(-6.91, -2.61)			
Female	Week 6 to Week 58	Sparsentan	63	-4.08 (1.65)	(-7.34, -0.82)	1.27 (2.55)	(-3.76, 6.30)	0.619
		Irbesartan	59	-5.35 (1.94)	(-9.18, -1.51)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGLA_FSRM: Rate of change in eGFR (chronic slope) - Year 1 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age	Overall	Sparsentan					Interaction:	0.493
<= 45 years	Week 6 to Week 58	Sparsentan	96	-4.07 (1.58)	(-7.17, -0.96)	1.40 (2.24)	(-3.02, 5.81)	0.533
		Irbesartan	99	-5.47 (1.59)	(-8.60, -2.33)			
> 45 years	Week 6 to Week 58	Sparsentan	106	-3.70 (1.06)	(-5.78, -1.62)	0.71 (1.53)	(-2.29, 3.72)	0.641
		Irbesartan	103	-4.41 (1.10)	(-6.58, -2.24)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGLA_FSRM: Rate of change in eGFR (chronic slope) - Year 1 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age at IgAN diagnosis	Overall	Sparsentan					Interaction:	0.102
<= 18 years	Week 6 to Week 58	Sparsentan	9	-6.01 (4.34)	(-16.11, 4.09)	4.46 (8.67)	(-16.48, 25.40)	0.624
		Irbesartan	5	-10.47 (7.52)	(-28.88, 7.94)			
> 18 to 40 years	Week 6 to Week 58	Sparsentan	102	-3.89 (1.41)	(-6.67, -1.11)	1.04 (1.98)	(-2.86, 4.93)	0.600
		Irbesartan	109	-4.93 (1.38)	(-7.66, -2.21)			
> 40 years	Week 6 to Week 58	Sparsentan	91	-3.55 (1.22)	(-5.96, -1.14)	1.26 (1.77)	(-2.23, 4.76)	0.477
		Irbesartan	88	-4.81 (1.28)	(-7.34, -2.28)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGLA_FSRM: Rate of change in eGFR (chronic slope) - Year 1 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Geographic region	Overall	Sparsentan					Interaction:	0.788
North America	Week 6 to Week 58	Sparsentan	35	-3.81 (2.70)	(-9.19, 1.56)	-0.61 (3.56)	(-7.68, 6.47)	0.865
		Irbesartan	46	-3.21 (2.32)	(-7.81, 1.40)			
Europe	Week 6 to Week 58	Sparsentan	98	-3.12 (1.37)	(-5.83, -0.42)	1.37 (1.84)	(-2.25, 4.99)	0.456
		Irbesartan	115	-4.50 (1.22)	(-6.90, -2.09)			
Asia Pacific	Week 6 to Week 58	Sparsentan	69	-4.87 (1.43)	(-7.71, -2.04)	2.62 (2.50)	(-2.32, 7.55)	0.297
		Irbesartan	41	-7.49 (2.05)	(-11.53, -3.44)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGLA_FSRM: Rate of change in eGFR (chronic slope) - Year 1 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline BMI	Overall	Sparsentan					Interaction:	0.067
< 27 kg/m**2	Week 6 to Week 58	Sparsentan	84	-3.53 (1.56)	(-6.60, -0.45)	3.04 (2.20)	(-1.31, 7.38)	0.169
		Irbesartan	94	-6.57 (1.56)	(-9.64, -3.49)			
>= 27 kg/m**2	Week 6 to Week 58	Sparsentan	118	-4.12 (1.15)	(-6.39, -1.86)	-0.41 (1.67)	(-3.70, 2.87)	0.804
		Irbesartan	107	-3.71 (1.21)	(-6.09, -1.33)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGLA_FSRM: Rate of change in eGFR (chronic slope) - Year 1 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Randomization strata	Overall	Sparsentan					Interaction:	0.036 #
eGFR Low and UP High	Week 6 to Week 58	Sparsentan	71	-4.57 (1.39)	(-7.32, -1.81)	2.70 (1.98)	(-1.22, 6.62)	0.175
		Irbesartan	74	-7.27 (1.41)	(-10.05, -4.48)			
eGFR Low and UP Low	Week 6 to Week 58	Sparsentan	55	-2.39 (1.42)	(-5.18, 0.40)	0.10 (1.98)	(-3.80, 4.01)	0.959
		Irbesartan	55	-2.49 (1.38)	(-5.22, 0.23)			
eGFR High and UP High	Week 6 to Week 58	Sparsentan	37	-1.94 (3.09)	(-8.09, 4.21)	1.05 (4.57)	(-8.03, 10.13)	0.819
		Irbesartan	36	-2.99 (3.36)	(-9.67, 3.69)			
eGFR High and UP Low	Week 6 to Week 58	Sparsentan	39	-7.34 (2.31)	(-11.92, -2.76)	-1.03 (3.37)	(-7.72, 5.65)	0.760
		Irbesartan	37	-6.31 (2.45)	(-11.17, -1.44)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGLA_FSRM: Rate of change in eGFR (chronic slope) - Year 1 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 1	Overall	Sparsentan					Interaction:	0.034 #
< 60 mL/min/1.73 m**2	Week 6 to Week 58	Sparsentan	127	-3.57 (0.97)	(-5.47, -1.66)	1.19 (1.37)	(-1.49, 3.88)	0.382
		Irbesartan	129	-4.76 (0.96)	(-6.66, -2.86)			
60 to < 90 mL/min/1.73 m**2	Week 6 to Week 58	Sparsentan	49	-4.18 (2.20)	(-8.55, 0.18)	1.08 (3.15)	(-5.17, 7.32)	0.734
		Irbesartan	48	-5.26 (2.25)	(-9.72, -0.80)			
>= 90 mL/min/1.73 m**2	Week 6 to Week 58	Sparsentan	26	-5.74 (3.61)	(-12.97, 1.50)	-1.23 (5.72)	(-12.68, 10.21)	0.830
		Irbesartan	25	-4.50 (4.43)	(-13.37, 4.36)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGLA_FSRM: Rate of change in eGFR (chronic slope) - Year 1 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 2	Overall	Sparsentan					Interaction:	0.035 #
< 45 mL/min/1.73 m**2	Week 6 to Week 58	Sparsentan	82	-4.53 (1.15)	(-6.80, -2.26)	2.01 (1.62)	(-1.18, 5.20)	0.216
		Irbesartan	80	-6.54 (1.14)	(-8.78, -4.29)			
45 to < 60 mL/min/1.73 m**2	Week 6 to Week 58	Sparsentan	45	-1.89 (1.85)	(-5.55, 1.77)	0.32 (2.62)	(-4.87, 5.51)	0.902
		Irbesartan	49	-2.22 (1.86)	(-5.90, 1.46)			
60 to < 90 mL/min/1.73 m**2	Week 6 to Week 58	Sparsentan	49	-4.18 (2.20)	(-8.55, 0.18)	1.08 (3.15)	(-5.17, 7.32)	0.734
		Irbesartan	48	-5.26 (2.25)	(-9.72, -0.80)			
>= 90 mL/min/1.73 m**2	Week 6 to Week 58	Sparsentan	26	-5.74 (3.61)	(-12.97, 1.50)	-1.23 (5.72)	(-12.68, 10.21)	0.830
		Irbesartan	25	-4.50 (4.43)	(-13.37, 4.36)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGLA_FSRM: Rate of change in eGFR (chronic slope) - Year 1 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline urine protein excretion	Overall	Sparsentan					Interaction:	0.639
<= 1.75 g/day	Week 6 to Week 58	Sparsentan	98	-3.62 (1.26)	(-6.11, -1.14)	-0.07 (1.90)	(-3.82, 3.68)	0.970
		Irbesartan	94	-3.55 (1.42)	(-6.36, -0.75)			
> 1.75 g/day	Week 6 to Week 58	Sparsentan	104	-4.18 (1.37)	(-6.87, -1.49)	1.82 (1.88)	(-1.90, 5.53)	0.336
		Irbesartan	108	-6.00 (1.30)	(-8.55, -3.44)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGLA_FSRM: Rate of change in eGFR (chronic slope) - Year 1 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline use of antihypertensives	Overall	Sparsentan					Interaction:	0.355
Yes	Week 6 to Week 58	Sparsentan	88	-4.03 (1.29)	(-6.57, -1.50)	0.35 (1.81)	(-3.22, 3.93)	0.847
		Irbesartan	83	-4.39 (1.28)	(-6.90, -1.87)			
No	Week 6 to Week 58	Sparsentan	114	-3.85 (1.31)	(-6.42, -1.28)	1.42 (1.90)	(-2.31, 5.15)	0.454
		Irbesartan	119	-5.28 (1.38)	(-7.98, -2.57)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGLA_FSRM: Rate of change in eGFR (chronic slope) - Year 1 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Time since renal biopsy	Overall	Sparsentan					Interaction:	0.339
<= 5 years	Week 6 to Week 58	Sparsentan	113	-4.11 (1.40)	(-6.88, -1.35)	0.42 (1.96)	(-3.43, 4.27)	0.829
		Irbesartan	127	-4.54 (1.36)	(-7.22, -1.86)			
> 5 years	Week 6 to Week 58	Sparsentan	89	-3.67 (1.15)	(-5.93, -1.40)	1.78 (1.72)	(-1.60, 5.17)	0.300
		Irbesartan	75	-5.45 (1.27)	(-7.96, -2.94)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1GGLA_FSRM: Rate of change in eGFR (chronic slope) - Year 1 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
History of hypertension	Overall	Sparsentan					Interaction:	0.550
Yes	Week 6 to Week 58	Sparsentan	153	-3.63 (1.03)	(-5.65, -1.60)	0.87 (1.46)	(-1.99, 3.74)	0.550
		Irbesartan	157	-4.50 (1.03)	(-6.53, -2.47)			
No	Week 6 to Week 58	Sparsentan	49	-4.75 (2.05)	(-8.82, -0.69)	1.69 (3.07)	(-4.39, 7.77)	0.582
		Irbesartan	45	-6.45 (2.28)	(-10.97, -1.93)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT1MIS_FSIM: Patients with systemic immunosuppressive medication by subgroup
Full Analysis Set

				Systemic immunosuppressive medication				
Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.039 #
Male	Double-blind period	Sparsentan	139	7 (5.0)	0.424 [0.181, 0.990]	0.393 [0.158, 0.980]	-6.9 [-14.0, 0.3]	0.053
		Irbesartan	143	17 (11.9)				
Female	Double-blind period	Sparsentan	63	7 (11.1)	2.185 [0.593, 8.059]	2.333 [0.574, 9.484]	6.0 [-5.2, 17.2]	0.326
		Irbesartan	59	3 (5.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1MIS_FSIM: Patients with systemic immunosuppressive medication by subgroup
Full Analysis Set

Systemic immunosuppressive medication

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.416
<= 45 years	Double-blind period	Sparsentan	96	8 (8.3)	0.917 [0.369, 2.277]	0.909 [0.336, 2.463]	-0.8 [-9.7, 8.2]	1.000
		Irbesartan	99	9 (9.1)				
> 45 years	Double-blind period	Sparsentan	106	6 (5.7)	0.530 [0.204, 1.380]	0.502 [0.178, 1.412]	-5.0 [-13.4, 3.3]	0.213
		Irbesartan	103	11 (10.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1MIS_FSIM: Patients with systemic immunosuppressive medication by subgroup
Full Analysis Set

Systemic immunosuppressive medication

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.673
<= 18 years	Double-blind period	Sparsentan	9	2 (22.2)	1.111 [0.131, 9.416]	1.143 [0.077, 16.947]	2.2 [-57.7, 62.1]	1.000
		Irbesartan	5	1 (20.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	7 (6.9)	0.831 [0.321, 2.149]	0.819 [0.293, 2.286]	-1.4 [-9.5, 6.7]	0.798
		Irbesartan	109	9 (8.3)				
> 40 years	Double-blind period	Sparsentan	91	5 (5.5)	0.484 [0.172, 1.358]	0.453 [0.148, 1.385]	-5.9 [-15.1, 3.4]	0.185
		Irbesartan	88	10 (11.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1MIS_FSIM: Patients with systemic immunosuppressive medication by subgroup
Full Analysis Set

Systemic immunosuppressive medication

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.253
North America	Double-blind period	Sparsentan	35	5 (14.3)	0.548 [0.213, 1.411]	0.472 [0.149, 1.496]	-11.8 [-31.5, 7.9]	0.273
		Irbesartan	46	12 (26.1)				
Europe	Double-blind period	Sparsentan	98	6 (6.1)	1.760 [0.511, 6.059]	1.810 [0.496, 6.607]	2.6 [-4.1, 9.4]	0.518
		Irbesartan	115	4 (3.5)				
Asia Pacific	Double-blind period	Sparsentan	69	3 (4.3)	0.446 [0.105, 1.893]	0.420 [0.089, 1.981]	-5.4 [-17.6, 6.8]	0.421
		Irbesartan	41	4 (9.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1MIS_FSIM: Patients with systemic immunosuppressive medication by subgroup
Full Analysis Set

Systemic immunosuppressive medication

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.430
< 27 kg/m**2	Double-blind period	Sparsentan	84	6 (7.1)	0.959 [0.336, 2.741]	0.956 [0.308, 2.967]	-0.3 [-9.1, 8.5]	1.000
		Irbesartan	94	7 (7.4)				
>= 27 kg/m**2	Double-blind period	Sparsentan	118	8 (6.8)	0.558 [0.241, 1.294]	0.526 [0.209, 1.323]	-5.4 [-13.9, 3.2]	0.178
		Irbesartan	107	13 (12.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1MIS_FSIM: Patients with systemic immunosuppressive medication by subgroup
Full Analysis Set

Systemic immunosuppressive medication

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.154	
eGFR Low and UP High	Double-blind period	Sparsentan	71	3 (4.2)	0.261 [0.077, 0.885]	0.228 [0.061, 0.846]	-12.0 [-23.0, -1.0]	0.027	*
		Irbesartan	74	12 (16.2)					
eGFR Low and UP Low	Double-blind period	Sparsentan	55	5 (9.1)	2.500 [0.506, 12.341]	2.650 [0.492, 14.286]	5.5 [-5.4, 16.3]	0.438	
		Irbesartan	55	2 (3.6)					
eGFR High and UP High	Double-blind period	Sparsentan	37	3 (8.1)	0.973 [0.210, 4.507]	0.971 [0.183, 5.158]	-0.2 [-15.6, 15.1]	1.000	
		Irbesartan	36	3 (8.3)					
eGFR High and UP Low	Double-blind period	Sparsentan	39	3 (7.7)	0.949 [0.204, 4.407]	0.944 [0.178, 5.005]	-0.4 [-15.2, 14.4]	1.000	
		Irbesartan	37	3 (8.1)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1MIS_FSIM: Patients with systemic immunosuppressive medication by subgroup
Full Analysis Set

Systemic immunosuppressive medication

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.371
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	8 (6.3)	0.508 [0.225, 1.145]	0.475 [0.196, 1.153]	-6.1 [-14.0, 1.8]	0.132
		Irbesartan	129	16 (12.4)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	3 (6.1)	1.469 [0.257, 8.408]	1.500 [0.239, 9.400]	2.0 [-8.9, 12.8]	1.000
		Irbesartan	48	2 (4.2)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	3 (11.5)	1.442 [0.263, 7.918]	1.500 [0.229, 9.832]	3.5 [-16.6, 23.7]	1.000
		Irbesartan	25	2 (8.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1MIS_FSIM: Patients with systemic immunosuppressive medication by subgroup
Full Analysis Set

Systemic immunosuppressive medication

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.551
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	4 (4.9)	0.434 [0.139, 1.351]	0.405 [0.119, 1.372]	-6.4 [-16.0, 3.2]	0.158
		Irbesartan	80	9 (11.3)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	4 (8.9)	0.622 [0.195, 1.985]	0.585 [0.159, 2.151]	-5.4 [-20.4, 9.6]	0.528
		Irbesartan	49	7 (14.3)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	3 (6.1)	1.469 [0.257, 8.408]	1.500 [0.239, 9.400]	2.0 [-8.9, 12.8]	1.000
		Irbesartan	48	2 (4.2)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	3 (11.5)	1.442 [0.263, 7.918]	1.500 [0.229, 9.832]	3.5 [-16.6, 23.7]	1.000
		Irbesartan	25	2 (8.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1MIS_FSIM: Patients with systemic immunosuppressive medication by subgroup
Full Analysis Set

Systemic immunosuppressive medication

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.058
<= 1.75 g/day	Double-blind period	Sparsentan	98	9 (9.2)	1.439 [0.533, 3.886]	1.483 [0.507, 4.342]	2.8 [-5.8, 11.4]	0.593
		Irbesartan	94	6 (6.4)				
> 1.75 g/day	Double-blind period	Sparsentan	104	5 (4.8)	0.371 [0.139, 0.993]	0.339 [0.118, 0.978]	-8.2 [-16.7, 0.3]	0.053
		Irbesartan	108	14 (13.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1MIS_FSIM: Patients with systemic immunosuppressive medication by subgroup
Full Analysis Set

Systemic immunosuppressive medication								
Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.253
Yes	Double-blind period	Sparsentan	88	4 (4.5)	0.419 [0.134, 1.309]	0.392 [0.116, 1.324]	-6.3 [-15.4, 2.9]	0.153
		Irbesartan	83	9 (10.8)				
No	Double-blind period	Sparsentan	114	10 (8.8)	0.949 [0.419, 2.148]	0.944 [0.385, 2.317]	-0.5 [-8.7, 7.7]	1.000
		Irbesartan	119	11 (9.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1MIS_FSIM: Patients with systemic immunosuppressive medication by subgroup
Full Analysis Set

Systemic immunosuppressive medication

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.012	#
<= 5 years	Double-blind period	Sparsentan	113	5 (4.4)	0.331 [0.126, 0.867]	0.300 [0.107, 0.841]	-9.0 [-16.8, -1.1]	0.023	*
		Irbesartan	127	17 (13.4)					
> 5 years	Double-blind period	Sparsentan	89	9 (10.1)	2.528 [0.710, 9.002]	2.700 [0.704, 10.362]	6.1 [-2.8, 15.0]	0.228	
		Irbesartan	75	3 (4.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1MIS_FSIM: Patients with systemic immunosuppressive medication by subgroup
Full Analysis Set

				Systemic immunosuppressive medication				
Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.413
Yes	Double-blind period	Sparsentan	153	11 (7.2)	0.627 [0.306, 1.284]	0.598 [0.273, 1.312]	-4.3 [-11.4, 2.8]	0.243
		Irbesartan	157	18 (11.5)				
No	Double-blind period	Sparsentan	49	3 (6.1)	1.378 [0.241, 7.871]	1.402 [0.223, 8.801]	1.7 [-9.5, 12.8]	1.000
		Irbesartan	45	2 (4.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1MIST_FSTM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive medication				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Sex	Sparsentan						Interaction test:	0.052	
Male	Sparsentan	139	7 (5.0)	NE		0.408	(0.169, 0.985)	0.046	*
	Irbesartan	143	17 (11.9)	NE					
Female	Sparsentan	63	7 (11.1)	NE		1.782	(0.449, 7.070)	0.411	
	Irbesartan	59	3 (5.1)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT1MIST_FSTM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive medication				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.448
<= 45 years	Sparsentan	96	8 (8.3)	NE		0.857	(0.330, 2.223)	0.751
	Irbesartan	99	9 (9.1)	NE				
> 45 years	Sparsentan	106	6 (5.7)	NE		0.528	(0.195, 1.430)	0.209
	Irbesartan	103	11 (10.7)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT1MIST_FSTM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive medication				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age at IgAN diagnosis	Sparsentan						Interaction test:	0.754
<= 18 years	Sparsentan	9	2 (22.2)	NE		0.785	(0.070, 8.812)	0.845
	Irbesartan	5	1 (20.0)	NE				
> 18 to 40 years	Sparsentan	102	7 (6.9)	NE		0.845	(0.313, 2.286)	0.741
	Irbesartan	109	9 (8.3)	NE				
> 40 years	Sparsentan	91	5 (5.5)	NE		0.464	(0.158, 1.366)	0.163
	Irbesartan	88	10 (11.4)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT1MIST_FSTM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive medication				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Geographic region	Sparsentan						Interaction test:	0.151
North America	Sparsentan	35	5 (14.3)	NE		0.501	(0.176, 1.424)	0.194
	Irbesartan	46	12 (26.1)	NE				
Europe	Sparsentan	98	6 (6.1)	NE		2.092	(0.590, 7.422)	0.253
	Irbesartan	115	4 (3.5)	NE				
Asia Pacific	Sparsentan	69	3 (4.3)	NE		0.293	(0.063, 1.361)	0.117
	Irbesartan	41	4 (9.8)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT1MIST_FSTM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive medication				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.460
< 27 kg/m**2	Sparsentan	84	6 (7.1)	NE		0.860	(0.287, 2.574)	0.787
	Irbesartan	94	7 (7.4)	NE				
>= 27 kg/m**2	Sparsentan	118	8 (6.8)	NE		0.543	(0.224, 1.311)	0.175
	Irbesartan	107	13 (12.1)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT1MIST_FSTM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive medication				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Randomization strata	Sparsentan						Interaction test:	0.081	
eGFR Low and UP High	Sparsentan	71	3 (4.2)	NE		0.226	(0.064, 0.803)	0.021	*
	Irbesartan	74	12 (16.2)	NE					
eGFR Low and UP Low	Sparsentan	55	5 (9.1)	NE		2.642	(0.512, 13.625)	0.246	
	Irbesartan	55	2 (3.6)	NE					
eGFR High and UP High	Sparsentan	37	3 (8.1)	NE		0.882	(0.178, 4.375)	0.878	
	Irbesartan	36	3 (8.3)	NE					
eGFR High and UP Low	Sparsentan	39	3 (7.7)	NE		0.947	(0.191, 4.699)	0.947	
	Irbesartan	37	3 (8.1)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT1MIST_FSTM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive medication				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.446
< 60 mL/min/1.73 m**2	Sparsentan	127	8 (6.3)	NE		0.498	(0.212, 1.172)	0.110
	Irbesartan	129	16 (12.4)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	3 (6.1)	NE		1.427	(0.238, 8.552)	0.697
	Irbesartan	48	2 (4.2)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	3 (11.5)	NE		1.095	(0.181, 6.613)	0.921
	Irbesartan	25	2 (8.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT1MIST_FSTM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive medication				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 2	Sparsentan						Interaction test:	0.621
< 45 mL/min/1.73 m**2	Sparsentan	82	4 (4.9)	NE		0.426	(0.131, 1.385)	0.156
	Irbesartan	80	9 (11.3)	NE				
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	4 (8.9)	NE		0.584	(0.167, 2.046)	0.401
	Irbesartan	49	7 (14.3)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	3 (6.1)	NE		1.427	(0.238, 8.552)	0.697
	Irbesartan	48	2 (4.2)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	3 (11.5)	NE		1.095	(0.181, 6.613)	0.921
	Irbesartan	25	2 (8.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT1MIST_FSTM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive medication				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline urine protein excretion	Sparsentan						Interaction test:	0.059	
<= 1.75 g/day	Sparsentan	98	9 (9.2)	NE		1.348	(0.479, 3.797)	0.572	
	Irbesartan	94	6 (6.4)	NE					
> 1.75 g/day	Sparsentan	104	5 (4.8)	NE		0.353	(0.127, 0.984)	0.047	*
	Irbesartan	108	14 (13.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT1MIST_FSTM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive medication				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.350
Yes	Sparsentan	88	4 (4.5)	NE		0.465	(0.142, 1.520)	0.205
	Irbesartan	83	9 (10.8)	NE				
No	Sparsentan	114	10 (8.8)	NE		0.877	(0.372, 2.068)	0.764
	Irbesartan	119	11 (9.2)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT1MIST_FSTM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive medication				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Time since renal biopsy	Sparsentan						Interaction test:	0.005	#
<= 5 years	Sparsentan	113	5 (4.4)	NE		0.276	(0.102, 0.751)	0.012	*
	Irbesartan	127	17 (13.4)	NE					
> 5 years	Sparsentan	89	9 (10.1)	NE		2.656	(0.718, 9.825)	0.143	
	Irbesartan	75	3 (4.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT1MIST_FSTM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive medication				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
History of hypertension	Sparsentan						Interaction test:	0.533
Yes	Sparsentan	153	11 (7.2)	NE		0.625	(0.295, 1.325)	0.220
	Irbesartan	157	18 (11.5)	NE				
No	Sparsentan	49	3 (6.1)	NE		1.241	(0.196, 7.864)	0.819
	Irbesartan	45	2 (4.4)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Figure PF1MIST_FSKM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Study: PROTECT
Time since renal biopsy: <= 5 years



Sparsentan	113	90	66	52	28	7
Irbesartan	127	88	61	48	28	10

Reference table: PT1MIST_FSTM

Figure PF1MIST_FSKM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Study: PROTECT
Time since renal biopsy: > 5 years



Sparsentan	89	66	55	45	22	9
Irbesartan	75	61	49	40	18	7

Reference table: PT1MIST_FSTM

Table PT1MIK_FSIM: Patients with systemic immunosuppressive renal medication by subgroup
Full Analysis Set

					Systemic immunosuppressive renal medication (renal indication)			
Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	NE
Male	Double-blind period	Sparsentan	139	1 (0.7) all n<10				NE
		Irbesartan	143	8 (5.6)				
Female	Double-blind period	Sparsentan	63	1 (1.6) all n<10				NE
		Irbesartan	59	1 (1.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1MIK_FSIM: Patients with systemic immunosuppressive renal medication by subgroup
Full Analysis Set

			Systemic immunosuppressive renal medication (renal indication)					
Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan				Interaction test:		NE
<= 45 years	Double-blind period	Sparsentan	96	2 (2.1) all n<10				NE
		Irbesartan	99	5 (5.1)				
> 45 years	Double-blind period	Sparsentan	106	0 (0.0) all n<10				NE
		Irbesartan	103	4 (3.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1MIK_FSIM: Patients with systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Systemic immunosuppressive renal medication (renal indication)								
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	NE
<= 18 years	Double-blind period	Sparsentan	9	2 (22.2) all n<10				NE
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	0 (0.0) all n<10				NE
		Irbesartan	109	5 (4.6)				
> 40 years	Double-blind period	Sparsentan	91	0 (0.0) all n<10				NE
		Irbesartan	88	4 (4.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1MIK_FSIM: Patients with systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Systemic immunosuppressive renal medication (renal indication)

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	NE
North America	Double-blind period	Sparsentan	35	2 (5.7) all n<10				NE
		Irbesartan	46	3 (6.5)				
Europe	Double-blind period	Sparsentan	98	0 (0.0) all n<10				NE
		Irbesartan	115	3 (2.6)				
Asia Pacific	Double-blind period	Sparsentan	69	0 (0.0) all n<10				NE
		Irbesartan	41	3 (7.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1MIK_FSIM: Patients with systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Systemic immunosuppressive renal medication (renal indication)							
Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan				Interaction test:		NE
< 27 kg/m**2	Double-blind period	Sparsentan	84	2 (2.4) all n<10				NE
		Irbesartan	94	5 (5.3)				
>= 27 kg/m**2	Double-blind period	Sparsentan	118	0 (0.0) all n<10				NE
		Irbesartan	107	4 (3.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1MIK_FSIM: Patients with systemic immunosuppressive renal medication by subgroup
Full Analysis Set

		Systemic immunosuppressive renal medication (renal indication)					
Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	NE
eGFR Low and UP High	Double-blind period	Sparsentan	71	0 (0.0) all n<10				NE
		Irbesartan	74	6 (8.1)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	0 (0.0) all n<10				NE
		Irbesartan	55	1 (1.8)				
eGFR High and UP High	Double-blind period	Sparsentan	37	2 (5.4) all n<10				NE
		Irbesartan	36	2 (5.6)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	0 (0.0) all n<10				NE
		Irbesartan	37	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1MIK_FSIM: Patients with systemic immunosuppressive renal medication by subgroup
Full Analysis Set

		Systemic immunosuppressive renal medication (renal indication)					
Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	NE
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	0 (0.0) all n<10				NE
		Irbesartan	129	7 (5.4)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	1 (2.0) all n<10				NE
		Irbesartan	48	1 (2.1)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8) all n<10				NE
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1MIK_FSIM: Patients with systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Systemic immunosuppressive renal medication (renal indication)							
Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	NE
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	0 (0.0) all n<10				NE
		Irbesartan	80	5 (6.3)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	0 (0.0) all n<10				NE
		Irbesartan	49	2 (4.1)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	1 (2.0) all n<10				NE
		Irbesartan	48	1 (2.1)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8) all n<10				NE
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1MIK_FSIM: Patients with systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Systemic immunosuppressive renal medication (renal indication)								
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.505
<= 1.75 g/day	Double-blind period	Sparsentan	98	0 (0.0)	0.960 + [0.019, 47.874]	0.959 + [0.019, 48.843]	0.0 [NE, NE]	NE
		Irbesartan	94	0 (0.0)				
> 1.75 g/day	Double-blind period	Sparsentan	104	2 (1.9)	0.231 [0.051, 1.043]	0.216 [0.045, 1.023]	-6.4 [-13.2, 0.4]	0.059
		Irbesartan	108	9 (8.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1MIK_FSIM: Patients with systemic immunosuppressive renal medication by subgroup
Full Analysis Set

		Systemic immunosuppressive renal medication (renal indication)					
Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan				Interaction test:		NE
Yes	Double-blind period	Sparsentan	88	0 (0.0) all n<10				NE
		Irbesartan	83	4 (4.8)				
No	Double-blind period	Sparsentan	114	2 (1.8) all n<10				NE
		Irbesartan	119	5 (4.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1MIK_FSIM: Patients with systemic immunosuppressive renal medication by subgroup
Full Analysis Set

		Systemic immunosuppressive renal medication (renal indication)					
Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	NE
<= 5 years	Double-blind period	Sparsentan	113	0 (0.0) all n<10				NE
		Irbesartan	127	7 (5.5)				
> 5 years	Double-blind period	Sparsentan	89	2 (2.2) all n<10				NE
		Irbesartan	75	2 (2.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1MIK_FSIM: Patients with systemic immunosuppressive renal medication by subgroup
Full Analysis Set

			Systemic immunosuppressive renal medication (renal indication)					
Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	NE
Yes	Double-blind period	Sparsentan	153	1 (0.7) all n<10				NE
		Irbesartan	157	8 (5.1)				
No	Double-blind period	Sparsentan	49	1 (2.0) all n<10				NE
		Irbesartan	45	1 (2.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1MIKT_FSTM: Time to systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Not done. Less than 10 patients with events in every subgroup level.

_____
N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Figure PF1MIKT_FSKM: Time to systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Not done. No significant subgroups.

Reference table: PT1MIKT_FSTM

Table PT1HOS_FSIM: Patients with hospitalizations by subgroup
Full Analysis Set

Hospitalizations

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.621
Male	Double-blind period	Sparsentan	139	15 (10.8)	1.102 [0.553, 2.197]	1.115 [0.517, 2.405]	1.0 [-6.8, 8.8]	0.846
		Irbesartan	143	14 (9.8)				
Female	Double-blind period	Sparsentan	63	7 (11.1)	0.819 [0.317, 2.119]	0.797 [0.270, 2.354]	-2.4 [-15.8, 10.9]	0.785
		Irbesartan	59	8 (13.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1HOS_FSIM: Patients with hospitalizations by subgroup
Full Analysis Set

Hospitalizations

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.672
<= 45 years	Double-blind period	Sparsentan	96	11 (11.5)	1.134 [0.505, 2.548]	1.152 [0.465, 2.851]	1.4 [-8.4, 11.1]	0.820
		Irbesartan	99	10 (10.1)				
> 45 years	Double-blind period	Sparsentan	106	11 (10.4)	0.891 [0.412, 1.927]	0.878 [0.369, 2.090]	-1.3 [-10.7, 8.2]	0.827
		Irbesartan	103	12 (11.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1HOS_FSIM: Patients with hospitalizations by subgroup
Full Analysis Set

Hospitalizations

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.394
<= 18 years	Double-blind period	Sparsentan	9	2 (22.2)	3.000 + [0.171, 52.527]	3.667 + [0.145, 92.653]	22.2 [-20.5, 64.9]	0.505
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	10 (9.8)	1.336 [0.549, 3.252]	1.372 [0.519, 3.626]	2.5 [-6.1, 11.0]	0.624
		Irbesartan	109	8 (7.3)				
> 40 years	Double-blind period	Sparsentan	91	10 (11.0)	0.691 [0.324, 1.472]	0.653 [0.273, 1.558]	-4.9 [-16.0, 6.2]	0.384
		Irbesartan	88	14 (15.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1HOS_FSIM: Patients with hospitalizations by subgroup
Full Analysis Set

Hospitalizations

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.987
North America	Double-blind period	Sparsentan	35	4 (11.4)	0.876 [0.268, 2.870]	0.860 [0.223, 3.316]	-1.6 [-18.5, 15.2]	1.000
		Irbesartan	46	6 (13.0)				
Europe	Double-blind period	Sparsentan	98	8 (8.2)	0.939 [0.386, 2.286]	0.933 [0.353, 2.466]	-0.5 [-9.0, 7.9]	1.000
		Irbesartan	115	10 (8.7)				
Asia Pacific	Double-blind period	Sparsentan	69	10 (14.5)	0.990 [0.389, 2.524]	0.989 [0.331, 2.956]	-0.1 [-15.7, 15.4]	1.000
		Irbesartan	41	6 (14.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1HOS_FSIM: Patients with hospitalizations by subgroup
Full Analysis Set

Hospitalizations

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.961
< 27 kg/m**2	Double-blind period	Sparsentan	84	10 (11.9)	1.017 [0.455, 2.274]	1.020 [0.410, 2.538]	0.2 [-10.4, 10.8]	1.000
		Irbesartan	94	11 (11.7)				
>= 27 kg/m**2	Double-blind period	Sparsentan	118	12 (10.2)	0.989 [0.456, 2.148]	0.988 [0.417, 2.343]	-0.1 [-8.9, 8.7]	1.000
		Irbesartan	107	11 (10.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1HOS_FSIM: Patients with hospitalizations by subgroup
Full Analysis Set

Hospitalizations

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.280
eGFR Low and UP High	Double-blind period	Sparsentan	71	8 (11.3)	0.695 [0.302, 1.599]	0.656 [0.251, 1.715]	-4.9 [-17.5, 7.6]	0.473
		Irbesartan	74	12 (16.2)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	8 (14.5)	1.600 [0.558, 4.586]	1.702 [0.520, 5.574]	5.5 [-8.4, 19.3]	0.556
		Irbesartan	55	5 (9.1)				
eGFR High and UP High	Double-blind period	Sparsentan	37	4 (10.8)	3.892 [0.457, 33.169]	4.242 [0.451, 39.943]	8.0 [-6.1, 22.1]	0.358
		Irbesartan	36	1 (2.8)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	2 (5.1)	0.474 [0.092, 2.437]	0.446 [0.077, 2.595]	-5.7 [-20.5, 9.1]	0.425
		Irbesartan	37	4 (10.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1HOS_FSIM: Patients with hospitalizations by subgroup
Full Analysis Set

Hospitalizations

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.541
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	16 (12.6)	0.855 [0.461, 1.587]	0.835 [0.408, 1.707]	-2.1 [-11.3, 7.1]	0.717
		Irbesartan	129	19 (14.7)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	6 (12.2)	1.959 [0.519, 7.389]	2.093 [0.492, 8.901]	6.0 [-7.5, 19.5]	0.487
		Irbesartan	48	3 (6.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.963 + [0.020, 46.760]	0.962 + [0.018, 50.349]	0.0 [NE, NE]	NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1HOS_FSIM: Patients with hospitalizations by subgroup
Full Analysis Set

Hospitalizations

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.679
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	11 (13.4)	0.976 [0.449, 2.122]	0.972 [0.396, 2.388]	-0.3 [-12.1, 11.5]	1.000
		Irbesartan	80	11 (13.8)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	5 (11.1)	0.681 [0.240, 1.928]	0.641 [0.193, 2.125]	-5.2 [-21.2, 10.8]	0.557
		Irbesartan	49	8 (16.3)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	6 (12.2)	1.959 [0.519, 7.389]	2.093 [0.492, 8.901]	6.0 [-7.5, 19.5]	0.487
		Irbesartan	48	3 (6.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.963 + [0.020, 46.760]	0.962 + [0.018, 50.349]	0.0 [NE, NE]	NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1HOS_FSIM: Patients with hospitalizations by subgroup
Full Analysis Set

Hospitalizations

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.149
<= 1.75 g/day	Double-blind period	Sparsentan	98	13 (13.3)	1.559 [0.677, 3.589]	1.644 [0.648, 4.168]	4.8 [-5.1, 14.6]	0.358
		Irbesartan	94	8 (8.5)				
> 1.75 g/day	Double-blind period	Sparsentan	104	9 (8.7)	0.668 [0.302, 1.475]	0.636 [0.263, 1.541]	-4.3 [-13.6, 5.0]	0.380
		Irbesartan	108	14 (13.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1HOS_FSIM: Patients with hospitalizations by subgroup
Full Analysis Set

Hospitalizations

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.618
Yes	Double-blind period	Sparsentan	88	9 (10.2)	0.849 [0.363, 1.984]	0.832 [0.320, 2.161]	-1.8 [-12.4, 8.8]	0.809
		Irbesartan	83	10 (12.0)				
No	Double-blind period	Sparsentan	114	13 (11.4)	1.131 [0.539, 2.373]	1.148 [0.500, 2.633]	1.3 [-7.5, 10.1]	0.833
		Irbesartan	119	12 (10.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1HOS_FSIM: Patients with hospitalizations by subgroup
Full Analysis Set

Hospitalizations

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.019 #
<= 5 years	Double-blind period	Sparsentan	113	9 (8.0)	0.562 [0.263, 1.200]	0.524 [0.225, 1.219]	-6.2 [-14.9, 2.5]	0.154
		Irbesartan	127	18 (14.2)				
> 5 years	Double-blind period	Sparsentan	89	13 (14.6)	2.739 [0.932, 8.046]	3.036 [0.946, 9.748]	9.3 [-0.9, 19.4]	0.071
		Irbesartan	75	4 (5.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1HOS_FSIM: Patients with hospitalizations by subgroup
Full Analysis Set

Hospitalizations

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.882
Yes	Double-blind period	Sparsentan	153	18 (11.8)	1.026 [0.555, 1.897]	1.030 [0.514, 2.063]	0.3 [-7.5, 8.1]	1.000
		Irbesartan	157	18 (11.5)				
No	Double-blind period	Sparsentan	49	4 (8.2)	0.918 [0.244, 3.457]	0.911 [0.214, 3.881]	-0.7 [-14.2, 12.7]	1.000
		Irbesartan	45	4 (8.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1HNS_FSNM: Number of hospitalizations by subgroup
Full Analysis Set

Number of hospitalizations							Negative binomial model		
Subgroup	Treatment	N	nval (%)	Time at risk (years)	Number of events	Crude rate	Rate ratio	95% CI	p-value
Sex	Sparsentan								NE
Male	Sparsentan	139	139 (100.0)	175.4	17	0.10	1.155	(0.564, 2.366)	0.693
	Irbesartan	143	143 (100.0)	194.0	16	0.08			
Female	Sparsentan	63	63 (100.0)	90.4	7	0.08	0.617	(0.229, 1.663)	0.340
	Irbesartan	59	59 (100.0)	68.9	10	0.15			
Age	Sparsentan								0.764
<= 45 years	Sparsentan	96	96 (100.0)	121.4	11	0.09	1.104	(0.486, 2.505)	0.813
	Irbesartan	99	99 (100.0)	129.7	12	0.09			
> 45 years	Sparsentan	106	106 (100.0)	144.4	13	0.09	0.917	(0.410, 2.051)	0.833
	Irbesartan	103	103 (100.0)	133.2	14	0.11			
Age at IgAN diagnosis	Sparsentan								NE
<= 18 years	Sparsentan	9	9 (100.0)	9.9	2	0.20			NE
	Irbesartan	5	5 (100.0)	3.5	0	0.00			
> 18 to 40 years	Sparsentan	102	102 (100.0)	133.1	11	0.08	1.342	(0.569, 3.168)	0.501
	Irbesartan	109	109 (100.0)	142.4	10	0.07			
> 40 years	Sparsentan	91	91 (100.0)	122.8	11	0.09	0.666	(0.305, 1.455)	0.308
	Irbesartan	88	88 (100.0)	117.0	16	0.14			

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. nval (%) = number of patients included in the analysis (i.e., with post-baseline data).
NE = not evaluable.
Number of events = number of considered hospitalizations. 95% CI = 95% confidence interval for rate ratio.
A negative binomial model was applied with factors treatment, randomisation strata, and log of offset. The study duration of double blind period was used as offset. Randomisation stratum will be included only once in the model, if this stratum is investigated subgroup.
* = significant treatment effect. # = significant interaction.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1HNS_FSNM: Number of hospitalizations by subgroup
Full Analysis Set

Number of hospitalizations							Negative binomial model		
Subgroup	Treatment	N	nval (%)	Time at risk (years)	Number of events	Crude rate	Rate ratio	95% CI	p-value
Geographic region	Sparsentan								NE
North America	Sparsentan	35	35 (100.0)	38.8	4	0.10	0.693	(0.205, 2.339)	0.554
	Irbesartan	46	46 (100.0)	54.5	8	0.15			
Europe	Sparsentan	98	98 (100.0)	116.1	8	0.07	0.956	(0.384, 2.378)	0.923
	Irbesartan	115	115 (100.0)	152.1	11	0.07			
Asia Pacific	Sparsentan	69	69 (100.0)	111.0	12	0.11	0.797	(0.301, 2.108)	0.648
	Irbesartan	41	41 (100.0)	56.3	7	0.12			
Baseline BMI	Sparsentan								0.907
< 27 kg/m**2	Sparsentan	84	84 (100.0)	109.3	11	0.10	0.997	(0.446, 2.229)	0.994
	Irbesartan	94	94 (100.0)	118.5	13	0.11			
>= 27 kg/m**2	Sparsentan	118	118 (100.0)	156.5	13	0.08	0.908	(0.411, 2.010)	0.813
	Irbesartan	107	107 (100.0)	142.4	13	0.09			
Randomization strata	Sparsentan								NE
eGFR Low and UP High	Sparsentan	71	71 (100.0)	96.1	9	0.09	0.659	(0.284, 1.528)	0.331
	Irbesartan	74	74 (100.0)	98.4	14	0.14			
eGFR Low and UP Low	Sparsentan	55	55 (100.0)	72.9	9	0.12	1.794	(0.601, 5.354)	0.295
	Irbesartan	55	55 (100.0)	72.7	5	0.07			
eGFR High and UP High	Sparsentan	37	37 (100.0)	47.0	4	0.09	3.917	(0.438, 35.048)	0.222
	Irbesartan	36	36 (100.0)	46.0	1	0.02			
eGFR High and UP Low	Sparsentan	39	39 (100.0)	49.8	2	0.04	0.329	(0.054, 1.997)	0.227
	Irbesartan	37	37 (100.0)	45.7	6	0.13			

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. nval (%) = number of patients included in the analysis (i.e., with post-baseline data).
NE = not evaluable.
Number of events = number of considered hospitalizations. 95% CI = 95% confidence interval for rate ratio.
A negative binomial model was applied with factors treatment, randomisation strata, and log of offset. The study duration of double blind period was used as offset. Randomisation stratum will be included only once in the model, if this stratum is investigated subgroup.
* = significant treatment effect. # = significant interaction.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1HNS_FSNM: Number of hospitalizations by subgroup
Full Analysis Set

Number of hospitalizations							Negative binomial model		
Subgroup	Treatment	N	nval (%)	Time at risk (years)	Number of events	Crude rate	Rate ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan								NE
< 60 mL/min/1.73 m**2	Sparsentan	127	127 (100.0)	171.0	18	0.11	0.879	(0.461, 1.673)	0.693
	Irbesartan	129	129 (100.0)	174.1	23	0.13			
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	49 (100.0)	59.8	6	0.10	2.081	(0.512, 8.464)	0.306
	Irbesartan	48	48 (100.0)	60.9	3	0.05			
>= 90 mL/min/1.73 m**2	Sparsentan	26	26 (100.0)	35.0	0	0.00			NE
	Irbesartan	25	25 (100.0)	27.9	0	0.00			
Baseline eGFR Group 2	Sparsentan								NE
< 45 mL/min/1.73 m**2	Sparsentan	82	82 (100.0)	110.0	13	0.12	1.016	(0.456, 2.264)	0.969
	Irbesartan	80	80 (100.0)	110.6	13	0.12			
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	45 (100.0)	61.0	5	0.08	0.653	(0.215, 1.980)	0.452
	Irbesartan	49	49 (100.0)	63.4	10	0.16			
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	49 (100.0)	59.8	6	0.10	2.081	(0.512, 8.464)	0.306
	Irbesartan	48	48 (100.0)	60.9	3	0.05			
>= 90 mL/min/1.73 m**2	Sparsentan	26	26 (100.0)	35.0	0	0.00			NE
	Irbesartan	25	25 (100.0)	27.9	0	0.00			
Baseline urine protein excretion	Sparsentan								0.158
<= 1.75 g/day	Sparsentan	98	98 (100.0)	137.3	14	0.10	1.433	(0.600, 3.421)	0.418
	Irbesartan	94	94 (100.0)	114.9	8	0.07			
> 1.75 g/day	Sparsentan	104	104 (100.0)	128.5	10	0.08	0.608	(0.280, 1.320)	0.208
	Irbesartan	108	108 (100.0)	148.0	18	0.12			

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. nval (%) = number of patients included in the analysis (i.e., with post-baseline data).
NE = not evaluable.
Number of events = number of considered hospitalizations. 95% CI = 95% confidence interval for rate ratio.
A negative binomial model was applied with factors treatment, randomisation strata, and log of offset. The study duration of double blind period was used as offset. Randomisation stratum will be included only once in the model, if this stratum is investigated subgroup.
* = significant treatment effect. # = significant interaction.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1HNS_FSNM: Number of hospitalizations by subgroup
Full Analysis Set

Number of hospitalizations							Negative binomial model			
Subgroup	Treatment	N	nval (%)	Time at risk (years)	Number of events	Crude rate	Rate ratio	95% CI	p-value	
Baseline use of antihypertensives	Sparsentan								0.757	
Yes	Sparsentan	88	88 (100.0)	110.2	10	0.09	0.943	(0.385, 2.309)	0.899	
	Irbesartan	83	83 (100.0)	115.1	12	0.10				
No	Sparsentan	114	114 (100.0)	155.6	14	0.09	1.056	(0.502, 2.221)	0.886	
	Irbesartan	119	119 (100.0)	147.8	14	0.09				
Time since renal biopsy	Sparsentan								0.017	#
<= 5 years	Sparsentan	113	113 (100.0)	144.6	10	0.07	0.535	(0.246, 1.162)	0.114	
	Irbesartan	127	127 (100.0)	162.0	21	0.13				
> 5 years	Sparsentan	89	89 (100.0)	121.2	14	0.12	2.429	(0.870, 6.780)	0.090	
	Irbesartan	75	75 (100.0)	100.8	5	0.05				
History of hypertension	Sparsentan								NE	
Yes	Sparsentan	153	153 (100.0)	199.2	19	0.10	0.974	(0.519, 1.827)	0.934	
	Irbesartan	157	157 (100.0)	207.9	20	0.10				
No	Sparsentan	49	49 (100.0)	66.6	5	0.08	0.753	(0.226, 2.503)	0.643	
	Irbesartan	45	45 (100.0)	55.0	6	0.11				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. nval (%) = number of patients included in the analysis (i.e., with post-baseline data).
NE = not evaluable.
Number of events = number of considered hospitalizations. 95% CI = 95% confidence interval for rate ratio.
A negative binomial model was applied with factors treatment, randomisation strata, and log of offset. The study duration of double blind period was used as offset. Randomisation stratum will be included only once in the model, if this stratum is investigated subgroup.
* = significant treatment effect. # = significant interaction.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1HDS_FSNM: Duration of hospitalizations by subgroup
Full Analysis Set

Duration of hospitalizations							Negative binomial model		
Subgroup	Treatment	N	nval (%)	Time at risk (years)	Number of events	Crude rate	Rate ratio	95% CI	p-value
Sex	Sparsentan								0.990
Male	Sparsentan	139	139 (100.0)	175.4	75	0.43	0.812	(0.237, 2.777)	0.740
	Irbesartan	143	143 (100.0)	194.0	134	0.69			
Female	Sparsentan	63	63 (100.0)	90.4	30	0.33	0.975	(0.200, 4.763)	0.975
	Irbesartan	59	59 (100.0)	68.9	44	0.64			
Age	Sparsentan								0.849
<= 45 years	Sparsentan	96	96 (100.0)	121.4	46	0.38	1.400	(0.321, 6.096)	0.654
	Irbesartan	99	99 (100.0)	129.7	76	0.59			
> 45 years	Sparsentan	106	106 (100.0)	144.4	59	0.41	0.840	(0.227, 3.104)	0.794
	Irbesartan	103	103 (100.0)	133.2	102	0.77			
Age at IgAN diagnosis	Sparsentan								NE
<= 18 years	Sparsentan	9	9 (100.0)	9.9	2	0.20			NE
	Irbesartan	5	5 (100.0)	3.5	0	0.00			
> 18 to 40 years	Sparsentan	102	102 (100.0)	133.1	53	0.40	1.369	(0.304, 6.162)	0.683
	Irbesartan	109	109 (100.0)	142.4	54	0.38			
> 40 years	Sparsentan	91	91 (100.0)	122.8	50	0.41	0.501	(0.137, 1.836)	0.297
	Irbesartan	88	88 (100.0)	117.0	124	1.06			

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. nval (%) = number of patients included in the analysis (i.e., with post-baseline data).
NE = not evaluable.
Number of events = number of days with considered hospitalizations. 95% CI = 95% confidence interval for rate ratio.
A negative binomial model was applied with factors treatment, randomisation strata, and log of offset. The study duration of double blind period was used as offset. Randomisation stratum will be included only once in the model, if this stratum is investigated subgroup.
* = significant treatment effect. # = significant interaction.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1HDS_FSNM: Duration of hospitalizations by subgroup
Full Analysis Set

Duration of hospitalizations							Negative binomial model		
Subgroup	Treatment	N	nval (%)	Time at risk (years)	Number of events	Crude rate	Rate ratio	95% CI	p-value
Geographic region	Sparsentan								0.954
North America	Sparsentan	35	35 (100.0)	38.8	15	0.39	0.840	(0.126, 5.583)	0.857
	Irbesartan	46	46 (100.0)	54.5	38	0.70			
Europe	Sparsentan	98	98 (100.0)	116.1	41	0.35	0.684	(0.083, 5.624)	0.724
	Irbesartan	115	115 (100.0)	152.1	94	0.62			
Asia Pacific	Sparsentan	69	69 (100.0)	111.0	49	0.44	0.837	(0.176, 3.983)	0.824
	Irbesartan	41	41 (100.0)	56.3	46	0.82			
Baseline BMI	Sparsentan								0.529
< 27 kg/m**2	Sparsentan	84	84 (100.0)	109.3	48	0.44	1.405	(0.395, 4.999)	0.600
	Irbesartan	94	94 (100.0)	118.5	68	0.57			
>= 27 kg/m**2	Sparsentan	118	118 (100.0)	156.5	57	0.36	0.438	(0.108, 1.773)	0.247
	Irbesartan	107	107 (100.0)	142.4	110	0.77			
Randomization strata	Sparsentan								0.219
eGFR Low and UP High	Sparsentan	71	71 (100.0)	96.1	32	0.33	0.401	(0.109, 1.481)	0.170
	Irbesartan	74	74 (100.0)	98.4	101	1.03			
eGFR Low and UP Low	Sparsentan	55	55 (100.0)	72.9	53	0.73	2.204	(0.447, 10.863)	0.331
	Irbesartan	55	55 (100.0)	72.7	24	0.33			
eGFR High and UP High	Sparsentan	37	37 (100.0)	47.0	9	0.19	2.824	(0.364, 21.921)	0.321
	Irbesartan	36	36 (100.0)	46.0	3	0.07			
eGFR High and UP Low	Sparsentan	39	39 (100.0)	49.8	11	0.22	0.277	(0.021, 3.729)	0.333
	Irbesartan	37	37 (100.0)	45.7	50	1.09			

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. nval (%) = number of patients included in the analysis (i.e., with post-baseline data).
NE = not evaluable.
Number of events = number of days with considered hospitalizations. 95% CI = 95% confidence interval for rate ratio.
A negative binomial model was applied with factors treatment, randomisation strata, and log of offset. The study duration of double blind period was used as offset. Randomisation stratum will be included only once in the model, if this stratum is investigated subgroup.
* = significant treatment effect. # = significant interaction.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1HDS_FSNM: Duration of hospitalizations by subgroup
Full Analysis Set

Duration of hospitalizations							Negative binomial model		
Subgroup	Treatment	N	nval (%)	Time at risk (years)	Number of events	Crude rate	Rate ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan								NE
< 60 mL/min/1.73 m**2	Sparsentan	127	127 (100.0)	171.0	85	0.50	0.838	(0.287, 2.450)	0.747
	Irbesartan	129	129 (100.0)	174.1	157	0.90			
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	49 (100.0)	59.8	20	0.33	3.023	(0.470, 19.456)	0.244
	Irbesartan	48	48 (100.0)	60.9	21	0.34			
>= 90 mL/min/1.73 m**2	Sparsentan	26	26 (100.0)	35.0	0	0.00			NE
	Irbesartan	25	25 (100.0)	27.9	0	0.00			
Baseline eGFR Group 2	Sparsentan								NE
< 45 mL/min/1.73 m**2	Sparsentan	82	82 (100.0)	110.0	68	0.62	0.918	(0.199, 4.227)	0.912
	Irbesartan	80	80 (100.0)	110.6	76	0.69			
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	45 (100.0)	61.0	17	0.28	0.574	(0.110, 2.999)	0.510
	Irbesartan	49	49 (100.0)	63.4	81	1.28			
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	49 (100.0)	59.8	20	0.33	3.023	(0.470, 19.456)	0.244
	Irbesartan	48	48 (100.0)	60.9	21	0.34			
>= 90 mL/min/1.73 m**2	Sparsentan	26	26 (100.0)	35.0	0	0.00			NE
	Irbesartan	25	25 (100.0)	27.9	0	0.00			
Baseline urine protein excretion	Sparsentan								0.339
<= 1.75 g/day	Sparsentan	98	98 (100.0)	137.3	68	0.50	1.076	(0.267, 4.340)	0.918
	Irbesartan	94	94 (100.0)	114.9	59	0.51			
> 1.75 g/day	Sparsentan	104	104 (100.0)	128.5	37	0.29	0.512	(0.143, 1.825)	0.302
	Irbesartan	108	108 (100.0)	148.0	119	0.80			

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. nval (%) = number of patients included in the analysis (i.e., with post-baseline data).
NE = not evaluable.
Number of events = number of days with considered hospitalizations. 95% CI = 95% confidence interval for rate ratio.
A negative binomial model was applied with factors treatment, randomisation strata, and log of offset. The study duration of double blind period was used as offset. Randomisation stratum will be included only once in the model, if this stratum is investigated subgroup.
* = significant treatment effect. # = significant interaction.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1HDS_FSNM: Duration of hospitalizations by subgroup
Full Analysis Set

Duration of hospitalizations							Negative binomial model		
Subgroup	Treatment	N	nval (%)	Time at risk (years)	Number of events	Crude rate	Rate ratio	95% CI	p-value
Baseline use of antihypertensives	Sparsentan								0.488
Yes	Sparsentan	88	88 (100.0)	110.2	40	0.36	0.844	(0.217, 3.286)	0.807
	Irbesartan	83	83 (100.0)	115.1	85	0.74			
No	Sparsentan	114	114 (100.0)	155.6	65	0.42	1.978	(0.496, 7.889)	0.334
	Irbesartan	119	119 (100.0)	147.8	93	0.63			
Time since renal biopsy	Sparsentan								0.320
<= 5 years	Sparsentan	113	113 (100.0)	144.6	36	0.25	0.486	(0.157, 1.505)	0.211
	Irbesartan	127	127 (100.0)	162.0	117	0.72			
> 5 years	Sparsentan	89	89 (100.0)	121.2	69	0.57	2.375	(0.338, 16.667)	0.384
	Irbesartan	75	75 (100.0)	100.8	61	0.61			
History of hypertension	Sparsentan								0.910
Yes	Sparsentan	153	153 (100.0)	199.2	84	0.42	0.765	(0.255, 2.294)	0.632
	Irbesartan	157	157 (100.0)	207.9	150	0.72			
No	Sparsentan	49	49 (100.0)	66.6	21	0.32	1.258	(0.091, 17.336)	0.864
	Irbesartan	45	45 (100.0)	55.0	28	0.51			

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. nval (%) = number of patients included in the analysis (i.e., with post-baseline data).
NE = not evaluable.
Number of events = number of days with considered hospitalizations. 95% CI = 95% confidence interval for rate ratio.
A negative binomial model was applied with factors treatment, randomisation strata, and log of offset. The study duration of double blind period was used as offset. Randomisation stratum will be included only once in the model, if this stratum is investigated subgroup.
* = significant treatment effect. # = significant interaction.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 28FEB2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	EQ-5D VAS	Baseline	Sparsentan	139	132 (95.0)	81.11 (11.21)	40.0	74.50	81.00	90.00	100.0	
			Irbesartan	143	131 (91.6)	79.58 (14.73)	19.0	75.00	80.00	90.00	100.0	
		Week 24	Sparsentan	139	91 (65.5)	83.32 (10.98)	50.0	76.00	84.00	91.00	100.0	
			Irbesartan	143	83 (58.0)	80.06 (18.01)	4.0	73.00	82.00	91.00	100.0	
		Week 48	Sparsentan	139	75 (54.0)	82.76 (9.78)	49.0	80.00	83.00	90.00	100.0	
			Irbesartan	143	61 (42.7)	83.44 (12.33)	40.0	79.00	85.00	91.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	139	91 (65.5)	2.46 (11.91)	-31.0	-4.00	2.00	8.00	44.0	0.12 [-0.18, 0.41]
			Irbesartan	143	83 (58.0)	0.66 (18.83)	-90.0	-6.00	0.00	11.00	52.0	
		Week 48	Sparsentan	139	75 (54.0)	2.61 (10.45)	-30.0	-2.00	1.00	7.00	41.0	-0.07 [-0.41, 0.27]
			Irbesartan	143	61 (42.7)	3.36 (10.16)	-35.0	-1.00	3.00	9.00	27.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Female	EQ-5D VAS	Baseline	Sparsentan	63	59 (93.7)	79.07 (19.44)	7.0	75.00	82.00	90.00	100.0	
			Irbesartan	59	53 (89.8)	82.30 (12.78)	37.0	75.00	83.00	91.00	100.0	
		Week 24	Sparsentan	63	41 (65.1)	82.95 (10.66)	51.0	78.00	83.00	90.00	100.0	
			Irbesartan	59	32 (54.2)	83.19 (10.21)	48.0	80.00	81.00	90.00	99.0	
		Week 48	Sparsentan	63	38 (60.3)	80.82 (12.07)	49.0	74.00	80.00	90.00	100.0	
			Irbesartan	59	22 (37.3)	80.91 (13.86)	50.0	80.00	82.00	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	63	41 (65.1)	4.85 (20.39)	-25.0	-9.00	0.00	12.00	75.0	0.26 [-0.20, 0.73]
			Irbesartan	59	32 (54.2)	0.34 (12.17)	-37.0	-3.50	0.50	7.00	23.0	
		Week 48	Sparsentan	63	38 (60.3)	3.29 (22.68)	-29.0	-11.00	0.00	10.00	87.0	0.25 [-0.28, 0.77]
			Irbesartan	59	22 (37.3)	-1.50 (11.66)	-31.0	-8.00	0.50	5.00	23.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
<= 45 years	EQ-5D VAS	Baseline	Sparsentan	96	89 (92.7)	79.93 (14.66)	7.0	75.00	81.00	90.00	100.0	
			Irbesartan	99	92 (92.9)	81.66 (14.94)	19.0	75.00	82.00	90.50	100.0	
		Week 24	Sparsentan	96	62 (64.6)	84.79 (10.90)	59.0	78.00	87.50	91.00	100.0	
			Irbesartan	99	58 (58.6)	79.76 (18.45)	10.0	71.00	83.50	91.00	100.0	
		Week 48	Sparsentan	96	54 (56.3)	82.39 (11.84)	49.0	79.00	82.50	91.00	100.0	
			Irbesartan	99	41 (41.4)	82.44 (14.21)	40.0	80.00	83.00	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	96	62 (64.6)	4.77 (16.93)	-31.0	-4.00	1.50	13.00	75.0	0.41 [0.04, 0.77]
			Irbesartan	99	58 (58.6)	-2.21 (17.48)	-90.0	-9.00	-1.00	9.00	23.0	
		Week 48	Sparsentan	96	54 (56.3)	2.15 (15.73)	-30.0	-6.00	1.00	10.00	64.0	0.19 [-0.22, 0.59]
			Irbesartan	99	41 (41.4)	-0.49 (11.86)	-35.0	-5.00	0.00	5.00	27.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 45 years	EQ-5D VAS	Baseline	Sparsentan	106	102 (96.2)	80.96 (13.92)	11.0	75.00	82.00	90.00	100.0	
			Irbesartan	103	92 (89.3)	79.07 (13.40)	34.0	74.00	80.00	89.00	100.0	
		Week 24	Sparsentan	106	70 (66.0)	81.80 (10.67)	50.0	75.00	80.50	90.00	100.0	
			Irbesartan	103	57 (55.3)	82.12 (13.69)	4.0	79.00	81.00	90.00	100.0	
		Week 48	Sparsentan	106	59 (55.7)	81.85 (9.41)	49.0	79.00	81.00	89.00	99.0	
			Irbesartan	103	42 (40.8)	83.10 (11.24)	52.0	80.00	82.50	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	106	70 (66.0)	1.81 (13.07)	-29.0	-5.00	0.50	7.00	44.0	-0.11 [-0.46, 0.24]
			Irbesartan	103	57 (55.3)	3.40 (16.56)	-71.0	-1.00	1.00	10.00	52.0	
		Week 48	Sparsentan	106	59 (55.7)	3.47 (15.51)	-20.0	-3.00	0.00	7.00	87.0	-0.08 [-0.48, 0.31]
			Irbesartan	103	42 (40.8)	4.57 (8.93)	-19.0	0.00	5.00	9.00	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age at IgAN diagnosis												
<= 18 years	EQ-5D VAS	Baseline	Sparsentan	9	9 (100.0)	74.67 (15.03)	51.0	62.00	79.00	82.00	95.0	
			Irbesartan	5	5 (100.0)	76.40 (11.59)	60.0	73.00	74.00	86.00	89.0	
		Week 24	Sparsentan	9	3 (33.3)	86.67 (23.09)	60.0	60.00	100.00	100.00	100.0	
			Irbesartan	5	2 (40.0)	50.00 (26.87)	31.0	31.00	50.00	69.00	69.0	
		Week 48	Sparsentan	9	5 (55.6)	83.00 (14.25)	66.0	71.00	86.00	92.00	100.0	
			Irbesartan	5	1 (20.0)	66.00	66.0	66.00	66.00	66.00	66.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	9	3 (33.3)	9.33 (10.69)	0.0	0.00	7.00	21.00	21.0	1.14 [-0.78, 3.07]
			Irbesartan	5	2 (40.0)	-16.50 (36.06)	-42.0	-42.00	-16.50	9.00	9.0	
		Week 48	Sparsentan	9	5 (55.6)	6.80 (9.28)	-9.0	7.00	10.00	11.00	15.0	NE
			Irbesartan	5	1 (20.0)	6.00	6.0	6.00	6.00	6.00	6.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 18 to 40 years	EQ-5D VAS	Baseline	Sparsentan	102	95 (93.1)	80.85 (14.44)	7.0	75.00	82.00	90.00	100.0	
			Irbesartan	109	100 (91.7)	81.14 (15.01)	19.0	75.00	82.00	90.00	100.0	
		Week 24	Sparsentan	102	66 (64.7)	84.33 (10.13)	59.0	78.00	85.50	91.00	100.0	
			Irbesartan	109	63 (57.8)	81.75 (16.66)	10.0	78.00	85.00	91.00	100.0	
		Week 48	Sparsentan	102	58 (56.9)	82.16 (10.83)	49.0	79.00	82.00	90.00	100.0	
			Irbesartan	109	45 (41.3)	82.29 (14.05)	40.0	80.00	84.00	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	102	66 (64.7)	4.62 (17.29)	-31.0	-4.00	1.50	12.00	75.0	0.28 [-0.06, 0.63]
			Irbesartan	109	63 (57.8)	-0.22 (16.72)	-90.0	-7.00	-1.00	11.00	23.0	
		Week 48	Sparsentan	102	58 (56.9)	2.07 (16.14)	-30.0	-6.00	1.00	9.00	64.0	0.12 [-0.27, 0.51]
			Irbesartan	109	45 (41.3)	0.38 (12.09)	-35.0	-5.00	0.00	7.00	27.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 40 years	EQ-5D VAS	Baseline	Sparsentan	91	87 (95.6)	80.68 (13.98)	11.0	72.00	81.00	90.00	100.0	
			Irbesartan	88	79 (89.8)	79.63 (13.37)	40.0	73.00	80.00	90.00	100.0	
		Week 24	Sparsentan	91	63 (69.2)	81.86 (10.95)	50.0	75.00	80.00	90.00	100.0	
			Irbesartan	88	50 (56.8)	81.14 (14.40)	4.0	79.00	80.00	90.00	100.0	
		Week 48	Sparsentan	91	50 (54.9)	81.96 (10.17)	49.0	79.00	81.00	90.00	100.0	
			Irbesartan	88	37 (42.0)	83.81 (10.86)	56.0	80.00	82.00	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	91	63 (69.2)	1.43 (12.35)	-29.0	-6.00	0.00	7.00	40.0	-0.06 [-0.43, 0.31]
			Irbesartan	88	50 (56.8)	2.26 (17.07)	-71.0	-1.00	0.50	10.00	52.0	
		Week 48	Sparsentan	91	50 (54.9)	3.34 (15.52)	-20.0	-3.00	0.00	5.00	87.0	-0.05 [-0.48, 0.37]
			Irbesartan	88	37 (42.0)	4.03 (8.69)	-19.0	0.00	4.00	9.00	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Geographic region												
North America	EQ-5D VAS	Baseline	Sparsentan	35	33 (94.3)	79.61 (18.57)	7.0	75.00	85.00	93.00	100.0	
			Irbesartan	46	44 (95.7)	81.18 (15.14)	34.0	75.00	82.50	92.50	100.0	
		Week 24	Sparsentan	35	15 (42.9)	85.73 (10.79)	70.0	75.00	85.00	95.00	100.0	
			Irbesartan	46	28 (60.9)	78.96 (23.68)	4.0	73.50	86.00	93.50	100.0	
		Week 48	Sparsentan	35	13 (37.1)	80.23 (13.59)	49.0	71.00	80.00	90.00	99.0	
			Irbesartan	46	18 (39.1)	83.33 (12.37)	56.0	75.00	82.00	96.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	35	15 (42.9)	6.40 (22.37)	-21.0	-2.00	0.00	10.00	75.0	0.39 [-0.24, 1.02]
			Irbesartan	46	28 (60.9)	-3.00 (24.84)	-90.0	-4.00	0.50	9.00	23.0	
		Week 48	Sparsentan	35	13 (37.1)	6.62 (20.44)	-15.0	-4.00	-1.00	15.00	64.0	0.26 [-0.45, 0.98]
			Irbesartan	46	18 (39.1)	2.72 (8.99)	-19.0	0.00	3.00	7.00	24.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Europe	EQ-5D VAS	Baseline	Sparsentan	98	91 (92.9)	80.81 (13.55)	11.0	75.00	81.00	90.00	100.0	
			Irbesartan	115	99 (86.1)	81.11 (13.68)	40.0	75.00	81.00	90.00	100.0	
		Week 24	Sparsentan	98	60 (61.2)	81.92 (11.89)	50.0	75.50	81.00	90.00	100.0	
			Irbesartan	115	52 (45.2)	82.73 (12.81)	31.0	78.50	85.00	91.00	100.0	
		Week 48	Sparsentan	98	45 (45.9)	83.20 (10.61)	50.0	79.00	83.00	91.00	100.0	
			Irbesartan	115	40 (34.8)	84.05 (14.15)	40.0	80.00	86.50	92.50	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	98	60 (61.2)	1.35 (13.57)	-31.0	-5.00	0.50	7.00	40.0	0.03 [-0.34, 0.40]
			Irbesartan	115	52 (45.2)	0.90 (14.23)	-42.0	-7.00	-0.50	10.50	52.0	
		Week 48	Sparsentan	98	45 (45.9)	2.98 (17.14)	-30.0	-2.00	1.00	7.00	87.0	0.05 [-0.37, 0.48]
			Irbesartan	115	40 (34.8)	2.20 (10.94)	-35.0	-1.00	1.00	7.50	27.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asia Pacific	EQ-5D VAS	Baseline	Sparsentan	69	67 (97.1)	80.46 (12.87)	40.0	73.00	81.00	90.00	100.0	
			Irbesartan	41	41 (100.0)	77.68 (14.49)	19.0	72.00	80.00	85.00	100.0	
		Week 24	Sparsentan	69	57 (82.6)	83.89 (9.64)	60.0	78.00	85.00	90.00	100.0	
			Irbesartan	41	35 (85.4)	79.83 (13.52)	30.0	72.00	80.00	90.00	100.0	
		Week 48	Sparsentan	69	55 (79.7)	81.65 (9.89)	49.0	80.00	82.00	89.00	100.0	
			Irbesartan	41	25 (61.0)	80.32 (10.48)	54.0	75.00	81.00	89.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	69	57 (82.6)	4.32 (14.18)	-25.0	-3.00	5.00	12.00	44.0	0.10 [-0.32, 0.52]
			Irbesartan	41	35 (85.4)	2.94 (13.42)	-37.0	-2.00	0.00	10.00	34.0	
		Week 48	Sparsentan	69	55 (79.7)	1.84 (12.87)	-29.0	-6.00	0.00	10.00	46.0	0.03 [-0.44, 0.51]
			Irbesartan	41	25 (61.0)	1.40 (11.84)	-31.0	-4.00	5.00	10.00	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline BMI												
< 27 kg/m**2	EQ-5D VAS	Baseline	Sparsentan	84	78 (92.9)	78.91 (14.89)	11.0	72.00	81.00	89.00	100.0	
			Irbesartan	94	86 (91.5)	84.01 (10.64)	52.0	77.00	83.00	91.00	100.0	
		Week 24	Sparsentan	84	54 (64.3)	81.33 (11.56)	51.0	72.00	80.00	90.00	100.0	
			Irbesartan	94	56 (59.6)	82.14 (13.66)	31.0	78.50	81.50	91.00	100.0	
		Week 48	Sparsentan	84	49 (58.3)	79.43 (11.27)	49.0	75.00	80.00	87.00	98.0	
			Irbesartan	94	39 (41.5)	83.67 (13.53)	40.0	80.00	82.00	92.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	84	54 (64.3)	1.89 (13.44)	-25.0	-6.00	0.00	7.00	40.0	0.23 [-0.15, 0.60]
			Irbesartan	94	56 (59.6)	-0.95 (11.50)	-42.0	-5.50	-1.00	7.00	19.0	
		Week 48	Sparsentan	84	49 (58.3)	1.04 (18.60)	-30.0	-8.00	-1.00	4.00	87.0	0.10 [-0.32, 0.52]
			Irbesartan	94	39 (41.5)	-0.49 (11.05)	-35.0	-5.00	0.00	6.00	27.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 27 kg/m**2	EQ-5D VAS	Baseline	Sparsentan	118	113 (95.8)	81.57 (13.74)	7.0	77.00	82.00	91.00	100.0	
			Irbesartan	107	97 (90.7)	77.55 (15.74)	19.0	73.00	80.00	88.00	100.0	
		Week 24	Sparsentan	118	78 (66.1)	84.50 (10.20)	50.0	80.00	85.50	91.00	100.0	
			Irbesartan	107	59 (55.1)	79.78 (18.40)	4.0	74.00	81.00	91.00	100.0	
		Week 48	Sparsentan	118	64 (54.2)	84.16 (9.64)	51.0	80.00	84.50	90.50	100.0	
			Irbesartan	107	44 (41.1)	81.98 (12.05)	50.0	77.00	83.50	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	118	78 (66.1)	4.12 (16.05)	-31.0	-4.00	3.00	10.00	75.0	0.11 [-0.22, 0.45]
			Irbesartan	107	59 (55.1)	2.02 (21.23)	-90.0	-5.00	1.00	13.00	52.0	
		Week 48	Sparsentan	118	64 (54.2)	4.22 (12.74)	-20.0	-1.00	1.50	10.00	64.0	-0.01 [-0.39, 0.37]
			Irbesartan	107	44 (41.1)	4.34 (10.00)	-20.0	0.00	5.00	10.00	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Randomization strata												
eGFR Low and UP High	EQ-5D VAS	Baseline	Sparsentan	71	66 (93.0)	82.14 (10.50)	51.0	79.00	81.50	90.00	100.0	
			Irbesartan	74	65 (87.8)	78.74 (15.05)	37.0	75.00	80.00	87.00	100.0	
		Week 24	Sparsentan	71	45 (63.4)	83.67 (11.19)	50.0	76.00	85.00	91.00	100.0	
			Irbesartan	74	38 (51.4)	76.74 (18.94)	4.0	70.00	80.00	90.00	100.0	
		Week 48	Sparsentan	71	39 (54.9)	84.67 (8.90)	60.0	80.00	84.00	91.00	100.0	
			Irbesartan	74	25 (33.8)	84.08 (12.35)	54.0	80.00	85.00	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	71	45 (63.4)	0.11 (11.89)	-31.0	-5.00	0.00	7.00	35.0	0.29 [-0.15, 0.72]
			Irbesartan	74	38 (51.4)	-4.55 (20.40)	-71.0	-11.00	-2.00	2.00	52.0	
		Week 48	Sparsentan	71	39 (54.9)	1.69 (8.25)	-13.0	-2.00	0.00	5.00	28.0	0.05 [-0.46, 0.55]
			Irbesartan	74	25 (33.8)	1.24 (11.66)	-31.0	-1.00	2.00	5.00	24.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR Low and UP Low	EQ-5D VAS	Baseline	Sparsentan	55	52 (94.5)	79.10 (17.39)	11.0	71.00	81.00	90.00	100.0	
			Irbesartan	55	51 (92.7)	81.61 (13.00)	34.0	74.00	80.00	90.00	100.0	
		Week 24	Sparsentan	55	40 (72.7)	81.88 (10.79)	51.0	76.50	81.00	90.00	100.0	
			Irbesartan	55	35 (63.6)	82.71 (14.89)	10.0	80.00	83.00	90.00	100.0	
		Week 48	Sparsentan	55	28 (50.9)	81.32 (10.99)	49.0	80.00	81.50	90.00	98.0	
			Irbesartan	55	26 (47.3)	83.00 (13.03)	50.0	80.00	83.00	92.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	55	40 (72.7)	4.25 (14.75)	-25.0	-3.50	0.00	10.50	44.0	0.20 [-0.26, 0.65]
			Irbesartan	55	35 (63.6)	0.91 (18.70)	-90.0	-2.00	1.00	10.00	23.0	
		Week 48	Sparsentan	55	28 (50.9)	5.04 (20.42)	-20.0	-4.00	0.50	10.50	87.0	0.18 [-0.35, 0.72]
			Irbesartan	55	26 (47.3)	2.04 (9.96)	-20.0	-5.00	2.00	9.00	23.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP High	EQ-5D VAS	Baseline	Sparsentan	37	35 (94.6)	78.66 (18.53)	7.0	70.00	82.00	91.00	100.0	
			Irbesartan	36	32 (88.9)	81.06 (11.59)	50.0	72.50	80.00	90.00	100.0	
		Week 24	Sparsentan	37	22 (59.5)	81.59 (11.67)	60.0	71.00	81.00	90.00	100.0	
			Irbesartan	36	20 (55.6)	85.90 (10.30)	69.0	76.00	90.00	91.50	99.0	
		Week 48	Sparsentan	37	22 (59.5)	77.50 (10.98)	50.0	71.00	79.00	86.00	90.0	
			Irbesartan	36	13 (36.1)	79.62 (15.16)	40.0	80.00	81.00	90.00	99.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	37	22 (59.5)	5.86 (21.28)	-25.0	-4.00	5.00	8.00	75.0	-0.14 [-0.75, 0.46]
			Irbesartan	36	20 (55.6)	8.30 (10.34)	-11.0	-1.00	9.00	15.00	34.0	
		Week 48	Sparsentan	37	22 (59.5)	2.36 (21.95)	-30.0	-12.00	-1.00	11.00	64.0	-0.04 [-0.72, 0.65]
			Irbesartan	36	13 (36.1)	3.08 (14.51)	-35.0	0.00	6.00	9.00	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP Low	EQ-5D VAS	Baseline	Sparsentan	39	38 (97.4)	81.18 (10.21)	50.0	75.00	80.50	90.00	100.0	
			Irbesartan	37	36 (97.3)	80.92 (16.54)	19.0	75.00	84.00	90.00	100.0	
		Week 24	Sparsentan	39	25 (64.1)	85.92 (9.52)	70.0	80.00	88.00	91.00	100.0	
			Irbesartan	37	22 (59.5)	80.82 (16.82)	30.0	78.00	80.00	91.00	100.0	
		Week 48	Sparsentan	39	24 (61.5)	83.08 (11.43)	49.0	80.00	84.50	91.00	100.0	
			Irbesartan	37	19 (51.4)	82.89 (11.62)	60.0	75.00	80.00	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	39	25 (64.1)	4.76 (13.93)	-20.0	-3.00	3.00	16.00	29.0	0.24 [-0.34, 0.81]
			Irbesartan	37	22 (59.5)	1.86 (10.03)	-10.0	-5.00	0.00	9.00	30.0	
		Week 48	Sparsentan	39	24 (61.5)	2.58 (11.37)	-29.0	-3.00	3.00	10.00	24.0	0.01 [-0.60, 0.61]
			Irbesartan	37	19 (51.4)	2.53 (7.92)	-10.0	-1.00	0.00	5.00	27.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 1												
< 60 mL/min/1.73 m**2	EQ-5D VAS	Baseline	Sparsentan	127	119 (93.7)	80.61 (13.81)	11.0	75.00	81.00	90.00	100.0	
			Irbesartan	129	117 (90.7)	79.89 (13.65)	34.0	75.00	80.00	89.00	100.0	
		Week 24	Sparsentan	127	87 (68.5)	82.74 (10.73)	50.0	76.00	82.00	91.00	100.0	
			Irbesartan	129	75 (58.1)	79.52 (17.07)	4.0	74.00	81.00	90.00	100.0	
		Week 48	Sparsentan	127	67 (52.8)	83.21 (9.72)	49.0	80.00	82.00	90.00	100.0	
			Irbesartan	129	53 (41.1)	83.11 (12.42)	50.0	80.00	83.00	91.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	127	87 (68.5)	2.29 (13.35)	-31.0	-5.00	0.00	10.00	44.0	0.19 [-0.12, 0.50]
			Irbesartan	129	75 (58.1)	-0.93 (19.64)	-90.0	-9.00	0.00	10.00	52.0	
		Week 48	Sparsentan	127	67 (52.8)	3.43 (14.61)	-20.0	-2.00	0.00	7.00	87.0	0.11 [-0.25, 0.47]
			Irbesartan	129	53 (41.1)	1.96 (10.50)	-31.0	-1.00	2.00	7.00	24.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	EQ-5D VAS	Baseline	Sparsentan	49	47 (95.9)	80.83 (16.08)	7.0	75.00	82.00	90.00	100.0	
			Irbesartan	48	43 (89.6)	80.44 (13.89)	37.0	71.00	81.00	90.00	100.0	
		Week 24	Sparsentan	49	29 (59.2)	84.55 (11.57)	60.0	75.00	87.00	91.00	100.0	
			Irbesartan	48	27 (56.3)	84.96 (10.01)	65.0	80.00	82.00	91.00	100.0	
		Week 48	Sparsentan	49	29 (59.2)	81.07 (10.59)	49.0	77.00	82.00	87.00	100.0	
			Irbesartan	48	20 (41.7)	82.20 (14.64)	40.0	80.00	85.00	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	49	29 (59.2)	4.00 (19.09)	-25.0	-8.00	3.00	8.00	75.0	0.04 [-0.48, 0.56]
			Irbesartan	48	27 (56.3)	3.37 (11.73)	-11.0	-5.00	0.00	9.00	34.0	
		Week 48	Sparsentan	49	29 (59.2)	1.10 (16.78)	-29.0	-6.00	0.00	5.00	64.0	-0.08 [-0.65, 0.49]
			Irbesartan	48	20 (41.7)	2.25 (11.98)	-35.0	-2.50	5.00	9.50	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	EQ-5D VAS	Baseline	Sparsentan	26	25 (96.2)	79.20 (13.04)	40.0	71.00	81.00	89.00	97.0	
			Irbesartan	25	24 (96.0)	82.54 (17.58)	19.0	78.00	86.00	92.50	100.0	
		Week 24	Sparsentan	26	16 (61.5)	83.31 (10.60)	60.0	78.00	84.00	90.50	100.0	
			Irbesartan	25	13 (52.0)	80.69 (21.01)	30.0	70.00	90.00	92.00	100.0	
		Week 48	Sparsentan	26	17 (65.4)	79.53 (13.62)	50.0	77.00	80.00	89.00	96.0	
			Irbesartan	25	10 (40.0)	82.10 (11.35)	66.0	75.00	80.00	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	26	16 (61.5)	6.75 (15.80)	-20.0	-2.00	5.50	17.00	40.0	0.25 [-0.49, 0.98]
			Irbesartan	25	13 (52.0)	3.46 (9.42)	-11.0	-4.00	0.00	11.00	21.0	
		Week 48	Sparsentan	26	17 (65.4)	3.47 (17.75)	-30.0	-6.00	4.00	11.00	46.0	0.08 [-0.71, 0.86]
			Irbesartan	25	10 (40.0)	2.30 (10.39)	-14.0	-1.00	0.00	5.00	27.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 2												
< 45 mL/min/1.73 m**2	EQ-5D VAS	Baseline	Sparsentan	82	75 (91.5)	79.11 (15.04)	11.0	71.00	81.00	88.00	100.0	
			Irbesartan	80	70 (87.5)	77.90 (14.78)	34.0	73.00	80.00	85.00	100.0	
		Week 24	Sparsentan	82	54 (65.9)	82.91 (11.28)	50.0	80.00	83.00	91.00	100.0	
			Irbesartan	80	48 (60.0)	77.54 (17.12)	4.0	71.00	80.00	90.00	99.0	
		Week 48	Sparsentan	82	44 (53.7)	84.55 (9.72)	49.0	80.00	84.00	90.50	100.0	
			Irbesartan	80	32 (40.0)	81.59 (13.61)	50.0	79.50	82.50	89.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	82	54 (65.9)	3.37 (12.98)	-29.0	-4.00	0.00	10.00	44.0	0.26 [-0.13, 0.65]
			Irbesartan	80	48 (60.0)	-0.96 (19.60)	-71.0	-9.00	0.00	10.00	52.0	
		Week 48	Sparsentan	82	44 (53.7)	6.07 (16.34)	-20.0	-1.00	1.50	9.50	87.0	0.31 [-0.15, 0.77]
			Irbesartan	80	32 (40.0)	1.47 (12.25)	-31.0	-0.50	3.50	7.50	24.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
45 to < 60 mL/min/1.73 m**2	EQ-5D VAS	Baseline	Sparsentan	45	44 (97.8)	83.18 (11.11)	50.0	78.50	81.50	91.00	100.0	
			Irbesartan	49	47 (95.9)	82.85 (11.28)	50.0	75.00	82.00	90.00	100.0	
		Week 24	Sparsentan	45	33 (73.3)	82.45 (9.92)	59.0	74.00	82.00	90.00	100.0	
			Irbesartan	49	27 (55.1)	83.04 (16.71)	10.0	80.00	85.00	91.00	100.0	
		Week 48	Sparsentan	45	23 (51.1)	80.65 (9.39)	55.0	75.00	80.00	90.00	95.0	
			Irbesartan	49	21 (42.9)	85.43 (10.22)	65.0	80.00	83.00	92.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	45	33 (73.3)	0.52 (13.95)	-31.0	-9.00	0.00	8.00	35.0	0.08 [-0.43, 0.59]
			Irbesartan	49	27 (55.1)	-0.89 (20.08)	-90.0	-5.00	0.00	9.00	22.0	
		Week 48	Sparsentan	45	23 (51.1)	-1.61 (8.82)	-20.0	-8.00	0.00	1.00	13.0	-0.53 [-1.13, 0.07]
			Irbesartan	49	21 (42.9)	2.71 (7.27)	-8.0	-1.00	1.00	5.00	19.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	EQ-5D VAS	Baseline	Sparsentan	49	47 (95.9)	80.83 (16.08)	7.0	75.00	82.00	90.00	100.0	
			Irbesartan	48	43 (89.6)	80.44 (13.89)	37.0	71.00	81.00	90.00	100.0	
		Week 24	Sparsentan	49	29 (59.2)	84.55 (11.57)	60.0	75.00	87.00	91.00	100.0	
			Irbesartan	48	27 (56.3)	84.96 (10.01)	65.0	80.00	82.00	91.00	100.0	
		Week 48	Sparsentan	49	29 (59.2)	81.07 (10.59)	49.0	77.00	82.00	87.00	100.0	
			Irbesartan	48	20 (41.7)	82.20 (14.64)	40.0	80.00	85.00	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	49	29 (59.2)	4.00 (19.09)	-25.0	-8.00	3.00	8.00	75.0	0.04 [-0.48, 0.56]
			Irbesartan	48	27 (56.3)	3.37 (11.73)	-11.0	-5.00	0.00	9.00	34.0	
		Week 48	Sparsentan	49	29 (59.2)	1.10 (16.78)	-29.0	-6.00	0.00	5.00	64.0	-0.08 [-0.65, 0.49]
			Irbesartan	48	20 (41.7)	2.25 (11.98)	-35.0	-2.50	5.00	9.50	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	EQ-5D VAS	Baseline	Sparsentan	26	25 (96.2)	79.20 (13.04)	40.0	71.00	81.00	89.00	97.0	
			Irbesartan	25	24 (96.0)	82.54 (17.58)	19.0	78.00	86.00	92.50	100.0	
		Week 24	Sparsentan	26	16 (61.5)	83.31 (10.60)	60.0	78.00	84.00	90.50	100.0	
			Irbesartan	25	13 (52.0)	80.69 (21.01)	30.0	70.00	90.00	92.00	100.0	
		Week 48	Sparsentan	26	17 (65.4)	79.53 (13.62)	50.0	77.00	80.00	89.00	96.0	
			Irbesartan	25	10 (40.0)	82.10 (11.35)	66.0	75.00	80.00	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	26	16 (61.5)	6.75 (15.80)	-20.0	-2.00	5.50	17.00	40.0	0.25 [-0.49, 0.98]
			Irbesartan	25	13 (52.0)	3.46 (9.42)	-11.0	-4.00	0.00	11.00	21.0	
		Week 48	Sparsentan	26	17 (65.4)	3.47 (17.75)	-30.0	-6.00	4.00	11.00	46.0	0.08 [-0.71, 0.86]
			Irbesartan	25	10 (40.0)	2.30 (10.39)	-14.0	-1.00	0.00	5.00	27.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline urine protein excretion												
<= 1.75 g/day	EQ-5D VAS	Baseline	Sparsentan	98	94 (95.9)	79.36 (16.33)	7.0	73.00	82.00	90.00	100.0	
			Irbesartan	94	84 (89.4)	81.11 (14.51)	19.0	74.50	81.00	90.00	100.0	
		Week 24	Sparsentan	98	69 (70.4)	82.28 (10.73)	51.0	75.00	81.00	90.00	100.0	
			Irbesartan	94	48 (51.1)	82.77 (12.93)	30.0	79.50	81.00	90.50	100.0	
		Week 48	Sparsentan	98	61 (62.2)	82.21 (11.02)	49.0	79.00	83.00	90.00	100.0	
			Irbesartan	94	36 (38.3)	85.25 (9.00)	66.0	80.00	84.00	91.50	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	98	69 (70.4)	4.38 (16.88)	-25.0	-5.00	0.00	11.00	75.0	0.20 [-0.16, 0.57]
			Irbesartan	94	48 (51.1)	1.48 (8.90)	-20.0	-4.50	0.00	9.50	21.0	
		Week 48	Sparsentan	98	61 (62.2)	4.38 (17.79)	-29.0	-2.00	1.00	10.00	87.0	0.08 [-0.33, 0.49]
			Irbesartan	94	36 (38.3)	3.19 (9.21)	-20.0	-1.00	3.50	9.00	27.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 1.75 g/day	EQ-5D VAS	Baseline	Sparsentan	104	97 (93.3)	81.57 (11.86)	40.0	75.00	81.00	91.00	100.0	
			Irbesartan	108	100 (92.6)	79.74 (14.00)	34.0	75.00	80.00	88.50	100.0	
		Week 24	Sparsentan	104	63 (60.6)	84.22 (10.97)	50.0	78.00	86.00	91.00	100.0	
			Irbesartan	108	67 (62.0)	79.61 (18.22)	4.0	72.00	82.00	91.00	100.0	
		Week 48	Sparsentan	104	52 (50.0)	81.98 (10.18)	50.0	78.50	81.50	89.00	100.0	
			Irbesartan	108	47 (43.5)	80.87 (14.77)	40.0	74.00	82.00	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	104	63 (60.6)	1.92 (12.70)	-31.0	-4.00	4.00	8.00	40.0	0.11 [-0.23, 0.46]
			Irbesartan	108	67 (62.0)	-0.07 (21.28)	-90.0	-7.00	0.00	11.00	52.0	
		Week 48	Sparsentan	104	52 (50.0)	1.04 (12.39)	-30.0	-6.00	0.00	7.00	46.0	-0.01 [-0.41, 0.38]
			Irbesartan	108	47 (43.5)	1.21 (11.78)	-35.0	-1.00	2.00	8.00	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline use of antihypertensives												
Yes	EQ-5D VAS	Baseline	Sparsentan	88	80 (90.9)	78.55 (17.02)	7.0	71.00	81.00	90.00	100.0	
			Irbesartan	83	74 (89.2)	78.82 (13.68)	37.0	72.00	80.00	89.00	100.0	
		Week 24	Sparsentan	88	55 (62.5)	84.27 (11.04)	51.0	78.00	89.00	91.00	100.0	
			Irbesartan	83	45 (54.2)	79.71 (14.94)	4.0	72.00	80.00	90.00	99.0	
		Week 48	Sparsentan	88	44 (50.0)	82.73 (12.17)	49.0	76.00	84.00	92.00	100.0	
			Irbesartan	83	32 (38.6)	81.88 (12.73)	50.0	74.50	83.50	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	88	55 (62.5)	6.89 (16.18)	-25.0	0.00	7.00	11.00	75.0	0.28 [-0.11, 0.68]
			Irbesartan	83	45 (54.2)	2.09 (18.01)	-71.0	-6.00	0.00	10.00	52.0	
		Week 48	Sparsentan	88	44 (50.0)	6.98 (18.40)	-19.0	-1.00	1.50	9.00	87.0	0.19 [-0.27, 0.64]
			Irbesartan	83	32 (38.6)	4.06 (10.35)	-19.0	0.00	5.00	9.50	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	EQ-5D VAS	Baseline	Sparsentan	114	111 (97.4)	81.87 (11.73)	40.0	77.00	81.00	90.00	100.0	
			Irbesartan	119	110 (92.4)	81.40 (14.53)	19.0	75.00	83.00	90.00	100.0	
		Week 24	Sparsentan	114	77 (67.5)	82.44 (10.71)	50.0	75.00	81.00	90.00	100.0	
			Irbesartan	119	70 (58.8)	81.71 (17.08)	10.0	80.00	85.00	91.00	100.0	
		Week 48	Sparsentan	114	69 (60.5)	81.71 (9.53)	49.0	80.00	82.00	88.00	100.0	
			Irbesartan	119	51 (42.9)	83.33 (12.81)	40.0	80.00	83.00	91.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	114	77 (67.5)	0.57 (13.64)	-31.0	-6.00	0.00	5.00	40.0	0.06 [-0.26, 0.39]
			Irbesartan	119	70 (58.8)	-0.40 (16.69)	-90.0	-5.00	0.00	11.00	23.0	
		Week 48	Sparsentan	114	69 (60.5)	0.20 (12.91)	-30.0	-6.00	0.00	9.00	46.0	-0.05 [-0.41, 0.31]
			Irbesartan	119	51 (42.9)	0.82 (10.87)	-35.0	-4.00	1.00	7.00	27.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Time since renal biopsy												
<= 5 years	EQ-5D VAS	Baseline	Sparsentan	113	107 (94.7)	80.36 (13.96)	11.0	74.00	81.00	90.00	100.0	
			Irbesartan	127	119 (93.7)	80.81 (14.66)	19.0	75.00	80.00	90.00	100.0	
		Week 24	Sparsentan	113	76 (67.3)	83.50 (11.55)	50.0	75.00	86.00	91.00	100.0	
			Irbesartan	127	75 (59.1)	80.56 (17.80)	4.0	79.00	82.00	91.00	100.0	
		Week 48	Sparsentan	113	62 (54.9)	81.29 (11.79)	49.0	77.00	82.00	91.00	100.0	
			Irbesartan	127	55 (43.3)	82.13 (13.78)	40.0	75.00	82.00	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	113	76 (67.3)	4.25 (13.90)	-29.0	-4.00	3.50	11.00	40.0	0.26 [-0.06, 0.58]
			Irbesartan	127	75 (59.1)	0.00 (18.78)	-90.0	-5.00	0.00	10.00	52.0	
		Week 48	Sparsentan	113	62 (54.9)	2.56 (16.44)	-30.0	-6.00	1.00	9.00	87.0	0.13 [-0.24, 0.49]
			Irbesartan	127	55 (43.3)	0.75 (11.09)	-35.0	-2.00	1.00	7.00	27.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 5 years	EQ-5D VAS	Baseline	Sparsentan	89	84 (94.4)	80.63 (14.68)	7.0	77.50	82.00	90.00	100.0	
			Irbesartan	75	65 (86.7)	79.55 (13.43)	34.0	73.00	80.00	89.00	100.0	
		Week 24	Sparsentan	89	56 (62.9)	82.80 (9.90)	59.0	78.00	82.00	90.00	100.0	
			Irbesartan	75	40 (53.3)	81.63 (12.97)	31.0	73.00	81.00	90.00	100.0	
		Week 48	Sparsentan	89	51 (57.3)	83.10 (8.94)	51.0	79.00	82.00	90.00	100.0	
			Irbesartan	75	28 (37.3)	84.04 (10.44)	52.0	80.00	85.00	90.50	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	89	56 (62.9)	1.79 (16.44)	-31.0	-6.00	0.00	7.50	75.0	0.01 [-0.40, 0.41]
			Irbesartan	75	40 (53.3)	1.65 (13.88)	-42.0	-4.50	0.00	10.00	34.0	
		Week 48	Sparsentan	89	51 (57.3)	3.18 (14.58)	-20.0	-3.00	0.00	7.00	64.0	-0.11 [-0.58, 0.35]
			Irbesartan	75	28 (37.3)	4.68 (9.63)	-20.0	-1.00	5.00	9.50	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: History of hypertension												
Yes	EQ-5D VAS	Baseline	Sparsentan	153	143 (93.5)	79.99 (13.66)	11.0	71.00	81.00	90.00	100.0	
			Irbesartan	157	140 (89.2)	79.76 (13.77)	34.0	74.50	80.00	90.00	100.0	
		Week 24	Sparsentan	153	100 (65.4)	83.44 (10.97)	50.0	76.00	83.50	91.00	100.0	
			Irbesartan	157	86 (54.8)	80.38 (16.54)	4.0	74.00	81.00	90.00	100.0	
		Week 48	Sparsentan	153	84 (54.9)	82.61 (11.06)	49.0	79.00	82.00	90.00	100.0	
			Irbesartan	157	62 (39.5)	82.55 (12.76)	40.0	80.00	84.50	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	153	100 (65.4)	3.46 (13.43)	-29.0	-4.00	2.00	10.00	44.0	0.16 [-0.12, 0.45]
			Irbesartan	157	86 (54.8)	0.80 (18.78)	-90.0	-6.00	0.00	11.00	52.0	
		Week 48	Sparsentan	153	84 (54.9)	3.85 (14.67)	-30.0	-1.50	1.00	10.00	87.0	0.10 [-0.23, 0.43]
			Irbesartan	157	62 (39.5)	2.56 (11.01)	-35.0	-1.00	2.50	9.00	27.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	EQ-5D VAS	Baseline	Sparsentan	49	48 (98.0)	81.96 (15.91)	7.0	80.00	83.50	90.00	100.0	
			Irbesartan	45	44 (97.8)	82.30 (15.55)	19.0	75.00	85.00	91.00	100.0	
		Week 24	Sparsentan	49	32 (65.3)	82.47 (10.58)	59.0	76.00	83.50	90.50	100.0	
			Irbesartan	45	29 (64.4)	82.55 (15.44)	30.0	80.00	82.00	91.00	100.0	
		Week 48	Sparsentan	49	29 (59.2)	80.66 (9.13)	49.0	77.00	80.00	87.00	95.0	
			Irbesartan	45	21 (46.7)	83.43 (12.87)	54.0	80.00	81.00	94.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	49	32 (65.3)	2.41 (19.41)	-31.0	-7.50	0.00	8.00	75.0	0.16 [-0.35, 0.66]
			Irbesartan	45	29 (64.4)	-0.10 (11.43)	-37.0	-3.00	0.00	5.00	22.0	
		Week 48	Sparsentan	49	29 (59.2)	-0.07 (17.85)	-29.0	-8.00	-2.00	4.00	64.0	-0.05 [-0.61, 0.52]
			Irbesartan	45	21 (46.7)	0.62 (9.95)	-31.0	-4.00	0.00	7.00	19.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Sex	Overall	Sparsentan						Interaction:	0.907
Male	Week 24	Sparsentan	139	91 (65.5)	2.88 (1.26)	(0.40, 5.36)	2.64 (1.83)	(-0.95, 6.24)	0.149
		Irbesartan	143	83 (58.0)	0.23 (1.32)	(-2.36, 2.83)			
	Week 48	Sparsentan	139	75 (54.0)	2.50 (1.38)	(-0.21, 5.21)	-0.77 (2.06)	(-4.82, 3.27)	0.707
		Irbesartan	143	61 (42.7)	3.27 (1.52)	(0.27, 6.27)			
Female	Week 24	Sparsentan	63	41 (65.1)	3.30 (1.76)	(-0.18, 6.78)	0.39 (2.66)	(-4.87, 5.64)	0.885
		Irbesartan	59	32 (54.2)	2.91 (1.98)	(-1.02, 6.84)			
	Week 48	Sparsentan	63	38 (60.3)	1.40 (1.81)	(-2.19, 4.99)	0.63 (3.01)	(-5.33, 6.60)	0.834
		Irbesartan	59	22 (37.3)	0.77 (2.39)	(-3.96, 5.50)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analouge scale.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age	Overall	Sparsentan						Interaction:	0.069
<= 45 years	Week 24	Sparsentan	96	62 (64.6)	4.01 (1.65)	(0.75, 7.27)	5.60 (2.38)	(0.92, 10.29)	0.019 *
		Irbesartan	99	58 (58.6)	-1.59 (1.70)	(-4.95, 1.77)			
	Week 48	Sparsentan	96	54 (56.3)	1.51 (1.76)	(-1.96, 4.98)	0.96 (2.68)	(-4.32, 6.24)	0.719
		Irbesartan	99	41 (41.4)	0.55 (2.02)	(-3.43, 4.52)			
> 45 years	Week 24	Sparsentan	106	70 (66.0)	2.53 (1.28)	(0.00, 5.05)	-0.70 (1.92)	(-4.48, 3.08)	0.715
		Irbesartan	103	57 (55.3)	3.23 (1.43)	(0.42, 6.04)			
	Week 48	Sparsentan	106	59 (55.7)	2.66 (1.38)	(-0.07, 5.39)	-1.83 (2.15)	(-6.06, 2.41)	0.396
		Irbesartan	103	42 (40.8)	4.49 (1.64)	(1.26, 7.72)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analouge scale.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age at IgAN diagnosis	Overall	Sparsentan						Interaction:	0.006 #
<= 18 years	Week 24	Sparsentan	9	3 (33.3)	4.69 (10.12)	(-21.57, 30.96)	23.09 (18.12)	(-25.95, 72.13)	0.267
		Irbesartan	5	2 (40.0)	-18.40 (14.14)	(-57.79, 20.99)			
	Week 48	Sparsentan	9	5 (55.6)	9.09 (9.00)	(-15.68, 33.87)	28.95 (18.65)	(-20.43, 78.33)	0.187
		Irbesartan	5	1 (20.0)	-19.86 (15.76)	(-60.86, 21.14)			
> 18 to 40 years	Week 24	Sparsentan	102	66 (64.7)	3.89 (1.52)	(0.89, 6.88)	3.36 (2.18)	(-0.94, 7.65)	0.125
		Irbesartan	109	63 (57.8)	0.53 (1.56)	(-2.54, 3.61)			
	Week 48	Sparsentan	102	58 (56.9)	1.68 (1.62)	(-1.52, 4.87)	0.60 (2.46)	(-4.25, 5.46)	0.807
		Irbesartan	109	45 (41.3)	1.07 (1.84)	(-2.55, 4.70)			
> 40 years	Week 24	Sparsentan	91	63 (69.2)	2.13 (1.38)	(-0.58, 4.85)	0.29 (2.07)	(-3.79, 4.37)	0.889
		Irbesartan	88	50 (56.8)	1.84 (1.54)	(-1.20, 4.89)			
	Week 48	Sparsentan	91	50 (54.9)	2.40 (1.53)	(-0.62, 5.41)	-1.99 (2.35)	(-6.61, 2.64)	0.398
		Irbesartan	88	37 (42.0)	4.38 (1.78)	(0.88, 7.89)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analouge scale.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Geographic region	Overall	Sparsentan						Interaction:	0.490
North America	Week 24	Sparsentan	35	15 (42.9)	5.72 (4.35)	(-2.98, 14.41)	7.40 (5.42)	(-3.44, 18.24)	0.177
		Irbesartan	46	28 (60.9)	-1.69 (3.22)	(-8.11, 4.74)			
	Week 48	Sparsentan	35	13 (37.1)	3.29 (4.76)	(-6.21, 12.80)	-1.90 (6.24)	(-14.37, 10.57)	0.762
		Irbesartan	46	18 (39.1)	5.19 (3.97)	(-2.74, 13.13)			
Europe	Week 24	Sparsentan	98	60 (61.2)	1.10 (1.46)	(-1.78, 3.97)	-0.14 (2.14)	(-4.35, 4.08)	0.949
		Irbesartan	115	52 (45.2)	1.24 (1.57)	(-1.86, 4.33)			
	Week 48	Sparsentan	98	45 (45.9)	2.64 (1.69)	(-0.68, 5.97)	0.32 (2.46)	(-4.54, 5.18)	0.897
		Irbesartan	115	40 (34.8)	2.32 (1.79)	(-1.21, 5.86)			
Asia Pacific	Week 24	Sparsentan	69	57 (82.6)	5.08 (1.33)	(2.46, 7.71)	3.68 (2.19)	(-0.65, 8.01)	0.095
		Irbesartan	41	35 (85.4)	1.41 (1.72)	(-2.00, 4.81)			
	Week 48	Sparsentan	69	55 (79.7)	2.05 (1.35)	(-0.61, 4.71)	2.17 (2.36)	(-2.50, 6.84)	0.360
		Irbesartan	41	25 (61.0)	-0.12 (1.92)	(-3.93, 3.68)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analouge scale.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline BMI	Overall	Sparsentan						Interaction:	0.180
< 27 kg/m**2	Week 24	Sparsentan	84	54 (64.3)	0.95 (1.55)	(-2.11, 4.02)	0.75 (2.19)	(-3.57, 5.06)	0.733
		Irbesartan	94	56 (59.6)	0.21 (1.53)	(-2.81, 3.23)			
	Week 48	Sparsentan	84	49 (58.3)	-0.58 (1.63)	(-3.80, 2.64)	-1.66 (2.46)	(-6.52, 3.20)	0.501
		Irbesartan	94	39 (41.5)	1.08 (1.82)	(-2.52, 4.67)			
>= 27 kg/m**2	Week 24	Sparsentan	118	78 (66.1)	4.99 (1.38)	(2.26, 7.71)	4.02 (2.11)	(-0.14, 8.18)	0.058
		Irbesartan	107	59 (55.1)	0.97 (1.59)	(-2.17, 4.10)			
	Week 48	Sparsentan	118	64 (54.2)	4.57 (1.52)	(1.58, 7.55)	1.06 (2.38)	(-3.62, 5.74)	0.655
		Irbesartan	107	44 (41.1)	3.50 (1.83)	(-0.10, 7.10)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analouge scale.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Randomization strata	Overall	Sparsentan						Interaction:	0.281
eGFR Low and UP High	Week 24	Sparsentan	71	45 (63.4)	0.77 (1.88)	(-2.95, 4.49)	6.27 (2.81)	(0.70, 11.85)	0.028 *
		Irbesartan	74	38 (51.4)	-5.50 (2.09)	(-9.64, -1.37)			
	Week 48	Sparsentan	71	39 (54.9)	1.41 (1.97)	(-2.48, 5.30)	-1.44 (3.09)	(-7.55, 4.68)	0.643
		Irbesartan	74	25 (33.8)	2.85 (2.38)	(-1.87, 7.57)			
eGFR Low and UP Low	Week 24	Sparsentan	55	40 (72.7)	3.17 (1.88)	(-0.54, 6.89)	0.27 (2.76)	(-5.19, 5.74)	0.922
		Irbesartan	55	35 (63.6)	2.90 (2.01)	(-1.08, 6.89)			
	Week 48	Sparsentan	55	28 (50.9)	3.00 (2.26)	(-1.47, 7.47)	-0.39 (3.26)	(-6.85, 6.06)	0.904
		Irbesartan	55	26 (47.3)	3.40 (2.34)	(-1.23, 8.02)			
eGFR High and UP High	Week 24	Sparsentan	37	22 (59.5)	5.79 (2.40)	(1.00, 10.57)	-3.81 (3.50)	(-10.79, 3.17)	0.280
		Irbesartan	36	20 (55.6)	9.60 (2.55)	(4.51, 14.68)			
	Week 48	Sparsentan	37	22 (59.5)	2.11 (2.40)	(-2.68, 6.89)	-0.55 (3.90)	(-8.32, 7.22)	0.889
		Irbesartan	36	13 (36.1)	2.65 (3.07)	(-3.47, 8.77)			
eGFR High and UP Low	Week 24	Sparsentan	39	25 (64.1)	5.18 (1.93)	(1.33, 9.02)	3.80 (2.83)	(-1.83, 9.42)	0.183
		Irbesartan	37	22 (59.5)	1.38 (2.06)	(-2.72, 5.48)			
	Week 48	Sparsentan	39	24 (61.5)	2.54 (1.97)	(-1.39, 6.46)	0.15 (2.97)	(-5.75, 6.05)	0.960
		Irbesartan	37	19 (51.4)	2.39 (2.22)	(-2.02, 6.80)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analouge scale.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 1	Overall	Sparsentan						Interaction:	0.698
< 60 mL/min/1.73 m**2	Week 24	Sparsentan	127	87 (68.5)	2.23 (1.31)	(-0.35, 4.82)	3.35 (1.93)	(-0.45, 7.15)	0.084
		Irbesartan	129	75 (58.1)	-1.12 (1.42)	(-3.90, 1.67)			
	Week 48	Sparsentan	127	67 (52.8)	2.86 (1.48)	(-0.06, 5.79)	0.38 (2.24)	(-4.04, 4.80)	0.865
		Irbesartan	129	53 (41.1)	2.48 (1.67)	(-0.81, 5.78)			
60 to < 90 mL/min/1.73 m**2	Week 24	Sparsentan	49	29 (59.2)	4.60 (1.98)	(0.67, 8.53)	0.64 (2.86)	(-5.04, 6.32)	0.823
		Irbesartan	48	27 (56.3)	3.96 (2.04)	(-0.10, 8.01)			
	Week 48	Sparsentan	49	29 (59.2)	1.22 (1.98)	(-2.72, 5.15)	0.05 (3.12)	(-6.14, 6.24)	0.987
		Irbesartan	48	20 (41.7)	1.16 (2.37)	(-3.55, 5.87)			
>= 90 mL/min/1.73 m**2	Week 24	Sparsentan	26	16 (61.5)	6.24 (3.06)	(0.07, 12.42)	2.53 (4.57)	(-6.69, 11.75)	0.584
		Irbesartan	25	13 (52.0)	3.72 (3.39)	(-3.12, 10.56)			
	Week 48	Sparsentan	26	17 (65.4)	3.13 (3.00)	(-2.93, 9.19)	-0.11 (4.87)	(-9.92, 9.69)	0.981
		Irbesartan	25	10 (40.0)	3.24 (3.81)	(-4.41, 10.90)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analouge scale.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 2	Overall	Sparsentan						Interaction:	0.280
< 45 mL/min/1.73 m**2	Week 24	Sparsentan	82	54 (65.9)	3.44 (1.71)	(0.07, 6.81)	4.85 (2.49)	(-0.07, 9.76)	0.053
		Irbesartan	80	48 (60.0)	-1.41 (1.81)	(-4.99, 2.18)			
	Week 48	Sparsentan	82	44 (53.7)	5.24 (1.87)	(1.55, 8.93)	2.73 (2.87)	(-2.94, 8.40)	0.344
		Irbesartan	80	32 (40.0)	2.51 (2.18)	(-1.79, 6.82)			
45 to < 60 mL/min/1.73 m**2	Week 24	Sparsentan	45	33 (73.3)	0.01 (2.05)	(-4.06, 4.09)	0.46 (3.09)	(-5.68, 6.60)	0.882
		Irbesartan	49	27 (55.1)	-0.45 (2.30)	(-5.02, 4.12)			
	Week 48	Sparsentan	45	23 (51.1)	-1.76 (2.47)	(-6.66, 3.15)	-4.25 (3.63)	(-11.45, 2.95)	0.244
		Irbesartan	49	21 (42.9)	2.49 (2.62)	(-2.72, 7.70)			
60 to < 90 mL/min/1.73 m**2	Week 24	Sparsentan	49	29 (59.2)	4.60 (1.98)	(0.67, 8.53)	0.64 (2.86)	(-5.04, 6.32)	0.823
		Irbesartan	48	27 (56.3)	3.96 (2.04)	(-0.10, 8.01)			
	Week 48	Sparsentan	49	29 (59.2)	1.22 (1.98)	(-2.72, 5.15)	0.05 (3.12)	(-6.14, 6.24)	0.987
		Irbesartan	48	20 (41.7)	1.16 (2.37)	(-3.55, 5.87)			
>= 90 mL/min/1.73 m**2	Week 24	Sparsentan	26	16 (61.5)	6.24 (3.06)	(0.07, 12.42)	2.53 (4.57)	(-6.69, 11.75)	0.584
		Irbesartan	25	13 (52.0)	3.72 (3.39)	(-3.12, 10.56)			
	Week 48	Sparsentan	26	17 (65.4)	3.13 (3.00)	(-2.93, 9.19)	-0.11 (4.87)	(-9.92, 9.69)	0.981
		Irbesartan	25	10 (40.0)	3.24 (3.81)	(-4.41, 10.90)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analouge scale.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline urine protein excretion	Overall	Sparsentan						Interaction:	0.329
<= 1.75 g/day	Week 24	Sparsentan	98	69 (70.4)	3.46 (1.18)	(1.13, 5.78)	0.68 (1.84)	(-2.95, 4.31)	0.712
		Irbesartan	94	48 (51.1)	2.77 (1.42)	(-0.02, 5.57)			
	Week 48	Sparsentan	98	61 (62.2)	3.21 (1.25)	(0.75, 5.68)	-1.54 (2.06)	(-5.59, 2.52)	0.455
		Irbesartan	94	36 (38.3)	4.75 (1.62)	(1.55, 7.95)			
> 1.75 g/day	Week 24	Sparsentan	104	63 (60.6)	2.92 (1.72)	(-0.46, 6.30)	3.70 (2.40)	(-1.04, 8.44)	0.125
		Irbesartan	108	67 (62.0)	-0.78 (1.67)	(-4.07, 2.51)			
	Week 48	Sparsentan	104	52 (50.0)	1.03 (1.89)	(-2.69, 4.75)	0.16 (2.77)	(-5.29, 5.61)	0.954
		Irbesartan	108	47 (43.5)	0.87 (1.99)	(-3.05, 4.78)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analouge scale.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline use of antihypertensives	Overall	Sparsentan						Interaction:	0.224
Yes	Week 24	Sparsentan	88	55 (62.5)	6.87 (1.60)	(3.72, 10.03)	4.42 (2.38)	(-0.28, 9.12)	0.065
		Irbesartan	83	45 (54.2)	2.45 (1.77)	(-1.04, 5.94)			
	Week 48	Sparsentan	88	44 (50.0)	5.96 (1.77)	(2.46, 9.46)	0.91 (2.73)	(-4.48, 6.30)	0.740
		Irbesartan	83	32 (38.6)	5.05 (2.07)	(0.97, 9.14)			
No	Week 24	Sparsentan	114	77 (67.5)	0.74 (1.34)	(-1.91, 3.39)	1.00 (1.95)	(-2.83, 4.84)	0.606
		Irbesartan	119	70 (58.8)	-0.27 (1.41)	(-3.04, 2.51)			
	Week 48	Sparsentan	114	69 (60.5)	-0.26 (1.42)	(-3.04, 2.53)	-1.19 (2.17)	(-5.46, 3.08)	0.584
		Irbesartan	119	51 (42.9)	0.93 (1.65)	(-2.31, 4.17)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analouge scale.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Time since renal biopsy	Overall	Sparsentan						Interaction:	0.549
<= 5 years	Week 24	Sparsentan	113	76 (67.3)	3.76 (1.48)	(0.84, 6.68)	3.47 (2.10)	(-0.67, 7.61)	0.100
		Irbesartan	127	75 (59.1)	0.29 (1.49)	(-2.65, 3.23)			
	Week 48	Sparsentan	113	62 (54.9)	1.51 (1.64)	(-1.72, 4.75)	-0.13 (2.39)	(-4.84, 4.58)	0.958
		Irbesartan	127	55 (43.3)	1.64 (1.74)	(-1.79, 5.07)			
> 5 years	Week 24	Sparsentan	89	56 (62.9)	2.67 (1.33)	(0.04, 5.31)	0.96 (2.09)	(-3.17, 5.10)	0.645
		Irbesartan	75	40 (53.3)	1.71 (1.62)	(-1.49, 4.91)			
	Week 48	Sparsentan	89	51 (57.3)	2.79 (1.38)	(0.07, 5.52)	-0.68 (2.28)	(-5.19, 3.83)	0.767
		Irbesartan	75	28 (37.3)	3.47 (1.81)	(-0.11, 7.05)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analouge scale.
Source Data: aqs, created on: 04APR2024

Table PT1VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
History of hypertension	Overall	Sparsentan						Interaction:	0.407
Yes	Week 24	Sparsentan	153	100 (65.4)	3.66 (1.22)	(1.26, 6.06)	2.87 (1.79)	(-0.65, 6.39)	0.110
		Irbesartan	157	86 (54.8)	0.79 (1.31)	(-1.80, 3.37)			
	Week 48	Sparsentan	153	84 (54.9)	3.28 (1.32)	(0.67, 5.89)	0.49 (2.03)	(-3.51, 4.49)	0.810
		Irbesartan	157	62 (39.5)	2.79 (1.54)	(-0.24, 5.83)			
No	Week 24	Sparsentan	49	32 (65.3)	1.72 (1.92)	(-2.10, 5.54)	1.10 (2.81)	(-4.49, 6.69)	0.697
		Irbesartan	45	29 (64.4)	0.62 (2.04)	(-3.44, 4.68)			
	Week 48	Sparsentan	49	29 (59.2)	-1.19 (1.99)	(-5.14, 2.75)	-2.32 (3.06)	(-8.41, 3.76)	0.450
		Irbesartan	45	21 (46.7)	1.13 (2.32)	(-3.47, 5.73)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analouge scale.
Source Data: aqs, created on: 04APR2024

Figure PF1VSC_FSGM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set
Study: PROTECT
Age at IgAN diagnosis: <= 18 years



Sparsentan	3	5
Irbesartan	2	1

Number of available records are presented for key visits up to Week 58 only. LS-Mean = Least square mean.
95% CI = 95% confidence interval. eGFR = estimated glomerular filtration rate. UP = urine protein. BMI = body mass index.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
IgAN = immunoglobulin A nephropathy. A decrease reflects a worsening of the status of the patient. Reference table: PT1VSC_FSCM.

Figure PF1VSC_FSGM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set
Study: PROTECT
Age at IgAN diagnosis: > 18 to 40 years



Sparsentan	66	58
Irbesartan	63	45

Number of available records are presented for key visits up to Week 58 only. LS-Mean = Least square mean.
95% CI = 95% confidence interval. eGFR = estimated glomerular filtration rate. UP = urine protein. BMI = body mass index.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
IgAN = immunoglobulin A nephropathy. A decrease reflects a worsening of the status of the patient. Reference table: PT1VSC_FSCM.

Figure PF1VSC_FSGM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set
Study: PROTECT
Age at IgAN diagnosis: > 40 years



Sparsentan	63	50
Irbesartan	50	37

Number of available records are presented for key visits up to Week 58 only. LS-Mean = Least square mean.
95% CI = 95% confidence interval. eGFR = estimated glomerular filtration rate. UP = urine protein. BMI = body mass index.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
IgAN = immunoglobulin A nephropathy. A decrease reflects a worsening of the status of the patient. Reference table: PT1VSC_FSCM.

Table PT1VSIT_FSTM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to increase in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sex	Sparsentan						Interaction test:	0.974
Male	Sparsentan	139	17 (12.2)	NE		0.949	(0.481, 1.872)	0.880
	Irbesartan	143	21 (14.7)	NE				
Female	Sparsentan	63	12 (19.0)	NE		1.178	(0.338, 4.110)	0.797
	Irbesartan	59	5 (8.5)	110.0	(NE, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1VSIT_FSTM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to increase in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.070
<= 45 years	Sparsentan	96	16 (16.7)	NE		1.572	(0.688, 3.593)	0.284
	Irbesartan	99	11 (11.1)	NE				
> 45 years	Sparsentan	106	13 (12.3)	NE		0.517	(0.234, 1.139)	0.101
	Irbesartan	103	15 (14.6)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1VSIT_FSTM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to increase in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age at IgAN diagnosis	Sparsentan						Interaction test:	NE
<= 18 years	Sparsentan	9	2 (22.2) No events in 1 group	NE		NE		NE
	Irbesartan	5	0 (0.0)	NE				
> 18 to 40 years	Sparsentan	102	15 (14.7)	NE		1.201	(0.553, 2.609)	0.644
	Irbesartan	109	14 (12.8)	110.0	(94.9, NE)			
> 40 years	Sparsentan	91	12 (13.2)	NE		0.662	(0.282, 1.558)	0.345
	Irbesartan	88	12 (13.6)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1VSIT_FSTM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to increase in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Geographic region	Sparsentan						Interaction test:	0.134
North America	Sparsentan	35	5 (14.3)	NE		0.580	(0.125, 2.690)	0.486
	Irbesartan	46	7 (15.2)	NE				
Europe	Sparsentan	98	12 (12.2)	108.0	(95.0, NE)	0.735	(0.318, 1.696)	0.470
	Irbesartan	115	13 (11.3)	NE				
Asia Pacific	Sparsentan	69	12 (17.4)	NE		2.818	(0.805, 9.861)	0.105
	Irbesartan	41	6 (14.6)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1VSIT_FSTM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to increase in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.332
< 27 kg/m**2	Sparsentan	84	14 (16.7)	108.0	(95.0, NE)	1.190	(0.452, 3.128)	0.725
	Irbesartan	94	7 (7.4)	NE				
>= 27 kg/m**2	Sparsentan	118	15 (12.7)	NE		0.771	(0.375, 1.586)	0.480
	Irbesartan	107	18 (16.8)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1VSIT_FSTM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to increase in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Randomization strata	Sparsentan						Interaction test:	0.007	#
eGFR Low and UP High	Sparsentan	71	6 (8.5)	NE		1.052	(0.302, 3.663)	0.937	
	Irbesartan	74	8 (10.8)	NE					
eGFR Low and UP Low	Sparsentan	55	9 (16.4)	NE		0.659	(0.221, 1.962)	0.453	
	Irbesartan	55	8 (14.5)	NE					
eGFR High and UP High	Sparsentan	37	7 (18.9)	NE		0.444	(0.141, 1.393)	0.164	
	Irbesartan	36	7 (19.4)	71.4	(25.1, NE)				
eGFR High and UP Low	Sparsentan	39	7 (17.9)	NE		7.790	(1.072, 56.617)	0.042	*
	Irbesartan	37	3 (8.1)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1VSIT_FSTM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to increase in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.191
< 60 mL/min/1.73 m**2	Sparsentan	127	16 (12.6)	NE		0.814	(0.402, 1.647)	0.567
	Irbesartan	129	18 (14.0)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	7 (14.3)	NE		0.853	(0.253, 2.870)	0.797
	Irbesartan	48	5 (10.4)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	6 (23.1)	NE		2.564	(0.452, 14.546)	0.288
	Irbesartan	25	3 (12.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1VSIT_FSTM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to increase in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 2	Sparsentan						Interaction test:	0.240
< 45 mL/min/1.73 m**2	Sparsentan	82	10 (12.2)	NE		0.710	(0.297, 1.695)	0.440
	Irbesartan	80	13 (16.3)	110.0	(94.9, NE)			
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	6 (13.3)	NE		1.132	(0.272, 4.710)	0.865
	Irbesartan	49	5 (10.2)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	7 (14.3)	NE		0.853	(0.253, 2.870)	0.797
	Irbesartan	48	5 (10.4)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	6 (23.1)	NE		2.564	(0.452, 14.546)	0.288
	Irbesartan	25	3 (12.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1VSIT_FSTM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to increase in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline urine protein excretion	Sparsentan						Interaction test:	0.429
<= 1.75 g/day	Sparsentan	98	16 (16.3)	NE		1.718	(0.699, 4.224)	0.238
	Irbesartan	94	9 (9.6)	110.0	(94.9, NE)			
> 1.75 g/day	Sparsentan	104	13 (12.5)	NE		0.908	(0.414, 1.992)	0.810
	Irbesartan	108	17 (15.7)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1VSIT_FSTM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to increase in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.157
Yes	Sparsentan	88	12 (13.6)	NE		0.677	(0.292, 1.568)	0.363
	Irbesartan	83	13 (15.7)	110.0	(94.9, NE)			
No	Sparsentan	114	17 (14.9)	NE		1.393	(0.634, 3.064)	0.409
	Irbesartan	119	13 (10.9)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1VSIT_FSTM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to increase in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Time since renal biopsy	Sparsentan						Interaction test:	0.081
<= 5 years	Sparsentan	113	18 (15.9)	NE		1.420	(0.707, 2.850)	0.324
	Irbesartan	127	17 (13.4)	NE				
> 5 years	Sparsentan	89	11 (12.4)	NE		0.515	(0.195, 1.356)	0.179
	Irbesartan	75	9 (12.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1VSIT_FSTM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to increase in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
History of hypertension	Sparsentan						Interaction test:	0.197
Yes	Sparsentan	153	23 (15.0)	NE		0.788	(0.434, 1.433)	0.436
	Irbesartan	157	24 (15.3)	NE				
No	Sparsentan	49	6 (12.2)	NE		3.535	(0.641, 19.492)	0.147
	Irbesartan	45	2 (4.4)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Figure PF1VSIT_FSKM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Randomization strata: eGFR Low and UP High



Sparsentan	71	47	39	31	16	4
Irbesartan	74	36	28	17	9	2

An increase reflects an improvement of the status of the patient.
Reference table: PT1VSIT_FSTM

Figure PF1VSIT_FSKM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Randomization strata: eGFR Low and UP Low



Sparsentan	55	38	24	15	6	3
Irbesartan	55	37	26	16	8	3

An increase reflects an improvement of the status of the patient.
Reference table: PT1VSIT_FSTM

Figure PF1VSIT_FSKM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Randomization strata: eGFR High and UP High



Sparsentan	37	26	19	12	4	1
Irbesartan	36	21	9	5	1	1

An increase reflects an improvement of the status of the patient.
Reference table: PT1VSIT_FSTM

Figure PF1VSIT_FSKM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Randomization strata: eGFR High and UP Low



Sparsentan	39	22	16	11	3	0
Irbesartan	37	24	17	12	2	1

An increase reflects an improvement of the status of the patient.
Reference table: PT1VSIT_FSTM

Table PT1VSDT_FSTM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to decrease in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sex	Sparsentan						Interaction test:	0.543
Male	Sparsentan	139	13 (9.4)	NE		1.013	(0.437, 2.350)	0.976
	Irbesartan	143	10 (7.0)	NE				
Female	Sparsentan	63	13 (20.6)	112.1	(112.1, NE)	1.612	(0.594, 4.372)	0.348
	Irbesartan	59	6 (10.2)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1VSDT_FSTM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to decrease in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.783
<= 45 years	Sparsentan	96	14 (14.6)	NE		1.305	(0.559, 3.047)	0.538
	Irbesartan	99	9 (9.1)	NE				
> 45 years	Sparsentan	106	12 (11.3)	112.1	(111.0, NE)	1.078	(0.413, 2.813)	0.878
	Irbesartan	103	7 (6.8)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1VSDT_FSTM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to decrease in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age at IgAN diagnosis	Sparsentan						Interaction test:	NE
<= 18 years	Sparsentan	9	0 (0.0) No events in 1 group	NE		NE		NE
	Irbesartan	5	1 (20.0)	NE				
> 18 to 40 years	Sparsentan	102	15 (14.7)	NE		1.521	(0.655, 3.534)	0.329
	Irbesartan	109	9 (8.3)	NE				
> 40 years	Sparsentan	91	11 (12.1)	112.1	(111.0, NE)	1.072	(0.388, 2.963)	0.893
	Irbesartan	88	6 (6.8)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1VSDT_FSTM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to decrease in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Geographic region	Sparsentan						Interaction test:	0.679
North America	Sparsentan	35	4 (11.4)	NE		1.370	(0.326, 5.761)	0.668
	Irbesartan	46	4 (8.7)	NE				
Europe	Sparsentan	98	11 (11.2)	112.1	(112.1, NE)	0.930	(0.384, 2.251)	0.872
	Irbesartan	115	10 (8.7)	NE				
Asia Pacific	Sparsentan	69	11 (15.9)	NE		3.090	(0.618, 15.452)	0.170
	Irbesartan	41	2 (4.9)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1VSDT_FSTM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to decrease in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.029 #
< 27 kg/m**2	Sparsentan	84	14 (16.7)	112.1	(112.1, NE)	2.575	(0.955, 6.944)	0.062
	Irbesartan	94	6 (6.4)	NE				
>= 27 kg/m**2	Sparsentan	118	12 (10.2)	NE		0.654	(0.272, 1.573)	0.343
	Irbesartan	107	10 (9.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1VSDT_FSTM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to decrease in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Randomization strata	Sparsentan						Interaction test:	NE
eGFR Low and UP High	Sparsentan	71	7 (9.9)	111.0	(111.0, NE)	0.437	(0.165, 1.160)	0.097
	Irbesartan	74	10 (13.5)	NE				
eGFR Low and UP Low	Sparsentan	55	8 (14.5)	112.1	(NE, NE)	2.002	(0.578, 6.939)	0.274
	Irbesartan	55	4 (7.3)	NE				
eGFR High and UP High	Sparsentan	37	6 (16.2)	NE		2.081	(0.413, 10.480)	0.374
	Irbesartan	36	2 (5.6)	NE				
eGFR High and UP Low	Sparsentan	39	5 (12.8)	NE		NE		NE
			No events in 1 group					
	Irbesartan	37	0 (0.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1VSDT_FSTM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to decrease in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan						Interaction test:	NE
< 60 mL/min/1.73 m**2	Sparsentan	127	15 (11.8)	112.1	(111.0, 112.1)	0.770	(0.365, 1.625)	0.493
	Irbesartan	129	14 (10.9)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	6 (12.2)	NE		2.239	(0.445, 11.270)	0.328
	Irbesartan	48	2 (4.2)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	5 (19.2)	NE		NE		NE
			No events in 1 group					
	Irbesartan	25	0 (0.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1VSDT_FSTM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to decrease in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eGFR Group 2	Sparsentan						Interaction test:	NE	
< 45 mL/min/1.73 m**2	Sparsentan	82	6 (7.3)	NE		0.337	(0.126, 0.902)	0.030	*
	Irbesartan	80	13 (16.3)	NE					
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	9 (20.0)	112.1	(94.0, 112.1)	8.124	(0.986, 66.937)	0.052	
	Irbesartan	49	1 (2.0)	NE					
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	6 (12.2)	NE		2.239	(0.445, 11.270)	0.328	
	Irbesartan	48	2 (4.2)	NE					
>= 90 mL/min/1.73 m**2	Sparsentan	26	5 (19.2)	NE		NE		NE	
			No events in 1 group						
	Irbesartan	25	0 (0.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1VSDT_FSTM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to decrease in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline urine protein excretion	Sparsentan						Interaction test:	0.003	#
<= 1.75 g/day	Sparsentan	98	16 (16.3)	112.1	(NE, NE)	7.300	(1.610, 33.094)	0.010	*
	Irbesartan	94	2 (2.1)	NE					
> 1.75 g/day	Sparsentan	104	10 (9.6)	NE		0.590	(0.257, 1.355)	0.213	
	Irbesartan	108	14 (13.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1VSDT_FSTM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to decrease in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.280
Yes	Sparsentan	88	7 (8.0)	NE		0.747	(0.239, 2.336)	0.616
	Irbesartan	83	6 (7.2)	NE				
No	Sparsentan	114	19 (16.7)	112.1	(112.1, NE)	1.535	(0.705, 3.342)	0.280
	Irbesartan	119	10 (8.4)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1VSDT_FSTM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to decrease in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Time since renal biopsy	Sparsentan						Interaction test:	0.202
<= 5 years	Sparsentan	113	17 (15.0)	111.0	(111.0, NE)	1.699	(0.749, 3.857)	0.205
	Irbesartan	127	9 (7.1)	NE				
> 5 years	Sparsentan	89	9 (10.1)	NE		0.778	(0.282, 2.141)	0.626
	Irbesartan	75	7 (9.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1VSDT_FSTM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to decrease in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
History of hypertension	Sparsentan						Interaction test:	0.240
Yes	Sparsentan	153	17 (11.1)	112.1	(111.0, NE)	0.992	(0.467, 2.108)	0.983
	Irbesartan	157	12 (7.6)	NE				
No	Sparsentan	49	9 (18.4)	NE		2.657	(0.748, 9.437)	0.131
	Irbesartan	45	4 (8.9)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Figure PF1VSDT_FSKM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline BMI: < 27 kg/m**2



Sparsentan	84	56	45	30	12	5
Irbesartan	94	55	39	24	9	4

_____
A decrease reflects a worsening of the status of the patient.
Reference table: PT1VSDT_FSTM

Figure PF1VSDT_FSKM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline BMI: >= 27 kg/m**2



Sparsentan	118	81	64	49	23	8
Irbesartan	107	63	42	30	11	4

A decrease reflects a worsening of the status of the patient.
Reference table: PT1VSDT_FSTM

Figure PF1VSDT_FSKM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline urine protein excretion: <= 1.75 g/day



Sparsentan	98	73	58	40	15	8
Irbesartan	94	53	40	27	10	5

_____
A decrease reflects a worsening of the status of the patient.
Reference table: PT1VSDT_FSTM

Figure PF1VSDT_FSKM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline urine protein excretion: > 1.75 g/day



Sparsentan	104	64	51	39	20	5
Irbesartan	108	66	42	28	11	3

A decrease reflects a worsening of the status of the patient.
Reference table: PT1VSDT_FSTM

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	KDQOL: burden of kidney disease	Baseline	Sparsentan	139	130 (93.5)	71.68 (23.02)	6.3	62.50	75.00	87.50	100.0	
			Irbesartan	143	128 (89.5)	79.25 (22.24)	6.3	68.75	87.50	100.00	100.0	
		Week 24	Sparsentan	139	87 (62.6)	75.86 (21.70)	12.5	68.75	81.25	93.75	100.0	
			Irbesartan	143	73 (51.0)	78.00 (22.99)	0.0	68.75	81.25	100.00	100.0	
		Week 48	Sparsentan	139	72 (51.8)	78.04 (20.34)	6.3	71.88	81.25	93.75	100.0	
			Irbesartan	143	55 (38.5)	83.75 (18.66)	25.0	75.00	93.75	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	139	87 (62.6)	6.11 (21.80)	-50.0	-6.25	6.25	18.75	62.5	0.43 [0.12, 0.75]
			Irbesartan	143	73 (51.0)	-2.65 (18.40)	-50.0	-12.50	0.00	6.25	50.0	
		Week 48	Sparsentan	139	72 (51.8)	7.55 (19.87)	-62.5	0.00	6.25	25.00	43.8	0.27 [-0.08, 0.62]
			Irbesartan	143	55 (38.5)	2.50 (16.99)	-43.8	-6.25	0.00	6.25	56.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Female	KDQOL: burden of kidney disease	Baseline	Sparsentan	63	56 (88.9)	64.51 (30.01)	0.0	46.88	68.75	93.75	100.0	
			Irbesartan	59	51 (86.4)	70.83 (23.31)	18.8	56.25	75.00	87.50	100.0	
		Week 24	Sparsentan	63	38 (60.3)	74.84 (22.95)	18.8	62.50	81.25	93.75	100.0	
			Irbesartan	59	31 (52.5)	80.85 (20.22)	25.0	75.00	81.25	100.00	100.0	
		Week 48	Sparsentan	63	38 (60.3)	75.99 (22.21)	31.3	62.50	81.25	93.75	100.0	
			Irbesartan	59	22 (37.3)	73.30 (22.59)	6.3	56.25	75.00	93.75	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	63	38 (60.3)	11.51 (25.27)	-81.3	0.00	6.25	31.25	75.0	0.26 [-0.22, 0.73]
			Irbesartan	59	31 (52.5)	6.05 (14.57)	-18.8	0.00	0.00	18.75	56.3	
		Week 48	Sparsentan	63	38 (60.3)	12.50 (21.36)	-25.0	0.00	6.25	25.00	62.5	0.44 [-0.09, 0.97]
			Irbesartan	59	22 (37.3)	3.69 (17.75)	-50.0	0.00	0.00	12.50	37.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
<= 45 years	KDQOL: burden of kidney disease	Baseline	Sparsentan	96	87 (90.6)	66.31 (27.25)	0.0	50.00	68.75	87.50	100.0	
			Irbesartan	99	92 (92.9)	71.20 (25.00)	6.3	53.13	75.00	93.75	100.0	
		Week 24	Sparsentan	96	57 (59.4)	74.45 (23.66)	18.8	62.50	81.25	93.75	100.0	
			Irbesartan	99	53 (53.5)	74.29 (26.19)	0.0	62.50	81.25	93.75	100.0	
		Week 48	Sparsentan	96	53 (55.2)	72.76 (24.02)	6.3	56.25	75.00	93.75	100.0	
			Irbesartan	99	40 (40.4)	78.75 (24.83)	6.3	62.50	87.50	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	96	57 (59.4)	9.87 (27.95)	-81.3	0.00	6.25	25.00	75.0	0.37 [-0.01, 0.75]
			Irbesartan	99	53 (53.5)	0.71 (20.79)	-50.0	-12.50	0.00	12.50	56.3	
		Week 48	Sparsentan	96	53 (55.2)	8.96 (21.60)	-62.5	0.00	6.25	25.00	50.0	0.29 [-0.13, 0.70]
			Irbesartan	99	40 (40.4)	3.28 (17.39)	-43.8	-6.25	0.00	9.38	56.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 45 years	KDQOL: burden of kidney disease	Baseline	Sparsentan	106	99 (93.4)	72.35 (23.56)	6.3	56.25	75.00	87.50	100.0	
			Irbesartan	103	87 (84.5)	82.83 (18.56)	18.8	75.00	87.50	100.00	100.0	
		Week 24	Sparsentan	106	68 (64.2)	76.47 (20.63)	12.5	68.75	81.25	93.75	100.0	
			Irbesartan	103	51 (49.5)	83.58 (15.86)	43.8	75.00	87.50	100.00	100.0	
		Week 48	Sparsentan	106	57 (53.8)	81.58 (16.68)	37.5	75.00	81.25	93.75	100.0	
			Irbesartan	103	37 (35.9)	82.94 (13.79)	50.0	75.00	81.25	93.75	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	106	68 (64.2)	5.97 (17.72)	-43.8	-3.13	0.00	18.75	43.8	0.42 [0.05, 0.79]
			Irbesartan	103	51 (49.5)	-0.86 (14.03)	-31.3	-12.50	0.00	6.25	37.5	
		Week 48	Sparsentan	106	57 (53.8)	9.54 (19.48)	-50.0	0.00	6.25	25.00	62.5	0.39 [-0.03, 0.80]
			Irbesartan	103	37 (35.9)	2.36 (17.01)	-50.0	-6.25	0.00	12.50	43.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age at IgAN diagnosis												
<= 18 years	KDQOL: burden of kidney disease	Baseline	Sparsentan	9	9 (100.0)	58.33 (30.94)	6.3	37.50	62.50	68.75	100.0	
			Irbesartan	5	5 (100.0)	72.50 (31.12)	18.8	75.00	81.25	93.75	93.8	
		Week 24	Sparsentan	9	3 (33.3)	95.83 (7.22)	87.5	87.50	100.00	100.00	100.0	
			Irbesartan	5	2 (40.0)	56.25 (35.36)	31.3	31.25	56.25	81.25	81.3	
		Week 48	Sparsentan	9	5 (55.6)	61.25 (40.84)	6.3	31.25	75.00	93.75	100.0	
			Irbesartan	5	1 (20.0)	81.25	81.3	81.25	81.25	81.25	81.3	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	9	3 (33.3)	27.08 (25.26)	0.0	0.00	31.25	50.00	50.0	0.98 [-0.91, 2.87]
			Irbesartan	5	2 (40.0)	6.25 (8.84)	0.0	0.00	6.25	12.50	12.5	
		Week 48	Sparsentan	9	5 (55.6)	-1.25 (38.63)	-62.5	-6.25	0.00	25.00	37.5	NE
			Irbesartan	5	1 (20.0)	0.00	0.0	0.00	0.00	0.00	0.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 18 to 40 years	KDQOL: burden of kidney disease	Baseline	Sparsentan	102	93 (91.2)	69.76 (25.21)	0.0	62.50	75.00	87.50	100.0	
			Irbesartan	109	99 (90.8)	73.23 (24.39)	6.3	56.25	75.00	93.75	100.0	
		Week 24	Sparsentan	102	62 (60.8)	74.70 (22.67)	18.8	62.50	81.25	93.75	100.0	
			Irbesartan	109	59 (54.1)	76.48 (24.87)	0.0	62.50	81.25	100.00	100.0	
		Week 48	Sparsentan	102	57 (55.9)	75.00 (21.26)	25.0	62.50	81.25	93.75	100.0	
			Irbesartan	109	44 (40.4)	78.84 (24.01)	6.3	65.63	87.50	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	102	62 (60.8)	8.57 (26.64)	-81.3	0.00	6.25	25.00	75.0	0.35 [-0.01, 0.71]
			Irbesartan	109	59 (54.1)	0.32 (19.85)	-50.0	-6.25	0.00	6.25	56.3	
		Week 48	Sparsentan	102	57 (55.9)	8.44 (21.05)	-50.0	0.00	0.00	25.00	50.0	0.25 [-0.15, 0.64]
			Irbesartan	109	44 (40.4)	3.69 (16.74)	-43.8	-6.25	0.00	12.50	56.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 40 years	KDQOL: burden of kidney disease	Baseline	Sparsentan	91	84 (92.3)	70.46 (25.18)	6.3	50.00	75.00	87.50	100.0	
			Irbesartan	88	75 (85.2)	81.92 (19.13)	18.8	75.00	87.50	100.00	100.0	
		Week 24	Sparsentan	91	60 (65.9)	75.42 (21.49)	12.5	68.75	78.13	93.75	100.0	
			Irbesartan	88	43 (48.9)	83.14 (16.34)	43.8	75.00	81.25	100.00	100.0	
		Week 48	Sparsentan	91	48 (52.7)	81.77 (16.75)	37.5	75.00	84.38	96.88	100.0	
			Irbesartan	88	32 (36.4)	83.40 (13.99)	50.0	75.00	81.25	93.75	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	91	60 (65.9)	5.94 (18.10)	-43.8	-6.25	0.00	18.75	43.8	0.40 [0.01, 0.80]
			Irbesartan	88	43 (48.9)	-0.87 (14.91)	-31.3	-12.50	0.00	6.25	37.5	
		Week 48	Sparsentan	91	48 (52.7)	11.33 (17.23)	-31.3	0.00	6.25	25.00	62.5	0.54 [0.09, 1.00]
			Irbesartan	88	32 (36.4)	1.76 (18.05)	-50.0	-6.25	0.00	9.38	43.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Geographic region												
North America	KDQOL: burden of kidney disease	Baseline	Sparsentan	35	32 (91.4)	70.70 (26.91)	6.3	59.38	75.00	93.75	100.0	
			Irbesartan	46	43 (93.5)	82.99 (17.11)	43.8	68.75	81.25	100.00	100.0	
		Week 24	Sparsentan	35	15 (42.9)	80.42 (19.32)	25.0	75.00	81.25	93.75	100.0	
			Irbesartan	46	26 (56.5)	80.53 (23.07)	6.3	68.75	87.50	100.00	100.0	
		Week 48	Sparsentan	35	13 (37.1)	76.44 (23.41)	31.3	68.75	81.25	93.75	100.0	
			Irbesartan	46	17 (37.0)	80.51 (20.24)	25.0	68.75	81.25	93.75	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	35	15 (42.9)	2.50 (19.45)	-37.5	-12.50	0.00	12.50	31.3	0.35 [-0.29, 0.99]
			Irbesartan	46	26 (56.5)	-3.61 (16.02)	-37.5	-12.50	-6.25	6.25	31.3	
		Week 48	Sparsentan	35	13 (37.1)	11.54 (14.62)	-12.5	0.00	12.50	25.00	37.5	0.92 [0.16, 1.67]
			Irbesartan	46	17 (37.0)	-3.68 (17.96)	-43.8	-6.25	0.00	6.25	37.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Europe	KDQOL: burden of kidney disease	Baseline	Sparsentan	98	87 (88.8)	75.86 (21.97)	6.3	68.75	81.25	93.75	100.0	
			Irbesartan	115	96 (83.5)	75.20 (24.19)	18.8	56.25	87.50	93.75	100.0	
		Week 24	Sparsentan	98	53 (54.1)	78.18 (21.25)	12.5	75.00	81.25	93.75	100.0	
			Irbesartan	115	47 (40.9)	78.99 (19.04)	31.3	68.75	81.25	93.75	100.0	
		Week 48	Sparsentan	98	44 (44.9)	79.12 (19.94)	6.3	75.00	81.25	93.75	100.0	
			Irbesartan	115	38 (33.0)	82.40 (18.77)	37.5	68.75	87.50	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	98	53 (54.1)	3.54 (26.02)	-81.3	-6.25	0.00	12.50	75.0	0.16 [-0.23, 0.55]
			Irbesartan	115	47 (40.9)	-0.13 (19.17)	-50.0	-12.50	0.00	12.50	56.3	
		Week 48	Sparsentan	98	44 (44.9)	5.11 (20.85)	-62.5	-3.13	0.00	18.75	50.0	0.04 [-0.40, 0.47]
			Irbesartan	115	38 (33.0)	4.44 (15.44)	-50.0	0.00	0.00	12.50	31.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asia Pacific	KDQOL: burden of kidney disease	Baseline	Sparsentan	69	67 (97.1)	60.73 (26.76)	0.0	43.75	62.50	87.50	100.0	
			Irbesartan	41	40 (97.6)	74.22 (24.03)	6.3	62.50	75.00	93.75	100.0	
		Week 24	Sparsentan	69	57 (82.6)	71.82 (23.06)	12.5	56.25	75.00	93.75	100.0	
			Irbesartan	41	31 (75.6)	77.22 (26.05)	0.0	68.75	81.25	100.00	100.0	
		Week 48	Sparsentan	69	53 (76.8)	76.06 (21.40)	25.0	62.50	75.00	93.75	100.0	
			Irbesartan	41	22 (53.7)	78.13 (23.29)	6.3	75.00	81.25	93.75	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	69	57 (82.6)	13.05 (19.74)	-25.0	0.00	6.25	31.25	62.5	0.53 [0.09, 0.98]
			Irbesartan	41	31 (75.6)	3.02 (16.76)	-37.5	0.00	0.00	6.25	50.0	
		Week 48	Sparsentan	69	53 (76.8)	12.15 (21.03)	-50.0	0.00	6.25	25.00	62.5	0.35 [-0.16, 0.85]
			Irbesartan	41	22 (53.7)	5.11 (18.66)	-25.0	0.00	0.00	6.25	56.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline BMI												
< 27 kg/m**2	KDQOL: burden of kidney disease	Baseline	Sparsentan	84	76 (90.5)	64.47 (25.88)	6.3	46.88	68.75	87.50	100.0	
			Irbesartan	94	84 (89.4)	72.77 (22.37)	18.8	56.25	75.00	93.75	100.0	
		Week 24	Sparsentan	84	52 (61.9)	73.08 (22.91)	12.5	68.75	75.00	87.50	100.0	
			Irbesartan	94	50 (53.2)	76.38 (23.09)	6.3	68.75	81.25	93.75	100.0	
		Week 48	Sparsentan	84	47 (56.0)	74.07 (21.69)	25.0	62.50	75.00	93.75	100.0	
			Irbesartan	94	36 (38.3)	75.17 (22.28)	6.3	65.63	81.25	93.75	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	84	52 (61.9)	9.25 (22.47)	-43.8	-3.13	6.25	21.88	62.5	0.23 [-0.16, 0.62]
			Irbesartan	94	50 (53.2)	4.38 (19.28)	-37.5	-12.50	0.00	12.50	56.3	
		Week 48	Sparsentan	84	47 (56.0)	10.90 (22.02)	-50.0	0.00	6.25	25.00	62.5	0.34 [-0.09, 0.78]
			Irbesartan	94	36 (38.3)	3.65 (20.07)	-50.0	-6.25	0.00	15.63	56.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 27 kg/m**2	KDQOL: burden of kidney disease	Baseline	Sparsentan	118	110 (93.2)	73.01 (24.68)	0.0	62.50	75.00	93.75	100.0	
			Irbesartan	107	94 (87.9)	81.12 (21.88)	6.3	68.75	87.50	100.00	100.0	
		Week 24	Sparsentan	118	73 (61.9)	77.31 (21.31)	12.5	68.75	81.25	93.75	100.0	
			Irbesartan	107	54 (50.5)	81.13 (21.19)	0.0	68.75	87.50	100.00	100.0	
		Week 48	Sparsentan	118	63 (53.4)	79.76 (20.17)	6.3	75.00	81.25	100.00	100.0	
			Irbesartan	107	41 (38.3)	85.67 (17.13)	31.3	75.00	93.75	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	118	73 (61.9)	6.68 (23.37)	-81.3	0.00	6.25	18.75	75.0	0.53 [0.18, 0.89]
			Irbesartan	107	54 (50.5)	-4.17 (15.21)	-50.0	-12.50	0.00	6.25	31.3	
		Week 48	Sparsentan	118	63 (53.4)	8.04 (19.26)	-62.5	0.00	6.25	25.00	50.0	0.34 [-0.06, 0.73]
			Irbesartan	107	41 (38.3)	2.13 (14.23)	-31.3	-6.25	0.00	6.25	43.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Randomization strata												
eGFR Low and UP High	KDQOL: burden of kidney disease	Baseline	Sparsentan	71	63 (88.7)	69.64 (25.02)	6.3	50.00	75.00	87.50	100.0	
			Irbesartan	74	63 (85.1)	72.82 (24.13)	18.8	56.25	75.00	93.75	100.0	
		Week 24	Sparsentan	71	44 (62.0)	75.71 (22.20)	12.5	65.63	81.25	93.75	100.0	
			Irbesartan	74	32 (43.2)	72.85 (25.48)	6.3	59.38	78.13	96.88	100.0	
		Week 48	Sparsentan	71	37 (52.1)	77.53 (19.79)	25.0	68.75	75.00	93.75	100.0	
			Irbesartan	74	22 (29.7)	79.55 (23.00)	6.3	75.00	81.25	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	71	44 (62.0)	6.96 (23.78)	-50.0	-6.25	6.25	25.00	62.5	0.54 [0.08, 1.01]
			Irbesartan	74	32 (43.2)	-3.91 (13.16)	-37.5	-12.50	-3.13	0.00	31.3	
		Week 48	Sparsentan	71	37 (52.1)	7.94 (19.52)	-50.0	-6.25	6.25	25.00	43.8	0.42 [-0.11, 0.96]
			Irbesartan	74	22 (29.7)	0.57 (13.21)	-25.0	-6.25	0.00	6.25	31.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR Low and UP Low	KDQOL: burden of kidney disease	Baseline	Sparsentan	55	51 (92.7)	66.91 (25.47)	0.0	50.00	68.75	87.50	100.0	
			Irbesartan	55	49 (89.1)	78.44 (22.28)	25.0	62.50	81.25	100.00	100.0	
		Week 24	Sparsentan	55	38 (69.1)	72.70 (24.07)	12.5	56.25	78.13	93.75	100.0	
			Irbesartan	55	33 (60.0)	83.52 (15.92)	50.0	68.75	87.50	100.00	100.0	
		Week 48	Sparsentan	55	28 (50.9)	82.37 (17.52)	37.5	75.00	81.25	100.00	100.0	
			Irbesartan	55	25 (45.5)	80.75 (18.83)	31.3	75.00	81.25	93.75	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	55	38 (69.1)	6.25 (24.10)	-81.3	0.00	0.00	18.75	62.5	0.11 [-0.36, 0.57]
			Irbesartan	55	33 (60.0)	3.98 (17.94)	-31.3	-6.25	0.00	12.50	50.0	
		Week 48	Sparsentan	55	28 (50.9)	12.95 (18.32)	-25.0	0.00	6.25	25.00	62.5	0.34 [-0.20, 0.88]
			Irbesartan	55	25 (45.5)	6.25 (21.19)	-50.0	-6.25	0.00	18.75	56.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP High	KDQOL: burden of kidney disease	Baseline	Sparsentan	37	35 (94.6)	67.68 (27.47)	6.3	50.00	75.00	87.50	100.0	
			Irbesartan	36	31 (86.1)	77.22 (21.32)	31.3	62.50	81.25	93.75	100.0	
		Week 24	Sparsentan	37	19 (51.4)	73.68 (19.83)	25.0	68.75	75.00	87.50	100.0	
			Irbesartan	36	18 (50.0)	77.78 (20.81)	31.3	68.75	81.25	93.75	100.0	
		Week 48	Sparsentan	37	22 (59.5)	63.92 (25.07)	6.3	50.00	71.88	81.25	100.0	
			Irbesartan	36	11 (30.6)	80.68 (18.64)	43.8	68.75	81.25	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	37	19 (51.4)	13.49 (25.28)	-31.3	-6.25	6.25	25.00	75.0	0.68 [0.01, 1.34]
			Irbesartan	36	18 (50.0)	-2.43 (21.56)	-50.0	-6.25	-3.13	6.25	50.0	
		Week 48	Sparsentan	37	22 (59.5)	5.40 (25.75)	-62.5	0.00	0.00	25.00	50.0	-0.04 [-0.76, 0.69]
			Irbesartan	36	11 (30.6)	6.25 (13.69)	-6.3	0.00	0.00	12.50	37.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP Low	KDQOL: burden of kidney disease	Baseline	Sparsentan	39	37 (94.9)	74.66 (24.47)	0.0	62.50	81.25	93.75	100.0	
			Irbesartan	37	36 (97.3)	81.42 (22.08)	6.3	75.00	90.63	96.88	100.0	
		Week 24	Sparsentan	39	24 (61.5)	81.25 (19.94)	25.0	71.88	84.38	100.00	100.0	
			Irbesartan	37	21 (56.8)	81.55 (25.35)	0.0	75.00	93.75	100.00	100.0	
		Week 48	Sparsentan	39	23 (59.0)	83.70 (17.24)	37.5	81.25	87.50	93.75	100.0	
			Irbesartan	37	19 (51.4)	82.24 (21.17)	25.0	68.75	93.75	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	39	24 (61.5)	7.03 (17.71)	-18.8	-6.25	3.13	15.63	43.8	0.30 [-0.29, 0.89]
			Irbesartan	37	21 (56.8)	1.49 (19.56)	-31.3	-12.50	0.00	6.25	56.3	
		Week 48	Sparsentan	39	23 (59.0)	10.60 (19.07)	-31.3	0.00	6.25	25.00	50.0	0.64 [0.02, 1.26]
			Irbesartan	37	19 (51.4)	-0.99 (16.83)	-43.8	-6.25	0.00	6.25	31.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 1												
< 60 mL/min/1.73 m**2	KDQOL: burden of kidney disease	Baseline	Sparsentan	127	115 (90.6)	69.24 (25.44)	0.0	50.00	75.00	87.50	100.0	
			Irbesartan	129	113 (87.6)	77.21 (22.84)	18.8	62.50	81.25	100.00	100.0	
		Week 24	Sparsentan	127	83 (65.4)	74.32 (22.87)	12.5	62.50	81.25	93.75	100.0	
			Irbesartan	129	68 (52.7)	78.31 (21.74)	6.3	68.75	81.25	100.00	100.0	
		Week 48	Sparsentan	127	65 (51.2)	79.52 (18.90)	25.0	68.75	81.25	93.75	100.0	
			Irbesartan	129	49 (38.0)	80.99 (20.41)	6.3	75.00	81.25	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	127	83 (65.4)	5.80 (23.70)	-81.3	-6.25	0.00	18.75	62.5	0.33 [0.01, 0.66]
			Irbesartan	129	68 (52.7)	-1.01 (15.60)	-37.5	-12.50	0.00	6.25	50.0	
		Week 48	Sparsentan	127	65 (51.2)	9.33 (18.92)	-50.0	0.00	6.25	25.00	62.5	0.37 [-0.01, 0.74]
			Irbesartan	129	49 (38.0)	2.55 (18.04)	-50.0	-6.25	0.00	12.50	56.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	KDQOL: burden of kidney disease	Baseline	Sparsentan	49	47 (95.9)	72.61 (23.91)	0.0	62.50	75.00	87.50	100.0	
			Irbesartan	48	43 (89.6)	77.91 (21.45)	18.8	62.50	87.50	93.75	100.0	
		Week 24	Sparsentan	49	27 (55.1)	75.23 (20.47)	25.0	68.75	81.25	87.50	100.0	
			Irbesartan	48	24 (50.0)	84.11 (17.77)	37.5	75.00	90.63	100.00	100.0	
		Week 48	Sparsentan	49	29 (59.2)	75.22 (23.89)	6.3	75.00	81.25	87.50	100.0	
			Irbesartan	48	19 (39.6)	78.29 (20.66)	25.0	68.75	81.25	93.75	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	49	27 (55.1)	8.33 (19.69)	-31.3	-6.25	6.25	25.00	50.0	0.29 [-0.26, 0.84]
			Irbesartan	48	24 (50.0)	2.86 (18.06)	-25.0	-9.38	0.00	15.63	50.0	
		Week 48	Sparsentan	49	29 (59.2)	8.62 (23.41)	-62.5	0.00	6.25	25.00	50.0	0.30 [-0.28, 0.88]
			Irbesartan	48	19 (39.6)	2.30 (17.46)	-43.8	0.00	0.00	12.50	37.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	KDQOL: burden of kidney disease	Baseline	Sparsentan	26	24 (92.3)	64.84 (28.66)	6.3	50.00	75.00	87.50	100.0	
			Irbesartan	25	23 (92.0)	73.10 (25.59)	6.3	56.25	75.00	93.75	100.0	
		Week 24	Sparsentan	26	15 (57.7)	82.92 (19.40)	31.3	75.00	87.50	100.00	100.0	
			Irbesartan	25	12 (48.0)	71.35 (30.44)	0.0	50.00	81.25	93.75	100.0	
		Week 48	Sparsentan	26	16 (61.5)	72.27 (23.16)	31.3	56.25	75.00	93.75	100.0	
			Irbesartan	25	9 (36.0)	84.72 (20.28)	43.8	75.00	93.75	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	26	15 (57.7)	17.50 (22.93)	-6.3	6.25	6.25	31.25	75.0	0.72 [-0.06, 1.50]
			Irbesartan	25	12 (48.0)	-0.52 (27.50)	-50.0	-9.38	-6.25	12.50	56.3	
		Week 48	Sparsentan	26	16 (61.5)	10.16 (21.99)	-31.3	-3.13	6.25	21.88	50.0	0.24 [-0.58, 1.06]
			Irbesartan	25	9 (36.0)	5.56 (11.46)	-6.3	0.00	6.25	6.25	31.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 2												
< 45 mL/min/1.73 m**2	KDQOL: burden of kidney disease	Baseline	Sparsentan	82	71 (86.6)	66.55 (24.96)	6.3	50.00	68.75	87.50	100.0	
			Irbesartan	80	69 (86.3)	73.82 (24.05)	18.8	62.50	81.25	93.75	100.0	
		Week 24	Sparsentan	82	53 (64.6)	73.70 (24.46)	12.5	62.50	81.25	93.75	100.0	
			Irbesartan	80	45 (56.3)	77.36 (23.70)	6.3	62.50	81.25	100.00	100.0	
		Week 48	Sparsentan	82	42 (51.2)	79.32 (20.26)	25.0	75.00	81.25	93.75	100.0	
			Irbesartan	80	29 (36.3)	80.39 (22.21)	6.3	75.00	81.25	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	82	53 (64.6)	6.37 (23.50)	-81.3	0.00	0.00	12.50	62.5	0.28 [-0.12, 0.68]
			Irbesartan	80	45 (56.3)	0.83 (14.75)	-37.5	-6.25	0.00	12.50	37.5	
		Week 48	Sparsentan	82	42 (51.2)	10.57 (20.82)	-50.0	0.00	6.25	25.00	62.5	0.36 [-0.12, 0.83]
			Irbesartan	80	29 (36.3)	4.09 (13.50)	-18.8	-6.25	0.00	6.25	43.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
45 to < 60 mL/min/1.73 m**2	KDQOL: burden of kidney disease	Baseline	Sparsentan	45	44 (97.8)	73.58 (25.89)	0.0	56.25	81.25	93.75	100.0	
			Irbesartan	49	44 (89.8)	82.53 (19.93)	25.0	68.75	90.63	100.00	100.0	
		Week 24	Sparsentan	45	30 (66.7)	75.42 (20.10)	25.0	62.50	75.00	93.75	100.0	
			Irbesartan	49	23 (46.9)	80.16 (17.64)	31.3	68.75	81.25	100.00	100.0	
		Week 48	Sparsentan	45	23 (51.1)	79.89 (16.53)	50.0	68.75	75.00	100.00	100.0	
			Irbesartan	49	20 (40.8)	81.88 (18.01)	31.3	75.00	81.25	96.88	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	45	30 (66.7)	4.79 (24.44)	-50.0	-6.25	0.00	25.00	50.0	0.44 [-0.11, 0.99]
			Irbesartan	49	23 (46.9)	-4.62 (16.88)	-37.5	-12.50	0.00	0.00	50.0	
		Week 48	Sparsentan	45	23 (51.1)	7.07 (14.99)	-25.0	0.00	0.00	25.00	37.5	0.35 [-0.25, 0.95]
			Irbesartan	49	20 (40.8)	0.31 (23.34)	-50.0	-6.25	0.00	12.50	56.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	KDQOL: burden of kidney disease	Baseline	Sparsentan	49	47 (95.9)	72.61 (23.91)	0.0	62.50	75.00	87.50	100.0	
			Irbesartan	48	43 (89.6)	77.91 (21.45)	18.8	62.50	87.50	93.75	100.0	
		Week 24	Sparsentan	49	27 (55.1)	75.23 (20.47)	25.0	68.75	81.25	87.50	100.0	
			Irbesartan	48	24 (50.0)	84.11 (17.77)	37.5	75.00	90.63	100.00	100.0	
		Week 48	Sparsentan	49	29 (59.2)	75.22 (23.89)	6.3	75.00	81.25	87.50	100.0	
			Irbesartan	48	19 (39.6)	78.29 (20.66)	25.0	68.75	81.25	93.75	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	49	27 (55.1)	8.33 (19.69)	-31.3	-6.25	6.25	25.00	50.0	0.29 [-0.26, 0.84]
			Irbesartan	48	24 (50.0)	2.86 (18.06)	-25.0	-9.38	0.00	15.63	50.0	
		Week 48	Sparsentan	49	29 (59.2)	8.62 (23.41)	-62.5	0.00	6.25	25.00	50.0	0.30 [-0.28, 0.88]
			Irbesartan	48	19 (39.6)	2.30 (17.46)	-43.8	0.00	0.00	12.50	37.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	KDQOL: burden of kidney disease	Baseline	Sparsentan	26	24 (92.3)	64.84 (28.66)	6.3	50.00	75.00	87.50	100.0	
			Irbesartan	25	23 (92.0)	73.10 (25.59)	6.3	56.25	75.00	93.75	100.0	
		Week 24	Sparsentan	26	15 (57.7)	82.92 (19.40)	31.3	75.00	87.50	100.00	100.0	
			Irbesartan	25	12 (48.0)	71.35 (30.44)	0.0	50.00	81.25	93.75	100.0	
		Week 48	Sparsentan	26	16 (61.5)	72.27 (23.16)	31.3	56.25	75.00	93.75	100.0	
			Irbesartan	25	9 (36.0)	84.72 (20.28)	43.8	75.00	93.75	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	26	15 (57.7)	17.50 (22.93)	-6.3	6.25	6.25	31.25	75.0	0.72 [-0.06, 1.50]
			Irbesartan	25	12 (48.0)	-0.52 (27.50)	-50.0	-9.38	-6.25	12.50	56.3	
		Week 48	Sparsentan	26	16 (61.5)	10.16 (21.99)	-31.3	-3.13	6.25	21.88	50.0	0.24 [-0.58, 1.06]
			Irbesartan	25	9 (36.0)	5.56 (11.46)	-6.3	0.00	6.25	6.25	31.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline urine protein excretion												
<= 1.75 g/day	KDQOL: burden of kidney disease	Baseline	Sparsentan	98	92 (93.9)	69.43 (24.97)	0.0	53.13	75.00	87.50	100.0	
			Irbesartan	94	82 (87.2)	78.35 (21.77)	6.3	68.75	87.50	93.75	100.0	
		Week 24	Sparsentan	98	66 (67.3)	75.38 (23.89)	12.5	68.75	81.25	93.75	100.0	
			Irbesartan	94	43 (45.7)	82.99 (21.23)	0.0	68.75	93.75	100.00	100.0	
		Week 48	Sparsentan	98	59 (60.2)	81.14 (18.51)	31.3	75.00	81.25	93.75	100.0	
			Irbesartan	94	34 (36.2)	81.80 (19.96)	25.0	75.00	84.38	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	98	66 (67.3)	8.14 (23.28)	-81.3	0.00	6.25	25.00	62.5	0.27 [-0.12, 0.65]
			Irbesartan	94	43 (45.7)	2.47 (17.47)	-31.3	-6.25	0.00	12.50	50.0	
		Week 48	Sparsentan	98	59 (60.2)	11.12 (18.75)	-31.3	0.00	6.25	25.00	62.5	0.43 [-0.00, 0.85]
			Irbesartan	94	34 (36.2)	2.94 (20.08)	-50.0	0.00	0.00	12.50	56.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 1.75 g/day	KDQOL: burden of kidney disease	Baseline	Sparsentan	104	94 (90.4)	69.61 (26.06)	6.3	50.00	75.00	87.50	100.0	
			Irbesartan	108	97 (89.8)	75.58 (23.68)	18.8	62.50	81.25	100.00	100.0	
		Week 24	Sparsentan	104	59 (56.7)	75.74 (19.87)	12.5	68.75	81.25	87.50	100.0	
			Irbesartan	108	61 (56.5)	75.92 (22.47)	6.3	62.50	81.25	93.75	100.0	
		Week 48	Sparsentan	104	51 (49.0)	72.92 (22.80)	6.3	56.25	75.00	93.75	100.0	
			Irbesartan	108	43 (39.8)	79.94 (20.71)	6.3	68.75	81.25	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	104	59 (56.7)	7.31 (22.75)	-50.0	-6.25	6.25	18.75	75.0	0.45 [0.09, 0.81]
			Irbesartan	108	61 (56.5)	-1.84 (17.84)	-50.0	-12.50	0.00	6.25	56.3	
		Week 48	Sparsentan	104	51 (49.0)	7.11 (22.22)	-62.5	0.00	6.25	25.00	50.0	0.23 [-0.18, 0.63]
			Irbesartan	108	43 (39.8)	2.76 (14.58)	-31.3	-6.25	0.00	6.25	37.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline use of antihypertensives												
Yes	KDQOL: burden of kidney disease	Baseline	Sparsentan	88	77 (87.5)	69.81 (25.01)	6.3	56.25	75.00	87.50	100.0	
			Irbesartan	83	70 (84.3)	77.50 (21.87)	18.8	62.50	84.38	100.00	100.0	
		Week 24	Sparsentan	88	50 (56.8)	79.13 (19.63)	12.5	68.75	81.25	93.75	100.0	
			Irbesartan	83	39 (47.0)	79.17 (23.58)	6.3	62.50	87.50	100.00	100.0	
		Week 48	Sparsentan	88	41 (46.6)	80.03 (16.55)	31.3	75.00	81.25	93.75	100.0	
			Irbesartan	83	28 (33.7)	77.90 (19.43)	31.3	71.88	81.25	93.75	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	88	50 (56.8)	10.25 (21.86)	-31.3	0.00	3.13	25.00	75.0	0.58 [0.15, 1.00]
			Irbesartan	83	39 (47.0)	-0.96 (15.94)	-37.5	-12.50	0.00	6.25	37.5	
		Week 48	Sparsentan	88	41 (46.6)	12.35 (19.08)	-50.0	0.00	6.25	25.00	50.0	0.58 [0.09, 1.07]
			Irbesartan	83	28 (33.7)	1.12 (19.55)	-50.0	-6.25	0.00	9.38	43.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	KDQOL: burden of kidney disease	Baseline	Sparsentan	114	109 (95.6)	69.32 (25.89)	0.0	50.00	75.00	87.50	100.0	
			Irbesartan	119	109 (91.6)	76.43 (23.47)	6.3	62.50	81.25	93.75	100.0	
		Week 24	Sparsentan	114	75 (65.8)	73.17 (23.27)	12.5	56.25	75.00	93.75	100.0	
			Irbesartan	119	65 (54.6)	78.65 (21.42)	0.0	68.75	81.25	93.75	100.0	
		Week 48	Sparsentan	114	69 (60.5)	75.72 (23.10)	6.3	62.50	81.25	93.75	100.0	
			Irbesartan	119	49 (41.2)	82.40 (20.76)	6.3	75.00	87.50	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	114	75 (65.8)	6.08 (23.63)	-81.3	-6.25	6.25	18.75	62.5	0.26 [-0.07, 0.59]
			Irbesartan	119	65 (54.6)	0.48 (18.82)	-50.0	-12.50	0.00	6.25	56.3	
		Week 48	Sparsentan	114	69 (60.5)	7.43 (21.12)	-62.5	0.00	0.00	25.00	62.5	0.19 [-0.18, 0.56]
			Irbesartan	119	49 (41.2)	3.83 (15.67)	-43.8	-6.25	0.00	12.50	56.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Time since renal biopsy												
<= 5 years	KDQOL: burden of kidney disease	Baseline	Sparsentan	113	104 (92.0)	67.25 (26.79)	0.0	50.00	75.00	87.50	100.0	
			Irbesartan	127	116 (91.3)	75.54 (22.97)	6.3	56.25	81.25	93.75	100.0	
		Week 24	Sparsentan	113	70 (61.9)	75.27 (22.05)	12.5	68.75	78.13	93.75	100.0	
			Irbesartan	127	67 (52.8)	78.36 (21.69)	0.0	62.50	81.25	93.75	100.0	
		Week 48	Sparsentan	113	61 (54.0)	75.41 (20.09)	25.0	62.50	75.00	93.75	100.0	
			Irbesartan	127	51 (40.2)	78.06 (22.86)	6.3	62.50	81.25	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	113	70 (61.9)	11.96 (21.38)	-50.0	0.00	6.25	31.25	62.5	0.52 [0.18, 0.86]
			Irbesartan	127	67 (52.8)	1.49 (18.66)	-50.0	-12.50	0.00	12.50	56.3	
		Week 48	Sparsentan	113	61 (54.0)	11.48 (18.48)	-31.3	0.00	6.25	25.00	50.0	0.42 [0.05, 0.80]
			Irbesartan	127	51 (40.2)	3.43 (19.82)	-50.0	-6.25	0.00	12.50	56.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 5 years	KDQOL: burden of kidney disease	Baseline	Sparsentan	89	82 (92.1)	72.41 (23.51)	0.0	62.50	75.00	87.50	100.0	
			Irbesartan	75	63 (84.0)	79.27 (22.47)	18.8	68.75	87.50	93.75	100.0	
		Week 24	Sparsentan	89	55 (61.8)	75.91 (22.13)	18.8	68.75	81.25	93.75	100.0	
			Irbesartan	75	37 (49.3)	79.73 (23.22)	6.3	68.75	81.25	100.00	100.0	
		Week 48	Sparsentan	89	49 (55.1)	79.72 (21.89)	6.3	75.00	87.50	93.75	100.0	
			Irbesartan	75	26 (34.7)	86.06 (12.66)	56.3	75.00	87.50	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	89	55 (61.8)	2.39 (23.92)	-81.3	-6.25	0.00	12.50	75.0	0.25 [-0.17, 0.67]
			Irbesartan	75	37 (49.3)	-2.87 (15.77)	-37.5	-6.25	0.00	0.00	37.5	
		Week 48	Sparsentan	89	49 (55.1)	6.51 (22.53)	-62.5	0.00	0.00	25.00	62.5	0.25 [-0.23, 0.73]
			Irbesartan	75	26 (34.7)	1.68 (10.09)	-25.0	-6.25	0.00	6.25	18.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: History of hypertension												
Yes	KDQOL: burden of kidney disease	Baseline	Sparsentan	153	138 (90.2)	68.98 (26.23)	0.0	50.00	75.00	87.50	100.0	
			Irbesartan	157	135 (86.0)	78.10 (21.82)	18.8	62.50	81.25	100.00	100.0	
		Week 24	Sparsentan	153	94 (61.4)	76.40 (21.22)	12.5	68.75	81.25	93.75	100.0	
			Irbesartan	157	76 (48.4)	79.93 (21.00)	6.3	68.75	81.25	100.00	100.0	
		Week 48	Sparsentan	153	81 (52.9)	77.93 (21.56)	6.3	68.75	81.25	93.75	100.0	
			Irbesartan	157	57 (36.3)	81.03 (18.60)	31.3	68.75	81.25	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	153	94 (61.4)	8.44 (22.11)	-43.8	-6.25	6.25	25.00	75.0	0.39 [0.08, 0.69]
			Irbesartan	157	76 (48.4)	0.49 (18.08)	-50.0	-9.38	0.00	12.50	56.3	
		Week 48	Sparsentan	153	81 (52.9)	9.57 (19.49)	-62.5	0.00	6.25	25.00	62.5	0.35 [0.01, 0.69]
			Irbesartan	157	57 (36.3)	3.07 (16.71)	-50.0	-6.25	0.00	12.50	43.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	KDQOL: burden of kidney disease	Baseline	Sparsentan	49	48 (98.0)	71.09 (23.30)	12.5	53.13	75.00	87.50	100.0	
			Irbesartan	45	44 (97.8)	73.01 (25.46)	6.3	56.25	75.00	93.75	100.0	
		Week 24	Sparsentan	49	31 (63.3)	72.98 (24.39)	12.5	68.75	75.00	87.50	100.0	
			Irbesartan	45	28 (62.2)	75.89 (25.16)	0.0	68.75	78.13	96.88	100.0	
		Week 48	Sparsentan	49	29 (59.2)	75.65 (19.29)	31.3	68.75	75.00	93.75	100.0	
			Irbesartan	45	20 (44.4)	80.00 (24.97)	6.3	75.00	84.38	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	49	31 (63.3)	5.65 (25.58)	-81.3	0.00	6.25	18.75	56.3	0.33 [-0.19, 0.84]
			Irbesartan	45	28 (62.2)	-1.56 (16.98)	-31.3	-12.50	-3.13	0.00	50.0	
		Week 48	Sparsentan	49	29 (59.2)	8.41 (23.22)	-50.0	0.00	12.50	25.00	50.0	0.29 [-0.28, 0.86]
			Irbesartan	45	20 (44.4)	2.19 (18.62)	-43.8	-6.25	0.00	9.38	56.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Sex	Overall	Sparsentan						Interaction:	0.890
Male	Week 24	Sparsentan	139	87 (62.6)	3.81 (1.84)	(0.18, 7.43)	4.06 (2.75)	(-1.36, 9.48)	0.142
		Irbesartan	143	73 (51.0)	-0.25 (2.01)	(-4.20, 3.70)			
	Week 48	Sparsentan	139	72 (51.8)	5.79 (1.99)	(1.87, 9.72)	1.51 (3.06)	(-4.51, 7.53)	0.622
		Irbesartan	143	55 (38.5)	4.28 (2.29)	(-0.22, 8.79)			
Female	Week 24	Sparsentan	63	38 (60.3)	8.94 (2.63)	(3.73, 14.14)	-0.82 (3.97)	(-8.69, 7.05)	0.837
		Irbesartan	59	31 (52.5)	9.76 (2.94)	(3.92, 15.59)			
	Week 48	Sparsentan	63	38 (60.3)	10.51 (2.60)	(5.35, 15.67)	5.35 (4.32)	(-3.20, 13.90)	0.218
		Irbesartan	59	22 (37.3)	5.16 (3.42)	(-1.60, 11.93)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age	Overall	Sparsentan						Interaction:	0.879
<= 45 years	Week 24	Sparsentan	96	57 (59.4)	7.18 (2.57)	(2.12, 12.25)	4.04 (3.73)	(-3.32, 11.40)	0.280
		Irbesartan	99	53 (53.5)	3.14 (2.67)	(-2.13, 8.41)			
	Week 48	Sparsentan	96	53 (55.2)	6.57 (2.64)	(1.37, 11.78)	1.65 (4.01)	(-6.27, 9.57)	0.682
		Irbesartan	99	40 (40.4)	4.92 (3.00)	(-0.99, 10.84)			
> 45 years	Week 24	Sparsentan	106	68 (64.2)	3.43 (1.68)	(0.12, 6.75)	0.16 (2.64)	(-5.05, 5.36)	0.953
		Irbesartan	103	51 (49.5)	3.28 (1.98)	(-0.63, 7.18)			
	Week 48	Sparsentan	106	57 (53.8)	7.61 (1.82)	(4.02, 11.20)	3.11 (2.94)	(-2.68, 8.90)	0.291
		Irbesartan	103	37 (35.9)	4.50 (2.27)	(0.02, 8.99)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age at IgAN diagnosis	Overall	Sparsentan						Interaction:	0.937
<= 18 years	Week 24	Sparsentan	9	3 (33.3)	13.10 (15.77)	(-30.17, 56.37)	12.51 (30.95)	(-73.20, 98.22)	0.707
		Irbesartan	5	2 (40.0)	0.59 (26.30)	(-72.51, 73.68)			
	Week 48	Sparsentan	9	5 (55.6)	3.45 (15.59)	(-39.81, 46.70)	2.79 (31.02)	(-82.91, 88.49)	0.933
		Irbesartan	5	1 (20.0)	0.66 (26.53)	(-72.42, 73.74)			
> 18 to 40 years	Week 24	Sparsentan	102	62 (60.8)	6.55 (2.32)	(1.97, 11.12)	3.90 (3.36)	(-2.72, 10.51)	0.247
		Irbesartan	109	59 (54.1)	2.65 (2.40)	(-2.08, 7.38)			
	Week 48	Sparsentan	102	57 (55.9)	6.83 (2.41)	(2.07, 11.58)	2.58 (3.66)	(-4.65, 9.80)	0.483
		Irbesartan	109	44 (40.4)	4.25 (2.73)	(-1.14, 9.63)			
> 40 years	Week 24	Sparsentan	91	60 (65.9)	3.58 (1.80)	(0.02, 7.14)	0.30 (2.83)	(-5.29, 5.89)	0.916
		Irbesartan	88	43 (48.9)	3.28 (2.14)	(-0.94, 7.50)			
	Week 48	Sparsentan	91	48 (52.7)	8.97 (1.99)	(5.05, 12.90)	4.06 (3.18)	(-2.21, 10.34)	0.203
		Irbesartan	88	32 (36.4)	4.91 (2.45)	(0.07, 9.75)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Geographic region	Overall	Sparsentan						Interaction:	0.545
North America	Week 24	Sparsentan	35	15 (42.9)	2.32 (4.19)	(-6.07, 10.71)	5.04 (5.34)	(-5.67, 15.75)	0.350
		Irbesartan	46	26 (56.5)	-2.72 (3.23)	(-9.19, 3.76)			
	Week 48	Sparsentan	35	13 (37.1)	9.31 (4.71)	(-0.11, 18.73)	12.35 (6.26)	(-0.15, 24.86)	0.053
		Irbesartan	46	17 (37.0)	-3.05 (3.92)	(-10.87, 4.78)			
Europe	Week 24	Sparsentan	98	53 (54.1)	2.57 (2.33)	(-2.03, 7.18)	1.05 (3.41)	(-5.67, 7.78)	0.757
		Irbesartan	115	47 (40.9)	1.52 (2.48)	(-3.38, 6.42)			
	Week 48	Sparsentan	98	44 (44.9)	3.86 (2.56)	(-1.20, 8.92)	-0.96 (3.78)	(-8.42, 6.50)	0.800
		Irbesartan	115	38 (33.0)	4.82 (2.76)	(-0.63, 10.27)			
Asia Pacific	Week 24	Sparsentan	69	57 (82.6)	10.88 (2.24)	(6.45, 15.31)	5.77 (3.86)	(-1.87, 13.42)	0.138
		Irbesartan	41	31 (75.6)	5.11 (3.07)	(-0.97, 11.19)			
	Week 48	Sparsentan	69	53 (76.8)	12.25 (2.29)	(7.72, 16.77)	5.91 (4.24)	(-2.47, 14.30)	0.165
		Irbesartan	41	22 (53.7)	6.33 (3.53)	(-0.64, 13.30)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline BMI	Overall	Sparsentan						Interaction:	0.850
< 27 kg/m**2	Week 24	Sparsentan	84	52 (61.9)	7.80 (2.44)	(2.98, 12.62)	1.08 (3.51)	(-5.86, 8.02)	0.759
		Irbesartan	94	50 (53.2)	6.72 (2.50)	(1.78, 11.67)			
	Week 48	Sparsentan	84	47 (56.0)	8.87 (2.56)	(3.82, 13.93)	4.02 (3.91)	(-3.68, 11.73)	0.304
		Irbesartan	94	36 (38.3)	4.85 (2.92)	(-0.91, 10.61)			
>= 27 kg/m**2	Week 24	Sparsentan	118	73 (61.9)	3.11 (1.89)	(-0.61, 6.84)	3.55 (2.97)	(-2.30, 9.40)	0.233
		Irbesartan	107	54 (50.5)	-0.43 (2.22)	(-4.81, 3.94)			
	Week 48	Sparsentan	118	63 (53.4)	5.93 (1.99)	(2.01, 9.86)	1.50 (3.20)	(-4.80, 7.81)	0.639
		Irbesartan	107	41 (38.3)	4.43 (2.47)	(-0.43, 9.29)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Randomization strata	Overall	Sparsentan						Interaction:	0.506
eGFR Low and UP High	Week 24	Sparsentan	71	44 (62.0)	5.61 (2.52)	(0.63, 10.60)	7.71 (3.90)	(-0.02, 15.44)	0.051
		Irbesartan	74	32 (43.2)	-2.10 (2.96)	(-7.96, 3.77)			
	Week 48	Sparsentan	71	37 (52.1)	6.50 (2.73)	(1.10, 11.89)	4.30 (4.47)	(-4.55, 13.16)	0.338
		Irbesartan	74	22 (29.7)	2.19 (3.53)	(-4.79, 9.18)			
eGFR Low and UP Low	Week 24	Sparsentan	55	38 (69.1)	3.25 (2.62)	(-1.94, 8.45)	-4.37 (3.90)	(-12.11, 3.36)	0.265
		Irbesartan	55	33 (60.0)	7.63 (2.83)	(2.02, 13.23)			
	Week 48	Sparsentan	55	28 (50.9)	11.89 (2.99)	(5.96, 17.82)	4.44 (4.38)	(-4.23, 13.11)	0.313
		Irbesartan	55	25 (45.5)	7.46 (3.17)	(1.17, 13.74)			
eGFR High and UP High	Week 24	Sparsentan	37	19 (51.4)	9.10 (4.25)	(0.59, 17.61)	5.33 (6.38)	(-7.44, 18.10)	0.407
		Irbesartan	36	18 (50.0)	3.77 (4.58)	(-5.42, 12.96)			
	Week 48	Sparsentan	37	22 (59.5)	1.05 (4.02)	(-7.01, 9.11)	-10.01 (6.92)	(-23.84, 3.82)	0.153
		Irbesartan	36	11 (30.6)	11.05 (5.51)	(0.05, 22.06)			
eGFR High and UP Low	Week 24	Sparsentan	39	24 (61.5)	5.93 (3.19)	(-0.41, 12.28)	2.75 (4.68)	(-6.56, 12.06)	0.558
		Irbesartan	37	21 (56.8)	3.18 (3.40)	(-3.60, 9.96)			
	Week 48	Sparsentan	39	23 (59.0)	9.10 (3.26)	(2.61, 15.59)	8.33 (4.88)	(-1.38, 18.04)	0.092
		Irbesartan	37	19 (51.4)	0.77 (3.59)	(-6.38, 7.92)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 1	Overall	Sparsentan						Interaction:	0.603
< 60 mL/min/1.73 m**2	Week 24	Sparsentan	127	83 (65.4)	3.53 (1.80)	(-0.03, 7.08)	2.10 (2.72)	(-3.26, 7.45)	0.441
		Irbesartan	129	68 (52.7)	1.43 (2.01)	(-2.53, 5.39)			
	Week 48	Sparsentan	127	65 (51.2)	7.79 (2.01)	(3.83, 11.74)	3.77 (3.09)	(-2.31, 9.85)	0.223
		Irbesartan	129	49 (38.0)	4.02 (2.32)	(-0.56, 8.59)			
60 to < 90 mL/min/1.73 m**2	Week 24	Sparsentan	49	27 (55.1)	6.11 (3.38)	(-0.61, 12.83)	-1.11 (5.05)	(-11.17, 8.95)	0.826
		Irbesartan	48	24 (50.0)	7.23 (3.64)	(-0.02, 14.47)			
	Week 48	Sparsentan	49	29 (59.2)	6.96 (3.29)	(0.41, 13.50)	3.79 (5.26)	(-6.68, 14.25)	0.474
		Irbesartan	48	19 (39.6)	3.17 (3.97)	(-4.72, 11.06)			
>= 90 mL/min/1.73 m**2	Week 24	Sparsentan	26	15 (57.7)	16.09 (4.47)	(7.10, 25.08)	15.15 (6.72)	(1.62, 28.67)	0.029 *
		Irbesartan	25	12 (48.0)	0.94 (5.00)	(-9.13, 11.02)			
	Week 48	Sparsentan	26	16 (61.5)	8.25 (4.36)	(-0.54, 17.04)	-1.17 (7.47)	(-16.20, 13.87)	0.877
		Irbesartan	25	9 (36.0)	9.41 (5.93)	(-2.53, 21.35)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 2	Overall	Sparsentan						Interaction:	0.794
< 45 mL/min/1.73 m**2	Week 24	Sparsentan	82	53 (64.6)	4.59 (2.30)	(0.04, 9.14)	2.08 (3.42)	(-4.68, 8.85)	0.544
		Irbesartan	80	45 (56.3)	2.51 (2.51)	(-2.46, 7.47)			
	Week 48	Sparsentan	82	42 (51.2)	9.46 (2.54)	(4.45, 14.48)	4.95 (3.97)	(-2.89, 12.80)	0.214
		Irbesartan	80	29 (36.3)	4.51 (3.04)	(-1.49, 10.51)			
45 to < 60 mL/min/1.73 m**2	Week 24	Sparsentan	45	30 (66.7)	1.33 (2.92)	(-4.47, 7.13)	1.30 (4.55)	(-7.76, 10.35)	0.776
		Irbesartan	49	23 (46.9)	0.03 (3.40)	(-6.74, 6.80)			
	Week 48	Sparsentan	45	23 (51.1)	4.78 (3.31)	(-1.80, 11.37)	1.61 (4.95)	(-8.23, 11.45)	0.746
		Irbesartan	49	20 (40.8)	3.17 (3.62)	(-4.02, 10.37)			
60 to < 90 mL/min/1.73 m**2	Week 24	Sparsentan	49	27 (55.1)	6.11 (3.38)	(-0.61, 12.83)	-1.11 (5.05)	(-11.17, 8.95)	0.826
		Irbesartan	48	24 (50.0)	7.23 (3.64)	(-0.02, 14.47)			
	Week 48	Sparsentan	49	29 (59.2)	6.96 (3.29)	(0.41, 13.50)	3.79 (5.26)	(-6.68, 14.25)	0.474
		Irbesartan	48	19 (39.6)	3.17 (3.97)	(-4.72, 11.06)			
>= 90 mL/min/1.73 m**2	Week 24	Sparsentan	26	15 (57.7)	16.09 (4.47)	(7.10, 25.08)	15.15 (6.72)	(1.62, 28.67)	0.029 *
		Irbesartan	25	12 (48.0)	0.94 (5.00)	(-9.13, 11.02)			
	Week 48	Sparsentan	26	16 (61.5)	8.25 (4.36)	(-0.54, 17.04)	-1.17 (7.47)	(-16.20, 13.87)	0.877
		Irbesartan	25	9 (36.0)	9.41 (5.93)	(-2.53, 21.35)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

					Repeated measures analysis				
KDQOL: Change from baseline in burden of kidney disease					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline urine protein excretion	Overall	Sparsentan						Interaction:	0.951
<= 1.75 g/day	Week 24	Sparsentan	98	66 (67.3)	5.73 (2.12)	(1.55, 9.92)	0.28 (3.43)	(-6.49, 7.06)	0.934
		Irbesartan	94	43 (45.7)	5.45 (2.66)	(0.21, 10.69)			
	Week 48	Sparsentan	98	59 (60.2)	10.33 (2.21)	(5.96, 14.69)	5.57 (3.69)	(-1.71, 12.85)	0.133
		Irbesartan	94	34 (36.2)	4.76 (2.92)	(-1.00, 10.51)			
> 1.75 g/day	Week 24	Sparsentan	104	59 (56.7)	5.51 (2.15)	(1.27, 9.76)	4.91 (3.06)	(-1.12, 10.95)	0.110
		Irbesartan	108	61 (56.5)	0.60 (2.13)	(-3.60, 4.80)			
	Week 48	Sparsentan	104	51 (49.0)	4.22 (2.33)	(-0.37, 8.82)	-0.13 (3.50)	(-7.04, 6.77)	0.969
		Irbesartan	108	43 (39.8)	4.36 (2.53)	(-0.64, 9.35)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline use of antihypertensives	Overall	Sparsentan						Interaction:	0.066
Yes	Week 24	Sparsentan	88	50 (56.8)	8.46 (2.27)	(3.97, 12.96)	6.60 (3.48)	(-0.28, 13.48)	0.060
		Irbesartan	83	39 (47.0)	1.86 (2.60)	(-3.28, 7.00)			
	Week 48	Sparsentan	88	41 (46.6)	8.91 (2.47)	(4.02, 13.80)	7.47 (3.89)	(-0.23, 15.16)	0.057
		Irbesartan	83	28 (33.7)	1.44 (2.97)	(-4.43, 7.31)			
No	Week 24	Sparsentan	114	75 (65.8)	3.46 (1.99)	(-0.47, 7.39)	0.35 (2.95)	(-5.46, 6.16)	0.905
		Irbesartan	119	65 (54.6)	3.11 (2.15)	(-1.12, 7.34)			
	Week 48	Sparsentan	114	69 (60.5)	5.93 (2.06)	(1.87, 9.99)	-0.06 (3.22)	(-6.39, 6.28)	0.986
		Irbesartan	119	49 (41.2)	5.98 (2.45)	(1.16, 10.81)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Time since renal biopsy	Overall	Sparsentan						Interaction:	0.704
<= 5 years	Week 24	Sparsentan	113	70 (61.9)	9.33 (1.95)	(5.48, 13.18)	4.68 (2.83)	(-0.89, 10.25)	0.099
		Irbesartan	127	67 (52.8)	4.65 (2.01)	(0.70, 8.61)			
	Week 48	Sparsentan	113	61 (54.0)	8.08 (2.07)	(4.01, 12.16)	2.48 (3.07)	(-3.57, 8.53)	0.420
		Irbesartan	127	51 (40.2)	5.60 (2.25)	(1.18, 10.03)			
> 5 years	Week 24	Sparsentan	89	55 (61.8)	0.47 (2.37)	(-4.21, 5.15)	0.40 (3.80)	(-7.11, 7.91)	0.917
		Irbesartan	75	37 (49.3)	0.07 (2.95)	(-5.76, 5.91)			
	Week 48	Sparsentan	89	49 (55.1)	6.16 (2.51)	(1.20, 11.12)	3.00 (4.30)	(-5.50, 11.50)	0.486
		Irbesartan	75	26 (34.7)	3.16 (3.45)	(-3.65, 9.97)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
History of hypertension	Overall	Sparsentan						Interaction:	0.998
Yes	Week 24	Sparsentan	153	94 (61.4)	5.77 (1.63)	(2.56, 8.97)	2.48 (2.46)	(-2.36, 7.31)	0.315
		Irbesartan	157	76 (48.4)	3.29 (1.82)	(-0.29, 6.87)			
	Week 48	Sparsentan	153	81 (52.9)	7.65 (1.73)	(4.24, 11.06)	3.09 (2.71)	(-2.24, 8.42)	0.255
		Irbesartan	157	57 (36.3)	4.56 (2.06)	(0.50, 8.62)			
No	Week 24	Sparsentan	49	31 (63.3)	4.14 (3.55)	(-2.91, 11.18)	3.09 (5.23)	(-7.29, 13.47)	0.556
		Irbesartan	45	28 (62.2)	1.05 (3.77)	(-6.44, 8.53)			
	Week 48	Sparsentan	49	29 (59.2)	6.32 (3.66)	(-0.94, 13.59)	2.32 (5.83)	(-9.26, 13.89)	0.692
		Irbesartan	45	20 (44.4)	4.00 (4.46)	(-4.84, 12.85)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Figure PF1KBUC_FSGM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

Not done: No significant subgroup found.

_____
Number of available records are presented for key visits up to Week 58 only. LS-Mean = Least square mean.
95% CI = 95% confidence interval. eGFR = estimated glomerular filtration rate. UP = urine protein. BMI = body mass index.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
IgAN = immunoglobulin A nephropathy. A decrease reflects a worsening of the status of the patient. Reference table: PT1KBUC_FSCM.

Table PT1KBUIT_FSTM: KDQOL: Time to increase in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Sex	Sparsentan						Interaction test:	0.149	
Male	Sparsentan	139	38 (27.3)	95.9	(70.1, NE)	1.991	(1.105, 3.588)	0.022	*
	Irbesartan	143	17 (11.9)	NE					
Female	Sparsentan	63	23 (36.5)	50.1	(46.3, NE)	1.054	(0.478, 2.327)	0.896	
	Irbesartan	59	12 (20.3)	71.9	(46.3, NE)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KBUIT_FSTM: KDQOL: Time to increase in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.935
<= 45 years	Sparsentan	96	29 (30.2)	87.7	(48.7, NE)	1.509	(0.798, 2.854)	0.205
	Irbesartan	99	17 (17.2)	NE				
> 45 years	Sparsentan	106	32 (30.2)	75.3	(49.1, NE)	1.156	(0.571, 2.343)	0.687
	Irbesartan	103	12 (11.7)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KBUIT_FSTM: KDQOL: Time to increase in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age at IgAN diagnosis	Sparsentan						Interaction test:	NE
<= 18 years	Sparsentan	9	3 (33.3) No events in 1 group	NE		NE		NE
	Irbesartan	5	0 (0.0)	NE				
> 18 to 40 years	Sparsentan	102	31 (30.4)	75.3	(49.7, NE)	1.686	(0.926, 3.072)	0.088
	Irbesartan	109	18 (16.5)	NE				
> 40 years	Sparsentan	91	27 (29.7)	111.0	(48.7, NE)	1.105	(0.519, 2.352)	0.795
	Irbesartan	88	11 (12.5)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KBUIT_FSTM: KDQOL: Time to increase in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Geographic region	Sparsentan						Interaction test:	0.370
North America	Sparsentan	35	8 (22.9)	87.7	(44.4, NE)	0.886	(0.251, 3.120)	0.850
	Irbesartan	46	6 (13.0)	NE				
Europe	Sparsentan	98	18 (18.4)	NE		1.922	(0.908, 4.066)	0.087
	Irbesartan	115	15 (13.0)	NE				
Asia Pacific	Sparsentan	69	35 (50.7)	50.1	(48.1, 111.0)	1.918	(0.881, 4.179)	0.101
	Irbesartan	41	8 (19.5)	95.1	(70.6, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KBUIT_FSTM: KDQOL: Time to increase in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.299
< 27 kg/m**2	Sparsentan	84	29 (34.5)	50.1	(48.1, NE)	1.093	(0.577, 2.070)	0.785
	Irbesartan	94	18 (19.1)	95.1	(71.0, NE)			
>= 27 kg/m**2	Sparsentan	118	32 (27.1)	95.9	(72.0, 111.0)	1.778	(0.867, 3.649)	0.117
	Irbesartan	107	11 (10.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KBUIT_FSTM: KDQOL: Time to increase in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Randomization strata	Sparsentan						Interaction test:	0.193	
eGFR Low and UP High	Sparsentan	71	21 (29.6)	75.3	(48.4, 111.0)	2.813	(1.191, 6.643)	0.018	*
	Irbesartan	74	8 (10.8)	NE					
eGFR Low and UP Low	Sparsentan	55	15 (27.3)	NE		0.819	(0.370, 1.809)	0.621	
	Irbesartan	55	12 (21.8)	73.0	(50.1, NE)				
eGFR High and UP High	Sparsentan	37	13 (35.1)	87.7	(25.7, NE)	1.472	(0.365, 5.932)	0.587	
	Irbesartan	36	3 (8.3)	NE					
eGFR High and UP Low	Sparsentan	39	12 (30.8)	50.1	(48.1, NE)	1.703	(0.628, 4.624)	0.296	
	Irbesartan	37	6 (16.2)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KBUIT_FSTM: KDQOL: Time to increase in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.696
< 60 mL/min/1.73 m**2	Sparsentan	127	35 (27.6)	111.0	(52.0, NE)	1.658	(0.946, 2.908)	0.078
	Irbesartan	129	20 (15.5)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	15 (30.6)	70.1	(44.4, NE)	1.307	(0.441, 3.870)	0.629
	Irbesartan	48	6 (12.5)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	11 (42.3)	70.0	(24.3, 95.9)	2.398	(0.528, 10.900)	0.257
	Irbesartan	25	3 (12.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KBUIT_FSTM: KDQOL: Time to increase in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 2	Sparsentan						Interaction test:	0.819
< 45 mL/min/1.73 m**2	Sparsentan	82	23 (28.0)	75.3	(50.1, NE)	1.621	(0.810, 3.244)	0.172
	Irbesartan	80	13 (16.3)	NE				
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	12 (26.7)	NE		1.452	(0.511, 4.124)	0.484
	Irbesartan	49	7 (14.3)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	15 (30.6)	70.1	(44.4, NE)	1.307	(0.441, 3.870)	0.629
	Irbesartan	48	6 (12.5)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	11 (42.3)	70.0	(24.3, 95.9)	2.398	(0.528, 10.900)	0.257
	Irbesartan	25	3 (12.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KBUIT_FSTM: KDQOL: Time to increase in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline urine protein excretion	Sparsentan						Interaction test:	0.947
<= 1.75 g/day	Sparsentan	98	32 (32.7)	NE		1.832	(0.961, 3.491)	0.066
	Irbesartan	94	14 (14.9)	NE				
> 1.75 g/day	Sparsentan	104	29 (27.9)	72.1	(49.3, 111.0)	1.505	(0.770, 2.940)	0.232
	Irbesartan	108	15 (13.9)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KBUIT_FSTM: KDQOL: Time to increase in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.287	
Yes	Sparsentan	88	25 (28.4)	72.1	(49.1, NE)	2.377	(1.102, 5.128)	0.027	*
	Irbesartan	83	10 (12.0)	NE					
No	Sparsentan	114	36 (31.6)	95.9	(49.1, NE)	1.297	(0.733, 2.298)	0.372	
	Irbesartan	119	19 (16.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KBUIT_FSTM: KDQOL: Time to increase in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Time since renal biopsy	Sparsentan						Interaction test:	0.211	
<= 5 years	Sparsentan	113	36 (31.9)	72.1	(48.7, NE)	1.291	(0.762, 2.188)	0.342	
	Irbesartan	127	24 (18.9)	NE					
> 5 years	Sparsentan	89	25 (28.1)	NE		3.550	(1.301, 9.689)	0.013	*
	Irbesartan	75	5 (6.7)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KBUIT_FSTM: KDQOL: Time to increase in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
History of hypertension	Sparsentan						Interaction test:	0.056	
Yes	Sparsentan	153	42 (27.5)	95.9	(70.1, NE)	1.193	(0.706, 2.015)	0.510	
	Irbesartan	157	24 (15.3)	NE					
No	Sparsentan	49	19 (38.8)	50.1	(48.1, NE)	3.578	(1.307, 9.792)	0.013	*
	Irbesartan	45	5 (11.1)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Figure PF1KBUIT_FSKM: KDQOL: Time to increase in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

Not done. No significant subgroups.

_____
An increase reflects an improvement of the status of the patient.
Reference table: PT1KBUIT_FSTM

Table PT1KBUDT_FSTM: KDQOL: Time to decrease in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sex	Sparsentan						Interaction test:	0.507
Male	Sparsentan	139	19 (13.7)	NE		0.816	(0.437, 1.525)	0.524
	Irbesartan	143	25 (17.5)	NE				
Female	Sparsentan	63	6 (9.5)	112.1	(112.1, NE)	0.466	(0.141, 1.534)	0.209
	Irbesartan	59	8 (13.6)	94.6	(70.1, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KBUDT_FSTM: KDQOL: Time to decrease in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.588
<= 45 years	Sparsentan	96	12 (12.5)	NE		0.819	(0.379, 1.773)	0.613
	Irbesartan	99	16 (16.2)	NE				
> 45 years	Sparsentan	106	13 (12.3)	112.1	(112.1, NE)	0.619	(0.286, 1.339)	0.223
	Irbesartan	103	17 (16.5)	95.1	(94.1, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KBUDT_FSTM: KDQOL: Time to decrease in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age at IgAN diagnosis	Sparsentan						Interaction test:	NE
<= 18 years	Sparsentan	9	1 (11.1) No events in 1 group	NE		NE		NE
	Irbesartan	5	0 (0.0)	NE				
> 18 to 40 years	Sparsentan	102	13 (12.7)	NE		0.861	(0.404, 1.833)	0.697
	Irbesartan	109	17 (15.6)	NE				
> 40 years	Sparsentan	91	11 (12.1)	112.1	(112.1, NE)	0.542	(0.240, 1.227)	0.142
	Irbesartan	88	16 (18.2)	96.1	(70.9, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KBUDT_FSTM: KDQOL: Time to decrease in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Geographic region	Sparsentan						Interaction test:	0.860
North America	Sparsentan	35	4 (11.4)	95.0	(30.4, NE)	0.478	(0.144, 1.589)	0.229
	Irbesartan	46	13 (28.3)	70.1	(48.6, 96.1)			
Europe	Sparsentan	98	12 (12.2)	112.1	(112.1, NE)	0.869	(0.393, 1.924)	0.730
	Irbesartan	115	14 (12.2)	NE				
Asia Pacific	Sparsentan	69	9 (13.0)	NE		0.543	(0.184, 1.602)	0.269
	Irbesartan	41	6 (14.6)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KBUDT_FSTM: KDQOL: Time to decrease in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.191
< 27 kg/m**2	Sparsentan	84	13 (15.5)	112.1	(112.1, NE)	0.989	(0.441, 2.218)	0.979
	Irbesartan	94	12 (12.8)	95.3	(95.1, NE)			
>= 27 kg/m**2	Sparsentan	118	12 (10.2)	NE		0.505	(0.239, 1.065)	0.073
	Irbesartan	107	21 (19.6)	94.6	(93.0, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KBUDT_FSTM: KDQOL: Time to decrease in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Randomization strata	Sparsentan						Interaction test:	0.954
eGFR Low and UP High	Sparsentan	71	12 (16.9)	NE		0.647	(0.291, 1.439)	0.286
	Irbesartan	74	13 (17.6)	95.1	(70.9, NE)			
eGFR Low and UP Low	Sparsentan	55	5 (9.1)	112.1	(NE, NE)	0.482	(0.151, 1.541)	0.218
	Irbesartan	55	10 (18.2)	NE				
eGFR High and UP High	Sparsentan	37	4 (10.8)	NE		0.567	(0.129, 2.487)	0.452
	Irbesartan	36	4 (11.1)	NE				
eGFR High and UP Low	Sparsentan	39	4 (10.3)	NE		0.755	(0.200, 2.843)	0.678
	Irbesartan	37	6 (16.2)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KBUDT_FSTM: KDQOL: Time to decrease in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.886
< 60 mL/min/1.73 m**2	Sparsentan	127	18 (14.2)	112.1	(95.0, 112.1)	0.668	(0.353, 1.263)	0.214
	Irbesartan	129	24 (18.6)	95.3	(94.1, NE)			
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	6 (12.2)	NE		0.587	(0.181, 1.906)	0.375
	Irbesartan	48	7 (14.6)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	1 (3.8)	NE		0.362	(0.020, 6.400)	0.488
	Irbesartan	25	2 (8.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KBUDT_FSTM: KDQOL: Time to decrease in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 2	Sparsentan						Interaction test:	0.929
< 45 mL/min/1.73 m**2	Sparsentan	82	9 (11.0)	NE		0.554	(0.238, 1.289)	0.170
	Irbesartan	80	15 (18.8)	95.1	(93.0, NE)			
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	9 (20.0)	112.1	(93.0, 112.1)	0.747	(0.274, 2.036)	0.569
	Irbesartan	49	9 (18.4)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	6 (12.2)	NE		0.587	(0.181, 1.906)	0.375
	Irbesartan	48	7 (14.6)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	1 (3.8)	NE		0.362	(0.020, 6.400)	0.488
	Irbesartan	25	2 (8.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KBUDT_FSTM: KDQOL: Time to decrease in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline urine protein excretion	Sparsentan						Interaction test:	0.722
<= 1.75 g/day	Sparsentan	98	12 (12.2)	112.1	(95.0, 112.1)	0.552	(0.238, 1.279)	0.166
	Irbesartan	94	13 (13.8)	NE				
> 1.75 g/day	Sparsentan	104	13 (12.5)	NE		0.702	(0.335, 1.471)	0.348
	Irbesartan	108	20 (18.5)	95.1	(94.1, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KBUDT_FSTM: KDQOL: Time to decrease in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.422
Yes	Sparsentan	88	8 (9.1)	NE		0.493	(0.203, 1.197)	0.118
	Irbesartan	83	14 (16.9)	96.1	(94.1, NE)			
No	Sparsentan	114	17 (14.9)	112.1	(112.1, NE)	0.782	(0.398, 1.535)	0.475
	Irbesartan	119	19 (16.0)	95.3	(70.1, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KBUDT_FSTM: KDQOL: Time to decrease in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Time since renal biopsy	Sparsentan						Interaction test:	0.333
<= 5 years	Sparsentan	113	11 (9.7)	112.1	(112.1, NE)	0.501	(0.237, 1.060)	0.071
	Irbesartan	127	21 (16.5)	96.1	(95.1, NE)			
> 5 years	Sparsentan	89	14 (15.7)	NE		0.795	(0.358, 1.765)	0.572
	Irbesartan	75	12 (16.0)	94.6	(70.9, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KBUDT_FSTM: KDQOL: Time to decrease in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
History of hypertension	Sparsentan						Interaction test:	0.141	
Yes	Sparsentan	153	17 (11.1)	112.1	(112.1, NE)	0.523	(0.278, 0.985)	0.045	*
	Irbesartan	157	25 (15.9)	96.1	(94.1, NE)				
No	Sparsentan	49	8 (16.3)	NE		0.939	(0.309, 2.855)	0.911	
	Irbesartan	45	8 (17.8)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Figure PF1KBUDT_FSKM: KDQOL: Time to decrease in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

Not done. No significant subgroups.

_____
A decrease reflects a worsening of the status of the patient.
Reference table: PT1KBUDT_FSTM

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	KDQOL: effect of kidney disease	Baseline	Sparsentan	139	130 (93.5)	89.93 (10.99)	28.1	84.38	93.75	96.88	100.0	
			Irbesartan	143	128 (89.5)	89.62 (13.07)	37.5	85.94	93.75	100.00	100.0	
		Week 24	Sparsentan	139	87 (62.6)	89.30 (14.85)	9.4	84.38	93.75	100.00	100.0	
			Irbesartan	143	73 (51.0)	88.78 (15.46)	28.1	84.38	96.88	100.00	100.0	
		Week 48	Sparsentan	139	72 (51.8)	89.80 (14.69)	0.0	87.50	93.75	100.00	100.0	
			Irbesartan	143	55 (38.5)	94.77 (8.92)	50.0	93.75	96.88	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	139	87 (62.6)	-0.61 (13.39)	-75.0	-3.13	0.00	6.25	21.9	0.11 [-0.20, 0.42]
			Irbesartan	143	73 (51.0)	-1.97 (11.95)	-53.1	-3.13	0.00	3.13	31.3	
		Week 48	Sparsentan	139	72 (51.8)	-0.39 (14.80)	-100.0	-3.13	0.00	6.25	15.6	-0.23 [-0.58, 0.12]
			Irbesartan	143	55 (38.5)	2.44 (8.04)	-21.9	0.00	0.00	6.25	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Female	KDQOL: effect of kidney disease	Baseline	Sparsentan	63	56 (88.9)	84.21 (18.01)	28.1	73.44	90.63	98.44	100.0	
			Irbesartan	59	51 (86.4)	87.01 (12.88)	46.9	78.13	90.63	100.00	100.0	
		Week 24	Sparsentan	63	38 (60.3)	90.54 (9.51)	59.4	87.50	93.75	96.88	100.0	
			Irbesartan	59	31 (52.5)	88.41 (20.29)	0.0	87.50	93.75	100.00	100.0	
		Week 48	Sparsentan	63	38 (60.3)	91.04 (9.56)	62.5	87.50	93.75	96.88	100.0	
			Irbesartan	59	22 (37.3)	87.78 (13.46)	40.6	81.25	89.06	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	63	38 (60.3)	6.58 (13.84)	-15.6	-3.13	4.69	15.63	34.4	0.47 [-0.01, 0.95]
			Irbesartan	59	31 (52.5)	-1.31 (20.09)	-100.0	-3.13	0.00	9.38	18.8	
		Week 48	Sparsentan	63	38 (60.3)	6.74 (16.70)	-37.5	-3.13	3.13	9.38	56.3	0.55 [0.01, 1.08]
			Irbesartan	59	22 (37.3)	-1.42 (11.28)	-25.0	-9.38	0.00	3.13	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
<= 45 years	KDQOL: effect of kidney disease	Baseline	Sparsentan	96	87 (90.6)	86.03 (16.11)	28.1	84.38	90.63	96.88	100.0	
			Irbesartan	99	92 (92.9)	86.58 (14.49)	37.5	79.69	90.63	96.88	100.0	
		Week 24	Sparsentan	96	57 (59.4)	87.50 (16.17)	9.4	84.38	93.75	100.00	100.0	
			Irbesartan	99	53 (53.5)	85.79 (20.16)	0.0	81.25	93.75	96.88	100.0	
		Week 48	Sparsentan	96	53 (55.2)	88.38 (17.00)	0.0	87.50	93.75	100.00	100.0	
			Irbesartan	99	40 (40.4)	91.33 (13.23)	40.6	89.06	96.88	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	96	57 (59.4)	0.55 (16.88)	-75.0	-6.25	3.13	6.25	34.4	0.17 [-0.20, 0.55]
			Irbesartan	99	53 (53.5)	-2.36 (17.10)	-100.0	-3.13	0.00	3.13	31.3	
		Week 48	Sparsentan	96	53 (55.2)	2.42 (21.00)	-100.0	0.00	3.13	6.25	56.3	0.06 [-0.35, 0.47]
			Irbesartan	99	40 (40.4)	1.33 (9.47)	-21.9	-3.13	0.00	4.69	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 45 years	KDQOL: effect of kidney disease	Baseline	Sparsentan	106	99 (93.4)	90.12 (10.89)	50.0	84.38	93.75	100.00	100.0	
			Irbesartan	103	87 (84.5)	91.31 (10.85)	46.9	87.50	93.75	100.00	100.0	
		Week 24	Sparsentan	106	68 (64.2)	91.50 (10.37)	50.0	87.50	93.75	100.00	100.0	
			Irbesartan	103	51 (49.5)	91.67 (12.26)	34.4	87.50	96.88	100.00	100.0	
		Week 48	Sparsentan	106	57 (53.8)	91.94 (7.77)	75.0	87.50	93.75	100.00	100.0	
			Irbesartan	103	37 (35.9)	94.34 (7.21)	75.0	90.63	96.88	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	106	68 (64.2)	2.44 (10.80)	-37.5	-3.13	0.00	6.25	31.3	0.32 [-0.05, 0.68]
			Irbesartan	103	51 (49.5)	-1.16 (11.96)	-53.1	-3.13	0.00	6.25	18.8	
		Week 48	Sparsentan	106	57 (53.8)	1.75 (8.66)	-21.9	-3.13	0.00	6.25	31.3	0.05 [-0.37, 0.46]
			Irbesartan	103	37 (35.9)	1.35 (8.98)	-25.0	0.00	0.00	3.13	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age at IgAN diagnosis												
<= 18 years	KDQOL: effect of kidney disease	Baseline	Sparsentan	9	9 (100.0)	76.74 (22.54)	28.1	71.88	84.38	90.63	96.9	
			Irbesartan	5	5 (100.0)	86.88 (23.01)	46.9	87.50	100.00	100.00	100.0	
		Week 24	Sparsentan	9	3 (33.3)	65.63 (49.11)	9.4	9.38	87.50	100.00	100.0	
			Irbesartan	5	2 (40.0)	79.69 (24.31)	62.5	62.50	79.69	96.88	96.9	
		Week 48	Sparsentan	9	5 (55.6)	89.38 (8.73)	75.0	87.50	93.75	93.75	96.9	
			Irbesartan	5	1 (20.0)	96.88	96.9	96.88	96.88	96.88	96.9	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	9	3 (33.3)	-17.71 (49.84)	-75.0	-75.00	6.25	15.63	15.6	-0.58 [-2.40, 1.25]
			Irbesartan	5	2 (40.0)	6.25 (13.26)	-3.1	-3.13	6.25	15.63	15.6	
		Week 48	Sparsentan	9	5 (55.6)	13.13 (19.94)	0.0	0.00	3.13	15.63	46.9	NE
			Irbesartan	5	1 (20.0)	-3.13	-3.1	-3.13	-3.13	-3.13	-3.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 18 to 40 years	KDQOL: effect of kidney disease	Baseline	Sparsentan	102	93 (91.2)	89.01 (12.76)	34.4	87.50	93.75	96.88	100.0	
			Irbesartan	109	99 (90.8)	87.31 (13.87)	37.5	84.38	90.63	96.88	100.0	
		Week 24	Sparsentan	102	62 (60.8)	89.67 (12.04)	56.3	84.38	93.75	100.00	100.0	
			Irbesartan	109	59 (54.1)	87.18 (19.70)	0.0	84.38	93.75	100.00	100.0	
		Week 48	Sparsentan	102	57 (55.9)	89.25 (16.58)	0.0	87.50	93.75	100.00	100.0	
			Irbesartan	109	44 (40.4)	91.76 (12.75)	40.6	90.63	96.88	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	102	62 (60.8)	1.41 (12.99)	-37.5	-6.25	0.00	6.25	34.4	0.24 [-0.11, 0.60]
			Irbesartan	109	59 (54.1)	-2.22 (16.80)	-100.0	-3.13	0.00	3.13	31.3	
		Week 48	Sparsentan	102	57 (55.9)	0.99 (19.47)	-100.0	-3.13	3.13	6.25	56.3	-0.07 [-0.46, 0.33]
			Irbesartan	109	44 (40.4)	2.06 (9.51)	-21.9	0.00	0.00	6.25	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 40 years	KDQOL: effect of kidney disease	Baseline	Sparsentan	91	84 (92.3)	88.54 (13.18)	28.1	84.38	93.75	96.88	100.0	
			Irbesartan	88	75 (85.2)	91.08 (10.81)	46.9	84.38	93.75	100.00	100.0	
		Week 24	Sparsentan	91	60 (65.9)	90.89 (10.78)	50.0	87.50	93.75	100.00	100.0	
			Irbesartan	88	43 (48.9)	91.13 (11.85)	34.4	84.38	93.75	100.00	100.0	
		Week 48	Sparsentan	91	48 (52.7)	91.47 (7.89)	75.0	87.50	93.75	100.00	100.0	
			Irbesartan	88	32 (36.4)	94.04 (7.55)	75.0	89.06	96.88	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	91	60 (65.9)	2.71 (11.22)	-37.5	-3.13	3.13	6.25	31.3	0.37 [-0.02, 0.77]
			Irbesartan	88	43 (48.9)	-1.53 (11.66)	-53.1	-6.25	0.00	6.25	18.8	
		Week 48	Sparsentan	91	48 (52.7)	2.21 (8.79)	-21.9	-1.56	1.56	6.25	31.3	0.20 [-0.25, 0.64]
			Irbesartan	88	32 (36.4)	0.49 (8.88)	-25.0	0.00	0.00	3.13	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Geographic region												
North America	KDQOL: effect of kidney disease	Baseline	Sparsentan	35	32 (91.4)	86.52 (18.37)	28.1	84.38	93.75	96.88	100.0	
			Irbesartan	46	43 (93.5)	91.28 (10.84)	46.9	87.50	96.88	100.00	100.0	
		Week 24	Sparsentan	35	15 (42.9)	87.92 (22.53)	9.4	87.50	93.75	96.88	100.0	
			Irbesartan	46	26 (56.5)	87.86 (20.08)	0.0	84.38	93.75	100.00	100.0	
		Week 48	Sparsentan	35	13 (37.1)	92.55 (7.39)	75.0	90.63	93.75	100.00	100.0	
			Irbesartan	46	17 (37.0)	92.65 (12.45)	50.0	87.50	96.88	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	35	15 (42.9)	-3.75 (21.33)	-75.0	-6.25	0.00	6.25	18.8	-0.01 [-0.65, 0.62]
			Irbesartan	46	26 (56.5)	-3.49 (21.46)	-100.0	-3.13	0.00	6.25	15.6	
		Week 48	Sparsentan	35	13 (37.1)	6.01 (13.41)	-6.3	0.00	3.13	6.25	46.9	0.35 [-0.38, 1.08]
			Irbesartan	46	17 (37.0)	2.02 (9.44)	-21.9	0.00	0.00	3.13	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Europe	KDQOL: effect of kidney disease	Baseline	Sparsentan	98	87 (88.8)	90.16 (11.32)	43.8	84.38	93.75	96.88	100.0	
			Irbesartan	115	96 (83.5)	86.95 (13.93)	43.8	78.13	90.63	96.88	100.0	
		Week 24	Sparsentan	98	53 (54.1)	91.39 (9.80)	56.3	87.50	93.75	100.00	100.0	
			Irbesartan	115	47 (40.9)	88.50 (15.57)	34.4	84.38	93.75	100.00	100.0	
		Week 48	Sparsentan	98	44 (44.9)	92.54 (8.95)	56.3	87.50	93.75	100.00	100.0	
			Irbesartan	115	38 (33.0)	94.16 (8.13)	65.6	90.63	96.88	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	98	53 (54.1)	1.89 (11.57)	-25.0	-3.13	0.00	6.25	31.3	0.26 [-0.14, 0.65]
			Irbesartan	115	47 (40.9)	-1.40 (14.09)	-53.1	-3.13	0.00	6.25	31.3	
		Week 48	Sparsentan	98	44 (44.9)	2.77 (13.36)	-40.6	-3.13	1.56	6.25	56.3	0.06 [-0.37, 0.50]
			Irbesartan	115	38 (33.0)	2.06 (8.67)	-15.6	0.00	0.00	6.25	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asia Pacific	KDQOL: effect of kidney disease	Baseline	Sparsentan	69	67 (97.1)	86.47 (13.82)	34.4	81.25	90.63	96.88	100.0	
			Irbesartan	41	40 (97.6)	90.94 (12.50)	37.5	87.50	93.75	100.00	100.0	
		Week 24	Sparsentan	69	57 (82.6)	88.54 (13.34)	50.0	84.38	93.75	100.00	100.0	
			Irbesartan	41	31 (75.6)	89.62 (16.60)	28.1	84.38	96.88	100.00	100.0	
		Week 48	Sparsentan	69	53 (76.8)	87.74 (16.42)	0.0	81.25	93.75	96.88	100.0	
			Irbesartan	41	22 (53.7)	90.48 (13.38)	40.6	84.38	93.75	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	69	57 (82.6)	2.69 (13.39)	-37.5	-3.13	3.13	9.38	34.4	0.31 [-0.13, 0.75]
			Irbesartan	41	31 (75.6)	-0.91 (7.40)	-15.6	-6.25	0.00	3.13	12.5	
		Week 48	Sparsentan	69	53 (76.8)	0.53 (18.05)	-100.0	-3.13	3.13	6.25	34.4	0.06 [-0.44, 0.56]
			Irbesartan	41	22 (53.7)	-0.43 (9.99)	-25.0	-3.13	0.00	3.13	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline BMI												
< 27 kg/m**2	KDQOL: effect of kidney disease	Baseline	Sparsentan	84	76 (90.5)	85.94 (13.34)	28.1	78.13	90.63	96.88	100.0	
			Irbesartan	94	84 (89.4)	88.50 (11.42)	46.9	84.38	90.63	100.00	100.0	
		Week 24	Sparsentan	84	52 (61.9)	88.46 (16.32)	9.4	87.50	93.75	98.44	100.0	
			Irbesartan	94	50 (53.2)	86.50 (18.71)	0.0	84.38	93.75	96.88	100.0	
		Week 48	Sparsentan	84	47 (56.0)	88.63 (11.26)	50.0	84.38	90.63	96.88	100.0	
			Irbesartan	94	36 (38.3)	89.93 (13.53)	40.6	84.38	93.75	98.44	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	84	52 (61.9)	1.98 (16.36)	-75.0	-4.69	1.56	9.38	34.4	0.16 [-0.23, 0.55]
			Irbesartan	94	50 (53.2)	-0.75 (17.55)	-100.0	-3.13	0.00	6.25	31.3	
		Week 48	Sparsentan	84	47 (56.0)	3.26 (12.97)	-40.6	-3.13	3.13	6.25	46.9	0.12 [-0.31, 0.56]
			Irbesartan	94	36 (38.3)	1.82 (9.22)	-21.9	0.00	0.00	6.25	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 27 kg/m**2	KDQOL: effect of kidney disease	Baseline	Sparsentan	118	110 (93.2)	89.77 (13.78)	28.1	87.50	93.75	100.00	100.0	
			Irbesartan	107	94 (87.9)	89.39 (14.33)	37.5	87.50	96.88	100.00	100.0	
		Week 24	Sparsentan	118	73 (61.9)	90.54 (10.95)	56.3	84.38	93.75	100.00	100.0	
			Irbesartan	107	54 (50.5)	90.68 (15.01)	28.1	87.50	96.88	100.00	100.0	
		Week 48	Sparsentan	118	63 (53.4)	91.42 (14.32)	0.0	90.63	93.75	100.00	100.0	
			Irbesartan	107	41 (38.3)	95.27 (6.92)	75.0	93.75	100.00	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	118	73 (61.9)	1.28 (11.91)	-37.5	-3.13	0.00	6.25	31.3	0.34 [-0.02, 0.69]
			Irbesartan	107	54 (50.5)	-2.72 (11.66)	-53.1	-3.13	0.00	3.13	15.6	
		Week 48	Sparsentan	118	63 (53.4)	1.19 (17.64)	-100.0	-3.13	3.13	6.25	56.3	0.02 [-0.37, 0.41]
			Irbesartan	107	41 (38.3)	0.91 (9.22)	-25.0	-3.13	0.00	3.13	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Randomization strata												
eGFR Low and UP High	KDQOL: effect of kidney disease	Baseline	Sparsentan	71	63 (88.7)	87.85 (13.81)	28.1	84.38	93.75	96.88	100.0	
			Irbesartan	74	63 (85.1)	85.66 (15.38)	43.8	81.25	90.63	96.88	100.0	
		Week 24	Sparsentan	71	44 (62.0)	89.42 (12.02)	56.3	84.38	93.75	98.44	100.0	
			Irbesartan	74	32 (43.2)	84.28 (15.84)	40.6	78.13	87.50	96.88	100.0	
		Week 48	Sparsentan	71	37 (52.1)	90.63 (10.72)	50.0	87.50	93.75	100.00	100.0	
			Irbesartan	74	22 (29.7)	90.34 (14.17)	40.6	84.38	95.31	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	71	44 (62.0)	0.36 (8.48)	-25.0	-3.13	3.13	6.25	12.5	0.47 [0.01, 0.93]
			Irbesartan	74	32 (43.2)	-3.91 (9.95)	-25.0	-12.50	-1.56	3.13	15.6	
		Week 48	Sparsentan	71	37 (52.1)	0.76 (6.35)	-15.6	-3.13	0.00	6.25	12.5	0.22 [-0.31, 0.75]
			Irbesartan	74	22 (29.7)	-0.71 (7.34)	-15.6	-6.25	0.00	3.13	15.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR Low and UP Low	KDQOL: effect of kidney disease	Baseline	Sparsentan	55	51 (92.7)	86.89 (13.13)	43.8	78.13	90.63	96.88	100.0	
			Irbesartan	55	49 (89.1)	91.39 (8.85)	71.9	87.50	93.75	100.00	100.0	
		Week 24	Sparsentan	55	38 (69.1)	89.23 (12.70)	50.0	81.25	93.75	100.00	100.0	
			Irbesartan	55	33 (60.0)	94.98 (9.76)	50.0	93.75	100.00	100.00	100.0	
		Week 48	Sparsentan	55	28 (50.9)	89.29 (19.18)	0.0	87.50	93.75	100.00	100.0	
			Irbesartan	55	25 (45.5)	93.50 (7.54)	75.0	87.50	96.88	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	55	38 (69.1)	3.45 (13.07)	-37.5	-3.13	1.56	9.38	31.3	0.13 [-0.33, 0.60]
			Irbesartan	55	33 (60.0)	1.89 (9.76)	-37.5	0.00	0.00	6.25	18.8	
		Week 48	Sparsentan	55	28 (50.9)	2.34 (24.02)	-100.0	0.00	3.13	7.81	56.3	0.07 [-0.47, 0.61]
			Irbesartan	55	25 (45.5)	1.00 (9.79)	-25.0	0.00	0.00	3.13	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP High	KDQOL: effect of kidney disease	Baseline	Sparsentan	37	35 (94.6)	89.73 (14.15)	28.1	84.38	93.75	100.00	100.0	
			Irbesartan	36	31 (86.1)	88.31 (11.86)	56.3	84.38	90.63	96.88	100.0	
		Week 24	Sparsentan	37	19 (51.4)	89.47 (20.36)	9.4	87.50	93.75	100.00	100.0	
			Irbesartan	36	18 (50.0)	88.02 (15.02)	34.4	84.38	92.19	96.88	100.0	
		Week 48	Sparsentan	37	22 (59.5)	89.20 (11.88)	56.3	87.50	92.19	96.88	100.0	
			Irbesartan	36	11 (30.6)	93.75 (6.56)	81.3	90.63	93.75	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	37	19 (51.4)	-0.66 (21.34)	-75.0	-6.25	3.13	9.38	34.4	0.04 [-0.61, 0.68]
			Irbesartan	36	18 (50.0)	-1.39 (17.22)	-53.1	-3.13	0.00	9.38	31.3	
		Week 48	Sparsentan	37	22 (59.5)	1.14 (18.51)	-40.6	-3.13	0.00	6.25	46.9	-0.33 [-1.05, 0.40]
			Irbesartan	36	11 (30.6)	6.53 (11.22)	-6.3	-3.13	3.13	15.63	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP Low	KDQOL: effect of kidney disease	Baseline	Sparsentan	39	37 (94.9)	89.19 (14.20)	34.4	87.50	93.75	100.00	100.0	
			Irbesartan	37	36 (97.3)	91.58 (13.48)	37.5	90.63	96.88	100.00	100.0	
		Week 24	Sparsentan	39	24 (61.5)	91.02 (10.72)	59.4	89.06	93.75	100.00	100.0	
			Irbesartan	37	21 (56.8)	86.01 (25.30)	0.0	87.50	96.88	100.00	100.0	
		Week 48	Sparsentan	39	23 (59.0)	91.71 (8.56)	65.6	90.63	93.75	96.88	100.0	
			Irbesartan	37	19 (51.4)	94.08 (12.19)	50.0	90.63	100.00	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	39	24 (61.5)	2.60 (16.08)	-37.5	-4.69	0.00	14.06	31.3	0.37 [-0.22, 0.96]
			Irbesartan	37	21 (56.8)	-4.61 (22.89)	-100.0	-3.13	0.00	3.13	12.5	
		Week 48	Sparsentan	39	23 (59.0)	4.76 (10.98)	-21.9	-3.13	3.13	9.38	31.3	0.36 [-0.25, 0.97]
			Irbesartan	37	19 (51.4)	1.15 (8.54)	-21.9	0.00	3.13	6.25	15.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 1												
< 60 mL/min/1.73 m**2	KDQOL: effect of kidney disease	Baseline	Sparsentan	127	115 (90.6)	87.55 (13.46)	28.1	84.38	93.75	96.88	100.0	
			Irbesartan	129	113 (87.6)	89.13 (12.29)	43.8	84.38	93.75	100.00	100.0	
		Week 24	Sparsentan	127	83 (65.4)	88.82 (12.65)	50.0	81.25	93.75	100.00	100.0	
			Irbesartan	129	68 (52.7)	90.17 (13.79)	40.6	84.38	96.88	100.00	100.0	
		Week 48	Sparsentan	127	65 (51.2)	90.19 (14.89)	0.0	87.50	93.75	100.00	100.0	
			Irbesartan	129	49 (38.0)	92.22 (11.03)	40.6	87.50	96.88	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	127	83 (65.4)	1.20 (11.70)	-37.5	-3.13	0.00	6.25	31.3	0.16 [-0.16, 0.48]
			Irbesartan	129	68 (52.7)	-0.55 (10.01)	-37.5	-3.13	0.00	6.25	18.8	
		Week 48	Sparsentan	127	65 (51.2)	1.54 (16.32)	-100.0	0.00	3.13	6.25	56.3	0.07 [-0.30, 0.44]
			Irbesartan	129	49 (38.0)	0.57 (8.65)	-25.0	0.00	0.00	3.13	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	KDQOL: effect of kidney disease	Baseline	Sparsentan	49	47 (95.9)	90.69 (12.66)	34.4	87.50	93.75	100.00	100.0	
			Irbesartan	48	43 (89.6)	87.79 (13.89)	46.9	78.13	90.63	100.00	100.0	
		Week 24	Sparsentan	49	27 (55.1)	88.66 (17.79)	9.4	87.50	93.75	96.88	100.0	
			Irbesartan	48	24 (50.0)	89.06 (13.85)	34.4	85.94	92.19	96.88	100.0	
		Week 48	Sparsentan	49	29 (59.2)	90.63 (9.81)	62.5	87.50	93.75	96.88	100.0	
			Irbesartan	48	19 (39.6)	92.76 (11.74)	50.0	90.63	96.88	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	49	27 (55.1)	-0.81 (19.47)	-75.0	-6.25	0.00	9.38	31.3	-0.01 [-0.56, 0.54]
			Irbesartan	48	24 (50.0)	-0.65 (14.69)	-53.1	-3.13	0.00	6.25	31.3	
		Week 48	Sparsentan	49	29 (59.2)	1.62 (11.92)	-37.5	0.00	3.13	6.25	31.3	-0.14 [-0.72, 0.44]
			Irbesartan	48	19 (39.6)	3.29 (11.29)	-21.9	-3.13	0.00	9.38	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	KDQOL: effect of kidney disease	Baseline	Sparsentan	26	24 (92.3)	86.46 (16.50)	28.1	84.38	90.63	98.44	100.0	
			Irbesartan	25	23 (92.0)	89.67 (15.29)	37.5	84.38	96.88	100.00	100.0	
		Week 24	Sparsentan	26	15 (57.7)	96.25 (4.29)	87.5	93.75	96.88	100.00	100.0	
			Irbesartan	25	12 (48.0)	79.43 (31.94)	0.0	79.69	93.75	96.88	100.0	
		Week 48	Sparsentan	26	16 (61.5)	89.65 (11.11)	56.3	87.50	93.75	96.88	100.0	
			Irbesartan	25	9 (36.0)	95.83 (7.49)	78.1	93.75	100.00	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	26	15 (57.7)	7.92 (12.04)	-12.5	0.00	6.25	12.50	34.4	0.87 [0.08, 1.67]
			Irbesartan	25	12 (48.0)	-10.94 (29.51)	-100.0	-12.50	-1.56	3.13	12.5	
		Week 48	Sparsentan	26	16 (61.5)	5.08 (19.89)	-40.6	-4.69	0.00	14.06	46.9	0.22 [-0.60, 1.04]
			Irbesartan	25	9 (36.0)	1.39 (7.18)	-12.5	0.00	0.00	3.13	15.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 2												
< 45 mL/min/1.73 m**2	KDQOL: effect of kidney disease	Baseline	Sparsentan	82	71 (86.6)	85.96 (13.24)	43.8	78.13	90.63	93.75	100.0	
			Irbesartan	80	69 (86.3)	87.14 (13.91)	43.8	81.25	90.63	96.88	100.0	
		Week 24	Sparsentan	82	53 (64.6)	89.21 (12.20)	50.0	84.38	93.75	100.00	100.0	
			Irbesartan	80	45 (56.3)	88.06 (15.80)	40.6	84.38	96.88	100.00	100.0	
		Week 48	Sparsentan	82	42 (51.2)	88.62 (17.11)	0.0	87.50	92.19	100.00	100.0	
			Irbesartan	80	29 (36.3)	90.63 (13.23)	40.6	84.38	96.88	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	82	53 (64.6)	2.42 (10.59)	-37.5	-3.13	3.13	6.25	28.1	0.31 [-0.09, 0.71]
			Irbesartan	80	45 (56.3)	-0.97 (11.28)	-37.5	-3.13	0.00	6.25	18.8	
		Week 48	Sparsentan	82	42 (51.2)	0.97 (19.54)	-100.0	-3.13	3.13	6.25	56.3	0.11 [-0.36, 0.59]
			Irbesartan	80	29 (36.3)	-0.86 (8.26)	-25.0	-3.13	0.00	3.13	18.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
45 to < 60 mL/min/1.73 m**2	KDQOL: effect of kidney disease	Baseline	Sparsentan	45	44 (97.8)	90.13 (13.58)	28.1	87.50	93.75	100.00	100.0	
			Irbesartan	49	44 (89.8)	92.26 (8.43)	71.9	87.50	95.31	100.00	100.0	
		Week 24	Sparsentan	45	30 (66.7)	88.13 (13.59)	56.3	81.25	93.75	96.88	100.0	
			Irbesartan	49	23 (46.9)	94.29 (7.28)	78.1	90.63	96.88	100.00	100.0	
		Week 48	Sparsentan	45	23 (51.1)	93.07 (9.28)	68.8	87.50	96.88	100.00	100.0	
			Irbesartan	49	20 (40.8)	94.53 (6.32)	81.3	89.06	96.88	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	45	30 (66.7)	-0.94 (13.36)	-37.5	-6.25	0.00	6.25	31.3	-0.11 [-0.65, 0.43]
			Irbesartan	49	23 (46.9)	0.27 (7.05)	-18.8	0.00	0.00	3.13	12.5	
		Week 48	Sparsentan	45	23 (51.1)	2.58 (7.86)	-9.4	0.00	0.00	6.25	31.3	-0.01 [-0.61, 0.59]
			Irbesartan	49	20 (40.8)	2.66 (8.97)	-15.6	0.00	3.13	6.25	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	KDQOL: effect of kidney disease	Baseline	Sparsentan	49	47 (95.9)	90.69 (12.66)	34.4	87.50	93.75	100.00	100.0	
			Irbesartan	48	43 (89.6)	87.79 (13.89)	46.9	78.13	90.63	100.00	100.0	
		Week 24	Sparsentan	49	27 (55.1)	88.66 (17.79)	9.4	87.50	93.75	96.88	100.0	
			Irbesartan	48	24 (50.0)	89.06 (13.85)	34.4	85.94	92.19	96.88	100.0	
		Week 48	Sparsentan	49	29 (59.2)	90.63 (9.81)	62.5	87.50	93.75	96.88	100.0	
			Irbesartan	48	19 (39.6)	92.76 (11.74)	50.0	90.63	96.88	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	49	27 (55.1)	-0.81 (19.47)	-75.0	-6.25	0.00	9.38	31.3	-0.01 [-0.56, 0.54]
			Irbesartan	48	24 (50.0)	-0.65 (14.69)	-53.1	-3.13	0.00	6.25	31.3	
		Week 48	Sparsentan	49	29 (59.2)	1.62 (11.92)	-37.5	0.00	3.13	6.25	31.3	-0.14 [-0.72, 0.44]
			Irbesartan	48	19 (39.6)	3.29 (11.29)	-21.9	-3.13	0.00	9.38	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	KDQOL: effect of kidney disease	Baseline	Sparsentan	26	24 (92.3)	86.46 (16.50)	28.1	84.38	90.63	98.44	100.0	
			Irbesartan	25	23 (92.0)	89.67 (15.29)	37.5	84.38	96.88	100.00	100.0	
		Week 24	Sparsentan	26	15 (57.7)	96.25 (4.29)	87.5	93.75	96.88	100.00	100.0	
			Irbesartan	25	12 (48.0)	79.43 (31.94)	0.0	79.69	93.75	96.88	100.0	
		Week 48	Sparsentan	26	16 (61.5)	89.65 (11.11)	56.3	87.50	93.75	96.88	100.0	
			Irbesartan	25	9 (36.0)	95.83 (7.49)	78.1	93.75	100.00	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	26	15 (57.7)	7.92 (12.04)	-12.5	0.00	6.25	12.50	34.4	0.87 [0.08, 1.67]
			Irbesartan	25	12 (48.0)	-10.94 (29.51)	-100.0	-12.50	-1.56	3.13	12.5	
		Week 48	Sparsentan	26	16 (61.5)	5.08 (19.89)	-40.6	-4.69	0.00	14.06	46.9	0.22 [-0.60, 1.04]
			Irbesartan	25	9 (36.0)	1.39 (7.18)	-12.5	0.00	0.00	3.13	15.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline urine protein excretion												
<= 1.75 g/day	KDQOL: effect of kidney disease	Baseline	Sparsentan	98	92 (93.9)	87.70 (13.75)	34.4	84.38	90.63	96.88	100.0	
			Irbesartan	94	82 (87.2)	89.90 (13.14)	37.5	84.38	95.31	100.00	100.0	
		Week 24	Sparsentan	98	66 (67.3)	88.64 (12.50)	50.0	84.38	93.75	96.88	100.0	
			Irbesartan	94	43 (45.7)	90.41 (19.64)	0.0	90.63	96.88	100.00	100.0	
		Week 48	Sparsentan	98	59 (60.2)	90.25 (15.08)	0.0	87.50	93.75	100.00	100.0	
			Irbesartan	94	34 (36.2)	94.21 (10.18)	50.0	90.63	98.44	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	98	66 (67.3)	2.18 (13.89)	-37.5	-6.25	0.00	9.38	31.3	0.24 [-0.15, 0.62]
			Irbesartan	94	43 (45.7)	-1.53 (17.92)	-100.0	0.00	3.13	6.25	18.8	
		Week 48	Sparsentan	98	59 (60.2)	2.38 (18.45)	-100.0	0.00	3.13	9.38	56.3	0.11 [-0.31, 0.53]
			Irbesartan	94	34 (36.2)	0.64 (9.32)	-25.0	0.00	0.00	3.13	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 1.75 g/day	KDQOL: effect of kidney disease	Baseline	Sparsentan	104	94 (90.4)	88.70 (13.70)	28.1	84.38	93.75	96.88	100.0	
			Irbesartan	108	97 (89.8)	88.02 (12.95)	46.9	84.38	90.63	96.88	100.0	
		Week 24	Sparsentan	104	59 (56.7)	90.84 (14.41)	9.4	87.50	96.88	100.00	100.0	
			Irbesartan	108	61 (56.5)	87.45 (14.80)	34.4	81.25	93.75	96.88	100.0	
		Week 48	Sparsentan	104	51 (49.0)	90.20 (10.55)	50.0	87.50	93.75	100.00	100.0	
			Irbesartan	108	43 (39.8)	91.64 (11.26)	40.6	87.50	93.75	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	104	59 (56.7)	0.90 (13.95)	-75.0	-3.13	3.13	6.25	34.4	0.22 [-0.14, 0.58]
			Irbesartan	108	61 (56.5)	-1.95 (12.19)	-53.1	-3.13	0.00	3.13	31.3	
		Week 48	Sparsentan	104	51 (49.0)	1.72 (12.16)	-40.6	-3.13	0.00	6.25	46.9	-0.02 [-0.42, 0.39]
			Irbesartan	108	43 (39.8)	1.89 (9.13)	-15.6	-3.13	0.00	6.25	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline use of antihypertensives												
Yes	KDQOL: effect of kidney disease	Baseline	Sparsentan	88	77 (87.5)	89.16 (12.93)	28.1	84.38	93.75	96.88	100.0	
			Irbesartan	83	70 (84.3)	88.97 (12.06)	43.8	81.25	93.75	100.00	100.0	
		Week 24	Sparsentan	88	50 (56.8)	92.38 (10.64)	50.0	90.63	96.88	100.00	100.0	
			Irbesartan	83	39 (47.0)	89.74 (14.32)	50.0	81.25	96.88	100.00	100.0	
		Week 48	Sparsentan	88	41 (46.6)	92.00 (6.85)	78.1	87.50	90.63	100.00	100.0	
			Irbesartan	83	28 (33.7)	94.98 (7.95)	65.6	93.75	96.88	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	88	50 (56.8)	2.56 (10.62)	-37.5	-3.13	3.13	6.25	31.3	0.37 [-0.05, 0.79]
			Irbesartan	83	39 (47.0)	-1.44 (10.92)	-37.5	-3.13	0.00	6.25	18.8	
		Week 48	Sparsentan	88	41 (46.6)	1.75 (8.67)	-21.9	-3.13	0.00	6.25	31.3	-0.06 [-0.54, 0.42]
			Irbesartan	83	28 (33.7)	2.23 (8.02)	-9.4	0.00	0.00	4.69	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	KDQOL: effect of kidney disease	Baseline	Sparsentan	114	109 (95.6)	87.53 (14.24)	28.1	84.38	90.63	96.88	100.0	
			Irbesartan	119	109 (91.6)	88.82 (13.68)	37.5	84.38	93.75	100.00	100.0	
		Week 24	Sparsentan	114	75 (65.8)	87.88 (14.79)	9.4	81.25	93.75	96.88	100.0	
			Irbesartan	119	65 (54.6)	88.03 (18.41)	0.0	84.38	93.75	96.88	100.0	
		Week 48	Sparsentan	114	69 (60.5)	89.18 (15.66)	0.0	87.50	93.75	100.00	100.0	
			Irbesartan	119	49 (41.2)	91.52 (12.04)	40.6	87.50	96.88	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	114	75 (65.8)	0.92 (15.72)	-75.0	-6.25	0.00	9.38	34.4	0.18 [-0.15, 0.51]
			Irbesartan	119	65 (54.6)	-1.97 (16.71)	-100.0	-3.13	0.00	3.13	31.3	
		Week 48	Sparsentan	114	69 (60.5)	2.26 (18.83)	-100.0	0.00	3.13	6.25	56.3	0.09 [-0.28, 0.46]
			Irbesartan	119	49 (41.2)	0.83 (9.82)	-25.0	-3.13	0.00	3.13	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Time since renal biopsy												
<= 5 years	KDQOL: effect of kidney disease	Baseline	Sparsentan	113	104 (92.0)	87.41 (13.71)	28.1	84.38	90.63	96.88	100.0	
			Irbesartan	127	116 (91.3)	88.39 (13.59)	37.5	82.81	93.75	100.00	100.0	
		Week 24	Sparsentan	113	70 (61.9)	91.43 (10.91)	50.0	87.50	93.75	100.00	100.0	
			Irbesartan	127	67 (52.8)	87.13 (19.18)	0.0	84.38	93.75	100.00	100.0	
		Week 48	Sparsentan	113	61 (54.0)	90.93 (10.44)	50.0	87.50	93.75	100.00	100.0	
			Irbesartan	127	51 (40.2)	92.03 (12.41)	40.6	87.50	96.88	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	113	70 (61.9)	5.00 (12.91)	-37.5	0.00	3.13	12.50	34.4	0.54 [0.19, 0.88]
			Irbesartan	127	67 (52.8)	-2.89 (16.44)	-100.0	-6.25	0.00	3.13	31.3	
		Week 48	Sparsentan	113	61 (54.0)	4.20 (11.47)	-40.6	0.00	3.13	9.38	34.4	0.29 [-0.08, 0.67]
			Irbesartan	127	51 (40.2)	1.04 (9.92)	-25.0	0.00	0.00	3.13	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 5 years	KDQOL: effect of kidney disease	Baseline	Sparsentan	89	82 (92.1)	89.21 (13.70)	28.1	87.50	93.75	100.00	100.0	
			Irbesartan	75	63 (84.0)	89.78 (12.00)	46.9	84.38	93.75	100.00	100.0	
		Week 24	Sparsentan	89	55 (61.8)	87.44 (15.89)	9.4	81.25	90.63	100.00	100.0	
			Irbesartan	75	37 (49.3)	91.47 (11.59)	50.0	87.50	96.88	100.00	100.0	
		Week 48	Sparsentan	89	49 (55.1)	89.35 (15.91)	0.0	87.50	93.75	100.00	100.0	
			Irbesartan	75	26 (34.7)	94.23 (6.60)	78.1	90.63	96.88	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	89	55 (61.8)	-2.78 (13.96)	-75.0	-6.25	0.00	6.25	28.1	-0.24 [-0.65, 0.18]
			Irbesartan	75	37 (49.3)	0.25 (10.96)	-37.5	-3.13	0.00	6.25	18.8	
		Week 48	Sparsentan	89	49 (55.1)	-0.57 (19.70)	-100.0	-3.13	0.00	6.25	56.3	-0.15 [-0.63, 0.33]
			Irbesartan	75	26 (34.7)	1.92 (7.66)	-9.4	0.00	0.00	6.25	18.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: History of hypertension												
Yes	KDQOL: effect of kidney disease	Baseline	Sparsentan	153	138 (90.2)	87.45 (14.01)	28.1	84.38	92.19	96.88	100.0	
			Irbesartan	157	135 (86.0)	88.82 (12.27)	43.8	84.38	93.75	100.00	100.0	
		Week 24	Sparsentan	153	94 (61.4)	91.16 (10.98)	56.3	87.50	93.75	100.00	100.0	
			Irbesartan	157	76 (48.4)	91.00 (11.74)	50.0	87.50	96.88	100.00	100.0	
		Week 48	Sparsentan	153	81 (52.9)	89.74 (14.31)	0.0	87.50	93.75	100.00	100.0	
			Irbesartan	157	57 (36.3)	94.63 (7.30)	65.6	93.75	96.88	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	153	94 (61.4)	3.42 (9.43)	-25.0	-3.13	3.13	6.25	31.3	0.31 [0.01, 0.61]
			Irbesartan	157	76 (48.4)	0.41 (10.11)	-37.5	-3.13	0.00	6.25	31.3	
		Week 48	Sparsentan	153	81 (52.9)	1.74 (15.60)	-100.0	0.00	3.13	6.25	46.9	-0.10 [-0.44, 0.24]
			Irbesartan	157	57 (36.3)	3.07 (8.45)	-12.5	0.00	0.00	6.25	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	KDQOL: effect of kidney disease	Baseline	Sparsentan	49	48 (98.0)	90.36 (12.65)	43.8	87.50	93.75	100.00	100.0	
			Irbesartan	45	44 (97.8)	89.06 (15.30)	37.5	87.50	95.31	100.00	100.0	
		Week 24	Sparsentan	49	31 (63.3)	85.18 (18.54)	9.4	81.25	87.50	100.00	100.0	
			Irbesartan	45	28 (62.2)	82.37 (25.60)	0.0	76.56	93.75	98.44	100.0	
		Week 48	Sparsentan	49	29 (59.2)	91.59 (9.04)	62.5	87.50	93.75	100.00	100.0	
			Irbesartan	45	20 (44.4)	87.50 (16.44)	40.6	82.81	92.19	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	49	31 (63.3)	-4.03 (21.85)	-75.0	-12.50	-3.13	9.38	34.4	0.17 [-0.35, 0.68]
			Irbesartan	45	28 (62.2)	-7.70 (22.27)	-100.0	-10.94	-1.56	3.13	15.6	
		Week 48	Sparsentan	49	29 (59.2)	3.02 (16.50)	-37.5	-3.13	0.00	6.25	56.3	0.47 [-0.11, 1.05]
			Irbesartan	45	20 (44.4)	-3.59 (9.58)	-25.0	-9.38	0.00	1.56	12.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Sex	Overall	Sparsentan						Interaction:	0.035 #
Male	Week 24	Sparsentan	139	87 (62.6)	-0.61 (1.32)	(-3.21, 2.00)	1.32 (1.96)	(-2.54, 5.18)	0.501
		Irbesartan	143	73 (51.0)	-1.93 (1.44)	(-4.76, 0.90)			
	Week 48	Sparsentan	139	72 (51.8)	-0.81 (1.44)	(-3.65, 2.02)	-2.85 (2.20)	(-7.18, 1.48)	0.197
		Irbesartan	143	55 (38.5)	2.03 (1.66)	(-1.23, 5.30)			
Female	Week 24	Sparsentan	63	38 (60.3)	5.39 (2.12)	(1.17, 9.61)	5.24 (3.28)	(-1.29, 11.76)	0.114
		Irbesartan	59	31 (52.5)	0.16 (2.46)	(-4.75, 5.06)			
	Week 48	Sparsentan	63	38 (60.3)	4.91 (2.11)	(0.71, 9.11)	7.30 (3.45)	(0.46, 14.15)	0.037 *
		Irbesartan	59	22 (37.3)	-2.39 (2.69)	(-7.73, 2.95)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age	Overall	Sparsentan						Interaction:	0.967
<= 45 years	Week 24	Sparsentan	96	57 (59.4)	0.24 (2.08)	(-3.86, 4.33)	1.77 (3.00)	(-4.14, 7.68)	0.555
		Irbesartan	99	53 (53.5)	-1.53 (2.15)	(-5.78, 2.71)			
	Week 48	Sparsentan	96	53 (55.2)	0.85 (2.14)	(-3.38, 5.08)	-0.12 (3.26)	(-6.55, 6.32)	0.971
		Irbesartan	99	40 (40.4)	0.97 (2.45)	(-3.87, 5.81)			
> 45 years	Week 24	Sparsentan	106	68 (64.2)	1.54 (1.11)	(-0.65, 3.73)	1.89 (1.73)	(-1.51, 5.30)	0.274
		Irbesartan	103	51 (49.5)	-0.35 (1.30)	(-2.93, 2.22)			
	Week 48	Sparsentan	106	57 (53.8)	0.88 (1.18)	(-1.44, 3.20)	-0.37 (1.88)	(-4.09, 3.35)	0.843
		Irbesartan	103	37 (35.9)	1.25 (1.46)	(-1.63, 4.13)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age at IgAN diagnosis	Overall	Sparsentan						Interaction:	0.786
<= 18 years	Week 24	Sparsentan	9	3 (33.3)	1.14 (16.71)	(-44.84, 47.12)	-0.44 (32.18)	(-89.71, 88.83)	0.990
		Irbesartan	5	2 (40.0)	1.58 (27.60)	(-75.23, 78.40)			
	Week 48	Sparsentan	9	5 (55.6)	-1.62 (16.55)	(-47.59, 44.36)	-3.31 (32.28)	(-92.56, 85.94)	0.923
		Irbesartan	5	1 (20.0)	1.69 (27.85)	(-75.11, 78.48)			
> 18 to 40 years	Week 24	Sparsentan	102	62 (60.8)	1.40 (1.81)	(-2.17, 4.96)	3.26 (2.60)	(-1.87, 8.38)	0.211
		Irbesartan	109	59 (54.1)	-1.86 (1.86)	(-5.54, 1.81)			
	Week 48	Sparsentan	102	57 (55.9)	0.71 (1.89)	(-3.01, 4.42)	-0.14 (2.86)	(-5.78, 5.50)	0.961
		Irbesartan	109	44 (40.4)	0.85 (2.14)	(-3.38, 5.07)			
> 40 years	Week 24	Sparsentan	91	60 (65.9)	1.43 (1.19)	(-0.92, 3.78)	1.91 (1.84)	(-1.73, 5.55)	0.301
		Irbesartan	88	43 (48.9)	-0.48 (1.39)	(-3.23, 2.27)			
	Week 48	Sparsentan	91	48 (52.7)	0.96 (1.28)	(-1.57, 3.50)	-0.17 (2.05)	(-4.20, 3.87)	0.935
		Irbesartan	88	32 (36.4)	1.13 (1.58)	(-1.98, 4.24)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Geographic region	Overall	Sparsentan						Interaction:	0.889
North America	Week 24	Sparsentan	35	15 (42.9)	-2.41 (4.72)	(-11.93, 7.11)	0.08 (6.08)	(-12.19, 12.34)	0.990
		Irbesartan	46	26 (56.5)	-2.48 (3.77)	(-10.09, 5.13)			
	Week 48	Sparsentan	35	13 (37.1)	0.13 (4.88)	(-9.69, 9.94)	1.04 (6.39)	(-11.80, 13.89)	0.871
		Irbesartan	46	17 (37.0)	-0.92 (4.05)	(-9.04, 7.21)			
Europe	Week 24	Sparsentan	98	53 (54.1)	1.61 (1.37)	(-1.09, 4.31)	3.32 (1.99)	(-0.61, 7.26)	0.097
		Irbesartan	115	47 (40.9)	-1.71 (1.45)	(-4.58, 1.16)			
	Week 48	Sparsentan	98	44 (44.9)	2.49 (1.48)	(-0.44, 5.42)	1.36 (2.18)	(-2.95, 5.67)	0.535
		Irbesartan	115	38 (33.0)	1.13 (1.60)	(-2.02, 4.28)			
Asia Pacific	Week 24	Sparsentan	69	57 (82.6)	2.20 (1.72)	(-1.19, 5.59)	2.04 (2.93)	(-3.74, 7.82)	0.486
		Irbesartan	41	31 (75.6)	0.16 (2.34)	(-4.47, 4.78)			
	Week 48	Sparsentan	69	53 (76.8)	0.05 (1.78)	(-3.46, 3.56)	-0.08 (3.30)	(-6.59, 6.44)	0.982
		Irbesartan	41	22 (53.7)	0.12 (2.76)	(-5.33, 5.58)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline BMI	Overall	Sparsentan						Interaction:	0.840
< 27 kg/m**2	Week 24	Sparsentan	84	52 (61.9)	2.15 (2.02)	(-1.86, 6.16)	2.06 (2.92)	(-3.72, 7.84)	0.482
		Irbesartan	94	50 (53.2)	0.09 (2.09)	(-4.04, 4.23)			
	Week 48	Sparsentan	84	47 (56.0)	0.80 (2.07)	(-3.29, 4.89)	0.81 (3.07)	(-5.26, 6.88)	0.792
		Irbesartan	94	36 (38.3)	-0.01 (2.25)	(-4.46, 4.44)			
>= 27 kg/m**2	Week 24	Sparsentan	118	73 (61.9)	0.04 (1.37)	(-2.65, 2.73)	1.58 (2.11)	(-2.57, 5.73)	0.455
		Irbesartan	107	54 (50.5)	-1.54 (1.58)	(-4.66, 1.58)			
	Week 48	Sparsentan	118	63 (53.4)	0.46 (1.46)	(-2.41, 3.34)	-1.70 (2.35)	(-6.33, 2.92)	0.469
		Irbesartan	107	41 (38.3)	2.17 (1.83)	(-1.44, 5.77)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Randomization strata	Overall	Sparsentan						Interaction:	0.339
eGFR Low and UP High	Week 24	Sparsentan	71	44 (62.0)	0.40 (1.23)	(-2.05, 2.84)	4.31 (1.91)	(0.54, 8.09)	0.025 *
		Irbesartan	74	32 (43.2)	-3.92 (1.45)	(-6.79, -1.04)			
	Week 48	Sparsentan	71	37 (52.1)	0.54 (1.34)	(-2.11, 3.19)	1.04 (2.19)	(-3.29, 5.36)	0.635
		Irbesartan	74	22 (29.7)	-0.50 (1.73)	(-3.92, 2.92)			
eGFR Low and UP Low	Week 24	Sparsentan	55	38 (69.1)	0.93 (2.09)	(-3.21, 5.07)	-3.67 (3.11)	(-9.83, 2.48)	0.240
		Irbesartan	55	33 (60.0)	4.60 (2.24)	(0.17, 9.04)			
	Week 48	Sparsentan	55	28 (50.9)	0.58 (2.42)	(-4.21, 5.37)	-2.61 (3.55)	(-9.64, 4.42)	0.464
		Irbesartan	55	25 (45.5)	3.19 (2.57)	(-1.90, 8.27)			
eGFR High and UP High	Week 24	Sparsentan	37	19 (51.4)	1.63 (3.54)	(-5.48, 8.74)	2.65 (5.20)	(-7.82, 13.12)	0.613
		Irbesartan	36	18 (50.0)	-1.02 (3.81)	(-8.71, 6.67)			
	Week 48	Sparsentan	37	22 (59.5)	-1.81 (3.39)	(-8.64, 5.02)	-3.73 (5.59)	(-14.91, 7.46)	0.507
		Irbesartan	36	11 (30.6)	1.92 (4.44)	(-6.95, 10.78)			
eGFR High and UP Low	Week 24	Sparsentan	39	24 (61.5)	2.21 (3.12)	(-4.06, 8.48)	5.31 (4.54)	(-3.78, 14.41)	0.246
		Irbesartan	37	21 (56.8)	-3.10 (3.27)	(-9.66, 3.45)			
	Week 48	Sparsentan	39	23 (59.0)	3.37 (3.16)	(-2.96, 9.71)	4.84 (4.65)	(-4.45, 14.14)	0.301
		Irbesartan	37	19 (51.4)	-1.47 (3.37)	(-8.22, 5.27)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 1	Overall	Sparsentan						Interaction:	0.035 #
< 60 mL/min/1.73 m**2	Week 24	Sparsentan	127	83 (65.4)	0.51 (1.25)	(-1.96, 2.97)	0.63 (1.87)	(-3.06, 4.32)	0.737
		Irbesartan	129	68 (52.7)	-0.12 (1.39)	(-2.86, 2.61)			
	Week 48	Sparsentan	127	65 (51.2)	1.05 (1.40)	(-1.72, 3.81)	0.12 (2.16)	(-4.12, 4.37)	0.954
		Irbesartan	129	49 (38.0)	0.92 (1.63)	(-2.28, 4.13)			
60 to < 90 mL/min/1.73 m**2	Week 24	Sparsentan	49	27 (55.1)	0.15 (2.64)	(-5.12, 5.41)	0.24 (3.86)	(-7.48, 7.96)	0.951
		Irbesartan	48	24 (50.0)	-0.09 (2.80)	(-5.68, 5.50)			
	Week 48	Sparsentan	49	29 (59.2)	-0.18 (2.59)	(-5.37, 5.00)	-0.91 (4.00)	(-8.88, 7.06)	0.820
		Irbesartan	48	19 (39.6)	0.73 (2.99)	(-5.22, 6.68)			
>= 90 mL/min/1.73 m**2	Week 24	Sparsentan	26	15 (57.7)	7.75 (4.89)	(-2.26, 17.76)	15.68 (7.37)	(0.59, 30.76)	0.042 *
		Irbesartan	25	12 (48.0)	-7.93 (5.42)	(-19.01, 3.15)			
	Week 48	Sparsentan	26	16 (61.5)	2.19 (4.87)	(-7.78, 12.16)	6.01 (7.71)	(-9.69, 21.70)	0.442
		Irbesartan	25	9 (36.0)	-3.82 (5.83)	(-15.64, 8.00)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

					Repeated measures analysis				
KDQOL: Change from baseline in effect of kidney disease					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 2	Overall	Sparsentan						Interaction:	0.056
< 45 mL/min/1.73 m**2	Week 24	Sparsentan	82	53 (64.6)	1.83 (1.73)	(-1.59, 5.26)	2.63 (2.55)	(-2.42, 7.67)	0.305
		Irbesartan	80	45 (56.3)	-0.79 (1.88)	(-4.50, 2.91)			
	Week 48	Sparsentan	82	42 (51.2)	0.47 (1.93)	(-3.34, 4.28)	0.58 (3.03)	(-5.40, 6.56)	0.849
		Irbesartan	80	29 (36.3)	-0.11 (2.33)	(-4.71, 4.49)			
45 to < 60 mL/min/1.73 m**2	Week 24	Sparsentan	45	30 (66.7)	-1.94 (1.62)	(-5.17, 1.29)	-3.52 (2.54)	(-8.57, 1.53)	0.169
		Irbesartan	49	23 (46.9)	1.58 (1.90)	(-2.20, 5.36)			
	Week 48	Sparsentan	45	23 (51.1)	2.08 (1.84)	(-1.57, 5.74)	-0.29 (2.75)	(-5.75, 5.17)	0.917
		Irbesartan	49	20 (40.8)	2.37 (2.01)	(-1.63, 6.37)			
60 to < 90 mL/min/1.73 m**2	Week 24	Sparsentan	49	27 (55.1)	0.15 (2.64)	(-5.12, 5.41)	0.24 (3.86)	(-7.48, 7.96)	0.951
		Irbesartan	48	24 (50.0)	-0.09 (2.80)	(-5.68, 5.50)			
	Week 48	Sparsentan	49	29 (59.2)	-0.18 (2.59)	(-5.37, 5.00)	-0.91 (4.00)	(-8.88, 7.06)	0.820
		Irbesartan	48	19 (39.6)	0.73 (2.99)	(-5.22, 6.68)			
>= 90 mL/min/1.73 m**2	Week 24	Sparsentan	26	15 (57.7)	7.75 (4.89)	(-2.26, 17.76)	15.68 (7.37)	(0.59, 30.76)	0.042 *
		Irbesartan	25	12 (48.0)	-7.93 (5.42)	(-19.01, 3.15)			
	Week 48	Sparsentan	26	16 (61.5)	2.19 (4.87)	(-7.78, 12.16)	6.01 (7.71)	(-9.69, 21.70)	0.442
		Irbesartan	25	9 (36.0)	-3.82 (5.83)	(-15.64, 8.00)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline urine protein excretion	Overall	Sparsentan						Interaction:	0.614
<= 1.75 g/day	Week 24	Sparsentan	98	66 (67.3)	0.71 (1.74)	(-2.72, 4.14)	0.83 (2.79)	(-4.68, 6.34)	0.767
		Irbesartan	94	43 (45.7)	-0.12 (2.16)	(-4.38, 4.15)			
	Week 48	Sparsentan	98	59 (60.2)	1.42 (1.82)	(-2.18, 5.02)	-0.50 (3.06)	(-6.54, 5.53)	0.869
		Irbesartan	94	34 (36.2)	1.93 (2.42)	(-2.85, 6.71)			
> 1.75 g/day	Week 24	Sparsentan	104	59 (56.7)	1.69 (1.51)	(-1.28, 4.66)	3.87 (2.13)	(-0.35, 8.09)	0.072
		Irbesartan	108	61 (56.5)	-2.18 (1.50)	(-5.14, 0.78)			
	Week 48	Sparsentan	104	51 (49.0)	0.60 (1.59)	(-2.53, 3.74)	0.52 (2.35)	(-4.12, 5.16)	0.825
		Irbesartan	108	43 (39.8)	0.08 (1.70)	(-3.28, 3.44)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline use of antihypertensives	Overall	Sparsentan						Interaction:	0.935
Yes	Week 24	Sparsentan	88	50 (56.8)	2.32 (1.31)	(-0.28, 4.92)	3.23 (1.98)	(-0.70, 7.16)	0.106
		Irbesartan	83	39 (47.0)	-0.92 (1.48)	(-3.86, 2.03)			
	Week 48	Sparsentan	88	41 (46.6)	0.71 (1.38)	(-2.03, 3.44)	-0.84 (2.14)	(-5.09, 3.40)	0.694
		Irbesartan	83	28 (33.7)	1.55 (1.63)	(-1.68, 4.77)			
No	Week 24	Sparsentan	114	75 (65.8)	0.28 (1.67)	(-3.01, 3.58)	1.44 (2.46)	(-3.40, 6.28)	0.559
		Irbesartan	119	65 (54.6)	-1.16 (1.80)	(-4.70, 2.39)			
	Week 48	Sparsentan	114	69 (60.5)	0.92 (1.73)	(-2.49, 4.33)	0.38 (2.69)	(-4.92, 5.68)	0.888
		Irbesartan	119	49 (41.2)	0.54 (2.06)	(-3.51, 4.59)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Time since renal biopsy	Overall	Sparsentan						Interaction:	0.020 #
<= 5 years	Week 24	Sparsentan	113	70 (61.9)	4.13 (1.47)	(1.24, 7.02)	5.94 (2.10)	(1.80, 10.08)	0.005 *
		Irbesartan	127	67 (52.8)	-1.81 (1.50)	(-4.76, 1.14)			
	Week 48	Sparsentan	113	61 (54.0)	2.91 (1.54)	(-0.12, 5.93)	2.37 (2.26)	(-2.08, 6.83)	0.295
		Irbesartan	127	51 (40.2)	0.53 (1.66)	(-2.73, 3.80)			
> 5 years	Week 24	Sparsentan	89	55 (61.8)	-2.90 (1.78)	(-6.41, 0.61)	-3.56 (2.81)	(-9.12, 1.99)	0.207
		Irbesartan	75	37 (49.3)	0.66 (2.19)	(-3.67, 5.00)			
	Week 48	Sparsentan	89	49 (55.1)	-1.11 (1.90)	(-4.86, 2.63)	-3.30 (3.23)	(-9.69, 3.08)	0.308
		Irbesartan	75	26 (34.7)	2.19 (2.60)	(-2.95, 7.33)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
History of hypertension	Overall	Sparsentan						Interaction:	0.121
Yes	Week 24	Sparsentan	153	94 (61.4)	2.84 (1.01)	(0.85, 4.83)	1.86 (1.51)	(-1.12, 4.83)	0.221
		Irbesartan	157	76 (48.4)	0.98 (1.12)	(-1.23, 3.19)			
	Week 48	Sparsentan	153	81 (52.9)	1.05 (1.08)	(-1.08, 3.18)	-2.58 (1.70)	(-5.92, 0.76)	0.129
		Irbesartan	157	57 (36.3)	3.63 (1.30)	(1.07, 6.19)			
No	Week 24	Sparsentan	49	31 (63.3)	-3.77 (3.43)	(-10.62, 3.08)	2.70 (5.03)	(-7.34, 12.75)	0.593
		Irbesartan	45	28 (62.2)	-6.48 (3.66)	(-13.78, 0.83)			
	Week 48	Sparsentan	49	29 (59.2)	-0.70 (3.48)	(-7.63, 6.24)	8.12 (5.29)	(-2.41, 18.66)	0.129
		Irbesartan	45	20 (44.4)	-8.82 (3.96)	(-16.69, -0.94)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Figure PF1KEFC_FSGM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set
Study: PROTECT
Sex: Male



Sparsentan	87	72
Irbesartan	73	55

Number of available records are presented for key visits up to Week 58 only. LS-Mean = Least square mean.
95% CI = 95% confidence interval. eGFR = estimated glomerular filtration rate. UP = urine protein. BMI = body mass index.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
IgAN = immunoglobulin A nephropathy. A decrease reflects a worsening of the status of the patient. Reference table: PT1KEFC_FSCM.

Figure PF1KEFC_FSGM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set
Study: PROTECT
Sex: Female



Sparsentan	38	38
Irbesartan	31	22

Number of available records are presented for key visits up to Week 58 only. LS-Mean = Least square mean.
95% CI = 95% confidence interval. eGFR = estimated glomerular filtration rate. UP = urine protein. BMI = body mass index.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
IgAN = immunoglobulin A nephropathy. A decrease reflects a worsening of the status of the patient. Reference table: PT1KEFC_FSCM.

Figure PF1KEFC_FSGM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 1: < 60 mL/min/1.73 m**2



Sparsentan	83	65
Irbesartan	68	49

Number of available records are presented for key visits up to Week 58 only. LS-Mean = Least square mean.
95% CI = 95% confidence interval. eGFR = estimated glomerular filtration rate. UP = urine protein. BMI = body mass index.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
IgAN = immunoglobulin A nephropathy. A decrease reflects a worsening of the status of the patient. Reference table: PT1KEFC_FSCM.

Figure PF1KEFC_FSGM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 1: 60 to < 90 mL/min/1.73 m**2



Sparsentan	27	29
Irbesartan	24	19

Number of available records are presented for key visits up to Week 58 only. LS-Mean = Least square mean.
95% CI = 95% confidence interval. eGFR = estimated glomerular filtration rate. UP = urine protein. BMI = body mass index.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
IgAN = immunoglobulin A nephropathy. A decrease reflects a worsening of the status of the patient. Reference table: PT1KEFC_FSCM.

Figure PF1KEFC_FSGM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 1: >= 90 mL/min/1.73 m**2



Sparsentan	15	16
Irbesartan	12	9

Number of available records are presented for key visits up to Week 58 only. LS-Mean = Least square mean.
95% CI = 95% confidence interval. eGFR = estimated glomerular filtration rate. UP = urine protein. BMI = body mass index.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
IgAN = immunoglobulin A nephropathy. A decrease reflects a worsening of the status of the patient. Reference table: PT1KEFC_FSCM.

Figure PF1KEFC_FSGM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set
Study: PROTECT
Time since renal biopsy: <= 5 years



Sparsentan	70	61
Irbesartan	67	51

Number of available records are presented for key visits up to Week 58 only. LS-Mean = Least square mean.
95% CI = 95% confidence interval. eGFR = estimated glomerular filtration rate. UP = urine protein. BMI = body mass index.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
IgAN = immunoglobulin A nephropathy. A decrease reflects a worsening of the status of the patient. Reference table: PT1KEFC_FSCM.

Figure PF1KEFC_FSGM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set
Study: PROTECT
Time since renal biopsy: > 5 years



Sparsentan	55	49
Irbesartan	37	26

Number of available records are presented for key visits up to Week 58 only. LS-Mean = Least square mean.
95% CI = 95% confidence interval. eGFR = estimated glomerular filtration rate. UP = urine protein. BMI = body mass index.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
IgAN = immunoglobulin A nephropathy. A decrease reflects a worsening of the status of the patient. Reference table: PT1KEFC_FSCM.

Table PT1KEFIT_FSTM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sex	Sparsentan						Interaction test:	0.229
Male	Sparsentan	139	11 (7.9)	NE		1.979	(0.707, 5.539)	0.194
	Irbesartan	143	9 (6.3)	NE				
Female	Sparsentan	63	12 (19.0)	NE		0.744	(0.191, 2.901)	0.671
	Irbesartan	59	5 (8.5)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KEFIT_FSTM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.851
<= 45 years	Sparsentan	96	13 (13.5)	NE		1.613	(0.585, 4.446)	0.355
	Irbesartan	99	7 (7.1)	NE				
> 45 years	Sparsentan	106	10 (9.4)	NE		1.354	(0.428, 4.280)	0.606
	Irbesartan	103	7 (6.8)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KEFIT_FSTM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age at IgAN diagnosis	Sparsentan						Interaction test:	<0.001 #
<= 18 years	Sparsentan	9	2 (22.2)	NE		0.191	(0.005, 6.762)	0.363
	Irbesartan	5	1 (20.0)	NE				
> 18 to 40 years	Sparsentan	102	11 (10.8)	NE		1.821	(0.698, 4.750)	0.221
	Irbesartan	109	9 (8.3)	NE				
> 40 years	Sparsentan	91	10 (11.0)	NE		1.489	(0.411, 5.392)	0.545
	Irbesartan	88	4 (4.5)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KEFIT_FSTM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Geographic region	Sparsentan						Interaction test:	0.009 #
North America	Sparsentan	35	3 (8.6)	NE		0.729	(0.101, 5.236)	0.753
	Irbesartan	46	3 (6.5)	NE				
Europe	Sparsentan	98	7 (7.1)	NE		0.723	(0.223, 2.343)	0.589
	Irbesartan	115	9 (7.8)	NE				
Asia Pacific	Sparsentan	69	13 (18.8)	NE		4.884	(0.941, 25.347)	0.059
	Irbesartan	41	2 (4.9)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KEFIT_FSTM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.860
< 27 kg/m**2	Sparsentan	84	14 (16.7)	NE		1.392	(0.538, 3.602)	0.495
	Irbesartan	94	8 (8.5)	NE				
>= 27 kg/m**2	Sparsentan	118	9 (7.6)	NE		1.322	(0.395, 4.431)	0.651
	Irbesartan	107	6 (5.6)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KEFIT_FSTM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Randomization strata	Sparsentan						Interaction test:	0.008	#
eGFR Low and UP High	Sparsentan	71	3 (4.2)	NE		0.316	(0.052, 1.923)	0.211	
	Irbesartan	74	3 (4.1)	NE					
eGFR Low and UP Low	Sparsentan	55	9 (16.4)	NE		0.998	(0.246, 4.050)	0.997	
	Irbesartan	55	4 (7.3)	NE					
eGFR High and UP High	Sparsentan	37	5 (13.5)	NE		0.542	(0.146, 2.015)	0.360	
	Irbesartan	36	5 (13.9)	NE					
eGFR High and UP Low	Sparsentan	39	6 (15.4)	NE		11.943	(1.281, 111.381)	0.029	*
	Irbesartan	37	2 (5.4)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KEFIT_FSTM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.761
< 60 mL/min/1.73 m**2	Sparsentan	127	12 (9.4)	NE		0.812	(0.286, 2.306)	0.696
	Irbesartan	129	7 (5.4)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	6 (12.2)	NE		1.919	(0.458, 8.045)	0.372
	Irbesartan	48	6 (12.5)	93.3	(70.1, NE)			
>= 90 mL/min/1.73 m**2	Sparsentan	26	5 (19.2)	NE		3.022	(0.301, 30.297)	0.347
	Irbesartan	25	1 (4.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KEFIT_FSTM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 2	Sparsentan						Interaction test:	0.906
< 45 mL/min/1.73 m**2	Sparsentan	82	7 (8.5)	NE		0.667	(0.153, 2.914)	0.590
	Irbesartan	80	4 (5.0)	NE				
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	5 (11.1)	NE		0.354	(0.046, 2.713)	0.318
	Irbesartan	49	3 (6.1)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	6 (12.2)	NE		1.919	(0.458, 8.045)	0.372
	Irbesartan	48	6 (12.5)	93.3	(70.1, NE)			
>= 90 mL/min/1.73 m**2	Sparsentan	26	5 (19.2)	NE		3.022	(0.301, 30.297)	0.347
	Irbesartan	25	1 (4.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KEFIT_FSTM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline urine protein excretion	Sparsentan						Interaction test:	0.024	#
<= 1.75 g/day	Sparsentan	98	15 (15.3)	NE		3.533	(1.085, 11.498)	0.036	*
	Irbesartan	94	5 (5.3)	NE					
> 1.75 g/day	Sparsentan	104	8 (7.7)	NE		0.569	(0.198, 1.637)	0.296	
	Irbesartan	108	9 (8.3)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KEFIT_FSTM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.329
Yes	Sparsentan	88	8 (9.1)	NE		1.549	(0.395, 6.065)	0.530
	Irbesartan	83	4 (4.8)	NE				
No	Sparsentan	114	15 (13.2)	NE		1.073	(0.451, 2.554)	0.874
	Irbesartan	119	10 (8.4)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KEFIT_FSTM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Time since renal biopsy	Sparsentan						Interaction test:	<0.001	#
<= 5 years	Sparsentan	113	18 (15.9)	NE		4.893	(1.782, 13.436)	0.002	*
	Irbesartan	127	6 (4.7)	NE					
> 5 years	Sparsentan	89	5 (5.6)	NE		0.035	(0.004, 0.308)	0.003	*
	Irbesartan	75	8 (10.7)	108.1	(108.1, NE)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KEFIT_FSTM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
History of hypertension	Sparsentan						Interaction test:	0.020	#
Yes	Sparsentan	153	17 (11.1)	NE		0.692	(0.302, 1.584)	0.383	
	Irbesartan	157	12 (7.6)	NE					
No	Sparsentan	49	6 (12.2)	NE		15.899	(1.260, 200.530)	0.032	*
	Irbesartan	45	2 (4.4)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Figure PF1KEFIT_FSKM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Age at IgAN diagnosis: <= 18 years



Sparsentan	9	6	4	1	0
Irbesartan	5	2	1	0	

An increase reflects an improvement of the status of the patient.
Reference table: PT1KEFIT_FSTM

Figure PF1KEFIT_FSKM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Age at IgAN diagnosis: > 18 to 40 years



Sparsentan	102	65	50	33	10	3
Irbesartan	109	68	47	27	9	5

An increase reflects an improvement of the status of the patient.
Reference table: PT1KEFIT_FSTM

Figure PF1KEFIT_FSKM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Age at IgAN diagnosis: > 40 years



Sparsentan	91	60	45	36	19	9
Irbesartan	88	45	37	24	12	4

_____
An increase reflects an improvement of the status of the patient.
Reference table: PT1KEFIT_FSTM

Figure PF1KEFIT_FSKM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Geographic region: North America



Sparsentan	35	16	11	8	5	1
Irbesartan	46	25	19	11	6	5

An increase reflects an improvement of the status of the patient.
Reference table: PT1KEFIT_FSTM

Figure PF1KEFIT_FSKM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Geographic region: Europe



Sparsentan	98	57	39	25	12	6
Irbesartan	115	60	44	28	10	2

An increase reflects an improvement of the status of the patient.
Reference table: PT1KEFIT_FSTM

Figure PF1KEFIT_FSKM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Geographic region: Asia Pacific



Sparsentan	69	58	49	37	12	5
Irbesartan	41	30	22	12	5	2

An increase reflects an improvement of the status of the patient.
Reference table: PT1KEFIT_FSTM

Figure PF1KEFIT_FSKM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Randomization strata: eGFR Low and UP High



Sparsentan	71	47	41	34	16	3
Irbesartan	74	34	27	14	7	2

An increase reflects an improvement of the status of the patient.
Reference table: PT1KEFIT_FSTM

Figure PF1KEFIT_FSKM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Randomization strata: eGFR Low and UP Low



Sparsentan	55	37	23	15	6	6
Irbesartan	55	38	29	20	10	5

_____
An increase reflects an improvement of the status of the patient.
Reference table: PT1KEFIT_FSTM

Figure PF1KEFIT_FSKM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Randomization strata: eGFR High and UP High



Sparsentan	37	23	19	12	5	2
Irbesartan	36	19	11	5	2	1

An increase reflects an improvement of the status of the patient.
Reference table: PT1KEFIT_FSTM

Figure PF1KEFIT_FSKM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Randomization strata: eGFR High and UP Low



Sparsentan	39	24	16	9	2	1
Irbesartan	37	24	18	12	2	1

An increase reflects an improvement of the status of the patient.
Reference table: PT1KEFIT_FSTM

Figure PF1KEFIT_FSKM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline urine protein excretion: <= 1.75 g/day



Sparsentan	98	71	50	33	13	9
Irbesartan	94	52	38	25	10	4

An increase reflects an improvement of the status of the patient.
Reference table: PT1KEFIT_FSTM

Figure PF1KEFIT_FSKM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline urine protein excretion: > 1.75 g/day



Sparsentan	104	60	49	37	16	3
Irbesartan	108	63	47	26	11	5

An increase reflects an improvement of the status of the patient.
Reference table: PT1KEFIT_FSTM

Figure PF1KEFIT_FSKM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Time since renal biopsy: <= 5 years



Sparsentan	113	69	48	35	14	5
Irbesartan	127	73	56	33	15	8

An increase reflects an improvement of the status of the patient.
Reference table: PT1KEFIT_FSTM

Figure PF1KEFIT_FSKM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Time since renal biopsy: > 5 years



Sparsentan	89	62	51	35	15	7
Irbesartan	75	42	29	18	6	1

An increase reflects an improvement of the status of the patient.
Reference table: PT1KEFIT_FSTM

Figure PF1KEFIT_FSKM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
History of hypertension: Yes



Sparsentan	153	98	75	56	23	9
Irbesartan	157	83	63	38	16	7

An increase reflects an improvement of the status of the patient.
Reference table: PT1KEFIT_FSTM

Figure PF1KEFIT_FSKM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
History of hypertension: No



Sparsentan	49	33	24	14	6	3
Irbesartan	45	32	22	13	5	2

An increase reflects an improvement of the status of the patient.
Reference table: PT1KEFIT_FSTM

Table PT1KEFDT_FSTM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Sex	Sparsentan						Interaction test:	0.047	#
Male	Sparsentan	139	17 (12.2)	NE		0.843	(0.416, 1.711)	0.637	
	Irbesartan	143	15 (10.5)	NE					
Female	Sparsentan	63	1 (1.6)	NE		0.133	(0.015, 1.199)	0.072	
	Irbesartan	59	5 (8.5)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KEFDT_FSTM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.255
<= 45 years	Sparsentan	96	11 (11.5)	NE		0.863	(0.372, 1.998)	0.730
	Irbesartan	99	11 (11.1)	NE				
> 45 years	Sparsentan	106	7 (6.6)	NE		0.512	(0.183, 1.433)	0.202
	Irbesartan	103	9 (8.7)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KEFDT_FSTM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age at IgAN diagnosis	Sparsentan						Interaction test:	NE
<= 18 years	Sparsentan	9	1 (11.1) No events in 1 group	NE		NE		NE
	Irbesartan	5	0 (0.0)	NE				
> 18 to 40 years	Sparsentan	102	11 (10.8)	NE		0.653	(0.288, 1.481)	0.308
	Irbesartan	109	13 (11.9)	NE				
> 40 years	Sparsentan	91	6 (6.6)	NE		0.606	(0.197, 1.859)	0.381
	Irbesartan	88	7 (8.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KEFDT_FSTM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Geographic region	Sparsentan						Interaction test:	0.665
North America	Sparsentan	35	2 (5.7)	NE		0.367	(0.071, 1.900)	0.232
	Irbesartan	46	6 (13.0)	NE				
Europe	Sparsentan	98	6 (6.1)	NE		0.488	(0.174, 1.366)	0.172
	Irbesartan	115	10 (8.7)	NE				
Asia Pacific	Sparsentan	69	10 (14.5)	NE		1.132	(0.338, 3.786)	0.841
	Irbesartan	41	4 (9.8)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KEFDT_FSTM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.945
< 27 kg/m**2	Sparsentan	84	7 (8.3)	NE		0.702	(0.250, 1.968)	0.501
	Irbesartan	94	8 (8.5)	NE				
>= 27 kg/m**2	Sparsentan	118	11 (9.3)	NE		0.719	(0.305, 1.697)	0.452
	Irbesartan	107	11 (10.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KEFDT_FSTM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Randomization strata	Sparsentan						Interaction test:	0.951
eGFR Low and UP High	Sparsentan	71	9 (12.7)	NE		0.503	(0.201, 1.256)	0.141
	Irbesartan	74	10 (13.5)	NE				
eGFR Low and UP Low	Sparsentan	55	3 (5.5)	NE		0.890	(0.198, 3.995)	0.879
	Irbesartan	55	4 (7.3)	NE				
eGFR High and UP High	Sparsentan	37	4 (10.8)	NE		0.793	(0.175, 3.591)	0.764
	Irbesartan	36	3 (8.3)	NE				
eGFR High and UP Low	Sparsentan	39	2 (5.1)	NE		0.717	(0.115, 4.458)	0.721
	Irbesartan	37	3 (8.1)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KEFDT_FSTM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.762
< 60 mL/min/1.73 m**2	Sparsentan	127	13 (10.2)	NE		0.625	(0.291, 1.342)	0.228
	Irbesartan	129	15 (11.6)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	3 (6.1)	NE		1.099	(0.182, 6.634)	0.918
	Irbesartan	48	2 (4.2)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	2 (7.7)	NE		0.579	(0.090, 3.717)	0.564
	Irbesartan	25	3 (12.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KEFDT_FSTM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eGFR Group 2	Sparsentan						Interaction test:	0.090	
< 45 mL/min/1.73 m**2	Sparsentan	82	7 (8.5)	NE		0.348	(0.136, 0.887)	0.027	*
	Irbesartan	80	13 (16.3)	NE					
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	6 (13.3)	NE		3.229	(0.568, 18.361)	0.186	
	Irbesartan	49	2 (4.1)	NE					
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	3 (6.1)	NE		1.099	(0.182, 6.634)	0.918	
	Irbesartan	48	2 (4.2)	NE					
>= 90 mL/min/1.73 m**2	Sparsentan	26	2 (7.7)	NE		0.579	(0.090, 3.717)	0.564	
	Irbesartan	25	3 (12.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KEFDT_FSTM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline urine protein excretion	Sparsentan						Interaction test:	0.863
<= 1.75 g/day	Sparsentan	98	8 (8.2)	NE		0.644	(0.231, 1.801)	0.402
	Irbesartan	94	8 (8.5)	NE				
> 1.75 g/day	Sparsentan	104	10 (9.6)	NE		0.572	(0.246, 1.333)	0.196
	Irbesartan	108	12 (11.1)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KEFDT_FSTM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.824
Yes	Sparsentan	88	8 (9.1)	NE		0.562	(0.211, 1.498)	0.250
	Irbesartan	83	9 (10.8)	NE				
No	Sparsentan	114	10 (8.8)	NE		0.730	(0.308, 1.727)	0.474
	Irbesartan	119	11 (9.2)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KEFDT_FSTM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Time since renal biopsy	Sparsentan						Interaction test:	0.867
<= 5 years	Sparsentan	113	9 (8.0)	NE		0.565	(0.240, 1.333)	0.192
	Irbesartan	127	13 (10.2)	NE				
> 5 years	Sparsentan	89	9 (10.1)	NE		0.643	(0.232, 1.780)	0.395
	Irbesartan	75	7 (9.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KEFDT_FSTM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
History of hypertension	Sparsentan						Interaction test:	0.949
Yes	Sparsentan	153	10 (6.5)	NE		0.569	(0.240, 1.348)	0.200
	Irbesartan	157	11 (7.0)	NE				
No	Sparsentan	49	8 (16.3)	NE		0.718	(0.268, 1.926)	0.510
	Irbesartan	45	9 (20.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Figure PF1KEFDT_FSKM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Sex: Male



Sparsentan	139	91	71	52	25	8
Irbesartan	143	84	61	39	19	8

_____
A decrease reflects a worsening of the status of the patient.
Reference table: PT1KEFDT_FSTM

Figure PF1KEFDT_FSKM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Sex: Female



Sparsentan	63	42	38	29	9	3
Irbesartan	59	30	21	12	2	0

A decrease reflects a worsening of the status of the patient.
Reference table: PT1KEFDT_FSTM

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	139	130 (93.5)	90.82 (8.32)	61.4	86.36	93.18	97.73	100.0	
			Irbesartan	143	128 (89.5)	89.83 (11.36)	38.6	86.36	93.18	97.73	100.0	
		Week 24	Sparsentan	139	87 (62.6)	89.05 (12.90)	4.5	84.09	93.18	97.73	100.0	
			Irbesartan	143	73 (51.0)	87.33 (17.46)	4.5	86.36	93.18	97.73	100.0	
		Week 48	Sparsentan	139	72 (51.8)	87.82 (17.50)	0.0	84.09	90.91	97.73	100.0	
			Irbesartan	143	55 (38.5)	91.49 (12.04)	47.7	88.64	95.45	100.00	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	139	87 (62.6)	-1.67 (11.01)	-72.7	-4.55	0.00	4.55	25.0	0.08 [-0.23, 0.39]
			Irbesartan	143	73 (51.0)	-2.77 (16.40)	-90.9	-4.55	-2.27	2.27	52.3	
		Week 48	Sparsentan	139	72 (51.8)	-2.81 (18.16)	-100.0	-4.55	0.00	4.55	27.3	-0.17 [-0.52, 0.18]
			Irbesartan	143	55 (38.5)	-0.25 (8.65)	-27.3	-2.27	2.27	4.55	15.9	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Female	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	63	56 (88.9)	84.25 (15.21)	31.8	77.27	88.64	95.45	100.0	
			Irbesartan	59	51 (86.4)	88.19 (10.22)	50.0	81.82	90.91	95.45	100.0	
		Week 24	Sparsentan	63	38 (60.3)	87.32 (12.90)	54.5	79.55	92.05	97.73	100.0	
			Irbesartan	59	31 (52.5)	86.95 (18.70)	4.5	81.82	95.45	97.73	100.0	
		Week 48	Sparsentan	63	38 (60.3)	88.40 (12.58)	61.4	77.27	94.32	100.00	100.0	
			Irbesartan	59	22 (37.3)	85.02 (12.79)	54.5	77.27	88.64	93.18	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	63	38 (60.3)	4.37 (14.95)	-25.0	-2.27	2.27	11.36	63.6	0.35 [-0.12, 0.83]
			Irbesartan	59	31 (52.5)	-1.61 (19.02)	-86.4	-9.09	0.00	4.55	29.5	
		Week 48	Sparsentan	63	38 (60.3)	5.44 (15.09)	-22.7	-2.27	2.27	11.36	59.1	0.48 [-0.05, 1.01]
			Irbesartan	59	22 (37.3)	-1.24 (11.50)	-15.9	-9.09	-2.27	2.27	34.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
<= 45 years	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	96	87 (90.6)	88.53 (12.27)	31.8	84.09	90.91	97.73	100.0	
			Irbesartan	99	92 (92.9)	89.30 (11.00)	52.3	86.36	92.05	97.73	100.0	
		Week 24	Sparsentan	96	57 (59.4)	89.59 (15.00)	4.5	84.09	93.18	97.73	100.0	
			Irbesartan	99	53 (53.5)	85.76 (20.69)	4.5	86.36	90.91	97.73	100.0	
		Week 48	Sparsentan	96	53 (55.2)	87.82 (16.18)	0.0	81.82	90.91	97.73	100.0	
			Irbesartan	99	40 (40.4)	90.68 (12.89)	47.7	88.64	95.45	100.00	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	96	57 (59.4)	1.28 (14.77)	-72.7	-2.27	2.27	4.55	63.6	0.32 [-0.06, 0.70]
			Irbesartan	99	53 (53.5)	-3.99 (18.17)	-90.9	-6.82	0.00	2.27	15.9	
		Week 48	Sparsentan	96	53 (55.2)	-0.04 (17.42)	-90.9	-4.55	0.00	4.55	59.1	0.12 [-0.29, 0.53]
			Irbesartan	99	40 (40.4)	-1.70 (8.59)	-27.3	-4.55	0.00	2.27	11.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 45 years	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	106	99 (93.4)	89.12 (10.29)	38.6	84.09	90.91	95.45	100.0	
			Irbesartan	103	87 (84.5)	89.42 (11.15)	38.6	84.09	93.18	97.73	100.0	
		Week 24	Sparsentan	106	68 (64.2)	87.63 (10.80)	50.0	82.95	90.91	95.45	100.0	
			Irbesartan	103	51 (49.5)	88.73 (14.10)	11.4	84.09	93.18	97.73	100.0	
		Week 48	Sparsentan	106	57 (53.8)	88.20 (15.81)	0.0	84.09	93.18	97.73	100.0	
			Irbesartan	103	37 (35.9)	88.51 (12.19)	47.7	84.09	93.18	95.45	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	106	68 (64.2)	-0.77 (10.44)	-25.0	-6.82	-2.27	4.55	36.4	0.00 [-0.36, 0.37]
			Irbesartan	103	51 (49.5)	-0.80 (16.01)	-77.3	-4.55	0.00	2.27	52.3	
		Week 48	Sparsentan	106	57 (53.8)	0.12 (17.80)	-100.0	-4.55	0.00	6.82	38.6	-0.04 [-0.45, 0.37]
			Irbesartan	103	37 (35.9)	0.74 (10.32)	-27.3	-2.27	0.00	2.27	34.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age at IgAN diagnosis												
<= 18 years	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	9	9 (100.0)	85.86 (9.22)	75.0	77.27	84.09	93.18	100.0	
			Irbesartan	5	5 (100.0)	87.27 (19.85)	52.3	90.91	95.45	97.73	100.0	
		Week 24	Sparsentan	9	3 (33.3)	62.12 (50.33)	4.5	4.55	84.09	97.73	97.7	
			Irbesartan	5	2 (40.0)	67.05 (30.53)	45.5	45.45	67.05	88.64	88.6	
		Week 48	Sparsentan	9	5 (55.6)	86.82 (9.29)	75.0	81.82	88.64	88.64	100.0	
			Irbesartan	5	1 (20.0)	90.91	90.9	90.91	90.91	90.91	90.9	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	9	3 (33.3)	-25.00 (41.35)	-72.7	-72.73	-2.27	0.00	0.0	-0.54 [-2.36, 1.28]
			Irbesartan	5	2 (40.0)	-6.82 (0.00)	-6.8	-6.82	-6.82	-6.82	-6.8	
		Week 48	Sparsentan	9	5 (55.6)	-1.82 (6.31)	-11.4	-4.55	0.00	2.27	4.5	NE
			Irbesartan	5	1 (20.0)	-4.55	-4.5	-4.55	-4.55	-4.55	-4.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 18 to 40 years	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	102	93 (91.2)	89.10 (12.16)	31.8	84.09	90.91	97.73	100.0	
			Irbesartan	109	99 (90.8)	89.69 (10.19)	52.3	86.36	93.18	97.73	100.0	
		Week 24	Sparsentan	102	62 (60.8)	90.54 (10.21)	54.5	84.09	93.18	97.73	100.0	
			Irbesartan	109	59 (54.1)	88.75 (16.06)	4.5	86.36	95.45	97.73	100.0	
		Week 48	Sparsentan	102	57 (55.9)	88.28 (16.00)	0.0	81.82	93.18	97.73	100.0	
			Irbesartan	109	44 (40.4)	89.41 (13.41)	47.7	87.50	92.05	100.00	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	102	62 (60.8)	2.53 (10.74)	-18.2	-2.27	2.27	4.55	63.6	0.37 [0.01, 0.73]
			Irbesartan	109	59 (54.1)	-1.85 (12.88)	-86.4	-4.55	0.00	2.27	15.9	
		Week 48	Sparsentan	102	57 (55.9)	0.16 (16.97)	-90.9	-4.55	0.00	6.82	59.1	0.21 [-0.18, 0.61]
			Irbesartan	109	44 (40.4)	-2.84 (9.29)	-27.3	-7.95	0.00	2.27	11.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 40 years	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	91	84 (92.3)	88.88 (10.40)	38.6	85.23	90.91	95.45	100.0	
			Irbesartan	88	75 (85.2)	89.06 (11.58)	38.6	84.09	90.91	97.73	100.0	
		Week 24	Sparsentan	91	60 (65.9)	87.77 (10.69)	50.0	82.95	90.91	95.45	100.0	
			Irbesartan	88	43 (48.9)	86.05 (19.22)	4.5	81.82	90.91	95.45	100.0	
		Week 48	Sparsentan	91	48 (52.7)	87.83 (16.58)	0.0	82.95	90.91	97.73	100.0	
			Irbesartan	88	32 (36.4)	89.91 (11.60)	47.7	84.09	93.18	98.86	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	91	60 (65.9)	-1.02 (10.79)	-25.0	-6.82	-2.27	3.41	36.4	0.12 [-0.27, 0.51]
			Irbesartan	88	43 (48.9)	-3.01 (22.12)	-90.9	-4.55	-2.27	4.55	52.3	
		Week 48	Sparsentan	91	48 (52.7)	0.09 (19.14)	-100.0	-4.55	1.14	7.95	38.6	-0.17 [-0.62, 0.28]
			Irbesartan	88	32 (36.4)	2.77 (9.01)	-11.4	-2.27	1.14	5.68	34.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Geographic region												
North America	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	35	32 (91.4)	90.98 (8.05)	75.0	85.23	93.18	97.73	100.0	
			Irbesartan	46	43 (93.5)	90.91 (10.80)	50.0	86.36	93.18	100.00	100.0	
		Week 24	Sparsentan	35	15 (42.9)	88.64 (23.96)	4.5	90.91	97.73	100.00	100.0	
			Irbesartan	46	26 (56.5)	86.63 (19.14)	4.5	81.82	90.91	97.73	100.0	
		Week 48	Sparsentan	35	13 (37.1)	93.71 (8.66)	75.0	93.18	95.45	100.00	100.0	
			Irbesartan	46	17 (37.0)	89.30 (11.58)	65.9	84.09	93.18	100.00	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	35	15 (42.9)	-3.94 (19.60)	-72.7	-2.27	0.00	2.27	11.4	-0.07 [-0.70, 0.57]
			Irbesartan	46	26 (56.5)	-2.62 (19.01)	-86.4	-4.55	0.00	2.27	29.5	
		Week 48	Sparsentan	35	13 (37.1)	1.92 (6.62)	-4.5	-2.27	0.00	2.27	18.2	-0.02 [-0.74, 0.70]
			Irbesartan	46	17 (37.0)	2.14 (11.21)	-15.9	-2.27	2.27	2.27	34.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Europe	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	98	87 (88.8)	88.27 (13.03)	31.8	84.09	90.91	97.73	100.0	
			Irbesartan	115	96 (83.5)	88.68 (11.56)	38.6	84.09	90.91	96.59	100.0	
		Week 24	Sparsentan	98	53 (54.1)	88.72 (10.50)	59.1	84.09	93.18	97.73	100.0	
			Irbesartan	115	47 (40.9)	86.32 (20.10)	4.5	84.09	93.18	97.73	100.0	
		Week 48	Sparsentan	98	44 (44.9)	85.64 (17.36)	0.0	79.55	88.64	97.73	100.0	
			Irbesartan	115	38 (33.0)	88.40 (14.23)	47.7	84.09	92.05	100.00	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	98	53 (54.1)	1.76 (13.99)	-25.0	-4.55	0.00	4.55	63.6	0.31 [-0.08, 0.71]
			Irbesartan	115	47 (40.9)	-3.58 (20.05)	-90.9	-6.82	0.00	4.55	52.3	
		Week 48	Sparsentan	98	44 (44.9)	0.21 (21.27)	-100.0	-6.82	0.00	6.82	59.1	0.17 [-0.27, 0.60]
			Irbesartan	115	38 (33.0)	-2.63 (9.46)	-27.3	-6.82	0.00	2.27	11.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asia Pacific	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	69	67 (97.1)	88.57 (9.98)	50.0	84.09	88.64	97.73	100.0	
			Irbesartan	41	40 (97.6)	89.32 (10.10)	52.3	85.23	93.18	95.45	100.0	
		Week 24	Sparsentan	69	57 (82.6)	88.32 (10.99)	50.0	84.09	90.91	97.73	100.0	
			Irbesartan	41	31 (75.6)	89.08 (12.30)	50.0	86.36	95.45	95.45	100.0	
		Week 48	Sparsentan	69	53 (76.8)	88.59 (15.85)	0.0	81.82	93.18	97.73	100.0	
			Irbesartan	41	22 (53.7)	92.05 (9.99)	54.5	90.91	93.18	100.00	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	69	57 (82.6)	-0.24 (8.13)	-22.7	-4.55	0.00	4.55	13.6	0.03 [-0.41, 0.47]
			Irbesartan	41	31 (75.6)	-0.51 (9.20)	-25.0	-4.55	0.00	2.27	20.5	
		Week 48	Sparsentan	69	53 (76.8)	-0.56 (16.10)	-90.9	-4.55	0.00	9.09	27.3	-0.11 [-0.61, 0.39]
			Irbesartan	41	22 (53.7)	1.03 (7.45)	-15.9	-2.27	0.00	4.55	20.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline BMI												
< 27 kg/m**2	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	84	76 (90.5)	89.17 (9.64)	47.7	84.09	89.77	97.73	100.0	
			Irbesartan	94	84 (89.4)	89.07 (10.98)	38.6	86.36	90.91	95.45	100.0	
		Week 24	Sparsentan	84	52 (61.9)	88.02 (15.75)	4.5	84.09	93.18	97.73	100.0	
			Irbesartan	94	50 (53.2)	86.36 (17.33)	4.5	81.82	92.05	97.73	100.0	
		Week 48	Sparsentan	84	47 (56.0)	89.22 (11.14)	65.9	79.55	93.18	100.00	100.0	
			Irbesartan	94	36 (38.3)	86.36 (15.35)	47.7	78.41	90.91	100.00	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	84	52 (61.9)	-1.40 (13.45)	-72.7	-6.82	0.00	4.55	20.5	0.03 [-0.35, 0.42]
			Irbesartan	94	50 (53.2)	-1.91 (16.31)	-86.4	-6.82	0.00	4.55	52.3	
		Week 48	Sparsentan	84	47 (56.0)	0.73 (10.03)	-18.2	-6.82	0.00	6.82	25.0	0.40 [-0.04, 0.84]
			Irbesartan	94	36 (38.3)	-3.16 (9.13)	-27.3	-6.82	0.00	2.27	11.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 27 kg/m**2	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	118	110 (93.2)	88.62 (12.25)	31.8	84.09	90.91	97.73	100.0	
			Irbesartan	107	94 (87.9)	89.94 (10.75)	47.7	84.09	93.18	97.73	100.0	
		Week 24	Sparsentan	118	73 (61.9)	88.89 (10.45)	50.0	84.09	90.91	97.73	100.0	
			Irbesartan	107	54 (50.5)	88.01 (18.25)	4.5	86.36	93.18	97.73	100.0	
		Week 48	Sparsentan	118	63 (53.4)	87.12 (18.75)	0.0	81.82	90.91	97.73	100.0	
			Irbesartan	107	41 (38.3)	92.52 (8.58)	61.4	90.91	95.45	100.00	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	118	73 (61.9)	1.28 (11.91)	-22.7	-4.55	0.00	4.55	63.6	0.28 [-0.07, 0.64]
			Irbesartan	107	54 (50.5)	-2.90 (18.01)	-90.9	-4.55	0.00	2.27	29.5	
		Week 48	Sparsentan	118	63 (53.4)	-0.47 (21.57)	-100.0	-4.55	0.00	6.82	59.1	-0.13 [-0.52, 0.27]
			Irbesartan	107	41 (38.3)	1.77 (9.28)	-15.9	-2.27	2.27	4.55	34.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Randomization strata												
eGFR Low and UP High	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	71	63 (88.7)	90.73 (8.57)	63.6	86.36	93.18	97.73	100.0	
			Irbesartan	74	63 (85.1)	86.51 (13.18)	38.6	81.82	88.64	95.45	100.0	
		Week 24	Sparsentan	71	44 (62.0)	89.46 (10.49)	50.0	85.23	93.18	96.59	100.0	
			Irbesartan	74	32 (43.2)	86.22 (13.19)	45.5	82.95	88.64	94.32	100.0	
		Week 48	Sparsentan	71	37 (52.1)	91.46 (9.71)	65.9	88.64	95.45	100.00	100.0	
			Irbesartan	74	22 (29.7)	84.71 (14.93)	47.7	79.55	90.91	95.45	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	71	44 (62.0)	-2.17 (8.74)	-25.0	-4.55	-2.27	2.27	25.0	-0.03 [-0.49, 0.42]
			Irbesartan	74	32 (43.2)	-1.85 (11.84)	-22.7	-6.82	-2.27	0.00	52.3	
		Week 48	Sparsentan	71	37 (52.1)	0.31 (9.97)	-20.5	-4.55	0.00	6.82	27.3	0.35 [-0.18, 0.89]
			Irbesartan	74	22 (29.7)	-3.20 (9.86)	-27.3	-6.82	0.00	2.27	11.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR Low and UP Low	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	55	51 (92.7)	86.54 (14.68)	31.8	84.09	88.64	97.73	100.0	
			Irbesartan	55	49 (89.1)	90.58 (7.35)	75.0	84.09	93.18	95.45	100.0	
		Week 24	Sparsentan	55	38 (69.1)	88.04 (10.59)	63.6	81.82	90.91	97.73	100.0	
			Irbesartan	55	33 (60.0)	92.22 (9.13)	68.2	88.64	95.45	97.73	100.0	
		Week 48	Sparsentan	55	28 (50.9)	82.14 (25.21)	0.0	78.41	90.91	95.45	100.0	
			Irbesartan	55	25 (45.5)	90.00 (10.56)	61.4	86.36	90.91	100.00	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	55	38 (69.1)	3.17 (14.22)	-18.2	-6.82	0.00	6.82	63.6	0.17 [-0.30, 0.64]
			Irbesartan	55	33 (60.0)	1.17 (7.85)	-18.2	-2.27	0.00	4.55	20.5	
		Week 48	Sparsentan	55	28 (50.9)	-1.95 (31.02)	-100.0	-4.55	0.00	11.36	59.1	-0.03 [-0.56, 0.51]
			Irbesartan	55	25 (45.5)	-1.36 (8.55)	-15.9	-9.09	0.00	2.27	20.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP High	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	37	35 (94.6)	88.05 (9.38)	65.9	84.09	88.64	97.73	100.0	
			Irbesartan	36	31 (86.1)	90.25 (10.63)	50.0	84.09	93.18	97.73	100.0	
		Week 24	Sparsentan	37	19 (51.4)	85.89 (21.86)	4.5	84.09	88.64	100.00	100.0	
			Irbesartan	36	18 (50.0)	86.99 (19.96)	11.4	86.36	92.05	95.45	100.0	
		Week 48	Sparsentan	37	22 (59.5)	87.09 (12.88)	61.4	77.27	89.77	97.73	100.0	
			Irbesartan	36	11 (30.6)	88.22 (14.55)	47.7	84.09	90.91	97.73	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	37	19 (51.4)	-1.32 (19.61)	-72.7	-2.27	0.00	9.09	22.7	0.05 [-0.60, 0.69]
			Irbesartan	36	18 (50.0)	-2.27 (21.05)	-77.3	-6.82	0.00	4.55	29.5	
		Week 48	Sparsentan	37	22 (59.5)	0.93 (11.15)	-22.7	-4.55	-1.14	11.36	20.5	-0.04 [-0.77, 0.68]
			Irbesartan	36	11 (30.6)	1.45 (14.77)	-27.3	-4.55	2.27	6.82	34.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP Low	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	39	37 (94.9)	89.56 (11.19)	50.0	86.36	90.91	97.73	100.0	
			Irbesartan	37	36 (97.3)	91.92 (10.83)	52.3	89.77	95.45	97.73	100.0	
		Week 24	Sparsentan	39	24 (61.5)	89.68 (11.11)	54.5	84.09	93.18	97.73	100.0	
			Irbesartan	37	21 (56.8)	81.06 (28.23)	4.5	75.00	95.45	95.45	97.7	
		Week 48	Sparsentan	39	23 (59.0)	90.51 (9.56)	65.9	88.64	93.18	97.73	100.0	
			Irbesartan	37	19 (51.4)	95.69 (8.12)	65.9	93.18	100.00	100.00	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	39	24 (61.5)	0.85 (7.58)	-22.7	0.00	2.27	4.55	13.6	0.51 [-0.09, 1.10]
			Irbesartan	37	21 (56.8)	-9.09 (27.41)	-90.9	-4.55	0.00	2.27	11.4	
		Week 48	Sparsentan	39	23 (59.0)	1.19 (7.34)	-11.4	-2.27	0.00	6.82	15.9	-0.21 [-0.82, 0.40]
			Irbesartan	37	19 (51.4)	2.51 (5.02)	-6.8	0.00	2.27	4.55	15.9	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 1												
< 60 mL/min/1.73 m**2	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	127	115 (90.6)	88.99 (11.78)	31.8	84.09	90.91	97.73	100.0	
			Irbesartan	129	113 (87.6)	88.66 (11.11)	38.6	84.09	90.91	95.45	100.0	
		Week 24	Sparsentan	127	83 (65.4)	88.64 (10.34)	50.0	84.09	93.18	95.45	100.0	
			Irbesartan	129	68 (52.7)	88.03 (15.38)	4.5	84.09	93.18	97.73	100.0	
		Week 48	Sparsentan	127	65 (51.2)	87.41 (18.51)	0.0	84.09	90.91	97.73	100.0	
			Irbesartan	129	49 (38.0)	88.03 (12.82)	47.7	79.55	93.18	97.73	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	127	83 (65.4)	0.05 (11.77)	-25.0	-4.55	-2.27	4.55	63.6	0.13 [-0.19, 0.45]
			Irbesartan	129	68 (52.7)	-1.70 (14.73)	-90.9	-5.68	0.00	2.27	52.3	
		Week 48	Sparsentan	127	65 (51.2)	-0.77 (21.50)	-100.0	-4.55	0.00	6.82	59.1	0.05 [-0.32, 0.42]
			Irbesartan	129	49 (38.0)	-1.58 (9.36)	-27.3	-6.82	0.00	2.27	20.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	49	47 (95.9)	88.83 (9.65)	50.0	84.09	88.64	97.73	100.0	
			Irbesartan	48	43 (89.6)	89.64 (10.62)	50.0	86.36	93.18	97.73	100.0	
		Week 24	Sparsentan	49	27 (55.1)	86.28 (19.69)	4.5	84.09	93.18	97.73	100.0	
			Irbesartan	48	24 (50.0)	87.12 (17.83)	11.4	85.23	92.05	95.45	100.0	
		Week 48	Sparsentan	49	29 (59.2)	87.70 (11.14)	65.9	81.82	88.64	97.73	100.0	
			Irbesartan	48	19 (39.6)	90.19 (13.30)	47.7	88.64	90.91	100.00	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	49	27 (55.1)	-2.27 (16.46)	-72.7	-2.27	0.00	4.55	13.6	-0.04 [-0.59, 0.51]
			Irbesartan	48	24 (50.0)	-1.61 (18.20)	-77.3	-4.55	1.14	4.55	29.5	
		Week 48	Sparsentan	49	29 (59.2)	0.08 (9.02)	-22.7	-6.82	0.00	4.55	18.2	-0.09 [-0.67, 0.49]
			Irbesartan	48	19 (39.6)	0.96 (11.40)	-27.3	-2.27	0.00	2.27	34.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	26	24 (92.3)	88.16 (11.84)	61.4	81.82	89.77	97.73	100.0	
			Irbesartan	25	23 (92.0)	92.29 (11.48)	52.3	88.64	97.73	100.00	100.0	
		Week 24	Sparsentan	26	15 (57.7)	91.97 (9.94)	70.5	88.64	97.73	100.00	100.0	
			Irbesartan	25	12 (48.0)	82.77 (28.58)	4.5	81.82	95.45	97.73	100.0	
		Week 48	Sparsentan	26	16 (61.5)	91.05 (11.66)	61.4	81.82	96.59	100.00	100.0	
			Irbesartan	25	9 (36.0)	97.22 (4.92)	88.6	97.73	100.00	100.00	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	26	15 (57.7)	5.15 (7.16)	-6.8	0.00	2.27	9.09	22.7	0.73 [-0.06, 1.51]
			Irbesartan	25	12 (48.0)	-8.14 (26.39)	-86.4	-5.68	-1.14	2.27	11.4	
		Week 48	Sparsentan	26	16 (61.5)	3.27 (9.82)	-18.2	-1.14	2.27	11.36	20.5	0.15 [-0.67, 0.97]
			Irbesartan	25	9 (36.0)	2.02 (4.01)	-6.8	2.27	2.27	2.27	6.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 2												
< 45 mL/min/1.73 m**2	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	82	71 (86.6)	87.74 (11.84)	31.8	81.82	90.91	95.45	100.0	
			Irbesartan	80	69 (86.3)	87.09 (12.66)	38.6	81.82	90.91	95.45	100.0	
		Week 24	Sparsentan	82	53 (64.6)	88.68 (10.11)	50.0	84.09	90.91	95.45	100.0	
			Irbesartan	80	45 (56.3)	87.73 (12.82)	45.5	84.09	90.91	97.73	100.0	
		Week 48	Sparsentan	82	42 (51.2)	86.53 (16.91)	0.0	79.55	90.91	95.45	100.0	
			Irbesartan	80	29 (36.3)	85.03 (14.95)	47.7	72.73	90.91	95.45	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	82	53 (64.6)	0.81 (12.54)	-22.7	-6.82	-2.27	4.55	63.6	0.13 [-0.27, 0.53]
			Irbesartan	80	45 (56.3)	-0.71 (11.09)	-22.7	-6.82	-2.27	2.27	52.3	
		Week 48	Sparsentan	82	42 (51.2)	-0.27 (20.08)	-90.9	-4.55	0.00	9.09	59.1	0.17 [-0.30, 0.64]
			Irbesartan	80	29 (36.3)	-3.13 (10.48)	-27.3	-9.09	0.00	2.27	20.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
45 to < 60 mL/min/1.73 m**2	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	45	44 (97.8)	91.01 (11.55)	38.6	86.36	95.45	98.86	100.0	
			Irbesartan	49	44 (89.8)	91.12 (7.61)	68.2	86.36	93.18	97.73	100.0	
		Week 24	Sparsentan	45	30 (66.7)	88.56 (10.90)	59.1	81.82	93.18	95.45	100.0	
			Irbesartan	49	23 (46.9)	88.64 (19.78)	4.5	88.64	95.45	97.73	100.0	
		Week 48	Sparsentan	45	23 (51.1)	89.03 (21.44)	0.0	86.36	97.73	100.00	100.0	
			Irbesartan	49	20 (40.8)	92.39 (7.24)	77.3	88.64	93.18	98.86	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	45	30 (66.7)	-1.29 (10.33)	-25.0	-4.55	-2.27	4.55	36.4	0.15 [-0.39, 0.70]
			Irbesartan	49	23 (46.9)	-3.66 (20.21)	-90.9	-4.55	0.00	2.27	15.9	
		Week 48	Sparsentan	45	23 (51.1)	-1.68 (24.34)	-100.0	-2.27	0.00	6.82	38.6	-0.13 [-0.73, 0.47]
			Irbesartan	49	20 (40.8)	0.68 (7.11)	-13.6	-1.14	0.00	4.55	15.9	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	49	47 (95.9)	88.83 (9.65)	50.0	84.09	88.64	97.73	100.0	
			Irbesartan	48	43 (89.6)	89.64 (10.62)	50.0	86.36	93.18	97.73	100.0	
		Week 24	Sparsentan	49	27 (55.1)	86.28 (19.69)	4.5	84.09	93.18	97.73	100.0	
			Irbesartan	48	24 (50.0)	87.12 (17.83)	11.4	85.23	92.05	95.45	100.0	
		Week 48	Sparsentan	49	29 (59.2)	87.70 (11.14)	65.9	81.82	88.64	97.73	100.0	
			Irbesartan	48	19 (39.6)	90.19 (13.30)	47.7	88.64	90.91	100.00	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	49	27 (55.1)	-2.27 (16.46)	-72.7	-2.27	0.00	4.55	13.6	-0.04 [-0.59, 0.51]
			Irbesartan	48	24 (50.0)	-1.61 (18.20)	-77.3	-4.55	1.14	4.55	29.5	
		Week 48	Sparsentan	49	29 (59.2)	0.08 (9.02)	-22.7	-6.82	0.00	4.55	18.2	-0.09 [-0.67, 0.49]
			Irbesartan	48	19 (39.6)	0.96 (11.40)	-27.3	-2.27	0.00	2.27	34.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	26	24 (92.3)	88.16 (11.84)	61.4	81.82	89.77	97.73	100.0	
			Irbesartan	25	23 (92.0)	92.29 (11.48)	52.3	88.64	97.73	100.00	100.0	
		Week 24	Sparsentan	26	15 (57.7)	91.97 (9.94)	70.5	88.64	97.73	100.00	100.0	
			Irbesartan	25	12 (48.0)	82.77 (28.58)	4.5	81.82	95.45	97.73	100.0	
		Week 48	Sparsentan	26	16 (61.5)	91.05 (11.66)	61.4	81.82	96.59	100.00	100.0	
			Irbesartan	25	9 (36.0)	97.22 (4.92)	88.6	97.73	100.00	100.00	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	26	15 (57.7)	5.15 (7.16)	-6.8	0.00	2.27	9.09	22.7	0.73 [-0.06, 1.51]
			Irbesartan	25	12 (48.0)	-8.14 (26.39)	-86.4	-5.68	-1.14	2.27	11.4	
		Week 48	Sparsentan	26	16 (61.5)	3.27 (9.82)	-18.2	-1.14	2.27	11.36	20.5	0.15 [-0.67, 0.97]
			Irbesartan	25	9 (36.0)	2.02 (4.01)	-6.8	2.27	2.27	2.27	6.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline urine protein excretion												
<= 1.75 g/day	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	98	92 (93.9)	88.02 (13.43)	31.8	84.09	90.91	97.73	100.0	
			Irbesartan	94	82 (87.2)	90.55 (9.51)	52.3	86.36	93.18	97.73	100.0	
		Week 24	Sparsentan	98	66 (67.3)	87.78 (10.66)	54.5	81.82	89.77	97.73	100.0	
			Irbesartan	94	43 (45.7)	87.32 (21.28)	4.5	86.36	95.45	97.73	100.0	
		Week 48	Sparsentan	98	59 (60.2)	86.90 (19.26)	0.0	79.55	93.18	97.73	100.0	
			Irbesartan	94	34 (36.2)	93.65 (9.56)	65.9	90.91	98.86	100.00	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	98	66 (67.3)	0.90 (12.19)	-22.7	-6.82	0.00	4.55	63.6	0.24 [-0.14, 0.63]
			Irbesartan	94	43 (45.7)	-3.01 (20.47)	-90.9	-2.27	0.00	4.55	20.5	
		Week 48	Sparsentan	98	59 (60.2)	-0.04 (22.18)	-100.0	-4.55	0.00	6.82	59.1	-0.08 [-0.51, 0.34]
			Irbesartan	94	34 (36.2)	1.47 (6.50)	-15.9	0.00	2.27	4.55	20.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 1.75 g/day	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	104	94 (90.4)	89.65 (8.56)	65.9	84.09	90.91	97.73	100.0	
			Irbesartan	108	97 (89.8)	88.36 (12.15)	38.6	84.09	90.91	97.73	100.0	
		Week 24	Sparsentan	104	59 (56.7)	89.37 (15.01)	4.5	88.64	93.18	97.73	100.0	
			Irbesartan	108	61 (56.5)	87.15 (14.95)	11.4	84.09	90.91	95.45	100.0	
		Week 48	Sparsentan	104	51 (49.0)	89.30 (10.90)	61.4	81.82	90.91	97.73	100.0	
			Irbesartan	108	43 (39.8)	86.47 (13.73)	47.7	79.55	90.91	95.45	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	104	59 (56.7)	-0.65 (13.08)	-72.7	-4.55	0.00	4.55	25.0	0.10 [-0.26, 0.46]
			Irbesartan	108	61 (56.5)	-2.01 (14.51)	-77.3	-6.82	-2.27	2.27	52.3	
		Week 48	Sparsentan	104	51 (49.0)	0.13 (9.99)	-20.5	-6.82	0.00	6.82	27.3	0.21 [-0.19, 0.62]
			Irbesartan	108	43 (39.8)	-2.11 (11.12)	-27.3	-9.09	0.00	2.27	34.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline use of antihypertensives												
Yes	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	88	77 (87.5)	88.34 (10.76)	38.6	84.09	90.91	95.45	100.0	
			Irbesartan	83	70 (84.3)	89.06 (10.21)	38.6	86.36	90.91	95.45	100.0	
		Week 24	Sparsentan	88	50 (56.8)	88.00 (11.39)	50.0	84.09	88.64	97.73	100.0	
			Irbesartan	83	39 (47.0)	90.09 (8.89)	56.8	86.36	93.18	95.45	100.0	
		Week 48	Sparsentan	88	41 (46.6)	90.02 (10.21)	61.4	88.64	90.91	97.73	100.0	
			Irbesartan	83	28 (33.7)	89.69 (11.99)	47.7	90.91	93.18	95.45	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	88	50 (56.8)	0.23 (10.96)	-25.0	-4.55	0.00	4.55	36.4	-0.01 [-0.42, 0.41]
			Irbesartan	83	39 (47.0)	0.29 (10.80)	-22.7	-4.55	0.00	2.27	52.3	
		Week 48	Sparsentan	88	41 (46.6)	2.99 (11.17)	-18.2	-2.27	2.27	6.82	38.6	0.29 [-0.20, 0.77]
			Irbesartan	83	28 (33.7)	0.00 (9.34)	-27.3	-2.27	0.00	4.55	15.9	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	114	109 (95.6)	89.20 (11.60)	31.8	84.09	90.91	97.73	100.0	
			Irbesartan	119	109 (91.6)	89.55 (11.59)	47.7	86.36	93.18	97.73	100.0	
		Week 24	Sparsentan	114	75 (65.8)	88.88 (13.83)	4.5	84.09	93.18	97.73	100.0	
			Irbesartan	119	65 (54.6)	85.49 (21.25)	4.5	81.82	93.18	97.73	100.0	
		Week 48	Sparsentan	114	69 (60.5)	86.82 (18.46)	0.0	79.55	93.18	97.73	100.0	
			Irbesartan	119	49 (41.2)	89.61 (12.94)	47.7	84.09	90.91	100.00	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	114	75 (65.8)	0.12 (13.64)	-72.7	-4.55	0.00	4.55	63.6	0.25 [-0.09, 0.58]
			Irbesartan	119	65 (54.6)	-4.06 (19.90)	-90.9	-6.82	0.00	2.27	29.5	
		Week 48	Sparsentan	114	69 (60.5)	-1.71 (20.28)	-100.0	-4.55	0.00	6.82	59.1	-0.05 [-0.42, 0.31]
			Irbesartan	119	49 (41.2)	-0.83 (9.64)	-27.3	-6.82	0.00	2.27	34.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Time since renal biopsy												
<= 5 years	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	113	104 (92.0)	88.81 (11.12)	38.6	84.09	90.91	97.73	100.0	
			Irbesartan	127	116 (91.3)	88.81 (12.03)	38.6	84.09	92.05	97.73	100.0	
		Week 24	Sparsentan	113	70 (61.9)	90.10 (10.53)	50.0	86.36	93.18	97.73	100.0	
			Irbesartan	127	67 (52.8)	85.45 (20.51)	4.5	81.82	93.18	97.73	100.0	
		Week 48	Sparsentan	113	61 (54.0)	89.79 (14.79)	0.0	86.36	93.18	100.00	100.0	
			Irbesartan	127	51 (40.2)	89.71 (13.68)	47.7	88.64	93.18	100.00	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	113	70 (61.9)	2.31 (8.92)	-22.7	-2.27	2.27	4.55	36.4	0.35 [0.01, 0.68]
			Irbesartan	127	67 (52.8)	-3.22 (20.90)	-90.9	-4.55	0.00	2.27	52.3	
		Week 48	Sparsentan	113	61 (54.0)	2.42 (16.70)	-100.0	-2.27	2.27	11.36	38.6	0.13 [-0.24, 0.50]
			Irbesartan	127	51 (40.2)	0.62 (9.61)	-27.3	-2.27	2.27	4.55	34.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 5 years	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	89	82 (92.1)	88.89 (11.45)	31.8	84.09	90.91	97.73	100.0	
			Irbesartan	75	63 (84.0)	90.37 (8.95)	52.3	86.36	93.18	97.73	100.0	
		Week 24	Sparsentan	89	55 (61.8)	86.53 (15.21)	4.5	79.55	88.64	97.73	100.0	
			Irbesartan	75	37 (49.3)	90.42 (10.63)	45.5	88.64	93.18	97.73	100.0	
		Week 48	Sparsentan	89	49 (55.1)	85.81 (17.12)	0.0	79.55	90.91	97.73	100.0	
			Irbesartan	75	26 (34.7)	89.51 (10.12)	61.4	84.09	90.91	95.45	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	89	55 (61.8)	-2.56 (15.77)	-72.7	-6.82	-2.27	2.27	63.6	-0.12 [-0.54, 0.29]
			Irbesartan	75	37 (49.3)	-0.98 (6.00)	-18.2	-4.55	-2.27	2.27	11.4	
		Week 48	Sparsentan	89	49 (55.1)	-2.92 (18.27)	-90.9	-6.82	-2.27	4.55	59.1	-0.01 [-0.48, 0.47]
			Irbesartan	75	26 (34.7)	-2.80 (8.96)	-27.3	-9.09	-1.14	2.27	11.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: History of hypertension												
Yes	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	153	138 (90.2)	88.18 (10.81)	38.6	84.09	90.91	95.45	100.0	
			Irbesartan	157	135 (86.0)	89.68 (10.49)	38.6	84.09	93.18	97.73	100.0	
		Week 24	Sparsentan	153	94 (61.4)	88.47 (11.24)	50.0	84.09	92.05	97.73	100.0	
			Irbesartan	157	76 (48.4)	89.41 (13.81)	4.5	86.36	93.18	97.73	100.0	
		Week 48	Sparsentan	153	81 (52.9)	87.88 (14.63)	0.0	81.82	90.91	97.73	100.0	
			Irbesartan	157	57 (36.3)	89.87 (12.73)	47.7	88.64	93.18	100.00	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	153	94 (61.4)	0.85 (9.46)	-25.0	-4.55	0.00	4.55	36.4	0.13 [-0.17, 0.44]
			Irbesartan	157	76 (48.4)	-0.72 (13.96)	-90.9	-4.55	0.00	2.27	52.3	
		Week 48	Sparsentan	153	81 (52.9)	0.28 (14.76)	-90.9	-4.55	0.00	6.82	38.6	0.06 [-0.28, 0.40]
			Irbesartan	157	57 (36.3)	-0.48 (10.08)	-27.3	-4.55	0.00	4.55	34.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	49	48 (98.0)	90.77 (12.30)	31.8	87.50	95.45	100.00	100.0	
			Irbesartan	45	44 (97.8)	88.38 (12.67)	47.7	86.36	90.91	98.86	100.0	
		Week 24	Sparsentan	49	31 (63.3)	88.71 (17.11)	4.5	84.09	93.18	97.73	100.0	
			Irbesartan	45	28 (62.2)	81.25 (24.91)	4.5	71.59	92.05	97.73	100.0	
		Week 48	Sparsentan	49	29 (59.2)	88.40 (19.35)	0.0	86.36	93.18	100.00	100.0	
			Irbesartan	45	20 (44.4)	88.98 (12.19)	54.5	85.23	90.91	100.00	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	49	31 (63.3)	-1.91 (19.29)	-72.7	-6.82	0.00	4.55	63.6	0.24 [-0.27, 0.75]
			Irbesartan	45	28 (62.2)	-7.06 (23.43)	-86.4	-7.95	-2.27	4.55	20.5	
		Week 48	Sparsentan	49	29 (59.2)	-0.63 (23.96)	-100.0	-6.82	0.00	11.36	59.1	0.00 [-0.57, 0.57]
			Irbesartan	45	20 (44.4)	-0.68 (7.74)	-13.6	-4.55	0.00	2.27	20.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Sex	Overall	Sparsentan						Interaction:	0.117
Male	Week 24	Sparsentan	139	87 (62.6)	-1.63 (1.50)	(-4.58, 1.31)	1.32 (2.22)	(-3.05, 5.68)	0.553
		Irbesartan	143	73 (51.0)	-2.95 (1.63)	(-6.16, 0.26)			
	Week 48	Sparsentan	139	72 (51.8)	-2.87 (1.64)	(-6.10, 0.36)	-2.94 (2.51)	(-7.87, 2.00)	0.243
		Irbesartan	143	55 (38.5)	0.06 (1.89)	(-3.66, 3.79)			
Female	Week 24	Sparsentan	63	38 (60.3)	3.06 (2.15)	(-1.21, 7.33)	3.42 (3.33)	(-3.20, 10.04)	0.307
		Irbesartan	59	31 (52.5)	-0.36 (2.51)	(-5.35, 4.62)			
	Week 48	Sparsentan	63	38 (60.3)	4.21 (2.14)	(-0.03, 8.46)	7.07 (3.51)	(0.10, 14.03)	0.047 *
		Irbesartan	59	22 (37.3)	-2.85 (2.75)	(-8.30, 2.59)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age	Overall	Sparsentan						Interaction:	0.355
<= 45 years	Week 24	Sparsentan	96	57 (59.4)	0.77 (1.99)	(-3.15, 4.69)	4.36 (2.87)	(-1.29, 10.02)	0.130
		Irbesartan	99	53 (53.5)	-3.60 (2.05)	(-7.65, 0.46)			
	Week 48	Sparsentan	96	53 (55.2)	-0.90 (2.06)	(-4.96, 3.16)	0.20 (3.15)	(-6.02, 6.42)	0.950
		Irbesartan	99	40 (40.4)	-1.10 (2.38)	(-5.79, 3.59)			
> 45 years	Week 24	Sparsentan	106	68 (64.2)	-1.56 (1.55)	(-4.62, 1.49)	-1.62 (2.39)	(-6.34, 3.09)	0.497
		Irbesartan	103	51 (49.5)	0.06 (1.81)	(-3.52, 3.64)			
	Week 48	Sparsentan	106	57 (53.8)	0.11 (1.67)	(-3.18, 3.39)	0.59 (2.66)	(-4.66, 5.84)	0.824
		Irbesartan	103	37 (35.9)	-0.49 (2.07)	(-4.57, 3.59)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age at IgAN diagnosis	Overall	Sparsentan						Interaction:	0.677
<= 18 years	Week 24	Sparsentan	9	3 (33.3)	-11.63 (14.66)	(-50.27, 27.00)	-9.73 (28.35)	(-88.56, 69.10)	0.749
		Irbesartan	5	2 (40.0)	-1.90 (24.05)	(-70.32, 66.51)			
	Week 48	Sparsentan	9	5 (55.6)	-11.52 (13.46)	(-49.14, 26.10)	-11.72 (28.63)	(-90.30, 66.85)	0.703
		Irbesartan	5	1 (20.0)	0.21 (25.12)	(-68.03, 68.44)			
> 18 to 40 years	Week 24	Sparsentan	102	62 (60.8)	2.18 (1.55)	(-0.88, 5.24)	3.55 (2.23)	(-0.84, 7.95)	0.113
		Irbesartan	109	59 (54.1)	-1.37 (1.59)	(-4.52, 1.77)			
	Week 48	Sparsentan	102	57 (55.9)	-0.39 (1.62)	(-3.58, 2.80)	2.49 (2.46)	(-2.37, 7.35)	0.314
		Irbesartan	109	44 (40.4)	-2.88 (1.84)	(-6.51, 0.75)			
> 40 years	Week 24	Sparsentan	91	60 (65.9)	-1.03 (1.89)	(-4.75, 2.70)	1.49 (2.89)	(-4.22, 7.20)	0.608
		Irbesartan	88	43 (48.9)	-2.51 (2.21)	(-6.87, 1.84)			
	Week 48	Sparsentan	91	48 (52.7)	-0.21 (2.10)	(-4.35, 3.93)	-2.09 (3.34)	(-8.68, 4.49)	0.532
		Irbesartan	88	32 (36.4)	1.88 (2.60)	(-3.25, 7.01)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Geographic region	Overall	Sparsentan						Interaction:	0.633
North America	Week 24	Sparsentan	35	15 (42.9)	-2.45 (4.53)	(-11.60, 6.70)	0.31 (5.86)	(-11.51, 12.14)	0.957
		Irbesartan	46	26 (56.5)	-2.76 (3.65)	(-10.13, 4.61)			
	Week 48	Sparsentan	35	13 (37.1)	-0.99 (4.61)	(-10.29, 8.31)	2.07 (6.03)	(-10.07, 14.21)	0.733
		Irbesartan	46	17 (37.0)	-3.06 (3.81)	(-10.72, 4.60)			
Europe	Week 24	Sparsentan	98	53 (54.1)	0.78 (2.06)	(-3.29, 4.86)	3.31 (3.01)	(-2.64, 9.26)	0.273
		Irbesartan	115	47 (40.9)	-2.53 (2.20)	(-6.87, 1.81)			
	Week 48	Sparsentan	98	44 (44.9)	-0.98 (2.28)	(-5.48, 3.51)	0.57 (3.38)	(-6.10, 7.23)	0.867
		Irbesartan	115	38 (33.0)	-1.55 (2.46)	(-6.40, 3.30)			
Asia Pacific	Week 24	Sparsentan	69	57 (82.6)	-0.27 (1.46)	(-3.16, 2.61)	0.38 (2.47)	(-4.51, 5.27)	0.879
		Irbesartan	41	31 (75.6)	-0.65 (1.99)	(-4.57, 3.27)			
	Week 48	Sparsentan	69	53 (76.8)	-0.53 (1.52)	(-3.53, 2.47)	-1.88 (2.82)	(-7.45, 3.70)	0.507
		Irbesartan	41	22 (53.7)	1.34 (2.37)	(-3.33, 6.02)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline BMI	Overall	Sparsentan						Interaction:	0.462
< 27 kg/m**2	Week 24	Sparsentan	84	52 (61.9)	-1.51 (1.80)	(-5.07, 2.06)	0.41 (2.59)	(-4.72, 5.53)	0.876
		Irbesartan	94	50 (53.2)	-1.91 (1.85)	(-5.58, 1.75)			
	Week 48	Sparsentan	84	47 (56.0)	-0.11 (1.86)	(-3.79, 3.57)	5.15 (2.79)	(-0.36, 10.66)	0.067
		Irbesartan	94	36 (38.3)	-5.26 (2.07)	(-9.34, -1.17)			
>= 27 kg/m**2	Week 24	Sparsentan	118	73 (61.9)	0.40 (1.68)	(-2.92, 3.71)	1.87 (2.59)	(-3.24, 6.98)	0.471
		Irbesartan	107	54 (50.5)	-1.47 (1.95)	(-5.32, 2.38)			
	Week 48	Sparsentan	118	63 (53.4)	-1.31 (1.80)	(-4.86, 2.24)	-4.40 (2.88)	(-10.08, 1.29)	0.129
		Irbesartan	107	41 (38.3)	3.09 (2.25)	(-1.34, 7.52)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Randomization strata	Overall	Sparsentan						Interaction:	0.365
eGFR Low and UP High	Week 24	Sparsentan	71	44 (62.0)	-1.55 (1.42)	(-4.36, 1.26)	0.93 (2.20)	(-3.41, 5.28)	0.671
		Irbesartan	74	32 (43.2)	-2.48 (1.66)	(-5.78, 0.81)			
	Week 48	Sparsentan	71	37 (52.1)	0.75 (1.54)	(-2.30, 3.81)	4.97 (2.54)	(-0.05, 9.99)	0.052
		Irbesartan	74	22 (29.7)	-4.22 (2.01)	(-8.19, -0.25)			
eGFR Low and UP Low	Week 24	Sparsentan	55	38 (69.1)	0.73 (2.39)	(-4.00, 5.46)	-3.02 (3.54)	(-10.02, 3.99)	0.395
		Irbesartan	55	33 (60.0)	3.75 (2.57)	(-1.34, 8.84)			
	Week 48	Sparsentan	55	28 (50.9)	-4.59 (2.79)	(-10.12, 0.93)	-5.82 (4.09)	(-13.93, 2.29)	0.158
		Irbesartan	55	25 (45.5)	1.23 (2.95)	(-4.62, 7.08)			
eGFR High and UP High	Week 24	Sparsentan	37	19 (51.4)	-0.74 (3.93)	(-8.63, 7.15)	0.57 (5.85)	(-11.21, 12.35)	0.923
		Irbesartan	36	18 (50.0)	-1.31 (4.33)	(-10.03, 7.41)			
	Week 48	Sparsentan	37	22 (59.5)	-1.90 (3.81)	(-9.57, 5.77)	2.20 (6.16)	(-10.15, 14.54)	0.723
		Irbesartan	36	11 (30.6)	-4.09 (4.83)	(-13.75, 5.57)			
eGFR High and UP Low	Week 24	Sparsentan	39	24 (61.5)	0.42 (2.96)	(-5.47, 6.30)	9.53 (4.34)	(0.90, 18.16)	0.031 *
		Irbesartan	37	21 (56.8)	-9.11 (3.17)	(-15.42, -2.80)			
	Week 48	Sparsentan	39	23 (59.0)	0.91 (3.03)	(-5.11, 6.93)	-2.48 (4.55)	(-11.53, 6.57)	0.587
		Irbesartan	37	19 (51.4)	3.39 (3.38)	(-3.33, 10.12)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 1	Overall	Sparsentan						Interaction:	0.380
< 60 mL/min/1.73 m**2	Week 24	Sparsentan	127	83 (65.4)	-0.29 (1.48)	(-3.21, 2.63)	0.94 (2.22)	(-3.43, 5.30)	0.673
		Irbesartan	129	68 (52.7)	-1.23 (1.65)	(-4.47, 2.01)			
	Week 48	Sparsentan	127	65 (51.2)	-1.27 (1.68)	(-4.58, 2.03)	-0.15 (2.57)	(-5.22, 4.92)	0.954
		Irbesartan	129	49 (38.0)	-1.13 (1.94)	(-4.95, 2.70)			
60 to < 90 mL/min/1.73 m**2	Week 24	Sparsentan	49	27 (55.1)	-2.09 (2.89)	(-7.87, 3.69)	-1.22 (4.26)	(-9.73, 7.29)	0.776
		Irbesartan	48	24 (50.0)	-0.87 (3.08)	(-7.03, 5.29)			
	Week 48	Sparsentan	49	29 (59.2)	-1.77 (2.86)	(-7.49, 3.95)	0.75 (4.37)	(-7.97, 9.46)	0.865
		Irbesartan	48	19 (39.6)	-2.52 (3.24)	(-8.98, 3.94)			
>= 90 mL/min/1.73 m**2	Week 24	Sparsentan	26	15 (57.7)	4.35 (3.96)	(-3.72, 12.43)	11.29 (5.93)	(-0.78, 23.36)	0.066
		Irbesartan	25	12 (48.0)	-6.94 (4.40)	(-15.90, 2.02)			
	Week 48	Sparsentan	26	16 (61.5)	2.42 (3.90)	(-5.55, 10.39)	-7.22 (6.26)	(-19.89, 5.45)	0.256
		Irbesartan	25	9 (36.0)	9.64 (4.87)	(-0.21, 19.48)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

					Repeated measures analysis				
KDQOL: Change from baseline in symptom/problems of kidney disease					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 2	Overall	Sparsentan						Interaction:	0.465
< 45 mL/min/1.73 m**2	Week 24	Sparsentan	82	53 (64.6)	0.84 (1.69)	(-2.51, 4.19)	1.23 (2.49)	(-3.70, 6.15)	0.623
		Irbesartan	80	45 (56.3)	-0.39 (1.84)	(-4.01, 3.24)			
	Week 48	Sparsentan	82	42 (51.2)	-0.76 (1.90)	(-4.51, 3.00)	2.36 (2.98)	(-3.52, 8.24)	0.430
		Irbesartan	80	29 (36.3)	-3.11 (2.29)	(-7.64, 1.41)			
45 to < 60 mL/min/1.73 m**2	Week 24	Sparsentan	45	30 (66.7)	-2.53 (2.88)	(-8.26, 3.21)	-0.15 (4.49)	(-9.07, 8.78)	0.974
		Irbesartan	49	23 (46.9)	-2.38 (3.38)	(-9.09, 4.33)			
	Week 48	Sparsentan	45	23 (51.1)	-2.18 (3.32)	(-8.77, 4.42)	-4.08 (4.95)	(-13.92, 5.76)	0.412
		Irbesartan	49	20 (40.8)	1.91 (3.63)	(-5.31, 9.12)			
60 to < 90 mL/min/1.73 m**2	Week 24	Sparsentan	49	27 (55.1)	-2.09 (2.89)	(-7.87, 3.69)	-1.22 (4.26)	(-9.73, 7.29)	0.776
		Irbesartan	48	24 (50.0)	-0.87 (3.08)	(-7.03, 5.29)			
	Week 48	Sparsentan	49	29 (59.2)	-1.77 (2.86)	(-7.49, 3.95)	0.75 (4.37)	(-7.97, 9.46)	0.865
		Irbesartan	48	19 (39.6)	-2.52 (3.24)	(-8.98, 3.94)			
>= 90 mL/min/1.73 m**2	Week 24	Sparsentan	26	15 (57.7)	4.35 (3.96)	(-3.72, 12.43)	11.29 (5.93)	(-0.78, 23.36)	0.066
		Irbesartan	25	12 (48.0)	-6.94 (4.40)	(-15.90, 2.02)			
	Week 48	Sparsentan	26	16 (61.5)	2.42 (3.90)	(-5.55, 10.39)	-7.22 (6.26)	(-19.89, 5.45)	0.256
		Irbesartan	25	9 (36.0)	9.64 (4.87)	(-0.21, 19.48)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline urine protein excretion	Overall	Sparsentan						Interaction:	0.335
<= 1.75 g/day	Week 24	Sparsentan	98	66 (67.3)	-0.28 (1.91)	(-4.04, 3.47)	1.60 (3.06)	(-4.43, 7.62)	0.602
		Irbesartan	94	43 (45.7)	-1.88 (2.38)	(-6.58, 2.82)			
	Week 48	Sparsentan	98	59 (60.2)	-1.09 (2.02)	(-5.06, 2.89)	-4.56 (3.38)	(-11.22, 2.10)	0.179
		Irbesartan	94	34 (36.2)	3.47 (2.68)	(-1.81, 8.76)			
> 1.75 g/day	Week 24	Sparsentan	104	59 (56.7)	-0.32 (1.59)	(-3.47, 2.82)	1.83 (2.25)	(-2.61, 6.27)	0.418
		Irbesartan	108	61 (56.5)	-2.15 (1.58)	(-5.26, 0.96)			
	Week 48	Sparsentan	104	51 (49.0)	-0.03 (1.70)	(-3.39, 3.33)	3.78 (2.54)	(-1.23, 8.79)	0.138
		Irbesartan	108	43 (39.8)	-3.81 (1.85)	(-7.46, -0.16)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline use of antihypertensives	Overall	Sparsentan						Interaction:	0.699
Yes	Week 24	Sparsentan	88	50 (56.8)	-0.11 (1.25)	(-2.57, 2.36)	-1.06 (1.89)	(-4.79, 2.66)	0.574
		Irbesartan	83	39 (47.0)	0.96 (1.41)	(-1.84, 3.75)			
	Week 48	Sparsentan	88	41 (46.6)	2.36 (1.39)	(-0.38, 5.10)	1.68 (2.19)	(-2.64, 6.01)	0.443
		Irbesartan	83	28 (33.7)	0.68 (1.68)	(-2.65, 4.00)			
No	Week 24	Sparsentan	114	75 (65.8)	-0.48 (1.87)	(-4.16, 3.20)	3.34 (2.74)	(-2.06, 8.75)	0.224
		Irbesartan	119	65 (54.6)	-3.83 (2.01)	(-7.79, 0.14)			
	Week 48	Sparsentan	114	69 (60.5)	-2.29 (1.94)	(-6.10, 1.53)	-0.85 (3.00)	(-6.77, 5.07)	0.777
		Irbesartan	119	49 (41.2)	-1.43 (2.30)	(-5.96, 3.09)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Time since renal biopsy	Overall	Sparsentan						Interaction:	0.062
<= 5 years	Week 24	Sparsentan	113	70 (61.9)	1.92 (1.68)	(-1.38, 5.23)	4.86 (2.40)	(0.13, 9.58)	0.044 *
		Irbesartan	127	67 (52.8)	-2.93 (1.71)	(-6.31, 0.44)			
	Week 48	Sparsentan	113	61 (54.0)	2.10 (1.80)	(-1.45, 5.65)	1.45 (2.67)	(-3.81, 6.71)	0.587
		Irbesartan	127	51 (40.2)	0.64 (1.98)	(-3.25, 4.54)			
> 5 years	Week 24	Sparsentan	89	55 (61.8)	-2.81 (1.79)	(-6.34, 0.73)	-2.94 (2.85)	(-8.56, 2.69)	0.304
		Irbesartan	75	37 (49.3)	0.13 (2.22)	(-4.26, 4.52)			
	Week 48	Sparsentan	89	49 (55.1)	-3.71 (1.91)	(-7.48, 0.06)	-1.50 (3.26)	(-7.93, 4.94)	0.647
		Irbesartan	75	26 (34.7)	-2.21 (2.61)	(-7.37, 2.95)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
History of hypertension	Overall	Sparsentan						Interaction:	0.302
Yes	Week 24	Sparsentan	153	94 (61.4)	0.41 (1.17)	(-1.89, 2.71)	0.56 (1.75)	(-2.88, 4.00)	0.748
		Irbesartan	157	76 (48.4)	-0.15 (1.30)	(-2.71, 2.41)			
	Week 48	Sparsentan	153	81 (52.9)	-0.22 (1.26)	(-2.70, 2.25)	-0.30 (1.97)	(-4.17, 3.57)	0.878
		Irbesartan	157	57 (36.3)	0.08 (1.51)	(-2.89, 3.04)			
No	Week 24	Sparsentan	49	31 (63.3)	-3.57 (3.88)	(-11.32, 4.18)	3.14 (5.69)	(-8.24, 14.52)	0.584
		Irbesartan	45	28 (62.2)	-6.71 (4.14)	(-14.98, 1.57)			
	Week 48	Sparsentan	49	29 (59.2)	-2.40 (3.90)	(-10.20, 5.39)	3.57 (5.84)	(-8.07, 15.22)	0.542
		Irbesartan	45	20 (44.4)	-5.98 (4.31)	(-14.57, 2.62)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Figure PF1KSYC_FSGM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

Not done: No significant subgroup found.

Number of available records are presented for key visits up to Week 58 only. LS-Mean = Least square mean.
95% CI = 95% confidence interval. eGFR = estimated glomerular filtration rate. UP = urine protein. BMI = body mass index.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
IgAN = immunoglobulin A nephropathy. A decrease reflects a worsening of the status of the patient. Reference table: PT1KSYC_FSCM.

Table PT1KSYIT_FSTM: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to increase in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sex	Sparsentan						Interaction test:	0.245
Male	Sparsentan	139	5 (3.6)	NE		5.238	(0.729, 37.628)	0.100
	Irbesartan	143	4 (2.8)	NE				
Female	Sparsentan	63	10 (15.9)	NE		0.907	(0.275, 2.988)	0.872
	Irbesartan	59	5 (8.5)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KSYIT_FSTM: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to increase in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.075
<= 45 years	Sparsentan	96	8 (8.3)	NE		4.343	(0.627, 30.094)	0.137
	Irbesartan	99	2 (2.0)	NE				
> 45 years	Sparsentan	106	7 (6.6)	NE		0.549	(0.175, 1.717)	0.303
	Irbesartan	103	7 (6.8)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KSYIT_FSTM: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to increase in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age at IgAN diagnosis	Sparsentan						Interaction test:	NE
<= 18 years	Sparsentan	9	0 (0.0) No events in 1 group	NE		NE		NE
	Irbesartan	5	0 (0.0)	NE				
> 18 to 40 years	Sparsentan	102	8 (7.8)	NE		2.163	(0.481, 9.728)	0.315
	Irbesartan	109	3 (2.8)	NE				
> 40 years	Sparsentan	91	7 (7.7)	NE		0.646	(0.187, 2.232)	0.490
	Irbesartan	88	6 (6.8)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KSYIT_FSTM: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to increase in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Geographic region	Sparsentan						Interaction test:	0.246
North America	Sparsentan	35	1 (2.9)	NE		0.666	(0.053, 8.425)	0.754
	Irbesartan	46	4 (8.7)	NE				
Europe	Sparsentan	98	8 (8.2)	NE		4.379	(0.705, 27.201)	0.113
	Irbesartan	115	2 (1.7)	NE				
Asia Pacific	Sparsentan	69	6 (8.7)	NE		0.355	(0.070, 1.810)	0.213
	Irbesartan	41	3 (7.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KSYIT_FSTM: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to increase in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.414
< 27 kg/m**2	Sparsentan	84	3 (3.6)	NE		0.699	(0.052, 9.333)	0.786
	Irbesartan	94	2 (2.1)	NE				
>= 27 kg/m**2	Sparsentan	118	12 (10.2)	NE		0.988	(0.357, 2.738)	0.982
	Irbesartan	107	7 (6.5)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KSYIT_FSTM: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to increase in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Randomization strata	Sparsentan						Interaction test:	0.176
eGFR Low and UP High	Sparsentan	71	3 (4.2)	NE		51.733	(0.982, NE)	NE
	Irbesartan	74	2 (2.7)	NE				
eGFR Low and UP Low	Sparsentan	55	7 (12.7)	NE		0.715	(0.149, 3.417)	0.674
	Irbesartan	55	4 (7.3)	NE				
eGFR High and UP High	Sparsentan	37	4 (10.8)	NE		3.984	(0.339, 46.873)	0.272
	Irbesartan	36	2 (5.6)	94.1	(94.1, NE)			
eGFR High and UP Low	Sparsentan	39	1 (2.6)	NE		0.540	(0.021, 13.995)	0.711
	Irbesartan	37	1 (2.7)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KSYIT_FSTM: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to increase in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan						Interaction test:	NE
< 60 mL/min/1.73 m**2	Sparsentan	127	10 (7.9)	NE		1.029	(0.344, 3.080)	0.959
	Irbesartan	129	7 (5.4)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	2 (4.1)	NE		0.996	(0.072, 13.717)	0.998
	Irbesartan	48	2 (4.2)	94.1	(94.1, NE)			
>= 90 mL/min/1.73 m**2	Sparsentan	26	3 (11.5)	NE		NE		NE
			No events in 1 group					
	Irbesartan	25	0 (0.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KSYIT_FSTM: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to increase in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 2	Sparsentan						Interaction test:	NE
< 45 mL/min/1.73 m**2	Sparsentan	82	7 (8.5)	NE		1.767	(0.453, 6.889)	0.413
	Irbesartan	80	4 (5.0)	NE				
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	3 (6.7)	NE		0.214	(0.014, 3.383)	0.274
	Irbesartan	49	3 (6.1)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	2 (4.1)	NE		0.996	(0.072, 13.717)	0.998
	Irbesartan	48	2 (4.2)	94.1	(94.1, NE)			
>= 90 mL/min/1.73 m**2	Sparsentan	26	3 (11.5)	NE		NE		NE
			No events in 1 group					
	Irbesartan	25	0 (0.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KSYIT_FSTM: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to increase in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline urine protein excretion	Sparsentan						Interaction test:	0.748
<= 1.75 g/day	Sparsentan	98	10 (10.2)	NE		1.791	(0.331, 9.694)	0.499
	Irbesartan	94	2 (2.1)	NE				
> 1.75 g/day	Sparsentan	104	5 (4.8)	NE		2.848	(0.544, 14.912)	0.215
	Irbesartan	108	7 (6.5)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KSYIT_FSTM: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in symptom/problems of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.895
Yes	Sparsentan	88	6 (6.8)	NE		3.275	(0.477, 22.488)	0.227
	Irbesartan	83	4 (4.8)	NE				
No	Sparsentan	114	9 (7.9)	NE		1.144	(0.358, 3.654)	0.820
	Irbesartan	119	5 (4.2)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KSYIT_FSTM: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to increase in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Time since renal biopsy	Sparsentan						Interaction test:	0.897
<= 5 years	Sparsentan	113	10 (8.8)	NE		1.385	(0.501, 3.828)	0.530
	Irbesartan	127	8 (6.3)	NE				
> 5 years	Sparsentan	89	5 (5.6)	NE		1.548	(0.109, 21.980)	0.747
	Irbesartan	75	1 (1.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KSYIT_FSTM: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to increase in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
History of hypertension	Sparsentan						Interaction test:	0.461
Yes	Sparsentan	153	12 (7.8)	NE		1.363	(0.459, 4.044)	0.577
	Irbesartan	157	7 (4.5)	NE				
No	Sparsentan	49	3 (6.1)	NE		0.707	(0.081, 6.185)	0.754
	Irbesartan	45	2 (4.4)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Figure PF1KSYIT_FSKM: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

Not done. No significant subgroups.

_____
An increase reflects an improvement of the status of the patient.
Reference table: PT1KSYIT_FSTM

Table PT1KSYDT_FSTM: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in symptom/problems of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sex	Sparsentan						Interaction test:	0.079
Male	Sparsentan	139	18 (12.9)	NE		1.488	(0.690, 3.210)	0.310
	Irbesartan	143	11 (7.7)	NE				
Female	Sparsentan	63	5 (7.9)	NE		0.353	(0.099, 1.257)	0.108
	Irbesartan	59	7 (11.9)	96.1	(70.1, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KSYDT_FSTM: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.201
<= 45 years	Sparsentan	96	9 (9.4)	NE		0.671	(0.278, 1.621)	0.375
	Irbesartan	99	12 (12.1)	NE				
> 45 years	Sparsentan	106	14 (13.2)	NE		1.575	(0.596, 4.160)	0.359
	Irbesartan	103	6 (5.8)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KSYDT_FSTM: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in symptom/problems of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age at IgAN diagnosis	Sparsentan						Interaction test:	0.508
<= 18 years	Sparsentan	9	1 (11.1)	NE		52.163	(NE, NE)	NE
	Irbesartan	5	1 (20.0)	70.0	(NE, NE)			
> 18 to 40 years	Sparsentan	102	10 (9.8)	NE		0.807	(0.332, 1.966)	0.637
	Irbesartan	109	11 (10.1)	NE				
> 40 years	Sparsentan	91	12 (13.2)	NE		1.362	(0.505, 3.672)	0.541
	Irbesartan	88	6 (6.8)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KSYDT_FSTM: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in symptom/problems of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Geographic region	Sparsentan						Interaction test:	0.429
North America	Sparsentan	35	1 (2.9)	NE		0.429	(0.038, 4.795)	0.492
	Irbesartan	46	3 (6.5)	NE				
Europe	Sparsentan	98	9 (9.2)	NE		0.726	(0.301, 1.753)	0.477
	Irbesartan	115	12 (10.4)	NE				
Asia Pacific	Sparsentan	69	13 (18.8)	NE		1.591	(0.444, 5.698)	0.476
	Irbesartan	41	3 (7.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KSYDT_FSTM: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.265
< 27 kg/m**2	Sparsentan	84	9 (10.7)	NE		0.623	(0.246, 1.573)	0.316
	Irbesartan	94	10 (10.6)	NE				
>= 27 kg/m**2	Sparsentan	118	14 (11.9)	NE		1.537	(0.608, 3.884)	0.364
	Irbesartan	107	7 (6.5)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KSYDT_FSTM: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in symptom/problems of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Randomization strata	Sparsentan						Interaction test:	0.896
eGFR Low and UP High	Sparsentan	71	9 (12.7)	NE		0.940	(0.330, 2.676)	0.908
	Irbesartan	74	7 (9.5)	NE				
eGFR Low and UP Low	Sparsentan	55	5 (9.1)	NE		1.127	(0.332, 3.822)	0.848
	Irbesartan	55	6 (10.9)	NE				
eGFR High and UP High	Sparsentan	37	6 (16.2)	NE		1.702	(0.338, 8.564)	0.519
	Irbesartan	36	2 (5.6)	NE				
eGFR High and UP Low	Sparsentan	39	3 (7.7)	NE		0.994	(0.199, 4.978)	0.995
	Irbesartan	37	3 (8.1)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KSYDT_FSTM: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.920
< 60 mL/min/1.73 m**2	Sparsentan	127	15 (11.8)	NE		0.895	(0.426, 1.882)	0.770
	Irbesartan	129	14 (10.9)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	4 (8.2)	NE		1.609	(0.290, 8.936)	0.587
	Irbesartan	48	2 (4.2)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	4 (15.4)	NE		1.296	(0.215, 7.794)	0.777
	Irbesartan	25	2 (8.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KSYDT_FSTM: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 2	Sparsentan						Interaction test:	0.328
< 45 mL/min/1.73 m**2	Sparsentan	82	11 (13.4)	NE		0.702	(0.312, 1.577)	0.391
	Irbesartan	80	13 (16.3)	96.1	(94.9, NE)			
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	4 (8.9)	NE		3.492	(0.351, 34.729)	0.286
	Irbesartan	49	1 (2.0)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	4 (8.2)	NE		1.609	(0.290, 8.936)	0.587
	Irbesartan	48	2 (4.2)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	4 (15.4)	NE		1.296	(0.215, 7.794)	0.777
	Irbesartan	25	2 (8.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KSYDT_FSTM: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in symptom/problems of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline urine protein excretion	Sparsentan						Interaction test:	0.937
<= 1.75 g/day	Sparsentan	98	11 (11.2)	NE		1.102	(0.411, 2.960)	0.846
	Irbesartan	94	7 (7.4)	NE				
> 1.75 g/day	Sparsentan	104	12 (11.5)	NE		1.092	(0.448, 2.659)	0.847
	Irbesartan	108	11 (10.2)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KSYDT_FSTM: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.248
Yes	Sparsentan	88	10 (11.4)	NE		1.623	(0.548, 4.805)	0.382
	Irbesartan	83	5 (6.0)	NE				
No	Sparsentan	114	13 (11.4)	NE		0.766	(0.352, 1.666)	0.501
	Irbesartan	119	13 (10.9)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KSYDT_FSTM: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in symptom/problems of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Time since renal biopsy	Sparsentan						Interaction test:	0.296
<= 5 years	Sparsentan	113	9 (8.0)	NE		0.656	(0.275, 1.568)	0.343
	Irbesartan	127	12 (9.4)	NE				
> 5 years	Sparsentan	89	14 (15.7)	NE		1.480	(0.553, 3.962)	0.435
	Irbesartan	75	6 (8.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KSYDT_FSTM: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
History of hypertension	Sparsentan						Interaction test:	0.974
Yes	Sparsentan	153	15 (9.8)	NE		0.932	(0.436, 1.995)	0.857
	Irbesartan	157	12 (7.6)	NE				
No	Sparsentan	49	8 (16.3)	NE		0.826	(0.261, 2.618)	0.745
	Irbesartan	45	6 (13.3)	96.1	(95.3, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Figure PF1KSYDT_FSKM: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

Not done. No significant subgroups.

_____
A decrease reflects a worsening of the status of the patient.
Reference table: PT1KSYDT_FSTM

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	KDQOL-SF12: PCS	Baseline	Sparsentan	139	130 (93.5)	51.62 (7.25)	25.5	47.38	53.46	56.74	62.3	
			Irbesartan	143	132 (92.3)	52.00 (7.33)	21.6	49.77	54.43	56.42	64.3	
		Week 24	Sparsentan	139	88 (63.3)	51.56 (7.11)	16.3	47.65	52.97	56.49	62.0	
			Irbesartan	143	81 (56.6)	51.54 (7.63)	20.8	47.89	53.82	56.21	64.3	
		Week 48	Sparsentan	139	74 (53.2)	51.54 (6.74)	33.2	46.91	53.22	56.15	66.1	
			Irbesartan	143	58 (40.6)	52.74 (6.86)	32.8	50.22	55.09	56.71	64.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	139	88 (63.3)	0.71 (5.56)	-13.4	-3.23	0.29	3.73	15.5	0.13 [-0.18, 0.43]
			Irbesartan	143	81 (56.6)	-0.01 (6.02)	-20.0	-1.86	0.00	2.01	16.9	
		Week 48	Sparsentan	139	74 (53.2)	0.51 (6.74)	-18.7	-3.24	-0.14	4.31	20.6	0.01 [-0.34, 0.35]
			Irbesartan	143	58 (40.6)	0.46 (7.82)	-24.7	-2.98	0.42	3.64	20.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Female	KDQOL-SF12: PCS	Baseline	Sparsentan	63	57 (90.5)	49.75 (9.72)	12.4	44.71	52.33	56.15	63.5	
			Irbesartan	59	52 (88.1)	50.94 (6.16)	29.6	48.38	51.16	55.60	61.1	
		Week 24	Sparsentan	63	40 (63.5)	49.90 (8.20)	27.3	42.75	52.26	56.19	62.9	
			Irbesartan	59	31 (52.5)	50.73 (5.99)	39.0	45.08	53.18	55.09	59.1	
		Week 48	Sparsentan	63	38 (60.3)	49.98 (7.34)	29.8	46.56	50.05	55.09	61.7	
			Irbesartan	59	22 (37.3)	48.53 (7.30)	33.7	44.25	48.44	54.51	60.0	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	63	40 (63.5)	-0.36 (8.94)	-24.8	-6.06	-0.22	4.08	20.4	0.04 [-0.43, 0.51]
			Irbesartan	59	31 (52.5)	-0.67 (4.83)	-12.8	-3.24	-0.78	3.24	7.8	
		Week 48	Sparsentan	63	38 (60.3)	0.58 (8.40)	-22.3	-3.11	1.07	5.05	24.7	0.30 [-0.23, 0.83]
			Irbesartan	59	22 (37.3)	-1.84 (7.33)	-18.8	-5.29	-0.55	1.62	16.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
<= 45 years	KDQOL-SF12: PCS	Baseline	Sparsentan	96	88 (91.7)	52.37 (7.89)	12.4	49.42	54.38	57.08	63.5	
			Irbesartan	99	92 (92.9)	52.20 (7.28)	21.6	50.06	54.38	56.39	64.3	
		Week 24	Sparsentan	96	59 (61.5)	52.61 (6.88)	27.3	50.37	53.26	56.95	61.8	
			Irbesartan	99	56 (56.6)	52.10 (7.44)	20.8	51.03	54.51	56.18	64.3	
		Week 48	Sparsentan	96	53 (55.2)	52.42 (6.97)	29.8	48.13	54.23	56.45	66.1	
			Irbesartan	99	40 (40.4)	52.64 (7.02)	32.8	49.19	55.20	56.71	63.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	96	59 (61.5)	0.43 (6.24)	-24.8	-3.37	0.82	4.08	14.7	0.15 [-0.21, 0.52]
			Irbesartan	99	56 (56.6)	-0.44 (5.02)	-15.6	-2.69	-0.77	1.54	13.3	
		Week 48	Sparsentan	96	53 (55.2)	0.57 (7.48)	-22.3	-2.38	0.27	3.77	24.7	0.20 [-0.21, 0.61]
			Irbesartan	99	40 (40.4)	-0.91 (7.05)	-24.7	-2.15	0.00	2.30	16.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 45 years	KDQOL-SF12: PCS	Baseline	Sparsentan	106	99 (93.4)	49.88 (8.14)	25.5	45.62	52.30	56.15	61.8	
			Irbesartan	103	92 (89.3)	51.21 (6.75)	27.9	49.01	53.04	56.15	59.7	
		Week 24	Sparsentan	106	69 (65.1)	49.70 (7.75)	16.3	43.91	51.81	54.80	62.9	
			Irbesartan	103	56 (54.4)	50.53 (6.92)	31.2	44.62	52.77	56.15	61.9	
		Week 48	Sparsentan	106	59 (55.7)	49.74 (6.75)	33.2	45.63	51.57	54.51	60.2	
			Irbesartan	103	40 (38.8)	50.52 (7.29)	33.7	44.78	52.51	56.31	64.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	106	69 (65.1)	0.33 (7.25)	-14.9	-4.03	-0.27	3.53	20.4	0.04 [-0.31, 0.39]
			Irbesartan	103	56 (54.4)	0.04 (6.35)	-20.0	-1.72	0.40	3.61	16.9	
		Week 48	Sparsentan	106	59 (55.7)	0.49 (7.21)	-15.4	-3.76	-0.29	5.05	20.6	-0.01 [-0.41, 0.39]
			Irbesartan	103	40 (38.8)	0.57 (8.35)	-18.8	-4.31	0.55	4.96	20.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age at IgAN diagnosis												
<= 18 years	KDQOL-SF12: PCS	Baseline	Sparsentan	9	9 (100.0)	49.16 (14.77)	12.4	53.62	54.80	55.47	58.8	
			Irbesartan	5	5 (100.0)	50.57 (8.50)	39.0	44.78	53.18	56.15	59.7	
		Week 24	Sparsentan	9	3 (33.3)	59.89 (1.04)	58.9	58.85	59.89	60.93	60.9	
			Irbesartan	5	2 (40.0)	48.12 (4.57)	44.9	44.90	48.12	51.35	51.4	
		Week 48	Sparsentan	9	5 (55.6)	51.76 (8.53)	37.1	52.50	54.23	56.15	58.8	
			Irbesartan	5	1 (20.0)	55.59	55.6	55.59	55.59	55.59	55.6	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	9	3 (33.3)	5.39 (1.41)	3.8	3.76	6.13	6.27	6.3	4.46 [1.17, 7.76]
			Irbesartan	5	2 (40.0)	-0.86 (1.38)	-1.8	-1.83	-0.86	0.12	0.1	
		Week 48	Sparsentan	9	5 (55.6)	4.69 (11.54)	-3.0	-2.69	0.60	3.75	24.7	NE
			Irbesartan	5	1 (20.0)	2.40	2.4	2.40	2.40	2.40	2.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 18 to 40 years	KDQOL-SF12: PCS	Baseline	Sparsentan	102	94 (92.2)	52.86 (7.28)	25.5	49.93	54.52	57.30	63.5	
			Irbesartan	109	100 (91.7)	52.36 (6.99)	21.6	50.06	54.33	56.34	64.3	
		Week 24	Sparsentan	102	64 (62.7)	52.00 (6.83)	27.3	49.91	52.97	56.49	61.8	
			Irbesartan	109	61 (56.0)	52.57 (6.86)	20.8	51.90	54.51	56.22	64.3	
		Week 48	Sparsentan	102	57 (55.9)	52.89 (6.84)	29.8	49.81	54.32	57.76	66.1	
			Irbesartan	109	45 (41.3)	52.31 (6.80)	32.8	49.48	54.80	56.71	63.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	102	64 (62.7)	0.34 (6.61)	-24.8	-3.53	0.31	4.08	14.7	0.07 [-0.28, 0.42]
			Irbesartan	109	61 (56.0)	-0.05 (4.71)	-15.0	-2.02	0.00	1.83	13.3	
		Week 48	Sparsentan	102	57 (55.9)	0.37 (6.67)	-22.3	-2.43	0.02	3.69	15.6	0.15 [-0.24, 0.54]
			Irbesartan	109	45 (41.3)	-0.65 (7.39)	-24.7	-2.15	0.00	1.62	16.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 40 years	KDQOL-SF12: PCS	Baseline	Sparsentan	91	84 (92.3)	49.23 (7.69)	25.8	44.61	50.82	55.33	60.2	
			Irbesartan	88	79 (89.8)	50.95 (6.98)	27.9	48.47	52.45	56.15	59.7	
		Week 24	Sparsentan	91	61 (67.0)	49.59 (7.89)	16.3	43.35	52.11	54.80	62.9	
			Irbesartan	88	49 (55.7)	49.90 (7.48)	31.2	43.80	52.91	56.15	61.9	
		Week 48	Sparsentan	91	50 (54.9)	48.80 (6.41)	33.2	45.02	49.07	53.83	59.4	
			Irbesartan	88	34 (38.6)	50.50 (7.73)	33.7	44.25	52.51	56.15	64.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	91	61 (67.0)	0.17 (7.08)	-14.9	-3.94	-0.98	3.49	20.4	0.07 [-0.30, 0.45]
			Irbesartan	88	49 (55.7)	-0.35 (6.88)	-20.0	-3.49	0.00	3.78	16.9	
		Week 48	Sparsentan	91	50 (54.9)	0.30 (7.57)	-15.4	-4.33	-0.25	5.28	20.6	-0.01 [-0.45, 0.42]
			Irbesartan	88	34 (38.6)	0.39 (8.29)	-18.8	-4.24	0.42	4.53	20.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Geographic region												
North America	KDQOL-SF12: PCS	Baseline	Sparsentan	35	32 (91.4)	52.20 (9.84)	12.4	50.86	54.80	57.76	62.3	
			Irbesartan	46	44 (95.7)	50.87 (8.24)	27.9	47.98	54.38	56.15	61.1	
		Week 24	Sparsentan	35	15 (42.9)	54.73 (4.24)	45.7	52.64	55.66	57.49	61.3	
			Irbesartan	46	28 (60.9)	50.77 (7.36)	31.2	45.48	53.32	56.03	59.2	
		Week 48	Sparsentan	35	13 (37.1)	53.19 (7.55)	37.1	53.17	55.59	57.76	61.7	
			Irbesartan	46	17 (37.0)	51.93 (7.14)	39.8	46.17	55.32	56.71	64.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	35	15 (42.9)	-0.30 (4.48)	-9.7	-3.22	0.00	3.24	6.1	-0.25 [-0.87, 0.38]
			Irbesartan	46	28 (60.9)	1.16 (6.55)	-20.0	-1.60	1.17	4.70	13.3	
		Week 48	Sparsentan	35	13 (37.1)	1.86 (8.93)	-15.4	-0.52	0.02	3.45	24.7	-0.07 [-0.79, 0.65]
			Irbesartan	46	17 (37.0)	2.43 (7.84)	-8.9	-1.11	1.06	7.14	20.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Europe	KDQOL-SF12: PCS	Baseline	Sparsentan	98	88 (89.8)	51.17 (7.68)	25.5	47.76	53.32	56.66	62.3	
			Irbesartan	115	99 (86.1)	52.29 (6.36)	29.2	49.79	53.95	56.71	62.0	
		Week 24	Sparsentan	98	56 (57.1)	51.18 (8.01)	16.3	48.69	52.59	56.83	62.9	
			Irbesartan	115	50 (43.5)	51.64 (6.42)	36.8	46.58	52.89	56.15	64.3	
		Week 48	Sparsentan	98	44 (44.9)	51.09 (6.33)	36.5	46.97	53.15	54.95	61.9	
			Irbesartan	115	40 (34.8)	52.41 (7.24)	32.8	49.86	54.80	57.35	63.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	98	56 (57.1)	0.61 (6.34)	-13.4	-3.47	0.22	3.92	14.7	0.39 [0.01, 0.78]
			Irbesartan	115	50 (43.5)	-1.60 (4.80)	-15.0	-3.49	-0.94	0.56	10.0	
		Week 48	Sparsentan	98	44 (44.9)	0.56 (6.19)	-18.7	-2.83	1.09	4.51	11.4	0.21 [-0.22, 0.64]
			Irbesartan	115	40 (34.8)	-0.91 (7.90)	-24.7	-3.84	0.14	2.29	16.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asia Pacific	KDQOL-SF12: PCS	Baseline	Sparsentan	69	67 (97.1)	50.34 (7.79)	32.4	44.69	52.08	56.15	63.5	
			Irbesartan	41	41 (100.0)	51.18 (7.18)	21.6	49.48	51.57	55.86	64.3	
		Week 24	Sparsentan	69	57 (82.6)	49.94 (7.38)	27.3	44.79	52.31	56.15	62.0	
			Irbesartan	41	34 (82.9)	51.30 (8.27)	20.8	47.89	54.44	56.15	59.4	
		Week 48	Sparsentan	69	55 (79.7)	50.44 (7.31)	29.8	46.11	52.35	56.15	66.1	
			Irbesartan	41	23 (56.1)	49.88 (7.16)	33.7	43.48	53.17	55.09	57.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	69	57 (82.6)	0.32 (7.72)	-24.8	-3.94	0.00	4.90	20.4	-0.06 [-0.49, 0.36]
			Irbesartan	41	34 (82.9)	0.75 (5.88)	-15.6	-1.62	0.28	3.78	16.9	
		Week 48	Sparsentan	69	55 (79.7)	0.20 (7.81)	-22.3	-3.58	-0.58	4.37	20.6	0.13 [-0.36, 0.62]
			Irbesartan	41	23 (56.1)	-0.80 (7.20)	-18.8	-4.39	0.00	3.24	15.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline BMI												
< 27 kg/m**2	KDQOL-SF12: PCS	Baseline	Sparsentan	84	76 (90.5)	51.57 (8.78)	12.4	47.39	53.48	57.49	63.5	
			Irbesartan	94	87 (92.6)	53.21 (5.20)	39.0	49.84	54.53	56.71	61.5	
		Week 24	Sparsentan	84	52 (61.9)	51.83 (6.49)	37.6	47.99	53.46	57.36	62.0	
			Irbesartan	94	54 (57.4)	52.06 (5.63)	36.8	49.56	53.52	55.88	60.8	
		Week 48	Sparsentan	84	48 (57.1)	51.25 (6.89)	33.2	46.74	53.02	56.15	66.1	
			Irbesartan	94	37 (39.4)	51.57 (7.19)	32.8	46.35	54.51	56.71	63.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	84	52 (61.9)	0.63 (6.66)	-11.9	-4.39	-0.22	6.02	20.4	0.26 [-0.12, 0.64]
			Irbesartan	94	54 (57.4)	-0.80 (4.14)	-15.0	-2.38	-0.64	1.35	10.4	
		Week 48	Sparsentan	84	48 (57.1)	0.57 (7.27)	-13.9	-4.35	-0.53	5.16	24.7	0.34 [-0.09, 0.78]
			Irbesartan	94	37 (39.4)	-1.81 (6.46)	-24.7	-4.22	0.00	1.61	11.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 27 kg/m**2	KDQOL-SF12: PCS	Baseline	Sparsentan	118	111 (94.1)	50.70 (7.63)	25.5	46.31	52.40	56.15	62.3	
			Irbesartan	107	96 (89.7)	50.47 (8.07)	21.6	47.36	52.90	56.10	64.3	
		Week 24	Sparsentan	118	76 (64.4)	50.50 (8.08)	16.3	46.38	52.45	56.19	62.9	
			Irbesartan	107	58 (54.2)	50.62 (8.39)	20.8	44.55	53.46	56.22	64.3	
		Week 48	Sparsentan	118	64 (54.2)	50.83 (7.05)	29.8	46.34	53.18	55.73	61.9	
			Irbesartan	107	43 (40.2)	51.59 (7.28)	33.7	48.01	54.80	56.40	64.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	118	76 (64.4)	0.20 (6.90)	-24.8	-3.41	0.31	3.51	15.5	-0.02 [-0.36, 0.32]
			Irbesartan	107	58 (54.2)	0.36 (6.84)	-20.0	-2.16	0.78	3.77	16.9	
		Week 48	Sparsentan	118	64 (54.2)	0.50 (7.39)	-22.3	-2.83	0.04	3.72	20.6	-0.09 [-0.48, 0.29]
			Irbesartan	107	43 (40.2)	1.24 (8.47)	-18.8	-3.45	1.07	5.40	20.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Randomization strata												
eGFR Low and UP High	KDQOL-SF12: PCS	Baseline	Sparsentan	71	64 (90.1)	51.45 (7.23)	29.7	46.69	53.18	56.41	63.5	
			Irbesartan	74	64 (86.5)	50.34 (7.86)	29.2	44.67	52.50	56.15	60.1	
		Week 24	Sparsentan	71	45 (63.4)	51.07 (7.77)	16.3	47.80	52.91	56.15	60.9	
			Irbesartan	74	36 (48.6)	49.69 (7.24)	34.9	43.14	52.16	56.01	61.9	
		Week 48	Sparsentan	71	39 (54.9)	52.28 (6.40)	33.2	47.92	53.46	57.49	61.9	
			Irbesartan	74	23 (31.1)	50.22 (8.16)	32.8	42.94	51.45	56.48	64.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	71	45 (63.4)	-0.62 (6.81)	-13.4	-4.04	-0.64	3.10	20.4	0.03 [-0.41, 0.47]
			Irbesartan	74	36 (48.6)	-0.82 (5.84)	-15.6	-2.69	0.06	2.60	12.3	
		Week 48	Sparsentan	71	39 (54.9)	0.70 (7.94)	-18.7	-3.58	0.00	4.71	20.6	0.18 [-0.34, 0.70]
			Irbesartan	74	23 (31.1)	-0.84 (9.49)	-24.7	-5.82	0.00	2.96	20.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR Low and UP Low	KDQOL-SF12: PCS	Baseline	Sparsentan	55	51 (92.7)	49.09 (8.20)	25.8	45.40	50.55	55.14	61.1	
			Irbesartan	55	51 (92.7)	52.43 (4.53)	39.6	50.07	52.91	56.15	62.0	
		Week 24	Sparsentan	55	39 (70.9)	50.04 (7.26)	31.2	43.35	52.40	54.26	62.0	
			Irbesartan	55	35 (63.6)	51.82 (6.61)	32.9	47.25	53.46	56.22	64.3	
		Week 48	Sparsentan	55	28 (50.9)	50.24 (7.05)	36.0	45.48	53.18	55.33	59.4	
			Irbesartan	55	25 (45.5)	51.60 (6.88)	37.7	47.21	53.46	56.97	63.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	55	39 (70.9)	1.54 (6.42)	-14.9	-3.25	0.69	4.90	14.7	0.34 [-0.12, 0.80]
			Irbesartan	55	35 (63.6)	-0.61 (6.28)	-20.0	-2.55	0.00	2.22	16.9	
		Week 48	Sparsentan	55	28 (50.9)	2.16 (4.61)	-7.4	-0.84	1.58	6.57	10.7	0.42 [-0.12, 0.97]
			Irbesartan	55	25 (45.5)	-0.33 (7.08)	-11.9	-2.86	0.56	1.61	16.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP High	KDQOL-SF12: PCS	Baseline	Sparsentan	37	35 (94.6)	52.49 (9.30)	12.4	50.75	54.80	56.71	62.9	
			Irbesartan	36	33 (91.7)	51.69 (7.00)	32.5	48.47	53.46	56.15	64.3	
		Week 24	Sparsentan	37	20 (54.1)	53.09 (8.47)	27.3	50.71	56.72	57.74	61.8	
			Irbesartan	36	19 (52.8)	52.59 (4.28)	43.0	51.35	53.46	56.15	58.9	
		Week 48	Sparsentan	37	22 (59.5)	50.41 (8.00)	29.8	45.68	52.98	55.09	61.7	
			Irbesartan	36	13 (36.1)	50.40 (4.98)	40.3	46.17	51.57	54.80	55.6	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	37	20 (54.1)	-0.02 (7.50)	-24.8	-1.45	1.59	3.64	9.9	-0.27 [-0.90, 0.36]
			Irbesartan	36	19 (52.8)	1.75 (5.21)	-5.9	-1.83	1.35	3.64	13.3	
		Week 48	Sparsentan	37	22 (59.5)	-0.78 (9.31)	-22.3	-3.76	-2.02	3.39	24.7	-0.09 [-0.77, 0.60]
			Irbesartan	36	13 (36.1)	-0.02 (7.58)	-15.8	-3.90	-1.06	4.31	13.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP Low	KDQOL-SF12: PCS	Baseline	Sparsentan	39	37 (94.9)	51.70 (8.03)	25.5	46.73	53.46	57.30	62.3	
			Irbesartan	37	36 (97.3)	53.11 (8.14)	21.6	51.72	55.73	56.96	60.8	
		Week 24	Sparsentan	39	24 (61.5)	50.89 (6.44)	39.4	46.74	51.57	55.24	62.9	
			Irbesartan	37	22 (59.5)	52.08 (9.65)	20.8	53.18	54.95	56.48	60.8	
		Week 48	Sparsentan	39	23 (59.0)	50.37 (6.87)	35.7	46.11	49.35	55.87	66.1	
			Irbesartan	37	19 (51.4)	54.01 (7.51)	33.7	54.80	56.40	57.49	62.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	39	24 (61.5)	0.68 (6.77)	-8.4	-3.98	-0.98	5.03	14.1	0.15 [-0.43, 0.73]
			Irbesartan	37	22 (59.5)	-0.20 (4.86)	-12.8	-2.16	-0.77	2.42	10.4	
		Week 48	Sparsentan	39	23 (59.0)	-0.48 (6.74)	-13.6	-5.01	0.27	3.77	11.4	-0.18 [-0.79, 0.43]
			Irbesartan	37	19 (51.4)	0.75 (6.67)	-18.8	-1.04	1.32	3.24	12.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 1												
< 60 mL/min/1.73 m**2	KDQOL-SF12: PCS	Baseline	Sparsentan	127	116 (91.3)	50.33 (7.67)	25.8	46.15	52.34	56.15	63.5	
			Irbesartan	129	116 (89.9)	51.42 (6.60)	27.9	48.61	52.90	56.15	62.0	
		Week 24	Sparsentan	127	85 (66.9)	50.39 (7.44)	16.3	45.43	52.40	55.66	62.0	
			Irbesartan	129	73 (56.6)	50.64 (7.05)	31.2	44.69	52.50	56.15	64.3	
		Week 48	Sparsentan	127	67 (52.8)	51.58 (6.60)	33.2	46.96	53.39	56.15	61.9	
			Irbesartan	129	50 (38.8)	51.43 (7.51)	32.8	46.35	53.58	56.71	64.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	127	85 (66.9)	0.27 (6.73)	-14.9	-3.69	0.00	3.69	20.4	0.10 [-0.21, 0.42]
			Irbesartan	129	73 (56.6)	-0.38 (5.87)	-20.0	-2.69	0.00	2.31	16.9	
		Week 48	Sparsentan	127	67 (52.8)	1.70 (6.49)	-18.7	-2.43	0.69	6.54	20.6	0.17 [-0.20, 0.54]
			Irbesartan	129	50 (38.8)	0.46 (8.29)	-24.7	-4.24	1.06	4.27	20.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	KDQOL-SF12: PCS	Baseline	Sparsentan	49	47 (95.9)	53.00 (6.69)	37.4	48.78	53.79	57.76	61.8	
			Irbesartan	48	44 (91.7)	52.03 (7.49)	29.6	49.15	54.95	56.30	64.3	
		Week 24	Sparsentan	49	28 (57.1)	52.61 (7.74)	27.3	48.92	53.07	58.39	62.9	
			Irbesartan	48	26 (54.2)	53.08 (6.00)	34.9	52.17	54.52	56.15	60.8	
		Week 48	Sparsentan	49	29 (59.2)	49.94 (8.14)	29.8	43.15	51.29	55.59	66.1	
			Irbesartan	48	20 (41.7)	50.46 (7.10)	33.7	45.94	53.18	55.87	58.6	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	49	28 (57.1)	0.18 (7.43)	-24.8	-3.63	0.25	5.14	11.8	0.03 [-0.50, 0.57]
			Irbesartan	48	26 (54.2)	-0.06 (6.31)	-15.6	-2.16	-0.04	3.24	13.3	
		Week 48	Sparsentan	49	29 (59.2)	-2.24 (7.65)	-22.3	-5.01	-2.13	3.45	11.4	0.05 [-0.52, 0.62]
			Irbesartan	48	20 (41.7)	-2.58 (7.17)	-18.8	-5.97	-1.20	0.55	9.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	KDQOL-SF12: PCS	Baseline	Sparsentan	26	24 (92.3)	50.73 (11.70)	12.4	49.48	54.33	56.81	62.9	
			Irbesartan	25	24 (96.0)	52.47 (8.27)	21.6	51.67	55.35	56.15	61.1	
		Week 24	Sparsentan	26	15 (57.7)	51.81 (7.16)	36.9	48.47	54.33	57.49	58.0	
			Irbesartan	25	13 (52.0)	51.62 (9.82)	20.8	52.50	54.36	56.40	58.6	
		Week 48	Sparsentan	26	16 (61.5)	50.56 (6.23)	37.1	46.13	51.27	55.48	58.6	
			Irbesartan	25	10 (40.0)	54.58 (5.26)	40.3	54.51	56.28	57.49	58.0	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	26	15 (57.7)	1.35 (6.15)	-6.4	-3.22	1.57	2.98	14.1	0.15 [-0.59, 0.90]
			Irbesartan	25	13 (52.0)	0.58 (3.20)	-3.2	-1.06	0.00	1.36	10.0	
		Week 48	Sparsentan	26	16 (61.5)	0.64 (8.93)	-11.7	-3.62	0.04	2.08	24.7	-0.11 [-0.90, 0.68]
			Irbesartan	25	10 (40.0)	1.48 (4.68)	-3.9	-1.04	1.33	1.63	13.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 2												
< 45 mL/min/1.73 m**2	KDQOL-SF12: PCS	Baseline	Sparsentan	82	72 (87.8)	49.73 (7.85)	29.2	44.55	51.65	56.05	60.8	
			Irbesartan	80	70 (87.5)	50.48 (6.75)	29.2	46.31	52.11	56.06	60.1	
		Week 24	Sparsentan	82	54 (65.9)	50.20 (7.46)	16.3	45.37	52.40	54.80	60.9	
			Irbesartan	80	48 (60.0)	50.24 (6.36)	36.8	44.17	52.11	56.01	61.9	
		Week 48	Sparsentan	82	44 (53.7)	51.72 (6.68)	36.0	46.74	53.42	56.82	61.9	
			Irbesartan	80	30 (37.5)	50.35 (7.92)	32.8	45.30	51.22	56.48	64.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	82	54 (65.9)	0.47 (6.22)	-13.4	-3.37	-0.09	4.07	15.5	0.12 [-0.27, 0.51]
			Irbesartan	80	48 (60.0)	-0.25 (5.71)	-15.0	-2.25	0.00	2.84	16.9	
		Week 48	Sparsentan	82	44 (53.7)	2.15 (6.33)	-18.7	-1.25	1.46	6.32	20.6	0.32 [-0.15, 0.79]
			Irbesartan	80	30 (37.5)	-0.33 (9.48)	-24.7	-4.39	-0.55	2.19	20.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
45 to < 60 mL/min/1.73 m**2	KDQOL-SF12: PCS	Baseline	Sparsentan	45	44 (97.8)	51.30 (7.34)	25.8	46.86	52.52	56.15	63.5	
			Irbesartan	49	46 (93.9)	52.86 (6.16)	27.9	50.34	53.66	57.20	62.0	
		Week 24	Sparsentan	45	31 (68.9)	50.71 (7.52)	31.2	45.43	53.03	56.15	62.0	
			Irbesartan	49	25 (51.0)	51.40 (8.30)	31.2	47.89	54.78	56.15	64.3	
		Week 48	Sparsentan	45	23 (51.1)	51.33 (6.58)	33.2	47.92	52.91	55.57	60.7	
			Irbesartan	49	20 (40.8)	53.05 (6.71)	39.0	51.02	54.67	57.76	62.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	45	31 (68.9)	-0.09 (7.62)	-14.9	-4.25	0.00	2.80	20.4	0.08 [-0.45, 0.61]
			Irbesartan	49	25 (51.0)	-0.64 (6.29)	-20.0	-3.84	0.00	2.22	10.1	
		Week 48	Sparsentan	45	23 (51.1)	0.84 (6.85)	-13.9	-3.11	-0.58	6.61	17.0	-0.13 [-0.72, 0.47]
			Irbesartan	49	20 (40.8)	1.65 (6.12)	-11.3	0.81	2.15	4.29	12.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	KDQOL-SF12: PCS	Baseline	Sparsentan	49	47 (95.9)	53.00 (6.69)	37.4	48.78	53.79	57.76	61.8	
			Irbesartan	48	44 (91.7)	52.03 (7.49)	29.6	49.15	54.95	56.30	64.3	
		Week 24	Sparsentan	49	28 (57.1)	52.61 (7.74)	27.3	48.92	53.07	58.39	62.9	
			Irbesartan	48	26 (54.2)	53.08 (6.00)	34.9	52.17	54.52	56.15	60.8	
		Week 48	Sparsentan	49	29 (59.2)	49.94 (8.14)	29.8	43.15	51.29	55.59	66.1	
			Irbesartan	48	20 (41.7)	50.46 (7.10)	33.7	45.94	53.18	55.87	58.6	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	49	28 (57.1)	0.18 (7.43)	-24.8	-3.63	0.25	5.14	11.8	0.03 [-0.50, 0.57]
			Irbesartan	48	26 (54.2)	-0.06 (6.31)	-15.6	-2.16	-0.04	3.24	13.3	
		Week 48	Sparsentan	49	29 (59.2)	-2.24 (7.65)	-22.3	-5.01	-2.13	3.45	11.4	0.05 [-0.52, 0.62]
			Irbesartan	48	20 (41.7)	-2.58 (7.17)	-18.8	-5.97	-1.20	0.55	9.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	KDQOL-SF12: PCS	Baseline	Sparsentan	26	24 (92.3)	50.73 (11.70)	12.4	49.48	54.33	56.81	62.9	
			Irbesartan	25	24 (96.0)	52.47 (8.27)	21.6	51.67	55.35	56.15	61.1	
		Week 24	Sparsentan	26	15 (57.7)	51.81 (7.16)	36.9	48.47	54.33	57.49	58.0	
			Irbesartan	25	13 (52.0)	51.62 (9.82)	20.8	52.50	54.36	56.40	58.6	
		Week 48	Sparsentan	26	16 (61.5)	50.56 (6.23)	37.1	46.13	51.27	55.48	58.6	
			Irbesartan	25	10 (40.0)	54.58 (5.26)	40.3	54.51	56.28	57.49	58.0	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	26	15 (57.7)	1.35 (6.15)	-6.4	-3.22	1.57	2.98	14.1	0.15 [-0.59, 0.90]
			Irbesartan	25	13 (52.0)	0.58 (3.20)	-3.2	-1.06	0.00	1.36	10.0	
		Week 48	Sparsentan	26	16 (61.5)	0.64 (8.93)	-11.7	-3.62	0.04	2.08	24.7	-0.11 [-0.90, 0.68]
			Irbesartan	25	10 (40.0)	1.48 (4.68)	-3.9	-1.04	1.33	1.63	13.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline urine protein excretion												
<= 1.75 g/day	KDQOL-SF12: PCS	Baseline	Sparsentan	98	92 (93.9)	50.30 (8.31)	25.5	45.89	52.36	56.84	62.3	
			Irbesartan	94	84 (89.4)	52.02 (6.72)	21.6	49.93	53.69	56.15	60.8	
		Week 24	Sparsentan	98	67 (68.4)	50.05 (7.46)	27.3	43.91	52.35	54.80	62.9	
			Irbesartan	94	47 (50.0)	51.97 (7.60)	20.8	50.61	54.51	56.44	60.8	
		Week 48	Sparsentan	98	60 (61.2)	50.56 (7.32)	29.8	46.34	51.96	55.73	66.1	
			Irbesartan	94	34 (36.2)	52.56 (6.57)	33.7	49.68	54.95	57.20	62.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	98	67 (68.4)	0.73 (7.76)	-24.8	-3.82	0.00	5.07	20.4	0.15 [-0.23, 0.52]
			Irbesartan	94	47 (50.0)	-0.33 (6.10)	-20.0	-2.16	0.00	2.31	16.9	
		Week 48	Sparsentan	98	60 (61.2)	0.74 (6.74)	-22.3	-2.53	1.07	4.74	17.0	0.18 [-0.24, 0.61]
			Irbesartan	94	34 (36.2)	-0.46 (6.06)	-18.8	-2.15	0.27	1.61	15.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 1.75 g/day	KDQOL-SF12: PCS	Baseline	Sparsentan	104	95 (91.3)	51.77 (7.87)	12.4	48.84	53.50	56.68	63.5	
			Irbesartan	108	100 (92.6)	51.44 (7.29)	27.9	48.39	53.46	56.34	64.3	
		Week 24	Sparsentan	104	61 (58.7)	52.12 (7.40)	16.3	50.30	53.46	57.49	61.8	
			Irbesartan	108	65 (60.2)	50.85 (6.91)	31.2	45.73	52.91	56.15	64.3	
		Week 48	Sparsentan	104	52 (50.0)	51.53 (6.55)	33.2	46.97	53.36	56.82	60.7	
			Irbesartan	108	46 (42.6)	50.86 (7.61)	32.8	45.72	53.04	56.48	64.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	104	61 (58.7)	-0.01 (5.54)	-13.4	-3.08	0.29	2.98	15.5	0.02 [-0.33, 0.37]
			Irbesartan	108	65 (60.2)	-0.10 (5.44)	-15.6	-2.38	0.29	2.69	13.3	
		Week 48	Sparsentan	104	52 (50.0)	0.29 (7.97)	-18.7	-3.36	-0.52	4.12	24.7	0.03 [-0.37, 0.43]
			Irbesartan	108	46 (42.6)	0.04 (8.80)	-24.7	-4.66	0.14	5.13	20.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline use of antihypertensives												
Yes	KDQOL-SF12: PCS	Baseline	Sparsentan	88	78 (88.6)	50.39 (8.19)	25.8	46.31	52.90	56.15	61.2	
			Irbesartan	83	73 (88.0)	50.33 (7.47)	27.9	45.74	51.28	55.88	64.3	
		Week 24	Sparsentan	88	53 (60.2)	51.16 (7.01)	36.9	45.67	52.70	56.95	62.9	
			Irbesartan	83	43 (51.8)	49.70 (6.56)	31.2	44.55	52.11	55.86	58.9	
		Week 48	Sparsentan	88	43 (48.9)	50.79 (7.39)	35.7	44.69	53.24	57.49	61.9	
			Irbesartan	83	30 (36.1)	50.18 (8.06)	32.8	43.48	51.22	56.15	64.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	88	53 (60.2)	1.04 (7.12)	-14.9	-3.45	-0.64	4.30	20.4	0.13 [-0.27, 0.54]
			Irbesartan	83	43 (51.8)	0.11 (6.75)	-15.0	-3.49	0.00	3.64	16.9	
		Week 48	Sparsentan	88	43 (48.9)	1.78 (7.50)	-15.4	-3.10	0.60	6.61	20.6	0.07 [-0.40, 0.53]
			Irbesartan	83	30 (36.1)	1.20 (10.41)	-24.7	-4.24	1.48	9.50	20.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	KDQOL-SF12: PCS	Baseline	Sparsentan	114	109 (95.6)	51.52 (8.04)	12.4	47.38	53.44	56.98	63.5	
			Irbesartan	119	111 (93.3)	52.61 (6.59)	21.6	50.34	54.51	56.30	62.0	
		Week 24	Sparsentan	114	75 (65.8)	50.95 (7.84)	16.3	48.65	52.64	56.24	62.0	
			Irbesartan	119	69 (58.0)	52.32 (7.44)	20.8	51.90	54.53	56.22	64.3	
		Week 48	Sparsentan	114	69 (60.5)	51.15 (6.73)	29.8	46.91	53.17	55.59	66.1	
			Irbesartan	119	50 (42.0)	52.42 (6.56)	37.7	48.88	54.80	56.71	63.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	114	75 (65.8)	-0.09 (6.54)	-24.8	-3.70	0.29	3.49	14.1	0.05 [-0.28, 0.38]
			Irbesartan	119	69 (58.0)	-0.38 (4.99)	-20.0	-2.13	0.00	1.83	10.4	
		Week 48	Sparsentan	114	69 (60.5)	-0.24 (7.12)	-22.3	-3.28	-0.52	3.24	24.7	0.12 [-0.25, 0.48]
			Irbesartan	119	50 (42.0)	-0.99 (5.48)	-15.8	-2.98	0.00	1.62	13.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Time since renal biopsy												
<= 5 years	KDQOL-SF12: PCS	Baseline	Sparsentan	113	105 (92.9)	49.79 (7.95)	25.8	45.62	51.57	56.15	63.5	
			Irbesartan	127	119 (93.7)	51.63 (7.63)	21.6	48.83	54.13	56.42	64.3	
		Week 24	Sparsentan	113	73 (64.6)	51.09 (7.47)	16.3	47.50	52.50	56.24	62.0	
			Irbesartan	127	73 (57.5)	50.60 (7.79)	20.8	45.08	53.82	56.15	59.4	
		Week 48	Sparsentan	113	61 (54.0)	50.08 (6.72)	33.2	45.70	51.29	55.57	60.7	
			Irbesartan	127	53 (41.7)	51.92 (7.67)	32.8	46.35	54.80	56.71	64.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	113	73 (64.6)	1.65 (6.57)	-13.4	-3.08	1.35	4.84	20.4	0.33 [0.00, 0.66]
			Irbesartan	127	73 (57.5)	-0.47 (6.33)	-20.0	-3.24	-1.06	2.42	16.9	
		Week 48	Sparsentan	113	61 (54.0)	1.05 (7.30)	-18.7	-3.15	0.02	5.28	20.6	0.05 [-0.32, 0.42]
			Irbesartan	127	53 (41.7)	0.64 (8.17)	-24.7	-2.98	1.09	4.27	20.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 5 years	KDQOL-SF12: PCS	Baseline	Sparsentan	89	82 (92.1)	52.67 (8.06)	12.4	49.93	54.80	57.25	62.3	
			Irbesartan	75	65 (86.7)	51.85 (5.81)	34.9	49.51	53.43	56.11	62.0	
		Week 24	Sparsentan	89	55 (61.8)	50.97 (7.56)	27.3	44.79	52.77	56.95	62.9	
			Irbesartan	75	39 (52.0)	52.66 (5.80)	39.0	51.35	53.46	56.40	64.3	
		Week 48	Sparsentan	89	51 (57.3)	52.13 (7.13)	29.8	48.86	53.39	56.15	66.1	
			Irbesartan	75	27 (36.0)	50.90 (6.23)	37.7	48.01	52.11	56.42	58.6	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	89	55 (61.8)	-1.32 (6.74)	-24.8	-5.08	-0.27	2.69	14.1	-0.28 [-0.69, 0.13]
			Irbesartan	75	39 (52.0)	0.31 (4.33)	-12.7	-0.83	0.56	2.31	10.8	
		Week 48	Sparsentan	89	51 (57.3)	-0.09 (7.33)	-22.3	-3.47	-0.04	3.69	24.7	0.24 [-0.23, 0.70]
			Irbesartan	75	27 (36.0)	-1.76 (6.58)	-12.5	-7.08	-1.81	1.33	13.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: History of hypertension												
Yes	KDQOL-SF12: PCS	Baseline	Sparsentan	153	139 (90.8)	50.02 (8.60)	12.4	45.69	52.30	56.19	62.3	
			Irbesartan	157	140 (89.2)	51.65 (6.66)	27.9	49.14	53.21	56.15	64.3	
		Week 24	Sparsentan	153	97 (63.4)	50.59 (7.61)	16.3	45.84	52.35	56.15	62.9	
			Irbesartan	157	83 (52.9)	50.64 (6.92)	31.2	44.90	52.91	55.88	61.9	
		Week 48	Sparsentan	153	83 (54.2)	50.39 (6.72)	33.2	45.70	52.50	55.59	61.9	
			Irbesartan	157	59 (37.6)	51.42 (7.48)	32.8	45.72	54.80	56.71	64.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	153	97 (63.4)	0.77 (6.64)	-14.9	-3.37	0.21	4.08	20.4	0.19 [-0.10, 0.48]
			Irbesartan	157	83 (52.9)	-0.45 (6.25)	-20.0	-3.24	0.00	2.42	16.9	
		Week 48	Sparsentan	153	83 (54.2)	0.87 (7.45)	-18.7	-3.47	0.00	5.11	24.7	0.07 [-0.26, 0.41]
			Irbesartan	157	59 (37.6)	0.30 (8.50)	-24.7	-3.90	1.06	3.64	20.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	KDQOL-SF12: PCS	Baseline	Sparsentan	49	48 (98.0)	54.03 (5.53)	37.4	51.94	54.80	57.39	63.5	
			Irbesartan	45	44 (97.8)	51.89 (8.15)	21.6	49.37	55.07	56.42	62.0	
		Week 24	Sparsentan	49	31 (63.3)	52.45 (6.97)	27.3	49.67	54.26	57.49	60.9	
			Irbesartan	45	29 (64.4)	53.25 (7.74)	20.8	52.39	54.80	56.48	64.3	
		Week 48	Sparsentan	49	29 (59.2)	52.78 (7.43)	29.8	50.03	53.71	56.45	66.1	
			Irbesartan	45	21 (46.7)	52.02 (6.47)	39.0	49.48	53.17	56.42	63.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	49	31 (63.3)	-0.87 (7.15)	-24.8	-4.04	0.00	2.70	12.0	-0.24 [-0.75, 0.27]
			Irbesartan	45	29 (64.4)	0.52 (3.71)	-8.9	-1.49	0.29	2.22	10.4	
		Week 48	Sparsentan	49	29 (59.2)	-0.45 (6.92)	-22.3	-2.88	-0.04	1.93	15.6	0.17 [-0.39, 0.73]
			Irbesartan	45	21 (46.7)	-1.49 (4.78)	-11.3	-4.66	0.00	1.32	6.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Sex	Overall	Sparsentan						Interaction:	0.980
Male	Week 24	Sparsentan	139	88 (63.3)	0.64 (0.61)	(-0.56, 1.85)	0.57 (0.88)	(-1.17, 2.31)	0.517
		Irbesartan	143	81 (56.6)	0.07 (0.64)	(-1.18, 1.32)			
	Week 48	Sparsentan	139	74 (53.2)	0.45 (0.65)	(-0.83, 1.74)	0.10 (0.98)	(-1.84, 2.03)	0.921
		Irbesartan	143	58 (40.6)	0.36 (0.73)	(-1.08, 1.80)			
Female	Week 24	Sparsentan	63	40 (63.5)	-0.29 (1.01)	(-2.30, 1.72)	-0.24 (1.55)	(-3.31, 2.84)	0.879
		Irbesartan	59	31 (52.5)	-0.05 (1.17)	(-2.37, 2.27)			
	Week 48	Sparsentan	63	38 (60.3)	-0.44 (1.03)	(-2.49, 1.60)	0.95 (1.71)	(-2.43, 4.33)	0.578
		Irbesartan	59	22 (37.3)	-1.40 (1.35)	(-4.06, 1.27)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age	Overall	Sparsentan						Interaction:	0.395
<= 45 years	Week 24	Sparsentan	96	59 (61.5)	0.33 (0.75)	(-1.14, 1.81)	0.63 (1.07)	(-1.48, 2.74)	0.558
		Irbesartan	99	56 (56.6)	-0.29 (0.77)	(-1.81, 1.22)			
	Week 48	Sparsentan	96	53 (55.2)	0.25 (0.78)	(-1.30, 1.80)	1.08 (1.19)	(-1.27, 3.43)	0.365
		Irbesartan	99	40 (40.4)	-0.83 (0.90)	(-2.60, 0.94)			
> 45 years	Week 24	Sparsentan	106	69 (65.1)	0.25 (0.73)	(-1.20, 1.70)	-0.22 (1.11)	(-2.41, 1.96)	0.841
		Irbesartan	103	56 (54.4)	0.47 (0.83)	(-1.16, 2.11)			
	Week 48	Sparsentan	106	59 (55.7)	-0.05 (0.77)	(-1.58, 1.47)	-0.86 (1.21)	(-3.25, 1.53)	0.477
		Irbesartan	103	40 (38.8)	0.81 (0.93)	(-1.02, 2.64)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age at IgAN diagnosis	Overall	Sparsentan						Interaction:	0.510
<= 18 years	Week 24	Sparsentan	9	3 (33.3)	NE		NE		NE
		Irbesartan	5	2 (40.0)	NE				
	Week 48	Sparsentan	9	5 (55.6)	NE		NE		NE
		Irbesartan	5	1 (20.0)	NE				
> 18 to 40 years	Week 24	Sparsentan	102	64 (62.7)	0.09 (0.70)	(-1.29, 1.47)	-0.00 (1.00)	(-1.98, 1.98)	0.999
		Irbesartan	109	61 (56.0)	0.09 (0.72)	(-1.33, 1.51)			
	Week 48	Sparsentan	102	57 (55.9)	0.44 (0.74)	(-1.02, 1.90)	1.15 (1.12)	(-1.06, 3.35)	0.306
		Irbesartan	109	45 (41.3)	-0.71 (0.83)	(-2.35, 0.93)			
> 40 years	Week 24	Sparsentan	91	61 (67.0)	0.30 (0.82)	(-1.33, 1.93)	0.31 (1.23)	(-2.13, 2.75)	0.801
		Irbesartan	88	49 (55.7)	-0.01 (0.92)	(-1.83, 1.80)			
	Week 48	Sparsentan	91	50 (54.9)	-0.56 (0.87)	(-2.28, 1.17)	-1.33 (1.35)	(-4.01, 1.34)	0.326
		Irbesartan	88	34 (38.6)	0.78 (1.03)	(-1.26, 2.82)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Geographic region	Overall	Sparsentan						Interaction:	0.854
North America	Week 24	Sparsentan	35	15 (42.9)	1.77 (1.45)	(-1.13, 4.68)	1.43 (1.82)	(-2.21, 5.07)	0.436
		Irbesartan	46	28 (60.9)	0.34 (1.06)	(-1.78, 2.47)			
	Week 48	Sparsentan	35	13 (37.1)	2.25 (1.55)	(-0.85, 5.36)	0.89 (2.07)	(-3.25, 5.02)	0.670
		Irbesartan	46	17 (37.0)	1.36 (1.35)	(-1.33, 4.06)			
Europe	Week 24	Sparsentan	98	56 (57.1)	0.25 (0.76)	(-1.24, 1.75)	1.28 (1.11)	(-0.92, 3.47)	0.253
		Irbesartan	115	50 (43.5)	-1.02 (0.81)	(-2.62, 0.57)			
	Week 48	Sparsentan	98	44 (44.9)	-0.04 (0.84)	(-1.71, 1.62)	0.43 (1.23)	(-2.00, 2.86)	0.728
		Irbesartan	115	40 (34.8)	-0.47 (0.89)	(-2.22, 1.28)			
Asia Pacific	Week 24	Sparsentan	69	57 (82.6)	0.21 (0.86)	(-1.49, 1.91)	-0.72 (1.42)	(-3.54, 2.10)	0.615
		Irbesartan	41	34 (82.9)	0.93 (1.13)	(-1.30, 3.16)			
	Week 48	Sparsentan	69	55 (79.7)	-0.07 (0.87)	(-1.79, 1.65)	0.93 (1.57)	(-2.17, 4.02)	0.554
		Irbesartan	41	23 (56.1)	-1.00 (1.29)	(-3.55, 1.55)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline BMI	Overall	Sparsentan						Interaction:	0.412
< 27 kg/m**2	Week 24	Sparsentan	84	52 (61.9)	0.36 (0.73)	(-1.07, 1.79)	0.57 (1.03)	(-1.45, 2.60)	0.577
		Irbesartan	94	54 (57.4)	-0.21 (0.72)	(-1.63, 1.20)			
	Week 48	Sparsentan	84	48 (57.1)	0.01 (0.75)	(-1.48, 1.49)	1.23 (1.14)	(-1.02, 3.48)	0.281
		Irbesartan	94	37 (39.4)	-1.22 (0.85)	(-2.89, 0.44)			
>= 27 kg/m**2	Week 24	Sparsentan	118	76 (64.4)	0.31 (0.74)	(-1.15, 1.77)	0.01 (1.13)	(-2.22, 2.24)	0.991
		Irbesartan	107	58 (54.2)	0.30 (0.85)	(-1.38, 1.98)			
	Week 48	Sparsentan	118	64 (54.2)	0.23 (0.79)	(-1.32, 1.79)	-0.68 (1.24)	(-3.13, 1.76)	0.582
		Irbesartan	107	43 (40.2)	0.92 (0.96)	(-0.97, 2.81)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Randomization strata	Overall	Sparsentan						Interaction:	0.722
eGFR Low and UP High	Week 24	Sparsentan	71	45 (63.4)	-0.37 (0.96)	(-2.28, 1.54)	0.79 (1.46)	(-2.09, 3.68)	0.586
		Irbesartan	74	36 (48.6)	-1.17 (1.09)	(-3.33, 0.99)			
	Week 48	Sparsentan	71	39 (54.9)	0.77 (1.01)	(-1.23, 2.78)	1.32 (1.63)	(-1.91, 4.54)	0.421
		Irbesartan	74	23 (31.1)	-0.54 (1.28)	(-3.07, 1.98)			
eGFR Low and UP Low	Week 24	Sparsentan	55	39 (70.9)	0.90 (0.90)	(-0.88, 2.67)	0.53 (1.33)	(-2.10, 3.16)	0.690
		Irbesartan	55	35 (63.6)	0.37 (0.95)	(-1.52, 2.26)			
	Week 48	Sparsentan	55	28 (50.9)	0.82 (1.04)	(-1.24, 2.89)	0.85 (1.53)	(-2.18, 3.89)	0.579
		Irbesartan	55	25 (45.5)	-0.03 (1.10)	(-2.22, 2.16)			
eGFR High and UP High	Week 24	Sparsentan	37	20 (54.1)	0.99 (1.26)	(-1.52, 3.51)	-0.36 (1.82)	(-3.99, 3.26)	0.843
		Irbesartan	36	19 (52.8)	1.36 (1.31)	(-1.25, 3.97)			
	Week 48	Sparsentan	37	22 (59.5)	-0.73 (1.20)	(-3.14, 1.67)	-0.06 (1.96)	(-3.96, 3.84)	0.975
		Irbesartan	36	13 (36.1)	-0.67 (1.54)	(-3.75, 2.41)			
eGFR High and UP Low	Week 24	Sparsentan	39	24 (61.5)	0.50 (1.16)	(-1.82, 2.81)	0.40 (1.68)	(-2.96, 3.75)	0.814
		Irbesartan	37	22 (59.5)	0.10 (1.21)	(-2.31, 2.51)			
	Week 48	Sparsentan	39	23 (59.0)	-0.66 (1.18)	(-3.02, 1.70)	-1.71 (1.76)	(-5.22, 1.81)	0.337
		Irbesartan	37	19 (51.4)	1.05 (1.30)	(-1.54, 3.63)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 1	Overall	Sparsentan						Interaction:	0.841
< 60 mL/min/1.73 m**2	Week 24	Sparsentan	127	85 (66.9)	0.17 (0.65)	(-1.10, 1.45)	0.34 (0.96)	(-1.55, 2.23)	0.725
		Irbesartan	129	73 (56.6)	-0.17 (0.71)	(-1.56, 1.22)			
	Week 48	Sparsentan	127	67 (52.8)	1.18 (0.71)	(-0.23, 2.58)	0.76 (1.09)	(-1.39, 2.91)	0.486
		Irbesartan	129	50 (38.8)	0.42 (0.82)	(-1.20, 2.04)			
60 to < 90 mL/min/1.73 m**2	Week 24	Sparsentan	49	28 (57.1)	0.50 (1.18)	(-1.85, 2.85)	0.23 (1.73)	(-3.21, 3.66)	0.895
		Irbesartan	48	26 (54.2)	0.28 (1.24)	(-2.19, 2.74)			
	Week 48	Sparsentan	49	29 (59.2)	-2.16 (1.17)	(-4.48, 0.17)	0.21 (1.81)	(-3.39, 3.82)	0.906
		Irbesartan	48	20 (41.7)	-2.37 (1.36)	(-5.08, 0.34)			
>= 90 mL/min/1.73 m**2	Week 24	Sparsentan	26	15 (57.7)	1.11 (1.23)	(-1.36, 3.58)	0.49 (1.80)	(-3.14, 4.11)	0.789
		Irbesartan	25	13 (52.0)	0.62 (1.32)	(-2.03, 3.28)			
	Week 48	Sparsentan	26	16 (61.5)	0.15 (1.20)	(-2.25, 2.56)	-2.39 (1.96)	(-6.33, 1.55)	0.229
		Irbesartan	25	10 (40.0)	2.54 (1.54)	(-0.54, 5.63)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 2	Overall	Sparsentan						Interaction:	0.912
< 45 mL/min/1.73 m**2	Week 24	Sparsentan	82	54 (65.9)	0.34 (0.81)	(-1.27, 1.95)	0.32 (1.19)	(-2.03, 2.68)	0.787
		Irbesartan	80	48 (60.0)	0.02 (0.87)	(-1.70, 1.74)			
	Week 48	Sparsentan	82	44 (53.7)	1.55 (0.88)	(-0.19, 3.29)	1.52 (1.37)	(-1.19, 4.22)	0.270
		Irbesartan	80	30 (37.5)	0.03 (1.05)	(-2.03, 2.10)			
45 to < 60 mL/min/1.73 m**2	Week 24	Sparsentan	45	31 (68.9)	-0.15 (1.10)	(-2.35, 2.04)	0.36 (1.68)	(-2.99, 3.72)	0.829
		Irbesartan	49	25 (51.0)	-0.52 (1.25)	(-3.01, 1.98)			
	Week 48	Sparsentan	45	23 (51.1)	0.45 (1.26)	(-2.05, 2.94)	-0.58 (1.88)	(-4.32, 3.15)	0.757
		Irbesartan	49	20 (40.8)	1.03 (1.38)	(-1.70, 3.77)			
60 to < 90 mL/min/1.73 m**2	Week 24	Sparsentan	49	28 (57.1)	0.50 (1.18)	(-1.85, 2.85)	0.23 (1.73)	(-3.21, 3.66)	0.895
		Irbesartan	48	26 (54.2)	0.28 (1.24)	(-2.19, 2.74)			
	Week 48	Sparsentan	49	29 (59.2)	-2.16 (1.17)	(-4.48, 0.17)	0.21 (1.81)	(-3.39, 3.82)	0.906
		Irbesartan	48	20 (41.7)	-2.37 (1.36)	(-5.08, 0.34)			
>= 90 mL/min/1.73 m**2	Week 24	Sparsentan	26	15 (57.7)	1.11 (1.23)	(-1.36, 3.58)	0.49 (1.80)	(-3.14, 4.11)	0.789
		Irbesartan	25	13 (52.0)	0.62 (1.32)	(-2.03, 3.28)			
	Week 48	Sparsentan	26	16 (61.5)	0.15 (1.20)	(-2.25, 2.56)	-2.39 (1.96)	(-6.33, 1.55)	0.229
		Irbesartan	25	10 (40.0)	2.54 (1.54)	(-0.54, 5.63)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline urine protein excretion	Overall	Sparsentan						Interaction:	0.629
<= 1.75 g/day	Week 24	Sparsentan	98	67 (68.4)	0.37 (0.73)	(-1.08, 1.82)	0.12 (1.16)	(-2.17, 2.41)	0.916
		Irbesartan	94	47 (50.0)	0.25 (0.89)	(-1.50, 2.00)			
	Week 48	Sparsentan	98	60 (61.2)	0.11 (0.76)	(-1.40, 1.62)	0.35 (1.27)	(-2.17, 2.86)	0.786
		Irbesartan	94	34 (36.2)	-0.23 (1.00)	(-2.21, 1.74)			
> 1.75 g/day	Week 24	Sparsentan	104	61 (58.7)	0.52 (0.76)	(-0.98, 2.02)	0.81 (1.07)	(-1.29, 2.92)	0.447
		Irbesartan	108	65 (60.2)	-0.30 (0.74)	(-1.76, 1.17)			
	Week 48	Sparsentan	104	52 (50.0)	0.36 (0.82)	(-1.25, 1.97)	0.56 (1.20)	(-1.80, 2.93)	0.640
		Irbesartan	108	46 (42.6)	-0.20 (0.86)	(-1.91, 1.50)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline use of antihypertensives	Overall	Sparsentan						Interaction:	0.478
Yes	Week 24	Sparsentan	88	53 (60.2)	1.39 (0.86)	(-0.31, 3.10)	1.19 (1.29)	(-1.35, 3.73)	0.357
		Irbesartan	83	43 (51.8)	0.21 (0.95)	(-1.68, 2.09)			
	Week 48	Sparsentan	88	43 (48.9)	1.25 (0.94)	(-0.61, 3.10)	0.22 (1.46)	(-2.67, 3.10)	0.883
		Irbesartan	83	30 (36.1)	1.03 (1.11)	(-1.17, 3.23)			
No	Week 24	Sparsentan	114	75 (65.8)	-0.20 (0.65)	(-1.49, 1.09)	-0.11 (0.95)	(-1.98, 1.76)	0.909
		Irbesartan	119	69 (58.0)	-0.09 (0.69)	(-1.45, 1.26)			
	Week 48	Sparsentan	114	69 (60.5)	-0.47 (0.67)	(-1.80, 0.85)	0.36 (1.04)	(-1.68, 2.40)	0.730
		Irbesartan	119	50 (42.0)	-0.83 (0.78)	(-2.38, 0.71)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Time since renal biopsy	Overall	Sparsentan						Interaction:	0.466
<= 5 years	Week 24	Sparsentan	113	73 (64.6)	1.42 (0.71)	(0.02, 2.83)	1.51 (1.01)	(-0.47, 3.50)	0.135
		Irbesartan	127	73 (57.5)	-0.09 (0.71)	(-1.49, 1.32)			
	Week 48	Sparsentan	113	61 (54.0)	0.34 (0.76)	(-1.16, 1.85)	-0.41 (1.11)	(-2.60, 1.79)	0.715
		Irbesartan	127	53 (41.7)	0.75 (0.81)	(-0.85, 2.35)			
> 5 years	Week 24	Sparsentan	89	55 (61.8)	-1.13 (0.77)	(-2.65, 0.38)	-1.66 (1.20)	(-4.04, 0.71)	0.168
		Irbesartan	75	39 (52.0)	0.53 (0.93)	(-1.31, 2.36)			
	Week 48	Sparsentan	89	51 (57.3)	-0.24 (0.79)	(-1.80, 1.33)	1.29 (1.34)	(-1.35, 3.93)	0.335
		Irbesartan	75	27 (36.0)	-1.53 (1.07)	(-3.64, 0.59)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 04APR2024

Table PT1KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
History of hypertension	Overall	Sparsentan						Interaction:	0.772
Yes	Week 24	Sparsentan	153	97 (63.4)	0.70 (0.61)	(-0.49, 1.89)	0.77 (0.89)	(-0.99, 2.53)	0.389
		Irbesartan	157	83 (52.9)	-0.07 (0.66)	(-1.37, 1.23)			
	Week 48	Sparsentan	153	83 (54.2)	0.24 (0.64)	(-1.03, 1.50)	-0.31 (0.99)	(-2.27, 1.64)	0.754
		Irbesartan	157	59 (37.6)	0.55 (0.76)	(-0.94, 2.04)			
No	Week 24	Sparsentan	49	31 (63.3)	-0.71 (1.02)	(-2.73, 1.31)	-1.33 (1.48)	(-4.26, 1.60)	0.371
		Irbesartan	45	29 (64.4)	0.62 (1.06)	(-1.49, 2.73)			
	Week 48	Sparsentan	49	29 (59.2)	-0.22 (1.05)	(-2.30, 1.85)	1.65 (1.61)	(-1.55, 4.85)	0.309
		Irbesartan	45	21 (46.7)	-1.87 (1.22)	(-4.30, 0.55)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 04APR2024

Figure PF1KPSC_FSGM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

Not done: No significant subgroup found.

_____
Number of available records are presented for key visits up to Week 58 only. LS-Mean = Least square mean.
95% CI = 95% confidence interval. eGFR = estimated glomerular filtration rate. UP = urine protein. BMI = body mass index.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
IgAN = immunoglobulin A nephropathy. A decrease reflects a worsening of the status of the patient. Reference table: PT1KPSC_FSCM.

Table PT1KPSIT_FSTM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sex	Sparsentan						Interaction test:	0.439
Male	Sparsentan	139	14 (10.1)	NE		1.072	(0.489, 2.351)	0.862
	Irbesartan	143	14 (9.8)	NE				
Female	Sparsentan	63	8 (12.7)	NE		1.109	(0.075, 16.413)	0.940
	Irbesartan	59	1 (1.7)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KPSIT_FSTM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.488
<= 45 years	Sparsentan	96	8 (8.3)	NE		0.768	(0.243, 2.426)	0.653
	Irbesartan	99	6 (6.1)	NE				
> 45 years	Sparsentan	106	14 (13.2)	NE		1.109	(0.441, 2.784)	0.826
	Irbesartan	103	9 (8.7)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KPSIT_FSTM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age at IgAN diagnosis	Sparsentan						Interaction test:	NE
<= 18 years	Sparsentan	9	1 (11.1)	NE		NE		NE
			No events in 1 group					
	Irbesartan	5	0 (0.0)	NE				
> 18 to 40 years	Sparsentan	102	10 (9.8)	NE		1.282	(0.485, 3.384)	0.617
	Irbesartan	109	8 (7.3)	NE				
> 40 years	Sparsentan	91	11 (12.1)	NE		1.126	(0.376, 3.371)	0.832
	Irbesartan	88	7 (8.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KPSIT_FSTM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Geographic region	Sparsentan						Interaction test:	<0.001	#
North America	Sparsentan	35	1 (2.9)	NE		0.093	(0.007, 1.237)	0.072	
	Irbesartan	46	6 (13.0)	NE					
Europe	Sparsentan	98	7 (7.1)	NE		0.436	(0.080, 2.362)	0.336	
	Irbesartan	115	5 (4.3)	NE					
Asia Pacific	Sparsentan	69	14 (20.3)	NE		1.939	(0.607, 6.199)	0.264	
	Irbesartan	41	4 (9.8)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KPSIT_FSTM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.956
< 27 kg/m**2	Sparsentan	84	10 (11.9)	NE		1.202	(0.357, 4.054)	0.767
	Irbesartan	94	5 (5.3)	NE				
>= 27 kg/m**2	Sparsentan	118	12 (10.2)	NE		1.150	(0.466, 2.839)	0.761
	Irbesartan	107	10 (9.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KPSIT_FSTM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Randomization strata	Sparsentan						Interaction test:	0.012	#
eGFR Low and UP High	Sparsentan	71	6 (8.5)	NE		1.140	(0.355, 3.662)	0.826	
	Irbesartan	74	6 (8.1)	NE					
eGFR Low and UP Low	Sparsentan	55	7 (12.7)	NE		0.875	(0.175, 4.389)	0.871	
	Irbesartan	55	3 (5.5)	NE					
eGFR High and UP High	Sparsentan	37	3 (8.1)	NE		0.261	(0.031, 2.183)	0.215	
	Irbesartan	36	3 (8.3)	NE					
eGFR High and UP Low	Sparsentan	39	6 (15.4)	NE		3.957	(0.642, 24.379)	0.138	
	Irbesartan	37	3 (8.1)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KPSIT_FSTM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.897
< 60 mL/min/1.73 m**2	Sparsentan	127	14 (11.0)	NE		1.126	(0.466, 2.723)	0.792
	Irbesartan	129	11 (8.5)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	4 (8.2)	NE		0.972	(0.101, 9.341)	0.981
	Irbesartan	48	3 (6.3)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	4 (15.4)	NE		1.447	(0.129, 16.254)	0.765
	Irbesartan	25	1 (4.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KPSIT_FSTM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 2	Sparsentan						Interaction test:	0.971
< 45 mL/min/1.73 m**2	Sparsentan	82	8 (9.8)	NE		0.865	(0.254, 2.947)	0.816
	Irbesartan	80	6 (7.5)	NE				
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	6 (13.3)	NE		1.250	(0.319, 4.896)	0.748
	Irbesartan	49	5 (10.2)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	4 (8.2)	NE		0.972	(0.101, 9.341)	0.981
	Irbesartan	48	3 (6.3)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	4 (15.4)	NE		1.447	(0.129, 16.254)	0.765
	Irbesartan	25	1 (4.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KPSIT_FSTM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline urine protein excretion	Sparsentan						Interaction test:	0.063
<= 1.75 g/day	Sparsentan	98	14 (14.3)	NE		2.448	(0.769, 7.790)	0.130
	Irbesartan	94	4 (4.3)	NE				
> 1.75 g/day	Sparsentan	104	8 (7.7)	NE		0.453	(0.158, 1.302)	0.142
	Irbesartan	108	11 (10.2)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KPSIT_FSTM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.828
Yes	Sparsentan	88	10 (11.4)	NE		0.792	(0.298, 2.106)	0.640
	Irbesartan	83	10 (12.0)	NE				
No	Sparsentan	114	12 (10.5)	NE		1.809	(0.612, 5.351)	0.284
	Irbesartan	119	5 (4.2)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KPSIT_FSTM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Time since renal biopsy	Sparsentan						Interaction test:	0.242
<= 5 years	Sparsentan	113	15 (13.3)	NE		1.484	(0.659, 3.341)	0.340
	Irbesartan	127	11 (8.7)	NE				
> 5 years	Sparsentan	89	7 (7.9)	NE		0.939	(0.225, 3.917)	0.931
	Irbesartan	75	4 (5.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KPSIT_FSTM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
History of hypertension	Sparsentan						Interaction test:	0.040	#
Yes	Sparsentan	153	16 (10.5)	NE		0.705	(0.312, 1.595)	0.402	
	Irbesartan	157	12 (7.6)	NE					
No	Sparsentan	49	6 (12.2)	NE		4.395	(0.738, 26.182)	0.104	
	Irbesartan	45	3 (6.7)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Figure PF1KPSIT_FSKM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Geographic region: North America



Sparsentan	35	18	13	9	6	1
Irbesartan	46	26	16	8	3	2

An increase reflects an improvement of the status of the patient.
Reference table: PT1KPSIT_FSTM

Figure PF1KPSIT_FSKM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Geographic region: Europe



Sparsentan	98	59	40	27	13	6
Irbesartan	115	61	46	30	12	3

An increase reflects an improvement of the status of the patient.
Reference table: PT1KPSIT_FSTM

Figure PF1KPSIT_FSKM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Geographic region: Asia Pacific



Sparsentan	69	59	48	36	13	8
Irbesartan	41	32	21	13	2	0

An increase reflects an improvement of the status of the patient.
Reference table: PT1KPSIT_FSTM

Figure PF1KPSIT_FSKM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Randomization strata: eGFR Low and UP High



Sparsentan	71	48	39	30	15	5
Irbesartan	74	37	29	17	6	0

An increase reflects an improvement of the status of the patient.
Reference table: PT1KPSIT_FSTM

Figure PF1KPSIT_FSKM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Randomization strata: eGFR Low and UP Low



Sparsentan	55	38	23	15	8	6
Irbesartan	55	38	27	18	8	4

An increase reflects an improvement of the status of the patient.
Reference table: PT1KPSIT_FSTM

Figure PF1KPSIT_FSKM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Randomization strata: eGFR High and UP High



Sparsentan	37	24	20	14	6	3
Irbesartan	36	20	11	5	1	0

An increase reflects an improvement of the status of the patient.
Reference table: PT1KPSIT_FSTM

Figure PF1KPSIT_FSKM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Randomization strata: eGFR High and UP Low



Sparsentan	39	26	19	13	3	1
Irbesartan	37	24	16	11	2	1

An increase reflects an improvement of the status of the patient.
Reference table: PT1KPSIT_FSTM

Figure PF1KPSIT_FSKM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
History of hypertension: Yes



Sparsentan	153	102	75	56	26	12
Irbesartan	157	87	62	39	13	4

An increase reflects an improvement of the status of the patient.
Reference table: PT1KPSIT_FSTM

Figure PF1KPSIT_FSKM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
History of hypertension: No



Sparsentan	49	34	26	16	6	3
Irbesartan	45	32	21	12	4	1

An increase reflects an improvement of the status of the patient.
Reference table: PT1KPSIT_FSTM

Table PT1KPSDT_FSTM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sex	Sparsentan						Interaction test:	0.795
Male	Sparsentan	139	13 (9.4)	NE		0.870	(0.391, 1.939)	0.734
	Irbesartan	143	12 (8.4)	NE				
Female	Sparsentan	63	12 (19.0)	NE		0.948	(0.323, 2.776)	0.922
	Irbesartan	59	6 (10.2)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KPSDT_FSTM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.325
<= 45 years	Sparsentan	96	12 (12.5)	NE		1.424	(0.549, 3.689)	0.467
	Irbesartan	99	7 (7.1)	NE				
> 45 years	Sparsentan	106	13 (12.3)	NE		0.823	(0.365, 1.856)	0.638
	Irbesartan	103	11 (10.7)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KPSDT_FSTM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age at IgAN diagnosis	Sparsentan						Interaction test:	NE
<= 18 years	Sparsentan	9	0 (0.0) No events in 1 group	NE		NE		NE
	Irbesartan	5	0 (0.0)	NE				
> 18 to 40 years	Sparsentan	102	15 (14.7)	NE		1.502	(0.635, 3.553)	0.354
	Irbesartan	109	9 (8.3)	NE				
> 40 years	Sparsentan	91	10 (11.0)	NE		0.832	(0.335, 2.064)	0.692
	Irbesartan	88	9 (10.2)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KPSDT_FSTM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Geographic region	Sparsentan						Interaction test:	0.517
North America	Sparsentan	35	3 (8.6)	NE		0.629	(0.130, 3.034)	0.563
	Irbesartan	46	5 (10.9)	NE				
Europe	Sparsentan	98	9 (9.2)	NE		0.817	(0.325, 2.050)	0.666
	Irbesartan	115	10 (8.7)	NE				
Asia Pacific	Sparsentan	69	13 (18.8)	NE		1.817	(0.507, 6.510)	0.359
	Irbesartan	41	3 (7.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KPSDT_FSTM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.863
< 27 kg/m**2	Sparsentan	84	8 (9.5)	NE		0.849	(0.290, 2.485)	0.766
	Irbesartan	94	7 (7.4)	NE				
>= 27 kg/m**2	Sparsentan	118	17 (14.4)	NE		1.130	(0.525, 2.433)	0.754
	Irbesartan	107	11 (10.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KPSDT_FSTM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Randomization strata	Sparsentan						Interaction test:	0.035	#
eGFR Low and UP High	Sparsentan	71	10 (14.1)	NE		1.004	(0.358, 2.817)	0.994	
	Irbesartan	74	6 (8.1)	NE					
eGFR Low and UP Low	Sparsentan	55	1 (1.8)	NE		0.137	(0.017, 1.109)	0.062	
	Irbesartan	55	8 (14.5)	NE					
eGFR High and UP High	Sparsentan	37	7 (18.9)	NE		1.585	(0.314, 8.017)	0.577	
	Irbesartan	36	2 (5.6)	NE					
eGFR High and UP Low	Sparsentan	39	7 (17.9)	NE		3.027	(0.602, 15.224)	0.179	
	Irbesartan	37	2 (5.4)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KPSDT_FSTM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan						Interaction test:	NE
< 60 mL/min/1.73 m**2	Sparsentan	127	12 (9.4)	NE		0.784	(0.351, 1.751)	0.553
	Irbesartan	129	13 (10.1)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	8 (16.3)	NE		0.873	(0.271, 2.812)	0.820
	Irbesartan	48	5 (10.4)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	5 (19.2)	NE		NE		NE
			No events in 1 group					
	Irbesartan	25	0 (0.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KPSDT_FSTM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 2	Sparsentan						Interaction test:	NE
< 45 mL/min/1.73 m**2	Sparsentan	82	6 (7.3)	NE		0.445	(0.158, 1.255)	0.126
	Irbesartan	80	10 (12.5)	NE				
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	6 (13.3)	NE		2.363	(0.553, 10.107)	0.246
	Irbesartan	49	3 (6.1)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	8 (16.3)	NE		0.873	(0.271, 2.812)	0.820
	Irbesartan	48	5 (10.4)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	5 (19.2)	NE		NE		NE
			No events in 1 group					
	Irbesartan	25	0 (0.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KPSDT_FSTM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline urine protein excretion	Sparsentan						Interaction test:	0.615
<= 1.75 g/day	Sparsentan	98	12 (12.2)	NE		1.157	(0.435, 3.080)	0.770
	Irbesartan	94	7 (7.4)	NE				
> 1.75 g/day	Sparsentan	104	13 (12.5)	NE		0.998	(0.418, 2.382)	0.996
	Irbesartan	108	11 (10.2)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KPSDT_FSTM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.649
Yes	Sparsentan	88	10 (11.4)	NE		0.878	(0.337, 2.284)	0.790
	Irbesartan	83	8 (9.6)	NE				
No	Sparsentan	114	15 (13.2)	NE		1.139	(0.508, 2.552)	0.753
	Irbesartan	119	10 (8.4)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KPSDT_FSTM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Time since renal biopsy	Sparsentan						Interaction test:	0.795
<= 5 years	Sparsentan	113	12 (10.6)	NE		1.075	(0.462, 2.503)	0.867
	Irbesartan	127	10 (7.9)	NE				
> 5 years	Sparsentan	89	13 (14.6)	NE		0.857	(0.335, 2.192)	0.748
	Irbesartan	75	8 (10.7)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KPSDT_FSTM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
History of hypertension	Sparsentan						Interaction test:	0.583
Yes	Sparsentan	153	19 (12.4)	NE		0.968	(0.487, 1.921)	0.925
	Irbesartan	157	15 (9.6)	NE				
No	Sparsentan	49	6 (12.2)	NE		1.584	(0.373, 6.733)	0.533
	Irbesartan	45	3 (6.7)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Figure PF1KPSDT_FSKM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Randomization strata: eGFR Low and UP High



Sparsentan	71	47	37	29	15	2
Irbesartan	74	37	26	18	7	2

A decrease reflects a worsening of the status of the patient.
Reference table: PT1KPSDT_FSTM

Figure PF1KPSDT_FSKM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Randomization strata: eGFR Low and UP Low



Sparsentan	55	38	29	20	11	6
Irbesartan	55	38	26	17	9	4

_____
A decrease reflects a worsening of the status of the patient.
Reference table: PT1KPSDT_FSTM

Figure PF1KPSDT_FSKM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Randomization strata: eGFR High and UP High



Sparsentan	37	24	19	13	3	1
Irbesartan	36	20	13	8	3	1

_____
A decrease reflects a worsening of the status of the patient.
Reference table: PT1KPSDT_FSTM

Figure PF1KPSDT_FSKM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Randomization strata: eGFR High and UP Low



Sparsentan	39	26	22	14	3	1
Irbesartan	37	24	17	11	3	2

A decrease reflects a worsening of the status of the patient.
Reference table: PT1KPSDT_FSTM

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	KDQOL-SF12: MCS	Baseline	Sparsentan	139	130 (93.5)	50.45 (7.97)	30.1	45.01	51.54	57.06	66.5	
			Irbesartan	143	132 (92.3)	51.61 (8.91)	24.3	48.28	53.36	57.16	66.6	
		Week 24	Sparsentan	139	88 (63.3)	51.32 (7.78)	20.8	47.69	51.92	57.16	66.8	
			Irbesartan	143	81 (56.6)	52.38 (8.56)	24.2	48.43	55.77	58.15	64.2	
		Week 48	Sparsentan	139	74 (53.2)	50.78 (7.92)	27.5	46.89	52.13	57.16	62.5	
			Irbesartan	143	58 (40.6)	52.97 (8.50)	28.5	49.58	54.88	58.58	64.6	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	139	88 (63.3)	0.17 (7.74)	-19.1	-4.42	-0.05	4.50	25.3	-0.01 [-0.31, 0.29]
			Irbesartan	143	81 (56.6)	0.25 (7.03)	-15.4	-4.36	0.00	2.98	28.7	
		Week 48	Sparsentan	139	74 (53.2)	0.86 (7.78)	-18.6	-3.85	0.69	6.32	18.7	0.06 [-0.28, 0.41]
			Irbesartan	143	58 (40.6)	0.39 (6.92)	-17.3	-2.88	0.00	4.92	17.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Female	KDQOL-SF12: MCS	Baseline	Sparsentan	63	57 (90.5)	50.24 (9.11)	16.2	44.79	51.77	56.05	65.2	
			Irbesartan	59	52 (88.1)	50.78 (7.91)	31.5	45.73	52.81	57.16	61.3	
		Week 24	Sparsentan	63	40 (63.5)	52.17 (7.51)	30.7	47.38	53.24	58.30	63.5	
			Irbesartan	59	31 (52.5)	53.55 (7.70)	32.5	51.19	54.45	57.76	62.6	
		Week 48	Sparsentan	63	38 (60.3)	50.61 (9.24)	27.5	42.67	51.71	59.46	63.4	
			Irbesartan	59	22 (37.3)	46.84 (12.07)	19.6	39.39	50.08	56.11	64.5	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	63	40 (63.5)	1.96 (9.36)	-23.6	-1.63	0.99	7.80	26.4	0.08 [-0.38, 0.55]
			Irbesartan	59	31 (52.5)	1.27 (6.09)	-9.4	-2.96	1.41	3.95	20.2	
		Week 48	Sparsentan	63	38 (60.3)	0.19 (11.16)	-23.7	-4.74	-0.10	4.70	28.1	0.51 [-0.02, 1.04]
			Irbesartan	59	22 (37.3)	-5.38 (10.48)	-33.9	-13.37	-2.99	2.79	6.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
<= 45 years	KDQOL-SF12: MCS	Baseline	Sparsentan	96	88 (91.7)	48.94 (8.49)	27.8	43.44	50.17	55.34	65.2	
			Irbesartan	99	92 (92.9)	50.34 (9.59)	24.3	44.08	52.45	57.16	64.2	
		Week 24	Sparsentan	96	59 (61.5)	50.89 (8.33)	20.8	46.59	52.22	57.24	63.5	
			Irbesartan	99	56 (56.6)	51.80 (9.33)	24.2	48.37	54.41	58.02	62.7	
		Week 48	Sparsentan	96	53 (55.2)	49.15 (8.58)	27.5	42.67	50.84	56.29	62.5	
			Irbesartan	99	40 (40.4)	51.51 (10.15)	21.5	47.22	54.50	58.35	64.6	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	96	59 (61.5)	0.14 (8.74)	-23.6	-5.04	0.00	5.32	26.4	-0.07 [-0.44, 0.30]
			Irbesartan	99	56 (56.6)	0.69 (6.96)	-14.1	-3.74	0.68	5.01	21.7	
		Week 48	Sparsentan	96	53 (55.2)	-0.27 (9.72)	-23.7	-4.61	0.00	4.70	21.1	0.10 [-0.31, 0.51]
			Irbesartan	99	40 (40.4)	-1.12 (7.66)	-23.5	-4.02	0.00	3.28	13.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 45 years	KDQOL-SF12: MCS	Baseline	Sparsentan	106	99 (93.4)	51.67 (7.97)	16.2	48.28	53.37	57.16	66.5	
			Irbesartan	103	92 (89.3)	52.41 (7.45)	26.4	49.05	53.29	57.16	66.6	
		Week 24	Sparsentan	106	69 (65.1)	52.18 (7.09)	34.3	48.18	53.96	57.33	66.8	
			Irbesartan	103	56 (54.4)	53.61 (7.13)	30.8	50.56	56.34	57.87	64.2	
		Week 48	Sparsentan	106	59 (55.7)	52.14 (7.95)	29.5	48.76	53.51	58.32	63.4	
			Irbesartan	103	40 (38.8)	51.06 (9.81)	19.6	47.43	52.82	57.37	64.5	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	106	69 (65.1)	1.23 (7.90)	-18.1	-2.86	0.61	4.20	25.9	0.12 [-0.24, 0.47]
			Irbesartan	103	56 (54.4)	0.38 (6.64)	-15.4	-4.23	0.00	3.27	28.7	
		Week 48	Sparsentan	106	59 (55.7)	1.45 (8.35)	-16.9	-3.83	1.89	6.43	28.1	0.31 [-0.09, 0.72]
			Irbesartan	103	40 (38.8)	-1.28 (9.17)	-33.9	-3.52	-0.62	4.90	17.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age at IgAN diagnosis												
<= 18 years	KDQOL-SF12: MCS	Baseline	Sparsentan	9	9 (100.0)	44.94 (11.76)	31.1	35.44	42.40	51.24	62.5	
			Irbesartan	5	5 (100.0)	50.09 (9.56)	34.8	46.63	54.94	56.91	57.2	
		Week 24	Sparsentan	9	3 (33.3)	37.69 (15.49)	20.8	20.79	41.07	51.21	51.2	
			Irbesartan	5	2 (40.0)	40.06 (14.65)	29.7	29.71	40.06	50.42	50.4	
		Week 48	Sparsentan	9	5 (55.6)	47.97 (7.75)	37.2	43.46	50.84	51.24	57.2	
			Irbesartan	5	1 (20.0)	49.58	49.6	49.58	49.58	49.58	49.6	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	9	3 (33.3)	-13.54 (4.80)	-19.1	-19.05	-11.28	-10.30	-10.3	-2.23 [-4.49, 0.03]
			Irbesartan	5	2 (40.0)	-4.81 (0.41)	-5.1	-5.10	-4.81	-4.51	-4.5	
		Week 48	Sparsentan	9	5 (55.6)	1.85 (8.68)	-11.3	0.45	1.73	5.92	12.4	NE
			Irbesartan	5	1 (20.0)	-5.36	-5.4	-5.36	-5.36	-5.36	-5.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 18 to 40 years	KDQOL-SF12: MCS	Baseline	Sparsentan	102	94 (92.2)	50.15 (7.60)	27.8	44.79	51.32	55.70	65.2	
			Irbesartan	109	100 (91.7)	50.61 (9.27)	24.3	45.26	52.05	57.16	64.2	
		Week 24	Sparsentan	102	64 (62.7)	51.50 (7.21)	30.7	46.85	52.83	57.20	63.5	
			Irbesartan	109	61 (56.0)	52.35 (8.62)	24.2	48.87	55.93	57.76	62.7	
		Week 48	Sparsentan	102	57 (55.9)	49.84 (8.46)	27.5	42.75	51.44	56.52	62.5	
			Irbesartan	109	45 (41.3)	51.59 (9.74)	21.5	48.28	54.79	58.12	62.5	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	102	64 (62.7)	0.57 (7.78)	-23.6	-3.61	0.00	4.82	26.4	-0.05 [-0.40, 0.30]
			Irbesartan	109	61 (56.0)	0.96 (7.20)	-14.1	-2.96	0.17	5.23	21.7	
		Week 48	Sparsentan	102	57 (55.9)	-0.15 (9.51)	-23.7	-4.61	-0.17	4.70	21.1	0.10 [-0.29, 0.49]
			Irbesartan	109	45 (41.3)	-1.00 (7.60)	-23.5	-2.96	0.00	2.79	13.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 40 years	KDQOL-SF12: MCS	Baseline	Sparsentan	91	84 (92.3)	51.24 (8.52)	16.2	46.28	53.18	57.16	66.5	
			Irbesartan	88	79 (89.8)	52.42 (7.67)	26.4	48.29	54.18	57.57	66.6	
		Week 24	Sparsentan	91	61 (67.0)	52.35 (7.21)	34.3	48.87	53.96	57.33	66.8	
			Irbesartan	88	49 (55.7)	53.67 (7.40)	30.8	51.06	55.77	58.15	64.2	
		Week 48	Sparsentan	91	50 (54.9)	52.01 (8.25)	29.5	48.76	53.85	58.32	63.4	
			Irbesartan	88	34 (38.6)	50.93 (10.43)	19.6	47.27	52.82	57.33	64.6	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	91	61 (67.0)	1.59 (8.36)	-18.1	-2.79	0.99	5.08	25.9	0.18 [-0.20, 0.56]
			Irbesartan	88	49 (55.7)	0.23 (6.31)	-15.4	-3.28	0.00	2.95	28.7	
		Week 48	Sparsentan	91	50 (54.9)	1.41 (8.57)	-16.9	-3.83	1.97	6.43	28.1	0.31 [-0.13, 0.74]
			Irbesartan	88	34 (38.6)	-1.34 (9.54)	-33.9	-3.95	-1.56	4.87	17.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Geographic region												
North America	KDQOL-SF12: MCS	Baseline	Sparsentan	35	32 (91.4)	49.84 (8.24)	32.9	44.11	51.11	56.51	62.6	
			Irbesartan	46	44 (95.7)	53.62 (7.01)	35.7	47.55	56.83	58.01	64.2	
		Week 24	Sparsentan	35	15 (42.9)	51.91 (4.62)	41.1	49.25	53.07	54.96	57.7	
			Irbesartan	46	28 (60.9)	54.59 (7.99)	24.2	54.26	57.20	58.43	63.2	
		Week 48	Sparsentan	35	13 (37.1)	50.34 (10.27)	30.9	41.17	50.84	57.06	63.4	
			Irbesartan	46	17 (37.0)	50.31 (12.30)	19.6	49.41	54.79	57.76	62.4	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	35	15 (42.9)	-0.36 (7.57)	-19.1	-2.86	-0.10	3.27	14.0	0.02 [-0.61, 0.64]
			Irbesartan	46	28 (60.9)	-0.46 (5.67)	-14.1	-3.12	0.28	2.41	13.0	
		Week 48	Sparsentan	35	13 (37.1)	1.87 (8.89)	-23.4	-0.03	3.95	6.32	14.7	0.46 [-0.27, 1.19]
			Irbesartan	46	17 (37.0)	-2.82 (11.20)	-33.9	-6.62	0.00	3.95	12.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Europe	KDQOL-SF12: MCS	Baseline	Sparsentan	98	88 (89.8)	50.56 (9.27)	16.2	45.11	51.83	57.16	66.5	
			Irbesartan	115	99 (86.1)	50.45 (9.15)	26.4	46.56	52.31	57.16	64.6	
		Week 24	Sparsentan	98	56 (57.1)	50.56 (8.23)	20.8	46.84	49.75	56.39	63.5	
			Irbesartan	115	50 (43.5)	52.32 (8.17)	29.7	47.84	54.29	58.29	62.7	
		Week 48	Sparsentan	98	44 (44.9)	49.65 (8.10)	29.5	42.65	51.24	56.43	62.5	
			Irbesartan	115	40 (34.8)	51.29 (9.06)	31.4	46.87	53.91	57.37	64.5	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	98	56 (57.1)	-0.39 (7.43)	-17.0	-4.93	0.00	3.25	25.9	-0.21 [-0.59, 0.17]
			Irbesartan	115	50 (43.5)	1.26 (8.15)	-15.4	-4.54	0.00	5.33	28.7	
		Week 48	Sparsentan	98	44 (44.9)	-0.79 (9.42)	-20.3	-5.13	-1.52	4.09	28.1	0.02 [-0.41, 0.44]
			Irbesartan	115	40 (34.8)	-0.92 (7.50)	-23.5	-3.23	-0.42	3.26	17.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asia Pacific	KDQOL-SF12: MCS	Baseline	Sparsentan	69	67 (97.1)	50.42 (7.02)	27.8	45.01	51.25	55.70	64.2	
			Irbesartan	41	41 (100.0)	51.19 (8.65)	24.3	49.04	51.77	57.16	66.6	
		Week 24	Sparsentan	69	57 (82.6)	52.50 (7.74)	30.7	47.94	54.20	57.34	66.8	
			Irbesartan	41	34 (82.9)	51.73 (8.76)	30.8	48.43	53.11	57.31	64.2	
		Week 48	Sparsentan	69	55 (79.7)	51.67 (8.11)	27.5	48.28	52.63	57.33	62.1	
			Irbesartan	41	23 (56.1)	51.98 (9.83)	21.5	47.27	54.20	59.29	64.6	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	69	57 (82.6)	2.11 (9.14)	-23.6	-2.29	1.28	7.00	26.4	0.23 [-0.20, 0.66]
			Irbesartan	41	34 (82.9)	0.29 (5.25)	-9.4	-2.88	0.18	3.16	15.5	
		Week 48	Sparsentan	69	55 (79.7)	1.49 (8.75)	-23.7	-4.61	1.97	6.67	21.1	0.23 [-0.26, 0.72]
			Irbesartan	41	23 (56.1)	-0.47 (7.70)	-18.5	-3.09	0.00	4.92	12.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline BMI												
< 27 kg/m**2	KDQOL-SF12: MCS	Baseline	Sparsentan	84	76 (90.5)	48.43 (8.99)	16.2	42.67	50.05	54.47	64.6	
			Irbesartan	94	87 (92.6)	51.23 (8.04)	27.9	46.93	52.48	57.16	62.7	
		Week 24	Sparsentan	84	52 (61.9)	50.35 (9.44)	20.8	43.84	51.31	57.33	66.8	
			Irbesartan	94	54 (57.4)	52.27 (9.37)	24.2	49.52	55.45	57.76	62.7	
		Week 48	Sparsentan	84	48 (57.1)	49.42 (9.00)	27.5	42.61	51.33	57.08	61.1	
			Irbesartan	94	37 (39.4)	50.08 (10.71)	19.6	46.16	52.00	57.33	64.5	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	84	52 (61.9)	1.37 (10.39)	-23.6	-5.45	-0.08	8.20	26.4	0.05 [-0.33, 0.43]
			Irbesartan	94	54 (57.4)	0.93 (7.20)	-14.1	-4.36	0.00	4.51	28.7	
		Week 48	Sparsentan	84	48 (57.1)	1.22 (9.80)	-23.4	-3.80	0.24	6.45	28.1	0.26 [-0.17, 0.69]
			Irbesartan	94	37 (39.4)	-1.27 (9.22)	-33.9	-3.50	-0.60	3.74	17.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 27 kg/m**2	KDQOL-SF12: MCS	Baseline	Sparsentan	118	111 (94.1)	51.73 (7.56)	31.4	47.07	53.19	57.16	66.5	
			Irbesartan	107	96 (89.7)	51.76 (8.86)	24.3	47.57	54.14	57.45	66.6	
		Week 24	Sparsentan	118	76 (64.4)	52.43 (6.12)	37.4	48.23	53.20	57.20	62.7	
			Irbesartan	107	58 (54.2)	53.11 (7.26)	33.5	48.43	55.28	58.15	64.2	
		Week 48	Sparsentan	118	64 (54.2)	51.71 (7.76)	27.5	48.52	52.34	58.01	63.4	
			Irbesartan	107	43 (40.2)	52.32 (9.19)	28.5	50.06	54.20	60.12	64.6	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	118	76 (64.4)	0.29 (6.50)	-18.1	-2.59	0.93	4.23	16.4	0.02 [-0.32, 0.36]
			Irbesartan	107	58 (54.2)	0.16 (6.39)	-15.4	-4.10	0.13	3.16	20.2	
		Week 48	Sparsentan	118	64 (54.2)	0.20 (8.45)	-23.7	-4.53	0.19	5.77	18.7	0.16 [-0.22, 0.55]
			Irbesartan	107	43 (40.2)	-1.13 (7.72)	-23.5	-3.95	0.25	4.87	12.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Randomization strata												
eGFR Low and UP High	KDQOL-SF12: MCS	Baseline	Sparsentan	71	64 (90.1)	51.84 (7.80)	31.4	45.00	54.20	57.25	64.6	
			Irbesartan	74	64 (86.5)	50.93 (8.84)	26.4	47.48	53.01	56.83	64.6	
		Week 24	Sparsentan	71	45 (63.4)	52.41 (6.90)	36.1	47.94	54.20	57.33	63.4	
			Irbesartan	74	36 (48.6)	53.48 (8.43)	29.7	49.86	57.11	59.42	62.6	
		Week 48	Sparsentan	71	39 (54.9)	51.85 (6.94)	37.3	47.66	52.63	57.33	63.4	
			Irbesartan	74	23 (31.1)	52.67 (12.98)	19.6	49.23	57.16	61.43	64.6	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	71	45 (63.4)	-0.75 (6.72)	-14.5	-5.09	-0.45	2.43	20.8	-0.18 [-0.62, 0.26]
			Irbesartan	74	36 (48.6)	0.51 (7.20)	-15.4	-3.12	0.34	3.25	28.7	
		Week 48	Sparsentan	71	39 (54.9)	-1.03 (7.22)	-16.9	-5.18	-1.04	4.45	11.8	-0.06 [-0.58, 0.45]
			Irbesartan	74	23 (31.1)	-0.46 (11.03)	-33.9	-2.96	0.69	4.87	17.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR Low and UP Low	KDQOL-SF12: MCS	Baseline	Sparsentan	55	51 (92.7)	50.29 (9.67)	16.2	44.79	52.99	57.16	65.2	
			Irbesartan	55	51 (92.7)	52.28 (7.70)	31.9	48.74	52.09	57.73	66.6	
		Week 24	Sparsentan	55	39 (70.9)	52.22 (7.78)	34.3	46.86	53.61	57.90	63.5	
			Irbesartan	55	35 (63.6)	52.65 (8.40)	30.8	47.84	54.45	57.66	64.2	
		Week 48	Sparsentan	55	28 (50.9)	50.24 (8.69)	29.5	43.33	52.24	56.27	62.5	
			Irbesartan	55	25 (45.5)	49.40 (9.71)	31.4	42.63	50.63	57.06	62.5	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	55	39 (70.9)	1.75 (7.58)	-17.0	-2.66	1.16	5.84	25.9	0.27 [-0.19, 0.73]
			Irbesartan	55	35 (63.6)	-0.20 (6.56)	-9.4	-6.30	0.00	4.66	20.2	
		Week 48	Sparsentan	55	28 (50.9)	0.41 (8.80)	-20.3	-4.74	-1.16	5.77	28.1	0.48 [-0.07, 1.02]
			Irbesartan	55	25 (45.5)	-3.68 (8.33)	-23.5	-6.62	-2.96	2.37	12.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP High	KDQOL-SF12: MCS	Baseline	Sparsentan	37	35 (94.6)	48.30 (7.97)	27.8	43.44	49.67	54.20	62.4	
			Irbesartan	36	33 (91.7)	52.02 (8.60)	27.9	46.56	54.45	57.33	64.2	
		Week 24	Sparsentan	37	20 (54.1)	48.78 (8.27)	20.8	46.84	49.62	54.20	57.3	
			Irbesartan	36	19 (52.8)	52.72 (7.11)	36.7	48.43	54.37	57.76	62.4	
		Week 48	Sparsentan	37	22 (59.5)	48.68 (10.07)	27.5	41.17	50.09	58.30	62.5	
			Irbesartan	36	13 (36.1)	52.04 (8.14)	32.8	50.11	51.36	60.12	61.3	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	37	20 (54.1)	1.72 (10.11)	-19.1	-3.71	2.30	7.52	26.4	0.06 [-0.57, 0.68]
			Irbesartan	36	19 (52.8)	1.23 (7.34)	-13.4	-2.96	1.02	3.16	21.7	
		Week 48	Sparsentan	37	22 (59.5)	2.90 (11.90)	-23.7	-1.47	5.25	12.38	21.1	0.16 [-0.52, 0.85]
			Irbesartan	36	13 (36.1)	1.29 (4.83)	-8.1	-2.20	2.43	5.33	6.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP Low	KDQOL-SF12: MCS	Baseline	Sparsentan	39	37 (94.9)	49.98 (7.21)	30.1	46.33	50.94	54.63	66.5	
			Irbesartan	37	36 (97.3)	50.30 (9.63)	24.3	45.44	51.94	57.16	62.5	
		Week 24	Sparsentan	39	24 (61.5)	51.34 (8.32)	30.7	48.13	50.43	57.63	66.8	
			Irbesartan	37	22 (59.5)	51.52 (9.31)	24.2	47.77	54.51	57.16	62.5	
		Week 48	Sparsentan	39	23 (59.0)	51.35 (8.50)	27.5	49.02	52.25	57.10	60.3	
			Irbesartan	37	19 (51.4)	51.56 (6.94)	37.5	46.16	54.20	57.16	62.5	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	39	24 (61.5)	1.02 (10.31)	-23.6	-3.88	0.62	7.08	25.3	-0.02 [-0.59, 0.56]
			Irbesartan	37	22 (59.5)	1.15 (6.19)	-13.9	-1.32	0.00	4.80	15.5	
		Week 48	Sparsentan	39	23 (59.0)	1.56 (8.93)	-18.6	-2.06	1.15	3.95	19.4	0.27 [-0.34, 0.88]
			Irbesartan	37	19 (51.4)	-0.53 (6.19)	-17.3	-2.85	0.00	2.79	13.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 1												
< 60 mL/min/1.73 m**2	KDQOL-SF12: MCS	Baseline	Sparsentan	127	116 (91.3)	51.36 (8.61)	16.2	46.28	53.55	57.19	65.2	
			Irbesartan	129	116 (89.9)	51.58 (8.12)	26.4	48.07	52.60	57.13	66.6	
		Week 24	Sparsentan	127	85 (66.9)	52.32 (7.26)	34.3	47.77	54.17	57.34	63.5	
			Irbesartan	129	73 (56.6)	52.84 (8.15)	29.7	49.28	55.77	58.15	64.2	
		Week 48	Sparsentan	127	67 (52.8)	50.90 (7.75)	29.5	44.50	52.05	57.33	62.5	
			Irbesartan	129	50 (38.8)	50.08 (11.06)	19.6	42.63	53.32	57.56	64.5	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	127	85 (66.9)	0.24 (7.23)	-17.0	-3.78	0.00	3.27	25.9	0.00 [-0.31, 0.31]
			Irbesartan	129	73 (56.6)	0.23 (6.84)	-15.4	-4.70	0.00	3.95	28.7	
		Week 48	Sparsentan	127	67 (52.8)	-0.92 (8.03)	-20.3	-5.08	-1.34	4.38	28.1	0.20 [-0.16, 0.57]
			Irbesartan	129	50 (38.8)	-2.72 (9.77)	-33.9	-6.62	-1.68	2.79	17.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	KDQOL-SF12: MCS	Baseline	Sparsentan	49	47 (95.9)	48.70 (7.66)	30.1	43.44	48.53	54.37	66.5	
			Irbesartan	48	44 (91.7)	51.20 (9.16)	27.9	44.31	54.27	57.45	64.2	
		Week 24	Sparsentan	49	28 (57.1)	48.72 (8.99)	20.8	45.38	49.41	54.20	66.8	
			Irbesartan	48	26 (54.2)	52.83 (8.42)	24.2	49.52	55.97	57.73	62.7	
		Week 48	Sparsentan	49	29 (59.2)	48.31 (10.22)	27.5	41.17	49.58	56.52	63.4	
			Irbesartan	48	20 (41.7)	53.59 (8.27)	32.8	50.19	53.97	60.62	64.6	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	49	28 (57.1)	0.05 (9.96)	-23.6	-3.95	0.19	5.31	25.3	-0.08 [-0.61, 0.46]
			Irbesartan	48	26 (54.2)	0.72 (6.66)	-13.9	-2.29	0.00	2.96	21.7	
		Week 48	Sparsentan	49	29 (59.2)	1.05 (9.54)	-23.7	-1.47	1.89	7.36	15.7	-0.12 [-0.69, 0.45]
			Irbesartan	48	20 (41.7)	1.97 (3.60)	-5.4	0.00	2.45	4.95	6.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	KDQOL-SF12: MCS	Baseline	Sparsentan	26	24 (92.3)	49.00 (7.58)	27.8	47.06	50.17	53.71	61.5	
			Irbesartan	25	24 (96.0)	50.68 (10.24)	24.3	46.60	53.61	57.51	62.5	
		Week 24	Sparsentan	26	15 (57.7)	52.76 (6.46)	40.3	47.09	52.62	58.72	62.4	
			Irbesartan	25	13 (52.0)	51.73 (9.58)	36.1	46.16	51.77	60.12	62.5	
		Week 48	Sparsentan	26	16 (61.5)	54.37 (5.61)	42.5	50.59	53.40	59.79	62.5	
			Irbesartan	25	10 (40.0)	52.71 (5.58)	41.8	52.00	54.20	54.96	60.0	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	26	15 (57.7)	4.76 (9.90)	-11.1	-0.57	4.25	10.63	26.4	0.33 [-0.41, 1.08]
			Irbesartan	25	13 (52.0)	1.86 (6.97)	-13.4	0.00	2.77	5.23	15.5	
		Week 48	Sparsentan	26	16 (61.5)	6.41 (10.11)	-14.6	0.00	5.45	15.07	21.1	0.72 [-0.09, 1.54]
			Irbesartan	25	10 (40.0)	0.06 (5.90)	-8.1	-2.47	-2.09	2.79	13.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 2												
< 45 mL/min/1.73 m**2	KDQOL-SF12: MCS	Baseline	Sparsentan	82	72 (87.8)	50.09 (9.01)	16.2	44.31	51.92	57.13	64.2	
			Irbesartan	80	70 (87.5)	50.90 (8.98)	26.4	47.81	52.12	57.16	66.6	
		Week 24	Sparsentan	82	54 (65.9)	52.52 (7.65)	34.3	47.15	54.29	57.65	63.5	
			Irbesartan	80	48 (60.0)	52.53 (8.47)	29.7	49.07	55.19	58.23	64.2	
		Week 48	Sparsentan	82	44 (53.7)	50.76 (7.77)	29.5	47.22	51.45	57.11	62.1	
			Irbesartan	80	30 (37.5)	48.83 (12.46)	19.6	42.02	51.14	58.58	64.5	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	82	54 (65.9)	1.50 (7.30)	-13.0	-2.79	1.20	4.59	25.9	0.15 [-0.24, 0.54]
			Irbesartan	80	48 (60.0)	0.36 (7.69)	-15.4	-4.81	0.00	4.06	28.7	
		Week 48	Sparsentan	82	44 (53.7)	0.18 (7.92)	-20.3	-4.17	-0.08	4.58	28.1	0.35 [-0.12, 0.82]
			Irbesartan	80	30 (37.5)	-3.16 (11.51)	-33.9	-13.91	-1.48	4.19	17.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
45 to < 60 mL/min/1.73 m**2	KDQOL-SF12: MCS	Baseline	Sparsentan	45	44 (97.8)	53.44 (7.56)	33.8	49.54	55.60	57.82	65.2	
			Irbesartan	49	46 (93.9)	52.63 (6.54)	31.9	49.35	54.14	57.09	64.6	
		Week 24	Sparsentan	45	31 (68.9)	51.98 (6.62)	41.0	47.77	50.91	57.16	63.5	
			Irbesartan	49	25 (51.0)	53.41 (7.64)	33.5	51.37	55.77	57.16	63.2	
		Week 48	Sparsentan	45	23 (51.1)	51.16 (7.88)	39.1	42.35	52.60	58.32	62.5	
			Irbesartan	49	20 (40.8)	51.95 (8.50)	31.4	47.93	56.68	57.25	62.4	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	45	31 (68.9)	-1.97 (6.65)	-17.0	-6.80	-1.05	1.38	13.1	-0.33 [-0.86, 0.20]
			Irbesartan	49	25 (51.0)	-0.00 (4.95)	-8.6	-4.10	1.02	3.95	7.1	
		Week 48	Sparsentan	45	23 (51.1)	-3.04 (7.99)	-18.6	-5.18	-2.98	4.34	11.8	-0.13 [-0.73, 0.47]
			Irbesartan	49	20 (40.8)	-2.06 (6.57)	-17.3	-4.15	-1.68	2.30	8.2	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	KDQOL-SF12: MCS	Baseline	Sparsentan	49	47 (95.9)	48.70 (7.66)	30.1	43.44	48.53	54.37	66.5	
			Irbesartan	48	44 (91.7)	51.20 (9.16)	27.9	44.31	54.27	57.45	64.2	
		Week 24	Sparsentan	49	28 (57.1)	48.72 (8.99)	20.8	45.38	49.41	54.20	66.8	
			Irbesartan	48	26 (54.2)	52.83 (8.42)	24.2	49.52	55.97	57.73	62.7	
		Week 48	Sparsentan	49	29 (59.2)	48.31 (10.22)	27.5	41.17	49.58	56.52	63.4	
			Irbesartan	48	20 (41.7)	53.59 (8.27)	32.8	50.19	53.97	60.62	64.6	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	49	28 (57.1)	0.05 (9.96)	-23.6	-3.95	0.19	5.31	25.3	-0.08 [-0.61, 0.46]
			Irbesartan	48	26 (54.2)	0.72 (6.66)	-13.9	-2.29	0.00	2.96	21.7	
		Week 48	Sparsentan	49	29 (59.2)	1.05 (9.54)	-23.7	-1.47	1.89	7.36	15.7	-0.12 [-0.69, 0.45]
			Irbesartan	48	20 (41.7)	1.97 (3.60)	-5.4	0.00	2.45	4.95	6.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	KDQOL-SF12: MCS	Baseline	Sparsentan	26	24 (92.3)	49.00 (7.58)	27.8	47.06	50.17	53.71	61.5	
			Irbesartan	25	24 (96.0)	50.68 (10.24)	24.3	46.60	53.61	57.51	62.5	
		Week 24	Sparsentan	26	15 (57.7)	52.76 (6.46)	40.3	47.09	52.62	58.72	62.4	
			Irbesartan	25	13 (52.0)	51.73 (9.58)	36.1	46.16	51.77	60.12	62.5	
		Week 48	Sparsentan	26	16 (61.5)	54.37 (5.61)	42.5	50.59	53.40	59.79	62.5	
			Irbesartan	25	10 (40.0)	52.71 (5.58)	41.8	52.00	54.20	54.96	60.0	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	26	15 (57.7)	4.76 (9.90)	-11.1	-0.57	4.25	10.63	26.4	0.33 [-0.41, 1.08]
			Irbesartan	25	13 (52.0)	1.86 (6.97)	-13.4	0.00	2.77	5.23	15.5	
		Week 48	Sparsentan	26	16 (61.5)	6.41 (10.11)	-14.6	0.00	5.45	15.07	21.1	0.72 [-0.09, 1.54]
			Irbesartan	25	10 (40.0)	0.06 (5.90)	-8.1	-2.47	-2.09	2.79	13.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline urine protein excretion												
<= 1.75 g/day	KDQOL-SF12: MCS	Baseline	Sparsentan	98	92 (93.9)	50.12 (8.77)	16.2	45.77	51.52	56.26	66.5	
			Irbesartan	94	84 (89.4)	50.87 (8.76)	24.3	47.39	52.05	57.16	66.6	
		Week 24	Sparsentan	98	67 (68.4)	50.91 (8.72)	20.8	46.85	50.71	57.35	66.8	
			Irbesartan	94	47 (50.0)	52.11 (8.83)	24.2	47.77	54.37	57.59	64.2	
		Week 48	Sparsentan	98	60 (61.2)	49.51 (9.09)	27.5	42.55	50.99	56.71	62.5	
			Irbesartan	94	34 (36.2)	51.24 (8.89)	19.6	47.58	53.61	57.16	62.5	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	98	67 (68.4)	0.93 (8.80)	-23.6	-3.44	0.61	5.84	25.9	0.11 [-0.26, 0.49]
			Irbesartan	94	47 (50.0)	0.07 (5.79)	-13.9	-4.70	0.00	3.95	15.5	
		Week 48	Sparsentan	98	60 (61.2)	-0.01 (9.61)	-23.7	-4.66	-0.20	4.52	28.1	0.12 [-0.30, 0.54]
			Irbesartan	94	34 (36.2)	-1.14 (8.48)	-33.9	-2.96	-0.05	2.47	13.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 1.75 g/day	KDQOL-SF12: MCS	Baseline	Sparsentan	104	95 (91.3)	50.65 (7.88)	27.8	44.79	51.83	57.16	64.6	
			Irbesartan	108	100 (92.6)	51.80 (8.54)	26.4	47.17	54.16	57.33	64.6	
		Week 24	Sparsentan	104	61 (58.7)	52.32 (6.33)	36.1	47.94	54.20	57.16	63.4	
			Irbesartan	108	65 (60.2)	53.13 (7.96)	29.7	49.52	55.93	58.17	62.6	
		Week 48	Sparsentan	104	52 (50.0)	52.13 (7.25)	36.0	48.53	53.07	57.33	63.4	
			Irbesartan	108	46 (42.6)	51.32 (10.71)	21.5	47.27	54.20	60.12	64.6	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	104	61 (58.7)	0.50 (7.74)	-19.1	-4.09	0.00	4.25	26.4	-0.05 [-0.40, 0.30]
			Irbesartan	108	65 (60.2)	0.87 (7.43)	-15.4	-3.28	0.72	3.55	28.7	
		Week 48	Sparsentan	104	52 (50.0)	1.38 (8.33)	-16.9	-3.43	1.36	6.94	21.1	0.31 [-0.09, 0.71]
			Irbesartan	108	46 (42.6)	-1.24 (8.42)	-23.5	-5.33	0.00	4.87	17.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline use of antihypertensives												
Yes	KDQOL-SF12: MCS	Baseline	Sparsentan	88	78 (88.6)	49.63 (9.22)	16.2	44.21	51.69	57.16	65.2	
			Irbesartan	83	73 (88.0)	52.01 (8.02)	27.2	48.29	54.13	57.16	66.6	
		Week 24	Sparsentan	88	53 (60.2)	51.10 (7.85)	20.8	48.18	51.21	57.06	62.4	
			Irbesartan	83	43 (51.8)	53.69 (7.69)	30.8	51.94	56.99	58.17	64.2	
		Week 48	Sparsentan	88	43 (48.9)	51.21 (7.57)	29.5	47.66	52.25	57.33	63.4	
			Irbesartan	83	30 (36.1)	51.88 (9.11)	28.5	49.23	53.32	57.76	64.5	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	88	53 (60.2)	0.59 (8.06)	-18.1	-3.78	0.61	4.80	25.9	0.04 [-0.37, 0.44]
			Irbesartan	83	43 (51.8)	0.33 (6.18)	-7.2	-4.54	0.00	3.16	28.7	
		Week 48	Sparsentan	88	43 (48.9)	0.96 (8.62)	-16.9	-4.49	1.48	6.04	28.1	0.23 [-0.24, 0.70]
			Irbesartan	83	30 (36.1)	-1.07 (9.21)	-23.5	-4.01	-0.62	4.87	17.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	KDQOL-SF12: MCS	Baseline	Sparsentan	114	109 (95.6)	50.93 (7.59)	27.8	45.63	51.53	56.44	66.5	
			Irbesartan	119	111 (93.3)	50.96 (9.01)	24.3	46.56	52.48	57.16	64.6	
		Week 24	Sparsentan	114	75 (65.8)	51.92 (7.59)	30.7	47.15	53.41	57.35	66.8	
			Irbesartan	119	69 (58.0)	52.10 (8.68)	24.2	47.84	54.37	57.76	63.2	
		Week 48	Sparsentan	114	69 (60.5)	50.42 (8.85)	27.5	44.50	51.44	57.16	62.5	
			Irbesartan	119	50 (42.0)	50.93 (10.45)	19.6	46.16	54.20	57.56	64.6	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	114	75 (65.8)	0.83 (8.49)	-23.6	-3.44	0.00	5.08	26.4	0.02 [-0.31, 0.35]
			Irbesartan	119	69 (58.0)	0.67 (7.16)	-15.4	-2.96	0.00	4.66	21.7	
		Week 48	Sparsentan	114	69 (60.5)	0.43 (9.32)	-23.7	-4.61	0.03	6.32	21.1	0.19 [-0.17, 0.56]
			Irbesartan	119	50 (42.0)	-1.27 (7.96)	-33.9	-3.09	0.00	3.76	13.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Time since renal biopsy												
<= 5 years	KDQOL-SF12: MCS	Baseline	Sparsentan	113	105 (92.9)	50.34 (8.81)	16.2	45.01	52.02	57.16	66.5	
			Irbesartan	127	119 (93.7)	51.23 (9.06)	24.3	46.63	53.45	57.32	66.6	
		Week 24	Sparsentan	113	73 (64.6)	51.96 (8.13)	20.8	47.61	53.04	57.35	66.8	
			Irbesartan	127	73 (57.5)	53.20 (8.34)	24.2	49.28	56.47	58.29	64.2	
		Week 48	Sparsentan	113	61 (54.0)	51.59 (7.35)	36.8	46.92	52.43	57.73	62.5	
			Irbesartan	127	53 (41.7)	50.69 (10.65)	19.6	47.27	54.20	57.16	64.6	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	113	73 (64.6)	1.63 (9.05)	-23.6	-4.29	1.38	6.42	26.4	0.05 [-0.28, 0.37]
			Irbesartan	127	73 (57.5)	1.25 (7.19)	-14.1	-2.88	0.72	4.80	28.7	
		Week 48	Sparsentan	113	61 (54.0)	2.11 (8.99)	-18.6	-4.49	1.97	7.21	28.1	0.41 [0.04, 0.78]
			Irbesartan	127	53 (41.7)	-1.55 (8.89)	-33.9	-3.50	0.00	3.74	17.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 5 years	KDQOL-SF12: MCS	Baseline	Sparsentan	89	82 (92.1)	50.44 (7.66)	30.1	44.79	51.32	56.08	64.2	
			Irbesartan	75	65 (86.7)	51.63 (7.83)	26.4	47.72	52.31	57.16	63.0	
		Week 24	Sparsentan	89	55 (61.8)	51.09 (7.07)	34.3	47.83	52.01	57.16	62.7	
			Irbesartan	75	39 (52.0)	51.78 (8.30)	29.7	48.43	53.00	57.33	62.7	
		Week 48	Sparsentan	89	51 (57.3)	49.69 (9.38)	27.5	42.75	51.62	57.16	63.4	
			Irbesartan	75	27 (36.0)	52.44 (8.36)	31.4	49.58	54.20	59.29	61.4	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	89	55 (61.8)	-0.47 (7.04)	-19.1	-2.86	0.00	3.02	20.8	0.05 [-0.36, 0.46]
			Irbesartan	75	39 (52.0)	-0.80 (5.76)	-15.4	-4.54	0.00	2.77	20.2	
		Week 48	Sparsentan	89	51 (57.3)	-1.12 (8.83)	-23.7	-5.16	-0.99	3.61	19.4	-0.07 [-0.54, 0.39]
			Irbesartan	75	27 (36.0)	-0.51 (7.43)	-18.5	-3.95	0.00	4.85	12.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: History of hypertension												
Yes	KDQOL-SF12: MCS	Baseline	Sparsentan	153	139 (90.8)	50.20 (8.31)	16.2	44.79	51.55	56.44	65.2	
			Irbesartan	157	140 (89.2)	51.81 (8.50)	26.4	48.07	54.10	57.33	66.6	
		Week 24	Sparsentan	153	97 (63.4)	51.99 (7.70)	20.8	48.18	53.04	57.34	66.8	
			Irbesartan	157	83 (52.9)	53.53 (7.44)	29.7	50.06	56.75	58.29	64.2	
		Week 48	Sparsentan	153	83 (54.2)	50.91 (8.03)	29.5	44.50	52.00	57.33	63.4	
			Irbesartan	157	59 (37.6)	51.61 (9.25)	19.6	48.28	54.20	57.41	64.6	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	153	97 (63.4)	1.15 (7.78)	-17.0	-3.78	0.99	4.84	25.9	0.07 [-0.22, 0.37]
			Irbesartan	157	83 (52.9)	0.61 (6.77)	-15.4	-4.36	0.00	3.89	28.7	
		Week 48	Sparsentan	153	83 (54.2)	1.08 (8.44)	-23.4	-4.49	1.15	6.43	28.1	0.30 [-0.03, 0.64]
			Irbesartan	157	59 (37.6)	-1.49 (8.67)	-33.9	-4.01	-0.11	2.79	17.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	KDQOL-SF12: MCS	Baseline	Sparsentan	49	48 (98.0)	50.93 (8.36)	27.8	47.06	51.68	57.11	66.5	
			Irbesartan	45	44 (97.8)	49.98 (8.96)	24.3	44.78	51.25	57.16	62.5	
		Week 24	Sparsentan	49	31 (63.3)	50.31 (7.60)	30.7	44.08	52.01	57.16	62.7	
			Irbesartan	45	29 (64.4)	50.35 (10.21)	24.2	46.16	54.37	57.16	62.6	
		Week 48	Sparsentan	49	29 (59.2)	50.19 (9.36)	27.5	46.89	51.44	57.16	62.5	
			Irbesartan	45	21 (46.7)	50.36 (11.81)	21.5	42.63	54.20	60.02	64.5	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	49	31 (63.3)	-0.60 (9.71)	-23.6	-2.86	-0.10	3.86	26.4	-0.11 [-0.62, 0.40]
			Irbesartan	45	29 (64.4)	0.33 (6.90)	-14.1	-2.96	0.00	3.55	15.5	
		Week 48	Sparsentan	49	29 (59.2)	-0.64 (10.59)	-23.7	-4.61	-0.24	4.38	21.1	-0.03 [-0.59, 0.53]
			Irbesartan	45	21 (46.7)	-0.37 (7.72)	-17.6	-2.47	0.00	4.85	12.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Sex	Overall	Sparsentan						Interaction:	0.210
Male	Week 24	Sparsentan	139	88 (63.3)	0.00 (0.70)	(-1.38, 1.39)	-0.51 (1.02)	(-2.53, 1.50)	0.615
		Irbesartan	143	81 (56.6)	0.52 (0.73)	(-0.93, 1.96)			
	Week 48	Sparsentan	139	74 (53.2)	0.20 (0.76)	(-1.30, 1.69)	-0.69 (1.15)	(-2.95, 1.57)	0.546
		Irbesartan	143	58 (40.6)	0.89 (0.85)	(-0.79, 2.57)			
Female	Week 24	Sparsentan	63	40 (63.5)	1.33 (1.31)	(-1.26, 3.93)	-0.69 (1.98)	(-4.62, 3.23)	0.727
		Irbesartan	59	31 (52.5)	2.03 (1.48)	(-0.91, 4.97)			
	Week 48	Sparsentan	63	38 (60.3)	-0.27 (1.34)	(-2.91, 2.38)	4.37 (2.22)	(-0.03, 8.77)	0.052
		Irbesartan	59	22 (37.3)	-4.64 (1.76)	(-8.13, -1.14)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age	Overall	Sparsentan						Interaction:	0.371
<= 45 years	Week 24	Sparsentan	96	59 (61.5)	0.12 (0.98)	(-1.81, 2.06)	-0.66 (1.40)	(-3.43, 2.11)	0.641
		Irbesartan	99	56 (56.6)	0.78 (1.00)	(-1.20, 2.76)			
	Week 48	Sparsentan	96	53 (55.2)	-0.96 (1.03)	(-2.99, 1.08)	-0.59 (1.57)	(-3.69, 2.50)	0.705
		Irbesartan	99	40 (40.4)	-0.36 (1.18)	(-2.69, 1.97)			
> 45 years	Week 24	Sparsentan	106	69 (65.1)	0.83 (0.83)	(-0.82, 2.47)	-0.48 (1.26)	(-2.96, 2.00)	0.701
		Irbesartan	103	56 (54.4)	1.31 (0.93)	(-0.53, 3.15)			
	Week 48	Sparsentan	106	59 (55.7)	0.88 (0.90)	(-0.89, 2.65)	1.77 (1.42)	(-1.02, 4.56)	0.213
		Irbesartan	103	40 (38.8)	-0.89 (1.09)	(-3.03, 1.26)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age at IgAN diagnosis	Overall	Sparsentan						Interaction:	0.612
<= 18 years	Week 24	Sparsentan	9	3 (33.3)	NE		NE		NE
		Irbesartan	5	2 (40.0)	NE				
	Week 48	Sparsentan	9	5 (55.6)	NE		NE		NE
		Irbesartan	5	1 (20.0)	NE				
> 18 to 40 years	Week 24	Sparsentan	102	64 (62.7)	0.55 (0.89)	(-1.21, 2.30)	-0.50 (1.28)	(-3.02, 2.02)	0.695
		Irbesartan	109	61 (56.0)	1.05 (0.92)	(-0.76, 2.85)			
	Week 48	Sparsentan	102	57 (55.9)	-0.70 (0.95)	(-2.56, 1.16)	-0.39 (1.43)	(-3.21, 2.43)	0.785
		Irbesartan	109	45 (41.3)	-0.31 (1.06)	(-2.40, 1.79)			
> 40 years	Week 24	Sparsentan	91	61 (67.0)	1.18 (0.92)	(-0.63, 2.99)	-0.03 (1.38)	(-2.75, 2.69)	0.982
		Irbesartan	88	49 (55.7)	1.21 (1.02)	(-0.81, 3.23)			
	Week 48	Sparsentan	91	50 (54.9)	0.93 (1.00)	(-1.05, 2.90)	1.95 (1.58)	(-1.16, 5.06)	0.218
		Irbesartan	88	34 (38.6)	-1.02 (1.21)	(-3.41, 1.37)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Geographic region	Overall	Sparsentan						Interaction:	0.365
North America	Week 24	Sparsentan	35	15 (42.9)	-0.45 (2.06)	(-4.57, 3.67)	-0.82 (2.58)	(-5.96, 4.33)	0.752
		Irbesartan	46	28 (60.9)	0.37 (1.53)	(-2.69, 3.43)			
	Week 48	Sparsentan	35	13 (37.1)	0.60 (2.31)	(-4.02, 5.22)	3.31 (3.04)	(-2.76, 9.37)	0.280
		Irbesartan	46	17 (37.0)	-2.71 (1.95)	(-6.61, 1.19)			
Europe	Week 24	Sparsentan	98	56 (57.1)	-0.37 (0.91)	(-2.16, 1.42)	-1.67 (1.32)	(-4.27, 0.94)	0.209
		Irbesartan	115	50 (43.5)	1.30 (0.96)	(-0.60, 3.20)			
	Week 48	Sparsentan	98	44 (44.9)	-0.96 (1.02)	(-2.97, 1.05)	-0.32 (1.48)	(-3.24, 2.61)	0.831
		Irbesartan	115	40 (34.8)	-0.64 (1.07)	(-2.75, 1.47)			
Asia Pacific	Week 24	Sparsentan	69	57 (82.6)	1.90 (0.98)	(-0.03, 3.84)	1.31 (1.62)	(-1.88, 4.51)	0.418
		Irbesartan	41	34 (82.9)	0.59 (1.27)	(-1.93, 3.11)			
	Week 48	Sparsentan	69	55 (79.7)	1.41 (1.00)	(-0.56, 3.38)	1.14 (1.83)	(-2.47, 4.75)	0.533
		Irbesartan	41	23 (56.1)	0.27 (1.52)	(-2.72, 3.27)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline BMI	Overall	Sparsentan						Interaction:	0.997
< 27 kg/m**2	Week 24	Sparsentan	84	52 (61.9)	0.92 (1.14)	(-1.34, 3.18)	-0.54 (1.61)	(-3.73, 2.64)	0.738
		Irbesartan	94	54 (57.4)	1.46 (1.13)	(-0.77, 3.69)			
	Week 48	Sparsentan	84	48 (57.1)	0.51 (1.19)	(-1.84, 2.86)	1.23 (1.81)	(-2.34, 4.80)	0.498
		Irbesartan	94	37 (39.4)	-0.72 (1.35)	(-3.38, 1.94)			
>= 27 kg/m**2	Week 24	Sparsentan	118	76 (64.4)	0.31 (0.72)	(-1.12, 1.73)	-0.13 (1.10)	(-2.30, 2.04)	0.906
		Irbesartan	107	58 (54.2)	0.44 (0.83)	(-1.19, 2.07)			
	Week 48	Sparsentan	118	64 (54.2)	-0.27 (0.78)	(-1.81, 1.27)	0.28 (1.24)	(-2.16, 2.71)	0.824
		Irbesartan	107	43 (40.2)	-0.55 (0.96)	(-2.43, 1.33)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Randomization strata	Overall	Sparsentan						Interaction:	0.539
eGFR Low and UP High	Week 24	Sparsentan	71	45 (63.4)	-0.70 (1.09)	(-2.85, 1.45)	-1.24 (1.63)	(-4.47, 1.98)	0.448
		Irbesartan	74	36 (48.6)	0.54 (1.22)	(-1.86, 2.95)			
	Week 48	Sparsentan	71	39 (54.9)	-1.17 (1.16)	(-3.46, 1.13)	-0.51 (1.90)	(-4.27, 3.25)	0.790
		Irbesartan	74	23 (31.1)	-0.66 (1.51)	(-3.64, 2.32)			
eGFR Low and UP Low	Week 24	Sparsentan	55	39 (70.9)	1.34 (1.07)	(-0.78, 3.46)	1.01 (1.56)	(-2.08, 4.10)	0.518
		Irbesartan	55	35 (63.6)	0.33 (1.13)	(-1.91, 2.57)			
	Week 48	Sparsentan	55	28 (50.9)	-0.20 (1.27)	(-2.70, 2.31)	2.76 (1.85)	(-0.90, 6.42)	0.138
		Irbesartan	55	25 (45.5)	-2.96 (1.34)	(-5.61, -0.31)			
eGFR High and UP High	Week 24	Sparsentan	37	20 (54.1)	1.04 (1.77)	(-2.49, 4.58)	-1.97 (2.58)	(-7.11, 3.17)	0.448
		Irbesartan	36	19 (52.8)	3.01 (1.84)	(-0.66, 6.68)			
	Week 48	Sparsentan	37	22 (59.5)	1.23 (1.71)	(-2.17, 4.64)	-1.37 (2.82)	(-7.00, 4.26)	0.628
		Irbesartan	36	13 (36.1)	2.61 (2.21)	(-1.80, 7.01)			
eGFR High and UP Low	Week 24	Sparsentan	39	24 (61.5)	0.51 (1.49)	(-2.45, 3.46)	-0.60 (2.14)	(-4.87, 3.67)	0.780
		Irbesartan	37	22 (59.5)	1.11 (1.55)	(-1.97, 4.19)			
	Week 48	Sparsentan	39	23 (59.0)	1.03 (1.52)	(-1.98, 4.05)	0.52 (2.25)	(-3.96, 5.01)	0.817
		Irbesartan	37	19 (51.4)	0.51 (1.66)	(-2.79, 3.81)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 1	Overall	Sparsentan						Interaction:	0.123
< 60 mL/min/1.73 m**2	Week 24	Sparsentan	127	85 (66.9)	0.16 (0.76)	(-1.34, 1.65)	-0.27 (1.12)	(-2.48, 1.93)	0.808
		Irbesartan	129	73 (56.6)	0.43 (0.82)	(-1.19, 2.05)			
	Week 48	Sparsentan	127	67 (52.8)	-1.15 (0.85)	(-2.82, 0.53)	1.27 (1.31)	(-1.30, 3.85)	0.332
		Irbesartan	129	50 (38.8)	-2.42 (0.99)	(-4.36, -0.47)			
60 to < 90 mL/min/1.73 m**2	Week 24	Sparsentan	49	28 (57.1)	-0.35 (1.47)	(-3.27, 2.56)	-1.91 (2.14)	(-6.16, 2.34)	0.375
		Irbesartan	48	26 (54.2)	1.56 (1.53)	(-1.48, 4.59)			
	Week 48	Sparsentan	49	29 (59.2)	0.15 (1.46)	(-2.75, 3.05)	-2.56 (2.30)	(-7.13, 2.02)	0.270
		Irbesartan	48	20 (41.7)	2.71 (1.74)	(-0.75, 6.16)			
>= 90 mL/min/1.73 m**2	Week 24	Sparsentan	26	15 (57.7)	4.15 (1.54)	(1.04, 7.27)	1.92 (2.27)	(-2.66, 6.49)	0.403
		Irbesartan	25	13 (52.0)	2.24 (1.66)	(-1.10, 5.58)			
	Week 48	Sparsentan	26	16 (61.5)	5.59 (1.51)	(2.54, 8.64)	3.09 (2.45)	(-1.84, 8.02)	0.213
		Irbesartan	25	10 (40.0)	2.50 (1.89)	(-1.32, 6.31)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 2	Overall	Sparsentan						Interaction:	0.070
< 45 mL/min/1.73 m**2	Week 24	Sparsentan	82	54 (65.9)	1.37 (1.02)	(-0.64, 3.38)	0.72 (1.49)	(-2.21, 3.65)	0.629
		Irbesartan	80	48 (60.0)	0.65 (1.08)	(-1.48, 2.78)			
	Week 48	Sparsentan	82	44 (53.7)	-0.16 (1.13)	(-2.38, 2.06)	2.83 (1.77)	(-0.66, 6.32)	0.111
		Irbesartan	80	30 (37.5)	-3.00 (1.36)	(-5.68, -0.31)			
45 to < 60 mL/min/1.73 m**2	Week 24	Sparsentan	45	31 (68.9)	-2.02 (1.09)	(-4.19, 0.15)	-2.32 (1.66)	(-5.62, 0.98)	0.166
		Irbesartan	49	25 (51.0)	0.30 (1.23)	(-2.15, 2.75)			
	Week 48	Sparsentan	45	23 (51.1)	-2.92 (1.25)	(-5.40, -0.44)	-1.44 (1.86)	(-5.14, 2.26)	0.442
		Irbesartan	49	20 (40.8)	-1.49 (1.36)	(-4.20, 1.23)			
60 to < 90 mL/min/1.73 m**2	Week 24	Sparsentan	49	28 (57.1)	-0.35 (1.47)	(-3.27, 2.56)	-1.91 (2.14)	(-6.16, 2.34)	0.375
		Irbesartan	48	26 (54.2)	1.56 (1.53)	(-1.48, 4.59)			
	Week 48	Sparsentan	49	29 (59.2)	0.15 (1.46)	(-2.75, 3.05)	-2.56 (2.30)	(-7.13, 2.02)	0.270
		Irbesartan	48	20 (41.7)	2.71 (1.74)	(-0.75, 6.16)			
>= 90 mL/min/1.73 m**2	Week 24	Sparsentan	26	15 (57.7)	4.15 (1.54)	(1.04, 7.27)	1.92 (2.27)	(-2.66, 6.49)	0.403
		Irbesartan	25	13 (52.0)	2.24 (1.66)	(-1.10, 5.58)			
	Week 48	Sparsentan	26	16 (61.5)	5.59 (1.51)	(2.54, 8.64)	3.09 (2.45)	(-1.84, 8.02)	0.213
		Irbesartan	25	10 (40.0)	2.50 (1.89)	(-1.32, 6.31)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline urine protein excretion	Overall	Sparsentan						Interaction:	0.666
<= 1.75 g/day	Week 24	Sparsentan	98	67 (68.4)	0.63 (0.91)	(-1.16, 2.42)	0.25 (1.42)	(-2.55, 3.05)	0.860
		Irbesartan	94	47 (50.0)	0.38 (1.09)	(-1.77, 2.53)			
	Week 48	Sparsentan	98	60 (61.2)	-0.36 (0.96)	(-2.25, 1.54)	0.11 (1.61)	(-3.07, 3.28)	0.948
		Irbesartan	94	34 (36.2)	-0.46 (1.28)	(-2.98, 2.06)			
> 1.75 g/day	Week 24	Sparsentan	104	61 (58.7)	0.27 (0.89)	(-1.48, 2.02)	-0.86 (1.24)	(-3.31, 1.59)	0.491
		Irbesartan	108	65 (60.2)	1.13 (0.86)	(-0.58, 2.83)			
	Week 48	Sparsentan	104	52 (50.0)	0.47 (0.96)	(-1.42, 2.36)	1.39 (1.41)	(-1.40, 4.17)	0.327
		Irbesartan	108	46 (42.6)	-0.92 (1.02)	(-2.92, 1.09)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline use of antihypertensives	Overall	Sparsentan						Interaction:	0.695
Yes	Week 24	Sparsentan	88	53 (60.2)	-0.02 (0.92)	(-1.84, 1.80)	-1.28 (1.38)	(-4.01, 1.46)	0.358
		Irbesartan	83	43 (51.8)	1.26 (1.03)	(-0.77, 3.28)			
	Week 48	Sparsentan	88	43 (48.9)	0.24 (1.02)	(-1.78, 2.26)	0.58 (1.60)	(-2.58, 3.74)	0.716
		Irbesartan	83	30 (36.1)	-0.34 (1.22)	(-2.75, 2.07)			
No	Week 24	Sparsentan	114	75 (65.8)	0.89 (0.87)	(-0.83, 2.61)	0.10 (1.26)	(-2.39, 2.59)	0.937
		Irbesartan	119	69 (58.0)	0.79 (0.91)	(-1.01, 2.59)			
	Week 48	Sparsentan	114	69 (60.5)	-0.10 (0.91)	(-1.88, 1.69)	0.73 (1.40)	(-2.03, 3.49)	0.603
		Irbesartan	119	50 (42.0)	-0.83 (1.07)	(-2.92, 1.27)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Time since renal biopsy	Overall	Sparsentan						Interaction:	0.326
<= 5 years	Week 24	Sparsentan	113	73 (64.6)	1.40 (0.85)	(-0.28, 3.07)	-0.34 (1.21)	(-2.72, 2.03)	0.776
		Irbesartan	127	73 (57.5)	1.74 (0.85)	(0.06, 3.42)			
	Week 48	Sparsentan	113	61 (54.0)	1.39 (0.93)	(-0.44, 3.22)	2.29 (1.36)	(-0.39, 4.96)	0.094
		Irbesartan	127	53 (41.7)	-0.90 (0.99)	(-2.85, 1.05)			
> 5 years	Week 24	Sparsentan	89	55 (61.8)	-0.58 (0.94)	(-2.43, 1.27)	-0.04 (1.46)	(-2.93, 2.85)	0.980
		Irbesartan	75	39 (52.0)	-0.55 (1.13)	(-2.78, 1.68)			
	Week 48	Sparsentan	89	51 (57.3)	-1.68 (0.98)	(-3.62, 0.26)	-1.62 (1.67)	(-4.93, 1.68)	0.333
		Irbesartan	75	27 (36.0)	-0.05 (1.34)	(-2.70, 2.60)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 04APR2024

Table PT1KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
History of hypertension	Overall	Sparsentan						Interaction:	0.692
Yes	Week 24	Sparsentan	153	97 (63.4)	0.78 (0.69)	(-0.57, 2.13)	-0.54 (1.01)	(-2.53, 1.46)	0.597
		Irbesartan	157	83 (52.9)	1.32 (0.74)	(-0.15, 2.78)			
	Week 48	Sparsentan	153	83 (54.2)	0.28 (0.74)	(-1.18, 1.73)	1.22 (1.15)	(-1.05, 3.49)	0.291
		Irbesartan	157	59 (37.6)	-0.94 (0.88)	(-2.66, 0.79)			
No	Week 24	Sparsentan	49	31 (63.3)	-0.47 (1.51)	(-3.46, 2.53)	-0.47 (2.18)	(-4.79, 3.86)	0.831
		Irbesartan	45	29 (64.4)	0.00 (1.57)	(-3.11, 3.11)			
	Week 48	Sparsentan	49	29 (59.2)	-0.71 (1.56)	(-3.79, 2.38)	-0.83 (2.42)	(-5.64, 3.98)	0.732
		Irbesartan	45	21 (46.7)	0.13 (1.85)	(-3.53, 3.79)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. NE= Not evaluable.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. A first order regressive covariance structure was used.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 58 are included in the model and also presented.
A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 04APR2024

Figure PF1KMSC_FSGM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

Not done: No significant subgroup found.

_____
Number of available records are presented for key visits up to Week 58 only. LS-Mean = Least square mean.
95% CI = 95% confidence interval. eGFR = estimated glomerular filtration rate. UP = urine protein. BMI = body mass index.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
IgAN = immunoglobulin A nephropathy. A decrease reflects a worsening of the status of the patient. Reference table: PT1KMSC_FSCM.

Table PT1KMSIT_FSTM: KDQOL-SF12: Time to increase in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sex	Sparsentan						Interaction test:	0.563
Male	Sparsentan	139	20 (14.4)	NE		1.567	(0.742, 3.311)	0.239
	Irbesartan	143	13 (9.1)	NE				
Female	Sparsentan	63	13 (20.6)	NE		2.406	(0.476, 12.166)	0.288
	Irbesartan	59	2 (3.4)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KMSIT_FSTM: KDQOL-SF12: Time to increase in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.621
<= 45 years	Sparsentan	96	15 (15.6)	NE		1.845	(0.733, 4.646)	0.193
	Irbesartan	99	9 (9.1)	NE				
> 45 years	Sparsentan	106	18 (17.0)	NE		1.502	(0.577, 3.907)	0.404
	Irbesartan	103	6 (5.8)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KMSIT_FSTM: KDQOL-SF12: Time to increase in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age at IgAN diagnosis	Sparsentan						Interaction test:	NE
<= 18 years	Sparsentan	9	1 (11.1) No events in 1 group	NE		NE		NE
	Irbesartan	5	0 (0.0)	NE				
> 18 to 40 years	Sparsentan	102	16 (15.7)	NE		1.903	(0.773, 4.689)	0.162
	Irbesartan	109	11 (10.1)	NE				
> 40 years	Sparsentan	91	16 (17.6)	NE		2.666	(0.860, 8.271)	0.090
	Irbesartan	88	4 (4.5)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KMSIT_FSTM: KDQOL-SF12: Time to increase in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Geographic region	Sparsentan						Interaction test:	0.117	
North America	Sparsentan	35	4 (11.4)	NE		2.796	(0.336, 23.267)	0.342	
	Irbesartan	46	3 (6.5)	NE					
Europe	Sparsentan	98	9 (9.2)	NE		0.959	(0.308, 2.980)	0.942	
	Irbesartan	115	8 (7.0)	NE					
Asia Pacific	Sparsentan	69	20 (29.0)	NE		3.804	(1.249, 11.587)	0.019	*
	Irbesartan	41	4 (9.8)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KMSIT_FSTM: KDQOL-SF12: Time to increase in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.814
< 27 kg/m**2	Sparsentan	84	17 (20.2)	NE		1.613	(0.634, 4.102)	0.315
	Irbesartan	94	7 (7.4)	NE				
>= 27 kg/m**2	Sparsentan	118	16 (13.6)	NE		1.992	(0.774, 5.126)	0.153
	Irbesartan	107	8 (7.5)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KMSIT_FSTM: KDQOL-SF12: Time to increase in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Randomization strata	Sparsentan						Interaction test:	0.240
eGFR Low and UP High	Sparsentan	71	7 (9.9)	NE		2.396	(0.539, 10.645)	0.251
	Irbesartan	74	4 (5.4)	NE				
eGFR Low and UP Low	Sparsentan	55	8 (14.5)	NE		0.739	(0.230, 2.379)	0.612
	Irbesartan	55	6 (10.9)	NE				
eGFR High and UP High	Sparsentan	37	11 (29.7)	94.4	(46.1, NE)	2.070	(0.440, 9.739)	0.357
	Irbesartan	36	2 (5.6)	NE				
eGFR High and UP Low	Sparsentan	39	7 (17.9)	NE		4.492	(0.907, 22.247)	0.066
	Irbesartan	37	3 (8.1)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KMSIT_FSTM: KDQOL-SF12: Time to increase in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.113	
< 60 mL/min/1.73 m**2	Sparsentan	127	14 (11.0)	NE		1.163	(0.510, 2.653)	0.720	
	Irbesartan	129	10 (7.8)	NE					
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	10 (20.4)	94.4	(69.7, NE)	1.649	(0.445, 6.112)	0.455	
	Irbesartan	48	3 (6.3)	NE					
>= 90 mL/min/1.73 m**2	Sparsentan	26	9 (34.6)	72.1	(24.1, NE)	36.556	(2.758, 484.571)	0.006	*
	Irbesartan	25	2 (8.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KMSIT_FSTM: KDQOL-SF12: Time to increase in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eGFR Group 2	Sparsentan						Interaction test:	0.200	
< 45 mL/min/1.73 m**2	Sparsentan	82	11 (13.4)	NE		1.314	(0.493, 3.499)	0.585	
	Irbesartan	80	7 (8.8)	NE					
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	3 (6.7)	NE		0.563	(0.104, 3.054)	0.506	
	Irbesartan	49	3 (6.1)	NE					
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	10 (20.4)	94.4	(69.7, NE)	1.649	(0.445, 6.112)	0.455	
	Irbesartan	48	3 (6.3)	NE					
>= 90 mL/min/1.73 m**2	Sparsentan	26	9 (34.6)	72.1	(24.1, NE)	36.556	(2.758, 484.571)	0.006	*
	Irbesartan	25	2 (8.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KMSIT_FSTM: KDQOL-SF12: Time to increase in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline urine protein excretion	Sparsentan						Interaction test:	0.184
<= 1.75 g/day	Sparsentan	98	18 (18.4)	NE		2.497	(0.875, 7.125)	0.087
	Irbesartan	94	5 (5.3)	NE				
> 1.75 g/day	Sparsentan	104	15 (14.4)	NE		1.610	(0.636, 4.079)	0.315
	Irbesartan	108	10 (9.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KMSIT_FSTM: KDQOL-SF12: Time to increase in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.295	
Yes	Sparsentan	88	14 (15.9)	NE		3.405	(1.023, 11.329)	0.046	*
	Irbesartan	83	4 (4.8)	NE					
No	Sparsentan	114	19 (16.7)	NE		1.480	(0.661, 3.310)	0.340	
	Irbesartan	119	11 (9.2)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KMSIT_FSTM: KDQOL-SF12: Time to increase in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Time since renal biopsy	Sparsentan						Interaction test:	0.058	
<= 5 years	Sparsentan	113	24 (21.2)	NE		2.645	(1.237, 5.656)	0.012	*
	Irbesartan	127	10 (7.9)	NE					
> 5 years	Sparsentan	89	9 (10.1)	NE		0.729	(0.221, 2.410)	0.605	
	Irbesartan	75	5 (6.7)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KMSIT_FSTM: KDQOL-SF12: Time to increase in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
History of hypertension	Sparsentan						Interaction test:	0.214	
Yes	Sparsentan	153	26 (17.0)	NE		3.123	(1.329, 7.341)	0.009	*
	Irbesartan	157	8 (5.1)	NE					
No	Sparsentan	49	7 (14.3)	NE		1.733	(0.446, 6.737)	0.428	
	Irbesartan	45	7 (15.6)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Figure PF1KMSIT_FSKM: KDQOL-SF12: Time to increase in MCS by at least 9.0 points by subgroup
Full Analysis Set

Not done. No significant subgroups.

_____
An increase reflects an improvement of the status of the patient.
Reference table: PT1KMSIT_FSTM

Table PT1KMSDT_FSTM: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sex	Sparsentan						Interaction test:	0.642
Male	Sparsentan	139	21 (15.1)	111.1	(111.1, NE)	1.478	(0.738, 2.961)	0.270
	Irbesartan	143	15 (10.5)	NE				
Female	Sparsentan	63	13 (20.6)	108.7	(87.7, 114.3)	1.166	(0.449, 3.026)	0.752
	Irbesartan	59	7 (11.9)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KMSDT_FSTM: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.226
<= 45 years	Sparsentan	96	18 (18.8)	108.7	(87.7, NE)	1.973	(0.889, 4.380)	0.095
	Irbesartan	99	10 (10.1)	NE				
> 45 years	Sparsentan	106	16 (15.1)	111.1	(96.1, 114.3)	0.944	(0.421, 2.115)	0.888
	Irbesartan	103	12 (11.7)	108.1	(95.1, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KMSDT_FSTM: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age at IgAN diagnosis	Sparsentan						Interaction test:	NE
<= 18 years	Sparsentan	9	3 (33.3) No events in 1 group	NE		NE		NE
	Irbesartan	5	0 (0.0)	NE				
> 18 to 40 years	Sparsentan	102	19 (18.6)	108.7	(87.7, NE)	1.777	(0.836, 3.778)	0.135
	Irbesartan	109	12 (11.0)	NE				
> 40 years	Sparsentan	91	12 (13.2)	111.1	(111.1, 114.3)	0.901	(0.368, 2.203)	0.819
	Irbesartan	88	10 (11.4)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KMSDT_FSTM: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Geographic region	Sparsentan						Interaction test:	0.785
North America	Sparsentan	35	5 (14.3)	NE		0.736	(0.203, 2.660)	0.640
	Irbesartan	46	7 (15.2)	NE				
Europe	Sparsentan	98	18 (18.4)	111.1	(95.1, 114.3)	2.032	(0.922, 4.478)	0.078
	Irbesartan	115	11 (9.6)	NE				
Asia Pacific	Sparsentan	69	11 (15.9)	NE		1.526	(0.472, 4.928)	0.480
	Irbesartan	41	4 (9.8)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KMSDT_FSTM: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.877
< 27 kg/m**2	Sparsentan	84	16 (19.0)	111.1	(111.1, 114.3)	1.350	(0.600, 3.036)	0.469
	Irbesartan	94	11 (11.7)	NE				
>= 27 kg/m**2	Sparsentan	118	18 (15.3)	NE		1.419	(0.650, 3.095)	0.380
	Irbesartan	107	11 (10.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KMSDT_FSTM: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Randomization strata	Sparsentan						Interaction test:	0.675
eGFR Low and UP High	Sparsentan	71	12 (16.9)	NE		1.066	(0.431, 2.636)	0.890
	Irbesartan	74	8 (10.8)	NE				
eGFR Low and UP Low	Sparsentan	55	10 (18.2)	111.1	(95.1, 111.1)	1.328	(0.522, 3.379)	0.552
	Irbesartan	55	9 (16.4)	NE				
eGFR High and UP High	Sparsentan	37	8 (21.6)	114.3	(87.7, 114.3)	3.699	(0.648, 21.114)	0.141
	Irbesartan	36	2 (5.6)	NE				
eGFR High and UP Low	Sparsentan	39	4 (10.3)	NE		1.372	(0.297, 6.344)	0.686
	Irbesartan	37	3 (8.1)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KMSDT_FSTM: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.220
< 60 mL/min/1.73 m**2	Sparsentan	127	23 (18.1)	111.1	(96.1, 111.1)	1.271	(0.665, 2.427)	0.468
	Irbesartan	129	19 (14.7)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	8 (16.3)	114.3	(NE, NE)	5.740	(0.669, 49.217)	0.111
	Irbesartan	48	1 (2.1)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	3 (11.5)	NE		1.397	(0.170, 11.486)	0.756
	Irbesartan	25	2 (8.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KMSDT_FSTM: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eGFR Group 2	Sparsentan						Interaction test:	0.101	
< 45 mL/min/1.73 m**2	Sparsentan	82	12 (14.6)	111.1	(96.1, 111.1)	0.734	(0.329, 1.641)	0.452	
	Irbesartan	80	13 (16.3)	NE					
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	11 (24.4)	108.7	(69.4, NE)	3.294	(1.036, 10.479)	0.043	*
	Irbesartan	49	6 (12.2)	NE					
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	8 (16.3)	114.3	(NE, NE)	5.740	(0.669, 49.217)	0.111	
	Irbesartan	48	1 (2.1)	NE					
>= 90 mL/min/1.73 m**2	Sparsentan	26	3 (11.5)	NE		1.397	(0.170, 11.486)	0.756	
	Irbesartan	25	2 (8.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KMSDT_FSTM: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline urine protein excretion	Sparsentan						Interaction test:	0.200
<= 1.75 g/day	Sparsentan	98	19 (19.4)	111.1	(95.1, 111.1)	2.037	(0.809, 5.129)	0.131
	Irbesartan	94	7 (7.4)	NE				
> 1.75 g/day	Sparsentan	104	15 (14.4)	114.3	(NE, NE)	1.260	(0.569, 2.793)	0.568
	Irbesartan	108	15 (13.9)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KMSDT_FSTM: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.154
Yes	Sparsentan	88	17 (19.3)	111.1	(72.1, 111.1)	2.198	(0.894, 5.405)	0.086
	Irbesartan	83	8 (9.6)	NE				
No	Sparsentan	114	17 (14.9)	114.3	(108.7, 114.3)	1.050	(0.500, 2.205)	0.898
	Irbesartan	119	14 (11.8)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KMSDT_FSTM: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Time since renal biopsy	Sparsentan						Interaction test:	0.672
<= 5 years	Sparsentan	113	15 (13.3)	NE		1.156	(0.544, 2.456)	0.705
	Irbesartan	127	14 (11.0)	NE				
> 5 years	Sparsentan	89	19 (21.3)	111.1	(96.1, 114.3)	1.712	(0.715, 4.099)	0.228
	Irbesartan	75	8 (10.7)	108.1	(108.1, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Table PT1KMSDT_FSTM: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
History of hypertension	Sparsentan						Interaction test:	0.987
Yes	Sparsentan	153	22 (14.4)	111.1	(108.7, 114.3)	1.444	(0.710, 2.937)	0.310
	Irbesartan	157	14 (8.9)	NE				
No	Sparsentan	49	12 (24.5)	NE		1.292	(0.518, 3.223)	0.583
	Irbesartan	45	8 (17.8)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 04APR2024

Figure PF1KMSDT_FSKM: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points by subgroup
Full Analysis Set

Not done. No significant subgroups.

_____
A decrease reflects a worsening of the status of the patient.
Reference table: PT1KMSDT_FSTM

Table PT1A_SSIM: Incidence of TEAEs during double-blind period by subgroup
Safety Set

TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.871
Male	Double-blind period	Sparsentan	139	114 (82.0)	1.128 [0.993, 1.280]	1.710 [0.969, 3.018]	9.3 [-1.1, 19.7]	0.066
		Irbesartan	143	104 (72.7)				
Female	Double-blind period	Sparsentan	63	52 (82.5)	1.107 [0.918, 1.335]	1.612 [0.671, 3.868]	8.0 [-8.2, 24.1]	0.377
		Irbesartan	59	44 (74.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSIM: Incidence of TEAEs during double-blind period by subgroup
Safety Set

TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Age	Double-blind period	Sparsentan					Interaction test:	0.579	
<= 45 years	Double-blind period	Sparsentan	96	83 (86.5)	1.157 [1.006, 1.329]	2.157 [1.029, 4.520]	11.7 [-0.3, 23.7]	0.047	*
		Irbesartan	99	74 (74.7)					
> 45 years	Double-blind period	Sparsentan	106	83 (78.3)	1.090 [0.931, 1.275]	1.414 [0.753, 2.657]	6.5 [-6.2, 19.1]	0.337	
		Irbesartan	103	74 (71.8)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSIM: Incidence of TEAEs during double-blind period by subgroup
Safety Set

TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.761
<= 18 years	Double-blind period	Sparsentan	9	8 (88.9)	1.481 [0.698, 3.143]	5.333 [0.343, 82.827]	28.9 [-34.3, 92.0]	0.505
		Irbesartan	5	3 (60.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	87 (85.3)	1.120 [0.981, 1.279]	1.817 [0.899, 3.670]	9.1 [-2.3, 20.6]	0.117
		Irbesartan	109	83 (76.1)				
> 40 years	Double-blind period	Sparsentan	91	71 (78.0)	1.107 [0.931, 1.318]	1.489 [0.758, 2.924]	7.6 [-6.3, 21.5]	0.305
		Irbesartan	88	62 (70.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSIM: Incidence of TEAEs during double-blind period by subgroup
Safety Set

TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.383
North America	Double-blind period	Sparsentan	35	28 (80.0)	1.082 [0.853, 1.374]	1.412 [0.490, 4.066]	6.1 [-14.8, 26.9]	0.603
		Irbesartan	46	34 (73.9)				
Europe	Double-blind period	Sparsentan	98	79 (80.6)	1.173 [1.003, 1.373]	1.895 [1.002, 3.584]	11.9 [-0.6, 24.4]	0.059
		Irbesartan	115	79 (68.7)				
Asia Pacific	Double-blind period	Sparsentan	69	59 (85.5)	1.002 [0.854, 1.175]	1.011 [0.338, 3.024]	0.1 [-15.4, 15.7]	1.000
		Irbesartan	41	35 (85.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSIM: Incidence of TEAEs during double-blind period by subgroup
Safety Set

TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.962
< 27 kg/m**2	Double-blind period	Sparsentan	84	68 (81.0)	1.119 [0.951, 1.316]	1.625 [0.801, 3.298]	8.6 [-4.9, 22.1]	0.217
		Irbesartan	94	68 (72.3)				
>= 27 kg/m**2	Double-blind period	Sparsentan	118	98 (83.1)	1.125 [0.979, 1.293]	1.737 [0.910, 3.313]	9.2 [-2.4, 20.8]	0.105
		Irbesartan	107	79 (73.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSIM: Incidence of TEAEs during double-blind period by subgroup
Safety Set

TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.250	
eGFR Low and UP High	Double-blind period	Sparsentan	71	61 (85.9)	1.177 [0.996, 1.392]	2.259 [0.973, 5.248]	12.9 [-1.4, 27.3]	0.066	
		Irbesartan	74	54 (73.0)					
eGFR Low and UP Low	Double-blind period	Sparsentan	55	44 (80.0)	1.023 [0.844, 1.240]	1.116 [0.445, 2.800]	1.8 [-15.2, 18.8]	1.000	
		Irbesartan	55	43 (78.2)					
eGFR High and UP High	Double-blind period	Sparsentan	37	31 (83.8)	1.371 [1.019, 1.844]	3.288 [1.093, 9.892]	22.7 [0.1, 45.3]	0.038	*
		Irbesartan	36	22 (61.1)					
eGFR High and UP Low	Double-blind period	Sparsentan	39	30 (76.9)	0.981 [0.771, 1.249]	0.920 [0.312, 2.709]	-1.5 [-22.8, 19.9]	1.000	
		Irbesartan	37	29 (78.4)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSIM: Incidence of TEAEs during double-blind period by subgroup
Safety Set

TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.861
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	106 (83.5)	1.099 [0.970, 1.244]	1.597 [0.860, 2.963]	7.5 [-3.1, 18.1]	0.163
		Irbesartan	129	98 (76.0)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	40 (81.6)	1.152 [0.920, 1.443]	1.830 [0.705, 4.751]	10.8 [-8.1, 29.7]	0.240
		Irbesartan	48	34 (70.8)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	20 (76.9)	1.202 [0.837, 1.726]	1.875 [0.551, 6.379]	12.9 [-15.8, 41.7]	0.368
		Irbesartan	25	16 (64.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSIM: Incidence of TEAEs during double-blind period by subgroup
Safety Set

TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.896
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	68 (82.9)	1.070 [0.918, 1.248]	1.410 [0.647, 3.072]	5.4 [-8.1, 18.9]	0.433
		Irbesartan	80	62 (77.5)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	38 (84.4)	1.149 [0.932, 1.418]	1.960 [0.703, 5.467]	11.0 [-7.4, 29.4]	0.217
		Irbesartan	49	36 (73.5)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	40 (81.6)	1.152 [0.920, 1.443]	1.830 [0.705, 4.751]	10.8 [-8.1, 29.7]	0.240
		Irbesartan	48	34 (70.8)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	20 (76.9)	1.202 [0.837, 1.726]	1.875 [0.551, 6.379]	12.9 [-15.8, 41.7]	0.368
		Irbesartan	25	16 (64.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSIM: Incidence of TEAEs during double-blind period by subgroup
Safety Set

TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.128	
<= 1.75 g/day	Double-blind period	Sparsentan	98	75 (76.5)	1.028 [0.875, 1.208]	1.118 [0.579, 2.159]	2.1 [-11.1, 15.3]	0.867	
		Irbesartan	94	70 (74.5)					
> 1.75 g/day	Double-blind period	Sparsentan	104	91 (87.5)	1.212 [1.056, 1.390]	2.692 [1.314, 5.518]	15.3 [3.8, 26.8]	0.006	*
		Irbesartan	108	78 (72.2)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSIM: Incidence of TEAEs during double-blind period by subgroup
Safety Set

TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.178	
Yes	Double-blind period	Sparsentan	88	70 (79.5)	1.032 [0.881, 1.208]	1.155 [0.557, 2.392]	2.4 [-11.1, 16.0]	0.714	
		Irbesartan	83	64 (77.1)					
No	Double-blind period	Sparsentan	114	96 (84.2)	1.193 [1.037, 1.373]	2.222 [1.172, 4.212]	13.6 [2.2, 25.1]	0.019	*
		Irbesartan	119	84 (70.6)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSIM: Incidence of TEAEs during double-blind period by subgroup
Safety Set

TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.486
<= 5 years	Double-blind period	Sparsentan	113	92 (81.4)	1.088 [0.952, 1.244]	1.476 [0.793, 2.745]	6.6 [-4.6, 17.9]	0.275
		Irbesartan	127	95 (74.8)				
> 5 years	Double-blind period	Sparsentan	89	74 (83.1)	1.177 [0.989, 1.399]	2.048 [0.972, 4.314]	12.5 [-1.7, 26.6]	0.063
		Irbesartan	75	53 (70.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSIM: Incidence of TEAEs during double-blind period by subgroup
Safety Set

TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.897
Yes	Double-blind period	Sparsentan	153	125 (81.7)	1.125 [0.996, 1.271]	1.684 [0.982, 2.888]	9.1 [-0.8, 19.0]	0.060
		Irbesartan	157	114 (72.6)				
No	Double-blind period	Sparsentan	49	41 (83.7)	1.107 [0.900, 1.362]	1.658 [0.599, 4.588]	8.1 [-10.3, 26.5]	0.442
		Irbesartan	45	34 (75.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AN_SSIM: Incidence of non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.607
Male	Double-blind period	Sparsentan	139	34 (24.5)	1.128 [0.736, 1.729]	1.170 [0.672, 2.037]	2.8 [-7.8, 13.3]	0.672
		Irbesartan	143	31 (21.7)				
Female	Double-blind period	Sparsentan	63	15 (23.8)	1.405 [0.686, 2.877]	1.531 [0.627, 3.743]	6.9 [-9.0, 22.7]	0.378
		Irbesartan	59	10 (16.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AN_SSIM: Incidence of non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.204
<= 45 years	Double-blind period	Sparsentan	96	29 (30.2)	1.495 [0.911, 2.455]	1.710 [0.887, 3.295]	10.0 [-3.1, 23.2]	0.137
		Irbesartan	99	20 (20.2)				
> 45 years	Double-blind period	Sparsentan	106	20 (18.9)	0.925 [0.534, 1.602]	0.908 [0.459, 1.798]	-1.5 [-13.2, 10.2]	0.862
		Irbesartan	103	21 (20.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AN_SSIM: Incidence of non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.617
<= 18 years	Double-blind period	Sparsentan	9	5 (55.6)	2.778 [0.438, 17.629]	5.000 [0.388, 64.387]	35.6 [-27.8, 98.9]	0.301
		Irbesartan	5	1 (20.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	23 (22.5)	1.069 [0.641, 1.781]	1.089 [0.566, 2.093]	1.4 [-10.7, 13.6]	0.868
		Irbesartan	109	23 (21.1)				
> 40 years	Double-blind period	Sparsentan	91	21 (23.1)	1.195 [0.677, 2.109]	1.253 [0.610, 2.573]	3.8 [-9.3, 16.8]	0.586
		Irbesartan	88	17 (19.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AN_SSIM: Incidence of non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.571
North America	Double-blind period	Sparsentan	35	7 (20.0)	1.533 [0.565, 4.159]	1.667 [0.506, 5.493]	7.0 [-12.0, 25.9]	0.543
		Irbesartan	46	6 (13.0)				
Europe	Double-blind period	Sparsentan	98	24 (24.5)	1.006 [0.626, 1.616]	1.008 [0.538, 1.887]	0.1 [-12.4, 12.7]	1.000
		Irbesartan	115	28 (24.3)				
Asia Pacific	Double-blind period	Sparsentan	69	18 (26.1)	1.528 [0.698, 3.343]	1.714 [0.647, 4.545]	9.0 [-8.4, 26.4]	0.350
		Irbesartan	41	7 (17.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AN_SSIM: Incidence of non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.028	#
< 27 kg/m**2	Double-blind period	Sparsentan	84	16 (19.0)	0.746 [0.426, 1.306]	0.686 [0.336, 1.403]	-6.5 [-19.8, 6.8]	0.369	
		Irbesartan	94	24 (25.5)					
>= 27 kg/m**2	Double-blind period	Sparsentan	118	33 (28.0)	1.760 [1.043, 2.971]	2.055 [1.067, 3.961]	12.1 [0.5, 23.6]	0.037	*
		Irbesartan	107	17 (15.9)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AN_SSIM: Incidence of non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.987
eGFR Low and UP High	Double-blind period	Sparsentan	71	21 (29.6)	1.152 [0.679, 1.954]	1.216 [0.586, 2.521]	3.9 [-12.0, 19.8]	0.711
		Irbesartan	74	19 (25.7)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	16 (29.1)	1.333 [0.697, 2.550]	1.470 [0.619, 3.491]	7.3 [-10.8, 25.3]	0.512
		Irbesartan	55	12 (21.8)				
eGFR High and UP High	Double-blind period	Sparsentan	37	6 (16.2)	1.168 [0.391, 3.488]	1.200 [0.331, 4.346]	2.3 [-16.8, 21.5]	1.000
		Irbesartan	36	5 (13.9)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	6 (15.4)	1.138 [0.380, 3.414]	1.164 [0.323, 4.196]	1.9 [-16.6, 20.3]	1.000
		Irbesartan	37	5 (13.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AN_SSIM: Incidence of non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.699
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	36 (28.3)	1.306 [0.851, 2.005]	1.427 [0.808, 2.522]	6.6 [-4.7, 18.0]	0.249
		Irbesartan	129	28 (21.7)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	9 (18.4)	0.882 [0.393, 1.977]	0.855 [0.313, 2.334]	-2.5 [-20.3, 15.4]	0.803
		Irbesartan	48	10 (20.8)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	4 (15.4)	1.282 [0.318, 5.161]	1.333 [0.267, 6.666]	3.4 [-19.4, 26.1]	1.000
		Irbesartan	25	3 (12.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AN_SSIM: Incidence of non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.825
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	26 (31.7)	1.208 [0.743, 1.963]	1.304 [0.660, 2.579]	5.5 [-9.7, 20.6]	0.491
		Irbesartan	80	21 (26.3)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	10 (22.2)	1.556 [0.647, 3.739]	1.714 [0.591, 4.973]	7.9 [-9.8, 25.7]	0.423
		Irbesartan	49	7 (14.3)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	9 (18.4)	0.882 [0.393, 1.977]	0.855 [0.313, 2.334]	-2.5 [-20.3, 15.4]	0.803
		Irbesartan	48	10 (20.8)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	4 (15.4)	1.282 [0.318, 5.161]	1.333 [0.267, 6.666]	3.4 [-19.4, 26.1]	1.000
		Irbesartan	25	3 (12.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AN_SSIM: Incidence of non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.200
<= 1.75 g/day	Double-blind period	Sparsentan	98	21 (21.4)	1.679 [0.876, 3.217]	1.864 [0.859, 4.043]	8.7 [-2.9, 20.3]	0.128
		Irbesartan	94	12 (12.8)				
> 1.75 g/day	Double-blind period	Sparsentan	104	28 (26.9)	1.003 [0.643, 1.563]	1.004 [0.547, 1.842]	0.1 [-12.8, 13.0]	1.000
		Irbesartan	108	29 (26.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AN_SSIM: Incidence of non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.080
Yes	Double-blind period	Sparsentan	88	26 (29.5)	1.752 [0.984, 3.117]	2.067 [0.991, 4.309]	12.7 [-1.0, 26.3]	0.070
		Irbesartan	83	14 (16.9)				
No	Double-blind period	Sparsentan	114	23 (20.2)	0.889 [0.543, 1.456]	0.861 [0.460, 1.612]	-2.5 [-13.9, 8.9]	0.750
		Irbesartan	119	27 (22.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AN_SSIM: Incidence of non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.072
<= 5 years	Double-blind period	Sparsentan	113	31 (27.4)	1.584 [0.976, 2.570]	1.804 [0.973, 3.348]	10.1 [-1.3, 21.5]	0.063
		Irbesartan	127	22 (17.3)				
> 5 years	Double-blind period	Sparsentan	89	18 (20.2)	0.798 [0.453, 1.407]	0.747 [0.359, 1.556]	-5.1 [-19.2, 9.0]	0.459
		Irbesartan	75	19 (25.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AN_SSIM: Incidence of non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.009	#
Yes	Double-blind period	Sparsentan	153	44 (28.8)	1.557 [1.031, 2.352]	1.782 [1.045, 3.039]	10.3 [0.2, 20.3]	0.044	*
		Irbesartan	157	29 (18.5)					
No	Double-blind period	Sparsentan	49	5 (10.2)	0.383 [0.146, 1.001]	0.313 [0.100, 0.974]	-16.5 [-34.0, 1.1]	0.059	
		Irbesartan	45	12 (26.7)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AC_SSIM: Incidence of severe TEAEs during double-blind period by subgroup
Safety Set

Severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.683
Male	Double-blind period	Sparsentan	139	10 (7.2)	1.029 [0.442, 2.395]	1.031 [0.415, 2.560]	0.2 [-6.5, 6.9]	1.000
		Irbesartan	143	10 (7.0)				
Female	Double-blind period	Sparsentan	63	4 (6.3)	0.749 [0.211, 2.657]	0.732 [0.187, 2.869]	-2.1 [-13.1, 8.8]	0.738
		Irbesartan	59	5 (8.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AC_SSIM: Incidence of severe TEAEs during double-blind period by subgroup
Safety Set

Severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.718
<= 45 years	Double-blind period	Sparsentan	96	10 (10.4)	1.031 [0.450, 2.366]	1.035 [0.410, 2.611]	0.3 [-9.2, 9.9]	1.000
		Irbesartan	99	10 (10.1)				
> 45 years	Double-blind period	Sparsentan	106	4 (3.8)	0.777 [0.215, 2.814]	0.769 [0.201, 2.946]	-1.1 [-7.6, 5.4]	0.746
		Irbesartan	103	5 (4.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AC_SSIM: Incidence of severe TEAEs during double-blind period by subgroup
Safety Set

Severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.690
<= 18 years	Double-blind period	Sparsentan	9	2 (22.2)	3.000 + [0.171, 52.527]	3.667 + [0.145, 92.653]	22.2 [-20.5, 64.9]	0.505
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	7 (6.9)	0.831 [0.321, 2.149]	0.819 [0.293, 2.286]	-1.4 [-9.5, 6.7]	0.798
		Irbesartan	109	9 (8.3)				
> 40 years	Double-blind period	Sparsentan	91	5 (5.5)	0.806 [0.255, 2.545]	0.795 [0.233, 2.704]	-1.3 [-9.5, 6.8]	0.764
		Irbesartan	88	6 (6.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AC_SSIM: Incidence of severe TEAEs during double-blind period by subgroup
Safety Set

Severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.303
North America	Double-blind period	Sparsentan	35	5 (14.3)	2.190 [0.561, 8.553]	2.389 [0.530, 10.764]	7.8 [-8.4, 23.9]	0.282
		Irbesartan	46	3 (6.5)				
Europe	Double-blind period	Sparsentan	98	7 (7.1)	0.913 [0.353, 2.361]	0.906 [0.325, 2.529]	-0.7 [-8.7, 7.3]	1.000
		Irbesartan	115	9 (7.8)				
Asia Pacific	Double-blind period	Sparsentan	69	2 (2.9)	0.396 [0.069, 2.273]	0.378 [0.060, 2.364]	-4.4 [-15.3, 6.4]	0.359
		Irbesartan	41	3 (7.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AC_SSIM: Incidence of severe TEAEs during double-blind period by subgroup
Safety Set

Severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.740
< 27 kg/m**2	Double-blind period	Sparsentan	84	5 (6.0)	0.799 [0.264, 2.424]	0.787 [0.240, 2.579]	-1.5 [-10.0, 7.0]	0.771
		Irbesartan	94	7 (7.4)				
>= 27 kg/m**2	Double-blind period	Sparsentan	118	9 (7.6)	1.020 [0.408, 2.549]	1.022 [0.379, 2.751]	0.2 [-7.7, 8.0]	1.000
		Irbesartan	107	8 (7.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AC_SSIM: Incidence of severe TEAEs during double-blind period by subgroup
Safety Set

Severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.726
eGFR Low and UP High	Double-blind period	Sparsentan	71	8 (11.3)	1.390 [0.508, 3.805]	1.439 [0.473, 4.378]	3.2 [-7.9, 14.2]	0.582
		Irbesartan	74	6 (8.1)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	2 (3.6)	0.500 [0.095, 2.618]	0.481 [0.084, 2.742]	-3.6 [-13.9, 6.6]	0.679
		Irbesartan	55	4 (7.3)				
eGFR High and UP High	Double-blind period	Sparsentan	37	2 (5.4)	0.649 [0.115, 3.656]	0.629 [0.099, 4.003]	-2.9 [-17.3, 11.4]	0.674
		Irbesartan	36	3 (8.3)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	2 (5.1)	0.949 [0.141, 6.392]	0.946 [0.126, 7.086]	-0.3 [-13.0, 12.4]	1.000
		Irbesartan	37	2 (5.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AC_SSIM: Incidence of severe TEAEs during double-blind period by subgroup
Safety Set

Severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.506
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	10 (7.9)	0.846 [0.379, 1.889]	0.833 [0.347, 2.004]	-1.4 [-9.1, 6.2]	0.824
		Irbesartan	129	12 (9.3)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	2 (4.1)	0.653 [0.114, 3.737]	0.638 [0.102, 4.000]	-2.2 [-13.0, 8.7]	0.678
		Irbesartan	48	3 (6.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	2 (7.7)	4.815 + [0.243, 95.576]	5.204 + [0.238, 113.979]	7.7 [-6.5, 21.9]	0.490
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AC_SSIM: Incidence of severe TEAEs during double-blind period by subgroup
Safety Set

Severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.715
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	6 (7.3)	0.836 [0.294, 2.380]	0.823 [0.264, 2.566]	-1.4 [-11.0, 8.2]	0.780
		Irbesartan	80	7 (8.8)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	4 (8.9)	0.871 [0.249, 3.043]	0.859 [0.216, 3.419]	-1.3 [-15.3, 12.7]	1.000
		Irbesartan	49	5 (10.2)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	2 (4.1)	0.653 [0.114, 3.737]	0.638 [0.102, 4.000]	-2.2 [-13.0, 8.7]	0.678
		Irbesartan	48	3 (6.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	2 (7.7)	4.815 + [0.243, 95.576]	5.204 + [0.238, 113.979]	7.7 [-6.5, 21.9]	0.490
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AC_SSIM: Incidence of severe TEAEs during double-blind period by subgroup
Safety Set

Severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.386
<= 1.75 g/day	Double-blind period	Sparsentan	98	5 (5.1)	1.599 [0.393, 6.503]	1.631 [0.379, 7.024]	1.9 [-4.8, 8.6]	0.721
		Irbesartan	94	3 (3.2)				
> 1.75 g/day	Double-blind period	Sparsentan	104	9 (8.7)	0.779 [0.343, 1.771]	0.758 [0.305, 1.882]	-2.5 [-11.4, 6.5]	0.648
		Irbesartan	108	12 (11.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AC_SSIM: Incidence of severe TEAEs during double-blind period by subgroup
Safety Set

Severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.723
Yes	Double-blind period	Sparsentan	88	6 (6.8)	0.808 [0.283, 2.306]	0.794 [0.256, 2.470]	-1.6 [-10.8, 7.5]	0.777
		Irbesartan	83	7 (8.4)				
No	Double-blind period	Sparsentan	114	8 (7.0)	1.044 [0.405, 2.688]	1.047 [0.379, 2.891]	0.3 [-7.1, 7.7]	1.000
		Irbesartan	119	8 (6.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AC_SSIM: Incidence of severe TEAEs during double-blind period by subgroup
Safety Set

Severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.538
<= 5 years	Double-blind period	Sparsentan	113	9 (8.0)	0.843 [0.369, 1.926]	0.829 [0.336, 2.048]	-1.5 [-9.4, 6.5]	0.820
		Irbesartan	127	12 (9.4)				
> 5 years	Double-blind period	Sparsentan	89	5 (5.6)	1.404 [0.347, 5.684]	1.429 [0.330, 6.186]	1.6 [-6.1, 9.4]	0.728
		Irbesartan	75	3 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AC_SSIM: Incidence of severe TEAEs during double-blind period by subgroup
Safety Set

Severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.282
Yes	Double-blind period	Sparsentan	153	13 (8.5)	1.112 [0.524, 2.359]	1.122 [0.495, 2.543]	0.9 [-5.9, 7.6]	0.837
		Irbesartan	157	12 (7.6)				
No	Double-blind period	Sparsentan	49	1 (2.0)	0.306 [0.033, 2.838]	0.292 [0.029, 2.911]	-4.6 [-15.1, 5.8]	0.346
		Irbesartan	45	3 (6.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AS_SSIM: Incidence of serious TEAEs during double-blind period by subgroup
Safety Set

Serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.847
Male	Double-blind period	Sparsentan	139	19 (13.7)	0.931 [0.524, 1.654]	0.920 [0.471, 1.797]	-1.0 [-9.9, 7.8]	0.865
		Irbesartan	143	21 (14.7)				
Female	Double-blind period	Sparsentan	63	9 (14.3)	0.843 [0.368, 1.928]	0.817 [0.306, 2.176]	-2.7 [-17.2, 11.9]	0.804
		Irbesartan	59	10 (16.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AS_SSIM: Incidence of serious TEAEs during double-blind period by subgroup
Safety Set

Serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.801
<= 45 years	Double-blind period	Sparsentan	96	15 (15.6)	0.859 [0.460, 1.606]	0.833 [0.393, 1.766]	-2.6 [-14.1, 9.0]	0.704
		Irbesartan	99	18 (18.2)				
> 45 years	Double-blind period	Sparsentan	106	13 (12.3)	0.972 [0.473, 1.995]	0.968 [0.426, 2.201]	-0.4 [-10.3, 9.6]	1.000
		Irbesartan	103	13 (12.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AS_SSIM: Incidence of serious TEAEs during double-blind period by subgroup
Safety Set

Serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.461
<= 18 years	Double-blind period	Sparsentan	9	2 (22.2)	3.000 + [0.171, 52.527]	3.667 + [0.145, 92.653]	22.2 [-20.5, 64.9]	0.505
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	14 (13.7)	1.069 [0.536, 2.130]	1.080 [0.487, 2.392]	0.9 [-9.2, 11.0]	1.000
		Irbesartan	109	14 (12.8)				
> 40 years	Double-blind period	Sparsentan	91	12 (13.2)	0.683 [0.346, 1.345]	0.634 [0.283, 1.420]	-6.1 [-18.0, 5.8]	0.313
		Irbesartan	88	17 (19.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AS_SSIM: Incidence of serious TEAEs during double-blind period by subgroup
Safety Set

Serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.680
North America	Double-blind period	Sparsentan	35	6 (17.1)	1.127 [0.415, 3.056]	1.153 [0.350, 3.795]	1.9 [-16.8, 20.7]	1.000
		Irbesartan	46	7 (15.2)				
Europe	Double-blind period	Sparsentan	98	10 (10.2)	0.690 [0.332, 1.437]	0.655 [0.285, 1.506]	-4.6 [-14.4, 5.2]	0.409
		Irbesartan	115	17 (14.8)				
Asia Pacific	Double-blind period	Sparsentan	69	12 (17.4)	1.019 [0.436, 2.379]	1.023 [0.367, 2.848]	0.3 [-16.2, 16.8]	1.000
		Irbesartan	41	7 (17.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AS_SSIM: Incidence of serious TEAEs during double-blind period by subgroup
Safety Set

Serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.996
< 27 kg/m**2	Double-blind period	Sparsentan	84	13 (15.5)	0.909 [0.465, 1.777]	0.893 [0.401, 1.985]	-1.5 [-13.5, 10.4]	0.841
		Irbesartan	94	16 (17.0)				
>= 27 kg/m**2	Double-blind period	Sparsentan	118	15 (12.7)	0.907 [0.466, 1.765]	0.893 [0.414, 1.927]	-1.3 [-11.1, 8.5]	0.845
		Irbesartan	107	15 (14.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AS_SSIM: Incidence of serious TEAEs during double-blind period by subgroup
Safety Set

Serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.382
eGFR Low and UP High	Double-blind period	Sparsentan	71	12 (16.9)	0.834 [0.420, 1.655]	0.800 [0.345, 1.854]	-3.4 [-17.4, 10.7]	0.672
		Irbesartan	74	15 (20.3)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	8 (14.5)	1.333 [0.495, 3.589]	1.390 [0.448, 4.310]	3.6 [-10.6, 17.9]	0.776
		Irbesartan	55	6 (10.9)				
eGFR High and UP High	Double-blind period	Sparsentan	37	6 (16.2)	1.459 [0.449, 4.745]	1.548 [0.398, 6.022]	5.1 [-13.3, 23.5]	0.736
		Irbesartan	36	4 (11.1)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	2 (5.1)	0.316 [0.068, 1.469]	0.279 [0.053, 1.483]	-11.1 [-27.5, 5.3]	0.148
		Irbesartan	37	6 (16.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AS_SSIM: Incidence of serious TEAEs during double-blind period by subgroup
Safety Set

Serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.694
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	20 (15.7)	0.813 [0.476, 1.387]	0.778 [0.407, 1.485]	-3.6 [-13.7, 6.5]	0.512
		Irbesartan	129	25 (19.4)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	7 (14.3)	1.371 [0.467, 4.024]	1.433 [0.422, 4.874]	3.9 [-11.3, 19.0]	0.759
		Irbesartan	48	5 (10.4)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8)	0.962 [0.064, 14.551]	0.960 [0.057, 16.232]	-0.2 [-14.7, 14.4]	1.000
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AS_SSIM: Incidence of serious TEAEs during double-blind period by subgroup
Safety Set

Serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.694
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	14 (17.1)	0.976 [0.497, 1.914]	0.971 [0.430, 2.192]	-0.4 [-13.3, 12.5]	1.000
		Irbesartan	80	14 (17.5)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	6 (13.3)	0.594 [0.239, 1.474]	0.531 [0.179, 1.581]	-9.1 [-26.6, 8.3]	0.293
		Irbesartan	49	11 (22.4)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	7 (14.3)	1.371 [0.467, 4.024]	1.433 [0.422, 4.874]	3.9 [-11.3, 19.0]	0.759
		Irbesartan	48	5 (10.4)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8)	0.962 [0.064, 14.551]	0.960 [0.057, 16.232]	-0.2 [-14.7, 14.4]	1.000
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AS_SSIM: Incidence of serious TEAEs during double-blind period by subgroup
Safety Set

Serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.186
<= 1.75 g/day	Double-blind period	Sparsentan	98	14 (14.3)	1.343 [0.628, 2.873]	1.400 [0.589, 3.328]	3.6 [-6.7, 14.0]	0.516
		Irbesartan	94	10 (10.6)				
> 1.75 g/day	Double-blind period	Sparsentan	104	14 (13.5)	0.692 [0.372, 1.287]	0.644 [0.308, 1.348]	-6.0 [-16.9, 4.9]	0.270
		Irbesartan	108	21 (19.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AS_SSIM: Incidence of serious TEAEs during double-blind period by subgroup
Safety Set

Serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.484
Yes	Double-blind period	Sparsentan	88	11 (12.5)	0.741 [0.357, 1.539]	0.704 [0.300, 1.654]	-4.4 [-16.2, 7.4]	0.517
		Irbesartan	83	14 (16.9)				
No	Double-blind period	Sparsentan	114	17 (14.9)	1.044 [0.561, 1.943]	1.052 [0.508, 2.177]	0.6 [-9.3, 10.6]	1.000
		Irbesartan	119	17 (14.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AS_SSIM: Incidence of serious TEAEs during double-blind period by subgroup
Safety Set

Serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.040 #
<= 5 years	Double-blind period	Sparsentan	113	14 (12.4)	0.629 [0.344, 1.150]	0.577 [0.284, 1.174]	-7.3 [-17.3, 2.7]	0.161
		Irbesartan	127	25 (19.7)				
> 5 years	Double-blind period	Sparsentan	89	14 (15.7)	1.966 [0.795, 4.864]	2.147 [0.781, 5.898]	7.7 [-3.2, 18.7]	0.156
		Irbesartan	75	6 (8.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AS_SSIM: Incidence of serious TEAEs during double-blind period by subgroup
Safety Set

Serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.704
Yes	Double-blind period	Sparsentan	153	22 (14.4)	0.868 [0.515, 1.464]	0.846 [0.456, 1.569]	-2.2 [-10.9, 6.5]	0.640
		Irbesartan	157	26 (16.6)				
No	Double-blind period	Sparsentan	49	6 (12.2)	1.102 [0.361, 3.363]	1.116 [0.316, 3.945]	1.1 [-14.0, 16.2]	1.000
		Irbesartan	45	5 (11.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AT_SSIM: Incidence of TEAEs leading to study drug discontinuation during double-blind period by subgroup
Safety Set

TEAEs leading to study drug discontinuation

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.312
Male	Double-blind period	Sparsentan	139	10 (7.2)	2.572 [0.826, 8.008]	2.694 [0.824, 8.802]	4.4 [-1.4, 10.2]	0.105
		Irbesartan	143	4 (2.8)				
Female	Double-blind period	Sparsentan	63	6 (9.5)	1.124 [0.362, 3.487]	1.137 [0.328, 3.943]	1.0 [-10.7, 12.8]	1.000
		Irbesartan	59	5 (8.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AT_SSIM: Incidence of TEAEs leading to study drug discontinuation during double-blind period by subgroup
Safety Set

TEAEs leading to study drug discontinuation

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.196
<= 45 years	Double-blind period	Sparsentan	96	8 (8.3)	1.179 [0.445, 3.124]	1.195 [0.416, 3.434]	1.3 [-7.3, 9.8]	0.793
		Irbesartan	99	7 (7.1)				
> 45 years	Double-blind period	Sparsentan	106	8 (7.5)	3.887 [0.845, 17.871]	4.122 [0.854, 19.899]	5.6 [-1.0, 12.3]	0.101
		Irbesartan	103	2 (1.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AT_SSIM: Incidence of TEAEs leading to study drug discontinuation during double-blind period by subgroup
Safety Set

TEAEs leading to study drug discontinuation

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.976
<= 18 years	Double-blind period	Sparsentan	9	1 (11.1)	1.800 + [0.086, 37.493]	1.941 + [0.066, 56.760]	11.1 [-25.0, 47.2]	1.000
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	9 (8.8)	1.603 [0.591, 4.345]	1.661 [0.570, 4.845]	3.3 [-4.6, 11.2]	0.426
		Irbesartan	109	6 (5.5)				
> 40 years	Double-blind period	Sparsentan	91	6 (6.6)	1.934 [0.499, 7.495]	2.000 [0.484, 8.259]	3.2 [-4.3, 10.7]	0.497
		Irbesartan	88	3 (3.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AT_SSIM: Incidence of TEAEs leading to study drug discontinuation during double-blind period by subgroup
Safety Set

TEAEs leading to study drug discontinuation

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.675
North America	Double-blind period	Sparsentan	35	5 (14.3)	3.286 [0.677, 15.949]	3.667 [0.667, 20.156]	9.9 [-5.6, 25.5]	0.230
		Irbesartan	46	2 (4.3)				
Europe	Double-blind period	Sparsentan	98	6 (6.1)	1.408 [0.443, 4.473]	1.435 [0.424, 4.854]	1.8 [-5.2, 8.8]	0.758
		Irbesartan	115	5 (4.3)				
Asia Pacific	Double-blind period	Sparsentan	69	5 (7.2)	1.486 [0.302, 7.311]	1.523 [0.282, 8.235]	2.4 [-8.6, 13.3]	1.000
		Irbesartan	41	2 (4.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AT_SSIM: Incidence of TEAEs leading to study drug discontinuation during double-blind period by subgroup
Safety Set

TEAEs leading to study drug discontinuation

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.823
< 27 kg/m**2	Double-blind period	Sparsentan	84	7 (8.3)	1.958 [0.594, 6.455]	2.045 [0.577, 7.252]	4.1 [-4.2, 12.4]	0.353
		Irbesartan	94	4 (4.3)				
>= 27 kg/m**2	Double-blind period	Sparsentan	118	9 (7.6)	1.632 [0.565, 4.718]	1.684 [0.546, 5.194]	3.0 [-4.2, 10.1]	0.417
		Irbesartan	107	5 (4.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AT_SSIM: Incidence of TEAEs leading to study drug discontinuation during double-blind period by subgroup
Safety Set

TEAEs leading to study drug discontinuation

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.305
eGFR Low and UP High	Double-blind period	Sparsentan	71	8 (11.3)	2.085 [0.657, 6.618]	2.222 [0.638, 7.737]	5.9 [-4.5, 16.2]	0.238
		Irbesartan	74	4 (5.4)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	4 (7.3)	9.000 + [0.496, 163.268]	9.699 + [0.510, 184.615]	7.3 [-1.4, 16.0]	0.118
		Irbesartan	55	0 (0.0)				
eGFR High and UP High	Double-blind period	Sparsentan	37	2 (5.4)	0.486 [0.095, 2.493]	0.457 [0.078, 2.667]	-5.7 [-21.0, 9.6]	0.430
		Irbesartan	36	4 (11.1)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	2 (5.1)	1.897 [0.180, 20.054]	1.946 [0.169, 22.413]	2.4 [-8.9, 13.7]	1.000
		Irbesartan	37	1 (2.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AT_SSIM: Incidence of TEAEs leading to study drug discontinuation during double-blind period by subgroup
Safety Set

TEAEs leading to study drug discontinuation

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.281	
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	12 (9.4)	3.047 [1.010, 9.198]	3.261 [1.023, 10.398]	6.3 [-0.3, 13.0]	0.041	*
		Irbesartan	129	4 (3.1)					
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	3 (6.1)	0.735 [0.174, 3.110]	0.717 [0.152, 3.390]	-2.2 [-14.6, 10.2]	0.715	
		Irbesartan	48	4 (8.3)					
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8)	0.962 [0.064, 14.551]	0.960 [0.057, 16.232]	-0.2 [-14.7, 14.4]	1.000	
		Irbesartan	25	1 (4.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AT_SSIM: Incidence of TEAEs leading to study drug discontinuation during double-blind period by subgroup
Safety Set

TEAEs leading to study drug discontinuation

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.420
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	7 (8.5)	2.276 [0.610, 8.496]	2.396 [0.597, 9.612]	4.8 [-3.8, 13.4]	0.328
		Irbesartan	80	3 (3.8)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	5 (11.1)	5.444 [0.661, 44.842]	6.000 [0.673, 53.486]	9.1 [-3.1, 21.2]	0.101
		Irbesartan	49	1 (2.0)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	3 (6.1)	0.735 [0.174, 3.110]	0.717 [0.152, 3.390]	-2.2 [-14.6, 10.2]	0.715
		Irbesartan	48	4 (8.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8)	0.962 [0.064, 14.551]	0.960 [0.057, 16.232]	-0.2 [-14.7, 14.4]	1.000
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AT_SSIM: Incidence of TEAEs leading to study drug discontinuation during double-blind period by subgroup
Safety Set

TEAEs leading to study drug discontinuation

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.200
<= 1.75 g/day	Double-blind period	Sparsentan	98	6 (6.1)	5.755 [0.706, 46.904]	6.065 [0.716, 51.372]	5.1 [-1.2, 11.3]	0.119
		Irbesartan	94	1 (1.1)				
> 1.75 g/day	Double-blind period	Sparsentan	104	10 (9.6)	1.298 [0.533, 3.160]	1.330 [0.503, 3.513]	2.2 [-6.3, 10.7]	0.628
		Irbesartan	108	8 (7.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AT_SSIM: Incidence of TEAEs leading to study drug discontinuation during double-blind period by subgroup
Safety Set

TEAEs leading to study drug discontinuation

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.647
Yes	Double-blind period	Sparsentan	88	9 (10.2)	2.122 [0.679, 6.629]	2.250 [0.665, 7.609]	5.4 [-3.6, 14.4]	0.251
		Irbesartan	83	4 (4.8)				
No	Double-blind period	Sparsentan	114	7 (6.1)	1.461 [0.478, 4.472]	1.492 [0.459, 4.842]	1.9 [-4.6, 8.5]	0.564
		Irbesartan	119	5 (4.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AT_SSIM: Incidence of TEAEs leading to study drug discontinuation during double-blind period by subgroup
Safety Set

TEAEs leading to study drug discontinuation

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.901
<= 5 years	Double-blind period	Sparsentan	113	10 (8.8)	1.873 [0.703, 4.990]	1.958 [0.688, 5.571]	4.1 [-3.1, 11.4]	0.300
		Irbesartan	127	6 (4.7)				
> 5 years	Double-blind period	Sparsentan	89	6 (6.7)	1.685 [0.436, 6.511]	1.735 [0.419, 7.188]	2.7 [-5.3, 10.8]	0.510
		Irbesartan	75	3 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AT_SSIM: Incidence of TEAEs leading to study drug discontinuation during double-blind period by subgroup
Safety Set

TEAEs leading to study drug discontinuation

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.248
Yes	Double-blind period	Sparsentan	153	12 (7.8)	2.463 [0.889, 6.824]	2.587 [0.889, 7.529]	4.7 [-1.1, 10.4]	0.084
		Irbesartan	157	5 (3.2)				
No	Double-blind period	Sparsentan	49	4 (8.2)	0.918 [0.244, 3.457]	0.911 [0.214, 3.881]	-0.7 [-14.2, 12.7]	1.000
		Irbesartan	45	4 (8.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AD_SSIM: Incidence of fatal TEAEs during double-blind period by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AA_SSIM: Incidence of non-disease related TEAEs during double-blind period by subgroup
Safety Set

Non-disease related TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.764
Male	Double-blind period	Sparsentan	139	112 (80.6)	1.130 [0.990, 1.289]	1.667 [0.957, 2.904]	9.2 [-1.4, 19.9]	0.072
		Irbesartan	143	102 (71.3)				
Female	Double-blind period	Sparsentan	63	50 (79.4)	1.089 [0.891, 1.330]	1.431 [0.619, 3.307]	6.5 [-10.3, 23.2]	0.524
		Irbesartan	59	43 (72.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AA_SSIM: Incidence of non-disease related TEAEs during double-blind period by subgroup
Safety Set

Non-disease related TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.872
<= 45 years	Double-blind period	Sparsentan	96	81 (84.4)	1.129 [0.978, 1.303]	1.824 [0.894, 3.724]	9.6 [-2.6, 21.9]	0.112
		Irbesartan	99	74 (74.7)				
> 45 years	Double-blind period	Sparsentan	106	81 (76.4)	1.109 [0.938, 1.310]	1.460 [0.791, 2.694]	7.5 [-5.5, 20.5]	0.277
		Irbesartan	103	71 (68.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AA_SSIM: Incidence of non-disease related TEAEs during double-blind period by subgroup
Safety Set

Non-disease related TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.920
<= 18 years	Double-blind period	Sparsentan	9	7 (77.8)	1.296 [0.585, 2.874]	2.333 [0.216, 25.245]	17.8 [-48.6, 84.1]	0.580
		Irbesartan	5	3 (60.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	86 (84.3)	1.107 [0.968, 1.266]	1.684 [0.843, 3.363]	8.2 [-3.5, 19.8]	0.168
		Irbesartan	109	83 (76.1)				
> 40 years	Double-blind period	Sparsentan	91	69 (75.8)	1.131 [0.938, 1.363]	1.542 [0.801, 2.965]	8.8 [-5.5, 23.1]	0.246
		Irbesartan	88	59 (67.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AA_SSIM: Incidence of non-disease related TEAEs during double-blind period by subgroup
Safety Set

Non-disease related TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.182	
North America	Double-blind period	Sparsentan	35	27 (77.1)	1.044 [0.814, 1.339]	1.191 [0.426, 3.328]	3.2 [-18.1, 24.6]	0.799	
		Irbesartan	46	34 (73.9)					
Europe	Double-blind period	Sparsentan	98	78 (79.6)	1.204 [1.021, 1.420]	2.001 [1.071, 3.738]	13.5 [0.8, 26.2]	0.032	*
		Irbesartan	115	76 (66.1)					
Asia Pacific	Double-blind period	Sparsentan	69	57 (82.6)	0.968 [0.819, 1.143]	0.814 [0.280, 2.366]	-2.8 [-18.7, 13.2]	0.794	
		Irbesartan	41	35 (85.4)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AA_SSIM: Incidence of non-disease related TEAEs during double-blind period by subgroup
Safety Set

Non-disease related TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.998
< 27 kg/m**2	Double-blind period	Sparsentan	84	67 (79.8)	1.119 [0.946, 1.323]	1.588 [0.793, 3.182]	8.5 [-5.2, 22.2]	0.225
		Irbesartan	94	67 (71.3)				
>= 27 kg/m**2	Double-blind period	Sparsentan	118	95 (80.5)	1.119 [0.965, 1.297]	1.609 [0.865, 2.994]	8.5 [-3.5, 20.6]	0.157
		Irbesartan	107	77 (72.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AA_SSIM: Incidence of non-disease related TEAEs during double-blind period by subgroup
Safety Set

Non-disease related TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.233	
eGFR Low and UP High	Double-blind period	Sparsentan	71	60 (84.5)	1.180 [0.991, 1.405]	2.161 [0.954, 4.896]	12.9 [-1.8, 27.5]	0.073	
		Irbesartan	74	53 (71.6)					
eGFR Low and UP Low	Double-blind period	Sparsentan	55	41 (74.5)	0.976 [0.789, 1.208]	0.906 [0.380, 2.161]	-1.8 [-19.7, 16.1]	1.000	
		Irbesartan	55	42 (76.4)					
eGFR High and UP High	Double-blind period	Sparsentan	37	31 (83.8)	1.371 [1.019, 1.844]	3.288 [1.093, 9.892]	22.7 [0.1, 45.3]	0.038	*
		Irbesartan	36	22 (61.1)					
eGFR High and UP Low	Double-blind period	Sparsentan	39	30 (76.9)	1.016 [0.791, 1.306]	1.071 [0.372, 3.086]	1.2 [-20.5, 23.0]	1.000	
		Irbesartan	37	28 (75.7)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AA_SSIM: Incidence of non-disease related TEAEs during double-blind period by subgroup
Safety Set

Non-disease related TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.828
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	103 (81.1)	1.090 [0.956, 1.243]	1.475 [0.814, 2.674]	6.7 [-4.2, 17.6]	0.230
		Irbesartan	129	96 (74.4)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	39 (79.6)	1.158 [0.913, 1.468]	1.773 [0.703, 4.469]	10.8 [-8.5, 30.2]	0.252
		Irbesartan	48	33 (68.8)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	20 (76.9)	1.202 [0.837, 1.726]	1.875 [0.551, 6.379]	12.9 [-15.8, 41.7]	0.368
		Irbesartan	25	16 (64.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AA_SSIM: Incidence of non-disease related TEAEs during double-blind period by subgroup
Safety Set

Non-disease related TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.866
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	65 (79.3)	1.057 [0.893, 1.250]	1.275 [0.611, 2.660]	4.3 [-9.9, 18.4]	0.577
		Irbesartan	80	60 (75.0)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	38 (84.4)	1.149 [0.932, 1.418]	1.960 [0.703, 5.467]	11.0 [-7.4, 29.4]	0.217
		Irbesartan	49	36 (73.5)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	39 (79.6)	1.158 [0.913, 1.468]	1.773 [0.703, 4.469]	10.8 [-8.5, 30.2]	0.252
		Irbesartan	48	33 (68.8)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	20 (76.9)	1.202 [0.837, 1.726]	1.875 [0.551, 6.379]	12.9 [-15.8, 41.7]	0.368
		Irbesartan	25	16 (64.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AA_SSIM: Incidence of non-disease related TEAEs during double-blind period by subgroup
Safety Set

Non-disease related TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.360	
<= 1.75 g/day	Double-blind period	Sparsentan	98	75 (76.5)	1.058 [0.896, 1.249]	1.247 [0.651, 2.388]	4.2 [-9.2, 17.6]	0.513	
		Irbesartan	94	68 (72.3)					
> 1.75 g/day	Double-blind period	Sparsentan	104	87 (83.7)	1.173 [1.013, 1.359]	2.060 [1.058, 4.011]	12.4 [0.3, 24.4]	0.034	*
		Irbesartan	108	77 (71.3)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AA_SSIM: Incidence of non-disease related TEAEs during double-blind period by subgroup
Safety Set

Non-disease related TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.100	
Yes	Double-blind period	Sparsentan	88	67 (76.1)	1.003 [0.848, 1.187]	1.013 [0.502, 2.044]	0.2 [-13.7, 14.2]	1.000	
		Irbesartan	83	63 (75.9)					
No	Double-blind period	Sparsentan	114	95 (83.3)	1.209 [1.045, 1.399]	2.256 [1.205, 4.224]	14.4 [2.8, 26.1]	0.014	*
		Irbesartan	119	82 (68.9)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AA_SSIM: Incidence of non-disease related TEAEs during double-blind period by subgroup
Safety Set

Non-disease related TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.395
<= 5 years	Double-blind period	Sparsentan	113	90 (79.6)	1.076 [0.936, 1.236]	1.374 [0.750, 2.518]	5.6 [-5.8, 17.1]	0.360
		Irbesartan	127	94 (74.0)				
> 5 years	Double-blind period	Sparsentan	89	72 (80.9)	1.190 [0.989, 1.432]	1.993 [0.973, 4.084]	12.9 [-1.7, 27.5]	0.071
		Irbesartan	75	51 (68.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AA_SSIM: Incidence of non-disease related TEAEs during double-blind period by subgroup
Safety Set

Non-disease related TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.822
Yes	Double-blind period	Sparsentan	153	121 (79.1)	1.109 [0.975, 1.260]	1.519 [0.902, 2.558]	7.7 [-2.5, 18.0]	0.117
		Irbesartan	157	112 (71.3)				
No	Double-blind period	Sparsentan	49	41 (83.7)	1.141 [0.920, 1.415]	1.864 [0.682, 5.092]	10.3 [-8.3, 29.0]	0.313
		Irbesartan	45	33 (73.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAN_SSIM: Incidence of non-disease related non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.705
Male	Double-blind period	Sparsentan	139	112 (80.6)	1.141 [0.998, 1.304]	1.725 [0.992, 3.000]	9.9 [-0.7, 20.6]	0.054
		Irbesartan	143	101 (70.6)				
Female	Double-blind period	Sparsentan	63	50 (79.4)	1.089 [0.891, 1.330]	1.431 [0.619, 3.307]	6.5 [-10.3, 23.2]	0.524
		Irbesartan	59	43 (72.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAN_SSIM: Incidence of non-disease related non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.972
<= 45 years	Double-blind period	Sparsentan	96	81 (84.4)	1.129 [0.978, 1.303]	1.824 [0.894, 3.724]	9.6 [-2.6, 21.9]	0.112
		Irbesartan	99	74 (74.7)				
> 45 years	Double-blind period	Sparsentan	106	81 (76.4)	1.124 [0.949, 1.332]	1.527 [0.830, 2.812]	8.5 [-4.6, 21.5]	0.216
		Irbesartan	103	70 (68.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAN_SSIM: Incidence of non-disease related non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.892
<= 18 years	Double-blind period	Sparsentan	9	7 (77.8)	1.296 [0.585, 2.874]	2.333 [0.216, 25.245]	17.8 [-48.6, 84.1]	0.580
		Irbesartan	5	3 (60.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	86 (84.3)	1.107 [0.968, 1.266]	1.684 [0.843, 3.363]	8.2 [-3.5, 19.8]	0.168
		Irbesartan	109	83 (76.1)				
> 40 years	Double-blind period	Sparsentan	91	69 (75.8)	1.150 [0.952, 1.391]	1.622 [0.846, 3.112]	9.9 [-4.4, 24.3]	0.188
		Irbesartan	88	58 (65.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAN_SSIM: Incidence of non-disease related non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.150	
North America	Double-blind period	Sparsentan	35	27 (77.1)	1.044 [0.814, 1.339]	1.191 [0.426, 3.328]	3.2 [-18.1, 24.6]	0.799	
		Irbesartan	46	34 (73.9)					
Europe	Double-blind period	Sparsentan	98	78 (79.6)	1.220 [1.033, 1.442]	2.080 [1.115, 3.880]	14.4 [1.6, 27.1]	0.022	*
		Irbesartan	115	75 (65.2)					
Asia Pacific	Double-blind period	Sparsentan	69	57 (82.6)	0.968 [0.819, 1.143]	0.814 [0.280, 2.366]	-2.8 [-18.7, 13.2]	0.794	
		Irbesartan	41	35 (85.4)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAN_SSIM: Incidence of non-disease related non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.911
< 27 kg/m**2	Double-blind period	Sparsentan	84	67 (79.8)	1.119 [0.946, 1.323]	1.588 [0.793, 3.182]	8.5 [-5.2, 22.2]	0.225
		Irbesartan	94	67 (71.3)				
>= 27 kg/m**2	Double-blind period	Sparsentan	118	95 (80.5)	1.133 [0.976, 1.317]	1.685 [0.908, 3.126]	9.5 [-2.6, 21.6]	0.118
		Irbesartan	107	76 (71.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAN_SSIM: Incidence of non-disease related non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.269	
eGFR Low and UP High	Double-blind period	Sparsentan	71	60 (84.5)	1.180 [0.991, 1.405]	2.161 [0.954, 4.896]	12.9 [-1.8, 27.5]	0.073	
		Irbesartan	74	53 (71.6)					
eGFR Low and UP Low	Double-blind period	Sparsentan	55	41 (74.5)	0.976 [0.789, 1.208]	0.906 [0.380, 2.161]	-1.8 [-19.7, 16.1]	1.000	
		Irbesartan	55	42 (76.4)					
eGFR High and UP High	Double-blind period	Sparsentan	37	31 (83.8)	1.371 [1.019, 1.844]	3.288 [1.093, 9.892]	22.7 [0.1, 45.3]	0.038	*
		Irbesartan	36	22 (61.1)					
eGFR High and UP Low	Double-blind period	Sparsentan	39	30 (76.9)	1.054 [0.812, 1.368]	1.235 [0.436, 3.492]	4.0 [-18.2, 26.1]	0.793	
		Irbesartan	37	27 (73.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAN_SSIM: Incidence of non-disease related non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.869
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	103 (81.1)	1.101 [0.964, 1.258]	1.536 [0.850, 2.777]	7.5 [-3.5, 18.4]	0.180
		Irbesartan	129	95 (73.6)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	39 (79.6)	1.158 [0.913, 1.468]	1.773 [0.703, 4.469]	10.8 [-8.5, 30.2]	0.252
		Irbesartan	48	33 (68.8)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	20 (76.9)	1.202 [0.837, 1.726]	1.875 [0.551, 6.379]	12.9 [-15.8, 41.7]	0.368
		Irbesartan	25	16 (64.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAN_SSIM: Incidence of non-disease related non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.822
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	65 (79.3)	1.057 [0.893, 1.250]	1.275 [0.611, 2.660]	4.3 [-9.9, 18.4]	0.577
		Irbesartan	80	60 (75.0)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	38 (84.4)	1.182 [0.952, 1.469]	2.171 [0.785, 6.003]	13.0 [-5.6, 31.6]	0.146
		Irbesartan	49	35 (71.4)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	39 (79.6)	1.158 [0.913, 1.468]	1.773 [0.703, 4.469]	10.8 [-8.5, 30.2]	0.252
		Irbesartan	48	33 (68.8)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	20 (76.9)	1.202 [0.837, 1.726]	1.875 [0.551, 6.379]	12.9 [-15.8, 41.7]	0.368
		Irbesartan	25	16 (64.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAN_SSIM: Incidence of non-disease related non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.437	
<= 1.75 g/day	Double-blind period	Sparsentan	98	75 (76.5)	1.074 [0.907, 1.271]	1.314 [0.688, 2.508]	5.3 [-8.2, 18.7]	0.417	
		Irbesartan	94	67 (71.3)					
> 1.75 g/day	Double-blind period	Sparsentan	104	87 (83.7)	1.173 [1.013, 1.359]	2.060 [1.058, 4.011]	12.4 [0.3, 24.4]	0.034	*
		Irbesartan	108	77 (71.3)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAN_SSIM: Incidence of non-disease related non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.136	
Yes	Double-blind period	Sparsentan	88	67 (76.1)	1.019 [0.859, 1.210]	1.081 [0.539, 2.169]	1.4 [-12.6, 15.5]	0.860	
		Irbesartan	83	62 (74.7)					
No	Double-blind period	Sparsentan	114	95 (83.3)	1.209 [1.045, 1.399]	2.256 [1.205, 4.224]	14.4 [2.8, 26.1]	0.014	*
		Irbesartan	119	82 (68.9)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAN_SSIM: Incidence of non-disease related non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.316	
<= 5 years	Double-blind period	Sparsentan	113	90 (79.6)	1.076 [0.936, 1.236]	1.374 [0.750, 2.518]	5.6 [-5.8, 17.1]	0.360	
		Irbesartan	127	94 (74.0)					
> 5 years	Double-blind period	Sparsentan	89	72 (80.9)	1.213 [1.004, 1.466]	2.118 [1.037, 4.325]	14.2 [-0.4, 28.9]	0.048	*
		Irbesartan	75	50 (66.7)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAN_SSIM: Incidence of non-disease related non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.877
Yes	Double-blind period	Sparsentan	153	121 (79.1)	1.119 [0.983, 1.273]	1.567 [0.932, 2.635]	8.4 [-1.9, 18.6]	0.116
		Irbesartan	157	111 (70.7)				
No	Double-blind period	Sparsentan	49	41 (83.7)	1.141 [0.920, 1.415]	1.864 [0.682, 5.092]	10.3 [-8.3, 29.0]	0.313
		Irbesartan	45	33 (73.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAC_SSIM: Incidence of non-disease related severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.566
Male	Double-blind period	Sparsentan	139	8 (5.8)	1.176 [0.438, 3.155]	1.186 [0.418, 3.365]	0.9 [-5.1, 6.8]	0.796
		Irbesartan	143	7 (4.9)				
Female	Double-blind period	Sparsentan	63	3 (4.8)	0.702 [0.164, 3.007]	0.688 [0.147, 3.210]	-2.0 [-12.0, 7.9]	0.711
		Irbesartan	59	4 (6.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAC_SSIM: Incidence of non-disease related severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.945
<= 45 years	Double-blind period	Sparsentan	96	7 (7.3)	1.031 [0.376, 2.829]	1.034 [0.348, 3.067]	0.2 [-8.1, 8.5]	1.000
		Irbesartan	99	7 (7.1)				
> 45 years	Double-blind period	Sparsentan	106	4 (3.8)	0.972 [0.250, 3.783]	0.971 [0.236, 3.988]	-0.1 [-6.3, 6.1]	1.000
		Irbesartan	103	4 (3.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAC_SSIM: Incidence of non-disease related severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.868
<= 18 years	Double-blind period	Sparsentan	9	1 (11.1)	1.800 + [0.086, 37.493]	1.941 + [0.066, 56.760]	11.1 [-25.0, 47.2]	1.000
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	5 (4.9)	1.069 [0.319, 3.583]	1.072 [0.301, 3.818]	0.3 [-6.4, 7.0]	1.000
		Irbesartan	109	5 (4.6)				
> 40 years	Double-blind period	Sparsentan	91	5 (5.5)	0.806 [0.255, 2.545]	0.795 [0.233, 2.704]	-1.3 [-9.5, 6.8]	0.764
		Irbesartan	88	6 (6.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAC_SSIM: Incidence of non-disease related severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.434
North America	Double-blind period	Sparsentan	35	5 (14.3)	2.190 [0.561, 8.553]	2.389 [0.530, 10.764]	7.8 [-8.4, 23.9]	0.282
		Irbesartan	46	3 (6.5)				
Europe	Double-blind period	Sparsentan	98	4 (4.1)	0.782 [0.227, 2.693]	0.773 [0.212, 2.822]	-1.1 [-7.7, 5.5]	0.756
		Irbesartan	115	6 (5.2)				
Asia Pacific	Double-blind period	Sparsentan	69	2 (2.9)	0.594 [0.087, 4.059]	0.582 [0.079, 4.298]	-2.0 [-11.6, 7.7]	0.628
		Irbesartan	41	2 (4.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAC_SSIM: Incidence of non-disease related severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.808
< 27 kg/m**2	Double-blind period	Sparsentan	84	4 (4.8)	1.119 [0.289, 4.335]	1.125 [0.272, 4.646]	0.5 [-6.7, 7.7]	1.000
		Irbesartan	94	4 (4.3)				
>= 27 kg/m**2	Double-blind period	Sparsentan	118	7 (5.9)	0.907 [0.329, 2.501]	0.901 [0.305, 2.658]	-0.6 [-7.8, 6.6]	1.000
		Irbesartan	107	7 (6.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAC_SSIM: Incidence of non-disease related severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	NE
eGFR Low and UP High	Double-blind period	Sparsentan	71	5 (7.0) all n<10				NE
		Irbesartan	74	4 (5.4)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	2 (3.6) all n<10				NE
		Irbesartan	55	3 (5.5)				
eGFR High and UP High	Double-blind period	Sparsentan	37	2 (5.4) all n<10				NE
		Irbesartan	36	2 (5.6)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	2 (5.1) all n<10				NE
		Irbesartan	37	2 (5.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAC_SSIM: Incidence of non-disease related severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.528
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	7 (5.5)	0.790 [0.303, 2.057]	0.778 [0.281, 2.156]	-1.5 [-8.2, 5.2]	0.797
		Irbesartan	129	9 (7.0)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	2 (4.1)	0.980 [0.144, 6.676]	0.979 [0.132, 7.244]	-0.1 [-10.1, 9.9]	1.000
		Irbesartan	48	2 (4.2)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	2 (7.7)	4.815 + [0.243, 95.576]	5.204 + [0.238, 113.979]	7.7 [-6.5, 21.9]	0.490
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAC_SSIM: Incidence of non-disease related severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	NE
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	3 (3.7) all n<10				NE
		Irbesartan	80	4 (5.0)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	4 (8.9) all n<10				NE
		Irbesartan	49	5 (10.2)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	2 (4.1) all n<10				NE
		Irbesartan	48	2 (4.2)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	2 (7.7) all n<10				NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAC_SSIM: Incidence of non-disease related severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.417
<= 1.75 g/day	Double-blind period	Sparsentan	98	5 (5.1)	1.599 [0.393, 6.503]	1.631 [0.379, 7.024]	1.9 [-4.8, 8.6]	0.721
		Irbesartan	94	3 (3.2)				
> 1.75 g/day	Double-blind period	Sparsentan	104	6 (5.8)	0.779 [0.280, 2.168]	0.765 [0.256, 2.287]	-1.6 [-9.3, 6.0]	0.784
		Irbesartan	108	8 (7.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAC_SSIM: Incidence of non-disease related severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.310
Yes	Double-blind period	Sparsentan	88	3 (3.4)	0.566 [0.140, 2.294]	0.551 [0.127, 2.380]	-2.6 [-10.2, 4.9]	0.487
		Irbesartan	83	5 (6.0)				
No	Double-blind period	Sparsentan	114	8 (7.0)	1.392 [0.498, 3.886]	1.421 [0.477, 4.233]	2.0 [-5.0, 9.0]	0.589
		Irbesartan	119	6 (5.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAC_SSIM: Incidence of non-disease related severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.227
<= 5 years	Double-blind period	Sparsentan	113	7 (6.2)	0.787 [0.310, 1.998]	0.773 [0.284, 2.102]	-1.7 [-9.0, 5.6]	0.802
		Irbesartan	127	10 (7.9)				
> 5 years	Double-blind period	Sparsentan	89	4 (4.5)	3.371 [0.385, 29.512]	3.482 [0.381, 31.851]	3.2 [-3.1, 9.4]	0.377
		Irbesartan	75	1 (1.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAC_SSIM: Incidence of non-disease related severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.229
Yes	Double-blind period	Sparsentan	153	11 (7.2)	1.254 [0.535, 2.941]	1.274 [0.512, 3.166]	1.5 [-4.7, 7.6]	0.649
		Irbesartan	157	9 (5.7)				
No	Double-blind period	Sparsentan	49	0 (0.0)	0.184 + [0.009, 3.732]	0.176 + [0.008, 3.762]	-4.4 [-12.6, 3.7]	0.226
		Irbesartan	45	2 (4.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAS_SSIM: Incidence of non-disease related serious TEAEs during double-blind period by subgroup
Safety Set

Non-disease related serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.878
Male	Double-blind period	Sparsentan	139	16 (11.5)	0.914 [0.486, 1.720]	0.903 [0.441, 1.852]	-1.1 [-9.4, 7.2]	0.856
		Irbesartan	143	18 (12.6)				
Female	Double-blind period	Sparsentan	63	9 (14.3)	0.843 [0.368, 1.928]	0.817 [0.306, 2.176]	-2.7 [-17.2, 11.9]	0.804
		Irbesartan	59	10 (16.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAS_SSIM: Incidence of non-disease related serious TEAEs during double-blind period by subgroup
Safety Set

Non-disease related serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.550
<= 45 years	Double-blind period	Sparsentan	96	12 (12.5)	0.773 [0.386, 1.548]	0.741 [0.330, 1.662]	-3.7 [-14.5, 7.2]	0.542
		Irbesartan	99	16 (16.2)				
> 45 years	Double-blind period	Sparsentan	106	13 (12.3)	1.053 [0.504, 2.198]	1.060 [0.459, 2.446]	0.6 [-9.1, 10.4]	1.000
		Irbesartan	103	12 (11.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAS_SSIM: Incidence of non-disease related serious TEAEs during double-blind period by subgroup
Safety Set

Non-disease related serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.680
<= 18 years	Double-blind period	Sparsentan	9	1 (11.1)	1.800 + [0.086, 37.493]	1.941 + [0.066, 56.760]	11.1 [-25.0, 47.2]	1.000
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	12 (11.8)	1.069 [0.503, 2.270]	1.078 [0.461, 2.522]	0.8 [-8.8, 10.3]	1.000
		Irbesartan	109	12 (11.0)				
> 40 years	Double-blind period	Sparsentan	91	12 (13.2)	0.725 [0.364, 1.444]	0.684 [0.303, 1.542]	-5.0 [-16.8, 6.8]	0.413
		Irbesartan	88	16 (18.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAS_SSIM: Incidence of non-disease related serious TEAEs during double-blind period by subgroup
Safety Set

Non-disease related serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.572
North America	Double-blind period	Sparsentan	35	6 (17.1)	1.127 [0.415, 3.056]	1.153 [0.350, 3.795]	1.9 [-16.8, 20.7]	1.000
		Irbesartan	46	7 (15.2)				
Europe	Double-blind period	Sparsentan	98	8 (8.2)	0.626 [0.277, 1.413]	0.593 [0.240, 1.464]	-4.9 [-14.0, 4.3]	0.277
		Irbesartan	115	15 (13.0)				
Asia Pacific	Double-blind period	Sparsentan	69	11 (15.9)	1.089 [0.436, 2.724]	1.106 [0.376, 3.256]	1.3 [-14.5, 17.1]	1.000
		Irbesartan	41	6 (14.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAS_SSIM: Incidence of non-disease related serious TEAEs during double-blind period by subgroup
Safety Set

Non-disease related serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.736
< 27 kg/m**2	Double-blind period	Sparsentan	84	11 (13.1)	0.821 [0.399, 1.686]	0.794 [0.342, 1.839]	-2.9 [-14.3, 8.6]	0.673
		Irbesartan	94	15 (16.0)				
>= 27 kg/m**2	Double-blind period	Sparsentan	118	14 (11.9)	0.977 [0.481, 1.983]	0.973 [0.435, 2.177]	-0.3 [-9.7, 9.1]	1.000
		Irbesartan	107	13 (12.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAS_SSIM: Incidence of non-disease related serious TEAEs during double-blind period by subgroup
Safety Set

Non-disease related serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.363
eGFR Low and UP High	Double-blind period	Sparsentan	71	10 (14.1)	0.802 [0.376, 1.710]	0.769 [0.314, 1.887]	-3.5 [-16.7, 9.8]	0.652
		Irbesartan	74	13 (17.6)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	8 (14.5)	1.333 [0.495, 3.589]	1.390 [0.448, 4.310]	3.6 [-10.6, 17.9]	0.776
		Irbesartan	55	6 (10.9)				
eGFR High and UP High	Double-blind period	Sparsentan	37	5 (13.5)	1.622 [0.418, 6.292]	1.719 [0.379, 7.794]	5.2 [-11.8, 22.2]	0.711
		Irbesartan	36	3 (8.3)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	2 (5.1)	0.316 [0.068, 1.469]	0.279 [0.053, 1.483]	-11.1 [-27.5, 5.3]	0.148
		Irbesartan	37	6 (16.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAS_SSIM: Incidence of non-disease related serious TEAEs during double-blind period by subgroup
Safety Set

Non-disease related serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.662
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	18 (14.2)	0.795 [0.451, 1.400]	0.761 [0.389, 1.491]	-3.7 [-13.4, 6.1]	0.496
		Irbesartan	129	23 (17.8)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	6 (12.2)	1.469 [0.442, 4.883]	1.535 [0.405, 5.822]	3.9 [-10.2, 18.0]	0.740
		Irbesartan	48	4 (8.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8)	0.962 [0.064, 14.551]	0.960 [0.057, 16.232]	-0.2 [-14.7, 14.4]	1.000
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAS_SSIM: Incidence of non-disease related serious TEAEs during double-blind period by subgroup
Safety Set

Non-disease related serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.684
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	12 (14.6)	0.976 [0.466, 2.042]	0.971 [0.408, 2.312]	-0.4 [-12.5, 11.8]	1.000
		Irbesartan	80	12 (15.0)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	6 (13.3)	0.594 [0.239, 1.474]	0.531 [0.179, 1.581]	-9.1 [-26.6, 8.3]	0.293
		Irbesartan	49	11 (22.4)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	6 (12.2)	1.469 [0.442, 4.883]	1.535 [0.405, 5.822]	3.9 [-10.2, 18.0]	0.740
		Irbesartan	48	4 (8.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8)	0.962 [0.064, 14.551]	0.960 [0.057, 16.232]	-0.2 [-14.7, 14.4]	1.000
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAS_SSIM: Incidence of non-disease related serious TEAEs during double-blind period by subgroup
Safety Set

Non-disease related serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.263
<= 1.75 g/day	Double-blind period	Sparsentan	98	13 (13.3)	1.247 [0.575, 2.705]	1.285 [0.534, 3.091]	2.6 [-7.6, 12.8]	0.659
		Irbesartan	94	10 (10.6)				
> 1.75 g/day	Double-blind period	Sparsentan	104	12 (11.5)	0.692 [0.351, 1.365]	0.652 [0.297, 1.431]	-5.1 [-15.4, 5.1]	0.328
		Irbesartan	108	18 (16.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAS_SSIM: Incidence of non-disease related serious TEAEs during double-blind period by subgroup
Safety Set

Non-disease related serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.461
Yes	Double-blind period	Sparsentan	88	9 (10.2)	0.707 [0.315, 1.591]	0.674 [0.268, 1.694]	-4.2 [-15.3, 6.8]	0.487
		Irbesartan	83	12 (14.5)				
No	Double-blind period	Sparsentan	114	16 (14.0)	1.044 [0.548, 1.987]	1.051 [0.498, 2.216]	0.6 [-9.1, 10.3]	1.000
		Irbesartan	119	16 (13.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAS_SSIM: Incidence of non-disease related serious TEAEs during double-blind period by subgroup
Safety Set

Non-disease related serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.014 #
<= 5 years	Double-blind period	Sparsentan	113	11 (9.7)	0.538 [0.274, 1.053]	0.488 [0.226, 1.052]	-8.4 [-17.9, 1.1]	0.067
		Irbesartan	127	23 (18.1)				
> 5 years	Double-blind period	Sparsentan	89	14 (15.7)	2.360 [0.891, 6.248]	2.613 [0.895, 7.633]	9.1 [-1.6, 19.7]	0.088
		Irbesartan	75	5 (6.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AAS_SSIM: Incidence of non-disease related serious TEAEs during double-blind period by subgroup
Safety Set

Non-disease related serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.681
Yes	Double-blind period	Sparsentan	153	19 (12.4)	0.848 [0.482, 1.492]	0.826 [0.430, 1.587]	-2.2 [-10.5, 6.0]	0.620
		Irbesartan	157	23 (14.6)				
No	Double-blind period	Sparsentan	49	6 (12.2)	1.102 [0.361, 3.363]	1.116 [0.316, 3.945]	1.1 [-14.0, 16.2]	1.000
		Irbesartan	45	5 (11.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
PT: Fatigue	Sex	Double-blind period	Sparsentan					Interaction test:	0.732
	Male	Double-blind period	Sparsentan	139	12 (8.6)	2.469 [0.893, 6.825]	2.608 [0.894, 7.609]	5.1 [-1.1, 11.4]	0.083
			Irbesartan	143	5 (3.5)				
	Female	Double-blind period	Sparsentan	63	4 (6.3)	3.746 [0.431, 32.559]	3.932 [0.427, 36.244]	4.7 [-3.9, 13.2]	0.366
			Irbesartan	59	1 (1.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
PT: Fatigue	Age	Double-blind period	Sparsentan					Interaction test:	0.697
	<= 45 years	Double-blind period	Sparsentan	96	9 (9.4)	2.320 [0.739, 7.283]	2.457 [0.730, 8.265]	5.3 [-2.7, 13.4]	0.160
			Irbesartan	99	4 (4.0)				
	> 45 years	Double-blind period	Sparsentan	106	7 (6.6)	3.401 [0.723, 15.990]	3.571 [0.724, 17.610]	4.7 [-1.7, 11.0]	0.171
			Irbesartan	103	2 (1.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
PT: Fatigue	Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.733
	<= 18 years	Double-blind period	Sparsentan	9	2 (22.2)	1.111 [0.131, 9.416]	1.143 [0.077, 16.947]	2.2 [-57.7, 62.1]	1.000
			Irbesartan	5	1 (20.0)				
	> 18 to 40 years	Double-blind period	Sparsentan	102	8 (7.8)	2.850 [0.777, 10.447]	3.007 [0.775, 11.665]	5.1 [-1.9, 12.1]	0.125
			Irbesartan	109	3 (2.8)				
	> 40 years	Double-blind period	Sparsentan	91	6 (6.6)	2.901 [0.602, 13.990]	3.035 [0.596, 15.463]	4.3 [-2.8, 11.4]	0.278
			Irbesartan	88	2 (2.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
PT: Fatigue	Geographic region	Double-blind period	Sparsentan					Interaction test:	0.985
	North America	Double-blind period	Sparsentan	35	2 (5.7)	2.629 [0.248, 27.835]	2.727 [0.237, 31.357]	3.5 [-7.7, 14.8]	0.575
			Irbesartan	46	1 (2.2)				
	Europe	Double-blind period	Sparsentan	98	10 (10.2)	2.934 [0.950, 9.062]	3.153 [0.957, 10.395]	6.7 [-1.1, 14.5]	0.056
			Irbesartan	115	4 (3.5)				
	Asia Pacific	Double-blind period	Sparsentan	69	4 (5.8)	2.377 [0.275, 20.547]	2.462 [0.266, 22.810]	3.4 [-5.8, 12.6]	0.649
			Irbesartan	41	1 (2.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Fatigue	Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.110	
	< 27 kg/m**2	Double-blind period	Sparsentan	84	6 (7.1)	1.343 [0.425, 4.240]	1.369 [0.402, 4.662]	1.8 [-6.4, 10.1]	0.758	
			Irbesartan	94	5 (5.3)					
	>= 27 kg/m**2	Double-blind period	Sparsentan	118	10 (8.5)	9.068 [1.180, 69.661]	9.815 [1.235, 78.016]	7.5 [1.3, 13.8]	0.011	*
			Irbesartan	107	1 (0.9)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
PT: Fatigue	Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.454
	eGFR Low and UP High	Double-blind period	Sparsentan	71	8 (11.3)	2.779 [0.768, 10.060]	3.005 [0.764, 11.822]	7.2 [-2.8, 17.2]	0.124
			Irbesartan	74	3 (4.1)				
	eGFR Low and UP Low	Double-blind period	Sparsentan	55	6 (10.9)	6.000 [0.747, 48.207]	6.612 [0.769, 56.881]	9.1 [-1.7, 19.9]	0.113
			Irbesartan	55	1 (1.8)				
	eGFR High and UP High	Double-blind period	Sparsentan	37	1 (2.7)	2.921 + [0.123, 69.434]	3.000 + [0.118, 76.091]	2.7 [-5.3, 10.7]	1.000
			Irbesartan	36	0 (0.0)				
	eGFR High and UP Low	Double-blind period	Sparsentan	39	1 (2.6)	0.474 [0.045, 5.014]	0.461 [0.040, 5.305]	-2.8 [-14.3, 8.6]	0.610
			Irbesartan	37	2 (5.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Fatigue	Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.516	
	< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	14 (11.0)	3.555 [1.203, 10.509]	3.872 [1.238, 12.105]	7.9 [0.9, 14.9]	0.015	*
			Irbesartan	129	4 (3.1)					
	60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	1 (2.0)	0.980 [0.063, 15.218]	0.979 [0.059, 16.116]	-0.0 [-7.8, 7.7]	1.000	
			Irbesartan	48	1 (2.1)					
	>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8)	0.962 [0.064, 14.551]	0.960 [0.057, 16.232]	-0.2 [-14.7, 14.4]	1.000	
			Irbesartan	25	1 (4.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
PT: Fatigue	Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.681
	< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	9 (11.0)	2.927 [0.822, 10.420]	3.164 [0.824, 12.149]	7.2 [-2.0, 16.4]	0.131
			Irbesartan	80	3 (3.8)				
	45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	5 (11.1)	5.444 [0.661, 44.842]	6.000 [0.673, 53.486]	9.1 [-3.1, 21.2]	0.101
			Irbesartan	49	1 (2.0)				
	60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	1 (2.0)	0.980 [0.063, 15.218]	0.979 [0.059, 16.116]	-0.0 [-7.8, 7.7]	1.000
			Irbesartan	48	1 (2.1)				
	>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8)	0.962 [0.064, 14.551]	0.960 [0.057, 16.232]	-0.2 [-14.7, 14.4]	1.000
			Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Fatigue	Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.134	
	<= 1.75 g/day	Double-blind period	Sparsentan	98	9 (9.2)	8.633 [1.115, 66.824]	9.404 [1.167, 75.756]	8.1 [1.0, 15.2]	0.019	*
			Irbesartan	94	1 (1.1)					
	> 1.75 g/day	Double-blind period	Sparsentan	104	7 (6.7)	1.454 [0.476, 4.436]	1.487 [0.456, 4.841]	2.1 [-5.1, 9.3]	0.564	
			Irbesartan	108	5 (4.6)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Fatigue	Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.204	
	Yes	Double-blind period	Sparsentan	88	8 (9.1)	7.545 [0.964, 59.031]	8.200 [1.003, 67.066]	7.9 [0.3, 15.5]	0.035	*
			Irbesartan	83	1 (1.2)					
	No	Double-blind period	Sparsentan	114	8 (7.0)	1.670 [0.563, 4.955]	1.721 [0.546, 5.425]	2.8 [-4.0, 9.6]	0.402	
			Irbesartan	119	5 (4.2)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
PT: Fatigue	Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.368
	<= 5 years	Double-blind period	Sparsentan	113	9 (8.0)	2.023 [0.698, 5.859]	2.112 [0.686, 6.498]	4.0 [-2.8, 10.9]	0.270
			Irbesartan	127	5 (3.9)				
	> 5 years	Double-blind period	Sparsentan	89	7 (7.9)	5.899 [0.742, 46.871]	6.317 [0.759, 52.561]	6.5 [-0.9, 13.9]	0.072
			Irbesartan	75	1 (1.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Fatigue	History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.021	#
	Yes	Double-blind period	Sparsentan	153	16 (10.5)	5.473 [1.627, 18.405]	5.995 [1.710, 21.018]	8.5 [2.6, 14.5]	0.002	*
			Irbesartan	157	3 (1.9)					
	No	Double-blind period	Sparsentan	49	0 (0.0)	0.131 + [0.007, 2.476]	0.123 + [0.006, 2.442]	-6.7 [-16.1, 2.8]	0.106	
			Irbesartan	45	3 (6.7)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Dizziness	Sex	Double-blind period	Sparsentan					Interaction test:	0.568	
	Male	Double-blind period	Sparsentan	139	14 (10.1)	2.400 [0.950, 6.068]	2.557 [0.953, 6.859]	5.9 [-0.8, 12.6]	0.065	
			Irbesartan	143	6 (4.2)					
	Female	Double-blind period	Sparsentan	63	12 (19.0)	3.746 [1.112, 12.616]	4.392 [1.172, 16.455]	14.0 [1.1, 26.8]	0.026	*
			Irbesartan	59	3 (5.1)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Dizziness	Age	Double-blind period	Sparsentan					Interaction test:	0.541	
	<= 45 years	Double-blind period	Sparsentan	96	14 (14.6)	2.406 [0.964, 6.003]	2.646 [0.972, 7.204]	8.5 [-1.0, 18.0]	0.060	
			Irbesartan	99	6 (6.1)					
	> 45 years	Double-blind period	Sparsentan	106	12 (11.3)	3.887 [1.130, 13.374]	4.255 [1.164, 15.553]	8.4 [0.6, 16.2]	0.029	*
			Irbesartan	103	3 (2.9)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Dizziness	Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.806	
	<= 18 years	Double-blind period	Sparsentan	9	1 (11.1)	1.800 + [0.086, 37.493]	1.941 + [0.066, 56.760]	11.1 [-25.0, 47.2]	1.000	
			Irbesartan	5	0 (0.0)					
	> 18 to 40 years	Double-blind period	Sparsentan	102	16 (15.7)	3.420 [1.300, 8.996]	3.870 [1.362, 10.993]	11.1 [2.1, 20.1]	0.010	*
			Irbesartan	109	5 (4.6)					
	> 40 years	Double-blind period	Sparsentan	91	9 (9.9)	2.176 [0.695, 6.808]	2.305 [0.683, 7.779]	5.3 [-3.3, 14.0]	0.250	
			Irbesartan	88	4 (4.5)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
PT: Dizziness	Geographic region	Double-blind period	Sparsentan					Interaction test:	0.305
	North America	Double-blind period	Sparsentan	35	3 (8.6)	3.943 [0.428, 36.305]	4.219 [0.420, 42.421]	6.4 [-6.3, 19.1]	0.311
			Irbesartan	46	1 (2.2)				
	Europe	Double-blind period	Sparsentan	98	6 (6.1)	7.041 [0.862, 57.484]	7.435 [0.879, 62.861]	5.3 [-0.7, 11.2]	0.050
			Irbesartan	115	1 (0.9)				
	Asia Pacific	Double-blind period	Sparsentan	69	17 (24.6)	1.443 [0.654, 3.182]	1.588 [0.596, 4.234]	7.6 [-9.7, 24.9]	0.475
			Irbesartan	41	7 (17.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Dizziness	Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.851	
	< 27 kg/m**2	Double-blind period	Sparsentan	84	14 (16.7)	3.133 [1.179, 8.330]	3.560 [1.223, 10.358]	11.3 [1.0, 21.6]	0.016	*
			Irbesartan	94	5 (5.3)					
	>= 27 kg/m**2	Double-blind period	Sparsentan	118	12 (10.2)	2.720 [0.905, 8.180]	2.915 [0.911, 9.333]	6.4 [-1.0, 13.9]	0.072	
			Irbesartan	107	4 (3.7)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Dizziness	Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.585	
	eGFR Low and UP High	Double-blind period	Sparsentan	71	8 (11.3)	1.668 [0.573, 4.856]	1.752 [0.545, 5.637]	4.5 [-6.2, 15.2]	0.394	
			Irbesartan	74	5 (6.8)					
	eGFR Low and UP Low	Double-blind period	Sparsentan	55	8 (14.5)	2.667 [0.747, 9.526]	2.950 [0.739, 11.778]	9.1 [-3.8, 22.0]	0.202	
			Irbesartan	55	3 (5.5)					
	eGFR High and UP High	Double-blind period	Sparsentan	37	4 (10.8)	3.892 [0.457, 33.169]	4.242 [0.451, 39.943]	8.0 [-6.1, 22.1]	0.358	
			Irbesartan	36	1 (2.8)					
	eGFR High and UP Low	Double-blind period	Sparsentan	39	6 (15.4)	12.350 + [0.720, 211.796]	14.552 + [0.790, 268.186]	15.4 [1.4, 29.3]	0.026	*
			Irbesartan	37	0 (0.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
PT: Dizziness	Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.541
	< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	17 (13.4)	2.158 [0.966, 4.822]	2.338 [0.970, 5.630]	7.2 [-0.8, 15.2]	0.060
			Irbesartan	129	8 (6.2)				
	60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	5 (10.2)	4.898 [0.594, 40.392]	5.341 [0.600, 47.534]	8.1 [-3.3, 19.6]	0.204
			Irbesartan	48	1 (2.1)				
	>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	4 (15.4)	8.667 + [0.491, 153.111]	10.200 + [0.520, 200.060]	15.4 [-2.4, 33.2]	0.110
			Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
PT: Dizziness	Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.737
	< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	8 (9.8)	1.951 [0.612, 6.224]	2.054 [0.593, 7.113]	4.8 [-4.5, 14.0]	0.370
			Irbesartan	80	4 (5.0)				
	45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	9 (20.0)	2.450 [0.811, 7.405]	2.813 [0.800, 9.882]	11.8 [-4.3, 27.9]	0.136
			Irbesartan	49	4 (8.2)				
	60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	5 (10.2)	4.898 [0.594, 40.392]	5.341 [0.600, 47.534]	8.1 [-3.3, 19.6]	0.204
			Irbesartan	48	1 (2.1)				
	>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	4 (15.4)	8.667 + [0.491, 153.111]	10.200 + [0.520, 200.060]	15.4 [-2.4, 33.2]	0.110
			Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Dizziness	Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.089	
	<= 1.75 g/day	Double-blind period	Sparsentan	98	15 (15.3)	7.194 [1.691, 30.608]	8.313 [1.846, 37.442]	13.2 [4.4, 21.9]	0.002	*
			Irbesartan	94	2 (2.1)					
	> 1.75 g/day	Double-blind period	Sparsentan	104	11 (10.6)	1.632 [0.658, 4.048]	1.707 [0.635, 4.586]	4.1 [-4.4, 12.6]	0.331	
			Irbesartan	108	7 (6.5)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Dizziness	Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.784	
	Yes	Double-blind period	Sparsentan	88	8 (9.1)	2.515 [0.691, 9.161]	2.667 [0.683, 10.417]	5.5 [-2.9, 13.9]	0.213	
			Irbesartan	83	3 (3.6)					
	No	Double-blind period	Sparsentan	114	18 (15.8)	3.132 [1.289, 7.607]	3.531 [1.348, 9.252]	10.7 [2.1, 19.4]	0.009	*
			Irbesartan	119	6 (5.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Dizziness	Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.571	
	<= 5 years	Double-blind period	Sparsentan	113	16 (14.2)	2.569 [1.097, 6.018]	2.828 [1.118, 7.150]	8.6 [0.3, 17.0]	0.028	*
			Irbesartan	127	7 (5.5)					
	> 5 years	Double-blind period	Sparsentan	89	10 (11.2)	4.213 [0.953, 18.635]	4.620 [0.979, 21.794]	8.6 [-0.2, 17.3]	0.040	*
			Irbesartan	75	2 (2.7)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Dizziness	History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.561	
	Yes	Double-blind period	Sparsentan	153	17 (11.1)	2.492 [1.063, 5.840]	2.679 [1.078, 6.656]	6.7 [0.1, 13.2]	0.034	*
			Irbesartan	157	7 (4.5)					
	No	Double-blind period	Sparsentan	49	9 (18.4)	4.133 [0.943, 18.114]	4.838 [0.985, 23.758]	13.9 [-0.6, 28.5]	0.053	
			Irbesartan	45	2 (4.4)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
SOC: Vascular disorders	Sex	Double-blind period	Sparsentan					Interaction test:	0.434	
	Male	Double-blind period	Sparsentan	139	27 (19.4)	1.462 [0.853, 2.505]	1.573 [0.830, 2.984]	6.1 [-3.2, 15.5]	0.198	
			Irbesartan	143	19 (13.3)					
	Female	Double-blind period	Sparsentan	63	20 (31.7)	2.081 [1.031, 4.199]	2.584 [1.065, 6.267]	16.5 [0.1, 32.8]	0.036	*
			Irbesartan	59	9 (15.3)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
SOC: Vascular disorders	Age	Double-blind period	Sparsentan					Interaction test:	0.525
	<= 45 years	Double-blind period	Sparsentan	96	21 (21.9)	1.969 [1.004, 3.860]	2.240 [1.015, 4.945]	10.8 [-0.6, 22.1]	0.053
			Irbesartan	99	11 (11.1)				
	> 45 years	Double-blind period	Sparsentan	106	26 (24.5)	1.486 [0.859, 2.570]	1.644 [0.830, 3.255]	8.0 [-3.8, 19.9]	0.173
			Irbesartan	103	17 (16.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
SOC: Vascular disorders	Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.663	
	<= 18 years	Double-blind period	Sparsentan	9	3 (33.3)	4.200 + [0.259, 68.038]	5.923 + [0.248, 141.482]	33.3 [-13.0, 79.7]	0.258	
			Irbesartan	5	0 (0.0)					
	> 18 to 40 years	Double-blind period	Sparsentan	102	18 (17.6)	1.374 [0.721, 2.616]	1.454 [0.682, 3.102]	4.8 [-5.9, 15.5]	0.345	
			Irbesartan	109	14 (12.8)					
	> 40 years	Double-blind period	Sparsentan	91	26 (28.6)	1.796 [1.006, 3.207]	2.114 [1.019, 4.388]	12.7 [-0.5, 25.8]	0.049	*
			Irbesartan	88	14 (15.9)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
SOC: Vascular disorders	Geographic region	Double-blind period	Sparsentan					Interaction test:	0.929
	North America	Double-blind period	Sparsentan	35	4 (11.4)	1.314 [0.353, 4.892]	1.355 [0.314, 5.843]	2.7 [-13.1, 18.6]	0.721
			Irbesartan	46	4 (8.7)				
	Europe	Double-blind period	Sparsentan	98	25 (25.5)	1.630 [0.947, 2.804]	1.846 [0.937, 3.634]	9.9 [-2.0, 21.7]	0.088
			Irbesartan	115	18 (15.7)				
	Asia Pacific	Double-blind period	Sparsentan	69	18 (26.1)	1.783 [0.770, 4.126]	2.059 [0.743, 5.705]	11.5 [-5.5, 28.4]	0.232
			Irbesartan	41	6 (14.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
SOC: Vascular disorders	Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.418	
	< 27 kg/m**2	Double-blind period	Sparsentan	84	17 (20.2)	1.359 [0.714, 2.585]	1.450 [0.666, 3.157]	5.3 [-7.0, 17.7]	0.429	
			Irbesartan	94	14 (14.9)					
	>= 27 kg/m**2	Double-blind period	Sparsentan	118	30 (25.4)	1.943 [1.090, 3.463]	2.265 [1.127, 4.552]	12.3 [1.3, 23.4]	0.028	*
			Irbesartan	107	14 (13.1)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
SOC: Vascular disorders	Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.802
	eGFR Low and UP High	Double-blind period	Sparsentan	71	16 (22.5)	1.516 [0.756, 3.038]	1.666 [0.713, 3.893]	7.7 [-6.4, 21.7]	0.288
			Irbesartan	74	11 (14.9)				
	eGFR Low and UP Low	Double-blind period	Sparsentan	55	16 (29.1)	2.000 [0.934, 4.285]	2.410 [0.933, 6.226]	14.5 [-2.5, 31.6]	0.105
			Irbesartan	55	8 (14.5)				
	eGFR High and UP High	Double-blind period	Sparsentan	37	9 (24.3)	2.189 [0.740, 6.477]	2.571 [0.713, 9.270]	13.2 [-6.7, 33.2]	0.221
			Irbesartan	36	4 (11.1)				
	eGFR High and UP Low	Double-blind period	Sparsentan	39	6 (15.4)	1.138 [0.380, 3.414]	1.164 [0.323, 4.196]	1.9 [-16.6, 20.3]	1.000
			Irbesartan	37	5 (13.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
SOC: Vascular disorders	Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.892	
	< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	33 (26.0)	1.764 [1.061, 2.933]	2.032 [1.085, 3.809]	11.3 [0.7, 21.8]	0.030	*
			Irbesartan	129	19 (14.7)					
	60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	10 (20.4)	1.399 [0.580, 3.374]	1.502 [0.520, 4.338]	5.8 [-11.3, 23.0]	0.595	
			Irbesartan	48	7 (14.6)					
	>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	4 (15.4)	1.923 [0.386, 9.584]	2.091 [0.347, 12.589]	7.4 [-14.0, 28.8]	0.668	
			Irbesartan	25	2 (8.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
SOC: Vascular disorders	Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.906
	< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	21 (25.6)	1.576 [0.848, 2.928]	1.774 [0.818, 3.847]	9.4 [-4.3, 23.0]	0.178
			Irbesartan	80	13 (16.3)				
	45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	12 (26.7)	2.178 [0.892, 5.317]	2.606 [0.885, 7.673]	14.4 [-3.6, 32.4]	0.114
			Irbesartan	49	6 (12.2)				
	60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	10 (20.4)	1.399 [0.580, 3.374]	1.502 [0.520, 4.338]	5.8 [-11.3, 23.0]	0.595
			Irbesartan	48	7 (14.6)				
	>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	4 (15.4)	1.923 [0.386, 9.584]	2.091 [0.347, 12.589]	7.4 [-14.0, 28.8]	0.668
			Irbesartan	25	2 (8.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
SOC: Vascular disorders	Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.040	#
	<= 1.75 g/day	Double-blind period	Sparsentan	98	25 (25.5)	2.997 [1.424, 6.309]	3.682 [1.566, 8.657]	17.0 [5.6, 28.4]	0.002	*
			Irbesartan	94	8 (8.5)					
	> 1.75 g/day	Double-blind period	Sparsentan	104	22 (21.2)	1.142 [0.664, 1.965]	1.180 [0.600, 2.321]	2.6 [-9.0, 14.3]	0.731	
			Irbesartan	108	20 (18.5)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
SOC: Vascular disorders	Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.543	
	Yes	Double-blind period	Sparsentan	88	21 (23.9)	1.981 [0.993, 3.952]	2.288 [1.005, 5.210]	11.8 [-0.7, 24.3]	0.049	*
			Irbesartan	83	10 (12.0)					
	No	Double-blind period	Sparsentan	114	26 (22.8)	1.508 [0.876, 2.596]	1.658 [0.852, 3.225]	7.7 [-3.2, 18.6]	0.180	
			Irbesartan	119	18 (15.1)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
SOC: Vascular disorders	Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.307	
	<= 5 years	Double-blind period	Sparsentan	113	27 (23.9)	2.023 [1.135, 3.606]	2.344 [1.175, 4.678]	12.1 [1.6, 22.6]	0.017	*
			Irbesartan	127	15 (11.8)					
	> 5 years	Double-blind period	Sparsentan	89	20 (22.5)	1.296 [0.693, 2.427]	1.382 [0.635, 3.009]	5.1 [-8.3, 18.6]	0.441	
			Irbesartan	75	13 (17.3)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
SOC: Vascular disorders	History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.102	
	Yes	Double-blind period	Sparsentan	153	41 (26.8)	2.003 [1.244, 3.226]	2.371 [1.324, 4.244]	13.4 [4.0, 22.9]	0.004	*
			Irbesartan	157	21 (13.4)					
	No	Double-blind period	Sparsentan	49	6 (12.2)	0.787 [0.286, 2.167]	0.757 [0.234, 2.452]	-3.3 [-19.5, 12.8]	0.768	
			Irbesartan	45	7 (15.6)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Hypotension	Sex	Double-blind period	Sparsentan					Interaction test:	0.538	
	Male	Double-blind period	Sparsentan	139	9 (6.5)	4.629 [1.018, 21.046]	4.881 [1.035, 23.009]	5.1 [-0.2, 10.3]	0.033	*
			Irbesartan	143	2 (1.4)					
	Female	Double-blind period	Sparsentan	63	11 (17.5)	2.575 [0.868, 7.644]	2.909 [0.871, 9.711]	10.7 [-2.3, 23.7]	0.099	
			Irbesartan	59	4 (6.8)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Hypotension	Age	Double-blind period	Sparsentan					Interaction test:	0.877	
	<= 45 years	Double-blind period	Sparsentan	96	9 (9.4)	3.094 [0.864, 11.084]	3.310 [0.868, 12.623]	6.3 [-1.4, 14.1]	0.079	
			Irbesartan	99	3 (3.0)					
	> 45 years	Double-blind period	Sparsentan	106	11 (10.4)	3.563 [1.023, 12.404]	3.860 [1.044, 14.263]	7.5 [-0.1, 15.1]	0.050	*
			Irbesartan	103	3 (2.9)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Hypotension	Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.914	
	<= 18 years	Double-blind period	Sparsentan	9	1 (11.1)	1.800 + [0.086, 37.493]	1.941 + [0.066, 56.760]	11.1 [-25.0, 47.2]	1.000	
			Irbesartan	5	0 (0.0)					
	> 18 to 40 years	Double-blind period	Sparsentan	102	10 (9.8)	3.562 [1.009, 12.578]	3.841 [1.026, 14.378]	7.1 [-0.4, 14.5]	0.044	*
			Irbesartan	109	3 (2.8)					
	> 40 years	Double-blind period	Sparsentan	91	9 (9.9)	2.901 [0.812, 10.365]	3.110 [0.813, 11.893]	6.5 [-1.8, 14.8]	0.133	
			Irbesartan	88	3 (3.4)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Hypotension	Geographic region	Double-blind period	Sparsentan					Interaction test:	0.524	
	North America	Double-blind period	Sparsentan	35	3 (8.6)	3.943 [0.428, 36.305]	4.219 [0.420, 42.421]	6.4 [-6.3, 19.1]	0.311	
			Irbesartan	46	1 (2.2)					
	Europe	Double-blind period	Sparsentan	98	12 (12.2)	4.694 [1.364, 16.157]	5.209 [1.425, 19.038]	9.6 [1.6, 17.7]	0.007	*
			Irbesartan	115	3 (2.6)					
	Asia Pacific	Double-blind period	Sparsentan	69	5 (7.2)	1.486 [0.302, 7.311]	1.523 [0.282, 8.235]	2.4 [-8.6, 13.3]	1.000	
			Irbesartan	41	2 (4.9)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Hypotension	Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.613	
	< 27 kg/m**2	Double-blind period	Sparsentan	84	10 (11.9)	2.798 [0.911, 8.588]	3.041 [0.916, 10.091]	7.6 [-1.5, 16.8]	0.092	
			Irbesartan	94	4 (4.3)					
	>= 27 kg/m**2	Double-blind period	Sparsentan	118	10 (8.5)	4.534 [1.016, 20.228]	4.861 [1.040, 22.715]	6.6 [0.1, 13.1]	0.036	*
			Irbesartan	107	2 (1.9)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
PT: Hypotension	Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.666
	eGFR Low and UP High	Double-blind period	Sparsentan	71	7 (9.9)	2.432 [0.654, 9.038]	2.589 [0.642, 10.435]	5.8 [-3.8, 15.4]	0.203
			Irbesartan	74	3 (4.1)				
	eGFR Low and UP Low	Double-blind period	Sparsentan	55	7 (12.7)	3.500 [0.761, 16.105]	3.865 [0.765, 19.514]	9.1 [-2.8, 21.0]	0.161
			Irbesartan	55	2 (3.6)				
	eGFR High and UP High	Double-blind period	Sparsentan	37	5 (13.5)	10.711 + [0.614, 186.919]	12.354 + [0.657, 232.145]	13.5 [-0.2, 27.3]	0.054
			Irbesartan	36	0 (0.0)				
	eGFR High and UP Low	Double-blind period	Sparsentan	39	1 (2.6)	0.949 [0.062, 14.620]	0.947 [0.057, 15.721]	-0.1 [-10.0, 9.7]	1.000
			Irbesartan	37	1 (2.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Hypotension	Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.802	
	< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	15 (11.8)	3.047 [1.141, 8.136]	3.321 [1.169, 9.433]	7.9 [0.6, 15.2]	0.020	*
			Irbesartan	129	5 (3.9)					
	60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	3 (6.1)	6.860 + [0.364, 129.358]	7.301 + [0.367, 145.240]	6.1 [-2.7, 14.9]	0.242	
			Irbesartan	48	0 (0.0)					
	>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	2 (7.7)	1.923 [0.186, 19.901]	2.000 [0.170, 23.556]	3.7 [-13.0, 20.4]	1.000	
			Irbesartan	25	1 (4.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Hypotension	Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.396	
	< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	6 (7.3)	1.463 [0.429, 4.992]	1.500 [0.407, 5.529]	2.3 [-6.3, 10.9]	0.746	
			Irbesartan	80	4 (5.0)					
	45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	9 (20.0)	9.800 [1.292, 74.317]	12.000 [1.454, 99.048]	18.0 [3.5, 32.4]	0.006	*
			Irbesartan	49	1 (2.0)					
	60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	3 (6.1)	6.860 + [0.364, 129.358]	7.301 + [0.367, 145.240]	6.1 [-2.7, 14.9]	0.242	
			Irbesartan	48	0 (0.0)					
	>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	2 (7.7)	1.923 [0.186, 19.901]	2.000 [0.170, 23.556]	3.7 [-13.0, 20.4]	1.000	
			Irbesartan	25	1 (4.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
PT: Hypotension	Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.665
	<= 1.75 g/day	Double-blind period	Sparsentan	98	9 (9.2)	4.316 [0.958, 19.457]	4.652 [0.978, 22.129]	7.1 [-0.4, 14.5]	0.059
			Irbesartan	94	2 (2.1)				
	> 1.75 g/day	Double-blind period	Sparsentan	104	11 (10.6)	2.856 [0.939, 8.685]	3.075 [0.947, 9.989]	6.9 [-1.0, 14.7]	0.063
			Irbesartan	108	4 (3.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Hypotension	Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.433	
	Yes	Double-blind period	Sparsentan	88	7 (8.0)	2.201 [0.589, 8.229]	2.305 [0.576, 9.228]	4.3 [-3.8, 12.4]	0.331	
			Irbesartan	83	3 (3.6)					
	No	Double-blind period	Sparsentan	114	13 (11.4)	4.523 [1.324, 15.457]	4.977 [1.379, 17.961]	8.9 [1.5, 16.2]	0.009	*
			Irbesartan	119	3 (2.5)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Hypotension	Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.671	
	<= 5 years	Double-blind period	Sparsentan	113	10 (8.8)	2.810 [0.906, 8.711]	2.985 [0.909, 9.801]	5.7 [-1.2, 12.6]	0.095	
			Irbesartan	127	4 (3.1)					
	> 5 years	Double-blind period	Sparsentan	89	10 (11.2)	4.213 [0.953, 18.635]	4.620 [0.979, 21.794]	8.6 [-0.2, 17.3]	0.040	*
			Irbesartan	75	2 (2.7)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Hypotension	History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.119	
	Yes	Double-blind period	Sparsentan	153	16 (10.5)	5.473 [1.627, 18.405]	5.995 [1.710, 21.018]	8.5 [2.6, 14.5]	0.002	*
			Irbesartan	157	3 (1.9)					
	No	Double-blind period	Sparsentan	49	4 (8.2)	1.224 [0.290, 5.174]	1.244 [0.263, 5.892]	1.5 [-11.2, 14.2]	1.000	
			Irbesartan	45	3 (6.7)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AC_SSSM: Incidence of severe TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

Not done: No significant soc/pts found.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AS_SSSM: Incidence of serious TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

Not done: No significant soc/pts found.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEF_SSIM: Incidence of AESI abnormal liver function during double-blind period by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEFN_SSIM: Incidence of AESI abnormal liver function during double-blind period – non-severe by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEFC_SSIM: Incidence of AESI abnormal liver function during double-blind period – severe by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEFS_SSIM: Incidence of AESI abnormal liver function during double-blind period – serious by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEV_SSIM: Incidence of AESI COVID-19 during double-blind period by subgroup
Safety Set

AESI COVID-19

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.326
Male	Double-blind period	Sparsentan	139	4 (2.9)	0.514 [0.158, 1.670]	0.500 [0.147, 1.700]	-2.7 [-8.1, 2.7]	0.378
		Irbesartan	143	8 (5.6)				
Female	Double-blind period	Sparsentan	63	1 (1.6)	2.813 + [0.117, 67.711]	2.856 + [0.114, 71.497]	1.6 [-3.1, 6.3]	1.000
		Irbesartan	59	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEV_SSIM: Incidence of AESI COVID-19 during double-blind period by subgroup
Safety Set

AESI COVID-19

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.218
<= 45 years	Double-blind period	Sparsentan	96	5 (5.2)	1.031 [0.308, 3.449]	1.033 [0.289, 3.688]	0.2 [-7.1, 7.4]	1.000
		Irbesartan	99	5 (5.1)				
> 45 years	Double-blind period	Sparsentan	106	0 (0.0)	0.139 + [0.007, 2.655]	0.135 + [0.007, 2.643]	-2.9 [-7.1, 1.3]	0.118
		Irbesartan	103	3 (2.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEV_SSIM: Incidence of AESI COVID-19 during double-blind period by subgroup
Safety Set

AESI COVID-19

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	NE
<= 18 years	Double-blind period	Sparsentan	9	0 (0.0) all n<10				NE
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	5 (4.9) all n<10				NE
		Irbesartan	109	4 (3.7)				
> 40 years	Double-blind period	Sparsentan	91	0 (0.0) all n<10				NE
		Irbesartan	88	4 (4.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEV_SSIM: Incidence of AESI COVID-19 during double-blind period by subgroup
Safety Set

AESI COVID-19

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.902
North America	Double-blind period	Sparsentan	35	1 (2.9)	1.314 [0.085, 20.288]	1.324 [0.080, 21.926]	0.7 [-8.8, 10.1]	1.000
		Irbesartan	46	1 (2.2)				
Europe	Double-blind period	Sparsentan	98	4 (4.1)	0.671 [0.202, 2.223]	0.657 [0.186, 2.313]	-2.0 [-8.8, 4.8]	0.553
		Irbesartan	115	7 (6.1)				
Asia Pacific	Double-blind period	Sparsentan	69	0 (0.0)	0.600 + [0.012, 29.678]	0.597 + [0.012, 30.665]	0.0 [NE, NE]	NE
		Irbesartan	41	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEV_SSIM: Incidence of AESI COVID-19 during double-blind period by subgroup
Safety Set

AESI COVID-19

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	NE
< 27 kg/m**2	Double-blind period	Sparsentan	84	1 (1.2) all n<10				NE
		Irbesartan	94	3 (3.2)				
>= 27 kg/m**2	Double-blind period	Sparsentan	118	4 (3.4) all n<10				NE
		Irbesartan	107	5 (4.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEV_SSIM: Incidence of AESI COVID-19 during double-blind period by subgroup
Safety Set

AESI COVID-19

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	NE
eGFR Low and UP High	Double-blind period	Sparsentan	71	2 (2.8) all n<10				NE
		Irbesartan	74	2 (2.7)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	1 (1.8) all n<10				NE
		Irbesartan	55	0 (0.0)				
eGFR High and UP High	Double-blind period	Sparsentan	37	1 (2.7) all n<10				NE
		Irbesartan	36	1 (2.8)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	1 (2.6) all n<10				NE
		Irbesartan	37	5 (13.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEV_SSIM: Incidence of AESI COVID-19 during double-blind period by subgroup
Safety Set

AESI COVID-19

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	NE
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	3 (2.4) all n<10				NE
		Irbesartan	129	5 (3.9)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	1 (2.0) all n<10				NE
		Irbesartan	48	2 (4.2)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8) all n<10				NE
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEV_SSIM: Incidence of AESI COVID-19 during double-blind period by subgroup
Safety Set

AESI COVID-19

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	NE
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	2 (2.4) all n<10				NE
		Irbesartan	80	1 (1.3)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	1 (2.2) all n<10				NE
		Irbesartan	49	4 (8.2)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	1 (2.0) all n<10				NE
		Irbesartan	48	2 (4.2)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8) all n<10				NE
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEV_SSIM: Incidence of AESI COVID-19 during double-blind period by subgroup
Safety Set

AESI COVID-19

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	NE
<= 1.75 g/day	Double-blind period	Sparsentan	98	3 (3.1) all n<10				NE
		Irbesartan	94	5 (5.3)				
> 1.75 g/day	Double-blind period	Sparsentan	104	2 (1.9) all n<10				NE
		Irbesartan	108	3 (2.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEV_SSIM: Incidence of AESI COVID-19 during double-blind period by subgroup
Safety Set

AESI COVID-19

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	NE
Yes	Double-blind period	Sparsentan	88	1 (1.1) all n<10				NE
		Irbesartan	83	3 (3.6)				
No	Double-blind period	Sparsentan	114	4 (3.5) all n<10				NE
		Irbesartan	119	5 (4.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEV_SSIM: Incidence of AESI COVID-19 during double-blind period by subgroup
Safety Set

AESI COVID-19

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	NE
<= 5 years	Double-blind period	Sparsentan	113	2 (1.8) all n<10				NE
		Irbesartan	127	5 (3.9)				
> 5 years	Double-blind period	Sparsentan	89	3 (3.4) all n<10				NE
		Irbesartan	75	3 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEV_SSIM: Incidence of AESI COVID-19 during double-blind period by subgroup
Safety Set

AESI COVID-19

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.138
Yes	Double-blind period	Sparsentan	153	3 (2.0)	0.385 [0.104, 1.423]	0.373 [0.097, 1.431]	-3.1 [-7.9, 1.6]	0.219
		Irbesartan	157	8 (5.1)				
No	Double-blind period	Sparsentan	49	2 (4.1)	4.600 + [0.227, 93.307]	4.789 + [0.224, 102.502]	4.1 [-3.6, 11.8]	0.496
		Irbesartan	45	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEVN_SSIM: Incidence of AESI COVID-19 during double-blind period – non-severe by subgroup
Safety Set

Not done. Less than 10 patients with events in every subgroup level.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEVC_SSIM: Incidence of AESI COVID-19 during double-blind period – severe by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEVS_SSIM: Incidence of AESI COVID-19 during double-blind period – serious by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEC_SSIM: Incidence of AESI cardiovascular system during double-blind period by subgroup
Safety Set

AESI cardiovascular system

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Sex	Double-blind period	Sparsentan					Interaction test:	0.051	
Male	Double-blind period	Sparsentan	139	30 (21.6)	0.964 [0.621, 1.498]	0.955 [0.543, 1.678]	-0.8 [-11.2, 9.6]	0.887	
		Irbesartan	143	32 (22.4)					
Female	Double-blind period	Sparsentan	63	21 (33.3)	2.185 [1.090, 4.381]	2.778 [1.150, 6.711]	18.1 [1.6, 34.5]	0.022	*
		Irbesartan	59	9 (15.3)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEC_SSIM: Incidence of AESI cardiovascular system during double-blind period by subgroup
Safety Set

AESI cardiovascular system

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.939
<= 45 years	Double-blind period	Sparsentan	96	22 (22.9)	1.260 [0.723, 2.198]	1.338 [0.666, 2.689]	4.7 [-7.6, 17.1]	0.479
		Irbesartan	99	18 (18.2)				
> 45 years	Double-blind period	Sparsentan	106	29 (27.4)	1.225 [0.762, 1.971]	1.310 [0.697, 2.461]	5.0 [-7.6, 17.7]	0.427
		Irbesartan	103	23 (22.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEC_SSIM: Incidence of AESI cardiovascular system during double-blind period by subgroup
Safety Set

AESI cardiovascular system

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.493
<= 18 years	Double-blind period	Sparsentan	9	4 (44.4)	2.222 [0.333, 14.845]	3.200 [0.248, 41.208]	24.4 [-38.9, 87.8]	0.580
		Irbesartan	5	1 (20.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	19 (18.6)	0.967 [0.553, 1.691]	0.959 [0.482, 1.911]	-0.6 [-12.2, 10.9]	1.000
		Irbesartan	109	21 (19.3)				
> 40 years	Double-blind period	Sparsentan	91	28 (30.8)	1.425 [0.861, 2.358]	1.614 [0.822, 3.171]	9.2 [-4.7, 23.1]	0.178
		Irbesartan	88	19 (21.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEC_SSIM: Incidence of AESI cardiovascular system during double-blind period by subgroup
Safety Set

AESI cardiovascular system

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.737
North America	Double-blind period	Sparsentan	35	5 (14.3)	0.939 [0.325, 2.710]	0.929 [0.268, 3.217]	-0.9 [-19.0, 17.1]	1.000
		Irbesartan	46	7 (15.2)				
Europe	Double-blind period	Sparsentan	98	28 (28.6)	1.369 [0.852, 2.199]	1.517 [0.809, 2.842]	7.7 [-4.9, 20.3]	0.204
		Irbesartan	115	24 (20.9)				
Asia Pacific	Double-blind period	Sparsentan	69	18 (26.1)	1.070 [0.548, 2.089]	1.094 [0.448, 2.671]	1.7 [-17.0, 20.4]	1.000
		Irbesartan	41	10 (24.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEC_SSIM: Incidence of AESI cardiovascular system during double-blind period by subgroup
Safety Set

AESI cardiovascular system

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.359
< 27 kg/m**2	Double-blind period	Sparsentan	84	18 (21.4)	1.007 [0.573, 1.771]	1.009 [0.492, 2.069]	0.2 [-13.0, 13.3]	1.000
		Irbesartan	94	20 (21.3)				
>= 27 kg/m**2	Double-blind period	Sparsentan	118	33 (28.0)	1.425 [0.881, 2.304]	1.590 [0.852, 2.967]	8.3 [-3.6, 20.3]	0.161
		Irbesartan	107	21 (19.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEC_SSIM: Incidence of AESI cardiovascular system during double-blind period by subgroup
Safety Set

AESI cardiovascular system

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.663
eGFR Low and UP High	Double-blind period	Sparsentan	71	19 (26.8)	1.414 [0.770, 2.600]	1.566 [0.715, 3.429]	7.8 [-7.2, 22.8]	0.323
		Irbesartan	74	14 (18.9)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	16 (29.1)	1.333 [0.697, 2.550]	1.470 [0.619, 3.491]	7.3 [-10.8, 25.3]	0.512
		Irbesartan	55	12 (21.8)				
eGFR High and UP High	Double-blind period	Sparsentan	37	10 (27.0)	1.390 [0.594, 3.252]	1.534 [0.511, 4.605]	7.6 [-14.4, 29.6]	0.581
		Irbesartan	36	7 (19.4)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	6 (15.4)	0.712 [0.273, 1.855]	0.659 [0.205, 2.124]	-6.2 [-26.3, 13.8]	0.561
		Irbesartan	37	8 (21.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEC_SSIM: Incidence of AESI cardiovascular system during double-blind period by subgroup
Safety Set

AESI cardiovascular system

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.793
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	35 (27.6)	1.270 [0.824, 1.956]	1.372 [0.775, 2.430]	5.9 [-5.5, 17.2]	0.311
		Irbesartan	129	28 (21.7)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	12 (24.5)	1.069 [0.523, 2.184]	1.091 [0.428, 2.783]	1.6 [-17.4, 20.6]	1.000
		Irbesartan	48	11 (22.9)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	4 (15.4)	1.923 [0.386, 9.584]	2.091 [0.347, 12.589]	7.4 [-14.0, 28.8]	0.668
		Irbesartan	25	2 (8.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEC_SSIM: Incidence of AESI cardiovascular system during double-blind period by subgroup
Safety Set

AESI cardiovascular system

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.926
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	22 (26.8)	1.263 [0.726, 2.195]	1.359 [0.658, 2.806]	5.6 [-8.8, 19.9]	0.464
		Irbesartan	80	17 (21.3)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	13 (28.9)	1.287 [0.643, 2.575]	1.403 [0.553, 3.559]	6.4 [-13.4, 26.2]	0.489
		Irbesartan	49	11 (22.4)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	12 (24.5)	1.069 [0.523, 2.184]	1.091 [0.428, 2.783]	1.6 [-17.4, 20.6]	1.000
		Irbesartan	48	11 (22.9)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	4 (15.4)	1.923 [0.386, 9.584]	2.091 [0.347, 12.589]	7.4 [-14.0, 28.8]	0.668
		Irbesartan	25	2 (8.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEC_SSIM: Incidence of AESI cardiovascular system during double-blind period by subgroup
Safety Set

AESI cardiovascular system

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.039	#
<= 1.75 g/day	Double-blind period	Sparsentan	98	27 (27.6)	1.992 [1.095, 3.623]	2.369 [1.137, 4.938]	13.7 [1.4, 26.0]	0.021	*
		Irbesartan	94	13 (13.8)					
> 1.75 g/day	Double-blind period	Sparsentan	104	24 (23.1)	0.890 [0.554, 1.430]	0.857 [0.458, 1.605]	-2.8 [-15.4, 9.7]	0.636	
		Irbesartan	108	28 (25.9)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEC_SSIM: Incidence of AESI cardiovascular system during double-blind period by subgroup
Safety Set

AESI cardiovascular system

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.644
Yes	Double-blind period	Sparsentan	88	24 (27.3)	1.132 [0.678, 1.889]	1.181 [0.594, 2.350]	3.2 [-11.1, 17.4]	0.727
		Irbesartan	83	20 (24.1)				
No	Double-blind period	Sparsentan	114	27 (23.7)	1.342 [0.807, 2.233]	1.448 [0.764, 2.744]	6.0 [-5.2, 17.3]	0.262
		Irbesartan	119	21 (17.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEC_SSIM: Incidence of AESI cardiovascular system during double-blind period by subgroup
Safety Set

AESI cardiovascular system

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.918
<= 5 years	Double-blind period	Sparsentan	113	28 (24.8)	1.259 [0.782, 2.026]	1.344 [0.729, 2.477]	5.1 [-6.3, 16.5]	0.354
		Irbesartan	127	25 (19.7)				
> 5 years	Double-blind period	Sparsentan	89	23 (25.8)	1.211 [0.692, 2.119]	1.285 [0.620, 2.662]	4.5 [-9.7, 18.7]	0.582
		Irbesartan	75	16 (21.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEC_SSIM: Incidence of AESI cardiovascular system during double-blind period by subgroup
Safety Set

AESI cardiovascular system

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.324
Yes	Double-blind period	Sparsentan	153	45 (29.4)	1.358 [0.923, 1.997]	1.507 [0.901, 2.523]	7.8 [-2.6, 18.1]	0.120
		Irbesartan	157	34 (21.7)				
No	Double-blind period	Sparsentan	49	6 (12.2)	0.787 [0.286, 2.167]	0.757 [0.234, 2.452]	-3.3 [-19.5, 12.8]	0.768
		Irbesartan	45	7 (15.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AECN_SSIM: Incidence of AESI cardiovascular system during double-blind period – non-severe by subgroup
Safety Set

AESI cardiovascular system - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Sex	Double-blind period	Sparsentan					Interaction test:	0.082	
Male	Double-blind period	Sparsentan	139	30 (21.6)	0.996 [0.638, 1.553]	0.994 [0.564, 1.753]	-0.1 [-10.4, 10.2]	1.000	
		Irbesartan	143	31 (21.7)					
Female	Double-blind period	Sparsentan	63	20 (31.7)	2.081 [1.031, 4.199]	2.584 [1.065, 6.267]	16.5 [0.1, 32.8]	0.036	*
		Irbesartan	59	9 (15.3)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AECN_SSIM: Incidence of AESI cardiovascular system during double-blind period – non-severe by subgroup
Safety Set

AESI cardiovascular system - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.750
<= 45 years	Double-blind period	Sparsentan	96	22 (22.9)	1.335 [0.757, 2.353]	1.434 [0.707, 2.907]	5.7 [-6.5, 18.0]	0.372
		Irbesartan	99	17 (17.2)				
> 45 years	Double-blind period	Sparsentan	106	28 (26.4)	1.183 [0.732, 1.912]	1.249 [0.663, 2.353]	4.1 [-8.5, 16.7]	0.523
		Irbesartan	103	23 (22.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AECN_SSIM: Incidence of AESI cardiovascular system during double-blind period – non-severe by subgroup
Safety Set

AESI cardiovascular system - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.608
<= 18 years	Double-blind period	Sparsentan	9	4 (44.4)	2.222 [0.333, 14.845]	3.200 [0.248, 41.208]	24.4 [-38.9, 87.8]	0.580
		Irbesartan	5	1 (20.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	19 (18.6)	1.015 [0.576, 1.790]	1.019 [0.508, 2.042]	0.3 [-11.2, 11.7]	1.000
		Irbesartan	109	20 (18.3)				
> 40 years	Double-blind period	Sparsentan	91	27 (29.7)	1.374 [0.826, 2.285]	1.532 [0.777, 3.019]	8.1 [-5.8, 21.9]	0.235
		Irbesartan	88	19 (21.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AECN_SSIM: Incidence of AESI cardiovascular system during double-blind period – non-severe by subgroup
Safety Set

AESI cardiovascular system - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.733
North America	Double-blind period	Sparsentan	35	5 (14.3)	0.939 [0.325, 2.710]	0.929 [0.268, 3.217]	-0.9 [-19.0, 17.1]	1.000
		Irbesartan	46	7 (15.2)				
Europe	Double-blind period	Sparsentan	98	27 (27.6)	1.378 [0.847, 2.241]	1.521 [0.805, 2.875]	7.6 [-4.9, 20.0]	0.200
		Irbesartan	115	23 (20.0)				
Asia Pacific	Double-blind period	Sparsentan	69	18 (26.1)	1.070 [0.548, 2.089]	1.094 [0.448, 2.671]	1.7 [-17.0, 20.4]	1.000
		Irbesartan	41	10 (24.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AECN_SSIM: Incidence of AESI cardiovascular system during double-blind period – non-severe by subgroup
Safety Set

AESI cardiovascular system - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.240
< 27 kg/m**2	Double-blind period	Sparsentan	84	17 (20.2)	0.951 [0.535, 1.692]	0.939 [0.454, 1.941]	-1.0 [-14.1, 12.0]	1.000
		Irbesartan	94	20 (21.3)				
>= 27 kg/m**2	Double-blind period	Sparsentan	118	33 (28.0)	1.496 [0.917, 2.442]	1.689 [0.899, 3.173]	9.3 [-2.6, 21.1]	0.117
		Irbesartan	107	20 (18.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AECN_SSIM: Incidence of AESI cardiovascular system during double-blind period – non-severe by subgroup
Safety Set

AESI cardiovascular system - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.629
eGFR Low and UP High	Double-blind period	Sparsentan	71	18 (25.4)	1.340 [0.722, 2.486]	1.456 [0.660, 3.208]	6.4 [-8.4, 21.3]	0.424
		Irbesartan	74	14 (18.9)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	16 (29.1)	1.333 [0.697, 2.550]	1.470 [0.619, 3.491]	7.3 [-10.8, 25.3]	0.512
		Irbesartan	55	12 (21.8)				
eGFR High and UP High	Double-blind period	Sparsentan	37	10 (27.0)	1.622 [0.658, 3.997]	1.852 [0.594, 5.778]	10.4 [-11.2, 31.9]	0.398
		Irbesartan	36	6 (16.7)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	6 (15.4)	0.712 [0.273, 1.855]	0.659 [0.205, 2.124]	-6.2 [-26.3, 13.8]	0.561
		Irbesartan	37	8 (21.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AECN_SSIM: Incidence of AESI cardiovascular system during double-blind period – non-severe by subgroup
Safety Set

AESI cardiovascular system - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.790
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	34 (26.8)	1.279 [0.822, 1.990]	1.381 [0.775, 2.462]	5.8 [-5.4, 17.0]	0.306
		Irbesartan	129	27 (20.9)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	12 (24.5)	1.069 [0.523, 2.184]	1.091 [0.428, 2.783]	1.6 [-17.4, 20.6]	1.000
		Irbesartan	48	11 (22.9)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	4 (15.4)	1.923 [0.386, 9.584]	2.091 [0.347, 12.589]	7.4 [-14.0, 28.8]	0.668
		Irbesartan	25	2 (8.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AECN_SSIM: Incidence of AESI cardiovascular system during double-blind period – non-severe by subgroup
Safety Set

AESI cardiovascular system - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.924
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	22 (26.8)	1.263 [0.726, 2.195]	1.359 [0.658, 2.806]	5.6 [-8.8, 19.9]	0.464
		Irbesartan	80	17 (21.3)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	12 (26.7)	1.307 [0.626, 2.726]	1.418 [0.544, 3.699]	6.3 [-13.0, 25.5]	0.626
		Irbesartan	49	10 (20.4)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	12 (24.5)	1.069 [0.523, 2.184]	1.091 [0.428, 2.783]	1.6 [-17.4, 20.6]	1.000
		Irbesartan	48	11 (22.9)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	4 (15.4)	1.923 [0.386, 9.584]	2.091 [0.347, 12.589]	7.4 [-14.0, 28.8]	0.668
		Irbesartan	25	2 (8.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AECN_SSIM: Incidence of AESI cardiovascular system during double-blind period – non-severe by subgroup
Safety Set

AESI cardiovascular system - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.039	#
<= 1.75 g/day	Double-blind period	Sparsentan	98	27 (27.6)	1.992 [1.095, 3.623]	2.369 [1.137, 4.938]	13.7 [1.4, 26.0]	0.021	*
		Irbesartan	94	13 (13.8)					
> 1.75 g/day	Double-blind period	Sparsentan	104	23 (22.1)	0.885 [0.544, 1.439]	0.852 [0.451, 1.609]	-2.9 [-15.2, 9.5]	0.632	
		Irbesartan	108	27 (25.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AECN_SSIM: Incidence of AESI cardiovascular system during double-blind period – non-severe by subgroup
Safety Set

AESI cardiovascular system - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.484
Yes	Double-blind period	Sparsentan	88	23 (26.1)	1.085 [0.646, 1.822]	1.115 [0.558, 2.227]	2.0 [-12.1, 16.2]	0.860
		Irbesartan	83	20 (24.1)				
No	Double-blind period	Sparsentan	114	27 (23.7)	1.409 [0.839, 2.366]	1.536 [0.805, 2.931]	6.9 [-4.3, 18.0]	0.197
		Irbesartan	119	20 (16.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AECN_SSIM: Incidence of AESI cardiovascular system during double-blind period – non-severe by subgroup
Safety Set

AESI cardiovascular system - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.745
<= 5 years	Double-blind period	Sparsentan	113	28 (24.8)	1.311 [0.809, 2.125]	1.414 [0.763, 2.618]	5.9 [-5.4, 17.2]	0.277
		Irbesartan	127	24 (18.9)				
> 5 years	Double-blind period	Sparsentan	89	22 (24.7)	1.159 [0.658, 2.041]	1.211 [0.582, 2.520]	3.4 [-10.7, 17.5]	0.711
		Irbesartan	75	16 (21.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AECN_SSIM: Incidence of AESI cardiovascular system during double-blind period – non-severe by subgroup
Safety Set

AESI cardiovascular system - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.318
Yes	Double-blind period	Sparsentan	153	44 (28.8)	1.368 [0.924, 2.026]	1.517 [0.902, 2.550]	7.7 [-2.5, 18.0]	0.148
		Irbesartan	157	33 (21.0)				
No	Double-blind period	Sparsentan	49	6 (12.2)	0.787 [0.286, 2.167]	0.757 [0.234, 2.452]	-3.3 [-19.5, 12.8]	0.768
		Irbesartan	45	7 (15.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AECC_SSIM: Incidence of AESI cardiovascular system during double-blind period – severe by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AECS_SSIM: Incidence of AESI cardiovascular system during double-blind period – serious by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEH_SSIM: Incidence of AESI hypotension during double-blind period by subgroup
Safety Set

AESI hypotension

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Sex	Double-blind period	Sparsentan					Interaction test:	0.757	
Male	Double-blind period	Sparsentan	139	28 (20.1)	2.216 [1.198, 4.098]	2.523 [1.247, 5.105]	11.1 [2.2, 19.9]	0.011	*
		Irbesartan	143	13 (9.1)					
Female	Double-blind period	Sparsentan	63	22 (34.9)	2.575 [1.245, 5.329]	3.421 [1.380, 8.478]	21.4 [5.1, 37.7]	0.007	*
		Irbesartan	59	8 (13.6)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEH_SSIM: Incidence of AESI hypotension during double-blind period by subgroup
Safety Set

AESI hypotension

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Age	Double-blind period	Sparsentan					Interaction test:	0.760	
<= 45 years	Double-blind period	Sparsentan	96	26 (27.1)	2.234 [1.197, 4.169]	2.693 [1.268, 5.718]	15.0 [3.0, 27.0]	0.011	*
		Irbesartan	99	12 (12.1)					
> 45 years	Double-blind period	Sparsentan	106	24 (22.6)	2.591 [1.266, 5.305]	3.057 [1.345, 6.950]	13.9 [3.3, 24.5]	0.007	*
		Irbesartan	103	9 (8.7)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEH_SSIM: Incidence of AESI hypotension during double-blind period by subgroup
Safety Set

AESI hypotension

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.933	
<= 18 years	Double-blind period	Sparsentan	9	2 (22.2)	3.000 + [0.171, 52.527]	3.667 + [0.145, 92.653]	22.2 [-20.5, 64.9]	0.505	
		Irbesartan	5	0 (0.0)					
> 18 to 40 years	Double-blind period	Sparsentan	102	29 (28.4)	2.214 [1.242, 3.945]	2.696 [1.329, 5.467]	15.6 [3.9, 27.3]	0.006	*
		Irbesartan	109	14 (12.8)					
> 40 years	Double-blind period	Sparsentan	91	19 (20.9)	2.625 [1.161, 5.933]	3.054 [1.213, 7.685]	12.9 [1.7, 24.1]	0.019	*
		Irbesartan	88	7 (8.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEH_SSIM: Incidence of AESI hypotension during double-blind period by subgroup
Safety Set

AESI hypotension

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.114	
North America	Double-blind period	Sparsentan	35	6 (17.1)	2.629 [0.706, 9.784]	2.966 [0.686, 12.817]	10.6 [-6.3, 27.5]	0.165	
		Irbesartan	46	3 (6.5)					
Europe	Double-blind period	Sparsentan	98	21 (21.4)	3.520 [1.563, 7.928]	4.208 [1.704, 10.391]	15.3 [5.2, 25.5]	0.001	*
		Irbesartan	115	7 (6.1)					
Asia Pacific	Double-blind period	Sparsentan	69	23 (33.3)	1.242 [0.678, 2.277]	1.364 [0.581, 3.200]	6.5 [-13.0, 26.0]	0.528	
		Irbesartan	41	11 (26.8)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEH_SSIM: Incidence of AESI hypotension during double-blind period by subgroup
Safety Set

AESI hypotension

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.873	
< 27 kg/m**2	Double-blind period	Sparsentan	84	25 (29.8)	2.331 [1.251, 4.344]	2.895 [1.347, 6.224]	17.0 [4.0, 30.0]	0.006	*
		Irbesartan	94	12 (12.8)					
>= 27 kg/m**2	Double-blind period	Sparsentan	118	25 (21.2)	2.519 [1.231, 5.152]	2.927 [1.298, 6.600]	12.8 [2.8, 22.7]	0.009	*
		Irbesartan	107	9 (8.4)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEH_SSIM: Incidence of AESI hypotension during double-blind period by subgroup
Safety Set

AESI hypotension

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.598	
eGFR Low and UP High	Double-blind period	Sparsentan	71	16 (22.5)	1.853 [0.876, 3.918]	2.101 [0.861, 5.127]	10.4 [-3.3, 24.0]	0.125	
		Irbesartan	74	9 (12.2)					
eGFR Low and UP Low	Double-blind period	Sparsentan	55	16 (29.1)	2.000 [0.934, 4.285]	2.410 [0.933, 6.226]	14.5 [-2.5, 31.6]	0.105	
		Irbesartan	55	8 (14.5)					
eGFR High and UP High	Double-blind period	Sparsentan	37	9 (24.3)	4.378 [1.015, 18.888]	5.464 [1.090, 27.385]	18.8 [0.3, 37.2]	0.046	*
		Irbesartan	36	2 (5.6)					
eGFR High and UP Low	Double-blind period	Sparsentan	39	9 (23.1)	4.269 [0.987, 18.469]	5.250 [1.052, 26.210]	17.7 [-0.1, 35.4]	0.048	*
		Irbesartan	37	2 (5.4)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEH_SSIM: Incidence of AESI hypotension during double-blind period by subgroup
Safety Set

AESI hypotension

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.545	
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	34 (26.8)	2.031 [1.198, 3.445]	2.409 [1.265, 4.586]	13.6 [3.1, 24.0]	0.008	*
		Irbesartan	129	17 (13.2)					
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	11 (22.4)	3.592 [1.068, 12.081]	4.342 [1.128, 16.710]	16.2 [0.6, 31.8]	0.040	*
		Irbesartan	48	3 (6.3)					
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	5 (19.2)	4.808 [0.603, 38.316]	5.714 [0.617, 52.902]	15.2 [-5.7, 36.1]	0.191	
		Irbesartan	25	1 (4.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEH_SSIM: Incidence of AESI hypotension during double-blind period by subgroup
Safety Set

AESI hypotension

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.589	
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	17 (20.7)	1.659 [0.809, 3.400]	1.831 [0.782, 4.287]	8.2 [-4.4, 20.8]	0.206	
		Irbesartan	80	10 (12.5)					
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	17 (37.8)	2.644 [1.210, 5.778]	3.643 [1.338, 9.919]	23.5 [4.1, 42.8]	0.017	*
		Irbesartan	49	7 (14.3)					
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	11 (22.4)	3.592 [1.068, 12.081]	4.342 [1.128, 16.710]	16.2 [0.6, 31.8]	0.040	*
		Irbesartan	48	3 (6.3)					
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	5 (19.2)	4.808 [0.603, 38.316]	5.714 [0.617, 52.902]	15.2 [-5.7, 36.1]	0.191	
		Irbesartan	25	1 (4.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEH_SSIM: Incidence of AESI hypotension during double-blind period by subgroup
Safety Set

AESI hypotension

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.080	
<= 1.75 g/day	Double-blind period	Sparsentan	98	26 (26.5)	4.156 [1.792, 9.641]	5.296 [2.067, 13.569]	20.1 [9.1, 31.2]	<0.001	*
		Irbesartan	94	6 (6.4)					
> 1.75 g/day	Double-blind period	Sparsentan	104	24 (23.1)	1.662 [0.925, 2.986]	1.860 [0.914, 3.787]	9.2 [-2.2, 20.5]	0.110	
		Irbesartan	108	15 (13.9)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEH_SSIM: Incidence of AESI hypotension during double-blind period by subgroup
Safety Set

AESI hypotension

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.252	
Yes	Double-blind period	Sparsentan	88	16 (18.2)	1.677 [0.784, 3.584]	1.827 [0.759, 4.400]	7.3 [-4.3, 19.0]	0.199	
		Irbesartan	83	9 (10.8)					
No	Double-blind period	Sparsentan	114	34 (29.8)	2.958 [1.614, 5.421]	3.790 [1.846, 7.778]	19.7 [8.9, 30.6]	<0.001	*
		Irbesartan	119	12 (10.1)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEH_SSIM: Incidence of AESI hypotension during double-blind period by subgroup
Safety Set

AESI hypotension

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.518	
<= 5 years	Double-blind period	Sparsentan	113	26 (23.0)	2.087 [1.148, 3.797]	2.412 [1.189, 4.893]	12.0 [1.7, 22.3]	0.015	*
		Irbesartan	127	14 (11.0)					
> 5 years	Double-blind period	Sparsentan	89	24 (27.0)	2.889 [1.319, 6.327]	3.587 [1.447, 8.893]	17.6 [5.1, 30.2]	0.005	*
		Irbesartan	75	7 (9.3)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEH_SSIM: Incidence of AESI hypotension during double-blind period by subgroup
Safety Set

AESI hypotension

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.936	
Yes	Double-blind period	Sparsentan	153	35 (22.9)	2.394 [1.364, 4.202]	2.808 [1.463, 5.391]	13.3 [4.6, 22.1]	0.002	*
		Irbesartan	157	15 (9.6)					
No	Double-blind period	Sparsentan	49	15 (30.6)	2.296 [0.976, 5.403]	2.868 [1.001, 8.216]	17.3 [-1.1, 35.7]	0.051	
		Irbesartan	45	6 (13.3)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEHN_SSIM: Incidence of AESI hypotension during double-blind period – non-severe by subgroup
Safety Set

AESI hypotension - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Sex	Double-blind period	Sparsentan					Interaction test:	0.832	
Male	Double-blind period	Sparsentan	139	28 (20.1)	2.216 [1.198, 4.098]	2.523 [1.247, 5.105]	11.1 [2.2, 19.9]	0.011	*
		Irbesartan	143	13 (9.1)					
Female	Double-blind period	Sparsentan	63	21 (33.3)	2.458 [1.181, 5.116]	3.188 [1.282, 7.927]	19.8 [3.6, 36.0]	0.011	*
		Irbesartan	59	8 (13.6)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEHN_SSIM: Incidence of AESI hypotension during double-blind period – non-severe by subgroup
Safety Set

AESI hypotension - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Age	Double-blind period	Sparsentan					Interaction test:	0.828	
<= 45 years	Double-blind period	Sparsentan	96	26 (27.1)	2.234 [1.197, 4.169]	2.693 [1.268, 5.718]	15.0 [3.0, 27.0]	0.011	*
		Irbesartan	99	12 (12.1)					
> 45 years	Double-blind period	Sparsentan	106	23 (21.7)	2.483 [1.207, 5.108]	2.894 [1.268, 6.606]	13.0 [2.4, 23.5]	0.012	*
		Irbesartan	103	9 (8.7)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEHN_SSIM: Incidence of AESI hypotension during double-blind period – non-severe by subgroup
Safety Set

AESI hypotension - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.959	
<= 18 years	Double-blind period	Sparsentan	9	2 (22.2)	3.000 + [0.171, 52.527]	3.667 + [0.145, 92.653]	22.2 [-20.5, 64.9]	0.505	
		Irbesartan	5	0 (0.0)					
> 18 to 40 years	Double-blind period	Sparsentan	102	29 (28.4)	2.214 [1.242, 3.945]	2.696 [1.329, 5.467]	15.6 [3.9, 27.3]	0.006	*
		Irbesartan	109	14 (12.8)					
> 40 years	Double-blind period	Sparsentan	91	18 (19.8)	2.487 [1.093, 5.659]	2.853 [1.127, 7.221]	11.8 [0.8, 22.9]	0.030	*
		Irbesartan	88	7 (8.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEHN_SSIM: Incidence of AESI hypotension during double-blind period – non-severe by subgroup
Safety Set

AESI hypotension - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.138	
North America	Double-blind period	Sparsentan	35	6 (17.1)	2.629 [0.706, 9.784]	2.966 [0.686, 12.817]	10.6 [-6.3, 27.5]	0.165	
		Irbesartan	46	3 (6.5)					
Europe	Double-blind period	Sparsentan	98	20 (20.4)	3.353 [1.480, 7.593]	3.956 [1.595, 9.815]	14.3 [4.3, 24.4]	0.002	*
		Irbesartan	115	7 (6.1)					
Asia Pacific	Double-blind period	Sparsentan	69	23 (33.3)	1.242 [0.678, 2.277]	1.364 [0.581, 3.200]	6.5 [-13.0, 26.0]	0.528	
		Irbesartan	41	11 (26.8)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEHN_SSIM: Incidence of AESI hypotension during double-blind period – non-severe by subgroup
Safety Set

AESI hypotension - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.808	
< 27 kg/m**2	Double-blind period	Sparsentan	84	24 (28.6)	2.238 [1.195, 4.191]	2.733 [1.267, 5.896]	15.8 [2.9, 28.7]	0.014	*
		Irbesartan	94	12 (12.8)					
>= 27 kg/m**2	Double-blind period	Sparsentan	118	25 (21.2)	2.519 [1.231, 5.152]	2.927 [1.298, 6.600]	12.8 [2.8, 22.7]	0.009	*
		Irbesartan	107	9 (8.4)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEHN_SSIM: Incidence of AESI hypotension during double-blind period – non-severe by subgroup
Safety Set

AESI hypotension - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.559	
eGFR Low and UP High	Double-blind period	Sparsentan	71	15 (21.1)	1.737 [0.813, 3.713]	1.935 [0.786, 4.760]	9.0 [-4.5, 22.4]	0.182	
		Irbesartan	74	9 (12.2)					
eGFR Low and UP Low	Double-blind period	Sparsentan	55	16 (29.1)	2.000 [0.934, 4.285]	2.410 [0.933, 6.226]	14.5 [-2.5, 31.6]	0.105	
		Irbesartan	55	8 (14.5)					
eGFR High and UP High	Double-blind period	Sparsentan	37	9 (24.3)	4.378 [1.015, 18.888]	5.464 [1.090, 27.385]	18.8 [0.3, 37.2]	0.046	*
		Irbesartan	36	2 (5.6)					
eGFR High and UP Low	Double-blind period	Sparsentan	39	9 (23.1)	4.269 [0.987, 18.469]	5.250 [1.052, 26.210]	17.7 [-0.1, 35.4]	0.048	*
		Irbesartan	37	2 (5.4)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEHN_SSIM: Incidence of AESI hypotension during double-blind period – non-severe by subgroup
Safety Set

AESI hypotension - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.516	
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	33 (26.0)	1.972 [1.159, 3.354]	2.313 [1.212, 4.414]	12.8 [2.4, 23.2]	0.012	*
		Irbesartan	129	17 (13.2)					
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	11 (22.4)	3.592 [1.068, 12.081]	4.342 [1.128, 16.710]	16.2 [0.6, 31.8]	0.040	*
		Irbesartan	48	3 (6.3)					
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	5 (19.2)	4.808 [0.603, 38.316]	5.714 [0.617, 52.902]	15.2 [-5.7, 36.1]	0.191	
		Irbesartan	25	1 (4.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEHN_SSIM: Incidence of AESI hypotension during double-blind period – non-severe by subgroup
Safety Set

AESI hypotension - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.607	
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	17 (20.7)	1.659 [0.809, 3.400]	1.831 [0.782, 4.287]	8.2 [-4.4, 20.8]	0.206	
		Irbesartan	80	10 (12.5)					
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	16 (35.6)	2.489 [1.129, 5.488]	3.310 [1.210, 9.056]	21.3 [2.1, 40.5]	0.029	*
		Irbesartan	49	7 (14.3)					
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	11 (22.4)	3.592 [1.068, 12.081]	4.342 [1.128, 16.710]	16.2 [0.6, 31.8]	0.040	*
		Irbesartan	48	3 (6.3)					
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	5 (19.2)	4.808 [0.603, 38.316]	5.714 [0.617, 52.902]	15.2 [-5.7, 36.1]	0.191	
		Irbesartan	25	1 (4.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEHN_SSIM: Incidence of AESI hypotension during double-blind period – non-severe by subgroup
Safety Set

AESI hypotension - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.068	
<= 1.75 g/day	Double-blind period	Sparsentan	98	26 (26.5)	4.156 [1.792, 9.641]	5.296 [2.067, 13.569]	20.1 [9.1, 31.2]	<0.001	*
		Irbesartan	94	6 (6.4)					
> 1.75 g/day	Double-blind period	Sparsentan	104	23 (22.1)	1.592 [0.881, 2.879]	1.760 [0.861, 3.600]	8.2 [-3.0, 19.5]	0.152	
		Irbesartan	108	15 (13.9)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEHN_SSIM: Incidence of AESI hypotension during double-blind period – non-severe by subgroup
Safety Set

AESI hypotension - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.206	
Yes	Double-blind period	Sparsentan	88	15 (17.0)	1.572 [0.728, 3.395]	1.689 [0.696, 4.103]	6.2 [-5.3, 17.7]	0.277	
		Irbesartan	83	9 (10.8)					
No	Double-blind period	Sparsentan	114	34 (29.8)	2.958 [1.614, 5.421]	3.790 [1.846, 7.778]	19.7 [8.9, 30.6]	<0.001	*
		Irbesartan	119	12 (10.1)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEHN_SSIM: Incidence of AESI hypotension during double-blind period – non-severe by subgroup
Safety Set

AESI hypotension - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.576	
<= 5 years	Double-blind period	Sparsentan	113	26 (23.0)	2.087 [1.148, 3.797]	2.412 [1.189, 4.893]	12.0 [1.7, 22.3]	0.015	*
		Irbesartan	127	14 (11.0)					
> 5 years	Double-blind period	Sparsentan	89	23 (25.8)	2.769 [1.259, 6.091]	3.385 [1.361, 8.421]	16.5 [4.1, 29.0]	0.008	*
		Irbesartan	75	7 (9.3)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEHN_SSIM: Incidence of AESI hypotension during double-blind period – non-severe by subgroup
Safety Set

AESI hypotension - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.980	
Yes	Double-blind period	Sparsentan	153	34 (22.2)	2.326 [1.322, 4.093]	2.705 [1.406, 5.205]	12.7 [4.0, 21.3]	0.003	*
		Irbesartan	157	15 (9.6)					
No	Double-blind period	Sparsentan	49	15 (30.6)	2.296 [0.976, 5.403]	2.868 [1.001, 8.216]	17.3 [-1.1, 35.7]	0.051	
		Irbesartan	45	6 (13.3)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEHC_SSIM: Incidence of AESI hypotension during double-blind period – severe by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEHS_SSIM: Incidence of AESI hypotension during double-blind period – serious by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEL_SSIM: Incidence of AESI hepatic disorders during double-blind period by subgroup
Safety Set

AESI hepatic disorders

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.207
Male	Double-blind period	Sparsentan	139	12 (8.6)	2.469 [0.893, 6.825]	2.608 [0.894, 7.609]	5.1 [-1.1, 11.4]	0.083
		Irbesartan	143	5 (3.5)				
Female	Double-blind period	Sparsentan	63	1 (1.6)	0.468 [0.044, 5.029]	0.460 [0.041, 5.207]	-1.8 [-9.0, 5.4]	0.610
		Irbesartan	59	2 (3.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEL_SSIM: Incidence of AESI hepatic disorders during double-blind period by subgroup
Safety Set

AESI hepatic disorders

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.099
<= 45 years	Double-blind period	Sparsentan	96	4 (4.2)	0.825 [0.228, 2.980]	0.817 [0.213, 3.140]	-0.9 [-7.8, 6.0]	1.000
		Irbesartan	99	5 (5.1)				
> 45 years	Double-blind period	Sparsentan	106	9 (8.5)	4.373 [0.968, 19.754]	4.686 [0.987, 22.238]	6.5 [-0.3, 13.4]	0.059
		Irbesartan	103	2 (1.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEL_SSIM: Incidence of AESI hepatic disorders during double-blind period by subgroup
Safety Set

AESI hepatic disorders

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.677
<= 18 years	Double-blind period	Sparsentan	9	0 (0.0)	0.600 + [0.014, 26.475]	0.579 + [0.010, 33.502]	0.0 [NE, NE]	NE
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	7 (6.9)	1.496 [0.490, 4.564]	1.533 [0.471, 4.992]	2.3 [-5.0, 9.5]	0.559
		Irbesartan	109	5 (4.6)				
> 40 years	Double-blind period	Sparsentan	91	6 (6.6)	2.901 [0.602, 13.990]	3.035 [0.596, 15.463]	4.3 [-2.8, 11.4]	0.278
		Irbesartan	88	2 (2.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEL_SSIM: Incidence of AESI hepatic disorders during double-blind period by subgroup
Safety Set

AESI hepatic disorders

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	NE
North America	Double-blind period	Sparsentan	35	3 (8.6) all n<10				NE
		Irbesartan	46	2 (4.3)				
Europe	Double-blind period	Sparsentan	98	7 (7.1) all n<10				NE
		Irbesartan	115	2 (1.7)				
Asia Pacific	Double-blind period	Sparsentan	69	3 (4.3) all n<10				NE
		Irbesartan	41	3 (7.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEL_SSIM: Incidence of AESI hepatic disorders during double-blind period by subgroup
Safety Set

AESI hepatic disorders

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.976
< 27 kg/m**2	Double-blind period	Sparsentan	84	5 (6.0)	1.865 [0.460, 7.569]	1.920 [0.445, 8.289]	2.8 [-4.5, 10.1]	0.478
		Irbesartan	94	3 (3.2)				
>= 27 kg/m**2	Double-blind period	Sparsentan	118	8 (6.8)	1.814 [0.562, 5.851]	1.873 [0.547, 6.407]	3.0 [-3.6, 9.7]	0.382
		Irbesartan	107	4 (3.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEL_SSIM: Incidence of AESI hepatic disorders during double-blind period by subgroup
Safety Set

AESI hepatic disorders

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	NE
eGFR Low and UP High	Double-blind period	Sparsentan	71	6 (8.5) all n<10				NE
		Irbesartan	74	2 (2.7)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	2 (3.6) all n<10				NE
		Irbesartan	55	2 (3.6)				
eGFR High and UP High	Double-blind period	Sparsentan	37	3 (8.1) all n<10				NE
		Irbesartan	36	3 (8.3)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	2 (5.1) all n<10				NE
		Irbesartan	37	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEL_SSIM: Incidence of AESI hepatic disorders during double-blind period by subgroup
Safety Set

AESI hepatic disorders

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.413
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	8 (6.3)	2.031 [0.627, 6.578]	2.101 [0.616, 7.160]	3.2 [-2.8, 9.2]	0.253
		Irbesartan	129	4 (3.1)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2)	3.918 [0.454, 33.802]	4.178 [0.450, 38.818]	6.1 [-4.6, 16.8]	0.362
		Irbesartan	48	1 (2.1)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8)	0.481 [0.046, 4.975]	0.460 [0.039, 5.418]	-4.2 [-21.0, 12.7]	0.610
		Irbesartan	25	2 (8.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEL_SSIM: Incidence of AESI hepatic disorders during double-blind period by subgroup
Safety Set

AESI hepatic disorders

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	NE
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	6 (7.3) all n<10				NE
		Irbesartan	80	3 (3.8)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	2 (4.4) all n<10				NE
		Irbesartan	49	1 (2.0)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2) all n<10				NE
		Irbesartan	48	1 (2.1)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8) all n<10				NE
		Irbesartan	25	2 (8.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEL_SSIM: Incidence of AESI hepatic disorders during double-blind period by subgroup
Safety Set

AESI hepatic disorders

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.526
<= 1.75 g/day	Double-blind period	Sparsentan	98	4 (4.1)	1.279 [0.294, 5.562]	1.291 [0.281, 5.928]	0.9 [-5.4, 7.2]	1.000
		Irbesartan	94	3 (3.2)				
> 1.75 g/day	Double-blind period	Sparsentan	104	9 (8.7)	2.337 [0.742, 7.354]	2.463 [0.734, 8.262]	5.0 [-2.5, 12.4]	0.160
		Irbesartan	108	4 (3.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEL_SSIM: Incidence of AESI hepatic disorders during double-blind period by subgroup
Safety Set

AESI hepatic disorders

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.502
Yes	Double-blind period	Sparsentan	88	6 (6.8)	2.830 [0.588, 13.627]	2.963 [0.581, 15.117]	4.4 [-3.0, 11.8]	0.279
		Irbesartan	83	2 (2.4)				
No	Double-blind period	Sparsentan	114	7 (6.1)	1.461 [0.478, 4.472]	1.492 [0.459, 4.842]	1.9 [-4.6, 8.5]	0.564
		Irbesartan	119	5 (4.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEL_SSIM: Incidence of AESI hepatic disorders during double-blind period by subgroup
Safety Set

AESI hepatic disorders

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.166
<= 5 years	Double-blind period	Sparsentan	113	6 (5.3)	1.124 [0.373, 3.386]	1.131 [0.354, 3.611]	0.6 [-5.8, 7.0]	1.000
		Irbesartan	127	6 (4.7)				
> 5 years	Double-blind period	Sparsentan	89	7 (7.9)	5.899 [0.742, 46.871]	6.317 [0.759, 52.561]	6.5 [-0.9, 13.9]	0.072
		Irbesartan	75	1 (1.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEL_SSIM: Incidence of AESI hepatic disorders during double-blind period by subgroup
Safety Set

AESI hepatic disorders

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.149
Yes	Double-blind period	Sparsentan	153	11 (7.2)	2.822 [0.918, 8.670]	2.963 [0.922, 9.518]	4.6 [-0.8, 10.1]	0.067
		Irbesartan	157	4 (2.5)				
No	Double-blind period	Sparsentan	49	2 (4.1)	0.612 [0.107, 3.498]	0.596 [0.095, 3.740]	-2.6 [-13.9, 8.7]	0.668
		Irbesartan	45	3 (6.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AELN_SSIM: Incidence of AESI hepatic disorders during double-blind period – non-severe by subgroup
Safety Set

AESI hepatic disorders - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.207
Male	Double-blind period	Sparsentan	139	12 (8.6)	2.469 [0.893, 6.825]	2.608 [0.894, 7.609]	5.1 [-1.1, 11.4]	0.083
		Irbesartan	143	5 (3.5)				
Female	Double-blind period	Sparsentan	63	1 (1.6)	0.468 [0.044, 5.029]	0.460 [0.041, 5.207]	-1.8 [-9.0, 5.4]	0.610
		Irbesartan	59	2 (3.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AELN_SSIM: Incidence of AESI hepatic disorders during double-blind period – non-severe by subgroup
Safety Set

AESI hepatic disorders - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.099
<= 45 years	Double-blind period	Sparsentan	96	4 (4.2)	0.825 [0.228, 2.980]	0.817 [0.213, 3.140]	-0.9 [-7.8, 6.0]	1.000
		Irbesartan	99	5 (5.1)				
> 45 years	Double-blind period	Sparsentan	106	9 (8.5)	4.373 [0.968, 19.754]	4.686 [0.987, 22.238]	6.5 [-0.3, 13.4]	0.059
		Irbesartan	103	2 (1.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AELN_SSIM: Incidence of AESI hepatic disorders during double-blind period – non-severe by subgroup
Safety Set

AESI hepatic disorders - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.677
<= 18 years	Double-blind period	Sparsentan	9	0 (0.0)	0.600 + [0.014, 26.475]	0.579 + [0.010, 33.502]	0.0 [NE, NE]	NE
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	7 (6.9)	1.496 [0.490, 4.564]	1.533 [0.471, 4.992]	2.3 [-5.0, 9.5]	0.559
		Irbesartan	109	5 (4.6)				
> 40 years	Double-blind period	Sparsentan	91	6 (6.6)	2.901 [0.602, 13.990]	3.035 [0.596, 15.463]	4.3 [-2.8, 11.4]	0.278
		Irbesartan	88	2 (2.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AELN_SSIM: Incidence of AESI hepatic disorders during double-blind period – non-severe by subgroup
Safety Set

AESI hepatic disorders - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	NE
North America	Double-blind period	Sparsentan	35	3 (8.6) all n<10				NE
		Irbesartan	46	2 (4.3)				
Europe	Double-blind period	Sparsentan	98	7 (7.1) all n<10				NE
		Irbesartan	115	2 (1.7)				
Asia Pacific	Double-blind period	Sparsentan	69	3 (4.3) all n<10				NE
		Irbesartan	41	3 (7.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AELN_SSIM: Incidence of AESI hepatic disorders during double-blind period – non-severe by subgroup
Safety Set

AESI hepatic disorders - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.976
< 27 kg/m**2	Double-blind period	Sparsentan	84	5 (6.0)	1.865 [0.460, 7.569]	1.920 [0.445, 8.289]	2.8 [-4.5, 10.1]	0.478
		Irbesartan	94	3 (3.2)				
>= 27 kg/m**2	Double-blind period	Sparsentan	118	8 (6.8)	1.814 [0.562, 5.851]	1.873 [0.547, 6.407]	3.0 [-3.6, 9.7]	0.382
		Irbesartan	107	4 (3.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AELN_SSIM: Incidence of AESI hepatic disorders during double-blind period – non-severe by subgroup
Safety Set

AESI hepatic disorders - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	NE
eGFR Low and UP High	Double-blind period	Sparsentan	71	6 (8.5) all n<10				NE
		Irbesartan	74	2 (2.7)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	2 (3.6) all n<10				NE
		Irbesartan	55	2 (3.6)				
eGFR High and UP High	Double-blind period	Sparsentan	37	3 (8.1) all n<10				NE
		Irbesartan	36	3 (8.3)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	2 (5.1) all n<10				NE
		Irbesartan	37	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AELN_SSIM: Incidence of AESI hepatic disorders during double-blind period – non-severe by subgroup
Safety Set

AESI hepatic disorders - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.413
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	8 (6.3)	2.031 [0.627, 6.578]	2.101 [0.616, 7.160]	3.2 [-2.8, 9.2]	0.253
		Irbesartan	129	4 (3.1)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2)	3.918 [0.454, 33.802]	4.178 [0.450, 38.818]	6.1 [-4.6, 16.8]	0.362
		Irbesartan	48	1 (2.1)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8)	0.481 [0.046, 4.975]	0.460 [0.039, 5.418]	-4.2 [-21.0, 12.7]	0.610
		Irbesartan	25	2 (8.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AELN_SSIM: Incidence of AESI hepatic disorders during double-blind period – non-severe by subgroup
Safety Set

AESI hepatic disorders - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	NE
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	6 (7.3) all n<10				NE
		Irbesartan	80	3 (3.8)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	2 (4.4) all n<10				NE
		Irbesartan	49	1 (2.0)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2) all n<10				NE
		Irbesartan	48	1 (2.1)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8) all n<10				NE
		Irbesartan	25	2 (8.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AELN_SSIM: Incidence of AESI hepatic disorders during double-blind period – non-severe by subgroup
Safety Set

AESI hepatic disorders - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.526
<= 1.75 g/day	Double-blind period	Sparsentan	98	4 (4.1)	1.279 [0.294, 5.562]	1.291 [0.281, 5.928]	0.9 [-5.4, 7.2]	1.000
		Irbesartan	94	3 (3.2)				
> 1.75 g/day	Double-blind period	Sparsentan	104	9 (8.7)	2.337 [0.742, 7.354]	2.463 [0.734, 8.262]	5.0 [-2.5, 12.4]	0.160
		Irbesartan	108	4 (3.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AELN_SSIM: Incidence of AESI hepatic disorders during double-blind period – non-severe by subgroup
Safety Set

AESI hepatic disorders - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.502
Yes	Double-blind period	Sparsentan	88	6 (6.8)	2.830 [0.588, 13.627]	2.963 [0.581, 15.117]	4.4 [-3.0, 11.8]	0.279
		Irbesartan	83	2 (2.4)				
No	Double-blind period	Sparsentan	114	7 (6.1)	1.461 [0.478, 4.472]	1.492 [0.459, 4.842]	1.9 [-4.6, 8.5]	0.564
		Irbesartan	119	5 (4.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AELN_SSIM: Incidence of AESI hepatic disorders during double-blind period – non-severe by subgroup
Safety Set

AESI hepatic disorders - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.166
<= 5 years	Double-blind period	Sparsentan	113	6 (5.3)	1.124 [0.373, 3.386]	1.131 [0.354, 3.611]	0.6 [-5.8, 7.0]	1.000
		Irbesartan	127	6 (4.7)				
> 5 years	Double-blind period	Sparsentan	89	7 (7.9)	5.899 [0.742, 46.871]	6.317 [0.759, 52.561]	6.5 [-0.9, 13.9]	0.072
		Irbesartan	75	1 (1.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AELN_SSIM: Incidence of AESI hepatic disorders during double-blind period – non-severe by subgroup
Safety Set

AESI hepatic disorders - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.149
Yes	Double-blind period	Sparsentan	153	11 (7.2)	2.822 [0.918, 8.670]	2.963 [0.922, 9.518]	4.6 [-0.8, 10.1]	0.067
		Irbesartan	157	4 (2.5)				
No	Double-blind period	Sparsentan	49	2 (4.1)	0.612 [0.107, 3.498]	0.596 [0.095, 3.740]	-2.6 [-13.9, 8.7]	0.668
		Irbesartan	45	3 (6.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AELC_SSIM: Incidence of AESI hepatic disorders during double-blind period – severe by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AELS_SSIM: Incidence of AESI hepatic disorders during double-blind period – serious by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEP_SSIM: Incidence of AESI acute pancreatitis during double-blind period by subgroup
Safety Set

AESI acute pancreatitis

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.600
Male	Double-blind period	Sparsentan	139	10 (7.2)	1.470 [0.576, 3.752]	1.506 [0.557, 4.075]	2.3 [-4.0, 8.6]	0.462
		Irbesartan	143	7 (4.9)				
Female	Double-blind period	Sparsentan	63	3 (4.8)	2.810 [0.301, 26.263]	2.900 [0.293, 28.688]	3.1 [-4.8, 10.9]	0.620
		Irbesartan	59	1 (1.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEP_SSIM: Incidence of AESI acute pancreatitis during double-blind period by subgroup
Safety Set

AESI acute pancreatitis

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.642
<= 45 years	Double-blind period	Sparsentan	96	6 (6.3)	2.063 [0.531, 8.013]	2.133 [0.518, 8.786]	3.2 [-3.7, 10.1]	0.326
		Irbesartan	99	3 (3.0)				
> 45 years	Double-blind period	Sparsentan	106	7 (6.6)	1.360 [0.446, 4.149]	1.386 [0.425, 4.515]	1.7 [-5.5, 9.0]	0.768
		Irbesartan	103	5 (4.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEP_SSIM: Incidence of AESI acute pancreatitis during double-blind period by subgroup
Safety Set

AESI acute pancreatitis

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.682
<= 18 years	Double-blind period	Sparsentan	9	1 (11.1)	1.800 + [0.086, 37.493]	1.941 + [0.066, 56.760]	11.1 [-25.0, 47.2]	1.000
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	8 (7.8)	2.137 [0.664, 6.883]	2.234 [0.652, 7.659]	4.2 [-3.1, 11.4]	0.240
		Irbesartan	109	4 (3.7)				
> 40 years	Double-blind period	Sparsentan	91	4 (4.4)	0.967 [0.250, 3.747]	0.966 [0.234, 3.986]	-0.1 [-7.3, 7.0]	1.000
		Irbesartan	88	4 (4.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEP_SSIM: Incidence of AESI acute pancreatitis during double-blind period by subgroup
Safety Set

AESI acute pancreatitis

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.410
North America	Double-blind period	Sparsentan	35	2 (5.7)	1.314 [0.195, 8.876]	1.333 [0.178, 9.964]	1.4 [-10.8, 13.6]	1.000
		Irbesartan	46	2 (4.3)				
Europe	Double-blind period	Sparsentan	98	9 (9.2)	2.640 [0.839, 8.310]	2.806 [0.836, 9.414]	5.7 [-1.9, 13.3]	0.094
		Irbesartan	115	4 (3.5)				
Asia Pacific	Double-blind period	Sparsentan	69	2 (2.9)	0.594 [0.087, 4.059]	0.582 [0.079, 4.298]	-2.0 [-11.6, 7.7]	0.628
		Irbesartan	41	2 (4.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEP_SSIM: Incidence of AESI acute pancreatitis during double-blind period by subgroup
Safety Set

AESI acute pancreatitis

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.949
< 27 kg/m**2	Double-blind period	Sparsentan	84	6 (7.1)	1.679 [0.490, 5.745]	1.731 [0.471, 6.357]	2.9 [-5.1, 10.9]	0.520
		Irbesartan	94	4 (4.3)				
>= 27 kg/m**2	Double-blind period	Sparsentan	118	7 (5.9)	1.587 [0.478, 5.270]	1.624 [0.462, 5.710]	2.2 [-4.3, 8.7]	0.544
		Irbesartan	107	4 (3.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEP_SSIM: Incidence of AESI acute pancreatitis during double-blind period by subgroup
Safety Set

AESI acute pancreatitis

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	NE
eGFR Low and UP High	Double-blind period	Sparsentan	71	6 (8.5) all n<10				NE
		Irbesartan	74	2 (2.7)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	3 (5.5) all n<10				NE
		Irbesartan	55	4 (7.3)				
eGFR High and UP High	Double-blind period	Sparsentan	37	3 (8.1) all n<10				NE
		Irbesartan	36	0 (0.0)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	1 (2.6) all n<10				NE
		Irbesartan	37	2 (5.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEP_SSIM: Incidence of AESI acute pancreatitis during double-blind period by subgroup
Safety Set

AESI acute pancreatitis

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.640
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	9 (7.1)	1.306 [0.502, 3.400]	1.329 [0.480, 3.685]	1.7 [-5.1, 8.4]	0.616
		Irbesartan	129	7 (5.4)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2)	3.918 [0.454, 33.802]	4.178 [0.450, 38.818]	6.1 [-4.6, 16.8]	0.362
		Irbesartan	48	1 (2.1)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.963 + [0.020, 46.760]	0.962 + [0.018, 50.349]	0.0 [NE, NE]	NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEP_SSIM: Incidence of AESI acute pancreatitis during double-blind period by subgroup
Safety Set

AESI acute pancreatitis

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	NE
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	3 (3.7) all n<10				NE
		Irbesartan	80	4 (5.0)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	6 (13.3) all n<10				NE
		Irbesartan	49	3 (6.1)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2) all n<10				NE
		Irbesartan	48	1 (2.1)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0) all n<10				NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEP_SSIM: Incidence of AESI acute pancreatitis during double-blind period by subgroup
Safety Set

AESI acute pancreatitis

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.241
<= 1.75 g/day	Double-blind period	Sparsentan	98	5 (5.1)	0.959 [0.287, 3.207]	0.957 [0.268, 3.419]	-0.2 [-7.5, 7.1]	1.000
		Irbesartan	94	5 (5.3)				
> 1.75 g/day	Double-blind period	Sparsentan	104	8 (7.7)	2.769 [0.755, 10.154]	2.917 [0.752, 11.312]	4.9 [-2.0, 11.8]	0.129
		Irbesartan	108	3 (2.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEP_SSIM: Incidence of AESI acute pancreatitis during double-blind period by subgroup
Safety Set

AESI acute pancreatitis

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.952
Yes	Double-blind period	Sparsentan	88	7 (8.0)	1.651 [0.501, 5.433]	1.707 [0.481, 6.059]	3.1 [-5.3, 11.6]	0.537
		Irbesartan	83	4 (4.8)				
No	Double-blind period	Sparsentan	114	6 (5.3)	1.566 [0.454, 5.404]	1.597 [0.439, 5.815]	1.9 [-4.2, 8.0]	0.532
		Irbesartan	119	4 (3.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEP_SSIM: Incidence of AESI acute pancreatitis during double-blind period by subgroup
Safety Set

AESI acute pancreatitis

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.939
<= 5 years	Double-blind period	Sparsentan	113	7 (6.2)	1.573 [0.514, 4.819]	1.611 [0.497, 5.227]	2.3 [-4.2, 8.7]	0.556
		Irbesartan	127	5 (3.9)				
> 5 years	Double-blind period	Sparsentan	89	6 (6.7)	1.685 [0.436, 6.511]	1.735 [0.419, 7.188]	2.7 [-5.3, 10.8]	0.510
		Irbesartan	75	3 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEP_SSIM: Incidence of AESI acute pancreatitis during double-blind period by subgroup
Safety Set

AESI acute pancreatitis

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.095
Yes	Double-blind period	Sparsentan	153	12 (7.8)	2.463 [0.889, 6.824]	2.587 [0.889, 7.529]	4.7 [-1.1, 10.4]	0.084
		Irbesartan	157	5 (3.2)				
No	Double-blind period	Sparsentan	49	1 (2.0)	0.306 [0.033, 2.838]	0.292 [0.029, 2.911]	-4.6 [-15.1, 5.8]	0.346
		Irbesartan	45	3 (6.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEPN_SSIM: Incidence of AESI acute pancreatitis during double-blind period – non-severe by subgroup
Safety Set

AESI acute pancreatitis - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.600
Male	Double-blind period	Sparsentan	139	10 (7.2)	1.470 [0.576, 3.752]	1.506 [0.557, 4.075]	2.3 [-4.0, 8.6]	0.462
		Irbesartan	143	7 (4.9)				
Female	Double-blind period	Sparsentan	63	3 (4.8)	2.810 [0.301, 26.263]	2.900 [0.293, 28.688]	3.1 [-4.8, 10.9]	0.620
		Irbesartan	59	1 (1.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEPN_SSIM: Incidence of AESI acute pancreatitis during double-blind period – non-severe by subgroup
Safety Set

AESI acute pancreatitis - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.642
<= 45 years	Double-blind period	Sparsentan	96	6 (6.3)	2.063 [0.531, 8.013]	2.133 [0.518, 8.786]	3.2 [-3.7, 10.1]	0.326
		Irbesartan	99	3 (3.0)				
> 45 years	Double-blind period	Sparsentan	106	7 (6.6)	1.360 [0.446, 4.149]	1.386 [0.425, 4.515]	1.7 [-5.5, 9.0]	0.768
		Irbesartan	103	5 (4.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEPN_SSIM: Incidence of AESI acute pancreatitis during double-blind period – non-severe by subgroup
Safety Set

AESI acute pancreatitis - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.682
<= 18 years	Double-blind period	Sparsentan	9	1 (11.1)	1.800 + [0.086, 37.493]	1.941 + [0.066, 56.760]	11.1 [-25.0, 47.2]	1.000
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	8 (7.8)	2.137 [0.664, 6.883]	2.234 [0.652, 7.659]	4.2 [-3.1, 11.4]	0.240
		Irbesartan	109	4 (3.7)				
> 40 years	Double-blind period	Sparsentan	91	4 (4.4)	0.967 [0.250, 3.747]	0.966 [0.234, 3.986]	-0.1 [-7.3, 7.0]	1.000
		Irbesartan	88	4 (4.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEPN_SSIM: Incidence of AESI acute pancreatitis during double-blind period – non-severe by subgroup
Safety Set

AESI acute pancreatitis - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.410
North America	Double-blind period	Sparsentan	35	2 (5.7)	1.314 [0.195, 8.876]	1.333 [0.178, 9.964]	1.4 [-10.8, 13.6]	1.000
		Irbesartan	46	2 (4.3)				
Europe	Double-blind period	Sparsentan	98	9 (9.2)	2.640 [0.839, 8.310]	2.806 [0.836, 9.414]	5.7 [-1.9, 13.3]	0.094
		Irbesartan	115	4 (3.5)				
Asia Pacific	Double-blind period	Sparsentan	69	2 (2.9)	0.594 [0.087, 4.059]	0.582 [0.079, 4.298]	-2.0 [-11.6, 7.7]	0.628
		Irbesartan	41	2 (4.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEPN_SSIM: Incidence of AESI acute pancreatitis during double-blind period – non-severe by subgroup
Safety Set

AESI acute pancreatitis - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.949
< 27 kg/m**2	Double-blind period	Sparsentan	84	6 (7.1)	1.679 [0.490, 5.745]	1.731 [0.471, 6.357]	2.9 [-5.1, 10.9]	0.520
		Irbesartan	94	4 (4.3)				
>= 27 kg/m**2	Double-blind period	Sparsentan	118	7 (5.9)	1.587 [0.478, 5.270]	1.624 [0.462, 5.710]	2.2 [-4.3, 8.7]	0.544
		Irbesartan	107	4 (3.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEPN_SSIM: Incidence of AESI acute pancreatitis during double-blind period – non-severe by subgroup
Safety Set

AESI acute pancreatitis - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	NE
eGFR Low and UP High	Double-blind period	Sparsentan	71	6 (8.5) all n<10				NE
		Irbesartan	74	2 (2.7)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	3 (5.5) all n<10				NE
		Irbesartan	55	4 (7.3)				
eGFR High and UP High	Double-blind period	Sparsentan	37	3 (8.1) all n<10				NE
		Irbesartan	36	0 (0.0)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	1 (2.6) all n<10				NE
		Irbesartan	37	2 (5.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEPN_SSIM: Incidence of AESI acute pancreatitis during double-blind period – non-severe by subgroup
Safety Set

AESI acute pancreatitis - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.640
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	9 (7.1)	1.306 [0.502, 3.400]	1.329 [0.480, 3.685]	1.7 [-5.1, 8.4]	0.616
		Irbesartan	129	7 (5.4)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2)	3.918 [0.454, 33.802]	4.178 [0.450, 38.818]	6.1 [-4.6, 16.8]	0.362
		Irbesartan	48	1 (2.1)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.963 + [0.020, 46.760]	0.962 + [0.018, 50.349]	0.0 [NE, NE]	NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEPN_SSIM: Incidence of AESI acute pancreatitis during double-blind period – non-severe by subgroup
Safety Set

AESI acute pancreatitis - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	NE
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	3 (3.7) all n<10				NE
		Irbesartan	80	4 (5.0)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	6 (13.3) all n<10				NE
		Irbesartan	49	3 (6.1)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2) all n<10				NE
		Irbesartan	48	1 (2.1)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0) all n<10				NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEPN_SSIM: Incidence of AESI acute pancreatitis during double-blind period – non-severe by subgroup
Safety Set

AESI acute pancreatitis - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.241
<= 1.75 g/day	Double-blind period	Sparsentan	98	5 (5.1)	0.959 [0.287, 3.207]	0.957 [0.268, 3.419]	-0.2 [-7.5, 7.1]	1.000
		Irbesartan	94	5 (5.3)				
> 1.75 g/day	Double-blind period	Sparsentan	104	8 (7.7)	2.769 [0.755, 10.154]	2.917 [0.752, 11.312]	4.9 [-2.0, 11.8]	0.129
		Irbesartan	108	3 (2.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEPN_SSIM: Incidence of AESI acute pancreatitis during double-blind period – non-severe by subgroup
Safety Set

AESI acute pancreatitis - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.952
Yes	Double-blind period	Sparsentan	88	7 (8.0)	1.651 [0.501, 5.433]	1.707 [0.481, 6.059]	3.1 [-5.3, 11.6]	0.537
		Irbesartan	83	4 (4.8)				
No	Double-blind period	Sparsentan	114	6 (5.3)	1.566 [0.454, 5.404]	1.597 [0.439, 5.815]	1.9 [-4.2, 8.0]	0.532
		Irbesartan	119	4 (3.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEPN_SSIM: Incidence of AESI acute pancreatitis during double-blind period – non-severe by subgroup
Safety Set

AESI acute pancreatitis - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.939
<= 5 years	Double-blind period	Sparsentan	113	7 (6.2)	1.573 [0.514, 4.819]	1.611 [0.497, 5.227]	2.3 [-4.2, 8.7]	0.556
		Irbesartan	127	5 (3.9)				
> 5 years	Double-blind period	Sparsentan	89	6 (6.7)	1.685 [0.436, 6.511]	1.735 [0.419, 7.188]	2.7 [-5.3, 10.8]	0.510
		Irbesartan	75	3 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEPN_SSIM: Incidence of AESI acute pancreatitis during double-blind period – non-severe by subgroup
Safety Set

AESI acute pancreatitis - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.095
Yes	Double-blind period	Sparsentan	153	12 (7.8)	2.463 [0.889, 6.824]	2.587 [0.889, 7.529]	4.7 [-1.1, 10.4]	0.084
		Irbesartan	157	5 (3.2)				
No	Double-blind period	Sparsentan	49	1 (2.0)	0.306 [0.033, 2.838]	0.292 [0.029, 2.911]	-4.6 [-15.1, 5.8]	0.346
		Irbesartan	45	3 (6.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEPC_SSIM: Incidence of AESI acute pancreatitis during double-blind period – severe by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEPS_SSIM: Incidence of AESI acute pancreatitis during double-blind period – serious by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEO_SSIM: Incidence of AESI fluid retention during double-blind period by subgroup
Safety Set

AESI fluid retention

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.985
Male	Double-blind period	Sparsentan	139	18 (12.9)	1.543 [0.772, 3.083]	1.624 [0.751, 3.511]	4.6 [-3.3, 12.5]	0.249
		Irbesartan	143	12 (8.4)				
Female	Double-blind period	Sparsentan	63	10 (15.9)	1.561 [0.605, 4.027]	1.667 [0.565, 4.915]	5.7 [-7.8, 19.2]	0.426
		Irbesartan	59	6 (10.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEO_SSIM: Incidence of AESI fluid retention during double-blind period by subgroup
Safety Set

AESI fluid retention

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.322
<= 45 years	Double-blind period	Sparsentan	96	16 (16.7)	2.063 [0.926, 4.594]	2.275 [0.925, 5.597]	8.6 [-1.6, 18.8]	0.082
		Irbesartan	99	8 (8.1)				
> 45 years	Double-blind period	Sparsentan	106	12 (11.3)	1.166 [0.527, 2.580]	1.187 [0.489, 2.882]	1.6 [-7.7, 10.9]	0.823
		Irbesartan	103	10 (9.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEO_SSIM: Incidence of AESI fluid retention during double-blind period by subgroup
Safety Set

AESI fluid retention

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.636
<= 18 years	Double-blind period	Sparsentan	9	0 (0.0)	0.600 + [0.014, 26.475]	0.579 + [0.010, 33.502]	0.0 [NE, NE]	NE
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	15 (14.7)	2.004 [0.887, 4.524]	2.177 [0.881, 5.379]	7.4 [-2.0, 16.8]	0.121
		Irbesartan	109	8 (7.3)				
> 40 years	Double-blind period	Sparsentan	91	13 (14.3)	1.257 [0.582, 2.717]	1.300 [0.538, 3.141]	2.9 [-8.0, 13.8]	0.657
		Irbesartan	88	10 (11.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEO_SSIM: Incidence of AESI fluid retention during double-blind period by subgroup
Safety Set

AESI fluid retention

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.951
North America	Double-blind period	Sparsentan	35	1 (2.9)	1.314 [0.085, 20.288]	1.324 [0.080, 21.926]	0.7 [-8.8, 10.1]	1.000
		Irbesartan	46	1 (2.2)				
Europe	Double-blind period	Sparsentan	98	18 (18.4)	1.625 [0.839, 3.145]	1.765 [0.816, 3.817]	7.1 [-3.5, 17.6]	0.174
		Irbesartan	115	13 (11.3)				
Asia Pacific	Double-blind period	Sparsentan	69	9 (13.0)	1.337 [0.439, 4.067]	1.388 [0.399, 4.828]	3.3 [-10.7, 17.3]	0.764
		Irbesartan	41	4 (9.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEO_SSIM: Incidence of AESI fluid retention during double-blind period by subgroup
Safety Set

AESI fluid retention

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.198
< 27 kg/m**2	Double-blind period	Sparsentan	84	9 (10.7)	1.007 [0.430, 2.359]	1.008 [0.389, 2.614]	0.1 [-10.1, 10.3]	1.000
		Irbesartan	94	10 (10.6)				
>= 27 kg/m**2	Double-blind period	Sparsentan	118	19 (16.1)	2.154 [0.984, 4.715]	2.375 [0.993, 5.679]	8.6 [-0.6, 17.8]	0.064
		Irbesartan	107	8 (7.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEO_SSIM: Incidence of AESI fluid retention during double-blind period by subgroup
Safety Set

AESI fluid retention

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.388
eGFR Low and UP High	Double-blind period	Sparsentan	71	10 (14.1)	1.303 [0.545, 3.112]	1.352 [0.501, 3.650]	3.3 [-8.9, 15.4]	0.620
		Irbesartan	74	8 (10.8)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	9 (16.4)	1.800 [0.644, 5.029]	1.957 [0.611, 6.268]	7.3 [-6.9, 21.5]	0.392
		Irbesartan	55	5 (9.1)				
eGFR High and UP High	Double-blind period	Sparsentan	37	4 (10.8)	0.778 [0.227, 2.669]	0.752 [0.185, 3.057]	-3.1 [-20.9, 14.8]	0.736
		Irbesartan	36	5 (13.9)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	5 (12.8)	10.450 + [0.598, 182.621]	11.957 + [0.637, 224.309]	12.8 [-0.3, 25.9]	0.055
		Irbesartan	37	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEO_SSIM: Incidence of AESI fluid retention during double-blind period by subgroup
Safety Set

AESI fluid retention

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.677
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	19 (15.0)	1.608 [0.815, 3.174]	1.715 [0.795, 3.699]	5.7 [-3.1, 14.4]	0.184
		Irbesartan	129	12 (9.3)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2)	0.980 [0.260, 3.695]	0.978 [0.230, 4.155]	-0.2 [-13.2, 12.8]	1.000
		Irbesartan	48	4 (8.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	5 (19.2)	2.404 [0.513, 11.271]	2.738 [0.479, 15.651]	11.2 [-11.2, 33.7]	0.419
		Irbesartan	25	2 (8.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEO_SSIM: Incidence of AESI fluid retention during double-blind period by subgroup
Safety Set

AESI fluid retention

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.366	
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	8 (9.8)	0.976 [0.385, 2.473]	0.973 [0.347, 2.732]	-0.2 [-10.7, 10.2]	1.000	
		Irbesartan	80	8 (10.0)					
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	11 (24.4)	2.994 [1.027, 8.734]	3.640 [1.066, 12.427]	16.3 [-0.6, 33.1]	0.047	*
		Irbesartan	49	4 (8.2)					
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2)	0.980 [0.260, 3.695]	0.978 [0.230, 4.155]	-0.2 [-13.2, 12.8]	1.000	
		Irbesartan	48	4 (8.3)					
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	5 (19.2)	2.404 [0.513, 11.271]	2.738 [0.479, 15.651]	11.2 [-11.2, 33.7]	0.419	
		Irbesartan	25	2 (8.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEO_SSIM: Incidence of AESI fluid retention during double-blind period by subgroup
Safety Set

AESI fluid retention

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.302
<= 1.75 g/day	Double-blind period	Sparsentan	98	14 (14.3)	2.238 [0.898, 5.580]	2.444 [0.897, 6.658]	7.9 [-1.6, 17.5]	0.098
		Irbesartan	94	6 (6.4)				
> 1.75 g/day	Double-blind period	Sparsentan	104	14 (13.5)	1.212 [0.588, 2.495]	1.244 [0.546, 2.834]	2.4 [-7.4, 12.1]	0.678
		Irbesartan	108	12 (11.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEO_SSIM: Incidence of AESI fluid retention during double-blind period by subgroup
Safety Set

AESI fluid retention

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.115	
Yes	Double-blind period	Sparsentan	88	13 (14.8)	1.022 [0.495, 2.110]	1.026 [0.439, 2.397]	0.3 [-11.4, 12.1]	1.000	
		Irbesartan	83	12 (14.5)					
No	Double-blind period	Sparsentan	114	15 (13.2)	2.610 [1.049, 6.491]	2.854 [1.066, 7.637]	8.1 [-0.1, 16.3]	0.039	*
		Irbesartan	119	6 (5.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEO_SSIM: Incidence of AESI fluid retention during double-blind period by subgroup
Safety Set

AESI fluid retention

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.033	#
<= 5 years	Double-blind period	Sparsentan	113	19 (16.8)	2.669 [1.216, 5.859]	3.007 [1.261, 7.171]	10.5 [1.6, 19.4]	0.013	*
		Irbesartan	127	8 (6.3)					
> 5 years	Double-blind period	Sparsentan	89	9 (10.1)	0.758 [0.325, 1.768]	0.731 [0.281, 1.906]	-3.2 [-14.4, 7.9]	0.626	
		Irbesartan	75	10 (13.3)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEO_SSIM: Incidence of AESI fluid retention during double-blind period by subgroup
Safety Set

AESI fluid retention

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.713
Yes	Double-blind period	Sparsentan	153	24 (15.7)	1.642 [0.896, 3.008]	1.761 [0.885, 3.503]	6.1 [-1.9, 14.1]	0.124
		Irbesartan	157	15 (9.6)				
No	Double-blind period	Sparsentan	49	4 (8.2)	1.224 [0.290, 5.174]	1.244 [0.263, 5.892]	1.5 [-11.2, 14.2]	1.000
		Irbesartan	45	3 (6.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEON_SSIM: Incidence of AESI fluid retention during double-blind period – non-severe by subgroup
Safety Set

AESI fluid retention - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.985
Male	Double-blind period	Sparsentan	139	18 (12.9)	1.543 [0.772, 3.083]	1.624 [0.751, 3.511]	4.6 [-3.3, 12.5]	0.249
		Irbesartan	143	12 (8.4)				
Female	Double-blind period	Sparsentan	63	10 (15.9)	1.561 [0.605, 4.027]	1.667 [0.565, 4.915]	5.7 [-7.8, 19.2]	0.426
		Irbesartan	59	6 (10.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEON_SSIM: Incidence of AESI fluid retention during double-blind period – non-severe by subgroup
Safety Set

AESI fluid retention - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.322
<= 45 years	Double-blind period	Sparsentan	96	16 (16.7)	2.063 [0.926, 4.594]	2.275 [0.925, 5.597]	8.6 [-1.6, 18.8]	0.082
		Irbesartan	99	8 (8.1)				
> 45 years	Double-blind period	Sparsentan	106	12 (11.3)	1.166 [0.527, 2.580]	1.187 [0.489, 2.882]	1.6 [-7.7, 10.9]	0.823
		Irbesartan	103	10 (9.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEON_SSIM: Incidence of AESI fluid retention during double-blind period – non-severe by subgroup
Safety Set

AESI fluid retention - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.636
<= 18 years	Double-blind period	Sparsentan	9	0 (0.0)	0.600 + [0.014, 26.475]	0.579 + [0.010, 33.502]	0.0 [NE, NE]	NE
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	15 (14.7)	2.004 [0.887, 4.524]	2.177 [0.881, 5.379]	7.4 [-2.0, 16.8]	0.121
		Irbesartan	109	8 (7.3)				
> 40 years	Double-blind period	Sparsentan	91	13 (14.3)	1.257 [0.582, 2.717]	1.300 [0.538, 3.141]	2.9 [-8.0, 13.8]	0.657
		Irbesartan	88	10 (11.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEON_SSIM: Incidence of AESI fluid retention during double-blind period – non-severe by subgroup
Safety Set

AESI fluid retention - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.951
North America	Double-blind period	Sparsentan	35	1 (2.9)	1.314 [0.085, 20.288]	1.324 [0.080, 21.926]	0.7 [-8.8, 10.1]	1.000
		Irbesartan	46	1 (2.2)				
Europe	Double-blind period	Sparsentan	98	18 (18.4)	1.625 [0.839, 3.145]	1.765 [0.816, 3.817]	7.1 [-3.5, 17.6]	0.174
		Irbesartan	115	13 (11.3)				
Asia Pacific	Double-blind period	Sparsentan	69	9 (13.0)	1.337 [0.439, 4.067]	1.388 [0.399, 4.828]	3.3 [-10.7, 17.3]	0.764
		Irbesartan	41	4 (9.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEON_SSIM: Incidence of AESI fluid retention during double-blind period – non-severe by subgroup
Safety Set

AESI fluid retention - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.198
< 27 kg/m**2	Double-blind period	Sparsentan	84	9 (10.7)	1.007 [0.430, 2.359]	1.008 [0.389, 2.614]	0.1 [-10.1, 10.3]	1.000
		Irbesartan	94	10 (10.6)				
>= 27 kg/m**2	Double-blind period	Sparsentan	118	19 (16.1)	2.154 [0.984, 4.715]	2.375 [0.993, 5.679]	8.6 [-0.6, 17.8]	0.064
		Irbesartan	107	8 (7.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEON_SSIM: Incidence of AESI fluid retention during double-blind period – non-severe by subgroup
Safety Set

AESI fluid retention - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.388
eGFR Low and UP High	Double-blind period	Sparsentan	71	10 (14.1)	1.303 [0.545, 3.112]	1.352 [0.501, 3.650]	3.3 [-8.9, 15.4]	0.620
		Irbesartan	74	8 (10.8)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	9 (16.4)	1.800 [0.644, 5.029]	1.957 [0.611, 6.268]	7.3 [-6.9, 21.5]	0.392
		Irbesartan	55	5 (9.1)				
eGFR High and UP High	Double-blind period	Sparsentan	37	4 (10.8)	0.778 [0.227, 2.669]	0.752 [0.185, 3.057]	-3.1 [-20.9, 14.8]	0.736
		Irbesartan	36	5 (13.9)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	5 (12.8)	10.450 + [0.598, 182.621]	11.957 + [0.637, 224.309]	12.8 [-0.3, 25.9]	0.055
		Irbesartan	37	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEON_SSIM: Incidence of AESI fluid retention during double-blind period – non-severe by subgroup
Safety Set

AESI fluid retention - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.677
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	19 (15.0)	1.608 [0.815, 3.174]	1.715 [0.795, 3.699]	5.7 [-3.1, 14.4]	0.184
		Irbesartan	129	12 (9.3)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2)	0.980 [0.260, 3.695]	0.978 [0.230, 4.155]	-0.2 [-13.2, 12.8]	1.000
		Irbesartan	48	4 (8.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	5 (19.2)	2.404 [0.513, 11.271]	2.738 [0.479, 15.651]	11.2 [-11.2, 33.7]	0.419
		Irbesartan	25	2 (8.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEON_SSIM: Incidence of AESI fluid retention during double-blind period – non-severe by subgroup
Safety Set

AESI fluid retention - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.366	
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	8 (9.8)	0.976 [0.385, 2.473]	0.973 [0.347, 2.732]	-0.2 [-10.7, 10.2]	1.000	
		Irbesartan	80	8 (10.0)					
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	11 (24.4)	2.994 [1.027, 8.734]	3.640 [1.066, 12.427]	16.3 [-0.6, 33.1]	0.047	*
		Irbesartan	49	4 (8.2)					
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2)	0.980 [0.260, 3.695]	0.978 [0.230, 4.155]	-0.2 [-13.2, 12.8]	1.000	
		Irbesartan	48	4 (8.3)					
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	5 (19.2)	2.404 [0.513, 11.271]	2.738 [0.479, 15.651]	11.2 [-11.2, 33.7]	0.419	
		Irbesartan	25	2 (8.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEON_SSIM: Incidence of AESI fluid retention during double-blind period – non-severe by subgroup
Safety Set

AESI fluid retention - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.302
<= 1.75 g/day	Double-blind period	Sparsentan	98	14 (14.3)	2.238 [0.898, 5.580]	2.444 [0.897, 6.658]	7.9 [-1.6, 17.5]	0.098
		Irbesartan	94	6 (6.4)				
> 1.75 g/day	Double-blind period	Sparsentan	104	14 (13.5)	1.212 [0.588, 2.495]	1.244 [0.546, 2.834]	2.4 [-7.4, 12.1]	0.678
		Irbesartan	108	12 (11.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEON_SSIM: Incidence of AESI fluid retention during double-blind period – non-severe by subgroup
Safety Set

AESI fluid retention - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.115	
Yes	Double-blind period	Sparsentan	88	13 (14.8)	1.022 [0.495, 2.110]	1.026 [0.439, 2.397]	0.3 [-11.4, 12.1]	1.000	
		Irbesartan	83	12 (14.5)					
No	Double-blind period	Sparsentan	114	15 (13.2)	2.610 [1.049, 6.491]	2.854 [1.066, 7.637]	8.1 [-0.1, 16.3]	0.039	*
		Irbesartan	119	6 (5.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEON_SSIM: Incidence of AESI fluid retention during double-blind period – non-severe by subgroup
Safety Set

AESI fluid retention - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.033	#
<= 5 years	Double-blind period	Sparsentan	113	19 (16.8)	2.669 [1.216, 5.859]	3.007 [1.261, 7.171]	10.5 [1.6, 19.4]	0.013	*
		Irbesartan	127	8 (6.3)					
> 5 years	Double-blind period	Sparsentan	89	9 (10.1)	0.758 [0.325, 1.768]	0.731 [0.281, 1.906]	-3.2 [-14.4, 7.9]	0.626	
		Irbesartan	75	10 (13.3)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEON_SSIM: Incidence of AESI fluid retention during double-blind period – non-severe by subgroup
Safety Set

AESI fluid retention - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.713
Yes	Double-blind period	Sparsentan	153	24 (15.7)	1.642 [0.896, 3.008]	1.761 [0.885, 3.503]	6.1 [-1.9, 14.1]	0.124
		Irbesartan	157	15 (9.6)				
No	Double-blind period	Sparsentan	49	4 (8.2)	1.224 [0.290, 5.174]	1.244 [0.263, 5.892]	1.5 [-11.2, 14.2]	1.000
		Irbesartan	45	3 (6.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEOC_SSIM: Incidence of AESI fluid retention during double-blind period – severe by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEOS_SSIM: Incidence of AESI fluid retention during double-blind period – serious by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEA_SSIM: Incidence of AESI anemia during double-blind period by subgroup
Safety Set

AESI anemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.692
Male	Double-blind period	Sparsentan	139	10 (7.2)	1.715 [0.640, 4.591]	1.770 [0.625, 5.009]	3.0 [-3.1, 9.1]	0.312
		Irbesartan	143	6 (4.2)				
Female	Double-blind period	Sparsentan	63	3 (4.8)	2.810 [0.301, 26.263]	2.900 [0.293, 28.688]	3.1 [-4.8, 10.9]	0.620
		Irbesartan	59	1 (1.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEA_SSIM: Incidence of AESI anemia during double-blind period by subgroup
Safety Set

AESI anemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.454
<= 45 years	Double-blind period	Sparsentan	96	5 (5.2)	1.289 [0.357, 4.657]	1.305 [0.340, 5.013]	1.2 [-5.8, 8.1]	0.745
		Irbesartan	99	4 (4.0)				
> 45 years	Double-blind period	Sparsentan	106	8 (7.5)	2.591 [0.707, 9.497]	2.721 [0.701, 10.558]	4.6 [-2.3, 11.6]	0.215
		Irbesartan	103	3 (2.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEA_SSIM: Incidence of AESI anemia during double-blind period by subgroup
Safety Set

AESI anemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.585
<= 18 years	Double-blind period	Sparsentan	9	0 (0.0)	0.600 + [0.014, 26.475]	0.579 + [0.010, 33.502]	0.0 [NE, NE]	NE
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	6 (5.9)	3.206 [0.662, 15.523]	3.344 [0.659, 16.961]	4.0 [-2.1, 10.2]	0.159
		Irbesartan	109	2 (1.8)				
> 40 years	Double-blind period	Sparsentan	91	7 (7.7)	1.354 [0.446, 4.106]	1.383 [0.422, 4.534]	2.0 [-6.4, 10.4]	0.767
		Irbesartan	88	5 (5.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEA_SSIM: Incidence of AESI anemia during double-blind period by subgroup
Safety Set

AESI anemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.335
North America	Double-blind period	Sparsentan	35	0 (0.0)	1.306 + [0.027, 64.228]	1.310 + [0.025, 67.634]	0.0 [NE, NE]	NE
		Irbesartan	46	0 (0.0)				
Europe	Double-blind period	Sparsentan	98	6 (6.1)	3.520 [0.727, 17.048]	3.685 [0.726, 18.690]	4.4 [-1.9, 10.6]	0.147
		Irbesartan	115	2 (1.7)				
Asia Pacific	Double-blind period	Sparsentan	69	7 (10.1)	0.832 [0.282, 2.451]	0.813 [0.240, 2.750]	-2.1 [-16.3, 12.2]	0.759
		Irbesartan	41	5 (12.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEA_SSIM: Incidence of AESI anemia during double-blind period by subgroup
Safety Set

AESI anemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.812
< 27 kg/m**2	Double-blind period	Sparsentan	84	8 (9.5)	1.790 [0.609, 5.261]	1.874 [0.588, 5.968]	4.2 [-4.7, 13.1]	0.389
		Irbesartan	94	5 (5.3)				
>= 27 kg/m**2	Double-blind period	Sparsentan	118	5 (4.2)	2.267 [0.449, 11.442]	2.323 [0.441, 12.232]	2.4 [-3.0, 7.7]	0.450
		Irbesartan	107	2 (1.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEA_SSIM: Incidence of AESI anemia during double-blind period by subgroup
Safety Set

AESI anemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.798
eGFR Low and UP High	Double-blind period	Sparsentan	71	8 (11.3)	2.085 [0.657, 6.618]	2.222 [0.638, 7.737]	5.9 [-4.5, 16.2]	0.238
		Irbesartan	74	4 (5.4)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	2 (3.6)	1.000 [0.146, 6.848]	1.000 [0.136, 7.364]	0.0 [-8.8, 8.8]	1.000
		Irbesartan	55	2 (3.6)				
eGFR High and UP High	Double-blind period	Sparsentan	37	1 (2.7)	0.973 [0.063, 14.972]	0.972 [0.058, 16.158]	-0.1 [-10.3, 10.2]	1.000
		Irbesartan	36	1 (2.8)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	2 (5.1)	4.750 + [0.236, 95.763]	5.000 + [0.232, 107.700]	5.1 [-4.4, 14.7]	0.494
		Irbesartan	37	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEA_SSIM: Incidence of AESI anemia during double-blind period by subgroup
Safety Set

AESI anemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.379
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	10 (7.9)	1.693 [0.634, 4.520]	1.752 [0.617, 4.974]	3.2 [-3.5, 9.9]	0.314
		Irbesartan	129	6 (4.7)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	3 (6.1)	6.860 + [0.364, 129.358]	7.301 + [0.367, 145.240]	6.1 [-2.7, 14.9]	0.242
		Irbesartan	48	0 (0.0)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.321 + [0.014, 7.528]	0.308 + [0.012, 7.927]	-4.0 [-15.6, 7.6]	0.490
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEA_SSIM: Incidence of AESI anemia during double-blind period by subgroup
Safety Set

AESI anemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	NE
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	6 (7.3) all n<10				NE
		Irbesartan	80	3 (3.8)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	4 (8.9) all n<10				NE
		Irbesartan	49	3 (6.1)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	3 (6.1) all n<10				NE
		Irbesartan	48	0 (0.0)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0) all n<10				NE
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEA_SSIM: Incidence of AESI anemia during double-blind period by subgroup
Safety Set

AESI anemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.712
<= 1.75 g/day	Double-blind period	Sparsentan	98	5 (5.1)	2.398 [0.477, 12.059]	2.473 [0.468, 13.072]	3.0 [-3.3, 9.3]	0.445
		Irbesartan	94	2 (2.1)				
> 1.75 g/day	Double-blind period	Sparsentan	104	8 (7.7)	1.662 [0.562, 4.914]	1.717 [0.543, 5.429]	3.1 [-4.4, 10.5]	0.402
		Irbesartan	108	5 (4.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEA_SSIM: Incidence of AESI anemia during double-blind period by subgroup
Safety Set

AESI anemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.207
Yes	Double-blind period	Sparsentan	88	4 (4.5)	0.943 [0.244, 3.649]	0.940 [0.227, 3.889]	-0.3 [-7.8, 7.2]	1.000
		Irbesartan	83	4 (4.8)				
No	Double-blind period	Sparsentan	114	9 (7.9)	3.132 [0.870, 11.276]	3.314 [0.874, 12.570]	5.4 [-1.2, 11.9]	0.079
		Irbesartan	119	3 (2.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEA_SSIM: Incidence of AESI anemia during double-blind period by subgroup
Safety Set

AESI anemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.260
<= 5 years	Double-blind period	Sparsentan	113	7 (6.2)	1.311 [0.454, 3.787]	1.332 [0.434, 4.086]	1.5 [-5.1, 8.1]	0.777
		Irbesartan	127	6 (4.7)				
> 5 years	Double-blind period	Sparsentan	89	6 (6.7)	5.056 [0.623, 41.067]	5.349 [0.629, 45.470]	5.4 [-1.6, 12.5]	0.127
		Irbesartan	75	1 (1.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEA_SSIM: Incidence of AESI anemia during double-blind period by subgroup
Safety Set

AESI anemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.701
Yes	Double-blind period	Sparsentan	153	10 (6.5)	1.710 [0.637, 4.590]	1.760 [0.624, 4.967]	2.7 [-2.9, 8.3]	0.314
		Irbesartan	157	6 (3.8)				
No	Double-blind period	Sparsentan	49	3 (6.1)	2.755 [0.297, 25.538]	2.870 [0.288, 28.639]	3.9 [-6.2, 14.0]	0.618
		Irbesartan	45	1 (2.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEAN_SSIM: Incidence of AESI anemia during double-blind period – non-severe by subgroup
Safety Set

AESI anemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.692
Male	Double-blind period	Sparsentan	139	10 (7.2)	1.715 [0.640, 4.591]	1.770 [0.625, 5.009]	3.0 [-3.1, 9.1]	0.312
		Irbesartan	143	6 (4.2)				
Female	Double-blind period	Sparsentan	63	3 (4.8)	2.810 [0.301, 26.263]	2.900 [0.293, 28.688]	3.1 [-4.8, 10.9]	0.620
		Irbesartan	59	1 (1.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEAN_SSIM: Incidence of AESI anemia during double-blind period – non-severe by subgroup
Safety Set

AESI anemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.454
<= 45 years	Double-blind period	Sparsentan	96	5 (5.2)	1.289 [0.357, 4.657]	1.305 [0.340, 5.013]	1.2 [-5.8, 8.1]	0.745
		Irbesartan	99	4 (4.0)				
> 45 years	Double-blind period	Sparsentan	106	8 (7.5)	2.591 [0.707, 9.497]	2.721 [0.701, 10.558]	4.6 [-2.3, 11.6]	0.215
		Irbesartan	103	3 (2.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEAN_SSIM: Incidence of AESI anemia during double-blind period – non-severe by subgroup
Safety Set

AESI anemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.585
<= 18 years	Double-blind period	Sparsentan	9	0 (0.0)	0.600 + [0.014, 26.475]	0.579 + [0.010, 33.502]	0.0 [NE, NE]	NE
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	6 (5.9)	3.206 [0.662, 15.523]	3.344 [0.659, 16.961]	4.0 [-2.1, 10.2]	0.159
		Irbesartan	109	2 (1.8)				
> 40 years	Double-blind period	Sparsentan	91	7 (7.7)	1.354 [0.446, 4.106]	1.383 [0.422, 4.534]	2.0 [-6.4, 10.4]	0.767
		Irbesartan	88	5 (5.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEAN_SSIM: Incidence of AESI anemia during double-blind period – non-severe by subgroup
Safety Set

AESI anemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.335
North America	Double-blind period	Sparsentan	35	0 (0.0)	1.306 + [0.027, 64.228]	1.310 + [0.025, 67.634]	0.0 [NE, NE]	NE
		Irbesartan	46	0 (0.0)				
Europe	Double-blind period	Sparsentan	98	6 (6.1)	3.520 [0.727, 17.048]	3.685 [0.726, 18.690]	4.4 [-1.9, 10.6]	0.147
		Irbesartan	115	2 (1.7)				
Asia Pacific	Double-blind period	Sparsentan	69	7 (10.1)	0.832 [0.282, 2.451]	0.813 [0.240, 2.750]	-2.1 [-16.3, 12.2]	0.759
		Irbesartan	41	5 (12.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEAN_SSIM: Incidence of AESI anemia during double-blind period – non-severe by subgroup
Safety Set

AESI anemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.812
< 27 kg/m**2	Double-blind period	Sparsentan	84	8 (9.5)	1.790 [0.609, 5.261]	1.874 [0.588, 5.968]	4.2 [-4.7, 13.1]	0.389
		Irbesartan	94	5 (5.3)				
>= 27 kg/m**2	Double-blind period	Sparsentan	118	5 (4.2)	2.267 [0.449, 11.442]	2.323 [0.441, 12.232]	2.4 [-3.0, 7.7]	0.450
		Irbesartan	107	2 (1.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEAN_SSIM: Incidence of AESI anemia during double-blind period – non-severe by subgroup
Safety Set

AESI anemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.798
eGFR Low and UP High	Double-blind period	Sparsentan	71	8 (11.3)	2.085 [0.657, 6.618]	2.222 [0.638, 7.737]	5.9 [-4.5, 16.2]	0.238
		Irbesartan	74	4 (5.4)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	2 (3.6)	1.000 [0.146, 6.848]	1.000 [0.136, 7.364]	0.0 [-8.8, 8.8]	1.000
		Irbesartan	55	2 (3.6)				
eGFR High and UP High	Double-blind period	Sparsentan	37	1 (2.7)	0.973 [0.063, 14.972]	0.972 [0.058, 16.158]	-0.1 [-10.3, 10.2]	1.000
		Irbesartan	36	1 (2.8)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	2 (5.1)	4.750 + [0.236, 95.763]	5.000 + [0.232, 107.700]	5.1 [-4.4, 14.7]	0.494
		Irbesartan	37	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEAN_SSIM: Incidence of AESI anemia during double-blind period – non-severe by subgroup
Safety Set

AESI anemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.379
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	10 (7.9)	1.693 [0.634, 4.520]	1.752 [0.617, 4.974]	3.2 [-3.5, 9.9]	0.314
		Irbesartan	129	6 (4.7)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	3 (6.1)	6.860 + [0.364, 129.358]	7.301 + [0.367, 145.240]	6.1 [-2.7, 14.9]	0.242
		Irbesartan	48	0 (0.0)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.321 + [0.014, 7.528]	0.308 + [0.012, 7.927]	-4.0 [-15.6, 7.6]	0.490
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEAN_SSIM: Incidence of AESI anemia during double-blind period – non-severe by subgroup
Safety Set

AESI anemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	NE
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	6 (7.3) all n<10				NE
		Irbesartan	80	3 (3.8)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	4 (8.9) all n<10				NE
		Irbesartan	49	3 (6.1)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	3 (6.1) all n<10				NE
		Irbesartan	48	0 (0.0)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0) all n<10				NE
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEAN_SSIM: Incidence of AESI anemia during double-blind period – non-severe by subgroup
Safety Set

AESI anemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.712
<= 1.75 g/day	Double-blind period	Sparsentan	98	5 (5.1)	2.398 [0.477, 12.059]	2.473 [0.468, 13.072]	3.0 [-3.3, 9.3]	0.445
		Irbesartan	94	2 (2.1)				
> 1.75 g/day	Double-blind period	Sparsentan	104	8 (7.7)	1.662 [0.562, 4.914]	1.717 [0.543, 5.429]	3.1 [-4.4, 10.5]	0.402
		Irbesartan	108	5 (4.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEAN_SSIM: Incidence of AESI anemia during double-blind period – non-severe by subgroup
Safety Set

AESI anemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.207
Yes	Double-blind period	Sparsentan	88	4 (4.5)	0.943 [0.244, 3.649]	0.940 [0.227, 3.889]	-0.3 [-7.8, 7.2]	1.000
		Irbesartan	83	4 (4.8)				
No	Double-blind period	Sparsentan	114	9 (7.9)	3.132 [0.870, 11.276]	3.314 [0.874, 12.570]	5.4 [-1.2, 11.9]	0.079
		Irbesartan	119	3 (2.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEAN_SSIM: Incidence of AESI anemia during double-blind period – non-severe by subgroup
Safety Set

AESI anemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.260
<= 5 years	Double-blind period	Sparsentan	113	7 (6.2)	1.311 [0.454, 3.787]	1.332 [0.434, 4.086]	1.5 [-5.1, 8.1]	0.777
		Irbesartan	127	6 (4.7)				
> 5 years	Double-blind period	Sparsentan	89	6 (6.7)	5.056 [0.623, 41.067]	5.349 [0.629, 45.470]	5.4 [-1.6, 12.5]	0.127
		Irbesartan	75	1 (1.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEAN_SSIM: Incidence of AESI anemia during double-blind period – non-severe by subgroup
Safety Set

AESI anemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.701
Yes	Double-blind period	Sparsentan	153	10 (6.5)	1.710 [0.637, 4.590]	1.760 [0.624, 4.967]	2.7 [-2.9, 8.3]	0.314
		Irbesartan	157	6 (3.8)				
No	Double-blind period	Sparsentan	49	3 (6.1)	2.755 [0.297, 25.538]	2.870 [0.288, 28.639]	3.9 [-6.2, 14.0]	0.618
		Irbesartan	45	1 (2.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEAC_SSIM: Incidence of AESI anemia during double-blind period – severe by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEAS_SSIM: Incidence of AESI anemia during double-blind period – serious by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEU_SSIM: Incidence of AESI hyperkalemia during double-blind period by subgroup
Safety Set

AESI hyperkalemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.205
Male	Double-blind period	Sparsentan	139	18 (12.9)	1.543 [0.772, 3.083]	1.624 [0.751, 3.511]	4.6 [-3.3, 12.5]	0.249
		Irbesartan	143	12 (8.4)				
Female	Double-blind period	Sparsentan	63	5 (7.9)	0.669 [0.225, 1.992]	0.640 [0.192, 2.141]	-3.9 [-16.2, 8.3]	0.551
		Irbesartan	59	7 (11.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEU_SSIM: Incidence of AESI hyperkalemia during double-blind period by subgroup
Safety Set

AESI hyperkalemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.771
<= 45 years	Double-blind period	Sparsentan	96	12 (12.5)	1.125 [0.522, 2.426]	1.143 [0.478, 2.731]	1.4 [-8.7, 11.5]	0.826
		Irbesartan	99	11 (11.1)				
> 45 years	Double-blind period	Sparsentan	106	11 (10.4)	1.336 [0.560, 3.187]	1.375 [0.530, 3.570]	2.6 [-6.1, 11.3]	0.632
		Irbesartan	103	8 (7.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEU_SSIM: Incidence of AESI hyperkalemia during double-blind period by subgroup
Safety Set

AESI hyperkalemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.339
<= 18 years	Double-blind period	Sparsentan	9	0 (0.0)	0.600 + [0.014, 26.475]	0.579 + [0.010, 33.502]	0.0 [NE, NE]	NE
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	13 (12.7)	0.926 [0.464, 1.850]	0.915 [0.412, 2.032]	-1.0 [-11.1, 9.1]	0.842
		Irbesartan	109	15 (13.8)				
> 40 years	Double-blind period	Sparsentan	91	10 (11.0)	2.418 [0.787, 7.424]	2.593 [0.782, 8.599]	6.4 [-2.4, 15.3]	0.163
		Irbesartan	88	4 (4.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEU_SSIM: Incidence of AESI hyperkalemia during double-blind period by subgroup
Safety Set

AESI hyperkalemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.371
North America	Double-blind period	Sparsentan	35	5 (14.3)	3.286 [0.677, 15.949]	3.667 [0.667, 20.156]	9.9 [-5.6, 25.5]	0.230
		Irbesartan	46	2 (4.3)				
Europe	Double-blind period	Sparsentan	98	10 (10.2)	0.978 [0.442, 2.165]	0.975 [0.402, 2.366]	-0.2 [-9.4, 8.9]	1.000
		Irbesartan	115	12 (10.4)				
Asia Pacific	Double-blind period	Sparsentan	69	8 (11.6)	0.951 [0.333, 2.712]	0.944 [0.287, 3.107]	-0.6 [-15.1, 13.9]	1.000
		Irbesartan	41	5 (12.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEU_SSIM: Incidence of AESI hyperkalemia during double-blind period by subgroup
Safety Set

AESI hyperkalemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.976
< 27 kg/m**2	Double-blind period	Sparsentan	84	11 (13.1)	1.231 [0.551, 2.751]	1.266 [0.508, 3.151]	2.5 [-8.2, 13.1]	0.648
		Irbesartan	94	10 (10.6)				
>= 27 kg/m**2	Double-blind period	Sparsentan	118	12 (10.2)	1.209 [0.531, 2.755]	1.233 [0.498, 3.053]	1.8 [-6.7, 10.2]	0.819
		Irbesartan	107	9 (8.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEU_SSIM: Incidence of AESI hyperkalemia during double-blind period by subgroup
Safety Set

AESI hyperkalemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.350
eGFR Low and UP High	Double-blind period	Sparsentan	71	14 (19.7)	1.621 [0.750, 3.507]	1.774 [0.714, 4.406]	7.6 [-5.7, 20.8]	0.259
		Irbesartan	74	9 (12.2)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	7 (12.7)	0.875 [0.341, 2.247]	0.857 [0.288, 2.551]	-1.8 [-16.5, 12.8]	1.000
		Irbesartan	55	8 (14.5)				
eGFR High and UP High	Double-blind period	Sparsentan	37	2 (5.4)	4.868 + [0.242, 98.023]	5.141 + [0.238, 110.889]	5.4 [-4.6, 15.4]	0.493
		Irbesartan	36	0 (0.0)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	0 (0.0)	0.190 + [0.009, 3.831]	0.180 + [0.008, 3.872]	-5.4 [-15.3, 4.5]	0.234
		Irbesartan	37	2 (5.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEU_SSIM: Incidence of AESI hyperkalemia during double-blind period by subgroup
Safety Set

AESI hyperkalemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.745
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	21 (16.5)	1.333 [0.730, 2.435]	1.399 [0.693, 2.824]	4.1 [-5.3, 13.5]	0.378
		Irbesartan	129	16 (12.4)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	2 (4.1)	0.653 [0.114, 3.737]	0.638 [0.102, 4.000]	-2.2 [-13.0, 8.7]	0.678
		Irbesartan	48	3 (6.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.963 + [0.020, 46.760]	0.962 + [0.018, 50.349]	0.0 [NE, NE]	NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEU_SSIM: Incidence of AESI hyperkalemia during double-blind period by subgroup
Safety Set

AESI hyperkalemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.805
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	17 (20.7)	1.185 [0.627, 2.239]	1.233 [0.562, 2.706]	3.2 [-10.1, 16.6]	0.691
		Irbesartan	80	14 (17.5)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	4 (8.9)	2.178 [0.419, 11.322]	2.293 [0.399, 13.171]	4.8 [-7.3, 16.9]	0.421
		Irbesartan	49	2 (4.1)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	2 (4.1)	0.653 [0.114, 3.737]	0.638 [0.102, 4.000]	-2.2 [-13.0, 8.7]	0.678
		Irbesartan	48	3 (6.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.963 + [0.020, 46.760]	0.962 + [0.018, 50.349]	0.0 [NE, NE]	NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEU_SSIM: Incidence of AESI hyperkalemia during double-blind period by subgroup
Safety Set

AESI hyperkalemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.192
<= 1.75 g/day	Double-blind period	Sparsentan	98	7 (7.1)	0.746 [0.290, 1.922]	0.726 [0.259, 2.037]	-2.4 [-11.3, 6.4]	0.608
		Irbesartan	94	9 (9.6)				
> 1.75 g/day	Double-blind period	Sparsentan	104	16 (15.4)	1.662 [0.791, 3.492]	1.782 [0.769, 4.131]	6.1 [-3.6, 15.9]	0.211
		Irbesartan	108	10 (9.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEU_SSIM: Incidence of AESI hyperkalemia during double-blind period by subgroup
Safety Set

AESI hyperkalemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.043 #
Yes	Double-blind period	Sparsentan	88	16 (18.2)	2.156 [0.934, 4.974]	2.413 [0.938, 6.207]	9.7 [-1.5, 21.0]	0.074
		Irbesartan	83	7 (8.4)				
No	Double-blind period	Sparsentan	114	7 (6.1)	0.609 [0.249, 1.492]	0.583 [0.221, 1.539]	-3.9 [-11.8, 3.9]	0.341
		Irbesartan	119	12 (10.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEU_SSIM: Incidence of AESI hyperkalemia during double-blind period by subgroup
Safety Set

AESI hyperkalemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.089
<= 5 years	Double-blind period	Sparsentan	113	15 (13.3)	1.873 [0.853, 4.113]	2.007 [0.842, 4.784]	6.2 [-2.3, 14.7]	0.133
		Irbesartan	127	9 (7.1)				
> 5 years	Double-blind period	Sparsentan	89	8 (9.0)	0.674 [0.280, 1.621]	0.642 [0.240, 1.720]	-4.3 [-15.3, 6.6]	0.455
		Irbesartan	75	10 (13.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEU_SSIM: Incidence of AESI hyperkalemia during double-blind period by subgroup
Safety Set

AESI hyperkalemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.049 #
Yes	Double-blind period	Sparsentan	153	21 (13.7)	1.658 [0.861, 3.191]	1.762 [0.848, 3.660]	5.4 [-2.2, 13.0]	0.147
		Irbesartan	157	13 (8.3)				
No	Double-blind period	Sparsentan	49	2 (4.1)	0.306 [0.065, 1.440]	0.277 [0.053, 1.448]	-9.3 [-22.8, 4.3]	0.147
		Irbesartan	45	6 (13.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEUN_SSIM: Incidence of AESI hyperkalemia during double-blind period – non-severe by subgroup
Safety Set

AESI hyperkalemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.205
Male	Double-blind period	Sparsentan	139	18 (12.9)	1.543 [0.772, 3.083]	1.624 [0.751, 3.511]	4.6 [-3.3, 12.5]	0.249
		Irbesartan	143	12 (8.4)				
Female	Double-blind period	Sparsentan	63	5 (7.9)	0.669 [0.225, 1.992]	0.640 [0.192, 2.141]	-3.9 [-16.2, 8.3]	0.551
		Irbesartan	59	7 (11.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEUN_SSIM: Incidence of AESI hyperkalemia during double-blind period – non-severe by subgroup
Safety Set

AESI hyperkalemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.771
<= 45 years	Double-blind period	Sparsentan	96	12 (12.5)	1.125 [0.522, 2.426]	1.143 [0.478, 2.731]	1.4 [-8.7, 11.5]	0.826
		Irbesartan	99	11 (11.1)				
> 45 years	Double-blind period	Sparsentan	106	11 (10.4)	1.336 [0.560, 3.187]	1.375 [0.530, 3.570]	2.6 [-6.1, 11.3]	0.632
		Irbesartan	103	8 (7.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEUN_SSIM: Incidence of AESI hyperkalemia during double-blind period – non-severe by subgroup
Safety Set

AESI hyperkalemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.339
<= 18 years	Double-blind period	Sparsentan	9	0 (0.0)	0.600 + [0.014, 26.475]	0.579 + [0.010, 33.502]	0.0 [NE, NE]	NE
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	13 (12.7)	0.926 [0.464, 1.850]	0.915 [0.412, 2.032]	-1.0 [-11.1, 9.1]	0.842
		Irbesartan	109	15 (13.8)				
> 40 years	Double-blind period	Sparsentan	91	10 (11.0)	2.418 [0.787, 7.424]	2.593 [0.782, 8.599]	6.4 [-2.4, 15.3]	0.163
		Irbesartan	88	4 (4.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEUN_SSIM: Incidence of AESI hyperkalemia during double-blind period – non-severe by subgroup
Safety Set

AESI hyperkalemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.371
North America	Double-blind period	Sparsentan	35	5 (14.3)	3.286 [0.677, 15.949]	3.667 [0.667, 20.156]	9.9 [-5.6, 25.5]	0.230
		Irbesartan	46	2 (4.3)				
Europe	Double-blind period	Sparsentan	98	10 (10.2)	0.978 [0.442, 2.165]	0.975 [0.402, 2.366]	-0.2 [-9.4, 8.9]	1.000
		Irbesartan	115	12 (10.4)				
Asia Pacific	Double-blind period	Sparsentan	69	8 (11.6)	0.951 [0.333, 2.712]	0.944 [0.287, 3.107]	-0.6 [-15.1, 13.9]	1.000
		Irbesartan	41	5 (12.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEUN_SSIM: Incidence of AESI hyperkalemia during double-blind period – non-severe by subgroup
Safety Set

AESI hyperkalemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.976
< 27 kg/m**2	Double-blind period	Sparsentan	84	11 (13.1)	1.231 [0.551, 2.751]	1.266 [0.508, 3.151]	2.5 [-8.2, 13.1]	0.648
		Irbesartan	94	10 (10.6)				
>= 27 kg/m**2	Double-blind period	Sparsentan	118	12 (10.2)	1.209 [0.531, 2.755]	1.233 [0.498, 3.053]	1.8 [-6.7, 10.2]	0.819
		Irbesartan	107	9 (8.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEUN_SSIM: Incidence of AESI hyperkalemia during double-blind period – non-severe by subgroup
Safety Set

AESI hyperkalemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.350
eGFR Low and UP High	Double-blind period	Sparsentan	71	14 (19.7)	1.621 [0.750, 3.507]	1.774 [0.714, 4.406]	7.6 [-5.7, 20.8]	0.259
		Irbesartan	74	9 (12.2)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	7 (12.7)	0.875 [0.341, 2.247]	0.857 [0.288, 2.551]	-1.8 [-16.5, 12.8]	1.000
		Irbesartan	55	8 (14.5)				
eGFR High and UP High	Double-blind period	Sparsentan	37	2 (5.4)	4.868 + [0.242, 98.023]	5.141 + [0.238, 110.889]	5.4 [-4.6, 15.4]	0.493
		Irbesartan	36	0 (0.0)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	0 (0.0)	0.190 + [0.009, 3.831]	0.180 + [0.008, 3.872]	-5.4 [-15.3, 4.5]	0.234
		Irbesartan	37	2 (5.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEUN_SSIM: Incidence of AESI hyperkalemia during double-blind period – non-severe by subgroup
Safety Set

AESI hyperkalemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.745
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	21 (16.5)	1.333 [0.730, 2.435]	1.399 [0.693, 2.824]	4.1 [-5.3, 13.5]	0.378
		Irbesartan	129	16 (12.4)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	2 (4.1)	0.653 [0.114, 3.737]	0.638 [0.102, 4.000]	-2.2 [-13.0, 8.7]	0.678
		Irbesartan	48	3 (6.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.963 + [0.020, 46.760]	0.962 + [0.018, 50.349]	0.0 [NE, NE]	NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEUN_SSIM: Incidence of AESI hyperkalemia during double-blind period – non-severe by subgroup
Safety Set

AESI hyperkalemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.805
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	17 (20.7)	1.185 [0.627, 2.239]	1.233 [0.562, 2.706]	3.2 [-10.1, 16.6]	0.691
		Irbesartan	80	14 (17.5)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	4 (8.9)	2.178 [0.419, 11.322]	2.293 [0.399, 13.171]	4.8 [-7.3, 16.9]	0.421
		Irbesartan	49	2 (4.1)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	2 (4.1)	0.653 [0.114, 3.737]	0.638 [0.102, 4.000]	-2.2 [-13.0, 8.7]	0.678
		Irbesartan	48	3 (6.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.963 + [0.020, 46.760]	0.962 + [0.018, 50.349]	0.0 [NE, NE]	NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEUN_SSIM: Incidence of AESI hyperkalemia during double-blind period – non-severe by subgroup
Safety Set

AESI hyperkalemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.192
<= 1.75 g/day	Double-blind period	Sparsentan	98	7 (7.1)	0.746 [0.290, 1.922]	0.726 [0.259, 2.037]	-2.4 [-11.3, 6.4]	0.608
		Irbesartan	94	9 (9.6)				
> 1.75 g/day	Double-blind period	Sparsentan	104	16 (15.4)	1.662 [0.791, 3.492]	1.782 [0.769, 4.131]	6.1 [-3.6, 15.9]	0.211
		Irbesartan	108	10 (9.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEUN_SSIM: Incidence of AESI hyperkalemia during double-blind period – non-severe by subgroup
Safety Set

AESI hyperkalemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.043 #
Yes	Double-blind period	Sparsentan	88	16 (18.2)	2.156 [0.934, 4.974]	2.413 [0.938, 6.207]	9.7 [-1.5, 21.0]	0.074
		Irbesartan	83	7 (8.4)				
No	Double-blind period	Sparsentan	114	7 (6.1)	0.609 [0.249, 1.492]	0.583 [0.221, 1.539]	-3.9 [-11.8, 3.9]	0.341
		Irbesartan	119	12 (10.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEUN_SSIM: Incidence of AESI hyperkalemia during double-blind period – non-severe by subgroup
Safety Set

AESI hyperkalemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.089
<= 5 years	Double-blind period	Sparsentan	113	15 (13.3)	1.873 [0.853, 4.113]	2.007 [0.842, 4.784]	6.2 [-2.3, 14.7]	0.133
		Irbesartan	127	9 (7.1)				
> 5 years	Double-blind period	Sparsentan	89	8 (9.0)	0.674 [0.280, 1.621]	0.642 [0.240, 1.720]	-4.3 [-15.3, 6.6]	0.455
		Irbesartan	75	10 (13.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEUN_SSIM: Incidence of AESI hyperkalemia during double-blind period – non-severe by subgroup
Safety Set

AESI hyperkalemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.049 #
Yes	Double-blind period	Sparsentan	153	21 (13.7)	1.658 [0.861, 3.191]	1.762 [0.848, 3.660]	5.4 [-2.2, 13.0]	0.147
		Irbesartan	157	13 (8.3)				
No	Double-blind period	Sparsentan	49	2 (4.1)	0.306 [0.065, 1.440]	0.277 [0.053, 1.448]	-9.3 [-22.8, 4.3]	0.147
		Irbesartan	45	6 (13.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEUC_SSIM: Incidence of AESI hyperkalemia during double-blind period – severe by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEUS_SSIM: Incidence of AESI hyperkalemia during double-blind period – serious by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEY_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period by subgroup
Safety Set

AESI cardiac arrhythmias

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.238
Male	Double-blind period	Sparsentan	139	5 (3.6)	0.429 [0.155, 1.185]	0.407 [0.140, 1.188]	-4.8 [-11.0, 1.4]	0.132
		Irbesartan	143	12 (8.4)				
Female	Double-blind period	Sparsentan	63	4 (6.3)	1.249 [0.292, 5.346]	1.266 [0.271, 5.909]	1.3 [-8.6, 11.1]	1.000
		Irbesartan	59	3 (5.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEY_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period by subgroup
Safety Set

AESI cardiac arrhythmias

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.493
<= 45 years	Double-blind period	Sparsentan	96	4 (4.2)	0.458 [0.146, 1.439]	0.435 [0.129, 1.463]	-4.9 [-12.9, 3.0]	0.251
		Irbesartan	99	9 (9.1)				
> 45 years	Double-blind period	Sparsentan	106	5 (4.7)	0.810 [0.255, 2.571]	0.800 [0.236, 2.708]	-1.1 [-8.1, 5.9]	0.766
		Irbesartan	103	6 (5.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEY_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period by subgroup
Safety Set

AESI cardiac arrhythmias

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.661
<= 18 years	Double-blind period	Sparsentan	9	1 (11.1)	0.556 [0.044, 7.095]	0.500 [0.024, 10.251]	-8.9 [-65.1, 47.3]	1.000
		Irbesartan	5	1 (20.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	4 (3.9)	0.427 [0.138, 1.320]	0.404 [0.123, 1.332]	-5.3 [-12.8, 2.3]	0.168
		Irbesartan	109	10 (9.2)				
> 40 years	Double-blind period	Sparsentan	91	4 (4.4)	0.967 [0.250, 3.747]	0.966 [0.234, 3.986]	-0.1 [-7.3, 7.0]	1.000
		Irbesartan	88	4 (4.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEY_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period by subgroup
Safety Set

AESI cardiac arrhythmias

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.229
North America	Double-blind period	Sparsentan	35	2 (5.7)	1.314 [0.195, 8.876]	1.333 [0.178, 9.964]	1.4 [-10.8, 13.6]	1.000
		Irbesartan	46	2 (4.3)				
Europe	Double-blind period	Sparsentan	98	5 (5.1)	0.838 [0.275, 2.558]	0.829 [0.255, 2.701]	-1.0 [-8.1, 6.1]	1.000
		Irbesartan	115	7 (6.1)				
Asia Pacific	Double-blind period	Sparsentan	69	2 (2.9)	0.198 [0.042, 0.936]	0.174 [0.033, 0.908]	-11.7 [-25.2, 1.7]	0.050
		Irbesartan	41	6 (14.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEY_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period by subgroup
Safety Set

AESI cardiac arrhythmias

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.470
< 27 kg/m**2	Double-blind period	Sparsentan	84	3 (3.6)	0.420 [0.115, 1.530]	0.398 [0.102, 1.553]	-4.9 [-13.0, 3.1]	0.220
		Irbesartan	94	8 (8.5)				
>= 27 kg/m**2	Double-blind period	Sparsentan	118	6 (5.1)	0.777 [0.270, 2.240]	0.765 [0.249, 2.353]	-1.5 [-8.5, 5.6]	0.777
		Irbesartan	107	7 (6.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEY_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period by subgroup
Safety Set

AESI cardiac arrhythmias

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	NE
eGFR Low and UP High	Double-blind period	Sparsentan	71	5 (7.0) all n<10				NE
		Irbesartan	74	4 (5.4)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	3 (5.5) all n<10				NE
		Irbesartan	55	6 (10.9)				
eGFR High and UP High	Double-blind period	Sparsentan	37	1 (2.7) all n<10				NE
		Irbesartan	36	3 (8.3)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	0 (0.0) all n<10				NE
		Irbesartan	37	2 (5.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEY_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period by subgroup
Safety Set

AESI cardiac arrhythmias

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.934
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	7 (5.5)	0.646 [0.259, 1.615]	0.626 [0.235, 1.669]	-3.0 [-10.0, 4.0]	0.465
		Irbesartan	129	11 (8.5)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	2 (4.1)	0.490 [0.094, 2.550]	0.468 [0.082, 2.684]	-4.3 [-15.9, 7.4]	0.436
		Irbesartan	48	4 (8.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.963 + [0.020, 46.760]	0.962 + [0.018, 50.349]	0.0 [NE, NE]	NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEY_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period by subgroup
Safety Set

AESI cardiac arrhythmias

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.762
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	3 (3.7)	0.418 [0.112, 1.560]	0.396 [0.099, 1.589]	-5.1 [-13.7, 3.5]	0.208
		Irbesartan	80	7 (8.8)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	4 (8.9)	1.089 [0.289, 4.099]	1.098 [0.258, 4.675]	0.7 [-12.7, 14.2]	1.000
		Irbesartan	49	4 (8.2)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	2 (4.1)	0.490 [0.094, 2.550]	0.468 [0.082, 2.684]	-4.3 [-15.9, 7.4]	0.436
		Irbesartan	48	4 (8.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.963 + [0.020, 46.760]	0.962 + [0.018, 50.349]	0.0 [NE, NE]	NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEY_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period by subgroup
Safety Set

AESI cardiac arrhythmias

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.235
<= 1.75 g/day	Double-blind period	Sparsentan	98	6 (6.1)	0.959 [0.321, 2.869]	0.957 [0.297, 3.078]	-0.3 [-8.2, 7.6]	1.000
		Irbesartan	94	6 (6.4)				
> 1.75 g/day	Double-blind period	Sparsentan	104	3 (2.9)	0.346 [0.096, 1.243]	0.327 [0.086, 1.242]	-5.4 [-12.5, 1.6]	0.135
		Irbesartan	108	9 (8.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEY_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period by subgroup
Safety Set

AESI cardiac arrhythmias

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.304
Yes	Double-blind period	Sparsentan	88	5 (5.7)	0.429 [0.156, 1.181]	0.394 [0.131, 1.188]	-7.6 [-17.5, 2.4]	0.116
		Irbesartan	83	11 (13.3)				
No	Double-blind period	Sparsentan	114	4 (3.5)	1.044 [0.267, 4.075]	1.045 [0.255, 4.284]	0.1 [-5.4, 5.7]	1.000
		Irbesartan	119	4 (3.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEY_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period by subgroup
Safety Set

AESI cardiac arrhythmias

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.113
<= 5 years	Double-blind period	Sparsentan	113	3 (2.7)	0.307 [0.088, 1.071]	0.288 [0.078, 1.058]	-6.0 [-12.6, 0.5]	0.056
		Irbesartan	127	11 (8.7)				
> 5 years	Double-blind period	Sparsentan	89	6 (6.7)	1.264 [0.370, 4.313]	1.283 [0.348, 4.728]	1.4 [-7.1, 9.9]	0.756
		Irbesartan	75	4 (5.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEY_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period by subgroup
Safety Set

AESI cardiac arrhythmias

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.647
Yes	Double-blind period	Sparsentan	153	9 (5.9)	0.660 [0.294, 1.479]	0.638 [0.268, 1.522]	-3.0 [-9.5, 3.4]	0.387
		Irbesartan	157	14 (8.9)				
No	Double-blind period	Sparsentan	49	0 (0.0)	0.307 + [0.013, 7.341]	0.300 + [0.012, 7.546]	-2.2 [-8.7, 4.2]	0.479
		Irbesartan	45	1 (2.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEYN_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – non-severe by subgroup
Safety Set

AESI cardiac arrhythmias - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.238
Male	Double-blind period	Sparsentan	139	5 (3.6)	0.429 [0.155, 1.185]	0.407 [0.140, 1.188]	-4.8 [-11.0, 1.4]	0.132
		Irbesartan	143	12 (8.4)				
Female	Double-blind period	Sparsentan	63	4 (6.3)	1.249 [0.292, 5.346]	1.266 [0.271, 5.909]	1.3 [-8.6, 11.1]	1.000
		Irbesartan	59	3 (5.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEYN_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – non-severe by subgroup
Safety Set

AESI cardiac arrhythmias - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.493
<= 45 years	Double-blind period	Sparsentan	96	4 (4.2)	0.458 [0.146, 1.439]	0.435 [0.129, 1.463]	-4.9 [-12.9, 3.0]	0.251
		Irbesartan	99	9 (9.1)				
> 45 years	Double-blind period	Sparsentan	106	5 (4.7)	0.810 [0.255, 2.571]	0.800 [0.236, 2.708]	-1.1 [-8.1, 5.9]	0.766
		Irbesartan	103	6 (5.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEYN_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – non-severe by subgroup
Safety Set

AESI cardiac arrhythmias - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.661
<= 18 years	Double-blind period	Sparsentan	9	1 (11.1)	0.556 [0.044, 7.095]	0.500 [0.024, 10.251]	-8.9 [-65.1, 47.3]	1.000
		Irbesartan	5	1 (20.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	4 (3.9)	0.427 [0.138, 1.320]	0.404 [0.123, 1.332]	-5.3 [-12.8, 2.3]	0.168
		Irbesartan	109	10 (9.2)				
> 40 years	Double-blind period	Sparsentan	91	4 (4.4)	0.967 [0.250, 3.747]	0.966 [0.234, 3.986]	-0.1 [-7.3, 7.0]	1.000
		Irbesartan	88	4 (4.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEYN_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – non-severe by subgroup
Safety Set

AESI cardiac arrhythmias - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.229
North America	Double-blind period	Sparsentan	35	2 (5.7)	1.314 [0.195, 8.876]	1.333 [0.178, 9.964]	1.4 [-10.8, 13.6]	1.000
		Irbesartan	46	2 (4.3)				
Europe	Double-blind period	Sparsentan	98	5 (5.1)	0.838 [0.275, 2.558]	0.829 [0.255, 2.701]	-1.0 [-8.1, 6.1]	1.000
		Irbesartan	115	7 (6.1)				
Asia Pacific	Double-blind period	Sparsentan	69	2 (2.9)	0.198 [0.042, 0.936]	0.174 [0.033, 0.908]	-11.7 [-25.2, 1.7]	0.050
		Irbesartan	41	6 (14.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEYN_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – non-severe by subgroup
Safety Set

AESI cardiac arrhythmias - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.470
< 27 kg/m**2	Double-blind period	Sparsentan	84	3 (3.6)	0.420 [0.115, 1.530]	0.398 [0.102, 1.553]	-4.9 [-13.0, 3.1]	0.220
		Irbesartan	94	8 (8.5)				
>= 27 kg/m**2	Double-blind period	Sparsentan	118	6 (5.1)	0.777 [0.270, 2.240]	0.765 [0.249, 2.353]	-1.5 [-8.5, 5.6]	0.777
		Irbesartan	107	7 (6.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEYN_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – non-severe by subgroup
Safety Set

AESI cardiac arrhythmias - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	NE
eGFR Low and UP High	Double-blind period	Sparsentan	71	5 (7.0) all n<10				NE
		Irbesartan	74	4 (5.4)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	3 (5.5) all n<10				NE
		Irbesartan	55	6 (10.9)				
eGFR High and UP High	Double-blind period	Sparsentan	37	1 (2.7) all n<10				NE
		Irbesartan	36	3 (8.3)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	0 (0.0) all n<10				NE
		Irbesartan	37	2 (5.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEYN_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – non-severe by subgroup
Safety Set

AESI cardiac arrhythmias - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.934
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	7 (5.5)	0.646 [0.259, 1.615]	0.626 [0.235, 1.669]	-3.0 [-10.0, 4.0]	0.465
		Irbesartan	129	11 (8.5)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	2 (4.1)	0.490 [0.094, 2.550]	0.468 [0.082, 2.684]	-4.3 [-15.9, 7.4]	0.436
		Irbesartan	48	4 (8.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.963 + [0.020, 46.760]	0.962 + [0.018, 50.349]	0.0 [NE, NE]	NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEYN_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – non-severe by subgroup
Safety Set

AESI cardiac arrhythmias - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.762
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	3 (3.7)	0.418 [0.112, 1.560]	0.396 [0.099, 1.589]	-5.1 [-13.7, 3.5]	0.208
		Irbesartan	80	7 (8.8)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	4 (8.9)	1.089 [0.289, 4.099]	1.098 [0.258, 4.675]	0.7 [-12.7, 14.2]	1.000
		Irbesartan	49	4 (8.2)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	2 (4.1)	0.490 [0.094, 2.550]	0.468 [0.082, 2.684]	-4.3 [-15.9, 7.4]	0.436
		Irbesartan	48	4 (8.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.963 + [0.020, 46.760]	0.962 + [0.018, 50.349]	0.0 [NE, NE]	NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEYN_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – non-severe by subgroup
Safety Set

AESI cardiac arrhythmias - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.235
<= 1.75 g/day	Double-blind period	Sparsentan	98	6 (6.1)	0.959 [0.321, 2.869]	0.957 [0.297, 3.078]	-0.3 [-8.2, 7.6]	1.000
		Irbesartan	94	6 (6.4)				
> 1.75 g/day	Double-blind period	Sparsentan	104	3 (2.9)	0.346 [0.096, 1.243]	0.327 [0.086, 1.242]	-5.4 [-12.5, 1.6]	0.135
		Irbesartan	108	9 (8.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEYN_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – non-severe by subgroup
Safety Set

AESI cardiac arrhythmias - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.304
Yes	Double-blind period	Sparsentan	88	5 (5.7)	0.429 [0.156, 1.181]	0.394 [0.131, 1.188]	-7.6 [-17.5, 2.4]	0.116
		Irbesartan	83	11 (13.3)				
No	Double-blind period	Sparsentan	114	4 (3.5)	1.044 [0.267, 4.075]	1.045 [0.255, 4.284]	0.1 [-5.4, 5.7]	1.000
		Irbesartan	119	4 (3.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEYN_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – non-severe by subgroup
Safety Set

AESI cardiac arrhythmias - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.113
<= 5 years	Double-blind period	Sparsentan	113	3 (2.7)	0.307 [0.088, 1.071]	0.288 [0.078, 1.058]	-6.0 [-12.6, 0.5]	0.056
		Irbesartan	127	11 (8.7)				
> 5 years	Double-blind period	Sparsentan	89	6 (6.7)	1.264 [0.370, 4.313]	1.283 [0.348, 4.728]	1.4 [-7.1, 9.9]	0.756
		Irbesartan	75	4 (5.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEYN_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – non-severe by subgroup
Safety Set

AESI cardiac arrhythmias - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.647
Yes	Double-blind period	Sparsentan	153	9 (5.9)	0.660 [0.294, 1.479]	0.638 [0.268, 1.522]	-3.0 [-9.5, 3.4]	0.387
		Irbesartan	157	14 (8.9)				
No	Double-blind period	Sparsentan	49	0 (0.0)	0.307 + [0.013, 7.341]	0.300 + [0.012, 7.546]	-2.2 [-8.7, 4.2]	0.479
		Irbesartan	45	1 (2.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEYC_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – severe by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEYS_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – serious by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEI_SSIM: Incidence of AESI acute kidney injury during double-blind period by subgroup
Safety Set

Not done. Less than 10 patients with events in every subgroup level.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEIN_SSIM: Incidence of AESI acute kidney injury during double-blind period – non-severe by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEIC_SSIM: Incidence of AESI acute kidney injury during double-blind period – severe by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT1AEIS_SSIM: Incidence of AESI acute kidney injury during double-blind period – serious by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Figure PF2URPT_FMK0: Time to partial remission - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	78	58	47	35	33
Irbesartan	202	134	104	90	77	71

Partial remission means an urinary protein excretion of <1.0 g/day. No event means no partial remission.
Reference table: PT2URPT_FMT0

Figure PF2URFT_FMK0: Time to complete remission - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	175	161	147	137	127
Irbesartan	202	198	181	172	156	148

_____
Complete remission means an urinary protein excretion of <0.3 g/day. No event means no Complete remission.
Reference table: PT2URFT_FMT0

Figure PF2GEDT_FMK0: Time to confirmed 40% reduction in eGFR, ESRD or death - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	196	190	182	174	123
Irbesartan	202	194	177	165	151	101

ESRD = End-stage renal disease. eGFR = Estimated glomerular filtration rate.
Reference table: PT2GEDT_FMT0

Figure PF2GT_FMK0: Time to confirmed 40% reduction in eGFR - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	196	190	182	174	123
Irbesartan	202	192	175	165	151	101

eGFR = Estimated glomerular filtration rate.
Reference table: PT2GT_FMT0

Figure PF2ET_FMK0: Time to ESRD - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	197	191	184	178	124
Irbesartan	202	195	178	169	163	109

ESRD = End-stage renal disease.
Reference table: PT2ET_FMT0

Figure PF2DT_FMK0: Time to death - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	197	191	186	178	125
Irbesartan	202	193	176	169	163	112

Reference table: PT2DT_FMT0

Figure PF2CKDT_FMK0: Time to CKD stage 4 or 5 - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	185	176	160	146	97
Irbesartan	202	179	155	140	130	84

Reference table: PT2CKDT_FMT0

Figure PF2MIST_FMK0: Time to systemic immunosuppressive medication - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	189	178	168	150	104
Irbesartan	202	181	163	152	138	98

Reference table: PT2MIST_FMT0

Figure PF2MIKT_FMK0: Time to systemic immunosuppressive renal medication - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	197	190	185	173	123
Irbesartan	202	188	169	159	152	108

Reference table: PT2MIKT_FMT0

Table PT2VSC_FMC0: Change from baseline in EQ-5D VAS
Full Analysis Set

Change from baseline in EQ-5D VAS				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Week 24	Sparsentan	202	164 (81.2)	3.45 (0.90)	(1.69, 5.22)	2.84 (1.32)	(0.26, 5.42)	0.031 *
	Irbesartan	202	143 (70.8)	0.61 (0.96)	(-1.27, 2.50)			
Week 48	Sparsentan	202	168 (83.2)	2.51 (0.89)	(0.77, 4.25)	0.43 (1.32)	(-2.16, 3.03)	0.743
	Irbesartan	202	132 (65.3)	2.07 (0.98)	(0.14, 4.00)			
Week 70	Sparsentan	202	166 (82.2)	0.55 (0.89)	(-1.20, 2.31)	-0.66 (1.33)	(-3.26, 1.95)	0.621
	Irbesartan	202	136 (67.3)	1.21 (0.98)	(-0.71, 3.13)			
Week 94	Sparsentan	202	156 (77.2)	1.47 (0.92)	(-0.33, 3.27)	-0.63 (1.35)	(-3.27, 2.01)	0.641
	Irbesartan	202	136 (67.3)	2.10 (0.99)	(0.17, 4.03)			
Week 110	Sparsentan	202	152 (75.2)	1.74 (0.93)	(-0.10, 3.57)	0.12 (1.40)	(-2.62, 2.86)	0.929
	Irbesartan	202	121 (59.9)	1.61 (1.04)	(-0.43, 3.65)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate.
A decrease reflects a worsening of the status of the patient.
A first order regressive covariance structure was used.
Source Data: aqs, created on: 08FEB2024

Figure PF2VSC_FMG0: Change from baseline in EQ-5D VAS
Full Analysis Set
Study: PROTECT



Sparsentan	164	168	166	156	152
Irbesartan	143	132	136	136	121

MMRM = Mixed model Repeated Measures. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate.
A decrease reflects a worsening of the status of the patient. Reference table: PT2VSC_FMC0

Figure PF2VSIT_FMK0: Time to increase in EQ-5D VAS by at least 15 points - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	174	155	144	131	113
Irbesartan	202	159	131	116	109	90

An increase reflects an improvement of the status of the patient.
Reference table: PT2VSIT_FMT0

Figure PF2VSDT_FMK0: Time to decrease in EQ-5D VAS by at least 15 points - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	179	166	156	138	114
Irbesartan	202	162	141	132	124	104

A decrease reflects a worsening of the status of the patient.
Reference table: PT2VSDT_FMT0

Table PT2KBUC_FMC0: KDQOL: Change from baseline in burden of kidney disease
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Week 24	Sparsentan	202	157 (77.7)	6.02 (1.43)	(3.22, 8.83)	3.16 (2.12)	(-1.00, 7.33)	0.137
	Irbesartan	202	131 (64.9)	2.86 (1.56)	(-0.21, 5.93)			
Week 48	Sparsentan	202	162 (80.2)	5.90 (1.40)	(3.15, 8.65)	1.60 (2.12)	(-2.55, 5.75)	0.449
	Irbesartan	202	124 (61.4)	4.30 (1.58)	(1.20, 7.39)			
Week 70	Sparsentan	202	160 (79.2)	6.90 (1.42)	(4.12, 9.67)	3.34 (2.11)	(-0.81, 7.48)	0.114
	Irbesartan	202	130 (64.4)	3.56 (1.56)	(0.50, 6.62)			
Week 94	Sparsentan	202	151 (74.8)	4.77 (1.45)	(1.93, 7.61)	3.90 (2.14)	(-0.30, 8.09)	0.069
	Irbesartan	202	130 (64.4)	0.87 (1.57)	(-2.20, 3.95)			
Week 110	Sparsentan	202	149 (73.8)	5.47 (1.47)	(2.59, 8.36)	4.97 (2.20)	(0.66, 9.28)	0.024 *
	Irbesartan	202	121 (59.9)	0.50 (1.62)	(-2.69, 3.69)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate.
A decrease reflects a worsening of the status of the patient.
A first order regressive covariance structure was used.
Source Data: aqs, created on: 08FEB2024

Figure PF2KBUC_FMG0: KDQOL: Change from baseline in burden of kidney disease
Full Analysis Set
Study: PROTECT



Sparsentan	157	162	160	151	149
Irbesartan	131	124	130	130	121

MMRM = Mixed model Repeated Measures. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate.
KD = kidney disease. A decrease reflects a worsening of the status of the patient. Reference table: PT2KBUC_FMC0

Figure PF2KBUIT_FMK0: KDQOL: Time to increase in burden of kidney disease by at least 15 points - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	168	132	111	92	74
Irbesartan	202	155	129	110	100	79

An increase reflects an improvement of the status of the patient.
Reference table: PT2KBUIT_FMT0

Figure PF2KBUDT_FMK0: KDQOL: Time to decrease in burden of kidney disease by at least 15 points - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	181	164	153	136	113
Irbesartan	202	158	136	118	103	78

A decrease reflects a worsening of the status of the patient.
Reference table: PT2KBUDT_FMT0

Table PT2KEFC_FMC0: KDQOL: Change from baseline in effect of kidney disease
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Week 24	Sparsentan	202	157 (77.7)	1.55 (0.85)	(-0.11, 3.22)	2.11 (1.26)	(-0.36, 4.57)	0.094
	Irbesartan	202	131 (64.9)	-0.55 (0.93)	(-2.37, 1.27)			
Week 48	Sparsentan	202	162 (80.2)	1.67 (0.83)	(0.03, 3.30)	0.77 (1.25)	(-1.69, 3.23)	0.539
	Irbesartan	202	124 (61.4)	0.90 (0.94)	(-0.94, 2.73)			
Week 70	Sparsentan	202	160 (79.2)	0.86 (0.84)	(-0.78, 2.51)	0.11 (1.25)	(-2.34, 2.56)	0.929
	Irbesartan	202	130 (64.4)	0.75 (0.92)	(-1.06, 2.57)			
Week 94	Sparsentan	202	151 (74.8)	1.58 (0.86)	(-0.11, 3.26)	0.16 (1.26)	(-2.32, 2.64)	0.899
	Irbesartan	202	130 (64.4)	1.42 (0.93)	(-0.40, 3.24)			
Week 110	Sparsentan	202	149 (73.8)	1.50 (0.87)	(-0.21, 3.21)	0.56 (1.30)	(-1.98, 3.11)	0.664
	Irbesartan	202	121 (59.9)	0.93 (0.96)	(-0.95, 2.82)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate.
A decrease reflects a worsening of the status of the patient.
A first order regressive covariance structure was used.
Source Data: aqs, created on: 08FEB2024

Figure PF2KEFC_FMG0: KDQOL: Change from baseline in effect of kidney disease
Full Analysis Set
Study: PROTECT



Sparsentan	157	162	160	151	149
Irbesartan	131	124	130	130	121

MMRM = Mixed model Repeated Measures. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate.
KD = kidney disease. A decrease reflects a worsening of the status of the patient. Reference table: PT2KEFC_FMC0

Figure PF2KEFIT_FMK0: KDQOL: Time to increase in effect of kidney disease by at least 15 points - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	173	151	147	133	112
Irbesartan	202	161	145	131	122	103

An increase reflects an improvement of the status of the patient.
Reference table: PT2KEFIT_FMT0

Figure PF2KEFDT_FMK0: KDQOL: Time to decrease in effect of kidney disease by at least 15 points - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	177	166	160	144	123
Irbesartan	202	159	138	127	119	102

A decrease reflects a worsening of the status of the patient.
Reference table: PT2KEFDT_FMT0

Table PT2KSYC_FMC0: KDQOL: Change from baseline in symptom/problems of kidney disease
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Week 24	Sparsentan	202	157 (77.7)	-0.13 (0.95)	(-2.00, 1.74)	1.49 (1.41)	(-1.28, 4.27)	0.291
	Irbesartan	202	131 (64.9)	-1.62 (1.04)	(-3.67, 0.43)			
Week 48	Sparsentan	202	162 (80.2)	-0.70 (0.94)	(-2.54, 1.14)	1.10 (1.42)	(-1.68, 3.87)	0.438
	Irbesartan	202	124 (61.4)	-1.80 (1.06)	(-3.88, 0.28)			
Week 70	Sparsentan	202	160 (79.2)	-1.37 (0.95)	(-3.22, 0.49)	-0.04 (1.41)	(-2.80, 2.73)	0.979
	Irbesartan	202	130 (64.4)	-1.33 (1.04)	(-3.38, 0.72)			
Week 94	Sparsentan	202	151 (74.8)	-1.28 (0.97)	(-3.19, 0.62)	0.98 (1.43)	(-1.82, 3.78)	0.494
	Irbesartan	202	130 (64.4)	-2.26 (1.05)	(-4.32, -0.21)			
Week 110	Sparsentan	202	149 (73.8)	-1.14 (0.98)	(-3.07, 0.79)	0.12 (1.46)	(-2.75, 3.00)	0.932
	Irbesartan	202	121 (59.9)	-1.27 (1.09)	(-3.40, 0.86)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate.
A decrease reflects a worsening of the status of the patient.
A first order regressive covariance structure was used.
Source Data: aqs, created on: 08FEB2024

Figure PF2KSYC_FMG0: KDQOL: Change from baseline in symptom/problems of kidney disease
Full Analysis Set
Study: PROTECT



Sparsentan	157	162	160	151	149
Irbesartan	131	124	130	130	121

MMRM = Mixed model Repeated Measures. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate.
KD = kidney disease. A decrease reflects a worsening of the status of the patient. Reference table: PT2KSYC_FMC0

Figure PF2KSYIT_FMK0: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	180	169	162	148	124
Irbesartan	202	159	146	138	129	110

An increase reflects an improvement of the status of the patient.
Reference table: PT2KSYIT_FMT0

Figure PF2KSYDT_FMK0: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	181	169	157	137	114
Irbesartan	202	161	144	131	122	98

A decrease reflects a worsening of the status of the patient.
Reference table: PT2KSYDT_FMT0

Table PT2KPSC_FMC0: KDQOL-SF12: Change from baseline in PCS
Full Analysis Set

				Repeated measures analysis				
KDQOL-SF12: change from baseline in PCS				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Week 24	Sparsentan	202	159 (78.7)	0.39 (0.49)	(-0.58, 1.36)	0.43 (0.72)	(-0.99, 1.85)	0.555
	Irbesartan	202	138 (68.3)	-0.04 (0.53)	(-1.08, 1.00)			
Week 48	Sparsentan	202	165 (81.7)	0.06 (0.48)	(-0.89, 1.01)	0.12 (0.73)	(-1.31, 1.54)	0.873
	Irbesartan	202	127 (62.9)	-0.06 (0.54)	(-1.12, 1.01)			
Week 70	Sparsentan	202	163 (80.7)	-0.58 (0.49)	(-1.53, 0.38)	0.35 (0.72)	(-1.07, 1.77)	0.627
	Irbesartan	202	135 (66.8)	-0.93 (0.53)	(-1.97, 0.12)			
Week 94	Sparsentan	202	155 (76.7)	-0.45 (0.50)	(-1.42, 0.53)	-0.11 (0.73)	(-1.55, 1.33)	0.885
	Irbesartan	202	133 (65.8)	-0.34 (0.54)	(-1.40, 0.72)			
Week 110	Sparsentan	202	150 (74.3)	-0.60 (0.51)	(-1.60, 0.40)	-0.19 (0.76)	(-1.68, 1.30)	0.804
	Irbesartan	202	121 (59.9)	-0.41 (0.56)	(-1.52, 0.69)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate.
A decrease reflects a worsening of the status of the patient.
A first order regressive covariance structure was used.
Source Data: aqs, created on: 08FEB2024

Figure PF2KPSC_FMG0: KDQOL-SF12: Change from baseline in PCS
Full Analysis Set
Study: PROTECT



Sparsentan	159	165	163	155	150
Irbesartan	138	127	135	133	121

MMRM = Mixed model Repeated Measures. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate.
A decrease reflects a worsening of the status of the patient. Reference table: PT2KPSC_FMC0

Figure PF2KPSIT_FMK0: KDQOL-SF12: Time to increase in PCS by at least 8.4 points - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	180	161	152	140	119
Irbesartan	202	163	143	129	123	105

An increase reflects an improvement of the status of the patient.
Reference table: PT2KPSIT_FMT0

Figure PF2KPSDT_FMK0: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	177	164	149	130	109
Irbesartan	202	163	143	128	113	94

_____
A decrease reflects a worsening of the status of the patient.
Reference table: PT2KPSDT_FMT0

Table PT2KMSC_FMC0: KDQOL-SF12: Change from baseline in MCS
Full Analysis Set

KDQOL-SF12: change from baseline in MCS				Repeated measures analysis				
				Change from Baseline		Treatment Difference		
Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Week 24	Sparsentan	202	159 (78.7)	0.85 (0.57)	(-0.26, 1.97)	-0.12 (0.83)	(-1.75, 1.52)	0.889
	Irbesartan	202	138 (68.3)	0.97 (0.61)	(-0.23, 2.17)			
Week 48	Sparsentan	202	165 (81.7)	0.11 (0.56)	(-0.98, 1.20)	1.39 (0.84)	(-0.25, 3.04)	0.097
	Irbesartan	202	127 (62.9)	-1.28 (0.63)	(-2.51, -0.06)			
Week 70	Sparsentan	202	163 (80.7)	-0.05 (0.56)	(-1.15, 1.06)	0.39 (0.83)	(-1.24, 2.03)	0.636
	Irbesartan	202	135 (66.8)	-0.44 (0.62)	(-1.65, 0.77)			
Week 94	Sparsentan	202	155 (76.7)	-0.33 (0.57)	(-1.46, 0.80)	1.07 (0.85)	(-0.59, 2.73)	0.205
	Irbesartan	202	133 (65.8)	-1.40 (0.62)	(-2.62, -0.19)			
Week 110	Sparsentan	202	150 (74.3)	-0.85 (0.59)	(-2.00, 0.30)	1.00 (0.87)	(-0.72, 2.72)	0.253
	Irbesartan	202	121 (59.9)	-1.85 (0.65)	(-3.12, -0.57)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate.
A decrease reflects a worsening of the status of the patient.
A first order regressive covariance structure was used.
Source Data: aqs, created on: 08FEB2024

Figure PF2KMSC_FMG0: KDQOL-SF12: Change from baseline in MCS
Full Analysis Set
Study: PROTECT



Sparsentan	159	165	163	155	150
Irbesartan	138	127	135	133	121

MMRM = Mixed model Repeated Measures. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate.
A decrease reflects a worsening of the status of the patient. Reference table: PT2KMSC_FMC0

Figure PF2KMSIT_FMK0: KDQOL-SF12: Time to increase in MCS by at least 9.0 points - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	175	152	143	129	110
Irbesartan	202	160	146	133	123	103

An increase reflects an improvement of the status of the patient.
Reference table: PT2KMSIT_FMT0

Figure PF2KMSDT_FMK0: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points - Kaplan-Meier plot
Full Analysis Set
Study: PROTECT



Sparsentan	202	180	162	149	131	109
Irbesartan	202	162	146	126	114	91

A decrease reflects a worsening of the status of the patient.
Reference table: PT2KMSDT_FMT0

Table PT2AC_SMS0: Incidence of severe TEAEs during double-blind period by SOC/PT
Safety Set

Not done. No valid soc/pt combination with sufficient high incidence found.

_____
Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher was used. * = significant treatment effect.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Only events are reported with at least 5% of affected patients in at least 1 treatment arm.
Source Data: aae, created on: 30JAN2024

Table PT2AD_SMSD: Incidence of fatal TEAEs during double-blind period by SOC/PT
Safety Set

Fatal TEAEs				
SOC/PT	Time	Treatment	N	n (%)
SOC: Cardiac disorders	Double-blind period	Sparsentan	202	0 (0.0)
		Irbesartan	202	1 (0.5)
PT: Cardio-respiratory arrest	Double-blind period	Sparsentan	202	0 (0.0)
		Irbesartan	202	1 (0.5)

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Source Data: aae, created on: 30JAN2024

Table PT2RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis				
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)		
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value
Sex	Overall	Sparsentan						Interaction:	0.015 #
Male	Week 6	Sparsentan	139	134 (96.4)	-40.75	(-47.48, -33.15)	0.597	(0.504, 0.707)	<0.001 *
		Irbesartan	143	138 (96.5)	-0.76	(-11.89, 11.77)			
	Week 36	Sparsentan	139	135 (97.1)	-47.93	(-53.84, -41.25)	0.560	(0.472, 0.664)	<0.001 *
		Irbesartan	143	132 (92.3)	-6.98	(-17.51, 4.90)			
	Week 58	Sparsentan	139	129 (92.8)	-43.32	(-49.82, -35.96)	0.597	(0.502, 0.709)	<0.001 *
		Irbesartan	143	127 (88.8)	-5.01	(-15.93, 7.33)			
	Week 110	Sparsentan	139	116 (83.5)	-41.90	(-48.82, -34.06)	0.608	(0.507, 0.730)	<0.001 *
		Irbesartan	143	107 (74.8)	-4.48	(-16.15, 8.81)			
Female	Week 6	Sparsentan	63	59 (93.7)	-34.29	(-44.52, -22.17)	0.808	(0.633, 1.031)	0.087
		Irbesartan	59	56 (94.9)	-18.64	(-31.73, -3.04)			
	Week 36	Sparsentan	63	59 (93.7)	-47.56	(-55.75, -37.85)	0.710	(0.556, 0.907)	0.006 *
		Irbesartan	59	55 (93.2)	-26.13	(-38.00, -11.99)			
	Week 58	Sparsentan	63	59 (93.7)	-45.59	(-54.10, -35.50)	0.733	(0.573, 0.938)	0.014 *
		Irbesartan	59	52 (88.1)	-25.80	(-37.89, -11.35)			
	Week 110	Sparsentan	63	52 (82.5)	-42.59	(-51.88, -31.52)	0.670	(0.515, 0.872)	0.003 *
		Irbesartan	59	42 (71.2)	-14.28	(-29.46, 4.18)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 110 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 110 are included in the model. An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis				
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)		
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value
Age	Overall	Sparsentan						Interaction:	0.876
<= 45 years	Week 6	Sparsentan	96	92 (95.8)	-43.69	(-51.43, -34.71)	0.616	(0.500, 0.759)	<0.001 *
		Irbesartan	99	96 (97.0)	-8.61	(-21.03, 5.77)			
	Week 36	Sparsentan	96	91 (94.8)	-50.29	(-57.16, -42.33)	0.628	(0.510, 0.774)	<0.001 *
		Irbesartan	99	91 (91.9)	-20.86	(-31.68, -8.33)			
	Week 58	Sparsentan	96	89 (92.7)	-42.51	(-50.52, -33.21)	0.693	(0.561, 0.857)	<0.001 *
		Irbesartan	99	85 (85.9)	-17.07	(-28.63, -3.64)			
	Week 110	Sparsentan	96	76 (79.2)	-41.78	(-50.28, -31.82)	0.660	(0.525, 0.830)	<0.001 *
		Irbesartan	99	69 (69.7)	-11.78	(-25.23, 4.09)			
> 45 years	Week 6	Sparsentan	106	101 (95.3)	-33.86	(-41.98, -24.60)	0.692	(0.575, 0.835)	<0.001 *
		Irbesartan	103	98 (95.1)	-4.48	(-16.38, 9.11)			
	Week 36	Sparsentan	106	103 (97.2)	-45.30	(-52.00, -37.66)	0.577	(0.478, 0.696)	<0.001 *
		Irbesartan	103	96 (93.2)	-5.17	(-17.08, 8.45)			
	Week 58	Sparsentan	106	99 (93.4)	-45.21	(-51.97, -37.49)	0.584	(0.484, 0.706)	<0.001 *
		Irbesartan	103	94 (91.3)	-6.26	(-18.15, 7.36)			
	Week 110	Sparsentan	106	92 (86.8)	-42.16	(-49.48, -33.79)	0.599	(0.492, 0.730)	<0.001 *
		Irbesartan	103	80 (77.7)	-3.47	(-16.32, 11.35)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 110 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 110 are included in the model. An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis				
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)		
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value
Age at IgAN diagnosis	Overall	Sparsentan						Interaction:	0.698
<= 18 years	Week 6	Sparsentan	9	8 (88.9)	-50.70	(-73.06, -9.78)	0.533	(0.190, 1.499)	0.220
		Irbesartan	5	5 (100.0)	-7.56	(-58.32, 105.01)			
	Week 36	Sparsentan	9	8 (88.9)	-37.36	(-65.94, 15.21)	0.741	(0.263, 2.086)	0.554
		Irbesartan	5	5 (100.0)	-15.49	(-61.90, 87.43)			
	Week 58	Sparsentan	9	7 (77.8)	-42.84	(-69.46, 6.99)	0.773	(0.269, 2.219)	0.618
		Irbesartan	5	4 (80.0)	-26.05	(-67.11, 66.29)			
	Week 110	Sparsentan	9	5 (55.6)	10.68	(-44.69, 121.46)	1.617	(0.526, 4.976)	0.387
		Irbesartan	5	4 (80.0)	-31.57	(-70.60, 59.25)			
> 18 to 40 years	Week 6	Sparsentan	102	99 (97.1)	-42.81	(-50.17, -34.35)	0.638	(0.526, 0.773)	<0.001 *
		Irbesartan	109	105 (96.3)	-10.33	(-21.59, 2.54)			
	Week 36	Sparsentan	102	97 (95.1)	-50.04	(-56.50, -42.62)	0.612	(0.504, 0.743)	<0.001 *
		Irbesartan	109	100 (91.7)	-18.37	(-28.69, -6.55)			
	Week 58	Sparsentan	102	95 (93.1)	-45.49	(-52.60, -37.31)	0.628	(0.516, 0.765)	<0.001 *
		Irbesartan	109	93 (85.3)	-13.19	(-24.40, -0.32)			
	Week 110	Sparsentan	102	82 (80.4)	-43.36	(-51.11, -34.37)	0.637	(0.516, 0.786)	<0.001 *
		Irbesartan	109	78 (71.6)	-11.05	(-23.44, 3.35)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 110 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 110 are included in the model. An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis				
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)		
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value
> 40 years	Week 6	Sparsentan	91	86 (94.5)	-31.60	(-40.72, -21.06)	0.709	(0.578, 0.869)	<0.001 *
		Irbesartan	88	84 (95.5)	-3.45	(-16.52, 11.66)			
	Week 36	Sparsentan	91	89 (97.8)	-45.02	(-52.33, -36.59)	0.597	(0.487, 0.732)	<0.001 *
		Irbesartan	88	82 (93.2)	-7.90	(-20.45, 6.62)			
	Week 58	Sparsentan	91	86 (94.5)	-41.25	(-49.09, -32.21)	0.656	(0.534, 0.805)	<0.001 *
		Irbesartan	88	82 (93.2)	-10.38	(-22.68, 3.87)			
	Week 110	Sparsentan	91	81 (89.0)	-42.07	(-49.93, -32.99)	0.598	(0.483, 0.741)	<0.001 *
		Irbesartan	88	67 (76.1)	-3.15	(-17.24, 13.34)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 110 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 110 are included in the model. An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis				
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)		
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value
Geographic region	Overall	Sparsentan						Interaction:	0.901
North America	Week 6	Sparsentan	35	33 (94.3)	-28.23	(-42.14, -10.98)	0.684	(0.514, 0.910)	0.009 *
		Irbesartan	46	45 (97.8)	4.94	(-12.97, 26.53)			
	Week 36	Sparsentan	35	33 (94.3)	-48.43	(-58.45, -36.00)	0.477	(0.358, 0.637)	<0.001 *
		Irbesartan	46	43 (93.5)	7.99	(-10.65, 30.53)			
	Week 58	Sparsentan	35	28 (80.0)	-38.72	(-51.02, -23.33)	0.607	(0.451, 0.817)	0.001 *
		Irbesartan	46	40 (87.0)	0.98	(-16.84, 22.63)			
	Week 110	Sparsentan	35	27 (77.1)	-42.20	(-54.25, -26.98)	0.571	(0.414, 0.786)	<0.001 *
		Irbesartan	46	31 (67.4)	1.29	(-18.52, 25.92)			
Europe	Week 6	Sparsentan	98	92 (93.9)	-42.24	(-49.83, -33.50)	0.632	(0.521, 0.766)	<0.001 *
		Irbesartan	115	109 (94.8)	-8.56	(-19.78, 4.22)			
	Week 36	Sparsentan	98	94 (95.9)	-47.63	(-54.51, -39.71)	0.621	(0.512, 0.752)	<0.001 *
		Irbesartan	115	108 (93.9)	-15.61	(-25.97, -3.81)			
	Week 58	Sparsentan	98	93 (94.9)	-41.54	(-49.26, -32.65)	0.668	(0.550, 0.811)	<0.001 *
		Irbesartan	115	101 (87.8)	-12.47	(-23.38, -0.00)			
	Week 110	Sparsentan	98	79 (80.6)	-42.38	(-50.32, -33.17)	0.637	(0.519, 0.782)	<0.001 *
		Irbesartan	115	87 (75.7)	-9.51	(-21.44, 4.24)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 110 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 110 are included in the model. An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis					
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)			
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value	
Asia Pacific	Week 6	Sparsentan	69	68 (98.6)	-40.09	(-49.70, -28.64)	0.653	(0.490, 0.869)	0.004	*
		Irbesartan	41	40 (97.6)	-8.19	(-26.77, 15.11)				
	Week 36	Sparsentan	69	67 (97.1)	-48.88	(-57.10, -39.09)	0.664	(0.497, 0.888)	0.006	*
		Irbesartan	41	36 (87.8)	-23.07	(-38.91, -3.11)				
	Week 58	Sparsentan	69	67 (97.1)	-51.02	(-58.91, -41.60)	0.603	(0.450, 0.807)	<0.001	*
		Irbesartan	41	38 (92.7)	-18.73	(-35.54, 2.48)				
	Week 110	Sparsentan	69	62 (89.9)	-43.42	(-52.74, -32.28)	0.603	(0.443, 0.820)	0.001	*
		Irbesartan	41	31 (75.6)	-6.18	(-26.85, 20.33)				

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 110 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 110 are included in the model. An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis				
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)		
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value
Baseline BMI	Overall	Sparsentan						Interaction:	0.968
< 27 kg/m**2	Week 6	Sparsentan	83	77 (92.8)	-42.10	(-50.22, -32.66)	0.658	(0.535, 0.810)	<0.001 *
		Irbesartan	94	90 (95.7)	-12.06	(-23.70, 1.36)			
	Week 36	Sparsentan	83	80 (96.4)	-51.66	(-58.41, -43.81)	0.629	(0.511, 0.774)	<0.001 *
		Irbesartan	94	85 (90.4)	-23.12	(-33.37, -11.29)			
	Week 58	Sparsentan	83	76 (91.6)	-50.83	(-57.76, -42.77)	0.622	(0.503, 0.768)	<0.001 *
		Irbesartan	94	80 (85.1)	-20.93	(-31.69, -8.47)			
	Week 110	Sparsentan	83	70 (84.3)	-45.20	(-53.18, -35.86)	0.670	(0.535, 0.837)	<0.001 *
		Irbesartan	94	66 (70.2)	-18.16	(-30.17, -4.07)			
>= 27 kg/m**2	Week 6	Sparsentan	119	116 (97.5)	-35.81	(-43.49, -27.08)	0.655	(0.544, 0.788)	<0.001 *
		Irbesartan	107	103 (96.3)	-1.97	(-14.33, 12.17)			
	Week 36	Sparsentan	119	114 (95.8)	-44.44	(-51.13, -36.84)	0.580	(0.481, 0.699)	<0.001 *
		Irbesartan	107	101 (94.4)	-4.15	(-16.31, 9.78)			
	Week 58	Sparsentan	119	112 (94.1)	-38.27	(-45.75, -29.76)	0.641	(0.531, 0.773)	<0.001 *
		Irbesartan	107	99 (92.5)	-3.64	(-15.97, 10.51)			
	Week 110	Sparsentan	119	98 (82.4)	-39.52	(-47.12, -30.82)	0.593	(0.486, 0.723)	<0.001 *
		Irbesartan	107	82 (76.6)	2.02	(-11.88, 18.12)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 110 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 110 are included in the model. An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis				
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)		
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value
Randomization strata	Overall	Sparsentan						Interaction:	0.126
eGFR Low and UP High	Week 6	Sparsentan	71	68 (95.8)	-31.96	(-42.23, -19.87)	0.670	(0.533, 0.842)	<0.001 *
		Irbesartan	74	73 (98.6)	1.58	(-13.43, 19.20)			
	Week 36	Sparsentan	71	68 (95.8)	-43.21	(-51.80, -33.08)	0.608	(0.483, 0.766)	<0.001 *
		Irbesartan	74	68 (91.9)	-6.62	(-20.55, 9.74)			
	Week 58	Sparsentan	71	67 (94.4)	-42.12	(-50.93, -31.73)	0.640	(0.507, 0.807)	<0.001 *
		Irbesartan	74	65 (87.8)	-9.50	(-23.18, 6.63)			
	Week 110	Sparsentan	71	59 (83.1)	-34.89	(-45.20, -22.66)	0.761	(0.593, 0.976)	0.032 *
		Irbesartan	74	53 (71.6)	-14.44	(-28.51, 2.39)			
eGFR Low and UP Low	Week 6	Sparsentan	55	51 (92.7)	-37.13	(-47.91, -24.11)	0.724	(0.555, 0.944)	0.017 *
		Irbesartan	55	53 (96.4)	-13.15	(-27.98, 4.74)			
	Week 36	Sparsentan	55	51 (92.7)	-42.54	(-52.42, -30.62)	0.624	(0.478, 0.814)	<0.001 *
		Irbesartan	55	51 (92.7)	-7.89	(-23.68, 11.17)			
	Week 58	Sparsentan	55	52 (94.5)	-37.61	(-48.34, -24.65)	0.720	(0.551, 0.940)	0.016 *
		Irbesartan	55	51 (92.7)	-13.37	(-28.27, 4.63)			
	Week 110	Sparsentan	55	46 (83.6)	-31.16	(-43.35, -16.35)	0.751	(0.568, 0.993)	0.045 *
		Irbesartan	55	42 (76.4)	-8.33	(-25.00, 12.04)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 110 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 110 are included in the model. An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis				
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)		
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value
eGFR High and UP High	Week 6	Sparsentan	37	35 (94.6)	-44.91	(-57.14, -29.18)	0.587	(0.408, 0.842)	0.004 *
		Irbesartan	36	32 (88.9)	-6.08	(-27.57, 21.80)			
	Week 36	Sparsentan	37	37 (100.0)	-53.20	(-63.53, -39.95)	0.580	(0.404, 0.833)	0.003 *
		Irbesartan	36	32 (88.9)	-19.35	(-37.92, 4.77)			
	Week 58	Sparsentan	37	32 (86.5)	-51.25	(-62.24, -37.07)	0.546	(0.377, 0.790)	0.001 *
		Irbesartan	36	31 (86.1)	-10.64	(-31.59, 16.71)			
	Week 110	Sparsentan	37	30 (81.1)	-59.64	(-69.07, -47.34)	0.402	(0.273, 0.594)	<0.001 *
		Irbesartan	36	27 (75.0)	0.28	(-24.43, 33.08)			
eGFR High and UP Low	Week 6	Sparsentan	39	39 (100.0)	-46.47	(-56.60, -33.97)	0.606	(0.448, 0.819)	0.001 *
		Irbesartan	37	36 (97.3)	-11.63	(-28.82, 9.72)			
	Week 36	Sparsentan	39	38 (97.4)	-56.62	(-64.88, -46.43)	0.584	(0.431, 0.790)	<0.001 *
		Irbesartan	37	36 (97.3)	-25.70	(-40.19, -7.71)			
	Week 58	Sparsentan	39	37 (94.9)	-49.18	(-58.93, -37.12)	0.591	(0.434, 0.806)	<0.001 *
		Irbesartan	37	32 (86.5)	-14.03	(-31.30, 7.58)			
	Week 110	Sparsentan	39	33 (84.6)	-49.45	(-59.44, -36.99)	0.512	(0.369, 0.708)	<0.001 *
		Irbesartan	37	27 (73.0)	-1.17	(-22.23, 25.60)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 110 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 110 are included in the model. An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis				
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)		
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value
Baseline eGFR Group 1	Overall	Sparsentan						Interaction:	<0.001 #
< 60 mL/min/1.73 m**2	Week 6	Sparsentan	127	120 (94.5)	-34.74	(-42.25, -26.25)	0.683	(0.575, 0.811)	<0.001 *
		Irbesartan	129	126 (97.7)	-4.38	(-15.28, 7.91)			
	Week 36	Sparsentan	127	120 (94.5)	-42.19	(-48.86, -34.65)	0.637	(0.535, 0.757)	<0.001 *
		Irbesartan	129	119 (92.2)	-9.20	(-19.61, 2.57)			
	Week 58	Sparsentan	127	120 (94.5)	-39.68	(-46.66, -31.78)	0.678	(0.570, 0.808)	<0.001 *
		Irbesartan	129	116 (89.9)	-11.09	(-21.40, 0.56)			
	Week 110	Sparsentan	127	105 (82.7)	-31.37	(-39.62, -22.00)	0.756	(0.629, 0.910)	0.003 *
		Irbesartan	129	96 (74.4)	-9.27	(-20.53, 3.59)			
60 to < 90 mL/min/1.73 m**2	Week 6	Sparsentan	49	48 (98.0)	-46.38	(-56.23, -34.32)	0.525	(0.393, 0.702)	<0.001 *
		Irbesartan	48	45 (93.8)	2.08	(-16.99, 25.54)			
	Week 36	Sparsentan	49	48 (98.0)	-54.63	(-62.98, -44.41)	0.445	(0.332, 0.596)	<0.001 *
		Irbesartan	48	45 (93.8)	2.05	(-17.21, 25.79)			
	Week 58	Sparsentan	49	43 (87.8)	-50.86	(-60.10, -39.47)	0.480	(0.356, 0.647)	<0.001 *
		Irbesartan	48	42 (87.5)	2.45	(-17.23, 26.81)			
	Week 110	Sparsentan	49	42 (85.7)	-58.08	(-66.13, -48.12)	0.381	(0.279, 0.521)	<0.001 *
		Irbesartan	48	36 (75.0)	9.98	(-12.31, 37.94)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 110 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 110 are included in the model. An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis				
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)		
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value
>= 90 mL/min/1.73 m**2	Week 6	Sparsentan	26	25 (96.2)	-42.16	(-55.91, -24.12)	0.806	(0.544, 1.193)	0.279
		Irbesartan	25	23 (92.0)	-28.21	(-45.84, -4.86)			
	Week 36	Sparsentan	26	26 (100.0)	-58.02	(-67.96, -45.01)	0.809	(0.548, 1.195)	0.285
		Irbesartan	25	23 (92.0)	-48.11	(-60.77, -31.37)			
	Week 58	Sparsentan	26	25 (96.2)	-50.80	(-62.49, -35.45)	0.748	(0.502, 1.113)	0.151
		Irbesartan	25	21 (84.0)	-34.19	(-50.71, -12.13)			
	Week 110	Sparsentan	26	21 (80.8)	-53.94	(-65.37, -38.75)	0.635	(0.415, 0.974)	0.038 *
		Irbesartan	25	17 (68.0)	-27.53	(-47.20, -0.53)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 110 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 110 are included in the model. An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis					
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)			
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value	
Baseline eGFR Group 2	Overall	Sparsentan						Interaction:	<0.001	#
< 45 mL/min/1.73 m**2	Week 6	Sparsentan	82	78 (95.1)	-29.26	(-39.49, -17.31)	0.756	(0.606, 0.944)	0.014	*
		Irbesartan	80	78 (97.5)	-6.49	(-20.14, 9.51)				
	Week 36	Sparsentan	82	78 (95.1)	-37.10	(-46.21, -26.44)	0.700	(0.560, 0.876)	0.002	*
		Irbesartan	80	72 (90.0)	-10.19	(-23.43, 5.34)				
	Week 58	Sparsentan	82	77 (93.9)	-36.45	(-45.70, -25.62)	0.743	(0.593, 0.930)	0.010	*
		Irbesartan	80	70 (87.5)	-14.42	(-27.15, 0.54)				
	Week 110	Sparsentan	82	67 (81.7)	-27.68	(-38.62, -14.80)	0.803	(0.632, 1.019)	0.071	
		Irbesartan	80	59 (73.8)	-9.90	(-24.25, 7.17)				
45 to < 60 mL/min/1.73 m**2	Week 6	Sparsentan	45	42 (93.3)	-43.33	(-53.36, -31.15)	0.572	(0.437, 0.749)	<0.001	*
		Irbesartan	49	48 (98.0)	-0.92	(-17.68, 19.24)				
	Week 36	Sparsentan	45	42 (93.3)	-50.30	(-59.12, -39.59)	0.537	(0.410, 0.704)	<0.001	*
		Irbesartan	49	47 (95.9)	-7.48	(-23.16, 11.41)				
	Week 58	Sparsentan	45	43 (95.6)	-44.99	(-54.75, -33.13)	0.583	(0.444, 0.766)	<0.001	*
		Irbesartan	49	46 (93.9)	-5.67	(-21.85, 13.85)				
	Week 110	Sparsentan	45	38 (84.4)	-37.49	(-48.96, -23.43)	0.683	(0.513, 0.911)	0.010	*
		Irbesartan	49	37 (75.5)	-8.53	(-25.30, 11.99)				

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 110 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 110 are included in the model. An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis					
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)			
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value	
60 to < 90 mL/min/1.73 m**2	Week 6	Sparsentan	49	48 (98.0)	-46.38	(-56.23, -34.32)	0.525	(0.393, 0.702)	<0.001	*
		Irbesartan	48	45 (93.8)	2.08	(-16.99, 25.54)				
	Week 36	Sparsentan	49	48 (98.0)	-54.63	(-62.98, -44.41)	0.445	(0.332, 0.596)	<0.001	*
		Irbesartan	48	45 (93.8)	2.05	(-17.21, 25.79)				
	Week 58	Sparsentan	49	43 (87.8)	-50.86	(-60.10, -39.47)	0.480	(0.356, 0.647)	<0.001	*
		Irbesartan	48	42 (87.5)	2.45	(-17.23, 26.81)				
	Week 110	Sparsentan	49	42 (85.7)	-58.08	(-66.13, -48.12)	0.381	(0.279, 0.521)	<0.001	*
		Irbesartan	48	36 (75.0)	9.98	(-12.31, 37.94)				
>= 90 mL/min/1.73 m**2	Week 6	Sparsentan	26	25 (96.2)	-42.16	(-55.91, -24.12)	0.806	(0.544, 1.193)	0.279	
		Irbesartan	25	23 (92.0)	-28.21	(-45.84, -4.86)				
	Week 36	Sparsentan	26	26 (100.0)	-58.02	(-67.96, -45.01)	0.809	(0.548, 1.195)	0.285	
		Irbesartan	25	23 (92.0)	-48.11	(-60.77, -31.37)				
	Week 58	Sparsentan	26	25 (96.2)	-50.80	(-62.49, -35.45)	0.748	(0.502, 1.113)	0.151	
		Irbesartan	25	21 (84.0)	-34.19	(-50.71, -12.13)				
	Week 110	Sparsentan	26	21 (80.8)	-53.94	(-65.37, -38.75)	0.635	(0.415, 0.974)	0.038	*
		Irbesartan	25	17 (68.0)	-27.53	(-47.20, -0.53)				

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 110 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 110 are included in the model. An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis					
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)			
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value	
Baseline urine protein excretion	Overall	Sparsentan						Interaction:	0.372	
<= 1.75 g/day	Week 6	Sparsentan	98	94 (95.9)	-33.40	(-42.39, -23.02)	0.699	(0.567, 0.860)	<0.001	*
		Irbesartan	93	89 (95.7)	-4.68	(-17.86, 10.62)				
	Week 36	Sparsentan	98	94 (95.9)	-44.02	(-51.58, -35.28)	0.600	(0.487, 0.740)	<0.001	*
		Irbesartan	93	87 (93.5)	-6.77	(-19.74, 8.29)				
	Week 58	Sparsentan	98	93 (94.9)	-36.30	(-44.93, -26.32)	0.669	(0.542, 0.826)	<0.001	*
		Irbesartan	93	82 (88.2)	-4.82	(-18.26, 10.85)				
	Week 110	Sparsentan	98	84 (85.7)	-33.39	(-42.65, -22.64)	0.657	(0.526, 0.819)	<0.001	*
		Irbesartan	93	70 (75.3)	1.41	(-13.81, 19.33)				
> 1.75 g/day	Week 6	Sparsentan	104	99 (95.2)	-43.48	(-50.56, -35.39)	0.619	(0.513, 0.746)	<0.001	*
		Irbesartan	109	105 (96.3)	-8.66	(-19.86, 4.11)				
	Week 36	Sparsentan	104	100 (96.2)	-51.09	(-57.22, -44.08)	0.603	(0.500, 0.728)	<0.001	*
		Irbesartan	109	100 (91.7)	-18.91	(-28.93, -7.48)				
	Week 58	Sparsentan	104	95 (91.3)	-50.50	(-56.78, -43.31)	0.603	(0.498, 0.730)	<0.001	*
		Irbesartan	109	97 (89.0)	-17.93	(-28.21, -6.18)				
	Week 110	Sparsentan	104	84 (80.8)	-49.39	(-56.09, -41.66)	0.599	(0.489, 0.734)	<0.001	*
		Irbesartan	109	79 (72.5)	-15.51	(-26.91, -2.34)				

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 110 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 110 are included in the model. An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis					
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)			
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value	
Baseline use of antihypertensives	Overall	Sparsentan						Interaction:	0.939	
Yes	Week 6	Sparsentan	90	84 (93.3)	-39.34	(-47.70, -29.64)	0.651	(0.527, 0.805)	<0.001	*
		Irbesartan	88	82 (93.2)	-6.84	(-19.91, 8.35)				
	Week 36	Sparsentan	90	87 (96.7)	-47.26	(-54.51, -38.85)	0.583	(0.472, 0.720)	<0.001	*
		Irbesartan	88	82 (93.2)	-9.51	(-22.21, 5.27)				
	Week 58	Sparsentan	90	83 (92.2)	-42.31	(-50.32, -33.02)	0.669	(0.540, 0.829)	<0.001	*
		Irbesartan	88	80 (90.9)	-13.82	(-26.06, 0.45)				
	Week 110	Sparsentan	90	74 (82.2)	-45.14	(-53.04, -35.93)	0.601	(0.480, 0.752)	<0.001	*
		Irbesartan	88	68 (77.3)	-8.70	(-22.39, 7.41)				
No	Week 6	Sparsentan	112	109 (97.3)	-38.12	(-45.76, -29.41)	0.661	(0.549, 0.795)	<0.001	*
		Irbesartan	114	112 (98.2)	-6.33	(-17.76, 6.68)				
	Week 36	Sparsentan	112	107 (95.5)	-47.99	(-54.43, -40.64)	0.620	(0.514, 0.747)	<0.001	*
		Irbesartan	114	105 (92.1)	-16.10	(-26.45, -4.30)				
	Week 58	Sparsentan	112	105 (93.8)	-45.20	(-52.03, -37.40)	0.611	(0.505, 0.738)	<0.001	*
		Irbesartan	114	99 (86.8)	-10.26	(-21.51, 2.60)				
	Week 110	Sparsentan	112	94 (83.9)	-39.08	(-46.94, -30.06)	0.655	(0.536, 0.800)	<0.001	*
		Irbesartan	114	81 (71.1)	-6.98	(-19.58, 7.59)				

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 110 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 110 are included in the model.
An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis				
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)		
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value
Time since renal biopsy	Overall	Sparsentan						Interaction:	0.555
<= 5 years	Week 6	Sparsentan	113	106 (93.8)	-40.00	(-47.67, -31.21)	0.663	(0.549, 0.800)	<0.001 *
		Irbesartan	127	124 (97.6)	-9.48	(-20.38, 2.91)			
	Week 36	Sparsentan	113	107 (94.7)	-51.62	(-57.80, -44.53)	0.595	(0.493, 0.718)	<0.001 *
		Irbesartan	127	117 (92.1)	-18.68	(-28.57, -7.42)			
	Week 58	Sparsentan	113	104 (92.0)	-41.87	(-49.35, -33.30)	0.741	(0.613, 0.896)	0.002 *
		Irbesartan	127	117 (92.1)	-21.57	(-31.17, -10.62)			
	Week 110	Sparsentan	113	96 (85.0)	-48.23	(-55.09, -40.33)	0.605	(0.495, 0.740)	<0.001 *
		Irbesartan	127	93 (73.2)	-14.50	(-25.81, -1.47)			
> 5 years	Week 6	Sparsentan	89	87 (97.8)	-36.98	(-45.15, -27.59)	0.639	(0.519, 0.786)	<0.001 *
		Irbesartan	75	70 (93.3)	-1.35	(-15.35, 14.96)			
	Week 36	Sparsentan	89	87 (97.8)	-42.29	(-49.79, -33.66)	0.595	(0.484, 0.732)	<0.001 *
		Irbesartan	75	70 (93.3)	-3.00	(-16.78, 13.06)			
	Week 58	Sparsentan	89	84 (94.4)	-46.36	(-53.40, -38.26)	0.494	(0.399, 0.610)	<0.001 *
		Irbesartan	75	62 (82.7)	8.64	(-7.24, 27.24)			
	Week 110	Sparsentan	89	72 (80.9)	-32.70	(-41.91, -22.03)	0.642	(0.514, 0.803)	<0.001 *
		Irbesartan	75	56 (74.7)	4.76	(-11.35, 23.78)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 110 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 110 are included in the model. An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSLM: Percent change from baseline in UP/C by subgroup
Full Analysis Set

Percent change from baseline in UP/C					Repeated measures analysis				
					Percentage change from Baseline		Ratio (Sparsentan/Irbesartan)		
Subgroup	Time	Treatment	N	n (%)	Geometric LS-Mean	95% CI	LS-Mean Ratio	95% CI	p-value
History of hypertension	Overall	Sparsentan						Interaction:	0.539
Yes	Week 6	Sparsentan	155	147 (94.8)	-37.69	(-44.25, -30.37)	0.673	(0.576, 0.786)	<0.001 *
		Irbesartan	161	153 (95.0)	-7.41	(-17.00, 3.28)			
	Week 36	Sparsentan	155	149 (96.1)	-44.44	(-50.28, -37.92)	0.622	(0.532, 0.727)	<0.001 *
		Irbesartan	161	150 (93.2)	-10.71	(-19.99, -0.34)			
	Week 58	Sparsentan	155	145 (93.5)	-39.97	(-46.32, -32.88)	0.680	(0.580, 0.796)	<0.001 *
		Irbesartan	161	145 (90.1)	-11.68	(-20.99, -1.27)			
	Week 110	Sparsentan	155	130 (83.9)	-40.05	(-46.59, -32.71)	0.642	(0.544, 0.758)	<0.001 *
		Irbesartan	161	121 (75.2)	-6.65	(-17.13, 5.17)			
No	Week 6	Sparsentan	47	46 (97.9)	-41.41	(-52.54, -27.67)	0.618	(0.454, 0.843)	0.002 *
		Irbesartan	41	41 (100.0)	-5.25	(-24.38, 18.72)			
	Week 36	Sparsentan	47	45 (95.7)	-56.72	(-65.01, -46.46)	0.569	(0.416, 0.779)	<0.001 *
		Irbesartan	41	37 (90.2)	-23.93	(-39.52, -4.32)			
	Week 58	Sparsentan	47	43 (91.5)	-54.92	(-63.68, -44.04)	0.521	(0.378, 0.717)	<0.001 *
		Irbesartan	41	34 (82.9)	-13.49	(-31.55, 9.35)			
	Week 110	Sparsentan	47	38 (80.9)	-47.17	(-57.91, -33.69)	0.610	(0.432, 0.860)	0.005 *
		Irbesartan	41	28 (68.3)	-13.35	(-33.00, 12.06)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. Analysis was performed using the natural logarithm of the dependent variable. Reported estimates are back-transformed to the ratio scale. LS-Mean = Least square mean. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. Only key visits up to Week 110 are displayed.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and log(baseline) as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment were added to the model. All observed values up to Week 110 are included in the model. An increase reflects a worsening of the status of the patient. Results are presented in g/g. Estimated LS Mean and 95% CIs were converted to percentage change as follows: [exp(least squares mean change from baseline in natural log(UP/C)) – 1] x 100. The Ratio (Sparsentan/Irbesartan) can be interpreted in an analogous way as other common summarizing ratios (e.g. RR).
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio. A first order autoregressive covariance structure was used.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
Subgroup: Sex											
Male	UP/C	Baseline	Sparsentan	139	139 (100.0)	1.30 (0.79)	0.1	0.72	1.09	1.77	4.2
			Irbesartan	143	143 (100.0)	1.33 (0.85)	0.2	0.85	1.13	1.57	6.9
		Week 6	Sparsentan	139	134 (96.4)	0.91 (0.82)	0.1	0.38	0.68	1.11	5.6
			Irbesartan	143	138 (96.5)	1.37 (0.87)	0.1	0.76	1.15	1.70	5.4
		Week 36	Sparsentan	139	135 (97.1)	0.92 (0.94)	0.1	0.29	0.56	1.32	5.2
			Irbesartan	143	132 (92.3)	1.36 (0.98)	0.1	0.65	1.17	1.80	6.2
		Week 58	Sparsentan	139	129 (92.8)	0.92 (0.91)	0.1	0.28	0.70	1.22	5.9
			Irbesartan	143	127 (88.8)	1.40 (1.03)	0.1	0.72	1.09	1.87	5.6
		Week 110	Sparsentan	139	116 (83.5)	0.93 (0.87)	0.0	0.31	0.69	1.30	5.3
			Irbesartan	143	107 (74.8)	1.50 (1.32)	0.1	0.66	1.22	1.91	7.8
	Percent change from baseline in UP/C	Week 6	Sparsentan	139	134 (96.4)	-0.40 (0.70)	-2.3	-0.76	-0.38	-0.05	2.3
			Irbesartan	143	138 (96.5)	0.03 (0.72)	-4.3	-0.29	-0.03	0.33	3.7
		Week 36	Sparsentan	139	135 (97.1)	-0.39 (0.82)	-3.1	-0.74	-0.42	-0.07	3.6
			Irbesartan	143	132 (92.3)	0.02 (0.86)	-4.3	-0.44	-0.01	0.39	2.6
		Week 58	Sparsentan	139	129 (92.8)	-0.38 (0.90)	-3.0	-0.82	-0.36	0.02	5.7
			Irbesartan	143	127 (88.8)	0.06 (0.85)	-1.8	-0.37	-0.06	0.42	3.5
		Week 110	Sparsentan	139	116 (83.5)	-0.31 (0.82)	-3.3	-0.73	-0.36	0.04	2.5
			Irbesartan	143	107 (74.8)	0.16 (1.19)	-5.5	-0.35	0.02	0.61	5.3

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
Female	UP/C	Baseline	Sparsentan	63	63 (100.0)	1.71 (1.06)	0.6	1.03	1.40	2.13	7.0
			Irbesartan	59	59 (100.0)	1.72 (0.94)	0.5	1.14	1.50	2.04	4.5
		Week 6	Sparsentan	63	59 (93.7)	1.10 (0.73)	0.1	0.57	0.92	1.39	3.3
			Irbesartan	59	56 (94.9)	1.54 (1.08)	0.4	0.75	1.15	2.06	6.2
		Week 36	Sparsentan	63	59 (93.7)	0.95 (0.69)	0.1	0.50	0.80	1.26	3.7
			Irbesartan	59	55 (93.2)	1.44 (1.18)	0.2	0.62	1.02	2.06	6.6
		Week 58	Sparsentan	63	59 (93.7)	0.99 (0.68)	0.1	0.49	0.77	1.55	3.0
			Irbesartan	59	52 (88.1)	1.39 (1.06)	0.2	0.60	1.07	1.77	5.5
		Week 110	Sparsentan	63	52 (82.5)	1.22 (1.23)	0.1	0.41	0.96	1.57	6.7
			Irbesartan	59	42 (71.2)	1.60 (1.05)	0.2	0.81	1.36	2.13	4.2
	Percent change from baseline in UP/C	Week 6	Sparsentan	63	59 (93.7)	-0.48 (0.82)	-2.3	-0.83	-0.48	-0.14	1.9
			Irbesartan	59	56 (94.9)	-0.19 (0.69)	-1.5	-0.57	-0.22	0.13	1.9
		Week 36	Sparsentan	63	59 (93.7)	-0.68 (0.85)	-3.2	-1.09	-0.60	-0.16	1.1
			Irbesartan	59	55 (93.2)	-0.22 (0.79)	-1.9	-0.62	-0.21	0.08	2.4
		Week 58	Sparsentan	63	59 (93.7)	-0.61 (0.93)	-2.8	-1.00	-0.54	-0.14	1.7
			Irbesartan	59	52 (88.1)	-0.29 (0.77)	-3.2	-0.72	-0.25	0.12	1.3
		Week 110	Sparsentan	63	52 (82.5)	-0.38 (1.17)	-2.9	-1.04	-0.38	0.17	3.5
			Irbesartan	59	42 (71.2)	0.00 (0.79)	-1.3	-0.50	-0.06	0.43	2.7

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
Subgroup: Age											
<= 45 years	UP/C	Baseline	Sparsentan	96	96 (100.0)	1.41 (0.96)	0.2	0.79	1.15	1.76	7.0
			Irbesartan	99	99 (100.0)	1.44 (0.76)	0.2	0.91	1.30	1.77	4.2
		Week 6	Sparsentan	96	92 (95.8)	0.91 (0.83)	0.1	0.37	0.76	1.11	5.6
			Irbesartan	99	96 (97.0)	1.43 (1.01)	0.1	0.70	1.15	1.89	6.2
		Week 36	Sparsentan	96	91 (94.8)	0.94 (0.93)	0.1	0.28	0.58	1.32	5.2
			Irbesartan	99	91 (91.9)	1.33 (1.11)	0.1	0.58	0.93	2.02	6.6
		Week 58	Sparsentan	96	89 (92.7)	0.93 (0.78)	0.1	0.29	0.71	1.22	3.5
			Irbesartan	99	85 (85.9)	1.34 (1.04)	0.1	0.57	1.05	1.86	5.6
		Week 110	Sparsentan	96	76 (79.2)	0.95 (0.88)	0.0	0.35	0.78	1.26	5.3
			Irbesartan	99	69 (69.7)	1.43 (1.20)	0.1	0.65	1.11	1.80	6.4
	Percent change from baseline in UP/C	Week 6	Sparsentan	96	92 (95.8)	-0.47 (0.76)	-2.3	-0.86	-0.46	-0.14	2.3
			Irbesartan	99	96 (97.0)	-0.01 (0.71)	-1.4	-0.45	-0.18	0.33	3.7
		Week 36	Sparsentan	96	91 (94.8)	-0.43 (0.89)	-2.6	-0.73	-0.46	-0.07	3.6
			Irbesartan	99	91 (91.9)	-0.07 (0.81)	-1.9	-0.55	-0.16	0.27	2.4
		Week 58	Sparsentan	96	89 (92.7)	-0.43 (0.79)	-2.8	-0.83	-0.36	0.04	1.7
			Irbesartan	99	85 (85.9)	-0.07 (0.99)	-3.2	-0.48	-0.24	0.25	3.5
		Week 110	Sparsentan	96	76 (79.2)	-0.33 (0.91)	-3.3	-0.79	-0.31	0.08	2.5
			Irbesartan	99	69 (69.7)	0.10 (1.07)	-1.8	-0.50	-0.06	0.46	4.3

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
> 45 years	UP/C	Baseline	Sparsentan	106	106 (100.0)	1.44 (0.84)	0.1	0.74	1.31	1.88	4.2
			Irbesartan	103	103 (100.0)	1.44 (1.01)	0.4	0.85	1.17	1.72	6.9
		Week 6	Sparsentan	106	101 (95.3)	1.03 (0.77)	0.1	0.47	0.82	1.33	3.5
			Irbesartan	103	98 (95.1)	1.40 (0.87)	0.4	0.80	1.15	1.70	5.4
		Week 36	Sparsentan	106	103 (97.2)	0.93 (0.81)	0.1	0.40	0.69	1.28	4.4
			Irbesartan	103	96 (93.2)	1.44 (0.97)	0.2	0.78	1.29	1.79	6.2
		Week 58	Sparsentan	106	99 (93.4)	0.95 (0.90)	0.1	0.32	0.75	1.29	5.9
			Irbesartan	103	94 (91.3)	1.45 (1.03)	0.1	0.82	1.18	1.84	5.5
		Week 110	Sparsentan	106	92 (86.8)	1.08 (1.09)	0.1	0.35	0.75	1.48	6.7
			Irbesartan	103	80 (77.7)	1.61 (1.29)	0.1	0.81	1.36	2.06	7.8
	Percent change from baseline in UP/C	Week 6	Sparsentan	106	101 (95.3)	-0.38 (0.71)	-2.3	-0.71	-0.36	-0.01	1.7
			Irbesartan	103	98 (95.1)	-0.06 (0.73)	-4.3	-0.31	-0.08	0.29	1.9
		Week 36	Sparsentan	106	103 (97.2)	-0.52 (0.79)	-3.2	-1.01	-0.52	-0.15	1.7
			Irbesartan	103	96 (93.2)	-0.04 (0.88)	-4.3	-0.48	-0.05	0.33	2.6
		Week 58	Sparsentan	106	99 (93.4)	-0.47 (1.01)	-3.0	-1.01	-0.45	-0.03	5.7
			Irbesartan	103	94 (91.3)	-0.01 (0.67)	-1.8	-0.31	-0.03	0.35	1.7
		Week 110	Sparsentan	106	92 (86.8)	-0.33 (0.96)	-2.9	-0.75	-0.40	0.04	3.5
			Irbesartan	103	80 (77.7)	0.13 (1.12)	-5.5	-0.36	0.09	0.56	5.3

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
Subgroup: Age at IgAN diagnosis											
<= 18 years	UP/C	Baseline	Sparsentan	9	9 (100.0)	2.47 (1.88)	0.7	1.33	1.86	2.43	7.0
			Irbesartan	5	5 (100.0)	1.35 (0.44)	0.7	1.30	1.41	1.49	1.9
		Week 6	Sparsentan	9	8 (88.9)	1.09 (0.79)	0.2	0.46	0.96	1.54	2.6
			Irbesartan	5	5 (100.0)	1.40 (0.78)	0.8	0.79	0.95	2.05	2.4
		Week 36	Sparsentan	9	8 (88.9)	1.29 (0.85)	0.4	0.58	1.19	1.73	2.9
			Irbesartan	5	5 (100.0)	1.23 (0.56)	0.7	0.84	0.92	1.84	1.8
		Week 58	Sparsentan	9	7 (77.8)	1.37 (1.06)	0.1	0.71	1.10	2.73	2.9
			Irbesartan	5	4 (80.0)	1.07 (0.69)	0.4	0.50	1.04	1.65	1.9
		Week 110	Sparsentan	9	5 (55.6)	2.40 (1.98)	0.1	1.31	2.09	3.20	5.3
			Irbesartan	5	4 (80.0)	1.07 (0.69)	0.3	0.54	1.08	1.61	1.9
	Percent change from baseline in UP/C	Week 6	Sparsentan	9	8 (88.9)	-0.82 (0.88)	-2.2	-1.36	-0.80	-0.19	0.4
			Irbesartan	5	5 (100.0)	0.06 (0.77)	-0.9	-0.51	0.13	0.64	0.9
		Week 36	Sparsentan	9	8 (88.9)	-0.61 (1.06)	-2.5	-1.22	-0.37	0.13	0.5
			Irbesartan	5	5 (100.0)	-0.11 (0.67)	-1.1	-0.46	0.25	0.35	0.4
		Week 58	Sparsentan	9	7 (77.8)	-0.62 (1.23)	-2.8	-1.15	-0.65	0.49	0.9
			Irbesartan	5	4 (80.0)	-0.24 (0.87)	-1.5	-0.77	0.05	0.29	0.5
		Week 110	Sparsentan	9	5 (55.6)	0.25 (1.07)	-0.9	-0.64	0.38	0.77	1.7
			Irbesartan	5	4 (80.0)	-0.29 (0.90)	-1.6	-0.83	0.05	0.26	0.4

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
> 18 to 40 years	UP/C	Baseline	Sparsentan	102	102 (100.0)	1.34 (0.75)	0.2	0.79	1.17	1.76	3.6
			Irbesartan	109	109 (100.0)	1.46 (0.77)	0.2	0.93	1.33	1.75	4.5
		Week 6	Sparsentan	102	99 (97.1)	0.92 (0.82)	0.1	0.37	0.75	1.12	5.6
			Irbesartan	109	105 (96.3)	1.43 (0.97)	0.1	0.72	1.14	1.87	6.2
		Week 36	Sparsentan	102	97 (95.1)	0.91 (0.92)	0.1	0.28	0.58	1.24	5.2
			Irbesartan	109	100 (91.7)	1.37 (1.06)	0.1	0.63	1.04	1.79	6.6
		Week 58	Sparsentan	102	95 (93.1)	0.85 (0.71)	0.1	0.29	0.67	1.11	3.5
			Irbesartan	109	93 (85.3)	1.41 (1.02)	0.1	0.70	1.12	1.75	5.6
		Week 110	Sparsentan	102	82 (80.4)	0.94 (0.95)	0.0	0.37	0.73	1.24	6.7
			Irbesartan	109	78 (71.6)	1.57 (1.38)	0.1	0.70	1.18	1.93	7.8
	Percent change from baseline in UP/C	Week 6	Sparsentan	102	99 (97.1)	-0.45 (0.72)	-2.3	-0.79	-0.45	-0.14	2.3
			Irbesartan	109	105 (96.3)	-0.04 (0.62)	-1.5	-0.47	-0.18	0.34	1.9
		Week 36	Sparsentan	102	97 (95.1)	-0.44 (0.86)	-2.6	-0.81	-0.51	-0.07	3.6
			Irbesartan	109	100 (91.7)	-0.08 (0.83)	-1.9	-0.60	-0.13	0.27	2.6
		Week 58	Sparsentan	102	95 (93.1)	-0.49 (0.73)	-2.8	-0.93	-0.38	-0.02	1.2
			Irbesartan	109	93 (85.3)	-0.06 (0.95)	-3.2	-0.47	-0.24	0.35	3.5
		Week 110	Sparsentan	102	82 (80.4)	-0.35 (0.98)	-3.3	-0.83	-0.38	0.02	3.5
			Irbesartan	109	78 (71.6)	0.18 (1.16)	-1.6	-0.50	-0.05	0.46	5.3

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
> 40 years	UP/C	Baseline	Sparsentan	91	91 (100.0)	1.42 (0.86)	0.1	0.73	1.27	1.79	4.2
			Irbesartan	88	88 (100.0)	1.42 (1.05)	0.4	0.82	1.11	1.72	6.9
		Week 6	Sparsentan	91	86 (94.5)	1.03 (0.78)	0.1	0.48	0.82	1.36	3.5
			Irbesartan	88	84 (95.5)	1.41 (0.91)	0.4	0.79	1.17	1.76	5.4
		Week 36	Sparsentan	91	89 (97.8)	0.92 (0.81)	0.1	0.42	0.69	1.28	4.4
			Irbesartan	88	82 (93.2)	1.42 (1.04)	0.2	0.62	1.16	2.14	6.2
		Week 58	Sparsentan	91	86 (94.5)	1.00 (0.94)	0.1	0.35	0.76	1.40	5.9
			Irbesartan	88	82 (93.2)	1.40 (1.07)	0.1	0.73	1.05	1.94	5.5
		Week 110	Sparsentan	91	81 (89.0)	1.02 (0.92)	0.1	0.34	0.76	1.47	5.3
			Irbesartan	88	67 (76.1)	1.51 (1.12)	0.1	0.68	1.35	2.06	7.3
	Percent change from baseline in UP/C	Week 6	Sparsentan	91	86 (94.5)	-0.35 (0.72)	-2.3	-0.71	-0.32	-0.00	1.7
			Irbesartan	88	84 (95.5)	-0.03 (0.82)	-4.3	-0.28	-0.07	0.27	3.7
		Week 36	Sparsentan	91	89 (97.8)	-0.50 (0.80)	-3.2	-0.85	-0.51	-0.15	1.7
			Irbesartan	88	82 (93.2)	-0.01 (0.88)	-4.3	-0.38	-0.05	0.35	2.3
		Week 58	Sparsentan	91	86 (94.5)	-0.39 (1.07)	-3.0	-0.94	-0.44	0.05	5.7
			Irbesartan	88	82 (93.2)	-0.00 (0.70)	-1.8	-0.31	-0.04	0.28	2.4
		Week 110	Sparsentan	91	81 (89.0)	-0.35 (0.89)	-2.9	-0.72	-0.38	0.05	2.0
			Irbesartan	88	67 (76.1)	0.07 (1.03)	-5.5	-0.36	0.03	0.81	1.8

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
Subgroup: Geographic region											
North America	UP/C	Baseline	Sparsentan	35	35 (100.0)	1.56 (0.97)	0.1	0.90	1.36	2.20	4.0
			Irbesartan	46	46 (100.0)	1.65 (1.05)	0.4	1.14	1.43	1.77	6.9
		Week 6	Sparsentan	35	33 (94.3)	1.12 (0.73)	0.2	0.52	1.00	1.40	3.3
			Irbesartan	46	45 (97.8)	1.75 (1.05)	0.4	1.04	1.47	2.22	6.2
		Week 36	Sparsentan	35	33 (94.3)	0.90 (0.68)	0.2	0.39	0.73	1.12	2.6
			Irbesartan	46	43 (93.5)	1.74 (1.07)	0.3	1.03	1.47	2.46	6.6
		Week 58	Sparsentan	35	28 (80.0)	1.08 (1.17)	0.1	0.41	0.67	1.37	5.9
			Irbesartan	46	40 (87.0)	1.77 (1.23)	0.3	0.82	1.46	2.53	5.6
		Week 110	Sparsentan	35	27 (77.1)	1.03 (1.00)	0.1	0.39	0.76	1.31	5.3
			Irbesartan	46	31 (67.4)	1.65 (0.94)	0.2	0.89	1.38	2.40	3.7
	Percent change from baseline in UP/C	Week 6	Sparsentan	35	33 (94.3)	-0.42 (1.04)	-2.3	-0.70	-0.18	0.16	1.9
			Irbesartan	46	45 (97.8)	0.09 (0.98)	-4.3	-0.27	0.06	0.51	1.9
		Week 36	Sparsentan	35	33 (94.3)	-0.68 (1.09)	-3.2	-1.18	-0.46	0.02	1.2
			Irbesartan	46	43 (93.5)	0.09 (1.03)	-4.3	-0.46	0.06	0.69	2.4
		Week 58	Sparsentan	35	28 (80.0)	-0.44 (1.58)	-2.8	-1.03	-0.48	0.13	5.7
			Irbesartan	46	40 (87.0)	0.07 (1.06)	-2.1	-0.55	-0.08	0.63	3.5
		Week 110	Sparsentan	35	27 (77.1)	-0.40 (1.00)	-2.8	-0.94	-0.20	0.08	1.7
			Irbesartan	46	31 (67.4)	-0.07 (1.27)	-5.5	-0.56	-0.10	0.79	2.0

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
Europe	UP/C	Baseline	Sparsentan	98	98 (100.0)	1.39 (0.94)	0.3	0.75	1.20	1.82	7.0
			Irbesartan	115	115 (100.0)	1.40 (0.80)	0.4	0.85	1.17	1.77	4.5
		Week 6	Sparsentan	98	92 (93.9)	0.88 (0.68)	0.1	0.39	0.75	1.08	3.5
			Irbesartan	115	109 (94.8)	1.33 (0.85)	0.3	0.71	1.04	1.66	4.2
		Week 36	Sparsentan	98	94 (95.9)	0.95 (0.96)	0.1	0.31	0.65	1.35	5.2
			Irbesartan	115	108 (93.9)	1.29 (0.95)	0.2	0.57	1.01	1.73	4.6
		Week 58	Sparsentan	98	93 (94.9)	0.91 (0.74)	0.1	0.32	0.75	1.24	4.1
			Irbesartan	115	101 (87.8)	1.31 (0.94)	0.1	0.65	0.99	1.75	5.5
		Week 110	Sparsentan	98	79 (80.6)	0.96 (0.93)	0.1	0.31	0.69	1.31	5.3
			Irbesartan	115	87 (75.7)	1.50 (1.31)	0.1	0.62	1.19	1.96	7.8
	Percent change from baseline in UP/C	Week 6	Sparsentan	98	92 (93.9)	-0.45 (0.66)	-2.3	-0.79	-0.43	-0.11	1.6
			Irbesartan	115	109 (94.8)	-0.08 (0.65)	-1.5	-0.48	-0.12	0.25	3.7
		Week 36	Sparsentan	98	94 (95.9)	-0.38 (0.82)	-3.1	-0.75	-0.47	-0.10	3.6
			Irbesartan	115	108 (93.9)	-0.08 (0.81)	-1.7	-0.53	-0.15	0.27	2.6
		Week 58	Sparsentan	98	93 (94.9)	-0.41 (0.68)	-2.2	-0.88	-0.36	-0.02	1.2
			Irbesartan	115	101 (87.8)	-0.08 (0.83)	-3.2	-0.41	-0.10	0.23	3.0
		Week 110	Sparsentan	98	79 (80.6)	-0.33 (0.87)	-2.9	-0.76	-0.44	0.05	2.5
			Irbesartan	115	87 (75.7)	0.16 (1.11)	-1.6	-0.44	-0.01	0.61	5.3

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
Asia Pacific	UP/C	Baseline	Sparsentan	69	69 (100.0)	1.41 (0.81)	0.2	0.79	1.22	1.76	4.2
			Irbesartan	41	41 (100.0)	1.32 (0.94)	0.2	0.80	1.02	1.54	5.5
		Week 6	Sparsentan	69	68 (98.6)	1.03 (0.95)	0.1	0.39	0.77	1.29	5.6
			Irbesartan	41	40 (97.6)	1.30 (0.98)	0.1	0.66	1.04	1.68	5.4
		Week 36	Sparsentan	69	67 (97.1)	0.92 (0.83)	0.1	0.30	0.69	1.24	4.0
			Irbesartan	41	36 (87.8)	1.26 (1.19)	0.1	0.54	0.90	1.58	6.2
		Week 58	Sparsentan	69	67 (97.1)	0.91 (0.82)	0.1	0.26	0.71	1.29	3.5
			Irbesartan	41	38 (92.7)	1.26 (0.97)	0.1	0.67	1.11	1.60	5.2
		Week 110	Sparsentan	69	62 (89.9)	1.10 (1.08)	0.0	0.37	0.83	1.54	6.7
			Irbesartan	41	31 (75.6)	1.48 (1.37)	0.1	0.68	1.22	1.80	7.3
	Percent change from baseline in UP/C	Week 6	Sparsentan	69	68 (98.6)	-0.38 (0.66)	-2.1	-0.71	-0.41	-0.10	2.3
			Irbesartan	41	40 (97.6)	-0.04 (0.52)	-1.4	-0.32	-0.11	0.32	1.1
		Week 36	Sparsentan	69	67 (97.1)	-0.50 (0.69)	-2.6	-0.84	-0.51	-0.16	1.1
			Irbesartan	41	36 (87.8)	-0.13 (0.70)	-1.9	-0.55	-0.15	0.15	2.2
		Week 58	Sparsentan	69	67 (97.1)	-0.51 (0.84)	-3.0	-0.97	-0.48	-0.07	1.7
			Irbesartan	41	38 (92.7)	-0.05 (0.54)	-1.3	-0.36	-0.07	0.28	1.3
		Week 110	Sparsentan	69	62 (89.9)	-0.31 (1.01)	-3.3	-0.68	-0.31	0.06	3.5
			Irbesartan	41	31 (75.6)	0.17 (0.85)	-1.8	-0.21	0.15	0.35	2.7

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
Subgroup: Baseline BMI											
< 27 kg/m**2	UP/C	Baseline	Sparsentan	83	83 (100.0)	1.40 (0.74)	0.3	0.79	1.27	1.79	3.6
			Irbesartan	94	94 (100.0)	1.51 (0.87)	0.4	0.92	1.31	1.80	5.5
		Week 6	Sparsentan	83	77 (92.8)	0.95 (0.74)	0.1	0.38	0.76	1.27	3.3
			Irbesartan	94	90 (95.7)	1.44 (0.96)	0.3	0.75	1.14	1.90	5.4
		Week 36	Sparsentan	83	80 (96.4)	0.93 (0.91)	0.1	0.34	0.63	1.27	5.2
			Irbesartan	94	85 (90.4)	1.29 (0.97)	0.2	0.62	1.03	1.61	6.2
		Week 58	Sparsentan	83	76 (91.6)	0.80 (0.60)	0.1	0.29	0.73	1.11	2.9
			Irbesartan	94	80 (85.1)	1.33 (1.05)	0.1	0.61	0.97	1.78	5.6
		Week 110	Sparsentan	83	70 (84.3)	1.09 (1.19)	0.1	0.30	0.79	1.31	6.7
			Irbesartan	94	66 (70.2)	1.50 (1.29)	0.1	0.68	1.24	1.84	7.3
	Percent change from baseline in UP/C	Week 6	Sparsentan	83	77 (92.8)	-0.45 (0.72)	-2.2	-0.88	-0.48	-0.12	1.9
			Irbesartan	94	90 (95.7)	-0.08 (0.57)	-1.5	-0.42	-0.19	0.25	1.5
		Week 36	Sparsentan	83	80 (96.4)	-0.49 (0.87)	-2.6	-0.85	-0.56	-0.17	3.6
			Irbesartan	94	85 (90.4)	-0.19 (0.64)	-1.9	-0.53	-0.18	0.22	1.5
		Week 58	Sparsentan	83	76 (91.6)	-0.61 (0.80)	-2.8	-1.02	-0.52	-0.07	1.1
			Irbesartan	94	80 (85.1)	-0.16 (0.83)	-3.2	-0.49	-0.24	0.16	3.5
		Week 110	Sparsentan	83	70 (84.3)	-0.29 (1.02)	-2.9	-0.74	-0.38	0.06	3.5
			Irbesartan	94	66 (70.2)	0.01 (0.85)	-1.8	-0.44	-0.09	0.43	3.6

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
>= 27 kg/m**2	UP/C	Baseline	Sparsentan	119	119 (100.0)	1.44 (1.00)	0.1	0.74	1.22	1.86	7.0
			Irbesartan	107	107 (100.0)	1.39 (0.92)	0.2	0.84	1.16	1.66	6.9
		Week 6	Sparsentan	119	116 (97.5)	0.99 (0.83)	0.1	0.46	0.80	1.17	5.6
			Irbesartan	107	103 (96.3)	1.41 (0.92)	0.1	0.79	1.16	1.75	6.2
		Week 36	Sparsentan	119	114 (95.8)	0.93 (0.84)	0.1	0.33	0.70	1.32	4.4
			Irbesartan	107	101 (94.4)	1.48 (1.09)	0.1	0.68	1.24	2.06	6.6
		Week 58	Sparsentan	119	112 (94.1)	1.04 (0.96)	0.1	0.36	0.73	1.34	5.9
			Irbesartan	107	99 (92.5)	1.46 (1.02)	0.1	0.73	1.18	1.94	5.5
		Week 110	Sparsentan	119	98 (82.4)	0.97 (0.83)	0.0	0.39	0.75	1.39	5.3
			Irbesartan	107	82 (76.6)	1.56 (1.22)	0.1	0.79	1.25	2.10	7.8
	Percent change from baseline in UP/C	Week 6	Sparsentan	119	116 (97.5)	-0.40 (0.75)	-2.3	-0.72	-0.33	0.02	2.3
			Irbesartan	107	103 (96.3)	0.02 (0.82)	-4.3	-0.29	0.05	0.34	3.7
		Week 36	Sparsentan	119	114 (95.8)	-0.46 (0.81)	-3.2	-0.85	-0.42	-0.07	1.7
			Irbesartan	107	101 (94.4)	0.07 (0.98)	-4.3	-0.46	-0.00	0.49	2.6
		Week 58	Sparsentan	119	112 (94.1)	-0.34 (0.97)	-3.0	-0.79	-0.33	0.06	5.7
			Irbesartan	107	99 (92.5)	0.06 (0.83)	-2.1	-0.36	-0.02	0.46	3.0
		Week 110	Sparsentan	119	98 (82.4)	-0.37 (0.88)	-3.3	-0.76	-0.37	0.04	2.0
			Irbesartan	107	82 (76.6)	0.21 (1.26)	-5.5	-0.35	0.05	0.84	5.3

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
Subgroup: Randomization strata											
eGFR Low and UP High	UP/C	Baseline	Sparsentan	71	71 (100.0)	1.91 (1.07)	0.1	1.26	1.74	2.39	7.0
			Irbesartan	74	74 (100.0)	1.97 (1.06)	0.5	1.25	1.69	2.51	6.9
		Week 6	Sparsentan	71	68 (95.8)	1.31 (0.80)	0.3	0.75	1.06	2.06	3.5
			Irbesartan	74	73 (98.6)	1.96 (1.00)	0.6	1.19	1.90	2.60	6.2
		Week 36	Sparsentan	71	68 (95.8)	1.30 (1.01)	0.1	0.55	0.97	1.79	4.4
			Irbesartan	74	68 (91.9)	1.92 (1.13)	0.2	1.19	1.64	2.60	6.6
		Week 58	Sparsentan	71	67 (94.4)	1.23 (0.99)	0.1	0.54	0.93	1.68	5.9
			Irbesartan	74	65 (87.8)	1.86 (1.19)	0.1	0.94	1.63	2.48	5.6
		Week 110	Sparsentan	71	59 (83.1)	1.45 (1.24)	0.1	0.53	1.21	2.00	6.7
			Irbesartan	74	53 (71.6)	1.96 (1.46)	0.1	1.04	1.49	2.48	7.8
	Percent change from baseline in UP/C	Week 6	Sparsentan	71	68 (95.8)	-0.51 (0.82)	-2.3	-1.00	-0.51	0.16	1.5
			Irbesartan	74	73 (98.6)	-0.00 (0.92)	-4.3	-0.50	0.07	0.47	1.9
		Week 36	Sparsentan	71	68 (95.8)	-0.54 (0.98)	-3.2	-1.11	-0.58	0.22	1.7
			Irbesartan	74	68 (91.9)	-0.04 (1.12)	-4.3	-0.76	-0.00	0.64	2.4
		Week 58	Sparsentan	71	67 (94.4)	-0.57 (1.17)	-3.0	-1.25	-0.59	-0.07	5.7
			Irbesartan	74	65 (87.8)	-0.09 (1.06)	-3.2	-0.85	0.03	0.51	3.5
		Week 110	Sparsentan	71	59 (83.1)	-0.27 (1.16)	-2.9	-0.94	-0.44	0.38	3.5
			Irbesartan	74	53 (71.6)	0.06 (1.50)	-5.5	-0.74	0.02	0.71	5.3

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
eGFR Low and UP Low	UP/C	Baseline	Sparsentan	55	55 (100.0)	1.02 (0.51)	0.3	0.66	0.93	1.31	2.8
			Irbesartan	55	55 (100.0)	1.01 (0.38)	0.4	0.71	0.92	1.32	1.9
		Week 6	Sparsentan	55	51 (92.7)	0.73 (0.53)	0.1	0.41	0.60	0.91	2.8
			Irbesartan	55	53 (96.4)	0.91 (0.40)	0.4	0.63	0.80	1.06	2.3
		Week 36	Sparsentan	55	51 (92.7)	0.72 (0.54)	0.1	0.32	0.58	1.00	2.2
			Irbesartan	55	51 (92.7)	1.02 (0.66)	0.2	0.49	0.88	1.52	3.1
		Week 58	Sparsentan	55	52 (94.5)	0.76 (0.57)	0.1	0.26	0.67	1.06	2.4
			Irbesartan	55	51 (92.7)	0.98 (0.61)	0.1	0.55	0.85	1.28	2.7
		Week 110	Sparsentan	55	46 (83.6)	0.87 (0.67)	0.1	0.35	0.75	1.31	3.4
			Irbesartan	55	42 (76.4)	1.10 (0.72)	0.1	0.49	0.88	1.80	2.6
	Percent change from baseline in UP/C	Week 6	Sparsentan	55	51 (92.7)	-0.31 (0.66)	-2.3	-0.58	-0.26	0.02	1.7
			Irbesartan	55	53 (96.4)	-0.11 (0.42)	-1.1	-0.30	-0.12	0.09	1.2
		Week 36	Sparsentan	55	51 (92.7)	-0.30 (0.66)	-1.9	-0.62	-0.30	0.02	1.2
			Irbesartan	55	51 (92.7)	-0.01 (0.66)	-1.2	-0.36	-0.14	0.26	2.6
		Week 58	Sparsentan	55	52 (94.5)	-0.25 (0.60)	-1.6	-0.54	-0.28	0.08	1.1
			Irbesartan	55	51 (92.7)	-0.03 (0.59)	-1.0	-0.37	-0.10	0.28	1.7
		Week 110	Sparsentan	55	46 (83.6)	-0.14 (0.73)	-1.7	-0.59	-0.23	0.20	2.0
			Irbesartan	55	42 (76.4)	0.09 (0.62)	-1.3	-0.35	0.02	0.51	1.2

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
eGFR High and UP High	UP/C	Baseline	Sparsentan	37	37 (100.0)	1.71 (0.76)	0.6	1.22	1.45	2.13	3.6
			Irbesartan	36	36 (100.0)	1.57 (0.83)	0.5	1.14	1.47	1.83	5.5
		Week 6	Sparsentan	37	35 (94.6)	1.19 (1.08)	0.1	0.48	1.05	1.47	5.6
			Irbesartan	36	32 (88.9)	1.66 (1.05)	0.6	1.02	1.39	1.88	5.4
		Week 36	Sparsentan	37	37 (100.0)	1.04 (1.02)	0.1	0.49	0.80	1.31	5.2
			Irbesartan	36	32 (88.9)	1.53 (1.21)	0.2	0.77	1.05	2.15	6.2
		Week 58	Sparsentan	37	32 (86.5)	1.04 (0.89)	0.1	0.38	0.91	1.18	3.5
			Irbesartan	36	31 (86.1)	1.67 (1.14)	0.3	0.75	1.35	2.39	5.2
		Week 110	Sparsentan	37	30 (81.1)	0.87 (1.00)	0.0	0.34	0.62	1.14	5.3
			Irbesartan	36	27 (75.0)	1.92 (1.54)	0.3	0.95	1.42	2.33	7.3
	Percent change from baseline in UP/C	Week 6	Sparsentan	37	35 (94.6)	-0.50 (0.97)	-2.2	-0.94	-0.62	-0.18	2.3
			Irbesartan	36	32 (88.9)	0.04 (0.85)	-0.9	-0.49	-0.25	0.28	3.7
		Week 36	Sparsentan	37	37 (100.0)	-0.68 (1.07)	-2.6	-1.16	-0.65	-0.26	3.6
			Irbesartan	36	32 (88.9)	-0.06 (0.78)	-1.3	-0.60	-0.03	0.25	2.2
		Week 58	Sparsentan	37	32 (86.5)	-0.73 (1.01)	-2.8	-1.17	-0.63	0.00	1.2
			Irbesartan	36	31 (86.1)	0.08 (0.94)	-1.2	-0.51	-0.23	0.25	3.0
		Week 110	Sparsentan	37	30 (81.1)	-0.83 (1.02)	-3.3	-1.41	-0.61	-0.22	1.7
			Irbesartan	36	27 (75.0)	0.31 (1.16)	-1.1	-0.50	-0.01	0.91	4.3

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
eGFR High and UP Low	UP/C	Baseline	Sparsentan	39	39 (100.0)	0.84 (0.38)	0.2	0.48	0.80	1.08	1.8
			Irbesartan	37	37 (100.0)	0.89 (0.31)	0.2	0.69	0.90	1.10	1.6
		Week 6	Sparsentan	39	39 (100.0)	0.49 (0.31)	0.1	0.29	0.38	0.60	1.4
			Irbesartan	37	36 (97.3)	0.85 (0.43)	0.1	0.58	0.81	1.14	1.9
		Week 36	Sparsentan	39	38 (97.4)	0.46 (0.36)	0.1	0.23	0.33	0.65	1.3
			Irbesartan	37	36 (97.3)	0.78 (0.48)	0.1	0.39	0.70	1.09	2.3
		Week 58	Sparsentan	39	37 (94.9)	0.59 (0.60)	0.1	0.20	0.32	0.75	3.0
			Irbesartan	37	32 (86.5)	0.86 (0.51)	0.1	0.41	0.80	1.07	1.9
		Week 110	Sparsentan	39	33 (84.6)	0.60 (0.54)	0.1	0.19	0.43	0.86	2.5
			Irbesartan	37	27 (73.0)	0.96 (0.52)	0.1	0.52	0.84	1.35	2.1
	Percent change from baseline in UP/C	Week 6	Sparsentan	39	39 (100.0)	-0.35 (0.26)	-1.0	-0.58	-0.31	-0.15	0.2
			Irbesartan	37	36 (97.3)	-0.04 (0.42)	-1.2	-0.29	-0.08	0.25	0.7
		Week 36	Sparsentan	39	38 (97.4)	-0.39 (0.32)	-1.0	-0.66	-0.40	-0.19	0.4
			Irbesartan	37	36 (97.3)	-0.13 (0.49)	-1.3	-0.40	-0.13	0.14	1.3
		Week 58	Sparsentan	39	37 (94.9)	-0.27 (0.53)	-1.1	-0.64	-0.34	-0.03	1.7
			Irbesartan	37	32 (86.5)	-0.05 (0.50)	-1.3	-0.28	-0.10	0.10	1.3
		Week 110	Sparsentan	39	33 (84.6)	-0.26 (0.43)	-0.9	-0.52	-0.30	-0.11	1.0
			Irbesartan	37	27 (73.0)	0.07 (0.53)	-1.1	-0.24	-0.04	0.44	1.3

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
Subgroup: Baseline eGFR Group 1											
< 60 mL/min/1.73 m**2	UP/C	Baseline	Sparsentan	127	127 (100.0)	1.48 (0.98)	0.1	0.77	1.28	1.88	7.0
			Irbesartan	129	129 (100.0)	1.52 (0.95)	0.4	0.88	1.32	1.77	6.9
		Week 6	Sparsentan	127	120 (94.5)	1.02 (0.74)	0.1	0.48	0.84	1.31	3.5
			Irbesartan	129	126 (97.7)	1.48 (0.94)	0.4	0.80	1.16	1.99	6.2
		Week 36	Sparsentan	127	120 (94.5)	1.04 (0.89)	0.1	0.39	0.73	1.51	4.4
			Irbesartan	129	119 (92.2)	1.46 (1.04)	0.2	0.65	1.28	1.82	6.6
		Week 58	Sparsentan	127	120 (94.5)	0.99 (0.86)	0.1	0.40	0.74	1.41	5.9
			Irbesartan	129	116 (89.9)	1.45 (1.07)	0.1	0.72	1.15	1.94	5.6
		Week 110	Sparsentan	127	105 (82.7)	1.18 (1.05)	0.1	0.46	0.87	1.62	6.7
			Irbesartan	129	96 (74.4)	1.56 (1.25)	0.1	0.80	1.28	2.06	7.8
	Percent change from baseline in UP/C	Week 6	Sparsentan	127	120 (94.5)	-0.42 (0.73)	-2.3	-0.86	-0.38	0.03	1.7
			Irbesartan	129	126 (97.7)	-0.05 (0.74)	-4.3	-0.37	-0.11	0.34	1.9
		Week 36	Sparsentan	127	120 (94.5)	-0.41 (0.85)	-3.2	-0.85	-0.43	0.10	1.7
			Irbesartan	129	119 (92.2)	-0.05 (0.93)	-4.3	-0.54	-0.10	0.35	2.6
		Week 58	Sparsentan	127	120 (94.5)	-0.41 (0.97)	-3.0	-0.97	-0.39	0.03	5.7
			Irbesartan	129	116 (89.9)	-0.05 (0.84)	-3.2	-0.47	-0.10	0.35	3.5
		Week 110	Sparsentan	127	105 (82.7)	-0.19 (0.97)	-2.9	-0.72	-0.28	0.26	3.5
			Irbesartan	129	96 (74.4)	0.11 (1.17)	-5.5	-0.43	0.03	0.66	5.3

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
60 to < 90 mL/min/1.73 m**2	UP/C	Baseline	Sparsentan	49	49 (100.0)	1.25 (0.59)	0.3	0.79	1.22	1.66	2.8
			Irbesartan	48	48 (100.0)	1.34 (0.63)	0.5	0.87	1.20	1.70	3.4
		Week 6	Sparsentan	49	48 (98.0)	0.88 (0.78)	0.1	0.32	0.58	1.21	3.5
			Irbesartan	48	45 (93.8)	1.49 (0.84)	0.4	0.84	1.35	1.78	4.2
		Week 36	Sparsentan	49	48 (98.0)	0.77 (0.81)	0.1	0.27	0.59	1.04	5.2
			Irbesartan	48	45 (93.8)	1.47 (0.85)	0.3	0.84	1.32	2.07	4.1
		Week 58	Sparsentan	49	43 (87.8)	0.83 (0.79)	0.1	0.18	0.77	1.16	3.1
			Irbesartan	48	42 (87.5)	1.50 (0.86)	0.3	0.85	1.39	1.86	3.8
		Week 110	Sparsentan	49	42 (85.7)	0.71 (0.64)	0.1	0.21	0.44	1.13	2.9
			Irbesartan	48	36 (75.0)	1.57 (1.03)	0.4	0.80	1.31	2.00	5.1
	Percent change from baseline in UP/C	Week 6	Sparsentan	49	48 (98.0)	-0.38 (0.69)	-2.3	-0.70	-0.43	-0.15	1.9
			Irbesartan	48	45 (93.8)	0.12 (0.77)	-1.4	-0.34	0.07	0.35	3.7
		Week 36	Sparsentan	49	48 (98.0)	-0.50 (0.77)	-1.8	-0.76	-0.54	-0.26	3.6
			Irbesartan	48	45 (93.8)	0.12 (0.72)	-1.3	-0.27	0.04	0.40	2.2
		Week 58	Sparsentan	49	43 (87.8)	-0.44 (0.67)	-1.8	-0.94	-0.52	-0.17	1.7
			Irbesartan	48	42 (87.5)	0.14 (0.94)	-2.1	-0.26	-0.02	0.47	3.0
		Week 110	Sparsentan	49	42 (85.7)	-0.57 (0.66)	-1.7	-1.01	-0.52	-0.19	1.0
			Irbesartan	48	36 (75.0)	0.20 (1.07)	-1.6	-0.31	0.03	0.62	4.3

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
>= 90 mL/min/1.73 m**2	UP/C	Baseline	Sparsentan	26	26 (100.0)	1.49 (0.98)	0.4	0.79	1.10	2.14	3.6
			Irbesartan	25	25 (100.0)	1.24 (0.99)	0.2	0.73	1.10	1.46	5.5
		Week 6	Sparsentan	26	25 (96.2)	0.91 (1.06)	0.2	0.37	0.63	0.93	5.6
			Irbesartan	25	23 (92.0)	0.96 (1.03)	0.1	0.59	0.79	1.00	5.4
		Week 36	Sparsentan	26	26 (100.0)	0.76 (0.83)	0.1	0.26	0.45	1.07	4.0
			Irbesartan	25	23 (92.0)	0.85 (1.22)	0.1	0.24	0.58	0.92	6.2
		Week 58	Sparsentan	26	25 (96.2)	0.86 (0.85)	0.2	0.29	0.55	0.85	3.5
			Irbesartan	25	21 (84.0)	0.92 (1.06)	0.1	0.41	0.64	0.99	5.2
		Week 110	Sparsentan	26	21 (80.8)	0.87 (1.17)	0.0	0.32	0.47	0.87	5.3
			Irbesartan	25	17 (68.0)	1.22 (1.65)	0.1	0.45	0.87	1.24	7.3
	Percent change from baseline in UP/C	Week 6	Sparsentan	26	25 (96.2)	-0.52 (0.85)	-2.2	-0.67	-0.50	-0.15	2.3
			Irbesartan	25	23 (92.0)	-0.26 (0.31)	-0.9	-0.45	-0.21	-0.09	0.4
		Week 36	Sparsentan	26	26 (100.0)	-0.73 (0.88)	-2.6	-0.95	-0.57	-0.19	0.6
			Irbesartan	25	23 (92.0)	-0.39 (0.47)	-1.3	-0.62	-0.44	-0.08	0.7
		Week 58	Sparsentan	26	25 (96.2)	-0.64 (1.01)	-2.8	-0.93	-0.36	0.04	0.7
			Irbesartan	25	21 (84.0)	-0.31 (0.44)	-1.2	-0.51	-0.31	-0.03	0.7
		Week 110	Sparsentan	26	21 (80.8)	-0.57 (1.15)	-3.3	-0.71	-0.37	-0.11	1.7
			Irbesartan	25	17 (68.0)	-0.05 (0.66)	-1.1	-0.33	-0.13	0.14	1.8

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
Subgroup: Baseline eGFR Group 2											
< 45 mL/min/1.73 m**2	UP/C	Baseline	Sparsentan	82	82 (100.0)	1.53 (1.05)	0.1	0.78	1.30	1.91	7.0
			Irbesartan	80	80 (100.0)	1.52 (0.95)	0.5	0.97	1.34	1.77	6.9
		Week 6	Sparsentan	82	78 (95.1)	1.08 (0.76)	0.1	0.51	0.85	1.33	3.5
			Irbesartan	80	78 (97.5)	1.42 (0.83)	0.4	0.72	1.16	2.06	4.1
		Week 36	Sparsentan	82	78 (95.1)	1.08 (0.86)	0.1	0.39	0.80	1.58	4.4
			Irbesartan	80	72 (90.0)	1.44 (0.92)	0.2	0.58	1.37	1.84	4.0
		Week 58	Sparsentan	82	77 (93.9)	1.09 (0.98)	0.1	0.47	0.76	1.52	5.9
			Irbesartan	80	70 (87.5)	1.38 (0.94)	0.1	0.71	1.27	1.88	5.1
		Week 110	Sparsentan	82	67 (81.7)	1.18 (0.94)	0.1	0.51	0.88	1.67	5.3
			Irbesartan	80	59 (73.8)	1.52 (1.22)	0.1	0.81	1.25	2.06	7.8
	Percent change from baseline in UP/C	Week 6	Sparsentan	82	78 (95.1)	-0.38 (0.79)	-2.3	-0.80	-0.31	0.05	1.7
			Irbesartan	80	78 (97.5)	-0.09 (0.79)	-4.3	-0.45	-0.12	0.33	1.8
		Week 36	Sparsentan	82	78 (95.1)	-0.37 (0.90)	-3.2	-0.93	-0.36	0.25	1.2
			Irbesartan	80	72 (90.0)	-0.07 (1.03)	-4.3	-0.65	-0.12	0.40	2.6
		Week 58	Sparsentan	82	77 (93.9)	-0.34 (1.07)	-3.0	-0.97	-0.36	0.09	5.7
			Irbesartan	80	70 (87.5)	-0.12 (0.86)	-3.2	-0.61	-0.11	0.36	2.8
		Week 110	Sparsentan	82	67 (81.7)	-0.21 (0.89)	-2.6	-0.72	-0.28	0.38	2.0
			Irbesartan	80	59 (73.8)	0.10 (1.28)	-5.5	-0.49	0.07	0.61	5.3

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
45 to < 60 mL/min/1.73 m**2	UP/C	Baseline	Sparsentan	45	45 (100.0)	1.40 (0.83)	0.2	0.77	1.22	1.75	3.6
			Irbesartan	49	49 (100.0)	1.51 (0.97)	0.4	0.85	1.25	1.82	4.5
		Week 6	Sparsentan	45	42 (93.3)	0.92 (0.71)	0.1	0.38	0.75	1.20	2.6
			Irbesartan	49	48 (98.0)	1.56 (1.09)	0.4	0.82	1.17	1.95	6.2
		Week 36	Sparsentan	45	42 (93.3)	0.95 (0.93)	0.1	0.33	0.62	1.08	3.7
			Irbesartan	49	47 (95.9)	1.48 (1.21)	0.2	0.73	1.12	1.62	6.6
		Week 58	Sparsentan	45	43 (95.6)	0.81 (0.54)	0.1	0.39	0.72	1.11	2.4
			Irbesartan	49	46 (93.9)	1.56 (1.25)	0.2	0.75	1.08	1.97	5.6
		Week 110	Sparsentan	45	38 (84.4)	1.17 (1.24)	0.1	0.40	0.86	1.54	6.7
			Irbesartan	49	37 (75.5)	1.63 (1.32)	0.1	0.79	1.35	2.06	6.4
	Percent change from baseline in UP/C	Week 6	Sparsentan	45	42 (93.3)	-0.48 (0.61)	-1.6	-0.94	-0.51	-0.07	0.8
			Irbesartan	49	48 (98.0)	0.03 (0.66)	-1.5	-0.28	0.02	0.37	1.9
		Week 36	Sparsentan	45	42 (93.3)	-0.48 (0.74)	-2.2	-0.85	-0.57	-0.15	1.7
			Irbesartan	49	47 (95.9)	-0.01 (0.74)	-1.7	-0.36	-0.05	0.32	2.4
		Week 58	Sparsentan	45	43 (95.6)	-0.56 (0.74)	-2.1	-1.00	-0.44	-0.04	1.1
			Irbesartan	49	46 (93.9)	0.04 (0.81)	-1.1	-0.45	-0.09	0.31	3.5
		Week 110	Sparsentan	45	38 (84.4)	-0.16 (1.11)	-2.9	-0.74	-0.26	0.24	3.5
			Irbesartan	49	37 (75.5)	0.13 (0.98)	-1.8	-0.36	-0.02	0.81	3.6

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
60 to < 90 mL/min/1.73 m**2	UP/C	Baseline	Sparsentan	49	49 (100.0)	1.25 (0.59)	0.3	0.79	1.22	1.66	2.8
			Irbesartan	48	48 (100.0)	1.34 (0.63)	0.5	0.87	1.20	1.70	3.4
		Week 6	Sparsentan	49	48 (98.0)	0.88 (0.78)	0.1	0.32	0.58	1.21	3.5
			Irbesartan	48	45 (93.8)	1.49 (0.84)	0.4	0.84	1.35	1.78	4.2
		Week 36	Sparsentan	49	48 (98.0)	0.77 (0.81)	0.1	0.27	0.59	1.04	5.2
			Irbesartan	48	45 (93.8)	1.47 (0.85)	0.3	0.84	1.32	2.07	4.1
		Week 58	Sparsentan	49	43 (87.8)	0.83 (0.79)	0.1	0.18	0.77	1.16	3.1
			Irbesartan	48	42 (87.5)	1.50 (0.86)	0.3	0.85	1.39	1.86	3.8
		Week 110	Sparsentan	49	42 (85.7)	0.71 (0.64)	0.1	0.21	0.44	1.13	2.9
			Irbesartan	48	36 (75.0)	1.57 (1.03)	0.4	0.80	1.31	2.00	5.1
	Percent change from baseline in UP/C	Week 6	Sparsentan	49	48 (98.0)	-0.38 (0.69)	-2.3	-0.70	-0.43	-0.15	1.9
			Irbesartan	48	45 (93.8)	0.12 (0.77)	-1.4	-0.34	0.07	0.35	3.7
		Week 36	Sparsentan	49	48 (98.0)	-0.50 (0.77)	-1.8	-0.76	-0.54	-0.26	3.6
			Irbesartan	48	45 (93.8)	0.12 (0.72)	-1.3	-0.27	0.04	0.40	2.2
		Week 58	Sparsentan	49	43 (87.8)	-0.44 (0.67)	-1.8	-0.94	-0.52	-0.17	1.7
			Irbesartan	48	42 (87.5)	0.14 (0.94)	-2.1	-0.26	-0.02	0.47	3.0
		Week 110	Sparsentan	49	42 (85.7)	-0.57 (0.66)	-1.7	-1.01	-0.52	-0.19	1.0
			Irbesartan	48	36 (75.0)	0.20 (1.07)	-1.6	-0.31	0.03	0.62	4.3

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
>= 90 mL/min/1.73 m**2	UP/C	Baseline	Sparsentan	26	26 (100.0)	1.49 (0.98)	0.4	0.79	1.10	2.14	3.6
			Irbesartan	25	25 (100.0)	1.24 (0.99)	0.2	0.73	1.10	1.46	5.5
		Week 6	Sparsentan	26	25 (96.2)	0.91 (1.06)	0.2	0.37	0.63	0.93	5.6
			Irbesartan	25	23 (92.0)	0.96 (1.03)	0.1	0.59	0.79	1.00	5.4
		Week 36	Sparsentan	26	26 (100.0)	0.76 (0.83)	0.1	0.26	0.45	1.07	4.0
			Irbesartan	25	23 (92.0)	0.85 (1.22)	0.1	0.24	0.58	0.92	6.2
		Week 58	Sparsentan	26	25 (96.2)	0.86 (0.85)	0.2	0.29	0.55	0.85	3.5
			Irbesartan	25	21 (84.0)	0.92 (1.06)	0.1	0.41	0.64	0.99	5.2
		Week 110	Sparsentan	26	21 (80.8)	0.87 (1.17)	0.0	0.32	0.47	0.87	5.3
			Irbesartan	25	17 (68.0)	1.22 (1.65)	0.1	0.45	0.87	1.24	7.3
	Percent change from baseline in UP/C	Week 6	Sparsentan	26	25 (96.2)	-0.52 (0.85)	-2.2	-0.67	-0.50	-0.15	2.3
			Irbesartan	25	23 (92.0)	-0.26 (0.31)	-0.9	-0.45	-0.21	-0.09	0.4
		Week 36	Sparsentan	26	26 (100.0)	-0.73 (0.88)	-2.6	-0.95	-0.57	-0.19	0.6
			Irbesartan	25	23 (92.0)	-0.39 (0.47)	-1.3	-0.62	-0.44	-0.08	0.7
		Week 58	Sparsentan	26	25 (96.2)	-0.64 (1.01)	-2.8	-0.93	-0.36	0.04	0.7
			Irbesartan	25	21 (84.0)	-0.31 (0.44)	-1.2	-0.51	-0.31	-0.03	0.7
		Week 110	Sparsentan	26	21 (80.8)	-0.57 (1.15)	-3.3	-0.71	-0.37	-0.11	1.7
			Irbesartan	25	17 (68.0)	-0.05 (0.66)	-1.1	-0.33	-0.13	0.14	1.8

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
Subgroup: Baseline urine protein excretion											
<= 1.75 g/day	UP/C	Baseline	Sparsentan	98	98 (100.0)	0.87 (0.41)	0.1	0.60	0.78	1.06	2.8
			Irbesartan	93	93 (100.0)	0.93 (0.42)	0.2	0.67	0.88	1.09	3.4
		Week 6	Sparsentan	98	94 (95.9)	0.69 (0.56)	0.1	0.32	0.52	0.86	3.3
			Irbesartan	93	89 (95.7)	0.95 (0.50)	0.1	0.62	0.81	1.18	2.8
		Week 36	Sparsentan	98	94 (95.9)	0.65 (0.53)	0.1	0.26	0.44	0.94	2.2
			Irbesartan	93	87 (93.5)	1.03 (0.77)	0.1	0.46	0.82	1.33	3.3
		Week 58	Sparsentan	98	93 (94.9)	0.75 (0.78)	0.1	0.22	0.58	0.93	5.9
			Irbesartan	93	82 (88.2)	1.04 (0.72)	0.1	0.48	0.85	1.43	3.8
		Week 110	Sparsentan	98	84 (85.7)	0.82 (0.71)	0.1	0.30	0.58	1.25	3.4
			Irbesartan	93	70 (75.3)	1.12 (0.83)	0.1	0.52	0.86	1.54	5.1
	Percent change from baseline in UP/C	Week 6	Sparsentan	98	94 (95.9)	-0.18 (0.51)	-1.7	-0.47	-0.24	-0.01	1.9
			Irbesartan	93	89 (95.7)	0.01 (0.51)	-1.4	-0.27	-0.10	0.32	1.8
		Week 36	Sparsentan	98	94 (95.9)	-0.23 (0.56)	-2.3	-0.59	-0.28	-0.05	1.2
			Irbesartan	93	87 (93.5)	0.08 (0.71)	-1.3	-0.35	-0.05	0.35	2.6
		Week 58	Sparsentan	98	93 (94.9)	-0.12 (0.83)	-2.2	-0.51	-0.23	0.09	5.7
			Irbesartan	93	82 (88.2)	0.09 (0.70)	-2.1	-0.29	-0.04	0.46	3.0
		Week 110	Sparsentan	98	84 (85.7)	-0.03 (0.64)	-1.1	-0.44	-0.19	0.15	2.5
			Irbesartan	93	70 (75.3)	0.21 (0.79)	-1.3	-0.24	0.07	0.57	4.3

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
> 1.75 g/day	UP/C	Baseline	Sparsentan	104	104 (100.0)	1.95 (0.92)	0.7	1.33	1.76	2.28	7.0
			Irbesartan	109	109 (100.0)	1.88 (0.96)	0.5	1.35	1.59	2.04	6.9
		Week 6	Sparsentan	104	99 (95.2)	1.24 (0.89)	0.1	0.59	1.03	1.62	5.6
			Irbesartan	109	105 (96.3)	1.82 (1.03)	0.5	1.05	1.61	2.38	6.2
		Week 36	Sparsentan	104	100 (96.2)	1.20 (1.03)	0.1	0.50	0.83	1.53	5.2
			Irbesartan	109	100 (91.7)	1.70 (1.14)	0.2	0.91	1.44	2.33	6.6
		Week 58	Sparsentan	104	95 (91.3)	1.13 (0.85)	0.1	0.48	0.89	1.61	4.1
			Irbesartan	109	97 (89.0)	1.71 (1.16)	0.1	0.92	1.48	2.21	5.6
		Week 110	Sparsentan	104	84 (80.8)	1.23 (1.19)	0.0	0.44	0.88	1.60	6.7
			Irbesartan	109	79 (72.5)	1.88 (1.44)	0.1	0.95	1.42	2.48	7.8
	Percent change from baseline in UP/C	Week 6	Sparsentan	104	99 (95.2)	-0.65 (0.84)	-2.3	-1.07	-0.71	-0.10	2.3
			Irbesartan	109	105 (96.3)	-0.07 (0.86)	-4.3	-0.53	-0.12	0.33	3.7
		Week 36	Sparsentan	104	100 (96.2)	-0.71 (0.98)	-3.2	-1.17	-0.71	-0.24	3.6
			Irbesartan	109	100 (91.7)	-0.16 (0.94)	-4.3	-0.71	-0.16	0.27	2.4
		Week 58	Sparsentan	104	95 (91.3)	-0.77 (0.88)	-3.0	-1.25	-0.82	-0.21	1.4
			Irbesartan	109	97 (89.0)	-0.15 (0.93)	-3.2	-0.74	-0.24	0.23	3.5
		Week 110	Sparsentan	104	84 (80.8)	-0.63 (1.08)	-3.3	-1.27	-0.68	-0.11	3.5
			Irbesartan	109	79 (72.5)	0.03 (1.30)	-5.5	-0.65	-0.06	0.54	5.3

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
Subgroup: Baseline use of antihypertensives											
Yes	UP/C	Baseline	Sparsentan	90	90 (100.0)	1.60 (1.04)	0.3	0.80	1.39	1.93	7.0
			Irbesartan	88	88 (100.0)	1.52 (1.08)	0.4	0.86	1.22	1.81	6.9
		Week 6	Sparsentan	90	84 (93.3)	1.08 (0.96)	0.1	0.47	0.81	1.32	5.6
			Irbesartan	88	82 (93.2)	1.45 (0.96)	0.4	0.79	1.13	1.75	5.4
		Week 36	Sparsentan	90	87 (96.7)	0.99 (0.95)	0.1	0.39	0.71	1.32	5.2
			Irbesartan	88	82 (93.2)	1.49 (1.12)	0.2	0.68	1.17	1.82	6.2
		Week 58	Sparsentan	90	83 (92.2)	1.01 (0.82)	0.1	0.47	0.71	1.52	4.1
			Irbesartan	88	80 (90.9)	1.49 (1.15)	0.1	0.76	1.18	1.85	5.5
		Week 110	Sparsentan	90	74 (82.2)	1.02 (0.89)	0.0	0.33	0.80	1.39	5.3
			Irbesartan	88	68 (77.3)	1.64 (1.55)	0.1	0.69	1.25	2.01	7.8
	Percent change from baseline in UP/C	Week 6	Sparsentan	90	84 (93.3)	-0.46 (0.86)	-2.3	-0.92	-0.48	-0.12	2.3
			Irbesartan	88	82 (93.2)	-0.09 (0.84)	-4.3	-0.39	-0.11	0.27	3.7
		Week 36	Sparsentan	90	87 (96.7)	-0.54 (0.92)	-3.2	-1.03	-0.53	-0.20	3.6
			Irbesartan	88	82 (93.2)	-0.04 (0.99)	-4.3	-0.52	-0.06	0.41	2.6
		Week 58	Sparsentan	90	83 (92.2)	-0.50 (0.78)	-3.0	-0.93	-0.44	-0.03	1.4
			Irbesartan	88	80 (90.9)	-0.03 (0.86)	-2.1	-0.43	-0.10	0.38	3.0
		Week 110	Sparsentan	90	74 (82.2)	-0.46 (0.89)	-3.3	-0.77	-0.44	0.05	1.2
			Irbesartan	88	68 (77.3)	0.13 (1.39)	-5.5	-0.56	-0.08	0.68	5.3

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
No	UP/C	Baseline	Sparsentan	112	112 (100.0)	1.29 (0.74)	0.1	0.74	1.14	1.75	3.6
			Irbesartan	114	114 (100.0)	1.38 (0.72)	0.2	0.88	1.24	1.66	4.2
		Week 6	Sparsentan	112	109 (97.3)	0.89 (0.64)	0.1	0.38	0.79	1.15	3.3
			Irbesartan	114	112 (98.2)	1.40 (0.93)	0.1	0.72	1.15	1.89	6.2
		Week 36	Sparsentan	112	107 (95.5)	0.88 (0.80)	0.1	0.29	0.58	1.30	3.7
			Irbesartan	114	105 (92.1)	1.31 (0.97)	0.1	0.59	1.04	1.80	6.6
		Week 58	Sparsentan	112	105 (93.8)	0.89 (0.85)	0.1	0.27	0.75	1.21	5.9
			Irbesartan	114	99 (86.8)	1.33 (0.93)	0.1	0.64	1.03	1.86	5.6
		Week 110	Sparsentan	112	94 (83.9)	1.03 (1.08)	0.1	0.35	0.74	1.31	6.7
			Irbesartan	114	81 (71.1)	1.43 (0.93)	0.1	0.78	1.22	1.93	4.2
	Percent change from baseline in UP/C	Week 6	Sparsentan	112	109 (97.3)	-0.39 (0.62)	-2.2	-0.69	-0.38	-0.01	1.9
			Irbesartan	114	112 (98.2)	0.01 (0.61)	-1.4	-0.35	-0.11	0.34	1.9
		Week 36	Sparsentan	112	107 (95.5)	-0.42 (0.76)	-2.6	-0.78	-0.39	-0.07	1.7
			Irbesartan	114	105 (92.1)	-0.06 (0.72)	-1.9	-0.54	-0.10	0.27	2.4
		Week 58	Sparsentan	112	105 (93.8)	-0.41 (1.01)	-2.8	-0.95	-0.39	0.02	5.7
			Irbesartan	114	99 (86.8)	-0.05 (0.82)	-3.2	-0.43	-0.07	0.28	3.5
		Week 110	Sparsentan	112	94 (83.9)	-0.23 (0.97)	-2.9	-0.72	-0.29	0.06	3.5
			Irbesartan	114	81 (71.1)	0.10 (0.77)	-1.8	-0.33	0.03	0.48	2.7

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
Subgroup: Time since renal biopsy											
<= 5 years	UP/C	Baseline	Sparsentan	113	113 (100.0)	1.41 (0.87)	0.1	0.78	1.14	1.82	4.2
			Irbesartan	127	127 (100.0)	1.45 (0.97)	0.2	0.88	1.17	1.72	6.9
		Week 6	Sparsentan	113	106 (93.8)	0.99 (0.89)	0.1	0.38	0.78	1.30	5.6
			Irbesartan	127	124 (97.6)	1.36 (0.96)	0.1	0.72	1.06	1.67	6.2
		Week 36	Sparsentan	113	107 (94.7)	0.92 (0.92)	0.1	0.28	0.61	1.30	5.2
			Irbesartan	127	117 (92.1)	1.36 (1.15)	0.1	0.57	1.02	1.80	6.6
		Week 58	Sparsentan	113	104 (92.0)	1.00 (0.92)	0.1	0.33	0.74	1.52	5.9
			Irbesartan	127	117 (92.1)	1.33 (1.14)	0.1	0.64	0.93	1.67	5.6
		Week 110	Sparsentan	113	96 (85.0)	0.86 (0.72)	0.0	0.34	0.67	1.25	3.4
			Irbesartan	127	93 (73.2)	1.42 (1.23)	0.1	0.65	1.16	1.80	7.3
	Percent change from baseline in UP/C	Week 6	Sparsentan	113	106 (93.8)	-0.42 (0.79)	-2.3	-0.81	-0.44	-0.07	2.3
			Irbesartan	127	124 (97.6)	-0.09 (0.69)	-4.3	-0.37	-0.11	0.24	1.9
		Week 36	Sparsentan	113	107 (94.7)	-0.51 (0.88)	-3.2	-0.84	-0.52	-0.14	3.6
			Irbesartan	127	117 (92.1)	-0.09 (0.85)	-4.3	-0.50	-0.12	0.27	2.4
		Week 58	Sparsentan	113	104 (92.0)	-0.39 (1.02)	-3.0	-0.80	-0.49	0.05	5.7
			Irbesartan	127	117 (92.1)	-0.11 (0.90)	-3.2	-0.48	-0.19	0.20	3.5
		Week 110	Sparsentan	113	96 (85.0)	-0.46 (0.91)	-3.3	-0.76	-0.45	-0.04	2.0
			Irbesartan	127	93 (73.2)	-0.00 (1.11)	-5.5	-0.56	-0.07	0.46	4.3

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
> 5 years	UP/C	Baseline	Sparsentan	89	89 (100.0)	1.45 (0.94)	0.3	0.80	1.32	1.81	7.0
			Irbesartan	75	75 (100.0)	1.42 (0.76)	0.4	0.88	1.30	1.77	4.5
		Week 6	Sparsentan	89	87 (97.8)	0.96 (0.67)	0.1	0.49	0.81	1.20	3.3
			Irbesartan	75	70 (93.3)	1.52 (0.89)	0.3	0.92	1.30	2.05	4.2
		Week 36	Sparsentan	89	87 (97.8)	0.95 (0.80)	0.1	0.38	0.70	1.32	4.4
			Irbesartan	75	70 (93.3)	1.43 (0.83)	0.2	0.79	1.34	1.84	3.5
		Week 58	Sparsentan	89	84 (94.4)	0.87 (0.73)	0.1	0.29	0.72	1.18	4.1
			Irbesartan	75	62 (82.7)	1.53 (0.79)	0.2	0.94	1.53	1.94	4.0
		Week 110	Sparsentan	89	72 (80.9)	1.23 (1.25)	0.1	0.41	0.87	1.61	6.7
			Irbesartan	75	56 (74.7)	1.70 (1.28)	0.2	0.87	1.36	2.18	7.8
	Percent change from baseline in UP/C	Week 6	Sparsentan	89	87 (97.8)	-0.43 (0.66)	-2.2	-0.73	-0.36	-0.03	1.9
			Irbesartan	75	70 (93.3)	0.08 (0.76)	-1.5	-0.39	-0.08	0.45	3.7
		Week 36	Sparsentan	89	87 (97.8)	-0.44 (0.78)	-2.6	-0.93	-0.42	0.03	1.7
			Irbesartan	75	70 (93.3)	0.01 (0.85)	-1.6	-0.54	-0.02	0.35	2.6
		Week 58	Sparsentan	89	84 (94.4)	-0.52 (0.76)	-2.8	-1.00	-0.37	-0.02	1.2
			Irbesartan	75	62 (82.7)	0.10 (0.69)	-1.5	-0.29	0.11	0.47	2.4
		Week 110	Sparsentan	89	72 (80.9)	-0.16 (0.96)	-2.4	-0.68	-0.21	0.23	3.5
			Irbesartan	75	56 (74.7)	0.31 (1.05)	-1.6	-0.23	0.18	0.84	5.3

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
Subgroup: History of hypertension											
Yes	UP/C	Baseline	Sparsentan	155	155 (100.0)	1.42 (0.82)	0.1	0.78	1.25	1.86	4.2
			Irbesartan	161	161 (100.0)	1.47 (0.93)	0.2	0.89	1.25	1.77	6.9
		Week 6	Sparsentan	155	147 (94.8)	1.01 (0.85)	0.1	0.44	0.82	1.27	5.6
			Irbesartan	161	153 (95.0)	1.43 (0.95)	0.1	0.76	1.16	1.80	6.2
		Week 36	Sparsentan	155	149 (96.1)	0.99 (0.89)	0.1	0.39	0.71	1.35	5.2
			Irbesartan	161	150 (93.2)	1.45 (1.09)	0.1	0.65	1.22	2.02	6.6
		Week 58	Sparsentan	155	145 (93.5)	1.01 (0.88)	0.1	0.39	0.76	1.48	5.9
			Irbesartan	161	145 (90.1)	1.47 (1.09)	0.1	0.72	1.12	1.94	5.6
		Week 110	Sparsentan	155	130 (83.9)	1.05 (0.95)	0.0	0.39	0.78	1.36	5.3
			Irbesartan	161	121 (75.2)	1.57 (1.31)	0.1	0.79	1.28	2.05	7.8
	Percent change from baseline in UP/C	Week 6	Sparsentan	155	147 (94.8)	-0.40 (0.79)	-2.3	-0.77	-0.38	-0.00	2.3
			Irbesartan	161	153 (95.0)	-0.05 (0.76)	-4.3	-0.39	-0.11	0.27	3.7
		Week 36	Sparsentan	155	149 (96.1)	-0.44 (0.86)	-3.2	-0.84	-0.47	-0.10	3.6
			Irbesartan	161	150 (93.2)	-0.03 (0.88)	-4.3	-0.53	-0.11	0.39	2.6
		Week 58	Sparsentan	155	145 (93.5)	-0.39 (0.95)	-3.0	-0.88	-0.36	-0.01	5.7
			Irbesartan	161	145 (90.1)	-0.00 (0.85)	-2.1	-0.45	-0.09	0.31	3.5
		Week 110	Sparsentan	155	130 (83.9)	-0.34 (0.93)	-3.3	-0.76	-0.38	0.05	2.5
			Irbesartan	161	121 (75.2)	0.11 (1.16)	-5.5	-0.50	-0.01	0.57	5.3

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Table PT2RPR_FSHM: Course of UP/C (percentage) by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max
No	UP/C	Baseline	Sparsentan	47	47 (100.0)	1.46 (1.13)	0.2	0.74	1.26	1.82	7.0
			Irbesartan	41	41 (100.0)	1.34 (0.73)	0.4	0.85	1.15	1.56	3.8
		Week 6	Sparsentan	47	46 (97.9)	0.84 (0.59)	0.1	0.37	0.71	1.15	2.6
			Irbesartan	41	41 (100.0)	1.39 (0.91)	0.3	0.79	1.09	1.68	3.6
		Week 36	Sparsentan	47	45 (95.7)	0.75 (0.76)	0.1	0.25	0.49	1.00	3.4
			Irbesartan	41	37 (90.2)	1.13 (0.77)	0.2	0.56	0.99	1.33	3.5
		Week 58	Sparsentan	47	43 (91.5)	0.71 (0.65)	0.1	0.18	0.58	0.95	2.9
			Irbesartan	41	34 (82.9)	1.12 (0.67)	0.3	0.58	0.95	1.60	3.0
		Week 110	Sparsentan	47	38 (80.9)	0.93 (1.16)	0.1	0.25	0.64	1.22	6.7
			Irbesartan	41	28 (68.3)	1.34 (0.95)	0.3	0.62	1.12	1.82	4.2
	Percent change from baseline in UP/C	Week 6	Sparsentan	47	46 (97.9)	-0.50 (0.52)	-2.1	-0.73	-0.44	-0.18	0.4
			Irbesartan	41	41 (100.0)	0.05 (0.55)	-0.9	-0.30	-0.07	0.39	1.2
		Week 36	Sparsentan	47	45 (95.7)	-0.59 (0.76)	-2.6	-0.93	-0.54	-0.17	1.0
			Irbesartan	41	37 (90.2)	-0.14 (0.67)	-1.9	-0.44	-0.08	0.15	1.8
		Week 58	Sparsentan	47	43 (91.5)	-0.64 (0.78)	-2.8	-1.08	-0.54	-0.17	0.7
			Irbesartan	41	34 (82.9)	-0.19 (0.78)	-3.2	-0.37	-0.08	0.25	1.1
		Week 110	Sparsentan	47	38 (80.9)	-0.31 (0.98)	-2.4	-0.72	-0.36	0.06	3.5
			Irbesartan	41	28 (68.3)	0.12 (0.76)	-1.6	-0.33	0.03	0.41	2.7

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
Only key visits up to Week 110 are displayed. An increase reflects a worsening of the status of the patient.
Results are presented in g/g.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Source Data: alb, created on: 19FEB2024

Figure PF2RPR_FSGM: Percent change from baseline in UP/C by subgroup
Full Analysis Set
Study: PROTECT
Sex: Male



Sparsentan	134	135	129	116
Irbesartan	138	132	127	107

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/g. Analysis was performed on log-transformed data.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Reference table: PT2RPR_FSLM

Figure PF2RPR_FSGM: Percent change from baseline in UP/C by subgroup
Full Analysis Set
Study: PROTECT
Sex: Female



Sparsentan	59	59	59	52
Irbesartan	56	55	52	42

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/g. Analysis was performed on log-transformed data.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Reference table: PT2RPR_FSLM

Figure PF2RPR_FSGM: Percent change from baseline in UP/C by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 1: < 60 mL/min/1.73 m**2



Sparsentan	120	120	120	105
Irbesartan	126	119	116	96

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/g. Analysis was performed on log-transformed data.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Reference table: PT2RPR_FSLM

Figure PF2RPR_FSGM: Percent change from baseline in UP/C by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 1: 60 to < 90 mL/min/1.73 m**2



Sparsentan	48	48	43	42
Irbesartan	45	45	42	36

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/g. Analysis was performed on log-transformed data.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Reference table: PT2RPR_FSLM

Figure PF2RPR_FSGM: Percent change from baseline in UP/C by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 1: >= 90 mL/min/1.73 m**2



Sparsentan	25	26	25	21
Irbesartan	23	23	21	17

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/g. Analysis was performed on log-transformed data.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Reference table: PT2RPR_FSLM

Figure PF2RPR_FSGM: Percent change from baseline in UP/C by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 2: < 45 mL/min/1.73 m**2



Sparsentan	78	78	77	67
Irbesartan	78	72	70	59

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/g. Analysis was performed on log-transformed data.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Reference table: PT2RPR_FSLM

Figure PF2RPR_FSGM: Percent change from baseline in UP/C by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 2: 45 to < 60 mL/min/1.73 m**2



Sparsentan	42	42	43	38
Irbesartan	48	47	46	37

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/g. Analysis was performed on log-transformed data.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Reference table: PT2RPR_FSLM

Figure PF2RPR_FSGM: Percent change from baseline in UP/C by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 2: 60 to < 90 mL/min/1.73 m**2



Sparsentan	48	48	43	42
Irbesartan	45	45	42	36

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/g. Analysis was performed on log-transformed data.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Reference table: PT2RPR_FSLM

Figure PF2RPR_FSGM: Percent change from baseline in UP/C by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 2: >= 90 mL/min/1.73 m**2



Sparsentan	25	26	25	21
Irbesartan	23	23	21	17

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/g. Analysis was performed on log-transformed data.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
UP/C = urine protein/creatinine ratio.
Reference table: PT2RPR_FSLM

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	Urine protein excretion	Baseline	Sparsentan	139	139 (100.0)	2.29 (1.38)	0.1	1.21	2.07	3.14	7.2	
			Irbesartan	143	143 (100.0)	2.25 (1.33)	0.5	1.34	1.85	2.85	7.5	
		Week 6	Sparsentan	139	135 (97.1)	1.59 (1.33)	0.2	0.64	1.17	2.03	6.5	
			Irbesartan	143	137 (95.8)	2.37 (1.70)	0.4	1.25	1.91	3.07	10.3	
		Week 36	Sparsentan	139	135 (97.1)	1.54 (1.60)	0.1	0.55	0.96	2.03	9.4	
			Irbesartan	143	132 (92.3)	2.33 (1.81)	0.2	1.01	1.89	3.09	9.2	
		Week 58	Sparsentan	139	129 (92.8)	1.60 (1.56)	0.1	0.57	1.15	1.99	7.5	
			Irbesartan	143	127 (88.8)	2.34 (1.85)	0.1	1.08	1.80	3.06	12.8	
		Week 110	Sparsentan	139	116 (83.5)	1.52 (1.36)	0.1	0.51	1.13	2.14	6.0	
			Irbesartan	143	108 (75.5)	2.49 (2.00)	0.1	1.11	1.94	3.29	9.2	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	139	135 (97.1)	-0.72 (1.20)	-4.2	-1.41	-0.71	-0.09	5.2	-0.64 [-0.88, -0.39]
			Irbesartan	143	137 (95.8)	0.11 (1.39)	-3.7	-0.57	-0.10	0.72	8.4	
		Week 36	Sparsentan	139	135 (97.1)	-0.76 (1.34)	-4.7	-1.54	-0.77	-0.11	4.6	-0.56 [-0.81, -0.32]
			Irbesartan	143	132 (92.3)	0.06 (1.57)	-3.3	-0.78	-0.15	0.76	6.5	
		Week 58	Sparsentan	139	129 (92.8)	-0.67 (1.49)	-4.4	-1.45	-0.72	0.04	6.4	-0.49 [-0.74, -0.24]
			Irbesartan	143	127 (88.8)	0.08 (1.57)	-3.3	-0.74	-0.17	0.58	6.7	
		Week 110	Sparsentan	139	116 (83.5)	-0.69 (1.46)	-7.1	-1.46	-0.71	-0.00	3.5	-0.54 [-0.80, -0.27]
			Irbesartan	143	108 (75.5)	0.18 (1.79)	-6.0	-0.67	0.02	1.13	5.9	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Female	Urine protein excretion	Baseline	Sparsentan	63	63 (100.0)	2.09 (2.14)	0.5	1.15	1.45	2.32	14.7	
			Irbesartan	59	59 (100.0)	1.95 (0.97)	0.6	1.33	1.77	2.33	5.7	
		Week 6	Sparsentan	63	60 (95.2)	1.28 (0.83)	0.2	0.69	1.03	1.72	3.9	
			Irbesartan	59	56 (94.9)	1.72 (1.20)	0.4	0.93	1.37	2.26	7.6	
		Week 36	Sparsentan	63	59 (93.7)	1.06 (0.79)	0.1	0.53	0.81	1.35	3.8	
			Irbesartan	59	55 (93.2)	1.75 (1.43)	0.2	0.92	1.22	2.44	7.1	
		Week 58	Sparsentan	63	59 (93.7)	1.05 (0.71)	0.1	0.57	0.91	1.40	3.4	
			Irbesartan	59	51 (86.4)	1.62 (1.56)	0.2	0.69	1.22	1.97	9.4	
		Week 110	Sparsentan	63	53 (84.1)	1.26 (1.21)	0.1	0.42	0.96	1.56	6.0	
			Irbesartan	59	42 (71.2)	1.75 (1.11)	0.3	0.94	1.60	2.38	4.8	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	63	60 (95.2)	-0.67 (1.84)	-13.0	-0.89	-0.45	-0.01	1.8	-0.28 [-0.64, 0.09]
			Irbesartan	59	56 (94.9)	-0.26 (0.84)	-1.8	-0.82	-0.20	0.06	3.0	
		Week 36	Sparsentan	63	59 (93.7)	-0.91 (1.95)	-13.7	-1.07	-0.66	-0.20	1.7	-0.46 [-0.83, -0.09]
			Irbesartan	59	55 (93.2)	-0.19 (1.02)	-2.0	-0.91	-0.28	0.39	2.6	
		Week 58	Sparsentan	63	59 (93.7)	-0.88 (1.95)	-13.3	-1.29	-0.71	-0.03	1.3	-0.38 [-0.76, -0.00]
			Irbesartan	59	51 (86.4)	-0.28 (0.97)	-2.1	-0.90	-0.34	0.16	3.6	
		Week 110	Sparsentan	63	53 (84.1)	-0.68 (2.21)	-13.5	-1.29	-0.34	0.32	3.2	-0.34 [-0.75, 0.07]
			Irbesartan	59	42 (71.2)	-0.08 (1.02)	-2.4	-0.69	-0.05	0.36	2.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
<= 45 years	Urine protein excretion	Baseline	Sparsentan	96	96 (100.0)	2.39 (2.00)	0.4	1.23	1.81	2.91	14.7	
			Irbesartan	99	99 (100.0)	2.18 (1.06)	0.5	1.41	1.92	2.70	5.9	
		Week 6	Sparsentan	96	93 (96.9)	1.45 (1.17)	0.2	0.60	1.08	1.95	6.2	
			Irbesartan	99	95 (96.0)	2.18 (1.63)	0.4	1.08	1.84	2.67	10.3	
		Week 36	Sparsentan	96	91 (94.8)	1.43 (1.40)	0.1	0.38	0.91	2.14	8.3	
			Irbesartan	99	91 (91.9)	2.03 (1.68)	0.2	0.81	1.44	2.92	9.2	
		Week 58	Sparsentan	96	89 (92.7)	1.54 (1.44)	0.1	0.59	1.09	2.03	7.5	
			Irbesartan	99	84 (84.8)	2.01 (1.68)	0.1	0.90	1.50	2.45	8.6	
		Week 110	Sparsentan	96	76 (79.2)	1.47 (1.30)	0.1	0.56	1.11	2.08	6.0	
			Irbesartan	99	69 (69.7)	2.23 (1.89)	0.1	0.94	1.72	2.75	8.8	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	96	93 (96.9)	-0.88 (1.68)	-13.0	-1.22	-0.71	-0.03	2.1	-0.56 [-0.85, -0.27]
			Irbesartan	99	95 (96.0)	-0.02 (1.39)	-3.2	-0.70	-0.20	0.44	8.4	
		Week 36	Sparsentan	96	91 (94.8)	-0.89 (1.86)	-13.7	-1.45	-0.66	0.01	2.6	-0.45 [-0.75, -0.16]
			Irbesartan	99	91 (91.9)	-0.13 (1.47)	-3.3	-1.10	-0.29	0.62	6.5	
		Week 58	Sparsentan	96	89 (92.7)	-0.79 (1.93)	-13.3	-1.36	-0.59	0.21	3.3	-0.37 [-0.67, -0.07]
			Irbesartan	99	84 (84.8)	-0.14 (1.58)	-3.3	-0.92	-0.43	0.38	6.7	
		Week 110	Sparsentan	96	76 (79.2)	-0.75 (2.13)	-13.5	-1.40	-0.55	0.25	3.5	-0.43 [-0.76, -0.10]
			Irbesartan	99	69 (69.7)	0.09 (1.76)	-3.6	-0.74	-0.08	0.93	5.9	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 45 years	Urine protein excretion	Baseline	Sparsentan	106	106 (100.0)	2.09 (1.24)	0.1	1.12	1.76	2.83	6.3	
			Irbesartan	103	103 (100.0)	2.16 (1.40)	0.6	1.25	1.77	2.43	7.5	
		Week 6	Sparsentan	106	102 (96.2)	1.53 (1.24)	0.2	0.73	1.09	2.01	6.5	
			Irbesartan	103	98 (95.1)	2.19 (1.57)	0.4	1.13	1.70	2.74	9.5	
		Week 36	Sparsentan	106	103 (97.2)	1.37 (1.44)	0.1	0.59	0.91	1.54	9.4	
			Irbesartan	103	96 (93.2)	2.28 (1.77)	0.2	1.07	1.71	2.68	9.2	
		Week 58	Sparsentan	106	99 (93.4)	1.33 (1.32)	0.1	0.49	0.94	1.58	6.8	
			Irbesartan	103	94 (91.3)	2.24 (1.89)	0.1	1.10	1.78	2.91	12.8	
		Week 110	Sparsentan	106	93 (87.7)	1.41 (1.34)	0.1	0.43	0.97	1.78	6.0	
			Irbesartan	103	81 (78.6)	2.33 (1.77)	0.1	1.16	1.78	2.87	9.2	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	106	102 (96.2)	-0.54 (1.13)	-3.8	-1.05	-0.56	-0.10	5.2	-0.50 [-0.78, -0.21]
			Irbesartan	103	98 (95.1)	0.02 (1.13)	-3.7	-0.56	-0.08	0.61	4.2	
		Week 36	Sparsentan	106	103 (97.2)	-0.73 (1.23)	-4.2	-1.36	-0.76	-0.27	4.6	-0.64 [-0.92, -0.35]
			Irbesartan	103	96 (93.2)	0.10 (1.39)	-2.5	-0.63	-0.13	0.62	5.0	
		Week 58	Sparsentan	106	99 (93.4)	-0.69 (1.35)	-4.4	-1.44	-0.74	-0.08	6.4	-0.58 [-0.87, -0.29]
			Irbesartan	103	94 (91.3)	0.08 (1.29)	-2.1	-0.63	-0.10	0.48	5.8	
		Week 110	Sparsentan	106	93 (87.7)	-0.64 (1.30)	-4.6	-1.34	-0.65	-0.06	3.4	-0.55 [-0.85, -0.24]
			Irbesartan	103	81 (78.6)	0.13 (1.49)	-6.0	-0.59	0.00	0.95	3.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age at IgAN diagnosis												
<= 18 years	Urine protein excretion	Baseline	Sparsentan	9	9 (100.0)	3.85 (2.41)	1.2	2.78	3.07	4.00	9.7	
			Irbesartan	5	5 (100.0)	1.91 (1.00)	0.6	1.22	2.14	2.56	3.1	
		Week 6	Sparsentan	9	8 (88.9)	2.24 (1.77)	0.4	0.81	1.66	3.84	4.9	
			Irbesartan	5	5 (100.0)	1.91 (1.46)	0.6	1.18	1.25	2.27	4.3	
		Week 36	Sparsentan	9	8 (88.9)	2.28 (1.55)	0.5	1.07	1.76	3.74	4.6	
			Irbesartan	5	5 (100.0)	1.99 (1.26)	0.6	1.11	1.65	2.94	3.6	
		Week 58	Sparsentan	9	7 (77.8)	2.42 (2.13)	0.1	0.87	1.55	4.99	5.6	
			Irbesartan	5	4 (80.0)	1.20 (0.76)	0.6	0.73	0.98	1.67	2.3	
		Week 110	Sparsentan	9	5 (55.6)	3.20 (2.45)	0.1	1.58	3.08	5.26	6.0	
			Irbesartan	5	4 (80.0)	1.48 (0.94)	0.4	0.83	1.44	2.14	2.7	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	9	8 (88.9)	-0.87 (1.57)	-2.5	-2.18	-1.03	-0.11	2.1	-0.59 [-1.73, 0.55]
			Irbesartan	5	5 (100.0)	-0.00 (1.28)	-1.9	-0.02	0.03	0.13	1.7	
		Week 36	Sparsentan	9	8 (88.9)	-0.84 (1.43)	-3.1	-2.00	-0.50	0.26	0.9	-0.68 [-1.83, 0.47]
			Irbesartan	5	5 (100.0)	0.08 (1.20)	-1.9	0.03	0.44	0.80	1.1	
		Week 58	Sparsentan	9	7 (77.8)	-0.75 (1.80)	-3.7	-1.52	-1.10	0.99	1.7	-0.12 [-1.35, 1.11]
			Irbesartan	5	4 (80.0)	-0.55 (1.31)	-2.5	-1.33	-0.01	0.23	0.3	
		Week 110	Sparsentan	9	5 (55.6)	0.14 (1.34)	-1.5	-1.09	0.68	1.26	1.3	0.68 [-0.67, 2.03]
			Irbesartan	5	4 (80.0)	-0.76 (1.30)	-2.7	-1.59	-0.24	0.07	0.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 18 to 40 years	Urine protein excretion	Baseline	Sparsentan	102	102 (100.0)	2.26 (1.79)	0.4	1.21	1.81	2.81	14.7	
			Irbesartan	109	109 (100.0)	2.21 (1.08)	0.5	1.42	1.96	2.70	5.9	
		Week 6	Sparsentan	102	100 (98.0)	1.40 (1.12)	0.2	0.60	1.07	1.80	6.2	
			Irbesartan	109	105 (96.3)	2.15 (1.48)	0.4	1.17	1.82	2.61	7.7	
		Week 36	Sparsentan	102	97 (95.1)	1.41 (1.53)	0.1	0.51	0.90	1.98	9.4	
			Irbesartan	109	100 (91.7)	2.03 (1.58)	0.2	1.00	1.59	2.57	9.2	
		Week 58	Sparsentan	102	95 (93.1)	1.42 (1.41)	0.1	0.59	0.94	1.67	7.5	
			Irbesartan	109	92 (84.4)	2.00 (1.44)	0.1	0.95	1.69	2.49	6.8	
		Week 110	Sparsentan	102	82 (80.4)	1.44 (1.29)	0.1	0.59	0.99	1.99	5.7	
			Irbesartan	109	79 (72.5)	2.26 (1.81)	0.1	1.00	1.79	2.69	8.8	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	102	100 (98.0)	-0.88 (1.59)	-13.0	-1.21	-0.69	-0.14	1.8	-0.58 [-0.86, -0.30]
			Irbesartan	109	105 (96.3)	-0.08 (1.17)	-3.2	-0.68	-0.20	0.44	4.2	
		Week 36	Sparsentan	102	97 (95.1)	-0.86 (1.85)	-13.7	-1.49	-0.73	-0.09	4.6	-0.40 [-0.68, -0.12]
			Irbesartan	109	100 (91.7)	-0.20 (1.44)	-3.3	-1.15	-0.30	0.41	6.5	
		Week 58	Sparsentan	102	95 (93.1)	-0.85 (1.84)	-13.3	-1.45	-0.71	-0.03	3.3	-0.39 [-0.68, -0.10]
			Irbesartan	109	92 (84.4)	-0.22 (1.38)	-3.3	-0.96	-0.41	0.39	5.6	
		Week 110	Sparsentan	102	82 (80.4)	-0.78 (2.10)	-13.5	-1.57	-0.61	0.18	3.5	-0.45 [-0.76, -0.14]
			Irbesartan	109	79 (72.5)	0.07 (1.65)	-3.6	-0.80	-0.08	0.97	5.9	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 40 years	Urine protein excretion	Baseline	Sparsentan	91	91 (100.0)	2.03 (1.29)	0.1	1.06	1.54	2.70	6.3	
			Irbesartan	88	88 (100.0)	2.12 (1.43)	0.6	1.27	1.68	2.37	7.5	
		Week 6	Sparsentan	91	87 (95.6)	1.53 (1.22)	0.2	0.72	1.17	2.08	6.5	
			Irbesartan	88	83 (94.3)	2.24 (1.75)	0.4	1.03	1.79	2.82	10.3	
		Week 36	Sparsentan	91	89 (97.8)	1.30 (1.26)	0.1	0.56	0.91	1.47	6.4	
			Irbesartan	88	82 (93.2)	2.33 (1.91)	0.2	0.96	1.60	3.38	9.2	
		Week 58	Sparsentan	91	86 (94.5)	1.36 (1.25)	0.1	0.49	1.09	1.62	6.6	
			Irbesartan	88	82 (93.2)	2.33 (2.14)	0.1	1.01	1.70	2.95	12.8	
		Week 110	Sparsentan	91	82 (90.1)	1.33 (1.20)	0.1	0.43	0.96	1.78	6.0	
			Irbesartan	88	67 (76.1)	2.36 (1.88)	0.1	1.10	1.77	3.28	9.2	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	91	87 (95.6)	-0.48 (1.17)	-3.8	-1.03	-0.51	0.01	5.2	-0.45 [-0.76, -0.15]
			Irbesartan	88	83 (94.3)	0.10 (1.39)	-3.7	-0.56	-0.06	0.62	8.4	
		Week 36	Sparsentan	91	89 (97.8)	-0.75 (1.18)	-4.2	-1.19	-0.73	-0.27	2.6	-0.74 [-1.05, -0.43]
			Irbesartan	88	82 (93.2)	0.20 (1.42)	-2.5	-0.61	-0.12	0.93	5.1	
		Week 58	Sparsentan	91	86 (94.5)	-0.61 (1.40)	-4.4	-1.29	-0.67	0.04	6.4	-0.58 [-0.89, -0.27]
			Irbesartan	88	82 (93.2)	0.22 (1.47)	-2.1	-0.59	-0.09	0.54	6.7	
		Week 110	Sparsentan	91	82 (90.1)	-0.65 (1.26)	-4.6	-1.29	-0.63	-0.06	3.4	-0.60 [-0.93, -0.27]
			Irbesartan	88	67 (76.1)	0.21 (1.59)	-6.0	-0.59	-0.00	1.05	4.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Geographic region												
North America	Urine protein excretion	Baseline	Sparsentan	35	35 (100.0)	2.73 (2.53)	0.1	1.18	2.19	3.14	14.7	
			Irbesartan	46	46 (100.0)	2.55 (1.46)	0.6	1.68	2.23	3.00	7.5	
		Week 6	Sparsentan	35	35 (100.0)	1.96 (1.33)	0.3	1.08	1.71	2.64	6.5	
			Irbesartan	46	45 (97.8)	2.65 (1.70)	0.5	1.41	2.43	3.66	7.7	
		Week 36	Sparsentan	35	33 (94.3)	1.43 (1.14)	0.2	0.63	1.21	1.61	4.3	
			Irbesartan	46	43 (93.5)	2.85 (1.97)	0.5	1.30	2.52	3.63	9.2	
		Week 58	Sparsentan	35	28 (80.0)	1.67 (1.63)	0.3	0.64	1.14	1.90	6.6	
			Irbesartan	46	40 (87.0)	2.74 (2.32)	0.5	1.19	2.22	3.13	12.8	
		Week 110	Sparsentan	35	27 (77.1)	1.60 (1.40)	0.2	0.70	1.24	2.16	6.0	
			Irbesartan	46	31 (67.4)	2.67 (2.09)	0.4	1.21	2.45	2.94	9.2	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	35	35 (100.0)	-0.77 (2.71)	-13.0	-1.65	-0.31	0.43	5.2	-0.41 [-0.86, 0.03]
			Irbesartan	46	45 (97.8)	0.11 (1.54)	-3.7	-0.54	-0.13	0.86	4.2	
		Week 36	Sparsentan	35	33 (94.3)	-1.29 (2.72)	-13.7	-1.71	-0.58	-0.11	2.6	-0.76 [-1.23, -0.29]
			Irbesartan	46	43 (93.5)	0.34 (1.56)	-2.5	-0.47	-0.06	1.07	4.3	
		Week 58	Sparsentan	35	28 (80.0)	-1.00 (3.25)	-13.3	-2.37	-0.68	0.39	6.4	-0.48 [-0.97, 0.01]
			Irbesartan	46	40 (87.0)	0.18 (1.69)	-2.7	-0.87	-0.19	0.95	5.8	
		Week 110	Sparsentan	35	27 (77.1)	-1.09 (2.95)	-13.5	-1.91	-0.64	0.18	3.4	-0.43 [-0.95, 0.09]
			Irbesartan	46	31 (67.4)	-0.03 (1.98)	-6.0	-0.91	-0.14	1.09	4.2	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Europe	Urine protein excretion	Baseline	Sparsentan	98	98 (100.0)	2.18 (1.41)	0.4	1.21	1.90	2.95	9.7	
			Irbesartan	115	115 (100.0)	2.12 (1.17)	0.5	1.32	1.82	2.60	5.9	
		Week 6	Sparsentan	98	92 (93.9)	1.36 (1.02)	0.2	0.67	1.08	1.91	5.5	
			Irbesartan	115	109 (94.8)	2.08 (1.54)	0.5	1.09	1.64	2.61	10.3	
		Week 36	Sparsentan	98	94 (95.9)	1.42 (1.35)	0.1	0.56	0.96	1.90	6.4	
			Irbesartan	115	108 (93.9)	2.00 (1.48)	0.2	0.90	1.60	2.60	7.0	
		Week 58	Sparsentan	98	93 (94.9)	1.46 (1.29)	0.1	0.64	1.13	1.79	7.5	
			Irbesartan	115	100 (87.0)	2.06 (1.66)	0.1	0.93	1.57	2.75	9.4	
		Week 110	Sparsentan	98	80 (81.6)	1.38 (1.25)	0.1	0.44	0.96	1.93	6.0	
			Irbesartan	115	88 (76.5)	2.24 (1.73)	0.1	1.00	1.74	2.95	8.8	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	98	92 (93.9)	-0.74 (1.06)	-4.2	-1.20	-0.71	-0.12	2.7	-0.59 [-0.87, -0.30]
			Irbesartan	115	109 (94.8)	-0.05 (1.26)	-2.4	-0.78	-0.12	0.44	8.4	
		Week 36	Sparsentan	98	94 (95.9)	-0.71 (1.17)	-4.1	-1.28	-0.77	-0.07	2.6	-0.45 [-0.73, -0.17]
			Irbesartan	115	108 (93.9)	-0.13 (1.38)	-3.3	-1.08	-0.23	0.61	5.1	
		Week 58	Sparsentan	98	93 (94.9)	-0.63 (1.21)	-4.2	-1.27	-0.74	-0.02	2.5	-0.43 [-0.71, -0.14]
			Irbesartan	115	100 (87.0)	-0.05 (1.49)	-3.3	-0.76	-0.25	0.43	6.7	
		Week 110	Sparsentan	98	80 (81.6)	-0.64 (1.29)	-3.6	-1.29	-0.73	-0.06	3.5	-0.53 [-0.83, -0.22]
			Irbesartan	115	88 (76.5)	0.13 (1.60)	-3.4	-0.73	-0.03	0.96	5.9	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asia Pacific	Urine protein excretion	Baseline	Sparsentan	69	69 (100.0)	2.04 (1.36)	0.4	1.15	1.49	2.51	7.2	
			Irbesartan	41	41 (100.0)	1.87 (1.08)	0.6	1.25	1.59	2.29	6.8	
		Week 6	Sparsentan	69	68 (98.6)	1.43 (1.32)	0.2	0.61	0.95	1.79	6.2	
			Irbesartan	41	39 (95.1)	1.93 (1.56)	0.4	0.93	1.55	2.64	9.5	
		Week 36	Sparsentan	69	67 (97.1)	1.35 (1.63)	0.1	0.50	0.83	1.74	9.4	
			Irbesartan	41	36 (87.8)	1.82 (1.93)	0.2	0.72	1.22	1.80	9.2	
		Week 58	Sparsentan	69	67 (97.1)	1.29 (1.38)	0.1	0.43	0.81	1.60	6.8	
			Irbesartan	41	38 (92.7)	1.69 (1.32)	0.1	0.90	1.52	2.20	6.6	
		Week 110	Sparsentan	69	62 (89.9)	1.44 (1.38)	0.1	0.44	1.07	1.71	5.7	
			Irbesartan	41	31 (75.6)	2.03 (1.78)	0.3	1.04	1.65	2.38	9.2	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	69	68 (98.6)	-0.62 (0.78)	-2.4	-1.01	-0.61	-0.10	0.9	-0.78 [-1.18, -0.37]
			Irbesartan	41	39 (95.1)	0.02 (0.88)	-1.7	-0.50	-0.20	0.42	2.8	
		Week 36	Sparsentan	69	67 (97.1)	-0.71 (1.18)	-3.1	-1.32	-0.73	-0.27	4.6	-0.50 [-0.91, -0.09]
			Irbesartan	41	36 (87.8)	-0.08 (1.41)	-2.0	-0.76	-0.34	-0.03	6.5	
		Week 58	Sparsentan	69	67 (97.1)	-0.77 (1.12)	-4.4	-1.44	-0.63	-0.04	2.0	-0.58 [-0.98, -0.17]
			Irbesartan	41	38 (92.7)	-0.17 (0.89)	-1.7	-0.84	-0.28	0.25	2.2	
		Week 110	Sparsentan	69	62 (89.9)	-0.58 (1.48)	-7.1	-1.29	-0.42	0.16	3.2	-0.54 [-0.98, -0.10]
			Irbesartan	41	31 (75.6)	0.18 (1.23)	-2.2	-0.42	0.00	0.43	3.2	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline BMI												
< 27 kg/m**2	Urine protein excretion	Baseline	Sparsentan	83	83 (100.0)	1.88 (1.03)	0.4	1.15	1.58	2.48	5.0	
			Irbesartan	94	94 (100.0)	2.14 (1.13)	0.6	1.38	1.82	2.56	6.8	
		Week 6	Sparsentan	83	78 (94.0)	1.33 (1.18)	0.2	0.64	0.98	1.72	6.5	
			Irbesartan	94	89 (94.7)	2.06 (1.58)	0.5	1.06	1.55	2.43	9.5	
		Week 36	Sparsentan	83	80 (96.4)	1.17 (1.15)	0.1	0.46	0.80	1.42	6.3	
			Irbesartan	94	85 (90.4)	1.81 (1.32)	0.2	0.96	1.44	2.54	7.7	
		Week 58	Sparsentan	83	76 (91.6)	1.06 (0.89)	0.1	0.38	0.85	1.30	5.0	
			Irbesartan	94	79 (84.0)	1.70 (1.23)	0.1	0.90	1.35	2.20	6.6	
		Week 110	Sparsentan	83	70 (84.3)	1.32 (1.38)	0.1	0.40	0.96	1.67	6.0	
			Irbesartan	94	66 (70.2)	1.96 (1.75)	0.1	0.94	1.46	2.39	9.2	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	83	78 (94.0)	-0.54 (1.12)	-2.4	-1.18	-0.65	0.01	5.2	-0.39 [-0.70, -0.09]
			Irbesartan	94	89 (94.7)	-0.11 (1.04)	-2.4	-0.73	-0.30	0.29	2.9	
		Week 36	Sparsentan	83	80 (96.4)	-0.75 (1.01)	-3.1	-1.39	-0.75	-0.27	2.2	-0.42 [-0.73, -0.12]
			Irbesartan	94	85 (90.4)	-0.33 (0.97)	-3.3	-0.91	-0.32	0.43	2.0	
		Week 58	Sparsentan	83	76 (91.6)	-0.81 (1.01)	-3.7	-1.44	-0.77	-0.17	1.3	-0.41 [-0.73, -0.09]
			Irbesartan	94	79 (84.0)	-0.39 (1.02)	-3.3	-0.97	-0.35	0.13	2.8	
		Week 110	Sparsentan	83	70 (84.3)	-0.51 (1.27)	-3.5	-1.32	-0.58	0.18	3.5	-0.30 [-0.64, 0.04]
			Irbesartan	94	66 (70.2)	-0.12 (1.35)	-3.4	-0.69	-0.12	0.34	3.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 27 kg/m**2	Urine protein excretion	Baseline	Sparsentan	119	119 (100.0)	2.47 (1.94)	0.1	1.18	1.92	3.16	14.7	
			Irbesartan	107	107 (100.0)	2.20 (1.33)	0.6	1.33	1.82	2.78	7.5	
		Week 6	Sparsentan	119	117 (98.3)	1.60 (1.21)	0.2	0.70	1.24	2.20	6.2	
			Irbesartan	107	103 (96.3)	2.30 (1.61)	0.4	1.19	1.93	2.82	10.3	
		Week 36	Sparsentan	119	114 (95.8)	1.55 (1.57)	0.1	0.56	1.01	2.00	9.4	
			Irbesartan	107	101 (94.4)	2.47 (1.97)	0.2	1.01	1.96	3.38	9.2	
		Week 58	Sparsentan	119	112 (94.1)	1.68 (1.58)	0.1	0.61	1.14	2.06	7.5	
			Irbesartan	107	99 (92.5)	2.48 (2.08)	0.1	1.05	1.89	3.14	12.8	
		Week 110	Sparsentan	119	99 (83.2)	1.52 (1.27)	0.1	0.53	1.15	2.30	5.5	
			Irbesartan	107	83 (77.6)	2.56 (1.84)	0.1	1.25	2.20	3.36	9.2	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	119	117 (98.3)	-0.81 (1.59)	-13.0	-1.28	-0.67	-0.09	2.7	-0.60 [-0.87, -0.33]
			Irbesartan	107	103 (96.3)	0.10 (1.43)	-3.7	-0.54	-0.04	0.62	8.4	
		Week 36	Sparsentan	119	114 (95.8)	-0.85 (1.84)	-13.7	-1.37	-0.70	-0.11	4.6	-0.62 [-0.90, -0.35]
			Irbesartan	107	101 (94.4)	0.25 (1.69)	-2.5	-0.78	-0.14	1.00	6.5	
		Week 58	Sparsentan	119	112 (94.1)	-0.68 (1.96)	-13.3	-1.29	-0.63	0.12	6.4	-0.52 [-0.80, -0.25]
			Irbesartan	107	99 (92.5)	0.27 (1.64)	-2.7	-0.73	0.02	0.89	6.7	
		Week 110	Sparsentan	119	99 (83.2)	-0.82 (1.98)	-13.5	-1.48	-0.65	-0.04	3.4	-0.58 [-0.88, -0.29]
			Irbesartan	107	83 (77.6)	0.29 (1.79)	-6.0	-0.65	0.18	1.45	5.9	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Randomization strata												
eGFR Low and UP High	Urine protein excretion	Baseline	Sparsentan	71	71 (100.0)	3.08 (1.57)	0.1	2.07	2.95	3.74	9.7	
			Irbesartan	74	74 (100.0)	2.96 (1.43)	0.5	1.86	2.59	3.77	7.5	
		Week 6	Sparsentan	71	68 (95.8)	2.10 (1.20)	0.5	1.24	1.86	2.49	5.7	
			Irbesartan	74	73 (98.6)	2.96 (1.63)	0.8	1.89	2.65	3.75	7.7	
		Week 36	Sparsentan	71	68 (95.8)	2.05 (1.74)	0.1	0.83	1.48	2.61	9.4	
			Irbesartan	74	68 (91.9)	3.04 (1.88)	0.2	1.73	2.68	3.71	9.2	
		Week 58	Sparsentan	71	67 (94.4)	2.03 (1.65)	0.2	0.82	1.34	2.70	7.5	
			Irbesartan	74	64 (86.5)	2.92 (2.13)	0.1	1.63	2.42	3.71	12.8	
		Week 110	Sparsentan	71	59 (83.1)	2.18 (1.63)	0.2	0.86	1.75	3.08	6.0	
			Irbesartan	74	54 (73.0)	2.92 (2.04)	0.1	1.48	2.48	3.72	9.2	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	71	68 (95.8)	-0.88 (1.31)	-4.2	-1.63	-0.84	0.10	1.9	-0.64 [-0.98, -0.30]
			Irbesartan	74	73 (98.6)	0.01 (1.45)	-3.7	-0.84	-0.04	0.72	4.2	
		Week 36	Sparsentan	71	68 (95.8)	-0.94 (1.66)	-4.7	-1.92	-1.00	-0.02	4.6	-0.59 [-0.94, -0.25]
			Irbesartan	74	68 (91.9)	0.06 (1.72)	-3.3	-1.22	-0.05	1.08	5.0	
		Week 58	Sparsentan	71	67 (94.4)	-0.89 (1.85)	-4.4	-2.13	-1.00	0.04	6.4	-0.50 [-0.84, -0.15]
			Irbesartan	74	64 (86.5)	-0.03 (1.63)	-3.3	-1.23	-0.01	0.73	5.8	
		Week 110	Sparsentan	71	59 (83.1)	-0.64 (1.77)	-4.6	-1.73	-0.66	0.57	3.5	-0.32 [-0.69, 0.05]
			Irbesartan	74	54 (73.0)	-0.05 (1.96)	-6.0	-1.23	-0.01	1.60	3.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR Low and UP Low	Urine protein excretion	Baseline	Sparsentan	55	55 (100.0)	1.56 (1.91)	0.4	0.97	1.19	1.51	14.7	
			Irbesartan	55	55 (100.0)	1.43 (0.46)	0.6	1.10	1.33	1.76	3.1	
		Week 6	Sparsentan	55	52 (94.5)	1.06 (0.96)	0.2	0.61	0.91	1.28	6.5	
			Irbesartan	55	53 (96.4)	1.32 (0.61)	0.6	0.89	1.29	1.64	4.0	
		Week 36	Sparsentan	55	51 (92.7)	0.99 (0.82)	0.1	0.52	0.65	1.29	4.0	
			Irbesartan	55	51 (92.7)	1.40 (0.99)	0.3	0.69	1.04	1.70	4.4	
		Week 58	Sparsentan	55	52 (94.5)	0.96 (0.75)	0.1	0.47	0.87	1.24	4.7	
			Irbesartan	55	51 (92.7)	1.37 (1.05)	0.1	0.67	1.16	1.72	5.0	
		Week 110	Sparsentan	55	46 (83.6)	1.12 (0.83)	0.1	0.39	0.96	1.58	3.0	
			Irbesartan	55	42 (76.4)	1.48 (0.96)	0.1	0.83	1.22	2.25	4.0	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	55	52 (94.5)	-0.53 (2.06)	-13.0	-0.80	-0.40	0.08	5.2	-0.27 [-0.65, 0.12]
			Irbesartan	55	53 (96.4)	-0.12 (0.70)	-1.5	-0.48	-0.19	0.30	2.9	
		Week 36	Sparsentan	55	51 (92.7)	-0.59 (2.12)	-13.7	-0.88	-0.29	0.11	2.6	-0.32 [-0.71, 0.07]
			Irbesartan	55	51 (92.7)	-0.05 (1.02)	-1.3	-0.75	-0.29	0.26	3.6	
		Week 58	Sparsentan	55	52 (94.5)	-0.58 (2.00)	-13.3	-0.93	-0.39	0.11	3.3	-0.31 [-0.70, 0.07]
			Irbesartan	55	51 (92.7)	-0.08 (1.05)	-1.5	-0.65	-0.34	0.13	3.7	
		Week 110	Sparsentan	55	46 (83.6)	-0.48 (2.18)	-13.5	-0.86	-0.35	0.37	1.9	-0.31 [-0.73, 0.11]
			Irbesartan	55	42 (76.4)	0.05 (0.87)	-1.8	-0.57	-0.08	0.93	1.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP High	Urine protein excretion	Baseline	Sparsentan	37	37 (100.0)	2.60 (1.20)	1.0	1.96	2.42	2.99	7.2	
			Irbesartan	36	36 (100.0)	2.47 (1.05)	0.6	1.95	2.32	2.84	6.8	
		Week 6	Sparsentan	37	36 (97.3)	1.82 (1.43)	0.2	0.77	1.35	2.43	6.2	
			Irbesartan	36	32 (88.9)	2.72 (2.13)	0.6	1.44	2.29	3.12	10.3	
		Week 36	Sparsentan	37	37 (100.0)	1.53 (1.53)	0.1	0.63	1.05	1.74	8.3	
			Irbesartan	36	32 (88.9)	2.57 (2.05)	0.3	1.36	1.95	2.88	9.2	
		Week 58	Sparsentan	37	32 (86.5)	1.63 (1.58)	0.1	0.54	1.21	1.86	5.6	
			Irbesartan	36	31 (86.1)	2.54 (1.95)	0.7	1.12	1.98	2.98	8.6	
		Week 110	Sparsentan	37	30 (81.1)	1.16 (1.20)	0.1	0.45	0.83	1.42	6.0	
			Irbesartan	36	27 (75.0)	2.92 (2.26)	0.4	1.58	2.22	3.21	9.2	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	37	36 (97.3)	-0.79 (1.14)	-2.4	-1.44	-0.92	-0.40	2.7	-0.63 [-1.12, -0.14]
			Irbesartan	36	32 (88.9)	0.19 (1.91)	-3.2	-0.80	-0.03	0.83	8.4	
		Week 36	Sparsentan	37	37 (100.0)	-1.07 (1.00)	-3.1	-1.65	-1.09	-0.50	1.0	-0.76 [-1.25, -0.27]
			Irbesartan	36	32 (88.9)	0.07 (1.91)	-2.5	-1.26	-0.19	0.73	6.5	
		Week 58	Sparsentan	37	32 (86.5)	-1.00 (1.20)	-3.7	-1.79	-1.02	-0.28	1.7	-0.65 [-1.16, -0.15]
			Irbesartan	36	31 (86.1)	0.07 (2.00)	-2.7	-1.05	-0.30	0.76	6.7	
		Week 110	Sparsentan	37	30 (81.1)	-1.42 (1.47)	-7.1	-2.06	-1.20	-0.76	1.3	-0.96 [-1.50, -0.41]
			Irbesartan	36	27 (75.0)	0.34 (2.18)	-3.6	-0.90	-0.00	1.53	5.9	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP Low	Urine protein excretion	Baseline	Sparsentan	39	39 (100.0)	1.26 (0.48)	0.4	0.96	1.18	1.51	3.3	
			Irbesartan	37	37 (100.0)	1.37 (0.44)	0.6	1.11	1.41	1.60	2.9	
		Week 6	Sparsentan	39	39 (100.0)	0.72 (0.38)	0.2	0.46	0.64	0.90	1.8	
			Irbesartan	37	35 (94.6)	1.38 (0.79)	0.4	0.87	1.19	1.91	3.6	
		Week 36	Sparsentan	39	38 (97.4)	0.65 (0.49)	0.1	0.30	0.56	0.88	2.3	
			Irbesartan	37	36 (97.3)	1.21 (0.75)	0.2	0.75	1.09	1.57	3.6	
		Week 58	Sparsentan	39	37 (94.9)	0.83 (0.73)	0.1	0.30	0.57	1.05	3.1	
			Irbesartan	37	32 (86.5)	1.38 (0.84)	0.2	0.92	1.12	1.59	3.6	
		Week 110	Sparsentan	39	34 (87.2)	0.83 (0.63)	0.1	0.30	0.70	1.35	2.3	
			Irbesartan	37	27 (73.0)	1.61 (1.10)	0.3	0.90	1.28	2.18	4.6	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	39	39 (100.0)	-0.54 (0.53)	-2.6	-0.79	-0.51	-0.19	0.6	-0.90 [-1.37, -0.42]
			Irbesartan	37	35 (94.6)	-0.01 (0.66)	-1.1	-0.52	-0.25	0.72	1.4	
		Week 36	Sparsentan	39	38 (97.4)	-0.62 (0.58)	-2.4	-0.89	-0.66	-0.31	0.7	-0.72 [-1.19, -0.25]
			Irbesartan	37	36 (97.3)	-0.17 (0.68)	-1.5	-0.64	-0.24	0.39	1.0	
		Week 58	Sparsentan	39	37 (94.9)	-0.43 (0.80)	-2.7	-0.90	-0.45	-0.02	1.4	-0.50 [-0.98, -0.02]
			Irbesartan	37	32 (86.5)	-0.02 (0.83)	-1.5	-0.50	-0.24	0.25	2.6	
		Week 110	Sparsentan	39	34 (87.2)	-0.42 (0.75)	-2.3	-0.96	-0.38	-0.04	1.0	-0.80 [-1.33, -0.28]
			Irbesartan	37	27 (73.0)	0.28 (1.01)	-0.9	-0.56	0.04	0.62	3.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 1												
< 60 mL/min/1.73 m**2	Urine protein excretion	Baseline	Sparsentan	127	127 (100.0)	2.28 (1.52)	0.1	1.19	1.85	3.12	9.7	
			Irbesartan	129	129 (100.0)	2.28 (1.34)	0.5	1.33	1.82	2.80	7.5	
		Week 6	Sparsentan	127	121 (95.3)	1.59 (1.21)	0.2	0.73	1.25	2.08	6.5	
			Irbesartan	129	126 (97.7)	2.22 (1.47)	0.5	1.17	1.86	2.73	7.7	
		Week 36	Sparsentan	127	120 (94.5)	1.57 (1.51)	0.1	0.60	1.04	2.08	9.4	
			Irbesartan	129	119 (92.2)	2.23 (1.74)	0.2	0.96	1.70	3.02	9.2	
		Week 58	Sparsentan	127	120 (94.5)	1.54 (1.43)	0.1	0.65	1.15	1.93	7.5	
			Irbesartan	129	115 (89.1)	2.19 (1.89)	0.1	0.95	1.72	2.80	12.8	
		Week 110	Sparsentan	127	105 (82.7)	1.69 (1.41)	0.1	0.66	1.40	2.42	6.0	
			Irbesartan	129	97 (75.2)	2.28 (1.79)	0.1	1.10	1.77	2.87	9.2	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	127	121 (95.3)	-0.64 (1.24)	-4.2	-1.29	-0.67	0.08	5.2	-0.47 [-0.72, -0.22]
			Irbesartan	129	126 (97.7)	-0.07 (1.17)	-3.7	-0.68	-0.19	0.42	4.2	
		Week 36	Sparsentan	127	120 (94.5)	-0.66 (1.43)	-4.7	-1.35	-0.68	0.09	4.6	-0.42 [-0.68, -0.16]
			Irbesartan	129	119 (92.2)	-0.06 (1.42)	-3.3	-0.92	-0.19	0.53	5.0	
		Week 58	Sparsentan	127	120 (94.5)	-0.63 (1.52)	-4.4	-1.45	-0.59	0.11	6.4	-0.39 [-0.64, -0.13]
			Irbesartan	129	115 (89.1)	-0.08 (1.34)	-2.7	-0.84	-0.30	0.44	5.8	
		Week 110	Sparsentan	127	105 (82.7)	-0.43 (1.48)	-4.6	-1.29	-0.51	0.41	3.5	-0.29 [-0.57, -0.01]
			Irbesartan	129	97 (75.2)	0.00 (1.52)	-6.0	-0.82	-0.08	0.76	3.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	Urine protein excretion	Baseline	Sparsentan	49	49 (100.0)	2.14 (2.03)	0.6	1.12	1.62	2.62	14.7	
			Irbesartan	48	48 (100.0)	1.97 (0.91)	0.6	1.36	1.84	2.45	4.6	
		Week 6	Sparsentan	49	48 (98.0)	1.33 (1.16)	0.2	0.56	0.86	1.84	5.5	
			Irbesartan	48	44 (91.7)	2.30 (1.75)	0.4	1.28	1.88	3.00	10.3	
		Week 36	Sparsentan	49	48 (98.0)	1.06 (0.92)	0.1	0.46	0.83	1.30	3.9	
			Irbesartan	48	45 (93.8)	2.40 (1.69)	0.2	1.30	1.94	2.94	9.2	
		Week 58	Sparsentan	49	43 (87.8)	1.18 (1.17)	0.1	0.29	0.88	1.50	5.6	
			Irbesartan	48	42 (87.5)	2.37 (1.65)	0.2	1.29	2.06	2.98	8.6	
		Week 110	Sparsentan	49	43 (87.8)	0.95 (0.88)	0.1	0.30	0.74	1.28	4.3	
			Irbesartan	48	36 (75.0)	2.53 (1.79)	0.4	1.26	2.12	3.07	7.6	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	49	48 (98.0)	-0.80 (2.04)	-13.0	-1.09	-0.67	-0.15	2.7	-0.58 [-1.00, -0.17]
			Irbesartan	48	44 (91.7)	0.28 (1.60)	-3.2	-0.52	0.04	0.80	8.4	
		Week 36	Sparsentan	49	48 (98.0)	-1.10 (2.00)	-13.7	-1.36	-0.71	-0.49	0.9	-0.85 [-1.27, -0.42]
			Irbesartan	48	45 (93.8)	0.44 (1.58)	-2.2	-0.42	0.26	0.93	6.5	
		Week 58	Sparsentan	49	43 (87.8)	-0.97 (2.15)	-13.3	-1.34	-0.76	-0.10	1.7	-0.69 [-1.12, -0.25]
			Irbesartan	48	42 (87.5)	0.39 (1.80)	-3.3	-0.42	0.03	1.01	6.7	
		Week 110	Sparsentan	49	43 (87.8)	-1.17 (2.12)	-13.5	-1.57	-0.82	-0.26	0.9	-0.82 [-1.28, -0.36]
			Irbesartan	48	36 (75.0)	0.52 (1.97)	-3.6	-0.58	0.31	1.56	5.9	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	Urine protein excretion	Baseline	Sparsentan	26	26 (100.0)	2.15 (1.51)	0.7	1.18	1.64	2.48	7.2	
			Irbesartan	25	25 (100.0)	1.94 (1.21)	0.6	1.30	1.63	2.10	6.8	
		Week 6	Sparsentan	26	26 (100.0)	1.32 (1.24)	0.4	0.57	0.92	1.60	6.2	
			Irbesartan	25	23 (92.0)	1.78 (1.96)	0.4	0.71	1.18	1.99	9.5	
		Week 36	Sparsentan	26	26 (100.0)	1.19 (1.64)	0.1	0.34	0.63	1.50	8.3	
			Irbesartan	25	23 (92.0)	1.33 (1.54)	0.2	0.47	0.95	1.56	7.7	
		Week 58	Sparsentan	26	25 (96.2)	1.32 (1.44)	0.2	0.41	0.83	1.67	5.4	
			Irbesartan	25	21 (84.0)	1.36 (1.32)	0.3	0.80	1.05	1.33	6.6	
		Week 110	Sparsentan	26	21 (80.8)	1.16 (1.32)	0.1	0.42	0.73	1.36	6.0	
			Irbesartan	25	17 (68.0)	1.80 (2.08)	0.3	0.81	1.26	1.99	9.2	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	26	26 (100.0)	-0.82 (0.72)	-2.4	-1.20	-0.68	-0.44	0.4	-0.82 [-1.40, -0.23]
			Irbesartan	25	23 (92.0)	-0.14 (0.96)	-1.9	-0.66	-0.32	0.18	2.8	
		Week 36	Sparsentan	26	26 (100.0)	-0.96 (1.03)	-3.1	-1.57	-0.89	-0.39	1.0	-0.35 [-0.92, 0.22]
			Irbesartan	25	23 (92.0)	-0.63 (0.86)	-2.5	-1.27	-0.55	-0.14	1.0	
		Week 58	Sparsentan	26	25 (96.2)	-0.82 (1.16)	-3.7	-1.29	-0.71	-0.09	1.4	-0.27 [-0.85, 0.31]
			Irbesartan	25	21 (84.0)	-0.54 (0.82)	-2.3	-0.92	-0.52	-0.12	1.4	
		Week 110	Sparsentan	26	21 (80.8)	-1.00 (1.77)	-7.1	-1.57	-0.49	-0.06	1.3	-0.55 [-1.20, 0.10]
			Irbesartan	25	17 (68.0)	-0.16 (1.15)	-2.3	-0.67	-0.30	0.05	2.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 2												
< 45 mL/min/1.73 m**2	Urine protein excretion	Baseline	Sparsentan	82	82 (100.0)	2.39 (1.59)	0.1	1.28	1.99	3.15	9.7	
			Irbesartan	80	80 (100.0)	2.32 (1.40)	0.5	1.33	1.95	2.94	7.5	
		Week 6	Sparsentan	82	78 (95.1)	1.75 (1.34)	0.2	0.92	1.28	2.15	6.5	
			Irbesartan	80	78 (97.5)	2.18 (1.37)	0.6	1.04	1.84	2.70	7.0	
		Week 36	Sparsentan	82	78 (95.1)	1.73 (1.62)	0.1	0.60	1.26	2.38	9.4	
			Irbesartan	80	72 (90.0)	2.30 (1.72)	0.2	1.00	2.09	3.14	9.2	
		Week 58	Sparsentan	82	77 (93.9)	1.75 (1.64)	0.1	0.65	1.19	2.03	7.5	
			Irbesartan	80	69 (86.3)	2.15 (1.93)	0.1	0.87	1.79	2.78	12.8	
		Week 110	Sparsentan	82	67 (81.7)	1.86 (1.49)	0.1	0.69	1.53	2.63	6.0	
			Irbesartan	80	59 (73.8)	2.27 (1.70)	0.1	1.10	1.72	3.03	9.2	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	82	78 (95.1)	-0.57 (1.34)	-4.2	-1.36	-0.65	0.11	5.2	-0.33 [-0.65, -0.02]
			Irbesartan	80	78 (97.5)	-0.14 (1.22)	-3.7	-0.78	-0.21	0.38	3.2	
		Week 36	Sparsentan	82	78 (95.1)	-0.59 (1.53)	-4.7	-1.45	-0.62	0.29	4.6	-0.35 [-0.67, -0.03]
			Irbesartan	80	72 (90.0)	-0.06 (1.47)	-2.5	-0.95	-0.18	0.62	5.0	
		Week 58	Sparsentan	82	77 (93.9)	-0.53 (1.66)	-4.4	-1.51	-0.49	0.27	6.4	-0.25 [-0.57, 0.08]
			Irbesartan	80	69 (86.3)	-0.15 (1.39)	-2.7	-0.97	-0.26	0.39	5.8	
		Week 110	Sparsentan	82	67 (81.7)	-0.38 (1.45)	-3.6	-1.48	-0.49	0.60	3.4	-0.26 [-0.61, 0.09]
			Irbesartan	80	59 (73.8)	0.01 (1.53)	-6.0	-0.82	0.00	0.95	3.2	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
45 to < 60 mL/min/1.73 m**2	Urine protein excretion	Baseline	Sparsentan	45	45 (100.0)	2.08 (1.39)	0.4	1.18	1.76	2.75	6.4	
			Irbesartan	49	49 (100.0)	2.22 (1.25)	0.6	1.39	1.77	2.64	5.7	
		Week 6	Sparsentan	45	43 (95.6)	1.31 (0.89)	0.2	0.60	1.09	2.01	3.5	
			Irbesartan	49	48 (98.0)	2.28 (1.62)	0.5	1.20	1.86	2.76	7.7	
		Week 36	Sparsentan	45	42 (93.3)	1.28 (1.25)	0.1	0.59	0.83	1.47	6.4	
			Irbesartan	49	47 (95.9)	2.12 (1.79)	0.3	0.93	1.30	2.63	7.8	
		Week 58	Sparsentan	45	43 (95.6)	1.17 (0.84)	0.1	0.59	1.03	1.53	4.5	
			Irbesartan	49	46 (93.9)	2.24 (1.85)	0.3	0.98	1.68	2.91	9.4	
		Week 110	Sparsentan	45	38 (84.4)	1.40 (1.21)	0.1	0.61	1.11	1.75	5.7	
			Irbesartan	49	38 (77.6)	2.29 (1.94)	0.1	1.08	1.78	2.86	8.8	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	45	43 (95.6)	-0.77 (1.04)	-4.0	-1.28	-0.69	-0.09	0.9	-0.76 [-1.19, -0.34]
			Irbesartan	49	48 (98.0)	0.04 (1.09)	-1.9	-0.61	-0.08	0.43	4.2	
		Week 36	Sparsentan	45	42 (93.3)	-0.80 (1.22)	-4.1	-1.26	-0.82	-0.07	2.6	-0.57 [-0.99, -0.14]
			Irbesartan	49	47 (95.9)	-0.07 (1.34)	-3.3	-0.78	-0.21	0.43	4.3	
		Week 58	Sparsentan	45	43 (95.6)	-0.81 (1.23)	-4.2	-1.44	-0.63	-0.03	2.4	-0.67 [-1.10, -0.24]
			Irbesartan	49	46 (93.9)	0.03 (1.26)	-1.9	-0.74	-0.39	0.48	3.7	
		Week 110	Sparsentan	45	38 (84.4)	-0.52 (1.54)	-4.6	-1.20	-0.52	0.04	3.5	-0.34 [-0.79, 0.11]
			Irbesartan	49	38 (77.6)	-0.00 (1.53)	-2.4	-0.90	-0.33	0.70	3.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	Urine protein excretion	Baseline	Sparsentan	49	49 (100.0)	2.14 (2.03)	0.6	1.12	1.62	2.62	14.7	
			Irbesartan	48	48 (100.0)	1.97 (0.91)	0.6	1.36	1.84	2.45	4.6	
		Week 6	Sparsentan	49	48 (98.0)	1.33 (1.16)	0.2	0.56	0.86	1.84	5.5	
			Irbesartan	48	44 (91.7)	2.30 (1.75)	0.4	1.28	1.88	3.00	10.3	
		Week 36	Sparsentan	49	48 (98.0)	1.06 (0.92)	0.1	0.46	0.83	1.30	3.9	
			Irbesartan	48	45 (93.8)	2.40 (1.69)	0.2	1.30	1.94	2.94	9.2	
		Week 58	Sparsentan	49	43 (87.8)	1.18 (1.17)	0.1	0.29	0.88	1.50	5.6	
			Irbesartan	48	42 (87.5)	2.37 (1.65)	0.2	1.29	2.06	2.98	8.6	
		Week 110	Sparsentan	49	43 (87.8)	0.95 (0.88)	0.1	0.30	0.74	1.28	4.3	
			Irbesartan	48	36 (75.0)	2.53 (1.79)	0.4	1.26	2.12	3.07	7.6	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	49	48 (98.0)	-0.80 (2.04)	-13.0	-1.09	-0.67	-0.15	2.7	-0.58 [-1.00, -0.17]
			Irbesartan	48	44 (91.7)	0.28 (1.60)	-3.2	-0.52	0.04	0.80	8.4	
		Week 36	Sparsentan	49	48 (98.0)	-1.10 (2.00)	-13.7	-1.36	-0.71	-0.49	0.9	-0.85 [-1.27, -0.42]
			Irbesartan	48	45 (93.8)	0.44 (1.58)	-2.2	-0.42	0.26	0.93	6.5	
		Week 58	Sparsentan	49	43 (87.8)	-0.97 (2.15)	-13.3	-1.34	-0.76	-0.10	1.7	-0.69 [-1.12, -0.25]
			Irbesartan	48	42 (87.5)	0.39 (1.80)	-3.3	-0.42	0.03	1.01	6.7	
		Week 110	Sparsentan	49	43 (87.8)	-1.17 (2.12)	-13.5	-1.57	-0.82	-0.26	0.9	-0.82 [-1.28, -0.36]
			Irbesartan	48	36 (75.0)	0.52 (1.97)	-3.6	-0.58	0.31	1.56	5.9	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	Urine protein excretion	Baseline	Sparsentan	26	26 (100.0)	2.15 (1.51)	0.7	1.18	1.64	2.48	7.2	
			Irbesartan	25	25 (100.0)	1.94 (1.21)	0.6	1.30	1.63	2.10	6.8	
		Week 6	Sparsentan	26	26 (100.0)	1.32 (1.24)	0.4	0.57	0.92	1.60	6.2	
			Irbesartan	25	23 (92.0)	1.78 (1.96)	0.4	0.71	1.18	1.99	9.5	
		Week 36	Sparsentan	26	26 (100.0)	1.19 (1.64)	0.1	0.34	0.63	1.50	8.3	
			Irbesartan	25	23 (92.0)	1.33 (1.54)	0.2	0.47	0.95	1.56	7.7	
		Week 58	Sparsentan	26	25 (96.2)	1.32 (1.44)	0.2	0.41	0.83	1.67	5.4	
			Irbesartan	25	21 (84.0)	1.36 (1.32)	0.3	0.80	1.05	1.33	6.6	
		Week 110	Sparsentan	26	21 (80.8)	1.16 (1.32)	0.1	0.42	0.73	1.36	6.0	
			Irbesartan	25	17 (68.0)	1.80 (2.08)	0.3	0.81	1.26	1.99	9.2	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	26	26 (100.0)	-0.82 (0.72)	-2.4	-1.20	-0.68	-0.44	0.4	-0.82 [-1.40, -0.23]
			Irbesartan	25	23 (92.0)	-0.14 (0.96)	-1.9	-0.66	-0.32	0.18	2.8	
		Week 36	Sparsentan	26	26 (100.0)	-0.96 (1.03)	-3.1	-1.57	-0.89	-0.39	1.0	-0.35 [-0.92, 0.22]
			Irbesartan	25	23 (92.0)	-0.63 (0.86)	-2.5	-1.27	-0.55	-0.14	1.0	
		Week 58	Sparsentan	26	25 (96.2)	-0.82 (1.16)	-3.7	-1.29	-0.71	-0.09	1.4	-0.27 [-0.85, 0.31]
			Irbesartan	25	21 (84.0)	-0.54 (0.82)	-2.3	-0.92	-0.52	-0.12	1.4	
		Week 110	Sparsentan	26	21 (80.8)	-1.00 (1.77)	-7.1	-1.57	-0.49	-0.06	1.3	-0.55 [-1.20, 0.10]
			Irbesartan	25	17 (68.0)	-0.16 (1.15)	-2.3	-0.67	-0.30	0.05	2.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline urine protein excretion												
<= 1.75 g/day	Urine protein excretion	Baseline	Sparsentan	98	98 (100.0)	1.14 (0.33)	0.1	0.97	1.16	1.40	1.7	
			Irbesartan	93	93 (100.0)	1.26 (0.32)	0.5	1.07	1.33	1.50	1.7	
		Week 6	Sparsentan	98	95 (96.9)	0.97 (0.80)	0.2	0.48	0.77	1.18	6.5	
			Irbesartan	93	88 (94.6)	1.45 (0.89)	0.4	0.89	1.26	1.80	4.8	
		Week 36	Sparsentan	98	94 (95.9)	0.91 (0.80)	0.1	0.34	0.64	1.21	4.0	
			Irbesartan	93	87 (93.5)	1.48 (1.16)	0.2	0.73	1.11	1.77	6.1	
		Week 58	Sparsentan	98	93 (94.9)	1.01 (0.98)	0.1	0.32	0.79	1.22	6.6	
			Irbesartan	93	82 (88.2)	1.50 (1.17)	0.1	0.81	1.17	1.74	6.7	
		Week 110	Sparsentan	98	85 (86.7)	1.09 (0.94)	0.1	0.40	0.88	1.53	4.8	
			Irbesartan	93	70 (75.3)	1.66 (1.22)	0.1	0.87	1.31	2.27	7.0	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	98	95 (96.9)	-0.18 (0.81)	-1.2	-0.67	-0.31	0.08	5.2	-0.44 [-0.74, -0.15]
			Irbesartan	93	88 (94.6)	0.18 (0.84)	-1.1	-0.35	0.01	0.48	3.2	
		Week 36	Sparsentan	98	94 (95.9)	-0.24 (0.79)	-1.4	-0.81	-0.42	0.13	2.6	-0.47 [-0.76, -0.17]
			Irbesartan	93	87 (93.5)	0.21 (1.13)	-1.4	-0.44	-0.13	0.53	5.0	
		Week 58	Sparsentan	98	93 (94.9)	-0.13 (1.01)	-1.4	-0.76	-0.30	0.23	6.4	-0.32 [-0.62, -0.02]
			Irbesartan	93	82 (88.2)	0.22 (1.17)	-1.5	-0.49	-0.10	0.55	5.6	
		Week 110	Sparsentan	98	85 (86.7)	-0.04 (0.95)	-1.3	-0.71	-0.26	0.36	3.5	-0.42 [-0.74, -0.10]
			Irbesartan	93	70 (75.3)	0.41 (1.18)	-1.3	-0.30	0.09	0.95	5.9	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 1.75 g/day	Urine protein excretion	Baseline	Sparsentan	104	104 (100.0)	3.25 (1.74)	1.8	2.23	2.82	3.50	14.7	
			Irbesartan	109	109 (100.0)	2.94 (1.21)	1.8	2.06	2.54	3.33	7.5	
		Week 6	Sparsentan	104	100 (96.2)	1.99 (1.31)	0.3	1.04	1.67	2.49	6.2	
			Irbesartan	109	105 (96.3)	2.80 (1.79)	0.7	1.59	2.38	3.31	10.3	
		Week 36	Sparsentan	104	100 (96.2)	1.85 (1.70)	0.1	0.71	1.28	2.52	9.4	
			Irbesartan	109	100 (91.7)	2.75 (1.92)	0.2	1.30	2.45	3.46	9.2	
		Week 58	Sparsentan	104	95 (91.3)	1.84 (1.58)	0.2	0.75	1.29	2.47	7.5	
			Irbesartan	109	96 (88.1)	2.67 (2.05)	0.1	1.40	2.18	3.13	12.8	
		Week 110	Sparsentan	104	84 (80.8)	1.79 (1.54)	0.1	0.67	1.40	2.58	6.0	
			Irbesartan	109	80 (73.4)	2.83 (2.08)	0.1	1.48	2.39	3.57	9.2	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	104	100 (96.2)	-1.20 (1.69)	-13.0	-1.82	-1.19	-0.55	2.7	-0.65 [-0.93, -0.37]
			Irbesartan	109	105 (96.3)	-0.15 (1.52)	-3.7	-1.00	-0.32	0.42	8.4	
		Week 36	Sparsentan	104	100 (96.2)	-1.34 (1.87)	-13.7	-2.14	-1.29	-0.54	4.6	-0.65 [-0.93, -0.36]
			Irbesartan	109	100 (91.7)	-0.21 (1.63)	-3.3	-1.28	-0.44	0.64	6.5	
		Week 58	Sparsentan	104	95 (91.3)	-1.33 (1.91)	-13.3	-2.13	-1.32	-0.52	2.5	-0.62 [-0.91, -0.33]
			Irbesartan	109	96 (88.1)	-0.23 (1.60)	-3.3	-1.24	-0.42	0.35	6.7	
		Week 110	Sparsentan	104	84 (80.8)	-1.35 (2.05)	-13.5	-2.07	-1.36	-0.43	3.2	-0.61 [-0.92, -0.29]
			Irbesartan	109	80 (73.4)	-0.16 (1.88)	-6.0	-1.25	-0.36	0.88	4.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline use of antihypertensives												
Yes	Urine protein excretion	Baseline	Sparsentan	90	90 (100.0)	2.59 (2.05)	0.4	1.31	2.18	3.16	14.7	
			Irbesartan	88	88 (100.0)	2.20 (1.42)	0.5	1.30	1.74	2.57	7.5	
		Week 6	Sparsentan	90	86 (95.6)	1.64 (1.32)	0.2	0.74	1.16	2.16	6.5	
			Irbesartan	88	82 (93.2)	2.29 (1.84)	0.4	1.13	1.64	2.87	10.3	
		Week 36	Sparsentan	90	87 (96.7)	1.49 (1.41)	0.1	0.62	0.96	1.92	8.3	
			Irbesartan	88	82 (93.2)	2.30 (1.85)	0.2	1.01	1.73	2.83	9.2	
		Week 58	Sparsentan	90	83 (92.2)	1.60 (1.43)	0.1	0.69	1.20	1.81	7.5	
			Irbesartan	88	80 (90.9)	2.23 (1.91)	0.1	0.99	1.71	2.76	9.4	
		Week 110	Sparsentan	90	75 (83.3)	1.49 (1.19)	0.1	0.53	1.24	2.26	5.3	
			Irbesartan	88	69 (78.4)	2.32 (2.01)	0.1	0.94	1.71	2.74	9.2	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	90	86 (95.6)	-0.88 (1.86)	-13.0	-1.45	-0.76	-0.12	5.2	-0.57 [-0.88, -0.26]
			Irbesartan	88	82 (93.2)	0.07 (1.41)	-3.7	-0.57	-0.05	0.46	8.4	
		Week 36	Sparsentan	90	87 (96.7)	-1.01 (1.88)	-13.7	-1.47	-0.76	-0.29	2.6	-0.63 [-0.94, -0.32]
			Irbesartan	88	82 (93.2)	0.09 (1.60)	-3.3	-0.78	-0.14	0.75	6.5	
		Week 58	Sparsentan	90	83 (92.2)	-0.87 (1.96)	-13.3	-1.60	-0.72	-0.02	3.3	-0.52 [-0.83, -0.20]
			Irbesartan	88	80 (90.9)	0.05 (1.60)	-3.3	-0.74	-0.21	0.53	6.7	
		Week 110	Sparsentan	90	75 (83.3)	-0.99 (2.07)	-13.5	-1.66	-0.71	0.04	1.9	-0.56 [-0.89, -0.22]
			Irbesartan	88	69 (78.4)	0.12 (1.90)	-6.0	-0.91	-0.11	0.95	5.9	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Urine protein excretion	Baseline	Sparsentan	112	112 (100.0)	1.94 (1.17)	0.1	1.10	1.53	2.54	6.4	
			Irbesartan	114	114 (100.0)	2.14 (1.08)	0.6	1.41	1.93	2.63	6.9	
		Week 6	Sparsentan	112	109 (97.3)	1.37 (1.09)	0.2	0.60	1.06	1.77	5.7	
			Irbesartan	114	111 (97.4)	2.10 (1.39)	0.4	1.08	1.84	2.67	7.7	
		Week 36	Sparsentan	112	107 (95.5)	1.32 (1.43)	0.1	0.50	0.85	1.70	9.4	
			Irbesartan	114	105 (92.1)	2.04 (1.62)	0.2	0.95	1.52	2.69	9.2	
		Week 58	Sparsentan	112	105 (93.8)	1.30 (1.32)	0.1	0.44	0.88	1.58	6.8	
			Irbesartan	114	98 (86.0)	2.05 (1.70)	0.2	0.98	1.56	2.75	12.8	
		Week 110	Sparsentan	112	94 (83.9)	1.40 (1.41)	0.1	0.43	0.96	1.65	6.0	
			Irbesartan	114	81 (71.1)	2.25 (1.66)	0.2	1.08	1.81	2.86	9.2	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	112	109 (97.3)	-0.56 (0.94)	-4.0	-1.00	-0.58	0.02	2.1	-0.49 [-0.76, -0.22]
			Irbesartan	114	111 (97.4)	-0.05 (1.15)	-3.2	-0.68	-0.20	0.44	4.2	
		Week 36	Sparsentan	112	107 (95.5)	-0.64 (1.21)	-4.1	-1.28	-0.67	-0.04	4.6	-0.44 [-0.71, -0.17]
			Irbesartan	114	105 (92.1)	-0.09 (1.29)	-2.5	-0.78	-0.26	0.58	4.3	
		Week 58	Sparsentan	112	105 (93.8)	-0.63 (1.35)	-4.2	-1.29	-0.71	0.02	6.4	-0.41 [-0.69, -0.13]
			Irbesartan	114	98 (86.0)	-0.09 (1.29)	-2.7	-0.84	-0.28	0.46	5.8	
		Week 110	Sparsentan	112	94 (83.9)	-0.45 (1.34)	-3.5	-1.26	-0.56	0.16	3.5	-0.41 [-0.71, -0.11]
			Irbesartan	114	81 (71.1)	0.10 (1.34)	-2.7	-0.65	0.05	0.93	4.2	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Time since renal biopsy												
<= 5 years	Urine protein excretion	Baseline	Sparsentan	113	113 (100.0)	2.28 (1.84)	0.1	1.17	1.67	2.95	14.7	
			Irbesartan	127	127 (100.0)	2.19 (1.32)	0.5	1.37	1.78	2.63	7.5	
		Week 6	Sparsentan	113	108 (95.6)	1.54 (1.30)	0.2	0.64	1.08	1.98	6.5	
			Irbesartan	127	123 (96.9)	2.11 (1.56)	0.4	1.05	1.55	2.69	9.5	
		Week 36	Sparsentan	113	107 (94.7)	1.35 (1.37)	0.1	0.50	0.88	1.72	8.3	
			Irbesartan	127	117 (92.1)	2.11 (1.84)	0.2	0.81	1.44	2.69	9.2	
		Week 58	Sparsentan	113	104 (92.0)	1.52 (1.46)	0.1	0.58	1.15	1.81	7.5	
			Irbesartan	127	116 (91.3)	2.10 (1.98)	0.1	0.91	1.47	2.65	12.8	
		Week 110	Sparsentan	113	96 (85.0)	1.26 (1.08)	0.1	0.43	0.96	1.88	6.0	
			Irbesartan	127	93 (73.2)	2.19 (1.96)	0.1	0.92	1.58	2.64	9.2	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	113	108 (95.6)	-0.76 (1.70)	-13.0	-1.21	-0.71	-0.00	5.2	-0.48 [-0.74, -0.22]
			Irbesartan	127	123 (96.9)	-0.09 (1.08)	-3.7	-0.66	-0.18	0.43	3.2	
		Week 36	Sparsentan	113	107 (94.7)	-0.97 (1.74)	-13.7	-1.46	-0.83	-0.20	2.6	-0.57 [-0.84, -0.31]
			Irbesartan	127	117 (92.1)	-0.07 (1.37)	-3.3	-0.78	-0.24	0.62	6.5	
		Week 58	Sparsentan	113	104 (92.0)	-0.74 (1.96)	-13.3	-1.44	-0.69	0.12	6.4	-0.40 [-0.66, -0.13]
			Irbesartan	127	116 (91.3)	-0.05 (1.49)	-3.3	-0.87	-0.28	0.42	5.8	
		Week 110	Sparsentan	113	96 (85.0)	-0.99 (1.96)	-13.5	-1.65	-0.72	-0.15	3.4	-0.54 [-0.83, -0.25]
			Irbesartan	127	93 (73.2)	0.01 (1.68)	-6.0	-0.80	-0.13	0.76	5.9	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 5 years	Urine protein excretion	Baseline	Sparsentan	89	89 (100.0)	2.16 (1.39)	0.4	1.18	1.77	2.81	9.7	
			Irbesartan	75	75 (100.0)	2.13 (1.09)	0.6	1.20	1.96	2.60	5.9	
		Week 6	Sparsentan	89	87 (97.8)	1.43 (1.07)	0.2	0.72	1.09	1.95	5.7	
			Irbesartan	75	70 (93.3)	2.30 (1.67)	0.5	1.18	1.91	2.74	10.3	
		Week 36	Sparsentan	89	87 (97.8)	1.46 (1.48)	0.1	0.60	1.00	1.92	9.4	
			Irbesartan	75	70 (93.3)	2.24 (1.54)	0.2	1.12	1.86	2.84	7.8	
		Week 58	Sparsentan	89	84 (94.4)	1.32 (1.27)	0.1	0.52	0.90	1.57	6.8	
			Irbesartan	75	62 (82.7)	2.19 (1.39)	0.3	1.22	1.93	2.91	8.6	
		Week 110	Sparsentan	89	73 (82.0)	1.68 (1.55)	0.1	0.53	1.15	2.12	6.0	
			Irbesartan	75	57 (76.0)	2.43 (1.56)	0.3	1.29	2.24	3.21	6.6	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	89	87 (97.8)	-0.63 (0.99)	-4.0	-1.00	-0.59	-0.12	2.1	-0.62 [-0.95, -0.30]
			Irbesartan	75	70 (93.3)	0.15 (1.53)	-2.4	-0.63	-0.09	0.61	8.4	
		Week 36	Sparsentan	89	87 (97.8)	-0.61 (1.26)	-4.1	-1.30	-0.64	-0.07	4.6	-0.50 [-0.82, -0.18]
			Irbesartan	75	70 (93.3)	0.09 (1.54)	-2.5	-0.78	-0.13	0.60	5.1	
		Week 58	Sparsentan	89	84 (94.4)	-0.73 (1.16)	-4.2	-1.33	-0.74	-0.09	2.0	-0.62 [-0.95, -0.28]
			Irbesartan	75	62 (82.7)	0.03 (1.33)	-2.5	-0.73	-0.14	0.52	6.7	
		Week 110	Sparsentan	89	73 (82.0)	-0.30 (1.24)	-2.8	-1.08	-0.55	0.37	3.5	-0.42 [-0.77, -0.07]
			Irbesartan	75	57 (76.0)	0.27 (1.50)	-2.7	-0.39	0.10	1.05	4.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: History of hypertension												
Yes	Urine protein excretion	Baseline	Sparsentan	155	155 (100.0)	2.26 (1.66)	0.1	1.18	1.85	3.07	14.7	
			Irbesartan	161	161 (100.0)	2.23 (1.31)	0.5	1.34	1.82	2.78	7.5	
		Week 6	Sparsentan	155	149 (96.1)	1.53 (1.21)	0.2	0.70	1.09	2.02	6.5	
			Irbesartan	161	153 (95.0)	2.22 (1.66)	0.4	1.17	1.81	2.74	10.3	
		Week 36	Sparsentan	155	149 (96.1)	1.46 (1.37)	0.1	0.60	0.97	1.72	8.3	
			Irbesartan	161	150 (93.2)	2.27 (1.84)	0.2	1.01	1.70	2.85	9.2	
		Week 58	Sparsentan	155	145 (93.5)	1.54 (1.41)	0.1	0.64	1.13	1.81	7.5	
			Irbesartan	161	145 (90.1)	2.27 (1.92)	0.1	0.98	1.74	2.95	12.8	
		Week 110	Sparsentan	155	131 (84.5)	1.50 (1.31)	0.1	0.53	1.12	2.12	6.0	
			Irbesartan	161	122 (75.8)	2.38 (1.92)	0.1	1.11	1.84	2.91	9.2	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	155	149 (96.1)	-0.73 (1.54)	-13.0	-1.29	-0.69	-0.03	5.2	-0.49 [-0.72, -0.27]
			Irbesartan	161	153 (95.0)	-0.02 (1.31)	-3.7	-0.66	-0.18	0.41	8.4	
		Week 36	Sparsentan	155	149 (96.1)	-0.82 (1.62)	-13.7	-1.42	-0.67	-0.07	2.6	-0.55 [-0.78, -0.32]
			Irbesartan	161	150 (93.2)	0.04 (1.51)	-3.3	-0.78	-0.20	0.60	6.5	
		Week 58	Sparsentan	155	145 (93.5)	-0.71 (1.77)	-13.3	-1.32	-0.59	-0.01	6.4	-0.46 [-0.69, -0.23]
			Irbesartan	161	145 (90.1)	0.05 (1.51)	-2.7	-0.79	-0.23	0.54	6.7	
		Week 110	Sparsentan	155	131 (84.5)	-0.74 (1.84)	-13.5	-1.48	-0.59	0.13	3.5	-0.49 [-0.74, -0.24]
			Irbesartan	161	122 (75.8)	0.13 (1.70)	-6.0	-0.77	-0.05	1.00	5.9	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSHM: Course of urine protein excretion by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	Urine protein excretion	Baseline	Sparsentan	47	47 (100.0)	2.13 (1.62)	0.4	1.15	1.58	2.63	9.7	
			Irbesartan	41	41 (100.0)	1.93 (0.90)	0.6	1.25	1.82	2.43	4.6	
		Week 6	Sparsentan	47	46 (97.9)	1.36 (1.18)	0.2	0.58	1.01	1.60	5.7	
			Irbesartan	41	40 (97.6)	2.03 (1.34)	0.5	0.99	1.76	2.57	7.2	
		Week 36	Sparsentan	47	45 (95.7)	1.17 (1.55)	0.1	0.31	0.69	1.61	9.4	
			Irbesartan	41	37 (90.2)	1.70 (1.10)	0.2	0.92	1.48	2.48	4.4	
		Week 58	Sparsentan	47	43 (91.5)	1.07 (1.19)	0.1	0.23	0.82	1.40	6.8	
			Irbesartan	41	33 (80.5)	1.53 (0.86)	0.3	0.98	1.33	1.98	4.6	
		Week 110	Sparsentan	47	38 (80.9)	1.24 (1.35)	0.1	0.30	0.76	1.67	5.7	
			Irbesartan	41	28 (68.3)	1.86 (1.26)	0.3	0.99	1.39	2.56	4.8	
	Change from baseline in urine protein excretion	Week 6	Sparsentan	47	46 (97.9)	-0.61 (0.95)	-4.0	-1.00	-0.54	-0.22	2.1	-0.69 [-1.13, -0.26]
			Irbesartan	41	40 (97.6)	0.09 (1.07)	-2.4	-0.57	0.04	0.73	2.9	
		Week 36	Sparsentan	47	45 (95.7)	-0.78 (1.32)	-4.1	-1.32	-0.82	-0.39	4.6	-0.46 [-0.90, -0.02]
			Irbesartan	41	37 (90.2)	-0.22 (1.04)	-2.5	-0.76	-0.24	0.62	1.6	
		Week 58	Sparsentan	47	43 (91.5)	-0.83 (1.12)	-4.2	-1.45	-0.76	-0.09	2.0	-0.45 [-0.91, 0.01]
			Irbesartan	41	33 (80.5)	-0.35 (1.01)	-3.3	-0.84	-0.30	0.24	2.3	
		Week 110	Sparsentan	47	38 (80.9)	-0.52 (1.22)	-3.1	-1.16	-0.75	-0.04	3.2	-0.44 [-0.93, 0.05]
			Irbesartan	41	28 (68.3)	0.02 (1.21)	-3.4	-0.57	0.07	0.35	2.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Sex	Overall	Sparsentan						Interaction:	0.037 #
Male	Week 6	Sparsentan	139	135 (97.1)	-0.72 (0.12)	(-0.96, -0.47)	-0.80 (0.18)	(-1.14, -0.46)	<0.001 *
		Irbesartan	143	137 (95.8)	0.08 (0.12)	(-0.16, 0.32)			
	Week 36	Sparsentan	139	135 (97.1)	-0.76 (0.12)	(-1.01, -0.52)	-0.84 (0.18)	(-1.19, -0.50)	<0.001 *
		Irbesartan	143	132 (92.3)	0.08 (0.12)	(-0.16, 0.33)			
	Week 58	Sparsentan	139	129 (92.8)	-0.63 (0.13)	(-0.88, -0.38)	-0.77 (0.18)	(-1.12, -0.41)	<0.001 *
		Irbesartan	143	127 (88.8)	0.13 (0.13)	(-0.11, 0.38)			
	Week 110	Sparsentan	139	116 (83.5)	-0.73 (0.13)	(-0.99, -0.47)	-0.91 (0.19)	(-1.29, -0.54)	<0.001 *
		Irbesartan	143	108 (75.5)	0.18 (0.14)	(-0.09, 0.45)			
Female	Week 6	Sparsentan	63	60 (95.2)	-0.55 (0.14)	(-0.83, -0.26)	-0.27 (0.21)	(-0.68, 0.14)	0.200
		Irbesartan	59	56 (94.9)	-0.28 (0.15)	(-0.57, 0.01)			
	Week 36	Sparsentan	63	59 (93.7)	-0.82 (0.14)	(-1.11, -0.54)	-0.60 (0.21)	(-1.02, -0.19)	0.004 *
		Irbesartan	59	55 (93.2)	-0.22 (0.15)	(-0.51, 0.08)			
	Week 58	Sparsentan	63	59 (93.7)	-0.81 (0.15)	(-1.09, -0.52)	-0.50 (0.21)	(-0.92, -0.09)	0.018 *
		Irbesartan	59	51 (86.4)	-0.30 (0.15)	(-0.61, -0.00)			
	Week 110	Sparsentan	63	53 (84.1)	-0.59 (0.15)	(-0.88, -0.29)	-0.37 (0.23)	(-0.81, 0.07)	0.102
		Irbesartan	59	42 (71.2)	-0.22 (0.17)	(-0.55, 0.11)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age	Overall	Sparsentan						Interaction:	0.656
<= 45 years	Week 6	Sparsentan	96	93 (96.9)	-0.77 (0.16)	(-1.08, -0.46)	-0.69 (0.22)	(-1.13, -0.26)	0.002 *
		Irbesartan	99	95 (96.0)	-0.08 (0.15)	(-0.38, 0.23)			
	Week 36	Sparsentan	96	91 (94.8)	-0.81 (0.16)	(-1.12, -0.51)	-0.62 (0.22)	(-1.05, -0.18)	0.005 *
		Irbesartan	99	91 (91.9)	-0.20 (0.16)	(-0.50, 0.11)			
	Week 58	Sparsentan	96	89 (92.7)	-0.66 (0.16)	(-0.97, -0.35)	-0.52 (0.23)	(-0.97, -0.08)	0.020 *
		Irbesartan	99	84 (84.8)	-0.13 (0.16)	(-0.45, 0.18)			
	Week 110	Sparsentan	96	76 (79.2)	-0.68 (0.17)	(-1.01, -0.35)	-0.68 (0.24)	(-1.16, -0.20)	0.006 *
		Irbesartan	99	69 (69.7)	-0.00 (0.18)	(-0.35, 0.35)			
> 45 years	Week 6	Sparsentan	106	102 (96.2)	-0.56 (0.12)	(-0.79, -0.32)	-0.57 (0.17)	(-0.91, -0.24)	<0.001 *
		Irbesartan	103	98 (95.1)	0.02 (0.12)	(-0.22, 0.26)			
	Week 36	Sparsentan	106	103 (97.2)	-0.74 (0.12)	(-0.97, -0.50)	-0.90 (0.17)	(-1.24, -0.56)	<0.001 *
		Irbesartan	103	96 (93.2)	0.16 (0.12)	(-0.08, 0.40)			
	Week 58	Sparsentan	106	99 (93.4)	-0.70 (0.12)	(-0.93, -0.46)	-0.82 (0.17)	(-1.17, -0.48)	<0.001 *
		Irbesartan	103	94 (91.3)	0.13 (0.12)	(-0.12, 0.37)			
	Week 110	Sparsentan	106	93 (87.7)	-0.68 (0.12)	(-0.93, -0.44)	-0.80 (0.18)	(-1.16, -0.45)	<0.001 *
		Irbesartan	103	81 (78.6)	0.12 (0.13)	(-0.14, 0.38)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age at IgAN diagnosis	Overall	Sparsentan						Interaction:	0.077
<= 18 years	Week 6	Sparsentan	9	8 (88.9)	-0.70 (0.65)	(-2.02, 0.61)	-0.40 (1.10)	(-2.62, 1.82)	0.717
		Irbesartan	5	5 (100.0)	-0.30 (0.83)	(-1.98, 1.38)			
	Week 36	Sparsentan	9	8 (88.9)	-0.69 (0.65)	(-2.00, 0.62)	-0.47 (1.09)	(-2.67, 1.73)	0.667
		Irbesartan	5	5 (100.0)	-0.22 (0.83)	(-1.90, 1.46)			
	Week 58	Sparsentan	9	7 (77.8)	-0.46 (0.68)	(-1.81, 0.90)	0.12 (1.13)	(-2.16, 2.40)	0.916
		Irbesartan	5	4 (80.0)	-0.58 (0.87)	(-2.33, 1.18)			
	Week 110	Sparsentan	9	5 (55.6)	0.46 (0.77)	(-1.08, 2.00)	1.22 (1.22)	(-1.23, 3.67)	0.321
		Irbesartan	5	4 (80.0)	-0.76 (0.92)	(-2.60, 1.07)			
> 18 to 40 years	Week 6	Sparsentan	102	100 (98.0)	-0.83 (0.14)	(-1.12, -0.55)	-0.74 (0.20)	(-1.13, -0.34)	<0.001 *
		Irbesartan	109	105 (96.3)	-0.10 (0.14)	(-0.37, 0.18)			
	Week 36	Sparsentan	102	97 (95.1)	-0.82 (0.15)	(-1.10, -0.54)	-0.64 (0.20)	(-1.04, -0.24)	0.002 *
		Irbesartan	109	100 (91.7)	-0.18 (0.14)	(-0.46, 0.10)			
	Week 58	Sparsentan	102	95 (93.1)	-0.76 (0.15)	(-1.05, -0.48)	-0.62 (0.21)	(-1.03, -0.21)	0.003 *
		Irbesartan	109	92 (84.4)	-0.14 (0.15)	(-0.43, 0.14)			
	Week 110	Sparsentan	102	82 (80.4)	-0.74 (0.16)	(-1.04, -0.43)	-0.74 (0.22)	(-1.17, -0.31)	<0.001 *
		Irbesartan	109	79 (72.5)	0.00 (0.16)	(-0.31, 0.31)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 40 years	Week 6	Sparsentan	91	87 (95.6)	-0.49 (0.13)	(-0.74, -0.23)	-0.57 (0.19)	(-0.94, -0.21)	0.002 *
		Irbesartan	88	83 (94.3)	0.08 (0.13)	(-0.18, 0.34)			
	Week 36	Sparsentan	91	89 (97.8)	-0.75 (0.13)	(-1.00, -0.49)	-0.96 (0.19)	(-1.33, -0.60)	<0.001 *
		Irbesartan	88	82 (93.2)	0.22 (0.13)	(-0.04, 0.48)			
	Week 58	Sparsentan	91	86 (94.5)	-0.61 (0.13)	(-0.87, -0.36)	-0.84 (0.19)	(-1.21, -0.47)	<0.001 *
		Irbesartan	88	82 (93.2)	0.22 (0.13)	(-0.04, 0.49)			
	Week 110	Sparsentan	91	82 (90.1)	-0.70 (0.13)	(-0.96, -0.44)	-0.91 (0.20)	(-1.30, -0.52)	<0.001 *
		Irbesartan	88	67 (76.1)	0.21 (0.15)	(-0.07, 0.50)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Geographic region	Overall	Sparsentan						Interaction:	0.061
North America	Week 6	Sparsentan	35	35 (100.0)	-0.63 (0.29)	(-1.21, -0.05)	-0.60 (0.39)	(-1.37, 0.17)	0.124
		Irbesartan	46	45 (97.8)	-0.03 (0.26)	(-0.53, 0.48)			
	Week 36	Sparsentan	35	33 (94.3)	-1.17 (0.30)	(-1.75, -0.58)	-1.39 (0.40)	(-2.17, -0.61)	<0.001 *
		Irbesartan	46	43 (93.5)	0.22 (0.26)	(-0.29, 0.74)			
	Week 58	Sparsentan	35	28 (80.0)	-0.77 (0.31)	(-1.39, -0.16)	-0.94 (0.41)	(-1.76, -0.13)	0.023 *
		Irbesartan	46	40 (87.0)	0.17 (0.27)	(-0.36, 0.70)			
	Week 110	Sparsentan	35	27 (77.1)	-1.06 (0.33)	(-1.70, -0.42)	-1.01 (0.45)	(-1.89, -0.14)	0.024 *
		Irbesartan	46	31 (67.4)	-0.05 (0.30)	(-0.65, 0.55)			
Europe	Week 6	Sparsentan	98	92 (93.9)	-0.74 (0.14)	(-1.01, -0.48)	-0.70 (0.18)	(-1.06, -0.34)	<0.001 *
		Irbesartan	115	109 (94.8)	-0.04 (0.13)	(-0.29, 0.20)			
	Week 36	Sparsentan	98	94 (95.9)	-0.71 (0.13)	(-0.97, -0.44)	-0.63 (0.18)	(-0.99, -0.27)	<0.001 *
		Irbesartan	115	108 (93.9)	-0.08 (0.13)	(-0.32, 0.17)			
	Week 58	Sparsentan	98	93 (94.9)	-0.61 (0.14)	(-0.88, -0.34)	-0.61 (0.19)	(-0.97, -0.24)	0.001 *
		Irbesartan	115	100 (87.0)	-0.00 (0.13)	(-0.25, 0.25)			
	Week 110	Sparsentan	98	80 (81.6)	-0.65 (0.14)	(-0.93, -0.37)	-0.74 (0.20)	(-1.12, -0.35)	<0.001 *
		Irbesartan	115	88 (76.5)	0.09 (0.14)	(-0.18, 0.36)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Asia Pacific	Week 6	Sparsentan	69	68 (98.6)	-0.61 (0.14)	(-0.88, -0.34)	-0.61 (0.22)	(-1.05, -0.17)	0.007 *
		Irbesartan	41	39 (95.1)	-0.00 (0.18)	(-0.35, 0.35)			
	Week 36	Sparsentan	69	67 (97.1)	-0.70 (0.14)	(-0.97, -0.44)	-0.60 (0.23)	(-1.04, -0.15)	0.009 *
		Irbesartan	41	36 (87.8)	-0.11 (0.18)	(-0.46, 0.25)			
	Week 58	Sparsentan	69	67 (97.1)	-0.76 (0.14)	(-1.03, -0.49)	-0.56 (0.23)	(-1.00, -0.11)	0.015 *
		Irbesartan	41	38 (92.7)	-0.20 (0.18)	(-0.56, 0.16)			
	Week 110	Sparsentan	69	62 (89.9)	-0.59 (0.14)	(-0.86, -0.31)	-0.70 (0.24)	(-1.17, -0.22)	0.004 *
		Irbesartan	41	31 (75.6)	0.11 (0.20)	(-0.28, 0.49)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline BMI	Overall	Sparsentan						Interaction:	0.050 #
< 27 kg/m**2	Week 6	Sparsentan	83	78 (94.0)	-0.56 (0.12)	(-0.80, -0.32)	-0.48 (0.17)	(-0.81, -0.15)	0.005 *
		Irbesartan	94	89 (94.7)	-0.08 (0.12)	(-0.31, 0.15)			
	Week 36	Sparsentan	83	80 (96.4)	-0.75 (0.12)	(-0.99, -0.51)	-0.47 (0.17)	(-0.80, -0.13)	0.006 *
		Irbesartan	94	85 (90.4)	-0.29 (0.12)	(-0.52, -0.06)			
	Week 58	Sparsentan	83	76 (91.6)	-0.78 (0.12)	(-1.02, -0.53)	-0.50 (0.17)	(-0.84, -0.16)	0.004 *
		Irbesartan	94	79 (84.0)	-0.28 (0.12)	(-0.52, -0.04)			
	Week 110	Sparsentan	83	70 (84.3)	-0.53 (0.13)	(-0.79, -0.28)	-0.36 (0.18)	(-0.72, 0.00)	0.052
		Irbesartan	94	66 (70.2)	-0.17 (0.13)	(-0.43, 0.08)			
>= 27 kg/m**2	Week 6	Sparsentan	119	117 (98.3)	-0.73 (0.14)	(-1.00, -0.45)	-0.71 (0.21)	(-1.11, -0.31)	<0.001 *
		Irbesartan	107	103 (96.3)	-0.02 (0.15)	(-0.31, 0.28)			
	Week 36	Sparsentan	119	114 (95.8)	-0.79 (0.14)	(-1.07, -0.51)	-0.98 (0.21)	(-1.39, -0.58)	<0.001 *
		Irbesartan	107	101 (94.4)	0.19 (0.15)	(-0.10, 0.49)			
	Week 58	Sparsentan	119	112 (94.1)	-0.61 (0.14)	(-0.90, -0.33)	-0.82 (0.21)	(-1.23, -0.41)	<0.001 *
		Irbesartan	107	99 (92.5)	0.20 (0.15)	(-0.09, 0.50)			
	Week 110	Sparsentan	119	99 (83.2)	-0.79 (0.15)	(-1.09, -0.50)	-1.03 (0.22)	(-1.47, -0.60)	<0.001 *
		Irbesartan	107	83 (77.6)	0.24 (0.16)	(-0.08, 0.56)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Randomization strata	Overall	Sparsentan						Interaction:	0.011 #
eGFR Low and UP High	Week 6	Sparsentan	71	68 (95.8)	-0.86 (0.20)	(-1.25, -0.47)	-0.85 (0.28)	(-1.40, -0.31)	0.002 *
		Irbesartan	74	73 (98.6)	-0.01 (0.19)	(-0.39, 0.37)			
	Week 36	Sparsentan	71	68 (95.8)	-0.95 (0.20)	(-1.34, -0.55)	-0.99 (0.28)	(-1.54, -0.44)	<0.001 *
		Irbesartan	74	68 (91.9)	0.04 (0.20)	(-0.35, 0.43)			
	Week 58	Sparsentan	71	67 (94.4)	-0.89 (0.20)	(-1.28, -0.49)	-0.93 (0.28)	(-1.49, -0.38)	0.001 *
		Irbesartan	74	64 (86.5)	0.05 (0.20)	(-0.35, 0.44)			
	Week 110	Sparsentan	71	59 (83.1)	-0.75 (0.21)	(-1.17, -0.33)	-0.65 (0.31)	(-1.25, -0.05)	0.034 *
		Irbesartan	74	54 (73.0)	-0.10 (0.22)	(-0.53, 0.33)			
eGFR Low and UP Low	Week 6	Sparsentan	55	52 (94.5)	-0.46 (0.12)	(-0.69, -0.24)	-0.27 (0.16)	(-0.59, 0.05)	0.102
		Irbesartan	55	53 (96.4)	-0.20 (0.12)	(-0.42, 0.03)			
	Week 36	Sparsentan	55	51 (92.7)	-0.53 (0.12)	(-0.75, -0.30)	-0.50 (0.16)	(-0.82, -0.18)	0.003 *
		Irbesartan	55	51 (92.7)	-0.03 (0.12)	(-0.25, 0.20)			
	Week 58	Sparsentan	55	52 (94.5)	-0.53 (0.12)	(-0.75, -0.30)	-0.45 (0.16)	(-0.77, -0.13)	0.006 *
		Irbesartan	55	51 (92.7)	-0.08 (0.12)	(-0.30, 0.15)			
	Week 110	Sparsentan	55	46 (83.6)	-0.41 (0.12)	(-0.65, -0.17)	-0.38 (0.17)	(-0.72, -0.03)	0.031 *
		Irbesartan	55	42 (76.4)	-0.03 (0.13)	(-0.28, 0.21)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
eGFR High and UP High	Week 6	Sparsentan	37	36 (97.3)	-0.79 (0.30)	(-1.37, -0.21)	-0.90 (0.43)	(-1.74, -0.06)	0.036 *
		Irbesartan	36	32 (88.9)	0.11 (0.31)	(-0.50, 0.71)			
	Week 36	Sparsentan	37	37 (100.0)	-1.05 (0.29)	(-1.63, -0.47)	-1.08 (0.43)	(-1.92, -0.24)	0.012 *
		Irbesartan	36	32 (88.9)	0.03 (0.31)	(-0.58, 0.64)			
	Week 58	Sparsentan	37	32 (86.5)	-0.87 (0.30)	(-1.47, -0.28)	-0.87 (0.44)	(-1.73, -0.00)	0.049 *
		Irbesartan	36	31 (86.1)	-0.01 (0.32)	(-0.63, 0.62)			
	Week 110	Sparsentan	37	30 (81.1)	-1.26 (0.32)	(-1.89, -0.64)	-1.58 (0.46)	(-2.49, -0.67)	<0.001 *
		Irbesartan	36	27 (75.0)	0.31 (0.34)	(-0.35, 0.97)			
eGFR High and UP Low	Week 6	Sparsentan	39	39 (100.0)	-0.57 (0.11)	(-0.78, -0.35)	-0.60 (0.16)	(-0.91, -0.29)	<0.001 *
		Irbesartan	37	35 (94.6)	0.03 (0.11)	(-0.19, 0.25)			
	Week 36	Sparsentan	39	38 (97.4)	-0.65 (0.11)	(-0.86, -0.43)	-0.50 (0.16)	(-0.81, -0.19)	0.002 *
		Irbesartan	37	36 (97.3)	-0.15 (0.11)	(-0.37, 0.07)			
	Week 58	Sparsentan	39	37 (94.9)	-0.46 (0.11)	(-0.67, -0.24)	-0.47 (0.16)	(-0.79, -0.15)	0.004 *
		Irbesartan	37	32 (86.5)	0.02 (0.12)	(-0.21, 0.25)			
	Week 110	Sparsentan	39	34 (87.2)	-0.47 (0.11)	(-0.70, -0.25)	-0.76 (0.17)	(-1.09, -0.42)	<0.001 *
		Irbesartan	37	27 (73.0)	0.29 (0.13)	(0.04, 0.53)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 1	Overall	Sparsentan						Interaction:	0.008 #
< 60 mL/min/1.73 m**2	Week 6	Sparsentan	127	121 (95.3)	-0.63 (0.12)	(-0.87, -0.39)	-0.57 (0.17)	(-0.91, -0.24)	<0.001 *
		Irbesartan	129	126 (97.7)	-0.06 (0.12)	(-0.30, 0.17)			
	Week 36	Sparsentan	127	120 (94.5)	-0.67 (0.12)	(-0.91, -0.43)	-0.66 (0.17)	(-1.00, -0.32)	<0.001 *
		Irbesartan	129	119 (92.2)	-0.01 (0.12)	(-0.25, 0.22)			
	Week 58	Sparsentan	127	120 (94.5)	-0.64 (0.12)	(-0.88, -0.40)	-0.65 (0.17)	(-1.00, -0.31)	<0.001 *
		Irbesartan	129	115 (89.1)	0.01 (0.12)	(-0.23, 0.26)			
	Week 110	Sparsentan	127	105 (82.7)	-0.51 (0.13)	(-0.77, -0.26)	-0.50 (0.19)	(-0.86, -0.13)	0.007 *
		Irbesartan	129	97 (75.2)	-0.02 (0.13)	(-0.28, 0.24)			
60 to < 90 mL/min/1.73 m**2	Week 6	Sparsentan	49	48 (98.0)	-0.71 (0.21)	(-1.13, -0.30)	-0.85 (0.30)	(-1.45, -0.25)	0.005 *
		Irbesartan	48	44 (91.7)	0.14 (0.22)	(-0.29, 0.56)			
	Week 36	Sparsentan	49	48 (98.0)	-0.99 (0.21)	(-1.40, -0.57)	-1.33 (0.31)	(-1.93, -0.73)	<0.001 *
		Irbesartan	48	45 (93.8)	0.34 (0.22)	(-0.09, 0.77)			
	Week 58	Sparsentan	49	43 (87.8)	-0.77 (0.22)	(-1.20, -0.34)	-1.06 (0.31)	(-1.68, -0.45)	<0.001 *
		Irbesartan	48	42 (87.5)	0.29 (0.22)	(-0.14, 0.73)			
	Week 110	Sparsentan	49	43 (87.8)	-1.07 (0.22)	(-1.50, -0.63)	-1.54 (0.32)	(-2.18, -0.91)	<0.001 *
		Irbesartan	48	36 (75.0)	0.47 (0.24)	(0.01, 0.94)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
>= 90 mL/min/1.73 m**2	Week 6	Sparsentan	26	26 (100.0)	-0.80 (0.22)	(-1.24, -0.37)	-0.65 (0.32)	(-1.28, -0.02)	0.044 *
		Irbesartan	25	23 (92.0)	-0.16 (0.23)	(-0.61, 0.30)			
	Week 36	Sparsentan	26	26 (100.0)	-0.94 (0.22)	(-1.37, -0.51)	-0.28 (0.32)	(-0.90, 0.35)	0.387
		Irbesartan	25	23 (92.0)	-0.66 (0.23)	(-1.12, -0.21)			
	Week 58	Sparsentan	26	25 (96.2)	-0.79 (0.22)	(-1.23, -0.35)	-0.19 (0.33)	(-0.84, 0.45)	0.558
		Irbesartan	25	21 (84.0)	-0.60 (0.24)	(-1.07, -0.13)			
	Week 110	Sparsentan	26	21 (80.8)	-0.82 (0.24)	(-1.29, -0.36)	-0.57 (0.35)	(-1.27, 0.13)	0.109
		Irbesartan	25	17 (68.0)	-0.25 (0.26)	(-0.77, 0.27)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 2	Overall	Sparsentan						Interaction:	0.004 #
< 45 mL/min/1.73 m**2	Week 6	Sparsentan	82	78 (95.1)	-0.54 (0.15)	(-0.83, -0.25)	-0.40 (0.21)	(-0.82, 0.01)	0.056
		Irbesartan	80	78 (97.5)	-0.14 (0.15)	(-0.43, 0.16)			
	Week 36	Sparsentan	82	78 (95.1)	-0.58 (0.15)	(-0.87, -0.29)	-0.59 (0.21)	(-1.01, -0.17)	0.006 *
		Irbesartan	80	72 (90.0)	0.01 (0.15)	(-0.29, 0.30)			
	Week 58	Sparsentan	82	77 (93.9)	-0.53 (0.15)	(-0.82, -0.23)	-0.51 (0.22)	(-0.93, -0.08)	0.019 *
		Irbesartan	80	69 (86.3)	-0.02 (0.15)	(-0.33, 0.28)			
	Week 110	Sparsentan	82	67 (81.7)	-0.39 (0.16)	(-0.70, -0.08)	-0.35 (0.23)	(-0.80, 0.10)	0.127
		Irbesartan	80	59 (73.8)	-0.04 (0.17)	(-0.37, 0.28)			
45 to < 60 mL/min/1.73 m**2	Week 6	Sparsentan	45	43 (95.6)	-0.80 (0.21)	(-1.21, -0.38)	-0.86 (0.29)	(-1.44, -0.29)	0.003 *
		Irbesartan	49	48 (98.0)	0.07 (0.20)	(-0.33, 0.46)			
	Week 36	Sparsentan	45	42 (93.3)	-0.84 (0.21)	(-1.26, -0.42)	-0.81 (0.29)	(-1.39, -0.23)	0.006 *
		Irbesartan	49	47 (95.9)	-0.03 (0.20)	(-0.43, 0.36)			
	Week 58	Sparsentan	45	43 (95.6)	-0.85 (0.21)	(-1.26, -0.43)	-0.93 (0.30)	(-1.51, -0.35)	0.002 *
		Irbesartan	49	46 (93.9)	0.08 (0.21)	(-0.32, 0.48)			
	Week 110	Sparsentan	45	38 (84.4)	-0.73 (0.22)	(-1.17, -0.29)	-0.76 (0.32)	(-1.38, -0.14)	0.017 *
		Irbesartan	49	38 (77.6)	0.03 (0.22)	(-0.41, 0.46)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
60 to < 90 mL/min/1.73 m**2	Week 6	Sparsentan	49	48 (98.0)	-0.71 (0.21)	(-1.13, -0.30)	-0.85 (0.30)	(-1.45, -0.25)	0.005 *
		Irbesartan	48	44 (91.7)	0.14 (0.22)	(-0.29, 0.56)			
	Week 36	Sparsentan	49	48 (98.0)	-0.99 (0.21)	(-1.40, -0.57)	-1.33 (0.31)	(-1.93, -0.73)	<0.001 *
		Irbesartan	48	45 (93.8)	0.34 (0.22)	(-0.09, 0.77)			
	Week 58	Sparsentan	49	43 (87.8)	-0.77 (0.22)	(-1.20, -0.34)	-1.06 (0.31)	(-1.68, -0.45)	<0.001 *
		Irbesartan	48	42 (87.5)	0.29 (0.22)	(-0.14, 0.73)			
	Week 110	Sparsentan	49	43 (87.8)	-1.07 (0.22)	(-1.50, -0.63)	-1.54 (0.32)	(-2.18, -0.91)	<0.001 *
		Irbesartan	48	36 (75.0)	0.47 (0.24)	(0.01, 0.94)			
>= 90 mL/min/1.73 m**2	Week 6	Sparsentan	26	26 (100.0)	-0.80 (0.22)	(-1.24, -0.37)	-0.65 (0.32)	(-1.28, -0.02)	0.044 *
		Irbesartan	25	23 (92.0)	-0.16 (0.23)	(-0.61, 0.30)			
	Week 36	Sparsentan	26	26 (100.0)	-0.94 (0.22)	(-1.37, -0.51)	-0.28 (0.32)	(-0.90, 0.35)	0.387
		Irbesartan	25	23 (92.0)	-0.66 (0.23)	(-1.12, -0.21)			
	Week 58	Sparsentan	26	25 (96.2)	-0.79 (0.22)	(-1.23, -0.35)	-0.19 (0.33)	(-0.84, 0.45)	0.558
		Irbesartan	25	21 (84.0)	-0.60 (0.24)	(-1.07, -0.13)			
	Week 110	Sparsentan	26	21 (80.8)	-0.82 (0.24)	(-1.29, -0.36)	-0.57 (0.35)	(-1.27, 0.13)	0.109
		Irbesartan	25	17 (68.0)	-0.25 (0.26)	(-0.77, 0.27)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline urine protein excretion	Overall	Sparsentan						Interaction:	<0.001 #
<= 1.75 g/day	Week 6	Sparsentan	98	95 (96.9)	-0.17 (0.10)	(-0.36, 0.03)	-0.33 (0.14)	(-0.61, -0.05)	0.020 *
		Irbesartan	93	88 (94.6)	0.16 (0.10)	(-0.04, 0.36)			
	Week 36	Sparsentan	98	94 (95.9)	-0.24 (0.10)	(-0.43, -0.04)	-0.47 (0.14)	(-0.75, -0.20)	<0.001 *
		Irbesartan	93	87 (93.5)	0.24 (0.10)	(0.04, 0.44)			
	Week 58	Sparsentan	98	93 (94.9)	-0.11 (0.10)	(-0.30, 0.09)	-0.35 (0.14)	(-0.63, -0.07)	0.016 *
		Irbesartan	93	82 (88.2)	0.24 (0.10)	(0.04, 0.45)			
	Week 110	Sparsentan	98	85 (86.7)	-0.07 (0.10)	(-0.27, 0.13)	-0.44 (0.15)	(-0.73, -0.14)	0.004 *
		Irbesartan	93	70 (75.3)	0.37 (0.11)	(0.15, 0.59)			
> 1.75 g/day	Week 6	Sparsentan	104	100 (96.2)	-1.23 (0.18)	(-1.58, -0.87)	-1.06 (0.25)	(-1.56, -0.56)	<0.001 *
		Irbesartan	109	105 (96.3)	-0.16 (0.18)	(-0.51, 0.19)			
	Week 36	Sparsentan	104	100 (96.2)	-1.37 (0.18)	(-1.73, -1.01)	-1.17 (0.26)	(-1.67, -0.66)	<0.001 *
		Irbesartan	109	100 (91.7)	-0.20 (0.18)	(-0.55, 0.15)			
	Week 58	Sparsentan	104	95 (91.3)	-1.30 (0.19)	(-1.66, -0.93)	-1.13 (0.26)	(-1.64, -0.62)	<0.001 *
		Irbesartan	109	96 (88.1)	-0.17 (0.18)	(-0.53, 0.19)			
	Week 110	Sparsentan	104	84 (80.8)	-1.33 (0.19)	(-1.71, -0.95)	-1.16 (0.28)	(-1.70, -0.62)	<0.001 *
		Irbesartan	109	80 (73.4)	-0.17 (0.20)	(-0.56, 0.22)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline use of antihypertensives	Overall	Sparsentan						Interaction:	0.413
Yes	Week 6	Sparsentan	90	86 (95.6)	-0.76 (0.16)	(-1.07, -0.45)	-0.72 (0.23)	(-1.17, -0.28)	0.001 *
		Irbesartan	88	82 (93.2)	-0.03 (0.16)	(-0.35, 0.28)			
	Week 36	Sparsentan	90	87 (96.7)	-0.93 (0.16)	(-1.24, -0.62)	-0.94 (0.23)	(-1.38, -0.49)	<0.001 *
		Irbesartan	88	82 (93.2)	0.01 (0.16)	(-0.31, 0.33)			
	Week 58	Sparsentan	90	83 (92.2)	-0.76 (0.16)	(-1.07, -0.45)	-0.73 (0.23)	(-1.18, -0.28)	0.002 *
		Irbesartan	88	80 (90.9)	-0.03 (0.16)	(-0.36, 0.29)			
	Week 110	Sparsentan	90	75 (83.3)	-0.88 (0.17)	(-1.21, -0.55)	-0.91 (0.24)	(-1.38, -0.44)	<0.001 *
		Irbesartan	88	69 (78.4)	0.03 (0.17)	(-0.31, 0.37)			
No	Week 6	Sparsentan	112	109 (97.3)	-0.58 (0.12)	(-0.82, -0.34)	-0.56 (0.17)	(-0.89, -0.22)	0.001 *
		Irbesartan	114	111 (97.4)	-0.03 (0.12)	(-0.26, 0.21)			
	Week 36	Sparsentan	112	107 (95.5)	-0.65 (0.12)	(-0.89, -0.41)	-0.62 (0.17)	(-0.96, -0.28)	<0.001 *
		Irbesartan	114	105 (92.1)	-0.03 (0.12)	(-0.27, 0.21)			
	Week 58	Sparsentan	112	105 (93.8)	-0.62 (0.12)	(-0.86, -0.38)	-0.65 (0.18)	(-0.99, -0.30)	<0.001 *
		Irbesartan	114	98 (86.0)	0.03 (0.13)	(-0.22, 0.27)			
	Week 110	Sparsentan	112	94 (83.9)	-0.52 (0.13)	(-0.78, -0.27)	-0.62 (0.19)	(-0.99, -0.25)	<0.001 *
		Irbesartan	114	81 (71.1)	0.10 (0.14)	(-0.17, 0.37)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Time since renal biopsy	Overall	Sparsentan						Interaction:	0.955
<= 5 years	Week 6	Sparsentan	113	108 (95.6)	-0.71 (0.14)	(-0.98, -0.45)	-0.59 (0.19)	(-0.96, -0.23)	0.002 *
		Irbesartan	127	123 (96.9)	-0.12 (0.13)	(-0.37, 0.13)			
	Week 36	Sparsentan	113	107 (94.7)	-0.93 (0.14)	(-1.20, -0.66)	-0.82 (0.19)	(-1.19, -0.45)	<0.001 *
		Irbesartan	127	117 (92.1)	-0.11 (0.13)	(-0.36, 0.15)			
	Week 58	Sparsentan	113	104 (92.0)	-0.68 (0.14)	(-0.95, -0.41)	-0.61 (0.19)	(-0.98, -0.24)	0.001 *
		Irbesartan	127	116 (91.3)	-0.07 (0.13)	(-0.33, 0.18)			
	Week 110	Sparsentan	113	96 (85.0)	-0.94 (0.14)	(-1.22, -0.66)	-0.89 (0.20)	(-1.29, -0.49)	<0.001 *
		Irbesartan	127	93 (73.2)	-0.05 (0.14)	(-0.34, 0.23)			
> 5 years	Week 6	Sparsentan	89	87 (97.8)	-0.62 (0.14)	(-0.90, -0.35)	-0.76 (0.21)	(-1.17, -0.35)	<0.001 *
		Irbesartan	75	70 (93.3)	0.14 (0.15)	(-0.16, 0.44)			
	Week 36	Sparsentan	89	87 (97.8)	-0.60 (0.14)	(-0.88, -0.33)	-0.76 (0.21)	(-1.17, -0.35)	<0.001 *
		Irbesartan	75	70 (93.3)	0.16 (0.15)	(-0.14, 0.46)			
	Week 58	Sparsentan	89	84 (94.4)	-0.70 (0.14)	(-0.97, -0.42)	-0.83 (0.21)	(-1.25, -0.40)	<0.001 *
		Irbesartan	75	62 (82.7)	0.13 (0.16)	(-0.19, 0.45)			
	Week 110	Sparsentan	89	73 (82.0)	-0.36 (0.15)	(-0.65, -0.06)	-0.63 (0.23)	(-1.07, -0.19)	0.005 *
		Irbesartan	75	57 (76.0)	0.27 (0.17)	(-0.06, 0.61)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2UEC_FSCM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set

Change from baseline in urine protein excretion					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
History of hypertension	Overall	Sparsentan						Interaction:	0.137
Yes	Week 6	Sparsentan	155	149 (96.1)	-0.71 (0.12)	(-0.94, -0.48)	-0.65 (0.17)	(-0.97, -0.33)	<0.001 *
		Irbesartan	161	153 (95.0)	-0.06 (0.12)	(-0.28, 0.17)			
	Week 36	Sparsentan	155	149 (96.1)	-0.79 (0.12)	(-1.03, -0.56)	-0.84 (0.17)	(-1.16, -0.51)	<0.001 *
		Irbesartan	161	150 (93.2)	0.04 (0.12)	(-0.18, 0.27)			
	Week 58	Sparsentan	155	145 (93.5)	-0.67 (0.12)	(-0.90, -0.43)	-0.70 (0.17)	(-1.03, -0.37)	<0.001 *
		Irbesartan	161	145 (90.1)	0.04 (0.12)	(-0.20, 0.27)			
	Week 110	Sparsentan	155	131 (84.5)	-0.71 (0.12)	(-0.95, -0.47)	-0.83 (0.18)	(-1.18, -0.48)	<0.001 *
		Irbesartan	161	122 (75.8)	0.12 (0.13)	(-0.13, 0.37)			
No	Week 6	Sparsentan	47	46 (97.9)	-0.55 (0.16)	(-0.87, -0.24)	-0.64 (0.23)	(-1.10, -0.18)	0.007 *
		Irbesartan	41	40 (97.6)	0.09 (0.17)	(-0.25, 0.42)			
	Week 36	Sparsentan	47	45 (95.7)	-0.73 (0.16)	(-1.05, -0.41)	-0.50 (0.24)	(-0.97, -0.04)	0.034 *
		Irbesartan	41	37 (90.2)	-0.23 (0.17)	(-0.57, 0.11)			
	Week 58	Sparsentan	47	43 (91.5)	-0.74 (0.16)	(-1.06, -0.42)	-0.61 (0.24)	(-1.09, -0.14)	0.012 *
		Irbesartan	41	33 (80.5)	-0.13 (0.18)	(-0.48, 0.22)			
	Week 110	Sparsentan	47	38 (80.9)	-0.60 (0.17)	(-0.93, -0.26)	-0.42 (0.26)	(-0.93, 0.09)	0.104
		Irbesartan	41	28 (68.3)	-0.17 (0.19)	(-0.55, 0.21)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Figure PF2UEC_FSGM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set
Study: PROTECT
Sex: Male



Sparsentan	135	135	129	116
Irbesartan	137	132	127	108

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2UEC_FSCM

Figure PF2UEC_FSGM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set
Study: PROTECT
Sex: Female



Sparsentan	60	59	59	53
Irbesartan	56	55	51	42

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2UEC_FSCM

Figure PF2UEC_FSGM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set
Study: PROTECT
Baseline BMI: < 27 kg/m**2



Sparsentan	78	80	76	70
Irbesartan	89	85	79	66

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2UEC_FSCM

Figure PF2UEC_FSGM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set
Study: PROTECT
Baseline BMI: >= 27 kg/m**2



Sparsentan	117	114	112	99
Irbesartan	103	101	99	83

_____
Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2UEC_FSCM

Figure PF2UEC_FSGM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set
Study: PROTECT
Randomization strata: eGFR Low and UP High



Sparsentan	68	68	67	59
Irbesartan	73	68	64	54

_____
Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2UEC_FSCM

Figure PF2UEC_FSGM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set
Study: PROTECT
Randomization strata: eGFR Low and UP Low



Sparsentan	52	51	52	46
Irbesartan	53	51	51	42

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2UEC_FSCM

Figure PF2UEC_FSGM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set
Study: PROTECT
Randomization strata: eGFR High and UP High



Sparsentan	36	37	32	30
Irbesartan	32	32	31	27

_____
Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2UEC_FSCM

Figure PF2UEC_FSGM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set
Study: PROTECT
Randomization strata: eGFR High and UP Low



Sparsentan	39	38	37	34
Irbesartan	35	36	32	27

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2UEC_FSCM

Figure PF2UEC_FSGM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 1: < 60 mL/min/1.73 m**2



Sparsentan	121	120	120	105
Irbesartan	126	119	115	97

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2UEC_FSCM

Figure PF2UEC_FSGM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 1: 60 to < 90 mL/min/1.73 m**2



Sparsentan	48	48	43	43
Irbesartan	44	45	42	36

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2UEC_FSCM

Figure PF2UEC_FSGM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 1: >= 90 mL/min/1.73 m**2



Sparsentan	26	26	25	21
Irbesartan	23	23	21	17

_____
Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2UEC_FSCM

Figure PF2UEC_FSGM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 2: < 45 mL/min/1.73 m**2



Sparsentan	78	78	77	67
Irbesartan	78	72	69	59

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2UEC_FSCM

Figure PF2UEC_FSGM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 2: 45 to < 60 mL/min/1.73 m**2



Sparsentan	43	42	43	38
Irbesartan	48	47	46	38

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2UEC_FSCM

Figure PF2UEC_FSGM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 2: 60 to < 90 mL/min/1.73 m**2



Sparsentan	48	48	43	43
Irbesartan	44	45	42	36

_____
Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2UEC_FSCM

Figure PF2UEC_FSGM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 2: >= 90 mL/min/1.73 m**2



Sparsentan	26	26	25	21
Irbesartan	23	23	21	17

_____
Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2UEC_FSCM

Figure PF2UEC_FSGM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set
Study: PROTECT
Baseline urine protein excretion: <= 1.75 g/day



Sparsentan	95	94	93	85
Irbesartan	88	87	82	70

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2UEC_FSCM

Figure PF2UEC_FSGM: Change from baseline in urine protein excretion by subgroup
Full Analysis Set
Study: PROTECT
Baseline urine protein excretion: > 1.75 g/day



Sparsentan	100	100	95	84
Irbesartan	105	100	96	80

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. An increase reflects a worsening of the status of the patient. Results are presented in g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2UEC_FSCM

Table PT2URP_FSPM: Patients with partial remission by subgroup
Full Analysis Set

Partial remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Sex	Week 58	Sparsentan						Interaction test:	0.075	
	Week 110	Sparsentan						Interaction test:	0.834	
Male	Week 58	Sparsentan	139	129 (92.8)	58 (45.0)	2.196 [1.483, 3.251]	3.173 [1.825, 5.518]	24.5 [12.6, 36.4]	<0.001	*
		Irbesartan	143	127 (88.8)	26 (20.5)					
	Week 110	Sparsentan	139	116 (83.5)	56 (48.3)	2.172 [1.456, 3.241]	3.267 [1.826, 5.845]	26.1 [13.2, 39.0]	<0.001	*
		Irbesartan	143	108 (75.5)	24 (22.2)					
Female	Week 58	Sparsentan	63	59 (93.7)	32 (54.2)	1.317 [0.880, 1.971]	1.693 [0.794, 3.610]	13.1 [-7.3, 33.4]	0.186	
		Irbesartan	59	51 (86.4)	21 (41.2)					
	Week 110	Sparsentan	63	53 (84.1)	28 (52.8)	2.017 [1.143, 3.559]	3.156 [1.317, 7.565]	26.6 [5.6, 47.7]	0.012	*
		Irbesartan	59	42 (71.2)	11 (26.2)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Partial remission means an urinary protein excretion of <1.0 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URP_FSPM: Patients with partial remission by subgroup
Full Analysis Set

Partial remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Age	Week 58	Sparsentan						Interaction test:	0.075	
	Week 110	Sparsentan						Interaction test:	0.446	
<= 45 years	Week 58	Sparsentan	96	89 (92.7)	40 (44.9)	1.398 [0.950, 2.058]	1.723 [0.927, 3.203]	12.8 [-2.7, 28.3]	0.089	
		Irbesartan	99	84 (84.8)	27 (32.1)					
	Week 110	Sparsentan	96	76 (79.2)	37 (48.7)	1.866 [1.179, 2.954]	2.688 [1.334, 5.417]	22.6 [5.9, 39.3]	0.006	*
		Irbesartan	99	69 (69.7)	18 (26.1)					
> 45 years	Week 58	Sparsentan	106	99 (93.4)	50 (50.5)	2.374 [1.536, 3.667]	3.776 [2.007, 7.102]	29.2 [15.3, 43.1]	<0.001	*
		Irbesartan	103	94 (91.3)	20 (21.3)					
	Week 110	Sparsentan	106	93 (87.7)	47 (50.5)	2.408 [1.508, 3.845]	3.847 [1.965, 7.530]	29.5 [14.9, 44.2]	<0.001	*
		Irbesartan	103	81 (78.6)	17 (21.0)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Partial remission means an urinary protein excretion of <1.0 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URP_FSPM: Patients with partial remission by subgroup
Full Analysis Set

Partial remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Age at IgAN diagnosis	Week 58	Sparsentan						Interaction test:	0.323	
	Week 110	Sparsentan						Interaction test:	0.701	
<= 18 years	Week 58	Sparsentan	9	7 (77.8)	2 (28.6)	0.571 [0.124, 2.632]	0.400 [0.031, 5.151]	-21.4 [-100.0, 57.6]	0.576	
		Irbesartan	5	4 (80.0)	2 (50.0)					
	Week 110	Sparsentan	9	5 (55.6)	1 (20.0)	0.800 [0.070, 9.180]	0.750 [0.032, 17.506]	-5.0 [-82.5, 72.5]	1.000	
		Irbesartan	5	4 (80.0)	1 (25.0)					
> 18 to 40 years	Week 58	Sparsentan	102	95 (93.1)	49 (51.6)	1.898 [1.289, 2.795]	2.855 [1.550, 5.257]	24.4 [9.8, 39.0]	<0.001	*
		Irbesartan	109	92 (84.4)	25 (27.2)					
	Week 110	Sparsentan	102	82 (80.4)	41 (50.0)	2.079 [1.329, 3.253]	3.158 [1.610, 6.193]	25.9 [10.4, 41.5]	0.001	*
		Irbesartan	109	79 (72.5)	19 (24.1)					
> 40 years	Week 58	Sparsentan	91	86 (94.5)	39 (45.3)	1.859 [1.190, 2.905]	2.572 [1.331, 4.972]	21.0 [5.7, 36.2]	0.006	*
		Irbesartan	88	82 (93.2)	20 (24.4)					
	Week 110	Sparsentan	91	82 (90.1)	42 (51.2)	2.288 [1.397, 3.747]	3.640 [1.773, 7.473]	28.8 [12.8, 44.9]	<0.001	*
		Irbesartan	88	67 (76.1)	15 (22.4)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Partial remission means an urinary protein excretion of <1.0 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URP_FSPM: Patients with partial remission by subgroup
Full Analysis Set

Partial remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Geographic region	Week 58	Sparsentan						Interaction test:	0.576	
	Week 110	Sparsentan						Interaction test:	0.933	
North America	Week 58	Sparsentan	35	28 (80.0)	12 (42.9)	2.449 [1.103, 5.436]	3.536 [1.169, 10.696]	25.4 [0.5, 50.2]	0.029	*
		Irbesartan	46	40 (87.0)	7 (17.5)					
	Week 110	Sparsentan	35	27 (77.1)	12 (44.4)	1.968 [0.906, 4.278]	2.743 [0.883, 8.522]	21.9 [-5.4, 49.2]	0.097	
		Irbesartan	46	31 (67.4)	7 (22.6)					
Europe	Week 58	Sparsentan	98	93 (94.9)	40 (43.0)	1.536 [1.038, 2.273]	1.941 [1.066, 3.533]	15.0 [0.6, 29.4]	0.035	*
		Irbesartan	115	100 (87.0)	28 (28.0)					
	Week 110	Sparsentan	98	80 (81.6)	43 (53.8)	2.150 [1.420, 3.256]	3.486 [1.815, 6.696]	28.8 [13.4, 44.1]	<0.001	*
		Irbesartan	115	88 (76.5)	22 (25.0)					
Asia Pacific	Week 58	Sparsentan	69	67 (97.1)	38 (56.7)	1.796 [1.076, 2.999]	2.839 [1.229, 6.560]	25.1 [4.1, 46.2]	0.015	*
		Irbesartan	41	38 (92.7)	12 (31.6)					
	Week 110	Sparsentan	69	62 (89.9)	29 (46.8)	2.417 [1.123, 5.199]	3.662 [1.319, 10.166]	27.4 [6.4, 48.5]	0.013	*
		Irbesartan	41	31 (75.6)	6 (19.4)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Partial remission means an urinary protein excretion of <1.0 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URP_FSPM: Patients with partial remission by subgroup
Full Analysis Set

Partial remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline BMI	Week 58	Sparsentan						Interaction test:	0.916	
	Week 110	Sparsentan						Interaction test:	0.671	
< 27 kg/m**2	Week 58	Sparsentan	83	76 (91.6)	43 (56.6)	1.862 [1.264, 2.744]	2.986 [1.543, 5.778]	26.2 [9.8, 42.6]	0.001	*
		Irbesartan	94	79 (84.0)	24 (30.4)					
	Week 110	Sparsentan	83	70 (84.3)	39 (55.7)	2.043 [1.308, 3.191]	3.355 [1.636, 6.880]	28.4 [11.1, 45.8]	<0.001	*
		Irbesartan	94	66 (70.2)	18 (27.3)					
>= 27 kg/m**2	Week 58	Sparsentan	119	112 (94.1)	47 (42.0)	1.806 [1.188, 2.747]	2.389 [1.313, 4.348]	18.7 [5.4, 32.0]	0.005	*
		Irbesartan	107	99 (92.5)	23 (23.2)					
	Week 110	Sparsentan	119	99 (83.2)	45 (45.5)	2.358 [1.444, 3.850]	3.490 [1.779, 6.845]	26.2 [12.1, 40.3]	<0.001	*
		Irbesartan	107	83 (77.6)	16 (19.3)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Partial remission means an urinary protein excretion of <1.0 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URP_FSPM: Patients with partial remission by subgroup
Full Analysis Set

Partial remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Randomization strata	Week 58	Sparsentan						Interaction test:	0.360	
	Week 110	Sparsentan						Interaction test:	0.282	
eGFR Low and UP High	Week 58	Sparsentan	71	67 (94.4)	17 (25.4)	2.706 [1.139, 6.430]	3.287 [1.204, 8.976]	16.0 [1.8, 30.2]	0.021	*
		Irbesartan	74	64 (86.5)	6 (9.4)					
	Week 110	Sparsentan	71	59 (83.1)	19 (32.2)	2.898 [1.251, 6.716]	3.800 [1.385, 10.425]	21.1 [4.7, 37.4]	0.012	*
		Irbesartan	74	54 (73.0)	6 (11.1)					
eGFR Low and UP Low	Week 58	Sparsentan	55	52 (94.5)	32 (61.5)	1.365 [0.941, 1.978]	1.948 [0.888, 4.271]	16.4 [-4.5, 37.4]	0.116	
		Irbesartan	55	51 (92.7)	23 (45.1)					
	Week 110	Sparsentan	55	46 (83.6)	25 (54.3)	1.522 [0.937, 2.470]	2.143 [0.909, 5.050]	18.6 [-4.1, 41.3]	0.091	
		Irbesartan	55	42 (76.4)	15 (35.7)					
eGFR High and UP High	Week 58	Sparsentan	37	32 (86.5)	14 (43.8)	2.260 [0.997, 5.127]	3.241 [1.045, 10.054]	24.4 [-0.9, 49.7]	0.058	
		Irbesartan	36	31 (86.1)	6 (19.4)					
	Week 110	Sparsentan	37	30 (81.1)	17 (56.7)	3.825 [1.469, 9.961]	7.519 [2.082, 27.154]	41.9 [16.1, 67.6]	0.002	*
		Irbesartan	36	27 (75.0)	4 (14.8)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Partial remission means an urinary protein excretion of <1.0 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URP_FSPM: Patients with partial remission by subgroup
Full Analysis Set

Partial remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
eGFR High and UP Low	Week 58	Sparsentan	39	37 (94.9)	27 (73.0)	1.946 [1.194, 3.171]	4.500 [1.624, 12.468]	35.5 [10.5, 60.4]	0.004	*
		Irbesartan	37	32 (86.5)	12 (37.5)					
	Week 110	Sparsentan	39	34 (87.2)	23 (67.6)	1.826 [1.060, 3.147]	3.555 [1.230, 10.273]	30.6 [3.2, 58.0]	0.022	*
		Irbesartan	37	27 (73.0)	10 (37.0)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Partial remission means an urinary protein excretion of <1.0 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URP_FSPM: Patients with partial remission by subgroup
Full Analysis Set

Partial remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eGFR Group 1	Week 58	Sparsentan						Interaction test:	0.139	
	Week 110	Sparsentan						Interaction test:	0.384	
< 60 mL/min/1.73 m**2	Week 58	Sparsentan	127	120 (94.5)	51 (42.5)	1.577 [1.094, 2.273]	2.003 [1.157, 3.466]	15.5 [2.7, 28.4]	0.014	*
		Irbesartan	129	115 (89.1)	31 (27.0)					
	Week 110	Sparsentan	127	105 (82.7)	44 (41.9)	1.936 [1.246, 3.007]	2.610 [1.405, 4.850]	20.3 [6.8, 33.7]	0.003	*
		Irbesartan	129	97 (75.2)	21 (21.6)					
60 to < 90 mL/min/1.73 m**2	Week 58	Sparsentan	49	43 (87.8)	22 (51.2)	3.581 [1.615, 7.941]	6.286 [2.198, 17.979]	36.9 [16.2, 57.5]	<0.001	*
		Irbesartan	48	42 (87.5)	6 (14.3)					
	Week 110	Sparsentan	49	43 (87.8)	26 (60.5)	3.110 [1.533, 6.309]	6.336 [2.269, 17.697]	41.0 [19.0, 63.1]	<0.001	*
		Irbesartan	48	36 (75.0)	7 (19.4)					
>= 90 mL/min/1.73 m**2	Week 58	Sparsentan	26	25 (96.2)	17 (68.0)	1.428 [0.846, 2.409]	2.338 [0.704, 7.759]	20.4 [-12.1, 52.9]	0.231	
		Irbesartan	25	21 (84.0)	10 (47.6)					
	Week 110	Sparsentan	26	21 (80.8)	14 (66.7)	1.619 [0.851, 3.082]	2.857 [0.759, 10.751]	25.5 [-10.7, 61.7]	0.190	
		Irbesartan	25	17 (68.0)	7 (41.2)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Partial remission means an urinary protein excretion of <1.0 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URP_FSPM: Patients with partial remission by subgroup
Full Analysis Set

Partial remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eGFR Group 2	Week 58	Sparsentan						Interaction test:	0.239	
	Week 110	Sparsentan						Interaction test:	0.591	
< 45 mL/min/1.73 m**2	Week 58	Sparsentan	82	77 (93.9)	31 (40.3)	1.462 [0.914, 2.338]	1.773 [0.883, 3.562]	12.7 [-3.9, 29.3]	0.119	
		Irbesartan	80	69 (86.3)	19 (27.5)					
	Week 110	Sparsentan	82	67 (81.7)	26 (38.8)	1.908 [1.060, 3.434]	2.484 [1.114, 5.539]	18.5 [1.3, 35.6]	0.032	*
		Irbesartan	80	59 (73.8)	12 (20.3)					
45 to < 60 mL/min/1.73 m**2	Week 58	Sparsentan	45	43 (95.6)	20 (46.5)	1.783 [0.996, 3.192]	2.464 [1.012, 6.000]	20.4 [-1.4, 42.3]	0.051	
		Irbesartan	49	46 (93.9)	12 (26.1)					
	Week 110	Sparsentan	45	38 (84.4)	18 (47.4)	2.000 [1.032, 3.877]	2.900 [1.086, 7.744]	23.7 [0.2, 47.2]	0.054	
		Irbesartan	49	38 (77.6)	9 (23.7)					
60 to < 90 mL/min/1.73 m**2	Week 58	Sparsentan	49	43 (87.8)	22 (51.2)	3.581 [1.615, 7.941]	6.286 [2.198, 17.979]	36.9 [16.2, 57.5]	<0.001	*
		Irbesartan	48	42 (87.5)	6 (14.3)					
	Week 110	Sparsentan	49	43 (87.8)	26 (60.5)	3.110 [1.533, 6.309]	6.336 [2.269, 17.697]	41.0 [19.0, 63.1]	<0.001	*
		Irbesartan	48	36 (75.0)	7 (19.4)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Partial remission means an urinary protein excretion of <1.0 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URP_FSPM: Patients with partial remission by subgroup
Full Analysis Set

Partial remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
>= 90 mL/min/1.73 m**2	Week 58	Sparsentan	26	25 (96.2)	17 (68.0)	1.428 [0.846, 2.409]	2.338 [0.704, 7.759]	20.4 [-12.1, 52.9]	0.231
		Irbesartan	25	21 (84.0)	10 (47.6)				
	Week 110	Sparsentan	26	21 (80.8)	14 (66.7)	1.619 [0.851, 3.082]	2.857 [0.759, 10.751]	25.5 [-10.7, 61.7]	0.190
		Irbesartan	25	17 (68.0)	7 (41.2)				

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Partial remission means an urinary protein excretion of <1.0 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URP_FSPM: Patients with partial remission by subgroup
Full Analysis Set

Partial remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline urine protein excretion	Week 58	Sparsentan						Interaction test:	0.174	
	Week 110	Sparsentan						Interaction test:	0.177	
<= 1.75 g/day	Week 58	Sparsentan	98	93 (94.9)	59 (63.4)	1.530 [1.134, 2.065]	2.450 [1.332, 4.505]	22.0 [6.4, 37.6]	0.004	*
		Irbesartan	93	82 (88.2)	34 (41.5)					
	Week 110	Sparsentan	98	85 (86.7)	51 (60.0)	1.750 [1.211, 2.528]	2.875 [1.490, 5.547]	25.7 [9.2, 42.3]	0.002	*
		Irbesartan	93	70 (75.3)	24 (34.3)					
> 1.75 g/day	Week 58	Sparsentan	104	95 (91.3)	31 (32.6)	2.410 [1.346, 4.313]	3.093 [1.498, 6.386]	19.1 [6.4, 31.8]	0.002	*
		Irbesartan	109	96 (88.1)	13 (13.5)					
	Week 110	Sparsentan	104	84 (80.8)	33 (39.3)	2.857 [1.553, 5.257]	4.059 [1.875, 8.787]	25.5 [11.4, 39.6]	<0.001	*
		Irbesartan	109	80 (73.4)	11 (13.8)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Partial remission means an urinary protein excretion of <1.0 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URP_FSPM: Patients with partial remission by subgroup
Full Analysis Set

				Partial remission						
Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline use of antihypertensives	Week 58	Sparsentan						Interaction test:	0.477	
	Week 110	Sparsentan						Interaction test:	0.262	
Yes	Week 58	Sparsentan	90	83 (92.2)	33 (39.8)	1.590 [1.001, 2.526]	1.980 [1.013, 3.871]	14.8 [-0.6, 30.2]	0.047	*
		Irbesartan	88	80 (90.9)	20 (25.0)					
	Week 110	Sparsentan	90	75 (83.3)	34 (45.3)	1.738 [1.088, 2.776]	2.350 [1.162, 4.750]	19.2 [2.5, 35.9]	0.024	*
		Irbesartan	88	69 (78.4)	18 (26.1)					
No	Week 58	Sparsentan	112	105 (93.8)	57 (54.3)	1.970 [1.367, 2.841]	3.123 [1.737, 5.613]	26.7 [12.7, 40.7]	<0.001	*
		Irbesartan	114	98 (86.0)	27 (27.6)					
	Week 110	Sparsentan	112	94 (83.9)	50 (53.2)	2.534 [1.595, 4.027]	4.278 [2.187, 8.368]	32.2 [17.6, 46.8]	<0.001	*
		Irbesartan	114	81 (71.1)	17 (21.0)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Partial remission means an urinary protein excretion of <1.0 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URP_FSPM: Patients with partial remission by subgroup
Full Analysis Set

Partial remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Time since renal biopsy	Week 58	Sparsentan						Interaction test:	0.024	#
	Week 110	Sparsentan						Interaction test:	0.659	
<= 5 years	Week 58	Sparsentan	113	104 (92.0)	45 (43.3)	1.394 [0.983, 1.977]	1.695 [0.975, 2.945]	12.2 [-1.4, 25.9]	0.069	
		Irbesartan	127	116 (91.3)	36 (31.0)					
	Week 110	Sparsentan	113	96 (85.0)	53 (55.2)	2.054 [1.404, 3.005]	3.353 [1.822, 6.169]	28.3 [13.8, 42.8]	<0.001	*
		Irbesartan	127	93 (73.2)	25 (26.9)					
> 5 years	Week 58	Sparsentan	89	84 (94.4)	45 (53.6)	3.019 [1.705, 5.349]	5.350 [2.452, 11.670]	35.8 [20.1, 51.5]	<0.001	*
		Irbesartan	75	62 (82.7)	11 (17.7)					
	Week 110	Sparsentan	89	73 (82.0)	31 (42.5)	2.421 [1.298, 4.513]	3.469 [1.520, 7.919]	24.9 [8.3, 41.5]	0.003	*
		Irbesartan	75	57 (76.0)	10 (17.5)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Partial remission means an urinary protein excretion of <1.0 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URP_FSPM: Patients with partial remission by subgroup
Full Analysis Set

Partial remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
History of hypertension	Week 58	Sparsentan						Interaction test:	0.672	
	Week 110	Sparsentan						Interaction test:	0.659	
Yes	Week 58	Sparsentan	155	145 (93.5)	64 (44.1)	1.730 [1.240, 2.413]	2.306 [1.403, 3.790]	18.6 [7.2, 30.1]	0.001	*
		Irbesartan	161	145 (90.1)	37 (25.5)					
	Week 110	Sparsentan	155	131 (84.5)	61 (46.6)	2.029 [1.397, 2.947]	2.926 [1.698, 5.040]	23.6 [11.5, 35.7]	<0.001	*
		Irbesartan	161	122 (75.8)	28 (23.0)					
No	Week 58	Sparsentan	47	43 (91.5)	26 (60.5)	1.995 [1.127, 3.532]	3.518 [1.345, 9.203]	30.2 [6.1, 54.3]	0.011	*
		Irbesartan	41	33 (80.5)	10 (30.3)					
	Week 110	Sparsentan	47	38 (80.9)	23 (60.5)	2.421 [1.213, 4.832]	4.600 [1.571, 13.473]	35.5 [10.1, 61.0]	0.006	*
		Irbesartan	41	28 (68.3)	7 (25.0)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Partial remission means an urinary protein excretion of <1.0 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URPT_FSTM: Time to partial remission by subgroup
Full Analysis Set

Time to partial remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Sex	Sparsentan						Interaction test:	0.488	
Male	Sparsentan	139	101 (72.7)	7.6	(6.0, 24.1)	2.730	(1.992, 3.742)	<0.001	*
	Irbesartan	143	70 (49.0)	81.1	(57.4, NE)				
Female	Sparsentan	63	56 (88.9)	6.1	(4.1, 12.3)	2.577	(1.646, 4.036)	<0.001	*
	Irbesartan	59	36 (61.0)	22.4	(6.7, 59.6)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 27FEB2024

Table PT2URPT_FSTM: Time to partial remission by subgroup
Full Analysis Set

Time to partial remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Age	Sparsentan						Interaction test:	0.101	
<= 45 years	Sparsentan	96	73 (76.0)	7.4	(4.7, 24.0)	2.221	(1.557, 3.168)	<0.001	*
	Irbesartan	99	56 (56.6)	47.6	(25.1, 70.0)				
> 45 years	Sparsentan	106	84 (79.2)	6.3	(4.9, 12.7)	3.108	(2.156, 4.481)	<0.001	*
	Irbesartan	103	50 (48.5)	92.1	(51.9, NE)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 27FEB2024

Table PT2URPT_FSTM: Time to partial remission by subgroup
Full Analysis Set

Time to partial remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Age at IgAN diagnosis	Sparsentan						Interaction test:	0.888	
<= 18 years	Sparsentan	9	4 (44.4)	NE		3.253	(0.280, 37.739)	0.346	
	Irbesartan	5	3 (60.0)	70.0	(6.0, NE)				
> 18 to 40 years	Sparsentan	102	79 (77.5)	6.6	(4.7, 13.1)	2.522	(1.772, 3.590)	<0.001	*
	Irbesartan	109	58 (53.2)	68.6	(36.0, NE)				
> 40 years	Sparsentan	91	74 (81.3)	6.1	(4.9, 12.4)	2.699	(1.841, 3.958)	<0.001	*
	Irbesartan	88	45 (51.1)	70.9	(36.0, NE)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 27FEB2024

Table PT2URPT_FSTM: Time to partial remission by subgroup
Full Analysis Set

Time to partial remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Geographic region	Sparsentan						Interaction test:	0.779	
North America	Sparsentan	35	27 (77.1)	13.3	(6.3, 34.6)	3.632	(1.897, 6.954)	<0.001	*
	Irbesartan	46	16 (34.8)	NE					
Europe	Sparsentan	98	73 (74.5)	7.6	(5.0, 24.1)	2.630	(1.846, 3.747)	<0.001	*
	Irbesartan	115	62 (53.9)	68.6	(36.1, NE)				
Asia Pacific	Sparsentan	69	57 (82.6)	4.9	(4.1, 6.9)	2.356	(1.483, 3.743)	<0.001	*
	Irbesartan	41	28 (68.3)	24.7	(6.9, 92.1)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 27FEB2024

Table PT2URPT_FSTM: Time to partial remission by subgroup
Full Analysis Set

Time to partial remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline BMI	Sparsentan						Interaction test:	0.996	
< 27 kg/m**2	Sparsentan	83	71 (85.5)	4.6	(4.1, 8.0)	2.542	(1.757, 3.677)	<0.001	*
	Irbesartan	94	55 (58.5)	46.1	(24.0, 92.1)				
>= 27 kg/m**2	Sparsentan	119	86 (72.3)	12.0	(6.1, 25.1)	2.900	(2.025, 4.152)	<0.001	*
	Irbesartan	107	50 (46.7)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 27FEB2024

Table PT2URPT_FSTM: Time to partial remission by subgroup
Full Analysis Set

Time to partial remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Randomization strata	Sparsentan						Interaction test:	0.965	
eGFR Low and UP High	Sparsentan	71	42 (59.2)	67.3	(25.1, NE)	2.454	(1.475, 4.083)	<0.001	*
	Irbesartan	74	23 (31.1)	NE					
eGFR Low and UP Low	Sparsentan	55	50 (90.9)	4.3	(4.1, 4.7)	2.378	(1.550, 3.649)	<0.001	*
	Irbesartan	55	41 (74.5)	12.1	(4.9, 35.7)				
eGFR High and UP High	Sparsentan	37	27 (73.0)	24.1	(8.0, 69.3)	3.193	(1.628, 6.263)	<0.001	*
	Irbesartan	36	13 (36.1)	NE					
eGFR High and UP Low	Sparsentan	39	38 (97.4)	4.1	(4.1, 4.4)	2.641	(1.590, 4.387)	<0.001	*
	Irbesartan	37	29 (78.4)	12.1	(6.1, 26.1)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 27FEB2024

Table PT2URPT_FSTM: Time to partial remission by subgroup
Full Analysis Set

Time to partial remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.318	
< 60 mL/min/1.73 m**2	Sparsentan	127	94 (74.0)	12.0	(6.0, 23.7)	2.531	(1.817, 3.526)	<0.001	*
	Irbesartan	129	64 (49.6)	70.9	(40.7, NE)				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	40 (81.6)	6.1	(4.6, 22.6)	3.982	(2.227, 7.119)	<0.001	*
	Irbesartan	48	22 (45.8)	NE					
>= 90 mL/min/1.73 m**2	Sparsentan	26	23 (88.5)	4.1	(4.1, 12.1)	1.760	(0.940, 3.294)	0.077	
	Irbesartan	25	20 (80.0)	17.4	(4.6, 36.3)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 27FEB2024

Table PT2URPT_FSTM: Time to partial remission by subgroup
Full Analysis Set

Time to partial remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eGFR Group 2	Sparsentan						Interaction test:	0.173	
< 45 mL/min/1.73 m**2	Sparsentan	82	56 (68.3)	12.4	(6.1, 48.6)	2.105	(1.390, 3.187)	<0.001	*
	Irbesartan	80	39 (48.8)	81.1	(36.0, NE)				
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	38 (84.4)	5.4	(4.1, 12.7)	3.810	(2.126, 6.829)	<0.001	*
	Irbesartan	49	25 (51.0)	68.6	(24.1, NE)				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	40 (81.6)	6.1	(4.6, 22.6)	3.982	(2.227, 7.119)	<0.001	*
	Irbesartan	48	22 (45.8)	NE					
>= 90 mL/min/1.73 m**2	Sparsentan	26	23 (88.5)	4.1	(4.1, 12.1)	1.760	(0.940, 3.294)	0.077	
	Irbesartan	25	20 (80.0)	17.4	(4.6, 36.3)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 27FEB2024

Table PT2URPT_FSTM: Time to partial remission by subgroup
Full Analysis Set

Time to partial remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline urine protein excretion	Sparsentan						Interaction test:	0.486	
<= 1.75 g/day	Sparsentan	98	89 (90.8)	4.3	(4.1, 4.7)	2.165	(1.567, 2.991)	<0.001	*
	Irbesartan	93	68 (73.1)	12.1	(6.1, 26.1)				
> 1.75 g/day	Sparsentan	104	68 (65.4)	36.1	(22.6, 69.3)	3.227	(2.117, 4.918)	<0.001	*
	Irbesartan	109	38 (34.9)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 27FEB2024

Table PT2URPT_FSTM: Time to partial remission by subgroup
Full Analysis Set

Time to partial remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.118	
Yes	Sparsentan	90	69 (76.7)	7.6	(6.0, 23.7)	3.498	(2.326, 5.259)	<0.001	*
	Irbesartan	88	46 (52.3)	70.0	(47.6, NE)				
No	Sparsentan	112	88 (78.6)	6.1	(4.7, 12.7)	2.146	(1.533, 3.004)	<0.001	*
	Irbesartan	114	60 (52.6)	59.6	(26.1, NE)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 27FEB2024

Table PT2URPT_FSTM: Time to partial remission by subgroup
Full Analysis Set

Time to partial remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Time since renal biopsy	Sparsentan						Interaction test:	0.132	
<= 5 years	Sparsentan	113	90 (79.6)	7.1	(5.0, 13.3)	2.387	(1.739, 3.275)	<0.001	*
	Irbesartan	127	74 (58.3)	46.1	(25.6, 70.0)				
> 5 years	Sparsentan	89	67 (75.3)	6.5	(4.7, 12.7)	3.384	(2.181, 5.250)	<0.001	*
	Irbesartan	75	32 (42.7)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 27FEB2024

Table PT2URPT_FSTM: Time to partial remission by subgroup
Full Analysis Set

Time to partial remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
History of hypertension	Sparsentan						Interaction test:	0.550	
Yes	Sparsentan	155	122 (78.7)	7.6	(6.0, 13.1)	2.977	(2.222, 3.989)	<0.001	*
	Irbesartan	161	80 (49.7)	70.6	(47.6, NE)				
No	Sparsentan	47	35 (74.5)	4.4	(4.1, 22.6)	1.989	(1.169, 3.384)	0.011	*
	Irbesartan	41	26 (63.4)	41.6	(6.9, 92.1)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 27FEB2024

Figure PF2URPT_FSKM: Time to partial remission by subgroup
Full Analysis Set

Not done. No significant subgroups.

_____
Partial remission means an urinary protein excretion of <1.0 g/day. No event means no partial remission.
eGFR = estimated glomerular filtration rate.
Reference table: PT2URPT_FSTM

Table PT2URF_FSPM: Patients with complete remission by subgroup
Full Analysis Set

Complete remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Sex	Week 58	Sparsentan						Interaction test:	0.886	
	Week 110	Sparsentan						Interaction test:	0.687	
Male	Week 58	Sparsentan	139	129 (92.8)	20 (15.5)	3.938 [1.525, 10.171]	4.477 [1.625, 12.335]	11.6 [3.7, 19.5]	0.003	*
		Irbesartan	143	127 (88.8)	5 (3.9)					
	Week 110	Sparsentan	139	116 (83.5)	17 (14.7)	5.276 [1.591, 17.500]	6.010 [1.709, 21.140]	11.9 [3.8, 19.9]	0.002	*
		Irbesartan	143	108 (75.5)	3 (2.8)					
Female	Week 58	Sparsentan	63	59 (93.7)	8 (13.6)	3.458 [0.769, 15.550]	3.843 [0.777, 19.003]	9.6 [-2.4, 21.7]	0.103	
		Irbesartan	59	51 (86.4)	2 (3.9)					
	Week 110	Sparsentan	63	53 (84.1)	9 (17.0)	3.566 [0.814, 15.630]	4.091 [0.834, 20.078]	12.2 [-1.9, 26.3]	0.105	
		Irbesartan	59	42 (71.2)	2 (4.8)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Complete remission means an urinary protein excretion of <0.3 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URF_FSPM: Patients with complete remission by subgroup
Full Analysis Set

Complete remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Age	Week 58	Sparsentan						Interaction test:	0.391	
	Week 110	Sparsentan						Interaction test:	0.762	
<= 45 years	Week 58	Sparsentan	96	89 (92.7)	13 (14.6)	6.135 [1.427, 26.378]	7.013 [1.532, 32.100]	12.2 [3.0, 21.4]	0.005	*
		Irbesartan	99	84 (84.8)	2 (2.4)					
	Week 110	Sparsentan	96	76 (79.2)	12 (15.8)	5.447 [1.264, 23.481]	6.281 [1.352, 29.172]	12.9 [2.4, 23.4]	0.010	*
		Irbesartan	99	69 (69.7)	2 (2.9)					
> 45 years	Week 58	Sparsentan	106	99 (93.4)	15 (15.2)	2.848 [1.078, 7.529]	3.179 [1.107, 9.130]	9.8 [0.4, 19.3]	0.033	*
		Irbesartan	103	94 (91.3)	5 (5.3)					
	Week 110	Sparsentan	106	93 (87.7)	14 (15.1)	4.065 [1.211, 13.642]	4.608 [1.274, 16.665]	11.4 [1.8, 20.9]	0.019	*
		Irbesartan	103	81 (78.6)	3 (3.7)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Complete remission means an urinary protein excretion of <0.3 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URF_FSPM: Patients with complete remission by subgroup
Full Analysis Set

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Complete remission										
Age at IgAN diagnosis	Week 58	Sparsentan						Interaction test:	0.586	
	Week 110	Sparsentan						Interaction test:	0.889	
<= 18 years	Week 58	Sparsentan	9	7 (77.8)	1 (14.3)	1.875 + [0.093, 37.632]	2.077 + [0.068, 63.417]	14.3 [-31.3, 59.9]	1.000	
		Irbesartan	5	4 (80.0)	0 (0.0)					
	Week 110	Sparsentan	9	5 (55.6)	1 (20.0)	2.500 + [0.128, 48.848]	3.000 + [0.095, 95.170]	20.0 [-37.6, 77.6]	1.000	
		Irbesartan	5	4 (80.0)	0 (0.0)					
> 18 to 40 years	Week 58	Sparsentan	102	95 (93.1)	13 (13.7)	6.295 [1.461, 27.127]	7.134 [1.563, 32.569]	11.5 [2.9, 20.1]	0.005	*
		Irbesartan	109	92 (84.4)	2 (2.2)					
	Week 110	Sparsentan	102	82 (80.4)	11 (13.4)	5.299 [1.213, 23.152]	5.965 [1.278, 27.845]	10.9 [1.5, 20.3]	0.018	*
		Irbesartan	109	79 (72.5)	2 (2.5)					
> 40 years	Week 58	Sparsentan	91	86 (94.5)	14 (16.3)	2.670 [1.007, 7.080]	2.994 [1.027, 8.734]	10.2 [-0.4, 20.7]	0.050	
		Irbesartan	88	82 (93.2)	5 (6.1)					
	Week 110	Sparsentan	91	82 (90.1)	14 (17.1)	3.813 [1.143, 12.716]	4.392 [1.206, 16.001]	12.6 [1.7, 23.5]	0.019	*
		Irbesartan	88	67 (76.1)	3 (4.5)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Complete remission means an urinary protein excretion of <0.3 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URF_FSPM: Patients with complete remission by subgroup
Full Analysis Set

Complete remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Geographic region	Week 58	Sparsentan						Interaction test:	0.631	
	Week 110	Sparsentan						Interaction test:	0.418	
North America	Week 58	Sparsentan	35	28 (80.0)	2 (7.1)	7.069 + [0.352, 141.826]	7.642 + [0.353, 165.537]	7.1 [-5.4, 19.7]	0.166	
		Irbesartan	46	40 (87.0)	0 (0.0)					
	Week 110	Sparsentan	35	27 (77.1)	4 (14.8)	10.286 + [0.579, 182.754]	12.064 + [0.619, 235.190]	14.8 [-2.0, 31.7]	0.041	*
		Irbesartan	46	31 (67.4)	0 (0.0)					
Europe	Week 58	Sparsentan	98	93 (94.9)	11 (11.8)	3.943 [1.135, 13.692]	4.337 [1.170, 16.076]	8.8 [0.4, 17.2]	0.025	*
		Irbesartan	115	100 (87.0)	3 (3.0)					
	Week 110	Sparsentan	98	80 (81.6)	11 (13.8)	2.420 [0.879, 6.663]	2.646 [0.877, 7.984]	8.1 [-2.1, 18.2]	0.113	
		Irbesartan	115	88 (76.5)	5 (5.7)					
Asia Pacific	Week 58	Sparsentan	69	67 (97.1)	15 (22.4)	2.127 [0.760, 5.949]	2.452 [0.750, 8.016]	11.9 [-4.2, 27.9]	0.188	
		Irbesartan	41	38 (92.7)	4 (10.5)					
	Week 110	Sparsentan	69	62 (89.9)	11 (17.7)	11.683 + [0.711, 191.976]	14.068 + [0.801, 247.107]	17.7 [5.8, 29.7]	0.014	*
		Irbesartan	41	31 (75.6)	0 (0.0)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Complete remission means an urinary protein excretion of <0.3 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URF_FSPM: Patients with complete remission by subgroup
Full Analysis Set

Complete remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline BMI	Week 58	Sparsentan						Interaction test:	0.092	
	Week 110	Sparsentan						Interaction test:	0.766	
< 27 kg/m**2	Week 58	Sparsentan	83	76 (91.6)	17 (22.4)	8.836 [2.112, 36.955]	11.093 [2.466, 49.910]	19.8 [8.6, 31.1]	<0.001	*
		Irbesartan	94	79 (84.0)	2 (2.5)					
	Week 110	Sparsentan	83	70 (84.3)	13 (18.6)	4.086 [1.219, 13.695]	4.789 [1.298, 17.671]	14.0 [2.2, 25.9]	0.015	*
		Irbesartan	94	66 (70.2)	3 (4.5)					
>= 27 kg/m**2	Week 58	Sparsentan	119	112 (94.1)	11 (9.8)	1.945 [0.700, 5.403]	2.048 [0.686, 6.113]	4.8 [-3.2, 12.7]	0.297	
		Irbesartan	107	99 (92.5)	5 (5.1)					
	Week 110	Sparsentan	119	99 (83.2)	13 (13.1)	5.449 [1.266, 23.462]	6.122 [1.340, 27.972]	10.7 [2.2, 19.3]	0.013	*
		Irbesartan	107	83 (77.6)	2 (2.4)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Complete remission means an urinary protein excretion of <0.3 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URF_FSPM: Patients with complete remission by subgroup
Full Analysis Set

Complete remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Randomization strata	Week 58	Sparsentan						Interaction test:	0.688	
	Week 110	Sparsentan						Interaction test:	0.547	
eGFR Low and UP High	Week 58	Sparsentan	71	67 (94.4)	2 (3.0)	1.910 [0.178, 20.557]	1.938 [0.171, 21.916]	1.4 [-5.2, 8.0]	1.000	
		Irbesartan	74	64 (86.5)	1 (1.6)					
	Week 110	Sparsentan	71	59 (83.1)	4 (6.8)	1.831 [0.349, 9.596]	1.891 [0.332, 10.765]	3.1 [-6.9, 13.0]	0.681	
		Irbesartan	74	54 (73.0)	2 (3.7)					
eGFR Low and UP Low	Week 58	Sparsentan	55	52 (94.5)	10 (19.2)	2.452 [0.822, 7.317]	2.798 [0.816, 9.590]	11.4 [-3.6, 26.3]	0.149	
		Irbesartan	55	51 (92.7)	4 (7.8)					
	Week 110	Sparsentan	55	46 (83.6)	9 (19.6)	2.739 [0.794, 9.445]	3.162 [0.794, 12.593]	12.4 [-3.7, 28.6]	0.123	
		Irbesartan	55	42 (76.4)	3 (7.1)					
eGFR High and UP High	Week 58	Sparsentan	37	32 (86.5)	6 (18.8)	12.606 + [0.740, 214.695]	15.453 + [0.831, 287.224]	18.8 [2.1, 35.4]	0.024	*
		Irbesartan	36	31 (86.1)	0 (0.0)					
	Week 110	Sparsentan	37	30 (81.1)	5 (16.7)	9.935 + [0.575, 171.695]	11.863 + [0.624, 225.468]	16.7 [-0.2, 33.5]	0.053	
		Irbesartan	36	27 (75.0)	0 (0.0)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Complete remission means an urinary protein excretion of <0.3 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URF_FSPM: Patients with complete remission by subgroup
Full Analysis Set

Complete remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
eGFR High and UP Low	Week 58	Sparsentan	39	37 (94.9)	10 (27.0)	4.324 [1.022, 18.299]	5.556 [1.116, 27.648]	20.8 [1.3, 40.3]	0.028	*
		Irbesartan	37	32 (86.5)	2 (6.3)					
	Week 110	Sparsentan	39	34 (87.2)	8 (23.5)	13.600 + [0.820, 225.566]	17.642 + [0.969, 321.145]	23.5 [5.9, 41.1]	0.007	*
		Irbesartan	37	27 (73.0)	0 (0.0)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Complete remission means an urinary protein excretion of <0.3 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URF_FSPM: Patients with complete remission by subgroup
Full Analysis Set

Complete remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eGFR Group 1	Week 58	Sparsentan						Interaction test:	0.361	
	Week 110	Sparsentan						Interaction test:	0.320	
< 60 mL/min/1.73 m**2	Week 58	Sparsentan	127	120 (94.5)	12 (10.0)	2.300 [0.837, 6.324]	2.444 [0.833, 7.173]	5.7 [-1.7, 13.0]	0.130	
		Irbesartan	129	115 (89.1)	5 (4.3)					
	Week 110	Sparsentan	127	105 (82.7)	12 (11.4)	2.217 [0.811, 6.064]	2.374 [0.804, 7.008]	6.3 [-2.2, 14.8]	0.132	
		Irbesartan	129	97 (75.2)	5 (5.2)					
60 to < 90 mL/min/1.73 m**2	Week 58	Sparsentan	49	43 (87.8)	12 (27.9)	11.721 [1.594, 86.191]	15.871 [1.958, 128.656]	25.5 [9.0, 42.1]	0.002	*
		Irbesartan	48	42 (87.5)	1 (2.4)					
	Week 110	Sparsentan	49	43 (87.8)	9 (20.9)	15.977 + [0.962, 265.384]	20.101 + [1.127, 358.682]	20.9 [6.2, 35.6]	0.003	*
		Irbesartan	48	36 (75.0)	0 (0.0)					
>= 90 mL/min/1.73 m**2	Week 58	Sparsentan	26	25 (96.2)	4 (16.0)	3.360 [0.406, 27.800]	3.810 [0.392, 37.068]	11.2 [-10.2, 32.6]	0.357	
		Irbesartan	25	21 (84.0)	1 (4.8)					
	Week 110	Sparsentan	26	21 (80.8)	5 (23.8)	9.000 + [0.533, 152.090]	11.667 + [0.597, 227.896]	23.8 [0.3, 47.3]	0.053	
		Irbesartan	25	17 (68.0)	0 (0.0)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Complete remission means an urinary protein excretion of <0.3 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URF_FSPM: Patients with complete remission by subgroup
Full Analysis Set

Complete remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eGFR Group 2	Week 58	Sparsentan						Interaction test:	0.356	
	Week 110	Sparsentan						Interaction test:	NE	
< 45 mL/min/1.73 m**2	Week 58	Sparsentan	82	77 (93.9)	7 (9.1)	1.568 [0.480, 5.128]	1.625 [0.455, 5.810]	3.3 [-6.5, 13.1]	0.540	
		Irbesartan	80	69 (86.3)	4 (5.8)					
	Week 110	Sparsentan	82	67 (81.7)	7 (10.4)	all n<10			NE	
		Irbesartan	80	59 (73.8)	2 (3.4)					
45 to < 60 mL/min/1.73 m**2	Week 58	Sparsentan	45	43 (95.6)	5 (11.6)	5.349 [0.651, 43.960]	5.921 [0.663, 52.907]	9.5 [-3.3, 22.2]	0.103	
		Irbesartan	49	46 (93.9)	1 (2.2)					
	Week 110	Sparsentan	45	38 (84.4)	5 (13.2)	all n<10			NE	
		Irbesartan	49	38 (77.6)	3 (7.9)					
60 to < 90 mL/min/1.73 m**2	Week 58	Sparsentan	49	43 (87.8)	12 (27.9)	11.721 [1.594, 86.191]	15.871 [1.958, 128.656]	25.5 [9.0, 42.1]	0.002	*
		Irbesartan	48	42 (87.5)	1 (2.4)					
	Week 110	Sparsentan	49	43 (87.8)	9 (20.9)	all n<10			NE	
		Irbesartan	48	36 (75.0)	0 (0.0)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Complete remission means an urinary protein excretion of <0.3 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URF_FSPM: Patients with complete remission by subgroup
Full Analysis Set

Complete remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
>= 90 mL/min/1.73 m**2	Week 58	Sparsentan	26	25 (96.2)	4 (16.0)	3.360 [0.406, 27.800]	3.810 [0.392, 37.068]	11.2 [-10.2, 32.6]	0.357
		Irbesartan	25	21 (84.0)	1 (4.8)				
	Week 110	Sparsentan	26	21 (80.8)	5 (23.8)	all n<10			NE
		Irbesartan	25	17 (68.0)	0 (0.0)				

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Complete remission means an urinary protein excretion of <0.3 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URF_FSPM: Patients with complete remission by subgroup
Full Analysis Set

Complete remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline urine protein excretion	Week 58	Sparsentan						Interaction test:	0.469	
	Week 110	Sparsentan						Interaction test:	0.930	
<= 1.75 g/day	Week 58	Sparsentan	98	93 (94.9)	21 (22.6)	3.086 [1.309, 7.273]	3.694 [1.411, 9.676]	15.3 [3.9, 26.6]	0.006	*
		Irbesartan	93	82 (88.2)	6 (7.3)					
	Week 110	Sparsentan	98	85 (86.7)	17 (20.0)	4.667 [1.426, 15.277]	5.583 [1.563, 19.939]	15.7 [4.7, 26.8]	0.004	*
		Irbesartan	93	70 (75.3)	3 (4.3)					
> 1.75 g/day	Week 58	Sparsentan	104	95 (91.3)	7 (7.4)	7.074 [0.887, 56.395]	7.557 [0.911, 62.659]	6.3 [-0.4, 13.0]	0.035	*
		Irbesartan	109	96 (88.1)	1 (1.0)					
	Week 110	Sparsentan	104	84 (80.8)	9 (10.7)	4.286 [0.955, 19.232]	4.680 [0.979, 22.374]	8.2 [-0.5, 16.9]	0.057	
		Irbesartan	109	80 (73.4)	2 (2.5)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Complete remission means an urinary protein excretion of <0.3 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URF_FSPM: Patients with complete remission by subgroup
Full Analysis Set

Subgroup	Time	Treatment	N	Complete remission nval (%)	Complete remission n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline use of antihypertensives	Week 58	Sparsentan						Interaction test:	0.048	#
	Week 110	Sparsentan						Interaction test:	0.405	
Yes	Week 58	Sparsentan	90	83 (92.2)	8 (9.6)	1.542 [0.527, 4.515]	1.600 [0.500, 5.116]	3.4 [-6.1, 12.9]	0.566	
		Irbesartan	88	80 (90.9)	5 (6.3)					
	Week 110	Sparsentan	90	75 (83.3)	10 (13.3)	3.067 [0.880, 10.683]	3.385 [0.891, 12.860]	9.0 [-1.5, 19.5]	0.081	
		Irbesartan	88	69 (78.4)	3 (4.3)					
No	Week 58	Sparsentan	112	105 (93.8)	20 (19.0)	9.333 [2.240, 38.894]	11.294 [2.564, 49.742]	17.0 [8.0, 26.0]	<0.001	*
		Irbesartan	114	98 (86.0)	2 (2.0)					
	Week 110	Sparsentan	112	94 (83.9)	16 (17.0)	6.894 [1.634, 29.085]	8.103 [1.803, 36.418]	14.6 [5.1, 24.0]	0.002	*
		Irbesartan	114	81 (71.1)	2 (2.5)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Complete remission means an urinary protein excretion of <0.3 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URF_FSPM: Patients with complete remission by subgroup
Full Analysis Set

Subgroup	Time	Treatment	N	Complete remission nval (%)	Complete remission n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Time since renal biopsy	Week 58	Sparsentan						Interaction test:	0.402	
	Week 110	Sparsentan						Interaction test:	0.548	
<= 5 years	Week 58	Sparsentan	113	104 (92.0)	17 (16.3)	3.160 [1.295, 7.713]	3.582 [1.355, 9.471]	11.2 [2.1, 20.3]	0.008	*
		Irbesartan	127	116 (91.3)	6 (5.2)					
	Week 110	Sparsentan	113	96 (85.0)	16 (16.7)	3.875 [1.345, 11.161]	4.450 [1.428, 13.866]	12.4 [2.8, 21.9]	0.008	*
		Irbesartan	127	93 (73.2)	4 (4.3)					
> 5 years	Week 58	Sparsentan	89	84 (94.4)	11 (13.1)	8.119 [1.076, 61.243]	9.192 [1.154, 73.220]	11.5 [2.2, 20.8]	0.014	*
		Irbesartan	75	62 (82.7)	1 (1.6)					
	Week 110	Sparsentan	89	73 (82.0)	10 (13.7)	7.808 [1.029, 59.228]	8.889 [1.103, 71.644]	11.9 [1.8, 22.1]	0.023	*
		Irbesartan	75	57 (76.0)	1 (1.8)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Complete remission means an urinary protein excretion of <0.3 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URF_FSPM: Patients with complete remission by subgroup
Full Analysis Set

Complete remission

Subgroup	Time	Treatment	N	nval (%)	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
History of hypertension	Week 58	Sparsentan						Interaction test:	0.152	
	Week 110	Sparsentan						Interaction test:	0.555	
Yes	Week 58	Sparsentan	155	145 (93.5)	16 (11.0)	2.286 [0.969, 5.390]	2.445 [0.974, 6.136]	6.2 [-0.7, 13.1]	0.080	
		Irbesartan	161	145 (90.1)	7 (4.8)					
	Week 110	Sparsentan	155	131 (84.5)	16 (12.2)	3.725 [1.281, 10.834]	4.104 [1.332, 12.647]	8.9 [1.7, 16.2]	0.010	*
		Irbesartan	161	122 (75.8)	4 (3.3)					
No	Week 58	Sparsentan	47	43 (91.5)	12 (27.9)	19.318 + [1.185, 314.849]	26.587 + [1.510, 468.101]	27.9 [11.8, 44.0]	<0.001	*
		Irbesartan	41	33 (80.5)	0 (0.0)					
	Week 110	Sparsentan	47	38 (80.9)	10 (26.3)	7.368 [1.000, 54.273]	9.643 [1.155, 80.538]	22.7 [4.0, 41.4]	0.018	*
		Irbesartan	41	28 (68.3)	1 (3.6)					

95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method). Percentages are based on number of evaluable values.
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
Complete remission means an urinary protein excretion of <0.3 g/day.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2URFT_FSTM: Time to complete remission by subgroup
Full Analysis Set

Time to complete remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Sex	Sparsentan						Interaction test:	0.358	
Male	Sparsentan	139	40 (28.8)	NE		3.837	(2.080, 7.077)	<0.001	*
	Irbesartan	143	14 (9.8)	NE					
Female	Sparsentan	63	22 (34.9)	111.4	(109.9, NE)	2.677	(1.213, 5.905)	0.015	*
	Irbesartan	59	9 (15.3)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 27FEB2024

Table PT2URFT_FSTM: Time to complete remission by subgroup
Full Analysis Set

Time to complete remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Age	Sparsentan						Interaction test:	0.890	
<= 45 years	Sparsentan	96	34 (35.4)	NE		3.268	(1.718, 6.218)	<0.001	*
	Irbesartan	99	13 (13.1)	NE					
> 45 years	Sparsentan	106	28 (26.4)	112.3	(112.3, NE)	3.147	(1.526, 6.491)	0.002	*
	Irbesartan	103	10 (9.7)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 27FEB2024

Table PT2URFT_FSTM: Time to complete remission by subgroup
Full Analysis Set

Time to complete remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Age at IgAN diagnosis	Sparsentan						Interaction test:	0.636	
<= 18 years	Sparsentan	9	1 (11.1)	NE		NE		NE	
	Irbesartan	5	1 (20.0)	NE					
> 18 to 40 years	Sparsentan	102	35 (34.3)	112.3	(111.4, NE)	3.545	(1.855, 6.774)	<0.001	*
	Irbesartan	109	13 (11.9)	NE					
> 40 years	Sparsentan	91	26 (28.6)	NE		3.159	(1.474, 6.770)	0.003	*
	Irbesartan	88	9 (10.2)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 27FEB2024

Table PT2URFT_FSTM: Time to complete remission by subgroup
Full Analysis Set

Time to complete remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Geographic region	Sparsentan						Interaction test:	0.393	
North America	Sparsentan	35	9 (25.7)	NE		3.676	(0.984, 13.731)	0.053	
	Irbesartan	46	3 (6.5)	NE					
Europe	Sparsentan	98	30 (30.6)	112.3	(111.4, 112.3)	4.387	(2.208, 8.719)	<0.001	*
	Irbesartan	115	12 (10.4)	NE					
Asia Pacific	Sparsentan	69	23 (33.3)	NE		2.081	(0.926, 4.674)	0.076	
	Irbesartan	41	8 (19.5)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 27FEB2024

Table PT2URFT_FSTM: Time to complete remission by subgroup
Full Analysis Set

Time to complete remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline BMI	Sparsentan						Interaction test:	0.755	
< 27 kg/m**2	Sparsentan	83	31 (37.3)	112.3	(104.4, NE)	3.309	(1.688, 6.488)	<0.001	*
	Irbesartan	94	12 (12.8)	NE					
>= 27 kg/m**2	Sparsentan	119	31 (26.1)	NE		3.126	(1.528, 6.395)	0.002	*
	Irbesartan	107	10 (9.3)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 27FEB2024

Table PT2URFT_FSTM: Time to complete remission by subgroup
Full Analysis Set

Time to complete remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Randomization strata	Sparsentan						Interaction test:	0.644	
eGFR Low and UP High	Sparsentan	71	10 (14.1)	112.3	(112.3, NE)	2.676	(0.830, 8.620)	0.099	
	Irbesartan	74	4 (5.4)	NE					
eGFR Low and UP Low	Sparsentan	55	22 (40.0)	111.4	(82.1, NE)	2.777	(1.313, 5.873)	0.008	*
	Irbesartan	55	10 (18.2)	NE					
eGFR High and UP High	Sparsentan	37	9 (24.3)	NE		9.656	(1.213, 76.871)	0.032	*
	Irbesartan	36	1 (2.8)	NE					
eGFR High and UP Low	Sparsentan	39	21 (53.8)	70.1	(47.7, NE)	2.848	(1.252, 6.478)	0.013	*
	Irbesartan	37	8 (21.6)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 27FEB2024

Table PT2URFT_FSTM: Time to complete remission by subgroup
Full Analysis Set

Time to complete remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.030	#
< 60 mL/min/1.73 m**2	Sparsentan	127	31 (24.4)	112.3	(112.3, NE)	2.506	(1.328, 4.728)	0.005	*
	Irbesartan	129	14 (10.9)	NE					
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	19 (38.8)	NE		13.934	(2.615, 74.264)	0.002	*
	Irbesartan	48	2 (4.2)	NE					
>= 90 mL/min/1.73 m**2	Sparsentan	26	12 (46.2)	NE		1.718	(0.674, 4.383)	0.257	
	Irbesartan	25	7 (28.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 27FEB2024

Table PT2URFT_FSTM: Time to complete remission by subgroup
Full Analysis Set

Time to complete remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eGFR Group 2	Sparsentan						Interaction test:	0.033	#
< 45 mL/min/1.73 m**2	Sparsentan	82	17 (20.7)	112.3	(111.4, NE)	1.891	(0.842, 4.247)	0.123	
	Irbesartan	80	9 (11.3)	NE					
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	14 (31.1)	NE		3.980	(1.407, 11.260)	0.009	*
	Irbesartan	49	5 (10.2)	NE					
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	19 (38.8)	NE		13.934	(2.615, 74.264)	0.002	*
	Irbesartan	48	2 (4.2)	NE					
>= 90 mL/min/1.73 m**2	Sparsentan	26	12 (46.2)	NE		1.718	(0.674, 4.383)	0.257	
	Irbesartan	25	7 (28.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 27FEB2024

Table PT2URFT_FSTM: Time to complete remission by subgroup
Full Analysis Set

Time to complete remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline urine protein excretion	Sparsentan						Interaction test:	0.560	
<= 1.75 g/day	Sparsentan	98	44 (44.9)	111.4	(70.1, NE)	2.891	(1.669, 5.006)	<0.001	*
	Irbesartan	93	18 (19.4)	NE					
> 1.75 g/day	Sparsentan	104	18 (17.3)	112.3	(112.3, NE)	4.367	(1.590, 11.997)	0.004	*
	Irbesartan	109	5 (4.6)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 27FEB2024

Table PT2URFT_FSTM: Time to complete remission by subgroup
Full Analysis Set

Time to complete remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.279	
Yes	Sparsentan	90	21 (23.3)	NE		2.284	(1.069, 4.877)	0.033	*
	Irbesartan	88	10 (11.4)	NE					
No	Sparsentan	112	41 (36.6)	112.3	(111.4, NE)	3.867	(2.048, 7.303)	<0.001	*
	Irbesartan	114	13 (11.4)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 27FEB2024

Table PT2URFT_FSTM: Time to complete remission by subgroup
Full Analysis Set

Time to complete remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Time since renal biopsy	Sparsentan						Interaction test:	0.512	
<= 5 years	Sparsentan	113	39 (34.5)	NE		2.985	(1.703, 5.232)	<0.001	*
	Irbesartan	127	18 (14.2)	NE					
> 5 years	Sparsentan	89	23 (25.8)	112.3	(111.4, 112.3)	4.838	(1.767, 13.248)	0.002	*
	Irbesartan	75	5 (6.7)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 27FEB2024

Table PT2URFT_FSTM: Time to complete remission by subgroup
Full Analysis Set

Time to complete remission				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
History of hypertension	Sparsentan						Interaction test:	0.429	
Yes	Sparsentan	155	44 (28.4)	NE		3.676	(2.013, 6.713)	<0.001	*
	Irbesartan	161	14 (8.7)	NE					
No	Sparsentan	47	18 (38.3)	111.4	(60.0, NE)	2.255	(0.997, 5.100)	0.051	
	Irbesartan	41	9 (22.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate. Baseline was omitted for subgroup Baseline protein excretion.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb_tte, created on: 27FEB2024

Figure PF2URFT_FSKM: Time to complete remission by subgroup
Full Analysis Set

Study: PROTECT
Baseline eGFR Group 1: < 60 mL/min/1.73 m**2



Sparsentan	127	115	105	100	93	88
Irbesartan	129	128	119	111	101	96

_____
Complete remission means an urinary protein excretion of <0.3 g/day. No event means no complete remission.
eGFR = estimated glomerular filtration rate.
Reference table: PT2URFT_FSTM

Figure PF2URFT_FSKM: Time to complete remission by subgroup
Full Analysis Set

Study: PROTECT
Baseline eGFR Group 1: 60 to < 90 mL/min/1.73 m**2



Sparsentan	49	37	35	29	29	26
Irbesartan	48	46	44	43	40	37

_____
Complete remission means an urinary protein excretion of <0.3 g/day. No event means no complete remission.
eGFR = estimated glomerular filtration rate.
Reference table: PT2URFT_FSTM

Figure PF2URFT_FSKM: Time to complete remission by subgroup
Full Analysis Set

Study: PROTECT
Baseline eGFR Group 1: >= 90 mL/min/1.73 m**2



Sparsentan	26	23	21	18	15	13
Irbesartan	25	24	18	18	15	15

_____
Complete remission means an urinary protein excretion of <0.3 g/day. No event means no complete remission.
eGFR = estimated glomerular filtration rate.
Reference table: PT2URFT_FSTM

Figure PF2URFT_FSKM: Time to complete remission by subgroup
Full Analysis Set

Study: PROTECT
Baseline eGFR Group 2: < 45 mL/min/1.73 m**2



Sparsentan	82	77	72	68	62	60
Irbesartan	80	79	72	67	59	57

_____
Complete remission means an urinary protein excretion of <0.3 g/day. No event means no complete remission.
eGFR = estimated glomerular filtration rate.
Reference table: PT2URFT_FSTM

Figure PF2URFT_FSKM: Time to complete remission by subgroup
Full Analysis Set

Study: PROTECT
Baseline eGFR Group 2: 45 to < 60 mL/min/1.73 m**2



Sparsentan	45	38	33	32	31	28
Irbesartan	49	49	47	44	42	39

_____
Complete remission means an urinary protein excretion of <0.3 g/day. No event means no complete remission.
eGFR = estimated glomerular filtration rate.
Reference table: PT2URFT_FSTM

Figure PF2URFT_FSKM: Time to complete remission by subgroup
Full Analysis Set

Study: PROTECT
Baseline eGFR Group 2: 60 to < 90 mL/min/1.73 m**2



Sparsentan	49	37	35	29	29	26
Irbesartan	48	46	44	43	40	37

_____
Complete remission means an urinary protein excretion of <0.3 g/day. No event means no complete remission.
eGFR = estimated glomerular filtration rate.
Reference table: PT2URFT_FSTM

Figure PF2URFT_FSKM: Time to complete remission by subgroup
Full Analysis Set

Study: PROTECT
Baseline eGFR Group 2: >= 90 mL/min/1.73 m**2



Sparsentan	26	23	21	18	15	13
Irbesartan	25	24	18	18	15	15

_____
Complete remission means an urinary protein excretion of <0.3 g/day. No event means no complete remission.
eGFR = estimated glomerular filtration rate.
Reference table: PT2URFT_FSTM

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	eGFR	Baseline	Sparsentan	139	139 (100.0)	53.42 (22.51)	25.0	36.00	45.00	66.00	126.0	
			Irbesartan	143	143 (100.0)	57.02 (23.53)	26.0	38.00	50.00	70.00	123.0	
		Week 6	Sparsentan	139	134 (96.4)	52.42 (22.36)	21.0	35.00	47.50	65.00	121.0	
			Irbesartan	143	139 (97.2)	55.72 (23.29)	21.0	37.00	50.00	70.00	120.0	
		Week 36	Sparsentan	139	135 (97.1)	50.21 (21.52)	18.0	34.00	46.00	63.00	123.0	
			Irbesartan	143	130 (90.9)	53.07 (24.76)	7.0	34.00	48.00	66.00	125.0	
		Week 58	Sparsentan	139	127 (91.4)	50.13 (23.00)	13.0	33.00	44.00	64.00	127.0	
			Irbesartan	143	124 (86.7)	50.98 (23.81)	11.0	33.00	46.00	69.00	122.0	
		Week 110	Sparsentan	139	117 (84.2)	47.26 (23.76)	14.0	30.00	42.00	60.00	126.0	
			Irbesartan	143	111 (77.6)	44.68 (24.71)	11.0	26.00	38.00	61.00	123.0	
	Change from baseline in eGFR	Week 6	Sparsentan	139	134 (96.4)	-0.88 (6.68)	-27.0	-4.00	-1.00	2.00	20.0	0.05 [-0.19, 0.28]
			Irbesartan	143	139 (97.2)	-1.18 (6.62)	-31.0	-5.00	-1.00	2.00	20.0	
		Week 36	Sparsentan	139	135 (97.1)	-3.28 (7.75)	-30.0	-8.00	-3.00	1.00	26.0	0.08 [-0.16, 0.32]
			Irbesartan	143	130 (90.9)	-3.98 (8.96)	-32.0	-8.00	-4.00	1.00	33.0	
		Week 58	Sparsentan	139	127 (91.4)	-3.25 (8.60)	-33.0	-8.00	-3.00	1.00	38.0	0.32 [0.07, 0.57]
			Irbesartan	143	124 (86.7)	-6.05 (8.72)	-32.0	-11.00	-7.00	0.00	20.0	
		Week 110	Sparsentan	139	117 (84.2)	-5.89 (10.66)	-34.0	-12.00	-6.00	0.00	45.0	0.44 [0.18, 0.71]
			Irbesartan	143	111 (77.6)	-10.65 (10.87)	-59.0	-16.00	-10.00	-4.00	13.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Female	eGFR	Baseline	Sparsentan	63	63 (100.0)	64.21 (26.63)	24.0	41.00	59.00	86.00	127.0	
			Irbesartan	59	59 (100.0)	57.19 (23.89)	27.0	39.00	50.00	70.00	123.0	
		Week 6	Sparsentan	63	60 (95.2)	63.28 (24.51)	26.0	44.00	60.00	82.00	120.0	
			Irbesartan	59	58 (98.3)	54.81 (23.52)	19.0	39.00	47.00	67.00	116.0	
		Week 36	Sparsentan	63	56 (88.9)	62.55 (23.00)	25.0	45.00	63.00	81.50	114.0	
			Irbesartan	59	56 (94.9)	53.34 (24.33)	15.0	37.00	44.50	66.00	114.0	
		Week 58	Sparsentan	63	61 (96.8)	60.33 (25.40)	18.0	43.00	57.00	84.00	132.0	
			Irbesartan	59	49 (83.1)	52.22 (24.30)	13.0	34.00	45.00	64.00	116.0	
		Week 110	Sparsentan	63	54 (85.7)	60.57 (25.04)	13.0	41.00	57.50	76.00	113.0	
			Irbesartan	59	44 (74.6)	49.95 (23.93)	23.0	32.50	43.00	56.50	113.0	
	Change from baseline in eGFR	Week 6	Sparsentan	63	60 (95.2)	-1.68 (9.58)	-43.0	-4.00	-0.50	3.00	14.0	0.12 [-0.24, 0.48]
			Irbesartan	59	58 (98.3)	-2.67 (6.44)	-19.0	-7.00	-3.00	3.00	9.0	
		Week 36	Sparsentan	63	56 (88.9)	-4.09 (9.54)	-39.0	-7.50	-2.00	0.50	17.0	0.11 [-0.26, 0.48]
			Irbesartan	59	56 (94.9)	-5.00 (6.33)	-24.0	-9.00	-4.50	-0.50	11.0	
		Week 58	Sparsentan	63	61 (96.8)	-4.80 (9.88)	-34.0	-10.00	-6.00	1.00	24.0	-0.03 [-0.40, 0.35]
			Irbesartan	59	49 (83.1)	-4.55 (8.97)	-24.0	-9.00	-3.00	0.00	23.0	
		Week 110	Sparsentan	63	54 (85.7)	-4.11 (8.82)	-30.0	-10.00	-3.50	1.00	17.0	0.28 [-0.12, 0.68]
			Irbesartan	59	44 (74.6)	-6.64 (9.17)	-26.0	-13.00	-6.50	0.00	15.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
<= 45 years	eGFR	Baseline	Sparsentan	96	96 (100.0)	63.15 (27.41)	25.0	41.00	55.50	83.00	127.0	
			Irbesartan	99	99 (100.0)	65.52 (26.04)	26.0	42.00	63.00	80.00	123.0	
		Week 6	Sparsentan	96	94 (97.9)	60.94 (26.38)	23.0	38.00	56.00	82.00	121.0	
			Irbesartan	99	98 (99.0)	63.04 (25.32)	23.0	43.00	57.00	80.00	120.0	
		Week 36	Sparsentan	96	91 (94.8)	58.91 (25.37)	18.0	37.00	51.00	78.00	123.0	
			Irbesartan	99	91 (91.9)	61.60 (28.00)	7.0	40.00	59.00	80.00	125.0	
		Week 58	Sparsentan	96	89 (92.7)	59.52 (27.26)	13.0	40.00	53.00	77.00	132.0	
			Irbesartan	99	82 (82.8)	59.61 (26.81)	13.0	38.00	56.00	77.00	122.0	
		Week 110	Sparsentan	96	77 (80.2)	57.58 (28.02)	18.0	34.00	50.00	75.00	126.0	
			Irbesartan	99	69 (69.7)	54.87 (28.25)	11.0	34.00	52.00	66.00	123.0	
	Change from baseline in eGFR	Week 6	Sparsentan	96	94 (97.9)	-2.27 (8.80)	-43.0	-5.00	-1.00	1.00	15.0	0.03 [-0.26, 0.31]
			Irbesartan	99	98 (99.0)	-2.47 (6.30)	-17.0	-7.00	-2.00	2.00	14.0	
		Week 36	Sparsentan	96	91 (94.8)	-5.02 (9.21)	-39.0	-10.00	-3.00	0.00	12.0	-0.00 [-0.29, 0.29]
			Irbesartan	99	91 (91.9)	-5.01 (9.85)	-32.0	-12.00	-5.00	1.00	33.0	
		Week 58	Sparsentan	96	89 (92.7)	-4.64 (9.68)	-34.0	-8.00	-4.00	1.00	24.0	0.16 [-0.14, 0.46]
			Irbesartan	99	82 (82.8)	-6.21 (9.90)	-32.0	-13.00	-7.00	0.00	23.0	
		Week 110	Sparsentan	96	77 (80.2)	-5.30 (9.11)	-30.0	-11.00	-4.00	0.00	15.0	0.47 [0.14, 0.80]
			Irbesartan	99	69 (69.7)	-10.59 (13.34)	-59.0	-17.00	-11.00	-1.00	15.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 45 years	eGFR	Baseline	Sparsentan	106	106 (100.0)	51.02 (19.56)	24.0	36.00	45.00	64.00	103.0	
			Irbesartan	103	103 (100.0)	48.95 (17.55)	27.0	36.00	44.00	56.00	104.0	
		Week 6	Sparsentan	106	100 (94.3)	50.93 (19.40)	21.0	34.50	49.00	64.00	104.0	
			Irbesartan	103	99 (96.1)	47.94 (18.36)	19.0	35.00	43.00	59.00	102.0	
		Week 36	Sparsentan	106	100 (94.3)	49.21 (18.74)	23.0	34.00	46.00	62.50	97.0	
			Irbesartan	103	95 (92.2)	45.05 (17.36)	21.0	32.00	40.00	54.00	98.0	
		Week 58	Sparsentan	106	99 (93.4)	47.97 (19.71)	18.0	32.00	44.00	61.00	97.0	
			Irbesartan	103	91 (88.3)	43.88 (18.02)	11.0	30.00	38.00	55.00	95.0	
		Week 110	Sparsentan	106	94 (88.7)	46.46 (20.83)	13.0	30.00	43.00	62.00	95.0	
			Irbesartan	103	86 (83.5)	39.21 (18.47)	12.0	26.00	34.50	47.00	92.0	
	Change from baseline in eGFR	Week 6	Sparsentan	106	100 (94.3)	-0.06 (6.30)	-21.0	-3.00	0.00	3.00	20.0	0.11 [-0.17, 0.39]
			Irbesartan	103	99 (96.1)	-0.78 (6.78)	-31.0	-4.00	0.00	3.00	20.0	
		Week 36	Sparsentan	106	100 (94.3)	-2.15 (7.14)	-22.0	-6.00	-2.00	1.00	26.0	0.21 [-0.07, 0.50]
			Irbesartan	103	95 (92.2)	-3.60 (6.34)	-25.0	-6.00	-4.00	-1.00	18.0	
		Week 58	Sparsentan	106	99 (93.4)	-2.96 (8.40)	-19.0	-8.00	-3.00	1.00	38.0	0.27 [-0.02, 0.55]
			Irbesartan	103	91 (88.3)	-5.10 (7.67)	-30.0	-9.00	-5.00	-1.00	20.0	
		Week 110	Sparsentan	106	94 (88.7)	-5.35 (10.93)	-34.0	-11.00	-6.00	0.00	45.0	0.35 [0.05, 0.64]
			Irbesartan	103	86 (83.5)	-8.64 (7.57)	-30.0	-13.00	-9.00	-4.00	13.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age at IgAN diagnosis												
<= 18 years	eGFR	Baseline	Sparsentan	9	9 (100.0)	57.33 (29.45)	32.0	35.00	41.00	70.00	119.0	
			Irbesartan	5	5 (100.0)	66.60 (34.46)	35.0	39.00	66.00	72.00	121.0	
		Week 6	Sparsentan	9	9 (100.0)	50.00 (20.99)	26.0	36.00	38.00	62.00	86.0	
			Irbesartan	5	5 (100.0)	64.80 (32.64)	34.0	37.00	61.00	79.00	113.0	
		Week 36	Sparsentan	9	8 (88.9)	51.75 (20.76)	34.0	35.00	46.00	66.50	85.0	
			Irbesartan	5	5 (100.0)	61.40 (38.80)	26.0	31.00	59.00	68.00	123.0	
		Week 58	Sparsentan	9	7 (77.8)	49.43 (24.58)	27.0	33.00	39.00	69.00	96.0	
			Irbesartan	5	4 (80.0)	67.00 (35.47)	26.0	40.50	66.00	93.50	110.0	
		Week 110	Sparsentan	9	5 (55.6)	56.60 (37.85)	23.0	29.00	41.00	77.00	113.0	
			Irbesartan	5	4 (80.0)	49.25 (39.76)	22.0	23.00	34.00	75.50	107.0	
	Change from baseline in eGFR	Week 6	Sparsentan	9	9 (100.0)	-7.33 (10.75)	-33.0	-8.00	-4.00	-1.00	1.0	-0.59 [-1.71, 0.52]
			Irbesartan	5	5 (100.0)	-1.80 (5.63)	-8.0	-5.00	-2.00	-1.00	7.0	
		Week 36	Sparsentan	9	8 (88.9)	-8.75 (12.10)	-34.0	-14.50	-3.00	-0.50	0.0	-0.35 [-1.48, 0.77]
			Irbesartan	5	5 (100.0)	-5.20 (4.44)	-9.0	-8.00	-7.00	-4.00	2.0	
		Week 58	Sparsentan	9	7 (77.8)	-11.00 (9.63)	-24.0	-23.00	-7.00	-2.00	-2.0	-0.38 [-1.62, 0.86]
			Irbesartan	5	4 (80.0)	-7.50 (8.39)	-13.0	-12.00	-11.00	-3.00	5.0	
		Week 110	Sparsentan	9	5 (55.6)	-6.00 (3.94)	-11.0	-7.00	-6.00	-6.00	0.0	2.34 [0.64, 4.04]
			Irbesartan	5	4 (80.0)	-16.00 (4.69)	-22.0	-19.50	-15.50	-12.50	-11.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 18 to 40 years	eGFR	Baseline	Sparsentan	102	102 (100.0)	63.25 (26.67)	25.0	42.00	56.50	85.00	127.0	
			Irbesartan	109	109 (100.0)	60.08 (25.53)	26.0	40.00	52.00	71.00	123.0	
		Week 6	Sparsentan	102	99 (97.1)	61.66 (26.00)	23.0	40.00	57.00	82.00	121.0	
			Irbesartan	109	106 (97.2)	58.44 (24.43)	23.0	40.00	54.00	72.00	120.0	
		Week 36	Sparsentan	102	97 (95.1)	59.29 (24.88)	18.0	39.00	55.00	77.00	123.0	
			Irbesartan	109	101 (92.7)	56.11 (26.73)	7.0	36.00	49.00	67.00	125.0	
		Week 58	Sparsentan	102	95 (93.1)	59.43 (26.68)	13.0	40.00	53.00	77.00	132.0	
			Irbesartan	109	90 (82.6)	55.01 (26.50)	13.0	35.00	49.50	71.00	122.0	
		Week 110	Sparsentan	102	83 (81.4)	57.30 (26.58)	23.0	35.00	52.00	74.00	126.0	
			Irbesartan	109	80 (73.4)	49.45 (26.84)	11.0	31.00	42.00	63.00	123.0	
	Change from baseline in eGFR	Week 6	Sparsentan	102	99 (97.1)	-1.43 (8.26)	-43.0	-4.00	-1.00	2.00	15.0	0.08 [-0.19, 0.36]
			Irbesartan	109	106 (97.2)	-2.04 (6.04)	-17.0	-5.00	-1.50	2.00	14.0	
		Week 36	Sparsentan	102	97 (95.1)	-4.58 (8.46)	-39.0	-10.00	-3.00	1.00	10.0	0.00 [-0.27, 0.28]
			Irbesartan	109	101 (92.7)	-4.61 (9.19)	-32.0	-10.00	-3.00	1.00	33.0	
		Week 58	Sparsentan	102	95 (93.1)	-4.20 (9.13)	-34.0	-8.00	-4.00	1.00	24.0	0.14 [-0.15, 0.43]
			Irbesartan	109	90 (82.6)	-5.44 (9.12)	-32.0	-10.00	-5.00	0.00	23.0	
		Week 110	Sparsentan	102	83 (81.4)	-5.72 (9.64)	-30.0	-12.00	-4.00	1.00	15.0	0.40 [0.09, 0.71]
			Irbesartan	109	80 (73.4)	-10.14 (12.16)	-59.0	-15.00	-9.00	-3.00	15.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 40 years	eGFR	Baseline	Sparsentan	91	91 (100.0)	49.47 (18.57)	24.0	35.00	45.00	64.00	101.0	
			Irbesartan	88	88 (100.0)	52.80 (19.63)	27.0	38.00	47.50	65.50	106.0	
		Week 6	Sparsentan	91	86 (94.5)	49.62 (18.80)	21.0	34.00	46.00	62.00	99.0	
			Irbesartan	88	86 (97.7)	51.22 (20.75)	19.0	36.00	45.00	69.00	108.0	
		Week 36	Sparsentan	91	86 (94.5)	47.87 (18.40)	22.0	33.00	45.00	62.00	97.0	
			Irbesartan	88	80 (90.9)	48.90 (19.96)	15.0	33.00	42.50	61.50	109.0	
		Week 58	Sparsentan	91	86 (94.5)	47.14 (19.47)	18.0	31.00	43.50	60.00	97.0	
			Irbesartan	88	79 (89.8)	46.35 (18.83)	11.0	32.00	42.00	59.00	95.0	
		Week 110	Sparsentan	91	83 (91.2)	45.33 (20.80)	13.0	29.00	43.00	59.00	95.0	
			Irbesartan	88	71 (80.7)	42.32 (20.38)	12.0	26.00	37.00	57.00	92.0	
	Change from baseline in eGFR	Week 6	Sparsentan	91	86 (94.5)	-0.13 (6.24)	-21.0	-3.00	0.00	3.00	20.0	0.14 [-0.16, 0.44]
			Irbesartan	88	86 (97.7)	-1.09 (7.28)	-31.0	-5.00	-2.00	3.00	20.0	
		Week 36	Sparsentan	91	86 (94.5)	-1.84 (7.37)	-22.0	-5.00	-2.00	1.00	26.0	0.27 [-0.03, 0.58]
			Irbesartan	88	80 (90.9)	-3.83 (7.16)	-25.0	-7.00	-4.00	0.00	18.0	
		Week 58	Sparsentan	91	86 (94.5)	-2.67 (8.68)	-19.0	-8.00	-3.00	0.00	38.0	0.36 [0.05, 0.66]
			Irbesartan	88	79 (89.8)	-5.73 (8.52)	-30.0	-10.00	-6.00	0.00	20.0	
		Week 110	Sparsentan	91	83 (91.2)	-4.89 (10.88)	-34.0	-11.00	-6.00	-1.00	45.0	0.36 [0.04, 0.68]
			Irbesartan	88	71 (80.7)	-8.44 (8.53)	-30.0	-14.00	-9.00	-3.00	13.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Geographic region												
North America	eGFR	Baseline	Sparsentan	35	35 (100.0)	56.54 (25.93)	25.0	38.00	50.00	67.00	121.0	
			Irbesartan	46	46 (100.0)	55.93 (23.44)	26.0	36.00	50.50	71.00	123.0	
		Week 6	Sparsentan	35	35 (100.0)	54.14 (25.21)	21.0	33.00	50.00	67.00	120.0	
			Irbesartan	46	45 (97.8)	53.33 (22.58)	21.0	36.00	46.00	68.00	107.0	
		Week 36	Sparsentan	35	34 (97.1)	53.41 (22.67)	23.0	34.00	48.00	65.00	104.0	
			Irbesartan	46	44 (95.7)	51.77 (24.21)	21.0	33.00	44.50	65.50	123.0	
		Week 58	Sparsentan	35	31 (88.6)	53.74 (24.97)	21.0	32.00	52.00	72.00	119.0	
			Irbesartan	46	39 (84.8)	49.72 (22.95)	16.0	31.00	43.00	67.00	114.0	
		Week 110	Sparsentan	35	26 (74.3)	49.88 (24.98)	16.0	28.00	45.00	71.00	113.0	
			Irbesartan	46	32 (69.6)	44.00 (21.59)	14.0	26.00	43.00	57.50	113.0	
	Change from baseline in eGFR	Week 6	Sparsentan	35	35 (100.0)	-2.40 (8.17)	-33.0	-4.00	-1.00	1.00	9.0	-0.04 [-0.48, 0.41]
			Irbesartan	46	45 (97.8)	-2.11 (7.92)	-17.0	-7.00	-3.00	3.00	20.0	
		Week 36	Sparsentan	35	34 (97.1)	-3.47 (7.99)	-34.0	-5.00	-2.00	0.00	9.0	0.09 [-0.35, 0.54]
			Irbesartan	46	44 (95.7)	-4.25 (8.37)	-19.0	-10.50	-4.00	0.50	18.0	
		Week 58	Sparsentan	35	31 (88.6)	-4.42 (10.28)	-33.0	-10.00	-4.00	1.00	24.0	-0.05 [-0.52, 0.43]
			Irbesartan	46	39 (84.8)	-3.97 (9.26)	-20.0	-10.00	-4.00	1.00	20.0	
		Week 110	Sparsentan	35	26 (74.3)	-5.19 (8.29)	-27.0	-12.00	-3.50	1.00	11.0	0.29 [-0.23, 0.81]
			Irbesartan	46	32 (69.6)	-8.13 (11.41)	-46.0	-14.50	-9.50	-1.00	15.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Europe	eGFR	Baseline	Sparsentan	98	98 (100.0)	55.84 (24.05)	24.0	36.00	47.50	71.00	127.0	
			Irbesartan	115	115 (100.0)	56.87 (24.29)	27.0	38.00	50.00	69.00	123.0	
		Week 6	Sparsentan	98	92 (93.9)	55.27 (23.93)	25.0	34.00	50.00	70.00	117.0	
			Irbesartan	115	112 (97.4)	55.64 (24.10)	19.0	37.00	48.00	69.00	120.0	
		Week 36	Sparsentan	98	91 (92.9)	53.55 (23.54)	18.0	36.00	47.00	68.00	123.0	
			Irbesartan	115	106 (92.2)	53.99 (25.91)	7.0	34.00	47.50	66.00	125.0	
		Week 58	Sparsentan	98	93 (94.9)	52.45 (24.38)	13.0	36.00	45.00	64.00	132.0	
			Irbesartan	115	98 (85.2)	51.84 (25.29)	11.0	33.00	46.50	65.00	122.0	
		Week 110	Sparsentan	98	83 (84.7)	49.95 (22.85)	14.0	33.00	45.00	64.00	126.0	
			Irbesartan	115	92 (80.0)	47.49 (26.59)	11.0	27.50	40.00	62.50	123.0	
	Change from baseline in eGFR	Week 6	Sparsentan	98	92 (93.9)	-0.50 (6.31)	-17.0	-4.00	0.00	3.00	15.0	0.16 [-0.12, 0.44]
			Irbesartan	115	112 (97.4)	-1.52 (6.33)	-31.0	-5.00	-1.50	2.00	14.0	
		Week 36	Sparsentan	98	91 (92.9)	-3.00 (7.62)	-30.0	-8.00	-2.00	2.00	17.0	0.10 [-0.18, 0.38]
			Irbesartan	115	106 (92.2)	-3.76 (8.21)	-32.0	-7.00	-4.00	0.00	33.0	
		Week 58	Sparsentan	98	93 (94.9)	-3.23 (7.25)	-24.0	-8.00	-2.00	1.00	14.0	0.32 [0.04, 0.61]
			Irbesartan	115	98 (85.2)	-5.76 (8.29)	-32.0	-10.00	-5.50	0.00	11.0	
		Week 110	Sparsentan	98	83 (84.7)	-5.47 (7.74)	-30.0	-11.00	-5.00	0.00	17.0	0.43 [0.13, 0.73]
			Irbesartan	115	92 (80.0)	-9.47 (10.35)	-59.0	-15.00	-9.00	-3.00	13.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asia Pacific	eGFR	Baseline	Sparsentan	69	69 (100.0)	58.25 (24.19)	26.0	40.00	51.00	74.00	121.0	
			Irbesartan	41	41 (100.0)	58.90 (22.11)	31.0	41.00	52.00	69.00	112.0	
		Week 6	Sparsentan	69	67 (97.1)	57.33 (22.30)	26.0	38.00	54.00	70.00	121.0	
			Irbesartan	41	40 (97.6)	57.30 (22.20)	23.0	41.50	53.50	70.00	119.0	
		Week 36	Sparsentan	69	66 (95.7)	54.44 (21.60)	19.0	34.00	50.50	67.00	108.0	
			Irbesartan	41	36 (87.8)	52.36 (21.19)	15.0	37.50	47.50	70.00	101.0	
		Week 58	Sparsentan	69	64 (92.8)	54.72 (23.93)	14.0	37.00	50.00	73.00	121.0	
			Irbesartan	41	36 (87.8)	51.72 (21.33)	13.0	35.00	47.50	67.50	98.0	
		Week 110	Sparsentan	69	62 (89.9)	54.16 (27.49)	13.0	31.00	49.50	69.00	123.0	
			Irbesartan	41	31 (75.6)	44.55 (21.20)	11.0	29.00	38.00	59.00	104.0	
	Change from baseline in eGFR	Week 6	Sparsentan	69	67 (97.1)	-1.33 (9.03)	-43.0	-4.00	-1.00	3.00	20.0	0.00 [-0.39, 0.39]
			Irbesartan	41	40 (97.6)	-1.35 (5.71)	-19.0	-4.00	-1.50	2.00	9.0	
		Week 36	Sparsentan	69	66 (95.7)	-4.26 (9.35)	-39.0	-8.00	-4.00	-1.00	26.0	0.18 [-0.23, 0.59]
			Irbesartan	41	36 (87.8)	-5.89 (8.28)	-24.0	-10.50	-5.50	-0.50	11.0	
		Week 58	Sparsentan	69	64 (92.8)	-4.20 (10.71)	-34.0	-8.00	-5.00	0.00	38.0	0.28 [-0.13, 0.69]
			Irbesartan	41	36 (87.8)	-7.06 (9.54)	-24.0	-13.00	-8.00	0.00	23.0	
		Week 110	Sparsentan	69	62 (89.9)	-5.19 (13.30)	-34.0	-12.00	-6.50	0.00	45.0	0.47 [0.04, 0.91]
			Irbesartan	41	31 (75.6)	-11.06 (10.34)	-34.0	-18.00	-11.00	-4.00	11.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline BMI												
< 27 kg/m**2	eGFR	Baseline	Sparsentan	83	83 (100.0)	58.66 (24.61)	24.0	39.00	53.00	72.00	126.0	
			Irbesartan	94	94 (100.0)	58.84 (26.11)	26.0	39.00	50.00	70.00	123.0	
		Week 6	Sparsentan	83	78 (94.0)	58.38 (22.75)	26.0	38.00	55.00	74.00	117.0	
			Irbesartan	94	91 (96.8)	56.63 (25.44)	19.0	37.00	50.00	71.00	120.0	
		Week 36	Sparsentan	83	77 (92.8)	56.36 (23.52)	19.0	34.00	51.00	72.00	123.0	
			Irbesartan	94	86 (91.5)	54.64 (28.46)	7.0	35.00	46.00	69.00	125.0	
		Week 58	Sparsentan	83	77 (92.8)	55.97 (24.36)	14.0	37.00	53.00	73.00	127.0	
			Irbesartan	94	75 (79.8)	53.33 (25.75)	13.0	34.00	49.00	67.00	122.0	
		Week 110	Sparsentan	83	70 (84.3)	53.83 (25.28)	13.0	33.00	49.50	68.00	126.0	
			Irbesartan	94	69 (73.4)	50.14 (27.37)	12.0	32.00	41.00	63.00	123.0	
	Change from baseline in eGFR	Week 6	Sparsentan	83	78 (94.0)	-1.12 (8.99)	-43.0	-4.00	0.00	3.00	20.0	0.15 [-0.15, 0.45]
			Irbesartan	94	91 (96.8)	-2.23 (5.56)	-16.0	-5.00	-2.00	2.00	12.0	
		Week 36	Sparsentan	83	77 (92.8)	-3.62 (9.89)	-39.0	-8.00	-2.00	0.00	26.0	0.19 [-0.12, 0.50]
			Irbesartan	94	86 (91.5)	-5.41 (8.95)	-32.0	-11.00	-4.50	-1.00	33.0	
		Week 58	Sparsentan	83	77 (92.8)	-3.39 (10.66)	-34.0	-8.00	-3.00	0.00	38.0	0.32 [-0.00, 0.64]
			Irbesartan	94	75 (79.8)	-6.40 (8.16)	-32.0	-11.00	-7.00	-2.00	16.0	
		Week 110	Sparsentan	83	70 (84.3)	-5.13 (11.91)	-34.0	-11.00	-6.00	0.00	45.0	0.36 [0.03, 0.70]
			Irbesartan	94	69 (73.4)	-9.07 (9.87)	-36.0	-15.00	-9.00	-3.00	15.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 27 kg/m**2	eGFR	Baseline	Sparsentan	119	119 (100.0)	55.47 (24.15)	25.0	38.00	49.00	69.00	127.0	
			Irbesartan	107	107 (100.0)	55.66 (21.19)	27.0	38.00	50.00	70.00	114.0	
		Week 6	Sparsentan	119	116 (97.5)	54.03 (23.97)	21.0	35.00	49.00	66.50	121.0	
			Irbesartan	107	105 (98.1)	54.59 (21.42)	21.0	39.00	48.00	69.00	119.0	
		Week 36	Sparsentan	119	114 (95.8)	52.12 (21.92)	18.0	36.00	47.00	65.00	114.0	
			Irbesartan	107	100 (93.5)	51.87 (20.70)	20.0	34.00	48.00	65.00	125.0	
		Week 58	Sparsentan	119	111 (93.3)	51.68 (24.08)	13.0	33.00	47.00	64.00	132.0	
			Irbesartan	107	98 (91.6)	49.81 (22.37)	11.0	32.00	45.50	66.00	121.0	
		Week 110	Sparsentan	119	101 (84.9)	49.83 (24.59)	14.0	31.00	45.00	63.00	123.0	
			Irbesartan	107	85 (79.4)	43.15 (21.71)	11.0	26.00	40.00	56.00	106.0	
	Change from baseline in eGFR	Week 6	Sparsentan	119	116 (97.5)	-1.14 (6.69)	-27.0	-4.00	-1.00	2.00	15.0	-0.01 [-0.27, 0.26]
			Irbesartan	107	105 (98.1)	-1.09 (7.37)	-31.0	-5.00	-1.00	3.00	20.0	
		Week 36	Sparsentan	119	114 (95.8)	-3.45 (7.07)	-26.0	-8.00	-3.00	1.00	12.0	-0.02 [-0.28, 0.25]
			Irbesartan	107	100 (93.5)	-3.33 (7.52)	-25.0	-6.50	-4.00	1.00	18.0	
		Week 58	Sparsentan	119	111 (93.3)	-4.01 (7.77)	-33.0	-8.00	-4.00	1.00	13.0	0.12 [-0.15, 0.39]
			Irbesartan	107	98 (91.6)	-5.03 (9.25)	-30.0	-10.00	-4.00	0.00	23.0	
		Week 110	Sparsentan	119	101 (84.9)	-5.47 (8.74)	-30.0	-11.00	-4.00	0.00	15.0	0.44 [0.15, 0.73]
			Irbesartan	107	85 (79.4)	-9.85 (11.16)	-59.0	-15.00	-11.00	-4.00	13.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Randomization strata												
eGFR Low and UP High	eGFR	Baseline	Sparsentan	71	71 (100.0)	40.28 (9.79)	25.0	31.00	39.00	47.00	67.0	
			Irbesartan	74	74 (100.0)	41.78 (9.97)	26.0	34.00	39.00	50.00	66.0	
		Week 6	Sparsentan	71	69 (97.2)	39.55 (10.77)	21.0	32.00	38.00	49.00	64.0	
			Irbesartan	74	72 (97.3)	39.76 (9.92)	21.0	32.00	39.00	46.50	64.0	
		Week 36	Sparsentan	71	68 (95.8)	38.09 (10.70)	18.0	31.50	36.50	46.00	65.0	
			Irbesartan	74	66 (89.2)	36.35 (12.05)	7.0	29.00	35.50	42.00	88.0	
		Week 58	Sparsentan	71	67 (94.4)	36.61 (10.86)	13.0	28.00	36.00	45.00	61.0	
			Irbesartan	74	62 (83.8)	34.76 (12.05)	11.0	27.00	34.00	43.00	66.0	
		Week 110	Sparsentan	71	59 (83.1)	33.95 (10.76)	14.0	27.00	33.00	42.00	56.0	
			Irbesartan	74	57 (77.0)	30.81 (11.67)	11.0	24.00	29.00	40.00	63.0	
	Change from baseline in eGFR	Week 6	Sparsentan	71	69 (97.2)	-0.54 (5.72)	-27.0	-3.00	-1.00	2.00	15.0	0.24 [-0.09, 0.57]
			Irbesartan	74	72 (97.3)	-1.82 (4.80)	-14.0	-5.00	-2.00	2.00	9.0	
		Week 36	Sparsentan	71	68 (95.8)	-2.37 (5.54)	-15.0	-5.50	-2.50	1.00	10.0	0.47 [0.13, 0.82]
			Irbesartan	74	66 (89.2)	-5.85 (8.85)	-32.0	-9.00	-5.00	-2.00	33.0	
		Week 58	Sparsentan	71	67 (94.4)	-4.01 (5.91)	-18.0	-8.00	-4.00	0.00	10.0	0.42 [0.07, 0.77]
			Irbesartan	74	62 (83.8)	-6.97 (8.18)	-32.0	-10.00	-7.00	-1.00	11.0	
		Week 110	Sparsentan	71	59 (83.1)	-6.64 (7.84)	-31.0	-12.00	-7.00	0.00	8.0	0.58 [0.21, 0.95]
			Irbesartan	74	57 (77.0)	-11.23 (7.89)	-36.0	-16.00	-11.00	-5.00	7.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR Low and UP Low	eGFR	Baseline	Sparsentan	55	55 (100.0)	42.13 (9.23)	24.0	35.00	42.00	50.00	62.0	
			Irbesartan	55	55 (100.0)	44.25 (9.36)	27.0	38.00	43.00	50.00	71.0	
		Week 6	Sparsentan	55	51 (92.7)	42.25 (10.06)	26.0	34.00	40.00	50.00	70.0	
			Irbesartan	55	54 (98.2)	43.24 (9.93)	19.0	36.00	43.00	48.00	68.0	
		Week 36	Sparsentan	55	49 (89.1)	42.27 (11.81)	25.0	34.00	41.00	48.00	76.0	
			Irbesartan	55	52 (94.5)	41.65 (9.85)	28.0	33.50	40.00	48.50	70.0	
		Week 58	Sparsentan	55	51 (92.7)	41.92 (13.53)	18.0	33.00	41.00	48.00	88.0	
			Irbesartan	55	49 (89.1)	41.51 (12.39)	22.0	33.00	39.00	49.00	82.0	
		Week 110	Sparsentan	55	47 (85.5)	39.96 (15.15)	13.0	29.00	35.00	48.00	95.0	
			Irbesartan	55	44 (80.0)	36.02 (11.13)	11.0	27.50	35.00	41.00	66.0	
	Change from baseline in eGFR	Week 6	Sparsentan	55	51 (92.7)	0.41 (6.69)	-17.0	-3.00	0.00	3.00	20.0	0.22 [-0.16, 0.61]
			Irbesartan	55	54 (98.2)	-1.09 (6.78)	-31.0	-4.00	0.00	3.00	16.0	
		Week 36	Sparsentan	55	49 (89.1)	0.20 (7.08)	-11.0	-4.00	-1.00	3.00	26.0	0.47 [0.08, 0.87]
			Irbesartan	55	52 (94.5)	-2.63 (4.79)	-12.0	-5.50	-3.00	0.50	13.0	
		Week 58	Sparsentan	55	51 (92.7)	-0.49 (8.78)	-11.0	-6.00	-2.00	3.00	38.0	0.36 [-0.04, 0.75]
			Irbesartan	55	49 (89.1)	-3.39 (7.42)	-23.0	-8.00	-4.00	1.00	23.0	
		Week 110	Sparsentan	55	47 (85.5)	-2.72 (11.20)	-15.0	-9.00	-4.00	0.00	45.0	0.49 [0.07, 0.90]
			Irbesartan	55	44 (80.0)	-7.50 (8.08)	-34.0	-12.00	-7.00	-1.50	11.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP High	eGFR	Baseline	Sparsentan	37	37 (100.0)	82.43 (20.55)	51.0	66.00	76.00	91.00	127.0	
			Irbesartan	36	36 (100.0)	79.81 (14.96)	57.0	69.00	74.00	91.50	109.0	
		Week 6	Sparsentan	37	35 (94.6)	78.86 (18.69)	56.0	62.00	74.00	90.00	121.0	
			Irbesartan	36	34 (94.4)	77.09 (14.76)	56.0	63.00	76.00	85.00	108.0	
		Week 36	Sparsentan	37	37 (100.0)	74.35 (18.89)	34.0	62.00	71.00	85.00	118.0	
			Irbesartan	36	33 (91.7)	73.76 (16.97)	40.0	62.00	68.00	86.00	123.0	
		Week 58	Sparsentan	37	34 (91.9)	78.12 (21.35)	46.0	62.00	74.00	88.00	132.0	
			Irbesartan	36	30 (83.3)	71.13 (15.67)	37.0	59.00	71.50	83.00	101.0	
		Week 110	Sparsentan	37	30 (81.1)	72.97 (21.22)	43.0	59.00	64.50	86.00	123.0	
			Irbesartan	36	27 (75.0)	64.15 (20.28)	14.0	53.00	63.00	74.00	106.0	
	Change from baseline in eGFR	Week 6	Sparsentan	37	35 (94.6)	-3.91 (11.54)	-43.0	-8.00	-1.00	4.00	12.0	-0.09 [-0.56, 0.38]
			Irbesartan	36	34 (94.4)	-3.09 (6.45)	-17.0	-6.00	-3.00	2.00	12.0	
		Week 36	Sparsentan	37	37 (100.0)	-8.08 (11.79)	-39.0	-13.00	-5.00	0.00	8.0	-0.16 [-0.63, 0.31]
			Irbesartan	36	33 (91.7)	-6.42 (9.11)	-25.0	-12.00	-6.00	-1.00	14.0	
		Week 58	Sparsentan	37	34 (91.9)	-5.29 (12.83)	-34.0	-14.00	-5.50	5.00	24.0	0.21 [-0.28, 0.70]
			Irbesartan	36	30 (83.3)	-7.60 (8.63)	-23.0	-14.00	-8.00	-2.00	10.0	
		Week 110	Sparsentan	37	30 (81.1)	-6.10 (11.65)	-34.0	-12.00	-5.00	1.00	15.0	0.63 [0.10, 1.16]
			Irbesartan	36	27 (75.0)	-14.48 (14.85)	-59.0	-22.00	-12.00	-5.00	13.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP Low	eGFR	Baseline	Sparsentan	39	39 (100.0)	83.15 (16.11)	57.0	70.00	80.00	96.00	126.0	
			Irbesartan	37	37 (100.0)	84.57 (22.97)	50.0	66.00	79.00	104.00	123.0	
		Week 6	Sparsentan	39	39 (100.0)	81.46 (16.34)	53.0	67.00	78.00	98.00	113.0	
			Irbesartan	37	37 (100.0)	83.92 (20.66)	43.0	69.00	76.00	101.00	120.0	
		Week 36	Sparsentan	39	37 (94.9)	77.57 (16.79)	47.0	65.00	73.00	91.00	123.0	
			Irbesartan	37	35 (94.6)	82.49 (23.25)	41.0	64.00	74.00	102.00	125.0	
		Week 58	Sparsentan	39	36 (92.3)	77.75 (16.89)	53.0	63.50	74.50	90.00	127.0	
			Irbesartan	37	32 (86.5)	79.94 (22.04)	37.0	64.50	74.50	95.00	122.0	
		Week 110	Sparsentan	39	35 (89.7)	78.03 (18.80)	43.0	64.00	76.00	88.00	126.0	
			Irbesartan	37	27 (73.0)	77.22 (25.01)	33.0	61.00	69.00	107.00	123.0	
	Change from baseline in eGFR	Week 6	Sparsentan	39	39 (100.0)	-1.69 (7.14)	-20.0	-7.00	-1.00	3.00	14.0	-0.13 [-0.58, 0.32]
			Irbesartan	37	37 (100.0)	-0.65 (9.02)	-19.0	-6.00	0.00	6.00	20.0	
		Week 36	Sparsentan	39	37 (94.9)	-6.00 (7.15)	-26.0	-12.00	-4.00	-2.00	12.0	-0.50 [-0.97, -0.03]
			Irbesartan	37	35 (94.6)	-1.80 (9.42)	-24.0	-10.00	-3.00	5.00	18.0	
		Week 58	Sparsentan	39	36 (92.3)	-6.44 (8.93)	-33.0	-10.50	-6.00	-1.50	13.0	-0.18 [-0.66, 0.29]
			Irbesartan	37	32 (86.5)	-4.59 (11.22)	-24.0	-12.50	-2.00	2.00	20.0	
		Week 110	Sparsentan	39	35 (89.7)	-5.94 (10.43)	-30.0	-13.00	-5.00	3.00	12.0	-0.16 [-0.67, 0.34]
			Irbesartan	37	27 (73.0)	-4.19 (11.28)	-36.0	-13.00	-3.00	5.00	15.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 1												
< 60 mL/min/1.73 m**2	eGFR	Baseline	Sparsentan	127	127 (100.0)	41.06 (9.32)	24.0	33.00	41.00	49.00	59.0	
			Irbesartan	129	129 (100.0)	42.27 (8.60)	26.0	35.00	41.00	50.00	59.0	
		Week 6	Sparsentan	127	121 (95.3)	40.95 (10.86)	21.0	33.00	38.00	50.00	73.0	
			Irbesartan	129	127 (98.4)	41.72 (10.87)	19.0	34.00	41.00	47.00	76.0	
		Week 36	Sparsentan	127	118 (92.9)	39.92 (11.22)	18.0	32.00	39.00	47.00	76.0	
			Irbesartan	129	118 (91.5)	39.16 (12.20)	7.0	32.00	37.00	45.00	88.0	
		Week 58	Sparsentan	127	118 (92.9)	38.87 (12.23)	13.0	30.00	38.50	46.00	88.0	
			Irbesartan	129	111 (86.0)	38.30 (13.43)	11.0	29.00	36.00	45.00	82.0	
		Week 110	Sparsentan	127	107 (84.3)	36.90 (13.28)	13.0	28.00	34.00	45.00	95.0	
			Irbesartan	129	102 (79.1)	33.95 (12.97)	11.0	25.00	32.00	41.00	72.0	
	Change from baseline in eGFR	Week 6	Sparsentan	127	121 (95.3)	0.15 (6.28)	-27.0	-3.00	0.00	2.00	20.0	0.13 [-0.12, 0.38]
			Irbesartan	129	127 (98.4)	-0.65 (6.12)	-31.0	-4.00	0.00	3.00	20.0	
		Week 36	Sparsentan	127	118 (92.9)	-1.18 (6.28)	-15.0	-5.00	-2.00	2.00	26.0	0.31 [0.06, 0.57]
			Irbesartan	129	118 (91.5)	-3.34 (7.51)	-32.0	-6.00	-3.00	0.00	33.0	
		Week 58	Sparsentan	127	118 (92.9)	-2.36 (7.43)	-18.0	-7.00	-2.50	1.00	38.0	0.25 [-0.01, 0.51]
			Irbesartan	129	111 (86.0)	-4.26 (8.02)	-30.0	-9.00	-5.00	1.00	23.0	
		Week 110	Sparsentan	127	107 (84.3)	-4.58 (9.41)	-31.0	-10.00	-6.00	0.00	45.0	0.42 [0.15, 0.70]
			Irbesartan	129	102 (79.1)	-8.32 (8.27)	-34.0	-14.00	-9.00	-2.00	13.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	eGFR	Baseline	Sparsentan	49	49 (100.0)	72.49 (8.30)	60.0	66.00	71.00	78.00	89.0	
			Irbesartan	48	48 (100.0)	71.58 (7.62)	60.0	66.00	70.00	76.00	89.0	
		Week 6	Sparsentan	49	47 (95.9)	69.62 (8.73)	56.0	62.00	69.00	75.00	90.0	
			Irbesartan	48	45 (93.8)	68.64 (9.54)	49.0	61.00	69.00	74.00	85.0	
		Week 36	Sparsentan	49	47 (95.9)	66.15 (10.57)	34.0	62.00	65.00	72.00	88.0	
			Irbesartan	48	44 (91.7)	64.77 (11.13)	36.0	58.00	64.00	70.00	87.0	
		Week 58	Sparsentan	49	44 (89.8)	67.16 (9.86)	46.0	59.50	65.00	74.00	91.0	
			Irbesartan	48	41 (85.4)	62.78 (11.30)	34.0	55.00	64.00	72.00	83.0	
		Week 110	Sparsentan	49	43 (87.8)	65.33 (12.16)	36.0	59.00	64.00	71.00	100.0	
			Irbesartan	48	37 (77.1)	57.08 (14.58)	14.0	52.00	57.00	67.00	86.0	
	Change from baseline in eGFR	Week 6	Sparsentan	49	47 (95.9)	-2.70 (7.27)	-21.0	-7.00	-2.00	3.00	12.0	0.04 [-0.37, 0.45]
			Irbesartan	48	45 (93.8)	-2.98 (7.62)	-19.0	-7.00	-3.00	3.00	14.0	
		Week 36	Sparsentan	49	47 (95.9)	-6.21 (8.66)	-30.0	-12.00	-5.00	-1.00	12.0	0.05 [-0.36, 0.46]
			Irbesartan	48	44 (91.7)	-6.64 (8.51)	-30.0	-12.00	-6.00	-1.50	12.0	
		Week 58	Sparsentan	49	44 (89.8)	-5.18 (9.56)	-24.0	-11.00	-7.00	-1.50	24.0	0.39 [-0.04, 0.82]
			Irbesartan	48	41 (85.4)	-8.95 (9.92)	-32.0	-16.00	-9.00	-2.00	10.0	
		Week 110	Sparsentan	49	43 (87.8)	-7.30 (10.41)	-34.0	-13.00	-5.00	0.00	14.0	0.57 [0.12, 1.01]
			Irbesartan	48	37 (77.1)	-14.14 (13.78)	-59.0	-21.00	-12.00	-5.00	6.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	eGFR	Baseline	Sparsentan	26	26 (100.0)	104.00 (11.43)	90.0	95.00	102.00	111.00	127.0	
			Irbesartan	25	25 (100.0)	105.56 (9.98)	91.0	98.00	105.00	112.00	123.0	
		Week 6	Sparsentan	26	26 (100.0)	99.77 (11.42)	77.0	92.00	99.00	104.00	121.0	
			Irbesartan	25	25 (100.0)	101.48 (10.76)	80.0	95.00	101.00	108.00	120.0	
		Week 36	Sparsentan	26	26 (100.0)	94.73 (12.40)	63.0	88.00	93.50	101.00	123.0	
			Irbesartan	25	24 (96.0)	100.63 (15.82)	73.0	89.00	99.50	112.50	125.0	
		Week 58	Sparsentan	26	26 (100.0)	96.31 (16.63)	61.0	85.00	94.00	105.00	132.0	
			Irbesartan	25	21 (84.0)	97.90 (13.03)	77.0	88.00	96.00	110.00	122.0	
		Week 110	Sparsentan	26	21 (80.8)	97.33 (16.09)	60.0	87.00	96.00	108.00	126.0	
			Irbesartan	25	16 (64.0)	98.94 (15.96)	68.0	86.00	105.00	112.00	123.0	
	Change from baseline in eGFR	Week 6	Sparsentan	26	26 (100.0)	-4.23 (12.06)	-43.0	-5.00	-1.00	1.00	13.0	-0.02 [-0.56, 0.53]
			Irbesartan	25	25 (100.0)	-4.08 (6.00)	-16.0	-8.00	-3.00	0.00	7.0	
		Week 36	Sparsentan	26	26 (100.0)	-9.27 (11.24)	-39.0	-13.00	-6.50	-2.00	7.0	-0.42 [-0.98, 0.14]
			Irbesartan	25	24 (96.0)	-4.67 (10.49)	-24.0	-12.00	-7.00	3.50	15.0	
		Week 58	Sparsentan	26	26 (100.0)	-7.69 (12.92)	-34.0	-17.00	-6.00	1.00	13.0	-0.12 [-0.70, 0.46]
			Irbesartan	25	21 (84.0)	-6.33 (8.96)	-24.0	-11.00	-8.00	0.00	16.0	
		Week 110	Sparsentan	26	21 (80.8)	-5.10 (12.77)	-30.0	-17.00	-6.00	5.00	15.0	0.10 [-0.55, 0.75]
			Irbesartan	25	16 (64.0)	-6.38 (12.33)	-30.0	-15.50	-6.00	0.50	15.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 2												
< 45 mL/min/1.73 m**2	eGFR	Baseline	Sparsentan	82	82 (100.0)	35.37 (5.59)	24.0	31.00	35.00	41.00	44.0	
			Irbesartan	80	80 (100.0)	36.58 (4.61)	26.0	33.00	37.00	40.00	44.0	
		Week 6	Sparsentan	82	79 (96.3)	36.08 (8.13)	21.0	31.00	34.00	40.00	58.0	
			Irbesartan	80	78 (97.5)	35.69 (6.41)	19.0	31.00	36.50	40.00	50.0	
		Week 36	Sparsentan	82	76 (92.7)	34.32 (8.11)	18.0	29.00	34.00	38.50	57.0	
			Irbesartan	80	71 (88.8)	32.23 (6.84)	7.0	29.00	33.00	37.00	47.0	
		Week 58	Sparsentan	82	76 (92.7)	32.68 (8.68)	13.0	27.00	33.00	38.00	63.0	
			Irbesartan	80	66 (82.5)	30.65 (7.82)	11.0	27.00	31.00	35.00	52.0	
		Week 110	Sparsentan	82	68 (82.9)	30.76 (9.53)	13.0	26.00	30.00	34.50	75.0	
			Irbesartan	80	63 (78.8)	27.60 (8.30)	11.0	23.00	26.00	32.00	55.0	
	Change from baseline in eGFR	Week 6	Sparsentan	82	79 (96.3)	0.85 (5.00)	-10.0	-2.00	0.00	3.00	15.0	0.37 [0.05, 0.68]
			Irbesartan	80	78 (97.5)	-0.90 (4.49)	-16.0	-4.00	-1.00	2.00	10.0	
		Week 36	Sparsentan	82	76 (92.7)	-1.05 (5.87)	-15.0	-4.00	-1.00	2.50	21.0	0.54 [0.22, 0.87]
			Irbesartan	80	71 (88.8)	-4.32 (6.15)	-32.0	-6.00	-3.00	0.00	5.0	
		Week 58	Sparsentan	82	76 (92.7)	-2.82 (6.34)	-18.0	-6.00	-3.00	0.00	27.0	0.46 [0.13, 0.80]
			Irbesartan	80	66 (82.5)	-5.77 (6.46)	-30.0	-9.00	-6.00	-1.00	8.0	
		Week 110	Sparsentan	82	68 (82.9)	-4.82 (7.97)	-21.0	-10.00	-6.00	-1.00	39.0	0.57 [0.22, 0.92]
			Irbesartan	80	63 (78.8)	-9.08 (6.90)	-28.0	-14.00	-10.00	-3.00	11.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
45 to < 60 mL/min/1.73 m**2	eGFR	Baseline	Sparsentan	45	45 (100.0)	51.42 (4.57)	45.0	48.00	51.00	55.00	59.0	
			Irbesartan	49	49 (100.0)	51.57 (4.47)	45.0	48.00	51.00	55.00	59.0	
		Week 6	Sparsentan	45	42 (93.3)	50.12 (9.36)	23.0	45.00	50.00	54.00	73.0	
			Irbesartan	49	49 (100.0)	51.31 (9.57)	21.0	46.00	50.00	57.00	76.0	
		Week 36	Sparsentan	45	42 (93.3)	50.05 (8.69)	34.0	45.00	48.00	56.00	76.0	
			Irbesartan	49	47 (95.9)	49.64 (11.00)	33.0	42.00	48.00	54.00	88.0	
		Week 58	Sparsentan	45	42 (93.3)	50.07 (9.46)	38.0	44.00	47.50	53.00	88.0	
			Irbesartan	49	45 (91.8)	49.51 (12.00)	27.0	42.00	49.00	56.00	82.0	
		Week 110	Sparsentan	45	39 (86.7)	47.59 (12.14)	27.0	40.00	47.00	52.00	95.0	
			Irbesartan	49	39 (79.6)	44.21 (12.64)	11.0	36.00	42.00	55.00	72.0	
	Change from baseline in eGFR	Week 6	Sparsentan	45	42 (93.3)	-1.17 (8.07)	-27.0	-4.00	-0.50	2.00	20.0	-0.11 [-0.52, 0.30]
			Irbesartan	49	49 (100.0)	-0.27 (8.11)	-31.0	-4.00	0.00	4.00	20.0	
		Week 36	Sparsentan	45	42 (93.3)	-1.40 (7.04)	-12.0	-5.00	-2.00	2.00	26.0	0.05 [-0.36, 0.47]
			Irbesartan	49	47 (95.9)	-1.85 (9.07)	-19.0	-7.00	-3.00	2.00	33.0	
		Week 58	Sparsentan	45	42 (93.3)	-1.52 (9.10)	-15.0	-8.00	-2.00	2.00	38.0	0.06 [-0.36, 0.48]
			Irbesartan	49	45 (91.8)	-2.04 (9.53)	-20.0	-8.00	-3.00	4.00	23.0	
		Week 110	Sparsentan	45	39 (86.7)	-4.15 (11.60)	-31.0	-11.00	-5.00	0.00	45.0	0.27 [-0.17, 0.72]
			Irbesartan	49	39 (79.6)	-7.10 (10.08)	-34.0	-15.00	-7.00	1.00	13.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	eGFR	Baseline	Sparsentan	49	49 (100.0)	72.49 (8.30)	60.0	66.00	71.00	78.00	89.0	
			Irbesartan	48	48 (100.0)	71.58 (7.62)	60.0	66.00	70.00	76.00	89.0	
		Week 6	Sparsentan	49	47 (95.9)	69.62 (8.73)	56.0	62.00	69.00	75.00	90.0	
			Irbesartan	48	45 (93.8)	68.64 (9.54)	49.0	61.00	69.00	74.00	85.0	
		Week 36	Sparsentan	49	47 (95.9)	66.15 (10.57)	34.0	62.00	65.00	72.00	88.0	
			Irbesartan	48	44 (91.7)	64.77 (11.13)	36.0	58.00	64.00	70.00	87.0	
		Week 58	Sparsentan	49	44 (89.8)	67.16 (9.86)	46.0	59.50	65.00	74.00	91.0	
			Irbesartan	48	41 (85.4)	62.78 (11.30)	34.0	55.00	64.00	72.00	83.0	
		Week 110	Sparsentan	49	43 (87.8)	65.33 (12.16)	36.0	59.00	64.00	71.00	100.0	
			Irbesartan	48	37 (77.1)	57.08 (14.58)	14.0	52.00	57.00	67.00	86.0	
	Change from baseline in eGFR	Week 6	Sparsentan	49	47 (95.9)	-2.70 (7.27)	-21.0	-7.00	-2.00	3.00	12.0	0.04 [-0.37, 0.45]
			Irbesartan	48	45 (93.8)	-2.98 (7.62)	-19.0	-7.00	-3.00	3.00	14.0	
		Week 36	Sparsentan	49	47 (95.9)	-6.21 (8.66)	-30.0	-12.00	-5.00	-1.00	12.0	0.05 [-0.36, 0.46]
			Irbesartan	48	44 (91.7)	-6.64 (8.51)	-30.0	-12.00	-6.00	-1.50	12.0	
		Week 58	Sparsentan	49	44 (89.8)	-5.18 (9.56)	-24.0	-11.00	-7.00	-1.50	24.0	0.39 [-0.04, 0.82]
			Irbesartan	48	41 (85.4)	-8.95 (9.92)	-32.0	-16.00	-9.00	-2.00	10.0	
		Week 110	Sparsentan	49	43 (87.8)	-7.30 (10.41)	-34.0	-13.00	-5.00	0.00	14.0	0.57 [0.12, 1.01]
			Irbesartan	48	37 (77.1)	-14.14 (13.78)	-59.0	-21.00	-12.00	-5.00	6.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	eGFR	Baseline	Sparsentan	26	26 (100.0)	104.00 (11.43)	90.0	95.00	102.00	111.00	127.0	
			Irbesartan	25	25 (100.0)	105.56 (9.98)	91.0	98.00	105.00	112.00	123.0	
		Week 6	Sparsentan	26	26 (100.0)	99.77 (11.42)	77.0	92.00	99.00	104.00	121.0	
			Irbesartan	25	25 (100.0)	101.48 (10.76)	80.0	95.00	101.00	108.00	120.0	
		Week 36	Sparsentan	26	26 (100.0)	94.73 (12.40)	63.0	88.00	93.50	101.00	123.0	
			Irbesartan	25	24 (96.0)	100.63 (15.82)	73.0	89.00	99.50	112.50	125.0	
		Week 58	Sparsentan	26	26 (100.0)	96.31 (16.63)	61.0	85.00	94.00	105.00	132.0	
			Irbesartan	25	21 (84.0)	97.90 (13.03)	77.0	88.00	96.00	110.00	122.0	
		Week 110	Sparsentan	26	21 (80.8)	97.33 (16.09)	60.0	87.00	96.00	108.00	126.0	
			Irbesartan	25	16 (64.0)	98.94 (15.96)	68.0	86.00	105.00	112.00	123.0	
	Change from baseline in eGFR	Week 6	Sparsentan	26	26 (100.0)	-4.23 (12.06)	-43.0	-5.00	-1.00	1.00	13.0	-0.02 [-0.56, 0.53]
			Irbesartan	25	25 (100.0)	-4.08 (6.00)	-16.0	-8.00	-3.00	0.00	7.0	
		Week 36	Sparsentan	26	26 (100.0)	-9.27 (11.24)	-39.0	-13.00	-6.50	-2.00	7.0	-0.42 [-0.98, 0.14]
			Irbesartan	25	24 (96.0)	-4.67 (10.49)	-24.0	-12.00	-7.00	3.50	15.0	
		Week 58	Sparsentan	26	26 (100.0)	-7.69 (12.92)	-34.0	-17.00	-6.00	1.00	13.0	-0.12 [-0.70, 0.46]
			Irbesartan	25	21 (84.0)	-6.33 (8.96)	-24.0	-11.00	-8.00	0.00	16.0	
		Week 110	Sparsentan	26	21 (80.8)	-5.10 (12.77)	-30.0	-17.00	-6.00	5.00	15.0	0.10 [-0.55, 0.75]
			Irbesartan	25	16 (64.0)	-6.38 (12.33)	-30.0	-15.50	-6.00	0.50	15.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline urine protein excretion												
<= 1.75 g/day	eGFR	Baseline	Sparsentan	98	98 (100.0)	59.05 (24.14)	24.0	40.00	53.50	77.00	126.0	
			Irbesartan	93	93 (100.0)	59.77 (25.25)	27.0	40.00	52.00	71.00	123.0	
		Week 6	Sparsentan	98	94 (95.9)	59.35 (23.61)	21.0	38.00	54.00	73.00	113.0	
			Irbesartan	93	91 (97.8)	58.98 (24.75)	19.0	41.00	53.00	72.00	120.0	
		Week 36	Sparsentan	98	91 (92.9)	57.85 (22.67)	23.0	38.00	55.00	73.00	123.0	
			Irbesartan	93	86 (92.5)	57.51 (26.15)	20.0	37.00	49.50	70.00	125.0	
		Week 58	Sparsentan	98	92 (93.9)	56.70 (23.26)	18.0	38.50	52.50	72.00	127.0	
			Irbesartan	93	79 (84.9)	56.34 (25.14)	13.0	36.00	52.00	72.00	122.0	
		Week 110	Sparsentan	98	87 (88.8)	55.64 (25.71)	13.0	33.00	52.00	75.00	126.0	
			Irbesartan	93	71 (76.3)	49.86 (26.35)	11.0	31.00	42.00	64.00	123.0	
	Change from baseline in eGFR	Week 6	Sparsentan	98	94 (95.9)	-0.27 (6.80)	-17.0	-4.00	0.00	3.00	20.0	0.09 [-0.20, 0.38]
			Irbesartan	93	91 (97.8)	-0.91 (7.95)	-31.0	-5.00	0.00	4.00	20.0	
		Week 36	Sparsentan	98	91 (92.9)	-1.77 (7.25)	-18.0	-5.00	-2.00	2.00	26.0	0.06 [-0.23, 0.36]
			Irbesartan	93	86 (92.5)	-2.24 (7.44)	-24.0	-7.00	-3.00	2.00	18.0	
		Week 58	Sparsentan	98	92 (93.9)	-2.72 (9.36)	-33.0	-7.00	-2.50	1.50	38.0	0.10 [-0.20, 0.40]
			Irbesartan	93	79 (84.9)	-3.67 (9.21)	-24.0	-10.00	-3.00	1.00	23.0	
		Week 110	Sparsentan	98	87 (88.8)	-3.47 (10.48)	-27.0	-10.00	-4.00	0.00	45.0	0.36 [0.04, 0.67]
			Irbesartan	93	71 (76.3)	-7.27 (10.87)	-59.0	-12.00	-6.00	-1.00	15.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 1.75 g/day	eGFR	Baseline	Sparsentan	104	104 (100.0)	54.64 (24.43)	25.0	37.00	48.00	66.00	127.0	
			Irbesartan	109	109 (100.0)	54.76 (21.90)	26.0	38.00	48.00	68.00	116.0	
		Week 6	Sparsentan	104	100 (96.2)	52.42 (23.07)	23.0	34.50	47.50	63.00	121.0	
			Irbesartan	109	106 (97.2)	52.42 (21.65)	21.0	37.00	46.00	64.00	116.0	
		Week 36	Sparsentan	104	100 (96.2)	50.18 (22.05)	18.0	34.00	46.00	63.50	118.0	
			Irbesartan	109	100 (91.7)	49.40 (22.58)	7.0	33.00	42.50	62.50	123.0	
		Week 58	Sparsentan	104	96 (92.3)	50.31 (24.83)	13.0	32.00	44.50	61.50	132.0	
			Irbesartan	109	94 (86.2)	47.13 (22.04)	11.0	31.00	40.50	60.00	116.0	
		Week 110	Sparsentan	104	84 (80.8)	47.14 (23.36)	14.0	30.00	42.50	56.00	123.0	
			Irbesartan	109	84 (77.1)	43.07 (22.56)	11.0	26.00	38.50	57.00	113.0	
	Change from baseline in eGFR	Week 6	Sparsentan	104	100 (96.2)	-1.94 (8.37)	-43.0	-4.00	-1.00	1.50	15.0	0.04 [-0.23, 0.31]
			Irbesartan	109	106 (97.2)	-2.23 (5.09)	-17.0	-5.00	-2.00	1.00	12.0	
		Week 36	Sparsentan	104	100 (96.2)	-5.11 (8.88)	-39.0	-9.50	-3.50	0.00	10.0	0.11 [-0.17, 0.39]
			Irbesartan	109	100 (91.7)	-6.05 (8.55)	-32.0	-10.00	-5.00	-2.00	33.0	
		Week 58	Sparsentan	104	96 (92.3)	-4.75 (8.65)	-34.0	-10.00	-5.00	0.00	13.0	0.30 [0.01, 0.59]
			Irbesartan	109	94 (86.2)	-7.27 (8.11)	-32.0	-12.00	-7.00	-2.00	11.0	
		Week 110	Sparsentan	104	84 (80.8)	-7.25 (9.42)	-34.0	-12.00	-7.00	-1.00	15.0	0.43 [0.12, 0.74]
			Irbesartan	109	84 (77.1)	-11.40 (9.93)	-46.0	-17.50	-11.00	-4.50	13.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline use of antihypertensives												
Yes	eGFR	Baseline	Sparsentan	90	90 (100.0)	50.91 (21.73)	25.0	35.00	44.00	65.00	127.0	
			Irbesartan	88	88 (100.0)	50.57 (18.19)	26.0	37.00	45.50	59.50	108.0	
		Week 6	Sparsentan	90	86 (95.6)	50.20 (21.77)	23.0	33.00	44.00	60.00	121.0	
			Irbesartan	88	84 (95.5)	48.64 (18.17)	19.0	35.00	44.00	57.50	108.0	
		Week 36	Sparsentan	90	86 (95.6)	48.28 (20.70)	18.0	33.00	45.00	57.00	114.0	
			Irbesartan	88	80 (90.9)	47.14 (19.70)	7.0	32.50	40.50	57.00	109.0	
		Week 58	Sparsentan	90	82 (91.1)	48.35 (22.56)	13.0	32.00	43.50	59.00	132.0	
			Irbesartan	88	77 (87.5)	43.65 (17.50)	11.0	31.00	38.00	54.00	97.0	
		Week 110	Sparsentan	90	75 (83.3)	46.47 (21.90)	14.0	31.00	40.00	56.00	123.0	
			Irbesartan	88	72 (81.8)	38.81 (17.80)	11.0	26.00	34.00	47.00	86.0	
	Change from baseline in eGFR	Week 6	Sparsentan	90	86 (95.6)	-0.83 (6.90)	-27.0	-4.00	-1.00	3.00	13.0	0.15 [-0.15, 0.45]
			Irbesartan	88	84 (95.5)	-1.87 (6.95)	-31.0	-4.50	-1.00	2.00	13.0	
		Week 36	Sparsentan	90	86 (95.6)	-2.74 (7.08)	-30.0	-5.00	-2.00	1.00	21.0	0.09 [-0.22, 0.39]
			Irbesartan	88	80 (90.9)	-3.40 (8.29)	-32.0	-6.00	-4.00	0.00	33.0	
		Week 58	Sparsentan	90	82 (91.1)	-3.27 (7.19)	-18.0	-8.00	-4.00	0.00	27.0	0.39 [0.07, 0.70]
			Irbesartan	88	77 (87.5)	-6.43 (9.12)	-32.0	-11.00	-7.00	1.00	12.0	
		Week 110	Sparsentan	90	75 (83.3)	-4.88 (9.41)	-34.0	-11.00	-6.00	0.00	39.0	0.56 [0.23, 0.89]
			Irbesartan	88	72 (81.8)	-10.60 (11.03)	-59.0	-16.50	-10.00	-3.00	13.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	eGFR	Baseline	Sparsentan	112	112 (100.0)	61.50 (25.35)	24.0	41.00	57.00	80.00	126.0	
			Irbesartan	114	114 (100.0)	62.09 (25.99)	28.0	41.00	55.50	76.00	123.0	
		Week 6	Sparsentan	112	108 (96.4)	60.22 (24.02)	21.0	38.00	57.00	74.00	120.0	
			Irbesartan	114	113 (99.1)	60.51 (25.40)	23.0	40.00	54.00	76.00	120.0	
		Week 36	Sparsentan	112	105 (93.8)	58.38 (23.20)	19.0	39.00	56.00	76.00	123.0	
			Irbesartan	114	106 (93.0)	57.69 (26.88)	15.0	37.00	53.50	70.00	125.0	
		Week 58	Sparsentan	112	106 (94.6)	57.37 (24.82)	14.0	39.00	53.00	74.00	127.0	
			Irbesartan	114	96 (84.2)	57.50 (26.49)	13.0	35.50	54.50	76.00	122.0	
		Week 110	Sparsentan	112	96 (85.7)	55.38 (26.44)	13.0	32.50	51.00	69.50	126.0	
			Irbesartan	114	83 (72.8)	52.58 (27.68)	11.0	32.00	46.00	65.00	123.0	
	Change from baseline in eGFR	Week 6	Sparsentan	112	108 (96.4)	-1.37 (8.26)	-43.0	-4.00	-0.50	2.00	20.0	0.01 [-0.26, 0.27]
			Irbesartan	114	113 (99.1)	-1.43 (6.33)	-17.0	-5.00	-2.00	3.00	20.0	
		Week 36	Sparsentan	112	105 (93.8)	-4.15 (9.16)	-39.0	-8.00	-3.00	1.00	26.0	0.09 [-0.18, 0.36]
			Irbesartan	114	106 (93.0)	-4.96 (8.20)	-25.0	-11.00	-4.00	0.00	18.0	
		Week 58	Sparsentan	112	106 (94.6)	-4.13 (10.26)	-34.0	-8.00	-3.50	1.00	38.0	0.09 [-0.19, 0.37]
			Irbesartan	114	96 (84.2)	-4.98 (8.51)	-24.0	-10.00	-5.00	0.00	23.0	
		Week 110	Sparsentan	112	96 (85.7)	-5.68 (10.68)	-31.0	-11.50	-5.50	0.00	45.0	0.28 [-0.02, 0.57]
			Irbesartan	114	83 (72.8)	-8.57 (10.07)	-46.0	-14.00	-9.00	-3.00	15.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Time since renal biopsy												
<= 5 years	eGFR	Baseline	Sparsentan	113	113 (100.0)	59.08 (25.60)	24.0	39.00	52.00	74.00	126.0	
			Irbesartan	127	127 (100.0)	61.36 (24.93)	28.0	41.00	56.00	73.00	123.0	
		Week 6	Sparsentan	113	107 (94.7)	58.21 (25.55)	21.0	37.00	53.00	75.00	121.0	
			Irbesartan	127	124 (97.6)	59.52 (25.06)	21.0	40.00	54.50	74.00	120.0	
		Week 36	Sparsentan	113	106 (93.8)	56.29 (24.64)	18.0	36.00	50.00	72.00	123.0	
			Irbesartan	127	116 (91.3)	58.09 (26.68)	7.0	38.00	50.00	70.50	125.0	
		Week 58	Sparsentan	113	105 (92.9)	56.21 (25.76)	13.0	38.00	53.00	72.00	127.0	
			Irbesartan	127	113 (89.0)	55.10 (25.08)	11.0	36.00	50.00	71.00	122.0	
		Week 110	Sparsentan	113	96 (85.0)	54.02 (26.70)	13.0	32.50	50.00	69.00	126.0	
			Irbesartan	127	95 (74.8)	50.85 (25.83)	11.0	32.00	44.00	64.00	123.0	
	Change from baseline in eGFR	Week 6	Sparsentan	113	107 (94.7)	-1.30 (8.36)	-43.0	-4.00	-1.00	3.00	20.0	0.04 [-0.22, 0.30]
			Irbesartan	127	124 (97.6)	-1.61 (7.22)	-31.0	-5.00	-2.00	3.00	20.0	
		Week 36	Sparsentan	113	106 (93.8)	-3.72 (9.04)	-39.0	-8.00	-2.00	0.00	26.0	0.04 [-0.23, 0.30]
			Irbesartan	127	116 (91.3)	-4.07 (9.51)	-32.0	-9.50	-4.00	1.00	33.0	
		Week 58	Sparsentan	113	105 (92.9)	-3.85 (9.76)	-34.0	-8.00	-4.00	0.00	38.0	0.17 [-0.09, 0.44]
			Irbesartan	127	113 (89.0)	-5.58 (10.19)	-32.0	-12.00	-7.00	1.00	23.0	
		Week 110	Sparsentan	113	96 (85.0)	-5.44 (11.62)	-34.0	-12.00	-6.50	0.00	45.0	0.33 [0.04, 0.61]
			Irbesartan	127	95 (74.8)	-9.35 (12.19)	-59.0	-16.00	-9.00	-1.00	15.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 5 years	eGFR	Baseline	Sparsentan	89	89 (100.0)	53.87 (22.42)	28.0	36.00	44.00	66.00	127.0	
			Irbesartan	75	75 (100.0)	49.80 (19.15)	26.0	36.00	43.00	64.00	108.0	
		Week 6	Sparsentan	89	87 (97.8)	52.79 (20.53)	26.0	36.00	46.00	64.00	114.0	
			Irbesartan	75	73 (97.3)	48.55 (18.13)	19.0	35.00	43.00	59.00	95.0	
		Week 36	Sparsentan	89	85 (95.5)	50.76 (19.51)	25.0	34.00	47.00	64.00	114.0	
			Irbesartan	75	70 (93.3)	44.97 (17.95)	23.0	32.00	38.00	57.00	93.0	
		Week 58	Sparsentan	89	83 (93.3)	49.93 (21.76)	21.0	33.00	43.00	61.00	132.0	
			Irbesartan	75	60 (80.0)	44.25 (19.77)	18.0	29.00	38.50	55.00	97.0	
		Week 110	Sparsentan	89	75 (84.3)	48.20 (22.09)	14.0	31.00	41.00	62.00	113.0	
			Irbesartan	75	60 (80.0)	38.78 (20.41)	11.0	24.50	34.00	46.50	106.0	
	Change from baseline in eGFR	Week 6	Sparsentan	89	87 (97.8)	-0.92 (6.77)	-33.0	-4.00	0.00	2.00	14.0	0.12 [-0.20, 0.43]
			Irbesartan	75	73 (97.3)	-1.63 (5.38)	-16.0	-5.00	-2.00	2.00	13.0	
		Week 36	Sparsentan	89	85 (95.5)	-3.27 (7.32)	-34.0	-6.00	-3.00	1.00	10.0	0.21 [-0.11, 0.53]
			Irbesartan	75	70 (93.3)	-4.66 (5.62)	-20.0	-8.00	-4.00	-1.00	10.0	
		Week 58	Sparsentan	89	83 (93.3)	-3.64 (8.10)	-29.0	-8.00	-3.00	1.00	24.0	0.29 [-0.04, 0.63]
			Irbesartan	75	60 (80.0)	-5.72 (5.30)	-18.0	-9.00	-5.50	-2.00	6.0	
		Week 110	Sparsentan	89	75 (84.3)	-5.19 (7.89)	-30.0	-10.00	-4.00	0.00	14.0	0.60 [0.25, 0.95]
			Irbesartan	75	60 (80.0)	-9.77 (7.31)	-28.0	-14.50	-10.00	-5.00	13.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: History of hypertension												
Yes	eGFR	Baseline	Sparsentan	155	155 (100.0)	53.36 (22.75)	24.0	36.00	46.00	66.00	127.0	
			Irbesartan	161	161 (100.0)	54.63 (21.55)	26.0	38.00	50.00	67.00	123.0	
		Week 6	Sparsentan	155	147 (94.8)	52.64 (22.43)	21.0	35.00	48.00	67.00	121.0	
			Irbesartan	161	157 (97.5)	53.21 (21.71)	19.0	37.00	47.00	64.00	120.0	
		Week 36	Sparsentan	155	146 (94.2)	50.86 (21.98)	18.0	34.00	46.00	63.00	118.0	
			Irbesartan	161	148 (91.9)	51.60 (23.87)	7.0	33.00	45.00	65.00	125.0	
		Week 58	Sparsentan	155	147 (94.8)	50.44 (23.26)	13.0	33.00	45.00	61.00	132.0	
			Irbesartan	161	140 (87.0)	49.19 (22.79)	11.0	32.50	44.50	63.50	122.0	
		Week 110	Sparsentan	155	133 (85.8)	48.52 (23.98)	13.0	30.00	44.00	61.00	123.0	
			Irbesartan	161	125 (77.6)	43.63 (22.71)	11.0	26.00	38.00	56.00	123.0	
	Change from baseline in eGFR	Week 6	Sparsentan	155	147 (94.8)	-0.70 (7.11)	-33.0	-4.00	0.00	3.00	20.0	0.10 [-0.12, 0.33]
			Irbesartan	161	157 (97.5)	-1.41 (6.83)	-31.0	-5.00	-1.00	2.00	20.0	
		Week 36	Sparsentan	155	146 (94.2)	-2.79 (7.63)	-34.0	-6.00	-2.00	1.00	26.0	0.07 [-0.16, 0.30]
			Irbesartan	161	148 (91.9)	-3.33 (8.04)	-32.0	-7.00	-4.00	1.00	33.0	
		Week 58	Sparsentan	155	147 (94.8)	-3.40 (8.09)	-24.0	-8.00	-3.00	1.00	38.0	0.21 [-0.03, 0.44]
			Irbesartan	161	140 (87.0)	-5.14 (8.71)	-30.0	-10.50	-5.00	0.00	23.0	
		Week 110	Sparsentan	155	133 (85.8)	-5.07 (9.41)	-34.0	-11.00	-5.00	0.00	45.0	0.46 [0.22, 0.71]
			Irbesartan	161	125 (77.6)	-9.65 (10.34)	-59.0	-15.00	-9.00	-3.00	13.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSHM: Course of eGFR by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	eGFR	Baseline	Sparsentan	47	47 (100.0)	68.06 (26.16)	29.0	45.00	69.00	89.00	126.0	
			Irbesartan	41	41 (100.0)	66.66 (28.59)	31.0	41.00	63.00	91.00	123.0	
		Week 6	Sparsentan	47	47 (100.0)	65.60 (24.40)	26.0	46.00	62.00	86.00	120.0	
			Irbesartan	41	40 (97.6)	64.25 (27.27)	23.0	42.00	55.00	84.00	119.0	
		Week 36	Sparsentan	47	45 (95.7)	63.49 (22.17)	27.0	46.00	64.00	77.00	123.0	
			Irbesartan	41	38 (92.7)	59.18 (26.58)	17.0	37.00	54.50	77.00	123.0	
		Week 58	Sparsentan	47	41 (87.2)	64.20 (24.82)	26.0	42.00	63.00	82.00	127.0	
			Irbesartan	41	33 (80.5)	60.42 (26.56)	13.0	35.00	52.00	82.00	114.0	
		Week 110	Sparsentan	47	38 (80.9)	61.79 (25.54)	26.0	40.00	59.50	81.00	126.0	
			Irbesartan	41	30 (73.2)	56.80 (29.06)	24.0	31.00	47.50	73.00	113.0	
	Change from baseline in eGFR	Week 6	Sparsentan	47	47 (100.0)	-2.47 (9.17)	-43.0	-5.00	-1.00	1.00	12.0	-0.01 [-0.43, 0.42]
			Irbesartan	41	40 (97.6)	-2.43 (5.54)	-16.0	-6.00	-2.50	1.50	7.0	
		Week 36	Sparsentan	47	45 (95.7)	-5.89 (9.90)	-39.0	-12.00	-4.00	-1.00	21.0	0.23 [-0.20, 0.67]
			Irbesartan	41	38 (92.7)	-8.03 (8.12)	-30.0	-12.00	-5.50	-3.00	4.0	
		Week 58	Sparsentan	47	41 (87.2)	-5.02 (11.86)	-34.0	-10.00	-5.00	1.00	27.0	0.25 [-0.21, 0.71]
			Irbesartan	41	33 (80.5)	-7.70 (8.97)	-32.0	-10.00	-7.00	-5.00	16.0	
		Week 110	Sparsentan	47	38 (80.9)	-6.24 (12.42)	-30.0	-12.00	-7.50	0.00	39.0	0.22 [-0.26, 0.70]
			Irbesartan	41	30 (73.2)	-8.93 (11.52)	-36.0	-14.00	-11.00	-3.00	15.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. Only key visits up to Week 110 are displayed.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Sex	Overall	Sparsentan						Interaction:	0.818
Male	Week 6	Sparsentan	139	134 (96.4)	-0.97 (0.73)	(-2.39, 0.46)	0.17 (1.02)	(-1.84, 2.17)	0.872
		Irbesartan	143	139 (97.2)	-1.13 (0.72)	(-2.54, 0.28)			
	Week 36	Sparsentan	139	135 (97.1)	-3.41 (0.73)	(-4.84, -1.98)	0.50 (1.03)	(-1.52, 2.52)	0.629
		Irbesartan	143	130 (90.9)	-3.91 (0.73)	(-5.34, -2.48)			
	Week 58	Sparsentan	139	127 (91.4)	-3.41 (0.74)	(-4.86, -1.97)	2.53 (1.05)	(0.48, 4.59)	0.016 *
		Irbesartan	143	124 (86.7)	-5.95 (0.74)	(-7.40, -4.49)			
	Week 110	Sparsentan	139	117 (84.2)	-6.43 (0.77)	(-7.93, -4.93)	4.28 (1.10)	(2.13, 6.44)	<0.001 *
		Irbesartan	143	111 (77.6)	-10.71 (0.79)	(-12.25, -9.17)			
Female	Week 6	Sparsentan	63	60 (95.2)	-1.75 (1.03)	(-3.79, 0.28)	0.94 (1.49)	(-1.98, 3.86)	0.529
		Irbesartan	59	58 (98.3)	-2.69 (1.06)	(-4.78, -0.60)			
	Week 36	Sparsentan	63	56 (88.9)	-4.09 (1.05)	(-6.15, -2.02)	1.37 (1.51)	(-1.59, 4.33)	0.364
		Irbesartan	59	56 (94.9)	-5.46 (1.07)	(-7.56, -3.35)			
	Week 58	Sparsentan	63	61 (96.8)	-4.91 (1.04)	(-6.94, -2.87)	0.57 (1.52)	(-2.42, 3.56)	0.709
		Irbesartan	59	49 (83.1)	-5.48 (1.11)	(-7.66, -3.29)			
	Week 110	Sparsentan	63	54 (85.7)	-4.24 (1.08)	(-6.36, -2.12)	3.40 (1.61)	(0.23, 6.56)	0.035 *
		Irbesartan	59	44 (74.6)	-7.64 (1.19)	(-9.98, -5.30)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age	Overall	Sparsentan						Interaction:	0.879
<= 45 years	Week 6	Sparsentan	96	94 (97.9)	-2.40 (0.98)	(-4.32, -0.49)	0.09 (1.37)	(-2.59, 2.78)	0.945
		Irbesartan	99	98 (99.0)	-2.50 (0.96)	(-4.38, -0.61)			
	Week 36	Sparsentan	96	91 (94.8)	-5.25 (0.98)	(-7.18, -3.32)	-0.13 (1.38)	(-2.85, 2.59)	0.926
		Irbesartan	99	91 (91.9)	-5.12 (0.97)	(-7.03, -3.21)			
	Week 58	Sparsentan	96	89 (92.7)	-5.01 (0.99)	(-6.95, -3.06)	1.68 (1.41)	(-1.10, 4.45)	0.235
		Irbesartan	99	82 (82.8)	-6.69 (1.01)	(-8.66, -4.71)			
	Week 110	Sparsentan	96	77 (80.2)	-6.32 (1.05)	(-8.38, -4.26)	4.81 (1.52)	(1.82, 7.79)	0.002 *
		Irbesartan	99	69 (69.7)	-11.12 (1.10)	(-13.29, -8.96)			
> 45 years	Week 6	Sparsentan	106	100 (94.3)	0.01 (0.71)	(-1.37, 1.40)	0.82 (1.01)	(-1.15, 2.79)	0.416
		Irbesartan	103	99 (96.1)	-0.81 (0.72)	(-2.21, 0.60)			
	Week 36	Sparsentan	106	100 (94.3)	-2.01 (0.71)	(-3.39, -0.62)	1.74 (1.01)	(-0.25, 3.73)	0.086
		Irbesartan	103	95 (92.2)	-3.74 (0.72)	(-5.17, -2.32)			
	Week 58	Sparsentan	106	99 (93.4)	-2.77 (0.71)	(-4.17, -1.38)	2.29 (1.02)	(0.28, 4.30)	0.025 *
		Irbesartan	103	91 (88.3)	-5.06 (0.74)	(-6.51, -3.62)			
	Week 110	Sparsentan	106	94 (88.7)	-5.07 (0.73)	(-6.50, -3.65)	3.67 (1.05)	(1.61, 5.74)	<0.001 *
		Irbesartan	103	86 (83.5)	-8.74 (0.76)	(-10.23, -7.25)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age at IgAN diagnosis	Overall	Sparsentan						Interaction:	0.100
<= 18 years	Week 6	Sparsentan	9	9 (100.0)	-7.77 (3.72)	(-15.18, -0.35)	-6.56 (6.34)	(-19.22, 6.10)	0.305
		Irbesartan	5	5 (100.0)	-1.21 (5.06)	(-11.31, 8.89)			
	Week 36	Sparsentan	9	8 (88.9)	-9.58 (3.90)	(-17.34, -1.82)	-4.97 (6.46)	(-17.84, 7.91)	0.444
		Irbesartan	5	5 (100.0)	-4.61 (5.06)	(-14.71, 5.49)			
	Week 58	Sparsentan	9	7 (77.8)	-11.83 (4.17)	(-20.13, -3.53)	-4.40 (6.94)	(-18.21, 9.42)	0.528
		Irbesartan	5	4 (80.0)	-7.43 (5.44)	(-18.24, 3.38)			
	Week 110	Sparsentan	9	5 (55.6)	-11.92 (4.88)	(-21.62, -2.22)	4.29 (7.50)	(-10.64, 19.23)	0.569
		Irbesartan	5	4 (80.0)	-16.21 (5.53)	(-27.22, -5.21)			
> 18 to 40 years	Week 6	Sparsentan	102	99 (97.1)	-1.44 (0.87)	(-3.15, 0.28)	0.73 (1.22)	(-1.66, 3.12)	0.547
		Irbesartan	109	106 (97.2)	-2.17 (0.85)	(-3.83, -0.51)			
	Week 36	Sparsentan	102	97 (95.1)	-4.59 (0.88)	(-6.32, -2.87)	0.29 (1.23)	(-2.12, 2.70)	0.814
		Irbesartan	109	101 (92.7)	-4.88 (0.86)	(-6.56, -3.20)			
	Week 58	Sparsentan	102	95 (93.1)	-4.14 (0.88)	(-5.88, -2.41)	1.82 (1.25)	(-0.63, 4.28)	0.146
		Irbesartan	109	90 (82.6)	-5.97 (0.89)	(-7.71, -4.23)			
	Week 110	Sparsentan	102	83 (81.4)	-5.81 (0.93)	(-7.64, -3.97)	4.97 (1.33)	(2.35, 7.59)	<0.001 *
		Irbesartan	109	80 (73.4)	-10.78 (0.95)	(-12.65, -8.91)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 40 years	Week 6	Sparsentan	91	86 (94.5)	-0.29 (0.79)	(-1.85, 1.27)	0.53 (1.13)	(-1.69, 2.75)	0.639
		Irbesartan	88	86 (97.7)	-0.82 (0.80)	(-2.40, 0.75)			
	Week 36	Sparsentan	91	86 (94.5)	-1.88 (0.80)	(-3.44, -0.31)	1.77 (1.14)	(-0.47, 4.02)	0.120
		Irbesartan	88	80 (90.9)	-3.65 (0.82)	(-5.26, -2.05)			
	Week 58	Sparsentan	91	86 (94.5)	-2.87 (0.80)	(-4.43, -1.30)	2.51 (1.15)	(0.26, 4.76)	0.029 *
		Irbesartan	88	79 (89.8)	-5.38 (0.83)	(-7.00, -3.75)			
	Week 110	Sparsentan	91	83 (91.2)	-4.93 (0.81)	(-6.52, -3.35)	3.36 (1.18)	(1.03, 5.68)	0.005 *
		Irbesartan	88	71 (80.7)	-8.29 (0.87)	(-9.99, -6.59)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Geographic region	Overall	Sparsentan						Interaction:	0.631
North America	Week 6	Sparsentan	35	35 (100.0)	-2.55 (1.39)	(-5.29, 0.19)	-0.82 (1.86)	(-4.47, 2.83)	0.660
		Irbesartan	46	45 (97.8)	-1.73 (1.22)	(-4.14, 0.67)			
	Week 36	Sparsentan	35	34 (97.1)	-3.71 (1.41)	(-6.47, -0.94)	0.37 (1.87)	(-3.31, 4.05)	0.844
		Irbesartan	46	44 (95.7)	-4.07 (1.23)	(-6.50, -1.65)			
	Week 58	Sparsentan	35	31 (88.6)	-4.65 (1.44)	(-7.49, -1.82)	-0.58 (1.93)	(-4.38, 3.21)	0.763
		Irbesartan	46	39 (84.8)	-4.07 (1.28)	(-6.58, -1.55)			
	Week 110	Sparsentan	35	26 (74.3)	-5.24 (1.55)	(-8.29, -2.19)	4.05 (2.10)	(-0.07, 8.18)	0.054
		Irbesartan	46	32 (69.6)	-9.29 (1.41)	(-12.07, -6.52)			
Europe	Week 6	Sparsentan	98	92 (93.9)	-0.59 (0.82)	(-2.20, 1.01)	1.00 (1.11)	(-1.18, 3.18)	0.370
		Irbesartan	115	112 (97.4)	-1.59 (0.75)	(-3.07, -0.12)			
	Week 36	Sparsentan	98	91 (92.9)	-3.06 (0.82)	(-4.67, -1.44)	0.99 (1.12)	(-1.21, 3.19)	0.376
		Irbesartan	115	106 (92.2)	-4.05 (0.76)	(-5.54, -2.55)			
	Week 58	Sparsentan	98	93 (94.9)	-3.30 (0.82)	(-4.91, -1.69)	2.73 (1.13)	(0.50, 4.95)	0.016 *
		Irbesartan	115	98 (85.2)	-6.03 (0.78)	(-7.56, -4.50)			
	Week 110	Sparsentan	98	83 (84.7)	-6.30 (0.86)	(-7.98, -4.62)	3.42 (1.18)	(1.10, 5.74)	0.004 *
		Irbesartan	115	92 (80.0)	-9.72 (0.81)	(-11.32, -8.12)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Asia Pacific	Week 6	Sparsentan	69	67 (97.1)	-1.22 (1.11)	(-3.40, 0.95)	0.25 (1.81)	(-3.31, 3.81)	0.891
		Irbesartan	41	40 (97.6)	-1.47 (1.43)	(-4.29, 1.34)			
	Week 36	Sparsentan	69	66 (95.7)	-4.21 (1.11)	(-6.40, -2.03)	1.44 (1.84)	(-2.18, 5.06)	0.436
		Irbesartan	41	36 (87.8)	-5.65 (1.47)	(-8.53, -2.77)			
	Week 58	Sparsentan	69	64 (92.8)	-4.23 (1.12)	(-6.43, -2.03)	3.14 (1.86)	(-0.51, 6.80)	0.092
		Irbesartan	41	36 (87.8)	-7.37 (1.48)	(-10.29, -4.46)			
	Week 110	Sparsentan	69	62 (89.9)	-5.00 (1.14)	(-7.24, -2.76)	5.86 (1.96)	(2.02, 9.71)	0.003 *
		Irbesartan	41	31 (75.6)	-10.86 (1.59)	(-13.98, -7.74)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline BMI	Overall	Sparsentan						Interaction:	0.187
< 27 kg/m**2	Week 6	Sparsentan	83	78 (94.0)	-1.29 (0.97)	(-3.19, 0.61)	1.04 (1.33)	(-1.56, 3.64)	0.432
		Irbesartan	94	91 (96.8)	-2.33 (0.90)	(-4.10, -0.56)			
	Week 36	Sparsentan	83	77 (92.8)	-3.61 (0.97)	(-5.52, -1.71)	2.03 (1.34)	(-0.59, 4.65)	0.129
		Irbesartan	94	86 (91.5)	-5.64 (0.92)	(-7.44, -3.85)			
	Week 58	Sparsentan	83	77 (92.8)	-3.51 (0.97)	(-5.42, -1.60)	3.49 (1.37)	(0.81, 6.17)	0.011 *
		Irbesartan	94	75 (79.8)	-7.00 (0.95)	(-8.87, -5.13)			
	Week 110	Sparsentan	83	70 (84.3)	-4.96 (1.01)	(-6.95, -2.97)	4.72 (1.44)	(1.91, 7.54)	0.001 *
		Irbesartan	94	69 (73.4)	-9.68 (1.01)	(-11.67, -7.69)			
>= 27 kg/m**2	Week 6	Sparsentan	119	116 (97.5)	-1.03 (0.75)	(-2.51, 0.45)	0.02 (1.10)	(-2.13, 2.17)	0.984
		Irbesartan	107	105 (98.1)	-1.05 (0.79)	(-2.61, 0.51)			
	Week 36	Sparsentan	119	114 (95.8)	-3.48 (0.76)	(-4.97, -1.99)	-0.09 (1.11)	(-2.26, 2.08)	0.934
		Irbesartan	107	100 (93.5)	-3.39 (0.80)	(-4.97, -1.81)			
	Week 58	Sparsentan	119	111 (93.3)	-4.03 (0.76)	(-5.53, -2.53)	0.91 (1.12)	(-1.28, 3.10)	0.414
		Irbesartan	107	98 (91.6)	-4.95 (0.81)	(-6.54, -3.35)			
	Week 110	Sparsentan	119	101 (84.9)	-6.16 (0.79)	(-7.72, -4.61)	3.92 (1.17)	(1.62, 6.22)	<0.001 *
		Irbesartan	107	85 (79.4)	-10.08 (0.86)	(-11.77, -8.39)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Randomization strata	Overall	Sparsentan						Interaction:	0.013 #
eGFR Low and UP High	Week 6	Sparsentan	71	69 (97.2)	-0.71 (0.83)	(-2.34, 0.92)	1.19 (1.16)	(-1.09, 3.47)	0.307
		Irbesartan	74	72 (97.3)	-1.89 (0.81)	(-3.49, -0.30)			
	Week 36	Sparsentan	71	68 (95.8)	-2.68 (0.83)	(-4.31, -1.04)	3.43 (1.17)	(1.13, 5.73)	0.004 *
		Irbesartan	74	66 (89.2)	-6.11 (0.82)	(-7.73, -4.49)			
	Week 58	Sparsentan	71	67 (94.4)	-4.43 (0.84)	(-6.08, -2.79)	3.38 (1.19)	(1.05, 5.71)	0.005 *
		Irbesartan	74	62 (83.8)	-7.81 (0.84)	(-9.47, -6.16)			
	Week 110	Sparsentan	71	59 (83.1)	-7.49 (0.88)	(-9.22, -5.77)	4.60 (1.26)	(2.12, 7.07)	<0.001 *
		Irbesartan	74	57 (77.0)	-12.09 (0.90)	(-13.86, -10.32)			
eGFR Low and UP Low	Week 6	Sparsentan	55	51 (92.7)	0.26 (0.99)	(-1.69, 2.20)	1.30 (1.40)	(-1.45, 4.05)	0.353
		Irbesartan	55	54 (98.2)	-1.04 (0.98)	(-2.98, 0.89)			
	Week 36	Sparsentan	55	49 (89.1)	0.01 (1.00)	(-1.95, 1.98)	2.62 (1.41)	(-0.15, 5.39)	0.064
		Irbesartan	55	52 (94.5)	-2.61 (0.99)	(-4.55, -0.66)			
	Week 58	Sparsentan	55	51 (92.7)	-0.50 (1.00)	(-2.46, 1.46)	2.87 (1.42)	(0.09, 5.65)	0.043 *
		Irbesartan	55	49 (89.1)	-3.37 (1.00)	(-5.34, -1.40)			
	Week 110	Sparsentan	55	47 (85.5)	-2.77 (1.02)	(-4.78, -0.75)	4.86 (1.47)	(1.98, 7.75)	0.001 *
		Irbesartan	55	44 (80.0)	-7.63 (1.05)	(-9.70, -5.56)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
eGFR High and UP High	Week 6	Sparsentan	37	35 (94.6)	-3.60 (1.84)	(-7.23, 0.02)	-0.52 (2.63)	(-5.69, 4.65)	0.844
		Irbesartan	36	34 (94.4)	-3.08 (1.87)	(-6.77, 0.60)			
	Week 36	Sparsentan	37	37 (100.0)	-7.95 (1.82)	(-11.54, -4.37)	-1.54 (2.64)	(-6.74, 3.65)	0.560
		Irbesartan	36	33 (91.7)	-6.41 (1.91)	(-10.17, -2.65)			
	Week 58	Sparsentan	37	34 (91.9)	-4.97 (1.86)	(-8.63, -1.30)	2.12 (2.72)	(-3.24, 7.47)	0.437
		Irbesartan	36	30 (83.3)	-7.09 (1.98)	(-10.99, -3.19)			
	Week 110	Sparsentan	37	30 (81.1)	-6.70 (1.97)	(-10.58, -2.83)	7.80 (2.87)	(2.16, 13.44)	0.007 *
		Irbesartan	36	27 (75.0)	-14.50 (2.09)	(-18.60, -10.40)			
eGFR High and UP Low	Week 6	Sparsentan	39	39 (100.0)	-1.74 (1.48)	(-4.65, 1.16)	-1.19 (2.12)	(-5.35, 2.97)	0.575
		Irbesartan	37	37 (100.0)	-0.56 (1.52)	(-3.54, 2.43)			
	Week 36	Sparsentan	39	37 (94.9)	-5.85 (1.49)	(-8.78, -2.91)	-4.09 (2.14)	(-8.30, 0.13)	0.057
		Irbesartan	37	35 (94.6)	-1.76 (1.54)	(-4.78, 1.26)			
	Week 58	Sparsentan	39	36 (92.3)	-6.50 (1.50)	(-9.45, -3.55)	-1.85 (2.19)	(-6.14, 2.45)	0.398
		Irbesartan	37	32 (86.5)	-4.65 (1.59)	(-7.77, -1.53)			
	Week 110	Sparsentan	39	35 (89.7)	-5.73 (1.53)	(-8.73, -2.72)	-1.01 (2.28)	(-5.49, 3.47)	0.658
		Irbesartan	37	27 (73.0)	-4.72 (1.69)	(-8.04, -1.39)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 1	Overall	Sparsentan						Interaction:	0.056
< 60 mL/min/1.73 m**2	Week 6	Sparsentan	127	121 (95.3)	0.17 (0.63)	(-1.07, 1.41)	0.92 (0.89)	(-0.82, 2.66)	0.298
		Irbesartan	129	127 (98.4)	-0.75 (0.62)	(-1.97, 0.47)			
	Week 36	Sparsentan	127	118 (92.9)	-1.23 (0.63)	(-2.47, 0.01)	2.54 (0.89)	(0.78, 4.29)	0.005 *
		Irbesartan	129	118 (91.5)	-3.77 (0.63)	(-5.01, -2.53)			
	Week 58	Sparsentan	127	118 (92.9)	-2.45 (0.64)	(-3.70, -1.20)	2.54 (0.90)	(0.76, 4.31)	0.005 *
		Irbesartan	129	111 (86.0)	-4.99 (0.64)	(-6.25, -3.73)			
	Week 110	Sparsentan	127	107 (84.3)	-4.97 (0.66)	(-6.27, -3.68)	4.14 (0.95)	(2.29, 6.00)	<0.001 *
		Irbesartan	129	102 (79.1)	-9.12 (0.68)	(-10.45, -7.79)			
60 to < 90 mL/min/1.73 m**2	Week 6	Sparsentan	49	47 (95.9)	-2.86 (1.43)	(-5.67, -0.05)	-0.01 (2.04)	(-4.02, 4.01)	0.997
		Irbesartan	48	45 (93.8)	-2.85 (1.45)	(-5.71, 0.00)			
	Week 36	Sparsentan	49	47 (95.9)	-6.39 (1.43)	(-9.19, -3.58)	-0.17 (2.06)	(-4.21, 3.88)	0.935
		Irbesartan	48	44 (91.7)	-6.22 (1.48)	(-9.12, -3.32)			
	Week 58	Sparsentan	49	44 (89.8)	-5.39 (1.45)	(-8.24, -2.53)	2.98 (2.10)	(-1.15, 7.10)	0.156
		Irbesartan	48	41 (85.4)	-8.37 (1.51)	(-11.33, -5.40)			
	Week 110	Sparsentan	49	43 (87.8)	-8.29 (1.49)	(-11.22, -5.37)	5.49 (2.17)	(1.21, 9.76)	0.012 *
		Irbesartan	48	37 (77.1)	-13.78 (1.58)	(-16.89, -10.67)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
>= 90 mL/min/1.73 m**2	Week 6	Sparsentan	26	26 (100.0)	-4.21 (2.08)	(-8.31, -0.12)	-0.11 (2.97)	(-5.96, 5.73)	0.969
		Irbesartan	25	25 (100.0)	-4.10 (2.12)	(-8.27, 0.08)			
	Week 36	Sparsentan	26	26 (100.0)	-9.25 (2.08)	(-13.35, -5.16)	-4.61 (2.99)	(-10.50, 1.27)	0.124
		Irbesartan	25	24 (96.0)	-4.64 (2.15)	(-8.87, -0.41)			
	Week 58	Sparsentan	26	26 (100.0)	-7.67 (2.08)	(-11.77, -3.58)	-1.69 (3.08)	(-7.74, 4.37)	0.584
		Irbesartan	25	21 (84.0)	-5.99 (2.26)	(-10.45, -1.53)			
	Week 110	Sparsentan	26	21 (80.8)	-4.12 (2.24)	(-8.52, 0.29)	2.47 (3.37)	(-4.17, 9.10)	0.465
		Irbesartan	25	16 (64.0)	-6.58 (2.52)	(-11.55, -1.62)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 2	Overall	Sparsentan						Interaction:	0.098
< 45 mL/min/1.73 m**2	Week 6	Sparsentan	82	79 (96.3)	0.79 (0.69)	(-0.57, 2.14)	1.66 (0.98)	(-0.27, 3.59)	0.092
		Irbesartan	80	78 (97.5)	-0.87 (0.70)	(-2.24, 0.50)			
	Week 36	Sparsentan	82	76 (92.7)	-1.27 (0.69)	(-2.64, 0.09)	3.56 (0.99)	(1.61, 5.50)	<0.001 *
		Irbesartan	80	71 (88.8)	-4.83 (0.71)	(-6.22, -3.44)			
	Week 58	Sparsentan	82	76 (92.7)	-3.03 (0.70)	(-4.40, -1.66)	3.43 (1.00)	(1.46, 5.40)	<0.001 *
		Irbesartan	80	66 (82.5)	-6.46 (0.72)	(-7.87, -5.05)			
	Week 110	Sparsentan	82	68 (82.9)	-5.44 (0.72)	(-6.86, -4.02)	4.26 (1.05)	(2.20, 6.32)	<0.001 *
		Irbesartan	80	63 (78.8)	-9.70 (0.76)	(-11.19, -8.21)			
45 to < 60 mL/min/1.73 m**2	Week 6	Sparsentan	45	42 (93.3)	-1.00 (1.26)	(-3.48, 1.48)	-0.46 (1.74)	(-3.88, 2.95)	0.790
		Irbesartan	49	49 (100.0)	-0.54 (1.19)	(-2.88, 1.81)			
	Week 36	Sparsentan	45	42 (93.3)	-1.20 (1.26)	(-3.68, 1.28)	0.89 (1.75)	(-2.54, 4.32)	0.612
		Irbesartan	49	47 (95.9)	-2.08 (1.20)	(-4.44, 0.28)			
	Week 58	Sparsentan	45	42 (93.3)	-1.47 (1.27)	(-3.96, 1.02)	1.31 (1.76)	(-2.15, 4.78)	0.456
		Irbesartan	49	45 (91.8)	-2.79 (1.22)	(-5.19, -0.39)			
	Week 110	Sparsentan	45	39 (86.7)	-4.29 (1.31)	(-6.85, -1.73)	4.00 (1.84)	(0.38, 7.62)	0.031 *
		Irbesartan	49	39 (79.6)	-8.29 (1.30)	(-10.84, -5.74)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
60 to < 90 mL/min/1.73 m**2	Week 6	Sparsentan	49	47 (95.9)	-2.86 (1.43)	(-5.67, -0.05)	-0.01 (2.04)	(-4.02, 4.01)	0.997
		Irbesartan	48	45 (93.8)	-2.85 (1.45)	(-5.71, 0.00)			
	Week 36	Sparsentan	49	47 (95.9)	-6.39 (1.43)	(-9.19, -3.58)	-0.17 (2.06)	(-4.21, 3.88)	0.935
		Irbesartan	48	44 (91.7)	-6.22 (1.48)	(-9.12, -3.32)			
	Week 58	Sparsentan	49	44 (89.8)	-5.39 (1.45)	(-8.24, -2.53)	2.98 (2.10)	(-1.15, 7.10)	0.156
		Irbesartan	48	41 (85.4)	-8.37 (1.51)	(-11.33, -5.40)			
	Week 110	Sparsentan	49	43 (87.8)	-8.29 (1.49)	(-11.22, -5.37)	5.49 (2.17)	(1.21, 9.76)	0.012 *
		Irbesartan	48	37 (77.1)	-13.78 (1.58)	(-16.89, -10.67)			
>= 90 mL/min/1.73 m**2	Week 6	Sparsentan	26	26 (100.0)	-4.21 (2.08)	(-8.31, -0.12)	-0.11 (2.97)	(-5.96, 5.73)	0.969
		Irbesartan	25	25 (100.0)	-4.10 (2.12)	(-8.27, 0.08)			
	Week 36	Sparsentan	26	26 (100.0)	-9.25 (2.08)	(-13.35, -5.16)	-4.61 (2.99)	(-10.50, 1.27)	0.124
		Irbesartan	25	24 (96.0)	-4.64 (2.15)	(-8.87, -0.41)			
	Week 58	Sparsentan	26	26 (100.0)	-7.67 (2.08)	(-11.77, -3.58)	-1.69 (3.08)	(-7.74, 4.37)	0.584
		Irbesartan	25	21 (84.0)	-5.99 (2.26)	(-10.45, -1.53)			
	Week 110	Sparsentan	26	21 (80.8)	-4.12 (2.24)	(-8.52, 0.29)	2.47 (3.37)	(-4.17, 9.10)	0.465
		Irbesartan	25	16 (64.0)	-6.58 (2.52)	(-11.55, -1.62)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline urine protein excretion	Overall	Sparsentan						Interaction:	0.801
<= 1.75 g/day	Week 6	Sparsentan	98	94 (95.9)	-0.35 (0.86)	(-2.04, 1.33)	0.52 (1.23)	(-1.89, 2.93)	0.672
		Irbesartan	93	91 (97.8)	-0.87 (0.88)	(-2.60, 0.85)			
	Week 36	Sparsentan	98	91 (92.9)	-1.77 (0.86)	(-3.47, -0.08)	0.47 (1.24)	(-1.97, 2.90)	0.706
		Irbesartan	93	86 (92.5)	-2.24 (0.89)	(-3.99, -0.49)			
	Week 58	Sparsentan	98	92 (93.9)	-2.79 (0.86)	(-4.49, -1.10)	0.93 (1.26)	(-1.54, 3.39)	0.461
		Irbesartan	93	79 (84.9)	-3.72 (0.91)	(-5.51, -1.93)			
	Week 110	Sparsentan	98	87 (88.8)	-3.31 (0.88)	(-5.04, -1.58)	4.17 (1.31)	(1.60, 6.74)	0.001 *
		Irbesartan	93	71 (76.3)	-7.48 (0.97)	(-9.38, -5.59)			
> 1.75 g/day	Week 6	Sparsentan	104	100 (96.2)	-1.93 (0.81)	(-3.52, -0.33)	0.36 (1.14)	(-1.88, 2.59)	0.755
		Irbesartan	109	106 (97.2)	-2.28 (0.79)	(-3.84, -0.73)			
	Week 36	Sparsentan	104	100 (96.2)	-5.24 (0.82)	(-6.84, -3.64)	1.02 (1.15)	(-1.23, 3.27)	0.372
		Irbesartan	109	100 (91.7)	-6.26 (0.80)	(-7.84, -4.68)			
	Week 58	Sparsentan	104	96 (92.3)	-4.84 (0.83)	(-6.46, -3.22)	2.85 (1.17)	(0.56, 5.14)	0.015 *
		Irbesartan	109	94 (86.2)	-7.69 (0.82)	(-9.30, -6.07)			
	Week 110	Sparsentan	104	84 (80.8)	-8.06 (0.87)	(-9.77, -6.35)	3.90 (1.24)	(1.48, 6.33)	0.002 *
		Irbesartan	109	84 (77.1)	-11.96 (0.88)	(-13.68, -10.24)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline use of antihypertensives	Overall	Sparsentan						Interaction:	0.201
Yes	Week 6	Sparsentan	90	86 (95.6)	-0.71 (0.83)	(-2.35, 0.92)	1.37 (1.19)	(-0.96, 3.70)	0.249
		Irbesartan	88	84 (95.5)	-2.08 (0.85)	(-3.74, -0.42)			
	Week 36	Sparsentan	90	86 (95.6)	-2.75 (0.83)	(-4.38, -1.11)	0.76 (1.20)	(-1.58, 3.11)	0.524
		Irbesartan	88	80 (90.9)	-3.51 (0.86)	(-5.19, -1.83)			
	Week 58	Sparsentan	90	82 (91.1)	-3.33 (0.84)	(-4.98, -1.67)	3.25 (1.21)	(0.87, 5.63)	0.007 *
		Irbesartan	88	77 (87.5)	-6.58 (0.87)	(-8.29, -4.87)			
	Week 110	Sparsentan	90	75 (83.3)	-4.96 (0.88)	(-6.69, -3.24)	5.93 (1.26)	(3.46, 8.41)	<0.001 *
		Irbesartan	88	72 (81.8)	-10.90 (0.91)	(-12.67, -9.12)			
No	Week 6	Sparsentan	112	108 (96.4)	-1.57 (0.84)	(-3.21, 0.07)	-0.30 (1.18)	(-2.61, 2.00)	0.795
		Irbesartan	114	113 (99.1)	-1.26 (0.82)	(-2.88, 0.35)			
	Week 36	Sparsentan	112	105 (93.8)	-4.26 (0.84)	(-5.91, -2.61)	0.81 (1.19)	(-1.52, 3.14)	0.495
		Irbesartan	114	106 (93.0)	-5.07 (0.84)	(-6.71, -3.43)			
	Week 58	Sparsentan	112	106 (94.6)	-4.29 (0.84)	(-5.95, -2.64)	0.97 (1.21)	(-1.40, 3.34)	0.422
		Irbesartan	114	96 (84.2)	-5.26 (0.86)	(-6.95, -3.57)			
	Week 110	Sparsentan	112	96 (85.7)	-6.26 (0.88)	(-7.98, -4.54)	2.72 (1.28)	(0.21, 5.23)	0.034 *
		Irbesartan	114	83 (72.8)	-8.98 (0.93)	(-10.81, -7.16)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Time since renal biopsy	Overall	Sparsentan						Interaction:	0.949
<= 5 years	Week 6	Sparsentan	113	107 (94.7)	-1.45 (0.88)	(-3.17, 0.27)	0.15 (1.20)	(-2.21, 2.51)	0.901
		Irbesartan	127	124 (97.6)	-1.60 (0.82)	(-3.21, 0.01)			
	Week 36	Sparsentan	113	106 (93.8)	-3.75 (0.88)	(-5.47, -2.02)	0.36 (1.21)	(-2.02, 2.74)	0.765
		Irbesartan	127	116 (91.3)	-4.11 (0.83)	(-5.75, -2.47)			
	Week 58	Sparsentan	113	105 (92.9)	-4.02 (0.88)	(-5.75, -2.29)	1.80 (1.22)	(-0.60, 4.20)	0.141
		Irbesartan	127	113 (89.0)	-5.82 (0.85)	(-7.48, -4.16)			
	Week 110	Sparsentan	113	96 (85.0)	-5.55 (0.92)	(-7.35, -3.76)	4.25 (1.29)	(1.72, 6.78)	0.001 *
		Irbesartan	127	95 (74.8)	-9.80 (0.91)	(-11.58, -8.01)			
> 5 years	Week 6	Sparsentan	89	87 (97.8)	-0.79 (0.74)	(-2.25, 0.67)	0.92 (1.10)	(-1.24, 3.08)	0.404
		Irbesartan	75	73 (97.3)	-1.71 (0.81)	(-3.31, -0.11)			
	Week 36	Sparsentan	89	85 (95.5)	-3.30 (0.75)	(-4.77, -1.83)	1.64 (1.11)	(-0.54, 3.82)	0.140
		Irbesartan	75	70 (93.3)	-4.94 (0.82)	(-6.55, -3.33)			
	Week 58	Sparsentan	89	83 (93.3)	-3.60 (0.76)	(-5.08, -2.11)	2.35 (1.15)	(0.09, 4.60)	0.041 *
		Irbesartan	75	60 (80.0)	-5.94 (0.86)	(-7.64, -4.25)			
	Week 110	Sparsentan	89	75 (84.3)	-5.77 (0.79)	(-7.32, -4.22)	4.34 (1.19)	(2.00, 6.67)	<0.001 *
		Irbesartan	75	60 (80.0)	-10.11 (0.89)	(-11.85, -8.36)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGC_FSCM: Change from baseline in eGFR by subgroup
Full Analysis Set

Change from baseline in eGFR					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
History of hypertension	Overall	Sparsentan						Interaction:	0.738
Yes	Week 6	Sparsentan	155	147 (94.8)	-0.79 (0.66)	(-2.09, 0.50)	0.53 (0.92)	(-1.28, 2.34)	0.563
		Irbesartan	161	157 (97.5)	-1.33 (0.65)	(-2.59, -0.06)			
	Week 36	Sparsentan	155	146 (94.2)	-2.80 (0.66)	(-4.10, -1.50)	0.52 (0.93)	(-1.31, 2.34)	0.577
		Irbesartan	161	148 (91.9)	-3.32 (0.65)	(-4.60, -2.04)			
	Week 58	Sparsentan	155	147 (94.8)	-3.50 (0.66)	(-4.80, -2.20)	1.68 (0.94)	(-0.16, 3.53)	0.073
		Irbesartan	161	140 (87.0)	-5.18 (0.67)	(-6.49, -3.87)			
	Week 110	Sparsentan	155	133 (85.8)	-5.43 (0.69)	(-6.78, -4.09)	4.46 (0.98)	(2.53, 6.39)	<0.001 *
		Irbesartan	161	125 (77.6)	-9.89 (0.71)	(-11.28, -8.51)			
No	Week 6	Sparsentan	47	47 (100.0)	-2.43 (1.35)	(-5.09, 0.23)	0.39 (1.99)	(-3.53, 4.32)	0.843
		Irbesartan	41	40 (97.6)	-2.82 (1.45)	(-5.68, 0.03)			
	Week 36	Sparsentan	47	45 (95.7)	-6.14 (1.37)	(-8.83, -3.45)	2.56 (2.02)	(-1.41, 6.53)	0.205
		Irbesartan	41	38 (92.7)	-8.70 (1.47)	(-11.60, -5.81)			
	Week 58	Sparsentan	47	41 (87.2)	-5.07 (1.41)	(-7.83, -2.31)	3.64 (2.08)	(-0.45, 7.73)	0.081
		Irbesartan	41	33 (80.5)	-8.71 (1.52)	(-11.70, -5.71)			
	Week 110	Sparsentan	47	38 (80.9)	-6.62 (1.47)	(-9.51, -3.73)	3.39 (2.21)	(-0.95, 7.73)	0.126
		Irbesartan	41	30 (73.2)	-10.01 (1.64)	(-13.23, -6.79)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures.
LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values up to Week 110 are included in the model. Only key visits up to Week 110 are displayed. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Figure PF2GGC_FSGM: Change from baseline in eGFR by subgroup
Full Analysis Set
Study: PROTECT
Randomization strata: eGFR Low and UP High



Sparsentan	69	68	67	59
Irbesartan	72	66	62	57

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2GGC_FSCM.

Figure PF2GGC_FSGM: Change from baseline in eGFR by subgroup
Full Analysis Set
Study: PROTECT
Randomization strata: eGFR Low and UP Low



Sparsentan	51	49	51	47
Irbesartan	54	52	49	44

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2GGC_FSCM.

Figure PF2GGC_FSGM: Change from baseline in eGFR by subgroup
Full Analysis Set
Study: PROTECT
Randomization strata: eGFR High and UP High



Sparsentan	35	37	34	30
Irbesartan	34	33	30	27

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2GGC_FSCM.

Figure PF2GGC_FSGM: Change from baseline in eGFR by subgroup
Full Analysis Set
Study: PROTECT
Randomization strata: eGFR High and UP Low



Sparsentan	39	37	36	35
Irbesartan	37	35	32	27

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2GGC_FSCM.

Table PT2GGA_FSRM: Rate of change in eGFR (total slope) - Year 1 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Sex	Overall	Sparsentan					Interaction:	0.015 #
Male	Baseline to Week 58	Sparsentan	139	-3.00 (0.81)	(-4.60, -1.39)	1.69 (1.15)	(-0.58, 3.96)	0.144
		Irbesartan	143	-4.68 (0.82)	(-6.29, -3.08)			
Female	Baseline to Week 58	Sparsentan	63	-4.41 (1.32)	(-7.01, -1.81)	-0.23 (1.90)	(-3.99, 3.53)	0.904
		Irbesartan	59	-4.18 (1.38)	(-6.90, -1.46)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGA_FSRM: Rate of change in eGFR (total slope) - Year 1 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age	Overall	Sparsentan					Interaction:	0.490
<= 45 years	Baseline to Week 58	Sparsentan	96	-4.18 (1.16)	(-6.46, -1.89)	0.74 (1.64)	(-2.48, 3.97)	0.651
		Irbesartan	99	-4.92 (1.16)	(-7.20, -2.64)			
> 45 years	Baseline to Week 58	Sparsentan	106	-2.77 (0.80)	(-4.34, -1.20)	1.39 (1.15)	(-0.87, 3.64)	0.227
		Irbesartan	103	-4.15 (0.82)	(-5.77, -2.53)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGA_FSRM: Rate of change in eGFR (total slope) - Year 1 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age at IgAN diagnosis	Overall	Sparsentan					Interaction:	<0.001 #
<= 18 years	Baseline to Week 58	Sparsentan	9	-5.49 (3.64)	(-13.03, 2.06)	1.51 (5.92)	(-10.74, 13.76)	0.801
		Irbesartan	5	-7.00 (4.67)	(-16.64, 2.65)			
> 18 to 40 years	Baseline to Week 58	Sparsentan	102	-3.88 (1.04)	(-5.92, -1.84)	0.33 (1.45)	(-2.53, 3.19)	0.821
		Irbesartan	109	-4.21 (1.02)	(-6.22, -2.20)			
> 40 years	Baseline to Week 58	Sparsentan	91	-2.63 (0.91)	(-4.43, -0.82)	2.13 (1.32)	(-0.46, 4.73)	0.106
		Irbesartan	88	-4.76 (0.95)	(-6.62, -2.90)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGA_FSRM: Rate of change in eGFR (total slope) - Year 1 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Geographic region	Overall	Sparsentan					Interaction:	0.121
North America	Baseline to Week 58	Sparsentan	35	-3.14 (1.66)	(-6.43, 0.15)	0.47 (2.21)	(-3.91, 4.85)	0.833
		Irbesartan	46	-3.61 (1.46)	(-6.51, -0.71)			
Europe	Baseline to Week 58	Sparsentan	98	-2.96 (0.93)	(-4.80, -1.12)	1.60 (1.28)	(-0.92, 4.13)	0.213
		Irbesartan	115	-4.56 (0.88)	(-6.29, -2.83)			
Asia Pacific	Baseline to Week 58	Sparsentan	69	-4.24 (1.29)	(-6.78, -1.69)	1.10 (2.13)	(-3.11, 5.32)	0.605
		Irbesartan	41	-5.34 (1.70)	(-8.70, -1.98)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGA_FSRM: Rate of change in eGFR (total slope) - Year 1 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline BMI	Overall	Sparsentan					Interaction:	0.078
< 27 kg/m**2	Baseline to Week 58	Sparsentan	83	-3.07 (1.19)	(-5.40, -0.73)	2.17 (1.64)	(-1.06, 5.41)	0.187
		Irbesartan	94	-5.24 (1.14)	(-7.49, -3.00)			
>= 27 kg/m**2	Baseline to Week 58	Sparsentan	119	-3.66 (0.83)	(-5.29, -2.04)	0.29 (1.21)	(-2.08, 2.67)	0.808
		Irbesartan	107	-3.96 (0.88)	(-5.69, -2.23)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGA_FSRM: Rate of change in eGFR (total slope) - Year 1 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Randomization strata	Overall	Sparsentan					Interaction:	0.005 #
eGFR Low and UP High	Baseline to Week 58	Sparsentan	71	-3.99 (1.05)	(-6.05, -1.92)	2.82 (1.47)	(-0.09, 5.72)	0.058
		Irbesartan	74	-6.80 (1.04)	(-8.85, -4.76)			
eGFR Low and UP Low	Baseline to Week 58	Sparsentan	55	-1.17 (1.11)	(-3.37, 1.03)	1.09 (1.57)	(-2.02, 4.19)	0.491
		Irbesartan	55	-2.26 (1.11)	(-4.45, -0.06)			
eGFR High and UP High	Baseline to Week 58	Sparsentan	37	-3.02 (2.09)	(-7.18, 1.13)	2.50 (3.05)	(-3.55, 8.56)	0.414
		Irbesartan	36	-5.53 (2.22)	(-9.93, -1.12)			
eGFR High and UP Low	Baseline to Week 58	Sparsentan	39	-6.08 (1.68)	(-9.41, -2.76)	-3.20 (2.43)	(-8.02, 1.61)	0.190
		Irbesartan	37	-2.88 (1.76)	(-6.36, 0.60)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGA_FSRM: Rate of change in eGFR (total slope) - Year 1 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 1	Overall	Sparsentan					Interaction:	0.057
< 60 mL/min/1.73 m**2	Baseline to Week 58	Sparsentan	127	-2.84 (0.75)	(-4.31, -1.37)	1.59 (1.06)	(-0.49, 3.67)	0.134
		Irbesartan	129	-4.43 (0.75)	(-5.90, -2.96)			
60 to < 90 mL/min/1.73 m**2	Baseline to Week 58	Sparsentan	49	-3.69 (1.56)	(-6.78, -0.61)	2.67 (2.26)	(-1.79, 7.13)	0.239
		Irbesartan	48	-6.36 (1.63)	(-9.58, -3.14)			
>= 90 mL/min/1.73 m**2	Baseline to Week 58	Sparsentan	26	-5.88 (2.49)	(-10.85, -0.91)	-4.29 (3.62)	(-11.51, 2.93)	0.240
		Irbesartan	25	-1.59 (2.63)	(-6.82, 3.64)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGA_FSRM: Rate of change in eGFR (total slope) - Year 1 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 2	Overall	Sparsentan					Interaction:	0.043 #
< 45 mL/min/1.73 m**2	Baseline to Week 58	Sparsentan	82	-3.66 (0.88)	(-5.39, -1.92)	2.36 (1.26)	(-0.13, 4.84)	0.063
		Irbesartan	80	-6.01 (0.90)	(-7.79, -4.24)			
45 to < 60 mL/min/1.73 m**2	Baseline to Week 58	Sparsentan	45	-1.40 (1.40)	(-4.18, 1.37)	0.70 (1.94)	(-3.13, 4.54)	0.717
		Irbesartan	49	-2.11 (1.34)	(-4.76, 0.54)			
60 to < 90 mL/min/1.73 m**2	Baseline to Week 58	Sparsentan	49	-3.69 (1.56)	(-6.78, -0.61)	2.67 (2.26)	(-1.79, 7.13)	0.239
		Irbesartan	48	-6.36 (1.63)	(-9.58, -3.14)			
>= 90 mL/min/1.73 m**2	Baseline to Week 58	Sparsentan	26	-5.88 (2.49)	(-10.85, -0.91)	-4.29 (3.62)	(-11.51, 2.93)	0.240
		Irbesartan	25	-1.59 (2.63)	(-6.82, 3.64)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGA_FSRM: Rate of change in eGFR (total slope) - Year 1 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline urine protein excretion	Overall	Sparsentan					Interaction:	0.620
<= 1.75 g/day	Baseline to Week 58	Sparsentan	98	-2.88 (0.99)	(-4.82, -0.93)	-0.12 (1.43)	(-2.93, 2.70)	0.935
		Irbesartan	93	-2.76 (1.03)	(-4.79, -0.73)			
> 1.75 g/day	Baseline to Week 58	Sparsentan	104	-3.98 (0.95)	(-5.85, -2.11)	2.07 (1.34)	(-0.56, 4.70)	0.123
		Irbesartan	109	-6.05 (0.94)	(-7.90, -4.20)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGA_FSRM: Rate of change in eGFR (total slope) - Year 1 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline use of antihypertensives	Overall	Sparsentan					Interaction:	0.614
Yes	Baseline to Week 58	Sparsentan	90	-2.84 (0.94)	(-4.70, -0.98)	1.80 (1.35)	(-0.86, 4.47)	0.184
		Irbesartan	88	-4.65 (0.97)	(-6.56, -2.73)			
No	Baseline to Week 58	Sparsentan	112	-3.87 (0.99)	(-5.82, -1.93)	0.57 (1.40)	(-2.19, 3.32)	0.687
		Irbesartan	114	-4.44 (0.99)	(-6.39, -2.48)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGA_FSRM: Rate of change in eGFR (total slope) - Year 1 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Time since renal biopsy	Overall	Sparsentan					Interaction:	0.393
<= 5 years	Baseline to Week 58	Sparsentan	113	-3.28 (1.03)	(-5.31, -1.25)	0.82 (1.42)	(-1.98, 3.62)	0.566
		Irbesartan	127	-4.10 (0.98)	(-6.03, -2.17)			
> 5 years	Baseline to Week 58	Sparsentan	89	-3.60 (0.83)	(-5.24, -1.96)	1.66 (1.25)	(-0.80, 4.12)	0.186
		Irbesartan	75	-5.25 (0.93)	(-7.09, -3.42)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGA_FSRM: Rate of change in eGFR (total slope) - Year 1 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
History of hypertension	Overall	Sparsentan					Interaction:	0.348
Yes	Baseline to Week 58	Sparsentan	155	-2.98 (0.75)	(-4.46, -1.51)	1.12 (1.06)	(-0.96, 3.21)	0.289
		Irbesartan	161	-4.11 (0.75)	(-5.58, -2.64)			
No	Baseline to Week 58	Sparsentan	47	-5.01 (1.66)	(-8.30, -1.73)	1.15 (2.44)	(-3.68, 5.98)	0.639
		Irbesartan	41	-6.16 (1.79)	(-9.70, -2.62)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGB_FSRM: Rate of change in eGFR (total slope) - Year 2 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 2				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Sex	Overall	Sparsentan					Interaction:	0.023 #
Male	Baseline to Week 110	Sparsentan	139	-3.12 (0.51)	(-4.12, -2.12)	1.43 (0.72)	(0.01, 2.85)	0.049 *
		Irbesartan	143	-4.55 (0.51)	(-5.56, -3.54)			
Female	Baseline to Week 110	Sparsentan	63	-2.88 (0.72)	(-4.30, -1.46)	0.53 (1.05)	(-1.54, 2.60)	0.615
		Irbesartan	59	-3.41 (0.76)	(-4.92, -1.90)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 110 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGB_FSRM: Rate of change in eGFR (total slope) - Year 2 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 2				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age	Overall	Sparsentan					Interaction:	0.147
<= 45 years	Baseline to Week 110	Sparsentan	96	-3.32 (0.71)	(-4.71, -1.93)	1.72 (1.00)	(-0.26, 3.70)	0.089
		Irbesartan	99	-5.03 (0.71)	(-6.44, -3.63)			
> 45 years	Baseline to Week 110	Sparsentan	106	-2.81 (0.47)	(-3.73, -1.89)	0.68 (0.67)	(-0.65, 2.01)	0.313
		Irbesartan	103	-3.49 (0.48)	(-4.45, -2.54)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 110 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGB_FSRM: Rate of change in eGFR (total slope) - Year 2 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 2				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age at IgAN diagnosis	Overall	Sparsentan					Interaction:	0.001 #
<= 18 years	Baseline to Week 110	Sparsentan	9	-7.59 (2.91)	(-13.94, -1.23)	-0.98 (4.58)	(-11.07, 9.10)	0.834
		Irbesartan	5	-6.60 (3.54)	(-14.43, 1.23)			
> 18 to 40 years	Baseline to Week 110	Sparsentan	102	-2.94 (0.62)	(-4.16, -1.73)	1.80 (0.87)	(0.09, 3.51)	0.040 *
		Irbesartan	109	-4.74 (0.61)	(-5.95, -3.53)			
> 40 years	Baseline to Week 110	Sparsentan	91	-2.77 (0.53)	(-3.81, -1.72)	0.72 (0.77)	(-0.80, 2.23)	0.351
		Irbesartan	88	-3.49 (0.56)	(-4.58, -2.39)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 110 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGB_FSRM: Rate of change in eGFR (total slope) - Year 2 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 2				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Geographic region	Overall	Sparsentan					Interaction:	0.053
North America	Baseline to Week 110	Sparsentan	35	-2.74 (1.01)	(-4.74, -0.74)	1.63 (1.35)	(-1.05, 4.31)	0.230
		Irbesartan	46	-4.37 (0.90)	(-6.16, -2.59)			
Europe	Baseline to Week 110	Sparsentan	98	-3.02 (0.56)	(-4.12, -1.91)	1.32 (0.77)	(-0.19, 2.84)	0.086
		Irbesartan	115	-4.34 (0.53)	(-5.38, -3.30)			
Asia Pacific	Baseline to Week 110	Sparsentan	69	-3.26 (0.78)	(-4.80, -1.71)	0.48 (1.31)	(-2.10, 3.07)	0.711
		Irbesartan	41	-3.74 (1.05)	(-5.82, -1.67)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 110 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGB_FSRM: Rate of change in eGFR (total slope) - Year 2 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 2				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline BMI	Overall	Sparsentan					Interaction:	0.019 #
< 27 kg/m**2	Baseline to Week 110	Sparsentan	83	-2.93 (0.69)	(-4.30, -1.57)	1.48 (0.96)	(-0.42, 3.38)	0.127
		Irbesartan	94	-4.41 (0.67)	(-5.73, -3.09)			
>= 27 kg/m**2	Baseline to Week 110	Sparsentan	119	-3.13 (0.52)	(-4.14, -2.11)	0.98 (0.76)	(-0.51, 2.46)	0.198
		Irbesartan	107	-4.10 (0.55)	(-5.19, -3.02)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 110 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGB_FSRM: Rate of change in eGFR (total slope) - Year 2 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 2				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Randomization strata	Overall	Sparsentan					Interaction:	<0.001 #
eGFR Low and UP High	Baseline to Week 110	Sparsentan	71	-4.11 (0.67)	(-5.44, -2.78)	2.00 (0.95)	(0.12, 3.87)	0.037 *
		Irbesartan	74	-6.11 (0.67)	(-7.43, -4.78)			
eGFR Low and UP Low	Baseline to Week 110	Sparsentan	55	-1.74 (0.68)	(-3.09, -0.39)	1.23 (0.96)	(-0.68, 3.14)	0.206
		Irbesartan	55	-2.96 (0.68)	(-4.32, -1.61)			
eGFR High and UP High	Baseline to Week 110	Sparsentan	37	-3.31 (1.21)	(-5.71, -0.91)	2.31 (1.76)	(-1.20, 5.82)	0.194
		Irbesartan	36	-5.62 (1.29)	(-8.18, -3.07)			
eGFR High and UP Low	Baseline to Week 110	Sparsentan	39	-2.95 (0.96)	(-4.85, -1.04)	-1.14 (1.40)	(-3.92, 1.64)	0.417
		Irbesartan	37	-1.81 (1.02)	(-3.83, 0.22)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 110 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGB_FSRM: Rate of change in eGFR (total slope) - Year 2 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 2				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 1	Overall	Sparsentan					Interaction:	0.008 #
< 60 mL/min/1.73 m**2	Baseline to Week 110	Sparsentan	127	-3.09 (0.47)	(-4.02, -2.16)	1.26 (0.67)	(-0.06, 2.58)	0.061
		Irbesartan	129	-4.35 (0.48)	(-5.29, -3.42)			
60 to < 90 mL/min/1.73 m**2	Baseline to Week 110	Sparsentan	49	-3.22 (0.91)	(-5.02, -1.43)	2.69 (1.31)	(0.10, 5.28)	0.042 *
		Irbesartan	48	-5.91 (0.95)	(-7.78, -4.04)			
>= 90 mL/min/1.73 m**2	Baseline to Week 110	Sparsentan	26	-2.78 (1.37)	(-5.52, -0.05)	-2.04 (2.02)	(-6.09, 2.01)	0.317
		Irbesartan	25	-0.74 (1.49)	(-3.72, 2.24)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 110 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGB_FSRM: Rate of change in eGFR (total slope) - Year 2 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 2				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 2	Overall	Sparsentan					Interaction:	0.003 #
< 45 mL/min/1.73 m**2	Baseline to Week 110	Sparsentan	82	-3.69 (0.59)	(-4.85, -2.53)	1.41 (0.84)	(-0.26, 3.07)	0.097
		Irbesartan	80	-5.09 (0.60)	(-6.28, -3.90)			
45 to < 60 mL/min/1.73 m**2	Baseline to Week 110	Sparsentan	45	-2.17 (0.87)	(-3.89, -0.46)	1.25 (1.20)	(-1.14, 3.63)	0.302
		Irbesartan	49	-3.42 (0.84)	(-5.08, -1.76)			
60 to < 90 mL/min/1.73 m**2	Baseline to Week 110	Sparsentan	49	-3.22 (0.91)	(-5.02, -1.43)	2.69 (1.31)	(0.10, 5.28)	0.042 *
		Irbesartan	48	-5.91 (0.95)	(-7.78, -4.04)			
>= 90 mL/min/1.73 m**2	Baseline to Week 110	Sparsentan	26	-2.78 (1.37)	(-5.52, -0.05)	-2.04 (2.02)	(-6.09, 2.01)	0.317
		Irbesartan	25	-0.74 (1.49)	(-3.72, 2.24)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 110 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGB_FSRM: Rate of change in eGFR (total slope) - Year 2 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 2				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline urine protein excretion	Overall	Sparsentan					Interaction:	0.718
<= 1.75 g/day	Baseline to Week 110	Sparsentan	98	-2.18 (0.55)	(-3.26, -1.09)	0.96 (0.80)	(-0.62, 2.53)	0.233
		Irbesartan	93	-3.13 (0.58)	(-4.28, -1.99)			
> 1.75 g/day	Baseline to Week 110	Sparsentan	104	-3.94 (0.61)	(-5.15, -2.74)	1.28 (0.86)	(-0.42, 2.98)	0.139
		Irbesartan	109	-5.23 (0.61)	(-6.42, -4.03)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 110 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGB_FSRM: Rate of change in eGFR (total slope) - Year 2 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 2				Mixed Random Coefficient Model					
				Annualized Slope		Slope Difference			
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value	
Baseline use of antihypertensives	Overall	Sparsentan					Interaction:	0.430	
Yes	Baseline to Week 110	Sparsentan	90	-2.73 (0.56)	(-3.83, -1.63)	1.68 (0.81)	(0.09, 3.27)	0.038	*
		Irbesartan	88	-4.41 (0.58)	(-5.56, -3.27)				
No	Baseline to Week 110	Sparsentan	112	-3.30 (0.60)	(-4.47, -2.12)	0.81 (0.85)	(-0.86, 2.48)	0.342	
		Irbesartan	114	-4.11 (0.61)	(-5.30, -2.92)				

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 110 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGB_FSRM: Rate of change in eGFR (total slope) - Year 2 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 2				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Time since renal biopsy	Overall	Sparsentan					Interaction:	0.102
<= 5 years	Baseline to Week 110	Sparsentan	113	-2.69 (0.62)	(-3.91, -1.47)	1.52 (0.86)	(-0.17, 3.21)	0.078
		Irbesartan	127	-4.21 (0.60)	(-5.38, -3.03)			
> 5 years	Baseline to Week 110	Sparsentan	89	-3.51 (0.50)	(-4.50, -2.51)	0.77 (0.76)	(-0.73, 2.26)	0.312
		Irbesartan	75	-4.27 (0.56)	(-5.39, -3.16)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 110 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGB_FSRM: Rate of change in eGFR (total slope) - Year 2 - by subgroup
Full Analysis Set

Rate of change in eGFR (total slope) - year 2				Mixed Random Coefficient Model					
				Annualized Slope		Slope Difference			
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value	
History of hypertension	Overall	Sparsentan					Interaction:	0.205	
Yes	Baseline to Week 110	Sparsentan	155	-2.95 (0.45)	(-3.84, -2.05)	1.36 (0.65)	(0.09, 2.63)	0.036	*
		Irbesartan	161	-4.30 (0.46)	(-5.21, -3.40)				
No	Baseline to Week 110	Sparsentan	47	-3.43 (0.98)	(-5.37, -1.48)	0.49 (1.44)	(-2.37, 3.35)	0.735	
		Irbesartan	41	-3.91 (1.06)	(-6.01, -1.82)				

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values up to Week 110 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGLA_FSRM: Rate of change in eGFR (chronic slope) - Year 1 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Sex	Overall	Sparsentan					Interaction:	0.018 #
Male	Week 6 to Week 58	Sparsentan	139	-2.73 (0.86)	(-4.43, -1.04)	2.37 (1.22)	(-0.03, 4.77)	0.053
		Irbesartan	143	-5.10 (0.87)	(-6.80, -3.40)			
Female	Week 6 to Week 58	Sparsentan	63	-3.92 (1.40)	(-6.69, -1.15)	-0.64 (2.03)	(-4.65, 3.37)	0.754
		Irbesartan	59	-3.28 (1.47)	(-6.19, -0.37)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGLA_FSRM: Rate of change in eGFR (chronic slope) - Year 1 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age	Overall	Sparsentan					Interaction:	0.378
<= 45 years	Week 6 to Week 58	Sparsentan	96	-3.66 (1.22)	(-6.06, -1.25)	1.26 (1.73)	(-2.14, 4.66)	0.466
		Irbesartan	99	-4.92 (1.22)	(-7.33, -2.51)			
> 45 years	Week 6 to Week 58	Sparsentan	106	-2.61 (0.86)	(-4.29, -0.92)	1.66 (1.23)	(-0.76, 4.08)	0.177
		Irbesartan	103	-4.27 (0.88)	(-6.00, -2.53)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGLA_FSRM: Rate of change in eGFR (chronic slope) - Year 1 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age at IgAN diagnosis	Overall	Sparsentan					Interaction:	0.005 #
<= 18 years	Week 6 to Week 58	Sparsentan	9	-5.27 (3.88)	(-13.36, 2.83)	3.07 (6.30)	(-10.05, 16.18)	0.632
		Irbesartan	5	-8.33 (4.95)	(-18.65, 1.99)			
> 18 to 40 years	Week 6 to Week 58	Sparsentan	102	-3.50 (1.10)	(-5.66, -1.34)	0.92 (1.54)	(-2.11, 3.96)	0.549
		Irbesartan	109	-4.42 (1.08)	(-6.56, -2.29)			
> 40 years	Week 6 to Week 58	Sparsentan	91	-2.39 (0.98)	(-4.32, -0.47)	2.14 (1.41)	(-0.63, 4.91)	0.129
		Irbesartan	88	-4.53 (1.01)	(-6.52, -2.55)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGLA_FSRM: Rate of change in eGFR (chronic slope) - Year 1 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Geographic region	Overall	Sparsentan					Interaction:	0.648
North America	Week 6 to Week 58	Sparsentan	35	-2.81 (1.78)	(-6.32, 0.71)	0.79 (2.37)	(-3.90, 5.48)	0.740
		Irbesartan	46	-3.59 (1.57)	(-6.69, -0.49)			
Europe	Week 6 to Week 58	Sparsentan	98	-2.88 (0.99)	(-4.84, -0.93)	1.67 (1.36)	(-1.01, 4.36)	0.221
		Irbesartan	115	-4.55 (0.93)	(-6.39, -2.72)			
Asia Pacific	Week 6 to Week 58	Sparsentan	69	-3.57 (1.35)	(-6.24, -0.90)	2.12 (2.25)	(-2.31, 6.55)	0.347
		Irbesartan	41	-5.69 (1.79)	(-9.23, -2.15)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGLA_FSRM: Rate of change in eGFR (chronic slope) - Year 1 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline BMI	Overall	Sparsentan					Interaction:	0.035 #
< 27 kg/m**2	Week 6 to Week 58	Sparsentan	83	-2.82 (1.25)	(-5.28, -0.36)	2.15 (1.74)	(-1.27, 5.56)	0.217
		Irbesartan	94	-4.97 (1.20)	(-7.34, -2.60)			
>= 27 kg/m**2	Week 6 to Week 58	Sparsentan	119	-3.27 (0.89)	(-5.02, -1.52)	1.00 (1.30)	(-1.55, 3.55)	0.442
		Irbesartan	107	-4.27 (0.95)	(-6.13, -2.41)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGLA_FSRM: Rate of change in eGFR (chronic slope) - Year 1 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Randomization strata	Overall	Sparsentan					Interaction:	0.002 #
eGFR Low and UP High	Week 6 to Week 58	Sparsentan	71	-4.00 (1.09)	(-6.15, -1.85)	2.72 (1.54)	(-0.31, 5.75)	0.079
		Irbesartan	74	-6.72 (1.08)	(-8.85, -4.58)			
eGFR Low and UP Low	Week 6 to Week 58	Sparsentan	55	-1.05 (1.19)	(-3.39, 1.30)	1.16 (1.68)	(-2.15, 4.47)	0.492
		Irbesartan	55	-2.20 (1.19)	(-4.54, 0.13)			
eGFR High and UP High	Week 6 to Week 58	Sparsentan	37	-1.79 (2.24)	(-6.22, 2.63)	3.00 (3.26)	(-3.46, 9.45)	0.360
		Irbesartan	36	-4.79 (2.37)	(-9.49, -0.09)			
eGFR High and UP Low	Week 6 to Week 58	Sparsentan	39	-5.67 (1.80)	(-9.23, -2.11)	-1.63 (2.62)	(-6.79, 3.54)	0.534
		Irbesartan	37	-4.04 (1.89)	(-7.78, -0.30)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGLA_FSRM: Rate of change in eGFR (chronic slope) - Year 1 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 1	Overall	Sparsentan					Interaction:	0.010 #
< 60 mL/min/1.73 m**2	Week 6 to Week 58	Sparsentan	127	-2.80 (0.79)	(-4.35, -1.25)	1.65 (1.12)	(-0.54, 3.84)	0.140
		Irbesartan	129	-4.45 (0.79)	(-6.00, -2.90)			
60 to < 90 mL/min/1.73 m**2	Week 6 to Week 58	Sparsentan	49	-3.13 (1.65)	(-6.38, 0.11)	2.80 (2.38)	(-1.89, 7.49)	0.240
		Irbesartan	48	-5.94 (1.71)	(-9.32, -2.56)			
>= 90 mL/min/1.73 m**2	Week 6 to Week 58	Sparsentan	26	-4.56 (2.70)	(-9.93, 0.80)	-1.83 (3.95)	(-9.67, 6.00)	0.643
		Irbesartan	25	-2.73 (2.88)	(-8.44, 2.98)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGLA_FSRM: Rate of change in eGFR (chronic slope) - Year 1 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 2	Overall	Sparsentan					Interaction:	0.013 #
< 45 mL/min/1.73 m**2	Week 6 to Week 58	Sparsentan	82	-3.91 (0.91)	(-5.70, -2.12)	2.43 (1.30)	(-0.13, 4.99)	0.063
		Irbesartan	80	-6.34 (0.93)	(-8.18, -4.51)			
45 to < 60 mL/min/1.73 m**2	Week 6 to Week 58	Sparsentan	45	-0.87 (1.52)	(-3.87, 2.12)	0.84 (2.10)	(-3.30, 4.98)	0.690
		Irbesartan	49	-1.71 (1.45)	(-4.57, 1.14)			
60 to < 90 mL/min/1.73 m**2	Week 6 to Week 58	Sparsentan	49	-3.13 (1.65)	(-6.38, 0.11)	2.80 (2.38)	(-1.89, 7.49)	0.240
		Irbesartan	48	-5.94 (1.71)	(-9.32, -2.56)			
>= 90 mL/min/1.73 m**2	Week 6 to Week 58	Sparsentan	26	-4.56 (2.70)	(-9.93, 0.80)	-1.83 (3.95)	(-9.67, 6.00)	0.643
		Irbesartan	25	-2.73 (2.88)	(-8.44, 2.98)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGLA_FSRM: Rate of change in eGFR (chronic slope) - Year 1 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline urine protein excretion	Overall	Sparsentan					Interaction:	0.817
<= 1.75 g/day	Week 6 to Week 58	Sparsentan	98	-2.84 (1.05)	(-4.90, -0.79)	0.17 (1.51)	(-2.80, 3.15)	0.908
		Irbesartan	93	-3.02 (1.10)	(-5.17, -0.86)			
> 1.75 g/day	Week 6 to Week 58	Sparsentan	104	-3.35 (1.02)	(-5.35, -1.35)	2.55 (1.43)	(-0.27, 5.36)	0.076
		Irbesartan	109	-5.90 (1.01)	(-7.88, -3.92)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGLA_FSRM: Rate of change in eGFR (chronic slope) - Year 1 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline use of antihypertensives	Overall	Sparsentan					Interaction:	0.178
Yes	Week 6 to Week 58	Sparsentan	90	-3.03 (1.00)	(-5.01, -1.06)	1.63 (1.44)	(-1.21, 4.46)	0.260
		Irbesartan	88	-4.66 (1.03)	(-6.69, -2.63)			
No	Week 6 to Week 58	Sparsentan	112	-3.13 (1.05)	(-5.19, -1.07)	1.37 (1.49)	(-1.56, 4.29)	0.359
		Irbesartan	114	-4.49 (1.06)	(-6.57, -2.42)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGLA_FSRM: Rate of change in eGFR (chronic slope) - Year 1 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Time since renal biopsy	Overall	Sparsentan					Interaction:	0.366
<= 5 years	Week 6 to Week 58	Sparsentan	113	-2.87 (1.09)	(-5.01, -0.74)	1.26 (1.50)	(-1.69, 4.22)	0.400
		Irbesartan	127	-4.14 (1.04)	(-6.18, -2.10)			
> 5 years	Week 6 to Week 58	Sparsentan	89	-3.34 (0.90)	(-5.10, -1.58)	1.97 (1.34)	(-0.67, 4.61)	0.144
		Irbesartan	75	-5.31 (1.00)	(-7.28, -3.34)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGLA_FSRM: Rate of change in eGFR (chronic slope) - Year 1 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 1				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
History of hypertension	Overall	Sparsentan					Interaction:	0.768
Yes	Week 6 to Week 58	Sparsentan	155	-2.97 (0.80)	(-4.53, -1.40)	1.30 (1.13)	(-0.92, 3.51)	0.251
		Irbesartan	161	-4.26 (0.80)	(-5.83, -2.70)			
No	Week 6 to Week 58	Sparsentan	47	-3.60 (1.74)	(-7.04, -0.16)	2.19 (2.57)	(-2.88, 7.27)	0.394
		Irbesartan	41	-5.79 (1.88)	(-9.52, -2.07)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 58 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGLB_FSRM: Rate of change in eGFR (chronic slope) - Year 2 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 2				Mixed Random Coefficient Model					
				Annualized Slope		Slope Difference			
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value	
Sex	Overall	Sparsentan					Interaction:	0.037	#
Male	Week 6 to Week 110	Sparsentan	139	-3.07 (0.52)	(-4.09, -2.05)	1.61 (0.74)	(0.16, 3.07)	0.030	*
		Irbesartan	143	-4.68 (0.53)	(-5.71, -3.65)				
Female	Week 6 to Week 110	Sparsentan	63	-2.52 (0.74)	(-3.98, -1.06)	0.49 (1.08)	(-1.65, 2.62)	0.653	
		Irbesartan	59	-3.01 (0.79)	(-4.57, -1.45)				

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 110 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGLB_FSRM: Rate of change in eGFR (chronic slope) - Year 2 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 2				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age	Overall	Sparsentan					Interaction:	0.089
<= 45 years	Week 6 to Week 110	Sparsentan	96	-3.05 (0.72)	(-4.47, -1.62)	2.02 (1.03)	(-0.00, 4.05)	0.050
		Irbesartan	99	-5.07 (0.73)	(-6.52, -3.62)			
> 45 years	Week 6 to Week 110	Sparsentan	106	-2.77 (0.48)	(-3.71, -1.83)	0.67 (0.69)	(-0.69, 2.03)	0.332
		Irbesartan	103	-3.44 (0.50)	(-4.42, -2.46)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 110 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGLB_FSRM: Rate of change in eGFR (chronic slope) - Year 2 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 2				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age at IgAN diagnosis	Overall	Sparsentan					Interaction:	0.005 #
<= 18 years	Week 6 to Week 110	Sparsentan	9	-8.80 (3.38)	(-16.29, -1.30)	-2.00 (5.35)	(-14.03, 10.02)	0.716
		Irbesartan	5	-6.79 (4.16)	(-16.20, 2.62)			
> 18 to 40 years	Week 6 to Week 110	Sparsentan	102	-2.70 (0.63)	(-3.94, -1.45)	2.21 (0.89)	(0.45, 3.97)	0.014 *
		Irbesartan	109	-4.91 (0.63)	(-6.15, -3.66)			
> 40 years	Week 6 to Week 110	Sparsentan	91	-2.71 (0.54)	(-3.78, -1.64)	0.52 (0.79)	(-1.03, 2.07)	0.506
		Irbesartan	88	-3.24 (0.57)	(-4.36, -2.11)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 110 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGLB_FSRM: Rate of change in eGFR (chronic slope) - Year 2 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 2				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Geographic region	Overall	Sparsentan					Interaction:	0.305
North America	Week 6 to Week 110	Sparsentan	35	-2.58 (1.02)	(-4.62, -0.55)	1.85 (1.38)	(-0.88, 4.58)	0.182
		Irbesartan	46	-4.43 (0.92)	(-6.26, -2.61)			
Europe	Week 6 to Week 110	Sparsentan	98	-3.02 (0.58)	(-4.16, -1.89)	1.31 (0.79)	(-0.24, 2.87)	0.098
		Irbesartan	115	-4.34 (0.54)	(-5.40, -3.27)			
Asia Pacific	Week 6 to Week 110	Sparsentan	69	-2.91 (0.80)	(-4.49, -1.33)	0.71 (1.34)	(-1.94, 3.36)	0.596
		Irbesartan	41	-3.62 (1.08)	(-5.75, -1.49)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 110 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGLB_FSRM: Rate of change in eGFR (chronic slope) - Year 2 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 2				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline BMI	Overall	Sparsentan					Interaction:	0.008 #
< 27 kg/m**2	Week 6 to Week 110	Sparsentan	83	-2.83 (0.71)	(-4.22, -1.43)	1.39 (0.99)	(-0.56, 3.33)	0.161
		Irbesartan	94	-4.21 (0.69)	(-5.57, -2.86)			
>= 27 kg/m**2	Week 6 to Week 110	Sparsentan	119	-2.95 (0.53)	(-4.00, -1.91)	1.27 (0.78)	(-0.26, 2.80)	0.102
		Irbesartan	107	-4.23 (0.57)	(-5.35, -3.11)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 110 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGLB_FSRM: Rate of change in eGFR (chronic slope) - Year 2 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 2				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Randomization strata	Overall	Sparsentan					Interaction:	<0.001 #
eGFR Low and UP High	Week 6 to Week 110	Sparsentan	71	-4.16 (0.68)	(-5.50, -2.82)	1.87 (0.96)	(-0.03, 3.77)	0.054
		Irbesartan	74	-6.03 (0.68)	(-7.37, -4.68)			
eGFR Low and UP Low	Week 6 to Week 110	Sparsentan	55	-1.79 (0.70)	(-3.16, -0.41)	1.25 (0.99)	(-0.70, 3.20)	0.207
		Irbesartan	55	-3.04 (0.70)	(-4.42, -1.65)			
eGFR High and UP High	Week 6 to Week 110	Sparsentan	37	-2.94 (1.26)	(-5.46, -0.43)	2.41 (1.85)	(-1.25, 6.08)	0.194
		Irbesartan	36	-5.36 (1.35)	(-8.03, -2.68)			
eGFR High and UP Low	Week 6 to Week 110	Sparsentan	39	-2.39 (0.99)	(-4.35, -0.42)	-0.37 (1.45)	(-3.23, 2.50)	0.801
		Irbesartan	37	-2.02 (1.05)	(-4.11, 0.07)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 110 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGLB_FSRM: Rate of change in eGFR (chronic slope) - Year 2 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 2				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 1	Overall	Sparsentan					Interaction:	<0.001 #
< 60 mL/min/1.73 m**2	Week 6 to Week 110	Sparsentan	127	-3.13 (0.48)	(-4.07, -2.18)	1.25 (0.68)	(-0.09, 2.59)	0.068
		Irbesartan	129	-4.37 (0.48)	(-5.32, -3.42)			
60 to < 90 mL/min/1.73 m**2	Week 6 to Week 110	Sparsentan	49	-3.00 (0.94)	(-4.86, -1.15)	2.69 (1.36)	(0.01, 5.37)	0.049 *
		Irbesartan	48	-5.69 (0.98)	(-7.63, -3.76)			
>= 90 mL/min/1.73 m**2	Week 6 to Week 110	Sparsentan	26	-1.89 (1.42)	(-4.73, 0.95)	-0.89 (2.11)	(-5.11, 3.32)	0.674
		Irbesartan	25	-1.00 (1.56)	(-4.11, 2.12)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 110 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGLB_FSRM: Rate of change in eGFR (chronic slope) - Year 2 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 2				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 2	Overall	Sparsentan					Interaction:	<0.001 #
< 45 mL/min/1.73 m**2	Week 6 to Week 110	Sparsentan	82	-3.78 (0.59)	(-4.95, -2.61)	1.36 (0.85)	(-0.32, 3.03)	0.112
		Irbesartan	80	-5.13 (0.61)	(-6.33, -3.93)			
45 to < 60 mL/min/1.73 m**2	Week 6 to Week 110	Sparsentan	45	-2.14 (0.89)	(-3.90, -0.39)	1.31 (1.23)	(-1.13, 3.76)	0.290
		Irbesartan	49	-3.46 (0.86)	(-5.16, -1.75)			
60 to < 90 mL/min/1.73 m**2	Week 6 to Week 110	Sparsentan	49	-3.00 (0.94)	(-4.86, -1.15)	2.69 (1.36)	(0.01, 5.37)	0.049 *
		Irbesartan	48	-5.69 (0.98)	(-7.63, -3.76)			
>= 90 mL/min/1.73 m**2	Week 6 to Week 110	Sparsentan	26	-1.89 (1.42)	(-4.73, 0.95)	-0.89 (2.11)	(-5.11, 3.32)	0.674
		Irbesartan	25	-1.00 (1.56)	(-4.11, 2.12)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 110 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGLB_FSRM: Rate of change in eGFR (chronic slope) - Year 2 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 2				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline urine protein excretion	Overall	Sparsentan					Interaction:	0.447
<= 1.75 g/day	Week 6 to Week 110	Sparsentan	98	-2.06 (0.57)	(-3.18, -0.95)	1.20 (0.83)	(-0.43, 2.83)	0.147
		Irbesartan	93	-3.26 (0.60)	(-4.45, -2.08)			
> 1.75 g/day	Week 6 to Week 110	Sparsentan	104	-3.76 (0.63)	(-5.00, -2.52)	1.32 (0.89)	(-0.43, 3.07)	0.138
		Irbesartan	109	-5.08 (0.63)	(-6.32, -3.85)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 110 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGLB_FSRM: Rate of change in eGFR (chronic slope) - Year 2 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 2				Mixed Random Coefficient Model				
				Annualized Slope		Slope Difference		
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline use of antihypertensives	Overall	Sparsentan					Interaction:	0.130
Yes	Week 6 to Week 110	Sparsentan	90	-2.80 (0.57)	(-3.93, -1.67)	1.61 (0.82)	(-0.02, 3.23)	0.053
		Irbesartan	88	-4.41 (0.59)	(-5.58, -3.24)			
No	Week 6 to Week 110	Sparsentan	112	-2.97 (0.61)	(-4.18, -1.77)	1.10 (0.87)	(-0.62, 2.82)	0.208
		Irbesartan	114	-4.07 (0.62)	(-5.30, -2.85)			

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 110 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGLB_FSRM: Rate of change in eGFR (chronic slope) - Year 2 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 2				Mixed Random Coefficient Model					
				Annualized Slope		Slope Difference			
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value	
Time since renal biopsy	Overall	Sparsentan					Interaction:	0.079	
<= 5 years	Week 6 to Week 110	Sparsentan	113	-2.49 (0.63)	(-3.72, -1.25)	1.75 (0.87)	(0.02, 3.47)	0.047	*
		Irbesartan	127	-4.23 (0.61)	(-5.43, -3.04)				
> 5 years	Week 6 to Week 110	Sparsentan	89	-3.42 (0.52)	(-4.44, -2.40)	0.75 (0.78)	(-0.79, 2.29)	0.338	
		Irbesartan	75	-4.17 (0.58)	(-5.32, -3.02)				

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 110 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GGLB_FSRM: Rate of change in eGFR (chronic slope) - Year 2 by subgroup
Full Analysis Set

Rate of change in eGFR (chronic slope) - year 2				Mixed Random Coefficient Model					
				Annualized Slope		Slope Difference			
Subgroup	Time	Treatment	N	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value	
History of hypertension	Overall	Sparsentan					Interaction:	0.445	
Yes	Week 6 to Week 110	Sparsentan	155	-2.94 (0.46)	(-3.86, -2.03)	1.44 (0.66)	(0.14, 2.74)	0.030	*
		Irbesartan	161	-4.39 (0.47)	(-5.31, -3.46)				
No	Week 6 to Week 110	Sparsentan	47	-2.75 (1.00)	(-4.74, -0.75)	0.76 (1.48)	(-2.18, 3.70)	0.609	
		Irbesartan	41	-3.51 (1.09)	(-5.67, -1.35)				

N = number of patients in analysis set. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction. MRCM = Mixed Random Coefficient Model.
An MRCM was applied including treatment, time, randomization strata, baseline (as covariate), and interaction term treatment-by-time, random intercept and random slope per subject. For interaction test, subgroup and interaction subgroup*treatment were added to the model.
All observed post-baseline values from Week 6 up to Week 110 are included in the model. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model.
A decrease reflects a worsening of the status of the patient. Results are presented in ml/min/1.73 m**2. eGFR = estimated glomerular filtration rate. A first order autoregressive covariance structure was used.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: alb, created on: 19FEB2024

Table PT2GED_FSIM: Patients with confirmed 40% reduction in eGFR, ESRD or death by subgroup
Full Analysis Set

Confirmed 40% reduction in eGFR, ESRD, or death

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.508
Male	Double-blind period	Sparsentan	139	15 (10.8)	0.772 [0.412, 1.445]	0.744 [0.364, 1.520]	-3.2 [-11.6, 5.2]	0.472
		Irbesartan	143	20 (14.0)				
Female	Double-blind period	Sparsentan	63	3 (4.8)	0.468 [0.123, 1.788]	0.442 [0.105, 1.854]	-5.4 [-16.4, 5.6]	0.312
		Irbesartan	59	6 (10.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
ESRD = End-stage renal disease.
Source Data: aeff, created on: 20FEB2024

Table PT2GED_FSIM: Patients with confirmed 40% reduction in eGFR, ESRD or death by subgroup
Full Analysis Set

Confirmed 40% reduction in eGFR, ESRD, or death

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.553
<= 45 years	Double-blind period	Sparsentan	96	10 (10.4)	0.607 [0.293, 1.257]	0.561 [0.243, 1.296]	-6.8 [-17.4, 3.9]	0.215
		Irbesartan	99	17 (17.2)				
> 45 years	Double-blind period	Sparsentan	106	8 (7.5)	0.864 [0.347, 2.152]	0.853 [0.316, 2.303]	-1.2 [-9.6, 7.2]	0.804
		Irbesartan	103	9 (8.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
ESRD = End-stage renal disease.
Source Data: aeff, created on: 20FEB2024

Table PT2GED_FSIM: Patients with confirmed 40% reduction in eGFR, ESRD or death by subgroup
Full Analysis Set

Confirmed 40% reduction in eGFR, ESRD, or death

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.407
<= 18 years	Double-blind period	Sparsentan	9	3 (33.3)	1.667 [0.230, 12.091]	2.000 [0.150, 26.734]	13.3 [-48.9, 75.6]	1.000
		Irbesartan	5	1 (20.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	7 (6.9)	0.468 [0.201, 1.090]	0.428 [0.168, 1.089]	-7.8 [-17.0, 1.4]	0.079
		Irbesartan	109	16 (14.7)				
> 40 years	Double-blind period	Sparsentan	91	8 (8.8)	0.860 [0.347, 2.127]	0.846 [0.311, 2.302]	-1.4 [-11.2, 8.3]	0.803
		Irbesartan	88	9 (10.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
ESRD = End-stage renal disease.
Source Data: aeff, created on: 20FEB2024

Table PT2GED_FSIM: Patients with confirmed 40% reduction in eGFR, ESRD or death by subgroup
Full Analysis Set

Confirmed 40% reduction in eGFR, ESRD, or death

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.728
North America	Double-blind period	Sparsentan	35	3 (8.6)	0.657 [0.177, 2.446]	0.625 [0.145, 2.696]	-4.5 [-20.4, 11.5]	0.725
		Irbesartan	46	6 (13.0)				
Europe	Double-blind period	Sparsentan	98	8 (8.2)	0.587 [0.262, 1.312]	0.550 [0.225, 1.347]	-5.7 [-15.0, 3.5]	0.201
		Irbesartan	115	16 (13.9)				
Asia Pacific	Double-blind period	Sparsentan	69	7 (10.1)	1.040 [0.324, 3.337]	1.044 [0.286, 3.810]	0.4 [-13.1, 13.9]	1.000
		Irbesartan	41	4 (9.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
ESRD = End-stage renal disease.
Source Data: aeff, created on: 20FEB2024

Table PT2GED_FSIM: Patients with confirmed 40% reduction in eGFR, ESRD or death by subgroup
Full Analysis Set

Confirmed 40% reduction in eGFR, ESRD, or death

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.246
< 27 kg/m**2	Double-blind period	Sparsentan	83	5 (6.0)	0.436 [0.162, 1.170]	0.399 [0.136, 1.173]	-7.8 [-17.6, 2.0]	0.133
		Irbesartan	94	13 (13.8)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	13 (10.9)	0.899 [0.436, 1.853]	0.887 [0.392, 2.008]	-1.2 [-10.5, 8.0]	0.836
		Irbesartan	107	13 (12.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
ESRD = End-stage renal disease.
Source Data: aeff, created on: 20FEB2024

Table PT2GED_FSIM: Patients with confirmed 40% reduction in eGFR, ESRD or death by subgroup
Full Analysis Set

Confirmed 40% reduction in eGFR, ESRD, or death

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.956
eGFR Low and UP High	Double-blind period	Sparsentan	71	13 (18.3)	0.713 [0.381, 1.333]	0.649 [0.293, 1.438]	-7.4 [-22.2, 7.4]	0.321
		Irbesartan	74	19 (25.7)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	2 (3.6)	0.500 [0.095, 2.618]	0.481 [0.084, 2.742]	-3.6 [-13.9, 6.6]	0.679
		Irbesartan	55	4 (7.3)				
eGFR High and UP High	Double-blind period	Sparsentan	37	2 (5.4)	0.973 [0.145, 6.541]	0.971 [0.129, 7.294]	-0.2 [-13.3, 13.0]	1.000
		Irbesartan	36	2 (5.6)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	1 (2.6)	0.949 [0.062, 14.620]	0.947 [0.057, 15.721]	-0.1 [-10.0, 9.7]	1.000
		Irbesartan	37	1 (2.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
ESRD = End-stage renal disease.
Source Data: aeff, created on: 20FEB2024

Table PT2GED_FSIM: Patients with confirmed 40% reduction in eGFR, ESRD or death by subgroup
Full Analysis Set

Confirmed 40% reduction in eGFR, ESRD, or death

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.846
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	14 (11.0)	0.646 [0.346, 1.206]	0.603 [0.293, 1.238]	-6.0 [-15.3, 3.2]	0.208
		Irbesartan	129	22 (17.1)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2)	0.980 [0.260, 3.695]	0.978 [0.230, 4.155]	-0.2 [-13.2, 12.8]	1.000
		Irbesartan	48	4 (8.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.963 + [0.020, 46.760]	0.962 + [0.018, 50.349]	0.0 [NE, NE]	NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
ESRD = End-stage renal disease.
Source Data: aeff, created on: 20FEB2024

Table PT2GED_FSIM: Patients with confirmed 40% reduction in eGFR, ESRD or death by subgroup
Full Analysis Set

Confirmed 40% reduction in eGFR, ESRD, or death

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.893
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	12 (14.6)	0.689 [0.352, 1.348]	0.635 [0.282, 1.433]	-6.6 [-19.6, 6.4]	0.310
		Irbesartan	80	17 (21.3)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	2 (4.4)	0.436 [0.089, 2.134]	0.409 [0.075, 2.224]	-5.8 [-18.3, 6.8]	0.438
		Irbesartan	49	5 (10.2)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2)	0.980 [0.260, 3.695]	0.978 [0.230, 4.155]	-0.2 [-13.2, 12.8]	1.000
		Irbesartan	48	4 (8.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.963 + [0.020, 46.760]	0.962 + [0.018, 50.349]	0.0 [NE, NE]	NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
ESRD = End-stage renal disease.
Source Data: aeff, created on: 20FEB2024

Table PT2GED_FSIM: Patients with confirmed 40% reduction in eGFR, ESRD or death by subgroup
Full Analysis Set

Confirmed 40% reduction in eGFR, ESRD, or death

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.506
<= 1.75 g/day	Double-blind period	Sparsentan	98	3 (3.1)	0.474 [0.122, 1.842]	0.458 [0.111, 1.887]	-3.4 [-10.5, 3.7]	0.321
		Irbesartan	93	6 (6.5)				
> 1.75 g/day	Double-blind period	Sparsentan	104	15 (14.4)	0.786 [0.426, 1.451]	0.750 [0.361, 1.558]	-3.9 [-14.8, 6.9]	0.465
		Irbesartan	109	20 (18.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
ESRD = End-stage renal disease.
Source Data: aeff, created on: 20FEB2024

Table PT2GED_FSIM: Patients with confirmed 40% reduction in eGFR, ESRD or death by subgroup
Full Analysis Set

Confirmed 40% reduction in eGFR, ESRD, or death

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.223
Yes	Double-blind period	Sparsentan	90	11 (12.2)	0.978 [0.447, 2.138]	0.975 [0.399, 2.380]	-0.3 [-11.1, 10.5]	1.000
		Irbesartan	88	11 (12.5)				
No	Double-blind period	Sparsentan	112	7 (6.3)	0.475 [0.201, 1.121]	0.440 [0.172, 1.124]	-6.9 [-15.4, 1.6]	0.115
		Irbesartan	114	15 (13.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
ESRD = End-stage renal disease.
Source Data: aeff, created on: 20FEB2024

Table PT2GED_FSIM: Patients with confirmed 40% reduction in eGFR, ESRD or death by subgroup
Full Analysis Set

Confirmed 40% reduction in eGFR, ESRD, or death

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.503
<= 5 years	Double-blind period	Sparsentan	113	13 (11.5)	0.812 [0.417, 1.581]	0.787 [0.367, 1.689]	-2.7 [-12.0, 6.6]	0.569
		Irbesartan	127	18 (14.2)				
> 5 years	Double-blind period	Sparsentan	89	5 (5.6)	0.527 [0.180, 1.542]	0.499 [0.156, 1.594]	-5.0 [-14.7, 4.6]	0.259
		Irbesartan	75	8 (10.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
ESRD = End-stage renal disease.
Source Data: aeff, created on: 20FEB2024

Table PT2GED_FSIM: Patients with confirmed 40% reduction in eGFR, ESRD or death by subgroup
Full Analysis Set

Confirmed 40% reduction in eGFR, ESRD, or death

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.159
Yes	Double-blind period	Sparsentan	155	17 (11.0)	0.841 [0.461, 1.532]	0.821 [0.416, 1.623]	-2.1 [-9.9, 5.7]	0.607
		Irbesartan	161	21 (13.0)				
No	Double-blind period	Sparsentan	47	1 (2.1)	0.174 [0.021, 1.433]	0.157 [0.018, 1.400]	-10.1 [-23.2, 3.0]	0.093
		Irbesartan	41	5 (12.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
ESRD = End-stage renal disease.
Source Data: aeff, created on: 20FEB2024

Table PT2GEDT_FSTM: Time to confirmed 40% reduction in eGFR, ESRD or death by subgroup
Full Analysis Set

Time to confirmed 40% reduction in eGFR, ESRD, or death				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sex	Sparsentan						Interaction test:	0.801
Male	Sparsentan	139	15 (10.8)	NE		0.645	(0.328, 1.270)	0.205
	Irbesartan	143	20 (14.0)	117.0	(117.0, NE)			
Female	Sparsentan	63	3 (4.8)	NE		0.625	(0.156, 2.506)	0.507
	Irbesartan	59	6 (10.2)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2GEDT_FSTM: Time to confirmed 40% reduction in eGFR, ESRD or death by subgroup
Full Analysis Set

Time to confirmed 40% reduction in eGFR, ESRD, or death				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.319
<= 45 years	Sparsentan	96	10 (10.4)	NE		0.482	(0.220, 1.058)	0.069
	Irbesartan	99	17 (17.2)	NE				
> 45 years	Sparsentan	106	8 (7.5)	NE		0.865	(0.328, 2.282)	0.770
	Irbesartan	103	9 (8.7)	117.0	(117.0, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2GEDT_FSTM: Time to confirmed 40% reduction in eGFR, ESRD or death by subgroup
Full Analysis Set

Time to confirmed 40% reduction in eGFR, ESRD, or death				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Age at IgAN diagnosis	Sparsentan						Interaction test:	0.419	
<= 18 years	Sparsentan	9	3 (33.3)	NE		NE		NE	
	Irbesartan	5	1 (20.0)	111.4	(NE, NE)				
> 18 to 40 years	Sparsentan	102	7 (6.9)	NE		0.399	(0.163, 0.973)	0.043	*
	Irbesartan	109	16 (14.7)	NE					
> 40 years	Sparsentan	91	8 (8.8)	NE		0.839	(0.318, 2.214)	0.724	
	Irbesartan	88	9 (10.2)	117.0	(NE, NE)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2GEDT_FSTM: Time to confirmed 40% reduction in eGFR, ESRD or death by subgroup
Full Analysis Set

Time to confirmed 40% reduction in eGFR, ESRD, or death				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Geographic region	Sparsentan						Interaction test:	0.964
North America	Sparsentan	35	3 (8.6)	NE		0.497	(0.124, 1.996)	0.324
	Irbesartan	46	6 (13.0)	NE				
Europe	Sparsentan	98	8 (8.2)	NE		0.608	(0.257, 1.437)	0.257
	Irbesartan	115	16 (13.9)	117.0	(117.0, NE)			
Asia Pacific	Sparsentan	69	7 (10.1)	NE		0.624	(0.178, 2.192)	0.462
	Irbesartan	41	4 (9.8)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2GEDT_FSTM: Time to confirmed 40% reduction in eGFR, ESRD or death by subgroup
Full Analysis Set

Time to confirmed 40% reduction in eGFR, ESRD, or death				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.355
< 27 kg/m**2	Sparsentan	83	5 (6.0)	NE		0.427	(0.152, 1.203)	0.107
	Irbesartan	94	13 (13.8)	NE				
>= 27 kg/m**2	Sparsentan	119	13 (10.9)	NE		0.815	(0.371, 1.792)	0.611
	Irbesartan	107	13 (12.1)	117.0	(NE, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2GEDT_FSTM: Time to confirmed 40% reduction in eGFR, ESRD or death by subgroup
Full Analysis Set

Time to confirmed 40% reduction in eGFR, ESRD, or death				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Randomization strata	Sparsentan						Interaction test:	0.959
eGFR Low and UP High	Sparsentan	71	13 (18.3)	NE		0.627	(0.307, 1.281)	0.200
	Irbesartan	74	19 (25.7)	117.0	(117.0, NE)			
eGFR Low and UP Low	Sparsentan	55	2 (3.6)	NE		0.479	(0.088, 2.616)	0.395
	Irbesartan	55	4 (7.3)	NE				
eGFR High and UP High	Sparsentan	37	2 (5.4)	NE		0.867	(0.122, 6.157)	0.886
	Irbesartan	36	2 (5.6)	NE				
eGFR High and UP Low	Sparsentan	39	1 (2.6)	NE		0.781	(0.049, 12.483)	0.861
	Irbesartan	37	1 (2.7)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2GEDT_FSTM: Time to confirmed 40% reduction in eGFR, ESRD or death by subgroup
Full Analysis Set

Time to confirmed 40% reduction in eGFR, ESRD, or death				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan						Interaction test:	NE
< 60 mL/min/1.73 m**2	Sparsentan	127	14 (11.0)	NE		0.566	(0.288, 1.111)	0.098
	Irbesartan	129	22 (17.1)	117.0	(117.0, NE)			
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	4 (8.2)	NE		0.919	(0.227, 3.721)	0.906
	Irbesartan	48	4 (8.3)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	0 (0.0) No events in 1 group	NE		NE		NE
	Irbesartan	25	0 (0.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2GEDT_FSTM: Time to confirmed 40% reduction in eGFR, ESRD or death by subgroup
Full Analysis Set

Time to confirmed 40% reduction in eGFR, ESRD, or death				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 2	Sparsentan						Interaction test:	NE
< 45 mL/min/1.73 m**2	Sparsentan	82	12 (14.6)	NE		0.637	(0.301, 1.346)	0.237
	Irbesartan	80	17 (21.3)	117.0	(117.0, NE)			
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	2 (4.4)	NE		0.350	(0.068, 1.805)	0.210
	Irbesartan	49	5 (10.2)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	4 (8.2)	NE		0.919	(0.227, 3.721)	0.906
	Irbesartan	48	4 (8.3)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	0 (0.0) No events in 1 group	NE		NE		NE
	Irbesartan	25	0 (0.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2GEDT_FSTM: Time to confirmed 40% reduction in eGFR, ESRD or death by subgroup
Full Analysis Set

Time to confirmed 40% reduction in eGFR, ESRD, or death				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline urine protein excretion	Sparsentan						Interaction test:	0.628
<= 1.75 g/day	Sparsentan	98	3 (3.1)	NE		0.441	(0.110, 1.769)	0.248
	Irbesartan	93	6 (6.5)	NE				
> 1.75 g/day	Sparsentan	104	15 (14.4)	NE		0.679	(0.344, 1.341)	0.265
	Irbesartan	109	20 (18.3)	117.0	(117.0, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2GEDT_FSTM: Time to confirmed 40% reduction in eGFR, ESRD or death by subgroup
Full Analysis Set

Time to confirmed 40% reduction in eGFR, ESRD, or death				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.201
Yes	Sparsentan	90	11 (12.2)	NE		0.888	(0.384, 2.051)	0.781
	Irbesartan	88	11 (12.5)	NE				
No	Sparsentan	112	7 (6.3)	NE		0.422	(0.170, 1.048)	0.063
	Irbesartan	114	15 (13.2)	117.0	(NE, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2GEDT_FSTM: Time to confirmed 40% reduction in eGFR, ESRD or death by subgroup
Full Analysis Set

Time to confirmed 40% reduction in eGFR, ESRD, or death				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Time since renal biopsy	Sparsentan						Interaction test:	0.873
<= 5 years	Sparsentan	113	13 (11.5)	NE		0.655	(0.320, 1.338)	0.245
	Irbesartan	127	18 (14.2)	NE				
> 5 years	Sparsentan	89	5 (5.6)	NE		0.609	(0.192, 1.926)	0.398
	Irbesartan	75	8 (10.7)	117.0	(117.0, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2GEDT_FSTM: Time to confirmed 40% reduction in eGFR, ESRD or death by subgroup
Full Analysis Set

Time to confirmed 40% reduction in eGFR, ESRD, or death				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
History of hypertension	Sparsentan						Interaction test:	0.091
Yes	Sparsentan	155	17 (11.0)	NE		0.763	(0.401, 1.454)	0.412
	Irbesartan	161	21 (13.0)	117.0	(117.0, NE)			
No	Sparsentan	47	1 (2.1)	NE		0.142	(0.016, 1.237)	0.077
	Irbesartan	41	5 (12.2)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Figure PF2GEDT_FSKM: Time to confirmed 40% reduction in eGFR, ESRD or death by subgroup
Full Analysis Set

Not done. No significant subgroups.

ESRD = End-stage renal disease. eGFR = Estimated glomerular filtration rate.
Reference table: PT2GEDT_FSTM

Table PT2G_FSIM: Patients with confirmed 40% reduction in eGFR by subgroup
Full Analysis Set

Confirmed 40% reduction in eGFR

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.806
Male	Double-blind period	Sparsentan	139	15 (10.8)	0.857 [0.450, 1.633]	0.840 [0.405, 1.741]	-1.8 [-10.0, 6.4]	0.713
		Irbesartan	143	18 (12.6)				
Female	Double-blind period	Sparsentan	63	3 (4.8)	0.702 [0.164, 3.007]	0.688 [0.147, 3.210]	-2.0 [-12.0, 7.9]	0.711
		Irbesartan	59	4 (6.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2G_FSIM: Patients with confirmed 40% reduction in eGFR by subgroup
Full Analysis Set

Confirmed 40% reduction in eGFR

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.654
<= 45 years	Double-blind period	Sparsentan	96	10 (10.4)	0.737 [0.344, 1.577]	0.706 [0.297, 1.677]	-3.7 [-13.9, 6.5]	0.515
		Irbesartan	99	14 (14.1)				
> 45 years	Double-blind period	Sparsentan	106	8 (7.5)	0.972 [0.379, 2.492]	0.969 [0.350, 2.688]	-0.2 [-8.4, 7.9]	1.000
		Irbesartan	103	8 (7.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2G_FSIM: Patients with confirmed 40% reduction in eGFR by subgroup
Full Analysis Set

Confirmed 40% reduction in eGFR

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.542
<= 18 years	Double-blind period	Sparsentan	9	3 (33.3)	1.667 [0.230, 12.091]	2.000 [0.150, 26.734]	13.3 [-48.9, 75.6]	1.000
		Irbesartan	5	1 (20.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	7 (6.9)	0.575 [0.239, 1.385]	0.544 [0.208, 1.423]	-5.1 [-13.8, 3.7]	0.245
		Irbesartan	109	13 (11.9)				
> 40 years	Double-blind period	Sparsentan	91	8 (8.8)	0.967 [0.380, 2.464]	0.964 [0.345, 2.692]	-0.3 [-9.8, 9.2]	1.000
		Irbesartan	88	8 (9.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2G_FSIM: Patients with confirmed 40% reduction in eGFR by subgroup
Full Analysis Set

Confirmed 40% reduction in eGFR

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.799
North America	Double-blind period	Sparsentan	35	3 (8.6)	0.986 [0.236, 4.123]	0.984 [0.206, 4.713]	-0.1 [-15.0, 14.7]	1.000
		Irbesartan	46	4 (8.7)				
Europe	Double-blind period	Sparsentan	98	8 (8.2)	0.671 [0.294, 1.531]	0.641 [0.257, 1.599]	-4.0 [-13.0, 5.0]	0.374
		Irbesartan	115	14 (12.2)				
Asia Pacific	Double-blind period	Sparsentan	69	7 (10.1)	1.040 [0.324, 3.337]	1.044 [0.286, 3.810]	0.4 [-13.1, 13.9]	1.000
		Irbesartan	41	4 (9.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2G_FSIM: Patients with confirmed 40% reduction in eGFR by subgroup
Full Analysis Set

Confirmed 40% reduction in eGFR

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.402
< 27 kg/m**2	Double-blind period	Sparsentan	83	5 (6.0)	0.566 [0.202, 1.590]	0.538 [0.176, 1.645]	-4.6 [-13.8, 4.6]	0.295
		Irbesartan	94	10 (10.6)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	13 (10.9)	0.974 [0.465, 2.041]	0.971 [0.423, 2.231]	-0.3 [-9.4, 8.8]	1.000
		Irbesartan	107	12 (11.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2G_FSIM: Patients with confirmed 40% reduction in eGFR by subgroup
Full Analysis Set

Confirmed 40% reduction in eGFR

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.929
eGFR Low and UP High	Double-blind period	Sparsentan	71	13 (18.3)	0.903 [0.463, 1.761]	0.882 [0.386, 2.015]	-2.0 [-16.2, 12.3]	0.835
		Irbesartan	74	15 (20.3)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	2 (3.6)	0.500 [0.095, 2.618]	0.481 [0.084, 2.742]	-3.6 [-13.9, 6.6]	0.679
		Irbesartan	55	4 (7.3)				
eGFR High and UP High	Double-blind period	Sparsentan	37	2 (5.4)	0.973 [0.145, 6.541]	0.971 [0.129, 7.294]	-0.2 [-13.3, 13.0]	1.000
		Irbesartan	36	2 (5.6)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	1 (2.6)	0.949 [0.062, 14.620]	0.947 [0.057, 15.721]	-0.1 [-10.0, 9.7]	1.000
		Irbesartan	37	1 (2.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2G_FSIM: Patients with confirmed 40% reduction in eGFR by subgroup
Full Analysis Set

Confirmed 40% reduction in eGFR

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.957
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	14 (11.0)	0.790 [0.411, 1.519]	0.764 [0.362, 1.611]	-2.9 [-11.8, 5.9]	0.572
		Irbesartan	129	18 (14.0)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2)	0.980 [0.260, 3.695]	0.978 [0.230, 4.155]	-0.2 [-13.2, 12.8]	1.000
		Irbesartan	48	4 (8.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.963 + [0.020, 46.760]	0.962 + [0.018, 50.349]	0.0 [NE, NE]	NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2G_FSIM: Patients with confirmed 40% reduction in eGFR by subgroup
Full Analysis Set

Confirmed 40% reduction in eGFR

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.862
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	12 (14.6)	0.901 [0.438, 1.853]	0.884 [0.376, 2.074]	-1.6 [-14.0, 10.7]	0.830
		Irbesartan	80	13 (16.3)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	2 (4.4)	0.436 [0.089, 2.134]	0.409 [0.075, 2.224]	-5.8 [-18.3, 6.8]	0.438
		Irbesartan	49	5 (10.2)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2)	0.980 [0.260, 3.695]	0.978 [0.230, 4.155]	-0.2 [-13.2, 12.8]	1.000
		Irbesartan	48	4 (8.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.963 + [0.020, 46.760]	0.962 + [0.018, 50.349]	0.0 [NE, NE]	NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2G_FSIM: Patients with confirmed 40% reduction in eGFR by subgroup
Full Analysis Set

Confirmed 40% reduction in eGFR

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.538
<= 1.75 g/day	Double-blind period	Sparsentan	98	3 (3.1)	0.569 [0.140, 2.316]	0.556 [0.129, 2.394]	-2.3 [-9.1, 4.4]	0.489
		Irbesartan	93	5 (5.4)				
> 1.75 g/day	Double-blind period	Sparsentan	104	15 (14.4)	0.925 [0.488, 1.754]	0.912 [0.430, 1.937]	-1.2 [-11.7, 9.4]	0.850
		Irbesartan	109	17 (15.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2G_FSIM: Patients with confirmed 40% reduction in eGFR by subgroup
Full Analysis Set

Confirmed 40% reduction in eGFR

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.333
Yes	Double-blind period	Sparsentan	90	11 (12.2)	1.076 [0.481, 2.404]	1.086 [0.436, 2.703]	0.9 [-9.7, 11.5]	1.000
		Irbesartan	88	10 (11.4)				
No	Double-blind period	Sparsentan	112	7 (6.3)	0.594 [0.243, 1.453]	0.567 [0.215, 1.497]	-4.3 [-12.4, 3.8]	0.338
		Irbesartan	114	12 (10.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2G_FSIM: Patients with confirmed 40% reduction in eGFR by subgroup
Full Analysis Set

Confirmed 40% reduction in eGFR

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.471
<= 5 years	Double-blind period	Sparsentan	113	13 (11.5)	0.974 [0.485, 1.958]	0.971 [0.440, 2.139]	-0.3 [-9.3, 8.7]	1.000
		Irbesartan	127	15 (11.8)				
> 5 years	Double-blind period	Sparsentan	89	5 (5.6)	0.602 [0.199, 1.819]	0.578 [0.176, 1.903]	-3.7 [-13.1, 5.7]	0.385
		Irbesartan	75	7 (9.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2G_FSIM: Patients with confirmed 40% reduction in eGFR by subgroup
Full Analysis Set

Confirmed 40% reduction in eGFR

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.324
Yes	Double-blind period	Sparsentan	155	17 (11.0)	0.929 [0.502, 1.721]	0.921 [0.459, 1.845]	-0.8 [-8.5, 6.8]	0.861
		Irbesartan	161	19 (11.8)				
No	Double-blind period	Sparsentan	47	1 (2.1)	0.291 [0.031, 2.688]	0.275 [0.028, 2.756]	-5.2 [-16.4, 6.1]	0.335
		Irbesartan	41	3 (7.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2GT_FSTM: Time to confirmed 40% reduction in eGFR by subgroup
Full Analysis Set

Time to confirmed 40% reduction in eGFR				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sex	Sparsentan						Interaction test:	0.927
Male	Sparsentan	139	15 (10.8)	NE		0.719	(0.359, 1.438)	0.351
	Irbesartan	143	18 (12.6)	117.0	(117.0, NE)			
Female	Sparsentan	63	3 (4.8)	NE		0.902	(0.202, 4.039)	0.893
	Irbesartan	59	4 (6.8)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2GT_FSTM: Time to confirmed 40% reduction in eGFR by subgroup
Full Analysis Set

Time to confirmed 40% reduction in eGFR				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.384
<= 45 years	Sparsentan	96	10 (10.4)	NE		0.576	(0.254, 1.304)	0.186
	Irbesartan	99	14 (14.1)	NE				
> 45 years	Sparsentan	106	8 (7.5)	NE		0.979	(0.360, 2.660)	0.967
	Irbesartan	103	8 (7.8)	117.0	(117.0, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2GT_FSTM: Time to confirmed 40% reduction in eGFR by subgroup
Full Analysis Set

Time to confirmed 40% reduction in eGFR				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age at IgAN diagnosis	Sparsentan						Interaction test:	0.538
<= 18 years	Sparsentan	9	3 (33.3)	NE		NE		NE
	Irbesartan	5	1 (20.0)	111.4	(NE, NE)			
> 18 to 40 years	Sparsentan	102	7 (6.9)	NE		0.485	(0.193, 1.222)	0.125
	Irbesartan	109	13 (11.9)	NE				
> 40 years	Sparsentan	91	8 (8.8)	NE		0.951	(0.350, 2.586)	0.922
	Irbesartan	88	8 (9.1)	117.0	(NE, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2GT_FSTM: Time to confirmed 40% reduction in eGFR by subgroup
Full Analysis Set

Time to confirmed 40% reduction in eGFR				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Geographic region	Sparsentan						Interaction test:	0.986
North America	Sparsentan	35	3 (8.6)	NE		0.726	(0.162, 3.256)	0.675
	Irbesartan	46	4 (8.7)	NE				
Europe	Sparsentan	98	8 (8.2)	NE		0.697	(0.289, 1.685)	0.423
	Irbesartan	115	14 (12.2)	117.0	(117.0, NE)			
Asia Pacific	Sparsentan	69	7 (10.1)	NE		0.624	(0.178, 2.192)	0.462
	Irbesartan	41	4 (9.8)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2GT_FSTM: Time to confirmed 40% reduction in eGFR by subgroup
Full Analysis Set

Time to confirmed 40% reduction in eGFR				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.509
< 27 kg/m**2	Sparsentan	83	5 (6.0)	NE		0.535	(0.182, 1.572)	0.255
	Irbesartan	94	10 (10.6)	NE				
>= 27 kg/m**2	Sparsentan	119	13 (10.9)	NE		0.892	(0.398, 1.999)	0.782
	Irbesartan	107	12 (11.2)	117.0	(NE, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2GT_FSTM: Time to confirmed 40% reduction in eGFR by subgroup
Full Analysis Set

Time to confirmed 40% reduction in eGFR				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Randomization strata	Sparsentan						Interaction test:	0.946
eGFR Low and UP High	Sparsentan	71	13 (18.3)	NE		0.794	(0.373, 1.691)	0.550
	Irbesartan	74	15 (20.3)	117.0	(117.0, NE)			
eGFR Low and UP Low	Sparsentan	55	2 (3.6)	NE		0.479	(0.088, 2.616)	0.395
	Irbesartan	55	4 (7.3)	NE				
eGFR High and UP High	Sparsentan	37	2 (5.4)	NE		0.867	(0.122, 6.157)	0.886
	Irbesartan	36	2 (5.6)	NE				
eGFR High and UP Low	Sparsentan	39	1 (2.6)	NE		0.781	(0.049, 12.483)	0.861
	Irbesartan	37	1 (2.7)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2GT_FSTM: Time to confirmed 40% reduction in eGFR by subgroup
Full Analysis Set

Time to confirmed 40% reduction in eGFR				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan						Interaction test:	NE
< 60 mL/min/1.73 m**2	Sparsentan	127	14 (11.0)	NE		0.689	(0.340, 1.395)	0.300
	Irbesartan	129	18 (14.0)	117.0	(117.0, NE)			
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	4 (8.2)	NE		0.919	(0.227, 3.721)	0.906
	Irbesartan	48	4 (8.3)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	0 (0.0) No events in 1 group	NE		NE		NE
	Irbesartan	25	0 (0.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2GT_FSTM: Time to confirmed 40% reduction in eGFR by subgroup
Full Analysis Set

Time to confirmed 40% reduction in eGFR				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 2	Sparsentan						Interaction test:	NE
< 45 mL/min/1.73 m**2	Sparsentan	82	12 (14.6)	NE		0.831	(0.374, 1.844)	0.648
	Irbesartan	80	13 (16.3)	117.0	(117.0, NE)			
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	2 (4.4)	NE		0.350	(0.068, 1.805)	0.210
	Irbesartan	49	5 (10.2)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	4 (8.2)	NE		0.919	(0.227, 3.721)	0.906
	Irbesartan	48	4 (8.3)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	0 (0.0) No events in 1 group	NE		NE		NE
	Irbesartan	25	0 (0.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2GT_FSTM: Time to confirmed 40% reduction in eGFR by subgroup
Full Analysis Set

Time to confirmed 40% reduction in eGFR				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline urine protein excretion	Sparsentan						Interaction test:	0.641
<= 1.75 g/day	Sparsentan	98	3 (3.1)	NE		0.520	(0.124, 2.185)	0.372
	Irbesartan	93	5 (5.4)	NE				
> 1.75 g/day	Sparsentan	104	15 (14.4)	NE		0.799	(0.394, 1.623)	0.535
	Irbesartan	109	17 (15.6)	117.0	(117.0, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2GT_FSTM: Time to confirmed 40% reduction in eGFR by subgroup
Full Analysis Set

Time to confirmed 40% reduction in eGFR				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.294
Yes	Sparsentan	90	11 (12.2)	NE		0.975	(0.414, 2.299)	0.954
	Irbesartan	88	10 (11.4)	NE				
No	Sparsentan	112	7 (6.3)	NE		0.525	(0.203, 1.359)	0.184
	Irbesartan	114	12 (10.5)	117.0	(NE, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2GT_FSTM: Time to confirmed 40% reduction in eGFR by subgroup
Full Analysis Set

Time to confirmed 40% reduction in eGFR				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Time since renal biopsy	Sparsentan						Interaction test:	0.844
<= 5 years	Sparsentan	113	13 (11.5)	NE		0.779	(0.370, 1.641)	0.512
	Irbesartan	127	15 (11.8)	NE				
> 5 years	Sparsentan	89	5 (5.6)	NE		0.709	(0.215, 2.337)	0.572
	Irbesartan	75	7 (9.3)	117.0	(117.0, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2GT_FSTM: Time to confirmed 40% reduction in eGFR by subgroup
Full Analysis Set

Time to confirmed 40% reduction in eGFR				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
History of hypertension	Sparsentan						Interaction test:	0.235
Yes	Sparsentan	155	17 (11.0)	NE		0.843	(0.436, 1.631)	0.612
	Irbesartan	161	19 (11.8)	117.0	(117.0, NE)			
No	Sparsentan	47	1 (2.1)	NE		0.227	(0.023, 2.228)	0.203
	Irbesartan	41	3 (7.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Figure PF2GT_FSKM: Time to confirmed 40% reduction in eGFR by subgroup
Full Analysis Set

Not done. No significant subgroups.

_____
eGFR = estimated glomerular filtration rate.
Reference table: PT2GT_FSTM

Table PT2E_FSIM: Patients reaching ESRD by subgroup
Full Analysis Set

Reaching ESRD

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.487
Male	Double-blind period	Sparsentan	139	6 (4.3)	0.686 [0.251, 1.876]	0.672 [0.233, 1.940]	-2.0 [-7.9, 4.0]	0.598
		Irbesartan	143	9 (6.3)				
Female	Double-blind period	Sparsentan	63	3 (4.8)	1.405 [0.243, 8.113]	1.425 [0.230, 8.844]	1.4 [-7.3, 10.0]	1.000
		Irbesartan	59	2 (3.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
ESRD = End-stage renal disease.
Source Data: aeff, created on: 20FEB2024

Table PT2E_FSIM: Patients reaching ESRD by subgroup
Full Analysis Set

Reaching ESRD								
Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.748
<= 45 years	Double-blind period	Sparsentan	96	7 (7.3)	0.902 [0.340, 2.392]	0.895 [0.311, 2.571]	-0.8 [-9.3, 7.7]	1.000
		Irbesartan	99	8 (8.1)				
> 45 years	Double-blind period	Sparsentan	106	2 (1.9)	0.648 [0.111, 3.798]	0.641 [0.105, 3.917]	-1.0 [-6.1, 4.1]	0.680
		Irbesartan	103	3 (2.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
ESRD = End-stage renal disease.
Source Data: aeff, created on: 20FEB2024

Table PT2E_FSIM: Patients reaching ESRD by subgroup
Full Analysis Set

Reaching ESRD

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.293
<= 18 years	Double-blind period	Sparsentan	9	3 (33.3)	4.200 + [0.259, 68.038]	5.923 + [0.248, 141.482]	33.3 [-13.0, 79.7]	0.258
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	3 (2.9)	0.401 [0.109, 1.469]	0.383 [0.099, 1.484]	-4.4 [-11.2, 2.4]	0.217
		Irbesartan	109	8 (7.3)				
> 40 years	Double-blind period	Sparsentan	91	3 (3.3)	0.967 [0.201, 4.663]	0.966 [0.190, 4.919]	-0.1 [-6.5, 6.3]	1.000
		Irbesartan	88	3 (3.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
ESRD = End-stage renal disease.
Source Data: aeff, created on: 20FEB2024

Table PT2E_FSIM: Patients reaching ESRD by subgroup
Full Analysis Set

Reaching ESRD

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.223
North America	Double-blind period	Sparsentan	35	0 (0.0)	0.145 + [0.008, 2.608]	0.133 + [0.007, 2.556]	-8.7 [-19.4, 2.0]	0.130
		Irbesartan	46	4 (8.7)				
Europe	Double-blind period	Sparsentan	98	5 (5.1)	0.838 [0.275, 2.558]	0.829 [0.255, 2.701]	-1.0 [-8.1, 6.1]	1.000
		Irbesartan	115	7 (6.1)				
Asia Pacific	Double-blind period	Sparsentan	69	4 (5.8)	5.400 + [0.298, 97.806]	5.702 + [0.299, 108.676]	5.8 [-1.7, 13.3]	0.295
		Irbesartan	41	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
ESRD = End-stage renal disease.
Source Data: aeff, created on: 20FEB2024

Table PT2E_FSIM: Patients reaching ESRD by subgroup
Full Analysis Set

Reaching ESRD								
Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.221
< 27 kg/m**2	Double-blind period	Sparsentan	83	2 (2.4)	0.378 [0.078, 1.820]	0.362 [0.071, 1.846]	-4.0 [-11.0, 3.1]	0.286
		Irbesartan	94	6 (6.4)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	7 (5.9)	1.259 [0.412, 3.849]	1.275 [0.392, 4.143]	1.2 [-5.5, 7.9]	0.772
		Irbesartan	107	5 (4.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
ESRD = End-stage renal disease.
Source Data: aeff, created on: 20FEB2024

Table PT2E_FSIM: Patients reaching ESRD by subgroup
Full Analysis Set

Reaching ESRD

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.637
eGFR Low and UP High	Double-blind period	Sparsentan	71	6 (8.5)	0.625 [0.240, 1.630]	0.591 [0.203, 1.721]	-5.1 [-16.6, 6.4]	0.429
		Irbesartan	74	10 (13.5)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	2 (3.6)	5.000 + [0.246, 101.812]	5.187 + [0.243, 110.569]	3.6 [-3.1, 10.4]	0.495
		Irbesartan	55	0 (0.0)				
eGFR High and UP High	Double-blind period	Sparsentan	37	1 (2.7)	0.973 [0.063, 14.972]	0.972 [0.058, 16.158]	-0.1 [-10.3, 10.2]	1.000
		Irbesartan	36	1 (2.8)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	0 (0.0)	0.950 + [0.019, 46.684]	0.949 + [0.018, 49.075]	0.0 [NE, NE]	NE
		Irbesartan	37	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
ESRD = End-stage renal disease.
Source Data: aeff, created on: 20FEB2024

Table PT2E_FSIM: Patients reaching ESRD by subgroup
Full Analysis Set

Reaching ESRD

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.989
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	8 (6.3)	0.813 [0.331, 1.992]	0.800 [0.305, 2.097]	-1.5 [-8.5, 5.6]	0.808
		Irbesartan	129	10 (7.8)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	1 (2.0)	0.980 [0.063, 15.218]	0.979 [0.059, 16.116]	-0.0 [-7.8, 7.7]	1.000
		Irbesartan	48	1 (2.1)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.963 + [0.020, 46.760]	0.962 + [0.018, 50.349]	0.0 [NE, NE]	NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
ESRD = End-stage renal disease.
Source Data: aeff, created on: 20FEB2024

Table PT2E_FSIM: Patients reaching ESRD by subgroup
Full Analysis Set

Reaching ESRD

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.962
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	8 (9.8)	0.867 [0.352, 2.136]	0.853 [0.312, 2.333]	-1.5 [-12.2, 9.2]	0.802
		Irbesartan	80	9 (11.3)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	0 (0.0)	0.362 + [0.015, 8.673]	0.355 + [0.014, 8.947]	-2.0 [-8.1, 4.0]	1.000
		Irbesartan	49	1 (2.0)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	1 (2.0)	0.980 [0.063, 15.218]	0.979 [0.059, 16.116]	-0.0 [-7.8, 7.7]	1.000
		Irbesartan	48	1 (2.1)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.963 + [0.020, 46.760]	0.962 + [0.018, 50.349]	0.0 [NE, NE]	NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
ESRD = End-stage renal disease.
Source Data: aeff, created on: 20FEB2024

Table PT2E_FSIM: Patients reaching ESRD by subgroup
Full Analysis Set

Reaching ESRD

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.604
<= 1.75 g/day	Double-blind period	Sparsentan	98	1 (1.0)	0.474 [0.044, 5.145]	0.469 [0.042, 5.262]	-1.1 [-5.7, 3.5]	0.613
		Irbesartan	93	2 (2.2)				
> 1.75 g/day	Double-blind period	Sparsentan	104	8 (7.7)	0.932 [0.374, 2.323]	0.926 [0.343, 2.499]	-0.6 [-8.8, 7.6]	1.000
		Irbesartan	109	9 (8.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
ESRD = End-stage renal disease.
Source Data: aeff, created on: 20FEB2024

Table PT2E_FSIM: Patients reaching ESRD by subgroup
Full Analysis Set

Reaching ESRD								
Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.189
Yes	Double-blind period	Sparsentan	90	6 (6.7)	1.467 [0.428, 5.021]	1.500 [0.408, 5.508]	2.1 [-5.7, 10.0]	0.747
		Irbesartan	88	4 (4.5)				
No	Double-blind period	Sparsentan	112	3 (2.7)	0.436 [0.116, 1.645]	0.421 [0.106, 1.670]	-3.5 [-9.7, 2.7]	0.333
		Irbesartan	114	7 (6.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
ESRD = End-stage renal disease.
Source Data: aeff, created on: 20FEB2024

Table PT2E_FSIM: Patients reaching ESRD by subgroup
Full Analysis Set

			Reaching ESRD				
Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	1.000
<= 5 years	Double-blind period	Sparsentan	113	6 (5.3)	0.843 [0.302, 2.356]	0.834 [0.280, 2.481]	-1.0 [-7.7, 5.8]	0.790
		Irbesartan	127	8 (6.3)				
> 5 years	Double-blind period	Sparsentan	89	3 (3.4)	0.843 [0.175, 4.053]	0.837 [0.164, 4.276]	-0.6 [-7.7, 6.4]	1.000
		Irbesartan	75	3 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
ESRD = End-stage renal disease.
Source Data: aeff, created on: 20FEB2024

Table PT2E_FSIM: Patients reaching ESRD by subgroup
Full Analysis Set

				Reaching ESRD				
Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.563
Yes	Double-blind period	Sparsentan	155	8 (5.2)	0.923 [0.366, 2.332]	0.919 [0.345, 2.446]	-0.4 [-6.0, 5.2]	1.000
		Irbesartan	161	9 (5.6)				
No	Double-blind period	Sparsentan	47	1 (2.1)	0.436 [0.041, 4.636]	0.424 [0.037, 4.854]	-2.8 [-12.8, 7.3]	0.596
		Irbesartan	41	2 (4.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
ESRD = End-stage renal disease.
Source Data: aeff, created on: 20FEB2024

Table PT2ET_FSTM: Time to ESRD by subgroup
Full Analysis Set

Time to ESRD				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sex	Sparsentan						Interaction test:	0.287
Male	Sparsentan	139	6 (4.3)	NE		0.568	(0.202, 1.599)	0.284
	Irbesartan	143	9 (6.3)	NE				
Female	Sparsentan	63	3 (4.8)	NE		1.913	(0.318, 11.487)	0.478
	Irbesartan	59	2 (3.4)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2ET_FSTM: Time to ESRD by subgroup
Full Analysis Set

Time to ESRD				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.889
<= 45 years	Sparsentan	96	7 (7.3)	NE		0.750	(0.271, 2.077)	0.580
	Irbesartan	99	8 (8.1)	NE				
> 45 years	Sparsentan	106	2 (1.9)	NE		0.641	(0.107, 3.841)	0.626
	Irbesartan	103	3 (2.9)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2ET_FSTM: Time to ESRD by subgroup
Full Analysis Set

Time to ESRD				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age at IgAN diagnosis	Sparsentan						Interaction test:	NE
<= 18 years	Sparsentan	9	3 (33.3) No events in 1 group	NE		NE		NE
	Irbesartan	5	0 (0.0)	NE				
> 18 to 40 years	Sparsentan	102	3 (2.9)	NE		0.362	(0.096, 1.366)	0.134
	Irbesartan	109	8 (7.3)	NE				
> 40 years	Sparsentan	91	3 (3.3)	NE		0.899	(0.181, 4.460)	0.896
	Irbesartan	88	3 (3.4)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2ET_FSTM: Time to ESRD by subgroup
Full Analysis Set

Time to ESRD				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Geographic region	Sparsentan						Interaction test:	NE
North America	Sparsentan	35	0 (0.0) No events in 1 group	NE		NE		NE
	Irbesartan	46	4 (8.7)	NE				
Europe	Sparsentan	98	5 (5.1)	NE		0.818	(0.259, 2.580)	0.731
	Irbesartan	115	7 (6.1)	NE				
Asia Pacific	Sparsentan	69	4 (5.8) No events in 1 group	NE		NE		NE
	Irbesartan	41	0 (0.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2ET_FSTM: Time to ESRD by subgroup
Full Analysis Set

Time to ESRD				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.311
< 27 kg/m**2	Sparsentan	83	2 (2.4)	NE		0.426	(0.086, 2.114)	0.297
	Irbesartan	94	6 (6.4)	NE				
>= 27 kg/m**2	Sparsentan	119	7 (5.9)	NE		1.093	(0.345, 3.466)	0.880
	Irbesartan	107	5 (4.7)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2ET_FSTM: Time to ESRD by subgroup
Full Analysis Set

Time to ESRD				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Randomization strata	Sparsentan						Interaction test:	NE
eGFR Low and UP High	Sparsentan	71	6 (8.5)	NE		0.540	(0.196, 1.488)	0.234
	Irbesartan	74	10 (13.5)	NE				
eGFR Low and UP Low	Sparsentan	55	2 (3.6)	NE		NE		NE
			No events in 1 group					
	Irbesartan	55	0 (0.0)	NE				
eGFR High and UP High	Sparsentan	37	1 (2.7)	NE		0.980	(0.061, 15.698)	0.988
	Irbesartan	36	1 (2.8)	NE				
eGFR High and UP Low	Sparsentan	39	0 (0.0)	NE		NE		NE
			No events in 1 group					
	Irbesartan	37	0 (0.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2ET_FSTM: Time to ESRD by subgroup
Full Analysis Set

Time to ESRD				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan						Interaction test:	NE
< 60 mL/min/1.73 m**2	Sparsentan	127	8 (6.3)	NE		0.696	(0.275, 1.766)	0.446
	Irbesartan	129	10 (7.8)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	1 (2.0)	NE		0.900	(0.056, 14.389)	0.941
	Irbesartan	48	1 (2.1)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	0 (0.0) No events in 1 group	NE		NE		NE
	Irbesartan	25	0 (0.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2ET_FSTM: Time to ESRD by subgroup
Full Analysis Set

Time to ESRD				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 2	Sparsentan						Interaction test:	NE
< 45 mL/min/1.73 m**2	Sparsentan	82	8 (9.8)	NE		0.762	(0.293, 1.978)	0.576
	Irbesartan	80	9 (11.3)	NE				
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	0 (0.0) No events in 1 group	NE		NE		NE
	Irbesartan	49	1 (2.0)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	1 (2.0)	NE		0.900	(0.056, 14.389)	0.941
	Irbesartan	48	1 (2.1)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	0 (0.0) No events in 1 group	NE		NE		NE
	Irbesartan	25	0 (0.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2ET_FSTM: Time to ESRD by subgroup
Full Analysis Set

Time to ESRD				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline urine protein excretion	Sparsentan						Interaction test:	0.706
<= 1.75 g/day	Sparsentan	98	1 (1.0)	NE		0.438	(0.039, 4.889)	0.502
	Irbesartan	93	2 (2.2)	NE				
> 1.75 g/day	Sparsentan	104	8 (7.7)	NE		0.792	(0.305, 2.056)	0.632
	Irbesartan	109	9 (8.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2ET_FSTM: Time to ESRD by subgroup
Full Analysis Set

Time to ESRD				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.184
Yes	Sparsentan	90	6 (6.7)	NE		1.350	(0.381, 4.790)	0.642
	Irbesartan	88	4 (4.5)	NE				
No	Sparsentan	112	3 (2.7)	NE		0.372	(0.096, 1.444)	0.153
	Irbesartan	114	7 (6.1)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2ET_FSTM: Time to ESRD by subgroup
Full Analysis Set

Time to ESRD				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Time since renal biopsy	Sparsentan						Interaction test:	0.832
<= 5 years	Sparsentan	113	6 (5.3)	NE		0.722	(0.250, 2.084)	0.547
	Irbesartan	127	8 (6.3)	NE				
> 5 years	Sparsentan	89	3 (3.4)	NE		0.841	(0.170, 4.169)	0.832
	Irbesartan	75	3 (4.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2ET_FSTM: Time to ESRD by subgroup
Full Analysis Set

Time to ESRD				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
History of hypertension	Sparsentan						Interaction test:	0.496
Yes	Sparsentan	155	8 (5.2)	NE		0.839	(0.323, 2.175)	0.718
	Irbesartan	161	9 (5.6)	NE				
No	Sparsentan	47	1 (2.1)	NE		0.431	(0.038, 4.843)	0.495
	Irbesartan	41	2 (4.9)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Figure PF2ET_FSKM: Time to ESRD by subgroup
Full Analysis Set

Not done. No significant subgroups.

_____
ESRD = End-stage renal disease.
Reference table: PT2ET_FSTM

Table PT2D_FSIM: Patients with death by subgroup
Full Analysis Set

Subgroup analysis will not be performed as only one death occured.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2DT_FSTM: Time to death by subgroup
Full Analysis Set

Not done. Less than 10 patients with events in main analysis.

_____
N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Figure PF2DT_FSKM: Time to death by subgroup
Full Analysis Set

Not done. Less than 10 patients with events in main analysis.

Reference table: PT2DT_FSTM

Table PT2CKD_FSIM: Patients entering CKD stage 4 or 5 by subgroup
Full Analysis Set

Entering CKD stage 4 or 5

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Sex	Double-blind period	Sparsentan					Interaction test:	0.074	
Male	Double-blind period	Sparsentan	139	40 (28.8)	0.857 [0.605, 1.215]	0.800 [0.482, 1.325]	-4.8 [-16.3, 6.7]	0.441	
		Irbesartan	143	48 (33.6)					
Female	Double-blind period	Sparsentan	63	7 (11.1)	0.386 [0.172, 0.863]	0.309 [0.117, 0.812]	-17.7 [-33.3, -2.1]	0.022	*
		Irbesartan	59	17 (28.8)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
CKD = Chronic kidney disease.
Source Data: aeff, created on: 20FEB2024

Table PT2CKD_FSIM: Patients entering CKD stage 4 or 5 by subgroup
Full Analysis Set

Entering CKD stage 4 or 5

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Age	Double-blind period	Sparsentan					Interaction test:	0.042	#
<= 45 years	Double-blind period	Sparsentan	96	23 (24.0)	1.078 [0.646, 1.800]	1.103 [0.566, 2.147]	1.7 [-11.1, 14.6]	0.865	
		Irbesartan	99	22 (22.2)					
> 45 years	Double-blind period	Sparsentan	106	24 (22.6)	0.542 [0.357, 0.825]	0.408 [0.224, 0.744]	-19.1 [-32.5, -5.7]	0.005	*
		Irbesartan	103	43 (41.7)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
CKD = Chronic kidney disease.
Source Data: aeff, created on: 20FEB2024

Table PT2CKD_FSIM: Patients entering CKD stage 4 or 5 by subgroup
Full Analysis Set

Entering CKD stage 4 or 5

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.287	
<= 18 years	Double-blind period	Sparsentan	9	6 (66.7)	1.667 [0.518, 5.363]	3.000 [0.312, 28.841]	26.7 [-41.7, 95.1]	0.580	
		Irbesartan	5	2 (40.0)					
> 18 to 40 years	Double-blind period	Sparsentan	102	21 (20.6)	0.724 [0.446, 1.174]	0.652 [0.346, 1.231]	-7.9 [-20.3, 4.6]	0.204	
		Irbesartan	109	31 (28.4)					
> 40 years	Double-blind period	Sparsentan	91	20 (22.0)	0.604 [0.376, 0.973]	0.493 [0.255, 0.953]	-14.4 [-28.7, -0.1]	0.048	*
		Irbesartan	88	32 (36.4)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
CKD = Chronic kidney disease.
Source Data: aeff, created on: 20FEB2024

Table PT2CKD_FSIM: Patients entering CKD stage 4 or 5 by subgroup
Full Analysis Set

Entering CKD stage 4 or 5

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.495
North America	Double-blind period	Sparsentan	35	6 (17.1)	0.526 [0.227, 1.216]	0.428 [0.146, 1.251]	-15.5 [-36.4, 5.5]	0.133
		Irbesartan	46	15 (32.6)				
Europe	Double-blind period	Sparsentan	98	23 (23.5)	0.692 [0.446, 1.074]	0.598 [0.326, 1.096]	-10.4 [-23.4, 2.6]	0.099
		Irbesartan	115	39 (33.9)				
Asia Pacific	Double-blind period	Sparsentan	69	18 (26.1)	0.972 [0.511, 1.849]	0.963 [0.401, 2.310]	-0.7 [-19.8, 18.3]	1.000
		Irbesartan	41	11 (26.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
CKD = Chronic kidney disease.
Source Data: aeff, created on: 20FEB2024

Table PT2CKD_FSIM: Patients entering CKD stage 4 or 5 by subgroup
Full Analysis Set

Entering CKD stage 4 or 5

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.796
< 27 kg/m**2	Double-blind period	Sparsentan	83	16 (19.3)	0.671 [0.390, 1.156]	0.593 [0.293, 1.199]	-9.4 [-23.1, 4.2]	0.163
		Irbesartan	94	27 (28.7)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	31 (26.1)	0.734 [0.494, 1.090]	0.640 [0.362, 1.131]	-9.5 [-22.4, 3.4]	0.148
		Irbesartan	107	38 (35.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
CKD = Chronic kidney disease.
Source Data: aeff, created on: 20FEB2024

Table PT2CKD_FSIM: Patients entering CKD stage 4 or 5 by subgroup
Full Analysis Set

Entering CKD stage 4 or 5

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.957	
eGFR Low and UP High	Double-blind period	Sparsentan	71	31 (43.7)	0.702 [0.511, 0.966]	0.472 [0.243, 0.916]	-18.5 [-35.9, -1.1]	0.031	*
		Irbesartan	74	46 (62.2)					
eGFR Low and UP Low	Double-blind period	Sparsentan	55	14 (25.5)	0.824 [0.452, 1.501]	0.763 [0.332, 1.757]	-5.5 [-24.1, 13.1]	0.672	
		Irbesartan	55	17 (30.9)					
eGFR High and UP High	Double-blind period	Sparsentan	37	2 (5.4)	0.973 [0.145, 6.541]	0.971 [0.129, 7.294]	-0.2 [-13.3, 13.0]	1.000	
		Irbesartan	36	2 (5.6)					
eGFR High and UP Low	Double-blind period	Sparsentan	39	0 (0.0)	0.950 + [0.019, 46.684]	0.949 + [0.018, 49.075]	0.0 [NE, NE]	NE	
		Irbesartan	37	0 (0.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
CKD = Chronic kidney disease.
Source Data: aeff, created on: 20FEB2024

Table PT2CKD_FSIM: Patients entering CKD stage 4 or 5 by subgroup
Full Analysis Set

Entering CKD stage 4 or 5

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.982	
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	45 (35.4)	0.737 [0.549, 0.991]	0.593 [0.359, 0.979]	-12.6 [-25.4, 0.1]	0.044	*
		Irbesartan	129	62 (48.1)					
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	2 (4.1)	0.653 [0.114, 3.737]	0.638 [0.102, 4.000]	-2.2 [-13.0, 8.7]	0.678	
		Irbesartan	48	3 (6.3)					
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.963 + [0.020, 46.760]	0.962 + [0.018, 50.349]	0.0 [NE, NE]	NE	
		Irbesartan	25	0 (0.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
CKD = Chronic kidney disease.
Source Data: aeff, created on: 20FEB2024

Table PT2CKD_FSIM: Patients entering CKD stage 4 or 5 by subgroup
Full Analysis Set

Entering CKD stage 4 or 5

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.997	
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	40 (48.8)	0.723 [0.552, 0.946]	0.459 [0.242, 0.867]	-18.7 [-34.9, -2.6]	0.018	*
		Irbesartan	80	54 (67.5)					
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	5 (11.1)	0.681 [0.240, 1.928]	0.641 [0.193, 2.125]	-5.2 [-21.2, 10.8]	0.557	
		Irbesartan	49	8 (16.3)					
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	2 (4.1)	0.653 [0.114, 3.737]	0.638 [0.102, 4.000]	-2.2 [-13.0, 8.7]	0.678	
		Irbesartan	48	3 (6.3)					
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.963 + [0.020, 46.760]	0.962 + [0.018, 50.349]	0.0 [NE, NE]	NE	
		Irbesartan	25	0 (0.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
CKD = Chronic kidney disease.
Source Data: aeff, created on: 20FEB2024

Table PT2CKD_FSIM: Patients entering CKD stage 4 or 5 by subgroup
Full Analysis Set

Entering CKD stage 4 or 5

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.584	
<= 1.75 g/day	Double-blind period	Sparsentan	98	16 (16.3)	0.844 [0.458, 1.554]	0.813 [0.387, 1.709]	-3.0 [-14.9, 8.9]	0.706	
		Irbesartan	93	18 (19.4)					
> 1.75 g/day	Double-blind period	Sparsentan	104	31 (29.8)	0.691 [0.480, 0.996]	0.560 [0.318, 0.986]	-13.3 [-27.0, 0.4]	0.048	*
		Irbesartan	109	47 (43.1)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
CKD = Chronic kidney disease.
Source Data: aeff, created on: 20FEB2024

Table PT2CKD_FSIM: Patients entering CKD stage 4 or 5 by subgroup
Full Analysis Set

Entering CKD stage 4 or 5

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.638
Yes	Double-blind period	Sparsentan	90	29 (32.2)	0.766 [0.520, 1.129]	0.655 [0.355, 1.208]	-9.8 [-25.1, 5.4]	0.215
		Irbesartan	88	37 (42.0)				
No	Double-blind period	Sparsentan	112	18 (16.1)	0.654 [0.385, 1.113]	0.588 [0.304, 1.138]	-8.5 [-19.8, 2.8]	0.137
		Irbesartan	114	28 (24.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
CKD = Chronic kidney disease.
Source Data: aeff, created on: 20FEB2024

Table PT2CKD_FSIM: Patients entering CKD stage 4 or 5 by subgroup
Full Analysis Set

Entering CKD stage 4 or 5

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.769
<= 5 years	Double-blind period	Sparsentan	113	23 (20.4)	0.680 [0.433, 1.068]	0.599 [0.330, 1.085]	-9.6 [-21.3, 2.2]	0.103
		Irbesartan	127	38 (29.9)				
> 5 years	Double-blind period	Sparsentan	89	24 (27.0)	0.749 [0.475, 1.182]	0.656 [0.338, 1.276]	-9.0 [-24.5, 6.4]	0.238
		Irbesartan	75	27 (36.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
CKD = Chronic kidney disease.
Source Data: aeff, created on: 20FEB2024

Table PT2CKD_FSIM: Patients entering CKD stage 4 or 5 by subgroup
Full Analysis Set

Entering CKD stage 4 or 5

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.261
Yes	Double-blind period	Sparsentan	155	42 (27.1)	0.793 [0.567, 1.110]	0.716 [0.443, 1.159]	-7.1 [-17.8, 3.7]	0.182
		Irbesartan	161	55 (34.2)				
No	Double-blind period	Sparsentan	47	5 (10.6)	0.436 [0.162, 1.172]	0.369 [0.115, 1.189]	-13.8 [-31.9, 4.4]	0.098
		Irbesartan	41	10 (24.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
CKD = Chronic kidney disease.
Source Data: aeff, created on: 20FEB2024

Table PT2CKDT_FSTM: Time to CKD stage 4 or 5 by subgroup
Full Analysis Set

Time to CKD stage 4 or 5				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sex	Sparsentan						Interaction test:	0.400
Male	Sparsentan	139	40 (28.8)	NE		0.713	(0.468, 1.086)	0.115
	Irbesartan	143	48 (33.6)	NE				
Female	Sparsentan	63	7 (11.1)	NE		0.497	(0.206, 1.202)	0.121
	Irbesartan	59	17 (28.8)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 03JUN2024

Table PT2CKDT_FSTM: Time to CKD stage 4 or 5 by subgroup
Full Analysis Set

Time to CKD stage 4 or 5				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Age	Sparsentan						Interaction test:	0.060	
<= 45 years	Sparsentan	96	23 (24.0)	NE		1.027	(0.572, 1.846)	0.928	
	Irbesartan	99	22 (22.2)	NE					
> 45 years	Sparsentan	106	24 (22.6)	NE		0.500	(0.303, 0.824)	0.007	*
	Irbesartan	103	43 (41.7)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 03JUN2024

Table PT2CKDT_FSTM: Time to CKD stage 4 or 5 by subgroup
Full Analysis Set

Time to CKD stage 4 or 5				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Age at IgAN diagnosis	Sparsentan						Interaction test:	0.525	
<= 18 years	Sparsentan	9	6 (66.7)	83.4	(3.9, NE)	1.293	(0.243, 6.880)	0.763	
	Irbesartan	5	2 (40.0)	NE					
> 18 to 40 years	Sparsentan	102	21 (20.6)	NE		0.749	(0.430, 1.305)	0.308	
	Irbesartan	109	31 (28.4)	NE					
> 40 years	Sparsentan	91	20 (22.0)	NE		0.493	(0.282, 0.863)	0.013	*
	Irbesartan	88	32 (36.4)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 03JUN2024

Table PT2CKDT_FSTM: Time to CKD stage 4 or 5 by subgroup
Full Analysis Set

Time to CKD stage 4 or 5				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Geographic region	Sparsentan						Interaction test:	0.513
North America	Sparsentan	35	6 (17.1)	NE		0.434	(0.167, 1.126)	0.086
	Irbesartan	46	15 (32.6)	NE				
Europe	Sparsentan	98	23 (23.5)	NE		0.683	(0.408, 1.146)	0.149
	Irbesartan	115	39 (33.9)	NE				
Asia Pacific	Sparsentan	69	18 (26.1)	NE		0.967	(0.452, 2.069)	0.932
	Irbesartan	41	11 (26.8)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 03JUN2024

Table PT2CKDT_FSTM: Time to CKD stage 4 or 5 by subgroup
Full Analysis Set

Time to CKD stage 4 or 5				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.948
< 27 kg/m**2	Sparsentan	83	16 (19.3)	NE		0.673	(0.362, 1.250)	0.210
	Irbesartan	94	27 (28.7)	NE				
>= 27 kg/m**2	Sparsentan	119	31 (26.1)	NE		0.641	(0.398, 1.031)	0.066
	Irbesartan	107	38 (35.5)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 03JUN2024

Table PT2CKDT_FSTM: Time to CKD stage 4 or 5 by subgroup
Full Analysis Set

Time to CKD stage 4 or 5				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Randomization strata	Sparsentan						Interaction test:	NE	
eGFR Low and UP High	Sparsentan	71	31 (43.7)	NE		0.623	(0.394, 0.983)	0.042	*
	Irbesartan	74	46 (62.2)	84.0	(51.0, 109.0)				
eGFR Low and UP Low	Sparsentan	55	14 (25.5)	NE		0.763	(0.376, 1.548)	0.454	
	Irbesartan	55	17 (30.9)	NE					
eGFR High and UP High	Sparsentan	37	2 (5.4)	NE		0.937	(0.132, 6.651)	0.948	
	Irbesartan	36	2 (5.6)	NE					
eGFR High and UP Low	Sparsentan	39	0 (0.0) No events in 1 group	NE		NE		NE	
	Irbesartan	37	0 (0.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 03JUN2024

Table PT2CKDT_FSTM: Time to CKD stage 4 or 5 by subgroup
Full Analysis Set

Time to CKD stage 4 or 5				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eGFR Group 1	Sparsentan						Interaction test:	NE	
< 60 mL/min/1.73 m**2	Sparsentan	127	45 (35.4)	NE		0.638	(0.434, 0.937)	0.022	*
	Irbesartan	129	62 (48.1)	110.1	(93.3, NE)				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	2 (4.1)	NE		0.735	(0.121, 4.459)	0.738	
	Irbesartan	48	3 (6.3)	NE					
>= 90 mL/min/1.73 m**2	Sparsentan	26	0 (0.0) No events in 1 group	NE		NE		NE	
	Irbesartan	25	0 (0.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 03JUN2024

Table PT2CKDT_FSTM: Time to CKD stage 4 or 5 by subgroup
Full Analysis Set

Time to CKD stage 4 or 5				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eGFR Group 2	Sparsentan						Interaction test:	NE	
< 45 mL/min/1.73 m**2	Sparsentan	82	40 (48.8)	109.1	(82.1, NE)	0.611	(0.405, 0.921)	0.019	*
	Irbesartan	80	54 (67.5)	70.1	(45.4, 106.3)				
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	5 (11.1)	NE		0.563	(0.184, 1.722)	0.314	
	Irbesartan	49	8 (16.3)	NE					
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	2 (4.1)	NE		0.735	(0.121, 4.459)	0.738	
	Irbesartan	48	3 (6.3)	NE					
>= 90 mL/min/1.73 m**2	Sparsentan	26	0 (0.0) No events in 1 group	NE		NE		NE	
	Irbesartan	25	0 (0.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 03JUN2024

Table PT2CKDT_FSTM: Time to CKD stage 4 or 5 by subgroup
Full Analysis Set

Time to CKD stage 4 or 5				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline urine protein excretion	Sparsentan						Interaction test:	0.382	
<= 1.75 g/day	Sparsentan	98	16 (16.3)	NE		0.872	(0.443, 1.714)	0.691	
	Irbesartan	93	18 (19.4)	NE					
> 1.75 g/day	Sparsentan	104	31 (29.8)	NE		0.601	(0.381, 0.949)	0.029	*
	Irbesartan	109	47 (43.1)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 03JUN2024

Table PT2CKDT_FSTM: Time to CKD stage 4 or 5 by subgroup
Full Analysis Set

Time to CKD stage 4 or 5				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.658
Yes	Sparsentan	90	29 (32.2)	NE		0.706	(0.434, 1.148)	0.161
	Irbesartan	88	37 (42.0)	NE				
No	Sparsentan	112	18 (16.1)	NE		0.595	(0.328, 1.077)	0.086
	Irbesartan	114	28 (24.6)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 03JUN2024

Table PT2CKDT_FSTM: Time to CKD stage 4 or 5 by subgroup
Full Analysis Set

Time to CKD stage 4 or 5				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Time since renal biopsy	Sparsentan						Interaction test:	0.348	
<= 5 years	Sparsentan	113	23 (20.4)	NE		0.557	(0.331, 0.936)	0.027	*
	Irbesartan	127	38 (29.9)	NE					
> 5 years	Sparsentan	89	24 (27.0)	NE		0.813	(0.469, 1.410)	0.461	
	Irbesartan	75	27 (36.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 03JUN2024

Table PT2CKDT_FSTM: Time to CKD stage 4 or 5 by subgroup
Full Analysis Set

Time to CKD stage 4 or 5				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
History of hypertension	Sparsentan						Interaction test:	0.358
Yes	Sparsentan	155	42 (27.1)	NE		0.710	(0.475, 1.062)	0.095
	Irbesartan	161	55 (34.2)	NE				
No	Sparsentan	47	5 (10.6)	NE		0.333	(0.110, 1.006)	0.051
	Irbesartan	41	10 (24.4)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 03JUN2024

Figure PF2CKDT_FSKM: Time to CKD stage 4 or 5 by subgroup
Full Analysis Set

Not done. No significant subgroups.

CKD = Chronic kidney disease.
Reference table: PT2CKDT_FSTM

Table PT2MIS_FSIM: Patients with systemic immunosuppressive medication by subgroup
Full Analysis Set

Systemic immunosuppressive medication

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.951
Male	Double-blind period	Sparsentan	139	23 (16.5)	0.876 [0.529, 1.452]	0.852 [0.462, 1.572]	-2.3 [-11.9, 7.3]	0.642
		Irbesartan	143	27 (18.9)				
Female	Double-blind period	Sparsentan	63	10 (15.9)	0.851 [0.391, 1.856]	0.823 [0.321, 2.110]	-2.8 [-17.8, 12.3]	0.811
		Irbesartan	59	11 (18.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2MIS_FSIM: Patients with systemic immunosuppressive medication by subgroup
Full Analysis Set

Systemic immunosuppressive medication

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.056
<= 45 years	Double-blind period	Sparsentan	96	22 (22.9)	1.260 [0.723, 2.198]	1.338 [0.666, 2.689]	4.7 [-7.6, 17.1]	0.479
		Irbesartan	99	18 (18.2)				
> 45 years	Double-blind period	Sparsentan	106	11 (10.4)	0.534 [0.270, 1.059]	0.481 [0.218, 1.061]	-9.0 [-19.6, 1.5]	0.080
		Irbesartan	103	20 (19.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2MIS_FSIM: Patients with systemic immunosuppressive medication by subgroup
Full Analysis Set

Systemic immunosuppressive medication

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.139
<= 18 years	Double-blind period	Sparsentan	9	3 (33.3)	1.667 [0.230, 12.091]	2.000 [0.150, 26.734]	13.3 [-48.9, 75.6]	1.000
		Irbesartan	5	1 (20.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	21 (20.6)	1.181 [0.676, 2.065]	1.228 [0.616, 2.447]	3.2 [-8.4, 14.7]	0.601
		Irbesartan	109	19 (17.4)				
> 40 years	Double-blind period	Sparsentan	91	9 (9.9)	0.484 [0.230, 1.018]	0.427 [0.180, 1.010]	-10.6 [-22.1, 1.0]	0.060
		Irbesartan	88	18 (20.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2MIS_FSIM: Patients with systemic immunosuppressive medication by subgroup
Full Analysis Set

Systemic immunosuppressive medication

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.275
North America	Double-blind period	Sparsentan	35	9 (25.7)	0.623 [0.322, 1.205]	0.492 [0.189, 1.283]	-15.6 [-38.4, 7.2]	0.164
		Irbesartan	46	19 (41.3)				
Europe	Double-blind period	Sparsentan	98	16 (16.3)	1.341 [0.690, 2.607]	1.408 [0.649, 3.053]	4.2 [-6.2, 14.5]	0.432
		Irbesartan	115	14 (12.2)				
Asia Pacific	Double-blind period	Sparsentan	69	8 (11.6)	0.951 [0.333, 2.712]	0.944 [0.287, 3.107]	-0.6 [-15.1, 13.9]	1.000
		Irbesartan	41	5 (12.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2MIS_FSIM: Patients with systemic immunosuppressive medication by subgroup
Full Analysis Set

Systemic immunosuppressive medication

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.295
< 27 kg/m**2	Double-blind period	Sparsentan	83	14 (16.9)	1.133 [0.574, 2.234]	1.159 [0.517, 2.600]	2.0 [-10.0, 13.9]	0.837
		Irbesartan	94	14 (14.9)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	19 (16.0)	0.712 [0.414, 1.224]	0.657 [0.337, 1.282]	-6.5 [-17.6, 4.7]	0.238
		Irbesartan	107	24 (22.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2MIS_FSIM: Patients with systemic immunosuppressive medication by subgroup
Full Analysis Set

Systemic immunosuppressive medication

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.431
eGFR Low and UP High	Double-blind period	Sparsentan	71	10 (14.1)	0.579 [0.287, 1.167]	0.510 [0.217, 1.198]	-10.2 [-24.3, 3.8]	0.143
		Irbesartan	74	18 (24.3)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	8 (14.5)	1.143 [0.445, 2.935]	1.167 [0.392, 3.476]	1.8 [-12.8, 16.5]	1.000
		Irbesartan	55	7 (12.7)				
eGFR High and UP High	Double-blind period	Sparsentan	37	7 (18.9)	0.851 [0.345, 2.104]	0.817 [0.262, 2.547]	-3.3 [-24.6, 18.0]	0.778
		Irbesartan	36	8 (22.2)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	8 (20.5)	1.518 [0.546, 4.221]	1.652 [0.487, 5.604]	7.0 [-12.4, 26.4]	0.546
		Irbesartan	37	5 (13.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2MIS_FSIM: Patients with systemic immunosuppressive medication by subgroup
Full Analysis Set

Systemic immunosuppressive medication

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.154
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	19 (15.0)	0.742 [0.433, 1.272]	0.697 [0.364, 1.335]	-5.2 [-15.3, 4.9]	0.325
		Irbesartan	129	26 (20.2)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	6 (12.2)	0.653 [0.252, 1.694]	0.605 [0.197, 1.854]	-6.5 [-22.9, 9.9]	0.413
		Irbesartan	48	9 (18.8)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	8 (30.8)	2.564 [0.766, 8.581]	3.259 [0.753, 14.116]	18.8 [-7.0, 44.5]	0.173
		Irbesartan	25	3 (12.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2MIS_FSIM: Patients with systemic immunosuppressive medication by subgroup
Full Analysis Set

Systemic immunosuppressive medication

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.259
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	10 (12.2)	0.887 [0.399, 1.972]	0.871 [0.348, 2.181]	-1.6 [-13.1, 10.0]	0.818
		Irbesartan	80	11 (13.8)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	9 (20.0)	0.653 [0.318, 1.343]	0.567 [0.219, 1.465]	-10.6 [-30.2, 8.9]	0.344
		Irbesartan	49	15 (30.6)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	6 (12.2)	0.653 [0.252, 1.694]	0.605 [0.197, 1.854]	-6.5 [-22.9, 9.9]	0.413
		Irbesartan	48	9 (18.8)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	8 (30.8)	2.564 [0.766, 8.581]	3.259 [0.753, 14.116]	18.8 [-7.0, 44.5]	0.173
		Irbesartan	25	3 (12.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2MIS_FSIM: Patients with systemic immunosuppressive medication by subgroup
Full Analysis Set

Systemic immunosuppressive medication

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.174
<= 1.75 g/day	Double-blind period	Sparsentan	98	16 (16.3)	1.265 [0.633, 2.529]	1.317 [0.586, 2.958]	3.4 [-7.6, 14.5]	0.545
		Irbesartan	93	12 (12.9)				
> 1.75 g/day	Double-blind period	Sparsentan	104	17 (16.3)	0.685 [0.396, 1.187]	0.624 [0.316, 1.233]	-7.5 [-19.1, 4.1]	0.232
		Irbesartan	109	26 (23.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2MIS_FSIM: Patients with systemic immunosuppressive medication by subgroup
Full Analysis Set

Systemic immunosuppressive medication								
Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.382
Yes	Double-blind period	Sparsentan	90	12 (13.3)	0.690 [0.350, 1.360]	0.643 [0.287, 1.438]	-6.0 [-17.9, 6.0]	0.315
		Irbesartan	88	17 (19.3)				
No	Double-blind period	Sparsentan	112	21 (18.8)	1.018 [0.590, 1.757]	1.022 [0.523, 1.998]	0.3 [-10.7, 11.4]	1.000
		Irbesartan	114	21 (18.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2MIS_FSIM: Patients with systemic immunosuppressive medication by subgroup
Full Analysis Set

Systemic immunosuppressive medication

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.046 #
<= 5 years	Double-blind period	Sparsentan	113	17 (15.0)	0.637 [0.372, 1.091]	0.573 [0.296, 1.106]	-8.6 [-19.3, 2.2]	0.105
		Irbesartan	127	30 (23.6)				
> 5 years	Double-blind period	Sparsentan	89	16 (18.0)	1.685 [0.764, 3.718]	1.836 [0.738, 4.566]	7.3 [-4.5, 19.1]	0.267
		Irbesartan	75	8 (10.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2MIS_FSIM: Patients with systemic immunosuppressive medication by subgroup
Full Analysis Set

Systemic immunosuppressive medication

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.994
Yes	Double-blind period	Sparsentan	155	27 (17.4)	0.876 [0.552, 1.391]	0.850 [0.482, 1.500]	-2.5 [-11.7, 6.8]	0.665
		Irbesartan	161	32 (19.9)				
No	Double-blind period	Sparsentan	47	6 (12.8)	0.872 [0.305, 2.496]	0.854 [0.252, 2.886]	-1.9 [-18.6, 14.8]	1.000
		Irbesartan	41	6 (14.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2MIST_FSTM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive medication				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sex	Sparsentan						Interaction test:	0.973
Male	Sparsentan	139	23 (16.5)	NE		0.799	(0.457, 1.396)	0.431
	Irbesartan	143	27 (18.9)	NE				
Female	Sparsentan	63	10 (15.9)	NE		0.828	(0.348, 1.967)	0.669
	Irbesartan	59	11 (18.6)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2MIST_FSTM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive medication				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.070
<= 45 years	Sparsentan	96	22 (22.9)	NE		1.171	(0.627, 2.188)	0.620
	Irbesartan	99	18 (18.2)	NE				
> 45 years	Sparsentan	106	11 (10.4)	NE		0.496	(0.237, 1.036)	0.062
	Irbesartan	103	20 (19.4)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2MIST_FSTM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive medication				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age at IgAN diagnosis	Sparsentan						Interaction test:	0.164
<= 18 years	Sparsentan	9	3 (33.3)	NE		1.493	(0.152, 14.626)	0.731
	Irbesartan	5	1 (20.0)	NE				
> 18 to 40 years	Sparsentan	102	21 (20.6)	NE		1.130	(0.604, 2.113)	0.702
	Irbesartan	109	19 (17.4)	NE				
> 40 years	Sparsentan	91	9 (9.9)	NE		0.449	(0.201, 1.003)	0.051
	Irbesartan	88	18 (20.5)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2MIST_FSTM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive medication				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Geographic region	Sparsentan						Interaction test:	0.193
North America	Sparsentan	35	9 (25.7)	NE		0.520	(0.234, 1.154)	0.108
	Irbesartan	46	19 (41.3)	NE				
Europe	Sparsentan	98	16 (16.3)	NE		1.359	(0.663, 2.790)	0.402
	Irbesartan	115	14 (12.2)	NE				
Asia Pacific	Sparsentan	69	8 (11.6)	NE		0.883	(0.285, 2.741)	0.830
	Irbesartan	41	5 (12.2)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2MIST_FSTM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive medication				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.345
< 27 kg/m**2	Sparsentan	83	14 (16.9)	NE		1.010	(0.480, 2.126)	0.978
	Irbesartan	94	14 (14.9)	NE				
>= 27 kg/m**2	Sparsentan	119	19 (16.0)	NE		0.644	(0.352, 1.178)	0.154
	Irbesartan	107	24 (22.4)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2MIST_FSTM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive medication				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Randomization strata	Sparsentan						Interaction test:	0.298
eGFR Low and UP High	Sparsentan	71	10 (14.1)	NE		0.481	(0.222, 1.044)	0.064
	Irbesartan	74	18 (24.3)	NE				
eGFR Low and UP Low	Sparsentan	55	8 (14.5)	NE		1.178	(0.427, 3.248)	0.752
	Irbesartan	55	7 (12.7)	NE				
eGFR High and UP High	Sparsentan	37	7 (18.9)	NE		0.812	(0.294, 2.239)	0.687
	Irbesartan	36	8 (22.2)	NE				
eGFR High and UP Low	Sparsentan	39	8 (20.5)	NE		1.511	(0.494, 4.621)	0.469
	Irbesartan	37	5 (13.5)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2MIST_FSTM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive medication				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.135
< 60 mL/min/1.73 m**2	Sparsentan	127	19 (15.0)	NE		0.700	(0.385, 1.271)	0.241
	Irbesartan	129	26 (20.2)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	6 (12.2)	NE		0.642	(0.227, 1.816)	0.403
	Irbesartan	48	9 (18.8)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	8 (30.8)	NE		2.560	(0.679, 9.657)	0.165
	Irbesartan	25	3 (12.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2MIST_FSTM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive medication				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 2	Sparsentan						Interaction test:	0.237
< 45 mL/min/1.73 m**2	Sparsentan	82	10 (12.2)	NE		0.809	(0.343, 1.906)	0.628
	Irbesartan	80	11 (13.8)	NE				
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	9 (20.0)	NE		0.608	(0.263, 1.406)	0.245
	Irbesartan	49	15 (30.6)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	6 (12.2)	NE		0.642	(0.227, 1.816)	0.403
	Irbesartan	48	9 (18.8)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	8 (30.8)	NE		2.560	(0.679, 9.657)	0.165
	Irbesartan	25	3 (12.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2MIST_FSTM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive medication				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline urine protein excretion	Sparsentan						Interaction test:	0.117
<= 1.75 g/day	Sparsentan	98	16 (16.3)	NE		1.274	(0.603, 2.694)	0.526
	Irbesartan	93	12 (12.9)	NE				
> 1.75 g/day	Sparsentan	104	17 (16.3)	NE		0.595	(0.322, 1.099)	0.097
	Irbesartan	109	26 (23.9)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2MIST_FSTM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive medication				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.448
Yes	Sparsentan	90	12 (13.3)	NE		0.645	(0.308, 1.354)	0.246
	Irbesartan	88	17 (19.3)	NE				
No	Sparsentan	112	21 (18.8)	NE		0.934	(0.510, 1.712)	0.826
	Irbesartan	114	21 (18.4)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2MIST_FSTM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive medication				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Time since renal biopsy	Sparsentan						Interaction test:	0.032	#
<= 5 years	Sparsentan	113	17 (15.0)	NE		0.549	(0.302, 0.997)	0.049	*
	Irbesartan	127	30 (23.6)	NE					
> 5 years	Sparsentan	89	16 (18.0)	NE		1.606	(0.684, 3.768)	0.276	
	Irbesartan	75	8 (10.7)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2MIST_FSTM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive medication				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
History of hypertension	Sparsentan						Interaction test:	0.858
Yes	Sparsentan	155	27 (17.4)	NE		0.841	(0.504, 1.405)	0.508
	Irbesartan	161	32 (19.9)	NE				
No	Sparsentan	47	6 (12.8)	NE		0.672	(0.212, 2.131)	0.500
	Irbesartan	41	6 (14.6)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Figure PF2MIST_FSKM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Study: PROTECT
Time since renal biopsy: <= 5 years



Sparsentan	113	106	101	96	83	54
Irbesartan	127	111	98	90	81	56

Reference table: PT2MIST_FSTM

Figure PF2MIST_FSKM: Time to systemic immunosuppressive medication by subgroup
Full Analysis Set

Study: PROTECT
Time since renal biopsy: > 5 years



Sparsentan	89	83	77	72	67	50
Irbesartan	75	70	65	62	57	42

Reference table: PT2MIST_FSTM

Table PT2MIK_FSIM: Patients with systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Systemic immunosuppressive renal medication (renal indication)

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.850
Male	Double-blind period	Sparsentan	139	5 (3.6)	0.396 [0.145, 1.081]	0.373 [0.129, 1.076]	-5.5 [-11.8, 0.9]	0.086
		Irbesartan	143	13 (9.1)				
Female	Double-blind period	Sparsentan	63	1 (1.6)	0.312 [0.033, 2.918]	0.301 [0.030, 2.979]	-3.5 [-11.5, 4.5]	0.353
		Irbesartan	59	3 (5.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2MIK_FSIM: Patients with systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Systemic immunosuppressive renal medication (renal indication)

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.610
<= 45 years	Double-blind period	Sparsentan	96	4 (4.2)	0.458 [0.146, 1.439]	0.435 [0.129, 1.463]	-4.9 [-12.9, 3.0]	0.251
		Irbesartan	99	9 (9.1)				
> 45 years	Double-blind period	Sparsentan	106	2 (1.9)	0.278 [0.059, 1.305]	0.264 [0.053, 1.301]	-4.9 [-11.4, 1.6]	0.098
		Irbesartan	103	7 (6.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2MIK_FSIM: Patients with systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Systemic immunosuppressive renal medication (renal indication)								
Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.112
<= 18 years	Double-blind period	Sparsentan	9	3 (33.3)	4.200 + [0.259, 68.038]	5.923 + [0.248, 141.482]	33.3 [-13.0, 79.7]	0.258
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	1 (1.0)	0.107 [0.014, 0.820]	0.098 [0.012, 0.780]	-8.2 [-14.9, -1.5]	0.010 *
		Irbesartan	109	10 (9.2)				
> 40 years	Double-blind period	Sparsentan	91	2 (2.2)	0.322 [0.067, 1.554]	0.307 [0.060, 1.565]	-4.6 [-11.8, 2.6]	0.164
		Irbesartan	88	6 (6.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2MIK_FSIM: Patients with systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Systemic immunosuppressive renal medication (renal indication)

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.276	
North America	Double-blind period	Sparsentan	35	3 (8.6)	0.986 [0.236, 4.123]	0.984 [0.206, 4.713]	-0.1 [-15.0, 14.7]	1.000	
		Irbesartan	46	4 (8.7)					
Europe	Double-blind period	Sparsentan	98	1 (1.0)	0.130 [0.017, 1.011]	0.121 [0.015, 0.976]	-6.8 [-13.0, -0.6]	0.022	*
		Irbesartan	115	9 (7.8)					
Asia Pacific	Double-blind period	Sparsentan	69	2 (2.9)	0.396 [0.069, 2.273]	0.378 [0.060, 2.364]	-4.4 [-15.3, 6.4]	0.359	
		Irbesartan	41	3 (7.3)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2MIK_FSIM: Patients with systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Systemic immunosuppressive renal medication (renal indication)

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.805
< 27 kg/m**2	Double-blind period	Sparsentan	83	3 (3.6)	0.425 [0.116, 1.548]	0.403 [0.103, 1.573]	-4.9 [-13.0, 3.2]	0.222
		Irbesartan	94	8 (8.5)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	3 (2.5)	0.337 [0.092, 1.238]	0.320 [0.083, 1.239]	-5.0 [-11.6, 1.7]	0.121
		Irbesartan	107	8 (7.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2MIK_FSIM: Patients with systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Systemic immunosuppressive renal medication (renal indication)

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.273	
eGFR Low and UP High	Double-blind period	Sparsentan	71	2 (2.8)	0.174 [0.040, 0.749]	0.150 [0.032, 0.696]	-13.4 [-24.0, -2.8]	0.009	*
		Irbesartan	74	12 (16.2)					
eGFR Low and UP Low	Double-blind period	Sparsentan	55	0 (0.0)	0.333 + [0.014, 8.008]	0.327 + [0.013, 8.212]	-1.8 [-7.2, 3.5]	1.000	
		Irbesartan	55	1 (1.8)					
eGFR High and UP High	Double-blind period	Sparsentan	37	4 (10.8)	1.297 [0.312, 5.393]	1.333 [0.277, 6.427]	2.5 [-13.7, 18.7]	1.000	
		Irbesartan	36	3 (8.3)					
eGFR High and UP Low	Double-blind period	Sparsentan	39	0 (0.0)	0.950 + [0.019, 46.684]	0.949 + [0.018, 49.075]	0.0 [NE, NE]	NE	
		Irbesartan	37	0 (0.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2MIK_FSIM: Patients with systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Systemic immunosuppressive renal medication (renal indication)

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.243	
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	2 (1.6)	0.185 [0.042, 0.817]	0.172 [0.037, 0.791]	-7.0 [-13.0, -0.9]	0.019	*
		Irbesartan	129	11 (8.5)					
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	2 (4.1)	0.490 [0.094, 2.550]	0.468 [0.082, 2.684]	-4.3 [-15.9, 7.4]	0.436	
		Irbesartan	48	4 (8.3)					
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	2 (7.7)	1.923 [0.186, 19.901]	2.000 [0.170, 23.556]	3.7 [-13.0, 20.4]	1.000	
		Irbesartan	25	1 (4.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2MIK_FSIM: Patients with systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Systemic immunosuppressive renal medication (renal indication)								
Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	NE
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	1 (1.2) all n<10				NE
		Irbesartan	80	6 (7.5)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	1 (2.2) all n<10				NE
		Irbesartan	49	5 (10.2)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	2 (4.1) all n<10				NE
		Irbesartan	48	4 (8.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	2 (7.7) all n<10				NE
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2MIK_FSIM: Patients with systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Systemic immunosuppressive renal medication (renal indication)									
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.667	
<= 1.75 g/day	Double-blind period	Sparsentan	98	0 (0.0)	0.949 + [0.019, 47.367]	0.949 + [0.019, 48.329]	0.0 [NE, NE]	NE	
		Irbesartan	93	0 (0.0)					
> 1.75 g/day	Double-blind period	Sparsentan	104	6 (5.8)	0.393 [0.160, 0.966]	0.356 [0.134, 0.948]	-8.9 [-17.9, 0.0]	0.042	*
		Irbesartan	109	16 (14.7)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2MIK_FSIM: Patients with systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Systemic immunosuppressive renal medication (renal indication)

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.505
Yes	Double-blind period	Sparsentan	90	4 (4.4)	0.489 [0.153, 1.565]	0.465 [0.135, 1.604]	-4.6 [-13.1, 3.8]	0.246
		Irbesartan	88	8 (9.1)				
No	Double-blind period	Sparsentan	112	2 (1.8)	0.254 [0.055, 1.172]	0.241 [0.050, 1.161]	-5.2 [-11.4, 0.9]	0.102
		Irbesartan	114	8 (7.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2MIK_FSIM: Patients with systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Systemic immunosuppressive renal medication (renal indication)

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.601
<= 5 years	Double-blind period	Sparsentan	113	3 (2.7)	0.307 [0.088, 1.071]	0.288 [0.078, 1.058]	-6.0 [-12.6, 0.5]	0.056
		Irbesartan	127	11 (8.7)				
> 5 years	Double-blind period	Sparsentan	89	3 (3.4)	0.506 [0.125, 2.046]	0.488 [0.113, 2.115]	-3.3 [-11.3, 4.7]	0.471
		Irbesartan	75	5 (6.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2MIK_FSIM: Patients with systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Systemic immunosuppressive renal medication (renal indication)								
Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.799
Yes	Double-blind period	Sparsentan	155	5 (3.2)	0.400 [0.146, 1.094]	0.379 [0.132, 1.091]	-4.8 [-10.5, 0.8]	0.088
		Irbesartan	161	13 (8.1)				
No	Double-blind period	Sparsentan	47	1 (2.1)	0.291 [0.031, 2.688]	0.275 [0.028, 2.756]	-5.2 [-16.4, 6.1]	0.335
		Irbesartan	41	3 (7.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2MIKT_FSTM: Time to systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive renal medication				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Sex	Sparsentan						Interaction test:	0.978	
Male	Sparsentan	139	5 (3.6)	NE		0.329	(0.117, 0.926)	0.035	*
	Irbesartan	143	13 (9.1)	NE					
Female	Sparsentan	63	1 (1.6)	NE		0.376	(0.038, 3.690)	0.401	
	Irbesartan	59	3 (5.1)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2MIKT_FSTM: Time to systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive renal medication				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.677
<= 45 years	Sparsentan	96	4 (4.2)	NE		0.393	(0.121, 1.281)	0.121
	Irbesartan	99	9 (9.1)	NE				
> 45 years	Sparsentan	106	2 (1.9)	NE		0.253	(0.052, 1.224)	0.087
	Irbesartan	103	7 (6.8)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2MIKT_FSTM: Time to systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive renal medication				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Age at IgAN diagnosis	Sparsentan						Interaction test:	NE	
<= 18 years	Sparsentan	9	3 (33.3) No events in 1 group	NE		NE		NE	
	Irbesartan	5	0 (0.0)	NE					
> 18 to 40 years	Sparsentan	102	1 (1.0)	NE		0.093	(0.012, 0.731)	0.024	*
	Irbesartan	109	10 (9.2)	NE					
> 40 years	Sparsentan	91	2 (2.2)	NE		0.291	(0.059, 1.445)	0.131	
	Irbesartan	88	6 (6.8)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2MIKT_FSTM: Time to systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive renal medication				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Geographic region	Sparsentan						Interaction test:	0.215	
North America	Sparsentan	35	3 (8.6)	NE		0.890	(0.198, 3.992)	0.879	
	Irbesartan	46	4 (8.7)	NE					
Europe	Sparsentan	98	1 (1.0)	NE		0.115	(0.015, 0.911)	0.041	*
	Irbesartan	115	9 (7.8)	NE					
Asia Pacific	Sparsentan	69	2 (2.9)	NE		0.341	(0.055, 2.124)	0.249	
	Irbesartan	41	3 (7.3)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2MIKT_FSTM: Time to systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive renal medication				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.889
< 27 kg/m**2	Sparsentan	83	3 (3.6)	NE		0.330	(0.087, 1.260)	0.105
	Irbesartan	94	8 (8.5)	NE				
>= 27 kg/m**2	Sparsentan	119	3 (2.5)	NE		0.281	(0.074, 1.066)	0.062
	Irbesartan	107	8 (7.5)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2MIKT_FSTM: Time to systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive renal medication				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Randomization strata	Sparsentan						Interaction test:	NE	
eGFR Low and UP High	Sparsentan	71	2 (2.8)	NE		0.140	(0.031, 0.628)	0.010	*
	Irbesartan	74	12 (16.2)	NE					
eGFR Low and UP Low	Sparsentan	55	0 (0.0) No events in 1 group	NE		NE		NE	
	Irbesartan	55	1 (1.8)	NE					
eGFR High and UP High	Sparsentan	37	4 (10.8)	NE		1.155	(0.259, 5.164)	0.850	
	Irbesartan	36	3 (8.3)	NE					
eGFR High and UP Low	Sparsentan	39	0 (0.0) No events in 1 group	NE		NE		NE	
	Irbesartan	37	0 (0.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2MIKT_FSTM: Time to systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive renal medication				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.155	
< 60 mL/min/1.73 m**2	Sparsentan	127	2 (1.6)	NE		0.152	(0.034, 0.685)	0.014	*
	Irbesartan	129	11 (8.5)	NE					
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	2 (4.1)	NE		0.539	(0.096, 3.036)	0.483	
	Irbesartan	48	4 (8.3)	NE					
>= 90 mL/min/1.73 m**2	Sparsentan	26	2 (7.7)	NE		1.687	(0.152, 18.691)	0.670	
	Irbesartan	25	1 (4.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2MIKT_FSTM: Time to systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive renal medication				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 2	Sparsentan						Interaction test:	NE
< 45 mL/min/1.73 m**2	Sparsentan	82	1 (1.2) all n<10	NE		NE		NE
	Irbesartan	80	6 (7.5)	NE				
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	1 (2.2) all n<10	NE		NE		NE
	Irbesartan	49	5 (10.2)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	2 (4.1) all n<10	NE		NE		NE
	Irbesartan	48	4 (8.3)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	2 (7.7) all n<10	NE		NE		NE
	Irbesartan	25	1 (4.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2MIKT_FSTM: Time to systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive renal medication				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline urine protein excretion	Sparsentan						Interaction test:	NE	
<= 1.75 g/day	Sparsentan	98	0 (0.0) No events in 1 group	NE		NE		NE	
	Irbesartan	93	0 (0.0)	NE					
> 1.75 g/day	Sparsentan	104	6 (5.8)	NE		0.321	(0.125, 0.821)	0.018	*
	Irbesartan	109	16 (14.7)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2MIKT_FSTM: Time to systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive renal medication				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.585
Yes	Sparsentan	90	4 (4.4)	NE		0.385	(0.116, 1.281)	0.120
	Irbesartan	88	8 (9.1)	NE				
No	Sparsentan	112	2 (1.8)	NE		0.246	(0.052, 1.159)	0.076
	Irbesartan	114	8 (7.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2MIKT_FSTM: Time to systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive renal medication				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Time since renal biopsy	Sparsentan						Interaction test:	0.435	
<= 5 years	Sparsentan	113	3 (2.7)	NE		0.238	(0.066, 0.854)	0.028	*
	Irbesartan	127	11 (8.7)	NE					
> 5 years	Sparsentan	89	3 (3.4)	NE		0.511	(0.122, 2.141)	0.358	
	Irbesartan	75	5 (6.7)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Table PT2MIKT_FSTM: Time to systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Time to systemic Immunosuppressive renal medication				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
History of hypertension	Sparsentan						Interaction test:	0.639
Yes	Sparsentan	155	5 (3.2)	NE		0.365	(0.130, 1.024)	0.056
	Irbesartan	161	13 (8.1)	NE				
No	Sparsentan	47	1 (2.1)	NE		0.188	(0.019, 1.826)	0.149
	Irbesartan	41	3 (7.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff_tte, created on: 28FEB2024

Figure PF2MIKT_FSKM: Time to systemic immunosuppressive renal medication by subgroup
Full Analysis Set

Not done. No significant subgroups.

Reference table: PT2MIKT_FSTM

Table PT2HOS_FSIM: Patients with hospitalizations by subgroup
Full Analysis Set

Hospitalizations

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.713
Male	Double-blind period	Sparsentan	139	28 (20.1)	1.108 [0.686, 1.791]	1.135 [0.627, 2.055]	2.0 [-7.9, 11.9]	0.762
		Irbesartan	143	26 (18.2)				
Female	Double-blind period	Sparsentan	63	11 (17.5)	0.937 [0.439, 1.996]	0.923 [0.367, 2.324]	-1.2 [-16.5, 14.1]	1.000
		Irbesartan	59	11 (18.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HOS_FSIM: Patients with hospitalizations by subgroup
Full Analysis Set

Hospitalizations

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.365
<= 45 years	Double-blind period	Sparsentan	96	21 (21.9)	1.274 [0.717, 2.263]	1.351 [0.663, 2.753]	4.7 [-7.4, 16.8]	0.471
		Irbesartan	99	17 (17.2)				
> 45 years	Double-blind period	Sparsentan	106	18 (17.0)	0.875 [0.492, 1.556]	0.849 [0.420, 1.716]	-2.4 [-13.9, 9.0]	0.721
		Irbesartan	103	20 (19.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HOS_FSIM: Patients with hospitalizations by subgroup
Full Analysis Set

Hospitalizations

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.330
<= 18 years	Double-blind period	Sparsentan	9	5 (55.6)	2.778 [0.438, 17.629]	5.000 [0.388, 64.387]	35.6 [-27.8, 98.9]	0.301
		Irbesartan	5	1 (20.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	16 (15.7)	1.221 [0.628, 2.374]	1.262 [0.582, 2.738]	2.8 [-7.6, 13.2]	0.562
		Irbesartan	109	14 (12.8)				
> 40 years	Double-blind period	Sparsentan	91	18 (19.8)	0.791 [0.457, 1.371]	0.740 [0.365, 1.499]	-5.2 [-18.5, 8.1]	0.474
		Irbesartan	88	22 (25.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HOS_FSIM: Patients with hospitalizations by subgroup
Full Analysis Set

Hospitalizations

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.805
North America	Double-blind period	Sparsentan	35	6 (17.1)	0.789 [0.317, 1.962]	0.745 [0.242, 2.292]	-4.6 [-24.4, 15.2]	0.779
		Irbesartan	46	10 (21.7)				
Europe	Double-blind period	Sparsentan	98	18 (18.4)	1.112 [0.619, 1.997]	1.137 [0.559, 2.312]	1.8 [-9.3, 13.0]	0.721
		Irbesartan	115	19 (16.5)				
Asia Pacific	Double-blind period	Sparsentan	69	15 (21.7)	1.114 [0.518, 2.397]	1.146 [0.438, 2.996]	2.2 [-15.3, 19.7]	1.000
		Irbesartan	41	8 (19.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HOS_FSIM: Patients with hospitalizations by subgroup
Full Analysis Set

Hospitalizations

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.851
< 27 kg/m**2	Double-blind period	Sparsentan	83	16 (19.3)	1.007 [0.550, 1.844]	1.008 [0.477, 2.133]	0.1 [-12.6, 12.9]	1.000
		Irbesartan	94	18 (19.1)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	23 (19.3)	1.088 [0.629, 1.884]	1.110 [0.566, 2.175]	1.6 [-9.5, 12.6]	0.864
		Irbesartan	107	19 (17.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HOS_FSIM: Patients with hospitalizations by subgroup
Full Analysis Set

Hospitalizations

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.150	
eGFR Low and UP High	Double-blind period	Sparsentan	71	13 (18.3)	0.753 [0.399, 1.420]	0.697 [0.313, 1.556]	-6.0 [-20.7, 8.7]	0.422	
		Irbesartan	74	18 (24.3)					
eGFR Low and UP Low	Double-blind period	Sparsentan	55	9 (16.4)	1.000 [0.430, 2.328]	1.000 [0.364, 2.746]	0.0 [-15.6, 15.6]	1.000	
		Irbesartan	55	9 (16.4)					
eGFR High and UP High	Double-blind period	Sparsentan	37	11 (29.7)	3.568 [1.084, 11.742]	4.654 [1.175, 18.428]	21.4 [1.4, 41.4]	0.035	*
		Irbesartan	36	3 (8.3)					
eGFR High and UP Low	Double-blind period	Sparsentan	39	6 (15.4)	0.813 [0.301, 2.196]	0.779 [0.235, 2.580]	-3.5 [-23.1, 16.1]	0.766	
		Irbesartan	37	7 (18.9)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HOS_FSIM: Patients with hospitalizations by subgroup
Full Analysis Set

Hospitalizations

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.244
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	24 (18.9)	0.841 [0.519, 1.361]	0.803 [0.438, 1.474]	-3.6 [-14.3, 7.1]	0.538
		Irbesartan	129	29 (22.5)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	12 (24.5)	1.679 [0.723, 3.901]	1.900 [0.676, 5.335]	9.9 [-7.8, 27.6]	0.307
		Irbesartan	48	7 (14.6)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	3 (11.5)	2.885 [0.321, 25.919]	3.130 [0.303, 32.314]	7.5 [-10.9, 25.9]	0.610
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HOS_FSIM: Patients with hospitalizations by subgroup
Full Analysis Set

Hospitalizations

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.329
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	17 (20.7)	0.976 [0.537, 1.773]	0.969 [0.455, 2.065]	-0.5 [-14.3, 13.3]	1.000
		Irbesartan	80	17 (21.3)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	7 (15.6)	0.635 [0.274, 1.471]	0.568 [0.202, 1.601]	-8.9 [-27.1, 9.2]	0.315
		Irbesartan	49	12 (24.5)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	12 (24.5)	1.679 [0.723, 3.901]	1.900 [0.676, 5.335]	9.9 [-7.8, 27.6]	0.307
		Irbesartan	48	7 (14.6)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	3 (11.5)	2.885 [0.321, 25.919]	3.130 [0.303, 32.314]	7.5 [-10.9, 25.9]	0.610
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HOS_FSIM: Patients with hospitalizations by subgroup
Full Analysis Set

Hospitalizations

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.742
<= 1.75 g/day	Double-blind period	Sparsentan	98	17 (17.3)	1.152 [0.603, 2.203]	1.184 [0.547, 2.564]	2.3 [-9.2, 13.8]	0.699
		Irbesartan	93	14 (15.1)				
> 1.75 g/day	Double-blind period	Sparsentan	104	22 (21.2)	1.003 [0.597, 1.685]	1.003 [0.519, 1.937]	0.1 [-11.9, 12.0]	1.000
		Irbesartan	109	23 (21.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HOS_FSIM: Patients with hospitalizations by subgroup
Full Analysis Set

Hospitalizations

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.928
Yes	Double-blind period	Sparsentan	90	19 (21.1)	1.032 [0.581, 1.832]	1.041 [0.504, 2.147]	0.7 [-12.4, 13.7]	1.000
		Irbesartan	88	18 (20.5)				
No	Double-blind period	Sparsentan	112	20 (17.9)	1.071 [0.605, 1.897]	1.087 [0.545, 2.168]	1.2 [-9.5, 11.9]	0.861
		Irbesartan	114	19 (16.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HOS_FSIM: Patients with hospitalizations by subgroup
Full Analysis Set

Hospitalizations

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.001	#
<= 5 years	Double-blind period	Sparsentan	113	18 (15.9)	0.632 [0.376, 1.062]	0.563 [0.296, 1.071]	-9.3 [-20.2, 1.7]	0.082	
		Irbesartan	127	32 (25.2)					
> 5 years	Double-blind period	Sparsentan	89	21 (23.6)	3.539 [1.403, 8.932]	4.324 [1.542, 12.120]	16.9 [5.2, 28.6]	0.005	*
		Irbesartan	75	5 (6.7)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HOS_FSIM: Patients with hospitalizations by subgroup
Full Analysis Set

Hospitalizations

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.266
Yes	Double-blind period	Sparsentan	155	29 (18.7)	0.941 [0.599, 1.479]	0.928 [0.530, 1.623]	-1.2 [-10.5, 8.2]	0.887
		Irbesartan	161	32 (19.9)				
No	Double-blind period	Sparsentan	47	10 (21.3)	1.745 [0.649, 4.688]	1.946 [0.605, 6.254]	9.1 [-8.6, 26.8]	0.395
		Irbesartan	41	5 (12.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HOK_FSIM: Patients with hospitalization related to kidney by subgroup
Full Analysis Set

Hospitalizations related to kidney

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.909
Male	Double-blind period	Sparsentan	139	9 (6.5)	1.029 [0.421, 2.515]	1.031 [0.397, 2.678]	0.2 [-6.2, 6.6]	1.000
		Irbesartan	143	9 (6.3)				
Female	Double-blind period	Sparsentan	63	4 (6.3)	0.937 [0.245, 3.575]	0.932 [0.222, 3.910]	-0.4 [-10.9, 10.0]	1.000
		Irbesartan	59	4 (6.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HOK_FSIM: Patients with hospitalization related to kidney by subgroup
Full Analysis Set

Hospitalizations related to kidney

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.701
<= 45 years	Double-blind period	Sparsentan	96	9 (9.4)	0.928 [0.394, 2.184]	0.921 [0.357, 2.375]	-0.7 [-10.1, 8.6]	1.000
		Irbesartan	99	10 (10.1)				
> 45 years	Double-blind period	Sparsentan	106	4 (3.8)	1.296 [0.297, 5.647]	1.307 [0.285, 5.990]	0.9 [-5.0, 6.7]	1.000
		Irbesartan	103	3 (2.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HOK_FSIM: Patients with hospitalization related to kidney by subgroup
Full Analysis Set

Hospitalizations related to kidney

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.557
<= 18 years	Double-blind period	Sparsentan	9	4 (44.4)	2.222 [0.333, 14.845]	3.200 [0.248, 41.208]	24.4 [-38.9, 87.8]	0.580
		Irbesartan	5	1 (20.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	5 (4.9)	0.668 [0.226, 1.975]	0.651 [0.206, 2.058]	-2.4 [-9.8, 5.0]	0.572
		Irbesartan	109	8 (7.3)				
> 40 years	Double-blind period	Sparsentan	91	4 (4.4)	0.967 [0.250, 3.747]	0.966 [0.234, 3.986]	-0.1 [-7.3, 7.0]	1.000
		Irbesartan	88	4 (4.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HOK_FSIM: Patients with hospitalization related to kidney by subgroup
Full Analysis Set

Hospitalizations related to kidney

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.649
North America	Double-blind period	Sparsentan	35	2 (5.7)	2.629 [0.248, 27.835]	2.727 [0.237, 31.357]	3.5 [-7.7, 14.8]	0.575
		Irbesartan	46	1 (2.2)				
Europe	Double-blind period	Sparsentan	98	6 (6.1)	0.782 [0.289, 2.121]	0.768 [0.263, 2.240]	-1.7 [-9.5, 6.1]	0.790
		Irbesartan	115	9 (7.8)				
Asia Pacific	Double-blind period	Sparsentan	69	5 (7.2)	0.990 [0.250, 3.929]	0.990 [0.224, 4.376]	-0.1 [-12.1, 11.9]	1.000
		Irbesartan	41	3 (7.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HOK_FSIM: Patients with hospitalization related to kidney by subgroup
Full Analysis Set

Hospitalizations related to kidney

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.089
< 27 kg/m**2	Double-blind period	Sparsentan	83	5 (6.0)	0.566 [0.202, 1.590]	0.538 [0.176, 1.645]	-4.6 [-13.8, 4.6]	0.295
		Irbesartan	94	10 (10.6)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	8 (6.7)	2.398 [0.653, 8.807]	2.498 [0.645, 9.672]	3.9 [-2.4, 10.3]	0.222
		Irbesartan	107	3 (2.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HOK_FSIM: Patients with hospitalization related to kidney by subgroup
Full Analysis Set

Hospitalizations related to kidney

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.154
eGFR Low and UP High	Double-blind period	Sparsentan	71	4 (5.6)	0.417 [0.137, 1.269]	0.382 [0.114, 1.280]	-7.9 [-18.7, 3.0]	0.159
		Irbesartan	74	10 (13.5)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	2 (3.6)	2.000 [0.187, 21.420]	2.038 [0.179, 23.151]	1.8 [-6.1, 9.7]	1.000
		Irbesartan	55	1 (1.8)				
eGFR High and UP High	Double-blind period	Sparsentan	37	7 (18.9)	3.405 [0.758, 15.308]	3.967 [0.765, 20.580]	13.4 [-4.0, 30.8]	0.152
		Irbesartan	36	2 (5.6)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	0 (0.0)	0.950 + [0.019, 46.684]	0.949 + [0.018, 49.075]	0.0 [NE, NE]	NE
		Irbesartan	37	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HOK_FSIM: Patients with hospitalization related to kidney by subgroup
Full Analysis Set

Hospitalizations related to kidney

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.156
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	6 (4.7)	0.554 [0.211, 1.453]	0.532 [0.191, 1.485]	-3.8 [-10.7, 3.0]	0.316
		Irbesartan	129	11 (8.5)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	6 (12.2)	2.939 [0.624, 13.846]	3.209 [0.614, 16.768]	8.1 [-4.8, 20.9]	0.268
		Irbesartan	48	2 (4.2)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8)	2.889 + [0.123, 67.752]	3.000 + [0.117, 77.165]	3.8 [-7.5, 15.2]	1.000
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HOK_FSIM: Patients with hospitalization related to kidney by subgroup
Full Analysis Set

Hospitalizations related to kidney

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.281
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	5 (6.1)	0.542 [0.190, 1.547]	0.512 [0.164, 1.601]	-5.2 [-15.0, 4.7]	0.275
		Irbesartan	80	9 (11.3)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	1 (2.2)	0.544 [0.051, 5.801]	0.534 [0.047, 6.100]	-1.9 [-11.0, 7.3]	1.000
		Irbesartan	49	2 (4.1)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	6 (12.2)	2.939 [0.624, 13.846]	3.209 [0.614, 16.768]	8.1 [-4.8, 20.9]	0.268
		Irbesartan	48	2 (4.2)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8)	2.889 + [0.123, 67.752]	3.000 + [0.117, 77.165]	3.8 [-7.5, 15.2]	1.000
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HOK_FSIM: Patients with hospitalization related to kidney by subgroup
Full Analysis Set

Hospitalizations related to kidney

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.184
<= 1.75 g/day	Double-blind period	Sparsentan	98	4 (4.1)	3.796 [0.432, 33.341]	3.915 [0.429, 35.690]	3.0 [-2.5, 8.5]	0.369
		Irbesartan	93	1 (1.1)				
> 1.75 g/day	Double-blind period	Sparsentan	104	9 (8.7)	0.786 [0.346, 1.787]	0.766 [0.308, 1.901]	-2.4 [-11.3, 6.6]	0.649
		Irbesartan	109	12 (11.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HOK_FSIM: Patients with hospitalization related to kidney by subgroup
Full Analysis Set

Hospitalizations related to kidney

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.449
Yes	Double-blind period	Sparsentan	90	8 (8.9)	1.304 [0.472, 3.604]	1.333 [0.443, 4.013]	2.1 [-6.9, 11.1]	0.782
		Irbesartan	88	6 (6.8)				
No	Double-blind period	Sparsentan	112	5 (4.5)	0.727 [0.238, 2.223]	0.714 [0.220, 2.321]	-1.7 [-8.4, 5.0]	0.768
		Irbesartan	114	7 (6.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HOK_FSIM: Patients with hospitalization related to kidney by subgroup
Full Analysis Set

Hospitalizations related to kidney

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.363
<= 5 years	Double-blind period	Sparsentan	113	7 (6.2)	0.787 [0.310, 1.998]	0.773 [0.284, 2.102]	-1.7 [-9.0, 5.6]	0.802
		Irbesartan	127	10 (7.9)				
> 5 years	Double-blind period	Sparsentan	89	6 (6.7)	1.685 [0.436, 6.511]	1.735 [0.419, 7.188]	2.7 [-5.3, 10.8]	0.510
		Irbesartan	75	3 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HOK_FSIM: Patients with hospitalization related to kidney by subgroup
Full Analysis Set

Hospitalizations related to kidney

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.846
Yes	Double-blind period	Sparsentan	155	10 (6.5)	1.039 [0.445, 2.426]	1.041 [0.421, 2.576]	0.2 [-5.8, 6.2]	1.000
		Irbesartan	161	10 (6.2)				
No	Double-blind period	Sparsentan	47	3 (6.4)	0.872 [0.186, 4.088]	0.864 [0.165, 4.534]	-0.9 [-13.8, 12.0]	1.000
		Irbesartan	41	3 (7.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HNS_FSNM: Number of hospitalizations by subgroup
Full Analysis Set

Number of hospitalizations							Negative binomial model		
Subgroup	Treatment	N	nval (%)	Time at risk (years)	Number of events	Crude rate	Rate ratio	95% CI	p-value
Sex	Sparsentan								0.559
Male	Sparsentan	139	139 (100.0)	304.9	33	0.11	0.988	(0.580, 1.685)	0.965
	Irbesartan	143	143 (100.0)	310.9	34	0.11			
Female	Sparsentan	63	63 (100.0)	138.9	12	0.09	0.838	(0.360, 1.950)	0.682
	Irbesartan	59	59 (100.0)	126.3	15	0.12			
Age	Sparsentan								0.981
<= 45 years	Sparsentan	96	96 (100.0)	210.4	23	0.11	0.934	(0.494, 1.764)	0.833
	Irbesartan	99	99 (100.0)	215.6	26	0.12			
> 45 years	Sparsentan	106	106 (100.0)	233.3	22	0.09	0.904	(0.482, 1.697)	0.755
	Irbesartan	103	103 (100.0)	221.6	23	0.10			
Age at IgAN diagnosis	Sparsentan								0.367
<= 18 years	Sparsentan	9	9 (100.0)	20.0	7	0.35	3.397	(0.418, 27.617)	0.253
	Irbesartan	5	5 (100.0)	10.9	1	0.09			
> 18 to 40 years	Sparsentan	102	102 (100.0)	223.4	17	0.08	0.813	(0.381, 1.734)	0.593
	Irbesartan	109	109 (100.0)	234.0	23	0.10			
> 40 years	Sparsentan	91	91 (100.0)	200.3	21	0.10	0.835	(0.458, 1.522)	0.557
	Irbesartan	88	88 (100.0)	192.3	25	0.13			

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. nval (%) = number of patients included in the analysis (i.e., with post-baseline data).
NE = not evaluable.
Number of events = number of considered hospitalizations. 95% CI = 95% confidence interval for rate ratio.
A negative binomial model was applied with factors treatment, randomisation strata, and log of offset. The study duration of double blind period was used as offset. Randomisation stratum will be included only once in the model, if this stratum is investigated subgroup.
* = significant treatment effect. # = significant interaction.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HNS_FSNM: Number of hospitalizations by subgroup
Full Analysis Set

Number of hospitalizations							Negative binomial model		
Subgroup	Treatment	N	nval (%)	Time at risk (years)	Number of events	Crude rate	Rate ratio	95% CI	p-value
Geographic region	Sparsentan								0.651
North America	Sparsentan	35	35 (100.0)	77.2	6	0.08	0.573	(0.209, 1.573)	0.280
	Irbesartan	46	46 (100.0)	97.8	13	0.13			
Europe	Sparsentan	98	98 (100.0)	214.6	19	0.09	0.832	(0.434, 1.597)	0.581
	Irbesartan	115	115 (100.0)	251.8	26	0.10			
Asia Pacific	Sparsentan	69	69 (100.0)	151.9	20	0.13	1.092	(0.456, 2.613)	0.844
	Irbesartan	41	41 (100.0)	87.6	10	0.11			
Baseline BMI	Sparsentan								0.900
< 27 kg/m**2	Sparsentan	83	83 (100.0)	182.3	20	0.11	0.965	(0.530, 1.757)	0.907
	Irbesartan	94	94 (100.0)	202.2	24	0.12			
>= 27 kg/m**2	Sparsentan	119	119 (100.0)	261.5	25	0.10	0.896	(0.494, 1.624)	0.717
	Irbesartan	107	107 (100.0)	232.7	25	0.11			
Randomization strata	Sparsentan								0.218
eGFR Low and UP High	Sparsentan	71	71 (100.0)	154.1	16	0.10	0.764	(0.384, 1.520)	0.444
	Irbesartan	74	74 (100.0)	162.9	22	0.14			
eGFR Low and UP Low	Sparsentan	55	55 (100.0)	122.3	10	0.08	0.800	(0.314, 2.041)	0.641
	Irbesartan	55	55 (100.0)	117.4	12	0.10			
eGFR High and UP High	Sparsentan	37	37 (100.0)	81.8	13	0.16	2.486	(0.791, 7.808)	0.119
	Irbesartan	36	36 (100.0)	78.1	5	0.06			
eGFR High and UP Low	Sparsentan	39	39 (100.0)	85.6	6	0.07	0.554	(0.182, 1.687)	0.299
	Irbesartan	37	37 (100.0)	78.7	10	0.13			

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. nval (%) = number of patients included in the analysis (i.e., with post-baseline data).
NE = not evaluable.
Number of events = number of considered hospitalizations. 95% CI = 95% confidence interval for rate ratio.
A negative binomial model was applied with factors treatment, randomisation strata, and log of offset. The study duration of double blind period was used as offset. Randomisation stratum will be included only once in the model, if this stratum is investigated subgroup.
* = significant treatment effect. # = significant interaction.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HNS_FSNM: Number of hospitalizations by subgroup
Full Analysis Set

Number of hospitalizations							Negative binomial model		
Subgroup	Treatment	N	nval (%)	Time at risk (years)	Number of events	Crude rate	Rate ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan								0.488
< 60 mL/min/1.73 m**2	Sparsentan	127	127 (100.0)	278.6	28	0.10	0.802	(0.472, 1.364)	0.416
	Irbesartan	129	129 (100.0)	279.9	38	0.14			
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	49 (100.0)	107.9	14	0.13	1.551	(0.618, 3.896)	0.350
	Irbesartan	48	48 (100.0)	105.2	9	0.09			
>= 90 mL/min/1.73 m**2	Sparsentan	26	26 (100.0)	57.2	3	0.05	1.375	(0.230, 8.230)	0.727
	Irbesartan	25	25 (100.0)	52.1	2	0.04			
Baseline eGFR Group 2	Sparsentan								0.399
< 45 mL/min/1.73 m**2	Sparsentan	82	82 (100.0)	179.4	21	0.12	0.991	(0.519, 1.891)	0.978
	Irbesartan	80	80 (100.0)	172.7	21	0.12			
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	45 (100.0)	99.2	7	0.07	0.536	(0.209, 1.373)	0.194
	Irbesartan	49	49 (100.0)	107.3	17	0.16			
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	49 (100.0)	107.9	14	0.13	1.551	(0.618, 3.896)	0.350
	Irbesartan	48	48 (100.0)	105.2	9	0.09			
>= 90 mL/min/1.73 m**2	Sparsentan	26	26 (100.0)	57.2	3	0.05	1.375	(0.230, 8.230)	0.727
	Irbesartan	25	25 (100.0)	52.1	2	0.04			
Baseline urine protein excretion	Sparsentan								0.989
<= 1.75 g/day	Sparsentan	98	98 (100.0)	216.3	18	0.08	0.908	(0.453, 1.822)	0.787
	Irbesartan	93	93 (100.0)	198.9	18	0.09			
> 1.75 g/day	Sparsentan	104	104 (100.0)	227.4	27	0.12	0.928	(0.516, 1.668)	0.803
	Irbesartan	109	109 (100.0)	238.3	31	0.13			

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. nval (%) = number of patients included in the analysis (i.e., with post-baseline data).
NE = not evaluable.
Number of events = number of considered hospitalizations. 95% CI = 95% confidence interval for rate ratio.
A negative binomial model was applied with factors treatment, randomisation strata, and log of offset. The study duration of double blind period was used as offset. Randomisation stratum will be included only once in the model, if this stratum is investigated subgroup.
* = significant treatment effect. # = significant interaction.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HNS_FSNM: Number of hospitalizations by subgroup
Full Analysis Set

Number of hospitalizations							Negative binomial model			
Subgroup	Treatment	N	nval (%)	Time at risk (years)	Number of events	Crude rate	Rate ratio	95% CI	p-value	
Baseline use of antihypertensives	Sparsentan								0.689	
Yes	Sparsentan	90	90 (100.0)	197.1	23	0.12	1.010	(0.535, 1.905)	0.977	
	Irbesartan	88	88 (100.0)	191.2	22	0.12				
No	Sparsentan	112	112 (100.0)	246.7	22	0.09	0.842	(0.444, 1.598)	0.598	
	Irbesartan	114	114 (100.0)	246.0	27	0.11				
Time since renal biopsy	Sparsentan								<0.001	#
<= 5 years	Sparsentan	113	113 (100.0)	247.7	21	0.08	0.531	(0.296, 0.952)	0.034	*
	Irbesartan	127	127 (100.0)	274.4	43	0.16				
> 5 years	Sparsentan	89	89 (100.0)	196.1	24	0.12	3.371	(1.370, 8.294)	0.008	*
	Irbesartan	75	75 (100.0)	162.8	6	0.04				
History of hypertension	Sparsentan								0.329	
Yes	Sparsentan	155	155 (100.0)	339.9	33	0.10	0.806	(0.486, 1.336)	0.404	
	Irbesartan	161	161 (100.0)	349.5	42	0.12				
No	Sparsentan	47	47 (100.0)	103.9	12	0.12	1.551	(0.560, 4.292)	0.398	
	Irbesartan	41	41 (100.0)	87.7	7	0.08				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. nval (%) = number of patients included in the analysis (i.e., with post-baseline data).
NE = not evaluable.
Number of events = number of considered hospitalizations. 95% CI = 95% confidence interval for rate ratio.
A negative binomial model was applied with factors treatment, randomisation strata, and log of offset. The study duration of double blind period was used as offset. Randomisation stratum will be included only once in the model, if this stratum is investigated subgroup.
* = significant treatment effect. # = significant interaction.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HNK_FSNM: Number of hospitalizations related to kidney by subgroup
Full Analysis Set

Number of hospitalizations related to kidney							Negative binomial model		
Subgroup	Treatment	N	nval (%)	Time at risk (years)	Number of events	Crude rate	Rate ratio	95% CI	p-value
Sex	Sparsentan								0.505
Male	Sparsentan	139	139 (100.0)	304.9	9	0.03	0.726	(0.278, 1.892)	0.512
	Irbesartan	143	143 (100.0)	310.9	12	0.04			
Female	Sparsentan	63	63 (100.0)	138.9	5	0.04	1.643	(0.397, 6.803)	0.493
	Irbesartan	59	59 (100.0)	126.3	4	0.03			
Age	Sparsentan								0.944
<= 45 years	Sparsentan	96	96 (100.0)	210.4	10	0.05	0.904	(0.366, 2.231)	0.827
	Irbesartan	99	99 (100.0)	215.6	12	0.06			
> 45 years	Sparsentan	106	106 (100.0)	233.3	4	0.02	0.944	(0.198, 4.500)	0.942
	Irbesartan	103	103 (100.0)	221.6	4	0.02			
Age at IgAN diagnosis	Sparsentan								0.516
<= 18 years	Sparsentan	9	9 (100.0)	20.0	5	0.25	2.392	(0.279, 20.479)	0.426
	Irbesartan	5	5 (100.0)	10.9	1	0.09			
> 18 to 40 years	Sparsentan	102	102 (100.0)	223.4	5	0.02	0.555	(0.172, 1.791)	0.325
	Irbesartan	109	109 (100.0)	234.0	10	0.04			
> 40 years	Sparsentan	91	91 (100.0)	200.3	4	0.02	0.835	(0.202, 3.457)	0.803
	Irbesartan	88	88 (100.0)	192.3	5	0.03			

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. nval (%) = number of patients included in the analysis (i.e., with post-baseline data).
NE = not evaluable.
Number of events = number of considered hospitalizations. 95% CI = 95% confidence interval for rate ratio.
A negative binomial model was applied with factors treatment, randomisation strata, and log of offset. The study duration of double blind period was used as offset. Randomisation stratum will be included only once in the model, if this stratum is investigated subgroup.
* = significant treatment effect. # = significant interaction.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HNK_FSNM: Number of hospitalizations related to kidney by subgroup
Full Analysis Set

Number of hospitalizations related to kidney							Negative binomial model			
Subgroup	Treatment	N	nval (%)	Time at risk (years)	Number of events	Crude rate	Rate ratio	95% CI	p-value	
Geographic region	Sparsentan								0.555	
North America	Sparsentan	35	35 (100.0)	77.2	2	0.03	2.942	(0.266, 32.534)	0.379	
	Irbesartan	46	46 (100.0)	97.8	1	0.01				
Europe	Sparsentan	98	98 (100.0)	214.6	7	0.03	0.665	(0.225, 1.963)	0.460	
	Irbesartan	115	115 (100.0)	251.8	12	0.05				
Asia Pacific	Sparsentan	69	69 (100.0)	151.9	5	0.03	1.024	(0.242, 4.332)	0.975	
	Irbesartan	41	41 (100.0)	87.6	3	0.03				
Baseline BMI	Sparsentan								0.027	#
< 27 kg/m**2	Sparsentan	83	83 (100.0)	182.3	5	0.03	0.426	(0.139, 1.305)	0.135	
	Irbesartan	94	94 (100.0)	202.2	13	0.06				
>= 27 kg/m**2	Sparsentan	119	119 (100.0)	261.5	9	0.03	2.776	(0.729, 10.580)	0.135	
	Irbesartan	107	107 (100.0)	232.7	3	0.01				
Randomization strata	Sparsentan								NE	
eGFR Low and UP High	Sparsentan	71	71 (100.0)	154.1	5	0.03	0.480	(0.157, 1.464)	0.197	
	Irbesartan	74	74 (100.0)	162.9	11	0.07				
eGFR Low and UP Low	Sparsentan	55	55 (100.0)	122.3	2	0.02	1.920	(0.174, 21.176)	0.594	
	Irbesartan	55	55 (100.0)	117.4	1	0.01				
eGFR High and UP High	Sparsentan	37	37 (100.0)	81.8	7	0.09	1.667	(0.415, 6.685)	0.471	
	Irbesartan	36	36 (100.0)	78.1	4	0.05				
eGFR High and UP Low	Sparsentan	39	39 (100.0)	85.6	0	0.00			NE	
	Irbesartan	37	37 (100.0)	78.7	0	0.00				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. nval (%) = number of patients included in the analysis (i.e., with post-baseline data).
NE = not evaluable.
Number of events = number of considered hospitalizations. 95% CI = 95% confidence interval for rate ratio.
A negative binomial model was applied with factors treatment, randomisation strata, and log of offset. The study duration of double blind period was used as offset. Randomisation stratum will be included only once in the model, if this stratum is investigated subgroup.
* = significant treatment effect. # = significant interaction.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HNK_FSNM: Number of hospitalizations related to kidney by subgroup
Full Analysis Set

Number of hospitalizations related to kidney							Negative binomial model		
Subgroup	Treatment	N	nval (%)	Time at risk (years)	Number of events	Crude rate	Rate ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan								NE
< 60 mL/min/1.73 m**2	Sparsentan	127	127 (100.0)	278.6	7	0.03	0.589	(0.222, 1.563)	0.288
	Irbesartan	129	129 (100.0)	279.9	12	0.04			
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	49 (100.0)	107.9	6	0.06	1.464	(0.346, 6.189)	0.604
	Irbesartan	48	48 (100.0)	105.2	4	0.04			
>= 90 mL/min/1.73 m**2	Sparsentan	26	26 (100.0)	57.2	1	0.02			NE
	Irbesartan	25	25 (100.0)	52.1	0	0.00			
Baseline eGFR Group 2	Sparsentan								NE
< 45 mL/min/1.73 m**2	Sparsentan	82	82 (100.0)	179.4	6	0.03	0.615	(0.212, 1.785)	0.372
	Irbesartan	80	80 (100.0)	172.7	10	0.06			
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	45 (100.0)	99.2	1	0.01	0.497	(0.045, 5.478)	0.568
	Irbesartan	49	49 (100.0)	107.3	2	0.02			
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	49 (100.0)	107.9	6	0.06	1.464	(0.346, 6.189)	0.604
	Irbesartan	48	48 (100.0)	105.2	4	0.04			
>= 90 mL/min/1.73 m**2	Sparsentan	26	26 (100.0)	57.2	1	0.02			NE
	Irbesartan	25	25 (100.0)	52.1	0	0.00			
Baseline urine protein excretion	Sparsentan								0.135
<= 1.75 g/day	Sparsentan	98	98 (100.0)	216.3	4	0.02	3.646	(0.406, 32.723)	0.248
	Irbesartan	93	93 (100.0)	198.9	1	0.01			
> 1.75 g/day	Sparsentan	104	104 (100.0)	227.4	10	0.04	0.684	(0.281, 1.668)	0.404
	Irbesartan	109	109 (100.0)	238.3	15	0.06			

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. nval (%) = number of patients included in the analysis (i.e., with post-baseline data).
NE = not evaluable.
Number of events = number of considered hospitalizations. 95% CI = 95% confidence interval for rate ratio.
A negative binomial model was applied with factors treatment, randomisation strata, and log of offset. The study duration of double blind period was used as offset. Randomisation stratum will be included only once in the model, if this stratum is investigated subgroup.
* = significant treatment effect. # = significant interaction.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HNK_FSNM: Number of hospitalizations related to kidney by subgroup
Full Analysis Set

Number of hospitalizations related to kidney							Negative binomial model		
Subgroup	Treatment	N	nval (%)	Time at risk (years)	Number of events	Crude rate	Rate ratio	95% CI	p-value
Baseline use of antihypertensives	Sparsentan								0.430
Yes	Sparsentan	90	90 (100.0)	197.1	9	0.05	1.184	(0.411, 3.414)	0.754
	Irbesartan	88	88 (100.0)	191.2	7	0.04			
No	Sparsentan	112	112 (100.0)	246.7	5	0.02	0.601	(0.180, 2.007)	0.408
	Irbesartan	114	114 (100.0)	246.0	9	0.04			
Time since renal biopsy	Sparsentan								0.165
<= 5 years	Sparsentan	113	113 (100.0)	247.7	7	0.03	0.609	(0.222, 1.673)	0.336
	Irbesartan	127	127 (100.0)	274.4	13	0.05			
> 5 years	Sparsentan	89	89 (100.0)	196.1	7	0.04	1.998	(0.488, 8.185)	0.336
	Irbesartan	75	75 (100.0)	162.8	3	0.02			
History of hypertension	Sparsentan								0.915
Yes	Sparsentan	155	155 (100.0)	339.9	10	0.03	0.832	(0.337, 2.052)	0.689
	Irbesartan	161	161 (100.0)	349.5	13	0.04			
No	Sparsentan	47	47 (100.0)	103.9	4	0.04	1.117	(0.221, 5.650)	0.894
	Irbesartan	41	41 (100.0)	87.7	3	0.03			

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. nval (%) = number of patients included in the analysis (i.e., with post-baseline data).
NE = not evaluable.
Number of events = number of considered hospitalizations. 95% CI = 95% confidence interval for rate ratio.
A negative binomial model was applied with factors treatment, randomisation strata, and log of offset. The study duration of double blind period was used as offset. Randomisation stratum will be included only once in the model, if this stratum is investigated subgroup.
* = significant treatment effect. # = significant interaction.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HDS_FSNM: Duration of hospitalizations by subgroup
Full Analysis Set

Duration of hospitalizations							Negative binomial model		
Subgroup	Treatment	N	nval (%)	Time at risk (years)	Number of events	Crude rate	Rate ratio	95% CI	p-value
Sex	Sparsentan								0.709
Male	Sparsentan	139	139 (100.0)	304.9	198	0.65	0.644	(0.231, 1.794)	0.399
	Irbesartan	143	143 (100.0)	310.9	361	1.16			
Female	Sparsentan	63	63 (100.0)	138.9	80	0.58	1.780	(0.425, 7.462)	0.430
	Irbesartan	59	59 (100.0)	126.3	67	0.53			
Age	Sparsentan								0.850
<= 45 years	Sparsentan	96	96 (100.0)	210.4	183	0.87	0.786	(0.225, 2.747)	0.706
	Irbesartan	99	99 (100.0)	215.6	278	1.29			
> 45 years	Sparsentan	106	106 (100.0)	233.3	95	0.41	0.713	(0.235, 2.159)	0.550
	Irbesartan	103	103 (100.0)	221.6	150	0.68			
Age at IgAN diagnosis	Sparsentan								0.783
<= 18 years	Sparsentan	9	9 (100.0)	20.0	53	2.65	2.540	(0.088, 73.222)	0.587
	Irbesartan	5	5 (100.0)	10.9	11	1.01			
> 18 to 40 years	Sparsentan	102	102 (100.0)	223.4	137	0.61	0.713	(0.160, 3.168)	0.657
	Irbesartan	109	109 (100.0)	234.0	245	1.05			
> 40 years	Sparsentan	91	91 (100.0)	200.3	88	0.44	0.536	(0.187, 1.541)	0.247
	Irbesartan	88	88 (100.0)	192.3	172	0.89			

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. nval (%) = number of patients included in the analysis (i.e., with post-baseline data).
NE = not evaluable.
Number of events = number of days with considered hospitalizations. 95% CI = 95% confidence interval for rate ratio.
A negative binomial model was applied with factors treatment, randomisation strata, and log of offset. The study duration of double blind period was used as offset. Randomisation stratum will be included only once in the model, if this stratum is investigated subgroup.
* = significant treatment effect. # = significant interaction.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HDS_FSNM: Duration of hospitalizations by subgroup
Full Analysis Set

Duration of hospitalizations							Negative binomial model		
Subgroup	Treatment	N	nval (%)	Time at risk (years)	Number of events	Crude rate	Rate ratio	95% CI	p-value
Geographic region	Sparsentan								0.955
North America	Sparsentan	35	35 (100.0)	77.2	23	0.30	0.553	(0.115, 2.668)	0.461
	Irbesartan	46	46 (100.0)	97.8	59	0.60			
Europe	Sparsentan	98	98 (100.0)	214.6	178	0.83	0.841	(0.233, 3.032)	0.791
	Irbesartan	115	115 (100.0)	251.8	315	1.25			
Asia Pacific	Sparsentan	69	69 (100.0)	151.9	77	0.51	0.906	(0.227, 3.620)	0.889
	Irbesartan	41	41 (100.0)	87.6	54	0.62			
Baseline BMI	Sparsentan								0.598
< 27 kg/m**2	Sparsentan	83	83 (100.0)	182.3	135	0.74	1.326	(0.365, 4.813)	0.668
	Irbesartan	94	94 (100.0)	202.2	152	0.75			
>= 27 kg/m**2	Sparsentan	119	119 (100.0)	261.5	143	0.55	0.850	(0.262, 2.757)	0.787
	Irbesartan	107	107 (100.0)	232.7	276	1.19			
Randomization strata	Sparsentan								0.216
eGFR Low and UP High	Sparsentan	71	71 (100.0)	154.1	90	0.58	0.529	(0.163, 1.714)	0.288
	Irbesartan	74	74 (100.0)	162.9	169	1.04			
eGFR Low and UP Low	Sparsentan	55	55 (100.0)	122.3	60	0.49	1.197	(0.273, 5.244)	0.812
	Irbesartan	55	55 (100.0)	117.4	48	0.41			
eGFR High and UP High	Sparsentan	37	37 (100.0)	81.8	89	1.09	2.791	(0.475, 16.398)	0.256
	Irbesartan	36	36 (100.0)	78.1	31	0.40			
eGFR High and UP Low	Sparsentan	39	39 (100.0)	85.6	39	0.46	0.212	(0.028, 1.594)	0.132
	Irbesartan	37	37 (100.0)	78.7	180	2.29			

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. nval (%) = number of patients included in the analysis (i.e., with post-baseline data).
NE = not evaluable.
Number of events = number of days with considered hospitalizations. 95% CI = 95% confidence interval for rate ratio.
A negative binomial model was applied with factors treatment, randomisation strata, and log of offset. The study duration of double blind period was used as offset. Randomisation stratum will be included only once in the model, if this stratum is investigated subgroup.
* = significant treatment effect. # = significant interaction.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HDS_FSNM: Duration of hospitalizations by subgroup
Full Analysis Set

Duration of hospitalizations							Negative binomial model		
Subgroup	Treatment	N	nval (%)	Time at risk (years)	Number of events	Crude rate	Rate ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan								0.419
< 60 mL/min/1.73 m**2	Sparsentan	127	127 (100.0)	278.6	157	0.56	0.817	(0.332, 2.011)	0.660
	Irbesartan	129	129 (100.0)	279.9	244	0.87			
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	49 (100.0)	107.9	95	0.88	1.829	(0.380, 8.807)	0.451
	Irbesartan	48	48 (100.0)	105.2	60	0.57			
>= 90 mL/min/1.73 m**2	Sparsentan	26	26 (100.0)	57.2	26	0.45	0.766	(0.002, 382.922)	0.933
	Irbesartan	25	25 (100.0)	52.1	124	2.38			
Baseline eGFR Group 2	Sparsentan								0.272
< 45 mL/min/1.73 m**2	Sparsentan	82	82 (100.0)	179.4	133	0.74	1.316	(0.398, 4.349)	0.652
	Irbesartan	80	80 (100.0)	172.7	125	0.72			
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	45 (100.0)	99.2	24	0.24	0.274	(0.067, 1.121)	0.072
	Irbesartan	49	49 (100.0)	107.3	119	1.11			
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	49 (100.0)	107.9	95	0.88	1.829	(0.380, 8.807)	0.451
	Irbesartan	48	48 (100.0)	105.2	60	0.57			
>= 90 mL/min/1.73 m**2	Sparsentan	26	26 (100.0)	57.2	26	0.45	0.766	(0.002, 382.922)	0.933
	Irbesartan	25	25 (100.0)	52.1	124	2.38			
Baseline urine protein excretion	Sparsentan								0.561
<= 1.75 g/day	Sparsentan	98	98 (100.0)	216.3	96	0.44	0.535	(0.140, 2.048)	0.361
	Irbesartan	93	93 (100.0)	198.9	212	1.07			
> 1.75 g/day	Sparsentan	104	104 (100.0)	227.4	182	0.80	0.880	(0.306, 2.530)	0.813
	Irbesartan	109	109 (100.0)	238.3	216	0.91			

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. nval (%) = number of patients included in the analysis (i.e., with post-baseline data).
NE = not evaluable.
Number of events = number of days with considered hospitalizations. 95% CI = 95% confidence interval for rate ratio.
A negative binomial model was applied with factors treatment, randomisation strata, and log of offset. The study duration of double blind period was used as offset. Randomisation stratum will be included only once in the model, if this stratum is investigated subgroup.
* = significant treatment effect. # = significant interaction.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HDS_FSNM: Duration of hospitalizations by subgroup
Full Analysis Set

Duration of hospitalizations							Negative binomial model			
Subgroup	Treatment	N	nval (%)	Time at risk (years)	Number of events	Crude rate	Rate ratio	95% CI	p-value	
Baseline use of antihypertensives	Sparsentan								0.285	
Yes	Sparsentan	90	90 (100.0)	197.1	166	0.84	1.001	(0.303, 3.305)	0.999	
	Irbesartan	88	88 (100.0)	191.2	152	0.79				
No	Sparsentan	112	112 (100.0)	246.7	112	0.45	0.421	(0.128, 1.386)	0.155	
	Irbesartan	114	114 (100.0)	246.0	276	1.12				
Time since renal biopsy	Sparsentan								0.048	#
<= 5 years	Sparsentan	113	113 (100.0)	247.7	134	0.54	0.319	(0.107, 0.956)	0.041	*
	Irbesartan	127	127 (100.0)	274.4	356	1.30				
> 5 years	Sparsentan	89	89 (100.0)	196.1	144	0.73	3.024	(0.673, 13.585)	0.149	
	Irbesartan	75	75 (100.0)	162.8	72	0.44				
History of hypertension	Sparsentan								0.399	
Yes	Sparsentan	155	155 (100.0)	339.9	192	0.56	0.554	(0.208, 1.476)	0.237	
	Irbesartan	161	161 (100.0)	349.5	390	1.12				
No	Sparsentan	47	47 (100.0)	103.9	86	0.83	3.962	(0.413, 37.968)	0.233	
	Irbesartan	41	41 (100.0)	87.7	38	0.43				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. nval (%) = number of patients included in the analysis (i.e., with post-baseline data).
NE = not evaluable.
Number of events = number of days with considered hospitalizations. 95% CI = 95% confidence interval for rate ratio.
A negative binomial model was applied with factors treatment, randomisation strata, and log of offset. The study duration of double blind period was used as offset. Randomisation stratum will be included only once in the model, if this stratum is investigated subgroup.
* = significant treatment effect. # = significant interaction.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HDK_FSNM: Duration of hospitalizations related to kidney by subgroup
Full Analysis Set

Duration of hospitalizations related to kidney							Negative binomial model			
Subgroup	Treatment	N	nval (%)	Time at risk (years)	Number of events	Crude rate	Rate ratio	95% CI	p-value	
Sex	Sparsentan								0.036	#
Male	Sparsentan	139	139 (100.0)	304.9	35	0.11	0.213	(0.041, 1.119)	0.068	
	Irbesartan	143	143 (100.0)	310.9	96	0.31				
Female	Sparsentan	63	63 (100.0)	138.9	51	0.37	14.622	(0.406, 526.863)	0.142	
	Irbesartan	59	59 (100.0)	126.3	27	0.21				
Age	Sparsentan								0.538	
<= 45 years	Sparsentan	96	96 (100.0)	210.4	68	0.32	1.043	(0.203, 5.364)	0.960	
	Irbesartan	99	99 (100.0)	215.6	100	0.46				
> 45 years	Sparsentan	106	106 (100.0)	233.3	18	0.08	2.393	(0.034, 170.982)	0.689	
	Irbesartan	103	103 (100.0)	221.6	23	0.10				
Age at IgAN diagnosis	Sparsentan								0.686	
<= 18 years	Sparsentan	9	9 (100.0)	20.0	51	2.55	2.562	(0.048, 136.943)	0.643	
	Irbesartan	5	5 (100.0)	10.9	11	1.01				
> 18 to 40 years	Sparsentan	102	102 (100.0)	223.4	17	0.08	0.397	(0.038, 4.120)	0.439	
	Irbesartan	109	109 (100.0)	234.0	83	0.35				
> 40 years	Sparsentan	91	91 (100.0)	200.3	18	0.09	1.947	(0.035, 107.159)	0.745	
	Irbesartan	88	88 (100.0)	192.3	29	0.15				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. nval (%) = number of patients included in the analysis (i.e., with post-baseline data).
NE = not evaluable.
Number of events = number of days with considered hospitalizations. 95% CI = 95% confidence interval for rate ratio.
A negative binomial model was applied with factors treatment, randomisation strata, and log of offset. The study duration of double blind period was used as offset. Randomisation stratum will be included only once in the model, if this stratum is investigated subgroup.
* = significant treatment effect. # = significant interaction.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HDK_FSNM: Duration of hospitalizations related to kidney by subgroup
Full Analysis Set

Duration of hospitalizations related to kidney							Negative binomial model		
Subgroup	Treatment	N	nval (%)	Time at risk (years)	Number of events	Crude rate	Rate ratio	95% CI	p-value
Geographic region	Sparsentan								0.985
North America	Sparsentan	35	35 (100.0)	77.2	6	0.08	2.016	(0.013, 308.597)	0.785
	Irbesartan	46	46 (100.0)	97.8	7	0.07			
Europe	Sparsentan	98	98 (100.0)	214.6	59	0.27	1.456	(0.178, 11.909)	0.726
	Irbesartan	115	115 (100.0)	251.8	99	0.39			
Asia Pacific	Sparsentan	69	69 (100.0)	151.9	21	0.14	1.018	(0.043, 23.918)	0.991
	Irbesartan	41	41 (100.0)	87.6	17	0.19			
Baseline BMI	Sparsentan								0.106
< 27 kg/m**2	Sparsentan	83	83 (100.0)	182.3	20	0.11	0.526	(0.050, 5.488)	0.591
	Irbesartan	94	94 (100.0)	202.2	108	0.53			
>= 27 kg/m**2	Sparsentan	119	119 (100.0)	261.5	66	0.25	5.597	(0.616, 50.872)	0.126
	Irbesartan	107	107 (100.0)	232.7	15	0.06			
Randomization strata	Sparsentan								NE
eGFR Low and UP High	Sparsentan	71	71 (100.0)	154.1	45	0.29	0.474	(0.070, 3.207)	0.444
	Irbesartan	74	74 (100.0)	162.9	94	0.58			
eGFR Low and UP Low	Sparsentan	55	55 (100.0)	122.3	14	0.11	12.909	(0.344, 484.408)	0.167
	Irbesartan	55	55 (100.0)	117.4	1	0.01			
eGFR High and UP High	Sparsentan	37	37 (100.0)	81.8	27	0.33	0.921	(0.104, 8.120)	0.941
	Irbesartan	36	36 (100.0)	78.1	28	0.36			
eGFR High and UP Low	Sparsentan	39	39 (100.0)	85.6	0	0.00			NE
	Irbesartan	37	37 (100.0)	78.7	0	0.00			

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. nval (%) = number of patients included in the analysis (i.e., with post-baseline data).
NE = not evaluable.
Number of events = number of days with considered hospitalizations. 95% CI = 95% confidence interval for rate ratio.
A negative binomial model was applied with factors treatment, randomisation strata, and log of offset. The study duration of double blind period was used as offset. Randomisation stratum will be included only once in the model, if this stratum is investigated subgroup.
* = significant treatment effect. # = significant interaction.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HDK_FSNM: Duration of hospitalizations related to kidney by subgroup
Full Analysis Set

Duration of hospitalizations related to kidney							Negative binomial model		
Subgroup	Treatment	N	nval (%)	Time at risk (years)	Number of events	Crude rate	Rate ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan								NE
< 60 mL/min/1.73 m**2	Sparsentan	127	127 (100.0)	278.6	59	0.21	1.343	(0.181, 9.945)	0.773
	Irbesartan	129	129 (100.0)	279.9	95	0.34			
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	49 (100.0)	107.9	22	0.20	0.769	(0.079, 7.457)	0.820
	Irbesartan	48	48 (100.0)	105.2	28	0.27			
>= 90 mL/min/1.73 m**2	Sparsentan	26	26 (100.0)	57.2	5	0.09			NE
	Irbesartan	25	25 (100.0)	52.1	0	0.00			
Baseline eGFR Group 2	Sparsentan								NE
< 45 mL/min/1.73 m**2	Sparsentan	82	82 (100.0)	179.4	57	0.32	1.778	(0.166, 19.052)	0.634
	Irbesartan	80	80 (100.0)	172.7	72	0.42			
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	45 (100.0)	99.2	2	0.02	0.070	(0.001, 3.741)	0.190
	Irbesartan	49	49 (100.0)	107.3	23	0.21			
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	49 (100.0)	107.9	22	0.20	0.769	(0.079, 7.457)	0.820
	Irbesartan	48	48 (100.0)	105.2	28	0.27			
>= 90 mL/min/1.73 m**2	Sparsentan	26	26 (100.0)	57.2	5	0.09			NE
	Irbesartan	25	25 (100.0)	52.1	0	0.00			
Baseline urine protein excretion	Sparsentan								0.093
<= 1.75 g/day	Sparsentan	98	98 (100.0)	216.3	11	0.05	10.367	(0.682, 157.613)	0.092
	Irbesartan	93	93 (100.0)	198.9	1	0.01			
> 1.75 g/day	Sparsentan	104	104 (100.0)	227.4	75	0.33	0.751	(0.146, 3.868)	0.732
	Irbesartan	109	109 (100.0)	238.3	122	0.51			

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. nval (%) = number of patients included in the analysis (i.e., with post-baseline data).
NE = not evaluable.
Number of events = number of days with considered hospitalizations. 95% CI = 95% confidence interval for rate ratio.
A negative binomial model was applied with factors treatment, randomisation strata, and log of offset. The study duration of double blind period was used as offset. Randomisation stratum will be included only once in the model, if this stratum is investigated subgroup.
* = significant treatment effect. # = significant interaction.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2HDK_FSNM: Duration of hospitalizations related to kidney by subgroup
Full Analysis Set

Duration of hospitalizations related to kidney							Negative binomial model		
Subgroup	Treatment	N	nval (%)	Time at risk (years)	Number of events	Crude rate	Rate ratio	95% CI	p-value
Baseline use of antihypertensives	Sparsentan								0.818
Yes	Sparsentan	90	90 (100.0)	197.1	59	0.30	2.020	(0.233, 17.501)	0.523
	Irbesartan	88	88 (100.0)	191.2	61	0.32			
No	Sparsentan	112	112 (100.0)	246.7	27	0.11	0.775	(0.062, 9.703)	0.843
	Irbesartan	114	114 (100.0)	246.0	62	0.25			
Time since renal biopsy	Sparsentan								0.226
<= 5 years	Sparsentan	113	113 (100.0)	247.7	23	0.09	0.452	(0.058, 3.531)	0.449
	Irbesartan	127	127 (100.0)	274.4	96	0.35			
> 5 years	Sparsentan	89	89 (100.0)	196.1	63	0.32	3.765	(0.276, 51.393)	0.320
	Irbesartan	75	75 (100.0)	162.8	27	0.17			
History of hypertension	Sparsentan								0.892
Yes	Sparsentan	155	155 (100.0)	339.9	45	0.13	0.680	(0.099, 4.652)	0.694
	Irbesartan	161	161 (100.0)	349.5	102	0.29			
No	Sparsentan	47	47 (100.0)	103.9	41	0.39	2.823	(0.107, 74.260)	0.534
	Irbesartan	41	41 (100.0)	87.7	21	0.24			

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. nval (%) = number of patients included in the analysis (i.e., with post-baseline data).
NE = not evaluable.
Number of events = number of days with considered hospitalizations. 95% CI = 95% confidence interval for rate ratio.
A negative binomial model was applied with factors treatment, randomisation strata, and log of offset. The study duration of double blind period was used as offset. Randomisation stratum will be included only once in the model, if this stratum is investigated subgroup.
* = significant treatment effect. # = significant interaction.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aeff, created on: 20FEB2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	EQ-5D VAS	Baseline	Sparsentan	139	132 (95.0)	81.11 (11.21)	40.0	74.50	81.00	90.00	100.0	
			Irbesartan	143	132 (92.3)	79.64 (14.68)	19.0	75.00	80.00	90.00	100.0	
		Week 24	Sparsentan	139	114 (82.0)	84.02 (10.82)	50.0	78.00	85.00	91.00	100.0	
			Irbesartan	143	103 (72.0)	80.04 (18.26)	4.0	73.00	83.00	91.00	100.0	
		Week 48	Sparsentan	139	118 (84.9)	83.19 (10.61)	49.0	80.00	84.00	90.00	100.0	
			Irbesartan	143	94 (65.7)	82.32 (13.44)	40.0	75.00	85.00	91.00	100.0	
		Week 70	Sparsentan	139	119 (85.6)	81.27 (10.56)	50.0	75.00	81.00	90.00	100.0	
			Irbesartan	143	97 (67.8)	82.01 (15.41)	20.0	75.00	85.00	93.00	100.0	
		Week 94	Sparsentan	139	109 (78.4)	83.09 (12.02)	34.0	79.00	85.00	91.00	100.0	
			Irbesartan	143	99 (69.2)	82.59 (14.49)	34.0	76.00	86.00	91.00	100.0	
		Week 110	Sparsentan	139	106 (76.3)	82.97 (11.21)	50.0	78.00	83.00	91.00	100.0	
			Irbesartan	143	89 (62.2)	81.40 (13.41)	35.0	76.00	84.00	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	139	114 (82.0)	2.54 (11.36)	-31.0	-3.00	2.00	10.00	44.0	0.10 [-0.17, 0.37]
			Irbesartan	143	103 (72.0)	1.11 (17.25)	-90.0	-5.00	0.00	10.00	52.0	
		Week 48	Sparsentan	139	118 (84.9)	1.90 (10.49)	-30.0	-3.00	1.00	7.00	41.0	-0.15 [-0.42, 0.12]
			Irbesartan	143	94 (65.7)	3.56 (12.20)	-35.0	-4.00	3.00	10.00	43.0	
		Week 70	Sparsentan	139	119 (85.6)	-0.20 (11.69)	-32.0	-9.00	0.00	8.00	40.0	-0.27 [-0.54, -0.00]
			Irbesartan	143	97 (67.8)	3.13 (12.82)	-60.0	-3.00	1.00	10.00	40.0	
		Week 94	Sparsentan	139	109 (78.4)	1.78 (12.93)	-61.0	-3.00	2.00	10.00	40.0	-0.17 [-0.45, 0.10]
			Irbesartan	143	99 (69.2)	4.15 (14.58)	-41.0	-3.00	3.00	10.00	50.0	
		Week 110	Sparsentan	139	106 (76.3)	1.10 (10.05)	-31.0	-4.00	1.00	7.00	21.0	-0.18 [-0.46, 0.10]
			Irbesartan	143	89 (62.2)	3.10 (12.02)	-26.0	-4.00	1.00	10.00	39.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Female	EQ-5D VAS	Baseline	Sparsentan	63	59 (93.7)	79.07 (19.44)	7.0	75.00	82.00	90.00	100.0	
			Irbesartan	59	52 (88.1)	82.29 (12.91)	37.0	74.00	83.00	91.50	100.0	
		Week 24	Sparsentan	63	50 (79.4)	84.60 (10.46)	51.0	80.00	88.50	91.00	100.0	
			Irbesartan	59	40 (67.8)	83.80 (9.93)	48.0	80.00	84.50	90.50	99.0	
		Week 48	Sparsentan	63	50 (79.4)	83.44 (12.18)	49.0	78.00	82.50	92.00	100.0	
			Irbesartan	59	38 (64.4)	82.21 (12.94)	50.0	80.00	82.00	90.00	100.0	
		Week 70	Sparsentan	63	47 (74.6)	81.49 (14.77)	27.0	75.00	82.00	90.00	100.0	
			Irbesartan	59	39 (66.1)	80.82 (16.48)	20.0	76.00	84.00	91.00	100.0	
		Week 94	Sparsentan	63	47 (74.6)	79.74 (15.23)	41.0	70.00	81.00	90.00	100.0	
			Irbesartan	59	37 (62.7)	81.81 (13.91)	40.0	78.00	82.00	90.00	100.0	
		Week 110	Sparsentan	63	46 (73.0)	81.07 (12.00)	48.0	76.00	81.00	90.00	100.0	
			Irbesartan	59	32 (54.2)	82.88 (9.41)	60.0	79.50	81.00	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	63	50 (79.4)	4.68 (18.98)	-25.0	-9.00	0.00	12.00	75.0	0.26 [-0.16, 0.68]
			Irbesartan	59	40 (67.8)	0.43 (11.91)	-37.0	-4.50	1.00	7.00	23.0	
		Week 48	Sparsentan	63	50 (79.4)	3.54 (20.84)	-29.0	-9.00	0.00	11.00	87.0	0.19 [-0.23, 0.62]
			Irbesartan	59	38 (64.4)	0.11 (12.53)	-31.0	-8.00	1.50	7.00	23.0	
		Week 70	Sparsentan	63	47 (74.6)	0.74 (17.49)	-51.0	-6.00	0.00	9.00	59.0	0.26 [-0.17, 0.68]
			Irbesartan	59	39 (66.1)	-3.26 (12.83)	-49.0	-10.00	-1.00	7.00	18.0	
		Week 94	Sparsentan	63	47 (74.6)	-0.30 (18.22)	-34.0	-12.00	0.00	10.00	45.0	0.04 [-0.39, 0.47]
			Irbesartan	59	37 (62.7)	-0.95 (14.41)	-45.0	-7.00	0.00	10.00	22.0	
		Week 110	Sparsentan	63	46 (73.0)	2.83 (23.17)	-40.0	-10.00	0.00	11.00	88.0	0.11 [-0.34, 0.56]
			Irbesartan	59	32 (54.2)	0.69 (10.07)	-21.0	-7.00	1.50	5.00	27.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
<= 45 years	EQ-5D VAS	Baseline	Sparsentan	96	89 (92.7)	79.93 (14.66)	7.0	75.00	81.00	90.00	100.0	
			Irbesartan	99	92 (92.9)	81.66 (14.94)	19.0	75.00	82.00	90.50	100.0	
		Week 24	Sparsentan	96	75 (78.1)	84.88 (10.79)	59.0	78.00	88.00	91.00	100.0	
			Irbesartan	99	72 (72.7)	81.65 (17.51)	10.0	72.50	85.00	92.50	100.0	
		Week 48	Sparsentan	96	79 (82.3)	83.62 (11.66)	49.0	79.00	86.00	91.00	100.0	
			Irbesartan	99	63 (63.6)	82.43 (13.86)	40.0	75.00	85.00	91.00	100.0	
		Week 70	Sparsentan	96	76 (79.2)	82.32 (11.82)	27.0	77.50	83.50	90.00	100.0	
			Irbesartan	99	64 (64.6)	83.45 (16.03)	20.0	78.50	88.00	94.00	100.0	
		Week 94	Sparsentan	96	71 (74.0)	81.52 (14.32)	34.0	77.00	84.00	91.00	100.0	
			Irbesartan	99	65 (65.7)	81.71 (15.46)	40.0	71.00	84.00	92.00	100.0	
		Week 110	Sparsentan	96	71 (74.0)	83.46 (11.20)	48.0	80.00	84.00	90.00	100.0	
			Irbesartan	99	59 (59.6)	83.73 (12.60)	47.0	79.00	87.00	92.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	96	75 (78.1)	4.85 (15.83)	-31.0	-4.00	2.00	12.00	75.0	0.39 [0.06, 0.72]
			Irbesartan	99	72 (72.7)	-1.42 (16.32)	-90.0	-6.00	-1.00	9.00	23.0	
		Week 48	Sparsentan	96	79 (82.3)	2.78 (14.37)	-30.0	-4.00	1.00	10.00	64.0	0.24 [-0.09, 0.58]
			Irbesartan	99	63 (63.6)	-0.51 (12.23)	-35.0	-6.00	0.00	6.00	27.0	
		Week 70	Sparsentan	96	76 (79.2)	1.28 (13.02)	-51.0	-6.00	0.00	9.00	41.0	0.09 [-0.24, 0.42]
			Irbesartan	99	64 (64.6)	0.13 (12.36)	-49.0	-5.50	0.00	10.00	29.0	
		Week 94	Sparsentan	96	71 (74.0)	0.38 (17.36)	-61.0	-9.00	1.00	11.00	45.0	0.05 [-0.29, 0.38]
			Irbesartan	99	65 (65.7)	-0.37 (15.64)	-45.0	-6.00	0.00	9.00	44.0	
		Week 110	Sparsentan	96	71 (74.0)	2.85 (16.95)	-40.0	-4.00	1.00	10.00	88.0	0.07 [-0.28, 0.41]
			Irbesartan	99	59 (59.6)	1.85 (11.38)	-26.0	-5.00	0.00	8.00	30.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 45 years	EQ-5D VAS	Baseline	Sparsentan	106	102 (96.2)	80.96 (13.92)	11.0	75.00	82.00	90.00	100.0	
			Irbesartan	103	92 (89.3)	79.11 (13.42)	34.0	74.00	80.00	89.00	100.0	
		Week 24	Sparsentan	106	89 (84.0)	83.62 (10.61)	50.0	78.00	84.00	90.00	100.0	
			Irbesartan	103	71 (68.9)	80.52 (15.34)	4.0	78.00	81.00	90.00	100.0	
		Week 48	Sparsentan	106	89 (84.0)	82.94 (10.56)	49.0	79.00	84.00	90.00	100.0	
			Irbesartan	103	69 (67.0)	82.16 (12.77)	50.0	79.00	83.00	90.00	100.0	
		Week 70	Sparsentan	106	90 (84.9)	80.50 (11.89)	40.0	75.00	81.00	90.00	100.0	
			Irbesartan	103	72 (69.9)	80.08 (15.29)	20.0	73.50	82.00	90.50	100.0	
		Week 94	Sparsentan	106	85 (80.2)	82.55 (12.08)	40.0	79.00	83.00	91.00	100.0	
			Irbesartan	103	71 (68.9)	82.99 (13.22)	34.0	79.00	84.00	90.00	100.0	
		Week 110	Sparsentan	106	81 (76.4)	81.46 (11.65)	50.0	75.00	81.00	90.00	100.0	
			Irbesartan	103	62 (60.2)	79.95 (12.14)	35.0	76.00	81.00	89.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	106	89 (84.0)	1.80 (12.37)	-29.0	-4.00	0.00	7.00	44.0	-0.11 [-0.42, 0.20]
			Irbesartan	103	71 (68.9)	3.28 (15.20)	-71.0	-1.00	2.00	10.00	52.0	
		Week 48	Sparsentan	106	89 (84.0)	2.03 (14.35)	-29.0	-3.00	0.00	7.00	87.0	-0.25 [-0.57, 0.06]
			Irbesartan	103	69 (67.0)	5.38 (11.86)	-19.0	-1.00	5.00	10.00	43.0	
		Week 70	Sparsentan	106	90 (84.9)	-0.96 (13.94)	-45.0	-10.00	-1.00	6.00	59.0	-0.24 [-0.55, 0.07]
			Irbesartan	103	72 (69.9)	2.35 (13.72)	-60.0	-4.50	0.50	9.50	40.0	
		Week 94	Sparsentan	106	85 (80.2)	1.80 (12.09)	-37.0	-3.00	1.00	8.00	40.0	-0.30 [-0.62, 0.01]
			Irbesartan	103	71 (68.9)	5.63 (13.17)	-41.0	-3.00	5.00	11.00	50.0	
		Week 110	Sparsentan	106	81 (76.4)	0.56 (13.49)	-31.0	-5.00	1.00	8.00	70.0	-0.20 [-0.53, 0.14]
			Irbesartan	103	62 (60.2)	3.05 (11.77)	-23.0	-4.00	1.50	10.00	39.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age at IgAN diagnosis												
<= 18 years	EQ-5D VAS	Baseline	Sparsentan	9	9 (100.0)	74.67 (15.03)	51.0	62.00	79.00	82.00	95.0	
			Irbesartan	5	5 (100.0)	76.40 (11.59)	60.0	73.00	74.00	86.00	89.0	
		Week 24	Sparsentan	9	5 (55.6)	86.00 (16.73)	60.0	80.00	90.00	100.00	100.0	
			Irbesartan	5	5 (100.0)	72.60 (25.04)	31.0	69.00	83.00	85.00	95.0	
		Week 48	Sparsentan	9	7 (77.8)	82.00 (11.79)	66.0	71.00	81.00	92.00	100.0	
			Irbesartan	5	3 (60.0)	79.67 (11.93)	66.0	66.00	85.00	88.00	88.0	
		Week 70	Sparsentan	9	7 (77.8)	82.29 (11.61)	66.0	70.00	85.00	90.00	100.0	
			Irbesartan	5	4 (80.0)	74.50 (17.25)	55.0	60.00	76.50	89.00	90.0	
		Week 94	Sparsentan	9	5 (55.6)	69.40 (27.40)	34.0	50.00	73.00	90.00	100.0	
			Irbesartan	5	4 (80.0)	74.25 (24.58)	49.0	53.50	74.00	95.00	100.0	
		Week 110	Sparsentan	9	4 (44.4)	87.75 (9.67)	80.0	80.00	85.50	95.50	100.0	
			Irbesartan	5	2 (40.0)	53.50 (9.19)	47.0	47.00	53.50	60.00	60.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	9	5 (55.6)	9.60 (7.57)	0.0	7.00	10.00	10.00	21.0	0.80 [-0.49, 2.09]
			Irbesartan	5	5 (100.0)	-3.80 (22.42)	-42.0	-6.00	9.00	9.00	11.0	
		Week 48	Sparsentan	9	7 (77.8)	6.14 (8.53)	-9.0	-2.00	10.00	11.00	15.0	0.09 [-1.26, 1.45]
			Irbesartan	5	3 (60.0)	5.33 (9.02)	-4.0	-4.00	6.00	14.00	14.0	
		Week 70	Sparsentan	9	7 (77.8)	6.43 (8.89)	-10.0	0.00	8.00	15.00	15.0	0.94 [-0.35, 2.23]
			Irbesartan	5	4 (80.0)	-2.50 (10.66)	-18.0	-9.50	1.50	4.50	5.0	
		Week 94	Sparsentan	9	5 (55.6)	-10.20 (34.35)	-61.0	-30.00	7.00	13.00	20.0	-0.27 [-1.59, 1.05]
			Irbesartan	5	4 (80.0)	-2.75 (15.13)	-24.0	-13.00	1.00	7.50	11.0	
		Week 110	Sparsentan	9	4 (44.4)	9.00 (8.29)	0.0	3.50	8.00	14.50	20.0	1.89 [-0.12, 3.89]
			Irbesartan	5	2 (40.0)	-13.00 (18.38)	-26.0	-26.00	-13.00	0.00	0.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 18 to 40 years	EQ-5D VAS	Baseline	Sparsentan	102	95 (93.1)	80.85 (14.44)	7.0	75.00	82.00	90.00	100.0	
			Irbesartan	109	100 (91.7)	81.14 (15.01)	19.0	75.00	82.00	90.00	100.0	
		Week 24	Sparsentan	102	82 (80.4)	84.83 (10.16)	59.0	78.00	87.00	91.00	100.0	
			Irbesartan	109	75 (68.8)	81.83 (17.09)	10.0	74.00	85.00	92.00	100.0	
		Week 48	Sparsentan	102	85 (83.3)	83.93 (10.76)	49.0	80.00	86.00	91.00	100.0	
			Irbesartan	109	69 (63.3)	81.87 (14.37)	40.0	79.00	85.00	92.00	100.0	
		Week 70	Sparsentan	102	81 (79.4)	82.41 (11.41)	27.0	77.00	83.00	90.00	100.0	
			Irbesartan	109	71 (65.1)	83.44 (15.49)	20.0	79.00	87.00	94.00	100.0	
		Week 94	Sparsentan	102	77 (75.5)	83.01 (12.15)	41.0	80.00	85.00	91.00	100.0	
			Irbesartan	109	71 (65.1)	81.52 (14.97)	39.0	71.00	84.00	91.00	100.0	
		Week 110	Sparsentan	102	75 (73.5)	83.07 (11.39)	48.0	79.00	84.00	90.00	100.0	
			Irbesartan	109	65 (59.6)	83.35 (13.26)	35.0	79.00	88.00	91.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	102	82 (80.4)	4.37 (16.12)	-31.0	-3.00	1.50	11.00	75.0	0.29 [-0.02, 0.61]
			Irbesartan	109	75 (68.8)	-0.31 (15.83)	-90.0	-6.00	-1.00	10.00	23.0	
		Week 48	Sparsentan	102	85 (83.3)	2.48 (14.53)	-30.0	-4.00	1.00	10.00	64.0	0.17 [-0.15, 0.49]
			Irbesartan	109	69 (63.3)	0.16 (12.35)	-35.0	-5.00	0.00	7.00	27.0	
		Week 70	Sparsentan	102	81 (79.4)	0.98 (13.41)	-51.0	-6.00	0.00	8.00	41.0	-0.00 [-0.32, 0.32]
			Irbesartan	109	71 (65.1)	0.99 (11.97)	-49.0	-6.00	0.00	10.00	29.0	
		Week 94	Sparsentan	102	77 (75.5)	1.88 (15.27)	-34.0	-5.00	2.00	9.00	45.0	0.10 [-0.22, 0.43]
			Irbesartan	109	71 (65.1)	0.28 (15.44)	-45.0	-9.00	0.00	10.00	44.0	
		Week 110	Sparsentan	102	75 (73.5)	2.05 (16.59)	-40.0	-5.00	1.00	7.00	88.0	-0.02 [-0.35, 0.31]
			Irbesartan	109	65 (59.6)	2.35 (11.57)	-23.0	-4.00	0.00	11.00	30.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 40 years	EQ-5D VAS	Baseline	Sparsentan	91	87 (95.6)	80.68 (13.98)	11.0	72.00	81.00	90.00	100.0	
			Irbesartan	88	79 (89.8)	79.68 (13.39)	40.0	73.00	80.00	90.00	100.0	
		Week 24	Sparsentan	91	77 (84.6)	83.40 (10.89)	50.0	78.00	83.00	90.00	100.0	
			Irbesartan	88	63 (71.6)	80.89 (14.90)	4.0	78.00	80.00	90.00	100.0	
		Week 48	Sparsentan	91	76 (83.5)	82.63 (11.44)	49.0	78.50	84.00	90.00	100.0	
			Irbesartan	88	60 (68.2)	82.90 (12.09)	50.0	77.00	82.50	90.00	100.0	
		Week 70	Sparsentan	91	78 (85.7)	80.13 (12.36)	40.0	75.00	81.00	90.00	100.0	
			Irbesartan	88	61 (69.3)	80.08 (15.75)	20.0	74.00	82.00	91.00	100.0	
		Week 94	Sparsentan	91	74 (81.3)	81.97 (12.58)	40.0	77.00	82.50	91.00	100.0	
			Irbesartan	88	61 (69.3)	83.90 (12.66)	34.0	80.00	85.00	90.00	100.0	
		Week 110	Sparsentan	91	73 (80.2)	81.41 (11.61)	50.0	75.00	81.00	90.00	100.0	
			Irbesartan	88	54 (61.4)	80.96 (10.19)	40.0	76.00	81.00	89.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	91	77 (84.6)	1.53 (11.81)	-29.0	-6.00	0.00	7.00	40.0	-0.09 [-0.42, 0.24]
			Irbesartan	88	63 (71.6)	2.75 (15.50)	-71.0	-1.00	1.00	9.00	52.0	
		Week 48	Sparsentan	91	76 (83.5)	1.93 (14.59)	-29.0	-4.50	0.00	5.00	87.0	-0.24 [-0.58, 0.10]
			Irbesartan	88	60 (68.2)	5.20 (12.08)	-19.0	0.00	5.00	10.00	43.0	
		Week 70	Sparsentan	91	78 (85.7)	-1.45 (13.88)	-45.0	-10.00	-1.50	6.00	59.0	-0.24 [-0.57, 0.10]
			Irbesartan	88	61 (69.3)	1.92 (14.55)	-60.0	-4.00	0.00	9.00	40.0	
		Week 94	Sparsentan	91	74 (81.3)	1.16 (11.90)	-37.0	-5.00	0.00	10.00	31.0	-0.39 [-0.73, -0.05]
			Irbesartan	88	61 (69.3)	6.02 (13.19)	-41.0	-1.00	5.00	10.00	50.0	
		Week 110	Sparsentan	91	73 (80.2)	0.78 (13.95)	-31.0	-5.00	1.00	9.00	70.0	-0.19 [-0.54, 0.17]
			Irbesartan	88	54 (61.4)	3.17 (11.16)	-14.0	-4.00	2.00	9.00	39.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Geographic region												
North America	EQ-5D VAS	Baseline	Sparsentan	35	33 (94.3)	79.61 (18.57)	7.0	75.00	85.00	93.00	100.0	
			Irbesartan	46	44 (95.7)	81.18 (15.14)	34.0	75.00	82.50	92.50	100.0	
		Week 24	Sparsentan	35	24 (68.6)	86.88 (9.29)	70.0	81.00	90.00	93.50	100.0	
			Irbesartan	46	38 (82.6)	79.74 (22.03)	4.0	74.00	85.00	94.00	100.0	
		Week 48	Sparsentan	35	26 (74.3)	83.77 (12.62)	49.0	79.00	88.00	92.00	99.0	
			Irbesartan	46	35 (76.1)	83.06 (13.44)	50.0	75.00	82.00	96.00	100.0	
		Week 70	Sparsentan	35	24 (68.6)	83.42 (10.29)	60.0	76.00	85.00	90.50	100.0	
			Irbesartan	46	32 (69.6)	85.53 (14.18)	35.0	80.00	90.00	95.00	100.0	
		Week 94	Sparsentan	35	24 (68.6)	83.25 (14.03)	41.0	73.00	87.00	94.50	100.0	
			Irbesartan	46	30 (65.2)	82.90 (16.24)	34.0	80.00	84.00	95.00	100.0	
		Week 110	Sparsentan	35	21 (60.0)	85.95 (10.78)	65.0	76.00	90.00	95.00	100.0	
			Irbesartan	46	31 (67.4)	83.39 (13.26)	35.0	79.00	87.00	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	35	24 (68.6)	4.63 (18.47)	-21.0	-2.00	0.50	9.00	75.0	0.32 [-0.20, 0.83]
			Irbesartan	46	38 (82.6)	-1.97 (21.94)	-90.0	-5.00	1.00	9.00	23.0	
		Week 48	Sparsentan	35	26 (74.3)	4.65 (15.79)	-15.0	-4.00	1.50	7.00	64.0	0.10 [-0.41, 0.61]
			Irbesartan	46	35 (76.1)	3.17 (14.27)	-26.0	-4.00	2.00	9.00	38.0	
		Week 70	Sparsentan	35	24 (68.6)	-0.38 (9.77)	-12.0	-7.50	-2.50	2.50	24.0	-0.33 [-0.86, 0.21]
			Irbesartan	46	32 (69.6)	3.28 (12.09)	-20.0	-3.00	1.50	8.00	40.0	
		Week 94	Sparsentan	35	24 (68.6)	-0.63 (11.97)	-34.0	-6.50	-1.00	2.50	23.0	-0.24 [-0.78, 0.30]
			Irbesartan	46	30 (65.2)	2.47 (13.52)	-41.0	-4.00	4.00	10.00	27.0	
		Week 110	Sparsentan	35	21 (60.0)	3.71 (20.43)	-12.0	-4.00	1.00	4.00	88.0	0.02 [-0.53, 0.58]
			Irbesartan	46	31 (67.4)	3.35 (12.00)	-13.0	-4.00	2.00	9.00	34.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Europe	EQ-5D VAS	Baseline	Sparsentan	98	91 (92.9)	80.81 (13.55)	11.0	75.00	81.00	90.00	100.0	
			Irbesartan	115	99 (86.1)	81.15 (13.69)	40.0	75.00	81.00	90.00	100.0	
		Week 24	Sparsentan	98	79 (80.6)	83.08 (11.65)	50.0	76.00	84.00	90.00	100.0	
			Irbesartan	115	68 (59.1)	82.32 (14.34)	31.0	78.00	85.00	91.50	100.0	
		Week 48	Sparsentan	98	79 (80.6)	84.33 (11.17)	50.0	79.00	85.00	92.00	100.0	
			Irbesartan	115	62 (53.9)	82.31 (14.44)	40.0	79.00	85.00	92.00	100.0	
		Week 70	Sparsentan	98	78 (79.6)	81.41 (11.11)	50.0	75.00	81.00	90.00	100.0	
			Irbesartan	115	72 (62.6)	79.76 (17.61)	20.0	70.50	83.50	93.00	100.0	
		Week 94	Sparsentan	98	72 (73.5)	81.53 (14.17)	34.0	76.50	83.00	91.00	100.0	
			Irbesartan	115	73 (63.5)	82.18 (14.91)	39.0	72.00	87.00	91.00	100.0	
		Week 110	Sparsentan	98	70 (71.4)	81.69 (10.94)	48.0	78.00	81.00	90.00	100.0	
			Irbesartan	115	61 (53.0)	80.46 (13.44)	40.0	74.00	81.00	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	98	79 (80.6)	1.76 (12.73)	-31.0	-5.00	1.00	9.00	40.0	0.03 [-0.29, 0.36]
			Irbesartan	115	68 (59.1)	1.34 (13.05)	-42.0	-5.50	0.00	10.00	52.0	
		Week 48	Sparsentan	98	79 (80.6)	2.75 (14.61)	-30.0	-3.00	1.00	10.00	87.0	0.03 [-0.31, 0.36]
			Irbesartan	115	62 (53.9)	2.39 (11.64)	-35.0	-4.00	1.00	8.00	43.0	
		Week 70	Sparsentan	98	78 (79.6)	0.15 (12.89)	-32.0	-9.00	0.00	8.00	59.0	0.03 [-0.29, 0.35]
			Irbesartan	115	72 (62.6)	-0.28 (15.03)	-60.0	-6.00	0.00	8.00	40.0	
		Week 94	Sparsentan	98	72 (73.5)	1.25 (15.27)	-61.0	-4.00	3.00	10.00	45.0	-0.07 [-0.40, 0.26]
			Irbesartan	115	73 (63.5)	2.33 (15.31)	-38.0	-4.00	1.00	10.00	50.0	
		Week 110	Sparsentan	98	70 (71.4)	1.60 (14.89)	-40.0	-7.00	1.00	10.00	70.0	0.02 [-0.32, 0.36]
			Irbesartan	115	61 (53.0)	1.34 (12.58)	-26.0	-5.00	0.00	10.00	39.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asia Pacific	EQ-5D VAS	Baseline	Sparsentan	69	67 (97.1)	80.46 (12.87)	40.0	73.00	81.00	90.00	100.0	
			Irbesartan	41	41 (100.0)	77.68 (14.49)	19.0	72.00	80.00	85.00	100.0	
		Week 24	Sparsentan	69	61 (88.4)	84.59 (9.79)	60.0	80.00	87.00	91.00	100.0	
			Irbesartan	41	37 (90.2)	80.22 (13.26)	30.0	79.00	80.00	90.00	100.0	
		Week 48	Sparsentan	69	63 (91.3)	81.71 (10.22)	49.0	79.00	81.00	90.00	100.0	
			Irbesartan	41	35 (85.4)	81.49 (10.97)	54.0	75.00	83.00	90.00	100.0	
		Week 70	Sparsentan	69	64 (92.8)	80.45 (13.28)	27.0	75.00	81.00	90.00	100.0	
			Irbesartan	41	32 (78.0)	82.09 (11.60)	40.0	78.00	83.50	90.00	100.0	
		Week 94	Sparsentan	69	60 (87.0)	82.28 (11.50)	40.0	80.00	83.50	90.00	100.0	
			Irbesartan	41	33 (80.5)	82.33 (11.06)	40.0	79.00	82.00	90.00	100.0	
		Week 110	Sparsentan	69	61 (88.4)	81.98 (12.18)	48.0	79.00	82.00	90.00	100.0	
			Irbesartan	41	29 (70.7)	82.90 (9.03)	60.0	80.00	83.00	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	69	61 (88.4)	4.49 (13.91)	-25.0	-3.00	5.00	12.00	44.0	0.10 [-0.31, 0.51]
			Irbesartan	41	37 (90.2)	3.11 (13.07)	-37.0	-1.00	0.00	10.00	34.0	
		Week 48	Sparsentan	69	63 (91.3)	1.00 (13.38)	-29.0	-8.00	0.00	10.00	46.0	-0.10 [-0.51, 0.31]
			Irbesartan	41	35 (85.4)	2.29 (11.86)	-31.0	-4.00	5.00	10.00	25.0	
		Week 70	Sparsentan	69	64 (92.8)	0.13 (15.54)	-51.0	-6.00	0.00	9.00	41.0	-0.20 [-0.63, 0.22]
			Irbesartan	41	32 (78.0)	2.88 (8.43)	-15.0	-3.00	0.00	10.00	18.0	
		Week 94	Sparsentan	69	60 (87.0)	1.75 (15.13)	-37.0	-6.00	0.00	8.50	44.0	-0.15 [-0.58, 0.27]
			Irbesartan	41	33 (80.5)	4.00 (14.55)	-45.0	-1.00	5.00	10.00	32.0	
		Week 110	Sparsentan	69	61 (88.4)	0.93 (13.60)	-31.0	-4.00	1.00	9.00	36.0	-0.24 [-0.68, 0.20]
			Irbesartan	41	29 (70.7)	3.86 (8.52)	-10.0	0.00	2.00	8.00	30.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline BMI												
< 27 kg/m**2	EQ-5D VAS	Baseline	Sparsentan	83	77 (92.8)	78.96 (14.98)	11.0	72.00	81.00	89.00	100.0	
			Irbesartan	94	87 (92.6)	84.05 (10.58)	52.0	77.00	83.00	91.00	100.0	
		Week 24	Sparsentan	83	68 (81.9)	82.84 (11.69)	51.0	74.00	82.50	90.00	100.0	
			Irbesartan	94	72 (76.6)	83.15 (13.29)	31.0	79.00	85.00	91.00	100.0	
		Week 48	Sparsentan	83	69 (83.1)	81.17 (11.72)	49.0	77.00	81.00	90.00	100.0	
			Irbesartan	94	63 (67.0)	83.59 (12.41)	40.0	80.00	85.00	91.00	100.0	
		Week 70	Sparsentan	83	68 (81.9)	79.29 (13.34)	27.0	70.00	80.50	90.00	100.0	
			Irbesartan	94	63 (67.0)	82.10 (15.27)	20.0	75.00	85.00	92.00	100.0	
		Week 94	Sparsentan	83	65 (78.3)	79.58 (13.65)	40.0	72.00	82.00	89.00	100.0	
			Irbesartan	94	65 (69.1)	83.15 (13.09)	49.0	76.00	85.00	92.00	100.0	
		Week 110	Sparsentan	83	64 (77.1)	80.84 (12.13)	48.0	75.50	81.00	90.00	100.0	
			Irbesartan	94	57 (60.6)	81.61 (12.20)	47.0	75.00	81.00	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	83	68 (81.9)	2.46 (12.39)	-25.0	-3.50	0.50	9.50	40.0	0.23 [-0.10, 0.56]
			Irbesartan	94	72 (76.6)	-0.19 (10.85)	-42.0	-5.00	-0.50	8.50	19.0	
		Week 48	Sparsentan	83	69 (83.1)	1.71 (16.66)	-30.0	-6.00	0.00	9.00	87.0	0.13 [-0.21, 0.47]
			Irbesartan	94	63 (67.0)	-0.13 (11.29)	-35.0	-5.00	0.00	7.00	27.0	
		Week 70	Sparsentan	83	68 (81.9)	-0.22 (15.54)	-51.0	-7.50	0.00	8.00	59.0	0.10 [-0.25, 0.44]
			Irbesartan	94	63 (67.0)	-1.59 (12.49)	-60.0	-5.00	0.00	5.00	29.0	
		Week 94	Sparsentan	83	65 (78.3)	0.15 (14.08)	-37.0	-7.00	0.00	7.00	44.0	0.04 [-0.30, 0.39]
			Irbesartan	94	65 (69.1)	-0.40 (12.54)	-38.0	-5.00	0.00	6.00	38.0	
		Week 110	Sparsentan	83	64 (77.1)	0.75 (15.04)	-31.0	-6.50	0.00	6.00	70.0	0.17 [-0.19, 0.52]
			Irbesartan	94	57 (60.6)	-1.40 (10.03)	-26.0	-7.00	0.00	2.00	28.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 27 kg/m**2	EQ-5D VAS	Baseline	Sparsentan	119	114 (95.8)	81.51 (13.69)	7.0	75.00	82.00	91.00	100.0	
			Irbesartan	107	96 (89.7)	77.49 (15.82)	19.0	72.50	80.00	88.50	100.0	
		Week 24	Sparsentan	119	96 (80.7)	85.16 (9.86)	50.0	80.00	88.00	91.00	100.0	
			Irbesartan	107	71 (66.4)	79.00 (18.95)	4.0	73.00	81.00	91.00	100.0	
		Week 48	Sparsentan	119	99 (83.2)	84.72 (10.40)	50.0	80.00	86.00	91.00	100.0	
			Irbesartan	107	69 (64.5)	81.10 (13.96)	50.0	74.00	83.00	90.00	100.0	
		Week 70	Sparsentan	119	98 (82.4)	82.74 (10.55)	50.0	79.00	82.00	90.00	100.0	
			Irbesartan	107	73 (68.2)	81.30 (16.10)	20.0	75.00	85.00	93.00	100.0	
		Week 94	Sparsentan	119	91 (76.5)	83.87 (12.48)	34.0	80.00	87.00	92.00	100.0	
			Irbesartan	107	70 (65.4)	81.63 (15.48)	34.0	78.00	84.00	90.00	100.0	
		Week 110	Sparsentan	119	88 (73.9)	83.52 (10.86)	48.0	78.50	84.50	90.00	100.0	
			Irbesartan	107	63 (58.9)	82.40 (12.37)	35.0	79.00	85.00	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	119	96 (80.7)	3.72 (15.23)	-31.0	-4.50	1.00	10.00	75.0	0.10 [-0.21, 0.40]
			Irbesartan	107	71 (66.4)	2.04 (19.77)	-90.0	-4.00	2.00	13.00	52.0	
		Week 48	Sparsentan	119	99 (83.2)	2.86 (12.50)	-29.0	-3.00	1.00	10.00	64.0	-0.17 [-0.48, 0.14]
			Irbesartan	107	69 (64.5)	5.03 (12.83)	-22.0	-1.00	5.00	10.00	43.0	
		Week 70	Sparsentan	119	98 (82.4)	0.27 (12.02)	-32.0	-8.00	0.00	8.00	40.0	-0.28 [-0.59, 0.02]
			Irbesartan	107	73 (68.2)	3.79 (13.18)	-49.0	-4.00	4.00	11.00	40.0	
		Week 94	Sparsentan	119	91 (76.5)	1.87 (15.15)	-61.0	-4.00	2.00	11.00	45.0	-0.21 [-0.53, 0.10]
			Irbesartan	107	70 (65.4)	5.11 (15.33)	-45.0	-3.00	5.00	12.00	50.0	
		Week 110	Sparsentan	119	88 (73.9)	2.26 (15.36)	-40.0	-4.00	1.00	9.00	88.0	-0.25 [-0.58, 0.07]
			Irbesartan	107	63 (58.9)	5.78 (11.84)	-21.0	-2.00	5.00	11.00	39.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Randomization strata												
eGFR Low and UP High	EQ-5D VAS	Baseline	Sparsentan	71	66 (93.0)	82.14 (10.50)	51.0	79.00	81.50	90.00	100.0	
			Irbesartan	74	64 (86.5)	78.67 (15.16)	37.0	75.00	80.00	87.50	100.0	
		Week 24	Sparsentan	71	54 (76.1)	83.89 (11.03)	50.0	76.00	85.00	91.00	100.0	
			Irbesartan	74	47 (63.5)	77.17 (19.06)	4.0	70.00	81.00	90.00	100.0	
		Week 48	Sparsentan	71	55 (77.5)	82.80 (10.43)	50.0	78.00	81.00	90.00	100.0	
			Irbesartan	74	41 (55.4)	82.27 (14.52)	50.0	79.00	85.00	90.00	100.0	
		Week 70	Sparsentan	71	58 (81.7)	79.91 (11.62)	50.0	72.00	80.50	89.00	100.0	
			Irbesartan	74	41 (55.4)	79.24 (15.87)	20.0	73.00	82.00	90.00	100.0	
		Week 94	Sparsentan	71	52 (73.2)	83.12 (12.31)	50.0	76.00	84.50	93.00	100.0	
			Irbesartan	74	40 (54.1)	79.50 (17.24)	34.0	75.00	84.00	90.50	100.0	
		Week 110	Sparsentan	71	53 (74.6)	82.21 (13.61)	48.0	75.00	84.00	91.00	100.0	
			Irbesartan	74	36 (48.6)	78.42 (14.19)	40.0	71.00	81.00	89.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	71	54 (76.1)	0.35 (11.30)	-31.0	-5.00	0.00	8.00	35.0	0.19 [-0.20, 0.58]
			Irbesartan	74	47 (63.5)	-2.57 (18.90)	-71.0	-10.00	-1.00	8.00	52.0	
		Week 48	Sparsentan	71	55 (77.5)	-0.51 (9.33)	-29.0	-6.00	-1.00	4.00	28.0	-0.43 [-0.84, -0.02]
			Irbesartan	74	41 (55.4)	4.78 (15.43)	-31.0	-1.00	3.00	10.00	43.0	
		Week 70	Sparsentan	71	58 (81.7)	-3.64 (10.26)	-32.0	-10.00	-2.50	4.00	19.0	-0.31 [-0.71, 0.10]
			Irbesartan	74	41 (55.4)	0.46 (16.94)	-60.0	-6.00	0.00	8.00	40.0	
		Week 94	Sparsentan	71	52 (73.2)	-0.04 (12.91)	-37.0	-4.50	0.50	7.50	45.0	-0.17 [-0.58, 0.24]
			Irbesartan	74	40 (54.1)	2.70 (19.40)	-45.0	-5.00	0.50	13.50	50.0	
		Week 110	Sparsentan	71	53 (74.6)	-0.51 (12.27)	-40.0	-3.00	0.00	5.00	35.0	-0.24 [-0.66, 0.18]
			Irbesartan	74	36 (48.6)	2.69 (14.82)	-26.0	-4.50	1.50	9.00	39.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR Low and UP Low	EQ-5D VAS	Baseline	Sparsentan	55	52 (94.5)	79.10 (17.39)	11.0	71.00	81.00	90.00	100.0	
			Irbesartan	55	51 (92.7)	81.61 (13.00)	34.0	74.00	80.00	90.00	100.0	
		Week 24	Sparsentan	55	46 (83.6)	82.74 (10.57)	51.0	78.00	82.00	90.00	100.0	
			Irbesartan	55	40 (72.7)	81.20 (16.32)	10.0	80.00	82.00	90.00	100.0	
		Week 48	Sparsentan	55	43 (78.2)	83.26 (10.87)	49.0	80.00	83.00	91.00	100.0	
			Irbesartan	55	38 (69.1)	82.11 (13.07)	50.0	80.00	83.00	91.00	100.0	
		Week 70	Sparsentan	55	44 (80.0)	83.20 (13.03)	40.0	79.50	86.50	91.00	100.0	
			Irbesartan	55	41 (74.5)	80.56 (16.86)	20.0	75.00	83.00	92.00	100.0	
		Week 94	Sparsentan	55	42 (76.4)	81.79 (14.41)	40.0	80.00	84.00	91.00	100.0	
			Irbesartan	55	40 (72.7)	81.90 (13.78)	39.0	76.00	83.00	90.00	100.0	
		Week 110	Sparsentan	55	38 (69.1)	80.87 (10.90)	59.0	75.00	81.50	88.00	100.0	
			Irbesartan	55	34 (61.8)	81.26 (13.23)	35.0	76.00	82.00	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	55	46 (83.6)	3.70 (14.17)	-25.0	-4.00	0.00	10.00	44.0	0.20 [-0.22, 0.63]
			Irbesartan	55	40 (72.7)	0.45 (17.72)	-90.0	-2.00	1.00	10.00	23.0	
		Week 48	Sparsentan	55	43 (78.2)	3.53 (17.62)	-22.0	-2.00	1.00	10.00	87.0	0.10 [-0.34, 0.53]
			Irbesartan	55	38 (69.1)	2.13 (10.45)	-22.0	-5.00	2.50	10.00	23.0	
		Week 70	Sparsentan	55	44 (80.0)	3.50 (16.72)	-45.0	-6.00	1.50	10.50	59.0	0.18 [-0.24, 0.61]
			Irbesartan	55	41 (74.5)	0.80 (12.56)	-49.0	-5.00	0.00	9.00	21.0	
		Week 94	Sparsentan	55	42 (76.4)	3.60 (14.17)	-34.0	-4.00	1.00	12.00	40.0	0.10 [-0.34, 0.53]
			Irbesartan	55	40 (72.7)	2.38 (11.16)	-22.0	-3.50	3.50	10.00	24.0	
		Week 110	Sparsentan	55	38 (69.1)	0.84 (16.12)	-28.0	-8.00	0.50	6.00	70.0	-0.08 [-0.54, 0.39]
			Irbesartan	55	34 (61.8)	1.91 (10.46)	-21.0	-4.00	0.50	11.00	20.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP High	EQ-5D VAS	Baseline	Sparsentan	37	35 (94.6)	78.66 (18.53)	7.0	70.00	82.00	91.00	100.0	
			Irbesartan	36	33 (91.7)	81.24 (11.45)	50.0	73.00	80.00	90.00	100.0	
		Week 24	Sparsentan	37	29 (78.4)	83.62 (11.12)	60.0	78.00	86.00	90.00	100.0	
			Irbesartan	36	27 (75.0)	85.44 (10.56)	69.0	72.00	90.00	95.00	99.0	
		Week 48	Sparsentan	37	34 (91.9)	81.94 (11.61)	50.0	78.00	83.00	89.00	100.0	
			Irbesartan	36	25 (69.4)	82.24 (14.51)	40.0	80.00	85.00	90.00	100.0	
		Week 70	Sparsentan	37	31 (83.8)	81.84 (9.82)	59.0	75.00	81.00	90.00	98.0	
			Irbesartan	36	25 (69.4)	81.80 (14.83)	40.0	71.00	85.00	91.00	100.0	
		Week 94	Sparsentan	37	27 (73.0)	80.52 (13.44)	34.0	78.00	84.00	90.00	96.0	
			Irbesartan	36	25 (69.4)	85.00 (11.80)	58.0	79.00	87.00	95.00	100.0	
		Week 110	Sparsentan	37	26 (70.3)	84.88 (8.44)	60.0	80.00	84.50	90.00	100.0	
			Irbesartan	36	22 (61.1)	83.18 (10.65)	60.0	79.00	86.50	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	37	29 (78.4)	4.52 (18.92)	-25.0	-2.00	5.00	8.00	75.0	-0.07 [-0.60, 0.45]
			Irbesartan	36	27 (75.0)	5.63 (11.02)	-21.0	-1.00	5.00	11.00	34.0	
		Week 48	Sparsentan	37	34 (91.9)	3.29 (18.43)	-30.0	-9.00	2.00	11.00	64.0	0.02 [-0.49, 0.54]
			Irbesartan	36	25 (69.4)	2.92 (11.91)	-35.0	0.00	5.00	9.00	25.0	
		Week 70	Sparsentan	37	31 (83.8)	2.06 (12.41)	-20.0	-6.00	1.00	10.00	41.0	0.04 [-0.49, 0.56]
			Irbesartan	36	25 (69.4)	1.68 (8.74)	-20.0	-3.00	3.00	8.00	18.0	
		Week 94	Sparsentan	37	27 (73.0)	-0.41 (19.17)	-61.0	-8.00	1.00	10.00	44.0	-0.34 [-0.89, 0.21]
			Irbesartan	36	25 (69.4)	4.92 (10.55)	-11.0	-2.00	2.00	10.00	32.0	
		Week 110	Sparsentan	37	26 (70.3)	6.85 (21.11)	-30.0	-5.00	4.50	14.00	88.0	0.23 [-0.34, 0.80]
			Irbesartan	36	22 (61.1)	2.95 (9.88)	-13.0	-3.00	4.50	9.00	30.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP Low	EQ-5D VAS	Baseline	Sparsentan	39	38 (97.4)	81.18 (10.21)	50.0	75.00	80.50	90.00	100.0	
			Irbesartan	37	36 (97.3)	80.92 (16.54)	19.0	75.00	84.00	90.00	100.0	
		Week 24	Sparsentan	39	35 (89.7)	87.06 (9.81)	64.0	80.00	89.00	91.00	100.0	
			Irbesartan	37	29 (78.4)	83.24 (15.72)	30.0	80.00	84.00	95.00	100.0	
		Week 48	Sparsentan	39	36 (92.3)	85.22 (11.90)	49.0	80.00	87.50	93.00	100.0	
			Irbesartan	37	28 (75.7)	82.61 (10.87)	60.0	75.00	80.00	90.00	100.0	
		Week 70	Sparsentan	39	33 (84.6)	80.85 (12.53)	27.0	77.00	80.00	90.00	100.0	
			Irbesartan	37	29 (78.4)	86.55 (13.95)	40.0	80.00	86.00	100.00	100.0	
		Week 94	Sparsentan	39	35 (89.7)	82.11 (12.80)	49.0	77.00	82.00	92.00	100.0	
			Irbesartan	37	31 (83.8)	84.58 (12.35)	50.0	80.00	86.00	94.00	100.0	
		Week 110	Sparsentan	39	35 (89.7)	82.49 (10.49)	48.0	78.00	81.00	90.00	98.0	
			Irbesartan	37	29 (78.4)	85.55 (9.54)	60.0	80.00	85.00	92.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	39	35 (89.7)	5.83 (13.10)	-20.0	-1.00	5.00	18.00	29.0	0.25 [-0.24, 0.75]
			Irbesartan	37	29 (78.4)	2.83 (9.93)	-10.0	-4.00	0.00	9.00	30.0	
		Week 48	Sparsentan	39	36 (92.3)	4.58 (11.45)	-29.0	-1.00	3.00	11.50	27.0	0.46 [-0.04, 0.96]
			Irbesartan	37	28 (75.7)	-0.39 (9.73)	-25.0	-5.00	-0.50	5.00	27.0	
		Week 70	Sparsentan	39	33 (84.6)	0.12 (13.85)	-51.0	-7.00	2.00	8.00	25.0	-0.22 [-0.72, 0.28]
			Irbesartan	37	29 (78.4)	2.86 (11.06)	-30.0	-1.00	0.00	10.00	29.0	
		Week 94	Sparsentan	39	35 (89.7)	1.20 (14.13)	-31.0	-7.00	3.00	11.00	30.0	-0.03 [-0.51, 0.45]
			Irbesartan	37	31 (83.8)	1.61 (14.89)	-38.0	-5.00	0.00	10.00	38.0	
		Week 110	Sparsentan	39	35 (89.7)	1.83 (12.47)	-30.0	-4.00	3.00	11.00	30.0	-0.05 [-0.55, 0.44]
			Irbesartan	37	29 (78.4)	2.45 (9.70)	-13.0	-5.00	0.00	9.00	28.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 1												
< 60 mL/min/1.73 m**2	EQ-5D VAS	Baseline	Sparsentan	127	119 (93.7)	80.61 (13.81)	11.0	75.00	81.00	90.00	100.0	
			Irbesartan	129	116 (89.9)	79.86 (13.70)	34.0	75.00	80.00	89.50	100.0	
		Week 24	Sparsentan	127	102 (80.3)	83.27 (10.57)	50.0	78.00	84.00	91.00	100.0	
			Irbesartan	129	89 (69.0)	78.97 (17.68)	4.0	74.00	81.00	90.00	100.0	
		Week 48	Sparsentan	127	99 (78.0)	83.22 (10.65)	49.0	80.00	83.00	91.00	100.0	
			Irbesartan	129	81 (62.8)	81.89 (13.60)	50.0	79.00	83.00	91.00	100.0	
		Week 70	Sparsentan	127	103 (81.1)	81.17 (12.12)	40.0	75.00	82.00	90.00	100.0	
			Irbesartan	129	84 (65.1)	79.49 (16.70)	20.0	74.00	82.50	90.50	100.0	
		Week 94	Sparsentan	127	94 (74.0)	82.18 (12.83)	40.0	77.00	83.00	91.00	100.0	
			Irbesartan	129	82 (63.6)	81.46 (15.20)	34.0	78.00	84.00	90.00	100.0	
		Week 110	Sparsentan	127	93 (73.2)	81.84 (12.27)	48.0	75.00	82.00	90.00	100.0	
			Irbesartan	129	72 (55.8)	79.99 (13.40)	35.0	73.00	81.00	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	127	102 (80.3)	2.09 (12.72)	-31.0	-5.00	0.00	10.00	44.0	0.16 [-0.13, 0.44]
			Irbesartan	129	89 (69.0)	-0.36 (18.30)	-90.0	-6.00	0.00	10.00	52.0	
		Week 48	Sparsentan	127	99 (78.0)	1.72 (13.82)	-29.0	-4.00	0.00	7.00	87.0	-0.13 [-0.43, 0.16]
			Irbesartan	129	81 (62.8)	3.49 (12.90)	-31.0	-1.00	3.00	10.00	43.0	
		Week 70	Sparsentan	127	103 (81.1)	-0.50 (13.73)	-45.0	-9.00	0.00	7.00	59.0	-0.07 [-0.36, 0.21]
			Irbesartan	129	84 (65.1)	0.55 (14.73)	-60.0	-6.00	0.00	8.50	40.0	
		Week 94	Sparsentan	127	94 (74.0)	1.49 (13.42)	-37.0	-4.00	1.00	8.00	45.0	-0.11 [-0.41, 0.18]
			Irbesartan	129	82 (63.6)	3.15 (15.68)	-45.0	-4.00	3.50	10.00	50.0	
		Week 110	Sparsentan	127	93 (73.2)	0.29 (13.79)	-40.0	-5.00	1.00	6.00	70.0	-0.15 [-0.46, 0.16]
			Irbesartan	129	72 (55.8)	2.31 (12.76)	-26.0	-4.50	1.00	10.00	39.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	EQ-5D VAS	Baseline	Sparsentan	49	47 (95.9)	80.83 (16.08)	7.0	75.00	82.00	90.00	100.0	
			Irbesartan	48	44 (91.7)	80.59 (13.76)	37.0	71.50	81.00	90.00	100.0	
		Week 24	Sparsentan	49	40 (81.6)	85.60 (11.14)	60.0	78.00	89.00	93.00	100.0	
			Irbesartan	48	34 (70.8)	85.21 (10.00)	65.0	80.00	84.50	95.00	100.0	
		Week 48	Sparsentan	49	45 (91.8)	83.89 (10.93)	49.0	79.00	85.00	90.00	100.0	
			Irbesartan	48	33 (68.8)	82.12 (13.83)	40.0	75.00	85.00	90.00	100.0	
		Week 70	Sparsentan	49	40 (81.6)	81.73 (13.23)	27.0	75.00	81.00	90.00	100.0	
			Irbesartan	48	32 (66.7)	83.22 (14.99)	40.0	72.50	86.00	95.50	100.0	
		Week 94	Sparsentan	49	41 (83.7)	80.63 (14.95)	34.0	73.00	82.00	92.00	100.0	
			Irbesartan	48	35 (72.9)	82.51 (13.87)	50.0	70.00	85.00	95.00	100.0	
		Week 110	Sparsentan	49	37 (75.5)	82.38 (11.13)	48.0	78.00	82.00	90.00	98.0	
			Irbesartan	48	32 (66.7)	82.59 (11.26)	60.0	78.50	83.00	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	49	40 (81.6)	4.35 (17.11)	-25.0	-2.50	2.00	10.50	75.0	0.09 [-0.37, 0.54]
			Irbesartan	48	34 (70.8)	3.09 (10.97)	-11.0	-4.00	-0.50	9.00	34.0	
		Week 48	Sparsentan	49	45 (91.8)	3.44 (14.86)	-29.0	-4.00	2.00	11.00	64.0	0.14 [-0.31, 0.59]
			Irbesartan	48	33 (68.8)	1.52 (11.56)	-35.0	-5.00	0.00	9.00	25.0	
		Week 70	Sparsentan	49	40 (81.6)	-0.13 (12.99)	-51.0	-6.00	0.00	8.00	23.0	-0.12 [-0.59, 0.34]
			Irbesartan	48	32 (66.7)	1.31 (10.39)	-30.0	-4.00	0.00	10.00	18.0	
		Week 94	Sparsentan	49	41 (83.7)	-1.27 (16.87)	-61.0	-8.00	0.00	10.00	30.0	-0.24 [-0.70, 0.21]
			Irbesartan	48	35 (72.9)	2.40 (12.46)	-33.0	-4.00	0.00	10.00	31.0	
		Week 110	Sparsentan	49	37 (75.5)	2.92 (19.21)	-30.0	-5.00	1.00	9.00	88.0	0.08 [-0.39, 0.55]
			Irbesartan	48	32 (66.7)	1.69 (10.06)	-13.0	-5.00	0.00	8.00	27.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	EQ-5D VAS	Baseline	Sparsentan	26	25 (96.2)	79.20 (13.04)	40.0	71.00	81.00	89.00	97.0	
			Irbesartan	25	24 (96.0)	82.54 (17.58)	19.0	78.00	86.00	92.50	100.0	
		Week 24	Sparsentan	26	22 (84.6)	85.91 (10.32)	60.0	80.00	88.50	91.00	100.0	
			Irbesartan	25	20 (80.0)	83.55 (18.30)	30.0	74.50	90.50	95.50	100.0	
		Week 48	Sparsentan	26	24 (92.3)	82.25 (13.24)	50.0	77.50	84.50	92.00	100.0	
			Irbesartan	25	18 (72.0)	84.39 (10.84)	66.0	75.00	80.50	92.00	100.0	
		Week 70	Sparsentan	26	23 (88.5)	81.39 (7.95)	66.0	77.00	80.00	89.00	95.0	
			Irbesartan	25	20 (80.0)	88.35 (9.39)	70.0	80.50	90.00	97.00	100.0	
		Week 94	Sparsentan	26	21 (80.8)	84.48 (10.47)	50.0	80.00	85.00	90.00	97.0	
			Irbesartan	25	19 (76.0)	86.05 (10.49)	62.0	80.00	90.00	94.00	100.0	
		Week 110	Sparsentan	26	22 (84.6)	84.77 (7.95)	62.0	81.00	84.50	90.00	100.0	
			Irbesartan	25	17 (68.0)	87.94 (8.07)	70.0	84.00	90.00	91.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	26	22 (84.6)	6.23 (14.25)	-20.0	-1.00	5.50	16.00	40.0	0.26 [-0.34, 0.87]
			Irbesartan	25	20 (80.0)	2.90 (10.39)	-21.0	-4.00	2.50	10.50	21.0	
		Week 48	Sparsentan	26	24 (92.3)	3.17 (15.77)	-30.0	-5.50	3.50	10.50	46.0	0.20 [-0.41, 0.81]
			Irbesartan	25	18 (72.0)	0.33 (11.36)	-25.0	-4.00	0.00	5.00	27.0	
		Week 70	Sparsentan	26	23 (88.5)	2.96 (13.77)	-22.0	-6.00	5.00	9.00	41.0	-0.13 [-0.73, 0.47]
			Irbesartan	25	20 (80.0)	4.45 (9.07)	-12.0	-1.00	4.00	10.00	29.0	
		Week 94	Sparsentan	26	21 (80.8)	4.38 (15.59)	-30.0	-4.00	5.00	11.00	44.0	0.17 [-0.45, 0.79]
			Irbesartan	25	19 (76.0)	1.79 (14.48)	-38.0	-3.00	0.00	9.00	38.0	
		Week 110	Sparsentan	26	22 (84.6)	5.09 (13.09)	-19.0	-4.00	5.50	11.00	36.0	0.04 [-0.59, 0.68]
			Irbesartan	25	17 (68.0)	4.59 (8.70)	-7.0	-2.00	5.00	9.00	28.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 2												
< 45 mL/min/1.73 m**2	EQ-5D VAS	Baseline	Sparsentan	82	75 (91.5)	79.11 (15.04)	11.0	71.00	81.00	88.00	100.0	
			Irbesartan	80	70 (87.5)	77.90 (14.78)	34.0	73.00	80.00	85.00	100.0	
		Week 24	Sparsentan	82	64 (78.0)	83.00 (10.89)	50.0	79.00	83.00	90.50	100.0	
			Irbesartan	80	52 (65.0)	75.65 (18.49)	4.0	70.00	80.00	90.00	99.0	
		Week 48	Sparsentan	82	63 (76.8)	83.68 (10.95)	49.0	80.00	84.00	91.00	100.0	
			Irbesartan	80	48 (60.0)	80.73 (14.16)	50.0	79.00	83.00	89.50	100.0	
		Week 70	Sparsentan	82	65 (79.3)	81.11 (13.00)	40.0	75.00	81.00	90.00	100.0	
			Irbesartan	80	50 (62.5)	75.88 (17.61)	20.0	70.00	79.50	89.00	100.0	
		Week 94	Sparsentan	82	61 (74.4)	82.08 (13.61)	40.0	76.00	83.00	91.00	100.0	
			Irbesartan	80	50 (62.5)	78.78 (17.14)	34.0	76.00	81.50	90.00	100.0	
		Week 110	Sparsentan	82	57 (69.5)	81.21 (13.67)	48.0	72.00	82.00	91.00	100.0	
			Irbesartan	80	44 (55.0)	77.16 (14.25)	35.0	71.00	80.00	87.50	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	82	64 (78.0)	3.19 (12.42)	-29.0	-4.50	0.50	10.00	44.0	0.24 [-0.13, 0.60]
			Irbesartan	80	52 (65.0)	-0.52 (18.91)	-71.0	-8.00	0.00	10.00	52.0	
		Week 48	Sparsentan	82	63 (76.8)	4.00 (14.80)	-29.0	-2.00	1.00	7.00	87.0	-0.03 [-0.41, 0.34]
			Irbesartan	80	48 (60.0)	4.50 (14.10)	-31.0	0.00	5.00	10.00	43.0	
		Week 70	Sparsentan	82	65 (79.3)	0.72 (14.75)	-45.0	-7.00	0.00	7.00	59.0	0.11 [-0.26, 0.48]
			Irbesartan	80	50 (62.5)	-1.08 (17.13)	-60.0	-10.00	0.00	8.00	40.0	
		Week 94	Sparsentan	82	61 (74.4)	2.56 (13.69)	-37.0	-3.00	1.00	9.00	45.0	0.02 [-0.35, 0.39]
			Irbesartan	80	50 (62.5)	2.24 (17.85)	-45.0	-6.00	4.50	10.00	50.0	
		Week 110	Sparsentan	82	57 (69.5)	0.72 (15.57)	-40.0	-6.00	1.00	7.00	70.0	-0.10 [-0.49, 0.29]
			Irbesartan	80	44 (55.0)	2.18 (13.55)	-26.0	-4.50	1.00	11.00	39.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
45 to < 60 mL/min/1.73 m**2	EQ-5D VAS	Baseline	Sparsentan	45	44 (97.8)	83.18 (11.11)	50.0	78.50	81.50	91.00	100.0	
			Irbesartan	49	46 (93.9)	82.85 (11.40)	50.0	75.00	82.00	90.00	100.0	
		Week 24	Sparsentan	45	38 (84.4)	83.74 (10.14)	59.0	75.00	86.00	91.00	100.0	
			Irbesartan	49	37 (75.5)	83.62 (15.56)	10.0	80.00	85.00	91.00	100.0	
		Week 48	Sparsentan	45	36 (80.0)	82.42 (10.19)	55.0	76.50	81.00	90.50	100.0	
			Irbesartan	49	33 (67.3)	83.58 (12.75)	51.0	80.00	83.00	94.00	100.0	
		Week 70	Sparsentan	45	38 (84.4)	81.26 (10.59)	60.0	75.00	82.00	90.00	100.0	
			Irbesartan	49	34 (69.4)	84.79 (13.86)	40.0	80.00	90.00	95.00	100.0	
		Week 94	Sparsentan	45	33 (73.3)	82.36 (11.43)	49.0	80.00	85.00	91.00	97.0	
			Irbesartan	49	32 (65.3)	85.66 (10.48)	55.0	80.00	88.50	93.00	100.0	
		Week 110	Sparsentan	45	36 (80.0)	82.83 (9.76)	60.0	75.50	82.00	90.00	100.0	
			Irbesartan	49	28 (57.1)	84.43 (10.75)	55.0	80.00	88.50	91.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	45	38 (84.4)	0.24 (13.17)	-31.0	-9.00	0.00	8.00	35.0	0.02 [-0.43, 0.48]
			Irbesartan	49	37 (75.5)	-0.14 (17.67)	-90.0	-3.00	1.00	9.00	22.0	
		Week 48	Sparsentan	45	36 (80.0)	-2.28 (10.99)	-23.0	-9.50	-1.00	2.00	19.0	-0.39 [-0.87, 0.08]
			Irbesartan	49	33 (67.3)	2.03 (10.98)	-22.0	-5.00	0.00	9.00	37.0	
		Week 70	Sparsentan	45	38 (84.4)	-2.61 (11.69)	-32.0	-12.00	-1.50	7.00	19.0	-0.51 [-0.98, -0.04]
			Irbesartan	49	34 (69.4)	2.94 (10.01)	-15.0	-4.00	1.50	10.00	27.0	
		Week 94	Sparsentan	45	33 (73.3)	-0.48 (12.86)	-31.0	-6.00	1.00	7.00	30.0	-0.41 [-0.90, 0.08]
			Irbesartan	49	32 (65.3)	4.56 (11.66)	-16.0	-2.50	2.50	10.50	32.0	
		Week 110	Sparsentan	45	36 (80.0)	-0.39 (10.54)	-28.0	-4.50	0.00	4.50	22.0	-0.26 [-0.76, 0.23]
			Irbesartan	49	28 (57.1)	2.50 (11.63)	-15.0	-5.50	1.50	8.50	30.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	EQ-5D VAS	Baseline	Sparsentan	49	47 (95.9)	80.83 (16.08)	7.0	75.00	82.00	90.00	100.0	
			Irbesartan	48	44 (91.7)	80.59 (13.76)	37.0	71.50	81.00	90.00	100.0	
		Week 24	Sparsentan	49	40 (81.6)	85.60 (11.14)	60.0	78.00	89.00	93.00	100.0	
			Irbesartan	48	34 (70.8)	85.21 (10.00)	65.0	80.00	84.50	95.00	100.0	
		Week 48	Sparsentan	49	45 (91.8)	83.89 (10.93)	49.0	79.00	85.00	90.00	100.0	
			Irbesartan	48	33 (68.8)	82.12 (13.83)	40.0	75.00	85.00	90.00	100.0	
		Week 70	Sparsentan	49	40 (81.6)	81.73 (13.23)	27.0	75.00	81.00	90.00	100.0	
			Irbesartan	48	32 (66.7)	83.22 (14.99)	40.0	72.50	86.00	95.50	100.0	
		Week 94	Sparsentan	49	41 (83.7)	80.63 (14.95)	34.0	73.00	82.00	92.00	100.0	
			Irbesartan	48	35 (72.9)	82.51 (13.87)	50.0	70.00	85.00	95.00	100.0	
		Week 110	Sparsentan	49	37 (75.5)	82.38 (11.13)	48.0	78.00	82.00	90.00	98.0	
			Irbesartan	48	32 (66.7)	82.59 (11.26)	60.0	78.50	83.00	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	49	40 (81.6)	4.35 (17.11)	-25.0	-2.50	2.00	10.50	75.0	0.09 [-0.37, 0.54]
			Irbesartan	48	34 (70.8)	3.09 (10.97)	-11.0	-4.00	-0.50	9.00	34.0	
		Week 48	Sparsentan	49	45 (91.8)	3.44 (14.86)	-29.0	-4.00	2.00	11.00	64.0	0.14 [-0.31, 0.59]
			Irbesartan	48	33 (68.8)	1.52 (11.56)	-35.0	-5.00	0.00	9.00	25.0	
		Week 70	Sparsentan	49	40 (81.6)	-0.13 (12.99)	-51.0	-6.00	0.00	8.00	23.0	-0.12 [-0.59, 0.34]
			Irbesartan	48	32 (66.7)	1.31 (10.39)	-30.0	-4.00	0.00	10.00	18.0	
		Week 94	Sparsentan	49	41 (83.7)	-1.27 (16.87)	-61.0	-8.00	0.00	10.00	30.0	-0.24 [-0.70, 0.21]
			Irbesartan	48	35 (72.9)	2.40 (12.46)	-33.0	-4.00	0.00	10.00	31.0	
		Week 110	Sparsentan	49	37 (75.5)	2.92 (19.21)	-30.0	-5.00	1.00	9.00	88.0	0.08 [-0.39, 0.55]
			Irbesartan	48	32 (66.7)	1.69 (10.06)	-13.0	-5.00	0.00	8.00	27.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	EQ-5D VAS	Baseline	Sparsentan	26	25 (96.2)	79.20 (13.04)	40.0	71.00	81.00	89.00	97.0	
			Irbesartan	25	24 (96.0)	82.54 (17.58)	19.0	78.00	86.00	92.50	100.0	
		Week 24	Sparsentan	26	22 (84.6)	85.91 (10.32)	60.0	80.00	88.50	91.00	100.0	
			Irbesartan	25	20 (80.0)	83.55 (18.30)	30.0	74.50	90.50	95.50	100.0	
		Week 48	Sparsentan	26	24 (92.3)	82.25 (13.24)	50.0	77.50	84.50	92.00	100.0	
			Irbesartan	25	18 (72.0)	84.39 (10.84)	66.0	75.00	80.50	92.00	100.0	
		Week 70	Sparsentan	26	23 (88.5)	81.39 (7.95)	66.0	77.00	80.00	89.00	95.0	
			Irbesartan	25	20 (80.0)	88.35 (9.39)	70.0	80.50	90.00	97.00	100.0	
		Week 94	Sparsentan	26	21 (80.8)	84.48 (10.47)	50.0	80.00	85.00	90.00	97.0	
			Irbesartan	25	19 (76.0)	86.05 (10.49)	62.0	80.00	90.00	94.00	100.0	
		Week 110	Sparsentan	26	22 (84.6)	84.77 (7.95)	62.0	81.00	84.50	90.00	100.0	
			Irbesartan	25	17 (68.0)	87.94 (8.07)	70.0	84.00	90.00	91.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	26	22 (84.6)	6.23 (14.25)	-20.0	-1.00	5.50	16.00	40.0	0.26 [-0.34, 0.87]
			Irbesartan	25	20 (80.0)	2.90 (10.39)	-21.0	-4.00	2.50	10.50	21.0	
		Week 48	Sparsentan	26	24 (92.3)	3.17 (15.77)	-30.0	-5.50	3.50	10.50	46.0	0.20 [-0.41, 0.81]
			Irbesartan	25	18 (72.0)	0.33 (11.36)	-25.0	-4.00	0.00	5.00	27.0	
		Week 70	Sparsentan	26	23 (88.5)	2.96 (13.77)	-22.0	-6.00	5.00	9.00	41.0	-0.13 [-0.73, 0.47]
			Irbesartan	25	20 (80.0)	4.45 (9.07)	-12.0	-1.00	4.00	10.00	29.0	
		Week 94	Sparsentan	26	21 (80.8)	4.38 (15.59)	-30.0	-4.00	5.00	11.00	44.0	0.17 [-0.45, 0.79]
			Irbesartan	25	19 (76.0)	1.79 (14.48)	-38.0	-3.00	0.00	9.00	38.0	
		Week 110	Sparsentan	26	22 (84.6)	5.09 (13.09)	-19.0	-4.00	5.50	11.00	36.0	0.04 [-0.59, 0.68]
			Irbesartan	25	17 (68.0)	4.59 (8.70)	-7.0	-2.00	5.00	9.00	28.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline urine protein excretion												
<= 1.75 g/day	EQ-5D VAS	Baseline	Sparsentan	98	94 (95.9)	79.36 (16.33)	7.0	73.00	82.00	90.00	100.0	
			Irbesartan	93	83 (89.2)	80.96 (14.54)	19.0	74.00	81.00	90.00	100.0	
		Week 24	Sparsentan	98	84 (85.7)	83.60 (10.74)	51.0	78.00	82.50	90.00	100.0	
			Irbesartan	93	60 (64.5)	83.52 (12.82)	30.0	80.00	84.50	91.00	100.0	
		Week 48	Sparsentan	98	84 (85.7)	83.73 (11.37)	49.0	80.00	85.00	91.00	100.0	
			Irbesartan	93	59 (63.4)	83.44 (10.47)	51.0	79.00	83.00	91.00	100.0	
		Week 70	Sparsentan	98	80 (81.6)	81.61 (12.84)	27.0	75.00	81.50	90.00	100.0	
			Irbesartan	93	62 (66.7)	84.73 (12.72)	40.0	79.00	87.00	94.00	100.0	
		Week 94	Sparsentan	98	80 (81.6)	81.35 (12.79)	40.0	76.00	82.00	90.00	100.0	
			Irbesartan	93	65 (69.9)	85.32 (10.54)	59.0	80.00	88.00	91.00	100.0	
		Week 110	Sparsentan	98	78 (79.6)	80.55 (11.15)	48.0	76.00	81.00	90.00	100.0	
			Irbesartan	93	57 (61.3)	84.02 (10.88)	54.0	79.00	85.00	91.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	98	84 (85.7)	4.61 (15.97)	-25.0	-4.50	1.00	11.50	75.0	0.22 [-0.11, 0.55]
			Irbesartan	93	60 (64.5)	1.62 (8.98)	-20.0	-4.50	0.00	9.00	21.0	
		Week 48	Sparsentan	98	84 (85.7)	4.30 (16.08)	-29.0	-2.00	1.00	10.00	87.0	0.18 [-0.15, 0.51]
			Irbesartan	93	59 (63.4)	1.76 (10.78)	-25.0	-5.00	2.00	9.00	27.0	
		Week 70	Sparsentan	98	80 (81.6)	1.29 (15.19)	-51.0	-6.50	0.50	8.50	59.0	-0.06 [-0.40, 0.27]
			Irbesartan	93	62 (66.7)	2.16 (10.83)	-30.0	-4.00	0.00	10.00	29.0	
		Week 94	Sparsentan	98	80 (81.6)	1.83 (13.70)	-31.0	-7.00	1.00	11.00	40.0	-0.21 [-0.54, 0.12]
			Irbesartan	93	65 (69.9)	4.54 (12.17)	-22.0	-3.00	4.00	10.00	44.0	
		Week 110	Sparsentan	98	78 (79.6)	1.28 (18.13)	-40.0	-7.00	1.00	9.00	88.0	-0.09 [-0.43, 0.26]
			Irbesartan	93	57 (61.3)	2.61 (11.15)	-21.0	-5.00	0.00	11.00	28.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 1.75 g/day	EQ-5D VAS	Baseline	Sparsentan	104	97 (93.3)	81.57 (11.86)	40.0	75.00	81.00	91.00	100.0	
			Irbesartan	109	101 (92.7)	79.91 (14.01)	34.0	75.00	80.00	89.00	100.0	
		Week 24	Sparsentan	104	80 (76.9)	84.83 (10.65)	50.0	78.00	87.00	91.00	100.0	
			Irbesartan	109	83 (76.1)	79.34 (18.47)	4.0	71.00	83.00	91.00	100.0	
		Week 48	Sparsentan	104	84 (80.8)	82.80 (10.80)	50.0	78.50	82.00	90.00	100.0	
			Irbesartan	109	73 (67.0)	81.36 (15.14)	40.0	74.00	83.00	90.00	100.0	
		Week 70	Sparsentan	104	86 (82.7)	81.07 (10.94)	50.0	75.00	81.00	90.00	100.0	
			Irbesartan	109	74 (67.9)	79.11 (17.45)	20.0	71.00	82.50	91.00	100.0	
		Week 94	Sparsentan	104	76 (73.1)	82.86 (13.48)	34.0	79.00	85.50	92.00	100.0	
			Irbesartan	109	71 (65.1)	79.68 (16.64)	34.0	71.00	83.00	90.00	100.0	
		Week 110	Sparsentan	104	74 (71.2)	84.34 (11.52)	50.0	79.00	86.00	92.00	100.0	
			Irbesartan	109	64 (58.7)	79.81 (13.49)	35.0	73.00	81.00	89.50	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	104	80 (76.9)	1.71 (11.74)	-31.0	-3.50	1.00	8.00	40.0	0.08 [-0.23, 0.39]
			Irbesartan	109	83 (76.1)	0.41 (19.47)	-90.0	-5.00	0.00	10.00	52.0	
		Week 48	Sparsentan	104	84 (80.8)	0.48 (12.11)	-30.0	-6.50	0.00	7.00	46.0	-0.21 [-0.53, 0.10]
			Irbesartan	109	73 (67.0)	3.22 (13.53)	-35.0	-1.00	3.00	9.00	43.0	
		Week 70	Sparsentan	104	86 (82.7)	-1.07 (11.76)	-32.0	-10.00	-0.50	6.00	41.0	-0.12 [-0.44, 0.19]
			Irbesartan	109	74 (67.9)	0.58 (14.77)	-60.0	-6.00	0.00	8.00	40.0	
		Week 94	Sparsentan	104	76 (73.1)	0.45 (15.73)	-61.0	-4.00	1.00	8.50	45.0	-0.04 [-0.37, 0.28]
			Irbesartan	109	71 (65.1)	1.14 (16.54)	-45.0	-4.00	0.00	9.00	50.0	
		Week 110	Sparsentan	104	74 (71.2)	1.99 (11.42)	-31.0	-4.00	1.00	9.00	36.0	-0.03 [-0.36, 0.31]
			Irbesartan	109	64 (58.7)	2.33 (11.97)	-26.0	-3.00	1.50	7.50	39.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline use of antihypertensives												
Yes	EQ-5D VAS	Baseline	Sparsentan	90	82 (91.1)	78.51 (16.81)	7.0	71.00	81.00	90.00	100.0	
			Irbesartan	88	78 (88.6)	78.95 (13.71)	37.0	72.00	80.00	90.00	100.0	
		Week 24	Sparsentan	90	71 (78.9)	84.14 (11.19)	50.0	78.00	89.00	90.00	100.0	
			Irbesartan	88	55 (62.5)	80.76 (13.99)	4.0	74.00	81.00	90.00	99.0	
		Week 48	Sparsentan	90	70 (77.8)	82.93 (12.35)	49.0	78.00	84.50	92.00	100.0	
			Irbesartan	88	51 (58.0)	81.51 (12.57)	50.0	75.00	83.00	90.00	100.0	
		Week 70	Sparsentan	90	71 (78.9)	81.13 (11.34)	50.0	75.00	81.00	90.00	100.0	
			Irbesartan	88	52 (59.1)	77.02 (17.68)	20.0	70.00	80.00	89.00	100.0	
		Week 94	Sparsentan	90	67 (74.4)	82.70 (14.05)	40.0	77.00	86.00	92.00	100.0	
			Irbesartan	88	58 (65.9)	82.12 (12.95)	34.0	76.00	84.00	90.00	100.0	
		Week 110	Sparsentan	90	65 (72.2)	82.62 (12.18)	50.0	76.00	83.00	92.00	100.0	
			Irbesartan	88	51 (58.0)	79.98 (10.43)	54.0	71.00	81.00	89.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	90	71 (78.9)	4.99 (15.45)	-29.0	-2.00	6.00	10.00	75.0	0.19 [-0.17, 0.54]
			Irbesartan	88	55 (62.5)	2.00 (16.86)	-71.0	-6.00	0.00	10.00	52.0	
		Week 48	Sparsentan	90	70 (77.8)	4.53 (16.27)	-29.0	-2.00	2.50	7.00	87.0	-0.04 [-0.40, 0.32]
			Irbesartan	88	51 (58.0)	5.06 (12.25)	-19.0	0.00	5.00	10.00	43.0	
		Week 70	Sparsentan	90	71 (78.9)	0.70 (13.82)	-32.0	-9.00	0.00	8.00	59.0	0.09 [-0.27, 0.45]
			Irbesartan	88	52 (59.1)	-0.63 (16.01)	-60.0	-6.00	0.00	8.00	40.0	
		Week 94	Sparsentan	90	67 (74.4)	3.73 (13.74)	-34.0	-4.00	3.00	12.00	45.0	-0.14 [-0.49, 0.22]
			Irbesartan	88	58 (65.9)	5.76 (15.99)	-41.0	-4.00	5.00	12.00	50.0	
		Week 110	Sparsentan	90	65 (72.2)	3.72 (18.35)	-31.0	-4.00	1.00	10.00	88.0	-0.00 [-0.37, 0.37]
			Irbesartan	88	51 (58.0)	3.73 (12.40)	-23.0	-4.00	1.00	11.00	39.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	EQ-5D VAS	Baseline	Sparsentan	112	109 (97.3)	81.96 (11.82)	40.0	78.00	82.00	90.00	100.0	
			Irbesartan	114	106 (93.0)	81.44 (14.55)	19.0	75.00	83.00	90.00	100.0	
		Week 24	Sparsentan	112	93 (83.0)	84.24 (10.34)	59.0	78.00	84.00	91.00	100.0	
			Irbesartan	114	88 (77.2)	81.30 (17.84)	10.0	78.50	85.00	92.50	100.0	
		Week 48	Sparsentan	112	98 (87.5)	83.50 (10.11)	49.0	80.00	83.50	90.00	100.0	
			Irbesartan	114	81 (71.1)	82.78 (13.72)	40.0	79.00	83.00	92.00	100.0	
		Week 70	Sparsentan	112	95 (84.8)	81.48 (12.29)	27.0	75.00	82.00	90.00	100.0	
			Irbesartan	114	84 (73.7)	84.55 (13.62)	35.0	79.00	86.50	95.00	100.0	
		Week 94	Sparsentan	112	89 (79.5)	81.62 (12.41)	34.0	80.00	83.00	90.00	100.0	
			Irbesartan	114	78 (68.4)	82.56 (15.29)	39.0	78.00	85.00	95.00	100.0	
		Week 110	Sparsentan	112	87 (77.7)	82.23 (10.94)	48.0	78.00	82.00	90.00	100.0	
			Irbesartan	114	70 (61.4)	83.11 (13.67)	35.0	79.00	85.00	91.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	112	93 (83.0)	1.83 (12.89)	-31.0	-4.00	0.00	8.00	40.0	0.11 [-0.18, 0.40]
			Irbesartan	114	88 (77.2)	0.24 (15.32)	-90.0	-4.00	0.00	9.50	23.0	
		Week 48	Sparsentan	112	98 (87.5)	0.86 (12.61)	-30.0	-6.00	0.00	10.00	46.0	-0.01 [-0.31, 0.28]
			Irbesartan	114	81 (71.1)	1.00 (12.23)	-35.0	-5.00	1.00	8.00	38.0	
		Week 70	Sparsentan	112	95 (84.8)	-0.41 (13.37)	-51.0	-7.00	0.00	8.00	41.0	-0.24 [-0.53, 0.06]
			Irbesartan	114	84 (73.7)	2.50 (10.85)	-20.0	-3.50	1.00	10.00	40.0	
		Week 94	Sparsentan	112	89 (79.5)	-0.79 (15.16)	-61.0	-7.00	0.00	5.00	44.0	-0.09 [-0.40, 0.21]
			Irbesartan	114	78 (68.4)	0.54 (13.26)	-45.0	-6.00	0.00	10.00	38.0	
		Week 110	Sparsentan	112	87 (77.7)	0.06 (12.20)	-40.0	-6.00	0.00	6.00	36.0	-0.13 [-0.44, 0.19]
			Irbesartan	114	70 (61.4)	1.54 (10.89)	-26.0	-5.00	0.00	7.00	34.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Time since renal biopsy												
<= 5 years	EQ-5D VAS	Baseline	Sparsentan	113	107 (94.7)	80.36 (13.96)	11.0	74.00	81.00	90.00	100.0	
			Irbesartan	127	119 (93.7)	80.84 (14.67)	19.0	75.00	80.00	90.00	100.0	
		Week 24	Sparsentan	113	94 (83.2)	84.89 (11.18)	50.0	78.00	89.00	91.00	100.0	
			Irbesartan	127	94 (74.0)	81.62 (17.02)	4.0	79.00	85.00	91.00	100.0	
		Week 48	Sparsentan	113	95 (84.1)	82.75 (12.19)	49.0	78.00	85.00	91.00	100.0	
			Irbesartan	127	89 (70.1)	82.17 (13.77)	40.0	75.00	83.00	90.00	100.0	
		Week 70	Sparsentan	113	94 (83.2)	80.60 (12.80)	27.0	75.00	81.00	90.00	100.0	
			Irbesartan	127	89 (70.1)	83.22 (15.92)	20.0	78.00	86.00	94.00	100.0	
		Week 94	Sparsentan	113	89 (78.8)	82.54 (13.49)	40.0	78.00	85.00	91.00	100.0	
			Irbesartan	127	89 (70.1)	83.28 (13.88)	34.0	79.00	85.00	91.00	100.0	
		Week 110	Sparsentan	113	89 (78.8)	83.71 (10.96)	48.0	79.00	84.00	91.00	100.0	
			Irbesartan	127	80 (63.0)	83.66 (11.17)	40.0	79.00	84.50	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	113	94 (83.2)	4.23 (13.03)	-29.0	-3.00	3.50	10.00	40.0	0.24 [-0.05, 0.53]
			Irbesartan	127	94 (74.0)	0.54 (17.30)	-90.0	-5.00	0.00	10.00	52.0	
		Week 48	Sparsentan	113	95 (84.1)	2.26 (15.11)	-30.0	-6.00	1.00	10.00	87.0	0.06 [-0.23, 0.35]
			Irbesartan	127	89 (70.1)	1.40 (13.55)	-35.0	-5.00	1.00	9.00	43.0	
		Week 70	Sparsentan	113	94 (83.2)	-0.65 (15.32)	-51.0	-10.00	0.00	8.00	59.0	-0.19 [-0.48, 0.10]
			Irbesartan	127	89 (70.1)	2.19 (14.70)	-60.0	-4.00	2.00	10.00	40.0	
		Week 94	Sparsentan	113	89 (78.8)	2.34 (14.22)	-34.0	-5.00	2.00	11.00	45.0	-0.05 [-0.34, 0.25]
			Irbesartan	127	89 (70.1)	3.03 (14.89)	-41.0	-4.00	1.00	10.00	50.0	
		Week 110	Sparsentan	113	89 (78.8)	3.28 (14.13)	-30.0	-4.00	2.00	11.00	70.0	-0.04 [-0.34, 0.27]
			Irbesartan	127	80 (63.0)	3.75 (11.11)	-19.0	-3.50	2.00	10.00	39.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 5 years	EQ-5D VAS	Baseline	Sparsentan	89	84 (94.4)	80.63 (14.68)	7.0	77.50	82.00	90.00	100.0	
			Irbesartan	75	65 (86.7)	79.55 (13.43)	34.0	73.00	80.00	89.00	100.0	
		Week 24	Sparsentan	89	70 (78.7)	83.26 (9.98)	59.0	78.00	82.00	90.00	100.0	
			Irbesartan	75	49 (65.3)	80.08 (15.31)	31.0	73.00	81.00	90.00	100.0	
		Week 48	Sparsentan	89	73 (82.0)	83.93 (9.44)	51.0	80.00	83.00	90.00	100.0	
			Irbesartan	75	43 (57.3)	82.53 (12.27)	50.0	79.00	85.00	91.00	100.0	
		Week 70	Sparsentan	89	72 (80.9)	82.29 (10.52)	59.0	75.00	82.50	90.00	100.0	
			Irbesartan	75	47 (62.7)	78.72 (14.91)	35.0	70.00	82.00	90.00	100.0	
		Week 94	Sparsentan	89	67 (75.3)	81.48 (12.66)	34.0	77.00	82.00	90.00	100.0	
			Irbesartan	75	47 (62.7)	80.66 (15.04)	39.0	72.00	84.00	91.00	100.0	
		Week 110	Sparsentan	89	63 (70.8)	80.54 (11.96)	48.0	75.00	81.00	90.00	100.0	
			Irbesartan	75	41 (54.7)	78.15 (14.10)	35.0	71.00	81.00	89.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	89	70 (78.7)	1.80 (15.40)	-31.0	-6.00	0.00	8.00	75.0	0.01 [-0.35, 0.38]
			Irbesartan	75	49 (65.3)	1.63 (12.93)	-42.0	-2.00	1.00	9.00	34.0	
		Week 48	Sparsentan	89	73 (82.0)	2.55 (13.33)	-22.0	-4.00	0.00	7.00	64.0	-0.20 [-0.58, 0.17]
			Irbesartan	75	43 (57.3)	4.98 (9.05)	-20.0	-1.00	5.00	10.00	25.0	
		Week 70	Sparsentan	89	72 (80.9)	1.00 (10.80)	-20.0	-6.00	0.00	8.00	40.0	0.14 [-0.23, 0.50]
			Irbesartan	75	47 (62.7)	-0.38 (9.27)	-18.0	-9.00	0.00	5.00	21.0	
		Week 94	Sparsentan	89	67 (75.3)	-0.42 (15.26)	-61.0	-7.00	1.00	8.00	40.0	-0.18 [-0.55, 0.19]
			Irbesartan	75	47 (62.7)	2.26 (14.35)	-45.0	-7.00	4.00	10.00	32.0	
		Week 110	Sparsentan	89	63 (70.8)	-0.71 (16.41)	-40.0	-7.00	0.00	6.00	88.0	-0.04 [-0.44, 0.35]
			Irbesartan	75	41 (54.7)	-0.05 (12.11)	-26.0	-9.00	0.00	5.00	30.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: History of hypertension												
Yes	EQ-5D VAS	Baseline	Sparsentan	155	145 (93.5)	80.06 (13.64)	11.0	71.00	81.00	90.00	100.0	
			Irbesartan	161	144 (89.4)	79.76 (14.12)	34.0	74.00	80.00	90.00	100.0	
		Week 24	Sparsentan	155	125 (80.6)	84.22 (10.79)	50.0	78.00	86.00	91.00	100.0	
			Irbesartan	161	111 (68.9)	80.56 (16.66)	4.0	74.00	83.00	91.00	100.0	
		Week 48	Sparsentan	155	126 (81.3)	83.26 (11.39)	49.0	79.00	84.00	91.00	100.0	
			Irbesartan	161	102 (63.4)	81.80 (13.68)	40.0	75.00	83.50	90.00	100.0	
		Week 70	Sparsentan	155	128 (82.6)	81.56 (11.55)	40.0	75.00	81.00	90.00	100.0	
			Irbesartan	161	105 (65.2)	80.21 (16.58)	20.0	74.00	84.00	92.00	100.0	
		Week 94	Sparsentan	155	119 (76.8)	81.93 (13.39)	34.0	78.00	83.00	91.00	100.0	
			Irbesartan	161	105 (65.2)	81.75 (14.26)	34.0	76.00	84.00	90.00	100.0	
		Week 110	Sparsentan	155	114 (73.5)	82.32 (11.17)	50.0	76.00	82.00	90.00	100.0	
			Irbesartan	161	92 (57.1)	80.75 (12.67)	35.0	75.00	82.00	90.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	155	125 (80.6)	3.39 (12.67)	-29.0	-4.00	2.00	10.00	44.0	0.15 [-0.10, 0.41]
			Irbesartan	161	111 (68.9)	1.12 (16.99)	-90.0	-5.00	0.00	10.00	52.0	
		Week 48	Sparsentan	155	126 (81.3)	2.89 (13.83)	-30.0	-2.00	1.00	10.00	87.0	-0.05 [-0.31, 0.21]
			Irbesartan	161	102 (63.4)	3.51 (12.63)	-35.0	-1.00	3.00	10.00	43.0	
		Week 70	Sparsentan	155	128 (82.6)	0.94 (13.18)	-45.0	-7.50	0.00	8.50	59.0	-0.04 [-0.30, 0.22]
			Irbesartan	161	105 (65.2)	1.50 (14.04)	-60.0	-5.00	0.00	10.00	40.0	
		Week 94	Sparsentan	155	119 (76.8)	1.73 (15.23)	-61.0	-4.00	2.00	11.00	45.0	-0.14 [-0.40, 0.12]
			Irbesartan	161	105 (65.2)	3.85 (14.73)	-41.0	-4.00	3.00	10.00	50.0	
		Week 110	Sparsentan	155	114 (73.5)	1.72 (13.32)	-31.0	-5.00	1.00	9.00	70.0	-0.11 [-0.39, 0.16]
			Irbesartan	161	92 (57.1)	3.16 (12.15)	-26.0	-4.00	1.00	10.50	39.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSHM: Course of EQ-5D VAS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	EQ-5D VAS	Baseline	Sparsentan	47	46 (97.9)	81.80 (16.09)	7.0	80.00	83.50	90.00	100.0	
			Irbesartan	41	40 (97.6)	82.65 (14.53)	19.0	75.00	85.00	90.50	100.0	
		Week 24	Sparsentan	47	39 (83.0)	84.10 (10.45)	59.0	78.00	86.00	90.00	100.0	
			Irbesartan	41	32 (78.0)	82.94 (15.65)	30.0	80.00	85.00	93.00	100.0	
		Week 48	Sparsentan	47	42 (89.4)	83.26 (10.15)	49.0	80.00	84.50	90.00	100.0	
			Irbesartan	41	30 (73.2)	83.93 (11.75)	54.0	79.00	83.00	92.00	100.0	
		Week 70	Sparsentan	47	38 (80.9)	80.55 (12.99)	27.0	74.00	80.00	90.00	96.0	
			Irbesartan	41	31 (75.6)	86.61 (10.92)	55.0	80.00	88.00	96.00	100.0	
		Week 94	Sparsentan	47	37 (78.7)	82.57 (12.32)	40.0	78.00	85.00	91.00	97.0	
			Irbesartan	41	31 (75.6)	84.48 (14.42)	40.0	80.00	86.00	95.00	100.0	
		Week 110	Sparsentan	47	38 (80.9)	82.61 (12.42)	48.0	80.00	82.50	90.00	99.0	
			Irbesartan	41	29 (70.7)	85.10 (11.34)	55.0	80.00	88.00	92.00	100.0	
	Change from baseline in EQ-5D VAS	Week 24	Sparsentan	47	39 (83.0)	2.56 (18.11)	-31.0	-6.00	0.00	10.00	75.0	0.15 [-0.32, 0.62]
			Irbesartan	41	32 (78.0)	0.22 (11.51)	-37.0	-4.00	0.00	9.00	22.0	
		Week 48	Sparsentan	47	42 (89.4)	0.88 (15.78)	-29.0	-8.00	-1.00	6.00	64.0	0.11 [-0.36, 0.58]
			Irbesartan	41	30 (73.2)	-0.63 (10.96)	-31.0	-5.00	0.00	7.00	19.0	
		Week 70	Sparsentan	47	38 (80.9)	-2.87 (14.47)	-51.0	-9.00	-0.50	4.00	41.0	-0.28 [-0.76, 0.19]
			Irbesartan	41	31 (75.6)	0.65 (9.38)	-18.0	-6.00	0.00	10.00	21.0	
		Week 94	Sparsentan	47	37 (78.7)	-0.70 (12.82)	-28.0	-8.00	-1.00	5.00	44.0	0.01 [-0.46, 0.49]
			Irbesartan	41	31 (75.6)	-0.90 (14.03)	-45.0	-6.00	1.00	10.00	20.0	
		Week 110	Sparsentan	47	38 (80.9)	1.34 (20.01)	-40.0	-6.00	0.00	7.00	88.0	0.07 [-0.42, 0.55]
			Irbesartan	41	29 (70.7)	0.24 (9.22)	-21.0	-5.00	0.00	5.00	21.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analogue scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Sex	Overall	Sparsentan						Interaction:	0.559
Male	Week 24	Sparsentan	139	114 (82.0)	3.13 (1.04)	(1.08, 5.17)	2.84 (1.51)	(-0.13, 5.80)	0.061
		Irbesartan	143	103 (72.0)	0.29 (1.09)	(-1.86, 2.44)			
	Week 48	Sparsentan	139	118 (84.9)	2.41 (1.02)	(0.40, 4.42)	-0.28 (1.52)	(-3.26, 2.71)	0.854
		Irbesartan	143	94 (65.7)	2.69 (1.12)	(0.49, 4.89)			
	Week 70	Sparsentan	139	119 (85.6)	0.42 (1.02)	(-1.59, 2.43)	-2.15 (1.52)	(-5.13, 0.83)	0.158
		Irbesartan	143	97 (67.8)	2.57 (1.12)	(0.37, 4.77)			
	Week 94	Sparsentan	139	109 (78.4)	2.26 (1.06)	(0.19, 4.34)	-1.01 (1.54)	(-4.03, 2.01)	0.512
		Irbesartan	143	99 (69.2)	3.27 (1.12)	(1.08, 5.46)			
	Week 110	Sparsentan	139	106 (76.3)	1.72 (1.08)	(-0.40, 3.84)	-0.62 (1.60)	(-3.76, 2.51)	0.695
		Irbesartan	143	89 (62.2)	2.34 (1.17)	(0.04, 4.64)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. VAS = visual analouge scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Female	Week 24	Sparsentan	63	50 (79.4)	3.74 (1.71)	(0.37, 7.11)	1.56 (2.58)	(-3.51, 6.63)	0.546
		Irbesartan	59	40 (67.8)	2.18 (1.92)	(-1.59, 5.96)			
	Week 48	Sparsentan	63	50 (79.4)	2.27 (1.71)	(-1.09, 5.63)	1.02 (2.59)	(-4.08, 6.12)	0.694
		Irbesartan	59	38 (64.4)	1.25 (1.95)	(-2.58, 5.08)			
	Week 70	Sparsentan	63	47 (74.6)	0.45 (1.75)	(-2.99, 3.90)	1.75 (2.62)	(-3.40, 6.90)	0.504
		Irbesartan	59	39 (66.1)	-1.30 (1.94)	(-5.11, 2.52)			
	Week 94	Sparsentan	63	47 (74.6)	-0.88 (1.76)	(-4.34, 2.58)	-0.79 (2.66)	(-6.02, 4.43)	0.765
		Irbesartan	59	37 (62.7)	-0.09 (1.99)	(-4.00, 3.82)			
	Week 110	Sparsentan	63	46 (73.0)	1.04 (1.79)	(-2.48, 4.56)	0.34 (2.79)	(-5.14, 5.82)	0.902
		Irbesartan	59	32 (54.2)	0.70 (2.13)	(-3.49, 4.88)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. VAS = visual analouge scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age	Overall	Sparsentan						Interaction:	0.172
<= 45 years	Week 24	Sparsentan	96	75 (78.1)	3.58 (1.41)	(0.80, 6.36)	4.15 (2.03)	(0.17, 8.13)	0.041 *
		Irbesartan	99	72 (72.7)	-0.57 (1.45)	(-3.41, 2.27)			
	Week 48	Sparsentan	96	79 (82.3)	2.38 (1.38)	(-0.33, 5.09)	2.35 (2.04)	(-1.67, 6.36)	0.251
		Irbesartan	99	63 (63.6)	0.04 (1.51)	(-2.92, 2.99)			
	Week 70	Sparsentan	96	76 (79.2)	1.03 (1.40)	(-1.72, 3.79)	0.30 (2.06)	(-3.75, 4.35)	0.886
		Irbesartan	99	64 (64.6)	0.74 (1.51)	(-2.23, 3.71)			
	Week 94	Sparsentan	96	71 (74.0)	0.01 (1.44)	(-2.82, 2.83)	0.38 (2.09)	(-3.72, 4.47)	0.857
		Irbesartan	99	65 (65.7)	-0.37 (1.51)	(-3.34, 2.60)			
	Week 110	Sparsentan	96	71 (74.0)	1.70 (1.46)	(-1.16, 4.55)	0.50 (2.15)	(-3.72, 4.72)	0.817
		Irbesartan	99	59 (59.6)	1.20 (1.58)	(-1.91, 4.30)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. VAS = visual analouge scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 45 years	Week 24	Sparsentan	106	89 (84.0)	3.17 (1.15)	(0.91, 5.43)	1.24 (1.73)	(-2.16, 4.64)	0.474
		Irbesartan	103	71 (68.9)	1.93 (1.29)	(-0.60, 4.45)			
	Week 48	Sparsentan	106	89 (84.0)	2.49 (1.15)	(0.24, 4.74)	-1.59 (1.73)	(-4.98, 1.81)	0.359
		Irbesartan	103	69 (67.0)	4.08 (1.29)	(1.54, 6.61)			
	Week 70	Sparsentan	106	90 (84.9)	0.03 (1.15)	(-2.22, 2.28)	-1.68 (1.72)	(-5.06, 1.69)	0.327
		Irbesartan	103	72 (69.9)	1.72 (1.27)	(-0.78, 4.22)			
	Week 94	Sparsentan	106	85 (80.2)	2.53 (1.17)	(0.23, 4.84)	-1.87 (1.74)	(-5.29, 1.56)	0.285
		Irbesartan	103	71 (68.9)	4.40 (1.29)	(1.87, 6.93)			
	Week 110	Sparsentan	106	81 (76.4)	1.57 (1.20)	(-0.80, 3.93)	-0.49 (1.83)	(-4.08, 3.10)	0.790
		Irbesartan	103	62 (60.2)	2.05 (1.37)	(-0.64, 4.75)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. VAS = visual analouge scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age at IgAN diagnosis	Overall	Sparsentan						Interaction:	0.066
<= 18 years	Week 24	Sparsentan	9	5 (55.6)	8.76 (7.92)	(-8.27, 25.80)	13.61 (12.32)	(-13.61, 40.83)	0.294
		Irbesartan	5	5 (100.0)	-4.85 (8.91)	(-24.81, 15.12)			
	Week 48	Sparsentan	9	7 (77.8)	7.82 (7.16)	(-8.03, 23.68)	9.95 (12.36)	(-17.22, 37.13)	0.438
		Irbesartan	5	3 (60.0)	-2.13 (9.65)	(-23.06, 18.80)			
	Week 70	Sparsentan	9	7 (77.8)	7.75 (7.29)	(-8.35, 23.85)	8.48 (12.35)	(-18.78, 35.74)	0.507
		Irbesartan	5	4 (80.0)	-0.73 (9.48)	(-21.52, 20.06)			
	Week 94	Sparsentan	9	5 (55.6)	-7.08 (7.93)	(-24.16, 10.01)	-5.35 (13.04)	(-33.77, 23.07)	0.689
		Irbesartan	5	4 (80.0)	-1.73 (9.81)	(-23.16, 19.71)			
	Week 110	Sparsentan	9	4 (44.4)	7.32 (8.70)	(-11.15, 25.79)	11.92 (14.91)	(-19.68, 43.51)	0.436
		Irbesartan	5	2 (40.0)	-4.59 (11.78)	(-29.37, 20.19)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. VAS = visual analouge scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 18 to 40 years	Week 24	Sparsentan	102	82 (80.4)	3.71 (1.30)	(1.16, 6.26)	3.60 (1.87)	(-0.08, 7.28)	0.055
		Irbesartan	109	75 (68.8)	0.11 (1.35)	(-2.54, 2.77)			
	Week 48	Sparsentan	102	85 (83.3)	2.56 (1.28)	(0.05, 5.07)	2.18 (1.88)	(-1.51, 5.88)	0.247
		Irbesartan	109	69 (63.3)	0.38 (1.38)	(-2.33, 3.09)			
	Week 70	Sparsentan	102	81 (79.4)	1.11 (1.30)	(-1.44, 3.67)	-0.21 (1.90)	(-3.93, 3.52)	0.914
		Irbesartan	109	71 (65.1)	1.32 (1.38)	(-1.39, 4.03)			
	Week 94	Sparsentan	102	77 (75.5)	1.68 (1.33)	(-0.93, 4.28)	1.76 (1.92)	(-2.01, 5.53)	0.360
		Irbesartan	109	71 (65.1)	-0.09 (1.39)	(-2.81, 2.64)			
	Week 110	Sparsentan	102	75 (73.5)	1.73 (1.36)	(-0.93, 4.39)	0.53 (1.98)	(-3.37, 4.42)	0.789
		Irbesartan	109	65 (59.6)	1.20 (1.44)	(-1.64, 4.04)			
> 40 years	Week 24	Sparsentan	91	77 (84.6)	2.76 (1.24)	(0.32, 5.21)	1.14 (1.86)	(-2.51, 4.78)	0.540
		Irbesartan	88	63 (71.6)	1.63 (1.37)	(-1.07, 4.32)			
	Week 48	Sparsentan	91	76 (83.5)	2.14 (1.25)	(-0.30, 4.59)	-2.08 (1.87)	(-5.76, 1.60)	0.267
		Irbesartan	88	60 (68.2)	4.23 (1.40)	(1.48, 6.97)			
	Week 70	Sparsentan	91	78 (85.7)	-0.53 (1.24)	(-2.96, 1.90)	-1.79 (1.86)	(-5.46, 1.87)	0.337
		Irbesartan	88	61 (69.3)	1.26 (1.39)	(-1.47, 4.00)			
	Week 94	Sparsentan	91	74 (81.3)	1.80 (1.26)	(-0.68, 4.28)	-3.13 (1.89)	(-6.84, 0.58)	0.098
		Irbesartan	88	61 (69.3)	4.93 (1.40)	(2.19, 7.67)			
	Week 110	Sparsentan	91	73 (80.2)	1.42 (1.28)	(-1.09, 3.92)	-1.09 (1.96)	(-4.94, 2.76)	0.579
		Irbesartan	88	54 (61.4)	2.50 (1.48)	(-0.41, 5.42)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. VAS = visual analouge scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Geographic region	Overall	Sparsentan						Interaction:	0.854
North America	Week 24	Sparsentan	35	24 (68.6)	3.98 (2.61)	(-1.17, 9.13)	6.38 (3.36)	(-0.24, 13.00)	0.059
		Irbesartan	46	38 (82.6)	-2.40 (2.10)	(-6.54, 1.75)			
	Week 48	Sparsentan	35	26 (74.3)	3.58 (2.52)	(-1.40, 8.56)	0.40 (3.32)	(-6.15, 6.95)	0.904
		Irbesartan	46	35 (76.1)	3.18 (2.15)	(-1.06, 7.42)			
	Week 70	Sparsentan	35	24 (68.6)	1.47 (2.60)	(-3.66, 6.59)	-1.46 (3.42)	(-8.22, 5.29)	0.669
		Irbesartan	46	32 (69.6)	2.93 (2.23)	(-1.47, 7.33)			
	Week 94	Sparsentan	35	24 (68.6)	1.33 (2.62)	(-3.83, 6.50)	-0.36 (3.50)	(-7.26, 6.54)	0.918
		Irbesartan	46	30 (65.2)	1.69 (2.31)	(-2.87, 6.26)			
	Week 110	Sparsentan	35	21 (60.0)	4.17 (2.78)	(-1.32, 9.66)	1.59 (3.63)	(-5.58, 8.75)	0.663
		Irbesartan	46	31 (67.4)	2.58 (2.33)	(-2.02, 7.18)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. VAS = visual analouge scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Europe	Week 24	Sparsentan	98	79 (80.6)	2.23 (1.32)	(-0.36, 4.81)	0.87 (1.93)	(-2.93, 4.67)	0.653
		Irbesartan	115	68 (59.1)	1.36 (1.42)	(-1.43, 4.14)			
	Week 48	Sparsentan	98	79 (80.6)	3.54 (1.31)	(0.96, 6.12)	1.84 (1.96)	(-2.01, 5.69)	0.349
		Irbesartan	115	62 (53.9)	1.70 (1.46)	(-1.17, 4.56)			
	Week 70	Sparsentan	98	78 (79.6)	0.63 (1.33)	(-1.98, 3.24)	1.11 (1.92)	(-2.65, 4.88)	0.561
		Irbesartan	115	72 (62.6)	-0.49 (1.38)	(-3.19, 2.22)			
	Week 94	Sparsentan	98	72 (73.5)	1.10 (1.37)	(-1.59, 3.80)	-0.65 (1.94)	(-4.46, 3.16)	0.737
		Irbesartan	115	73 (63.5)	1.75 (1.37)	(-0.94, 4.45)			
	Week 110	Sparsentan	98	70 (71.4)	1.36 (1.40)	(-1.39, 4.10)	1.30 (2.04)	(-2.71, 5.31)	0.524
		Irbesartan	115	61 (53.0)	0.05 (1.49)	(-2.86, 2.97)			
Asia Pacific	Week 24	Sparsentan	69	61 (88.4)	4.97 (1.35)	(2.32, 7.62)	3.29 (2.20)	(-1.04, 7.62)	0.136
		Irbesartan	41	37 (90.2)	1.68 (1.74)	(-1.74, 5.09)			
	Week 48	Sparsentan	69	63 (91.3)	1.03 (1.33)	(-1.58, 3.64)	-0.09 (2.21)	(-4.45, 4.26)	0.966
		Irbesartan	41	35 (85.4)	1.12 (1.76)	(-2.35, 4.59)			
	Week 70	Sparsentan	69	64 (92.8)	0.42 (1.32)	(-2.18, 3.02)	-2.14 (2.27)	(-6.60, 2.32)	0.346
		Irbesartan	41	32 (78.0)	2.56 (1.83)	(-1.05, 6.17)			
	Week 94	Sparsentan	69	60 (87.0)	2.39 (1.35)	(-0.27, 5.04)	-0.06 (2.28)	(-4.56, 4.43)	0.978
		Irbesartan	41	33 (80.5)	2.45 (1.84)	(-1.17, 6.06)			
	Week 110	Sparsentan	69	61 (88.4)	1.79 (1.35)	(-0.87, 4.45)	-1.45 (2.36)	(-6.10, 3.20)	0.539
		Irbesartan	41	29 (70.7)	3.25 (1.93)	(-0.56, 7.05)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. VAS = visual analouge scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline BMI	Overall	Sparsentan						Interaction:	0.346
< 27 kg/m**2	Week 24	Sparsentan	83	68 (81.9)	1.90 (1.37)	(-0.79, 4.58)	1.17 (1.92)	(-2.60, 4.93)	0.543
		Irbesartan	94	72 (76.6)	0.73 (1.34)	(-1.89, 3.36)			
	Week 48	Sparsentan	83	69 (83.1)	0.21 (1.36)	(-2.46, 2.88)	-0.60 (1.96)	(-4.45, 3.25)	0.759
		Irbesartan	94	63 (67.0)	0.81 (1.40)	(-1.95, 3.56)			
	Week 70	Sparsentan	83	68 (81.9)	-1.50 (1.37)	(-4.19, 1.20)	-0.98 (1.97)	(-4.86, 2.89)	0.618
		Irbesartan	94	63 (67.0)	-0.51 (1.41)	(-3.29, 2.26)			
	Week 94	Sparsentan	83	65 (78.3)	-1.06 (1.40)	(-3.80, 1.69)	-1.48 (1.98)	(-5.38, 2.42)	0.456
		Irbesartan	94	65 (69.1)	0.43 (1.40)	(-2.33, 3.18)			
	Week 110	Sparsentan	83	64 (77.1)	0.01 (1.41)	(-2.77, 2.78)	0.89 (2.05)	(-3.15, 4.93)	0.665
		Irbesartan	94	57 (60.6)	-0.88 (1.49)	(-3.81, 2.04)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. VAS = visual analouge scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
>= 27 kg/m**2	Week 24	Sparsentan	119	96 (80.7)	4.69 (1.19)	(2.35, 7.03)	4.73 (1.83)	(1.13, 8.33)	0.010 *
		Irbesartan	107	71 (66.4)	-0.03 (1.39)	(-2.75, 2.69)			
	Week 48	Sparsentan	119	99 (83.2)	4.37 (1.17)	(2.06, 6.67)	1.67 (1.82)	(-1.91, 5.24)	0.360
		Irbesartan	107	69 (64.5)	2.70 (1.38)	(-0.02, 5.42)			
	Week 70	Sparsentan	119	98 (82.4)	2.26 (1.18)	(-0.06, 4.59)	0.06 (1.81)	(-3.50, 3.62)	0.972
		Irbesartan	107	73 (68.2)	2.20 (1.37)	(-0.48, 4.88)			
	Week 94	Sparsentan	119	91 (76.5)	3.47 (1.22)	(1.08, 5.86)	0.58 (1.85)	(-3.06, 4.22)	0.753
		Irbesartan	107	70 (65.4)	2.89 (1.39)	(0.15, 5.62)			
	Week 110	Sparsentan	119	88 (73.9)	3.07 (1.24)	(0.63, 5.52)	-0.53 (1.92)	(-4.31, 3.25)	0.782
		Irbesartan	107	63 (58.9)	3.61 (1.46)	(0.74, 6.48)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. VAS = visual analouge scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Randomization strata	Overall	Sparsentan						Interaction:	0.880
eGFR Low and UP High	Week 24	Sparsentan	71	54 (76.1)	1.67 (1.71)	(-1.69, 5.03)	5.41 (2.51)	(0.48, 10.34)	0.032 *
		Irbesartan	74	47 (63.5)	-3.74 (1.83)	(-7.33, -0.14)			
	Week 48	Sparsentan	71	55 (77.5)	1.12 (1.68)	(-2.19, 4.43)	-1.73 (2.55)	(-6.75, 3.29)	0.498
		Irbesartan	74	41 (55.4)	2.85 (1.90)	(-0.90, 6.59)			
	Week 70	Sparsentan	71	58 (81.7)	-1.93 (1.66)	(-5.20, 1.34)	-1.26 (2.56)	(-6.29, 3.77)	0.622
		Irbesartan	74	41 (55.4)	-0.66 (1.93)	(-4.46, 3.13)			
	Week 94	Sparsentan	71	52 (73.2)	0.77 (1.72)	(-2.62, 4.15)	0.04 (2.63)	(-5.13, 5.21)	0.987
		Irbesartan	74	40 (54.1)	0.72 (1.97)	(-3.15, 4.60)			
	Week 110	Sparsentan	71	53 (74.6)	0.12 (1.73)	(-3.29, 3.52)	-0.31 (2.72)	(-5.66, 5.04)	0.909
		Irbesartan	74	36 (48.6)	0.43 (2.08)	(-3.66, 4.52)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. VAS = visual analouge scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
eGFR Low and UP Low	Week 24	Sparsentan	55	46 (83.6)	3.36 (1.68)	(0.05, 6.67)	2.16 (2.47)	(-2.70, 7.01)	0.383
		Irbesartan	55	40 (72.7)	1.20 (1.80)	(-2.35, 4.75)			
	Week 48	Sparsentan	55	43 (78.2)	2.91 (1.72)	(-0.47, 6.30)	0.09 (2.51)	(-4.85, 5.02)	0.972
		Irbesartan	55	38 (69.1)	2.82 (1.82)	(-0.76, 6.41)			
	Week 70	Sparsentan	55	44 (80.0)	3.03 (1.72)	(-0.35, 6.40)	1.72 (2.47)	(-3.14, 6.57)	0.487
		Irbesartan	55	41 (74.5)	1.31 (1.77)	(-2.18, 4.80)			
	Week 94	Sparsentan	55	42 (76.4)	2.83 (1.75)	(-0.62, 6.27)	0.40 (2.51)	(-4.54, 5.34)	0.875
		Irbesartan	55	40 (72.7)	2.43 (1.80)	(-1.11, 5.97)			
	Week 110	Sparsentan	55	38 (69.1)	1.77 (1.84)	(-1.84, 5.39)	0.26 (2.67)	(-5.00, 5.51)	0.923
		Irbesartan	55	34 (61.8)	1.52 (1.94)	(-2.30, 5.33)			
eGFR High and UP High	Week 24	Sparsentan	37	29 (78.4)	4.19 (2.02)	(0.21, 8.16)	-1.77 (2.92)	(-7.53, 4.00)	0.546
		Irbesartan	36	27 (75.0)	5.95 (2.12)	(1.78, 10.13)			
	Week 48	Sparsentan	37	34 (91.9)	2.83 (1.89)	(-0.90, 6.55)	0.11 (2.88)	(-5.57, 5.79)	0.970
		Irbesartan	36	25 (69.4)	2.72 (2.18)	(-1.57, 7.00)			
	Week 70	Sparsentan	37	31 (83.8)	2.67 (1.96)	(-1.20, 6.54)	0.54 (2.94)	(-5.25, 6.33)	0.854
		Irbesartan	36	25 (69.4)	2.13 (2.18)	(-2.17, 6.43)			
	Week 94	Sparsentan	37	27 (73.0)	1.29 (2.08)	(-2.81, 5.40)	-3.47 (3.01)	(-9.41, 2.47)	0.251
		Irbesartan	36	25 (69.4)	4.76 (2.18)	(0.46, 9.05)			
	Week 110	Sparsentan	37	26 (70.3)	4.79 (2.14)	(0.56, 9.01)	1.42 (3.15)	(-4.79, 7.63)	0.653
		Irbesartan	36	22 (61.1)	3.37 (2.31)	(-1.18, 7.92)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. VAS = visual analouge scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
eGFR High and UP Low	Week 24	Sparsentan	39	35 (89.7)	5.65 (1.77)	(2.17, 9.13)	3.33 (2.61)	(-1.82, 8.48)	0.204
		Irbesartan	37	29 (78.4)	2.32 (1.93)	(-1.48, 6.11)			
	Week 48	Sparsentan	39	36 (92.3)	3.99 (1.75)	(0.54, 7.43)	3.78 (2.61)	(-1.36, 8.93)	0.149
		Irbesartan	37	28 (75.7)	0.20 (1.94)	(-3.61, 4.02)			
	Week 70	Sparsentan	39	33 (84.6)	-0.48 (1.80)	(-4.03, 3.07)	-3.99 (2.64)	(-9.19, 1.21)	0.132
		Irbesartan	37	29 (78.4)	3.51 (1.93)	(-0.29, 7.30)			
	Week 94	Sparsentan	39	35 (89.7)	0.88 (1.77)	(-2.61, 4.37)	-1.21 (2.59)	(-6.31, 3.88)	0.639
		Irbesartan	37	31 (83.8)	2.09 (1.88)	(-1.62, 5.81)			
	Week 110	Sparsentan	39	35 (89.7)	1.37 (1.77)	(-2.13, 4.86)	-1.31 (2.63)	(-6.48, 3.87)	0.619
		Irbesartan	37	29 (78.4)	2.67 (1.93)	(-1.14, 6.48)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. VAS = visual analouge scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 1	Overall	Sparsentan						Interaction:	0.772
< 60 mL/min/1.73 m**2	Week 24	Sparsentan	127	102 (80.3)	2.60 (1.18)	(0.28, 4.92)	3.68 (1.73)	(0.27, 7.08)	0.034 *
		Irbesartan	129	89 (69.0)	-1.08 (1.27)	(-3.56, 1.41)			
	Week 48	Sparsentan	127	99 (78.0)	2.41 (1.19)	(0.08, 4.75)	-0.10 (1.77)	(-3.56, 3.37)	0.956
		Irbesartan	129	81 (62.8)	2.51 (1.30)	(-0.04, 5.07)			
	Week 70	Sparsentan	127	103 (81.1)	0.33 (1.18)	(-1.99, 2.64)	0.38 (1.75)	(-3.06, 3.83)	0.827
		Irbesartan	129	84 (65.1)	-0.06 (1.29)	(-2.60, 2.48)			
	Week 94	Sparsentan	127	94 (74.0)	1.74 (1.22)	(-0.66, 4.13)	-0.42 (1.80)	(-3.95, 3.10)	0.814
		Irbesartan	129	82 (63.6)	2.16 (1.31)	(-0.42, 4.74)			
	Week 110	Sparsentan	127	93 (73.2)	1.27 (1.24)	(-1.16, 3.70)	0.45 (1.87)	(-3.22, 4.13)	0.809
		Irbesartan	129	72 (55.8)	0.82 (1.40)	(-1.92, 3.56)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. VAS = visual analouge scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
60 to < 90 mL/min/1.73 m**2	Week 24	Sparsentan	49	40 (81.6)	4.94 (1.78)	(1.43, 8.44)	1.17 (2.64)	(-4.02, 6.37)	0.657
		Irbesartan	48	34 (70.8)	3.76 (1.94)	(-0.05, 7.58)			
	Week 48	Sparsentan	49	45 (91.8)	3.29 (1.70)	(-0.06, 6.64)	2.37 (2.59)	(-2.73, 7.47)	0.361
		Irbesartan	48	33 (68.8)	0.92 (1.95)	(-2.91, 4.75)			
	Week 70	Sparsentan	49	40 (81.6)	1.01 (1.77)	(-2.48, 4.50)	-0.63 (2.65)	(-5.85, 4.60)	0.814
		Irbesartan	48	32 (66.7)	1.64 (1.97)	(-2.24, 5.51)			
	Week 94	Sparsentan	49	41 (83.7)	0.06 (1.77)	(-3.43, 3.55)	-1.19 (2.61)	(-6.33, 3.95)	0.650
		Irbesartan	48	35 (72.9)	1.25 (1.91)	(-2.52, 5.01)			
	Week 110	Sparsentan	49	37 (75.5)	1.65 (1.86)	(-2.00, 5.31)	-0.06 (2.72)	(-5.42, 5.30)	0.982
		Irbesartan	48	32 (66.7)	1.71 (1.99)	(-2.20, 5.62)			
>= 90 mL/min/1.73 m**2	Week 24	Sparsentan	26	22 (84.6)	5.09 (2.15)	(0.84, 9.33)	2.40 (3.11)	(-3.74, 8.54)	0.442
		Irbesartan	25	20 (80.0)	2.69 (2.25)	(-1.76, 7.13)			
	Week 48	Sparsentan	26	24 (92.3)	2.03 (2.07)	(-2.07, 6.13)	-0.12 (3.13)	(-6.30, 6.07)	0.970
		Irbesartan	25	18 (72.0)	2.14 (2.34)	(-2.47, 6.76)			
	Week 70	Sparsentan	26	23 (88.5)	1.22 (2.11)	(-2.96, 5.39)	-4.56 (3.11)	(-10.70, 1.59)	0.145
		Irbesartan	25	20 (80.0)	5.78 (2.27)	(1.29, 10.26)			
	Week 94	Sparsentan	26	21 (80.8)	3.61 (2.19)	(-0.72, 7.93)	0.23 (3.19)	(-6.08, 6.54)	0.942
		Irbesartan	25	19 (76.0)	3.37 (2.31)	(-1.20, 7.95)			
	Week 110	Sparsentan	26	22 (84.6)	4.13 (2.16)	(-0.15, 8.40)	-0.95 (3.26)	(-7.39, 5.49)	0.771
		Irbesartan	25	17 (68.0)	5.08 (2.43)	(0.28, 9.88)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. VAS = visual analouge scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 2	Overall	Sparsentan						Interaction:	0.097
< 45 mL/min/1.73 m**2	Week 24	Sparsentan	82	64 (78.0)	3.91 (1.58)	(0.80, 7.01)	5.59 (2.36)	(0.95, 10.23)	0.018 *
		Irbesartan	80	52 (65.0)	-1.69 (1.75)	(-5.13, 1.76)			
	Week 48	Sparsentan	82	63 (76.8)	4.44 (1.58)	(1.32, 7.55)	1.34 (2.38)	(-3.35, 6.03)	0.575
		Irbesartan	80	48 (60.0)	3.10 (1.78)	(-0.40, 6.60)			
	Week 70	Sparsentan	82	65 (79.3)	1.93 (1.57)	(-1.16, 5.02)	3.57 (2.36)	(-1.08, 8.21)	0.132
		Irbesartan	80	50 (62.5)	-1.64 (1.76)	(-5.10, 1.82)			
	Week 94	Sparsentan	82	61 (74.4)	3.25 (1.61)	(0.08, 6.41)	2.07 (2.40)	(-2.65, 6.78)	0.389
		Irbesartan	80	50 (62.5)	1.18 (1.78)	(-2.31, 4.67)			
	Week 110	Sparsentan	82	57 (69.5)	2.34 (1.67)	(-0.94, 5.62)	2.05 (2.52)	(-2.92, 7.01)	0.418
		Irbesartan	80	44 (55.0)	0.29 (1.89)	(-3.42, 4.00)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. VAS = visual analouge scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
45 to < 60 mL/min/1.73 m**2	Week 24	Sparsentan	45	38 (84.4)	0.41 (1.72)	(-2.97, 3.80)	0.60 (2.45)	(-4.22, 5.43)	0.805
		Irbesartan	49	37 (75.5)	-0.19 (1.74)	(-3.62, 3.24)			
	Week 48	Sparsentan	45	36 (80.0)	-1.08 (1.75)	(-4.52, 2.36)	-2.87 (2.53)	(-7.86, 2.12)	0.259
		Irbesartan	49	33 (67.3)	1.79 (1.82)	(-1.80, 5.38)			
	Week 70	Sparsentan	45	38 (84.4)	-2.40 (1.72)	(-5.79, 1.00)	-4.71 (2.52)	(-9.67, 0.24)	0.062
		Irbesartan	49	34 (69.4)	2.32 (1.83)	(-1.28, 5.91)			
	Week 94	Sparsentan	45	33 (73.3)	-0.87 (1.81)	(-4.44, 2.71)	-4.54 (2.62)	(-9.69, 0.61)	0.084
		Irbesartan	49	32 (65.3)	3.67 (1.88)	(-0.02, 7.37)			
	Week 110	Sparsentan	45	36 (80.0)	-0.46 (1.77)	(-3.95, 3.03)	-2.03 (2.68)	(-7.30, 3.25)	0.450
		Irbesartan	49	28 (57.1)	1.57 (2.00)	(-2.37, 5.51)			
60 to < 90 mL/min/1.73 m**2	Week 24	Sparsentan	49	40 (81.6)	4.94 (1.78)	(1.43, 8.44)	1.17 (2.64)	(-4.02, 6.37)	0.657
		Irbesartan	48	34 (70.8)	3.76 (1.94)	(-0.05, 7.58)			
	Week 48	Sparsentan	49	45 (91.8)	3.29 (1.70)	(-0.06, 6.64)	2.37 (2.59)	(-2.73, 7.47)	0.361
		Irbesartan	48	33 (68.8)	0.92 (1.95)	(-2.91, 4.75)			
	Week 70	Sparsentan	49	40 (81.6)	1.01 (1.77)	(-2.48, 4.50)	-0.63 (2.65)	(-5.85, 4.60)	0.814
		Irbesartan	48	32 (66.7)	1.64 (1.97)	(-2.24, 5.51)			
	Week 94	Sparsentan	49	41 (83.7)	0.06 (1.77)	(-3.43, 3.55)	-1.19 (2.61)	(-6.33, 3.95)	0.650
		Irbesartan	48	35 (72.9)	1.25 (1.91)	(-2.52, 5.01)			
	Week 110	Sparsentan	49	37 (75.5)	1.65 (1.86)	(-2.00, 5.31)	-0.06 (2.72)	(-5.42, 5.30)	0.982
		Irbesartan	48	32 (66.7)	1.71 (1.99)	(-2.20, 5.62)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. VAS = visual analouge scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
>= 90 mL/min/1.73 m**2	Week 24	Sparsentan	26	22 (84.6)	5.09 (2.15)	(0.84, 9.33)	2.40 (3.11)	(-3.74, 8.54)	0.442
		Irbesartan	25	20 (80.0)	2.69 (2.25)	(-1.76, 7.13)			
	Week 48	Sparsentan	26	24 (92.3)	2.03 (2.07)	(-2.07, 6.13)	-0.12 (3.13)	(-6.30, 6.07)	0.970
		Irbesartan	25	18 (72.0)	2.14 (2.34)	(-2.47, 6.76)			
	Week 70	Sparsentan	26	23 (88.5)	1.22 (2.11)	(-2.96, 5.39)	-4.56 (3.11)	(-10.70, 1.59)	0.145
		Irbesartan	25	20 (80.0)	5.78 (2.27)	(1.29, 10.26)			
	Week 94	Sparsentan	26	21 (80.8)	3.61 (2.19)	(-0.72, 7.93)	0.23 (3.19)	(-6.08, 6.54)	0.942
		Irbesartan	25	19 (76.0)	3.37 (2.31)	(-1.20, 7.95)			
	Week 110	Sparsentan	26	22 (84.6)	4.13 (2.16)	(-0.15, 8.40)	-0.95 (3.26)	(-7.39, 5.49)	0.771
		Irbesartan	25	17 (68.0)	5.08 (2.43)	(0.28, 9.88)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. VAS = visual analouge scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline urine protein excretion	Overall	Sparsentan						Interaction:	0.075
<= 1.75 g/day	Week 24	Sparsentan	98	84 (85.7)	3.64 (1.13)	(1.42, 5.85)	1.32 (1.74)	(-2.11, 4.74)	0.450
		Irbesartan	93	60 (64.5)	2.32 (1.33)	(-0.29, 4.93)			
	Week 48	Sparsentan	98	84 (85.7)	3.16 (1.12)	(0.95, 5.37)	0.44 (1.73)	(-2.97, 3.84)	0.801
		Irbesartan	93	59 (63.4)	2.72 (1.32)	(0.13, 5.31)			
	Week 70	Sparsentan	98	80 (81.6)	1.00 (1.15)	(-1.25, 3.26)	-2.42 (1.74)	(-5.83, 1.00)	0.165
		Irbesartan	93	62 (66.7)	3.42 (1.30)	(0.86, 5.98)			
	Week 94	Sparsentan	98	80 (81.6)	1.58 (1.15)	(-0.68, 3.85)	-3.05 (1.73)	(-6.45, 0.35)	0.078
		Irbesartan	93	65 (69.9)	4.63 (1.29)	(2.10, 7.17)			
	Week 110	Sparsentan	98	78 (79.6)	0.77 (1.17)	(-1.53, 3.07)	-2.49 (1.80)	(-6.02, 1.03)	0.165
		Irbesartan	93	57 (61.3)	3.26 (1.36)	(0.59, 5.94)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. VAS = visual analouge scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 1.75 g/day	Week 24	Sparsentan	104	80 (76.9)	3.06 (1.39)	(0.33, 5.80)	3.57 (1.96)	(-0.29, 7.43)	0.070
		Irbesartan	109	83 (76.1)	-0.51 (1.38)	(-3.21, 2.20)			
	Week 48	Sparsentan	104	84 (80.8)	1.64 (1.36)	(-1.04, 4.31)	-0.08 (1.99)	(-3.98, 3.82)	0.969
		Irbesartan	109	73 (67.0)	1.71 (1.44)	(-1.11, 4.54)			
	Week 70	Sparsentan	104	86 (82.7)	-0.06 (1.35)	(-2.72, 2.59)	0.37 (1.98)	(-3.52, 4.27)	0.851
		Irbesartan	109	74 (67.9)	-0.44 (1.44)	(-3.27, 2.40)			
	Week 94	Sparsentan	104	76 (73.1)	1.25 (1.42)	(-1.55, 4.04)	1.18 (2.05)	(-2.85, 5.20)	0.567
		Irbesartan	109	71 (65.1)	0.07 (1.47)	(-2.82, 2.96)			
	Week 110	Sparsentan	104	74 (71.2)	2.63 (1.45)	(-0.23, 5.48)	2.18 (2.13)	(-2.00, 6.36)	0.306
		Irbesartan	109	64 (58.7)	0.45 (1.55)	(-2.60, 3.49)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. VAS = visual analouge scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline use of antihypertensives	Overall	Sparsentan						Interaction:	0.414
Yes	Week 24	Sparsentan	90	71 (78.9)	5.25 (1.39)	(2.53, 7.98)	3.00 (2.10)	(-1.12, 7.12)	0.153
		Irbesartan	88	55 (62.5)	2.25 (1.57)	(-0.84, 5.33)			
	Week 48	Sparsentan	90	70 (77.8)	4.54 (1.39)	(1.81, 7.27)	0.17 (2.13)	(-4.01, 4.36)	0.935
		Irbesartan	88	51 (58.0)	4.37 (1.61)	(1.20, 7.53)			
	Week 70	Sparsentan	90	71 (78.9)	2.03 (1.39)	(-0.69, 4.75)	2.76 (2.12)	(-1.41, 6.93)	0.195
		Irbesartan	88	52 (59.1)	-0.72 (1.60)	(-3.87, 2.43)			
	Week 94	Sparsentan	90	67 (74.4)	4.11 (1.42)	(1.32, 6.90)	-0.55 (2.09)	(-4.66, 3.56)	0.794
		Irbesartan	88	58 (65.9)	4.66 (1.54)	(1.64, 7.68)			
	Week 110	Sparsentan	90	65 (72.2)	4.02 (1.45)	(1.17, 6.86)	1.25 (2.18)	(-3.03, 5.54)	0.566
		Irbesartan	88	51 (58.0)	2.76 (1.63)	(-0.43, 5.96)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. VAS = visual analouge scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
No	Week 24	Sparsentan	112	93 (83.0)	2.13 (1.16)	(-0.16, 4.41)	2.48 (1.67)	(-0.81, 5.76)	0.139
		Irbesartan	114	88 (77.2)	-0.35 (1.20)	(-2.71, 2.01)			
	Week 48	Sparsentan	112	98 (87.5)	0.93 (1.14)	(-1.30, 3.17)	0.38 (1.67)	(-2.90, 3.67)	0.819
		Irbesartan	114	81 (71.1)	0.55 (1.23)	(-1.86, 2.96)			
	Week 70	Sparsentan	112	95 (84.8)	-0.58 (1.16)	(-2.85, 1.69)	-2.84 (1.68)	(-6.15, 0.47)	0.092
		Irbesartan	114	84 (73.7)	2.26 (1.23)	(-0.14, 4.67)			
	Week 94	Sparsentan	112	89 (79.5)	-0.59 (1.19)	(-2.92, 1.74)	-0.75 (1.74)	(-4.16, 2.66)	0.666
		Irbesartan	114	78 (68.4)	0.16 (1.27)	(-2.33, 2.65)			
	Week 110	Sparsentan	112	87 (77.7)	-0.06 (1.21)	(-2.43, 2.32)	-0.82 (1.80)	(-4.36, 2.71)	0.647
		Irbesartan	114	70 (61.4)	0.77 (1.34)	(-1.85, 3.39)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. VAS = visual analouge scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Time since renal biopsy	Overall	Sparsentan						Interaction:	0.781
<= 5 years	Week 24	Sparsentan	113	94 (83.2)	4.08 (1.22)	(1.68, 6.48)	3.54 (1.73)	(0.15, 6.93)	0.041 *
		Irbesartan	127	94 (74.0)	0.54 (1.22)	(-1.86, 2.94)			
	Week 48	Sparsentan	113	95 (84.1)	1.99 (1.21)	(-0.38, 4.37)	0.30 (1.73)	(-3.10, 3.70)	0.862
		Irbesartan	127	89 (70.1)	1.69 (1.24)	(-0.74, 4.13)			
	Week 70	Sparsentan	113	94 (83.2)	-0.37 (1.22)	(-2.76, 2.02)	-2.49 (1.74)	(-5.91, 0.93)	0.154
		Irbesartan	127	89 (70.1)	2.11 (1.25)	(-0.33, 4.56)			
	Week 94	Sparsentan	113	89 (78.8)	1.91 (1.25)	(-0.53, 4.36)	-0.71 (1.76)	(-4.17, 2.75)	0.687
		Irbesartan	127	89 (70.1)	2.63 (1.25)	(0.17, 5.08)			
	Week 110	Sparsentan	113	89 (78.8)	3.13 (1.26)	(0.66, 5.59)	0.15 (1.82)	(-3.42, 3.72)	0.934
		Irbesartan	127	80 (63.0)	2.97 (1.32)	(0.39, 5.56)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. VAS = visual analouge scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 5 years	Week 24	Sparsentan	89	70 (78.7)	2.69 (1.32)	(0.10, 5.28)	1.83 (2.07)	(-2.24, 5.91)	0.377
		Irbesartan	75	49 (65.3)	0.86 (1.59)	(-2.27, 3.99)			
	Week 48	Sparsentan	89	73 (82.0)	3.26 (1.30)	(0.71, 5.81)	0.41 (2.09)	(-3.71, 4.53)	0.844
		Irbesartan	75	43 (57.3)	2.85 (1.64)	(-0.38, 6.07)			
	Week 70	Sparsentan	89	72 (80.9)	1.86 (1.31)	(-0.72, 4.44)	2.29 (2.08)	(-1.80, 6.39)	0.271
		Irbesartan	75	47 (62.7)	-0.43 (1.61)	(-3.60, 2.73)			
	Week 94	Sparsentan	89	67 (75.3)	1.03 (1.35)	(-1.62, 3.68)	-0.05 (2.12)	(-4.21, 4.11)	0.982
		Irbesartan	75	47 (62.7)	1.08 (1.63)	(-2.12, 4.27)			
	Week 110	Sparsentan	89	63 (70.8)	-0.16 (1.39)	(-2.89, 2.56)	0.76 (2.21)	(-3.60, 5.11)	0.733
		Irbesartan	75	41 (54.7)	-0.92 (1.72)	(-4.30, 2.46)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. VAS = visual analouge scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
History of hypertension	Overall	Sparsentan						Interaction:	0.554
Yes	Week 24	Sparsentan	155	125 (80.6)	4.05 (1.04)	(2.01, 6.10)	3.15 (1.52)	(0.17, 6.12)	0.038 *
		Irbesartan	161	111 (68.9)	0.91 (1.10)	(-1.26, 3.07)			
	Week 48	Sparsentan	155	126 (81.3)	3.15 (1.03)	(1.13, 5.18)	0.22 (1.53)	(-2.79, 3.23)	0.885
		Irbesartan	161	102 (63.4)	2.93 (1.13)	(0.71, 5.16)			
	Week 70	Sparsentan	155	128 (82.6)	1.47 (1.03)	(-0.55, 3.49)	0.30 (1.53)	(-2.70, 3.30)	0.845
		Irbesartan	161	105 (65.2)	1.17 (1.13)	(-1.04, 3.38)			
	Week 94	Sparsentan	155	119 (76.8)	1.98 (1.06)	(-0.10, 4.06)	-0.93 (1.55)	(-3.98, 2.11)	0.548
		Irbesartan	161	105 (65.2)	2.91 (1.13)	(0.69, 5.13)			
	Week 110	Sparsentan	155	114 (73.5)	2.25 (1.09)	(0.12, 4.38)	0.35 (1.62)	(-2.83, 3.54)	0.828
		Irbesartan	161	92 (57.1)	1.90 (1.20)	(-0.47, 4.26)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. VAS = visual analouge scale.
Source Data: aqs, created on: 05MAR2024

Table PT2VSC_FSCM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Change from baseline in EQ-5D VAS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
No	Week 24	Sparsentan	47	39 (83.0)	0.95 (1.80)	(-2.59, 4.49)	1.25 (2.68)	(-4.03, 6.54)	0.640
		Irbesartan	41	32 (78.0)	-0.30 (1.98)	(-4.21, 3.61)			
	Week 48	Sparsentan	47	42 (89.4)	0.07 (1.75)	(-3.38, 3.52)	0.86 (2.67)	(-4.40, 6.12)	0.746
		Irbesartan	41	30 (73.2)	-0.79 (2.00)	(-4.74, 3.15)			
	Week 70	Sparsentan	47	38 (80.9)	-2.61 (1.80)	(-6.17, 0.95)	-4.13 (2.71)	(-9.46, 1.21)	0.129
		Irbesartan	41	31 (75.6)	1.52 (2.00)	(-2.43, 5.47)			
	Week 94	Sparsentan	47	37 (78.7)	-0.36 (1.84)	(-3.98, 3.26)	0.01 (2.75)	(-5.42, 5.44)	0.997
		Irbesartan	41	31 (75.6)	-0.37 (2.03)	(-4.38, 3.64)			
	Week 110	Sparsentan	47	38 (80.9)	-0.33 (1.84)	(-3.96, 3.30)	-1.17 (2.81)	(-6.70, 4.36)	0.677
		Irbesartan	41	29 (70.7)	0.84 (2.10)	(-3.30, 4.98)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. VAS = visual analouge scale.
Source Data: aqs, created on: 05MAR2024

Figure PF2VSC_FSGM: Change from baseline in EQ-5D VAS by subgroup
Full Analysis Set

Not done: No significant subgroup found.

_____
Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
VAS = visual analouge scale.
Reference table: PT2VSC_FSCM

Table PT2VSIT_FSTM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to increase in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sex	Sparsentan						Interaction test:	0.938
Male	Sparsentan	139	28 (20.1)	NE		1.011	(0.589, 1.735)	0.968
	Irbesartan	143	31 (21.7)	NE				
Female	Sparsentan	63	17 (27.0)	NE		1.159	(0.517, 2.600)	0.720
	Irbesartan	59	12 (20.3)	117.1	(NE, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2VSIT_FSTM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to increase in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.116
<= 45 years	Sparsentan	96	26 (27.1)	NE		1.354	(0.742, 2.471)	0.324
	Irbesartan	99	20 (20.2)	117.1	(NE, NE)			
> 45 years	Sparsentan	106	19 (17.9)	NE		0.738	(0.396, 1.374)	0.338
	Irbesartan	103	23 (22.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2VSIT_FSTM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to increase in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age at IgAN diagnosis	Sparsentan						Interaction test:	NE
<= 18 years	Sparsentan	9	4 (44.4) No events in 1 group	110.3	(25.0, NE)	NE		NE
	Irbesartan	5	0 (0.0)	NE				
> 18 to 40 years	Sparsentan	102	23 (22.5)	NE		1.173	(0.645, 2.133)	0.601
	Irbesartan	109	24 (22.0)	117.1	(117.1, NE)			
> 40 years	Sparsentan	91	18 (19.8)	NE		0.795	(0.402, 1.570)	0.509
	Irbesartan	88	19 (21.6)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2VSIT_FSTM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to increase in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Geographic region	Sparsentan						Interaction test:	0.298
North America	Sparsentan	35	9 (25.7)	NE		0.749	(0.302, 1.861)	0.534
	Irbesartan	46	12 (26.1)	NE				
Europe	Sparsentan	98	22 (22.4)	NE		0.994	(0.542, 1.821)	0.984
	Irbesartan	115	23 (20.0)	117.1	(117.1, NE)			
Asia Pacific	Sparsentan	69	14 (20.3)	NE		2.014	(0.713, 5.692)	0.187
	Irbesartan	41	8 (19.5)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2VSIT_FSTM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to increase in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.764
< 27 kg/m**2	Sparsentan	83	19 (22.9)	NE		0.953	(0.450, 2.019)	0.901
	Irbesartan	94	13 (13.8)	NE				
>= 27 kg/m**2	Sparsentan	119	26 (21.8)	NE		1.000	(0.575, 1.741)	0.999
	Irbesartan	107	29 (27.1)	117.1	(NE, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2VSIT_FSTM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to increase in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Randomization strata	Sparsentan						Interaction test:	0.078	
eGFR Low and UP High	Sparsentan	71	7 (9.9)	NE		0.731	(0.253, 2.107)	0.561	
	Irbesartan	74	13 (17.6)	NE					
eGFR Low and UP Low	Sparsentan	55	13 (23.6)	NE		0.708	(0.323, 1.551)	0.388	
	Irbesartan	55	14 (25.5)	NE					
eGFR High and UP High	Sparsentan	37	12 (32.4)	NE		0.929	(0.360, 2.392)	0.878	
	Irbesartan	36	8 (22.2)	NE					
eGFR High and UP Low	Sparsentan	39	13 (33.3)	NE		3.011	(1.039, 8.729)	0.042	*
	Irbesartan	37	8 (21.6)	117.1	(NE, NE)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2VSIT_FSTM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to increase in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.181
< 60 mL/min/1.73 m**2	Sparsentan	127	22 (17.3)	NE		0.810	(0.453, 1.448)	0.478
	Irbesartan	129	27 (20.9)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	15 (30.6)	NE		1.151	(0.507, 2.611)	0.737
	Irbesartan	48	12 (25.0)	117.1	(NE, NE)			
>= 90 mL/min/1.73 m**2	Sparsentan	26	8 (30.8)	NE		2.543	(0.628, 10.294)	0.191
	Irbesartan	25	4 (16.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2VSIT_FSTM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to increase in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 2	Sparsentan						Interaction test:	0.182
< 45 mL/min/1.73 m**2	Sparsentan	82	13 (15.9)	NE		0.626	(0.302, 1.298)	0.208
	Irbesartan	80	19 (23.8)	NE				
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	9 (20.0)	NE		1.522	(0.530, 4.371)	0.435
	Irbesartan	49	8 (16.3)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	15 (30.6)	NE		1.151	(0.507, 2.611)	0.737
	Irbesartan	48	12 (25.0)	117.1	(NE, NE)			
>= 90 mL/min/1.73 m**2	Sparsentan	26	8 (30.8)	NE		2.543	(0.628, 10.294)	0.191
	Irbesartan	25	4 (16.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2VSIT_FSTM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to increase in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline urine protein excretion	Sparsentan						Interaction test:	0.689
<= 1.75 g/day	Sparsentan	98	25 (25.5)	NE		1.006	(0.550, 1.840)	0.986
	Irbesartan	93	22 (23.7)	117.1	(NE, NE)			
> 1.75 g/day	Sparsentan	104	20 (19.2)	NE		1.277	(0.655, 2.490)	0.473
	Irbesartan	109	21 (19.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2VSIT_FSTM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to increase in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.048	#
Yes	Sparsentan	90	19 (21.1)	NE		0.636	(0.326, 1.243)	0.186	
	Irbesartan	88	20 (22.7)	NE					
No	Sparsentan	112	26 (23.2)	NE		1.539	(0.838, 2.827)	0.165	
	Irbesartan	114	23 (20.2)	117.1	(NE, NE)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2VSIT_FSTM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to increase in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Time since renal biopsy	Sparsentan						Interaction test:	0.526
<= 5 years	Sparsentan	113	28 (24.8)	NE		1.158	(0.674, 1.992)	0.595
	Irbesartan	127	29 (22.8)	NE				
> 5 years	Sparsentan	89	17 (19.1)	NE		1.024	(0.484, 2.168)	0.950
	Irbesartan	75	14 (18.7)	117.1	(117.1, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2VSIT_FSTM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to increase in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
History of hypertension	Sparsentan						Interaction test:	0.176
Yes	Sparsentan	155	36 (23.2)	NE		0.945	(0.595, 1.501)	0.810
	Irbesartan	161	40 (24.8)	117.1	(117.1, NE)			
No	Sparsentan	47	9 (19.1)	NE		2.503	(0.648, 9.675)	0.183
	Irbesartan	41	3 (7.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Figure PF2VSIT_FSKM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline use of antihypertensives: Yes



Sparsentan	90	75	69	64	57	49
Irbesartan	88	65	53	48	47	36

An increase reflects an improvement of the status of the patient.
Reference table: PT2VSIT_FSTM

Figure PF2VSIT_FSKM: Time to increase in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline use of antihypertensives: No



Sparsentan	112	99	86	80	74	64
Irbesartan	114	94	78	68	62	54

An increase reflects an improvement of the status of the patient.
Reference table: PT2VSIT_FSTM

Table PT2VSDT_FSTM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to decrease in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sex	Sparsentan						Interaction test:	0.941
Male	Sparsentan	139	29 (20.9)	NE		1.268	(0.707, 2.275)	0.426
	Irbesartan	143	19 (13.3)	118.1	(NE, NE)			
Female	Sparsentan	63	20 (31.7)	NE		1.323	(0.653, 2.679)	0.437
	Irbesartan	59	13 (22.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2VSDT_FSTM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to decrease in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.510
<= 45 years	Sparsentan	96	24 (25.0)	NE		1.186	(0.651, 2.162)	0.578
	Irbesartan	99	20 (20.2)	NE				
> 45 years	Sparsentan	106	25 (23.6)	NE		1.621	(0.810, 3.244)	0.172
	Irbesartan	103	12 (11.7)	118.1	(NE, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2VSDT_FSTM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to decrease in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age at IgAN diagnosis	Sparsentan						Interaction test:	0.648
<= 18 years	Sparsentan	9	2 (22.2)	NE		0.473	(0.025, 8.929)	0.618
	Irbesartan	5	1 (20.0)	NE				
> 18 to 40 years	Sparsentan	102	23 (22.5)	NE		1.170	(0.639, 2.139)	0.611
	Irbesartan	109	21 (19.3)	118.1	(NE, NE)			
> 40 years	Sparsentan	91	24 (26.4)	NE		1.714	(0.810, 3.630)	0.159
	Irbesartan	88	10 (11.4)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2VSDT_FSTM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to decrease in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Geographic region	Sparsentan						Interaction test:	0.298
North America	Sparsentan	35	5 (14.3)	NE		0.796	(0.258, 2.453)	0.691
	Irbesartan	46	8 (17.4)	NE				
Europe	Sparsentan	98	25 (25.5)	NE		1.256	(0.693, 2.278)	0.453
	Irbesartan	115	20 (17.4)	118.1	(NE, NE)			
Asia Pacific	Sparsentan	69	19 (27.5)	NE		2.253	(0.752, 6.752)	0.147
	Irbesartan	41	4 (9.8)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2VSDT_FSTM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to decrease in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline BMI	Sparsentan						Interaction test:	0.087	
< 27 kg/m**2	Sparsentan	83	25 (30.1)	NE		2.031	(1.069, 3.860)	0.031	*
	Irbesartan	94	17 (18.1)	118.1	(NE, NE)				
>= 27 kg/m**2	Sparsentan	119	24 (20.2)	NE		0.906	(0.468, 1.752)	0.769	
	Irbesartan	107	15 (14.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2VSDT_FSTM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to decrease in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Randomization strata	Sparsentan						Interaction test:	0.159
eGFR Low and UP High	Sparsentan	71	17 (23.9)	NE		0.764	(0.386, 1.515)	0.441
	Irbesartan	74	17 (23.0)	118.1	(NE, NE)			
eGFR Low and UP Low	Sparsentan	55	12 (21.8)	NE		1.637	(0.644, 4.163)	0.301
	Irbesartan	55	7 (12.7)	NE				
eGFR High and UP High	Sparsentan	37	9 (24.3)	NE		2.496	(0.670, 9.301)	0.173
	Irbesartan	36	3 (8.3)	NE				
eGFR High and UP Low	Sparsentan	39	11 (28.2)	NE		2.569	(0.875, 7.544)	0.086
	Irbesartan	37	5 (13.5)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2VSDT_FSTM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to decrease in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.272
< 60 mL/min/1.73 m**2	Sparsentan	127	29 (22.8)	NE		1.037	(0.597, 1.802)	0.898
	Irbesartan	129	23 (17.8)	118.1	(NE, NE)			
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	11 (22.4)	NE		1.757	(0.636, 4.852)	0.277
	Irbesartan	48	6 (12.5)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	9 (34.6)	NE		3.688	(0.907, 15.000)	0.068
	Irbesartan	25	3 (12.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2VSDT_FSTM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to decrease in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eGFR Group 2	Sparsentan						Interaction test:	0.009	#
< 45 mL/min/1.73 m**2	Sparsentan	82	15 (18.3)	NE		0.549	(0.272, 1.106)	0.093	
	Irbesartan	80	18 (22.5)	118.1	(NE, NE)				
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	14 (31.1)	NE		3.421	(1.172, 9.981)	0.024	*
	Irbesartan	49	5 (10.2)	NE					
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	11 (22.4)	NE		1.757	(0.636, 4.852)	0.277	
	Irbesartan	48	6 (12.5)	NE					
>= 90 mL/min/1.73 m**2	Sparsentan	26	9 (34.6)	NE		3.688	(0.907, 15.000)	0.068	
	Irbesartan	25	3 (12.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2VSDT_FSTM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to decrease in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline urine protein excretion	Sparsentan						Interaction test:	0.020	#
<= 1.75 g/day	Sparsentan	98	26 (26.5)	NE		2.995	(1.340, 6.691)	0.007	*
	Irbesartan	93	8 (8.6)	NE					
> 1.75 g/day	Sparsentan	104	23 (22.1)	NE		0.882	(0.494, 1.577)	0.673	
	Irbesartan	109	24 (22.0)	118.1	(NE, NE)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2VSDT_FSTM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to decrease in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.793
Yes	Sparsentan	90	19 (21.1)	NE		1.236	(0.593, 2.576)	0.572
	Irbesartan	88	12 (13.6)	118.1	(NE, NE)			
No	Sparsentan	112	30 (26.8)	NE		1.399	(0.792, 2.472)	0.248
	Irbesartan	114	20 (17.5)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2VSDT_FSTM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to decrease in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Time since renal biopsy	Sparsentan						Interaction test:	0.557
<= 5 years	Sparsentan	113	30 (26.5)	NE		1.510	(0.860, 2.651)	0.151
	Irbesartan	127	21 (16.5)	NE				
> 5 years	Sparsentan	89	19 (21.3)	NE		1.169	(0.551, 2.477)	0.684
	Irbesartan	75	11 (14.7)	118.1	(NE, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2VSDT_FSTM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Time to decrease in EQ-5D VAS by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
History of hypertension	Sparsentan						Interaction test:	0.532
Yes	Sparsentan	155	37 (23.9)	NE		1.461	(0.861, 2.480)	0.160
	Irbesartan	161	22 (13.7)	118.1	(NE, NE)			
No	Sparsentan	47	12 (25.5)	NE		1.154	(0.475, 2.799)	0.752
	Irbesartan	41	10 (24.4)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Figure PF2VSDT_FSKM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline eGFR Group 2: < 45 mL/min/1.73 m**2



Sparsentan	82	67	66	64	56	46
Irbesartan	80	62	49	44	42	34

_____
A decrease reflects a worsening of the status of the patient.
Reference table: PT2VSDT_FSTM

Figure PF2VSDT_FSKM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline eGFR Group 2: 45 to < 60 mL/min/1.73 m**2



Sparsentan	45	42	35	33	29	22
Irbesartan	49	39	35	34	32	28

A decrease reflects a worsening of the status of the patient.
Reference table: PT2VSDT_FSTM

Figure PF2VSDT_FSKM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline eGFR Group 2: 60 to < 90 mL/min/1.73 m**2



Sparsentan	49	46	42	39	35	29
Irbesartan	48	41	39	36	33	28

A decrease reflects a worsening of the status of the patient.
Reference table: PT2VSDT_FSTM

Figure PF2VSDT_FSKM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline eGFR Group 2: >= 90 mL/min/1.73 m**2



Sparsentan	26	24	23	20	18	17
Irbesartan	25	20	18	18	17	14

_____
A decrease reflects a worsening of the status of the patient.
Reference table: PT2VSDT_FSTM

Figure PF2VSDT_FSKM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline urine protein excretion: <= 1.75 g/day



Sparsentan	98	89	82	78	69	57
Irbesartan	93	73	68	63	58	47

_____
A decrease reflects a worsening of the status of the patient.
Reference table: PT2VSDT_FSTM

Figure PF2VSDT_FSKM: Time to decrease in EQ-5D VAS by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline urine protein excretion: > 1.75 g/day



Sparsentan	104	90	84	78	69	57
Irbesartan	109	89	73	69	66	57

A decrease reflects a worsening of the status of the patient.
Reference table: PT2VSDT_FSTM

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	KDQOL: burden of kidney disease	Baseline	Sparsentan	139	129 (92.8)	72.09 (22.63)	6.3	62.50	75.00	87.50	100.0	
			Irbesartan	143	131 (91.6)	79.29 (22.24)	6.3	68.75	87.50	100.00	100.0	
		Week 24	Sparsentan	139	109 (78.4)	76.38 (22.25)	0.0	68.75	81.25	93.75	100.0	
			Irbesartan	143	93 (65.0)	76.88 (23.92)	0.0	68.75	81.25	100.00	100.0	
		Week 48	Sparsentan	139	112 (80.6)	77.23 (22.74)	0.0	68.75	81.25	100.00	100.0	
			Irbesartan	143	87 (60.8)	81.11 (21.35)	0.0	75.00	87.50	100.00	100.0	
		Week 70	Sparsentan	139	114 (82.0)	78.89 (21.51)	6.3	68.75	81.25	93.75	100.0	
			Irbesartan	143	92 (64.3)	79.48 (22.72)	12.5	68.75	87.50	100.00	100.0	
		Week 94	Sparsentan	139	105 (75.5)	78.51 (21.48)	0.0	75.00	81.25	93.75	100.0	
			Irbesartan	143	96 (67.1)	75.91 (23.46)	12.5	68.75	78.13	96.88	100.0	
		Week 110	Sparsentan	139	103 (74.1)	77.97 (21.82)	25.0	62.50	81.25	100.00	100.0	
			Irbesartan	143	89 (62.2)	75.42 (23.72)	12.5	62.50	75.00	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	139	109 (78.4)	6.02 (20.94)	-50.0	-6.25	6.25	12.50	62.5	0.43 [0.15, 0.71]
			Irbesartan	143	93 (65.0)	-2.35 (17.68)	-50.0	-12.50	0.00	6.25	50.0	
		Week 48	Sparsentan	139	112 (80.6)	6.03 (20.01)	-68.8	0.00	6.25	18.75	50.0	0.24 [-0.04, 0.52]
			Irbesartan	143	87 (60.8)	1.51 (17.83)	-62.5	-6.25	0.00	12.50	56.3	
		Week 70	Sparsentan	139	114 (82.0)	7.13 (18.65)	-50.0	0.00	6.25	18.75	56.3	0.30 [0.02, 0.57]
			Irbesartan	143	92 (64.3)	1.77 (17.44)	-43.8	-6.25	0.00	9.38	56.3	
		Week 94	Sparsentan	139	105 (75.5)	7.50 (23.93)	-87.5	0.00	6.25	25.00	68.8	0.43 [0.15, 0.71]
			Irbesartan	143	96 (67.1)	-1.89 (19.22)	-75.0	-12.50	0.00	6.25	56.3	
		Week 110	Sparsentan	139	103 (74.1)	6.67 (21.78)	-50.0	-6.25	6.25	18.75	62.5	0.44 [0.16, 0.73]
			Irbesartan	143	89 (62.2)	-2.53 (19.62)	-62.5	-12.50	0.00	6.25	56.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Female	KDQOL: burden of kidney disease	Baseline	Sparsentan	63	58 (92.1)	65.52 (29.99)	0.0	50.00	71.88	93.75	100.0	
			Irbesartan	59	51 (86.4)	70.83 (23.31)	18.8	56.25	75.00	87.50	100.0	
		Week 24	Sparsentan	63	48 (76.2)	77.60 (22.47)	18.8	68.75	81.25	100.00	100.0	
			Irbesartan	59	38 (64.4)	83.06 (19.27)	25.0	75.00	87.50	100.00	100.0	
		Week 48	Sparsentan	63	50 (79.4)	77.88 (23.26)	12.5	62.50	84.38	100.00	100.0	
			Irbesartan	59	37 (62.7)	77.53 (21.27)	6.3	68.75	81.25	100.00	100.0	
		Week 70	Sparsentan	63	46 (73.0)	77.45 (22.92)	25.0	62.50	81.25	100.00	100.0	
			Irbesartan	59	38 (64.4)	79.77 (18.75)	25.0	75.00	81.25	100.00	100.0	
		Week 94	Sparsentan	63	46 (73.0)	71.06 (25.19)	0.0	56.25	75.00	93.75	100.0	
			Irbesartan	59	34 (57.6)	78.86 (18.72)	37.5	68.75	75.00	100.00	100.0	
		Week 110	Sparsentan	63	46 (73.0)	74.46 (20.83)	18.8	62.50	75.00	93.75	100.0	
			Irbesartan	59	32 (54.2)	78.13 (17.53)	25.0	68.75	78.13	93.75	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	63	48 (76.2)	11.72 (25.09)	-81.3	0.00	6.25	25.00	81.3	0.17 [-0.25, 0.60]
			Irbesartan	59	38 (64.4)	8.06 (14.88)	-18.8	0.00	6.25	18.75	56.3	
		Week 48	Sparsentan	63	50 (79.4)	11.50 (21.22)	-25.0	0.00	6.25	25.00	62.5	0.38 [-0.05, 0.81]
			Irbesartan	59	37 (62.7)	3.89 (18.48)	-50.0	-6.25	0.00	12.50	50.0	
		Week 70	Sparsentan	63	46 (73.0)	11.28 (28.12)	-43.8	0.00	0.00	25.00	87.5	0.26 [-0.17, 0.69]
			Irbesartan	59	38 (64.4)	4.93 (19.45)	-25.0	-6.25	0.00	12.50	50.0	
		Week 94	Sparsentan	63	46 (73.0)	6.66 (26.33)	-50.0	-12.50	0.00	25.00	75.0	0.09 [-0.35, 0.54]
			Irbesartan	59	34 (57.6)	4.23 (24.80)	-50.0	-6.25	0.00	18.75	50.0	
		Week 110	Sparsentan	63	46 (73.0)	9.10 (29.86)	-56.3	-6.25	6.25	18.75	87.5	0.23 [-0.22, 0.69]
			Irbesartan	59	32 (54.2)	2.73 (22.89)	-43.8	-12.50	0.00	21.88	43.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
<= 45 years	KDQOL: burden of kidney disease	Baseline	Sparsentan	96	87 (90.6)	67.10 (26.85)	0.0	50.00	75.00	87.50	100.0	
			Irbesartan	99	92 (92.9)	71.20 (25.00)	6.3	53.13	75.00	93.75	100.0	
		Week 24	Sparsentan	96	71 (74.0)	76.23 (22.70)	18.8	62.50	81.25	100.00	100.0	
			Irbesartan	99	67 (67.7)	76.31 (25.50)	0.0	62.50	81.25	100.00	100.0	
		Week 48	Sparsentan	96	75 (78.1)	75.83 (23.46)	6.3	62.50	81.25	93.75	100.0	
			Irbesartan	99	62 (62.6)	77.82 (26.07)	0.0	62.50	87.50	100.00	100.0	
		Week 70	Sparsentan	96	72 (75.0)	76.91 (19.84)	25.0	68.75	75.00	93.75	100.0	
			Irbesartan	99	62 (62.6)	78.02 (23.70)	12.5	68.75	84.38	100.00	100.0	
		Week 94	Sparsentan	96	68 (70.8)	73.62 (23.92)	0.0	62.50	78.13	93.75	100.0	
			Irbesartan	99	64 (64.6)	75.49 (25.35)	12.5	62.50	81.25	100.00	100.0	
		Week 110	Sparsentan	96	69 (71.9)	75.91 (21.36)	25.0	62.50	75.00	93.75	100.0	
			Irbesartan	99	59 (59.6)	73.31 (24.94)	25.0	56.25	75.00	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	96	71 (74.0)	10.83 (27.16)	-81.3	0.00	6.25	25.00	81.3	0.36 [0.02, 0.70]
			Irbesartan	99	67 (67.7)	2.15 (20.40)	-50.0	-6.25	0.00	12.50	56.3	
		Week 48	Sparsentan	96	75 (78.1)	9.33 (20.20)	-62.5	0.00	6.25	25.00	50.0	0.32 [-0.02, 0.65]
			Irbesartan	99	62 (62.6)	2.92 (20.36)	-62.5	-6.25	0.00	12.50	56.3	
		Week 70	Sparsentan	96	72 (75.0)	9.72 (25.41)	-43.8	-6.25	6.25	25.00	87.5	0.24 [-0.10, 0.58]
			Irbesartan	99	62 (62.6)	4.23 (18.83)	-43.8	-6.25	3.13	12.50	43.8	
		Week 94	Sparsentan	96	68 (70.8)	6.80 (27.03)	-62.5	-9.38	6.25	25.00	75.0	0.16 [-0.18, 0.50]
			Irbesartan	99	64 (64.6)	3.03 (20.32)	-37.5	-12.50	6.25	18.75	56.3	
		Week 110	Sparsentan	96	69 (71.9)	8.42 (29.19)	-56.3	-12.50	0.00	18.75	87.5	0.35 [-0.00, 0.70]
			Irbesartan	99	59 (59.6)	-0.53 (20.64)	-56.3	-12.50	0.00	6.25	50.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 45 years	KDQOL: burden of kidney disease	Baseline	Sparsentan	106	100 (94.3)	72.63 (23.60)	6.3	56.25	75.00	90.63	100.0	
			Irbesartan	103	90 (87.4)	82.78 (18.70)	18.8	75.00	87.50	100.00	100.0	
		Week 24	Sparsentan	106	86 (81.1)	77.18 (22.00)	0.0	68.75	81.25	93.75	100.0	
			Irbesartan	103	64 (62.1)	81.15 (19.40)	18.8	68.75	81.25	100.00	100.0	
		Week 48	Sparsentan	106	87 (82.1)	78.81 (22.32)	0.0	75.00	81.25	100.00	100.0	
			Irbesartan	103	62 (60.2)	82.26 (15.02)	37.5	75.00	81.25	93.75	100.0	
		Week 70	Sparsentan	106	88 (83.0)	79.76 (23.42)	6.3	75.00	87.50	100.00	100.0	
			Irbesartan	103	68 (66.0)	80.97 (19.48)	12.5	75.00	84.38	100.00	100.0	
		Week 94	Sparsentan	106	83 (78.3)	78.39 (21.83)	0.0	75.00	81.25	100.00	100.0	
			Irbesartan	103	66 (64.1)	77.84 (18.96)	25.0	68.75	75.00	93.75	100.0	
		Week 110	Sparsentan	106	80 (75.5)	77.73 (21.74)	18.8	62.50	81.25	93.75	100.0	
			Irbesartan	103	62 (60.2)	78.83 (19.08)	12.5	75.00	81.25	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	106	86 (81.1)	5.23 (17.20)	-43.8	-6.25	0.00	12.50	43.8	0.39 [0.06, 0.71]
			Irbesartan	103	64 (62.1)	-0.88 (13.86)	-31.3	-9.38	0.00	6.25	37.5	
		Week 48	Sparsentan	106	87 (82.1)	6.32 (20.74)	-68.8	0.00	6.25	18.75	62.5	0.26 [-0.07, 0.58]
			Irbesartan	103	62 (60.2)	1.51 (15.38)	-50.0	-6.25	0.00	6.25	43.8	
		Week 70	Sparsentan	106	88 (83.0)	7.17 (18.36)	-50.0	0.00	6.25	18.75	50.0	0.33 [0.01, 0.65]
			Irbesartan	103	68 (66.0)	1.29 (17.30)	-37.5	-6.25	0.00	6.25	56.3	
		Week 94	Sparsentan	106	83 (78.3)	7.61 (22.58)	-87.5	0.00	6.25	25.00	68.8	0.51 [0.18, 0.83]
			Irbesartan	103	66 (64.1)	-3.50 (21.09)	-75.0	-12.50	0.00	6.25	50.0	
		Week 110	Sparsentan	106	80 (75.5)	6.56 (19.69)	-43.8	-6.25	6.25	18.75	56.3	0.41 [0.08, 0.75]
			Irbesartan	103	62 (60.2)	-1.71 (20.66)	-62.5	-12.50	0.00	6.25	56.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age at IgAN diagnosis												
<= 18 years	KDQOL: burden of kidney disease	Baseline	Sparsentan	9	9 (100.0)	58.33 (30.94)	6.3	37.50	62.50	68.75	100.0	
			Irbesartan	5	5 (100.0)	72.50 (31.12)	18.8	75.00	81.25	93.75	93.8	
		Week 24	Sparsentan	9	5 (55.6)	91.25 (13.69)	68.8	87.50	100.00	100.00	100.0	
			Irbesartan	5	5 (100.0)	77.50 (28.16)	31.3	75.00	81.25	100.00	100.0	
		Week 48	Sparsentan	9	7 (77.8)	64.29 (33.80)	6.3	31.25	75.00	93.75	100.0	
			Irbesartan	5	3 (60.0)	87.50 (10.83)	81.3	81.25	81.25	100.00	100.0	
		Week 70	Sparsentan	9	7 (77.8)	68.75 (24.47)	43.8	43.75	68.75	100.00	100.0	
			Irbesartan	5	4 (80.0)	76.56 (35.49)	25.0	53.13	90.63	100.00	100.0	
		Week 94	Sparsentan	9	5 (55.6)	71.25 (21.01)	37.5	68.75	75.00	81.25	93.8	
			Irbesartan	5	4 (80.0)	68.75 (34.99)	25.0	40.63	75.00	96.88	100.0	
		Week 110	Sparsentan	9	4 (44.4)	81.25 (16.14)	62.5	68.75	81.25	93.75	100.0	
			Irbesartan	5	2 (40.0)	50.00 (26.52)	31.3	31.25	50.00	68.75	68.8	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	9	5 (55.6)	27.50 (19.06)	0.0	18.75	31.25	37.50	50.0	1.61 [0.18, 3.04]
			Irbesartan	5	5 (100.0)	5.00 (5.23)	0.0	0.00	6.25	6.25	12.5	
		Week 48	Sparsentan	9	7 (77.8)	3.57 (32.65)	-62.5	-6.25	12.50	25.00	37.5	-0.02 [-1.37, 1.33]
			Irbesartan	5	3 (60.0)	4.17 (3.61)	0.0	0.00	6.25	6.25	6.3	
		Week 70	Sparsentan	9	7 (77.8)	8.04 (13.84)	0.0	0.00	0.00	12.50	37.5	0.29 [-0.94, 1.53]
			Irbesartan	5	4 (80.0)	4.69 (3.13)	0.0	3.13	6.25	6.25	6.3	
		Week 94	Sparsentan	9	5 (55.6)	7.50 (26.66)	-31.3	-6.25	12.50	31.25	31.3	0.47 [-0.86, 1.81]
			Irbesartan	5	4 (80.0)	-3.13 (14.88)	-25.0	-12.50	3.13	6.25	6.3	
		Week 110	Sparsentan	9	4 (44.4)	9.38 (21.35)	-12.5	-6.25	6.25	25.00	37.5	0.46 [-1.26, 2.17]
			Irbesartan	5	2 (40.0)	0.00 (17.68)	-12.5	-12.50	0.00	12.50	12.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 18 to 40 years	KDQOL: burden of kidney disease	Baseline	Sparsentan	102	94 (92.2)	69.95 (25.14)	0.0	62.50	75.00	87.50	100.0	
			Irbesartan	109	99 (90.8)	73.23 (24.39)	6.3	56.25	75.00	93.75	100.0	
		Week 24	Sparsentan	102	79 (77.5)	76.34 (21.76)	18.8	62.50	81.25	93.75	100.0	
			Irbesartan	109	71 (65.1)	76.76 (24.94)	0.0	62.50	81.25	100.00	100.0	
		Week 48	Sparsentan	102	82 (80.4)	76.37 (22.82)	0.0	62.50	81.25	93.75	100.0	
			Irbesartan	109	67 (61.5)	77.24 (25.51)	0.0	62.50	87.50	100.00	100.0	
		Week 70	Sparsentan	102	78 (76.5)	79.57 (19.18)	25.0	68.75	81.25	93.75	100.0	
			Irbesartan	109	68 (62.4)	78.77 (23.06)	12.5	68.75	87.50	100.00	100.0	
		Week 94	Sparsentan	102	73 (71.6)	74.91 (23.33)	0.0	68.75	81.25	93.75	100.0	
			Irbesartan	109	69 (63.3)	76.81 (24.63)	12.5	62.50	81.25	100.00	100.0	
		Week 110	Sparsentan	102	72 (70.6)	75.52 (21.41)	25.0	62.50	75.00	96.88	100.0	
			Irbesartan	109	65 (59.6)	75.29 (24.24)	25.0	62.50	75.00	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	102	79 (77.5)	8.54 (25.70)	-81.3	0.00	6.25	18.75	81.3	0.33 [0.01, 0.65]
			Irbesartan	109	71 (65.1)	0.97 (19.47)	-50.0	-6.25	0.00	6.25	56.3	
		Week 48	Sparsentan	102	82 (80.4)	7.24 (21.64)	-68.8	0.00	3.13	18.75	50.0	0.25 [-0.07, 0.57]
			Irbesartan	109	67 (61.5)	2.15 (18.86)	-62.5	-6.25	0.00	12.50	56.3	
		Week 70	Sparsentan	102	78 (76.5)	10.10 (25.29)	-43.8	-6.25	6.25	25.00	87.5	0.28 [-0.05, 0.61]
			Irbesartan	109	68 (62.4)	3.77 (18.80)	-43.8	-6.25	0.00	12.50	50.0	
		Week 94	Sparsentan	102	73 (71.6)	6.76 (25.51)	-62.5	-6.25	6.25	18.75	75.0	0.17 [-0.16, 0.50]
			Irbesartan	109	69 (63.3)	2.72 (20.85)	-50.0	-6.25	0.00	12.50	56.3	
		Week 110	Sparsentan	102	72 (70.6)	8.33 (28.69)	-56.3	-12.50	3.13	18.75	87.5	0.36 [0.02, 0.69]
			Irbesartan	109	65 (59.6)	-0.58 (20.18)	-56.3	-12.50	0.00	6.25	50.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 40 years	KDQOL: burden of kidney disease	Baseline	Sparsentan	91	84 (92.3)	71.43 (24.72)	6.3	50.00	75.00	90.63	100.0	
			Irbesartan	88	78 (88.6)	81.89 (19.26)	18.8	75.00	87.50	100.00	100.0	
		Week 24	Sparsentan	91	73 (80.2)	76.20 (23.12)	0.0	68.75	81.25	93.75	100.0	
			Irbesartan	88	55 (62.5)	81.25 (19.28)	18.8	68.75	81.25	100.00	100.0	
		Week 48	Sparsentan	91	73 (80.2)	79.88 (21.46)	6.3	75.00	81.25	100.00	100.0	
			Irbesartan	88	54 (61.4)	83.10 (14.70)	50.0	75.00	81.25	100.00	100.0	
		Week 70	Sparsentan	91	75 (82.4)	78.25 (24.19)	6.3	75.00	81.25	100.00	100.0	
			Irbesartan	88	58 (65.9)	80.71 (18.92)	12.5	75.00	78.13	100.00	100.0	
		Week 94	Sparsentan	91	73 (80.2)	77.91 (22.63)	0.0	75.00	81.25	93.75	100.0	
			Irbesartan	88	57 (64.8)	77.08 (18.35)	25.0	68.75	75.00	93.75	100.0	
		Week 110	Sparsentan	91	73 (80.2)	78.00 (22.00)	18.8	62.50	81.25	93.75	100.0	
			Irbesartan	88	54 (61.4)	78.13 (19.07)	12.5	75.00	81.25	93.75	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	91	73 (80.2)	5.57 (17.76)	-43.8	-6.25	0.00	12.50	43.8	0.34 [-0.02, 0.69]
			Irbesartan	88	55 (62.5)	-0.11 (15.57)	-31.3	-12.50	0.00	6.25	43.8	
		Week 48	Sparsentan	91	73 (80.2)	8.65 (17.88)	-43.8	0.00	6.25	18.75	62.5	0.36 [0.01, 0.72]
			Irbesartan	88	54 (61.4)	2.20 (17.52)	-50.0	-6.25	0.00	12.50	50.0	
		Week 70	Sparsentan	91	75 (82.4)	6.50 (18.22)	-50.0	0.00	6.25	18.75	50.0	0.29 [-0.06, 0.63]
			Irbesartan	88	58 (65.9)	1.29 (17.78)	-37.5	-6.25	0.00	6.25	56.3	
		Week 94	Sparsentan	91	73 (80.2)	7.71 (23.88)	-87.5	0.00	6.25	25.00	68.8	0.50 [0.15, 0.86]
			Irbesartan	88	57 (64.8)	-3.73 (21.02)	-75.0	-18.75	0.00	6.25	50.0	
		Week 110	Sparsentan	91	73 (80.2)	6.42 (19.98)	-43.8	-6.25	6.25	18.75	56.3	0.40 [0.05, 0.76]
			Irbesartan	88	54 (61.4)	-1.85 (21.43)	-62.5	-18.75	0.00	6.25	56.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Geographic region												
North America	KDQOL: burden of kidney disease	Baseline	Sparsentan	35	31 (88.6)	72.38 (25.61)	6.3	62.50	75.00	93.75	100.0	
			Irbesartan	46	43 (93.5)	82.99 (17.11)	43.8	68.75	81.25	100.00	100.0	
		Week 24	Sparsentan	35	23 (65.7)	80.71 (18.84)	25.0	68.75	81.25	100.00	100.0	
			Irbesartan	46	35 (76.1)	83.21 (21.37)	6.3	75.00	87.50	100.00	100.0	
		Week 48	Sparsentan	35	25 (71.4)	78.00 (24.94)	12.5	68.75	81.25	100.00	100.0	
			Irbesartan	46	32 (69.6)	79.49 (25.11)	0.0	71.88	84.38	100.00	100.0	
		Week 70	Sparsentan	35	22 (62.9)	79.55 (19.31)	31.3	75.00	81.25	93.75	100.0	
			Irbesartan	46	30 (65.2)	82.29 (23.56)	12.5	75.00	87.50	100.00	100.0	
		Week 94	Sparsentan	35	23 (65.7)	73.91 (27.67)	0.0	62.50	81.25	100.00	100.0	
			Irbesartan	46	30 (65.2)	80.63 (23.92)	12.5	68.75	87.50	100.00	100.0	
		Week 110	Sparsentan	35	21 (60.0)	76.19 (19.63)	37.5	56.25	75.00	93.75	100.0	
			Irbesartan	46	31 (67.4)	82.46 (19.86)	25.0	75.00	87.50	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	35	23 (65.7)	6.52 (24.75)	-37.5	-12.50	0.00	12.50	81.3	0.38 [-0.15, 0.91]
			Irbesartan	46	35 (76.1)	-1.07 (15.79)	-37.5	-12.50	0.00	6.25	31.3	
		Week 48	Sparsentan	35	25 (71.4)	8.75 (17.02)	-12.5	0.00	0.00	18.75	56.3	0.65 [0.11, 1.19]
			Irbesartan	46	32 (69.6)	-3.13 (19.18)	-62.5	-6.25	0.00	6.25	37.5	
		Week 70	Sparsentan	35	22 (62.9)	4.83 (17.67)	-25.0	-6.25	0.00	12.50	43.8	0.38 [-0.17, 0.94]
			Irbesartan	46	30 (65.2)	-1.46 (15.46)	-31.3	-12.50	0.00	6.25	31.3	
		Week 94	Sparsentan	35	23 (65.7)	0.00 (24.06)	-62.5	-12.50	0.00	12.50	68.8	0.21 [-0.33, 0.76]
			Irbesartan	46	30 (65.2)	-4.58 (19.07)	-75.0	-12.50	0.00	6.25	25.0	
		Week 110	Sparsentan	35	21 (60.0)	1.19 (20.02)	-43.8	-6.25	0.00	6.25	56.3	0.20 [-0.36, 0.75]
			Irbesartan	46	31 (67.4)	-2.22 (15.01)	-31.3	-12.50	0.00	6.25	31.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Europe	KDQOL: burden of kidney disease	Baseline	Sparsentan	98	89 (90.8)	76.26 (21.90)	6.3	68.75	81.25	93.75	100.0	
			Irbesartan	115	98 (85.2)	75.64 (24.14)	18.8	56.25	87.50	93.75	100.0	
		Week 24	Sparsentan	98	73 (74.5)	80.57 (20.56)	12.5	75.00	87.50	100.00	100.0	
			Irbesartan	115	62 (53.9)	77.72 (21.04)	25.0	62.50	81.25	93.75	100.0	
		Week 48	Sparsentan	98	76 (77.6)	79.44 (22.33)	0.0	75.00	81.25	100.00	100.0	
			Irbesartan	115	59 (51.3)	80.72 (18.87)	37.5	68.75	81.25	100.00	100.0	
		Week 70	Sparsentan	98	75 (76.5)	82.50 (18.95)	12.5	75.00	87.50	100.00	100.0	
			Irbesartan	115	69 (60.0)	79.44 (20.59)	25.0	68.75	87.50	100.00	100.0	
		Week 94	Sparsentan	98	68 (69.4)	79.69 (20.04)	6.3	68.75	81.25	93.75	100.0	
			Irbesartan	115	70 (60.9)	74.46 (23.88)	12.5	62.50	75.00	93.75	100.0	
		Week 110	Sparsentan	98	67 (68.4)	80.32 (19.86)	25.0	68.75	81.25	100.00	100.0	
			Irbesartan	115	61 (53.0)	75.72 (22.68)	25.0	62.50	75.00	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	98	73 (74.5)	4.45 (23.28)	-81.3	-6.25	0.00	12.50	75.0	0.19 [-0.15, 0.53]
			Irbesartan	115	62 (53.9)	0.40 (18.24)	-50.0	-12.50	0.00	6.25	56.3	
		Week 48	Sparsentan	98	76 (77.6)	3.29 (20.45)	-68.8	-3.13	6.25	12.50	50.0	-0.03 [-0.37, 0.31]
			Irbesartan	115	59 (51.3)	3.92 (16.61)	-50.0	-6.25	0.00	18.75	50.0	
		Week 70	Sparsentan	98	75 (76.5)	5.42 (19.83)	-50.0	0.00	0.00	18.75	87.5	0.04 [-0.29, 0.36]
			Irbesartan	115	69 (60.0)	4.71 (18.11)	-37.5	-6.25	0.00	12.50	56.3	
		Week 94	Sparsentan	98	68 (69.4)	3.86 (21.49)	-50.0	-6.25	0.00	12.50	75.0	0.18 [-0.15, 0.52]
			Irbesartan	115	70 (60.9)	-0.09 (21.40)	-50.0	-12.50	0.00	12.50	50.0	
		Week 110	Sparsentan	98	67 (68.4)	3.64 (22.83)	-56.3	-6.25	0.00	12.50	62.5	0.13 [-0.22, 0.47]
			Irbesartan	115	61 (53.0)	0.92 (20.34)	-56.3	-12.50	0.00	12.50	56.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asia Pacific	KDQOL: burden of kidney disease	Baseline	Sparsentan	69	67 (97.1)	60.73 (26.76)	0.0	43.75	62.50	87.50	100.0	
			Irbesartan	41	41 (100.0)	73.63 (24.02)	6.3	62.50	75.00	93.75	100.0	
		Week 24	Sparsentan	69	61 (88.4)	70.70 (24.27)	0.0	56.25	75.00	87.50	100.0	
			Irbesartan	41	34 (82.9)	75.74 (26.86)	0.0	68.75	81.25	100.00	100.0	
		Week 48	Sparsentan	69	61 (88.4)	74.69 (22.66)	6.3	62.50	75.00	93.75	100.0	
			Irbesartan	41	33 (80.5)	79.36 (22.07)	6.3	75.00	81.25	100.00	100.0	
		Week 70	Sparsentan	69	63 (91.3)	73.31 (24.98)	6.3	68.75	75.00	93.75	100.0	
			Irbesartan	41	31 (75.6)	77.22 (22.10)	12.5	75.00	75.00	93.75	100.0	
		Week 94	Sparsentan	69	60 (87.0)	73.23 (23.67)	0.0	62.50	75.00	90.63	100.0	
			Irbesartan	41	30 (73.2)	77.92 (15.81)	25.0	75.00	75.00	81.25	100.0	
		Week 110	Sparsentan	69	61 (88.4)	73.36 (23.52)	18.8	56.25	75.00	93.75	100.0	
			Irbesartan	41	29 (70.7)	70.26 (22.58)	12.5	62.50	75.00	81.25	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	69	61 (88.4)	12.19 (19.78)	-25.0	0.00	6.25	31.25	62.5	0.48 [0.06, 0.91]
			Irbesartan	41	34 (82.9)	2.94 (18.09)	-37.5	0.00	0.00	6.25	50.0	
		Week 48	Sparsentan	69	61 (88.4)	12.81 (20.87)	-50.0	0.00	12.50	25.00	62.5	0.42 [-0.01, 0.85]
			Irbesartan	41	33 (80.5)	4.36 (18.65)	-37.5	0.00	0.00	6.25	56.3	
		Week 70	Sparsentan	69	63 (91.3)	13.00 (24.60)	-37.5	0.00	12.50	31.25	87.5	0.46 [0.03, 0.90]
			Irbesartan	41	31 (75.6)	2.22 (19.93)	-43.8	-6.25	0.00	12.50	37.5	
		Week 94	Sparsentan	69	60 (87.0)	13.85 (26.84)	-87.5	0.00	18.75	31.25	62.5	0.41 [-0.03, 0.85]
			Irbesartan	41	30 (73.2)	3.54 (21.32)	-31.3	0.00	0.00	18.75	56.3	
		Week 110	Sparsentan	69	61 (88.4)	13.73 (26.49)	-43.8	0.00	12.50	31.25	87.5	0.69 [0.23, 1.14]
			Irbesartan	41	29 (70.7)	-4.31 (25.78)	-62.5	-25.00	0.00	6.25	50.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline BMI												
< 27 kg/m**2	KDQOL: burden of kidney disease	Baseline	Sparsentan	83	75 (90.4)	64.08 (25.83)	6.3	43.75	68.75	87.50	100.0	
			Irbesartan	94	86 (91.5)	72.75 (22.36)	18.8	56.25	75.00	93.75	100.0	
		Week 24	Sparsentan	83	66 (79.5)	72.82 (23.88)	0.0	62.50	75.00	87.50	100.0	
			Irbesartan	94	66 (70.2)	76.14 (23.69)	6.3	68.75	81.25	93.75	100.0	
		Week 48	Sparsentan	83	66 (79.5)	72.82 (24.67)	6.3	50.00	75.00	93.75	100.0	
			Irbesartan	94	60 (63.8)	74.17 (23.03)	0.0	65.63	81.25	87.50	100.0	
		Week 70	Sparsentan	83	64 (77.1)	74.32 (24.55)	6.3	59.38	81.25	93.75	100.0	
			Irbesartan	94	59 (62.8)	73.52 (22.78)	12.5	62.50	75.00	93.75	100.0	
		Week 94	Sparsentan	83	63 (75.9)	74.01 (21.69)	0.0	62.50	75.00	87.50	100.0	
			Irbesartan	94	62 (66.0)	76.21 (19.10)	12.5	68.75	75.00	93.75	100.0	
		Week 110	Sparsentan	83	63 (75.9)	74.70 (22.63)	18.8	56.25	81.25	93.75	100.0	
			Irbesartan	94	57 (60.6)	75.00 (21.49)	25.0	68.75	75.00	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	83	66 (79.5)	9.00 (22.66)	-43.8	0.00	6.25	18.75	81.3	0.25 [-0.09, 0.59]
			Irbesartan	94	66 (70.2)	3.79 (18.83)	-37.5	-12.50	0.00	12.50	56.3	
		Week 48	Sparsentan	83	66 (79.5)	9.94 (21.20)	-50.0	0.00	6.25	25.00	62.5	0.38 [0.03, 0.73]
			Irbesartan	94	60 (63.8)	1.98 (20.54)	-62.5	-6.25	0.00	15.63	56.3	
		Week 70	Sparsentan	83	64 (77.1)	9.47 (23.78)	-37.5	0.00	6.25	25.00	87.5	0.38 [0.02, 0.74]
			Irbesartan	94	59 (62.8)	1.27 (19.10)	-37.5	-6.25	0.00	12.50	43.8	
		Week 94	Sparsentan	83	63 (75.9)	10.52 (23.73)	-37.5	0.00	6.25	25.00	68.8	0.40 [0.05, 0.76]
			Irbesartan	94	62 (66.0)	1.81 (19.19)	-37.5	-6.25	0.00	12.50	56.3	
		Week 110	Sparsentan	83	63 (75.9)	9.52 (26.58)	-43.8	-6.25	6.25	25.00	87.5	0.39 [0.03, 0.75]
			Irbesartan	94	57 (60.6)	0.33 (19.35)	-56.3	-12.50	0.00	6.25	50.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 27 kg/m**2	KDQOL: burden of kidney disease	Baseline	Sparsentan	119	112 (94.1)	74.05 (24.14)	0.0	62.50	78.13	93.75	100.0	
			Irbesartan	107	95 (88.8)	81.32 (21.85)	6.3	68.75	87.50	100.00	100.0	
		Week 24	Sparsentan	119	91 (76.5)	79.60 (20.66)	12.5	68.75	87.50	100.00	100.0	
			Irbesartan	107	65 (60.7)	81.25 (21.68)	0.0	68.75	87.50	100.00	100.0	
		Week 48	Sparsentan	119	96 (80.7)	80.60 (21.02)	0.0	75.00	84.38	100.00	100.0	
			Irbesartan	107	64 (59.8)	85.55 (18.06)	31.3	75.00	93.75	100.00	100.0	
		Week 70	Sparsentan	119	96 (80.7)	81.25 (19.51)	12.5	75.00	81.25	100.00	100.0	
			Irbesartan	107	71 (66.4)	84.60 (19.24)	12.5	75.00	87.50	100.00	100.0	
		Week 94	Sparsentan	119	88 (73.9)	77.84 (23.63)	0.0	71.88	81.25	100.00	100.0	
			Irbesartan	107	67 (62.6)	78.08 (23.85)	25.0	68.75	81.25	100.00	100.0	
		Week 110	Sparsentan	119	86 (72.3)	78.49 (20.64)	25.0	62.50	81.25	100.00	100.0	
			Irbesartan	107	63 (58.9)	77.98 (22.16)	12.5	62.50	81.25	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	119	91 (76.5)	6.87 (22.23)	-81.3	-6.25	6.25	18.75	75.0	0.47 [0.15, 0.80]
			Irbesartan	107	65 (60.7)	-2.50 (15.58)	-50.0	-6.25	0.00	6.25	43.8	
		Week 48	Sparsentan	119	96 (80.7)	6.18 (19.94)	-68.8	-6.25	3.13	18.75	56.3	0.21 [-0.11, 0.52]
			Irbesartan	107	64 (59.8)	2.44 (15.37)	-37.5	-6.25	0.00	6.25	50.0	
		Week 70	Sparsentan	119	96 (80.7)	7.55 (20.44)	-50.0	0.00	6.25	18.75	87.5	0.19 [-0.11, 0.50]
			Irbesartan	107	71 (66.4)	3.87 (17.14)	-43.8	0.00	0.00	12.50	56.3	
		Week 94	Sparsentan	119	88 (73.9)	4.90 (25.08)	-87.5	-6.25	6.25	18.75	75.0	0.29 [-0.03, 0.61]
			Irbesartan	107	67 (62.6)	-2.15 (22.47)	-75.0	-18.75	0.00	12.50	50.0	
		Week 110	Sparsentan	119	86 (72.3)	5.89 (22.86)	-56.3	-6.25	0.00	18.75	75.0	0.38 [0.05, 0.71]
			Irbesartan	107	63 (58.9)	-2.58 (21.81)	-62.5	-18.75	0.00	6.25	56.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Randomization strata												
eGFR Low and UP High	KDQOL: burden of kidney disease	Baseline	Sparsentan	71	63 (88.7)	70.73 (24.25)	6.3	50.00	75.00	87.50	100.0	
			Irbesartan	74	63 (85.1)	72.82 (24.13)	18.8	56.25	75.00	93.75	100.0	
		Week 24	Sparsentan	71	54 (76.1)	76.97 (21.92)	12.5	62.50	81.25	93.75	100.0	
			Irbesartan	74	40 (54.1)	73.28 (24.72)	6.3	62.50	75.00	93.75	100.0	
		Week 48	Sparsentan	71	51 (71.8)	75.74 (21.71)	18.8	62.50	75.00	93.75	100.0	
			Irbesartan	74	37 (50.0)	77.20 (25.31)	0.0	75.00	81.25	93.75	100.0	
		Week 70	Sparsentan	71	57 (80.3)	75.33 (23.28)	12.5	62.50	75.00	93.75	100.0	
			Irbesartan	74	37 (50.0)	74.32 (21.84)	12.5	68.75	75.00	87.50	100.0	
		Week 94	Sparsentan	71	51 (71.8)	71.32 (24.94)	0.0	56.25	75.00	93.75	100.0	
			Irbesartan	74	37 (50.0)	69.26 (24.27)	12.5	62.50	75.00	81.25	100.0	
		Week 110	Sparsentan	71	53 (74.6)	75.24 (22.86)	25.0	50.00	81.25	93.75	100.0	
			Irbesartan	74	36 (48.6)	73.44 (21.46)	25.0	59.38	75.00	90.63	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	71	54 (76.1)	7.87 (22.75)	-50.0	-6.25	6.25	25.00	62.5	0.53 [0.11, 0.94]
			Irbesartan	74	40 (54.1)	-2.50 (14.42)	-37.5	-12.50	0.00	3.13	37.5	
		Week 48	Sparsentan	71	51 (71.8)	6.74 (19.24)	-50.0	-6.25	0.00	25.00	43.8	0.32 [-0.11, 0.74]
			Irbesartan	74	37 (50.0)	0.84 (17.38)	-62.5	-6.25	0.00	6.25	31.3	
		Week 70	Sparsentan	71	57 (80.3)	5.37 (20.40)	-50.0	0.00	6.25	18.75	56.3	0.25 [-0.17, 0.66]
			Irbesartan	74	37 (50.0)	0.51 (18.18)	-37.5	-6.25	0.00	6.25	56.3	
		Week 94	Sparsentan	71	51 (71.8)	1.35 (26.41)	-87.5	-6.25	0.00	18.75	56.3	0.17 [-0.25, 0.60]
			Irbesartan	74	37 (50.0)	-2.70 (18.90)	-50.0	-12.50	0.00	6.25	31.3	
		Week 110	Sparsentan	71	53 (74.6)	4.72 (22.83)	-56.3	-6.25	6.25	18.75	50.0	0.23 [-0.20, 0.65]
			Irbesartan	74	36 (48.6)	-0.35 (21.07)	-43.8	-12.50	0.00	9.38	56.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR Low and UP Low	KDQOL: burden of kidney disease	Baseline	Sparsentan	55	52 (94.5)	67.55 (25.64)	0.0	50.00	71.88	87.50	100.0	
			Irbesartan	55	50 (90.9)	78.88 (22.26)	25.0	62.50	84.38	100.00	100.0	
		Week 24	Sparsentan	55	43 (78.2)	71.95 (25.96)	0.0	56.25	75.00	93.75	100.0	
			Irbesartan	55	37 (67.3)	82.77 (17.46)	37.5	68.75	87.50	100.00	100.0	
		Week 48	Sparsentan	55	43 (78.2)	79.80 (21.08)	6.3	75.00	81.25	100.00	100.0	
			Irbesartan	55	35 (63.6)	80.54 (19.10)	31.3	75.00	81.25	100.00	100.0	
		Week 70	Sparsentan	55	42 (76.4)	76.79 (23.03)	6.3	75.00	81.25	93.75	100.0	
			Irbesartan	55	39 (70.9)	79.65 (20.57)	12.5	75.00	81.25	100.00	100.0	
		Week 94	Sparsentan	55	41 (74.5)	79.88 (19.84)	18.8	68.75	81.25	100.00	100.0	
			Irbesartan	55	39 (70.9)	76.92 (20.34)	25.0	68.75	75.00	93.75	100.0	
		Week 110	Sparsentan	55	37 (67.3)	75.17 (22.36)	18.8	62.50	75.00	93.75	100.0	
			Irbesartan	55	34 (61.8)	76.84 (20.67)	25.0	68.75	78.13	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	55	43 (78.2)	5.96 (23.89)	-81.3	0.00	0.00	18.75	62.5	0.11 [-0.33, 0.55]
			Irbesartan	55	37 (67.3)	3.72 (17.33)	-31.3	-6.25	0.00	12.50	50.0	
		Week 48	Sparsentan	55	43 (78.2)	10.61 (18.58)	-25.0	0.00	6.25	25.00	62.5	0.38 [-0.07, 0.83]
			Irbesartan	55	35 (63.6)	3.57 (18.95)	-50.0	-6.25	0.00	18.75	56.3	
		Week 70	Sparsentan	55	42 (76.4)	8.78 (22.30)	-43.8	-6.25	6.25	25.00	62.5	0.27 [-0.17, 0.71]
			Irbesartan	55	39 (70.9)	3.21 (18.80)	-43.8	-6.25	0.00	12.50	50.0	
		Week 94	Sparsentan	55	41 (74.5)	13.87 (23.78)	-50.0	0.00	12.50	25.00	68.8	0.59 [0.15, 1.04]
			Irbesartan	55	39 (70.9)	-0.48 (24.52)	-37.5	-12.50	0.00	12.50	56.3	
		Week 110	Sparsentan	55	37 (67.3)	7.77 (28.66)	-50.0	-12.50	6.25	31.25	62.5	0.19 [-0.28, 0.65]
			Irbesartan	55	34 (61.8)	3.13 (20.43)	-31.3	-12.50	0.00	12.50	50.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP High	KDQOL: burden of kidney disease	Baseline	Sparsentan	37	35 (94.6)	67.68 (27.47)	6.3	50.00	75.00	87.50	100.0	
			Irbesartan	36	33 (91.7)	76.89 (21.39)	31.3	62.50	81.25	93.75	100.0	
		Week 24	Sparsentan	37	26 (70.3)	75.48 (18.79)	25.0	68.75	78.13	87.50	100.0	
			Irbesartan	36	26 (72.2)	78.85 (23.05)	18.8	68.75	84.38	100.00	100.0	
		Week 48	Sparsentan	37	33 (89.2)	72.92 (24.74)	6.3	62.50	75.00	93.75	100.0	
			Irbesartan	36	24 (66.7)	79.95 (21.17)	31.3	71.88	81.25	100.00	100.0	
		Week 70	Sparsentan	37	31 (83.8)	79.64 (22.88)	25.0	75.00	87.50	100.00	100.0	
			Irbesartan	36	25 (69.4)	76.75 (27.33)	12.5	62.50	87.50	100.00	100.0	
		Week 94	Sparsentan	37	27 (73.0)	73.61 (21.74)	25.0	68.75	75.00	87.50	100.0	
			Irbesartan	36	24 (66.7)	80.47 (21.44)	25.0	71.88	87.50	100.00	100.0	
		Week 110	Sparsentan	37	26 (70.3)	76.44 (21.74)	25.0	68.75	75.00	100.00	100.0	
			Irbesartan	36	22 (61.1)	77.27 (26.55)	25.0	62.50	90.63	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	37	26 (70.3)	9.13 (23.00)	-31.3	-6.25	6.25	18.75	75.0	0.43 [-0.12, 0.98]
			Irbesartan	36	26 (72.2)	-0.24 (21.03)	-50.0	-6.25	0.00	6.25	50.0	
		Week 48	Sparsentan	37	33 (89.2)	6.25 (24.05)	-62.5	0.00	6.25	18.75	56.3	0.02 [-0.50, 0.55]
			Irbesartan	36	24 (66.7)	5.73 (19.93)	-37.5	-6.25	0.00	18.75	50.0	
		Week 70	Sparsentan	37	31 (83.8)	12.70 (25.39)	-25.0	0.00	6.25	18.75	87.5	0.46 [-0.08, 0.99]
			Irbesartan	36	25 (69.4)	2.25 (19.08)	-37.5	-6.25	0.00	6.25	43.8	
		Week 94	Sparsentan	37	27 (73.0)	7.64 (23.34)	-31.3	0.00	0.00	18.75	75.0	0.14 [-0.41, 0.69]
			Irbesartan	36	24 (66.7)	4.95 (13.91)	-25.0	-3.13	6.25	15.63	25.0	
		Week 110	Sparsentan	37	26 (70.3)	11.30 (23.52)	-25.0	0.00	6.25	18.75	87.5	0.61 [0.03, 1.19]
			Irbesartan	36	22 (61.1)	-1.14 (15.98)	-31.3	-12.50	0.00	6.25	37.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP Low	KDQOL: burden of kidney disease	Baseline	Sparsentan	39	37 (94.9)	74.66 (24.47)	0.0	62.50	81.25	93.75	100.0	
			Irbesartan	37	36 (97.3)	81.42 (22.08)	6.3	75.00	90.63	96.88	100.0	
		Week 24	Sparsentan	39	34 (87.2)	83.46 (19.15)	25.0	75.00	87.50	100.00	100.0	
			Irbesartan	37	28 (75.7)	80.80 (25.40)	0.0	75.00	90.63	100.00	100.0	
		Week 48	Sparsentan	39	35 (89.7)	81.25 (24.58)	0.0	75.00	87.50	100.00	100.0	
			Irbesartan	37	28 (75.7)	83.26 (18.72)	25.0	75.00	87.50	100.00	100.0	
		Week 70	Sparsentan	39	30 (76.9)	85.63 (14.32)	50.0	81.25	87.50	100.00	100.0	
			Irbesartan	37	29 (78.4)	88.58 (13.68)	56.3	75.00	93.75	100.00	100.0	
		Week 94	Sparsentan	39	32 (82.1)	81.64 (22.89)	0.0	75.00	87.50	100.00	100.0	
			Irbesartan	37	30 (81.1)	82.50 (21.30)	25.0	68.75	93.75	100.00	100.0	
		Week 110	Sparsentan	39	33 (84.6)	81.82 (18.04)	37.5	75.00	87.50	93.75	100.0	
			Irbesartan	37	29 (78.4)	77.80 (22.20)	12.5	68.75	75.00	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	39	34 (87.2)	8.82 (19.95)	-18.8	0.00	6.25	12.50	81.3	0.35 [-0.15, 0.86]
			Irbesartan	37	28 (75.7)	2.01 (18.32)	-31.3	-12.50	0.00	9.38	56.3	
		Week 48	Sparsentan	39	35 (89.7)	6.96 (21.37)	-68.8	0.00	6.25	18.75	50.0	0.40 [-0.10, 0.90]
			Irbesartan	37	28 (75.7)	-0.67 (15.99)	-43.8	-6.25	0.00	6.25	31.3	
		Week 70	Sparsentan	39	30 (76.9)	8.75 (19.74)	-12.5	-6.25	0.00	18.75	50.0	0.20 [-0.31, 0.71]
			Irbesartan	37	29 (78.4)	5.17 (16.37)	-25.0	0.00	0.00	18.75	31.3	
		Week 94	Sparsentan	39	32 (82.1)	7.81 (22.39)	-43.8	-6.25	3.13	21.88	62.5	0.40 [-0.10, 0.90]
			Irbesartan	37	30 (81.1)	-1.25 (22.94)	-75.0	-12.50	0.00	12.50	37.5	
		Week 110	Sparsentan	39	33 (84.6)	8.33 (23.32)	-18.8	-6.25	0.00	18.75	75.0	0.67 [0.16, 1.18]
			Irbesartan	37	29 (78.4)	-7.11 (22.70)	-62.5	-25.00	0.00	6.25	31.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 1												
< 60 mL/min/1.73 m**2	KDQOL: burden of kidney disease	Baseline	Sparsentan	127	116 (91.3)	70.10 (25.09)	0.0	50.00	75.00	87.50	100.0	
			Irbesartan	129	114 (88.4)	77.41 (22.84)	18.8	62.50	81.25	100.00	100.0	
		Week 24	Sparsentan	127	98 (77.2)	74.74 (23.69)	0.0	62.50	81.25	93.75	100.0	
			Irbesartan	129	80 (62.0)	77.89 (21.97)	6.3	68.75	81.25	100.00	100.0	
		Week 48	Sparsentan	127	95 (74.8)	77.76 (21.43)	6.3	68.75	81.25	100.00	100.0	
			Irbesartan	129	74 (57.4)	79.31 (22.80)	0.0	75.00	81.25	100.00	100.0	
		Week 70	Sparsentan	127	100 (78.7)	76.13 (23.05)	6.3	68.75	81.25	93.75	100.0	
			Irbesartan	129	78 (60.5)	78.37 (21.53)	12.5	68.75	78.13	100.00	100.0	
		Week 94	Sparsentan	127	92 (72.4)	75.07 (23.27)	0.0	65.63	78.13	93.75	100.0	
			Irbesartan	129	77 (59.7)	74.19 (22.81)	12.5	62.50	75.00	93.75	100.0	
		Week 110	Sparsentan	127	92 (72.4)	76.36 (22.41)	18.8	62.50	81.25	93.75	100.0	
			Irbesartan	129	72 (55.8)	76.56 (20.39)	25.0	65.63	81.25	96.88	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	127	98 (77.2)	6.31 (23.12)	-81.3	-6.25	0.00	18.75	62.5	0.34 [0.04, 0.63]
			Irbesartan	129	80 (62.0)	-0.47 (15.65)	-37.5	-12.50	0.00	6.25	50.0	
		Week 48	Sparsentan	127	95 (74.8)	7.70 (18.56)	-50.0	0.00	6.25	18.75	62.5	0.35 [0.04, 0.66]
			Irbesartan	129	74 (57.4)	1.18 (18.61)	-62.5	-6.25	0.00	12.50	56.3	
		Week 70	Sparsentan	127	100 (78.7)	6.06 (20.97)	-50.0	-6.25	6.25	18.75	62.5	0.20 [-0.10, 0.50]
			Irbesartan	129	78 (60.5)	2.08 (18.26)	-43.8	-6.25	0.00	12.50	56.3	
		Week 94	Sparsentan	127	92 (72.4)	6.18 (26.31)	-87.5	-6.25	6.25	25.00	68.8	0.34 [0.04, 0.65]
			Irbesartan	129	77 (59.7)	-2.27 (22.92)	-75.0	-12.50	0.00	6.25	56.3	
		Week 110	Sparsentan	127	92 (72.4)	6.05 (24.94)	-56.3	-6.25	6.25	21.88	62.5	0.22 [-0.09, 0.53]
			Irbesartan	129	72 (55.8)	0.95 (19.98)	-43.8	-12.50	0.00	9.38	56.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	KDQOL: burden of kidney disease	Baseline	Sparsentan	49	47 (95.9)	72.61 (23.91)	0.0	62.50	75.00	87.50	100.0	
			Irbesartan	48	44 (91.7)	78.27 (21.33)	18.8	65.63	87.50	93.75	100.0	
		Week 24	Sparsentan	49	38 (77.6)	79.28 (19.45)	25.0	68.75	81.25	93.75	100.0	
			Irbesartan	48	31 (64.6)	85.28 (16.89)	37.5	75.00	93.75	100.00	100.0	
		Week 48	Sparsentan	49	44 (89.8)	78.13 (23.67)	6.3	75.00	81.25	96.88	100.0	
			Irbesartan	48	32 (66.7)	79.88 (20.00)	25.0	68.75	81.25	100.00	100.0	
		Week 70	Sparsentan	49	38 (77.6)	81.41 (19.63)	25.0	75.00	84.38	100.00	100.0	
			Irbesartan	48	32 (66.7)	80.47 (22.21)	25.0	71.88	87.50	100.00	100.0	
		Week 94	Sparsentan	49	39 (79.6)	77.56 (23.55)	0.0	68.75	81.25	100.00	100.0	
			Irbesartan	48	34 (70.8)	77.02 (20.34)	25.0	68.75	75.00	93.75	100.0	
		Week 110	Sparsentan	49	36 (73.5)	74.83 (20.02)	37.5	56.25	78.13	93.75	100.0	
			Irbesartan	48	32 (66.7)	75.59 (22.47)	25.0	65.63	75.00	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	49	38 (77.6)	7.89 (21.34)	-31.3	-6.25	6.25	18.75	81.3	0.19 [-0.29, 0.66]
			Irbesartan	48	31 (64.6)	4.23 (17.48)	-25.0	-6.25	0.00	12.50	50.0	
		Week 48	Sparsentan	49	44 (89.8)	6.68 (20.77)	-62.5	0.00	3.13	21.88	50.0	0.21 [-0.25, 0.66]
			Irbesartan	48	32 (66.7)	2.54 (18.64)	-43.8	-6.25	0.00	9.38	50.0	
		Week 70	Sparsentan	49	38 (77.6)	7.73 (17.88)	-25.0	0.00	0.00	18.75	50.0	0.31 [-0.16, 0.78]
			Irbesartan	48	32 (66.7)	2.15 (18.28)	-25.0	-9.38	0.00	9.38	43.8	
		Week 94	Sparsentan	49	39 (79.6)	6.73 (19.15)	-31.3	0.00	6.25	18.75	62.5	0.47 [0.01, 0.94]
			Irbesartan	48	34 (70.8)	-1.84 (16.68)	-37.5	-12.50	0.00	6.25	25.0	
		Week 110	Sparsentan	49	36 (73.5)	6.25 (21.02)	-25.0	-9.38	0.00	15.63	75.0	0.56 [0.07, 1.04]
			Irbesartan	48	32 (66.7)	-5.47 (20.99)	-56.3	-25.00	0.00	6.25	37.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	KDQOL: burden of kidney disease	Baseline	Sparsentan	26	24 (92.3)	64.84 (28.66)	6.3	50.00	75.00	87.50	100.0	
			Irbesartan	25	24 (96.0)	72.14 (25.47)	6.3	53.13	75.00	93.75	100.0	
		Week 24	Sparsentan	26	21 (80.8)	81.55 (19.61)	31.3	75.00	87.50	100.00	100.0	
			Irbesartan	25	20 (80.0)	71.56 (31.05)	0.0	50.00	81.25	100.00	100.0	
		Week 48	Sparsentan	26	23 (88.5)	74.73 (27.34)	0.0	56.25	87.50	100.00	100.0	
			Irbesartan	25	18 (72.0)	83.33 (17.55)	43.8	75.00	84.38	100.00	100.0	
		Week 70	Sparsentan	26	22 (84.6)	84.09 (18.97)	25.0	81.25	87.50	100.00	100.0	
			Irbesartan	25	20 (80.0)	82.81 (21.35)	12.5	71.88	87.50	100.00	100.0	
		Week 94	Sparsentan	26	20 (76.9)	79.06 (20.00)	25.0	75.00	81.25	100.00	100.0	
			Irbesartan	25	19 (76.0)	86.18 (21.91)	25.0	75.00	100.00	100.00	100.0	
		Week 110	Sparsentan	26	21 (80.8)	82.74 (19.85)	25.0	75.00	87.50	100.00	100.0	
			Irbesartan	25	17 (68.0)	75.37 (29.60)	12.5	56.25	93.75	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	26	21 (80.8)	14.29 (20.27)	-6.3	0.00	6.25	18.75	75.0	0.66 [0.03, 1.29]
			Irbesartan	25	20 (80.0)	-0.31 (23.86)	-50.0	-9.38	0.00	9.38	56.3	
		Week 48	Sparsentan	26	23 (88.5)	9.78 (27.36)	-68.8	0.00	12.50	25.00	56.3	0.17 [-0.45, 0.79]
			Irbesartan	25	18 (72.0)	5.90 (14.13)	-18.8	-6.25	6.25	12.50	31.3	
		Week 70	Sparsentan	26	22 (84.6)	19.60 (28.24)	-12.5	0.00	12.50	31.25	87.5	0.58 [-0.04, 1.20]
			Irbesartan	25	20 (80.0)	5.94 (17.26)	-37.5	0.00	6.25	18.75	31.3	
		Week 94	Sparsentan	26	20 (76.9)	13.13 (26.20)	-18.8	-3.13	3.13	28.13	75.0	0.12 [-0.51, 0.75]
			Irbesartan	25	19 (76.0)	10.53 (16.01)	-25.0	0.00	6.25	25.00	37.5	
		Week 110	Sparsentan	26	21 (80.8)	15.48 (27.43)	-18.8	0.00	6.25	18.75	87.5	0.69 [0.03, 1.34]
			Irbesartan	25	17 (68.0)	-1.84 (22.18)	-62.5	-12.50	6.25	12.50	31.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 2												
< 45 mL/min/1.73 m**2	KDQOL: burden of kidney disease	Baseline	Sparsentan	82	73 (89.0)	67.29 (25.03)	6.3	50.00	75.00	87.50	100.0	
			Irbesartan	80	69 (86.3)	73.82 (24.05)	18.8	62.50	81.25	93.75	100.0	
		Week 24	Sparsentan	82	64 (78.0)	75.10 (24.00)	12.5	62.50	81.25	100.00	100.0	
			Irbesartan	80	48 (60.0)	76.69 (24.39)	6.3	62.50	81.25	100.00	100.0	
		Week 48	Sparsentan	82	61 (74.4)	76.13 (23.32)	6.3	62.50	81.25	93.75	100.0	
			Irbesartan	80	43 (53.8)	78.63 (24.44)	0.0	75.00	81.25	100.00	100.0	
		Week 70	Sparsentan	82	65 (79.3)	75.87 (24.13)	6.3	68.75	81.25	93.75	100.0	
			Irbesartan	80	45 (56.3)	76.25 (21.76)	12.5	68.75	75.00	93.75	100.0	
		Week 94	Sparsentan	82	60 (73.2)	75.31 (22.85)	0.0	68.75	81.25	93.75	100.0	
			Irbesartan	80	47 (58.8)	70.88 (23.47)	12.5	62.50	75.00	93.75	100.0	
		Week 110	Sparsentan	82	56 (68.3)	76.45 (23.57)	18.8	59.38	81.25	96.88	100.0	
			Irbesartan	80	44 (55.0)	75.00 (19.90)	25.0	62.50	78.13	90.63	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	82	64 (78.0)	8.01 (22.73)	-81.3	0.00	6.25	18.75	62.5	0.37 [-0.01, 0.74]
			Irbesartan	80	48 (60.0)	0.78 (14.79)	-37.5	-6.25	0.00	12.50	37.5	
		Week 48	Sparsentan	82	61 (74.4)	8.81 (20.71)	-50.0	0.00	6.25	25.00	62.5	0.29 [-0.10, 0.68]
			Irbesartan	80	43 (53.8)	3.20 (17.38)	-62.5	-6.25	0.00	18.75	43.8	
		Week 70	Sparsentan	82	65 (79.3)	7.98 (19.78)	-43.8	0.00	6.25	18.75	56.3	0.23 [-0.15, 0.61]
			Irbesartan	80	45 (56.3)	3.47 (20.01)	-37.5	-6.25	0.00	12.50	56.3	
		Week 94	Sparsentan	82	60 (73.2)	7.19 (25.70)	-87.5	-6.25	6.25	25.00	68.8	0.39 [0.00, 0.77]
			Irbesartan	80	47 (58.8)	-2.39 (23.59)	-50.0	-18.75	0.00	12.50	50.0	
		Week 110	Sparsentan	82	56 (68.3)	7.81 (24.23)	-56.3	0.00	6.25	25.00	62.5	0.26 [-0.13, 0.66]
			Irbesartan	80	44 (55.0)	1.85 (20.69)	-43.8	-12.50	0.00	9.38	56.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
45 to < 60 mL/min/1.73 m**2	KDQOL: burden of kidney disease	Baseline	Sparsentan	45	43 (95.6)	74.85 (24.76)	0.0	62.50	81.25	93.75	100.0	
			Irbesartan	49	45 (91.8)	82.92 (19.87)	25.0	68.75	93.75	100.00	100.0	
		Week 24	Sparsentan	45	34 (75.6)	74.08 (23.44)	0.0	62.50	75.00	93.75	100.0	
			Irbesartan	49	32 (65.3)	79.69 (17.96)	31.3	68.75	81.25	96.88	100.0	
		Week 48	Sparsentan	45	34 (75.6)	80.70 (17.50)	43.8	68.75	81.25	100.00	100.0	
			Irbesartan	49	31 (63.3)	80.24 (20.67)	31.3	75.00	81.25	100.00	100.0	
		Week 70	Sparsentan	45	35 (77.8)	76.61 (21.24)	12.5	62.50	75.00	93.75	100.0	
			Irbesartan	49	33 (67.3)	81.25 (21.19)	12.5	68.75	87.50	100.00	100.0	
		Week 94	Sparsentan	45	32 (71.1)	74.61 (24.38)	18.8	59.38	75.00	96.88	100.0	
			Irbesartan	49	30 (61.2)	79.38 (21.09)	25.0	75.00	81.25	100.00	100.0	
		Week 110	Sparsentan	45	36 (80.0)	76.22 (20.80)	25.0	65.63	78.13	93.75	100.0	
			Irbesartan	49	28 (57.1)	79.02 (21.26)	25.0	71.88	81.25	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	45	34 (75.6)	3.13 (23.85)	-50.0	-12.50	0.00	18.75	50.0	0.26 [-0.22, 0.75]
			Irbesartan	49	32 (65.3)	-2.34 (16.93)	-37.5	-12.50	0.00	0.00	50.0	
		Week 48	Sparsentan	45	34 (75.6)	5.70 (13.96)	-25.0	0.00	3.13	12.50	37.5	0.43 [-0.07, 0.92]
			Irbesartan	49	31 (63.3)	-1.61 (20.15)	-50.0	-6.25	0.00	6.25	56.3	
		Week 70	Sparsentan	45	35 (77.8)	2.50 (22.90)	-50.0	-12.50	0.00	18.75	62.5	0.12 [-0.36, 0.59]
			Irbesartan	49	33 (67.3)	0.19 (15.66)	-43.8	-6.25	0.00	6.25	37.5	
		Week 94	Sparsentan	45	32 (71.1)	4.30 (27.74)	-62.5	-15.63	6.25	25.00	56.3	0.25 [-0.25, 0.75]
			Irbesartan	49	30 (61.2)	-2.08 (22.22)	-75.0	-12.50	0.00	6.25	56.3	
		Week 110	Sparsentan	45	36 (80.0)	3.30 (26.11)	-50.0	-12.50	0.00	15.63	62.5	0.16 [-0.33, 0.66]
			Irbesartan	49	28 (57.1)	-0.45 (19.09)	-31.3	-9.38	0.00	9.38	50.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	KDQOL: burden of kidney disease	Baseline	Sparsentan	49	47 (95.9)	72.61 (23.91)	0.0	62.50	75.00	87.50	100.0	
			Irbesartan	48	44 (91.7)	78.27 (21.33)	18.8	65.63	87.50	93.75	100.0	
		Week 24	Sparsentan	49	38 (77.6)	79.28 (19.45)	25.0	68.75	81.25	93.75	100.0	
			Irbesartan	48	31 (64.6)	85.28 (16.89)	37.5	75.00	93.75	100.00	100.0	
		Week 48	Sparsentan	49	44 (89.8)	78.13 (23.67)	6.3	75.00	81.25	96.88	100.0	
			Irbesartan	48	32 (66.7)	79.88 (20.00)	25.0	68.75	81.25	100.00	100.0	
		Week 70	Sparsentan	49	38 (77.6)	81.41 (19.63)	25.0	75.00	84.38	100.00	100.0	
			Irbesartan	48	32 (66.7)	80.47 (22.21)	25.0	71.88	87.50	100.00	100.0	
		Week 94	Sparsentan	49	39 (79.6)	77.56 (23.55)	0.0	68.75	81.25	100.00	100.0	
			Irbesartan	48	34 (70.8)	77.02 (20.34)	25.0	68.75	75.00	93.75	100.0	
		Week 110	Sparsentan	49	36 (73.5)	74.83 (20.02)	37.5	56.25	78.13	93.75	100.0	
			Irbesartan	48	32 (66.7)	75.59 (22.47)	25.0	65.63	75.00	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	49	38 (77.6)	7.89 (21.34)	-31.3	-6.25	6.25	18.75	81.3	0.19 [-0.29, 0.66]
			Irbesartan	48	31 (64.6)	4.23 (17.48)	-25.0	-6.25	0.00	12.50	50.0	
		Week 48	Sparsentan	49	44 (89.8)	6.68 (20.77)	-62.5	0.00	3.13	21.88	50.0	0.21 [-0.25, 0.66]
			Irbesartan	48	32 (66.7)	2.54 (18.64)	-43.8	-6.25	0.00	9.38	50.0	
		Week 70	Sparsentan	49	38 (77.6)	7.73 (17.88)	-25.0	0.00	0.00	18.75	50.0	0.31 [-0.16, 0.78]
			Irbesartan	48	32 (66.7)	2.15 (18.28)	-25.0	-9.38	0.00	9.38	43.8	
		Week 94	Sparsentan	49	39 (79.6)	6.73 (19.15)	-31.3	0.00	6.25	18.75	62.5	0.47 [0.01, 0.94]
			Irbesartan	48	34 (70.8)	-1.84 (16.68)	-37.5	-12.50	0.00	6.25	25.0	
		Week 110	Sparsentan	49	36 (73.5)	6.25 (21.02)	-25.0	-9.38	0.00	15.63	75.0	0.56 [0.07, 1.04]
			Irbesartan	48	32 (66.7)	-5.47 (20.99)	-56.3	-25.00	0.00	6.25	37.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	KDQOL: burden of kidney disease	Baseline	Sparsentan	26	24 (92.3)	64.84 (28.66)	6.3	50.00	75.00	87.50	100.0	
			Irbesartan	25	24 (96.0)	72.14 (25.47)	6.3	53.13	75.00	93.75	100.0	
		Week 24	Sparsentan	26	21 (80.8)	81.55 (19.61)	31.3	75.00	87.50	100.00	100.0	
			Irbesartan	25	20 (80.0)	71.56 (31.05)	0.0	50.00	81.25	100.00	100.0	
		Week 48	Sparsentan	26	23 (88.5)	74.73 (27.34)	0.0	56.25	87.50	100.00	100.0	
			Irbesartan	25	18 (72.0)	83.33 (17.55)	43.8	75.00	84.38	100.00	100.0	
		Week 70	Sparsentan	26	22 (84.6)	84.09 (18.97)	25.0	81.25	87.50	100.00	100.0	
			Irbesartan	25	20 (80.0)	82.81 (21.35)	12.5	71.88	87.50	100.00	100.0	
		Week 94	Sparsentan	26	20 (76.9)	79.06 (20.00)	25.0	75.00	81.25	100.00	100.0	
			Irbesartan	25	19 (76.0)	86.18 (21.91)	25.0	75.00	100.00	100.00	100.0	
		Week 110	Sparsentan	26	21 (80.8)	82.74 (19.85)	25.0	75.00	87.50	100.00	100.0	
			Irbesartan	25	17 (68.0)	75.37 (29.60)	12.5	56.25	93.75	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	26	21 (80.8)	14.29 (20.27)	-6.3	0.00	6.25	18.75	75.0	0.66 [0.03, 1.29]
			Irbesartan	25	20 (80.0)	-0.31 (23.86)	-50.0	-9.38	0.00	9.38	56.3	
		Week 48	Sparsentan	26	23 (88.5)	9.78 (27.36)	-68.8	0.00	12.50	25.00	56.3	0.17 [-0.45, 0.79]
			Irbesartan	25	18 (72.0)	5.90 (14.13)	-18.8	-6.25	6.25	12.50	31.3	
		Week 70	Sparsentan	26	22 (84.6)	19.60 (28.24)	-12.5	0.00	12.50	31.25	87.5	0.58 [-0.04, 1.20]
			Irbesartan	25	20 (80.0)	5.94 (17.26)	-37.5	0.00	6.25	18.75	31.3	
		Week 94	Sparsentan	26	20 (76.9)	13.13 (26.20)	-18.8	-3.13	3.13	28.13	75.0	0.12 [-0.51, 0.75]
			Irbesartan	25	19 (76.0)	10.53 (16.01)	-25.0	0.00	6.25	25.00	37.5	
		Week 110	Sparsentan	26	21 (80.8)	15.48 (27.43)	-18.8	0.00	6.25	18.75	87.5	0.69 [0.03, 1.34]
			Irbesartan	25	17 (68.0)	-1.84 (22.18)	-62.5	-12.50	6.25	12.50	31.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline urine protein excretion												
<= 1.75 g/day	KDQOL: burden of kidney disease	Baseline	Sparsentan	98	93 (94.9)	69.76 (25.04)	0.0	56.25	75.00	87.50	100.0	
			Irbesartan	93	83 (89.2)	78.61 (21.76)	6.3	68.75	87.50	93.75	100.0	
		Week 24	Sparsentan	98	80 (81.6)	77.42 (23.20)	12.5	68.75	81.25	100.00	100.0	
			Irbesartan	93	55 (59.1)	81.82 (22.12)	0.0	68.75	87.50	100.00	100.0	
		Week 48	Sparsentan	98	82 (83.7)	78.89 (22.84)	0.0	75.00	81.25	100.00	100.0	
			Irbesartan	93	57 (61.3)	81.69 (18.86)	25.0	75.00	81.25	100.00	100.0	
		Week 70	Sparsentan	98	75 (76.5)	78.33 (21.73)	6.3	68.75	81.25	100.00	100.0	
			Irbesartan	93	61 (65.6)	83.61 (18.86)	12.5	75.00	87.50	100.00	100.0	
		Week 94	Sparsentan	98	76 (77.6)	76.89 (23.94)	0.0	68.75	81.25	100.00	100.0	
			Irbesartan	93	63 (67.7)	78.08 (22.53)	12.5	68.75	81.25	100.00	100.0	
		Week 110	Sparsentan	98	75 (76.5)	77.00 (21.09)	18.8	62.50	81.25	93.75	100.0	
			Irbesartan	93	57 (61.3)	76.97 (22.94)	12.5	68.75	81.25	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	98	80 (81.6)	8.98 (23.32)	-81.3	0.00	6.25	21.88	81.3	0.34 [-0.01, 0.68]
			Irbesartan	93	55 (59.1)	1.93 (16.62)	-31.3	-6.25	0.00	12.50	50.0	
		Week 48	Sparsentan	98	82 (83.7)	8.00 (20.21)	-68.8	-6.25	6.25	25.00	62.5	0.32 [-0.02, 0.66]
			Irbesartan	93	57 (61.3)	1.86 (17.72)	-50.0	-6.25	0.00	12.50	56.3	
		Week 70	Sparsentan	98	75 (76.5)	7.42 (21.84)	-43.8	-6.25	0.00	25.00	62.5	0.17 [-0.17, 0.51]
			Irbesartan	93	61 (65.6)	4.00 (16.73)	-43.8	-6.25	0.00	12.50	43.8	
		Week 94	Sparsentan	98	76 (77.6)	8.22 (25.27)	-62.5	-6.25	6.25	25.00	68.8	0.36 [0.03, 0.70]
			Irbesartan	93	63 (67.7)	-0.10 (19.43)	-37.5	-12.50	0.00	12.50	56.3	
		Week 110	Sparsentan	98	75 (76.5)	8.25 (25.73)	-50.0	-6.25	0.00	25.00	75.0	0.34 [-0.00, 0.69]
			Irbesartan	93	57 (61.3)	0.22 (19.90)	-62.5	-12.50	0.00	12.50	50.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 1.75 g/day	KDQOL: burden of kidney disease	Baseline	Sparsentan	104	94 (90.4)	70.35 (25.58)	6.3	56.25	75.00	87.50	100.0	
			Irbesartan	109	99 (90.8)	75.51 (23.65)	18.8	56.25	81.25	100.00	100.0	
		Week 24	Sparsentan	104	77 (74.0)	76.06 (21.35)	0.0	68.75	81.25	93.75	100.0	
			Irbesartan	109	76 (69.7)	76.40 (23.11)	6.3	65.63	81.25	93.75	100.0	
		Week 48	Sparsentan	104	80 (76.9)	75.94 (22.87)	6.3	62.50	81.25	96.88	100.0	
			Irbesartan	109	67 (61.5)	78.64 (23.24)	0.0	68.75	81.25	100.00	100.0	
		Week 70	Sparsentan	104	85 (81.7)	78.60 (22.11)	12.5	68.75	81.25	93.75	100.0	
			Irbesartan	109	69 (63.3)	76.00 (23.25)	12.5	68.75	75.00	93.75	100.0	
		Week 94	Sparsentan	104	75 (72.1)	75.58 (21.82)	0.0	68.75	81.25	93.75	100.0	
			Irbesartan	109	67 (61.5)	75.37 (22.13)	12.5	62.50	75.00	93.75	100.0	
		Week 110	Sparsentan	104	74 (71.2)	76.77 (22.08)	25.0	62.50	81.25	93.75	100.0	
			Irbesartan	109	64 (58.7)	75.39 (21.70)	25.0	62.50	75.00	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	104	77 (74.0)	6.49 (21.40)	-50.0	-6.25	6.25	12.50	75.0	0.34 [0.02, 0.66]
			Irbesartan	109	76 (69.7)	-0.25 (18.18)	-50.0	-9.38	0.00	6.25	56.3	
		Week 48	Sparsentan	104	80 (76.9)	7.42 (20.89)	-62.5	0.00	6.25	18.75	56.3	0.25 [-0.08, 0.57]
			Irbesartan	109	67 (61.5)	2.52 (18.34)	-62.5	-6.25	0.00	18.75	50.0	
		Week 70	Sparsentan	104	85 (81.7)	9.12 (21.83)	-50.0	0.00	6.25	18.75	87.5	0.37 [0.05, 0.69]
			Irbesartan	109	69 (63.3)	1.54 (19.16)	-37.5	-6.25	0.00	6.25	56.3	
		Week 94	Sparsentan	104	75 (72.1)	6.25 (24.03)	-87.5	0.00	6.25	18.75	75.0	0.29 [-0.04, 0.62]
			Irbesartan	109	67 (61.5)	-0.47 (22.33)	-75.0	-12.50	0.00	12.50	50.0	
		Week 110	Sparsentan	104	74 (71.2)	6.59 (23.29)	-56.3	0.00	6.25	18.75	87.5	0.40 [0.06, 0.74]
			Irbesartan	109	64 (58.7)	-2.34 (21.23)	-56.3	-18.75	0.00	6.25	56.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline use of antihypertensives												
Yes	KDQOL: burden of kidney disease	Baseline	Sparsentan	90	79 (87.8)	70.17 (25.28)	6.3	56.25	75.00	87.50	100.0	
			Irbesartan	88	76 (86.4)	77.80 (21.73)	18.8	62.50	84.38	100.00	100.0	
		Week 24	Sparsentan	90	66 (73.3)	77.18 (22.80)	0.0	68.75	81.25	93.75	100.0	
			Irbesartan	88	49 (55.7)	78.57 (23.18)	6.3	68.75	81.25	100.00	100.0	
		Week 48	Sparsentan	90	65 (72.2)	78.17 (21.37)	6.3	68.75	81.25	100.00	100.0	
			Irbesartan	88	47 (53.4)	76.99 (20.32)	25.0	68.75	81.25	93.75	100.0	
		Week 70	Sparsentan	90	68 (75.6)	77.67 (23.69)	6.3	75.00	81.25	93.75	100.0	
			Irbesartan	88	49 (55.7)	75.77 (24.43)	12.5	62.50	75.00	100.00	100.0	
		Week 94	Sparsentan	90	63 (70.0)	77.68 (22.16)	6.3	68.75	81.25	93.75	100.0	
			Irbesartan	88	54 (61.4)	72.45 (24.27)	12.5	62.50	75.00	93.75	100.0	
		Week 110	Sparsentan	90	63 (70.0)	76.29 (22.73)	25.0	62.50	81.25	93.75	100.0	
			Irbesartan	88	51 (58.0)	73.16 (21.55)	25.0	68.75	75.00	87.50	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	90	66 (73.3)	8.43 (20.58)	-31.3	-6.25	0.00	18.75	75.0	0.49 [0.11, 0.86]
			Irbesartan	88	49 (55.7)	-0.77 (16.12)	-37.5	-6.25	0.00	6.25	37.5	
		Week 48	Sparsentan	90	65 (72.2)	9.90 (19.51)	-50.0	0.00	6.25	25.00	56.3	0.49 [0.11, 0.87]
			Irbesartan	88	47 (53.4)	0.53 (18.56)	-50.0	-6.25	0.00	6.25	43.8	
		Week 70	Sparsentan	90	68 (75.6)	7.17 (21.93)	-50.0	-6.25	3.13	18.75	87.5	0.34 [-0.03, 0.71]
			Irbesartan	88	49 (55.7)	0.00 (19.39)	-43.8	-12.50	0.00	12.50	37.5	
		Week 94	Sparsentan	90	63 (70.0)	9.62 (24.31)	-62.5	0.00	6.25	25.00	75.0	0.54 [0.17, 0.91]
			Irbesartan	88	54 (61.4)	-3.24 (23.25)	-75.0	-18.75	0.00	12.50	50.0	
		Week 110	Sparsentan	90	63 (70.0)	7.04 (22.10)	-56.3	0.00	6.25	18.75	62.5	0.49 [0.12, 0.87]
			Irbesartan	88	51 (58.0)	-3.06 (18.51)	-43.8	-12.50	0.00	6.25	43.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	KDQOL: burden of kidney disease	Baseline	Sparsentan	112	108 (96.4)	69.97 (25.34)	0.0	53.13	75.00	87.50	100.0	
			Irbesartan	114	106 (93.0)	76.30 (23.62)	6.3	62.50	81.25	93.75	100.0	
		Week 24	Sparsentan	112	91 (81.3)	76.44 (21.97)	18.8	62.50	81.25	100.00	100.0	
			Irbesartan	114	82 (71.9)	78.73 (22.67)	0.0	68.75	81.25	100.00	100.0	
		Week 48	Sparsentan	112	97 (86.6)	76.93 (23.86)	0.0	62.50	81.25	100.00	100.0	
			Irbesartan	114	77 (67.5)	81.90 (21.81)	0.0	75.00	87.50	100.00	100.0	
		Week 70	Sparsentan	112	92 (82.1)	79.08 (20.52)	25.0	68.75	81.25	100.00	100.0	
			Irbesartan	114	81 (71.1)	81.87 (19.43)	25.0	75.00	87.50	100.00	100.0	
		Week 94	Sparsentan	112	88 (78.6)	75.21 (23.39)	0.0	68.75	78.13	93.75	100.0	
			Irbesartan	114	76 (66.7)	79.69 (20.39)	25.0	68.75	81.25	100.00	100.0	
		Week 110	Sparsentan	112	86 (76.8)	77.33 (20.70)	18.8	62.50	81.25	100.00	100.0	
			Irbesartan	114	70 (61.4)	78.30 (22.59)	12.5	62.50	81.25	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	112	91 (81.3)	7.28 (23.67)	-81.3	0.00	6.25	18.75	81.3	0.27 [-0.03, 0.57]
			Irbesartan	114	82 (71.9)	1.52 (18.34)	-50.0	-6.25	0.00	6.25	56.3	
		Week 48	Sparsentan	112	97 (86.6)	6.25 (21.08)	-68.8	0.00	0.00	18.75	62.5	0.15 [-0.15, 0.45]
			Irbesartan	114	77 (67.5)	3.25 (17.67)	-62.5	-6.25	0.00	12.50	56.3	
		Week 70	Sparsentan	112	92 (82.1)	9.17 (21.76)	-43.8	0.00	6.25	18.75	87.5	0.25 [-0.05, 0.55]
			Irbesartan	114	81 (71.1)	4.32 (17.08)	-25.0	-6.25	0.00	6.25	56.3	
		Week 94	Sparsentan	112	88 (78.6)	5.54 (24.81)	-87.5	-6.25	6.25	18.75	62.5	0.17 [-0.14, 0.47]
			Irbesartan	114	76 (66.7)	1.81 (18.92)	-50.0	-6.25	0.00	12.50	56.3	
		Week 110	Sparsentan	112	86 (76.8)	7.70 (26.21)	-50.0	-6.25	6.25	18.75	87.5	0.30 [-0.01, 0.62]
			Irbesartan	114	70 (61.4)	0.27 (21.97)	-62.5	-12.50	0.00	12.50	56.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Time since renal biopsy												
<= 5 years	KDQOL: burden of kidney disease	Baseline	Sparsentan	113	104 (92.0)	67.91 (26.43)	0.0	50.00	75.00	87.50	100.0	
			Irbesartan	127	118 (92.9)	75.48 (22.96)	6.3	56.25	81.25	93.75	100.0	
		Week 24	Sparsentan	113	88 (77.9)	76.70 (23.13)	0.0	68.75	81.25	100.00	100.0	
			Irbesartan	127	86 (67.7)	77.83 (22.84)	0.0	62.50	81.25	100.00	100.0	
		Week 48	Sparsentan	113	92 (81.4)	76.02 (23.24)	6.3	62.50	81.25	100.00	100.0	
			Irbesartan	127	85 (66.9)	79.56 (22.21)	0.0	75.00	81.25	100.00	100.0	
		Week 70	Sparsentan	113	90 (79.6)	76.46 (23.46)	6.3	68.75	81.25	93.75	100.0	
			Irbesartan	127	86 (67.7)	79.36 (21.48)	12.5	68.75	84.38	100.00	100.0	
		Week 94	Sparsentan	113	86 (76.1)	76.16 (22.82)	0.0	68.75	81.25	93.75	100.0	
			Irbesartan	127	86 (67.7)	77.11 (22.10)	12.5	68.75	78.13	100.00	100.0	
		Week 110	Sparsentan	113	88 (77.9)	76.14 (22.58)	18.8	59.38	81.25	93.75	100.0	
			Irbesartan	127	80 (63.0)	76.64 (22.82)	12.5	62.50	75.00	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	113	88 (77.9)	11.15 (21.76)	-50.0	0.00	6.25	25.00	81.3	0.45 [0.15, 0.75]
			Irbesartan	127	86 (67.7)	2.03 (18.48)	-50.0	-6.25	0.00	12.50	56.3	
		Week 48	Sparsentan	113	92 (81.4)	9.71 (18.59)	-43.8	0.00	6.25	25.00	56.3	0.31 [0.01, 0.61]
			Irbesartan	127	85 (66.9)	3.75 (20.00)	-62.5	-6.25	0.00	12.50	56.3	
		Week 70	Sparsentan	113	90 (79.6)	8.68 (21.87)	-50.0	-6.25	6.25	18.75	87.5	0.28 [-0.02, 0.57]
			Irbesartan	127	86 (67.7)	3.05 (18.58)	-43.8	-6.25	0.00	12.50	43.8	
		Week 94	Sparsentan	113	86 (76.1)	10.10 (25.00)	-62.5	0.00	6.25	25.00	68.8	0.39 [0.09, 0.69]
			Irbesartan	127	86 (67.7)	1.02 (21.58)	-75.0	-12.50	0.00	12.50	56.3	
		Week 110	Sparsentan	113	88 (77.9)	8.38 (25.67)	-56.3	-6.25	6.25	18.75	87.5	0.36 [0.06, 0.67]
			Irbesartan	127	80 (63.0)	-0.16 (21.19)	-62.5	-9.38	0.00	9.38	50.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 5 years	KDQOL: burden of kidney disease	Baseline	Sparsentan	89	83 (93.3)	72.74 (23.56)	0.0	62.50	75.00	87.50	100.0	
			Irbesartan	75	64 (85.3)	79.59 (22.44)	18.8	68.75	87.50	93.75	100.0	
		Week 24	Sparsentan	89	69 (77.5)	76.81 (21.25)	18.8	68.75	81.25	93.75	100.0	
			Irbesartan	75	45 (60.0)	80.28 (22.81)	6.3	68.75	81.25	100.00	100.0	
		Week 48	Sparsentan	89	70 (78.7)	79.29 (22.31)	0.0	75.00	84.38	100.00	100.0	
			Irbesartan	75	39 (52.0)	81.09 (19.42)	25.0	75.00	81.25	93.75	100.0	
		Week 70	Sparsentan	89	70 (78.7)	81.07 (19.47)	25.0	68.75	87.50	100.00	100.0	
			Irbesartan	75	44 (58.7)	79.97 (21.97)	12.5	75.00	84.38	100.00	100.0	
		Week 94	Sparsentan	89	65 (73.0)	76.35 (23.06)	0.0	68.75	81.25	93.75	100.0	
			Irbesartan	75	44 (58.7)	75.85 (22.86)	12.5	65.63	75.00	96.88	100.0	
		Week 110	Sparsentan	89	61 (68.5)	77.97 (20.01)	31.3	62.50	81.25	93.75	100.0	
			Irbesartan	75	41 (54.7)	75.15 (21.22)	25.0	62.50	81.25	93.75	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	89	69 (77.5)	3.44 (22.52)	-81.3	-6.25	0.00	12.50	75.0	0.27 [-0.11, 0.65]
			Irbesartan	75	45 (60.0)	-1.94 (15.36)	-37.5	-6.25	0.00	6.25	37.5	
		Week 48	Sparsentan	89	70 (78.7)	5.09 (22.60)	-68.8	0.00	0.00	18.75	62.5	0.32 [-0.08, 0.71]
			Irbesartan	75	39 (52.0)	-1.12 (12.07)	-37.5	-6.25	0.00	6.25	18.8	
		Week 70	Sparsentan	89	70 (78.7)	7.86 (21.82)	-43.8	0.00	0.00	18.75	87.5	0.29 [-0.09, 0.67]
			Irbesartan	75	44 (58.7)	1.99 (17.09)	-31.3	-6.25	0.00	6.25	56.3	
		Week 94	Sparsentan	89	65 (73.0)	3.46 (23.72)	-87.5	-6.25	0.00	18.75	75.0	0.29 [-0.10, 0.67]
			Irbesartan	75	44 (58.7)	-2.84 (19.46)	-50.0	-15.63	0.00	9.38	50.0	
		Week 110	Sparsentan	89	61 (68.5)	6.05 (22.79)	-50.0	-6.25	0.00	18.75	62.5	0.42 [0.02, 0.82]
			Irbesartan	75	41 (54.7)	-3.05 (19.42)	-43.8	-18.75	0.00	6.25	56.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: History of hypertension												
Yes	KDQOL: burden of kidney disease	Baseline	Sparsentan	155	141 (91.0)	69.95 (25.90)	0.0	56.25	75.00	87.50	100.0	
			Irbesartan	161	142 (88.2)	78.30 (21.89)	18.8	62.50	84.38	100.00	100.0	
		Week 24	Sparsentan	155	119 (76.8)	76.94 (21.81)	0.0	62.50	81.25	93.75	100.0	
			Irbesartan	161	100 (62.1)	80.38 (21.52)	6.3	68.75	87.50	100.00	100.0	
		Week 48	Sparsentan	155	121 (78.1)	77.12 (23.27)	0.0	62.50	81.25	100.00	100.0	
			Irbesartan	161	95 (59.0)	80.53 (21.14)	0.0	68.75	87.50	100.00	100.0	
		Week 70	Sparsentan	155	123 (79.4)	78.35 (22.08)	12.5	68.75	81.25	93.75	100.0	
			Irbesartan	161	100 (62.1)	79.31 (22.45)	12.5	68.75	84.38	100.00	100.0	
		Week 94	Sparsentan	155	114 (73.5)	76.04 (24.18)	0.0	68.75	81.25	93.75	100.0	
			Irbesartan	161	101 (62.7)	75.06 (23.63)	12.5	62.50	75.00	100.00	100.0	
		Week 110	Sparsentan	155	112 (72.3)	76.95 (21.85)	18.8	62.50	81.25	93.75	100.0	
			Irbesartan	161	92 (57.1)	77.51 (21.31)	25.0	68.75	81.25	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	155	119 (76.8)	8.40 (22.08)	-43.8	-6.25	6.25	18.75	81.3	0.35 [0.08, 0.62]
			Irbesartan	161	100 (62.1)	1.38 (17.53)	-50.0	-6.25	0.00	12.50	56.3	
		Week 48	Sparsentan	155	121 (78.1)	7.95 (20.33)	-68.8	0.00	6.25	18.75	62.5	0.29 [0.02, 0.56]
			Irbesartan	161	95 (59.0)	2.37 (18.19)	-62.5	-6.25	0.00	12.50	50.0	
		Week 70	Sparsentan	155	123 (79.4)	8.64 (20.83)	-50.0	0.00	6.25	18.75	87.5	0.29 [0.03, 0.56]
			Irbesartan	161	100 (62.1)	2.81 (18.54)	-43.8	-6.25	0.00	12.50	56.3	
		Week 94	Sparsentan	155	114 (73.5)	7.46 (24.31)	-87.5	-6.25	6.25	25.00	75.0	0.38 [0.11, 0.65]
			Irbesartan	161	101 (62.7)	-1.36 (21.26)	-75.0	-12.50	0.00	12.50	50.0	
		Week 110	Sparsentan	155	112 (72.3)	7.42 (23.93)	-56.3	-6.25	6.25	18.75	75.0	0.33 [0.05, 0.61]
			Irbesartan	161	92 (57.1)	0.34 (18.17)	-43.8	-12.50	0.00	6.25	56.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSHM: KDQOL: Course of burden of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	KDQOL: burden of kidney disease	Baseline	Sparsentan	47	46 (97.9)	70.38 (23.40)	12.5	50.00	75.00	87.50	100.0	
			Irbesartan	41	40 (97.6)	72.03 (25.48)	6.3	56.25	75.00	93.75	100.0	
		Week 24	Sparsentan	47	38 (80.9)	76.15 (23.87)	12.5	68.75	78.13	100.00	100.0	
			Irbesartan	41	31 (75.6)	73.19 (26.03)	0.0	56.25	75.00	93.75	100.0	
		Week 48	Sparsentan	47	41 (87.2)	78.35 (21.75)	6.3	68.75	87.50	93.75	100.0	
			Irbesartan	41	29 (70.7)	78.45 (22.13)	6.3	75.00	81.25	93.75	100.0	
		Week 70	Sparsentan	47	37 (78.7)	78.89 (21.42)	6.3	68.75	81.25	100.00	100.0	
			Irbesartan	41	30 (73.2)	80.42 (18.62)	31.3	75.00	84.38	93.75	100.0	
		Week 94	Sparsentan	47	37 (78.7)	76.86 (18.39)	37.5	68.75	75.00	93.75	100.0	
			Irbesartan	41	29 (70.7)	82.33 (15.85)	37.5	75.00	81.25	93.75	100.0	
		Week 110	Sparsentan	47	37 (78.7)	76.69 (20.76)	37.5	62.50	75.00	100.00	100.0	
			Irbesartan	41	29 (70.7)	71.77 (24.75)	12.5	62.50	75.00	100.00	100.0	
	KDQOL: Change from baseline in burden of kidney disease	Week 24	Sparsentan	47	38 (80.9)	5.76 (23.40)	-81.3	0.00	6.25	12.50	56.3	0.35 [-0.13, 0.83]
			Irbesartan	41	31 (75.6)	-1.61 (17.53)	-31.3	-12.50	-6.25	0.00	50.0	
		Week 48	Sparsentan	47	41 (87.2)	7.01 (21.16)	-50.0	0.00	6.25	18.75	50.0	0.27 [-0.21, 0.75]
			Irbesartan	41	29 (70.7)	1.72 (17.59)	-43.8	-6.25	0.00	12.50	56.3	
		Week 70	Sparsentan	47	37 (78.7)	7.26 (24.98)	-43.8	-6.25	6.25	18.75	87.5	0.23 [-0.25, 0.71]
			Irbesartan	41	30 (73.2)	2.29 (16.53)	-25.0	-6.25	0.00	6.25	43.8	
		Week 94	Sparsentan	47	37 (78.7)	6.59 (25.81)	-50.0	-6.25	6.25	18.75	62.5	0.14 [-0.35, 0.62]
			Irbesartan	41	29 (70.7)	3.45 (19.45)	-37.5	-6.25	0.00	12.50	56.3	
		Week 110	Sparsentan	47	37 (78.7)	7.43 (26.43)	-50.0	-6.25	6.25	18.75	87.5	0.50 [0.01, 0.99]
			Irbesartan	41	29 (70.7)	-5.82 (26.67)	-62.5	-25.00	0.00	6.25	50.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Sex	Overall	Sparsentan						Interaction:	0.210
Male	Week 24	Sparsentan	139	109 (78.4)	4.59 (1.70)	(1.25, 7.94)	5.19 (2.52)	(0.25, 10.12)	0.040 *
		Irbesartan	143	93 (65.0)	-0.59 (1.84)	(-4.20, 3.02)			
	Week 48	Sparsentan	139	112 (80.6)	4.56 (1.67)	(1.28, 7.85)	1.01 (2.51)	(-3.92, 5.94)	0.688
		Irbesartan	143	87 (60.8)	3.55 (1.86)	(-0.10, 7.21)			
	Week 70	Sparsentan	139	114 (82.0)	6.22 (1.67)	(2.94, 9.50)	4.18 (2.49)	(-0.71, 9.07)	0.093
		Irbesartan	143	92 (64.3)	2.04 (1.84)	(-1.57, 5.64)			
	Week 94	Sparsentan	139	105 (75.5)	5.39 (1.72)	(2.01, 8.77)	6.32 (2.51)	(1.40, 11.25)	0.012 *
		Irbesartan	143	96 (67.1)	-0.93 (1.82)	(-4.50, 2.63)			
	Week 110	Sparsentan	139	103 (74.1)	5.19 (1.75)	(1.75, 8.64)	6.56 (2.58)	(1.50, 11.62)	0.011 *
		Irbesartan	143	89 (62.2)	-1.37 (1.88)	(-5.06, 2.33)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Female	Week 24	Sparsentan	63	48 (76.2)	9.06 (2.58)	(3.98, 14.14)	-2.25 (3.91)	(-9.94, 5.44)	0.565
		Irbesartan	59	38 (64.4)	11.31 (2.92)	(5.57, 17.05)			
	Week 48	Sparsentan	63	50 (79.4)	8.77 (2.53)	(3.80, 13.74)	2.16 (3.87)	(-5.46, 9.78)	0.578
		Irbesartan	59	37 (62.7)	6.61 (2.92)	(0.86, 12.36)			
	Week 70	Sparsentan	63	46 (73.0)	8.21 (2.61)	(3.07, 13.35)	0.54 (3.92)	(-7.19, 8.26)	0.891
		Irbesartan	59	38 (64.4)	7.67 (2.91)	(1.94, 13.40)			
	Week 94	Sparsentan	63	46 (73.0)	3.04 (2.63)	(-2.13, 8.22)	-2.78 (4.04)	(-10.72, 5.16)	0.491
		Irbesartan	59	34 (57.6)	5.83 (3.04)	(-0.15, 11.81)			
	Week 110	Sparsentan	63	46 (73.0)	5.81 (2.65)	(0.59, 11.03)	0.06 (4.14)	(-8.09, 8.21)	0.989
		Irbesartan	59	32 (54.2)	5.75 (3.16)	(-0.46, 11.97)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age	Overall	Sparsentan						Interaction:	0.988
<= 45 years	Week 24	Sparsentan	96	71 (74.0)	7.94 (2.32)	(3.38, 12.50)	4.23 (3.34)	(-2.33, 10.80)	0.206
		Irbesartan	99	67 (67.7)	3.71 (2.39)	(-0.99, 8.40)			
	Week 48	Sparsentan	96	75 (78.1)	7.04 (2.27)	(2.58, 11.49)	1.75 (3.31)	(-4.76, 8.27)	0.597
		Irbesartan	99	62 (62.6)	5.28 (2.41)	(0.55, 10.02)			
	Week 70	Sparsentan	96	72 (75.0)	7.57 (2.30)	(3.05, 12.08)	2.98 (3.35)	(-3.60, 9.57)	0.374
		Irbesartan	99	62 (62.6)	4.58 (2.43)	(-0.20, 9.36)			
	Week 94	Sparsentan	96	68 (70.8)	4.25 (2.34)	(-0.35, 8.85)	0.81 (3.38)	(-5.83, 7.46)	0.810
		Irbesartan	99	64 (64.6)	3.44 (2.43)	(-1.35, 8.22)			
	Week 110	Sparsentan	96	69 (71.9)	6.20 (2.37)	(1.55, 10.85)	4.59 (3.47)	(-2.22, 11.41)	0.186
		Irbesartan	99	59 (59.6)	1.61 (2.53)	(-3.36, 6.58)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 45 years	Week 24	Sparsentan	106	86 (81.1)	3.99 (1.78)	(0.50, 7.47)	2.02 (2.74)	(-3.36, 7.41)	0.460
		Irbesartan	103	64 (62.1)	1.96 (2.07)	(-2.10, 6.03)			
	Week 48	Sparsentan	106	87 (82.1)	4.78 (1.76)	(1.33, 8.24)	1.22 (2.73)	(-4.15, 6.58)	0.656
		Irbesartan	103	62 (60.2)	3.56 (2.08)	(-0.52, 7.64)			
	Week 70	Sparsentan	106	88 (83.0)	6.06 (1.76)	(2.61, 9.51)	3.51 (2.67)	(-1.73, 8.76)	0.189
		Irbesartan	103	68 (66.0)	2.55 (2.00)	(-1.37, 6.47)			
	Week 94	Sparsentan	106	83 (78.3)	5.14 (1.81)	(1.59, 8.69)	6.70 (2.73)	(1.33, 12.06)	0.014 *
		Irbesartan	103	66 (64.1)	-1.56 (2.03)	(-5.54, 2.43)			
	Week 110	Sparsentan	106	80 (75.5)	4.65 (1.85)	(1.03, 8.28)	4.83 (2.81)	(-0.68, 10.33)	0.086
		Irbesartan	103	62 (60.2)	-0.17 (2.10)	(-4.29, 3.95)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age at IgAN diagnosis	Overall	Sparsentan						Interaction:	0.959
<= 18 years	Week 24	Sparsentan	9	5 (55.6)	23.28 (8.23)	(6.37, 40.18)	17.44 (11.82)	(-7.05, 41.92)	0.154
		Irbesartan	5	5 (100.0)	5.84 (8.18)	(-11.20, 22.88)			
	Week 48	Sparsentan	9	7 (77.8)	2.31 (6.88)	(-11.94, 16.56)	-6.89 (12.51)	(-32.54, 18.76)	0.586
		Irbesartan	5	3 (60.0)	9.20 (10.33)	(-11.88, 30.27)			
	Week 70	Sparsentan	9	7 (77.8)	6.48 (6.89)	(-7.84, 20.79)	1.94 (11.84)	(-22.61, 26.50)	0.871
		Irbesartan	5	4 (80.0)	4.53 (9.34)	(-14.75, 23.82)			
	Week 94	Sparsentan	9	5 (55.6)	7.06 (8.21)	(-9.79, 23.90)	10.48 (12.72)	(-15.85, 36.82)	0.418
		Irbesartan	5	4 (80.0)	-3.43 (9.36)	(-22.88, 16.02)			
	Week 110	Sparsentan	9	4 (44.4)	10.59 (9.26)	(-8.40, 29.58)	11.61 (15.90)	(-20.98, 44.20)	0.471
		Irbesartan	5	2 (40.0)	-1.02 (12.86)	(-27.34, 25.29)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 18 to 40 years	Week 24	Sparsentan	102	79 (77.5)	6.87 (2.17)	(2.60, 11.14)	4.65 (3.15)	(-1.55, 10.84)	0.141
		Irbesartan	109	71 (65.1)	2.22 (2.28)	(-2.25, 6.70)			
	Week 48	Sparsentan	102	82 (80.4)	5.57 (2.13)	(1.38, 9.75)	2.07 (3.13)	(-4.08, 8.23)	0.508
		Irbesartan	109	67 (61.5)	3.49 (2.29)	(-1.00, 7.99)			
	Week 70	Sparsentan	102	78 (76.5)	8.37 (2.17)	(4.11, 12.63)	4.40 (3.17)	(-1.83, 10.62)	0.166
		Irbesartan	109	68 (62.4)	3.97 (2.30)	(-0.55, 8.49)			
	Week 94	Sparsentan	102	73 (71.6)	4.06 (2.22)	(-0.31, 8.43)	1.24 (3.21)	(-5.08, 7.55)	0.701
		Irbesartan	109	69 (63.3)	2.82 (2.31)	(-1.71, 7.36)			
	Week 110	Sparsentan	102	72 (70.6)	5.63 (2.27)	(1.16, 10.10)	4.87 (3.30)	(-1.62, 11.36)	0.141
		Irbesartan	109	65 (59.6)	0.76 (2.38)	(-3.92, 5.44)			
> 40 years	Week 24	Sparsentan	91	73 (80.2)	4.09 (1.94)	(0.29, 7.90)	1.14 (2.97)	(-4.69, 6.97)	0.702
		Irbesartan	88	55 (62.5)	2.96 (2.23)	(-1.42, 7.34)			
	Week 48	Sparsentan	91	73 (80.2)	6.71 (1.92)	(2.93, 10.49)	1.77 (2.96)	(-4.04, 7.58)	0.549
		Irbesartan	88	54 (61.4)	4.94 (2.23)	(0.55, 9.32)			
	Week 70	Sparsentan	91	75 (82.4)	5.30 (1.91)	(1.55, 9.04)	2.50 (2.90)	(-3.19, 8.19)	0.388
		Irbesartan	88	58 (65.9)	2.80 (2.17)	(-1.46, 7.05)			
	Week 94	Sparsentan	91	73 (80.2)	5.18 (1.93)	(1.39, 8.98)	6.60 (2.93)	(0.85, 12.36)	0.025 *
		Irbesartan	88	57 (64.8)	-1.42 (2.19)	(-5.71, 2.88)			
	Week 110	Sparsentan	91	73 (80.2)	4.88 (1.94)	(1.07, 8.68)	4.65 (2.98)	(-1.20, 10.50)	0.119
		Irbesartan	88	54 (61.4)	0.23 (2.25)	(-4.20, 4.65)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Geographic region	Overall	Sparsentan						Interaction:	0.612
North America	Week 24	Sparsentan	35	23 (65.7)	5.23 (3.72)	(-2.11, 12.56)	5.35 (4.83)	(-4.17, 14.87)	0.269
		Irbesartan	46	35 (76.1)	-0.12 (3.02)	(-6.08, 5.83)			
	Week 48	Sparsentan	35	25 (71.4)	5.43 (3.62)	(-1.70, 12.56)	7.13 (4.83)	(-2.38, 16.65)	0.141
		Irbesartan	46	32 (69.6)	-1.70 (3.12)	(-7.85, 4.45)			
	Week 70	Sparsentan	35	22 (62.9)	3.70 (3.79)	(-3.77, 11.17)	5.78 (5.00)	(-4.08, 15.64)	0.249
		Irbesartan	46	30 (65.2)	-2.07 (3.22)	(-8.41, 4.26)			
	Week 94	Sparsentan	35	23 (65.7)	-1.36 (3.74)	(-8.74, 6.02)	2.44 (5.00)	(-7.43, 12.30)	0.627
		Irbesartan	46	30 (65.2)	-3.79 (3.25)	(-10.20, 2.61)			
	Week 110	Sparsentan	35	21 (60.0)	-0.14 (3.90)	(-7.82, 7.54)	0.48 (5.09)	(-9.55, 10.52)	0.925
		Irbesartan	46	31 (67.4)	-0.63 (3.23)	(-6.99, 5.74)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Europe	Week 24	Sparsentan	98	73 (74.5)	4.81 (1.99)	(0.89, 8.72)	3.70 (2.94)	(-2.08, 9.49)	0.209
		Irbesartan	115	62 (53.9)	1.10 (2.17)	(-3.16, 5.36)			
	Week 48	Sparsentan	98	76 (77.6)	2.90 (1.95)	(-0.94, 6.73)	-0.50 (2.92)	(-6.24, 5.24)	0.864
		Irbesartan	115	59 (51.3)	3.39 (2.17)	(-0.86, 7.65)			
	Week 70	Sparsentan	98	75 (76.5)	5.54 (1.98)	(1.65, 9.43)	2.00 (2.86)	(-3.62, 7.62)	0.485
		Irbesartan	115	69 (60.0)	3.54 (2.06)	(-0.51, 7.58)			
	Week 94	Sparsentan	98	68 (69.4)	3.08 (2.06)	(-0.96, 7.12)	4.47 (2.90)	(-1.24, 10.17)	0.125
		Irbesartan	115	70 (60.9)	-1.38 (2.05)	(-5.40, 2.64)			
	Week 110	Sparsentan	98	67 (68.4)	3.97 (2.09)	(-0.14, 8.09)	4.02 (3.02)	(-1.92, 9.95)	0.184
		Irbesartan	115	61 (53.0)	-0.05 (2.17)	(-4.31, 4.22)			
Asia Pacific	Week 24	Sparsentan	69	61 (88.4)	9.45 (2.47)	(4.60, 14.31)	2.98 (4.15)	(-5.18, 11.14)	0.473
		Irbesartan	41	34 (82.9)	6.48 (3.29)	(-0.00, 12.95)			
	Week 48	Sparsentan	69	61 (88.4)	11.37 (2.45)	(6.56, 16.19)	2.36 (4.17)	(-5.84, 10.55)	0.572
		Irbesartan	41	33 (80.5)	9.02 (3.33)	(2.46, 15.57)			
	Week 70	Sparsentan	69	63 (91.3)	11.38 (2.42)	(6.61, 16.15)	5.02 (4.25)	(-3.35, 13.38)	0.239
		Irbesartan	41	31 (75.6)	6.36 (3.45)	(-0.43, 13.14)			
	Week 94	Sparsentan	69	60 (87.0)	10.76 (2.47)	(5.91, 15.61)	3.01 (4.33)	(-5.50, 11.52)	0.487
		Irbesartan	41	30 (73.2)	7.75 (3.51)	(0.85, 14.65)			
	Week 110	Sparsentan	69	61 (88.4)	11.03 (2.47)	(6.17, 15.89)	11.36 (4.39)	(2.73, 20.00)	0.010 *
		Irbesartan	41	29 (70.7)	-0.33 (3.58)	(-7.38, 6.71)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline BMI	Overall	Sparsentan						Interaction:	0.887
< 27 kg/m**2	Week 24	Sparsentan	83	66 (79.5)	7.23 (2.27)	(2.76, 11.69)	1.47 (3.23)	(-4.87, 7.81)	0.648
		Irbesartan	94	66 (70.2)	5.75 (2.27)	(1.29, 10.22)			
	Week 48	Sparsentan	83	66 (79.5)	6.50 (2.26)	(2.06, 10.94)	2.58 (3.26)	(-3.83, 8.99)	0.430
		Irbesartan	94	60 (63.8)	3.92 (2.33)	(-0.66, 8.50)			
	Week 70	Sparsentan	83	64 (77.1)	7.80 (2.29)	(3.30, 12.31)	5.83 (3.31)	(-0.66, 12.33)	0.078
		Irbesartan	94	59 (62.8)	1.97 (2.36)	(-2.67, 6.61)			
	Week 94	Sparsentan	83	63 (75.9)	6.85 (2.32)	(2.30, 11.40)	3.08 (3.31)	(-3.42, 9.58)	0.352
		Irbesartan	94	62 (66.0)	3.77 (2.34)	(-0.82, 8.36)			
	Week 110	Sparsentan	83	63 (75.9)	8.00 (2.33)	(3.42, 12.58)	5.48 (3.38)	(-1.17, 12.13)	0.106
		Irbesartan	94	57 (60.6)	2.52 (2.44)	(-2.27, 7.31)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
>= 27 kg/m**2	Week 24	Sparsentan	119	91 (76.5)	4.72 (1.83)	(1.13, 8.30)	3.96 (2.85)	(-1.64, 9.56)	0.165
		Irbesartan	107	65 (60.7)	0.75 (2.17)	(-3.51, 5.02)			
	Week 48	Sparsentan	119	96 (80.7)	5.00 (1.78)	(1.51, 8.49)	-0.20 (2.79)	(-5.69, 5.29)	0.943
		Irbesartan	107	64 (59.8)	5.20 (2.15)	(0.98, 9.41)			
	Week 70	Sparsentan	119	96 (80.7)	5.76 (1.79)	(2.25, 9.27)	0.40 (2.75)	(-5.00, 5.79)	0.885
		Irbesartan	107	71 (66.4)	5.36 (2.08)	(1.28, 9.44)			
	Week 94	Sparsentan	119	88 (73.9)	2.75 (1.85)	(-0.87, 6.38)	3.71 (2.83)	(-1.84, 9.26)	0.190
		Irbesartan	107	67 (62.6)	-0.95 (2.13)	(-5.13, 3.22)			
	Week 110	Sparsentan	119	86 (72.3)	3.17 (1.89)	(-0.53, 6.88)	3.88 (2.91)	(-1.83, 9.59)	0.183
		Irbesartan	107	63 (58.9)	-0.70 (2.20)	(-5.02, 3.61)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Randomization strata	Overall	Sparsentan						Interaction:	0.748
eGFR Low and UP High	Week 24	Sparsentan	71	54 (76.1)	6.96 (2.51)	(2.02, 11.89)	8.20 (3.83)	(0.67, 15.73)	0.033 *
		Irbesartan	74	40 (54.1)	-1.24 (2.89)	(-6.92, 4.44)			
	Week 48	Sparsentan	71	51 (71.8)	5.71 (2.54)	(0.72, 10.70)	3.20 (3.88)	(-4.42, 10.83)	0.409
		Irbesartan	74	37 (50.0)	2.51 (2.93)	(-3.25, 8.26)			
	Week 70	Sparsentan	71	57 (80.3)	4.38 (2.46)	(-0.46, 9.21)	4.28 (3.84)	(-3.28, 11.84)	0.266
		Irbesartan	74	37 (50.0)	0.10 (2.95)	(-5.71, 5.91)			
	Week 94	Sparsentan	71	51 (71.8)	0.28 (2.55)	(-4.73, 5.30)	3.77 (3.92)	(-3.94, 11.48)	0.337
		Irbesartan	74	37 (50.0)	-3.48 (2.98)	(-9.34, 2.37)			
	Week 110	Sparsentan	71	53 (74.6)	3.02 (2.54)	(-1.98, 8.02)	3.54 (3.97)	(-4.27, 11.35)	0.373
		Irbesartan	74	36 (48.6)	-0.52 (3.05)	(-6.52, 5.48)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
eGFR Low and UP Low	Week 24	Sparsentan	55	43 (78.2)	3.63 (2.67)	(-1.63, 8.88)	-3.97 (3.96)	(-11.78, 3.83)	0.317
		Irbesartan	55	37 (67.3)	7.60 (2.90)	(1.90, 13.30)			
	Week 48	Sparsentan	55	43 (78.2)	8.56 (2.64)	(3.35, 13.76)	1.92 (3.93)	(-5.83, 9.67)	0.626
		Irbesartan	55	35 (63.6)	6.64 (2.89)	(0.94, 12.33)			
	Week 70	Sparsentan	55	42 (76.4)	7.06 (2.68)	(1.77, 12.34)	0.91 (3.89)	(-6.76, 8.58)	0.815
		Irbesartan	55	39 (70.9)	6.15 (2.80)	(0.64, 11.66)			
	Week 94	Sparsentan	55	41 (74.5)	10.07 (2.72)	(4.70, 15.43)	8.36 (3.93)	(0.62, 16.11)	0.034 *
		Irbesartan	55	39 (70.9)	1.70 (2.81)	(-3.83, 7.24)			
	Week 110	Sparsentan	55	37 (67.3)	6.02 (2.85)	(0.40, 11.64)	0.92 (4.13)	(-7.22, 9.05)	0.825
		Irbesartan	55	34 (61.8)	5.10 (2.97)	(-0.75, 10.95)			
eGFR High and UP High	Week 24	Sparsentan	37	26 (70.3)	6.72 (3.56)	(-0.29, 13.74)	3.31 (5.13)	(-6.80, 13.43)	0.519
		Irbesartan	36	26 (72.2)	3.41 (3.66)	(-3.81, 10.63)			
	Week 48	Sparsentan	37	33 (89.2)	4.20 (3.23)	(-2.18, 10.57)	-4.22 (4.95)	(-13.99, 5.54)	0.395
		Irbesartan	36	24 (66.7)	8.42 (3.73)	(1.06, 15.78)			
	Week 70	Sparsentan	37	31 (83.8)	10.91 (3.32)	(4.35, 17.47)	6.64 (4.99)	(-3.21, 16.49)	0.185
		Irbesartan	36	25 (69.4)	4.27 (3.70)	(-3.04, 11.58)			
	Week 94	Sparsentan	37	27 (73.0)	5.34 (3.52)	(-1.60, 12.27)	-1.18 (5.17)	(-11.37, 9.01)	0.819
		Irbesartan	36	24 (66.7)	6.52 (3.76)	(-0.90, 13.94)			
	Week 110	Sparsentan	37	26 (70.3)	8.33 (3.62)	(1.18, 15.47)	6.83 (5.37)	(-3.77, 17.42)	0.205
		Irbesartan	36	22 (61.1)	1.50 (3.93)	(-6.25, 9.25)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
eGFR High and UP Low	Week 24	Sparsentan	39	34 (87.2)	7.12 (2.97)	(1.27, 12.98)	4.33 (4.41)	(-4.35, 13.01)	0.326
		Irbesartan	37	28 (75.7)	2.79 (3.25)	(-3.61, 9.19)			
	Week 48	Sparsentan	39	35 (89.7)	4.94 (2.93)	(-0.84, 10.73)	3.32 (4.39)	(-5.32, 11.96)	0.450
		Irbesartan	37	28 (75.7)	1.63 (3.24)	(-4.76, 8.01)			
	Week 70	Sparsentan	39	30 (76.9)	7.42 (3.13)	(1.27, 13.58)	1.47 (4.49)	(-7.37, 10.32)	0.743
		Irbesartan	37	29 (78.4)	5.95 (3.21)	(-0.37, 12.27)			
	Week 94	Sparsentan	39	32 (82.1)	4.74 (3.05)	(-1.27, 10.75)	3.05 (4.41)	(-5.64, 11.73)	0.490
		Irbesartan	37	30 (81.1)	1.69 (3.16)	(-4.54, 7.92)			
	Week 110	Sparsentan	39	33 (84.6)	5.89 (3.02)	(-0.06, 11.83)	9.57 (4.44)	(0.83, 18.31)	0.032 *
		Irbesartan	37	29 (78.4)	-3.68 (3.22)	(-10.03, 2.66)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 1	Overall	Sparsentan						Interaction:	0.607
< 60 mL/min/1.73 m**2	Week 24	Sparsentan	127	98 (77.2)	4.56 (1.82)	(0.97, 8.14)	2.68 (2.73)	(-2.69, 8.04)	0.327
		Irbesartan	129	80 (62.0)	1.88 (2.02)	(-2.08, 5.84)			
	Week 48	Sparsentan	127	95 (74.8)	6.19 (1.83)	(2.60, 9.78)	2.74 (2.75)	(-2.66, 8.13)	0.319
		Irbesartan	129	74 (57.4)	3.45 (2.04)	(-0.56, 7.46)			
	Week 70	Sparsentan	127	100 (78.7)	4.81 (1.81)	(1.26, 8.37)	2.35 (2.72)	(-2.99, 7.69)	0.387
		Irbesartan	129	78 (60.5)	2.46 (2.02)	(-1.50, 6.42)			
	Week 94	Sparsentan	127	92 (72.4)	3.82 (1.86)	(0.16, 7.48)	5.38 (2.77)	(-0.05, 10.82)	0.052
		Irbesartan	129	77 (59.7)	-1.56 (2.04)	(-5.56, 2.44)			
	Week 110	Sparsentan	127	92 (72.4)	4.78 (1.88)	(1.08, 8.48)	2.89 (2.84)	(-2.69, 8.46)	0.310
		Irbesartan	129	72 (55.8)	1.89 (2.11)	(-2.26, 6.04)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
60 to < 90 mL/min/1.73 m**2	Week 24	Sparsentan	49	38 (77.6)	6.50 (2.73)	(1.12, 11.89)	-0.66 (4.10)	(-8.74, 7.42)	0.872
		Irbesartan	48	31 (64.6)	7.17 (3.03)	(1.20, 13.13)			
	Week 48	Sparsentan	49	44 (89.8)	4.91 (2.57)	(-0.16, 9.97)	0.78 (3.94)	(-6.98, 8.54)	0.843
		Irbesartan	48	32 (66.7)	4.12 (2.96)	(-1.70, 9.95)			
	Week 70	Sparsentan	49	38 (77.6)	6.86 (2.71)	(1.53, 12.20)	3.22 (4.03)	(-4.72, 11.16)	0.426
		Irbesartan	48	32 (66.7)	3.64 (2.97)	(-2.20, 9.48)			
	Week 94	Sparsentan	49	39 (79.6)	4.42 (2.71)	(-0.92, 9.76)	4.67 (4.00)	(-3.22, 12.55)	0.245
		Irbesartan	48	34 (70.8)	-0.25 (2.92)	(-6.00, 5.49)			
	Week 110	Sparsentan	49	36 (73.5)	2.49 (2.83)	(-3.09, 8.06)	5.20 (4.16)	(-2.99, 13.39)	0.212
		Irbesartan	48	32 (66.7)	-2.71 (3.00)	(-8.63, 3.20)			
>= 90 mL/min/1.73 m**2	Week 24	Sparsentan	26	21 (80.8)	12.19 (4.20)	(3.89, 20.49)	11.72 (6.02)	(-0.17, 23.60)	0.053
		Irbesartan	25	20 (80.0)	0.47 (4.30)	(-8.03, 8.97)			
	Week 48	Sparsentan	26	23 (88.5)	7.16 (4.04)	(-0.83, 15.14)	-2.04 (6.08)	(-14.04, 9.96)	0.738
		Irbesartan	25	18 (72.0)	9.19 (4.51)	(0.30, 18.09)			
	Week 70	Sparsentan	26	22 (84.6)	16.42 (4.12)	(8.28, 24.57)	7.58 (6.01)	(-4.29, 19.45)	0.209
		Irbesartan	25	20 (80.0)	8.84 (4.33)	(0.29, 17.40)			
	Week 94	Sparsentan	26	20 (76.9)	10.03 (4.30)	(1.54, 18.52)	-3.09 (6.19)	(-15.31, 9.13)	0.618
		Irbesartan	25	19 (76.0)	13.12 (4.43)	(4.38, 21.86)			
	Week 110	Sparsentan	26	21 (80.8)	13.73 (4.22)	(5.40, 22.06)	12.18 (6.31)	(-0.28, 24.65)	0.055
		Irbesartan	25	17 (68.0)	1.54 (4.67)	(-7.68, 10.77)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 2	Overall	Sparsentan						Interaction:	0.595
< 45 mL/min/1.73 m**2	Week 24	Sparsentan	82	64 (78.0)	6.72 (2.30)	(2.20, 11.24)	3.85 (3.51)	(-3.05, 10.76)	0.273
		Irbesartan	80	48 (60.0)	2.87 (2.64)	(-2.33, 8.06)			
	Week 48	Sparsentan	82	61 (74.4)	6.78 (2.32)	(2.22, 11.33)	1.94 (3.56)	(-5.06, 8.93)	0.586
		Irbesartan	80	43 (53.8)	4.84 (2.69)	(-0.45, 10.12)			
	Week 70	Sparsentan	82	65 (79.3)	6.73 (2.29)	(2.24, 11.23)	3.75 (3.51)	(-3.15, 10.64)	0.286
		Irbesartan	80	45 (56.3)	2.98 (2.65)	(-2.23, 8.20)			
	Week 94	Sparsentan	82	60 (73.2)	5.59 (2.35)	(0.97, 10.21)	8.99 (3.54)	(2.03, 15.94)	0.011 *
		Irbesartan	80	47 (58.8)	-3.40 (2.64)	(-8.58, 1.79)			
	Week 110	Sparsentan	82	56 (68.3)	7.58 (2.43)	(2.79, 12.36)	5.58 (3.67)	(-1.63, 12.79)	0.129
		Irbesartan	80	44 (55.0)	2.00 (2.74)	(-3.38, 7.38)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
45 to < 60 mL/min/1.73 m**2	Week 24	Sparsentan	45	34 (75.6)	0.47 (3.02)	(-5.47, 6.42)	0.07 (4.36)	(-8.52, 8.67)	0.987
		Irbesartan	49	32 (65.3)	0.40 (3.12)	(-5.75, 6.55)			
	Week 48	Sparsentan	45	34 (75.6)	5.41 (2.98)	(-0.46, 11.27)	3.87 (4.34)	(-4.68, 12.42)	0.373
		Irbesartan	49	31 (63.3)	1.54 (3.14)	(-4.64, 7.72)			
	Week 70	Sparsentan	45	35 (77.8)	1.42 (2.97)	(-4.44, 7.28)	-0.41 (4.32)	(-8.92, 8.10)	0.925
		Irbesartan	49	33 (67.3)	1.83 (3.11)	(-4.30, 7.96)			
	Week 94	Sparsentan	45	32 (71.1)	0.68 (3.07)	(-5.37, 6.72)	-0.44 (4.46)	(-9.23, 8.34)	0.921
		Irbesartan	49	30 (61.2)	1.12 (3.21)	(-5.20, 7.44)			
	Week 110	Sparsentan	45	36 (80.0)	0.22 (2.98)	(-5.66, 6.09)	-1.20 (4.49)	(-10.06, 7.65)	0.789
		Irbesartan	49	28 (57.1)	1.42 (3.33)	(-5.15, 7.99)			
60 to < 90 mL/min/1.73 m**2	Week 24	Sparsentan	49	38 (77.6)	6.50 (2.73)	(1.12, 11.89)	-0.66 (4.10)	(-8.74, 7.42)	0.872
		Irbesartan	48	31 (64.6)	7.17 (3.03)	(1.20, 13.13)			
	Week 48	Sparsentan	49	44 (89.8)	4.91 (2.57)	(-0.16, 9.97)	0.78 (3.94)	(-6.98, 8.54)	0.843
		Irbesartan	48	32 (66.7)	4.12 (2.96)	(-1.70, 9.95)			
	Week 70	Sparsentan	49	38 (77.6)	6.86 (2.71)	(1.53, 12.20)	3.22 (4.03)	(-4.72, 11.16)	0.426
		Irbesartan	48	32 (66.7)	3.64 (2.97)	(-2.20, 9.48)			
	Week 94	Sparsentan	49	39 (79.6)	4.42 (2.71)	(-0.92, 9.76)	4.67 (4.00)	(-3.22, 12.55)	0.245
		Irbesartan	48	34 (70.8)	-0.25 (2.92)	(-6.00, 5.49)			
	Week 110	Sparsentan	49	36 (73.5)	2.49 (2.83)	(-3.09, 8.06)	5.20 (4.16)	(-2.99, 13.39)	0.212
		Irbesartan	48	32 (66.7)	-2.71 (3.00)	(-8.63, 3.20)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
>= 90 mL/min/1.73 m**2	Week 24	Sparsentan	26	21 (80.8)	12.19 (4.20)	(3.89, 20.49)	11.72 (6.02)	(-0.17, 23.60)	0.053
		Irbesartan	25	20 (80.0)	0.47 (4.30)	(-8.03, 8.97)			
	Week 48	Sparsentan	26	23 (88.5)	7.16 (4.04)	(-0.83, 15.14)	-2.04 (6.08)	(-14.04, 9.96)	0.738
		Irbesartan	25	18 (72.0)	9.19 (4.51)	(0.30, 18.09)			
	Week 70	Sparsentan	26	22 (84.6)	16.42 (4.12)	(8.28, 24.57)	7.58 (6.01)	(-4.29, 19.45)	0.209
		Irbesartan	25	20 (80.0)	8.84 (4.33)	(0.29, 17.40)			
	Week 94	Sparsentan	26	20 (76.9)	10.03 (4.30)	(1.54, 18.52)	-3.09 (6.19)	(-15.31, 9.13)	0.618
		Irbesartan	25	19 (76.0)	13.12 (4.43)	(4.38, 21.86)			
	Week 110	Sparsentan	26	21 (80.8)	13.73 (4.22)	(5.40, 22.06)	12.18 (6.31)	(-0.28, 24.65)	0.055
		Irbesartan	25	17 (68.0)	1.54 (4.67)	(-7.68, 10.77)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline urine protein excretion	Overall	Sparsentan						Interaction:	0.583
<= 1.75 g/day	Week 24	Sparsentan	98	80 (81.6)	6.83 (2.01)	(2.88, 10.78)	2.16 (3.15)	(-4.03, 8.35)	0.493
		Irbesartan	93	55 (59.1)	4.67 (2.41)	(-0.06, 9.40)			
	Week 48	Sparsentan	98	82 (83.7)	6.41 (1.98)	(2.52, 10.29)	2.38 (3.08)	(-3.67, 8.42)	0.441
		Irbesartan	93	57 (61.3)	4.03 (2.34)	(-0.58, 8.64)			
	Week 70	Sparsentan	98	75 (76.5)	6.27 (2.05)	(2.24, 10.29)	0.21 (3.09)	(-5.86, 6.27)	0.947
		Irbesartan	93	61 (65.6)	6.06 (2.30)	(1.55, 10.57)			
	Week 94	Sparsentan	98	76 (77.6)	5.29 (2.05)	(1.27, 9.32)	3.40 (3.07)	(-2.63, 9.43)	0.269
		Irbesartan	93	63 (67.7)	1.89 (2.27)	(-2.57, 6.36)			
	Week 110	Sparsentan	98	75 (76.5)	6.09 (2.08)	(2.01, 10.17)	4.51 (3.16)	(-1.70, 10.72)	0.154
		Irbesartan	93	57 (61.3)	1.58 (2.37)	(-3.08, 6.24)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 1.75 g/day	Week 24	Sparsentan	104	77 (74.0)	5.29 (2.04)	(1.27, 9.30)	3.87 (2.92)	(-1.87, 9.60)	0.186
		Irbesartan	109	76 (69.7)	1.42 (2.07)	(-2.65, 5.49)			
	Week 48	Sparsentan	104	80 (76.9)	5.47 (2.00)	(1.54, 9.39)	0.96 (2.94)	(-4.82, 6.74)	0.745
		Irbesartan	109	67 (61.5)	4.51 (2.15)	(0.29, 8.73)			
	Week 70	Sparsentan	104	85 (81.7)	7.45 (1.97)	(3.59, 11.32)	6.12 (2.92)	(0.39, 11.85)	0.036 *
		Irbesartan	109	69 (63.3)	1.33 (2.14)	(-2.88, 5.54)			
	Week 94	Sparsentan	104	75 (72.1)	4.30 (2.06)	(0.24, 8.35)	4.27 (3.01)	(-1.64, 10.18)	0.156
		Irbesartan	109	67 (61.5)	0.02 (2.18)	(-4.26, 4.31)			
	Week 110	Sparsentan	104	74 (71.2)	4.95 (2.10)	(0.82, 9.07)	5.49 (3.08)	(-0.56, 11.54)	0.075
		Irbesartan	109	64 (58.7)	-0.55 (2.24)	(-4.96, 3.86)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline use of antihypertensives	Overall	Sparsentan						Interaction:	0.128
Yes	Week 24	Sparsentan	90	66 (73.3)	7.21 (2.21)	(2.88, 11.55)	5.48 (3.39)	(-1.18, 12.14)	0.107
		Irbesartan	88	49 (55.7)	1.74 (2.56)	(-3.29, 6.76)			
	Week 48	Sparsentan	90	65 (72.2)	7.53 (2.20)	(3.21, 11.85)	5.06 (3.38)	(-1.58, 11.71)	0.135
		Irbesartan	88	47 (53.4)	2.47 (2.56)	(-2.56, 7.50)			
	Week 70	Sparsentan	90	68 (75.6)	6.56 (2.18)	(2.29, 10.84)	5.85 (3.35)	(-0.73, 12.43)	0.081
		Irbesartan	88	49 (55.7)	0.71 (2.53)	(-4.26, 5.69)			
	Week 94	Sparsentan	90	63 (70.0)	7.14 (2.24)	(2.75, 11.54)	8.87 (3.32)	(2.34, 15.40)	0.008 *
		Irbesartan	88	54 (61.4)	-1.73 (2.44)	(-6.53, 3.08)			
	Week 110	Sparsentan	90	63 (70.0)	5.26 (2.27)	(0.80, 9.72)	6.60 (3.40)	(-0.08, 13.27)	0.053
		Irbesartan	88	51 (58.0)	-1.34 (2.51)	(-6.27, 3.60)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
No	Week 24	Sparsentan	112	91 (81.3)	5.21 (1.88)	(1.52, 8.90)	1.72 (2.74)	(-3.66, 7.10)	0.530
		Irbesartan	114	82 (71.9)	3.49 (1.98)	(-0.40, 7.38)			
	Week 48	Sparsentan	112	97 (86.6)	4.79 (1.82)	(1.21, 8.38)	-0.63 (2.72)	(-5.97, 4.72)	0.818
		Irbesartan	114	77 (67.5)	5.42 (2.01)	(1.47, 9.37)			
	Week 70	Sparsentan	112	92 (82.1)	7.18 (1.87)	(3.51, 10.85)	1.85 (2.73)	(-3.52, 7.21)	0.500
		Irbesartan	114	81 (71.1)	5.34 (1.99)	(1.44, 9.24)			
	Week 94	Sparsentan	112	88 (78.6)	3.12 (1.91)	(-0.62, 6.86)	0.43 (2.81)	(-5.08, 5.94)	0.878
		Irbesartan	114	76 (66.7)	2.69 (2.05)	(-1.34, 6.71)			
	Week 110	Sparsentan	112	86 (76.8)	5.68 (1.94)	(1.87, 9.49)	3.87 (2.90)	(-1.81, 9.56)	0.182
		Irbesartan	114	70 (61.4)	1.81 (2.14)	(-2.39, 6.01)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Time since renal biopsy	Overall	Sparsentan						Interaction:	0.941
<= 5 years	Week 24	Sparsentan	113	88 (77.9)	8.97 (1.95)	(5.15, 12.79)	5.27 (2.77)	(-0.17, 10.70)	0.058
		Irbesartan	127	86 (67.7)	3.71 (1.96)	(-0.14, 7.55)			
	Week 48	Sparsentan	113	92 (81.4)	6.71 (1.90)	(2.98, 10.44)	1.03 (2.73)	(-4.32, 6.38)	0.706
		Irbesartan	127	85 (66.9)	5.68 (1.94)	(1.86, 9.50)			
	Week 70	Sparsentan	113	90 (79.6)	6.89 (1.92)	(3.13, 10.65)	3.00 (2.74)	(-2.38, 8.38)	0.274
		Irbesartan	127	86 (67.7)	3.89 (1.95)	(0.06, 7.72)			
	Week 94	Sparsentan	113	86 (76.1)	6.87 (1.95)	(3.03, 10.70)	4.20 (2.77)	(-1.25, 9.64)	0.130
		Irbesartan	127	86 (67.7)	2.67 (1.95)	(-1.17, 6.51)			
	Week 110	Sparsentan	113	88 (77.9)	6.50 (1.96)	(2.65, 10.34)	4.43 (2.83)	(-1.13, 9.98)	0.118
		Irbesartan	127	80 (63.0)	2.07 (2.03)	(-1.92, 6.06)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 5 years	Week 24	Sparsentan	89	69 (77.5)	2.12 (2.11)	(-2.03, 6.27)	0.52 (3.41)	(-6.18, 7.21)	0.879
		Irbesartan	75	45 (60.0)	1.60 (2.66)	(-3.62, 6.82)			
	Week 48	Sparsentan	89	70 (78.7)	4.72 (2.09)	(0.62, 8.83)	2.83 (3.47)	(-3.98, 9.65)	0.414
		Irbesartan	75	39 (52.0)	1.89 (2.76)	(-3.53, 7.30)			
	Week 70	Sparsentan	89	70 (78.7)	6.74 (2.10)	(2.60, 10.87)	3.52 (3.39)	(-3.13, 10.18)	0.299
		Irbesartan	75	44 (58.7)	3.21 (2.64)	(-1.98, 8.41)			
	Week 94	Sparsentan	89	65 (73.0)	1.85 (2.17)	(-2.41, 6.11)	4.10 (3.44)	(-2.67, 10.86)	0.234
		Irbesartan	75	44 (58.7)	-2.25 (2.66)	(-7.48, 2.98)			
	Week 110	Sparsentan	89	61 (68.5)	4.00 (2.24)	(-0.41, 8.41)	6.23 (3.56)	(-0.77, 13.23)	0.081
		Irbesartan	75	41 (54.7)	-2.24 (2.75)	(-7.64, 3.17)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
History of hypertension	Overall	Sparsentan						Interaction:	0.440
Yes	Week 24	Sparsentan	155	119 (76.8)	6.40 (1.62)	(3.23, 9.57)	2.45 (2.40)	(-2.26, 7.16)	0.308
		Irbesartan	161	100 (62.1)	3.95 (1.76)	(0.49, 7.41)			
	Week 48	Sparsentan	155	121 (78.1)	5.80 (1.59)	(2.67, 8.93)	1.29 (2.39)	(-3.41, 5.98)	0.591
		Irbesartan	161	95 (59.0)	4.51 (1.78)	(1.03, 8.00)			
	Week 70	Sparsentan	155	123 (79.4)	6.87 (1.59)	(3.75, 9.99)	3.06 (2.37)	(-1.60, 7.71)	0.198
		Irbesartan	161	100 (62.1)	3.81 (1.75)	(0.37, 7.25)			
	Week 94	Sparsentan	155	114 (73.5)	4.82 (1.64)	(1.61, 8.03)	5.01 (2.40)	(0.30, 9.73)	0.037 *
		Irbesartan	161	101 (62.7)	-0.19 (1.75)	(-3.63, 3.24)			
	Week 110	Sparsentan	155	112 (72.3)	5.53 (1.67)	(2.26, 8.80)	3.37 (2.48)	(-1.50, 8.24)	0.175
		Irbesartan	161	92 (57.1)	2.16 (1.83)	(-1.43, 5.75)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KBUC_FSCM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in burden of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
No	Week 24	Sparsentan	47	38 (80.9)	4.63 (3.11)	(-1.51, 10.77)	5.13 (4.66)	(-4.05, 14.31)	0.272
		Irbesartan	41	31 (75.6)	-0.50 (3.44)	(-7.29, 6.29)			
	Week 48	Sparsentan	47	41 (87.2)	6.02 (3.02)	(0.06, 11.99)	2.33 (4.63)	(-6.79, 11.46)	0.615
		Irbesartan	41	29 (70.7)	3.69 (3.48)	(-3.17, 10.55)			
	Week 70	Sparsentan	47	37 (78.7)	6.97 (3.12)	(0.81, 13.13)	4.30 (4.69)	(-4.96, 13.56)	0.361
		Irbesartan	41	30 (73.2)	2.67 (3.48)	(-4.18, 9.53)			
	Week 94	Sparsentan	47	37 (78.7)	4.45 (3.16)	(-1.78, 10.68)	-0.01 (4.79)	(-9.46, 9.43)	0.998
		Irbesartan	41	29 (70.7)	4.46 (3.56)	(-2.56, 11.49)			
	Week 110	Sparsentan	47	37 (78.7)	5.09 (3.19)	(-1.21, 11.38)	9.60 (4.86)	(0.02, 19.18)	0.049 *
		Irbesartan	41	29 (70.7)	-4.51 (3.62)	(-11.64, 2.62)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Figure PF2KBUC_FSGM: KDQOL: Change from baseline in burden of kidney disease by subgroup
Full Analysis Set

Not done: No significant subgroup found.

_____
Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2KBUC_FSCM

Table PT2KBUIT_FSTM: KDQOL: Time to increase in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Sex	Sparsentan						Interaction test:	0.086	
Male	Sparsentan	139	53 (38.1)	NE		1.711	(1.081, 2.706)	0.022	*
	Irbesartan	143	29 (20.3)	NE					
Female	Sparsentan	63	29 (46.0)	87.7	(48.1, NE)	0.860	(0.465, 1.593)	0.633	
	Irbesartan	59	20 (33.9)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KBUIT_FSTM: KDQOL: Time to increase in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.921
<= 45 years	Sparsentan	96	40 (41.7)	114.6	(69.0, NE)	1.336	(0.812, 2.196)	0.254
	Irbesartan	99	28 (28.3)	NE				
> 45 years	Sparsentan	106	42 (39.6)	NE		1.312	(0.767, 2.244)	0.322
	Irbesartan	103	21 (20.4)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KBUIT_FSTM: KDQOL: Time to increase in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age at IgAN diagnosis	Sparsentan						Interaction test:	NE
<= 18 years	Sparsentan	9	5 (55.6) No events in 1 group	37.1	(22.7, NE)	NE		NE
	Irbesartan	5	0 (0.0)	NE				
> 18 to 40 years	Sparsentan	102	41 (40.2)	114.6	(72.0, NE)	1.369	(0.843, 2.224)	0.204
	Irbesartan	109	29 (26.6)	NE				
> 40 years	Sparsentan	91	36 (39.6)	NE		1.201	(0.679, 2.125)	0.529
	Irbesartan	88	20 (22.7)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KBUIT_FSTM: KDQOL: Time to increase in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Geographic region	Sparsentan						Interaction test:	0.189
North America	Sparsentan	35	14 (40.0)	114.6	(49.1, NE)	0.679	(0.286, 1.611)	0.379
	Irbesartan	46	14 (30.4)	NE				
Europe	Sparsentan	98	27 (27.6)	NE		1.759	(0.981, 3.153)	0.058
	Irbesartan	115	22 (19.1)	NE				
Asia Pacific	Sparsentan	69	41 (59.4)	60.3	(48.1, 111.0)	1.588	(0.837, 3.010)	0.157
	Irbesartan	41	13 (31.7)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KBUIT_FSTM: KDQOL: Time to increase in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.691
< 27 kg/m**2	Sparsentan	83	39 (47.0)	93.0	(49.3, NE)	1.151	(0.676, 1.958)	0.604
	Irbesartan	94	26 (27.7)	NE				
>= 27 kg/m**2	Sparsentan	119	43 (36.1)	NE		1.385	(0.829, 2.314)	0.214
	Irbesartan	107	23 (21.5)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KBUIT_FSTM: KDQOL: Time to increase in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Randomization strata	Sparsentan						Interaction test:	0.665
eGFR Low and UP High	Sparsentan	71	26 (36.6)	NE		1.757	(0.944, 3.271)	0.075
	Irbesartan	74	17 (23.0)	NE				
eGFR Low and UP Low	Sparsentan	55	24 (43.6)	114.1	(49.7, NE)	1.192	(0.597, 2.379)	0.619
	Irbesartan	55	14 (25.5)	NE				
eGFR High and UP High	Sparsentan	37	17 (45.9)	109.0	(50.6, NE)	1.078	(0.454, 2.559)	0.865
	Irbesartan	36	9 (25.0)	NE				
eGFR High and UP Low	Sparsentan	39	15 (38.5)	NE		1.366	(0.593, 3.146)	0.464
	Irbesartan	37	9 (24.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KBUIT_FSTM: KDQOL: Time to increase in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.676
< 60 mL/min/1.73 m**2	Sparsentan	127	48 (37.8)	NE		1.462	(0.920, 2.323)	0.108
	Irbesartan	129	30 (23.3)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	20 (40.8)	NE		1.429	(0.624, 3.271)	0.398
	Irbesartan	48	10 (20.8)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	14 (53.8)	91.8	(47.0, NE)	1.049	(0.426, 2.585)	0.917
	Irbesartan	25	9 (36.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KBUIT_FSTM: KDQOL: Time to increase in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 2	Sparsentan						Interaction test:	0.840
< 45 mL/min/1.73 m**2	Sparsentan	82	33 (40.2)	114.1	(52.0, NE)	1.430	(0.815, 2.508)	0.213
	Irbesartan	80	20 (25.0)	NE				
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	15 (33.3)	NE		1.380	(0.584, 3.260)	0.463
	Irbesartan	49	10 (20.4)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	20 (40.8)	NE		1.429	(0.624, 3.271)	0.398
	Irbesartan	48	10 (20.8)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	14 (53.8)	91.8	(47.0, NE)	1.049	(0.426, 2.585)	0.917
	Irbesartan	25	9 (36.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KBUIT_FSTM: KDQOL: Time to increase in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline urine protein excretion	Sparsentan						Interaction test:	0.284	
<= 1.75 g/day	Sparsentan	98	42 (42.9)	114.6	(52.0, NE)	1.807	(1.051, 3.109)	0.032	*
	Irbesartan	93	20 (21.5)	NE					
> 1.75 g/day	Sparsentan	104	40 (38.5)	NE		1.133	(0.693, 1.851)	0.619	
	Irbesartan	109	29 (26.6)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KBUIT_FSTM: KDQOL: Time to increase in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.199	
Yes	Sparsentan	90	35 (38.9)	NE		1.911	(1.045, 3.495)	0.035	*
	Irbesartan	88	16 (18.2)	NE					
No	Sparsentan	112	47 (42.0)	114.6	(87.7, NE)	1.119	(0.712, 1.761)	0.625	
	Irbesartan	114	33 (28.9)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KBUIT_FSTM: KDQOL: Time to increase in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Time since renal biopsy	Sparsentan						Interaction test:	0.154	
<= 5 years	Sparsentan	113	50 (44.2)	114.1	(70.1, NE)	1.175	(0.763, 1.810)	0.464	
	Irbesartan	127	38 (29.9)	NE					
> 5 years	Sparsentan	89	32 (36.0)	NE		2.192	(1.071, 4.487)	0.032	*
	Irbesartan	75	11 (14.7)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KBUIT_FSTM: KDQOL: Time to increase in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to increase in burden of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
History of hypertension	Sparsentan						Interaction test:	0.551
Yes	Sparsentan	155	60 (38.7)	NE		1.259	(0.829, 1.911)	0.280
	Irbesartan	161	38 (23.6)	NE				
No	Sparsentan	47	22 (46.8)	114.6	(49.1, NE)	1.625	(0.778, 3.398)	0.197
	Irbesartan	41	11 (26.8)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Figure PF2KBUIT_FSKM: KDQOL: Time to increase in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

Not done. No significant subgroups.

_____
An increase reflects an improvement of the status of the patient.
Reference table: PT2KBUIT_FSTM

Table PT2KBUDT_FSTM: KDQOL: Time to decrease in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sex	Sparsentan						Interaction test:	0.922
Male	Sparsentan	139	35 (25.2)	NE		0.685	(0.438, 1.072)	0.098
	Irbesartan	143	47 (32.9)	NE				
Female	Sparsentan	63	14 (22.2)	NE		0.717	(0.344, 1.494)	0.375
	Irbesartan	59	18 (30.5)	116.0	(95.6, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KBUDT_FSTM: KDQOL: Time to decrease in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.991
<= 45 years	Sparsentan	96	22 (22.9)	NE		0.674	(0.383, 1.186)	0.171
	Irbesartan	99	29 (29.3)	NE				
> 45 years	Sparsentan	106	27 (25.5)	NE		0.701	(0.419, 1.174)	0.177
	Irbesartan	103	36 (35.0)	116.0	(108.1, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KBUDT_FSTM: KDQOL: Time to decrease in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age at IgAN diagnosis	Sparsentan						Interaction test:	0.741
<= 18 years	Sparsentan	9	1 (11.1)	NE		35.739	(0.050, NE)	NE
	Irbesartan	5	1 (20.0)	NE				
> 18 to 40 years	Sparsentan	102	24 (23.5)	NE		0.736	(0.425, 1.274)	0.274
	Irbesartan	109	31 (28.4)	NE				
> 40 years	Sparsentan	91	24 (26.4)	NE		0.595	(0.348, 1.015)	0.057
	Irbesartan	88	33 (37.5)	114.1	(94.1, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KBUDT_FSTM: KDQOL: Time to decrease in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Geographic region	Sparsentan						Interaction test:	0.980
North America	Sparsentan	35	9 (25.7)	NE		0.477	(0.200, 1.137)	0.095
	Irbesartan	46	18 (39.1)	NE				
Europe	Sparsentan	98	24 (24.5)	NE		0.636	(0.375, 1.077)	0.092
	Irbesartan	115	34 (29.6)	116.0	(113.1, NE)			
Asia Pacific	Sparsentan	69	16 (23.2)	NE		0.705	(0.326, 1.528)	0.376
	Irbesartan	41	13 (31.7)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KBUDT_FSTM: KDQOL: Time to decrease in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.530
< 27 kg/m**2	Sparsentan	83	21 (25.3)	NE		0.747	(0.423, 1.319)	0.314
	Irbesartan	94	32 (34.0)	116.0	(108.1, NE)			
>= 27 kg/m**2	Sparsentan	119	28 (23.5)	NE		0.642	(0.383, 1.077)	0.093
	Irbesartan	107	33 (30.8)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KBUDT_FSTM: KDQOL: Time to decrease in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Randomization strata	Sparsentan						Interaction test:	0.985
eGFR Low and UP High	Sparsentan	71	19 (26.8)	NE		0.672	(0.369, 1.225)	0.194
	Irbesartan	74	26 (35.1)	114.1	(94.6, NE)			
eGFR Low and UP Low	Sparsentan	55	11 (20.0)	NE		0.729	(0.334, 1.591)	0.428
	Irbesartan	55	16 (29.1)	NE				
eGFR High and UP High	Sparsentan	37	8 (21.6)	NE		0.655	(0.245, 1.754)	0.400
	Irbesartan	36	9 (25.0)	NE				
eGFR High and UP Low	Sparsentan	39	11 (28.2)	NE		0.580	(0.259, 1.298)	0.185
	Irbesartan	37	14 (37.8)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KBUDT_FSTM: KDQOL: Time to decrease in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.947
< 60 mL/min/1.73 m**2	Sparsentan	127	31 (24.4)	NE		0.701	(0.438, 1.123)	0.140
	Irbesartan	129	43 (33.3)	116.0	(110.1, NE)			
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	13 (26.5)	NE		0.591	(0.274, 1.275)	0.180
	Irbesartan	48	15 (31.3)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	5 (19.2)	NE		0.542	(0.168, 1.753)	0.307
	Irbesartan	25	7 (28.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KBUDT_FSTM: KDQOL: Time to decrease in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eGFR Group 2	Sparsentan						Interaction test:	0.379	
< 45 mL/min/1.73 m**2	Sparsentan	82	15 (18.3)	NE		0.493	(0.259, 0.938)	0.031	*
	Irbesartan	80	28 (35.0)	116.0	(95.3, NE)				
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	16 (35.6)	NE		1.100	(0.534, 2.266)	0.796	
	Irbesartan	49	15 (30.6)	NE					
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	13 (26.5)	NE		0.591	(0.274, 1.275)	0.180	
	Irbesartan	48	15 (31.3)	NE					
>= 90 mL/min/1.73 m**2	Sparsentan	26	5 (19.2)	NE		0.542	(0.168, 1.753)	0.307	
	Irbesartan	25	7 (28.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KBUDT_FSTM: KDQOL: Time to decrease in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline urine protein excretion	Sparsentan						Interaction test:	0.883
<= 1.75 g/day	Sparsentan	98	23 (23.5)	NE		0.701	(0.397, 1.238)	0.221
	Irbesartan	93	26 (28.0)	NE				
> 1.75 g/day	Sparsentan	104	26 (25.0)	NE		0.655	(0.394, 1.088)	0.102
	Irbesartan	109	39 (35.8)	114.3	(96.1, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KBUDT_FSTM: KDQOL: Time to decrease in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.406	
Yes	Sparsentan	90	20 (22.2)	NE		0.547	(0.307, 0.974)	0.041	*
	Irbesartan	88	30 (34.1)	116.0	(95.1, NE)				
No	Sparsentan	112	29 (25.9)	NE		0.736	(0.444, 1.219)	0.234	
	Irbesartan	114	35 (30.7)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KBUDT_FSTM: KDQOL: Time to decrease in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Time since renal biopsy	Sparsentan						Interaction test:	0.840
<= 5 years	Sparsentan	113	27 (23.9)	NE		0.628	(0.384, 1.025)	0.063
	Irbesartan	127	42 (33.1)	116.0	(113.1, NE)			
> 5 years	Sparsentan	89	22 (24.7)	NE		0.732	(0.398, 1.345)	0.315
	Irbesartan	75	23 (30.7)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KBUDT_FSTM: KDQOL: Time to decrease in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in burden of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
History of hypertension	Sparsentan						Interaction test:	0.824
Yes	Sparsentan	155	37 (23.9)	NE		0.674	(0.437, 1.038)	0.073
	Irbesartan	161	49 (30.4)	NE				
No	Sparsentan	47	12 (25.5)	NE		0.573	(0.253, 1.299)	0.182
	Irbesartan	41	16 (39.0)	114.1	(95.3, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Figure PF2KBUDT_FSKM: KDQOL: Time to decrease in burden of kidney disease by at least 15 points by subgroup
Full Analysis Set

Not done. No significant subgroups.

_____
A decrease reflects a worsening of the status of the patient.
Reference table: PT2KBUDT_FSTM

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	KDQOL: effect of kidney disease	Baseline	Sparsentan	139	129 (92.8)	90.41 (9.58)	50.0	84.38	93.75	96.88	100.0	
			Irbesartan	143	131 (91.6)	89.72 (12.96)	37.5	87.50	93.75	100.00	100.0	
		Week 24	Sparsentan	139	109 (78.4)	89.28 (14.44)	9.4	84.38	93.75	100.00	100.0	
			Irbesartan	143	93 (65.0)	88.88 (14.59)	28.1	84.38	96.88	100.00	100.0	
		Week 48	Sparsentan	139	112 (80.6)	90.79 (12.62)	0.0	87.50	93.75	100.00	100.0	
			Irbesartan	143	87 (60.8)	92.64 (10.03)	50.0	90.63	96.88	100.00	100.0	
		Week 70	Sparsentan	139	114 (82.0)	90.27 (11.92)	43.8	87.50	93.75	100.00	100.0	
			Irbesartan	143	92 (64.3)	90.83 (14.38)	15.6	87.50	96.88	100.00	100.0	
		Week 94	Sparsentan	139	105 (75.5)	90.71 (10.10)	56.3	84.38	93.75	100.00	100.0	
			Irbesartan	143	96 (67.1)	91.08 (12.00)	43.8	87.50	93.75	100.00	100.0	
		Week 110	Sparsentan	139	103 (74.1)	90.81 (10.22)	43.8	84.38	93.75	100.00	100.0	
			Irbesartan	143	89 (62.2)	90.59 (11.70)	46.9	84.38	96.88	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	139	109 (78.4)	-0.52 (14.00)	-75.0	-3.13	0.00	6.25	25.0	0.06 [-0.21, 0.34]
			Irbesartan	143	93 (65.0)	-1.31 (11.10)	-53.1	-3.13	0.00	3.13	31.3	
		Week 48	Sparsentan	139	112 (80.6)	0.53 (13.17)	-100.0	-3.13	0.00	6.25	28.1	-0.05 [-0.33, 0.23]
			Irbesartan	143	87 (60.8)	1.08 (8.88)	-21.9	-3.13	0.00	6.25	25.0	
		Week 70	Sparsentan	139	114 (82.0)	-0.16 (10.83)	-43.8	-3.13	0.00	6.25	21.9	-0.05 [-0.33, 0.22]
			Irbesartan	143	92 (64.3)	0.48 (14.50)	-71.9	-3.13	0.00	6.25	40.6	
		Week 94	Sparsentan	139	105 (75.5)	0.63 (9.50)	-40.6	-3.13	0.00	3.13	21.9	-0.09 [-0.36, 0.19]
			Irbesartan	143	96 (67.1)	1.43 (9.14)	-21.9	-3.13	0.00	6.25	40.6	
		Week 110	Sparsentan	139	103 (74.1)	0.64 (9.38)	-28.1	-3.13	0.00	6.25	21.9	-0.01 [-0.29, 0.27]
			Irbesartan	143	89 (62.2)	0.74 (10.90)	-28.1	-3.13	0.00	6.25	43.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Female	KDQOL: effect of kidney disease	Baseline	Sparsentan	63	58 (92.1)	84.00 (18.07)	28.1	71.88	90.63	96.88	100.0	
			Irbesartan	59	51 (86.4)	87.01 (12.88)	46.9	78.13	90.63	100.00	100.0	
		Week 24	Sparsentan	63	48 (76.2)	91.67 (9.15)	59.4	87.50	93.75	100.00	100.0	
			Irbesartan	59	38 (64.4)	89.31 (18.65)	0.0	87.50	93.75	100.00	100.0	
		Week 48	Sparsentan	63	50 (79.4)	91.44 (9.55)	62.5	87.50	93.75	100.00	100.0	
			Irbesartan	59	37 (62.7)	89.44 (12.74)	40.6	84.38	90.63	100.00	100.0	
		Week 70	Sparsentan	63	46 (73.0)	89.20 (12.77)	50.0	84.38	92.19	100.00	100.0	
			Irbesartan	59	38 (64.4)	91.28 (10.43)	56.3	87.50	93.75	100.00	100.0	
		Week 94	Sparsentan	63	46 (73.0)	89.95 (12.13)	46.9	81.25	93.75	100.00	100.0	
			Irbesartan	59	34 (57.6)	92.00 (9.55)	59.4	87.50	93.75	100.00	100.0	
		Week 110	Sparsentan	63	46 (73.0)	90.15 (10.35)	56.3	87.50	92.19	96.88	100.0	
			Irbesartan	59	32 (54.2)	90.63 (9.75)	59.4	84.38	93.75	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	63	48 (76.2)	6.97 (14.20)	-15.6	-3.13	3.13	14.06	43.8	0.43 [-0.00, 0.86]
			Irbesartan	59	38 (64.4)	0.00 (18.65)	-100.0	0.00	0.00	6.25	25.0	
		Week 48	Sparsentan	63	50 (79.4)	6.38 (15.77)	-37.5	-3.13	3.13	9.38	56.3	0.35 [-0.08, 0.78]
			Irbesartan	59	37 (62.7)	1.52 (10.54)	-25.0	0.00	0.00	3.13	25.0	
		Week 70	Sparsentan	63	46 (73.0)	5.03 (15.32)	-31.3	-3.13	0.00	9.38	56.3	0.30 [-0.13, 0.73]
			Irbesartan	59	38 (64.4)	1.15 (9.46)	-31.3	-3.13	0.00	6.25	21.9	
		Week 94	Sparsentan	63	46 (73.0)	5.98 (14.26)	-18.8	0.00	3.13	9.38	56.3	0.23 [-0.22, 0.67]
			Irbesartan	59	34 (57.6)	3.22 (8.86)	-15.6	0.00	0.00	9.38	25.0	
		Week 110	Sparsentan	63	46 (73.0)	4.35 (14.68)	-21.9	-6.25	3.13	6.25	46.9	0.19 [-0.26, 0.64]
			Irbesartan	59	32 (54.2)	1.95 (9.04)	-25.0	-1.56	1.56	6.25	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
<= 45 years	KDQOL: effect of kidney disease	Baseline	Sparsentan	96	87 (90.6)	86.82 (14.88)	28.1	84.38	90.63	96.88	100.0	
			Irbesartan	99	92 (92.9)	86.58 (14.49)	37.5	79.69	90.63	96.88	100.0	
		Week 24	Sparsentan	96	71 (74.0)	88.25 (15.29)	9.4	81.25	93.75	100.00	100.0	
			Irbesartan	99	67 (67.7)	87.17 (18.45)	0.0	81.25	93.75	96.88	100.0	
		Week 48	Sparsentan	96	75 (78.1)	88.88 (15.03)	0.0	87.50	93.75	96.88	100.0	
			Irbesartan	99	62 (62.6)	90.42 (12.75)	40.6	84.38	96.88	100.00	100.0	
		Week 70	Sparsentan	96	72 (75.0)	88.89 (12.14)	43.8	84.38	93.75	96.88	100.0	
			Irbesartan	99	62 (62.6)	91.13 (11.87)	40.6	87.50	93.75	100.00	100.0	
		Week 94	Sparsentan	96	68 (70.8)	89.52 (11.45)	46.9	81.25	93.75	100.00	100.0	
			Irbesartan	99	64 (64.6)	89.65 (13.86)	43.8	87.50	93.75	100.00	100.0	
		Week 110	Sparsentan	96	69 (71.9)	90.58 (10.58)	43.8	87.50	93.75	100.00	100.0	
			Irbesartan	99	59 (59.6)	88.72 (12.35)	46.9	84.38	90.63	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	96	71 (74.0)	1.54 (17.04)	-75.0	-6.25	3.13	9.38	43.8	0.16 [-0.17, 0.50]
			Irbesartan	99	67 (67.7)	-1.12 (15.75)	-100.0	-3.13	0.00	6.25	31.3	
		Week 48	Sparsentan	96	75 (78.1)	2.21 (18.53)	-100.0	-3.13	3.13	6.25	56.3	0.07 [-0.26, 0.41]
			Irbesartan	99	62 (62.6)	1.11 (9.64)	-21.9	-3.13	0.00	3.13	25.0	
		Week 70	Sparsentan	96	72 (75.0)	2.26 (13.94)	-31.3	-3.13	0.00	6.25	56.3	0.08 [-0.26, 0.42]
			Irbesartan	99	62 (62.6)	1.31 (10.43)	-31.3	-3.13	0.00	6.25	21.9	
		Week 94	Sparsentan	96	68 (70.8)	2.94 (14.10)	-40.6	-3.13	3.13	9.38	56.3	0.14 [-0.20, 0.48]
			Irbesartan	99	64 (64.6)	1.27 (9.36)	-21.9	-4.69	0.00	6.25	25.0	
		Week 110	Sparsentan	96	69 (71.9)	3.17 (13.53)	-28.1	-3.13	3.13	9.38	46.9	0.22 [-0.13, 0.57]
			Irbesartan	99	59 (59.6)	0.58 (9.70)	-28.1	-6.25	0.00	6.25	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 45 years	KDQOL: effect of kidney disease	Baseline	Sparsentan	106	100 (94.3)	89.81 (11.26)	50.0	84.38	93.75	100.00	100.0	
			Irbesartan	103	90 (87.4)	91.39 (10.72)	46.9	87.50	93.75	100.00	100.0	
		Week 24	Sparsentan	106	86 (81.1)	91.46 (10.79)	50.0	87.50	93.75	100.00	100.0	
			Irbesartan	103	64 (62.1)	90.92 (12.30)	34.4	85.94	96.88	100.00	100.0	
		Week 48	Sparsentan	106	87 (82.1)	92.82 (7.48)	75.0	87.50	93.75	100.00	100.0	
			Irbesartan	103	62 (60.2)	92.94 (8.73)	68.8	87.50	96.88	100.00	100.0	
		Week 70	Sparsentan	106	88 (83.0)	90.84 (12.13)	46.9	87.50	93.75	100.00	100.0	
			Irbesartan	103	68 (66.0)	90.81 (14.58)	15.6	87.50	96.88	100.00	100.0	
		Week 94	Sparsentan	106	83 (78.3)	91.27 (10.09)	56.3	87.50	93.75	100.00	100.0	
			Irbesartan	103	66 (64.1)	92.95 (8.10)	68.8	87.50	96.88	100.00	100.0	
		Week 110	Sparsentan	106	80 (75.5)	90.63 (9.99)	56.3	87.50	93.75	98.44	100.0	
			Irbesartan	103	62 (60.2)	92.39 (9.70)	62.5	87.50	96.88	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	106	86 (81.1)	1.96 (11.97)	-37.5	-3.13	0.00	6.25	31.3	0.23 [-0.09, 0.56]
			Irbesartan	103	64 (62.1)	-0.73 (11.17)	-53.1	-3.13	0.00	6.25	18.8	
		Week 48	Sparsentan	106	87 (82.1)	2.44 (9.16)	-21.9	-3.13	0.00	6.25	34.4	0.12 [-0.20, 0.45]
			Irbesartan	103	62 (60.2)	1.31 (9.15)	-25.0	0.00	0.00	6.25	25.0	
		Week 70	Sparsentan	106	88 (83.0)	0.57 (11.14)	-43.8	-3.13	0.00	6.25	40.6	0.04 [-0.28, 0.35]
			Irbesartan	103	68 (66.0)	0.09 (15.35)	-71.9	0.00	0.00	6.25	40.6	
		Week 94	Sparsentan	106	83 (78.3)	1.69 (8.61)	-18.8	-3.13	0.00	3.13	28.1	-0.09 [-0.42, 0.23]
			Irbesartan	103	66 (64.1)	2.51 (8.79)	-18.8	0.00	0.00	6.25	40.6	
		Week 110	Sparsentan	106	80 (75.5)	0.59 (9.01)	-21.9	-3.13	0.00	4.69	34.4	-0.09 [-0.42, 0.24]
			Irbesartan	103	62 (60.2)	1.51 (11.11)	-25.0	-3.13	0.00	6.25	43.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age at IgAN diagnosis												
<= 18 years	KDQOL: effect of kidney disease	Baseline	Sparsentan	9	9 (100.0)	76.74 (22.54)	28.1	71.88	84.38	90.63	96.9	
			Irbesartan	5	5 (100.0)	86.88 (23.01)	46.9	87.50	100.00	100.00	100.0	
		Week 24	Sparsentan	9	5 (55.6)	75.63 (37.91)	9.4	81.25	87.50	100.00	100.0	
			Irbesartan	5	5 (100.0)	89.38 (15.08)	62.5	93.75	96.88	96.88	96.9	
		Week 48	Sparsentan	9	7 (77.8)	88.39 (7.81)	75.0	81.25	90.63	93.75	96.9	
			Irbesartan	5	3 (60.0)	97.92 (1.80)	96.9	96.88	96.88	100.00	100.0	
		Week 70	Sparsentan	9	7 (77.8)	87.95 (9.95)	75.0	78.13	84.38	96.88	100.0	
			Irbesartan	5	4 (80.0)	79.69 (27.30)	40.6	60.94	89.06	98.44	100.0	
		Week 94	Sparsentan	9	5 (55.6)	92.50 (7.19)	84.4	87.50	90.63	100.00	100.0	
			Irbesartan	5	4 (80.0)	82.81 (24.27)	46.9	68.75	92.19	96.88	100.0	
		Week 110	Sparsentan	9	4 (44.4)	92.97 (8.22)	81.3	87.50	95.31	98.44	100.0	
			Irbesartan	5	2 (40.0)	70.31 (33.15)	46.9	46.88	70.31	93.75	93.8	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	9	5 (55.6)	-8.75 (38.11)	-75.0	-6.25	6.25	15.63	15.6	-0.41 [-1.66, 0.84]
			Irbesartan	5	5 (100.0)	2.50 (8.39)	-3.1	-3.13	-3.13	6.25	15.6	
		Week 48	Sparsentan	9	7 (77.8)	9.38 (17.86)	-6.3	0.00	3.13	15.63	46.9	0.46 [-0.91, 1.83]
			Irbesartan	5	3 (60.0)	2.08 (6.51)	-3.1	-3.13	0.00	9.38	9.4	
		Week 70	Sparsentan	9	7 (77.8)	8.93 (22.49)	-12.5	-6.25	6.25	12.50	56.3	0.84 [-0.44, 2.12]
			Irbesartan	5	4 (80.0)	-7.03 (8.22)	-18.8	-12.50	-4.69	-1.56	0.0	
		Week 94	Sparsentan	9	5 (55.6)	6.88 (7.46)	-3.1	3.13	6.25	12.50	15.6	1.68 [0.15, 3.21]
			Irbesartan	5	4 (80.0)	-3.91 (4.69)	-9.4	-7.81	-3.13	0.00	0.0	
		Week 110	Sparsentan	9	4 (44.4)	5.47 (12.07)	-6.3	-3.13	3.13	14.06	21.9	0.80 [-0.95, 2.56]
			Irbesartan	5	2 (40.0)	-3.13 (4.42)	-6.3	-6.25	-3.13	0.00	0.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 18 to 40 years	KDQOL: effect of kidney disease	Baseline	Sparsentan	102	94 (92.2)	89.10 (12.71)	34.4	87.50	93.75	96.88	100.0	
			Irbesartan	109	99 (90.8)	87.31 (13.87)	37.5	84.38	90.63	96.88	100.0	
		Week 24	Sparsentan	102	79 (77.5)	90.31 (11.60)	56.3	87.50	93.75	100.00	100.0	
			Irbesartan	109	71 (65.1)	87.81 (18.38)	0.0	84.38	93.75	100.00	100.0	
		Week 48	Sparsentan	102	82 (80.4)	89.94 (14.56)	0.0	87.50	93.75	100.00	100.0	
			Irbesartan	109	67 (61.5)	90.44 (12.49)	40.6	84.38	96.88	100.00	100.0	
		Week 70	Sparsentan	102	78 (76.5)	89.78 (12.69)	43.8	87.50	93.75	100.00	100.0	
			Irbesartan	109	68 (62.4)	91.08 (11.98)	37.5	87.50	93.75	100.00	100.0	
		Week 94	Sparsentan	102	73 (71.6)	90.20 (11.34)	46.9	84.38	93.75	100.00	100.0	
			Irbesartan	109	69 (63.3)	90.35 (12.74)	43.8	87.50	93.75	100.00	100.0	
		Week 110	Sparsentan	102	72 (70.6)	90.89 (10.66)	43.8	87.50	93.75	100.00	100.0	
			Irbesartan	109	65 (59.6)	90.14 (11.05)	59.4	84.38	93.75	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	102	79 (77.5)	2.14 (13.75)	-37.5	-6.25	0.00	9.38	43.8	0.25 [-0.07, 0.58]
			Irbesartan	109	71 (65.1)	-1.58 (15.49)	-100.0	-3.13	0.00	3.13	31.3	
		Week 48	Sparsentan	102	82 (80.4)	1.30 (17.20)	-100.0	-3.13	1.56	6.25	56.3	0.03 [-0.30, 0.35]
			Irbesartan	109	67 (61.5)	0.93 (9.28)	-21.9	-3.13	0.00	3.13	25.0	
		Week 70	Sparsentan	102	78 (76.5)	1.24 (12.85)	-43.8	-3.13	0.00	6.25	34.4	0.01 [-0.31, 0.34]
			Irbesartan	109	68 (62.4)	1.10 (13.01)	-62.5	-3.13	0.00	6.25	37.5	
		Week 94	Sparsentan	102	73 (71.6)	2.61 (13.67)	-40.6	-3.13	3.13	9.38	56.3	0.06 [-0.27, 0.39]
			Irbesartan	109	69 (63.3)	1.86 (9.92)	-21.9	-3.13	0.00	6.25	40.6	
		Week 110	Sparsentan	102	72 (70.6)	2.99 (13.09)	-28.1	-3.13	3.13	7.81	46.9	0.15 [-0.19, 0.48]
			Irbesartan	109	65 (59.6)	1.25 (10.29)	-28.1	-3.13	0.00	6.25	40.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 40 years	KDQOL: effect of kidney disease	Baseline	Sparsentan	91	84 (92.3)	88.91 (11.83)	50.0	84.38	93.75	96.88	100.0	
			Irbesartan	88	78 (88.6)	91.19 (10.66)	46.9	84.38	93.75	100.00	100.0	
		Week 24	Sparsentan	91	73 (80.2)	90.67 (11.38)	50.0	87.50	93.75	100.00	100.0	
			Irbesartan	88	55 (62.5)	90.51 (11.91)	34.4	84.38	93.75	100.00	100.0	
		Week 48	Sparsentan	91	73 (80.2)	92.42 (7.76)	75.0	87.50	93.75	100.00	100.0	
			Irbesartan	88	54 (61.4)	92.88 (8.87)	68.8	84.38	96.88	100.00	100.0	
		Week 70	Sparsentan	91	75 (82.4)	90.33 (11.85)	46.9	87.50	93.75	100.00	100.0	
			Irbesartan	88	58 (65.9)	91.59 (13.54)	15.6	87.50	96.88	100.00	100.0	
		Week 94	Sparsentan	91	73 (80.2)	90.63 (10.38)	56.3	87.50	93.75	96.88	100.0	
			Irbesartan	88	57 (64.8)	93.09 (7.78)	68.8	87.50	93.75	100.00	100.0	
		Week 110	Sparsentan	91	73 (80.2)	90.20 (10.00)	56.3	87.50	93.75	96.88	100.0	
			Irbesartan	88	54 (61.4)	91.90 (9.85)	62.5	84.38	96.88	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	91	73 (80.2)	2.10 (12.58)	-37.5	-3.13	0.00	6.25	31.3	0.21 [-0.14, 0.56]
			Irbesartan	88	55 (62.5)	-0.40 (11.44)	-53.1	-3.13	0.00	6.25	25.0	
		Week 48	Sparsentan	91	73 (80.2)	2.83 (9.35)	-21.9	0.00	0.00	6.25	34.4	0.14 [-0.21, 0.49]
			Irbesartan	88	54 (61.4)	1.50 (9.71)	-25.0	0.00	0.00	6.25	25.0	
		Week 70	Sparsentan	91	75 (82.4)	0.71 (10.72)	-28.1	-3.13	0.00	6.25	40.6	0.00 [-0.34, 0.34]
			Irbesartan	88	58 (65.9)	0.70 (13.68)	-71.9	0.00	0.00	6.25	40.6	
		Week 94	Sparsentan	91	73 (80.2)	1.58 (8.84)	-18.8	-3.13	0.00	3.13	28.1	-0.09 [-0.44, 0.26]
			Irbesartan	88	57 (64.8)	2.36 (8.13)	-18.8	0.00	0.00	6.25	37.5	
		Week 110	Sparsentan	91	73 (80.2)	0.39 (9.29)	-21.9	-3.13	0.00	3.13	34.4	-0.06 [-0.41, 0.29]
			Irbesartan	88	54 (61.4)	0.98 (10.81)	-25.0	-3.13	0.00	6.25	43.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Geographic region												
North America	KDQOL: effect of kidney disease	Baseline	Sparsentan	35	31 (88.6)	88.41 (15.21)	28.1	84.38	93.75	96.88	100.0	
			Irbesartan	46	43 (93.5)	91.28 (10.84)	46.9	87.50	96.88	100.00	100.0	
		Week 24	Sparsentan	35	23 (65.7)	87.23 (20.14)	9.4	87.50	93.75	96.88	100.0	
			Irbesartan	46	35 (76.1)	89.91 (17.71)	0.0	87.50	96.88	100.00	100.0	
		Week 48	Sparsentan	35	25 (71.4)	91.88 (8.70)	75.0	90.63	93.75	100.00	100.0	
			Irbesartan	46	32 (69.6)	92.09 (12.90)	50.0	89.06	98.44	100.00	100.0	
		Week 70	Sparsentan	35	22 (62.9)	90.77 (9.42)	68.8	87.50	92.19	96.88	100.0	
			Irbesartan	46	30 (65.2)	93.75 (10.98)	56.3	93.75	100.00	100.00	100.0	
		Week 94	Sparsentan	35	23 (65.7)	89.81 (13.23)	46.9	81.25	96.88	100.00	100.0	
			Irbesartan	46	30 (65.2)	92.92 (9.91)	59.4	87.50	96.88	100.00	100.0	
		Week 110	Sparsentan	35	21 (60.0)	91.37 (10.50)	62.5	87.50	93.75	100.00	100.0	
			Irbesartan	46	31 (67.4)	93.04 (9.87)	59.4	90.63	96.88	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	35	23 (65.7)	-1.90 (22.17)	-75.0	-6.25	0.00	6.25	43.8	0.03 [-0.50, 0.56]
			Irbesartan	46	35 (76.1)	-2.50 (18.53)	-100.0	-3.13	0.00	6.25	15.6	
		Week 48	Sparsentan	35	25 (71.4)	4.88 (11.45)	-15.6	0.00	3.13	6.25	46.9	0.33 [-0.20, 0.86]
			Irbesartan	46	32 (69.6)	1.56 (8.84)	-21.9	0.00	0.00	4.69	25.0	
		Week 70	Sparsentan	35	22 (62.9)	2.98 (14.61)	-18.8	-3.13	0.00	6.25	56.3	0.29 [-0.27, 0.84]
			Irbesartan	46	30 (65.2)	-0.21 (7.70)	-31.3	0.00	0.00	3.13	12.5	
		Week 94	Sparsentan	35	23 (65.7)	0.82 (9.94)	-21.9	-6.25	0.00	6.25	18.8	-0.08 [-0.62, 0.47]
			Irbesartan	46	30 (65.2)	1.46 (6.90)	-15.6	0.00	0.00	3.13	18.8	
		Week 110	Sparsentan	35	21 (60.0)	1.34 (7.43)	-18.8	0.00	3.13	6.25	15.6	-0.07 [-0.62, 0.48]
			Irbesartan	46	31 (67.4)	1.81 (6.39)	-12.5	0.00	0.00	6.25	12.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Europe	KDQOL: effect of kidney disease	Baseline	Sparsentan	98	89 (90.8)	89.89 (11.68)	43.8	84.38	93.75	96.88	100.0	
			Irbesartan	115	98 (85.2)	87.15 (13.87)	43.8	78.13	90.63	96.88	100.0	
		Week 24	Sparsentan	98	73 (74.5)	92.12 (9.29)	56.3	87.50	93.75	100.00	100.0	
			Irbesartan	115	62 (53.9)	88.36 (14.60)	34.4	84.38	93.75	96.88	100.0	
		Week 48	Sparsentan	98	76 (77.6)	93.01 (8.11)	56.3	90.63	93.75	100.00	100.0	
			Irbesartan	115	59 (51.3)	91.58 (9.56)	65.6	84.38	96.88	100.00	100.0	
		Week 70	Sparsentan	98	75 (76.5)	91.17 (10.48)	43.8	87.50	93.75	100.00	100.0	
			Irbesartan	115	69 (60.0)	88.68 (15.89)	15.6	84.38	93.75	100.00	100.0	
		Week 94	Sparsentan	98	68 (69.4)	91.45 (9.73)	56.3	85.94	93.75	100.00	100.0	
			Irbesartan	115	70 (60.9)	89.46 (12.98)	43.8	87.50	93.75	96.88	100.0	
		Week 110	Sparsentan	98	67 (68.4)	92.26 (9.27)	43.8	90.63	93.75	100.00	100.0	
			Irbesartan	115	61 (53.0)	88.93 (12.56)	46.9	84.38	90.63	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	98	73 (74.5)	2.65 (11.86)	-25.0	-3.13	0.00	6.25	31.3	0.21 [-0.13, 0.55]
			Irbesartan	115	62 (53.9)	0.05 (13.13)	-53.1	-3.13	0.00	6.25	31.3	
		Week 48	Sparsentan	98	76 (77.6)	3.13 (12.47)	-40.6	-3.13	1.56	6.25	56.3	0.09 [-0.25, 0.43]
			Irbesartan	115	59 (51.3)	2.12 (9.82)	-21.9	-3.13	0.00	6.25	25.0	
		Week 70	Sparsentan	98	75 (76.5)	0.79 (9.98)	-28.1	-3.13	0.00	6.25	40.6	-0.04 [-0.37, 0.28]
			Irbesartan	115	69 (60.0)	1.40 (16.78)	-71.9	-3.13	0.00	6.25	40.6	
		Week 94	Sparsentan	98	68 (69.4)	2.25 (11.23)	-15.6	-3.13	0.00	4.69	56.3	-0.06 [-0.39, 0.28]
			Irbesartan	115	70 (60.9)	2.86 (10.69)	-21.9	-3.13	0.00	6.25	40.6	
		Week 110	Sparsentan	98	67 (68.4)	2.01 (11.48)	-28.1	-3.13	0.00	6.25	46.9	-0.01 [-0.36, 0.33]
			Irbesartan	115	61 (53.0)	2.15 (12.55)	-25.0	-3.13	0.00	6.25	43.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asia Pacific	KDQOL: effect of kidney disease	Baseline	Sparsentan	69	67 (97.1)	86.47 (13.82)	34.4	81.25	90.63	96.88	100.0	
			Irbesartan	41	41 (100.0)	90.85 (12.35)	37.5	87.50	93.75	100.00	100.0	
		Week 24	Sparsentan	69	61 (88.4)	88.52 (13.46)	50.0	84.38	93.75	100.00	100.0	
			Irbesartan	41	34 (82.9)	89.25 (16.25)	28.1	84.38	95.31	100.00	100.0	
		Week 48	Sparsentan	69	61 (88.4)	88.11 (15.58)	0.0	87.50	90.63	96.88	100.0	
			Irbesartan	41	33 (80.5)	91.48 (11.59)	40.6	90.63	93.75	100.00	100.0	
		Week 70	Sparsentan	69	63 (91.3)	88.24 (14.55)	46.9	81.25	93.75	100.00	100.0	
			Irbesartan	41	31 (75.6)	93.35 (6.83)	75.0	87.50	96.88	100.00	100.0	
		Week 94	Sparsentan	69	60 (87.0)	89.64 (10.85)	56.3	84.38	93.75	96.88	100.0	
			Irbesartan	41	30 (73.2)	94.06 (7.67)	68.8	90.63	96.88	100.00	100.0	
		Week 110	Sparsentan	69	61 (88.4)	88.52 (10.93)	56.3	81.25	90.63	96.88	100.0	
			Irbesartan	41	29 (70.7)	91.49 (8.91)	68.8	84.38	93.75	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	69	61 (88.4)	2.10 (13.65)	-37.5	-3.13	3.13	9.38	34.4	0.27 [-0.15, 0.69]
			Irbesartan	41	34 (82.9)	-1.10 (7.61)	-15.6	-6.25	0.00	3.13	12.5	
		Week 48	Sparsentan	69	61 (88.4)	0.31 (17.01)	-100.0	-3.13	0.00	6.25	34.4	0.07 [-0.35, 0.50]
			Irbesartan	41	33 (80.5)	-0.76 (8.98)	-25.0	-3.13	0.00	3.13	25.0	
		Week 70	Sparsentan	69	63 (91.3)	1.39 (14.35)	-43.8	-3.13	0.00	9.38	34.4	0.12 [-0.31, 0.55]
			Irbesartan	41	31 (75.6)	-0.10 (7.10)	-21.9	-3.13	0.00	3.13	15.6	
		Week 94	Sparsentan	69	60 (87.0)	2.81 (12.19)	-40.6	-1.56	3.13	9.38	34.4	0.26 [-0.18, 0.69]
			Irbesartan	41	30 (73.2)	0.10 (6.33)	-18.8	-3.13	0.00	3.13	18.8	
		Week 110	Sparsentan	69	61 (88.4)	1.69 (12.44)	-21.9	-6.25	0.00	6.25	37.5	0.33 [-0.11, 0.78]
			Irbesartan	41	29 (70.7)	-2.05 (8.41)	-28.1	-6.25	0.00	0.00	15.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline BMI												
< 27 kg/m**2	KDQOL: effect of kidney disease	Baseline	Sparsentan	83	75 (90.4)	85.83 (13.40)	28.1	78.13	90.63	96.88	100.0	
			Irbesartan	94	86 (91.5)	88.55 (11.30)	46.9	84.38	90.63	100.00	100.0	
		Week 24	Sparsentan	83	66 (79.5)	88.83 (15.61)	9.4	87.50	93.75	100.00	100.0	
			Irbesartan	94	66 (70.2)	87.55 (16.99)	0.0	84.38	93.75	96.88	100.0	
		Week 48	Sparsentan	83	66 (79.5)	89.11 (10.63)	50.0	84.38	92.19	96.88	100.0	
			Irbesartan	94	60 (63.8)	89.74 (12.26)	40.6	84.38	93.75	96.88	100.0	
		Week 70	Sparsentan	83	64 (77.1)	88.62 (13.99)	43.8	84.38	93.75	100.00	100.0	
			Irbesartan	94	59 (62.8)	89.51 (13.28)	37.5	84.38	93.75	100.00	100.0	
		Week 94	Sparsentan	83	63 (75.9)	90.08 (10.52)	46.9	84.38	93.75	100.00	100.0	
			Irbesartan	94	62 (66.0)	90.47 (11.74)	43.8	87.50	93.75	100.00	100.0	
		Week 110	Sparsentan	83	63 (75.9)	88.89 (11.77)	43.8	81.25	93.75	96.88	100.0	
			Irbesartan	94	57 (60.6)	89.91 (11.63)	46.9	84.38	93.75	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	83	66 (79.5)	2.23 (16.92)	-75.0	-3.13	3.13	9.38	43.8	0.16 [-0.18, 0.51]
			Irbesartan	94	66 (70.2)	-0.43 (15.53)	-100.0	-3.13	0.00	6.25	31.3	
		Week 48	Sparsentan	83	66 (79.5)	3.17 (12.39)	-40.6	-3.13	1.56	6.25	46.9	0.16 [-0.19, 0.51]
			Irbesartan	94	60 (63.8)	1.41 (9.00)	-21.9	-1.56	0.00	6.25	25.0	
		Week 70	Sparsentan	83	64 (77.1)	2.34 (14.12)	-43.8	-3.13	3.13	9.38	56.3	0.15 [-0.21, 0.50]
			Irbesartan	94	59 (62.8)	0.42 (12.08)	-62.5	-3.13	0.00	6.25	18.8	
		Week 94	Sparsentan	83	63 (75.9)	3.47 (9.48)	-15.6	-3.13	3.13	9.38	34.4	0.22 [-0.13, 0.57]
			Irbesartan	94	62 (66.0)	1.51 (8.37)	-18.8	-3.13	0.00	6.25	18.8	
		Week 110	Sparsentan	83	63 (75.9)	1.54 (11.20)	-28.1	-3.13	0.00	6.25	31.3	0.05 [-0.30, 0.41]
			Irbesartan	94	57 (60.6)	0.99 (8.96)	-25.0	-3.13	0.00	6.25	18.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 27 kg/m**2	KDQOL: effect of kidney disease	Baseline	Sparsentan	119	112 (94.1)	90.15 (12.69)	34.4	87.50	93.75	100.00	100.0	
			Irbesartan	107	95 (88.8)	89.51 (14.29)	37.5	87.50	96.88	100.00	100.0	
		Week 24	Sparsentan	119	91 (76.5)	90.87 (10.88)	56.3	84.38	93.75	100.00	100.0	
			Irbesartan	107	65 (60.7)	90.48 (14.47)	28.1	87.50	96.88	100.00	100.0	
		Week 48	Sparsentan	119	96 (80.7)	92.29 (12.32)	0.0	90.63	93.75	100.00	100.0	
			Irbesartan	107	64 (59.8)	93.51 (9.31)	59.4	90.63	98.44	100.00	100.0	
		Week 70	Sparsentan	119	96 (80.7)	90.85 (10.71)	46.9	87.50	93.75	96.88	100.0	
			Irbesartan	107	71 (66.4)	92.17 (13.30)	15.6	87.50	96.88	100.00	100.0	
		Week 94	Sparsentan	119	88 (73.9)	90.77 (10.92)	56.3	84.38	93.75	100.00	100.0	
			Irbesartan	107	67 (62.6)	92.72 (9.87)	53.1	87.50	96.88	100.00	100.0	
		Week 110	Sparsentan	119	86 (72.3)	91.86 (8.80)	56.3	87.50	93.75	100.00	100.0	
			Irbesartan	107	63 (58.9)	91.52 (10.61)	59.4	87.50	96.88	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	119	91 (76.5)	1.44 (12.42)	-37.5	-3.13	0.00	6.25	31.3	0.24 [-0.08, 0.56]
			Irbesartan	107	65 (60.7)	-1.44 (11.55)	-53.1	-3.13	0.00	3.13	25.0	
		Week 48	Sparsentan	119	96 (80.7)	1.76 (15.42)	-100.0	-3.13	1.56	6.25	56.3	0.05 [-0.26, 0.37]
			Irbesartan	107	64 (59.8)	1.03 (9.76)	-25.0	-3.13	0.00	3.13	25.0	
		Week 70	Sparsentan	119	96 (80.7)	0.65 (11.25)	-31.3	-3.13	0.00	6.25	40.6	-0.02 [-0.33, 0.29]
			Irbesartan	107	71 (66.4)	0.88 (14.14)	-71.9	-3.13	0.00	3.13	40.6	
		Week 94	Sparsentan	119	88 (73.9)	1.38 (12.56)	-40.6	-3.13	0.00	6.25	56.3	-0.11 [-0.43, 0.21]
			Irbesartan	107	67 (62.6)	2.61 (9.31)	-15.6	0.00	0.00	3.13	40.6	
		Week 110	Sparsentan	119	86 (72.3)	1.96 (11.54)	-21.9	-3.13	0.00	6.25	46.9	0.07 [-0.25, 0.40]
			Irbesartan	107	63 (58.9)	1.14 (11.72)	-28.1	-3.13	0.00	6.25	43.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Randomization strata												
eGFR Low and UP High	KDQOL: effect of kidney disease	Baseline	Sparsentan	71	63 (88.7)	88.94 (11.54)	50.0	84.38	93.75	96.88	100.0	
			Irbesartan	74	63 (85.1)	85.66 (15.38)	43.8	81.25	90.63	96.88	100.0	
		Week 24	Sparsentan	71	54 (76.1)	89.24 (12.17)	56.3	84.38	93.75	96.88	100.0	
			Irbesartan	74	40 (54.1)	85.39 (15.23)	40.6	79.69	87.50	96.88	100.0	
		Week 48	Sparsentan	71	51 (71.8)	90.75 (10.04)	50.0	87.50	93.75	100.00	100.0	
			Irbesartan	74	37 (50.0)	88.60 (14.27)	40.6	81.25	93.75	100.00	100.0	
		Week 70	Sparsentan	71	57 (80.3)	88.43 (14.25)	43.8	84.38	93.75	96.88	100.0	
			Irbesartan	74	37 (50.0)	88.43 (15.32)	37.5	87.50	93.75	96.88	100.0	
		Week 94	Sparsentan	71	51 (71.8)	89.71 (11.22)	56.3	84.38	93.75	100.00	100.0	
			Irbesartan	74	37 (50.0)	87.75 (13.73)	46.9	84.38	90.63	96.88	100.0	
		Week 110	Sparsentan	71	53 (74.6)	89.62 (11.58)	43.8	81.25	93.75	100.00	100.0	
			Irbesartan	74	36 (48.6)	87.93 (14.45)	46.9	82.81	95.31	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	71	54 (76.1)	0.58 (10.27)	-37.5	-3.13	3.13	6.25	18.8	0.30 [-0.11, 0.71]
			Irbesartan	74	40 (54.1)	-2.42 (9.69)	-25.0	-7.81	0.00	3.13	15.6	
		Week 48	Sparsentan	71	51 (71.8)	2.02 (7.68)	-15.6	-3.13	3.13	6.25	28.1	0.16 [-0.26, 0.59]
			Irbesartan	74	37 (50.0)	0.68 (9.06)	-21.9	-6.25	0.00	6.25	21.9	
		Week 70	Sparsentan	71	57 (80.3)	-0.66 (11.08)	-43.8	-3.13	0.00	6.25	21.9	-0.10 [-0.51, 0.32]
			Irbesartan	74	37 (50.0)	0.59 (15.60)	-62.5	-3.13	0.00	6.25	40.6	
		Week 94	Sparsentan	71	51 (71.8)	0.86 (8.03)	-21.9	-3.13	0.00	3.13	18.8	-0.13 [-0.56, 0.29]
			Irbesartan	74	37 (50.0)	2.03 (9.61)	-21.9	0.00	0.00	6.25	37.5	
		Week 110	Sparsentan	71	53 (74.6)	0.59 (8.52)	-28.1	-3.13	0.00	6.25	18.8	-0.05 [-0.47, 0.38]
			Irbesartan	74	36 (48.6)	1.04 (11.43)	-18.8	-6.25	0.00	6.25	43.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR Low and UP Low	KDQOL: effect of kidney disease	Baseline	Sparsentan	55	52 (94.5)	86.36 (13.54)	43.8	78.13	90.63	95.31	100.0	
			Irbesartan	55	50 (90.9)	91.56 (8.84)	71.9	87.50	93.75	100.00	100.0	
		Week 24	Sparsentan	55	43 (78.2)	88.52 (13.11)	50.0	81.25	93.75	100.00	100.0	
			Irbesartan	55	37 (67.3)	94.26 (10.06)	50.0	93.75	96.88	100.00	100.0	
		Week 48	Sparsentan	55	43 (78.2)	89.53 (16.03)	0.0	87.50	93.75	100.00	100.0	
			Irbesartan	55	35 (63.6)	92.95 (8.10)	75.0	87.50	96.88	100.00	100.0	
		Week 70	Sparsentan	55	42 (76.4)	89.06 (13.37)	50.0	84.38	93.75	100.00	100.0	
			Irbesartan	55	39 (70.9)	91.11 (10.84)	56.3	87.50	96.88	100.00	100.0	
		Week 94	Sparsentan	55	41 (74.5)	90.17 (10.59)	59.4	84.38	93.75	100.00	100.0	
			Irbesartan	55	39 (70.9)	93.11 (8.30)	71.9	90.63	96.88	100.00	100.0	
		Week 110	Sparsentan	55	37 (67.3)	90.12 (10.66)	56.3	84.38	93.75	96.88	100.0	
			Irbesartan	55	34 (61.8)	91.45 (9.01)	71.9	87.50	93.75	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	55	43 (78.2)	3.27 (14.83)	-37.5	-3.13	3.13	12.50	31.3	0.12 [-0.32, 0.56]
			Irbesartan	55	37 (67.3)	1.77 (9.39)	-37.5	0.00	0.00	6.25	18.8	
		Week 48	Sparsentan	55	43 (78.2)	1.89 (20.47)	-100.0	0.00	0.00	6.25	56.3	0.03 [-0.42, 0.47]
			Irbesartan	55	35 (63.6)	1.43 (9.14)	-25.0	0.00	0.00	6.25	25.0	
		Week 70	Sparsentan	55	42 (76.4)	2.23 (12.69)	-28.1	-3.13	3.13	9.38	40.6	0.19 [-0.25, 0.62]
			Irbesartan	55	39 (70.9)	0.16 (9.07)	-31.3	-3.13	0.00	6.25	18.8	
		Week 94	Sparsentan	55	41 (74.5)	4.12 (13.59)	-15.6	-3.13	0.00	9.38	56.3	0.17 [-0.27, 0.61]
			Irbesartan	55	39 (70.9)	2.24 (7.59)	-15.6	0.00	0.00	6.25	18.8	
		Week 110	Sparsentan	55	37 (67.3)	2.62 (13.93)	-18.8	-3.13	0.00	6.25	46.9	0.04 [-0.42, 0.51]
			Irbesartan	55	34 (61.8)	2.11 (8.59)	-25.0	0.00	0.00	6.25	18.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP High	KDQOL: effect of kidney disease	Baseline	Sparsentan	37	35 (94.6)	89.73 (14.15)	28.1	84.38	93.75	100.00	100.0	
			Irbesartan	36	33 (91.7)	88.45 (11.52)	56.3	84.38	90.63	96.88	100.0	
		Week 24	Sparsentan	37	26 (70.3)	91.23 (17.68)	9.4	90.63	95.31	100.00	100.0	
			Irbesartan	36	26 (72.2)	88.46 (13.51)	34.4	84.38	92.19	96.88	100.0	
		Week 48	Sparsentan	37	33 (89.2)	91.86 (10.51)	56.3	90.63	93.75	100.00	100.0	
			Irbesartan	36	24 (66.7)	92.97 (7.39)	75.0	89.06	95.31	100.00	100.0	
		Week 70	Sparsentan	37	31 (83.8)	91.53 (7.95)	68.8	87.50	93.75	100.00	100.0	
			Irbesartan	36	25 (69.4)	88.50 (17.92)	15.6	84.38	96.88	100.00	100.0	
		Week 94	Sparsentan	37	27 (73.0)	92.36 (7.22)	78.1	84.38	93.75	100.00	100.0	
			Irbesartan	36	24 (66.7)	91.54 (12.65)	43.8	87.50	95.31	100.00	100.0	
		Week 110	Sparsentan	37	26 (70.3)	92.79 (7.44)	71.9	90.63	93.75	100.00	100.0	
			Irbesartan	36	22 (61.1)	89.06 (11.36)	62.5	81.25	93.75	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	37	26 (70.3)	0.60 (19.08)	-75.0	-6.25	1.56	9.38	34.4	0.06 [-0.48, 0.61]
			Irbesartan	36	26 (72.2)	-0.48 (15.48)	-53.1	-3.13	0.00	3.13	31.3	
		Week 48	Sparsentan	37	33 (89.2)	2.27 (16.22)	-40.6	-3.13	0.00	6.25	46.9	-0.13 [-0.65, 0.40]
			Irbesartan	36	24 (66.7)	4.04 (10.45)	-15.6	-1.56	1.56	9.38	25.0	
		Week 70	Sparsentan	37	31 (83.8)	2.52 (14.91)	-31.3	-3.13	0.00	6.25	56.3	0.11 [-0.41, 0.64]
			Irbesartan	36	25 (69.4)	0.63 (18.97)	-71.9	-3.13	3.13	6.25	37.5	
		Week 94	Sparsentan	37	27 (73.0)	2.31 (10.17)	-18.8	-3.13	0.00	9.38	34.4	-0.11 [-0.66, 0.44]
			Irbesartan	36	24 (66.7)	3.52 (11.99)	-18.8	-3.13	3.13	7.81	40.6	
		Week 110	Sparsentan	37	26 (70.3)	2.52 (10.42)	-21.9	-3.13	3.13	6.25	31.3	0.22 [-0.35, 0.79]
			Irbesartan	36	22 (61.1)	-0.28 (14.78)	-28.1	-6.25	0.00	6.25	40.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP Low	KDQOL: effect of kidney disease	Baseline	Sparsentan	39	37 (94.9)	89.19 (14.20)	34.4	87.50	93.75	100.00	100.0	
			Irbesartan	37	36 (97.3)	91.58 (13.48)	37.5	90.63	96.88	100.00	100.0	
		Week 24	Sparsentan	39	34 (87.2)	92.19 (10.21)	59.4	90.63	93.75	100.00	100.0	
			Irbesartan	37	28 (75.7)	87.72 (22.44)	0.0	85.94	96.88	100.00	100.0	
		Week 48	Sparsentan	39	35 (89.7)	92.32 (8.75)	65.6	90.63	93.75	100.00	100.0	
			Irbesartan	37	28 (75.7)	93.08 (11.29)	50.0	90.63	96.88	100.00	100.0	
		Week 70	Sparsentan	39	30 (76.9)	92.50 (9.09)	65.6	90.63	93.75	100.00	100.0	
			Irbesartan	37	29 (78.4)	96.12 (6.12)	78.1	93.75	100.00	100.00	100.0	
		Week 94	Sparsentan	39	32 (82.1)	90.53 (12.69)	46.9	85.94	93.75	98.44	100.0	
			Irbesartan	37	30 (81.1)	93.23 (10.05)	53.1	90.63	96.88	100.00	100.0	
		Week 110	Sparsentan	39	33 (84.6)	91.00 (9.46)	62.5	87.50	93.75	96.88	100.0	
			Irbesartan	37	29 (78.4)	94.07 (7.58)	68.8	90.63	96.88	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	39	34 (87.2)	2.67 (15.90)	-37.5	-3.13	0.00	9.38	43.8	0.30 [-0.20, 0.81]
			Irbesartan	37	28 (75.7)	-2.79 (20.15)	-100.0	-3.13	0.00	4.69	12.5	
		Week 48	Sparsentan	39	35 (89.7)	3.39 (10.29)	-21.9	-3.13	3.13	6.25	31.3	0.43 [-0.07, 0.93]
			Irbesartan	37	28 (75.7)	-0.78 (8.95)	-21.9	-1.56	0.00	3.13	15.6	
		Week 70	Sparsentan	39	30 (76.9)	2.60 (12.04)	-31.3	0.00	0.00	3.13	34.4	0.11 [-0.40, 0.62]
			Irbesartan	37	29 (78.4)	1.51 (8.25)	-18.8	0.00	0.00	3.13	21.9	
		Week 94	Sparsentan	39	32 (82.1)	2.05 (13.81)	-40.6	-3.13	1.56	7.81	34.4	0.18 [-0.32, 0.68]
			Irbesartan	37	30 (81.1)	0.00 (7.43)	-12.5	-6.25	0.00	3.13	18.8	
		Week 110	Sparsentan	39	33 (84.6)	2.18 (13.13)	-21.9	-3.13	0.00	6.25	37.5	0.12 [-0.38, 0.62]
			Irbesartan	37	29 (78.4)	0.86 (6.93)	-15.6	0.00	0.00	3.13	15.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 1												
< 60 mL/min/1.73 m**2	KDQOL: effect of kidney disease	Baseline	Sparsentan	127	116 (91.3)	87.90 (12.51)	43.8	84.38	93.75	96.88	100.0	
			Irbesartan	129	114 (88.4)	89.23 (12.28)	43.8	84.38	93.75	100.00	100.0	
		Week 24	Sparsentan	127	98 (77.2)	88.49 (12.84)	50.0	81.25	93.75	100.00	100.0	
			Irbesartan	129	80 (62.0)	90.04 (13.44)	40.6	84.38	96.88	100.00	100.0	
		Week 48	Sparsentan	127	95 (74.8)	90.43 (13.08)	0.0	87.50	93.75	100.00	100.0	
			Irbesartan	129	74 (57.4)	91.51 (11.09)	40.6	84.38	96.88	100.00	100.0	
		Week 70	Sparsentan	127	100 (78.7)	88.41 (13.90)	43.8	84.38	93.75	100.00	100.0	
			Irbesartan	129	78 (60.5)	90.38 (13.07)	37.5	87.50	95.31	100.00	100.0	
		Week 94	Sparsentan	127	92 (72.4)	89.71 (11.41)	56.3	84.38	93.75	100.00	100.0	
			Irbesartan	129	77 (59.7)	91.56 (10.89)	46.9	87.50	93.75	100.00	100.0	
		Week 110	Sparsentan	127	92 (72.4)	89.91 (11.12)	43.8	84.38	93.75	100.00	100.0	
			Irbesartan	129	72 (55.8)	90.76 (11.32)	46.9	87.50	93.75	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	127	98 (77.2)	1.28 (13.09)	-37.5	-3.13	1.56	6.25	31.3	0.12 [-0.18, 0.41]
			Irbesartan	129	80 (62.0)	-0.08 (9.55)	-37.5	-3.13	0.00	6.25	18.8	
		Week 48	Sparsentan	127	95 (74.8)	2.04 (14.78)	-100.0	0.00	3.13	6.25	56.3	0.08 [-0.23, 0.38]
			Irbesartan	129	74 (57.4)	1.06 (8.96)	-25.0	-3.13	0.00	6.25	25.0	
		Week 70	Sparsentan	127	100 (78.7)	0.13 (12.21)	-43.8	-6.25	0.00	6.25	40.6	-0.01 [-0.31, 0.29]
			Irbesartan	129	78 (60.5)	0.24 (12.28)	-62.5	-3.13	0.00	6.25	40.6	
		Week 94	Sparsentan	127	92 (72.4)	2.07 (11.77)	-40.6	-3.13	0.00	6.25	56.3	-0.01 [-0.31, 0.30]
			Irbesartan	129	77 (59.7)	2.15 (8.08)	-21.9	0.00	0.00	6.25	37.5	
		Week 110	Sparsentan	127	92 (72.4)	1.29 (11.15)	-28.1	-3.13	0.00	6.25	46.9	-0.02 [-0.33, 0.29]
			Irbesartan	129	72 (55.8)	1.48 (10.16)	-28.1	-3.13	0.00	6.25	43.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	KDQOL: effect of kidney disease	Baseline	Sparsentan	49	47 (95.9)	90.69 (12.66)	34.4	87.50	93.75	100.00	100.0	
			Irbesartan	48	44 (91.7)	87.93 (13.76)	46.9	81.25	92.19	100.00	100.0	
		Week 24	Sparsentan	49	38 (77.6)	90.46 (15.85)	9.4	87.50	93.75	100.00	100.0	
			Irbesartan	48	31 (64.6)	90.02 (12.69)	34.4	84.38	93.75	96.88	100.0	
		Week 48	Sparsentan	49	44 (89.8)	91.69 (9.31)	62.5	90.63	93.75	98.44	100.0	
			Irbesartan	48	32 (66.7)	90.43 (12.17)	50.0	84.38	95.31	100.00	100.0	
		Week 70	Sparsentan	49	38 (77.6)	92.19 (8.40)	68.8	90.63	93.75	100.00	100.0	
			Irbesartan	48	32 (66.7)	90.23 (16.61)	15.6	87.50	96.88	100.00	100.0	
		Week 94	Sparsentan	49	39 (79.6)	90.22 (10.47)	46.9	84.38	93.75	96.88	100.0	
			Irbesartan	48	34 (70.8)	90.17 (12.26)	43.8	87.50	93.75	100.00	100.0	
		Week 110	Sparsentan	49	36 (73.5)	90.45 (9.82)	62.5	87.50	93.75	96.88	100.0	
			Irbesartan	48	32 (66.7)	88.96 (11.69)	59.4	82.81	93.75	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	49	38 (77.6)	-0.25 (18.39)	-75.0	-6.25	0.00	6.25	43.8	-0.05 [-0.52, 0.43]
			Irbesartan	48	31 (64.6)	0.50 (13.74)	-53.1	-3.13	0.00	6.25	31.3	
		Week 48	Sparsentan	49	44 (89.8)	1.28 (10.83)	-37.5	-3.13	0.00	6.25	31.3	-0.05 [-0.51, 0.40]
			Irbesartan	48	32 (66.7)	1.86 (11.72)	-21.9	-3.13	0.00	9.38	25.0	
		Week 70	Sparsentan	49	38 (77.6)	0.99 (9.61)	-31.3	-3.13	0.00	3.13	34.4	-0.01 [-0.48, 0.46]
			Irbesartan	48	32 (66.7)	1.07 (17.31)	-71.9	-3.13	0.00	9.38	37.5	
		Week 94	Sparsentan	49	39 (79.6)	0.72 (9.19)	-18.8	-3.13	0.00	3.13	34.4	-0.15 [-0.61, 0.31]
			Irbesartan	48	34 (70.8)	2.30 (11.47)	-15.6	-6.25	0.00	9.38	40.6	
		Week 110	Sparsentan	49	36 (73.5)	0.95 (11.92)	-21.9	-3.13	0.00	4.69	37.5	0.06 [-0.41, 0.54]
			Irbesartan	48	32 (66.7)	0.20 (12.42)	-25.0	-6.25	0.00	6.25	40.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	KDQOL: effect of kidney disease	Baseline	Sparsentan	26	24 (92.3)	86.46 (16.50)	28.1	84.38	90.63	98.44	100.0	
			Irbesartan	25	24 (96.0)	89.58 (14.96)	37.5	85.94	96.88	100.00	100.0	
		Week 24	Sparsentan	26	21 (80.8)	96.28 (3.91)	87.5	93.75	96.88	100.00	100.0	
			Irbesartan	25	20 (80.0)	83.28 (25.73)	0.0	78.13	93.75	96.88	100.0	
		Week 48	Sparsentan	26	23 (88.5)	91.98 (10.14)	56.3	87.50	93.75	100.00	100.0	
			Irbesartan	25	18 (72.0)	94.62 (7.64)	75.0	90.63	96.88	100.00	100.0	
		Week 70	Sparsentan	26	22 (84.6)	93.18 (7.00)	75.0	90.63	93.75	100.00	100.0	
			Irbesartan	25	20 (80.0)	94.38 (6.69)	81.3	89.06	96.88	100.00	100.0	
		Week 94	Sparsentan	26	20 (76.9)	94.53 (6.72)	78.1	93.75	96.88	100.00	100.0	
			Irbesartan	25	19 (76.0)	92.43 (12.21)	53.1	90.63	96.88	100.00	100.0	
		Week 110	Sparsentan	26	21 (80.8)	93.90 (5.46)	81.3	90.63	93.75	96.88	100.0	
			Irbesartan	25	17 (68.0)	93.01 (9.60)	68.8	90.63	100.00	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	26	21 (80.8)	7.74 (11.08)	-12.5	3.13	3.13	12.50	34.4	0.78 [0.15, 1.42]
			Irbesartan	25	20 (80.0)	-6.56 (23.65)	-100.0	-6.25	0.00	3.13	12.5	
		Week 48	Sparsentan	26	23 (88.5)	5.57 (17.50)	-40.6	-3.13	3.13	15.63	46.9	0.35 [-0.27, 0.98]
			Irbesartan	25	18 (72.0)	0.69 (6.12)	-12.5	0.00	0.00	3.13	15.6	
		Week 70	Sparsentan	26	22 (84.6)	7.39 (16.27)	-15.6	-3.13	3.13	9.38	56.3	0.43 [-0.19, 1.04]
			Irbesartan	25	20 (80.0)	1.72 (8.92)	-18.8	-1.56	3.13	4.69	21.9	
		Week 94	Sparsentan	26	20 (76.9)	6.09 (13.08)	-15.6	0.00	3.13	12.50	34.4	0.54 [-0.10, 1.18]
			Irbesartan	25	19 (76.0)	0.16 (8.23)	-18.8	0.00	0.00	3.13	18.8	
		Week 110	Sparsentan	26	21 (80.8)	5.36 (11.19)	-12.5	0.00	6.25	9.38	31.3	0.46 [-0.19, 1.11]
			Irbesartan	25	17 (68.0)	0.92 (7.39)	-12.5	0.00	3.13	6.25	15.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 2												
< 45 mL/min/1.73 m**2	KDQOL: effect of kidney disease	Baseline	Sparsentan	82	73 (89.0)	85.74 (13.48)	43.8	78.13	90.63	93.75	100.0	
			Irbesartan	80	69 (86.3)	87.14 (13.91)	43.8	81.25	90.63	96.88	100.0	
		Week 24	Sparsentan	82	64 (78.0)	89.06 (12.17)	50.0	82.81	93.75	100.00	100.0	
			Irbesartan	80	48 (60.0)	87.83 (15.81)	40.6	82.81	95.31	100.00	100.0	
		Week 48	Sparsentan	82	61 (74.4)	89.09 (14.68)	0.0	87.50	90.63	96.88	100.0	
			Irbesartan	80	43 (53.8)	90.12 (12.81)	40.6	84.38	93.75	100.00	100.0	
		Week 70	Sparsentan	82	65 (79.3)	87.36 (14.46)	46.9	84.38	93.75	96.88	100.0	
			Irbesartan	80	45 (56.3)	87.36 (15.28)	37.5	84.38	90.63	100.00	100.0	
		Week 94	Sparsentan	82	60 (73.2)	89.22 (11.35)	56.3	84.38	93.75	98.44	100.0	
			Irbesartan	80	47 (58.8)	90.03 (12.48)	46.9	84.38	93.75	100.00	100.0	
		Week 110	Sparsentan	82	56 (68.3)	89.12 (10.56)	56.3	81.25	90.63	96.88	100.0	
			Irbesartan	80	44 (55.0)	89.56 (12.22)	46.9	85.94	93.75	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	82	64 (78.0)	3.22 (12.24)	-37.5	-3.13	3.13	9.38	31.3	0.31 [-0.07, 0.69]
			Irbesartan	80	48 (60.0)	-0.46 (11.22)	-37.5	-3.13	0.00	6.25	18.8	
		Week 48	Sparsentan	82	61 (74.4)	2.51 (17.36)	-100.0	0.00	3.13	6.25	56.3	0.13 [-0.26, 0.52]
			Irbesartan	80	43 (53.8)	0.65 (9.46)	-25.0	-3.13	0.00	6.25	21.9	
		Week 70	Sparsentan	82	65 (79.3)	0.87 (12.16)	-43.8	-3.13	0.00	6.25	40.6	0.13 [-0.25, 0.51]
			Irbesartan	80	45 (56.3)	-0.83 (14.81)	-62.5	-3.13	0.00	6.25	40.6	
		Week 94	Sparsentan	82	60 (73.2)	2.66 (11.77)	-18.8	-3.13	0.00	7.81	56.3	0.05 [-0.33, 0.43]
			Irbesartan	80	47 (58.8)	2.13 (9.26)	-21.9	0.00	0.00	6.25	37.5	
		Week 110	Sparsentan	82	56 (68.3)	1.84 (10.47)	-15.6	-3.13	0.00	6.25	46.9	-0.02 [-0.42, 0.37]
			Irbesartan	80	44 (55.0)	2.06 (9.95)	-15.6	-3.13	0.00	6.25	43.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
45 to < 60 mL/min/1.73 m**2	KDQOL: effect of kidney disease	Baseline	Sparsentan	45	43 (95.6)	91.57 (9.75)	62.5	87.50	93.75	100.00	100.0	
			Irbesartan	49	45 (91.8)	92.43 (8.41)	71.9	87.50	96.88	100.00	100.0	
		Week 24	Sparsentan	45	34 (75.6)	87.41 (14.13)	56.3	81.25	93.75	96.88	100.0	
			Irbesartan	49	32 (65.3)	93.36 (7.89)	75.0	85.94	96.88	100.00	100.0	
		Week 48	Sparsentan	45	34 (75.6)	92.83 (9.31)	68.8	87.50	96.88	100.00	100.0	
			Irbesartan	49	31 (63.3)	93.45 (7.92)	75.0	87.50	96.88	100.00	100.0	
		Week 70	Sparsentan	45	35 (77.8)	90.36 (12.76)	43.8	84.38	93.75	100.00	100.0	
			Irbesartan	49	33 (67.3)	94.51 (7.74)	71.9	93.75	96.88	100.00	100.0	
		Week 94	Sparsentan	45	32 (71.1)	90.63 (11.64)	56.3	85.94	93.75	100.00	100.0	
			Irbesartan	49	30 (61.2)	93.96 (7.34)	71.9	90.63	96.88	100.00	100.0	
		Week 110	Sparsentan	45	36 (80.0)	91.15 (11.99)	43.8	89.06	95.31	100.00	100.0	
			Irbesartan	49	28 (57.1)	92.63 (9.63)	68.8	87.50	96.88	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	45	34 (75.6)	-2.39 (14.02)	-37.5	-9.38	0.00	6.25	31.3	-0.26 [-0.75, 0.22]
			Irbesartan	49	32 (65.3)	0.49 (6.40)	-18.8	0.00	0.00	3.13	12.5	
		Week 48	Sparsentan	45	34 (75.6)	1.19 (8.57)	-15.6	-3.13	0.00	6.25	31.3	-0.05 [-0.54, 0.44]
			Irbesartan	49	31 (63.3)	1.61 (8.34)	-15.6	0.00	0.00	6.25	25.0	
		Week 70	Sparsentan	45	35 (77.8)	-1.25 (12.37)	-31.3	-6.25	0.00	6.25	25.0	-0.29 [-0.76, 0.19]
			Irbesartan	49	33 (67.3)	1.70 (7.58)	-21.9	0.00	0.00	3.13	15.6	
		Week 94	Sparsentan	45	32 (71.1)	0.98 (11.86)	-40.6	-3.13	1.56	6.25	28.1	-0.13 [-0.63, 0.37]
			Irbesartan	49	30 (61.2)	2.19 (5.93)	-9.4	0.00	0.00	3.13	18.8	
		Week 110	Sparsentan	45	36 (80.0)	0.43 (12.23)	-28.1	-6.25	0.00	4.69	34.4	-0.01 [-0.50, 0.48]
			Irbesartan	49	28 (57.1)	0.56 (10.59)	-28.1	-1.56	0.00	6.25	18.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	KDQOL: effect of kidney disease	Baseline	Sparsentan	49	47 (95.9)	90.69 (12.66)	34.4	87.50	93.75	100.00	100.0	
			Irbesartan	48	44 (91.7)	87.93 (13.76)	46.9	81.25	92.19	100.00	100.0	
		Week 24	Sparsentan	49	38 (77.6)	90.46 (15.85)	9.4	87.50	93.75	100.00	100.0	
			Irbesartan	48	31 (64.6)	90.02 (12.69)	34.4	84.38	93.75	96.88	100.0	
		Week 48	Sparsentan	49	44 (89.8)	91.69 (9.31)	62.5	90.63	93.75	98.44	100.0	
			Irbesartan	48	32 (66.7)	90.43 (12.17)	50.0	84.38	95.31	100.00	100.0	
		Week 70	Sparsentan	49	38 (77.6)	92.19 (8.40)	68.8	90.63	93.75	100.00	100.0	
			Irbesartan	48	32 (66.7)	90.23 (16.61)	15.6	87.50	96.88	100.00	100.0	
		Week 94	Sparsentan	49	39 (79.6)	90.22 (10.47)	46.9	84.38	93.75	96.88	100.0	
			Irbesartan	48	34 (70.8)	90.17 (12.26)	43.8	87.50	93.75	100.00	100.0	
		Week 110	Sparsentan	49	36 (73.5)	90.45 (9.82)	62.5	87.50	93.75	96.88	100.0	
			Irbesartan	48	32 (66.7)	88.96 (11.69)	59.4	82.81	93.75	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	49	38 (77.6)	-0.25 (18.39)	-75.0	-6.25	0.00	6.25	43.8	-0.05 [-0.52, 0.43]
			Irbesartan	48	31 (64.6)	0.50 (13.74)	-53.1	-3.13	0.00	6.25	31.3	
		Week 48	Sparsentan	49	44 (89.8)	1.28 (10.83)	-37.5	-3.13	0.00	6.25	31.3	-0.05 [-0.51, 0.40]
			Irbesartan	48	32 (66.7)	1.86 (11.72)	-21.9	-3.13	0.00	9.38	25.0	
		Week 70	Sparsentan	49	38 (77.6)	0.99 (9.61)	-31.3	-3.13	0.00	3.13	34.4	-0.01 [-0.48, 0.46]
			Irbesartan	48	32 (66.7)	1.07 (17.31)	-71.9	-3.13	0.00	9.38	37.5	
		Week 94	Sparsentan	49	39 (79.6)	0.72 (9.19)	-18.8	-3.13	0.00	3.13	34.4	-0.15 [-0.61, 0.31]
			Irbesartan	48	34 (70.8)	2.30 (11.47)	-15.6	-6.25	0.00	9.38	40.6	
		Week 110	Sparsentan	49	36 (73.5)	0.95 (11.92)	-21.9	-3.13	0.00	4.69	37.5	0.06 [-0.41, 0.54]
			Irbesartan	48	32 (66.7)	0.20 (12.42)	-25.0	-6.25	0.00	6.25	40.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	KDQOL: effect of kidney disease	Baseline	Sparsentan	26	24 (92.3)	86.46 (16.50)	28.1	84.38	90.63	98.44	100.0	
			Irbesartan	25	24 (96.0)	89.58 (14.96)	37.5	85.94	96.88	100.00	100.0	
		Week 24	Sparsentan	26	21 (80.8)	96.28 (3.91)	87.5	93.75	96.88	100.00	100.0	
			Irbesartan	25	20 (80.0)	83.28 (25.73)	0.0	78.13	93.75	96.88	100.0	
		Week 48	Sparsentan	26	23 (88.5)	91.98 (10.14)	56.3	87.50	93.75	100.00	100.0	
			Irbesartan	25	18 (72.0)	94.62 (7.64)	75.0	90.63	96.88	100.00	100.0	
		Week 70	Sparsentan	26	22 (84.6)	93.18 (7.00)	75.0	90.63	93.75	100.00	100.0	
			Irbesartan	25	20 (80.0)	94.38 (6.69)	81.3	89.06	96.88	100.00	100.0	
		Week 94	Sparsentan	26	20 (76.9)	94.53 (6.72)	78.1	93.75	96.88	100.00	100.0	
			Irbesartan	25	19 (76.0)	92.43 (12.21)	53.1	90.63	96.88	100.00	100.0	
		Week 110	Sparsentan	26	21 (80.8)	93.90 (5.46)	81.3	90.63	93.75	96.88	100.0	
			Irbesartan	25	17 (68.0)	93.01 (9.60)	68.8	90.63	100.00	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	26	21 (80.8)	7.74 (11.08)	-12.5	3.13	3.13	12.50	34.4	0.78 [0.15, 1.42]
			Irbesartan	25	20 (80.0)	-6.56 (23.65)	-100.0	-6.25	0.00	3.13	12.5	
		Week 48	Sparsentan	26	23 (88.5)	5.57 (17.50)	-40.6	-3.13	3.13	15.63	46.9	0.35 [-0.27, 0.98]
			Irbesartan	25	18 (72.0)	0.69 (6.12)	-12.5	0.00	0.00	3.13	15.6	
		Week 70	Sparsentan	26	22 (84.6)	7.39 (16.27)	-15.6	-3.13	3.13	9.38	56.3	0.43 [-0.19, 1.04]
			Irbesartan	25	20 (80.0)	1.72 (8.92)	-18.8	-1.56	3.13	4.69	21.9	
		Week 94	Sparsentan	26	20 (76.9)	6.09 (13.08)	-15.6	0.00	3.13	12.50	34.4	0.54 [-0.10, 1.18]
			Irbesartan	25	19 (76.0)	0.16 (8.23)	-18.8	0.00	0.00	3.13	18.8	
		Week 110	Sparsentan	26	21 (80.8)	5.36 (11.19)	-12.5	0.00	6.25	9.38	31.3	0.46 [-0.19, 1.11]
			Irbesartan	25	17 (68.0)	0.92 (7.39)	-12.5	0.00	3.13	6.25	15.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline urine protein excretion												
<= 1.75 g/day	KDQOL: effect of kidney disease	Baseline	Sparsentan	98	93 (94.9)	87.40 (13.99)	34.4	84.38	90.63	96.88	100.0	
			Irbesartan	93	83 (89.2)	90.02 (13.11)	37.5	84.38	96.88	100.00	100.0	
		Week 24	Sparsentan	98	80 (81.6)	88.87 (12.68)	50.0	84.38	93.75	100.00	100.0	
			Irbesartan	93	55 (59.1)	90.68 (17.89)	0.0	87.50	96.88	100.00	100.0	
		Week 48	Sparsentan	98	82 (83.7)	90.47 (13.61)	0.0	87.50	93.75	100.00	100.0	
			Irbesartan	93	57 (61.3)	92.43 (10.68)	50.0	90.63	96.88	100.00	100.0	
		Week 70	Sparsentan	98	75 (76.5)	88.88 (13.08)	43.8	84.38	93.75	100.00	100.0	
			Irbesartan	93	61 (65.6)	93.24 (9.01)	56.3	87.50	96.88	100.00	100.0	
		Week 94	Sparsentan	98	76 (77.6)	89.39 (11.89)	46.9	82.81	93.75	100.00	100.0	
			Irbesartan	93	63 (67.7)	91.77 (11.26)	50.0	87.50	96.88	100.00	100.0	
		Week 110	Sparsentan	98	75 (76.5)	89.50 (11.78)	43.8	87.50	93.75	96.88	100.0	
			Irbesartan	93	57 (61.3)	91.61 (10.11)	59.4	87.50	93.75	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	98	80 (81.6)	1.99 (15.14)	-37.5	-6.25	0.00	9.38	43.8	0.18 [-0.16, 0.53]
			Irbesartan	93	55 (59.1)	-0.85 (16.06)	-100.0	-3.13	0.00	6.25	18.8	
		Week 48	Sparsentan	98	82 (83.7)	1.91 (16.64)	-100.0	-3.13	3.13	6.25	56.3	0.11 [-0.23, 0.45]
			Irbesartan	93	57 (61.3)	0.38 (8.96)	-25.0	0.00	0.00	3.13	25.0	
		Week 70	Sparsentan	98	75 (76.5)	0.96 (12.51)	-31.3	-6.25	0.00	6.25	40.6	-0.00 [-0.34, 0.34]
			Irbesartan	93	61 (65.6)	0.97 (9.08)	-31.3	0.00	0.00	3.13	21.9	
		Week 94	Sparsentan	98	76 (77.6)	2.51 (13.26)	-40.6	-3.13	0.00	7.81	56.3	0.13 [-0.20, 0.47]
			Irbesartan	93	63 (67.7)	0.99 (8.26)	-21.9	-3.13	0.00	6.25	18.8	
		Week 110	Sparsentan	98	75 (76.5)	1.71 (13.49)	-28.1	-3.13	0.00	6.25	46.9	0.04 [-0.30, 0.39]
			Irbesartan	93	57 (61.3)	1.21 (7.69)	-25.0	0.00	0.00	6.25	15.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 1.75 g/day	KDQOL: effect of kidney disease	Baseline	Sparsentan	104	94 (90.4)	89.43 (12.19)	28.1	84.38	93.75	96.88	100.0	
			Irbesartan	109	99 (90.8)	88.07 (12.83)	46.9	84.38	90.63	96.88	100.0	
		Week 24	Sparsentan	104	77 (74.0)	91.19 (13.44)	9.4	87.50	96.88	100.00	100.0	
			Irbesartan	109	76 (69.7)	87.79 (14.10)	34.4	81.25	93.75	96.88	100.0	
		Week 48	Sparsentan	104	80 (76.9)	91.52 (9.49)	50.0	87.50	93.75	100.00	100.0	
			Irbesartan	109	67 (61.5)	91.04 (11.23)	40.6	84.38	93.75	100.00	100.0	
		Week 70	Sparsentan	104	85 (81.7)	90.92 (11.23)	46.9	87.50	93.75	100.00	100.0	
			Irbesartan	109	69 (63.3)	88.95 (15.98)	15.6	84.38	93.75	100.00	100.0	
		Week 94	Sparsentan	104	75 (72.1)	91.58 (9.35)	56.3	87.50	93.75	100.00	100.0	
			Irbesartan	109	67 (61.5)	90.90 (11.57)	43.8	87.50	93.75	100.00	100.0	
		Week 110	Sparsentan	104	74 (71.2)	91.72 (8.32)	71.9	87.50	93.75	100.00	100.0	
			Irbesartan	109	64 (58.7)	89.70 (12.05)	46.9	84.38	93.75	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	104	77 (74.0)	1.54 (13.76)	-75.0	-3.13	3.13	6.25	34.4	0.20 [-0.12, 0.52]
			Irbesartan	109	76 (69.7)	-0.99 (11.73)	-53.1	-3.13	0.00	3.13	31.3	
		Week 48	Sparsentan	104	80 (76.9)	2.77 (11.34)	-40.6	-3.13	0.00	6.25	46.9	0.08 [-0.24, 0.41]
			Irbesartan	109	67 (61.5)	1.91 (9.70)	-21.9	-3.13	0.00	6.25	25.0	
		Week 70	Sparsentan	104	85 (81.7)	1.65 (12.49)	-43.8	-3.13	0.00	6.25	56.3	0.09 [-0.23, 0.41]
			Irbesartan	109	69 (63.3)	0.41 (16.04)	-71.9	-3.13	0.00	6.25	40.6	
		Week 94	Sparsentan	104	75 (72.1)	2.00 (9.20)	-18.8	-3.13	0.00	6.25	34.4	-0.08 [-0.41, 0.25]
			Irbesartan	109	67 (61.5)	2.75 (9.74)	-18.8	0.00	0.00	6.25	40.6	
		Week 110	Sparsentan	104	74 (71.2)	1.86 (8.79)	-15.6	-3.13	0.00	6.25	31.3	0.09 [-0.25, 0.42]
			Irbesartan	109	64 (58.7)	0.93 (12.41)	-28.1	-6.25	0.00	6.25	43.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline use of antihypertensives												
Yes	KDQOL: effect of kidney disease	Baseline	Sparsentan	90	79 (87.8)	89.79 (11.08)	50.0	84.38	93.75	96.88	100.0	
			Irbesartan	88	76 (86.4)	89.14 (11.91)	43.8	81.25	93.75	100.00	100.0	
		Week 24	Sparsentan	90	66 (73.3)	91.48 (10.89)	50.0	87.50	95.31	100.00	100.0	
			Irbesartan	88	49 (55.7)	89.48 (13.35)	50.0	84.38	93.75	100.00	100.0	
		Week 48	Sparsentan	90	65 (72.2)	91.59 (7.59)	75.0	87.50	93.75	100.00	100.0	
			Irbesartan	88	47 (53.4)	92.22 (10.05)	59.4	84.38	96.88	100.00	100.0	
		Week 70	Sparsentan	90	68 (75.6)	89.61 (11.81)	46.9	87.50	93.75	96.88	100.0	
			Irbesartan	88	49 (55.7)	91.26 (10.99)	56.3	87.50	96.88	100.00	100.0	
		Week 94	Sparsentan	90	63 (70.0)	89.98 (10.43)	56.3	84.38	93.75	100.00	100.0	
			Irbesartan	88	54 (61.4)	90.74 (11.50)	50.0	87.50	95.31	100.00	100.0	
		Week 110	Sparsentan	90	63 (70.0)	91.42 (9.31)	56.3	87.50	93.75	100.00	100.0	
			Irbesartan	88	51 (58.0)	89.95 (11.41)	59.4	84.38	93.75	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	90	66 (73.3)	2.13 (11.36)	-37.5	-3.13	0.00	6.25	31.3	0.32 [-0.06, 0.69]
			Irbesartan	88	49 (55.7)	-1.34 (10.40)	-37.5	-3.13	0.00	6.25	18.8	
		Week 48	Sparsentan	90	65 (72.2)	1.68 (8.99)	-21.9	-3.13	0.00	6.25	31.3	-0.04 [-0.41, 0.34]
			Irbesartan	88	47 (53.4)	1.99 (8.70)	-15.6	0.00	0.00	6.25	25.0	
		Week 70	Sparsentan	90	68 (75.6)	-0.74 (10.77)	-43.8	-3.13	0.00	6.25	21.9	-0.13 [-0.49, 0.24]
			Irbesartan	88	49 (55.7)	0.57 (9.62)	-31.3	-3.13	0.00	6.25	18.8	
		Week 94	Sparsentan	90	63 (70.0)	0.84 (10.09)	-21.9	-3.13	0.00	6.25	28.1	-0.04 [-0.40, 0.32]
			Irbesartan	88	54 (61.4)	1.22 (8.31)	-21.9	0.00	0.00	6.25	18.8	
		Week 110	Sparsentan	90	63 (70.0)	1.84 (10.13)	-21.9	-3.13	0.00	6.25	34.4	0.13 [-0.24, 0.50]
			Irbesartan	88	51 (58.0)	0.55 (9.18)	-28.1	-3.13	0.00	6.25	18.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	KDQOL: effect of kidney disease	Baseline	Sparsentan	112	108 (96.4)	87.41 (14.39)	28.1	84.38	90.63	96.88	100.0	
			Irbesartan	114	106 (93.0)	88.83 (13.71)	37.5	84.38	93.75	100.00	100.0	
		Week 24	Sparsentan	112	91 (81.3)	88.94 (14.41)	9.4	84.38	93.75	100.00	100.0	
			Irbesartan	114	82 (71.9)	88.72 (17.17)	0.0	84.38	95.31	96.88	100.0	
		Week 48	Sparsentan	112	97 (86.6)	90.59 (13.85)	0.0	87.50	93.75	100.00	100.0	
			Irbesartan	114	77 (67.5)	91.36 (11.53)	40.6	87.50	96.88	100.00	100.0	
		Week 70	Sparsentan	112	92 (82.1)	90.22 (12.43)	43.8	87.50	93.75	100.00	100.0	
			Irbesartan	114	81 (71.1)	90.78 (14.59)	15.6	87.50	96.88	100.00	100.0	
		Week 94	Sparsentan	112	88 (78.6)	90.84 (10.98)	46.9	84.38	93.75	100.00	100.0	
			Irbesartan	114	76 (66.7)	91.74 (11.36)	43.8	87.50	93.75	100.00	100.0	
		Week 110	Sparsentan	112	86 (76.8)	90.01 (10.88)	43.8	84.38	93.75	96.88	100.0	
			Irbesartan	114	70 (61.4)	91.07 (11.06)	46.9	84.38	93.75	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	112	91 (81.3)	1.51 (16.37)	-75.0	-6.25	3.13	9.38	43.8	0.14 [-0.16, 0.44]
			Irbesartan	114	82 (71.9)	-0.69 (15.33)	-100.0	-3.13	0.00	3.13	31.3	
		Week 48	Sparsentan	112	97 (86.6)	2.77 (16.89)	-100.0	-3.13	3.13	6.25	56.3	0.14 [-0.16, 0.44]
			Irbesartan	114	77 (67.5)	0.73 (9.76)	-25.0	-3.13	0.00	3.13	25.0	
		Week 70	Sparsentan	112	92 (82.1)	2.85 (13.43)	-31.3	-3.13	0.00	7.81	56.3	0.15 [-0.15, 0.45]
			Irbesartan	114	81 (71.1)	0.73 (15.01)	-71.9	-3.13	0.00	6.25	40.6	
		Week 94	Sparsentan	112	88 (78.6)	3.27 (12.19)	-40.6	-3.13	3.13	6.25	56.3	0.08 [-0.23, 0.39]
			Irbesartan	114	76 (66.7)	2.38 (9.59)	-12.5	-3.13	0.00	6.25	40.6	
		Week 110	Sparsentan	112	86 (76.8)	1.74 (12.25)	-28.1	-3.13	0.00	6.25	46.9	0.03 [-0.29, 0.34]
			Irbesartan	114	70 (61.4)	1.43 (11.28)	-25.0	-6.25	0.00	6.25	43.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Time since renal biopsy												
<= 5 years	KDQOL: effect of kidney disease	Baseline	Sparsentan	113	104 (92.0)	88.07 (12.42)	34.4	84.38	92.19	96.88	100.0	
			Irbesartan	127	118 (92.9)	88.43 (13.48)	37.5	84.38	93.75	100.00	100.0	
		Week 24	Sparsentan	113	88 (77.9)	91.26 (11.47)	50.0	89.06	93.75	100.00	100.0	
			Irbesartan	127	86 (67.7)	87.61 (17.66)	0.0	84.38	93.75	96.88	100.0	
		Week 48	Sparsentan	113	92 (81.4)	91.78 (9.66)	50.0	87.50	93.75	100.00	100.0	
			Irbesartan	127	85 (66.9)	91.21 (12.04)	40.6	84.38	96.88	100.00	100.0	
		Week 70	Sparsentan	113	90 (79.6)	90.03 (11.26)	46.9	87.50	93.75	96.88	100.0	
			Irbesartan	127	86 (67.7)	91.64 (12.83)	15.6	87.50	96.88	100.00	100.0	
		Week 94	Sparsentan	113	86 (76.1)	90.08 (11.65)	46.9	84.38	93.75	100.00	100.0	
			Irbesartan	127	86 (67.7)	91.02 (11.72)	43.8	87.50	93.75	100.00	100.0	
		Week 110	Sparsentan	113	88 (77.9)	90.63 (9.48)	56.3	87.50	93.75	96.88	100.0	
			Irbesartan	127	80 (63.0)	90.43 (11.03)	59.4	84.38	93.75	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	113	88 (77.9)	4.05 (14.26)	-37.5	-1.56	3.13	12.50	43.8	0.38 [0.08, 0.68]
			Irbesartan	127	86 (67.7)	-1.53 (15.24)	-100.0	-3.13	0.00	6.25	31.3	
		Week 48	Sparsentan	113	92 (81.4)	4.08 (10.86)	-40.6	0.00	3.13	7.81	34.4	0.26 [-0.04, 0.55]
			Irbesartan	127	85 (66.9)	1.40 (9.92)	-25.0	0.00	0.00	6.25	25.0	
		Week 70	Sparsentan	113	90 (79.6)	1.63 (11.92)	-31.3	-3.13	0.00	6.25	34.4	0.06 [-0.24, 0.35]
			Irbesartan	127	86 (67.7)	0.91 (12.54)	-71.9	0.00	0.00	6.25	28.1	
		Week 94	Sparsentan	113	86 (76.1)	2.54 (11.98)	-40.6	-3.13	0.00	6.25	34.4	0.09 [-0.21, 0.39]
			Irbesartan	127	86 (67.7)	1.60 (9.22)	-21.9	0.00	0.00	6.25	37.5	
		Week 110	Sparsentan	113	88 (77.9)	2.52 (11.30)	-21.9	-3.13	0.00	6.25	37.5	0.16 [-0.14, 0.46]
			Irbesartan	127	80 (63.0)	0.86 (9.54)	-25.0	-3.13	0.00	6.25	25.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 5 years	KDQOL: effect of kidney disease	Baseline	Sparsentan	89	83 (93.3)	88.86 (14.00)	28.1	84.38	93.75	100.00	100.0	
			Irbesartan	75	64 (85.3)	89.94 (11.97)	46.9	85.94	93.75	100.00	100.0	
		Week 24	Sparsentan	89	69 (77.5)	88.41 (14.80)	9.4	81.25	93.75	100.00	100.0	
			Irbesartan	75	45 (60.0)	91.67 (11.13)	50.0	87.50	96.88	100.00	100.0	
		Week 48	Sparsentan	89	70 (78.7)	89.96 (14.00)	0.0	87.50	93.75	100.00	100.0	
			Irbesartan	75	39 (52.0)	92.71 (8.15)	75.0	87.50	96.88	100.00	100.0	
		Week 70	Sparsentan	89	70 (78.7)	89.87 (13.26)	43.8	87.50	93.75	100.00	100.0	
			Irbesartan	75	44 (58.7)	89.63 (14.25)	37.5	84.38	95.31	100.00	100.0	
		Week 94	Sparsentan	89	65 (73.0)	91.01 (9.43)	59.4	84.38	93.75	100.00	100.0	
			Irbesartan	75	44 (58.7)	91.90 (10.81)	46.9	87.50	96.88	100.00	100.0	
		Week 110	Sparsentan	89	61 (68.5)	90.57 (11.32)	43.8	87.50	93.75	100.00	100.0	
			Irbesartan	75	41 (54.7)	90.93 (11.58)	46.9	87.50	93.75	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	89	69 (77.5)	-1.13 (14.23)	-75.0	-6.25	0.00	6.25	31.3	-0.11 [-0.48, 0.27]
			Irbesartan	75	45 (60.0)	0.21 (10.02)	-37.5	-3.13	0.00	3.13	18.8	
		Week 48	Sparsentan	89	70 (78.7)	0.04 (17.55)	-100.0	-3.13	0.00	6.25	56.3	-0.05 [-0.44, 0.34]
			Irbesartan	75	39 (52.0)	0.80 (8.10)	-15.6	-6.25	0.00	3.13	18.8	
		Week 70	Sparsentan	89	70 (78.7)	0.94 (13.21)	-43.8	-3.13	0.00	6.25	56.3	0.05 [-0.32, 0.43]
			Irbesartan	75	44 (58.7)	0.21 (14.54)	-62.5	-3.13	0.00	3.13	40.6	
		Week 94	Sparsentan	89	65 (73.0)	1.88 (10.64)	-18.8	-3.13	0.00	6.25	56.3	-0.06 [-0.44, 0.32]
			Irbesartan	75	44 (58.7)	2.49 (8.83)	-12.5	-1.56	0.00	6.25	40.6	
		Week 110	Sparsentan	89	61 (68.5)	0.72 (11.46)	-28.1	-3.13	0.00	6.25	46.9	-0.06 [-0.46, 0.33]
			Irbesartan	75	41 (54.7)	1.45 (12.06)	-28.1	-3.13	0.00	3.13	43.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: History of hypertension												
Yes	KDQOL: effect of kidney disease	Baseline	Sparsentan	155	141 (91.0)	87.61 (13.34)	28.1	84.38	93.75	96.88	100.0	
			Irbesartan	161	142 (88.2)	88.78 (12.57)	43.8	84.38	93.75	100.00	100.0	
		Week 24	Sparsentan	155	119 (76.8)	90.81 (11.28)	56.3	87.50	93.75	100.00	100.0	
			Irbesartan	161	100 (62.1)	90.88 (11.41)	50.0	84.38	96.88	100.00	100.0	
		Week 48	Sparsentan	155	121 (78.1)	90.37 (12.66)	0.0	87.50	93.75	100.00	100.0	
			Irbesartan	161	95 (59.0)	92.86 (9.21)	59.4	90.63	96.88	100.00	100.0	
		Week 70	Sparsentan	155	123 (79.4)	89.94 (11.77)	43.8	87.50	93.75	100.00	100.0	
			Irbesartan	161	100 (62.1)	91.84 (11.05)	40.6	87.50	96.88	100.00	100.0	
		Week 94	Sparsentan	155	114 (73.5)	89.86 (11.07)	46.9	84.38	93.75	100.00	100.0	
			Irbesartan	161	101 (62.7)	90.81 (12.15)	43.8	87.50	93.75	100.00	100.0	
		Week 110	Sparsentan	155	112 (72.3)	90.07 (10.94)	43.8	84.38	93.75	98.44	100.0	
			Irbesartan	161	92 (57.1)	91.13 (11.21)	46.9	87.50	95.31	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	155	119 (76.8)	3.62 (12.08)	-37.5	-3.13	3.13	9.38	43.8	0.24 [-0.03, 0.51]
			Irbesartan	161	100 (62.1)	1.00 (9.60)	-37.5	-1.56	0.00	6.25	31.3	
		Week 48	Sparsentan	155	121 (78.1)	2.76 (14.44)	-100.0	0.00	3.13	6.25	46.9	0.00 [-0.27, 0.27]
			Irbesartan	161	95 (59.0)	2.73 (8.89)	-21.9	0.00	0.00	6.25	25.0	
		Week 70	Sparsentan	155	123 (79.4)	2.18 (12.03)	-28.1	-3.13	0.00	6.25	56.3	-0.06 [-0.32, 0.21]
			Irbesartan	161	100 (62.1)	2.84 (10.36)	-31.3	0.00	0.00	6.25	40.6	
		Week 94	Sparsentan	155	114 (73.5)	2.58 (9.88)	-21.9	-3.13	0.00	6.25	34.4	0.00 [-0.27, 0.27]
			Irbesartan	161	101 (62.7)	2.57 (9.40)	-21.9	0.00	0.00	6.25	40.6	
		Week 110	Sparsentan	155	112 (72.3)	2.04 (10.67)	-28.1	-3.13	0.00	6.25	37.5	-0.06 [-0.34, 0.21]
			Irbesartan	161	92 (57.1)	2.72 (10.23)	-28.1	-1.56	0.00	6.25	43.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSHM: KDQOL: Course of effect of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	KDQOL: effect of kidney disease	Baseline	Sparsentan	47	46 (97.9)	90.90 (12.22)	43.8	87.50	93.75	100.00	100.0	
			Irbesartan	41	40 (97.6)	89.61 (14.41)	37.5	87.50	95.31	100.00	100.0	
		Week 24	Sparsentan	47	38 (80.9)	87.50 (17.48)	9.4	81.25	93.75	100.00	100.0	
			Irbesartan	41	31 (75.6)	82.96 (24.55)	0.0	75.00	93.75	96.88	100.0	
		Week 48	Sparsentan	47	41 (87.2)	92.84 (8.28)	62.5	87.50	93.75	100.00	100.0	
			Irbesartan	41	29 (70.7)	87.82 (14.90)	40.6	81.25	93.75	100.00	100.0	
		Week 70	Sparsentan	47	37 (78.7)	90.03 (13.46)	50.0	87.50	93.75	100.00	100.0	
			Irbesartan	41	30 (73.2)	88.02 (18.95)	15.6	84.38	95.31	100.00	100.0	
		Week 94	Sparsentan	47	37 (78.7)	92.40 (9.48)	56.3	87.50	96.88	100.00	100.0	
			Irbesartan	41	29 (70.7)	93.10 (8.11)	71.9	90.63	93.75	100.00	100.0	
		Week 110	Sparsentan	47	37 (78.7)	92.23 (7.61)	75.0	87.50	93.75	100.00	100.0	
			Irbesartan	41	29 (70.7)	88.90 (11.10)	62.5	81.25	90.63	100.00	100.0	
	KDQOL: Change from baseline in effect of kidney disease	Week 24	Sparsentan	47	38 (80.9)	-4.03 (19.18)	-75.0	-12.50	0.00	3.13	34.4	0.16 [-0.32, 0.63]
			Irbesartan	41	31 (75.6)	-7.16 (21.26)	-100.0	-9.38	-3.13	3.13	15.6	
		Week 48	Sparsentan	47	41 (87.2)	1.07 (13.70)	-37.5	-3.13	0.00	6.25	56.3	0.40 [-0.08, 0.88]
			Irbesartan	41	29 (70.7)	-3.77 (9.28)	-25.0	-9.38	0.00	0.00	12.5	
		Week 70	Sparsentan	47	37 (78.7)	-1.52 (13.59)	-43.8	-6.25	0.00	6.25	34.4	0.32 [-0.17, 0.80]
			Irbesartan	41	30 (73.2)	-6.56 (18.38)	-71.9	-6.25	0.00	3.13	12.5	
		Week 94	Sparsentan	47	37 (78.7)	1.27 (15.26)	-40.6	-3.13	0.00	3.13	56.3	0.14 [-0.35, 0.62]
			Irbesartan	41	29 (70.7)	-0.43 (7.46)	-15.6	-6.25	0.00	3.13	18.8	
		Week 110	Sparsentan	47	37 (78.7)	1.01 (13.38)	-21.9	-3.13	0.00	6.25	46.9	0.44 [-0.05, 0.93]
			Irbesartan	41	29 (70.7)	-4.20 (9.35)	-25.0	-9.38	0.00	3.13	12.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Sex	Overall	Sparsentan						Interaction:	0.148
Male	Week 24	Sparsentan	139	109 (78.4)	-0.37 (1.02)	(-2.37, 1.63)	0.85 (1.50)	(-2.10, 3.80)	0.572
		Irbesartan	143	93 (65.0)	-1.22 (1.10)	(-3.38, 0.94)			
	Week 48	Sparsentan	139	112 (80.6)	0.16 (1.00)	(-1.81, 2.13)	-0.29 (1.50)	(-3.24, 2.65)	0.847
		Irbesartan	143	87 (60.8)	0.45 (1.11)	(-1.74, 2.63)			
	Week 70	Sparsentan	139	114 (82.0)	-0.30 (1.00)	(-2.27, 1.67)	-0.40 (1.49)	(-3.33, 2.52)	0.787
		Irbesartan	143	92 (64.3)	0.10 (1.10)	(-2.06, 2.26)			
	Week 94	Sparsentan	139	105 (75.5)	0.16 (1.03)	(-1.87, 2.19)	-0.58 (1.50)	(-3.53, 2.37)	0.699
		Irbesartan	143	96 (67.1)	0.74 (1.09)	(-1.39, 2.88)			
	Week 110	Sparsentan	139	103 (74.1)	0.43 (1.05)	(-1.64, 2.49)	0.20 (1.54)	(-2.84, 3.23)	0.899
		Irbesartan	143	89 (62.2)	0.23 (1.13)	(-1.98, 2.45)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Female	Week 24	Sparsentan	63	48 (76.2)	5.84 (1.49)	(2.90, 8.77)	4.44 (2.25)	(0.00, 8.87)	0.050 *
		Irbesartan	59	38 (64.4)	1.40 (1.68)	(-1.90, 4.71)			
	Week 48	Sparsentan	63	50 (79.4)	4.96 (1.46)	(2.09, 7.83)	2.99 (2.24)	(-1.41, 7.38)	0.183
		Irbesartan	59	37 (62.7)	1.97 (1.69)	(-1.35, 5.30)			
	Week 70	Sparsentan	63	46 (73.0)	3.28 (1.52)	(0.30, 6.26)	0.73 (2.27)	(-3.73, 5.19)	0.748
		Irbesartan	59	38 (64.4)	2.55 (1.68)	(-0.75, 5.86)			
	Week 94	Sparsentan	63	46 (73.0)	4.57 (1.52)	(1.58, 7.56)	1.16 (2.33)	(-3.43, 5.75)	0.621
		Irbesartan	59	34 (57.6)	3.41 (1.76)	(-0.05, 6.87)			
	Week 110	Sparsentan	63	46 (73.0)	3.80 (1.53)	(0.79, 6.81)	0.96 (2.39)	(-3.73, 5.65)	0.687
		Irbesartan	59	32 (54.2)	2.84 (1.82)	(-0.75, 6.43)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age	Overall	Sparsentan						Interaction:	0.538
<= 45 years	Week 24	Sparsentan	96	71 (74.0)	1.21 (1.40)	(-1.54, 3.97)	1.94 (2.01)	(-2.02, 5.90)	0.336
		Irbesartan	99	67 (67.7)	-0.73 (1.44)	(-3.56, 2.11)			
	Week 48	Sparsentan	96	75 (78.1)	0.91 (1.36)	(-1.77, 3.59)	-0.25 (2.01)	(-4.20, 3.69)	0.900
		Irbesartan	99	62 (62.6)	1.16 (1.47)	(-1.73, 4.06)			
	Week 70	Sparsentan	96	72 (75.0)	1.13 (1.39)	(-1.60, 3.85)	-0.20 (2.03)	(-4.20, 3.79)	0.920
		Irbesartan	99	62 (62.6)	1.33 (1.49)	(-1.59, 4.25)			
	Week 94	Sparsentan	96	68 (70.8)	2.24 (1.42)	(-0.55, 5.03)	1.32 (2.05)	(-2.70, 5.34)	0.520
		Irbesartan	99	64 (64.6)	0.92 (1.47)	(-1.97, 3.82)			
	Week 110	Sparsentan	96	69 (71.9)	2.84 (1.43)	(0.03, 5.65)	2.45 (2.09)	(-1.66, 6.57)	0.242
		Irbesartan	99	59 (59.6)	0.39 (1.53)	(-2.63, 3.40)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 45 years	Week 24	Sparsentan	106	86 (81.1)	1.60 (1.01)	(-0.39, 3.58)	1.66 (1.55)	(-1.38, 4.71)	0.283
		Irbesartan	103	64 (62.1)	-0.07 (1.17)	(-2.37, 2.24)			
	Week 48	Sparsentan	106	87 (82.1)	2.16 (1.00)	(0.20, 4.13)	1.42 (1.54)	(-1.60, 4.45)	0.356
		Irbesartan	103	62 (60.2)	0.74 (1.17)	(-1.55, 3.04)			
	Week 70	Sparsentan	106	88 (83.0)	0.50 (1.00)	(-1.47, 2.47)	0.27 (1.52)	(-2.70, 3.25)	0.857
		Irbesartan	103	68 (66.0)	0.22 (1.13)	(-2.00, 2.45)			
	Week 94	Sparsentan	106	83 (78.3)	0.84 (1.03)	(-1.17, 2.86)	-1.00 (1.54)	(-4.03, 2.03)	0.518
		Irbesartan	103	66 (64.1)	1.84 (1.15)	(-0.42, 4.10)			
	Week 110	Sparsentan	106	80 (75.5)	0.18 (1.05)	(-1.88, 2.24)	-1.25 (1.59)	(-4.38, 1.87)	0.430
		Irbesartan	103	62 (60.2)	1.44 (1.19)	(-0.90, 3.78)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age at IgAN diagnosis	Overall	Sparsentan						Interaction:	0.495
<= 18 years	Week 24	Sparsentan	9	5 (55.6)	-1.59 (11.36)	(-28.17, 24.99)	-6.90 (19.01)	(-51.74, 37.95)	0.727
		Irbesartan	5	5 (100.0)	5.30 (14.27)	(-28.45, 39.06)			
	Week 48	Sparsentan	9	7 (77.8)	-4.77 (11.20)	(-31.20, 21.66)	-8.39 (19.02)	(-53.23, 36.46)	0.672
		Irbesartan	5	3 (60.0)	3.62 (14.41)	(-30.27, 37.50)			
	Week 70	Sparsentan	9	7 (77.8)	-4.97 (11.25)	(-31.44, 21.50)	-2.84 (19.04)	(-47.71, 42.02)	0.885
		Irbesartan	5	4 (80.0)	-2.13 (14.39)	(-36.00, 31.74)			
	Week 94	Sparsentan	9	5 (55.6)	0.36 (11.39)	(-26.24, 26.97)	-0.59 (19.21)	(-45.63, 44.45)	0.976
		Irbesartan	5	4 (80.0)	0.95 (14.50)	(-33.03, 34.94)			
	Week 110	Sparsentan	9	4 (44.4)	-0.16 (11.61)	(-27.00, 26.68)	-0.87 (19.68)	(-46.38, 44.65)	0.966
		Irbesartan	5	2 (40.0)	0.70 (15.02)	(-33.83, 35.24)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 18 to 40 years	Week 24	Sparsentan	102	79 (77.5)	2.06 (1.29)	(-0.47, 4.60)	3.46 (1.87)	(-0.21, 7.14)	0.065
		Irbesartan	109	71 (65.1)	-1.40 (1.36)	(-4.07, 1.26)			
	Week 48	Sparsentan	102	82 (80.4)	1.11 (1.27)	(-1.38, 3.59)	0.57 (1.87)	(-3.11, 4.24)	0.762
		Irbesartan	109	67 (61.5)	0.54 (1.38)	(-2.16, 3.24)			
	Week 70	Sparsentan	102	78 (76.5)	0.93 (1.29)	(-1.61, 3.47)	0.22 (1.89)	(-3.49, 3.93)	0.907
		Irbesartan	109	68 (62.4)	0.71 (1.38)	(-1.99, 3.42)			
	Week 94	Sparsentan	102	73 (71.6)	1.70 (1.33)	(-0.91, 4.31)	1.04 (1.92)	(-2.73, 4.80)	0.589
		Irbesartan	109	69 (63.3)	0.67 (1.38)	(-2.04, 3.37)			
	Week 110	Sparsentan	102	72 (70.6)	2.32 (1.35)	(-0.34, 4.98)	1.69 (1.96)	(-2.17, 5.55)	0.390
		Irbesartan	109	65 (59.6)	0.63 (1.42)	(-2.16, 3.42)			
> 40 years	Week 24	Sparsentan	91	73 (80.2)	1.36 (1.06)	(-0.73, 3.44)	1.16 (1.61)	(-2.02, 4.33)	0.474
		Irbesartan	88	55 (62.5)	0.20 (1.21)	(-2.19, 2.59)			
	Week 48	Sparsentan	91	73 (80.2)	2.30 (1.05)	(0.24, 4.37)	1.04 (1.61)	(-2.12, 4.20)	0.517
		Irbesartan	88	54 (61.4)	1.26 (1.21)	(-1.12, 3.65)			
	Week 70	Sparsentan	91	75 (82.4)	0.52 (1.04)	(-1.53, 2.58)	-0.61 (1.58)	(-3.72, 2.49)	0.699
		Irbesartan	88	58 (65.9)	1.14 (1.18)	(-1.19, 3.46)			
	Week 94	Sparsentan	91	73 (80.2)	0.92 (1.06)	(-1.16, 3.00)	-1.54 (1.60)	(-4.68, 1.59)	0.334
		Irbesartan	88	57 (64.8)	2.46 (1.19)	(0.12, 4.81)			
	Week 110	Sparsentan	91	73 (80.2)	0.20 (1.06)	(-1.89, 2.29)	-1.16 (1.63)	(-4.36, 2.04)	0.477
		Irbesartan	88	54 (61.4)	1.36 (1.23)	(-1.06, 3.78)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Geographic region	Overall	Sparsentan						Interaction:	0.296
North America	Week 24	Sparsentan	35	23 (65.7)	-2.17 (2.45)	(-7.02, 2.68)	0.18 (3.18)	(-6.10, 6.46)	0.954
		Irbesartan	46	35 (76.1)	-2.35 (2.00)	(-6.31, 1.61)			
	Week 48	Sparsentan	35	25 (71.4)	1.83 (2.38)	(-2.86, 6.53)	0.02 (3.16)	(-6.22, 6.26)	0.995
		Irbesartan	46	32 (69.6)	1.81 (2.05)	(-2.24, 5.87)			
	Week 70	Sparsentan	35	22 (62.9)	0.66 (2.49)	(-4.25, 5.58)	-0.16 (3.28)	(-6.63, 6.32)	0.962
		Irbesartan	46	30 (65.2)	0.82 (2.12)	(-3.36, 5.00)			
	Week 94	Sparsentan	35	23 (65.7)	0.70 (2.46)	(-4.17, 5.56)	-0.66 (3.27)	(-7.13, 5.80)	0.839
		Irbesartan	46	30 (65.2)	1.36 (2.14)	(-2.87, 5.59)			
	Week 110	Sparsentan	35	21 (60.0)	1.16 (2.57)	(-3.91, 6.23)	-0.87 (3.35)	(-7.48, 5.75)	0.796
		Irbesartan	46	31 (67.4)	2.03 (2.14)	(-2.21, 6.26)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Europe	Week 24	Sparsentan	98	73 (74.5)	3.32 (1.18)	(0.99, 5.64)	3.53 (1.75)	(0.10, 6.97)	0.044 *
		Irbesartan	115	62 (53.9)	-0.22 (1.29)	(-2.75, 2.31)			
	Week 48	Sparsentan	98	76 (77.6)	3.65 (1.16)	(1.36, 5.93)	3.38 (1.73)	(-0.02, 6.79)	0.051
		Irbesartan	115	59 (51.3)	0.26 (1.28)	(-2.25, 2.78)			
	Week 70	Sparsentan	98	75 (76.5)	1.42 (1.18)	(-0.90, 3.74)	1.45 (1.70)	(-1.90, 4.80)	0.395
		Irbesartan	115	69 (60.0)	-0.03 (1.22)	(-2.43, 2.37)			
	Week 94	Sparsentan	98	68 (69.4)	2.18 (1.22)	(-0.22, 4.57)	1.43 (1.73)	(-1.96, 4.83)	0.408
		Irbesartan	115	70 (60.9)	0.74 (1.22)	(-1.65, 3.14)			
	Week 110	Sparsentan	98	67 (68.4)	2.94 (1.24)	(0.49, 5.39)	2.65 (1.80)	(-0.89, 6.18)	0.142
		Irbesartan	115	61 (53.0)	0.29 (1.29)	(-2.24, 2.83)			
Asia Pacific	Week 24	Sparsentan	69	61 (88.4)	1.24 (1.39)	(-1.49, 3.98)	1.45 (2.32)	(-3.12, 6.01)	0.533
		Irbesartan	41	34 (82.9)	-0.20 (1.85)	(-3.84, 3.44)			
	Week 48	Sparsentan	69	61 (88.4)	-0.33 (1.38)	(-3.04, 2.39)	-0.42 (2.34)	(-5.02, 4.18)	0.858
		Irbesartan	41	33 (80.5)	0.09 (1.88)	(-3.60, 3.79)			
	Week 70	Sparsentan	69	63 (91.3)	0.69 (1.37)	(-2.00, 3.37)	-0.66 (2.39)	(-5.37, 4.05)	0.783
		Irbesartan	41	31 (75.6)	1.34 (1.95)	(-2.49, 5.18)			
	Week 94	Sparsentan	69	60 (87.0)	1.69 (1.39)	(-1.05, 4.43)	-0.12 (2.44)	(-4.92, 4.67)	0.960
		Irbesartan	41	30 (73.2)	1.81 (1.98)	(-2.09, 5.71)			
	Week 110	Sparsentan	69	61 (88.4)	0.67 (1.39)	(-2.06, 3.41)	0.88 (2.47)	(-3.97, 5.73)	0.722
		Irbesartan	41	29 (70.7)	-0.20 (2.02)	(-4.18, 3.77)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline BMI	Overall	Sparsentan						Interaction:	0.826
< 27 kg/m**2	Week 24	Sparsentan	83	66 (79.5)	2.01 (1.45)	(-0.85, 4.86)	2.26 (2.06)	(-1.79, 6.31)	0.273
		Irbesartan	94	66 (70.2)	-0.25 (1.45)	(-3.10, 2.60)			
	Week 48	Sparsentan	83	66 (79.5)	1.36 (1.44)	(-1.48, 4.20)	0.31 (2.07)	(-3.76, 4.38)	0.883
		Irbesartan	94	60 (63.8)	1.05 (1.47)	(-1.85, 3.95)			
	Week 70	Sparsentan	83	64 (77.1)	0.70 (1.46)	(-2.18, 3.58)	-0.02 (2.10)	(-4.14, 4.11)	0.993
		Irbesartan	94	59 (62.8)	0.72 (1.49)	(-2.22, 3.66)			
	Week 94	Sparsentan	83	63 (75.9)	2.02 (1.48)	(-0.89, 4.92)	1.07 (2.10)	(-3.06, 5.21)	0.610
		Irbesartan	94	62 (66.0)	0.94 (1.49)	(-1.98, 3.87)			
	Week 110	Sparsentan	83	63 (75.9)	1.14 (1.49)	(-1.79, 4.08)	0.40 (2.15)	(-3.83, 4.63)	0.852
		Irbesartan	94	57 (60.6)	0.74 (1.55)	(-2.30, 3.78)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
>= 27 kg/m**2	Week 24	Sparsentan	119	91 (76.5)	1.04 (1.03)	(-0.99, 3.07)	1.60 (1.61)	(-1.55, 4.76)	0.318
		Irbesartan	107	65 (60.7)	-0.57 (1.23)	(-2.97, 1.84)			
	Week 48	Sparsentan	119	96 (80.7)	1.63 (1.01)	(-0.35, 3.60)	0.40 (1.58)	(-2.71, 3.50)	0.802
		Irbesartan	107	64 (59.8)	1.23 (1.22)	(-1.17, 3.63)			
	Week 70	Sparsentan	119	96 (80.7)	0.57 (1.01)	(-1.41, 2.55)	-0.58 (1.55)	(-3.62, 2.46)	0.710
		Irbesartan	107	71 (66.4)	1.14 (1.17)	(-1.16, 3.45)			
	Week 94	Sparsentan	119	88 (73.9)	0.82 (1.05)	(-1.24, 2.88)	-1.41 (1.60)	(-4.55, 1.72)	0.376
		Irbesartan	107	67 (62.6)	2.23 (1.20)	(-0.13, 4.60)			
	Week 110	Sparsentan	119	86 (72.3)	1.52 (1.07)	(-0.57, 3.62)	0.42 (1.64)	(-2.80, 3.64)	0.798
		Irbesartan	107	63 (58.9)	1.10 (1.24)	(-1.34, 3.55)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Randomization strata	Overall	Sparsentan						Interaction:	0.614
eGFR Low and UP High	Week 24	Sparsentan	71	54 (76.1)	0.82 (1.33)	(-1.80, 3.44)	3.60 (2.03)	(-0.39, 7.60)	0.077
		Irbesartan	74	40 (54.1)	-2.78 (1.53)	(-5.79, 0.22)			
	Week 48	Sparsentan	71	51 (71.8)	1.80 (1.35)	(-0.85, 4.45)	1.81 (2.05)	(-2.23, 5.84)	0.379
		Irbesartan	74	37 (50.0)	-0.00 (1.54)	(-3.04, 3.03)			
	Week 70	Sparsentan	71	57 (80.3)	-0.56 (1.31)	(-3.14, 2.02)	-0.24 (2.04)	(-4.25, 3.77)	0.907
		Irbesartan	74	37 (50.0)	-0.32 (1.56)	(-3.39, 2.75)			
	Week 94	Sparsentan	71	51 (71.8)	0.46 (1.35)	(-2.20, 3.12)	0.33 (2.08)	(-3.77, 4.42)	0.876
		Irbesartan	74	37 (50.0)	0.13 (1.58)	(-2.97, 3.24)			
	Week 110	Sparsentan	71	53 (74.6)	0.25 (1.35)	(-2.42, 2.91)	0.09 (2.11)	(-4.06, 4.24)	0.966
		Irbesartan	74	36 (48.6)	0.16 (1.62)	(-3.03, 3.34)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
eGFR Low and UP Low	Week 24	Sparsentan	55	43 (78.2)	1.33 (1.61)	(-1.84, 4.50)	-2.88 (2.39)	(-7.57, 1.82)	0.229
		Irbesartan	55	37 (67.3)	4.21 (1.74)	(0.79, 7.64)			
	Week 48	Sparsentan	55	43 (78.2)	1.07 (1.60)	(-2.07, 4.22)	-1.57 (2.39)	(-6.27, 3.14)	0.513
		Irbesartan	55	35 (63.6)	2.64 (1.77)	(-0.85, 6.13)			
	Week 70	Sparsentan	55	42 (76.4)	1.27 (1.62)	(-1.93, 4.46)	-0.29 (2.35)	(-4.90, 4.33)	0.902
		Irbesartan	55	39 (70.9)	1.55 (1.69)	(-1.76, 4.87)			
	Week 94	Sparsentan	55	41 (74.5)	2.50 (1.65)	(-0.73, 5.74)	-0.74 (2.36)	(-5.39, 3.91)	0.755
		Irbesartan	55	39 (70.9)	3.24 (1.69)	(-0.08, 6.56)			
	Week 110	Sparsentan	55	37 (67.3)	1.81 (1.73)	(-1.59, 5.21)	-0.82 (2.50)	(-5.73, 4.09)	0.743
		Irbesartan	55	34 (61.8)	2.63 (1.80)	(-0.91, 6.17)			
eGFR High and UP High	Week 24	Sparsentan	37	26 (70.3)	2.60 (2.37)	(-2.08, 7.29)	3.17 (3.42)	(-3.60, 9.94)	0.356
		Irbesartan	36	26 (72.2)	-0.56 (2.47)	(-5.45, 4.32)			
	Week 48	Sparsentan	37	33 (89.2)	0.99 (2.20)	(-3.37, 5.34)	-1.17 (3.33)	(-7.77, 5.42)	0.725
		Irbesartan	36	24 (66.7)	2.16 (2.50)	(-2.79, 7.11)			
	Week 70	Sparsentan	37	31 (83.8)	1.34 (2.25)	(-3.11, 5.80)	1.27 (3.36)	(-5.39, 7.92)	0.707
		Irbesartan	36	25 (69.4)	0.08 (2.50)	(-4.87, 5.02)			
	Week 94	Sparsentan	37	27 (73.0)	2.67 (2.36)	(-1.98, 7.33)	0.29 (3.46)	(-6.55, 7.14)	0.933
		Irbesartan	36	24 (66.7)	2.38 (2.53)	(-2.63, 7.39)			
	Week 110	Sparsentan	37	26 (70.3)	2.94 (2.43)	(-1.87, 7.75)	4.33 (3.58)	(-2.75, 11.42)	0.228
		Irbesartan	36	22 (61.1)	-1.39 (2.63)	(-6.59, 3.80)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
eGFR High and UP Low	Week 24	Sparsentan	39	34 (87.2)	1.93 (1.74)	(-1.51, 5.36)	4.56 (2.58)	(-0.53, 9.65)	0.079
		Irbesartan	37	28 (75.7)	-2.64 (1.90)	(-6.39, 1.11)			
	Week 48	Sparsentan	39	35 (89.7)	2.32 (1.73)	(-1.08, 5.72)	2.01 (2.57)	(-3.05, 7.07)	0.435
		Irbesartan	37	28 (75.7)	0.31 (1.89)	(-3.42, 4.04)			
	Week 70	Sparsentan	39	30 (76.9)	1.38 (1.83)	(-2.22, 4.98)	-1.53 (2.63)	(-6.71, 3.65)	0.561
		Irbesartan	37	29 (78.4)	2.91 (1.88)	(-0.80, 6.61)			
	Week 94	Sparsentan	39	32 (82.1)	0.41 (1.79)	(-3.12, 3.93)	-0.79 (2.58)	(-5.88, 4.30)	0.760
		Irbesartan	37	30 (81.1)	1.20 (1.85)	(-2.46, 4.85)			
	Week 110	Sparsentan	39	33 (84.6)	1.08 (1.77)	(-2.41, 4.58)	-0.92 (2.59)	(-6.04, 4.19)	0.722
		Irbesartan	37	29 (78.4)	2.00 (1.89)	(-1.71, 5.72)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 1	Overall	Sparsentan						Interaction:	0.040 #
< 60 mL/min/1.73 m**2	Week 24	Sparsentan	127	98 (77.2)	0.68 (1.04)	(-1.37, 2.73)	0.29 (1.56)	(-2.77, 3.35)	0.854
		Irbesartan	129	80 (62.0)	0.39 (1.15)	(-1.88, 2.66)			
	Week 48	Sparsentan	127	95 (74.8)	1.65 (1.05)	(-0.41, 3.72)	0.75 (1.58)	(-2.35, 3.86)	0.634
		Irbesartan	129	74 (57.4)	0.90 (1.18)	(-1.42, 3.22)			
	Week 70	Sparsentan	127	100 (78.7)	-0.07 (1.03)	(-2.10, 1.97)	-0.39 (1.56)	(-3.44, 2.67)	0.805
		Irbesartan	129	78 (60.5)	0.32 (1.16)	(-1.96, 2.60)			
	Week 94	Sparsentan	127	92 (72.4)	1.34 (1.07)	(-0.76, 3.44)	-0.34 (1.59)	(-3.45, 2.78)	0.833
		Irbesartan	129	77 (59.7)	1.67 (1.17)	(-0.63, 3.97)			
	Week 110	Sparsentan	127	92 (72.4)	1.11 (1.08)	(-1.01, 3.22)	-0.41 (1.63)	(-3.61, 2.78)	0.800
		Irbesartan	129	72 (55.8)	1.52 (1.22)	(-0.87, 3.90)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
60 to < 90 mL/min/1.73 m**2	Week 24	Sparsentan	49	38 (77.6)	0.98 (1.83)	(-2.63, 4.59)	-0.28 (2.73)	(-5.67, 5.12)	0.919
		Irbesartan	48	31 (64.6)	1.26 (2.02)	(-2.72, 5.24)			
	Week 48	Sparsentan	49	44 (89.8)	0.44 (1.75)	(-3.03, 3.91)	0.01 (2.66)	(-5.24, 5.25)	0.998
		Irbesartan	48	32 (66.7)	0.43 (1.98)	(-3.47, 4.33)			
	Week 70	Sparsentan	49	38 (77.6)	0.29 (1.81)	(-3.29, 3.87)	-0.45 (2.70)	(-5.78, 4.89)	0.869
		Irbesartan	48	32 (66.7)	0.73 (1.98)	(-3.18, 4.65)			
	Week 94	Sparsentan	49	39 (79.6)	-0.42 (1.82)	(-4.02, 3.18)	-1.65 (2.69)	(-6.97, 3.67)	0.542
		Irbesartan	48	34 (70.8)	1.23 (1.97)	(-2.66, 5.11)			
	Week 110	Sparsentan	49	36 (73.5)	0.38 (1.89)	(-3.35, 4.10)	1.20 (2.77)	(-4.27, 6.66)	0.666
		Irbesartan	48	32 (66.7)	-0.82 (2.01)	(-4.80, 3.16)			
>= 90 mL/min/1.73 m**2	Week 24	Sparsentan	26	21 (80.8)	7.02 (2.31)	(2.45, 11.58)	13.29 (3.31)	(6.76, 19.82)	<0.001 *
		Irbesartan	25	20 (80.0)	-6.27 (2.37)	(-10.95, -1.60)			
	Week 48	Sparsentan	26	23 (88.5)	3.45 (2.22)	(-0.95, 7.85)	0.48 (3.35)	(-6.13, 7.09)	0.886
		Irbesartan	25	18 (72.0)	2.97 (2.48)	(-1.92, 7.87)			
	Week 70	Sparsentan	26	22 (84.6)	4.82 (2.27)	(0.33, 9.32)	1.28 (3.31)	(-5.26, 7.82)	0.700
		Irbesartan	25	20 (80.0)	3.55 (2.38)	(-1.16, 8.25)			
	Week 94	Sparsentan	26	20 (76.9)	5.49 (2.36)	(0.82, 10.15)	3.54 (3.40)	(-3.17, 10.26)	0.299
		Irbesartan	25	19 (76.0)	1.94 (2.43)	(-2.86, 6.75)			
	Week 110	Sparsentan	26	21 (80.8)	4.69 (2.32)	(0.10, 9.27)	2.20 (3.46)	(-4.64, 9.04)	0.526
		Irbesartan	25	17 (68.0)	2.49 (2.56)	(-2.58, 7.55)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 2	Overall	Sparsentan						Interaction:	0.027 #
< 45 mL/min/1.73 m**2	Week 24	Sparsentan	82	64 (78.0)	2.68 (1.37)	(-0.02, 5.38)	2.92 (2.10)	(-1.20, 7.04)	0.164
		Irbesartan	80	48 (60.0)	-0.25 (1.58)	(-3.36, 2.87)			
	Week 48	Sparsentan	82	61 (74.4)	1.92 (1.40)	(-0.82, 4.66)	1.43 (2.16)	(-2.81, 5.68)	0.507
		Irbesartan	80	43 (53.8)	0.49 (1.65)	(-2.75, 3.72)			
	Week 70	Sparsentan	82	65 (79.3)	0.37 (1.36)	(-2.30, 3.05)	1.37 (2.12)	(-2.79, 5.52)	0.519
		Irbesartan	80	45 (56.3)	-0.99 (1.62)	(-4.17, 2.18)			
	Week 94	Sparsentan	82	60 (73.2)	2.12 (1.41)	(-0.65, 4.89)	0.47 (2.13)	(-3.71, 4.65)	0.827
		Irbesartan	80	47 (58.8)	1.65 (1.59)	(-1.48, 4.78)			
	Week 110	Sparsentan	82	56 (68.3)	1.90 (1.46)	(-0.98, 4.77)	-0.00 (2.21)	(-4.34, 4.33)	0.998
		Irbesartan	80	44 (55.0)	1.90 (1.65)	(-1.34, 5.14)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
45 to < 60 mL/min/1.73 m**2	Week 24	Sparsentan	45	34 (75.6)	-3.08 (1.56)	(-6.16, 0.00)	-4.60 (2.26)	(-9.04, -0.15)	0.043 *
		Irbesartan	49	32 (65.3)	1.52 (1.62)	(-1.67, 4.70)			
	Week 48	Sparsentan	45	34 (75.6)	1.44 (1.55)	(-1.60, 4.49)	-0.37 (2.25)	(-4.80, 4.06)	0.869
		Irbesartan	49	31 (63.3)	1.81 (1.62)	(-1.39, 5.01)			
	Week 70	Sparsentan	45	35 (77.8)	-0.64 (1.54)	(-3.68, 2.40)	-2.96 (2.24)	(-7.37, 1.45)	0.187
		Irbesartan	49	33 (67.3)	2.32 (1.61)	(-0.85, 5.50)			
	Week 94	Sparsentan	45	32 (71.1)	-0.01 (1.59)	(-3.14, 3.13)	-1.85 (2.31)	(-6.39, 2.70)	0.424
		Irbesartan	49	30 (61.2)	1.84 (1.66)	(-1.44, 5.12)			
	Week 110	Sparsentan	45	36 (80.0)	-0.30 (1.55)	(-3.36, 2.75)	-1.36 (2.33)	(-5.95, 3.23)	0.560
		Irbesartan	49	28 (57.1)	1.06 (1.73)	(-2.35, 4.47)			
60 to < 90 mL/min/1.73 m**2	Week 24	Sparsentan	49	38 (77.6)	0.98 (1.83)	(-2.63, 4.59)	-0.28 (2.73)	(-5.67, 5.12)	0.919
		Irbesartan	48	31 (64.6)	1.26 (2.02)	(-2.72, 5.24)			
	Week 48	Sparsentan	49	44 (89.8)	0.44 (1.75)	(-3.03, 3.91)	0.01 (2.66)	(-5.24, 5.25)	0.998
		Irbesartan	48	32 (66.7)	0.43 (1.98)	(-3.47, 4.33)			
	Week 70	Sparsentan	49	38 (77.6)	0.29 (1.81)	(-3.29, 3.87)	-0.45 (2.70)	(-5.78, 4.89)	0.869
		Irbesartan	48	32 (66.7)	0.73 (1.98)	(-3.18, 4.65)			
	Week 94	Sparsentan	49	39 (79.6)	-0.42 (1.82)	(-4.02, 3.18)	-1.65 (2.69)	(-6.97, 3.67)	0.542
		Irbesartan	48	34 (70.8)	1.23 (1.97)	(-2.66, 5.11)			
	Week 110	Sparsentan	49	36 (73.5)	0.38 (1.89)	(-3.35, 4.10)	1.20 (2.77)	(-4.27, 6.66)	0.666
		Irbesartan	48	32 (66.7)	-0.82 (2.01)	(-4.80, 3.16)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
>= 90 mL/min/1.73 m**2	Week 24	Sparsentan	26	21 (80.8)	7.02 (2.31)	(2.45, 11.58)	13.29 (3.31)	(6.76, 19.82)	<0.001 *
		Irbesartan	25	20 (80.0)	-6.27 (2.37)	(-10.95, -1.60)			
	Week 48	Sparsentan	26	23 (88.5)	3.45 (2.22)	(-0.95, 7.85)	0.48 (3.35)	(-6.13, 7.09)	0.886
		Irbesartan	25	18 (72.0)	2.97 (2.48)	(-1.92, 7.87)			
	Week 70	Sparsentan	26	22 (84.6)	4.82 (2.27)	(0.33, 9.32)	1.28 (3.31)	(-5.26, 7.82)	0.700
		Irbesartan	25	20 (80.0)	3.55 (2.38)	(-1.16, 8.25)			
	Week 94	Sparsentan	26	20 (76.9)	5.49 (2.36)	(0.82, 10.15)	3.54 (3.40)	(-3.17, 10.26)	0.299
		Irbesartan	25	19 (76.0)	1.94 (2.43)	(-2.86, 6.75)			
	Week 110	Sparsentan	26	21 (80.8)	4.69 (2.32)	(0.10, 9.27)	2.20 (3.46)	(-4.64, 9.04)	0.526
		Irbesartan	25	17 (68.0)	2.49 (2.56)	(-2.58, 7.55)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline urine protein excretion	Overall	Sparsentan						Interaction:	0.165
<= 1.75 g/day	Week 24	Sparsentan	98	80 (81.6)	0.87 (1.21)	(-1.50, 3.25)	0.66 (1.89)	(-3.06, 4.38)	0.728
		Irbesartan	93	55 (59.1)	0.22 (1.45)	(-2.64, 3.07)			
	Week 48	Sparsentan	98	82 (83.7)	1.36 (1.19)	(-0.98, 3.70)	0.39 (1.85)	(-3.25, 4.04)	0.832
		Irbesartan	93	57 (61.3)	0.97 (1.42)	(-1.82, 3.76)			
	Week 70	Sparsentan	98	75 (76.5)	0.28 (1.24)	(-2.15, 2.71)	-1.58 (1.86)	(-5.23, 2.08)	0.397
		Irbesartan	93	61 (65.6)	1.86 (1.38)	(-0.86, 4.57)			
	Week 94	Sparsentan	98	76 (77.6)	1.24 (1.24)	(-1.18, 3.67)	-0.23 (1.84)	(-3.84, 3.39)	0.903
		Irbesartan	93	63 (67.7)	1.47 (1.36)	(-1.21, 4.14)			
	Week 110	Sparsentan	98	75 (76.5)	0.93 (1.25)	(-1.52, 3.38)	-0.75 (1.90)	(-4.48, 2.98)	0.694
		Irbesartan	93	57 (61.3)	1.68 (1.43)	(-1.13, 4.48)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 1.75 g/day	Week 24	Sparsentan	104	77 (74.0)	2.28 (1.21)	(-0.10, 4.66)	3.56 (1.73)	(0.16, 6.96)	0.040 *
		Irbesartan	109	76 (69.7)	-1.28 (1.23)	(-3.70, 1.14)			
	Week 48	Sparsentan	104	80 (76.9)	1.94 (1.19)	(-0.40, 4.27)	1.13 (1.73)	(-2.27, 4.54)	0.513
		Irbesartan	109	67 (61.5)	0.80 (1.26)	(-1.67, 3.28)			
	Week 70	Sparsentan	104	85 (81.7)	1.33 (1.18)	(-0.99, 3.64)	1.64 (1.73)	(-1.76, 5.04)	0.343
		Irbesartan	109	69 (63.3)	-0.31 (1.26)	(-2.79, 2.17)			
	Week 94	Sparsentan	104	75 (72.1)	1.81 (1.22)	(-0.59, 4.21)	0.70 (1.78)	(-2.79, 4.19)	0.693
		Irbesartan	109	67 (61.5)	1.11 (1.28)	(-1.42, 3.63)			
	Week 110	Sparsentan	104	74 (71.2)	2.01 (1.25)	(-0.44, 4.46)	2.22 (1.82)	(-1.36, 5.80)	0.223
		Irbesartan	109	64 (58.7)	-0.21 (1.32)	(-2.81, 2.39)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline use of antihypertensives	Overall	Sparsentan						Interaction:	0.940
Yes	Week 24	Sparsentan	90	66 (73.3)	2.11 (1.09)	(-0.04, 4.25)	3.16 (1.67)	(-0.11, 6.44)	0.058
		Irbesartan	88	49 (55.7)	-1.06 (1.26)	(-3.53, 1.41)			
	Week 48	Sparsentan	90	65 (72.2)	1.64 (1.09)	(-0.49, 3.78)	0.70 (1.66)	(-2.57, 3.97)	0.673
		Irbesartan	88	47 (53.4)	0.94 (1.26)	(-1.53, 3.41)			
	Week 70	Sparsentan	90	68 (75.6)	-0.41 (1.08)	(-2.53, 1.71)	-0.59 (1.65)	(-3.84, 2.65)	0.720
		Irbesartan	88	49 (55.7)	0.18 (1.25)	(-2.27, 2.63)			
	Week 94	Sparsentan	90	63 (70.0)	0.25 (1.10)	(-1.93, 2.42)	-0.55 (1.64)	(-3.77, 2.68)	0.738
		Irbesartan	88	54 (61.4)	0.79 (1.21)	(-1.58, 3.17)			
	Week 110	Sparsentan	90	63 (70.0)	1.27 (1.12)	(-0.94, 3.47)	0.96 (1.68)	(-2.34, 4.26)	0.567
		Irbesartan	88	51 (58.0)	0.31 (1.24)	(-2.13, 2.75)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
No	Week 24	Sparsentan	112	91 (81.3)	1.12 (1.23)	(-1.28, 3.53)	1.39 (1.78)	(-2.11, 4.89)	0.437
		Irbesartan	114	82 (71.9)	-0.26 (1.29)	(-2.80, 2.28)			
	Week 48	Sparsentan	112	97 (86.6)	1.71 (1.19)	(-0.62, 4.05)	0.85 (1.77)	(-2.63, 4.33)	0.631
		Irbesartan	114	77 (67.5)	0.86 (1.31)	(-1.72, 3.44)			
	Week 70	Sparsentan	112	92 (82.1)	1.81 (1.22)	(-0.59, 4.20)	0.71 (1.78)	(-2.78, 4.21)	0.689
		Irbesartan	114	81 (71.1)	1.09 (1.30)	(-1.45, 3.64)			
	Week 94	Sparsentan	112	88 (78.6)	2.53 (1.24)	(0.08, 4.97)	0.66 (1.83)	(-2.93, 4.24)	0.720
		Irbesartan	114	76 (66.7)	1.87 (1.34)	(-0.75, 4.50)			
	Week 110	Sparsentan	112	86 (76.8)	1.59 (1.26)	(-0.89, 4.08)	0.17 (1.88)	(-3.53, 3.87)	0.929
		Irbesartan	114	70 (61.4)	1.42 (1.40)	(-1.32, 4.16)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Time since renal biopsy	Overall	Sparsentan						Interaction:	0.080
<= 5 years	Week 24	Sparsentan	113	88 (77.9)	3.42 (1.10)	(1.25, 5.59)	4.76 (1.57)	(1.68, 7.84)	0.002 *
		Irbesartan	127	86 (67.7)	-1.34 (1.11)	(-3.52, 0.84)			
	Week 48	Sparsentan	113	92 (81.4)	3.43 (1.08)	(1.31, 5.54)	2.50 (1.54)	(-0.53, 5.54)	0.105
		Irbesartan	127	85 (66.9)	0.92 (1.10)	(-1.25, 3.09)			
	Week 70	Sparsentan	113	90 (79.6)	1.34 (1.09)	(-0.80, 3.48)	0.21 (1.55)	(-2.84, 3.26)	0.893
		Irbesartan	127	86 (67.7)	1.13 (1.11)	(-1.04, 3.30)			
	Week 94	Sparsentan	113	86 (76.1)	1.82 (1.11)	(-0.36, 4.00)	0.47 (1.57)	(-2.61, 3.55)	0.764
		Irbesartan	127	86 (67.7)	1.35 (1.11)	(-0.83, 3.52)			
	Week 110	Sparsentan	113	88 (77.9)	2.21 (1.11)	(0.03, 4.40)	1.25 (1.60)	(-1.90, 4.39)	0.436
		Irbesartan	127	80 (63.0)	0.97 (1.15)	(-1.30, 3.23)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 5 years	Week 24	Sparsentan	89	69 (77.5)	-0.86 (1.32)	(-3.46, 1.75)	-1.97 (2.13)	(-6.15, 2.21)	0.355
		Irbesartan	75	45 (60.0)	1.11 (1.66)	(-2.15, 4.38)			
	Week 48	Sparsentan	89	70 (78.7)	-0.55 (1.31)	(-3.13, 2.03)	-1.59 (2.17)	(-5.86, 2.69)	0.465
		Irbesartan	75	39 (52.0)	1.04 (1.73)	(-2.36, 4.44)			
	Week 70	Sparsentan	89	70 (78.7)	0.25 (1.32)	(-2.34, 2.85)	0.29 (2.12)	(-3.88, 4.47)	0.890
		Irbesartan	75	44 (58.7)	-0.04 (1.66)	(-3.30, 3.22)			
	Week 94	Sparsentan	89	65 (73.0)	1.30 (1.36)	(-1.37, 3.97)	-0.27 (2.15)	(-4.50, 3.97)	0.901
		Irbesartan	75	44 (58.7)	1.57 (1.67)	(-1.71, 4.85)			
	Week 110	Sparsentan	89	61 (68.5)	0.53 (1.41)	(-2.24, 3.29)	-0.37 (2.23)	(-4.76, 4.01)	0.867
		Irbesartan	75	41 (54.7)	0.90 (1.73)	(-2.49, 4.29)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
History of hypertension	Overall	Sparsentan						Interaction:	0.022 #
Yes	Week 24	Sparsentan	155	119 (76.8)	3.34 (0.84)	(1.70, 4.98)	1.70 (1.24)	(-0.73, 4.13)	0.170
		Irbesartan	161	100 (62.1)	1.64 (0.91)	(-0.14, 3.43)			
	Week 48	Sparsentan	155	121 (78.1)	2.20 (0.82)	(0.59, 3.82)	-0.90 (1.24)	(-3.33, 1.53)	0.468
		Irbesartan	161	95 (59.0)	3.10 (0.92)	(1.29, 4.91)			
	Week 70	Sparsentan	155	123 (79.4)	1.82 (0.82)	(0.20, 3.43)	-0.97 (1.22)	(-3.37, 1.43)	0.428
		Irbesartan	161	100 (62.1)	2.79 (0.91)	(1.01, 4.57)			
	Week 94	Sparsentan	155	114 (73.5)	2.05 (0.85)	(0.39, 3.72)	-0.19 (1.24)	(-2.63, 2.24)	0.876
		Irbesartan	161	101 (62.7)	2.25 (0.90)	(0.47, 4.02)			
	Week 110	Sparsentan	155	112 (72.3)	1.89 (0.86)	(0.19, 3.58)	-0.69 (1.28)	(-3.20, 1.82)	0.589
		Irbesartan	161	92 (57.1)	2.58 (0.95)	(0.72, 4.44)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KEFC_FSCM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in effect of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
No	Week 24	Sparsentan	47	38 (80.9)	-3.81 (2.36)	(-8.46, 0.84)	4.36 (3.53)	(-2.60, 11.32)	0.218
		Irbesartan	41	31 (75.6)	-8.17 (2.61)	(-13.33, -3.00)			
	Week 48	Sparsentan	47	41 (87.2)	-0.12 (2.29)	(-4.65, 4.41)	6.91 (3.50)	(0.00, 13.82)	0.050 *
		Irbesartan	41	29 (70.7)	-7.03 (2.63)	(-12.22, -1.84)			
	Week 70	Sparsentan	47	37 (78.7)	-2.14 (2.36)	(-6.81, 2.52)	4.11 (3.55)	(-2.88, 11.11)	0.248
		Irbesartan	41	30 (73.2)	-6.26 (2.63)	(-11.45, -1.07)			
	Week 94	Sparsentan	47	37 (78.7)	-0.03 (2.39)	(-4.75, 4.69)	1.92 (3.61)	(-5.20, 9.05)	0.595
		Irbesartan	41	29 (70.7)	-1.95 (2.69)	(-7.26, 3.35)			
	Week 110	Sparsentan	47	37 (78.7)	0.17 (2.41)	(-4.60, 4.94)	5.16 (3.66)	(-2.07, 12.38)	0.161
		Irbesartan	41	29 (70.7)	-4.99 (2.73)	(-10.38, 0.40)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Figure PF2KEFC_FSGM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 1: < 60 mL/min/1.73 m**2



Sparsentan	98	95	100	92	92
Irbesartan	80	74	78	77	72

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2KEFC_FSCM

Figure PF2KEFC_FSGM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 1: 60 to < 90 mL/min/1.73 m**2



Sparsentan	38	44	38	39	36
Irbesartan	31	32	32	34	32

_____
Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2KEFC_FSCM

Figure PF2KEFC_FSGM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 1: >= 90 mL/min/1.73 m**2



Sparsentan	21	23	22	20	21
Irbesartan	20	18	20	19	17

_____
Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2KEFC_FSCM

Figure PF2KEFC_FSGM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 2: < 45 mL/min/1.73 m**2



Sparsentan	64	61	65	60	56
Irbesartan	48	43	45	47	44

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2KEFC_FSCM

Figure PF2KEFC_FSGM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 2: 45 to < 60 mL/min/1.73 m**2



Sparsentan	34	34	35	32	36
Irbesartan	32	31	33	30	28

_____
Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2KEFC_FSCM

Figure PF2KEFC_FSGM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 2: 60 to < 90 mL/min/1.73 m**2



Sparsentan	38	44	38	39	36
Irbesartan	31	32	32	34	32

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2KEFC_FSCM

Figure PF2KEFC_FSGM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set
Study: PROTECT
Baseline eGFR Group 2: >= 90 mL/min/1.73 m**2



Sparsentan	21	23	22	20	21
Irbesartan	20	18	20	19	17

_____
Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2KEFC_FSCM

Figure PF2KEFC_FSGM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set
Study: PROTECT
History of hypertension: Yes



Sparsentan	119	121	123	114	112
Irbesartan	100	95	100	101	92

_____
Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2KEFC_FSCM

Figure PF2KEFC_FSGM: KDQOL: Change from baseline in effect of kidney disease by subgroup
Full Analysis Set
Study: PROTECT
History of hypertension: No



Sparsentan	38	41	37	37	37
Irbesartan	31	29	30	29	29

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2KEFC_FSCM

Table PT2KEFIT_FSTM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sex	Sparsentan						Interaction test:	0.438
Male	Sparsentan	139	19 (13.7)	NE		1.853	(0.873, 3.932)	0.108
	Irbesartan	143	15 (10.5)	NE				
Female	Sparsentan	63	16 (25.4)	NE		0.935	(0.320, 2.734)	0.902
	Irbesartan	59	7 (11.9)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KEFIT_FSTM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.776
<= 45 years	Sparsentan	96	19 (19.8)	NE		1.434	(0.667, 3.084)	0.356
	Irbesartan	99	12 (12.1)	NE				
> 45 years	Sparsentan	106	16 (15.1)	NE		1.749	(0.737, 4.151)	0.205
	Irbesartan	103	10 (9.7)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KEFIT_FSTM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age at IgAN diagnosis	Sparsentan						Interaction test:	<0.001 #
<= 18 years	Sparsentan	9	3 (33.3)	NE		0.263	(0.007, 9.271)	0.463
	Irbesartan	5	1 (20.0)	NE				
> 18 to 40 years	Sparsentan	102	17 (16.7)	NE		2.171	(0.985, 4.783)	0.054
	Irbesartan	109	13 (11.9)	NE				
> 40 years	Sparsentan	91	15 (16.5)	NE		1.820	(0.704, 4.701)	0.216
	Irbesartan	88	8 (9.1)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KEFIT_FSTM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Geographic region	Sparsentan						Interaction test:	0.065	
North America	Sparsentan	35	6 (17.1)	NE		1.532	(0.354, 6.639)	0.568	
	Irbesartan	46	4 (8.7)	NE					
Europe	Sparsentan	98	14 (14.3)	NE		1.272	(0.585, 2.766)	0.545	
	Irbesartan	115	16 (13.9)	NE					
Asia Pacific	Sparsentan	69	15 (21.7)	NE		7.401	(1.454, 37.680)	0.016	*
	Irbesartan	41	2 (4.9)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KEFIT_FSTM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.676
< 27 kg/m**2	Sparsentan	83	18 (21.7)	NE		1.417	(0.619, 3.247)	0.410
	Irbesartan	94	10 (10.6)	NE				
>= 27 kg/m**2	Sparsentan	119	17 (14.3)	NE		1.688	(0.749, 3.804)	0.206
	Irbesartan	107	12 (11.2)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KEFIT_FSTM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Randomization strata	Sparsentan						Interaction test:	0.050	
eGFR Low and UP High	Sparsentan	71	7 (9.9)	NE		1.428	(0.463, 4.410)	0.536	
	Irbesartan	74	6 (8.1)	NE					
eGFR Low and UP Low	Sparsentan	55	13 (23.6)	NE		1.118	(0.379, 3.294)	0.840	
	Irbesartan	55	6 (10.9)	NE					
eGFR High and UP High	Sparsentan	37	7 (18.9)	NE		0.731	(0.222, 2.407)	0.606	
	Irbesartan	36	6 (16.7)	NE					
eGFR High and UP Low	Sparsentan	39	8 (20.5)	NE		5.973	(1.219, 29.260)	0.027	*
	Irbesartan	37	4 (10.8)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KEFIT_FSTM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.794
< 60 mL/min/1.73 m**2	Sparsentan	127	20 (15.7)	NE		1.113	(0.525, 2.363)	0.780
	Irbesartan	129	12 (9.3)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	7 (14.3)	NE		1.807	(0.484, 6.753)	0.379
	Irbesartan	48	8 (16.7)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	8 (30.8)	NE		3.301	(0.665, 16.394)	0.144
	Irbesartan	25	2 (8.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KEFIT_FSTM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 2	Sparsentan						Interaction test:	0.909
< 45 mL/min/1.73 m**2	Sparsentan	82	15 (18.3)	NE		1.115	(0.447, 2.780)	0.815
	Irbesartan	80	8 (10.0)	NE				
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	5 (11.1)	NE		0.739	(0.169, 3.224)	0.687
	Irbesartan	49	4 (8.2)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	7 (14.3)	NE		1.807	(0.484, 6.753)	0.379
	Irbesartan	48	8 (16.7)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	8 (30.8)	NE		3.301	(0.665, 16.394)	0.144
	Irbesartan	25	2 (8.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KEFIT_FSTM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline urine protein excretion	Sparsentan						Interaction test:	0.033	#
<= 1.75 g/day	Sparsentan	98	20 (20.4)	NE		2.881	(1.165, 7.124)	0.022	*
	Irbesartan	93	8 (8.6)	NE					
> 1.75 g/day	Sparsentan	104	15 (14.4)	NE		0.855	(0.395, 1.853)	0.692	
	Irbesartan	109	14 (12.8)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KEFIT_FSTM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.082	
Yes	Sparsentan	90	14 (15.6)	NE		2.829	(1.094, 7.320)	0.032	*
	Irbesartan	88	7 (8.0)	NE					
No	Sparsentan	112	21 (18.8)	NE		1.023	(0.506, 2.068)	0.950	
	Irbesartan	114	15 (13.2)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KEFIT_FSTM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Time since renal biopsy	Sparsentan						Interaction test:	<0.001	#
<= 5 years	Sparsentan	113	25 (22.1)	NE		4.053	(1.905, 8.623)	<0.001	*
	Irbesartan	127	13 (10.2)	NE					
> 5 years	Sparsentan	89	10 (11.2)	NE		0.396	(0.140, 1.119)	0.080	
	Irbesartan	75	9 (12.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KEFIT_FSTM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to increase in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
History of hypertension	Sparsentan						Interaction test:	0.163
Yes	Sparsentan	155	30 (19.4)	NE		1.131	(0.625, 2.047)	0.685
	Irbesartan	161	20 (12.4)	NE				
No	Sparsentan	47	5 (10.6)	NE		10.943	(0.684, 175.145)	0.091
	Irbesartan	41	2 (4.9)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Figure PF2KEFIT_FSKM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Age at IgAN diagnosis: <= 18 years



Sparsentan	9	7	5	4	4	2
Irbesartan	5	5	3	3	2	1

An increase reflects an improvement of the status of the patient.
Reference table: PT2KEFIT_FSTM

Figure PF2KEFIT_FSKM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Age at IgAN diagnosis: > 18 to 40 years



Sparsentan	102	86	77	74	64	54
Irbesartan	109	88	79	68	62	58

An increase reflects an improvement of the status of the patient.
Reference table: PT2KEFIT_FSTM

Figure PF2KEFIT_FSKM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Age at IgAN diagnosis: > 40 years



Sparsentan	91	80	69	69	65	56
Irbesartan	88	68	63	60	58	44

An increase reflects an improvement of the status of the patient.
Reference table: PT2KEFIT_FSTM

Figure PF2KEFIT_FSKM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline urine protein excretion: <= 1.75 g/day



Sparsentan	98	87	73	73	68	56
Irbesartan	93	73	68	63	58	46

An increase reflects an improvement of the status of the patient.
Reference table: PT2KEFIT_FSTM

Figure PF2KEFIT_FSKM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline urine protein excretion: > 1.75 g/day



Sparsentan	104	86	78	74	65	56
Irbesartan	109	88	77	68	64	57

An increase reflects an improvement of the status of the patient.
Reference table: PT2KEFIT_FSTM

Figure PF2KEFIT_FSKM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Time since renal biopsy: <= 5 years



Sparsentan	113	96	81	79	70	58
Irbesartan	127	106	99	88	82	70

An increase reflects an improvement of the status of the patient.
Reference table: PT2KEFIT_FSTM

Figure PF2KEFIT_FSKM: KDQOL: Time to increase in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Time since renal biopsy: > 5 years



Sparsentan	89	77	70	68	63	54
Irbesartan	75	55	46	43	40	33

An increase reflects an improvement of the status of the patient.
Reference table: PT2KEFIT_FSTM

Table PT2KEFDT_FSTM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sex	Sparsentan						Interaction test:	0.717
Male	Sparsentan	139	25 (18.0)	NE		0.933	(0.529, 1.648)	0.812
	Irbesartan	143	23 (16.1)	NE				
Female	Sparsentan	63	6 (9.5)	NE		0.712	(0.221, 2.294)	0.570
	Irbesartan	59	6 (10.2)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KEFDT_FSTM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.770
<= 45 years	Sparsentan	96	16 (16.7)	NE		0.963	(0.476, 1.949)	0.916
	Irbesartan	99	15 (15.2)	NE				
> 45 years	Sparsentan	106	15 (14.2)	NE		0.870	(0.414, 1.829)	0.714
	Irbesartan	103	14 (13.6)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KEFDT_FSTM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age at IgAN diagnosis	Sparsentan						Interaction test:	0.945
<= 18 years	Sparsentan	9	1 (11.1)	NE		NE		NE
	Irbesartan	5	1 (20.0)	NE				
> 18 to 40 years	Sparsentan	102	16 (15.7)	NE		0.883	(0.439, 1.776)	0.728
	Irbesartan	109	16 (14.7)	NE				
> 40 years	Sparsentan	91	14 (15.4)	NE		0.876	(0.401, 1.912)	0.739
	Irbesartan	88	12 (13.6)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KEFDT_FSTM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Geographic region	Sparsentan						Interaction test:	0.605
North America	Sparsentan	35	5 (14.3)	NE		0.762	(0.242, 2.400)	0.643
	Irbesartan	46	8 (17.4)	NE				
Europe	Sparsentan	98	10 (10.2)	NE		0.588	(0.259, 1.338)	0.206
	Irbesartan	115	14 (12.2)	NE				
Asia Pacific	Sparsentan	69	16 (23.2)	NE		1.382	(0.552, 3.461)	0.490
	Irbesartan	41	7 (17.1)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KEFDT_FSTM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.518
< 27 kg/m**2	Sparsentan	83	15 (18.1)	NE		1.026	(0.490, 2.148)	0.946
	Irbesartan	94	14 (14.9)	NE				
>= 27 kg/m**2	Sparsentan	119	16 (13.4)	NE		0.815	(0.395, 1.678)	0.578
	Irbesartan	107	14 (13.1)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KEFDT_FSTM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Randomization strata	Sparsentan						Interaction test:	0.563
eGFR Low and UP High	Sparsentan	71	12 (16.9)	NE		0.742	(0.337, 1.634)	0.459
	Irbesartan	74	13 (17.6)	NE				
eGFR Low and UP Low	Sparsentan	55	9 (16.4)	NE		1.889	(0.628, 5.685)	0.258
	Irbesartan	55	5 (9.1)	NE				
eGFR High and UP High	Sparsentan	37	5 (13.5)	NE		0.722	(0.207, 2.513)	0.609
	Irbesartan	36	5 (13.9)	NE				
eGFR High and UP Low	Sparsentan	39	5 (12.8)	NE		0.705	(0.212, 2.344)	0.568
	Irbesartan	37	6 (16.2)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KEFDT_FSTM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.526
< 60 mL/min/1.73 m**2	Sparsentan	127	22 (17.3)	NE		1.042	(0.556, 1.956)	0.897
	Irbesartan	129	18 (14.0)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	6 (12.2)	NE		0.704	(0.223, 2.226)	0.550
	Irbesartan	48	6 (12.5)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	3 (11.5)	NE		0.622	(0.145, 2.658)	0.522
	Irbesartan	25	5 (20.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KEFDT_FSTM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eGFR Group 2	Sparsentan						Interaction test:	0.012	#
< 45 mL/min/1.73 m**2	Sparsentan	82	11 (13.4)	NE		0.515	(0.238, 1.114)	0.092	
	Irbesartan	80	16 (20.0)	NE					
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	11 (24.4)	NE		6.080	(1.291, 28.628)	0.022	*
	Irbesartan	49	2 (4.1)	NE					
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	6 (12.2)	NE		0.704	(0.223, 2.226)	0.550	
	Irbesartan	48	6 (12.5)	NE					
>= 90 mL/min/1.73 m**2	Sparsentan	26	3 (11.5)	NE		0.622	(0.145, 2.658)	0.522	
	Irbesartan	25	5 (20.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KEFDT_FSTM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline urine protein excretion	Sparsentan						Interaction test:	0.534
<= 1.75 g/day	Sparsentan	98	17 (17.3)	NE		1.030	(0.498, 2.130)	0.937
	Irbesartan	93	13 (14.0)	NE				
> 1.75 g/day	Sparsentan	104	14 (13.5)	NE		0.709	(0.345, 1.457)	0.349
	Irbesartan	109	16 (14.7)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KEFDT_FSTM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.655
Yes	Sparsentan	90	14 (15.6)	NE		0.736	(0.346, 1.563)	0.424
	Irbesartan	88	14 (15.9)	NE				
No	Sparsentan	112	17 (15.2)	NE		0.984	(0.490, 1.977)	0.964
	Irbesartan	114	15 (13.2)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KEFDT_FSTM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Time since renal biopsy	Sparsentan						Interaction test:	0.432
<= 5 years	Sparsentan	113	18 (15.9)	NE		0.772	(0.414, 1.441)	0.417
	Irbesartan	127	22 (17.3)	NE				
> 5 years	Sparsentan	89	13 (14.6)	NE		1.219	(0.476, 3.124)	0.679
	Irbesartan	75	7 (9.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KEFDT_FSTM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in effect of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
History of hypertension	Sparsentan						Interaction test:	0.260
Yes	Sparsentan	155	21 (13.5)	NE		1.044	(0.551, 1.981)	0.894
	Irbesartan	161	17 (10.6)	NE				
No	Sparsentan	47	10 (21.3)	NE		0.586	(0.249, 1.382)	0.222
	Irbesartan	41	12 (29.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Figure PF2KEFDT_FSKM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline eGFR Group 2: < 45 mL/min/1.73 m**2



Sparsentan	82	68	66	63	55	48
Irbesartan	80	61	51	45	43	36

_____
A decrease reflects a worsening of the status of the patient.
Reference table: PT2KEFDT_FSTM

Figure PF2KEFDT_FSKM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline eGFR Group 2: 45 to < 60 mL/min/1.73 m**2



Sparsentan	45	39	33	32	29	22
Irbesartan	49	37	34	33	31	27

A decrease reflects a worsening of the status of the patient.
Reference table: PT2KEFDT_FSTM

Figure PF2KEFDT_FSKM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline eGFR Group 2: 60 to < 90 mL/min/1.73 m**2



Sparsentan	49	46	43	42	39	34
Irbesartan	48	40	37	33	30	25

A decrease reflects a worsening of the status of the patient.
Reference table: PT2KEFDT_FSTM

Figure PF2KEFDT_FSKM: KDQOL: Time to decrease in effect of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline eGFR Group 2: >= 90 mL/min/1.73 m**2



Sparsentan	26	24	24	23	21	19
Irbesartan	25	21	16	16	15	14

A decrease reflects a worsening of the status of the patient.
Reference table: PT2KEFDT_FSTM

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	139	129 (92.8)	90.94 (8.24)	61.4	86.36	93.18	97.73	100.0	
			Irbesartan	143	131 (91.6)	89.63 (11.32)	38.6	86.36	93.18	97.73	100.0	
		Week 24	Sparsentan	139	109 (78.4)	89.51 (12.25)	4.5	84.09	93.18	97.73	100.0	
			Irbesartan	143	93 (65.0)	87.41 (16.42)	4.5	84.09	93.18	97.73	100.0	
		Week 48	Sparsentan	139	112 (80.6)	88.92 (15.05)	0.0	85.23	92.05	97.73	100.0	
			Irbesartan	143	87 (60.8)	89.58 (13.67)	36.4	86.36	93.18	100.00	100.0	
		Week 70	Sparsentan	139	114 (82.0)	88.98 (12.40)	38.6	86.36	93.18	97.73	100.0	
			Irbesartan	143	92 (64.3)	89.38 (14.25)	29.5	86.36	93.18	100.00	100.0	
		Week 94	Sparsentan	139	105 (75.5)	88.90 (10.74)	52.3	84.09	90.91	97.73	100.0	
			Irbesartan	143	96 (67.1)	87.57 (15.17)	25.0	81.82	92.05	97.73	100.0	
		Week 110	Sparsentan	139	103 (74.1)	88.83 (12.89)	6.8	84.09	93.18	97.73	100.0	
			Irbesartan	143	89 (62.2)	88.02 (15.04)	6.8	81.82	93.18	97.73	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	139	109 (78.4)	-1.48 (10.23)	-72.7	-4.55	0.00	2.27	25.0	0.01 [-0.26, 0.29]
			Irbesartan	143	93 (65.0)	-1.66 (14.94)	-90.9	-4.55	0.00	2.27	52.3	
		Week 48	Sparsentan	139	112 (80.6)	-1.75 (15.15)	-100.0	-4.55	0.00	4.55	27.3	-0.02 [-0.30, 0.26]
			Irbesartan	143	87 (60.8)	-1.49 (10.19)	-52.3	-4.55	0.00	2.27	15.9	
		Week 70	Sparsentan	139	114 (82.0)	-2.17 (10.81)	-45.5	-4.55	0.00	4.55	20.5	-0.10 [-0.37, 0.17]
			Irbesartan	143	92 (64.3)	-1.11 (10.40)	-59.1	-4.55	0.00	2.27	31.8	
		Week 94	Sparsentan	139	105 (75.5)	-1.90 (9.05)	-29.5	-4.55	0.00	4.55	20.5	0.05 [-0.22, 0.33]
			Irbesartan	143	96 (67.1)	-2.44 (11.21)	-63.6	-4.55	0.00	2.27	20.5	
		Week 110	Sparsentan	139	103 (74.1)	-2.29 (12.25)	-84.1	-6.82	0.00	2.27	18.2	-0.08 [-0.36, 0.21]
			Irbesartan	143	89 (62.2)	-1.35 (12.55)	-81.8	-4.55	0.00	4.55	22.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Female	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	63	58 (92.1)	84.17 (15.05)	31.8	77.27	88.64	95.45	100.0	
			Irbesartan	59	51 (86.4)	88.19 (10.22)	50.0	81.82	90.91	95.45	100.0	
		Week 24	Sparsentan	63	48 (76.2)	88.30 (12.05)	54.5	81.82	92.05	97.73	100.0	
			Irbesartan	59	38 (64.4)	88.04 (17.36)	4.5	81.82	95.45	97.73	100.0	
		Week 48	Sparsentan	63	50 (79.4)	87.77 (12.68)	54.5	77.27	93.18	100.00	100.0	
			Irbesartan	59	37 (62.7)	86.24 (11.35)	54.5	79.55	88.64	93.18	100.0	
		Week 70	Sparsentan	63	46 (73.0)	84.39 (16.53)	27.3	79.55	89.77	97.73	100.0	
			Irbesartan	59	38 (64.4)	87.32 (13.26)	40.9	84.09	90.91	95.45	100.0	
		Week 94	Sparsentan	63	46 (73.0)	84.58 (14.81)	45.5	77.27	88.64	97.73	100.0	
			Irbesartan	59	34 (57.6)	88.90 (10.57)	59.1	84.09	93.18	97.73	100.0	
		Week 110	Sparsentan	63	46 (73.0)	85.92 (14.30)	43.2	77.27	90.91	97.73	100.0	
			Irbesartan	59	32 (54.2)	89.56 (8.73)	65.9	85.23	90.91	96.59	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	63	48 (76.2)	4.07 (13.54)	-25.0	-2.27	2.27	10.23	63.6	0.33 [-0.10, 0.76]
			Irbesartan	59	38 (64.4)	-1.02 (17.35)	-86.4	-2.27	0.00	4.55	29.5	
		Week 48	Sparsentan	63	50 (79.4)	3.55 (14.45)	-29.5	-2.27	0.00	11.36	59.1	0.42 [-0.01, 0.85]
			Irbesartan	59	37 (62.7)	-1.84 (9.93)	-18.2	-9.09	-2.27	2.27	34.1	
		Week 70	Sparsentan	63	46 (73.0)	0.30 (16.38)	-61.4	-2.27	2.27	9.09	25.0	0.14 [-0.29, 0.57]
			Irbesartan	59	38 (64.4)	-1.56 (9.15)	-27.3	-4.55	-2.27	4.55	20.5	
		Week 94	Sparsentan	63	46 (73.0)	1.28 (16.92)	-34.1	-6.82	0.00	9.09	68.2	0.19 [-0.25, 0.64]
			Irbesartan	59	34 (57.6)	-1.54 (10.43)	-34.1	-6.82	0.00	2.27	20.5	
		Week 110	Sparsentan	63	46 (73.0)	1.73 (18.76)	-34.1	-6.82	1.14	9.09	68.2	0.16 [-0.29, 0.61]
			Irbesartan	59	32 (54.2)	-0.78 (8.61)	-18.2	-5.68	-1.14	2.27	20.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
<= 45 years	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	96	87 (90.6)	88.71 (12.19)	31.8	84.09	90.91	97.73	100.0	
			Irbesartan	99	92 (92.9)	89.30 (11.00)	52.3	86.36	92.05	97.73	100.0	
		Week 24	Sparsentan	96	71 (74.0)	90.08 (14.00)	4.5	86.36	93.18	97.73	100.0	
			Irbesartan	99	67 (67.7)	86.77 (18.91)	4.5	84.09	90.91	97.73	100.0	
		Week 48	Sparsentan	96	75 (78.1)	88.73 (15.03)	0.0	81.82	93.18	97.73	100.0	
			Irbesartan	99	62 (62.6)	88.42 (13.72)	36.4	84.09	90.91	100.00	100.0	
		Week 70	Sparsentan	96	72 (75.0)	88.57 (15.09)	27.3	84.09	93.18	100.00	100.0	
			Irbesartan	99	62 (62.6)	90.03 (12.48)	36.4	86.36	93.18	100.00	100.0	
		Week 94	Sparsentan	96	68 (70.8)	88.47 (12.29)	50.0	81.82	90.91	98.86	100.0	
			Irbesartan	99	64 (64.6)	86.65 (17.13)	25.0	79.55	93.18	100.00	100.0	
		Week 110	Sparsentan	96	69 (71.9)	89.69 (12.12)	43.2	81.82	93.18	100.00	100.0	
			Irbesartan	99	59 (59.6)	88.79 (11.77)	45.5	81.82	93.18	97.73	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	96	71 (74.0)	1.18 (13.52)	-72.7	-2.27	2.27	4.55	63.6	0.27 [-0.07, 0.60]
			Irbesartan	99	67 (67.7)	-2.85 (16.59)	-90.9	-6.82	0.00	2.27	15.9	
		Week 48	Sparsentan	96	75 (78.1)	-0.12 (15.45)	-90.9	-4.55	0.00	4.55	59.1	0.26 [-0.08, 0.59]
			Irbesartan	99	62 (62.6)	-3.59 (10.67)	-52.3	-9.09	0.00	2.27	11.4	
		Week 70	Sparsentan	96	72 (75.0)	-0.19 (13.74)	-61.4	-3.41	2.27	6.82	22.7	0.14 [-0.20, 0.48]
			Irbesartan	99	62 (62.6)	-1.87 (8.70)	-27.3	-4.55	0.00	2.27	25.0	
		Week 94	Sparsentan	96	68 (70.8)	-0.10 (13.60)	-34.1	-4.55	0.00	4.55	68.2	0.30 [-0.04, 0.64]
			Irbesartan	99	64 (64.6)	-4.15 (13.30)	-63.6	-7.95	0.00	2.27	20.5	
		Week 110	Sparsentan	96	69 (71.9)	0.79 (15.11)	-45.5	-6.82	0.00	6.82	68.2	0.19 [-0.16, 0.54]
			Irbesartan	99	59 (59.6)	-1.66 (9.19)	-27.3	-6.82	0.00	2.27	22.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 45 years	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	106	100 (94.3)	88.95 (10.37)	38.6	84.09	90.91	95.45	100.0	
			Irbesartan	103	90 (87.4)	89.14 (11.10)	38.6	84.09	92.05	97.73	100.0	
		Week 24	Sparsentan	106	86 (81.1)	88.37 (10.43)	50.0	84.09	90.91	95.45	100.0	
			Irbesartan	103	64 (62.1)	88.46 (13.96)	11.4	84.09	93.18	95.45	100.0	
		Week 48	Sparsentan	106	87 (82.1)	88.43 (13.80)	0.0	84.09	90.91	97.73	100.0	
			Irbesartan	103	62 (60.2)	88.75 (12.49)	43.2	84.09	93.18	97.73	100.0	
		Week 70	Sparsentan	106	88 (83.0)	86.91 (12.73)	38.6	80.68	90.91	95.45	100.0	
			Irbesartan	103	68 (66.0)	87.63 (15.16)	29.5	84.09	90.91	97.73	100.0	
		Week 94	Sparsentan	106	83 (78.3)	86.86 (12.21)	45.5	79.55	90.91	95.45	100.0	
			Irbesartan	103	66 (64.1)	89.15 (10.30)	54.5	81.82	92.05	97.73	100.0	
		Week 110	Sparsentan	106	80 (75.5)	86.42 (14.24)	6.8	78.41	89.77	95.45	100.0	
			Irbesartan	103	62 (60.2)	88.09 (15.29)	6.8	81.82	92.05	97.73	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	106	86 (81.1)	-0.58 (9.71)	-25.0	-4.55	0.00	4.55	36.4	-0.05 [-0.37, 0.28]
			Irbesartan	103	64 (62.1)	-0.04 (14.51)	-77.3	-4.55	0.00	4.55	52.3	
		Week 48	Sparsentan	106	87 (82.1)	-0.10 (14.87)	-100.0	-4.55	0.00	6.82	38.6	-0.04 [-0.37, 0.29]
			Irbesartan	103	62 (60.2)	0.40 (9.09)	-27.3	-4.55	0.00	2.27	34.1	
		Week 70	Sparsentan	106	88 (83.0)	-2.51 (11.68)	-45.5	-6.82	0.00	3.41	25.0	-0.16 [-0.48, 0.16]
			Irbesartan	103	68 (66.0)	-0.67 (11.12)	-59.1	-4.55	0.00	2.27	31.8	
		Week 94	Sparsentan	106	83 (78.3)	-1.62 (10.62)	-27.3	-6.82	-2.27	4.55	40.9	-0.14 [-0.46, 0.19]
			Irbesartan	103	66 (64.1)	-0.31 (7.76)	-18.2	-4.55	0.00	4.55	20.5	
		Week 110	Sparsentan	106	80 (75.5)	-2.64 (14.09)	-84.1	-6.82	0.00	2.27	36.4	-0.13 [-0.47, 0.20]
			Irbesartan	103	62 (60.2)	-0.77 (13.58)	-81.8	-4.55	0.00	4.55	22.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age at IgAN diagnosis												
<= 18 years	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	9	9 (100.0)	85.86 (9.22)	75.0	77.27	84.09	93.18	100.0	
			Irbesartan	5	5 (100.0)	87.27 (19.85)	52.3	90.91	95.45	97.73	100.0	
		Week 24	Sparsentan	9	5 (55.6)	74.55 (39.48)	4.5	84.09	90.91	95.45	97.7	
			Irbesartan	5	5 (100.0)	85.45 (22.87)	45.5	88.64	93.18	100.00	100.0	
		Week 48	Sparsentan	9	7 (77.8)	86.04 (10.12)	72.7	75.00	88.64	95.45	100.0	
			Irbesartan	5	3 (60.0)	93.18 (2.27)	90.9	90.91	93.18	95.45	95.5	
		Week 70	Sparsentan	9	7 (77.8)	89.61 (5.99)	81.8	84.09	88.64	95.45	97.7	
			Irbesartan	5	4 (80.0)	77.84 (28.41)	36.4	60.23	87.50	95.45	100.0	
		Week 94	Sparsentan	9	5 (55.6)	84.55 (15.28)	68.2	68.18	90.91	95.45	100.0	
			Irbesartan	5	4 (80.0)	78.98 (23.65)	45.5	62.50	86.36	95.45	97.7	
		Week 110	Sparsentan	9	4 (44.4)	94.32 (8.40)	81.8	89.77	97.73	98.86	100.0	
			Irbesartan	5	2 (40.0)	61.36 (22.50)	45.5	45.45	61.36	77.27	77.3	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	9	5 (55.6)	-12.73 (33.81)	-72.7	-2.27	0.00	2.27	9.1	-0.45 [-1.71, 0.80]
			Irbesartan	5	5 (100.0)	-1.82 (4.66)	-6.8	-6.82	0.00	2.27	2.3	
		Week 48	Sparsentan	9	7 (77.8)	-2.27 (6.15)	-11.4	-9.09	0.00	2.27	4.5	-0.14 [-1.49, 1.22]
			Irbesartan	5	3 (60.0)	-1.52 (3.47)	-4.5	-4.55	-2.27	2.27	2.3	
		Week 70	Sparsentan	9	7 (77.8)	1.30 (5.23)	-4.5	-4.55	2.27	4.55	9.1	1.59 [0.19, 2.99]
			Irbesartan	5	4 (80.0)	-8.52 (7.74)	-15.9	-13.64	-10.23	-3.41	2.3	
		Week 94	Sparsentan	9	5 (55.6)	-4.55 (11.48)	-18.2	-13.64	-4.55	6.82	6.8	0.29 [-1.03, 1.62]
			Irbesartan	5	4 (80.0)	-7.39 (6.53)	-15.9	-11.36	-6.82	-3.41	0.0	
		Week 110	Sparsentan	9	4 (44.4)	3.41 (7.07)	-2.3	-1.14	1.14	7.95	13.6	2.17 [0.08, 4.27]
			Irbesartan	5	2 (40.0)	-12.50 (8.04)	-18.2	-18.18	-12.50	-6.82	-6.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 18 to 40 years	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	102	94 (92.2)	89.12 (12.10)	31.8	84.09	90.91	97.73	100.0	
			Irbesartan	109	99 (90.8)	89.69 (10.19)	52.3	86.36	93.18	97.73	100.0	
		Week 24	Sparsentan	102	79 (77.5)	90.91 (9.86)	54.5	86.36	93.18	97.73	100.0	
			Irbesartan	109	71 (65.1)	88.96 (14.96)	4.5	86.36	93.18	97.73	100.0	
		Week 48	Sparsentan	102	82 (80.4)	88.91 (14.70)	0.0	81.82	94.32	97.73	100.0	
			Irbesartan	109	67 (61.5)	87.96 (13.85)	36.4	84.09	90.91	100.00	100.0	
		Week 70	Sparsentan	102	78 (76.5)	87.82 (15.22)	27.3	81.82	93.18	100.00	100.0	
			Irbesartan	109	68 (62.4)	90.71 (10.03)	54.5	86.36	93.18	97.73	100.0	
		Week 94	Sparsentan	102	73 (71.6)	88.48 (11.83)	50.0	81.82	90.91	97.73	100.0	
			Irbesartan	109	69 (63.3)	87.58 (15.84)	25.0	81.82	93.18	97.73	100.0	
		Week 110	Sparsentan	102	72 (70.6)	89.05 (12.29)	43.2	81.82	93.18	98.86	100.0	
			Irbesartan	109	65 (59.6)	89.97 (10.64)	52.3	84.09	93.18	97.73	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	102	79 (77.5)	2.04 (9.95)	-18.2	-2.27	2.27	4.55	63.6	0.30 [-0.02, 0.63]
			Irbesartan	109	71 (65.1)	-1.31 (12.13)	-86.4	-4.55	0.00	2.27	15.9	
		Week 48	Sparsentan	102	82 (80.4)	0.08 (14.97)	-90.9	-4.55	0.00	4.55	59.1	0.31 [-0.01, 0.64]
			Irbesartan	109	67 (61.5)	-4.07 (10.80)	-52.3	-11.36	0.00	2.27	11.4	
		Week 70	Sparsentan	102	78 (76.5)	-0.82 (13.74)	-61.4	-4.55	0.00	6.82	22.7	0.07 [-0.25, 0.40]
			Irbesartan	109	68 (62.4)	-1.64 (8.20)	-27.3	-4.55	0.00	2.27	25.0	
		Week 94	Sparsentan	102	73 (71.6)	0.09 (12.91)	-34.1	-4.55	0.00	4.55	68.2	0.29 [-0.04, 0.62]
			Irbesartan	109	69 (63.3)	-3.62 (12.97)	-63.6	-6.82	0.00	2.27	20.5	
		Week 110	Sparsentan	102	72 (70.6)	0.54 (14.88)	-45.5	-6.82	0.00	6.82	68.2	0.15 [-0.19, 0.48]
			Irbesartan	109	65 (59.6)	-1.29 (9.17)	-27.3	-4.55	0.00	2.27	22.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 40 years	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	91	84 (92.3)	88.85 (10.44)	38.6	85.23	90.91	95.45	100.0	
			Irbesartan	88	78 (88.6)	88.75 (11.49)	38.6	84.09	90.91	97.73	100.0	
		Week 24	Sparsentan	91	73 (80.2)	88.23 (10.47)	50.0	81.82	90.91	95.45	100.0	
			Irbesartan	88	55 (62.5)	86.03 (18.22)	4.5	81.82	90.91	95.45	100.0	
		Week 48	Sparsentan	91	73 (80.2)	88.42 (14.38)	0.0	84.09	90.91	97.73	100.0	
			Irbesartan	88	54 (61.4)	89.10 (12.45)	43.2	84.09	93.18	97.73	100.0	
		Week 70	Sparsentan	91	75 (82.4)	87.30 (12.88)	38.6	81.82	93.18	95.45	100.0	
			Irbesartan	88	58 (65.9)	87.26 (16.26)	29.5	84.09	90.91	97.73	100.0	
		Week 94	Sparsentan	91	73 (80.2)	86.89 (12.53)	45.5	79.55	90.91	95.45	100.0	
			Irbesartan	88	57 (64.8)	88.96 (10.74)	54.5	81.82	90.91	97.73	100.0	
		Week 110	Sparsentan	91	73 (80.2)	86.49 (14.47)	6.8	79.55	90.91	95.45	100.0	
			Irbesartan	88	54 (61.4)	87.58 (15.60)	6.8	81.82	90.91	97.73	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	91	73 (80.2)	-0.87 (10.18)	-25.0	-4.55	-2.27	2.27	36.4	0.05 [-0.30, 0.40]
			Irbesartan	88	55 (62.5)	-1.65 (19.85)	-90.9	-4.55	0.00	4.55	52.3	
		Week 48	Sparsentan	91	73 (80.2)	-0.12 (15.93)	-100.0	-2.27	0.00	6.82	38.6	-0.12 [-0.47, 0.23]
			Irbesartan	88	54 (61.4)	1.47 (8.51)	-20.5	-2.27	0.00	4.55	34.1	
		Week 70	Sparsentan	91	75 (82.4)	-2.39 (11.98)	-45.5	-6.82	0.00	2.27	25.0	-0.18 [-0.52, 0.17]
			Irbesartan	88	58 (65.9)	-0.27 (11.84)	-59.1	-4.55	0.00	4.55	31.8	
		Week 94	Sparsentan	91	73 (80.2)	-1.71 (11.18)	-27.3	-6.82	-2.27	4.55	40.9	-0.16 [-0.51, 0.19]
			Irbesartan	88	57 (64.8)	-0.12 (7.89)	-18.2	-4.55	0.00	4.55	20.5	
		Week 110	Sparsentan	91	73 (80.2)	-2.86 (14.57)	-84.1	-6.82	0.00	2.27	36.4	-0.15 [-0.51, 0.20]
			Irbesartan	88	54 (61.4)	-0.67 (14.04)	-81.8	-2.27	0.00	4.55	22.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Geographic region												
North America	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	35	31 (88.6)	91.50 (7.63)	75.0	86.36	93.18	97.73	100.0	
			Irbesartan	46	43 (93.5)	90.91 (10.80)	50.0	86.36	93.18	100.00	100.0	
		Week 24	Sparsentan	35	23 (65.7)	90.71 (19.71)	4.5	90.91	97.73	100.00	100.0	
			Irbesartan	46	35 (76.1)	89.03 (17.09)	4.5	84.09	93.18	100.00	100.0	
		Week 48	Sparsentan	35	25 (71.4)	91.45 (10.56)	54.5	88.64	95.45	97.73	100.0	
			Irbesartan	46	32 (69.6)	88.57 (13.99)	36.4	84.09	93.18	97.73	100.0	
		Week 70	Sparsentan	35	22 (62.9)	93.39 (7.55)	72.7	90.91	95.45	100.00	100.0	
			Irbesartan	46	30 (65.2)	90.38 (14.52)	40.9	88.64	95.45	100.00	100.0	
		Week 94	Sparsentan	35	23 (65.7)	90.91 (10.68)	50.0	88.64	90.91	97.73	100.0	
			Irbesartan	46	30 (65.2)	91.21 (10.76)	63.6	81.82	95.45	100.00	100.0	
		Week 110	Sparsentan	35	21 (60.0)	92.75 (8.02)	75.0	90.91	95.45	97.73	100.0	
			Irbesartan	46	31 (67.4)	91.13 (9.14)	65.9	84.09	93.18	97.73	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	35	23 (65.7)	-2.77 (15.83)	-72.7	-2.27	0.00	2.27	11.4	-0.07 [-0.59, 0.46]
			Irbesartan	46	35 (76.1)	-1.69 (16.41)	-86.4	-4.55	0.00	2.27	29.5	
		Week 48	Sparsentan	35	25 (71.4)	-1.00 (8.14)	-29.5	-2.27	-2.27	2.27	18.2	0.10 [-0.42, 0.62]
			Irbesartan	46	32 (69.6)	-2.13 (13.50)	-52.3	-7.95	0.00	2.27	34.1	
		Week 70	Sparsentan	35	22 (62.9)	0.10 (5.18)	-11.4	-2.27	0.00	2.27	9.1	0.21 [-0.34, 0.76]
			Irbesartan	46	30 (65.2)	-1.36 (8.17)	-27.3	-4.55	0.00	2.27	18.2	
		Week 94	Sparsentan	35	23 (65.7)	-2.57 (9.10)	-34.1	-4.55	-2.27	0.00	20.5	-0.25 [-0.80, 0.30]
			Irbesartan	46	30 (65.2)	-0.38 (8.48)	-18.2	-4.55	0.00	2.27	20.5	
		Week 110	Sparsentan	35	21 (60.0)	-1.41 (8.11)	-22.7	-2.27	0.00	2.27	18.2	-0.14 [-0.69, 0.42]
			Irbesartan	46	31 (67.4)	-0.22 (9.15)	-18.2	-4.55	0.00	4.55	22.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Europe	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	98	89 (90.8)	88.13 (12.99)	31.8	84.09	90.91	97.73	100.0	
			Irbesartan	115	98 (85.2)	88.59 (11.45)	38.6	84.09	90.91	95.45	100.0	
		Week 24	Sparsentan	98	73 (74.5)	89.35 (10.00)	59.1	84.09	93.18	97.73	100.0	
			Irbesartan	115	62 (53.9)	86.44 (18.46)	4.5	84.09	92.05	97.73	100.0	
		Week 48	Sparsentan	98	76 (77.6)	87.41 (14.86)	0.0	80.68	90.91	97.73	100.0	
			Irbesartan	115	59 (51.3)	86.98 (14.10)	43.2	79.55	90.91	100.00	100.0	
		Week 70	Sparsentan	98	75 (76.5)	88.00 (11.67)	50.0	81.82	90.91	95.45	100.0	
			Irbesartan	115	69 (60.0)	86.69 (15.74)	29.5	84.09	90.91	95.45	100.0	
		Week 94	Sparsentan	98	68 (69.4)	87.67 (11.75)	45.5	79.55	90.91	97.73	100.0	
			Irbesartan	115	70 (60.9)	85.29 (16.56)	25.0	79.55	89.77	97.73	100.0	
		Week 110	Sparsentan	98	67 (68.4)	87.62 (15.19)	6.8	81.82	93.18	97.73	100.0	
			Irbesartan	115	61 (53.0)	86.62 (16.74)	6.8	81.82	90.91	97.73	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	98	73 (74.5)	1.46 (12.31)	-25.0	-4.55	0.00	4.55	63.6	0.23 [-0.11, 0.57]
			Irbesartan	115	62 (53.9)	-2.02 (18.03)	-90.9	-4.55	0.00	4.55	52.3	
		Week 48	Sparsentan	98	76 (77.6)	0.33 (16.79)	-100.0	-4.55	0.00	4.55	59.1	0.22 [-0.12, 0.57]
			Irbesartan	115	59 (51.3)	-2.81 (9.15)	-27.3	-6.82	0.00	2.27	11.4	
		Week 70	Sparsentan	98	75 (76.5)	-0.21 (10.88)	-45.5	-4.55	0.00	4.55	25.0	0.16 [-0.16, 0.49]
			Irbesartan	115	69 (60.0)	-2.08 (11.72)	-59.1	-4.55	0.00	2.27	31.8	
		Week 94	Sparsentan	98	68 (69.4)	0.94 (13.07)	-29.5	-4.55	0.00	4.55	68.2	0.35 [0.01, 0.69]
			Irbesartan	115	70 (60.9)	-3.60 (12.82)	-63.6	-6.82	0.00	2.27	18.2	
		Week 110	Sparsentan	98	67 (68.4)	0.24 (16.73)	-84.1	-4.55	0.00	4.55	68.2	0.11 [-0.24, 0.45]
			Irbesartan	115	61 (53.0)	-1.42 (13.96)	-81.8	-6.82	0.00	4.55	22.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asia Pacific	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	69	67 (97.1)	88.57 (9.98)	50.0	84.09	88.64	97.73	100.0	
			Irbesartan	41	41 (100.0)	88.97 (10.22)	52.3	84.09	93.18	95.45	100.0	
		Week 24	Sparsentan	69	61 (88.4)	88.30 (10.98)	50.0	84.09	90.91	97.73	100.0	
			Irbesartan	41	34 (82.9)	88.24 (12.40)	50.0	86.36	93.18	95.45	100.0	
		Week 48	Sparsentan	69	61 (88.4)	88.82 (15.02)	0.0	84.09	93.18	97.73	100.0	
			Irbesartan	41	33 (80.5)	91.46 (9.64)	54.5	88.64	93.18	97.73	100.0	
		Week 70	Sparsentan	69	63 (91.3)	85.25 (17.03)	27.3	79.55	93.18	95.45	100.0	
			Irbesartan	41	31 (75.6)	91.86 (6.96)	70.5	88.64	90.91	97.73	100.0	
		Week 94	Sparsentan	69	60 (87.0)	86.21 (13.23)	52.3	78.41	89.77	96.59	100.0	
			Irbesartan	41	30 (73.2)	90.76 (8.87)	65.9	84.09	93.18	97.73	100.0	
		Week 110	Sparsentan	69	61 (88.4)	86.62 (12.45)	50.0	79.55	90.91	95.45	100.0	
			Irbesartan	41	29 (70.7)	89.34 (9.55)	59.1	84.09	90.91	95.45	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	69	61 (88.4)	-0.15 (8.36)	-22.7	-4.55	0.00	4.55	13.6	0.01 [-0.41, 0.43]
			Irbesartan	41	34 (82.9)	-0.27 (8.93)	-25.0	-4.55	0.00	2.27	20.5	
		Week 48	Sparsentan	69	61 (88.4)	-0.30 (15.23)	-90.9	-4.55	0.00	9.09	27.3	-0.11 [-0.53, 0.32]
			Irbesartan	41	33 (80.5)	1.10 (7.14)	-15.9	-2.27	0.00	4.55	20.5	
		Week 70	Sparsentan	69	63 (91.3)	-3.50 (15.92)	-61.4	-6.82	0.00	6.82	22.7	-0.31 [-0.74, 0.12]
			Irbesartan	41	31 (75.6)	0.73 (7.05)	-13.6	-4.55	0.00	4.55	20.5	
		Week 94	Sparsentan	69	60 (87.0)	-2.42 (11.66)	-27.3	-7.95	-1.14	3.41	25.0	-0.16 [-0.60, 0.28]
			Irbesartan	41	30 (73.2)	-0.76 (7.93)	-18.2	-4.55	0.00	2.27	20.5	
		Week 110	Sparsentan	69	61 (88.4)	-2.35 (13.93)	-45.5	-6.82	0.00	4.55	29.5	-0.04 [-0.49, 0.40]
			Irbesartan	41	29 (70.7)	-1.80 (8.29)	-18.2	-4.55	0.00	2.27	20.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline BMI												
< 27 kg/m**2	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	83	75 (90.4)	89.09 (9.68)	47.7	84.09	88.64	97.73	100.0	
			Irbesartan	94	86 (91.5)	88.85 (10.97)	38.6	86.36	90.91	95.45	100.0	
		Week 24	Sparsentan	83	66 (79.5)	88.22 (14.76)	4.5	84.09	92.05	97.73	100.0	
			Irbesartan	94	66 (70.2)	86.95 (15.74)	4.5	81.82	92.05	97.73	100.0	
		Week 48	Sparsentan	83	66 (79.5)	89.39 (10.68)	65.9	81.82	93.18	97.73	100.0	
			Irbesartan	94	60 (63.8)	85.53 (14.82)	36.4	78.41	89.77	96.59	100.0	
		Week 70	Sparsentan	83	64 (77.1)	87.71 (13.31)	27.3	81.82	93.18	96.59	100.0	
			Irbesartan	94	59 (62.8)	87.37 (14.38)	36.4	84.09	90.91	95.45	100.0	
		Week 94	Sparsentan	83	63 (75.9)	88.02 (12.25)	45.5	84.09	90.91	97.73	100.0	
			Irbesartan	94	62 (66.0)	86.25 (15.71)	25.0	79.55	90.91	97.73	100.0	
		Week 110	Sparsentan	83	63 (75.9)	88.28 (11.05)	50.0	81.82	90.91	97.73	100.0	
			Irbesartan	94	57 (60.6)	86.28 (12.88)	45.5	77.27	88.64	97.73	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	83	66 (79.5)	-1.41 (12.36)	-72.7	-6.82	0.00	4.55	20.5	-0.01 [-0.35, 0.33]
			Irbesartan	94	66 (70.2)	-1.24 (14.50)	-86.4	-4.55	0.00	4.55	52.3	
		Week 48	Sparsentan	83	66 (79.5)	0.45 (9.47)	-18.2	-4.55	0.00	4.55	25.0	0.39 [0.04, 0.75]
			Irbesartan	94	60 (63.8)	-3.60 (11.14)	-52.3	-6.82	0.00	2.27	13.6	
		Week 70	Sparsentan	83	64 (77.1)	-1.92 (12.63)	-61.4	-6.82	0.00	4.55	25.0	0.05 [-0.30, 0.40]
			Irbesartan	94	59 (62.8)	-2.47 (8.15)	-27.3	-4.55	0.00	2.27	15.9	
		Week 94	Sparsentan	83	63 (75.9)	-1.77 (10.55)	-29.5	-6.82	0.00	4.55	20.5	0.20 [-0.15, 0.55]
			Irbesartan	94	62 (66.0)	-4.03 (12.42)	-63.6	-6.82	0.00	2.27	13.6	
		Week 110	Sparsentan	83	63 (75.9)	-1.84 (10.64)	-34.1	-6.82	0.00	4.55	20.5	0.10 [-0.26, 0.45]
			Irbesartan	94	57 (60.6)	-2.79 (9.21)	-27.3	-9.09	0.00	2.27	18.2	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 27 kg/m**2	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	119	112 (94.1)	88.68 (12.19)	31.8	84.09	90.91	97.73	100.0	
			Irbesartan	107	95 (88.8)	89.88 (10.71)	47.7	84.09	93.18	97.73	100.0	
		Week 24	Sparsentan	119	91 (76.5)	89.81 (9.90)	50.0	84.09	93.18	97.73	100.0	
			Irbesartan	107	65 (60.7)	88.25 (17.59)	4.5	86.36	93.18	97.73	100.0	
		Week 48	Sparsentan	119	96 (80.7)	88.00 (16.41)	0.0	84.09	92.05	97.73	100.0	
			Irbesartan	107	64 (59.8)	91.44 (10.50)	43.2	88.64	94.32	100.00	100.0	
		Week 70	Sparsentan	119	96 (80.7)	87.62 (14.21)	38.6	82.95	93.18	97.73	100.0	
			Irbesartan	107	71 (66.4)	89.95 (13.57)	29.5	86.36	93.18	100.00	100.0	
		Week 94	Sparsentan	119	88 (73.9)	87.27 (12.29)	50.0	79.55	90.91	97.73	100.0	
			Irbesartan	107	67 (62.6)	90.23 (10.56)	54.5	84.09	95.45	97.73	100.0	
		Week 110	Sparsentan	119	86 (72.3)	87.68 (14.89)	6.8	81.82	93.18	97.73	100.0	
			Irbesartan	107	63 (58.9)	90.95 (13.36)	6.8	86.36	93.18	97.73	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	119	91 (76.5)	1.40 (10.90)	-22.7	-4.55	2.27	4.55	63.6	0.23 [-0.09, 0.55]
			Irbesartan	107	65 (60.7)	-1.71 (16.77)	-90.9	-4.55	0.00	2.27	29.5	
		Week 48	Sparsentan	119	96 (80.7)	-0.50 (18.01)	-100.0	-3.41	0.00	4.55	59.1	-0.05 [-0.37, 0.26]
			Irbesartan	107	64 (59.8)	0.28 (8.62)	-18.2	-3.41	1.14	4.55	34.1	
		Week 70	Sparsentan	119	96 (80.7)	-1.16 (12.74)	-50.0	-4.55	0.00	4.55	22.7	-0.08 [-0.38, 0.23]
			Irbesartan	107	71 (66.4)	-0.22 (11.29)	-59.1	-4.55	0.00	4.55	31.8	
		Week 94	Sparsentan	119	88 (73.9)	-0.34 (13.02)	-34.1	-4.55	0.00	4.55	68.2	-0.01 [-0.33, 0.31]
			Irbesartan	107	67 (62.6)	-0.20 (8.91)	-34.1	-4.55	0.00	4.55	20.5	
		Week 110	Sparsentan	119	86 (72.3)	-0.48 (17.00)	-84.1	-4.55	0.00	4.55	68.2	-0.05 [-0.38, 0.27]
			Irbesartan	107	63 (58.9)	0.32 (13.38)	-81.8	-2.27	0.00	4.55	22.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Randomization strata												
eGFR Low and UP High	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	71	63 (88.7)	90.98 (8.33)	63.6	86.36	93.18	97.73	100.0	
			Irbesartan	74	63 (85.1)	86.51 (13.18)	38.6	81.82	88.64	95.45	100.0	
		Week 24	Sparsentan	71	54 (76.1)	89.77 (9.86)	50.0	86.36	93.18	97.73	100.0	
			Irbesartan	74	40 (54.1)	86.25 (13.71)	45.5	82.95	88.64	95.45	100.0	
		Week 48	Sparsentan	71	51 (71.8)	90.55 (10.07)	65.9	84.09	93.18	100.00	100.0	
			Irbesartan	74	37 (50.0)	83.97 (17.24)	36.4	77.27	90.91	97.73	100.0	
		Week 70	Sparsentan	71	57 (80.3)	87.60 (13.97)	38.6	86.36	93.18	95.45	100.0	
			Irbesartan	74	37 (50.0)	85.57 (16.84)	36.4	84.09	90.91	97.73	100.0	
		Week 94	Sparsentan	71	51 (71.8)	87.97 (11.84)	52.3	84.09	90.91	95.45	100.0	
			Irbesartan	74	37 (50.0)	84.52 (15.59)	36.4	79.55	88.64	95.45	100.0	
		Week 110	Sparsentan	71	53 (74.6)	88.64 (11.79)	43.2	81.82	93.18	97.73	100.0	
			Irbesartan	74	36 (48.6)	85.80 (14.83)	45.5	77.27	90.91	97.73	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	71	54 (76.1)	-1.81 (8.13)	-25.0	-4.55	-2.27	2.27	25.0	-0.11 [-0.52, 0.30]
			Irbesartan	74	40 (54.1)	-0.80 (10.85)	-22.7	-6.82	-1.14	2.27	52.3	
		Week 48	Sparsentan	71	51 (71.8)	-0.53 (9.05)	-20.5	-6.82	0.00	4.55	27.3	0.36 [-0.07, 0.79]
			Irbesartan	74	37 (50.0)	-4.36 (12.46)	-52.3	-9.09	0.00	2.27	11.4	
		Week 70	Sparsentan	71	57 (80.3)	-3.47 (11.80)	-45.5	-6.82	0.00	2.27	18.2	-0.16 [-0.57, 0.26]
			Irbesartan	74	37 (50.0)	-1.72 (10.08)	-22.7	-9.09	0.00	2.27	31.8	
		Week 94	Sparsentan	71	51 (71.8)	-2.99 (7.50)	-20.5	-6.82	-2.27	0.00	13.6	-0.02 [-0.44, 0.40]
			Irbesartan	74	37 (50.0)	-2.83 (8.94)	-22.7	-6.82	0.00	2.27	18.2	
		Week 110	Sparsentan	71	53 (74.6)	-3.00 (9.04)	-27.3	-6.82	-2.27	2.27	18.2	-0.33 [-0.76, 0.09]
			Irbesartan	74	36 (48.6)	0.06 (9.32)	-18.2	-6.82	0.00	4.55	22.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR Low and UP Low	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	55	52 (94.5)	86.28 (14.66)	31.8	81.82	88.64	96.59	100.0	
			Irbesartan	55	50 (90.9)	90.45 (7.33)	75.0	84.09	92.05	95.45	100.0	
		Week 24	Sparsentan	55	43 (78.2)	87.95 (10.62)	63.6	79.55	90.91	97.73	100.0	
			Irbesartan	55	37 (67.3)	91.58 (8.95)	68.2	88.64	95.45	97.73	100.0	
		Week 48	Sparsentan	55	43 (78.2)	84.25 (21.53)	0.0	79.55	90.91	95.45	100.0	
			Irbesartan	55	35 (63.6)	89.55 (9.99)	61.4	84.09	90.91	100.00	100.0	
		Week 70	Sparsentan	55	42 (76.4)	88.47 (11.99)	54.5	79.55	93.18	97.73	100.0	
			Irbesartan	55	39 (70.9)	89.10 (10.48)	54.5	84.09	90.91	97.73	100.0	
		Week 94	Sparsentan	55	41 (74.5)	86.97 (14.00)	45.5	79.55	90.91	97.73	100.0	
			Irbesartan	55	39 (70.9)	89.74 (9.93)	59.1	84.09	90.91	97.73	100.0	
		Week 110	Sparsentan	55	37 (67.3)	84.28 (17.84)	6.8	77.27	86.36	97.73	100.0	
			Irbesartan	55	34 (61.8)	88.84 (10.96)	59.1	81.82	92.05	97.73	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	55	43 (78.2)	2.54 (13.73)	-18.2	-6.82	0.00	6.82	63.6	0.12 [-0.32, 0.56]
			Irbesartan	55	37 (67.3)	1.23 (7.62)	-18.2	-2.27	0.00	4.55	20.5	
		Week 48	Sparsentan	55	43 (78.2)	-1.69 (25.72)	-100.0	-4.55	0.00	9.09	59.1	-0.06 [-0.50, 0.39]
			Irbesartan	55	35 (63.6)	-0.58 (7.80)	-15.9	-4.55	0.00	4.55	20.5	
		Week 70	Sparsentan	55	42 (76.4)	1.57 (10.58)	-22.7	-4.55	2.27	6.82	25.0	0.23 [-0.20, 0.67]
			Irbesartan	55	39 (70.9)	-0.70 (8.60)	-27.3	-4.55	0.00	4.55	20.5	
		Week 94	Sparsentan	55	41 (74.5)	1.94 (17.06)	-34.1	-4.55	0.00	6.82	68.2	0.21 [-0.23, 0.65]
			Irbesartan	55	39 (70.9)	-0.99 (9.41)	-34.1	-4.55	0.00	4.55	20.5	
		Week 110	Sparsentan	55	37 (67.3)	-0.80 (22.33)	-84.1	-6.82	0.00	6.82	68.2	0.04 [-0.43, 0.50]
			Irbesartan	55	34 (61.8)	-1.47 (9.38)	-27.3	-4.55	0.00	2.27	20.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP High	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	37	35 (94.6)	88.05 (9.38)	65.9	84.09	88.64	97.73	100.0	
			Irbesartan	36	33 (91.7)	89.60 (10.68)	50.0	84.09	93.18	97.73	100.0	
		Week 24	Sparsentan	37	26 (70.3)	87.85 (19.12)	4.5	84.09	90.91	100.00	100.0	
			Irbesartan	36	26 (72.2)	88.29 (17.41)	11.4	86.36	93.18	97.73	100.0	
		Week 48	Sparsentan	37	33 (89.2)	88.43 (11.37)	61.4	81.82	90.91	97.73	100.0	
			Irbesartan	36	24 (66.7)	88.07 (12.07)	47.7	84.09	90.91	95.45	100.0	
		Week 70	Sparsentan	37	31 (83.8)	85.70 (17.76)	27.3	81.82	90.91	97.73	100.0	
			Irbesartan	36	25 (69.4)	86.36 (18.16)	29.5	86.36	90.91	95.45	100.0	
		Week 94	Sparsentan	37	27 (73.0)	87.12 (10.64)	63.6	79.55	90.91	95.45	100.0	
			Irbesartan	36	24 (66.7)	88.54 (14.96)	29.5	84.09	93.18	97.73	100.0	
		Week 110	Sparsentan	37	26 (70.3)	91.43 (9.19)	59.1	88.64	93.18	97.73	100.0	
			Irbesartan	36	22 (61.1)	87.19 (19.72)	6.8	86.36	92.05	97.73	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	37	26 (70.3)	-0.52 (16.88)	-72.7	-2.27	1.14	9.09	22.7	0.01 [-0.54, 0.55]
			Irbesartan	36	26 (72.2)	-0.61 (17.82)	-77.3	-4.55	1.14	9.09	29.5	
		Week 48	Sparsentan	37	33 (89.2)	0.41 (9.53)	-22.7	-4.55	0.00	4.55	20.5	0.15 [-0.37, 0.68]
			Irbesartan	36	24 (66.7)	-1.23 (12.08)	-27.3	-6.82	0.00	2.27	34.1	
		Week 70	Sparsentan	37	31 (83.8)	-2.57 (16.66)	-61.4	-4.55	0.00	4.55	22.7	0.05 [-0.48, 0.57]
			Irbesartan	36	25 (69.4)	-3.27 (14.12)	-59.1	-4.55	-2.27	2.27	15.9	
		Week 94	Sparsentan	37	27 (73.0)	-1.35 (11.59)	-29.5	-6.82	0.00	4.55	25.0	0.04 [-0.51, 0.59]
			Irbesartan	36	24 (66.7)	-1.80 (12.25)	-45.5	-5.68	0.00	3.41	20.5	
		Week 110	Sparsentan	37	26 (70.3)	2.71 (11.82)	-31.8	-2.27	2.27	6.82	34.1	0.41 [-0.16, 0.99]
			Irbesartan	36	22 (61.1)	-3.93 (19.98)	-81.8	-4.55	-1.14	4.55	22.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP Low	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	39	37 (94.9)	89.56 (11.19)	50.0	86.36	90.91	97.73	100.0	
			Irbesartan	37	36 (97.3)	91.92 (10.83)	52.3	89.77	95.45	97.73	100.0	
		Week 24	Sparsentan	39	34 (87.2)	90.64 (10.79)	54.5	86.36	94.32	97.73	100.0	
			Irbesartan	37	28 (75.7)	83.60 (25.14)	4.5	79.55	94.32	97.73	100.0	
		Week 48	Sparsentan	39	35 (89.7)	91.10 (9.66)	65.9	88.64	93.18	97.73	100.0	
			Irbesartan	37	28 (75.7)	93.91 (8.46)	65.9	92.05	96.59	100.00	100.0	
		Week 70	Sparsentan	39	30 (76.9)	88.64 (11.59)	59.1	84.09	92.05	97.73	100.0	
			Irbesartan	37	29 (78.4)	94.51 (6.83)	68.2	90.91	95.45	100.00	100.0	
		Week 94	Sparsentan	39	32 (82.1)	88.14 (12.21)	52.3	82.95	90.91	97.73	100.0	
			Irbesartan	37	30 (81.1)	89.24 (15.90)	25.0	86.36	95.45	100.00	100.0	
		Week 110	Sparsentan	39	33 (84.6)	88.15 (12.21)	52.3	79.55	90.91	97.73	100.0	
			Irbesartan	37	29 (78.4)	92.16 (8.00)	75.0	88.64	95.45	100.00	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	39	34 (87.2)	1.07 (7.59)	-22.7	0.00	2.27	4.55	13.6	0.46 [-0.05, 0.96]
			Irbesartan	37	28 (75.7)	-6.82 (24.31)	-90.9	-4.55	0.00	2.27	15.9	
		Week 48	Sparsentan	39	35 (89.7)	1.95 (6.89)	-11.4	-2.27	2.27	6.82	15.9	0.22 [-0.28, 0.72]
			Irbesartan	37	28 (75.7)	0.49 (6.13)	-15.9	-2.27	1.14	2.27	15.9	
		Week 70	Sparsentan	39	30 (76.9)	-0.76 (11.88)	-38.6	-4.55	2.27	6.82	13.6	-0.12 [-0.63, 0.39]
			Irbesartan	37	29 (78.4)	0.39 (7.29)	-13.6	-2.27	0.00	4.55	25.0	
		Week 94	Sparsentan	39	32 (82.1)	-0.99 (10.16)	-25.0	-6.82	0.00	5.68	15.9	0.19 [-0.31, 0.69]
			Irbesartan	37	30 (81.1)	-3.33 (14.07)	-63.6	-6.82	0.00	2.27	13.6	
		Week 110	Sparsentan	39	33 (84.6)	-1.17 (12.97)	-45.5	-6.82	0.00	4.55	27.3	-0.07 [-0.57, 0.43]
			Irbesartan	37	29 (78.4)	-0.39 (7.56)	-20.5	-4.55	0.00	2.27	11.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 1												
< 60 mL/min/1.73 m**2	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	127	116 (91.3)	88.99 (11.76)	31.8	84.09	90.91	97.73	100.0	
			Irbesartan	129	114 (88.4)	88.62 (11.07)	38.6	84.09	90.91	95.45	100.0	
		Week 24	Sparsentan	127	98 (77.2)	88.82 (10.06)	50.0	84.09	90.91	95.45	100.0	
			Irbesartan	129	80 (62.0)	87.78 (15.06)	4.5	84.09	92.05	97.73	100.0	
		Week 48	Sparsentan	127	95 (74.8)	88.18 (16.14)	0.0	84.09	90.91	97.73	100.0	
			Irbesartan	129	74 (57.4)	87.62 (13.97)	36.4	79.55	93.18	97.73	100.0	
		Week 70	Sparsentan	127	100 (78.7)	87.68 (13.33)	38.6	81.82	93.18	95.45	100.0	
			Irbesartan	129	78 (60.5)	88.00 (13.71)	36.4	84.09	90.91	97.73	100.0	
		Week 94	Sparsentan	127	92 (72.4)	87.48 (12.23)	45.5	80.68	90.91	97.73	100.0	
			Irbesartan	129	77 (59.7)	87.66 (13.47)	36.4	81.82	90.91	97.73	100.0	
		Week 110	Sparsentan	127	92 (72.4)	86.51 (14.93)	6.8	78.41	90.91	97.73	100.0	
			Irbesartan	129	72 (55.8)	87.72 (13.00)	45.5	81.82	90.91	97.73	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	127	98 (77.2)	-0.09 (11.06)	-25.0	-4.55	-1.14	4.55	63.6	0.08 [-0.22, 0.37]
			Irbesartan	129	80 (62.0)	-1.02 (13.75)	-90.9	-4.55	0.00	2.27	52.3	
		Week 48	Sparsentan	127	95 (74.8)	-0.72 (18.19)	-100.0	-4.55	0.00	4.55	59.1	0.07 [-0.23, 0.37]
			Irbesartan	129	74 (57.4)	-1.78 (10.37)	-52.3	-4.55	0.00	2.27	20.5	
		Week 70	Sparsentan	127	100 (78.7)	-1.77 (12.06)	-45.5	-4.55	0.00	4.55	25.0	-0.08 [-0.38, 0.22]
			Irbesartan	129	78 (60.5)	-0.90 (9.01)	-27.3	-4.55	0.00	2.27	31.8	
		Week 94	Sparsentan	127	92 (72.4)	-0.96 (12.69)	-27.3	-6.82	-2.27	2.27	68.2	0.05 [-0.25, 0.36]
			Irbesartan	129	77 (59.7)	-1.56 (9.24)	-34.1	-4.55	0.00	4.55	20.5	
		Week 110	Sparsentan	127	92 (72.4)	-2.59 (16.34)	-84.1	-7.95	0.00	2.27	68.2	-0.15 [-0.46, 0.16]
			Irbesartan	129	72 (55.8)	-0.51 (9.27)	-27.3	-4.55	0.00	4.55	22.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	49	47 (95.9)	88.83 (9.65)	50.0	84.09	88.64	97.73	100.0	
			Irbesartan	48	44 (91.7)	89.51 (10.53)	50.0	86.36	93.18	97.73	100.0	
		Week 24	Sparsentan	49	38 (77.6)	88.52 (17.64)	4.5	84.09	94.32	97.73	100.0	
			Irbesartan	48	31 (64.6)	88.12 (16.30)	11.4	84.09	93.18	97.73	100.0	
		Week 48	Sparsentan	49	44 (89.8)	88.58 (11.60)	54.5	82.95	92.05	97.73	100.0	
			Irbesartan	48	32 (66.7)	87.57 (13.33)	47.7	84.09	90.91	100.00	100.0	
		Week 70	Sparsentan	49	38 (77.6)	88.94 (12.12)	40.9	84.09	92.05	97.73	100.0	
			Irbesartan	48	32 (66.7)	86.22 (17.13)	29.5	86.36	90.91	97.73	100.0	
		Week 94	Sparsentan	49	39 (79.6)	87.88 (12.60)	50.0	86.36	90.91	97.73	100.0	
			Irbesartan	48	34 (70.8)	85.16 (16.58)	25.0	81.82	88.64	95.45	100.0	
		Week 110	Sparsentan	49	36 (73.5)	90.15 (9.93)	59.1	87.50	93.18	97.73	100.0	
			Irbesartan	48	32 (66.7)	87.43 (16.67)	6.8	84.09	90.91	96.59	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	49	38 (77.6)	-0.84 (14.37)	-72.7	-2.27	2.27	4.55	13.6	-0.02 [-0.49, 0.46]
			Irbesartan	48	31 (64.6)	-0.59 (16.21)	-77.3	-4.55	2.27	4.55	29.5	
		Week 48	Sparsentan	49	44 (89.8)	-0.15 (8.90)	-29.5	-4.55	0.00	4.55	18.2	0.23 [-0.23, 0.69]
			Irbesartan	48	32 (66.7)	-2.41 (10.89)	-27.3	-6.82	-2.27	2.27	34.1	
		Week 70	Sparsentan	49	38 (77.6)	-0.18 (10.95)	-50.0	-2.27	2.27	4.55	13.6	0.39 [-0.08, 0.87]
			Irbesartan	48	32 (66.7)	-4.76 (12.33)	-59.1	-7.95	-2.27	1.14	13.6	
		Week 94	Sparsentan	49	39 (79.6)	-1.28 (10.28)	-34.1	-2.27	0.00	4.55	15.9	0.35 [-0.12, 0.81]
			Irbesartan	48	34 (70.8)	-5.61 (14.65)	-63.6	-9.09	-3.41	0.00	20.5	
		Week 110	Sparsentan	49	36 (73.5)	1.01 (11.11)	-31.8	-5.68	0.00	6.82	27.3	0.36 [-0.12, 0.84]
			Irbesartan	48	32 (66.7)	-3.98 (16.29)	-81.8	-6.82	-2.27	2.27	22.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	26	24 (92.3)	88.16 (11.84)	61.4	81.82	89.77	97.73	100.0	
			Irbesartan	25	24 (96.0)	91.57 (11.77)	52.3	87.50	96.59	100.00	100.0	
		Week 24	Sparsentan	26	21 (80.8)	91.77 (8.87)	70.5	88.64	90.91	100.00	100.0	
			Irbesartan	25	20 (80.0)	86.02 (22.97)	4.5	85.23	95.45	97.73	100.0	
		Week 48	Sparsentan	26	23 (88.5)	90.12 (11.13)	61.4	81.82	93.18	100.00	100.0	
			Irbesartan	25	18 (72.0)	94.32 (5.69)	81.8	88.64	94.32	100.00	100.0	
		Week 70	Sparsentan	26	22 (84.6)	85.33 (18.46)	27.3	79.55	89.77	100.00	100.0	
			Irbesartan	25	20 (80.0)	95.91 (3.58)	88.6	94.32	95.45	100.00	100.0	
		Week 94	Sparsentan	26	20 (76.9)	87.50 (12.13)	63.6	77.27	92.05	98.86	100.0	
			Irbesartan	25	19 (76.0)	93.90 (9.99)	70.5	95.45	97.73	100.00	100.0	
		Week 110	Sparsentan	26	21 (80.8)	90.37 (10.46)	68.2	84.09	93.18	100.00	100.0	
			Irbesartan	25	17 (68.0)	93.32 (8.78)	75.0	88.64	97.73	100.00	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	26	21 (80.8)	3.57 (7.56)	-9.1	0.00	2.27	9.09	22.7	0.52 [-0.10, 1.14]
			Irbesartan	25	20 (80.0)	-4.66 (21.30)	-86.4	-3.41	-1.14	2.27	15.9	
		Week 48	Sparsentan	26	23 (88.5)	2.47 (9.52)	-18.2	-2.27	0.00	11.36	20.5	0.22 [-0.40, 0.83]
			Irbesartan	25	18 (72.0)	0.63 (7.05)	-15.9	-2.27	2.27	6.82	13.6	
		Week 70	Sparsentan	26	22 (84.6)	-2.27 (17.66)	-61.4	-9.09	0.00	6.82	22.7	-0.38 [-0.99, 0.23]
			Irbesartan	25	20 (80.0)	3.07 (7.95)	-9.1	-2.27	1.14	6.82	25.0	
		Week 94	Sparsentan	26	20 (76.9)	-0.11 (12.61)	-29.5	-4.55	1.14	7.95	25.0	-0.13 [-0.76, 0.50]
			Irbesartan	25	19 (76.0)	1.32 (8.55)	-25.0	0.00	0.00	2.27	13.6	
		Week 110	Sparsentan	26	21 (80.8)	2.16 (11.05)	-18.2	-4.55	2.27	6.82	34.1	0.10 [-0.53, 0.74]
			Irbesartan	25	17 (68.0)	1.07 (9.61)	-20.5	0.00	0.00	6.82	15.9	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 2												
< 45 mL/min/1.73 m**2	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	82	73 (89.0)	87.58 (11.81)	31.8	81.82	90.91	95.45	100.0	
			Irbesartan	80	69 (86.3)	87.09 (12.66)	38.6	81.82	90.91	95.45	100.0	
		Week 24	Sparsentan	82	64 (78.0)	88.81 (9.58)	50.0	84.09	90.91	95.45	100.0	
			Irbesartan	80	48 (60.0)	87.12 (13.59)	45.5	82.95	90.91	96.59	100.0	
		Week 48	Sparsentan	82	61 (74.4)	86.74 (14.89)	0.0	79.55	90.91	95.45	100.0	
			Irbesartan	80	43 (53.8)	84.73 (16.75)	36.4	72.73	90.91	97.73	100.0	
		Week 70	Sparsentan	82	65 (79.3)	86.75 (13.46)	38.6	79.55	93.18	95.45	100.0	
			Irbesartan	80	45 (56.3)	84.49 (16.51)	36.4	77.27	88.64	97.73	100.0	
		Week 94	Sparsentan	82	60 (73.2)	86.52 (13.02)	45.5	78.41	90.91	95.45	100.0	
			Irbesartan	80	47 (58.8)	84.48 (15.25)	36.4	77.27	88.64	97.73	100.0	
		Week 110	Sparsentan	82	56 (68.3)	85.59 (16.52)	6.8	77.27	90.91	96.59	100.0	
			Irbesartan	80	44 (55.0)	84.81 (14.80)	45.5	78.41	88.64	97.73	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	82	64 (78.0)	0.67 (11.57)	-22.7	-4.55	-1.14	4.55	63.6	0.10 [-0.27, 0.48]
			Irbesartan	80	48 (60.0)	-0.47 (10.77)	-22.7	-5.68	0.00	2.27	52.3	
		Week 48	Sparsentan	82	61 (74.4)	-0.89 (17.08)	-90.9	-6.82	-2.27	4.55	59.1	0.14 [-0.25, 0.53]
			Irbesartan	80	43 (53.8)	-3.07 (12.15)	-52.3	-9.09	0.00	2.27	20.5	
		Week 70	Sparsentan	82	65 (79.3)	-1.05 (11.39)	-40.9	-4.55	0.00	4.55	25.0	0.10 [-0.28, 0.48]
			Irbesartan	80	45 (56.3)	-2.17 (10.70)	-27.3	-9.09	0.00	2.27	31.8	
		Week 94	Sparsentan	82	60 (73.2)	-1.10 (12.81)	-25.0	-6.82	-2.27	3.41	68.2	0.14 [-0.24, 0.52]
			Irbesartan	80	47 (58.8)	-2.80 (11.00)	-34.1	-9.09	0.00	2.27	20.5	
		Week 110	Sparsentan	82	56 (68.3)	-2.64 (17.71)	-84.1	-7.95	-1.14	2.27	68.2	-0.11 [-0.50, 0.29]
			Irbesartan	80	44 (55.0)	-0.98 (11.04)	-27.3	-7.95	0.00	4.55	22.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
45 to < 60 mL/min/1.73 m**2	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	45	43 (95.6)	91.38 (11.41)	38.6	86.36	95.45	100.00	100.0	
			Irbesartan	49	45 (91.8)	90.96 (7.59)	68.2	86.36	93.18	97.73	100.0	
		Week 24	Sparsentan	45	34 (75.6)	88.84 (11.05)	59.1	81.82	93.18	95.45	100.0	
			Irbesartan	49	32 (65.3)	88.78 (17.21)	4.5	86.36	94.32	97.73	100.0	
		Week 48	Sparsentan	45	34 (75.6)	90.78 (18.12)	0.0	90.91	97.73	100.00	100.0	
			Irbesartan	49	31 (63.3)	91.64 (7.29)	77.3	86.36	93.18	97.73	100.0	
		Week 70	Sparsentan	45	35 (77.8)	89.42 (13.09)	50.0	81.82	95.45	100.00	100.0	
			Irbesartan	49	33 (67.3)	92.77 (6.05)	79.5	88.64	93.18	97.73	100.0	
		Week 94	Sparsentan	45	32 (71.1)	89.28 (10.57)	59.1	82.95	92.05	97.73	100.0	
			Irbesartan	49	30 (61.2)	92.65 (8.02)	68.2	88.64	95.45	97.73	100.0	
		Week 110	Sparsentan	45	36 (80.0)	87.94 (12.15)	52.3	79.55	93.18	97.73	100.0	
			Irbesartan	49	28 (57.1)	92.29 (7.73)	75.0	87.50	94.32	98.86	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	45	34 (75.6)	-1.54 (10.04)	-25.0	-4.55	-1.14	2.27	36.4	0.02 [-0.46, 0.50]
			Irbesartan	49	32 (65.3)	-1.85 (17.46)	-90.9	-3.41	0.00	4.55	15.9	
		Week 48	Sparsentan	45	34 (75.6)	-0.40 (20.29)	-100.0	-2.27	0.00	4.55	38.6	-0.03 [-0.51, 0.46]
			Irbesartan	49	31 (63.3)	0.00 (7.02)	-13.6	-2.27	0.00	4.55	15.9	
		Week 70	Sparsentan	45	35 (77.8)	-3.12 (13.30)	-45.5	-6.82	0.00	4.55	22.7	-0.38 [-0.86, 0.10]
			Irbesartan	49	33 (67.3)	0.83 (5.71)	-13.6	-2.27	2.27	4.55	13.6	
		Week 94	Sparsentan	45	32 (71.1)	-0.71 (12.68)	-27.3	-4.55	-1.14	2.27	40.9	-0.11 [-0.61, 0.39]
			Irbesartan	49	30 (61.2)	0.38 (5.03)	-11.4	-2.27	1.14	4.55	6.8	
		Week 110	Sparsentan	45	36 (80.0)	-2.53 (14.19)	-45.5	-6.82	0.00	2.27	36.4	-0.25 [-0.74, 0.25]
			Irbesartan	49	28 (57.1)	0.24 (5.54)	-13.6	-2.27	0.00	3.41	11.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	49	47 (95.9)	88.83 (9.65)	50.0	84.09	88.64	97.73	100.0	
			Irbesartan	48	44 (91.7)	89.51 (10.53)	50.0	86.36	93.18	97.73	100.0	
		Week 24	Sparsentan	49	38 (77.6)	88.52 (17.64)	4.5	84.09	94.32	97.73	100.0	
			Irbesartan	48	31 (64.6)	88.12 (16.30)	11.4	84.09	93.18	97.73	100.0	
		Week 48	Sparsentan	49	44 (89.8)	88.58 (11.60)	54.5	82.95	92.05	97.73	100.0	
			Irbesartan	48	32 (66.7)	87.57 (13.33)	47.7	84.09	90.91	100.00	100.0	
		Week 70	Sparsentan	49	38 (77.6)	88.94 (12.12)	40.9	84.09	92.05	97.73	100.0	
			Irbesartan	48	32 (66.7)	86.22 (17.13)	29.5	86.36	90.91	97.73	100.0	
		Week 94	Sparsentan	49	39 (79.6)	87.88 (12.60)	50.0	86.36	90.91	97.73	100.0	
			Irbesartan	48	34 (70.8)	85.16 (16.58)	25.0	81.82	88.64	95.45	100.0	
		Week 110	Sparsentan	49	36 (73.5)	90.15 (9.93)	59.1	87.50	93.18	97.73	100.0	
			Irbesartan	48	32 (66.7)	87.43 (16.67)	6.8	84.09	90.91	96.59	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	49	38 (77.6)	-0.84 (14.37)	-72.7	-2.27	2.27	4.55	13.6	-0.02 [-0.49, 0.46]
			Irbesartan	48	31 (64.6)	-0.59 (16.21)	-77.3	-4.55	2.27	4.55	29.5	
		Week 48	Sparsentan	49	44 (89.8)	-0.15 (8.90)	-29.5	-4.55	0.00	4.55	18.2	0.23 [-0.23, 0.69]
			Irbesartan	48	32 (66.7)	-2.41 (10.89)	-27.3	-6.82	-2.27	2.27	34.1	
		Week 70	Sparsentan	49	38 (77.6)	-0.18 (10.95)	-50.0	-2.27	2.27	4.55	13.6	0.39 [-0.08, 0.87]
			Irbesartan	48	32 (66.7)	-4.76 (12.33)	-59.1	-7.95	-2.27	1.14	13.6	
		Week 94	Sparsentan	49	39 (79.6)	-1.28 (10.28)	-34.1	-2.27	0.00	4.55	15.9	0.35 [-0.12, 0.81]
			Irbesartan	48	34 (70.8)	-5.61 (14.65)	-63.6	-9.09	-3.41	0.00	20.5	
		Week 110	Sparsentan	49	36 (73.5)	1.01 (11.11)	-31.8	-5.68	0.00	6.82	27.3	0.36 [-0.12, 0.84]
			Irbesartan	48	32 (66.7)	-3.98 (16.29)	-81.8	-6.82	-2.27	2.27	22.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	26	24 (92.3)	88.16 (11.84)	61.4	81.82	89.77	97.73	100.0	
			Irbesartan	25	24 (96.0)	91.57 (11.77)	52.3	87.50	96.59	100.00	100.0	
		Week 24	Sparsentan	26	21 (80.8)	91.77 (8.87)	70.5	88.64	90.91	100.00	100.0	
			Irbesartan	25	20 (80.0)	86.02 (22.97)	4.5	85.23	95.45	97.73	100.0	
		Week 48	Sparsentan	26	23 (88.5)	90.12 (11.13)	61.4	81.82	93.18	100.00	100.0	
			Irbesartan	25	18 (72.0)	94.32 (5.69)	81.8	88.64	94.32	100.00	100.0	
		Week 70	Sparsentan	26	22 (84.6)	85.33 (18.46)	27.3	79.55	89.77	100.00	100.0	
			Irbesartan	25	20 (80.0)	95.91 (3.58)	88.6	94.32	95.45	100.00	100.0	
		Week 94	Sparsentan	26	20 (76.9)	87.50 (12.13)	63.6	77.27	92.05	98.86	100.0	
			Irbesartan	25	19 (76.0)	93.90 (9.99)	70.5	95.45	97.73	100.00	100.0	
		Week 110	Sparsentan	26	21 (80.8)	90.37 (10.46)	68.2	84.09	93.18	100.00	100.0	
			Irbesartan	25	17 (68.0)	93.32 (8.78)	75.0	88.64	97.73	100.00	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	26	21 (80.8)	3.57 (7.56)	-9.1	0.00	2.27	9.09	22.7	0.52 [-0.10, 1.14]
			Irbesartan	25	20 (80.0)	-4.66 (21.30)	-86.4	-3.41	-1.14	2.27	15.9	
		Week 48	Sparsentan	26	23 (88.5)	2.47 (9.52)	-18.2	-2.27	0.00	11.36	20.5	0.22 [-0.40, 0.83]
			Irbesartan	25	18 (72.0)	0.63 (7.05)	-15.9	-2.27	2.27	6.82	13.6	
		Week 70	Sparsentan	26	22 (84.6)	-2.27 (17.66)	-61.4	-9.09	0.00	6.82	22.7	-0.38 [-0.99, 0.23]
			Irbesartan	25	20 (80.0)	3.07 (7.95)	-9.1	-2.27	1.14	6.82	25.0	
		Week 94	Sparsentan	26	20 (76.9)	-0.11 (12.61)	-29.5	-4.55	1.14	7.95	25.0	-0.13 [-0.76, 0.50]
			Irbesartan	25	19 (76.0)	1.32 (8.55)	-25.0	0.00	0.00	2.27	13.6	
		Week 110	Sparsentan	26	21 (80.8)	2.16 (11.05)	-18.2	-4.55	2.27	6.82	34.1	0.10 [-0.53, 0.74]
			Irbesartan	25	17 (68.0)	1.07 (9.61)	-20.5	0.00	0.00	6.82	15.9	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline urine protein excretion												
<= 1.75 g/day	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	98	93 (94.9)	87.85 (13.45)	31.8	84.09	90.91	97.73	100.0	
			Irbesartan	93	83 (89.2)	90.47 (9.47)	52.3	86.36	93.18	97.73	100.0	
		Week 24	Sparsentan	98	80 (81.6)	88.55 (10.53)	54.5	81.82	90.91	97.73	100.0	
			Irbesartan	93	55 (59.1)	87.89 (19.21)	4.5	84.09	95.45	97.73	100.0	
		Week 48	Sparsentan	98	82 (83.7)	87.97 (17.09)	0.0	81.82	93.18	97.73	100.0	
			Irbesartan	93	57 (61.3)	91.71 (9.54)	65.9	88.64	93.18	100.00	100.0	
		Week 70	Sparsentan	98	75 (76.5)	87.24 (13.54)	40.9	79.55	90.91	97.73	100.0	
			Irbesartan	93	61 (65.6)	91.54 (9.38)	61.4	88.64	95.45	100.00	100.0	
		Week 94	Sparsentan	98	76 (77.6)	87.35 (12.63)	45.5	79.55	90.91	97.73	100.0	
			Irbesartan	93	63 (67.7)	88.28 (14.79)	25.0	81.82	93.18	97.73	100.0	
		Week 110	Sparsentan	98	75 (76.5)	87.06 (13.40)	43.2	77.27	90.91	97.73	100.0	
			Irbesartan	93	57 (61.3)	89.87 (10.86)	52.3	84.09	93.18	97.73	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	98	80 (81.6)	0.94 (11.43)	-22.7	-5.68	0.00	4.55	63.6	0.22 [-0.13, 0.56]
			Irbesartan	93	55 (59.1)	-2.27 (18.41)	-90.9	-2.27	0.00	4.55	20.5	
		Week 48	Sparsentan	98	82 (83.7)	0.19 (19.15)	-100.0	-2.27	0.00	6.82	59.1	0.01 [-0.33, 0.35]
			Irbesartan	93	57 (61.3)	0.04 (6.84)	-18.2	-2.27	0.00	2.27	20.5	
		Week 70	Sparsentan	98	75 (76.5)	-0.97 (12.79)	-50.0	-4.55	0.00	4.55	25.0	-0.08 [-0.41, 0.26]
			Irbesartan	93	61 (65.6)	-0.15 (7.51)	-15.9	-4.55	0.00	4.55	25.0	
		Week 94	Sparsentan	98	76 (77.6)	0.39 (13.85)	-27.3	-6.82	0.00	5.68	68.2	0.24 [-0.09, 0.58]
			Irbesartan	93	63 (67.7)	-2.78 (11.87)	-63.6	-6.82	0.00	2.27	20.5	
		Week 110	Sparsentan	98	75 (76.5)	-0.42 (15.81)	-45.5	-9.09	0.00	6.82	68.2	0.05 [-0.29, 0.40]
			Irbesartan	93	57 (61.3)	-1.12 (7.62)	-20.5	-4.55	0.00	2.27	20.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 1.75 g/day	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	104	94 (90.4)	89.82 (8.42)	65.9	84.09	90.91	97.73	100.0	
			Irbesartan	109	99 (90.8)	88.18 (12.11)	38.6	84.09	90.91	97.73	100.0	
		Week 24	Sparsentan	104	77 (74.0)	89.76 (13.69)	4.5	88.64	93.18	97.73	100.0	
			Irbesartan	109	76 (69.7)	87.38 (14.62)	11.4	84.09	90.91	95.45	100.0	
		Week 48	Sparsentan	104	80 (76.9)	89.18 (10.89)	54.5	82.95	90.91	97.73	100.0	
			Irbesartan	109	67 (61.5)	85.92 (15.01)	36.4	79.55	90.91	97.73	100.0	
		Week 70	Sparsentan	104	85 (81.7)	88.02 (14.13)	27.3	86.36	93.18	97.73	100.0	
			Irbesartan	109	69 (63.3)	86.33 (16.69)	29.5	84.09	90.91	97.73	100.0	
		Week 94	Sparsentan	104	75 (72.1)	87.82 (11.91)	50.0	84.09	90.91	95.45	100.0	
			Irbesartan	109	67 (61.5)	87.58 (13.50)	29.5	81.82	90.91	97.73	100.0	
		Week 110	Sparsentan	104	74 (71.2)	88.82 (13.35)	6.8	81.82	93.18	97.73	100.0	
			Irbesartan	109	64 (58.7)	87.14 (15.68)	6.8	81.82	92.05	97.73	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	104	77 (74.0)	-0.53 (11.77)	-72.7	-4.55	0.00	4.55	25.0	0.03 [-0.29, 0.35]
			Irbesartan	109	76 (69.7)	-0.90 (13.33)	-77.3	-5.68	0.00	2.27	52.3	
		Week 48	Sparsentan	104	80 (76.9)	-0.43 (9.38)	-29.5	-4.55	0.00	4.55	27.3	0.24 [-0.09, 0.57]
			Irbesartan	109	67 (61.5)	-2.99 (12.05)	-52.3	-9.09	0.00	2.27	34.1	
		Week 70	Sparsentan	104	85 (81.7)	-1.90 (12.60)	-61.4	-4.55	0.00	4.55	22.7	0.03 [-0.29, 0.34]
			Irbesartan	109	69 (63.3)	-2.21 (11.77)	-59.1	-4.55	0.00	2.27	31.8	
		Week 94	Sparsentan	104	75 (72.1)	-2.27 (9.77)	-34.1	-4.55	-2.27	2.27	25.0	-0.06 [-0.39, 0.27]
			Irbesartan	109	67 (61.5)	-1.66 (10.13)	-45.5	-6.82	0.00	4.55	20.5	
		Week 110	Sparsentan	104	74 (71.2)	-1.69 (13.40)	-84.1	-4.55	0.00	2.27	34.1	-0.03 [-0.36, 0.30]
			Irbesartan	109	64 (58.7)	-1.28 (14.32)	-81.8	-4.55	0.00	4.55	22.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline use of antihypertensives												
Yes	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	90	79 (87.8)	88.38 (10.79)	38.6	84.09	90.91	95.45	100.0	
			Irbesartan	88	76 (86.4)	88.88 (10.04)	38.6	84.09	90.91	95.45	100.0	
		Week 24	Sparsentan	90	66 (73.3)	88.81 (10.77)	50.0	84.09	90.91	97.73	100.0	
			Irbesartan	88	49 (55.7)	89.42 (9.27)	56.8	86.36	93.18	95.45	100.0	
		Week 48	Sparsentan	90	65 (72.2)	89.13 (10.79)	54.5	84.09	90.91	97.73	100.0	
			Irbesartan	88	47 (53.4)	88.88 (11.49)	47.7	86.36	93.18	95.45	100.0	
		Week 70	Sparsentan	90	68 (75.6)	86.80 (13.84)	38.6	81.82	90.91	95.45	100.0	
			Irbesartan	88	49 (55.7)	88.50 (12.00)	40.9	84.09	90.91	97.73	100.0	
		Week 94	Sparsentan	90	63 (70.0)	86.15 (13.39)	45.5	79.55	90.91	95.45	100.0	
			Irbesartan	88	54 (61.4)	87.54 (11.80)	36.4	81.82	90.91	97.73	100.0	
		Week 110	Sparsentan	90	63 (70.0)	88.17 (14.02)	6.8	81.82	93.18	97.73	100.0	
			Irbesartan	88	51 (58.0)	88.95 (10.53)	52.3	84.09	90.91	97.73	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	90	66 (73.3)	0.48 (10.40)	-25.0	-4.55	0.00	4.55	36.4	-0.01 [-0.38, 0.36]
			Irbesartan	88	49 (55.7)	0.56 (9.99)	-22.7	-4.55	0.00	4.55	52.3	
		Week 48	Sparsentan	90	65 (72.2)	1.08 (10.71)	-29.5	-2.27	0.00	4.55	38.6	0.19 [-0.18, 0.57]
			Irbesartan	88	47 (53.4)	-0.87 (9.50)	-27.3	-4.55	0.00	4.55	15.9	
		Week 70	Sparsentan	90	68 (75.6)	-2.47 (12.35)	-45.5	-7.95	0.00	4.55	25.0	-0.08 [-0.45, 0.28]
			Irbesartan	88	49 (55.7)	-1.58 (8.24)	-22.7	-4.55	0.00	2.27	18.2	
		Week 94	Sparsentan	90	63 (70.0)	-1.55 (11.86)	-34.1	-4.55	-2.27	4.55	40.9	0.08 [-0.28, 0.44]
			Irbesartan	88	54 (61.4)	-2.40 (8.82)	-22.7	-6.82	0.00	2.27	20.5	
		Week 110	Sparsentan	90	63 (70.0)	-0.11 (14.79)	-84.1	-4.55	0.00	4.55	36.4	-0.02 [-0.39, 0.35]
			Irbesartan	88	51 (58.0)	0.13 (7.75)	-18.2	-2.27	0.00	4.55	22.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	112	108 (96.4)	89.18 (11.57)	31.8	84.09	90.91	97.73	100.0	
			Irbesartan	114	106 (93.0)	89.47 (11.71)	47.7	84.09	93.18	97.73	100.0	
		Week 24	Sparsentan	112	91 (81.3)	89.39 (13.13)	4.5	86.36	93.18	97.73	100.0	
			Irbesartan	114	82 (71.9)	86.50 (19.75)	4.5	84.09	93.18	97.73	100.0	
		Week 48	Sparsentan	112	97 (86.6)	88.19 (16.33)	0.0	81.82	93.18	97.73	100.0	
			Irbesartan	114	77 (67.5)	88.40 (14.01)	36.4	84.09	90.91	100.00	100.0	
		Week 70	Sparsentan	112	92 (82.1)	88.29 (13.84)	27.3	81.82	93.18	97.73	100.0	
			Irbesartan	114	81 (71.1)	88.95 (15.07)	29.5	86.36	93.18	100.00	100.0	
		Week 94	Sparsentan	112	88 (78.6)	88.61 (11.30)	52.3	81.82	90.91	97.73	100.0	
			Irbesartan	114	76 (66.7)	88.19 (15.58)	25.0	82.95	95.45	98.86	100.0	
		Week 110	Sparsentan	112	86 (76.8)	87.76 (12.94)	43.2	79.55	92.05	97.73	100.0	
			Irbesartan	114	70 (61.4)	88.05 (15.58)	6.8	81.82	93.18	97.73	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	112	91 (81.3)	0.02 (12.43)	-72.7	-4.55	0.00	4.55	63.6	0.18 [-0.12, 0.48]
			Irbesartan	114	82 (71.9)	-2.69 (18.11)	-90.9	-4.55	0.00	4.55	29.5	
		Week 48	Sparsentan	112	97 (86.6)	-0.91 (17.43)	-100.0	-4.55	0.00	4.55	59.1	0.08 [-0.22, 0.38]
			Irbesartan	114	77 (67.5)	-2.04 (10.44)	-52.3	-4.55	0.00	2.27	34.1	
		Week 70	Sparsentan	112	92 (82.1)	-0.72 (12.90)	-61.4	-4.55	0.00	6.82	22.7	0.03 [-0.27, 0.33]
			Irbesartan	114	81 (71.1)	-1.04 (11.00)	-59.1	-4.55	0.00	4.55	31.8	
		Week 94	Sparsentan	112	88 (78.6)	-0.49 (12.20)	-29.5	-6.82	0.00	4.55	68.2	0.13 [-0.18, 0.44]
			Irbesartan	114	76 (66.7)	-2.06 (12.34)	-63.6	-4.55	0.00	2.27	20.5	
		Week 110	Sparsentan	112	86 (76.8)	-1.74 (14.55)	-45.5	-6.82	0.00	2.27	68.2	0.03 [-0.29, 0.35]
			Irbesartan	114	70 (61.4)	-2.18 (13.73)	-81.8	-6.82	0.00	4.55	22.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Time since renal biopsy												
<= 5 years	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	113	104 (92.0)	88.96 (11.04)	38.6	84.09	90.91	97.73	100.0	
			Irbesartan	127	118 (92.9)	88.66 (12.00)	38.6	84.09	90.91	97.73	100.0	
		Week 24	Sparsentan	113	88 (77.9)	90.55 (10.12)	50.0	86.36	93.18	97.73	100.0	
			Irbesartan	127	86 (67.7)	86.05 (19.07)	4.5	81.82	93.18	97.73	100.0	
		Week 48	Sparsentan	113	92 (81.4)	90.04 (13.52)	0.0	86.36	93.18	97.73	100.0	
			Irbesartan	127	85 (66.9)	88.32 (14.37)	36.4	86.36	93.18	100.00	100.0	
		Week 70	Sparsentan	113	90 (79.6)	87.55 (14.62)	27.3	81.82	93.18	97.73	100.0	
			Irbesartan	127	86 (67.7)	88.64 (14.91)	29.5	86.36	93.18	97.73	100.0	
		Week 94	Sparsentan	113	86 (76.1)	87.63 (12.97)	45.5	81.82	90.91	97.73	100.0	
			Irbesartan	127	86 (67.7)	88.37 (13.55)	29.5	81.82	93.18	97.73	100.0	
		Week 110	Sparsentan	113	88 (77.9)	89.46 (10.54)	50.0	82.95	92.05	97.73	100.0	
			Irbesartan	127	80 (63.0)	88.15 (14.42)	6.8	81.82	93.18	97.73	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	113	88 (77.9)	1.60 (8.50)	-22.7	-2.27	1.14	4.55	36.4	0.25 [-0.05, 0.54]
			Irbesartan	127	86 (67.7)	-1.98 (18.82)	-90.9	-4.55	0.00	4.55	52.3	
		Week 48	Sparsentan	113	92 (81.4)	1.24 (14.56)	-100.0	-2.27	0.00	6.82	38.6	0.18 [-0.12, 0.48]
			Irbesartan	127	85 (66.9)	-1.10 (10.89)	-52.3	-4.55	0.00	2.27	34.1	
		Week 70	Sparsentan	113	90 (79.6)	-1.99 (13.49)	-61.4	-4.55	0.00	4.55	25.0	-0.07 [-0.37, 0.22]
			Irbesartan	127	86 (67.7)	-1.11 (10.73)	-59.1	-4.55	0.00	4.55	25.0	
		Week 94	Sparsentan	113	86 (76.1)	-0.90 (11.51)	-34.1	-4.55	0.00	4.55	40.9	0.07 [-0.23, 0.37]
			Irbesartan	127	86 (67.7)	-1.61 (9.91)	-45.5	-6.82	0.00	4.55	20.5	
		Week 110	Sparsentan	113	88 (77.9)	0.31 (11.52)	-45.5	-4.55	0.00	4.55	36.4	0.11 [-0.19, 0.42]
			Irbesartan	127	80 (63.0)	-1.05 (12.74)	-81.8	-4.55	0.00	4.55	22.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 5 years	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	89	83 (93.3)	88.69 (11.52)	31.8	84.09	90.91	97.73	100.0	
			Irbesartan	75	64 (85.3)	90.27 (8.91)	52.3	86.36	93.18	96.59	100.0	
		Week 24	Sparsentan	89	69 (77.5)	87.35 (14.23)	4.5	81.82	90.91	97.73	100.0	
			Irbesartan	75	45 (60.0)	90.56 (10.07)	45.5	86.36	93.18	97.73	100.0	
		Week 48	Sparsentan	89	70 (78.7)	86.62 (15.22)	0.0	79.55	90.91	97.73	100.0	
			Irbesartan	75	39 (52.0)	89.16 (9.77)	61.4	84.09	90.91	95.45	100.0	
		Week 70	Sparsentan	89	70 (78.7)	87.79 (12.81)	40.9	81.82	93.18	95.45	100.0	
			Irbesartan	75	44 (58.7)	89.05 (12.01)	36.4	84.09	90.91	97.73	100.0	
		Week 94	Sparsentan	89	65 (73.0)	87.52 (11.29)	63.6	77.27	90.91	95.45	100.0	
			Irbesartan	75	44 (58.7)	87.04 (15.20)	25.0	81.82	88.64	97.73	100.0	
		Week 110	Sparsentan	89	61 (68.5)	85.73 (16.45)	6.8	77.27	93.18	97.73	100.0	
			Irbesartan	75	41 (54.7)	88.97 (12.11)	45.5	81.82	90.91	100.00	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	89	69 (77.5)	-1.55 (14.48)	-72.7	-6.82	-2.27	4.55	63.6	-0.09 [-0.46, 0.29]
			Irbesartan	75	45 (60.0)	-0.51 (5.85)	-18.2	-4.55	0.00	2.27	11.4	
		Week 48	Sparsentan	89	70 (78.7)	-1.88 (15.69)	-90.9	-6.82	-2.27	4.55	59.1	0.06 [-0.33, 0.45]
			Irbesartan	75	39 (52.0)	-2.68 (8.04)	-27.3	-6.82	-2.27	2.27	11.4	
		Week 70	Sparsentan	89	70 (78.7)	-0.78 (11.57)	-50.0	-4.55	0.00	4.55	22.7	0.07 [-0.31, 0.45]
			Irbesartan	75	44 (58.7)	-1.50 (8.57)	-15.9	-4.55	-1.14	2.27	31.8	
		Week 94	Sparsentan	89	65 (73.0)	-0.98 (12.78)	-27.3	-6.82	-2.27	2.27	68.2	0.19 [-0.20, 0.57]
			Irbesartan	75	44 (58.7)	-3.36 (12.86)	-63.6	-6.82	0.00	2.27	18.2	
		Week 110	Sparsentan	89	61 (68.5)	-3.02 (18.13)	-84.1	-9.09	-2.27	2.27	68.2	-0.10 [-0.50, 0.30]
			Irbesartan	75	41 (54.7)	-1.50 (9.13)	-18.2	-4.55	0.00	2.27	22.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: History of hypertension												
Yes	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	155	141 (91.0)	88.31 (10.78)	38.6	84.09	90.91	95.45	100.0	
			Irbesartan	161	142 (88.2)	89.34 (10.98)	38.6	84.09	93.18	97.73	100.0	
		Week 24	Sparsentan	155	119 (76.8)	88.92 (10.87)	50.0	84.09	93.18	97.73	100.0	
			Irbesartan	161	100 (62.1)	89.30 (13.32)	4.5	86.36	93.18	97.73	100.0	
		Week 48	Sparsentan	155	121 (78.1)	87.94 (13.44)	0.0	81.82	90.91	97.73	100.0	
			Irbesartan	161	95 (59.0)	88.66 (13.46)	36.4	84.09	93.18	97.73	100.0	
		Week 70	Sparsentan	155	123 (79.4)	87.84 (12.72)	38.6	81.82	93.18	97.73	100.0	
			Irbesartan	161	100 (62.1)	88.91 (13.98)	36.4	85.23	93.18	97.73	100.0	
		Week 94	Sparsentan	155	114 (73.5)	86.86 (12.33)	45.5	79.55	90.91	95.45	100.0	
			Irbesartan	161	101 (62.7)	87.56 (14.67)	25.0	81.82	90.91	97.73	100.0	
		Week 110	Sparsentan	155	112 (72.3)	87.60 (13.00)	6.8	81.82	90.91	97.73	100.0	
			Irbesartan	161	92 (57.1)	89.70 (11.16)	45.5	84.09	93.18	97.73	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	155	119 (76.8)	0.67 (8.86)	-25.0	-4.55	0.00	4.55	36.4	0.05 [-0.21, 0.32]
			Irbesartan	161	100 (62.1)	0.09 (12.56)	-90.9	-4.55	0.00	4.55	52.3	
		Week 48	Sparsentan	155	121 (78.1)	-0.11 (13.02)	-90.9	-4.55	0.00	4.55	38.6	0.12 [-0.15, 0.39]
			Irbesartan	161	95 (59.0)	-1.60 (10.71)	-52.3	-4.55	0.00	2.27	34.1	
		Week 70	Sparsentan	155	123 (79.4)	-0.76 (11.01)	-45.5	-4.55	0.00	4.55	25.0	-0.03 [-0.29, 0.23]
			Irbesartan	161	100 (62.1)	-0.45 (8.81)	-27.3	-4.55	0.00	2.27	31.8	
		Week 94	Sparsentan	155	114 (73.5)	-0.96 (10.67)	-34.1	-6.82	-1.14	4.55	40.9	0.13 [-0.14, 0.39]
			Irbesartan	161	101 (62.7)	-2.32 (10.86)	-63.6	-6.82	0.00	2.27	20.5	
		Week 110	Sparsentan	155	112 (72.3)	-0.89 (13.49)	-84.1	-4.55	0.00	4.55	36.4	-0.11 [-0.38, 0.17]
			Irbesartan	161	92 (57.1)	0.32 (8.08)	-18.2	-4.55	0.00	4.55	22.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSHM: KDQOL: Course of symptom/problems of kidney disease by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	KDQOL: symptom/ problems of kidney disease	Baseline	Sparsentan	47	46 (97.9)	90.46 (12.47)	31.8	86.36	94.32	100.00	100.0	
			Irbesartan	41	40 (97.6)	88.81 (11.29)	52.3	86.36	90.91	97.73	100.0	
		Week 24	Sparsentan	47	38 (80.9)	89.83 (15.70)	4.5	88.64	93.18	97.73	100.0	
			Irbesartan	41	31 (75.6)	82.11 (23.93)	4.5	72.73	90.91	97.73	100.0	
		Week 48	Sparsentan	47	41 (87.2)	90.41 (16.74)	0.0	88.64	95.45	100.00	100.0	
			Irbesartan	41	29 (70.7)	88.32 (11.91)	54.5	84.09	90.91	97.73	100.0	
		Week 70	Sparsentan	47	37 (78.7)	87.04 (17.15)	27.3	84.09	93.18	95.45	100.0	
			Irbesartan	41	30 (73.2)	88.33 (14.07)	29.5	86.36	90.91	97.73	100.0	
		Week 94	Sparsentan	47	37 (78.7)	89.80 (11.84)	63.6	86.36	93.18	100.00	100.0	
			Irbesartan	41	29 (70.7)	89.18 (11.99)	59.1	81.82	93.18	100.00	100.0	
		Week 110	Sparsentan	47	37 (78.7)	88.94 (14.52)	43.2	86.36	93.18	100.00	100.0	
			Irbesartan	41	29 (70.7)	84.40 (19.23)	6.8	77.27	88.64	97.73	100.0	
	KDQOL: Change from baseline in symptom/ problems of kidney disease	Week 24	Sparsentan	47	38 (80.9)	-1.20 (17.69)	-72.7	-6.82	0.00	4.55	63.6	0.27 [-0.21, 0.74]
			Irbesartan	41	31 (75.6)	-6.52 (22.39)	-86.4	-9.09	0.00	4.55	20.5	
		Week 48	Sparsentan	47	41 (87.2)	-0.11 (20.22)	-100.0	-2.27	0.00	6.82	59.1	0.09 [-0.39, 0.57]
			Irbesartan	41	29 (70.7)	-1.57 (7.80)	-20.5	-4.55	0.00	2.27	20.5	
		Week 70	Sparsentan	47	37 (78.7)	-3.81 (17.02)	-61.4	-4.55	0.00	4.55	22.7	0.00 [-0.48, 0.49]
			Irbesartan	41	30 (73.2)	-3.86 (13.12)	-59.1	-4.55	-2.27	0.00	20.5	
		Week 94	Sparsentan	47	37 (78.7)	-0.86 (15.68)	-27.3	-4.55	0.00	2.27	68.2	0.07 [-0.42, 0.55]
			Irbesartan	41	29 (70.7)	-1.80 (11.56)	-34.1	-6.82	0.00	2.27	20.5	
		Week 110	Sparsentan	47	37 (78.7)	-1.54 (17.84)	-45.5	-9.09	0.00	4.55	68.2	0.25 [-0.24, 0.74]
			Irbesartan	41	29 (70.7)	-6.03 (18.26)	-81.8	-13.64	-2.27	2.27	20.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Sex	Overall	Sparsentan						Interaction:	0.334
Male	Week 24	Sparsentan	139	109 (78.4)	-1.49 (1.13)	(-3.70, 0.72)	0.59 (1.66)	(-2.67, 3.85)	0.723
		Irbesartan	143	93 (65.0)	-2.08 (1.22)	(-4.47, 0.31)			
	Week 48	Sparsentan	139	112 (80.6)	-2.11 (1.11)	(-4.28, 0.07)	-0.19 (1.67)	(-3.46, 3.08)	0.909
		Irbesartan	143	87 (60.8)	-1.92 (1.24)	(-4.36, 0.52)			
	Week 70	Sparsentan	139	114 (82.0)	-2.08 (1.10)	(-4.24, 0.09)	-0.73 (1.65)	(-3.97, 2.50)	0.657
		Irbesartan	143	92 (64.3)	-1.34 (1.22)	(-3.74, 1.05)			
	Week 94	Sparsentan	139	105 (75.5)	-2.05 (1.14)	(-4.29, 0.19)	0.60 (1.66)	(-2.66, 3.86)	0.719
		Irbesartan	143	96 (67.1)	-2.65 (1.20)	(-5.01, -0.29)			
	Week 110	Sparsentan	139	103 (74.1)	-2.15 (1.16)	(-4.43, 0.12)	-0.33 (1.71)	(-3.68, 3.02)	0.845
		Irbesartan	143	89 (62.2)	-1.82 (1.25)	(-4.27, 0.63)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Female	Week 24	Sparsentan	63	48 (76.2)	2.51 (1.76)	(-0.95, 5.96)	2.18 (2.66)	(-3.05, 7.41)	0.412
		Irbesartan	59	38 (64.4)	0.32 (1.98)	(-3.57, 4.22)			
	Week 48	Sparsentan	63	50 (79.4)	2.14 (1.72)	(-1.24, 5.52)	3.20 (2.64)	(-1.99, 8.40)	0.226
		Irbesartan	59	37 (62.7)	-1.06 (1.99)	(-4.98, 2.85)			
	Week 70	Sparsentan	63	46 (73.0)	-0.25 (1.78)	(-3.75, 3.25)	0.60 (2.68)	(-4.67, 5.86)	0.824
		Irbesartan	59	38 (64.4)	-0.85 (1.98)	(-4.74, 3.05)			
	Week 94	Sparsentan	63	46 (73.0)	0.08 (1.79)	(-3.45, 3.60)	0.74 (2.76)	(-4.70, 6.17)	0.790
		Irbesartan	59	34 (57.6)	-0.66 (2.08)	(-4.75, 3.42)			
	Week 110	Sparsentan	63	46 (73.0)	0.66 (1.80)	(-2.89, 4.21)	-0.20 (2.83)	(-5.77, 5.37)	0.944
		Irbesartan	59	32 (54.2)	0.86 (2.16)	(-3.39, 5.10)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age	Overall	Sparsentan						Interaction:	0.045 #
<= 45 years	Week 24	Sparsentan	96	71 (74.0)	0.69 (1.49)	(-2.24, 3.62)	3.56 (2.14)	(-0.65, 7.76)	0.097
		Irbesartan	99	67 (67.7)	-2.87 (1.54)	(-5.88, 0.15)			
	Week 48	Sparsentan	96	75 (78.1)	-1.10 (1.45)	(-3.94, 1.75)	1.77 (2.14)	(-2.44, 5.98)	0.408
		Irbesartan	99	62 (62.6)	-2.87 (1.58)	(-5.97, 0.23)			
	Week 70	Sparsentan	96	72 (75.0)	-0.82 (1.48)	(-3.72, 2.08)	0.96 (2.17)	(-3.30, 5.22)	0.659
		Irbesartan	99	62 (62.6)	-1.78 (1.59)	(-4.90, 1.34)			
	Week 94	Sparsentan	96	68 (70.8)	-0.60 (1.52)	(-3.57, 2.38)	3.68 (2.18)	(-0.60, 7.97)	0.092
		Irbesartan	99	64 (64.6)	-4.28 (1.57)	(-7.36, -1.20)			
	Week 110	Sparsentan	96	69 (71.9)	0.36 (1.52)	(-2.62, 3.34)	1.90 (2.23)	(-2.47, 6.28)	0.394
		Irbesartan	99	59 (59.6)	-1.54 (1.63)	(-4.75, 1.67)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 45 years	Week 24	Sparsentan	106	86 (81.1)	-1.00 (1.23)	(-3.42, 1.42)	-1.03 (1.89)	(-4.74, 2.68)	0.586
		Irbesartan	103	64 (62.1)	0.03 (1.43)	(-2.77, 2.84)			
	Week 48	Sparsentan	106	87 (82.1)	-0.42 (1.22)	(-2.82, 1.97)	0.34 (1.88)	(-3.35, 4.03)	0.856
		Irbesartan	103	62 (60.2)	-0.76 (1.43)	(-3.56, 2.04)			
	Week 70	Sparsentan	106	88 (83.0)	-1.88 (1.22)	(-4.28, 0.52)	-1.02 (1.85)	(-4.64, 2.61)	0.582
		Irbesartan	103	68 (66.0)	-0.86 (1.38)	(-3.58, 1.85)			
	Week 94	Sparsentan	106	83 (78.3)	-1.99 (1.25)	(-4.44, 0.47)	-1.64 (1.88)	(-5.33, 2.06)	0.384
		Irbesartan	103	66 (64.1)	-0.35 (1.40)	(-3.11, 2.40)			
	Week 110	Sparsentan	106	80 (75.5)	-2.51 (1.28)	(-5.02, 0.00)	-1.52 (1.94)	(-5.32, 2.29)	0.434
		Irbesartan	103	62 (60.2)	-1.00 (1.45)	(-3.85, 1.86)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age at IgAN diagnosis	Overall	Sparsentan						Interaction:	0.252
<= 18 years	Week 24	Sparsentan	9	5 (55.6)	-6.74 (9.23)	(-28.15, 14.67)	-6.64 (15.33)	(-42.75, 29.48)	0.678
		Irbesartan	5	5 (100.0)	-0.10 (11.52)	(-27.42, 27.22)			
	Week 48	Sparsentan	9	7 (77.8)	-11.32 (8.98)	(-32.48, 9.85)	-9.14 (15.33)	(-45.24, 26.96)	0.569
		Irbesartan	5	3 (60.0)	-2.18 (11.73)	(-29.67, 25.32)			
	Week 70	Sparsentan	9	7 (77.8)	-7.40 (9.04)	(-28.62, 13.83)	-2.15 (15.37)	(-38.30, 33.99)	0.892
		Irbesartan	5	4 (80.0)	-5.24 (11.71)	(-32.74, 22.25)			
	Week 94	Sparsentan	9	5 (55.6)	-12.30 (9.25)	(-33.75, 9.15)	-8.21 (15.64)	(-44.64, 28.22)	0.615
		Irbesartan	5	4 (80.0)	-4.09 (11.88)	(-31.76, 23.59)			
	Week 110	Sparsentan	9	4 (44.4)	-3.92 (9.58)	(-25.74, 17.91)	1.40 (16.36)	(-35.84, 38.64)	0.934
		Irbesartan	5	2 (40.0)	-5.32 (12.63)	(-33.87, 23.23)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 18 to 40 years	Week 24	Sparsentan	102	79 (77.5)	1.66 (1.27)	(-0.84, 4.15)	3.08 (1.84)	(-0.54, 6.70)	0.095
		Irbesartan	109	71 (65.1)	-1.42 (1.34)	(-4.05, 1.20)			
	Week 48	Sparsentan	102	82 (80.4)	-0.43 (1.25)	(-2.87, 2.02)	3.12 (1.85)	(-0.52, 6.75)	0.092
		Irbesartan	109	67 (61.5)	-3.55 (1.36)	(-6.22, -0.87)			
	Week 70	Sparsentan	102	78 (76.5)	-1.26 (1.27)	(-3.76, 1.25)	0.25 (1.87)	(-3.42, 3.92)	0.894
		Irbesartan	109	68 (62.4)	-1.51 (1.36)	(-4.19, 1.17)			
	Week 94	Sparsentan	102	73 (71.6)	-0.45 (1.31)	(-3.04, 2.13)	3.35 (1.89)	(-0.37, 7.07)	0.077
		Irbesartan	109	69 (63.3)	-3.80 (1.36)	(-6.47, -1.14)			
	Week 110	Sparsentan	102	72 (70.6)	0.02 (1.33)	(-2.60, 2.64)	1.22 (1.94)	(-2.59, 5.02)	0.531
		Irbesartan	109	65 (59.6)	-1.20 (1.40)	(-3.95, 1.55)			
> 40 years	Week 24	Sparsentan	91	73 (80.2)	-1.22 (1.46)	(-4.09, 1.66)	0.75 (2.23)	(-3.63, 5.13)	0.738
		Irbesartan	88	55 (62.5)	-1.97 (1.68)	(-5.26, 1.33)			
	Week 48	Sparsentan	91	73 (80.2)	-0.38 (1.45)	(-3.23, 2.48)	-0.57 (2.22)	(-4.93, 3.80)	0.798
		Irbesartan	88	54 (61.4)	0.19 (1.68)	(-3.11, 3.49)			
	Week 70	Sparsentan	91	75 (82.4)	-1.52 (1.44)	(-4.36, 1.32)	-0.69 (2.19)	(-4.98, 3.61)	0.753
		Irbesartan	88	58 (65.9)	-0.83 (1.64)	(-4.05, 2.39)			
	Week 94	Sparsentan	91	73 (80.2)	-1.86 (1.46)	(-4.73, 1.01)	-1.56 (2.20)	(-5.89, 2.77)	0.479
		Irbesartan	88	57 (64.8)	-0.30 (1.65)	(-3.54, 2.94)			
	Week 110	Sparsentan	91	73 (80.2)	-2.46 (1.47)	(-5.35, 0.42)	-1.32 (2.25)	(-5.74, 3.10)	0.557
		Irbesartan	88	54 (61.4)	-1.14 (1.70)	(-4.49, 2.21)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Geographic region	Overall	Sparsentan						Interaction:	0.095
North America	Week 24	Sparsentan	35	23 (65.7)	-2.87 (2.49)	(-7.79, 2.05)	0.18 (3.23)	(-6.21, 6.57)	0.956
		Irbesartan	46	35 (76.1)	-3.05 (2.05)	(-7.10, 1.00)			
	Week 48	Sparsentan	35	25 (71.4)	-3.17 (2.41)	(-7.94, 1.60)	-1.10 (3.20)	(-7.43, 5.23)	0.732
		Irbesartan	46	32 (69.6)	-2.07 (2.08)	(-6.19, 2.05)			
	Week 70	Sparsentan	35	22 (62.9)	0.66 (2.50)	(-4.28, 5.61)	2.91 (3.30)	(-3.62, 9.44)	0.379
		Irbesartan	46	30 (65.2)	-2.25 (2.14)	(-6.49, 1.99)			
	Week 94	Sparsentan	35	23 (65.7)	-1.81 (2.49)	(-6.74, 3.11)	0.35 (3.32)	(-6.21, 6.91)	0.917
		Irbesartan	46	30 (65.2)	-2.16 (2.18)	(-6.46, 2.14)			
	Week 110	Sparsentan	35	21 (60.0)	-0.60 (2.60)	(-5.74, 4.55)	0.30 (3.41)	(-6.45, 7.04)	0.931
		Irbesartan	46	31 (67.4)	-0.89 (2.19)	(-5.23, 3.44)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Europe	Week 24	Sparsentan	98	73 (74.5)	1.01 (1.49)	(-1.92, 3.95)	2.76 (2.21)	(-1.58, 7.10)	0.213
		Irbesartan	115	62 (53.9)	-1.75 (1.63)	(-4.94, 1.45)			
	Week 48	Sparsentan	98	76 (77.6)	0.05 (1.47)	(-2.82, 2.93)	3.30 (2.20)	(-1.02, 7.62)	0.134
		Irbesartan	115	59 (51.3)	-3.24 (1.64)	(-6.46, -0.03)			
	Week 70	Sparsentan	98	75 (76.5)	0.20 (1.48)	(-2.71, 3.12)	2.33 (2.14)	(-1.88, 6.54)	0.277
		Irbesartan	115	69 (60.0)	-2.13 (1.54)	(-5.16, 0.90)			
	Week 94	Sparsentan	98	68 (69.4)	0.21 (1.54)	(-2.83, 3.24)	3.62 (2.18)	(-0.66, 7.90)	0.097
		Irbesartan	115	70 (60.9)	-3.41 (1.53)	(-6.43, -0.40)			
	Week 110	Sparsentan	98	67 (68.4)	0.02 (1.57)	(-3.07, 3.10)	1.73 (2.27)	(-2.72, 6.19)	0.445
		Irbesartan	115	61 (53.0)	-1.72 (1.63)	(-4.92, 1.49)			
Asia Pacific	Week 24	Sparsentan	69	61 (88.4)	-0.29 (1.43)	(-3.10, 2.51)	0.28 (2.39)	(-4.41, 4.97)	0.906
		Irbesartan	41	34 (82.9)	-0.58 (1.91)	(-4.33, 3.18)			
	Week 48	Sparsentan	69	61 (88.4)	-0.50 (1.42)	(-3.30, 2.30)	-1.54 (2.41)	(-6.28, 3.19)	0.521
		Irbesartan	41	33 (80.5)	1.04 (1.94)	(-2.77, 4.85)			
	Week 70	Sparsentan	69	63 (91.3)	-3.63 (1.41)	(-6.39, -0.87)	-4.58 (2.46)	(-9.41, 0.24)	0.063
		Irbesartan	41	31 (75.6)	0.96 (2.00)	(-2.99, 4.90)			
	Week 94	Sparsentan	69	60 (87.0)	-2.63 (1.44)	(-5.45, 0.19)	-2.18 (2.50)	(-7.10, 2.73)	0.383
		Irbesartan	41	30 (73.2)	-0.45 (2.04)	(-4.46, 3.56)			
	Week 110	Sparsentan	69	61 (88.4)	-2.44 (1.43)	(-5.26, 0.37)	-1.04 (2.52)	(-6.00, 3.92)	0.680
		Irbesartan	41	29 (70.7)	-1.40 (2.07)	(-5.48, 2.67)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline BMI	Overall	Sparsentan						Interaction:	0.265
< 27 kg/m**2	Week 24	Sparsentan	83	66 (79.5)	-1.51 (1.37)	(-4.20, 1.18)	0.07 (1.94)	(-3.74, 3.89)	0.969
		Irbesartan	94	66 (70.2)	-1.58 (1.37)	(-4.28, 1.11)			
	Week 48	Sparsentan	83	66 (79.5)	-0.28 (1.36)	(-2.96, 2.40)	3.59 (1.97)	(-0.27, 7.45)	0.069
		Irbesartan	94	60 (63.8)	-3.87 (1.41)	(-6.65, -1.09)			
	Week 70	Sparsentan	83	64 (77.1)	-2.07 (1.39)	(-4.79, 0.65)	0.68 (1.99)	(-3.24, 4.60)	0.733
		Irbesartan	94	59 (62.8)	-2.75 (1.43)	(-5.56, 0.06)			
	Week 94	Sparsentan	83	63 (75.9)	-2.00 (1.40)	(-4.74, 0.75)	2.39 (1.99)	(-1.51, 6.30)	0.228
		Irbesartan	94	62 (66.0)	-4.39 (1.41)	(-7.16, -1.62)			
	Week 110	Sparsentan	83	63 (75.9)	-1.62 (1.41)	(-4.38, 1.15)	1.78 (2.03)	(-2.22, 5.77)	0.383
		Irbesartan	94	57 (60.6)	-3.39 (1.47)	(-6.28, -0.51)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
>= 27 kg/m**2	Week 24	Sparsentan	119	91 (76.5)	0.76 (1.30)	(-1.78, 3.31)	2.16 (2.01)	(-1.79, 6.12)	0.283
		Irbesartan	107	65 (60.7)	-1.40 (1.54)	(-4.42, 1.62)			
	Week 48	Sparsentan	119	96 (80.7)	-1.07 (1.26)	(-3.55, 1.40)	-1.52 (1.98)	(-5.42, 2.37)	0.443
		Irbesartan	107	64 (59.8)	0.45 (1.53)	(-2.55, 3.46)			
	Week 70	Sparsentan	119	96 (80.7)	-1.06 (1.26)	(-3.54, 1.42)	-1.27 (1.94)	(-5.08, 2.55)	0.515
		Irbesartan	107	71 (66.4)	0.20 (1.47)	(-2.69, 3.09)			
	Week 94	Sparsentan	119	88 (73.9)	-1.02 (1.31)	(-3.60, 1.56)	-1.26 (2.00)	(-5.19, 2.68)	0.530
		Irbesartan	107	67 (62.6)	0.24 (1.51)	(-2.73, 3.20)			
	Week 110	Sparsentan	119	86 (72.3)	-1.05 (1.34)	(-3.68, 1.57)	-2.08 (2.06)	(-6.12, 1.96)	0.313
		Irbesartan	107	63 (58.9)	1.03 (1.56)	(-2.04, 4.09)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Randomization strata	Overall	Sparsentan						Interaction:	0.749
eGFR Low and UP High	Week 24	Sparsentan	71	54 (76.1)	-1.15 (1.32)	(-3.74, 1.45)	0.49 (2.02)	(-3.49, 4.46)	0.810
		Irbesartan	74	40 (54.1)	-1.63 (1.52)	(-4.62, 1.35)			
	Week 48	Sparsentan	71	51 (71.8)	-0.63 (1.33)	(-3.26, 1.99)	4.32 (2.04)	(0.30, 8.34)	0.035 *
		Irbesartan	74	37 (50.0)	-4.96 (1.54)	(-7.99, -1.93)			
	Week 70	Sparsentan	71	57 (80.3)	-3.18 (1.29)	(-5.72, -0.63)	0.23 (2.03)	(-3.77, 4.22)	0.912
		Irbesartan	74	37 (50.0)	-3.40 (1.56)	(-6.46, -0.34)			
	Week 94	Sparsentan	71	51 (71.8)	-3.12 (1.34)	(-5.75, -0.48)	0.55 (2.07)	(-3.52, 4.63)	0.790
		Irbesartan	74	37 (50.0)	-3.67 (1.57)	(-6.76, -0.58)			
	Week 110	Sparsentan	71	53 (74.6)	-2.85 (1.34)	(-5.48, -0.22)	-1.94 (2.10)	(-6.08, 2.20)	0.356
		Irbesartan	74	36 (48.6)	-0.90 (1.61)	(-4.07, 2.26)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
eGFR Low and UP Low	Week 24	Sparsentan	55	43 (78.2)	0.26 (1.91)	(-3.50, 4.02)	-2.68 (2.82)	(-8.24, 2.87)	0.343
		Irbesartan	55	37 (67.3)	2.94 (2.07)	(-1.12, 7.01)			
	Week 48	Sparsentan	55	43 (78.2)	-3.16 (1.90)	(-6.91, 0.58)	-3.73 (2.84)	(-9.32, 1.86)	0.190
		Irbesartan	55	35 (63.6)	0.57 (2.10)	(-3.56, 4.70)			
	Week 70	Sparsentan	55	42 (76.4)	1.37 (1.93)	(-2.42, 5.17)	0.85 (2.79)	(-4.63, 6.33)	0.761
		Irbesartan	55	39 (70.9)	0.52 (2.00)	(-3.42, 4.46)			
	Week 94	Sparsentan	55	41 (74.5)	0.11 (1.96)	(-3.74, 3.96)	-0.33 (2.82)	(-5.87, 5.21)	0.906
		Irbesartan	55	39 (70.9)	0.44 (2.01)	(-3.51, 4.40)			
	Week 110	Sparsentan	55	37 (67.3)	-2.29 (2.06)	(-6.34, 1.76)	-2.55 (2.99)	(-8.43, 3.32)	0.393
		Irbesartan	55	34 (61.8)	0.27 (2.15)	(-3.96, 4.49)			
eGFR High and UP High	Week 24	Sparsentan	37	26 (70.3)	-0.40 (2.82)	(-5.96, 5.16)	0.01 (4.03)	(-7.94, 7.97)	0.998
		Irbesartan	36	26 (72.2)	-0.42 (2.88)	(-6.11, 5.28)			
	Week 48	Sparsentan	37	33 (89.2)	-0.98 (2.56)	(-6.04, 4.08)	2.12 (3.91)	(-5.59, 9.83)	0.588
		Irbesartan	36	24 (66.7)	-3.10 (2.95)	(-8.92, 2.72)			
	Week 70	Sparsentan	37	31 (83.8)	-2.81 (2.63)	(-8.01, 2.39)	-0.45 (3.94)	(-8.23, 7.33)	0.908
		Irbesartan	36	25 (69.4)	-2.36 (2.93)	(-8.14, 3.43)			
	Week 94	Sparsentan	37	27 (73.0)	-1.17 (2.79)	(-6.67, 4.33)	0.11 (4.08)	(-7.94, 8.15)	0.979
		Irbesartan	36	24 (66.7)	-1.28 (2.97)	(-7.15, 4.59)			
	Week 110	Sparsentan	37	26 (70.3)	2.21 (2.87)	(-3.45, 7.87)	6.68 (4.23)	(-1.67, 15.02)	0.116
		Irbesartan	36	22 (61.1)	-4.46 (3.11)	(-10.59, 1.66)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
eGFR High and UP Low	Week 24	Sparsentan	39	34 (87.2)	0.53 (1.94)	(-3.28, 4.35)	7.43 (2.87)	(1.78, 13.09)	0.010 *
		Irbesartan	37	28 (75.7)	-6.90 (2.12)	(-11.08, -2.72)			
	Week 48	Sparsentan	39	35 (89.7)	1.35 (1.91)	(-2.42, 5.11)	-0.52 (2.86)	(-6.15, 5.11)	0.857
		Irbesartan	37	28 (75.7)	1.87 (2.12)	(-2.31, 6.04)			
	Week 70	Sparsentan	39	30 (76.9)	-1.61 (2.04)	(-5.64, 2.41)	-3.16 (2.93)	(-8.93, 2.62)	0.283
		Irbesartan	37	29 (78.4)	1.54 (2.09)	(-2.58, 5.67)			
	Week 94	Sparsentan	39	32 (82.1)	-1.61 (1.99)	(-5.52, 2.31)	1.14 (2.87)	(-4.51, 6.79)	0.691
		Irbesartan	37	30 (81.1)	-2.75 (2.06)	(-6.80, 1.31)			
	Week 110	Sparsentan	39	33 (84.6)	-1.71 (1.97)	(-5.58, 2.16)	-2.06 (2.88)	(-7.72, 3.61)	0.476
		Irbesartan	37	29 (78.4)	0.35 (2.09)	(-3.78, 4.47)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 1	Overall	Sparsentan						Interaction:	0.493
< 60 mL/min/1.73 m**2	Week 24	Sparsentan	127	98 (77.2)	-0.35 (1.19)	(-2.69, 1.98)	0.84 (1.78)	(-2.64, 4.33)	0.635
		Irbesartan	129	80 (62.0)	-1.20 (1.32)	(-3.78, 1.39)			
	Week 48	Sparsentan	127	95 (74.8)	-1.10 (1.20)	(-3.45, 1.26)	0.87 (1.80)	(-2.67, 4.41)	0.629
		Irbesartan	129	74 (57.4)	-1.97 (1.35)	(-4.61, 0.68)			
	Week 70	Sparsentan	127	100 (78.7)	-1.33 (1.18)	(-3.65, 0.98)	0.14 (1.77)	(-3.35, 3.62)	0.939
		Irbesartan	129	78 (60.5)	-1.47 (1.32)	(-4.07, 1.13)			
	Week 94	Sparsentan	127	92 (72.4)	-1.36 (1.22)	(-3.76, 1.03)	0.59 (1.81)	(-2.96, 4.15)	0.743
		Irbesartan	129	77 (59.7)	-1.96 (1.33)	(-4.58, 0.66)			
	Week 110	Sparsentan	127	92 (72.4)	-2.47 (1.23)	(-4.88, -0.05)	-1.74 (1.86)	(-5.38, 1.90)	0.349
		Irbesartan	129	72 (55.8)	-0.73 (1.39)	(-3.45, 1.99)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
60 to < 90 mL/min/1.73 m**2	Week 24	Sparsentan	49	38 (77.6)	-1.55 (2.10)	(-5.68, 2.58)	-1.30 (3.13)	(-7.47, 4.87)	0.678
		Irbesartan	48	31 (64.6)	-0.25 (2.32)	(-4.81, 4.32)			
	Week 48	Sparsentan	49	44 (89.8)	-1.37 (1.98)	(-5.28, 2.54)	2.08 (3.02)	(-3.87, 8.03)	0.491
		Irbesartan	48	32 (66.7)	-3.45 (2.26)	(-7.91, 1.01)			
	Week 70	Sparsentan	49	38 (77.6)	-0.87 (2.08)	(-4.97, 3.22)	2.74 (3.09)	(-3.34, 8.83)	0.375
		Irbesartan	48	32 (66.7)	-3.61 (2.27)	(-8.09, 0.86)			
	Week 94	Sparsentan	49	39 (79.6)	-1.69 (2.08)	(-5.79, 2.41)	3.47 (3.06)	(-2.57, 9.51)	0.259
		Irbesartan	48	34 (70.8)	-5.16 (2.24)	(-9.58, -0.75)			
	Week 110	Sparsentan	49	36 (73.5)	0.32 (2.16)	(-3.95, 4.58)	4.53 (3.17)	(-1.71, 10.77)	0.154
		Irbesartan	48	32 (66.7)	-4.21 (2.30)	(-8.75, 0.33)			
>= 90 mL/min/1.73 m**2	Week 24	Sparsentan	26	21 (80.8)	2.80 (2.45)	(-2.03, 7.63)	7.05 (3.51)	(0.13, 13.96)	0.046 *
		Irbesartan	25	20 (80.0)	-4.25 (2.51)	(-9.19, 0.70)			
	Week 48	Sparsentan	26	23 (88.5)	1.38 (2.34)	(-3.24, 6.00)	-1.06 (3.55)	(-8.07, 5.95)	0.766
		Irbesartan	25	18 (72.0)	2.44 (2.65)	(-2.79, 7.67)			
	Week 70	Sparsentan	26	22 (84.6)	-3.30 (2.40)	(-8.03, 1.43)	-7.71 (3.49)	(-14.59, -0.83)	0.028 *
		Irbesartan	25	20 (80.0)	4.41 (2.52)	(-0.56, 9.37)			
	Week 94	Sparsentan	26	20 (76.9)	-1.08 (2.51)	(-6.03, 3.88)	-3.66 (3.61)	(-10.78, 3.47)	0.313
		Irbesartan	25	19 (76.0)	2.58 (2.58)	(-2.51, 7.67)			
	Week 110	Sparsentan	26	21 (80.8)	1.40 (2.45)	(-3.44, 6.23)	-0.65 (3.67)	(-7.90, 6.59)	0.859
		Irbesartan	25	17 (68.0)	2.05 (2.72)	(-3.32, 7.42)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 2	Overall	Sparsentan						Interaction:	0.252
< 45 mL/min/1.73 m**2	Week 24	Sparsentan	82	64 (78.0)	1.05 (1.50)	(-1.90, 4.00)	1.69 (2.29)	(-2.80, 6.19)	0.460
		Irbesartan	80	48 (60.0)	-0.64 (1.73)	(-4.04, 2.75)			
	Week 48	Sparsentan	82	61 (74.4)	-1.27 (1.52)	(-4.26, 1.72)	2.41 (2.35)	(-2.20, 7.03)	0.304
		Irbesartan	80	43 (53.8)	-3.68 (1.79)	(-7.19, -0.17)			
	Week 70	Sparsentan	82	65 (79.3)	-0.91 (1.49)	(-3.84, 2.02)	2.39 (2.30)	(-2.14, 6.92)	0.300
		Irbesartan	80	45 (56.3)	-3.30 (1.76)	(-6.75, 0.15)			
	Week 94	Sparsentan	82	60 (73.2)	-1.21 (1.54)	(-4.24, 1.81)	2.43 (2.32)	(-2.12, 6.99)	0.295
		Irbesartan	80	47 (58.8)	-3.65 (1.74)	(-7.06, -0.24)			
	Week 110	Sparsentan	82	56 (68.3)	-2.00 (1.60)	(-5.14, 1.14)	-0.26 (2.41)	(-5.00, 4.47)	0.913
		Irbesartan	80	44 (55.0)	-1.74 (1.80)	(-5.28, 1.80)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
45 to < 60 mL/min/1.73 m**2	Week 24	Sparsentan	45	34 (75.6)	-3.09 (1.93)	(-6.89, 0.70)	-0.99 (2.77)	(-6.45, 4.47)	0.721
		Irbesartan	49	32 (65.3)	-2.10 (1.99)	(-6.02, 1.81)			
	Week 48	Sparsentan	45	34 (75.6)	-0.76 (1.91)	(-4.52, 3.00)	-1.43 (2.78)	(-6.90, 4.04)	0.608
		Irbesartan	49	31 (63.3)	0.67 (2.01)	(-3.29, 4.62)			
	Week 70	Sparsentan	45	35 (77.8)	-2.16 (1.90)	(-5.90, 1.58)	-3.59 (2.74)	(-8.99, 1.81)	0.192
		Irbesartan	49	33 (67.3)	1.43 (1.97)	(-2.45, 5.31)			
	Week 94	Sparsentan	45	32 (71.1)	-1.78 (1.97)	(-5.66, 2.11)	-2.72 (2.85)	(-8.34, 2.89)	0.341
		Irbesartan	49	30 (61.2)	0.94 (2.05)	(-3.09, 4.98)			
	Week 110	Sparsentan	45	36 (80.0)	-3.40 (1.89)	(-7.13, 0.32)	-4.51 (2.86)	(-10.14, 1.11)	0.116
		Irbesartan	49	28 (57.1)	1.11 (2.13)	(-3.09, 5.31)			
60 to < 90 mL/min/1.73 m**2	Week 24	Sparsentan	49	38 (77.6)	-1.55 (2.10)	(-5.68, 2.58)	-1.30 (3.13)	(-7.47, 4.87)	0.678
		Irbesartan	48	31 (64.6)	-0.25 (2.32)	(-4.81, 4.32)			
	Week 48	Sparsentan	49	44 (89.8)	-1.37 (1.98)	(-5.28, 2.54)	2.08 (3.02)	(-3.87, 8.03)	0.491
		Irbesartan	48	32 (66.7)	-3.45 (2.26)	(-7.91, 1.01)			
	Week 70	Sparsentan	49	38 (77.6)	-0.87 (2.08)	(-4.97, 3.22)	2.74 (3.09)	(-3.34, 8.83)	0.375
		Irbesartan	48	32 (66.7)	-3.61 (2.27)	(-8.09, 0.86)			
	Week 94	Sparsentan	49	39 (79.6)	-1.69 (2.08)	(-5.79, 2.41)	3.47 (3.06)	(-2.57, 9.51)	0.259
		Irbesartan	48	34 (70.8)	-5.16 (2.24)	(-9.58, -0.75)			
	Week 110	Sparsentan	49	36 (73.5)	0.32 (2.16)	(-3.95, 4.58)	4.53 (3.17)	(-1.71, 10.77)	0.154
		Irbesartan	48	32 (66.7)	-4.21 (2.30)	(-8.75, 0.33)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
>= 90 mL/min/1.73 m**2	Week 24	Sparsentan	26	21 (80.8)	2.80 (2.45)	(-2.03, 7.63)	7.05 (3.51)	(0.13, 13.96)	0.046 *
		Irbesartan	25	20 (80.0)	-4.25 (2.51)	(-9.19, 0.70)			
	Week 48	Sparsentan	26	23 (88.5)	1.38 (2.34)	(-3.24, 6.00)	-1.06 (3.55)	(-8.07, 5.95)	0.766
		Irbesartan	25	18 (72.0)	2.44 (2.65)	(-2.79, 7.67)			
	Week 70	Sparsentan	26	22 (84.6)	-3.30 (2.40)	(-8.03, 1.43)	-7.71 (3.49)	(-14.59, -0.83)	0.028 *
		Irbesartan	25	20 (80.0)	4.41 (2.52)	(-0.56, 9.37)			
	Week 94	Sparsentan	26	20 (76.9)	-1.08 (2.51)	(-6.03, 3.88)	-3.66 (3.61)	(-10.78, 3.47)	0.313
		Irbesartan	25	19 (76.0)	2.58 (2.58)	(-2.51, 7.67)			
	Week 110	Sparsentan	26	21 (80.8)	1.40 (2.45)	(-3.44, 6.23)	-0.65 (3.67)	(-7.90, 6.59)	0.859
		Irbesartan	25	17 (68.0)	2.05 (2.72)	(-3.32, 7.42)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline urine protein excretion	Overall	Sparsentan						Interaction:	0.510
<= 1.75 g/day	Week 24	Sparsentan	98	80 (81.6)	-0.17 (1.35)	(-2.81, 2.48)	1.81 (2.11)	(-2.33, 5.94)	0.391
		Irbesartan	93	55 (59.1)	-1.98 (1.62)	(-5.15, 1.20)			
	Week 48	Sparsentan	98	82 (83.7)	-0.89 (1.33)	(-3.49, 1.72)	-1.95 (2.07)	(-6.01, 2.11)	0.346
		Irbesartan	93	57 (61.3)	1.06 (1.58)	(-2.04, 4.17)			
	Week 70	Sparsentan	98	75 (76.5)	-1.09 (1.38)	(-3.80, 1.62)	-1.62 (2.07)	(-5.70, 2.45)	0.434
		Irbesartan	93	61 (65.6)	0.53 (1.54)	(-2.49, 3.56)			
	Week 94	Sparsentan	98	76 (77.6)	-0.52 (1.38)	(-3.22, 2.19)	1.52 (2.05)	(-2.51, 5.56)	0.459
		Irbesartan	93	63 (67.7)	-2.04 (1.52)	(-5.03, 0.95)			
	Week 110	Sparsentan	98	75 (76.5)	-1.03 (1.39)	(-3.76, 1.71)	-0.91 (2.12)	(-5.07, 3.26)	0.670
		Irbesartan	93	57 (61.3)	-0.12 (1.60)	(-3.25, 3.01)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 1.75 g/day	Week 24	Sparsentan	104	77 (74.0)	-0.37 (1.35)	(-3.02, 2.28)	0.92 (1.92)	(-2.86, 4.70)	0.633
		Irbesartan	109	76 (69.7)	-1.29 (1.37)	(-3.97, 1.40)			
	Week 48	Sparsentan	104	80 (76.9)	-0.70 (1.32)	(-3.29, 1.89)	3.26 (1.94)	(-0.55, 7.08)	0.094
		Irbesartan	109	67 (61.5)	-3.96 (1.42)	(-6.76, -1.17)			
	Week 70	Sparsentan	104	85 (81.7)	-1.87 (1.30)	(-4.41, 0.68)	0.77 (1.92)	(-3.01, 4.55)	0.690
		Irbesartan	109	69 (63.3)	-2.63 (1.42)	(-5.42, 0.15)			
	Week 94	Sparsentan	104	75 (72.1)	-2.36 (1.36)	(-5.04, 0.32)	-0.27 (1.99)	(-4.17, 3.63)	0.893
		Irbesartan	109	67 (61.5)	-2.09 (1.44)	(-4.92, 0.74)			
	Week 110	Sparsentan	104	74 (71.2)	-1.59 (1.38)	(-4.31, 1.13)	0.43 (2.03)	(-3.56, 4.41)	0.833
		Irbesartan	109	64 (58.7)	-2.02 (1.48)	(-4.93, 0.89)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline use of antihypertensives	Overall	Sparsentan						Interaction:	0.512
Yes	Week 24	Sparsentan	90	66 (73.3)	0.11 (1.22)	(-2.29, 2.50)	-0.43 (1.87)	(-4.10, 3.23)	0.816
		Irbesartan	88	49 (55.7)	0.54 (1.41)	(-2.23, 3.32)			
	Week 48	Sparsentan	90	65 (72.2)	0.43 (1.22)	(-1.96, 2.83)	1.23 (1.88)	(-2.46, 4.92)	0.513
		Irbesartan	88	47 (53.4)	-0.80 (1.43)	(-3.60, 2.01)			
	Week 70	Sparsentan	90	68 (75.6)	-2.01 (1.20)	(-4.38, 0.35)	-0.92 (1.85)	(-4.57, 2.72)	0.619
		Irbesartan	88	49 (55.7)	-1.09 (1.41)	(-3.86, 1.68)			
	Week 94	Sparsentan	90	63 (70.0)	-2.03 (1.24)	(-4.47, 0.41)	-0.27 (1.84)	(-3.87, 3.34)	0.884
		Irbesartan	88	54 (61.4)	-1.77 (1.35)	(-4.42, 0.89)			
	Week 110	Sparsentan	90	63 (70.0)	-0.35 (1.25)	(-2.81, 2.11)	-0.67 (1.87)	(-4.35, 3.01)	0.721
		Irbesartan	88	51 (58.0)	0.32 (1.39)	(-2.41, 3.05)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
No	Week 24	Sparsentan	112	91 (81.3)	-0.42 (1.38)	(-3.13, 2.29)	2.40 (2.01)	(-1.54, 6.34)	0.233
		Irbesartan	114	82 (71.9)	-2.81 (1.46)	(-5.67, 0.04)			
	Week 48	Sparsentan	112	97 (86.6)	-1.52 (1.34)	(-4.15, 1.11)	0.79 (2.00)	(-3.13, 4.71)	0.693
		Irbesartan	114	77 (67.5)	-2.31 (1.48)	(-5.22, 0.60)			
	Week 70	Sparsentan	112	92 (82.1)	-0.97 (1.37)	(-3.66, 1.73)	0.32 (2.00)	(-3.62, 4.25)	0.875
		Irbesartan	114	81 (71.1)	-1.29 (1.46)	(-4.15, 1.58)			
	Week 94	Sparsentan	112	88 (78.6)	-0.83 (1.40)	(-3.58, 1.92)	1.57 (2.06)	(-2.47, 5.61)	0.445
		Irbesartan	114	76 (66.7)	-2.40 (1.51)	(-5.36, 0.56)			
	Week 110	Sparsentan	112	86 (76.8)	-1.91 (1.42)	(-4.70, 0.89)	0.28 (2.12)	(-3.89, 4.45)	0.894
		Irbesartan	114	70 (61.4)	-2.19 (1.57)	(-5.28, 0.90)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

					Repeated measures analysis				
KDQOL: Change from baseline in symptom/problems of kidney disease					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Time since renal biopsy	Overall	Sparsentan						Interaction:	0.117
<= 5 years	Week 24	Sparsentan	113	88 (77.9)	1.04 (1.28)	(-1.47, 3.56)	3.61 (1.82)	(0.03, 7.19)	0.048 *
		Irbesartan	127	86 (67.7)	-2.57 (1.30)	(-5.11, -0.02)			
	Week 48	Sparsentan	113	92 (81.4)	0.99 (1.25)	(-1.47, 3.44)	2.47 (1.80)	(-1.06, 6.00)	0.170
		Irbesartan	127	85 (66.9)	-1.49 (1.29)	(-4.02, 1.05)			
	Week 70	Sparsentan	113	90 (79.6)	-1.49 (1.26)	(-3.97, 0.99)	-0.05 (1.81)	(-3.59, 3.50)	0.979
		Irbesartan	127	86 (67.7)	-1.44 (1.29)	(-3.98, 1.09)			
	Week 94	Sparsentan	113	86 (76.1)	-1.21 (1.29)	(-3.74, 1.33)	0.60 (1.83)	(-2.99, 4.18)	0.744
		Irbesartan	127	86 (67.7)	-1.80 (1.29)	(-4.34, 0.73)			
	Week 110	Sparsentan	113	88 (77.9)	0.37 (1.29)	(-2.16, 2.90)	1.67 (1.86)	(-1.98, 5.32)	0.369
		Irbesartan	127	80 (63.0)	-1.30 (1.34)	(-3.94, 1.33)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 5 years	Week 24	Sparsentan	89	69 (77.5)	-1.63 (1.43)	(-4.45, 1.19)	-1.98 (2.31)	(-6.52, 2.55)	0.390
		Irbesartan	75	45 (60.0)	0.36 (1.80)	(-3.18, 3.89)			
	Week 48	Sparsentan	89	70 (78.7)	-3.02 (1.42)	(-5.82, -0.23)	-0.73 (2.36)	(-5.36, 3.91)	0.758
		Irbesartan	75	39 (52.0)	-2.30 (1.87)	(-5.98, 1.38)			
	Week 70	Sparsentan	89	70 (78.7)	-1.35 (1.43)	(-4.16, 1.46)	-0.36 (2.30)	(-4.89, 4.17)	0.876
		Irbesartan	75	44 (58.7)	-0.99 (1.80)	(-4.52, 2.55)			
	Week 94	Sparsentan	89	65 (73.0)	-1.44 (1.47)	(-4.33, 1.46)	1.57 (2.34)	(-3.03, 6.16)	0.503
		Irbesartan	75	44 (58.7)	-3.00 (1.81)	(-6.56, 0.55)			
	Week 110	Sparsentan	89	61 (68.5)	-3.40 (1.52)	(-6.39, -0.40)	-2.33 (2.42)	(-7.08, 2.43)	0.336
		Irbesartan	75	41 (54.7)	-1.07 (1.87)	(-4.74, 2.61)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
History of hypertension	Overall	Sparsentan						Interaction:	0.101
Yes	Week 24	Sparsentan	155	119 (76.8)	0.49 (0.95)	(-1.37, 2.36)	0.44 (1.41)	(-2.32, 3.20)	0.753
		Irbesartan	161	100 (62.1)	0.05 (1.04)	(-1.98, 2.08)			
	Week 48	Sparsentan	155	121 (78.1)	-0.59 (0.94)	(-2.43, 1.26)	0.85 (1.41)	(-1.92, 3.62)	0.547
		Irbesartan	161	95 (59.0)	-1.44 (1.05)	(-3.50, 0.63)			
	Week 70	Sparsentan	155	123 (79.4)	-0.62 (0.94)	(-2.46, 1.21)	0.02 (1.40)	(-2.72, 2.76)	0.989
		Irbesartan	161	100 (62.1)	-0.64 (1.03)	(-2.67, 1.39)			
	Week 94	Sparsentan	155	114 (73.5)	-1.40 (0.97)	(-3.30, 0.49)	0.92 (1.41)	(-1.85, 3.70)	0.513
		Irbesartan	161	101 (62.7)	-2.33 (1.03)	(-4.35, -0.30)			
	Week 110	Sparsentan	155	112 (72.3)	-0.95 (0.98)	(-2.88, 0.98)	-1.34 (1.46)	(-4.20, 1.52)	0.359
		Irbesartan	161	92 (57.1)	0.39 (1.08)	(-1.73, 2.51)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Table PT2KSYC_FSCM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set

KDQOL: Change from baseline in symptom/problems of kidney disease					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
No	Week 24	Sparsentan	47	38 (80.9)	-1.81 (2.62)	(-6.98, 3.35)	5.68 (3.92)	(-2.05, 13.41)	0.149
		Irbesartan	41	31 (75.6)	-7.49 (2.91)	(-13.23, -1.76)			
	Week 48	Sparsentan	47	41 (87.2)	-0.95 (2.54)	(-5.96, 4.06)	2.76 (3.90)	(-4.92, 10.45)	0.479
		Irbesartan	41	29 (70.7)	-3.72 (2.95)	(-9.52, 2.09)			
	Week 70	Sparsentan	47	37 (78.7)	-3.70 (2.64)	(-8.89, 1.50)	0.17 (3.95)	(-7.62, 7.96)	0.965
		Irbesartan	41	30 (73.2)	-3.87 (2.93)	(-9.65, 1.92)			
	Week 94	Sparsentan	47	37 (78.7)	-0.69 (2.66)	(-5.93, 4.55)	1.62 (4.02)	(-6.30, 9.54)	0.688
		Irbesartan	41	29 (70.7)	-2.31 (3.00)	(-8.22, 3.61)			
	Week 110	Sparsentan	47	37 (78.7)	-1.49 (2.68)	(-6.77, 3.79)	5.35 (4.06)	(-2.66, 13.35)	0.189
		Irbesartan	41	29 (70.7)	-6.84 (3.04)	(-12.83, -0.86)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs, created on: 05MAR2024

Figure PF2KSYC_FSGM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set
Study: PROTECT
Age: <= 45 years



Sparsentan	71	75	72	68	69
Irbesartan	67	62	62	64	59

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2KSYC_FSCM

Figure PF2KSYC_FSGM: KDQOL: Change from baseline in symptom/problems of kidney disease by subgroup
Full Analysis Set
Study: PROTECT
Age: > 45 years



Sparsentan	86	87	88	83	80
Irbesartan	64	62	68	66	62

_____
Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Reference table: PT2KSYC_FSCM

Table PT2KSYIT_FSTM: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to increase in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sex	Sparsentan						Interaction test:	0.125
Male	Sparsentan	139	9 (6.5)	NE		2.500	(0.730, 8.555)	0.144
	Irbesartan	143	7 (4.9)	NE				
Female	Sparsentan	63	11 (17.5)	NE		0.733	(0.236, 2.277)	0.591
	Irbesartan	59	6 (10.2)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KSYIT_FSTM: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to increase in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.130
<= 45 years	Sparsentan	96	11 (11.5)	NE		2.831	(0.703, 11.395)	0.143
	Irbesartan	99	3 (3.0)	NE				
> 45 years	Sparsentan	106	9 (8.5)	NE		0.741	(0.271, 2.028)	0.559
	Irbesartan	103	10 (9.7)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KSYIT_FSTM: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to increase in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age at IgAN diagnosis	Sparsentan						Interaction test:	NE
<= 18 years	Sparsentan	9	0 (0.0) No events in 1 group	NE		NE		NE
	Irbesartan	5	0 (0.0)	NE				
> 18 to 40 years	Sparsentan	102	12 (11.8)	NE		1.873	(0.557, 6.294)	0.310
	Irbesartan	109	4 (3.7)	NE				
> 40 years	Sparsentan	91	8 (8.8)	NE		0.790	(0.263, 2.373)	0.675
	Irbesartan	88	9 (10.2)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KSYIT_FSTM: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to increase in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Geographic region	Sparsentan						Interaction test:	0.692
North America	Sparsentan	35	2 (5.7)	NE		0.883	(0.121, 6.425)	0.902
	Irbesartan	46	4 (8.7)	NE				
Europe	Sparsentan	98	10 (10.2)	NE		1.703	(0.456, 6.355)	0.428
	Irbesartan	115	5 (4.3)	NE				
Asia Pacific	Sparsentan	69	8 (11.6)	NE		0.789	(0.223, 2.795)	0.714
	Irbesartan	41	4 (9.8)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KSYIT_FSTM: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to increase in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.118
< 27 kg/m**2	Sparsentan	83	7 (8.4)	NE		4.117	(0.671, 25.245)	0.126
	Irbesartan	94	3 (3.2)	NE				
>= 27 kg/m**2	Sparsentan	119	13 (10.9)	NE		0.973	(0.384, 2.468)	0.954
	Irbesartan	107	10 (9.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KSYIT_FSTM: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to increase in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Randomization strata	Sparsentan						Interaction test:	0.247
eGFR Low and UP High	Sparsentan	71	3 (4.2)	NE		16.002	(0.623, 411.105)	0.094
	Irbesartan	74	3 (4.1)	NE				
eGFR Low and UP Low	Sparsentan	55	9 (16.4)	NE		0.953	(0.246, 3.692)	0.945
	Irbesartan	55	4 (7.3)	NE				
eGFR High and UP High	Sparsentan	37	4 (10.8)	NE		1.267	(0.253, 6.358)	0.774
	Irbesartan	36	4 (11.1)	NE				
eGFR High and UP Low	Sparsentan	39	4 (10.3)	NE		0.805	(0.132, 4.908)	0.814
	Irbesartan	37	2 (5.4)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KSYIT_FSTM: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to increase in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.863
< 60 mL/min/1.73 m**2	Sparsentan	127	12 (9.4)	NE		1.302	(0.471, 3.597)	0.611
	Irbesartan	129	8 (6.2)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	3 (6.1)	NE		1.368	(0.162, 11.554)	0.774
	Irbesartan	48	2 (4.2)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	5 (19.2)	NE		0.641	(0.142, 2.886)	0.562
	Irbesartan	25	3 (12.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KSYIT_FSTM: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to increase in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 2	Sparsentan						Interaction test:	0.696
< 45 mL/min/1.73 m**2	Sparsentan	82	8 (9.8)	NE		1.883	(0.522, 6.796)	0.334
	Irbesartan	80	5 (6.3)	NE				
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	4 (8.9)	NE		0.512	(0.068, 3.843)	0.515
	Irbesartan	49	3 (6.1)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	3 (6.1)	NE		1.368	(0.162, 11.554)	0.774
	Irbesartan	48	2 (4.2)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	5 (19.2)	NE		0.641	(0.142, 2.886)	0.562
	Irbesartan	25	3 (12.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KSYIT_FSTM: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to increase in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline urine protein excretion	Sparsentan						Interaction test:	0.472
<= 1.75 g/day	Sparsentan	98	14 (14.3)	NE		2.246	(0.591, 8.539)	0.235
	Irbesartan	93	3 (3.2)	NE				
> 1.75 g/day	Sparsentan	104	6 (5.8)	NE		1.291	(0.389, 4.285)	0.676
	Irbesartan	109	10 (9.2)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KSYIT_FSTM: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to increase in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.724
Yes	Sparsentan	90	9 (10.0)	NE		2.709	(0.680, 10.790)	0.157
	Irbesartan	88	5 (5.7)	NE				
No	Sparsentan	112	11 (9.8)	NE		0.851	(0.314, 2.307)	0.752
	Irbesartan	114	8 (7.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KSYIT_FSTM: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to increase in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Time since renal biopsy	Sparsentan						Interaction test:	0.445
<= 5 years	Sparsentan	113	13 (11.5)	NE		1.405	(0.556, 3.552)	0.472
	Irbesartan	127	10 (7.9)	NE				
> 5 years	Sparsentan	89	7 (7.9)	NE		0.798	(0.126, 5.030)	0.810
	Irbesartan	75	3 (4.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KSYIT_FSTM: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to increase in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
History of hypertension	Sparsentan						Interaction test:	0.786
Yes	Sparsentan	155	15 (9.7)	NE		1.044	(0.412, 2.647)	0.928
	Irbesartan	161	11 (6.8)	NE				
No	Sparsentan	47	5 (10.6)	NE		1.752	(0.316, 9.718)	0.521
	Irbesartan	41	2 (4.9)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Figure PF2KSYIT_FSKM: KDQOL: Time to increase in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

Not done. No significant subgroups.

_____
An increase reflects an improvement of the status of the patient.
Reference table: PT2KSYIT_FSTM

Table PT2KSYDT_FSTM: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sex	Sparsentan						Interaction test:	0.839
Male	Sparsentan	139	31 (22.3)	NE		1.221	(0.709, 2.104)	0.471
	Irbesartan	143	23 (16.1)	NE				
Female	Sparsentan	63	14 (22.2)	NE		1.161	(0.503, 2.682)	0.726
	Irbesartan	59	10 (16.9)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KSYDT_FSTM: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Age	Sparsentan						Interaction test:	0.024	#
<= 45 years	Sparsentan	96	17 (17.7)	NE		0.665	(0.349, 1.267)	0.215	
	Irbesartan	99	21 (21.2)	NE					
> 45 years	Sparsentan	106	28 (26.4)	NE		2.030	(1.025, 4.024)	0.042	*
	Irbesartan	103	12 (11.7)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KSYDT_FSTM: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in symptom/problems of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age at IgAN diagnosis	Sparsentan						Interaction test:	0.117
<= 18 years	Sparsentan	9	2 (22.2)	NE		0.286	(0.019, 4.375)	0.369
	Irbesartan	5	2 (40.0)	95.3	(70.0, NE)			
> 18 to 40 years	Sparsentan	102	19 (18.6)	NE		0.771	(0.410, 1.449)	0.420
	Irbesartan	109	21 (19.3)	NE				
> 40 years	Sparsentan	91	24 (26.4)	NE		1.922	(0.915, 4.036)	0.084
	Irbesartan	88	10 (11.4)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KSYDT_FSTM: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in symptom/problems of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Geographic region	Sparsentan						Interaction test:	0.409
North America	Sparsentan	35	5 (14.3)	115.7	(115.7, NE)	0.737	(0.232, 2.346)	0.606
	Irbesartan	46	8 (17.4)	NE				
Europe	Sparsentan	98	20 (20.4)	NE		0.967	(0.514, 1.821)	0.918
	Irbesartan	115	19 (16.5)	NE				
Asia Pacific	Sparsentan	69	20 (29.0)	NE		1.929	(0.764, 4.870)	0.165
	Irbesartan	41	6 (14.6)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KSYDT_FSTM: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.197
< 27 kg/m**2	Sparsentan	83	21 (25.3)	NE		0.941	(0.516, 1.717)	0.843
	Irbesartan	94	22 (23.4)	NE				
>= 27 kg/m**2	Sparsentan	119	24 (20.2)	NE		1.785	(0.849, 3.750)	0.126
	Irbesartan	107	10 (9.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KSYDT_FSTM: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in symptom/problems of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Randomization strata	Sparsentan						Interaction test:	0.799
eGFR Low and UP High	Sparsentan	71	16 (22.5)	NE		1.010	(0.478, 2.132)	0.980
	Irbesartan	74	14 (18.9)	NE				
eGFR Low and UP Low	Sparsentan	55	13 (23.6)	NE		1.703	(0.699, 4.148)	0.241
	Irbesartan	55	8 (14.5)	NE				
eGFR High and UP High	Sparsentan	37	8 (21.6)	115.7	(115.7, NE)	1.269	(0.413, 3.898)	0.677
	Irbesartan	36	5 (13.9)	NE				
eGFR High and UP Low	Sparsentan	39	8 (20.5)	NE		1.241	(0.426, 3.620)	0.692
	Irbesartan	37	6 (16.2)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KSYDT_FSTM: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.569
< 60 mL/min/1.73 m**2	Sparsentan	127	29 (22.8)	NE		1.220	(0.694, 2.147)	0.490
	Irbesartan	129	21 (16.3)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	9 (18.4)	115.7	(115.7, NE)	0.856	(0.333, 2.200)	0.747
	Irbesartan	48	9 (18.8)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	7 (26.9)	NE		1.885	(0.480, 7.404)	0.364
	Irbesartan	25	3 (12.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KSYDT_FSTM: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in symptom/problems of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eGFR Group 2	Sparsentan						Interaction test:	0.054	
< 45 mL/min/1.73 m**2	Sparsentan	82	18 (22.0)	NE		0.773	(0.405, 1.479)	0.437	
	Irbesartan	80	19 (23.8)	NE					
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	11 (24.4)	NE		6.308	(1.379, 28.862)	0.018	*
	Irbesartan	49	2 (4.1)	NE					
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	9 (18.4)	115.7	(115.7, NE)	0.856	(0.333, 2.200)	0.747	
	Irbesartan	48	9 (18.8)	NE					
>= 90 mL/min/1.73 m**2	Sparsentan	26	7 (26.9)	NE		1.885	(0.480, 7.404)	0.364	
	Irbesartan	25	3 (12.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KSYDT_FSTM: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in symptom/problems of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline urine protein excretion	Sparsentan						Interaction test:	0.580
<= 1.75 g/day	Sparsentan	98	23 (23.5)	NE		1.354	(0.681, 2.689)	0.387
	Irbesartan	93	13 (14.0)	NE				
> 1.75 g/day	Sparsentan	104	22 (21.2)	NE		1.069	(0.577, 1.981)	0.832
	Irbesartan	109	20 (18.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KSYDT_FSTM: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.460
Yes	Sparsentan	90	20 (22.2)	NE		1.513	(0.737, 3.106)	0.260
	Irbesartan	88	12 (13.6)	NE				
No	Sparsentan	112	25 (22.3)	NE		1.018	(0.567, 1.826)	0.953
	Irbesartan	114	21 (18.4)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KSYDT_FSTM: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL:
Time to decrease in symptom/problems of kidney disease by at least 15

				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Time since renal biopsy	Sparsentan						Interaction test:	0.965
<= 5 years	Sparsentan	113	23 (20.4)	NE		1.113	(0.611, 2.028)	0.726
	Irbesartan	127	20 (15.7)	NE				
> 5 years	Sparsentan	89	22 (24.7)	NE		1.133	(0.562, 2.285)	0.726
	Irbesartan	75	13 (17.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KSYDT_FSTM: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
History of hypertension	Sparsentan						Interaction test:	0.490
Yes	Sparsentan	155	31 (20.0)	NE		1.239	(0.717, 2.140)	0.443
	Irbesartan	161	22 (13.7)	NE				
No	Sparsentan	47	14 (29.8)	NE		0.888	(0.393, 2.007)	0.775
	Irbesartan	41	11 (26.8)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Figure PF2KSYDT_FSKM: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Age: <= 45 years



Sparsentan	96	85	81	76	65	53
Irbesartan	99	79	70	62	56	46

_____
A decrease reflects a worsening of the status of the patient.
Reference table: PT2KSYDT_FSTM

Figure PF2KSYDT_FSKM: KDQOL: Time to decrease in symptom/problems of kidney disease by at least 15 points by subgroup
Full Analysis Set

Study: PROTECT
Age: > 45 years



Sparsentan	106	96	88	81	72	61
Irbesartan	103	82	74	69	66	52

A decrease reflects a worsening of the status of the patient.
Reference table: PT2KSYDT_FSTM

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	KDQOL-SF12: PCS	Baseline	Sparsentan	139	130 (93.5)	51.62 (7.25)	25.5	47.38	53.46	56.74	62.3	
			Irbesartan	143	132 (92.3)	52.00 (7.33)	21.6	49.77	54.43	56.42	64.3	
		Week 24	Sparsentan	139	110 (79.1)	52.25 (6.99)	16.3	49.67	53.52	56.66	64.0	
			Irbesartan	143	100 (69.9)	51.71 (7.37)	20.8	48.17	54.17	56.22	64.3	
		Week 48	Sparsentan	139	115 (82.7)	51.97 (7.34)	25.4	47.31	53.93	56.71	66.1	
			Irbesartan	143	90 (62.9)	52.53 (7.88)	18.0	50.59	54.95	57.20	64.5	
		Week 70	Sparsentan	139	117 (84.2)	51.33 (7.30)	28.0	46.39	53.18	56.42	66.8	
			Irbesartan	143	97 (67.8)	51.81 (7.62)	21.7	49.01	54.24	56.71	63.0	
		Week 94	Sparsentan	139	108 (77.7)	51.71 (7.53)	23.8	48.01	54.39	56.83	63.5	
			Irbesartan	143	99 (69.2)	52.02 (7.24)	20.0	49.60	54.08	56.42	62.7	
		Week 110	Sparsentan	139	104 (74.8)	51.66 (7.11)	22.8	47.42	53.21	56.46	63.2	
			Irbesartan	143	89 (62.2)	51.90 (7.59)	25.4	49.07	53.50	56.71	62.6	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	139	110 (79.1)	0.62 (5.47)	-13.4	-2.71	0.18	3.69	15.5	0.14 [-0.13, 0.41]
			Irbesartan	143	100 (69.9)	-0.14 (5.63)	-20.0	-2.39	0.00	1.92	16.9	
		Week 48	Sparsentan	139	115 (82.7)	0.43 (6.43)	-18.7	-3.27	-0.08	4.02	20.6	0.04 [-0.24, 0.31]
			Irbesartan	143	90 (62.9)	0.16 (8.54)	-35.7	-3.45	0.29	3.64	20.4	
		Week 70	Sparsentan	139	117 (84.2)	-0.45 (6.85)	-25.7	-3.10	-0.04	2.98	15.6	0.04 [-0.23, 0.31]
			Irbesartan	143	97 (67.8)	-0.75 (7.82)	-28.0	-3.16	0.00	2.69	17.8	
		Week 94	Sparsentan	139	108 (77.7)	0.11 (7.08)	-19.6	-3.22	-0.27	5.10	20.7	0.04 [-0.23, 0.31]
			Irbesartan	143	99 (69.2)	-0.17 (6.49)	-20.1	-3.49	0.41	3.17	15.4	
		Week 110	Sparsentan	139	104 (74.8)	-0.17 (7.24)	-20.5	-2.88	-0.17	4.77	16.4	0.00 [-0.28, 0.28]
			Irbesartan	143	89 (62.2)	-0.19 (7.01)	-18.5	-3.49	0.00	4.22	15.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Female	KDQOL-SF12: PCS	Baseline	Sparsentan	63	58 (92.1)	49.83 (9.66)	12.4	44.71	52.36	56.15	63.5	
			Irbesartan	59	51 (86.4)	50.77 (6.10)	29.6	48.31	51.04	55.59	61.1	
		Week 24	Sparsentan	63	49 (77.8)	50.38 (8.06)	27.3	45.43	52.50	56.24	62.9	
			Irbesartan	59	38 (64.4)	51.59 (6.04)	39.0	46.70	53.46	55.88	60.2	
		Week 48	Sparsentan	63	50 (79.4)	50.37 (7.18)	29.8	46.58	51.30	55.57	61.7	
			Irbesartan	59	37 (62.7)	49.54 (6.70)	33.7	45.30	50.13	55.33	60.0	
		Week 70	Sparsentan	63	46 (73.0)	48.77 (8.67)	21.9	42.16	51.61	55.86	59.2	
			Irbesartan	59	38 (64.4)	49.44 (8.93)	22.3	47.10	51.36	56.95	60.2	
		Week 94	Sparsentan	63	47 (74.6)	48.82 (7.52)	27.9	41.40	50.23	54.80	59.6	
			Irbesartan	59	34 (57.6)	50.58 (6.70)	37.0	43.33	52.45	56.69	59.9	
		Week 110	Sparsentan	63	46 (73.0)	48.94 (8.08)	32.6	41.42	50.68	55.31	64.2	
			Irbesartan	59	32 (54.2)	49.47 (6.89)	39.0	43.26	49.88	55.37	60.0	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	63	49 (77.8)	-0.10 (8.69)	-24.8	-5.43	0.00	4.08	20.4	-0.00 [-0.42, 0.42]
			Irbesartan	59	38 (64.4)	-0.10 (5.02)	-12.8	-2.61	0.14	3.78	10.9	
		Week 48	Sparsentan	63	50 (79.4)	0.29 (7.96)	-22.3	-3.28	0.16	2.67	24.7	0.20 [-0.23, 0.63]
			Irbesartan	59	37 (62.7)	-1.24 (7.23)	-18.8	-5.09	0.00	2.18	16.4	
		Week 70	Sparsentan	63	46 (73.0)	-0.57 (9.59)	-30.2	-5.20	0.17	3.73	31.3	0.19 [-0.24, 0.62]
			Irbesartan	59	38 (64.4)	-2.16 (6.85)	-27.2	-6.02	-1.18	1.91	9.7	
		Week 94	Sparsentan	63	47 (74.6)	-1.09 (7.75)	-24.1	-4.58	-0.14	2.40	15.9	-0.04 [-0.48, 0.41]
			Irbesartan	59	34 (57.6)	-0.83 (6.69)	-14.7	-5.11	-1.58	3.53	18.0	
		Week 110	Sparsentan	63	46 (73.0)	-1.52 (7.87)	-17.4	-6.37	-0.89	2.13	16.1	0.08 [-0.37, 0.53]
			Irbesartan	59	32 (54.2)	-2.12 (6.13)	-11.9	-7.60	-1.66	0.97	15.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
<= 45 years	KDQOL-SF12: PCS	Baseline	Sparsentan	96	88 (91.7)	52.37 (7.89)	12.4	49.42	54.38	57.08	63.5	
			Irbesartan	99	92 (92.9)	52.20 (7.28)	21.6	50.06	54.38	56.39	64.3	
		Week 24	Sparsentan	96	72 (75.0)	53.39 (6.68)	27.3	51.19	54.47	57.49	64.0	
			Irbesartan	99	70 (70.7)	52.86 (6.92)	20.8	52.09	54.79	56.40	64.3	
		Week 48	Sparsentan	96	76 (79.2)	53.07 (6.85)	29.8	48.45	54.70	57.34	66.1	
			Irbesartan	99	62 (62.6)	52.18 (7.81)	18.0	48.88	54.95	56.71	63.5	
		Week 70	Sparsentan	96	75 (78.1)	51.68 (7.84)	21.9	48.98	54.09	56.44	66.8	
			Irbesartan	99	64 (64.6)	52.94 (7.05)	34.6	50.89	55.87	57.63	63.0	
		Week 94	Sparsentan	96	70 (72.9)	52.49 (7.11)	27.9	50.22	54.70	56.95	63.5	
			Irbesartan	99	64 (64.6)	51.82 (7.29)	30.4	47.74	54.15	56.95	62.7	
		Week 110	Sparsentan	96	70 (72.9)	52.63 (7.00)	34.7	50.22	54.82	57.49	63.2	
			Irbesartan	99	59 (59.6)	52.09 (7.54)	25.4	46.91	54.80	57.58	62.6	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	96	72 (75.0)	0.53 (5.86)	-24.8	-3.15	0.75	4.08	14.7	0.14 [-0.19, 0.47]
			Irbesartan	99	70 (70.7)	-0.23 (4.91)	-15.6	-2.69	-0.41	1.65	13.3	
		Week 48	Sparsentan	96	76 (79.2)	0.27 (6.85)	-22.3	-2.78	0.00	3.76	24.7	0.17 [-0.16, 0.51]
			Irbesartan	99	62 (62.6)	-1.03 (8.22)	-35.7	-2.77	0.04	2.42	16.4	
		Week 70	Sparsentan	96	75 (78.1)	-0.46 (7.74)	-30.2	-2.95	0.08	3.37	31.3	0.00 [-0.33, 0.34]
			Irbesartan	99	64 (64.6)	-0.48 (6.73)	-24.4	-2.58	0.33	3.05	11.2	
		Week 94	Sparsentan	96	70 (72.9)	-0.43 (6.22)	-24.1	-3.46	0.03	3.24	11.9	0.09 [-0.25, 0.43]
			Irbesartan	99	64 (64.6)	-1.01 (7.23)	-20.1	-4.17	0.00	2.98	18.0	
		Week 110	Sparsentan	96	70 (72.9)	-0.78 (6.58)	-20.5	-2.86	-0.04	2.33	12.2	-0.08 [-0.42, 0.27]
			Irbesartan	99	59 (59.6)	-0.27 (6.91)	-18.5	-3.49	0.00	4.56	15.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 45 years	KDQOL-SF12: PCS	Baseline	Sparsentan	106	100 (94.3)	49.92 (8.11)	25.5	45.69	52.32	56.15	61.8	
			Irbesartan	103	91 (88.3)	51.12 (6.73)	27.9	48.76	52.91	56.15	59.6	
		Week 24	Sparsentan	106	87 (82.1)	50.25 (7.63)	16.3	44.66	52.35	56.15	62.9	
			Irbesartan	103	68 (66.0)	50.47 (6.94)	31.2	45.43	52.51	56.15	61.9	
		Week 48	Sparsentan	106	89 (84.0)	50.14 (7.45)	25.4	46.31	52.59	55.09	62.1	
			Irbesartan	103	65 (63.1)	51.17 (7.53)	24.9	47.87	53.71	56.48	64.5	
		Week 70	Sparsentan	106	88 (83.0)	49.69 (7.64)	28.0	43.41	51.73	56.15	60.9	
			Irbesartan	103	71 (68.9)	49.53 (8.59)	21.7	46.63	52.09	55.35	59.6	
		Week 94	Sparsentan	106	85 (80.2)	49.47 (7.80)	23.8	42.20	52.40	55.40	61.7	
			Irbesartan	103	69 (67.0)	51.50 (7.00)	20.0	49.27	53.46	56.15	60.9	
		Week 110	Sparsentan	106	80 (75.5)	49.24 (7.60)	22.8	43.65	50.21	54.95	64.2	
			Irbesartan	103	62 (60.2)	50.47 (7.36)	28.1	44.94	51.97	55.93	62.0	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	106	87 (82.1)	0.30 (7.20)	-16.1	-3.48	-0.27	3.53	20.4	0.05 [-0.27, 0.37]
			Irbesartan	103	68 (66.0)	-0.03 (5.99)	-20.0	-2.36	0.29	3.47	16.9	
		Week 48	Sparsentan	106	89 (84.0)	0.49 (6.99)	-15.4	-3.60	-0.29	3.93	20.6	-0.00 [-0.32, 0.32]
			Irbesartan	103	65 (63.1)	0.50 (8.13)	-20.8	-4.24	0.29	3.64	20.4	
		Week 70	Sparsentan	106	88 (83.0)	-0.50 (7.69)	-20.6	-4.44	-0.09	3.07	21.2	0.16 [-0.16, 0.47]
			Irbesartan	103	71 (68.9)	-1.74 (8.24)	-28.0	-5.89	-0.50	2.42	17.8	
		Week 94	Sparsentan	106	85 (80.2)	-0.11 (8.09)	-20.0	-4.03	-0.27	5.11	20.7	-0.05 [-0.37, 0.26]
			Irbesartan	103	69 (67.0)	0.28 (5.78)	-13.0	-2.83	0.29	4.53	13.6	
		Week 110	Sparsentan	106	80 (75.5)	-0.42 (8.15)	-17.9	-4.89	-0.65	4.62	16.4	0.09 [-0.24, 0.42]
			Irbesartan	103	62 (60.2)	-1.11 (6.77)	-17.3	-4.93	-1.04	2.61	15.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age at IgAN diagnosis												
<= 18 years	KDQOL-SF12: PCS	Baseline	Sparsentan	9	9 (100.0)	49.16 (14.77)	12.4	53.62	54.80	55.47	58.8	
			Irbesartan	5	5 (100.0)	50.57 (8.50)	39.0	44.78	53.18	56.15	59.7	
		Week 24	Sparsentan	9	5 (55.6)	56.34 (5.69)	47.0	55.09	58.85	59.89	60.9	
			Irbesartan	5	5 (100.0)	51.63 (6.38)	44.9	46.02	51.35	56.15	59.7	
		Week 48	Sparsentan	9	7 (77.8)	50.92 (9.91)	36.9	37.10	54.23	58.84	60.8	
			Irbesartan	5	3 (60.0)	55.44 (0.79)	54.6	54.59	55.59	56.15	56.1	
		Week 70	Sparsentan	9	7 (77.8)	51.64 (7.11)	40.9	43.65	53.37	57.76	59.4	
			Irbesartan	5	4 (80.0)	52.79 (8.96)	40.5	46.31	54.96	59.27	60.8	
		Week 94	Sparsentan	9	5 (55.6)	45.61 (7.92)	36.5	39.66	44.96	51.36	55.6	
			Irbesartan	5	4 (80.0)	53.17 (7.73)	46.3	46.91	51.85	59.44	62.7	
		Week 110	Sparsentan	9	4 (44.4)	50.36 (6.59)	40.9	46.52	52.20	54.19	56.1	
			Irbesartan	5	2 (40.0)	48.22 (4.59)	45.0	44.97	48.22	51.46	51.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	9	5 (55.6)	4.11 (3.63)	-2.1	3.76	6.13	6.27	6.5	0.87 [-0.43, 2.16]
			Irbesartan	5	5 (100.0)	1.06 (3.42)	-1.8	0.00	0.00	0.12	7.0	
		Week 48	Sparsentan	9	7 (77.8)	3.35 (9.92)	-3.6	-2.97	0.60	3.75	24.7	-0.28 [-1.63, 1.08]
			Irbesartan	5	3 (60.0)	5.99 (8.38)	0.0	0.00	2.40	15.57	15.6	
		Week 70	Sparsentan	9	7 (77.8)	4.07 (12.15)	-3.3	-2.10	0.40	2.25	31.3	0.47 [-0.77, 1.72]
			Irbesartan	5	4 (80.0)	-0.67 (2.68)	-4.3	-2.67	0.01	1.33	1.6	
		Week 94	Sparsentan	9	5 (55.6)	-6.76 (7.79)	-19.0	-10.13	-2.27	-1.61	-0.8	-1.01 [-2.41, 0.38]
			Irbesartan	5	4 (80.0)	-0.28 (3.77)	-5.6	-2.82	0.74	2.25	3.0	
		Week 110	Sparsentan	9	4 (44.4)	-1.65 (1.50)	-2.9	-2.77	-2.07	-0.53	0.4	-0.60 [-2.34, 1.13]
			Irbesartan	5	2 (40.0)	-0.76 (1.36)	-1.7	-1.73	-0.76	0.20	0.2	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 18 to 40 years	KDQOL-SF12: PCS	Baseline	Sparsentan	102	94 (92.2)	52.86 (7.28)	25.5	49.93	54.52	57.30	63.5	
			Irbesartan	109	100 (91.7)	52.36 (6.99)	21.6	50.06	54.33	56.34	64.3	
		Week 24	Sparsentan	102	80 (78.4)	53.14 (6.62)	27.3	50.98	54.47	57.49	64.0	
			Irbesartan	109	73 (67.0)	52.87 (6.54)	20.8	51.90	54.53	56.71	64.3	
		Week 48	Sparsentan	102	83 (81.4)	53.40 (6.87)	29.8	50.03	54.80	57.76	66.1	
			Irbesartan	109	69 (63.3)	52.20 (7.45)	18.0	49.48	54.80	56.71	63.5	
		Week 70	Sparsentan	102	80 (78.4)	51.73 (8.11)	21.9	49.29	54.80	56.53	66.8	
			Irbesartan	109	71 (65.1)	52.43 (7.44)	22.3	48.59	55.28	57.22	63.0	
		Week 94	Sparsentan	102	76 (74.5)	52.84 (7.17)	27.9	51.07	54.80	57.33	63.5	
			Irbesartan	109	69 (63.3)	51.72 (6.71)	34.4	47.89	53.47	56.62	61.3	
		Week 110	Sparsentan	102	73 (71.6)	52.42 (7.72)	22.8	50.22	54.84	57.76	63.2	
			Irbesartan	109	65 (59.6)	52.38 (7.39)	25.4	49.07	55.01	57.58	62.0	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	102	80 (78.4)	0.43 (6.07)	-24.8	-2.87	0.22	4.04	14.7	0.13 [-0.19, 0.45]
			Irbesartan	109	73 (67.0)	-0.27 (4.50)	-15.0	-2.38	0.00	1.65	13.3	
		Week 48	Sparsentan	102	83 (81.4)	0.20 (6.16)	-22.3	-2.88	0.00	3.69	15.6	0.15 [-0.17, 0.46]
			Irbesartan	109	69 (63.3)	-0.84 (8.19)	-35.7	-2.98	0.56	2.22	16.4	
		Week 70	Sparsentan	102	80 (78.4)	-0.95 (7.45)	-30.2	-3.95	0.17	3.21	15.6	-0.01 [-0.33, 0.31]
			Irbesartan	109	71 (65.1)	-0.84 (7.33)	-27.2	-2.69	0.67	2.69	15.7	
		Week 94	Sparsentan	102	76 (74.5)	-0.00 (6.16)	-24.1	-3.24	0.30	3.47	11.9	0.18 [-0.15, 0.51]
			Irbesartan	109	69 (63.3)	-1.16 (6.82)	-18.6	-4.31	0.00	2.45	18.0	
		Week 110	Sparsentan	102	73 (71.6)	-0.97 (6.47)	-20.5	-3.20	-0.52	2.13	12.2	-0.08 [-0.42, 0.25]
			Irbesartan	109	65 (59.6)	-0.42 (6.78)	-18.5	-3.25	0.00	3.57	15.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 40 years	KDQOL-SF12: PCS	Baseline	Sparsentan	91	85 (93.4)	49.29 (7.67)	25.8	44.69	50.89	54.80	60.2	
			Irbesartan	88	78 (88.6)	50.84 (6.96)	27.9	48.47	52.28	56.15	59.6	
		Week 24	Sparsentan	91	74 (81.3)	49.77 (7.79)	16.3	43.35	52.21	56.15	62.9	
			Irbesartan	88	60 (68.2)	50.24 (7.44)	31.2	44.37	53.20	56.15	61.9	
		Week 48	Sparsentan	91	75 (82.4)	49.42 (7.04)	25.4	45.70	51.29	54.80	59.6	
			Irbesartan	88	55 (62.5)	50.79 (8.04)	24.9	45.30	52.76	56.97	64.5	
		Week 70	Sparsentan	91	76 (83.5)	49.32 (7.35)	28.0	43.41	51.43	55.87	59.6	
			Irbesartan	88	60 (68.2)	49.51 (8.52)	21.7	46.86	51.57	54.80	59.6	
		Week 94	Sparsentan	91	74 (81.3)	49.13 (7.57)	23.8	42.20	50.72	55.33	61.7	
			Irbesartan	88	60 (68.2)	51.47 (7.62)	20.0	49.44	53.46	56.18	61.3	
		Week 110	Sparsentan	91	73 (80.2)	49.25 (7.06)	32.6	43.40	49.86	54.80	64.2	
			Irbesartan	88	54 (61.4)	50.02 (7.50)	28.1	44.69	51.33	55.09	62.6	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	91	74 (81.3)	0.12 (7.28)	-16.1	-3.94	-0.73	3.49	20.4	0.03 [-0.32, 0.37]
			Irbesartan	88	60 (68.2)	-0.06 (6.58)	-20.0	-3.29	0.00	3.78	16.9	
		Week 48	Sparsentan	91	75 (82.4)	0.32 (7.40)	-15.4	-4.33	-0.54	5.05	20.6	0.02 [-0.33, 0.37]
			Irbesartan	88	55 (62.5)	0.15 (8.14)	-20.8	-4.31	0.00	4.04	20.4	
		Week 70	Sparsentan	91	76 (83.5)	-0.41 (7.43)	-20.4	-4.10	-0.33	3.31	21.2	0.15 [-0.19, 0.48]
			Irbesartan	88	60 (68.2)	-1.54 (8.10)	-28.0	-6.07	-0.27	2.43	17.8	
		Week 94	Sparsentan	91	74 (81.3)	-0.07 (8.16)	-19.6	-4.39	-0.14	5.11	20.7	-0.09 [-0.43, 0.25]
			Irbesartan	88	60 (68.2)	0.61 (6.27)	-20.1	-2.67	0.35	4.97	13.6	
		Week 110	Sparsentan	91	73 (80.2)	-0.15 (8.49)	-17.9	-5.45	0.00	5.40	16.4	0.11 [-0.24, 0.46]
			Irbesartan	88	54 (61.4)	-1.03 (7.04)	-17.3	-5.80	-1.11	3.16	15.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Geographic region												
North America	KDQOL-SF12: PCS	Baseline	Sparsentan	35	32 (91.4)	52.20 (9.84)	12.4	50.86	54.80	57.76	62.3	
			Irbesartan	46	43 (93.5)	50.66 (8.22)	27.9	47.65	54.24	56.15	61.1	
		Week 24	Sparsentan	35	23 (65.7)	54.24 (6.48)	35.4	52.64	56.15	57.49	64.0	
			Irbesartan	46	37 (80.4)	51.74 (6.97)	31.2	48.45	54.51	56.22	60.2	
		Week 48	Sparsentan	35	25 (71.4)	53.35 (6.94)	37.1	50.24	55.59	57.76	66.0	
			Irbesartan	46	33 (71.7)	52.26 (8.67)	18.0	47.21	55.64	57.47	64.5	
		Week 70	Sparsentan	35	23 (65.7)	52.71 (6.17)	42.2	48.98	53.17	57.20	63.2	
			Irbesartan	46	31 (67.4)	53.82 (6.76)	23.5	52.64	55.86	57.31	59.9	
		Week 94	Sparsentan	35	24 (68.6)	54.43 (4.00)	44.8	51.80	56.02	57.12	61.3	
			Irbesartan	46	30 (65.2)	52.63 (6.78)	29.2	47.92	55.12	56.95	59.9	
		Week 110	Sparsentan	35	21 (60.0)	52.83 (6.87)	35.4	49.10	54.80	57.76	63.2	
			Irbesartan	46	31 (67.4)	52.87 (5.82)	35.0	47.77	54.51	57.58	60.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	35	23 (65.7)	-1.34 (5.27)	-16.1	-3.22	-0.27	2.88	6.1	-0.41 [-0.94, 0.12]
			Irbesartan	46	37 (80.4)	0.99 (5.94)	-20.0	-1.35	0.80	3.27	13.3	
		Week 48	Sparsentan	35	25 (71.4)	0.40 (6.91)	-15.4	-1.90	-0.52	2.67	24.7	-0.14 [-0.66, 0.38]
			Irbesartan	46	33 (71.7)	1.64 (10.41)	-35.7	-1.06	1.35	6.73	20.4	
		Week 70	Sparsentan	35	23 (65.7)	0.10 (7.78)	-9.4	-2.89	-0.47	1.61	31.3	-0.16 [-0.70, 0.38]
			Irbesartan	46	31 (67.4)	1.19 (5.88)	-13.6	-1.74	1.35	2.69	17.8	
		Week 94	Sparsentan	35	24 (68.6)	0.51 (5.69)	-7.3	-3.14	-0.32	3.20	20.7	-0.20 [-0.74, 0.33]
			Irbesartan	46	30 (65.2)	1.75 (6.41)	-10.7	-1.82	1.05	5.11	18.0	
		Week 110	Sparsentan	35	21 (60.0)	-2.48 (5.35)	-20.5	-3.51	-1.35	0.56	3.9	-0.76 [-1.33, -0.19]
			Irbesartan	46	31 (67.4)	2.12 (6.46)	-10.2	-1.42	1.35	6.00	15.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Europe	KDQOL-SF12: PCS	Baseline	Sparsentan	98	89 (90.8)	51.21 (7.64)	25.5	48.20	53.46	56.62	62.3	
			Irbesartan	115	99 (86.1)	52.29 (6.36)	29.2	49.79	53.95	56.71	62.0	
		Week 24	Sparsentan	98	75 (76.5)	52.04 (7.44)	16.3	50.24	53.44	56.71	62.9	
			Irbesartan	115	65 (56.5)	51.69 (6.45)	33.8	46.99	52.94	56.15	64.3	
		Week 48	Sparsentan	98	77 (78.6)	51.47 (7.46)	25.4	47.31	54.23	56.15	62.1	
			Irbesartan	115	61 (53.0)	51.74 (7.75)	24.9	48.01	54.63	57.49	63.5	
		Week 70	Sparsentan	98	76 (77.6)	50.75 (7.42)	28.0	46.33	52.50	56.15	63.2	
			Irbesartan	115	72 (62.6)	49.95 (8.98)	21.7	44.37	52.41	56.43	63.0	
		Week 94	Sparsentan	98	71 (72.4)	50.39 (7.84)	23.8	43.49	53.18	56.15	61.7	
			Irbesartan	115	72 (62.6)	51.30 (7.34)	20.0	47.72	53.21	56.18	62.7	
		Week 110	Sparsentan	98	68 (69.4)	51.46 (7.96)	22.8	47.18	52.77	56.59	64.2	
			Irbesartan	115	61 (53.0)	50.85 (8.69)	25.4	44.97	53.46	56.71	62.6	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	98	75 (76.5)	1.11 (6.03)	-13.4	-2.71	0.29	4.30	14.7	0.41 [0.07, 0.75]
			Irbesartan	115	65 (56.5)	-1.15 (4.85)	-15.0	-3.09	-0.83	1.33	10.9	
		Week 48	Sparsentan	98	77 (78.6)	0.68 (6.33)	-18.7	-3.10	0.56	4.31	17.5	0.26 [-0.08, 0.59]
			Irbesartan	115	61 (53.0)	-1.08 (7.43)	-24.7	-4.24	0.00	2.40	16.0	
		Week 70	Sparsentan	98	76 (77.6)	-0.37 (7.63)	-25.7	-4.01	0.55	3.93	21.2	0.29 [-0.04, 0.61]
			Irbesartan	115	72 (62.6)	-2.63 (8.17)	-28.0	-7.08	-1.08	1.75	15.7	
		Week 94	Sparsentan	98	71 (72.4)	-0.17 (7.70)	-20.0	-3.04	0.27	4.86	15.9	0.19 [-0.14, 0.52]
			Irbesartan	115	72 (62.6)	-1.50 (6.08)	-18.6	-4.29	-0.61	2.19	13.6	
		Week 110	Sparsentan	98	68 (69.4)	0.69 (7.30)	-17.8	-1.91	0.41	5.45	16.1	0.35 [-0.00, 0.69]
			Irbesartan	115	61 (53.0)	-1.77 (6.92)	-18.5	-4.79	-1.06	2.69	11.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asia Pacific	KDQOL-SF12: PCS	Baseline	Sparsentan	69	67 (97.1)	50.34 (7.79)	32.4	44.69	52.08	56.15	63.5	
			Irbesartan	41	41 (100.0)	51.18 (7.18)	21.6	49.48	51.57	55.86	64.3	
		Week 24	Sparsentan	69	61 (88.4)	50.25 (7.37)	27.3	45.37	52.40	56.15	62.0	
			Irbesartan	41	36 (87.8)	51.61 (8.14)	20.8	49.25	54.51	56.33	59.4	
		Week 48	Sparsentan	69	63 (91.3)	50.77 (7.24)	29.8	46.56	52.88	56.15	66.1	
			Irbesartan	41	33 (80.5)	50.93 (6.47)	33.7	48.88	53.17	55.09	58.8	
		Week 70	Sparsentan	69	64 (92.8)	49.68 (8.60)	21.9	44.11	53.05	56.31	66.8	
			Irbesartan	41	32 (78.0)	51.24 (6.41)	30.0	48.52	52.16	55.66	58.8	
		Week 94	Sparsentan	69	60 (87.0)	49.92 (8.13)	27.9	42.66	52.71	56.28	63.5	
			Irbesartan	41	31 (75.6)	51.52 (7.03)	30.4	49.06	53.46	56.15	60.9	
		Week 110	Sparsentan	69	61 (88.4)	49.43 (7.02)	34.7	43.07	50.91	55.31	59.7	
			Irbesartan	41	29 (70.7)	50.41 (6.02)	40.0	45.69	50.55	55.09	61.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	69	61 (88.4)	0.19 (7.63)	-24.8	-3.94	0.00	4.90	20.4	-0.05 [-0.46, 0.36]
			Irbesartan	41	36 (87.8)	0.56 (5.77)	-15.6	-2.46	0.00	3.77	16.9	
		Week 48	Sparsentan	69	63 (91.3)	0.03 (7.64)	-22.3	-3.58	-0.86	4.02	20.6	0.08 [-0.34, 0.51]
			Irbesartan	41	33 (80.5)	-0.59 (6.82)	-18.8	-4.39	0.00	3.24	15.5	
		Week 70	Sparsentan	69	64 (92.8)	-0.82 (7.83)	-30.2	-4.44	-0.23	3.31	15.6	-0.10 [-0.52, 0.32]
			Irbesartan	41	32 (78.0)	-0.06 (7.00)	-25.1	-3.10	0.73	3.71	15.2	
		Week 94	Sparsentan	69	60 (87.0)	-0.65 (7.43)	-24.1	-4.30	-0.41	5.51	13.7	-0.13 [-0.57, 0.30]
			Irbesartan	41	31 (75.6)	0.33 (7.23)	-20.1	-5.11	1.10	5.07	12.0	
		Week 110	Sparsentan	69	61 (88.4)	-1.37 (8.04)	-17.9	-5.47	-1.34	4.70	16.4	0.01 [-0.43, 0.45]
			Irbesartan	41	29 (70.7)	-1.45 (6.33)	-11.3	-5.71	-1.09	1.73	15.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline BMI												
< 27 kg/m**2	KDQOL-SF12: PCS	Baseline	Sparsentan	83	75 (90.4)	51.42 (8.74)	12.4	47.38	53.46	57.49	63.5	
			Irbesartan	94	86 (91.5)	53.13 (5.19)	39.0	49.84	54.52	56.42	61.5	
		Week 24	Sparsentan	83	66 (79.5)	52.61 (6.55)	37.6	49.19	53.85	57.49	64.0	
			Irbesartan	94	69 (73.4)	52.59 (5.57)	36.8	50.19	54.51	56.15	60.8	
		Week 48	Sparsentan	83	68 (81.9)	51.99 (6.87)	33.2	47.22	53.23	57.09	66.1	
			Irbesartan	94	60 (63.8)	51.48 (7.72)	18.0	47.16	54.52	56.84	63.5	
		Week 70	Sparsentan	83	66 (79.5)	50.70 (8.08)	30.4	44.81	53.05	56.15	66.8	
			Irbesartan	94	62 (66.0)	51.66 (7.58)	26.4	47.78	54.38	57.20	60.8	
		Week 94	Sparsentan	83	64 (77.1)	51.48 (7.81)	31.0	45.82	53.46	57.46	63.5	
			Irbesartan	94	64 (68.1)	52.49 (5.29)	38.9	48.29	54.23	56.35	62.7	
		Week 110	Sparsentan	83	63 (75.9)	51.36 (7.74)	32.6	44.33	53.46	57.76	64.2	
			Irbesartan	94	57 (60.6)	52.54 (6.45)	36.2	49.31	54.80	57.55	61.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	83	66 (79.5)	0.67 (6.29)	-11.9	-3.48	-0.07	5.98	20.4	0.24 [-0.10, 0.58]
			Irbesartan	94	69 (73.4)	-0.62 (4.08)	-15.0	-2.61	-0.51	1.35	10.4	
		Week 48	Sparsentan	83	68 (81.9)	0.35 (6.64)	-13.9	-4.13	-0.30	4.34	24.7	0.29 [-0.06, 0.64]
			Irbesartan	94	60 (63.8)	-1.71 (7.67)	-35.7	-4.06	0.00	2.04	15.6	
		Week 70	Sparsentan	83	66 (79.5)	-1.02 (8.60)	-25.7	-5.11	-1.09	2.90	31.3	0.08 [-0.26, 0.43]
			Irbesartan	94	62 (66.0)	-1.69 (7.54)	-28.0	-2.69	-0.13	1.89	15.7	
		Week 94	Sparsentan	83	64 (77.1)	-0.66 (7.26)	-20.0	-3.59	-0.64	3.59	20.7	0.09 [-0.25, 0.44]
			Irbesartan	94	64 (68.1)	-1.27 (5.54)	-18.6	-3.76	0.14	2.21	9.1	
		Week 110	Sparsentan	83	63 (75.9)	-1.39 (7.72)	-17.9	-6.37	-0.52	2.22	15.6	-0.08 [-0.44, 0.28]
			Irbesartan	94	57 (60.6)	-0.84 (5.55)	-18.3	-3.45	-0.54	1.95	11.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 27 kg/m**2	KDQOL-SF12: PCS	Baseline	Sparsentan	119	113 (95.0)	50.83 (7.64)	25.5	46.66	52.40	56.15	62.3	
			Irbesartan	107	96 (89.7)	50.47 (8.07)	21.6	47.36	52.90	56.10	64.3	
		Week 24	Sparsentan	119	93 (78.2)	51.01 (7.85)	16.3	47.24	52.70	56.42	62.9	
			Irbesartan	107	69 (64.5)	50.77 (8.14)	20.8	45.88	53.46	56.15	64.3	
		Week 48	Sparsentan	119	97 (81.5)	51.14 (7.62)	25.4	46.91	53.71	56.15	62.1	
			Irbesartan	107	67 (62.6)	51.83 (7.64)	24.9	48.88	54.80	56.71	64.5	
		Week 70	Sparsentan	119	97 (81.5)	50.54 (7.59)	21.9	46.03	52.61	56.19	61.1	
			Irbesartan	107	73 (68.2)	50.70 (8.46)	21.7	48.04	52.62	56.15	63.0	
		Week 94	Sparsentan	119	91 (76.5)	50.38 (7.50)	23.8	45.84	52.91	56.15	59.3	
			Irbesartan	107	68 (63.6)	51.11 (8.26)	20.0	48.08	53.46	56.43	61.3	
		Week 110	Sparsentan	119	87 (73.1)	50.44 (7.34)	22.8	46.04	52.50	55.92	63.1	
			Irbesartan	107	63 (58.9)	50.51 (7.57)	28.1	46.13	51.57	56.15	62.6	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	119	93 (78.2)	0.21 (6.86)	-24.8	-3.22	0.21	3.49	15.5	-0.02 [-0.33, 0.29]
			Irbesartan	107	69 (64.5)	0.36 (6.54)	-20.0	-2.55	0.29	3.64	16.9	
		Week 48	Sparsentan	119	97 (81.5)	0.42 (7.12)	-22.3	-3.10	0.00	3.60	20.6	-0.08 [-0.40, 0.23]
			Irbesartan	107	67 (62.6)	1.06 (8.45)	-20.8	-4.31	1.09	5.40	20.4	
		Week 70	Sparsentan	119	97 (81.5)	-0.12 (7.02)	-30.2	-2.69	0.27	3.37	15.8	0.08 [-0.23, 0.38]
			Irbesartan	107	73 (68.2)	-0.68 (7.61)	-27.2	-5.05	0.51	2.69	17.8	
		Week 94	Sparsentan	119	91 (76.5)	0.03 (7.33)	-24.1	-3.52	0.27	4.51	15.9	-0.08 [-0.39, 0.24]
			Irbesartan	107	68 (63.6)	0.59 (7.29)	-20.1	-3.36	0.61	5.09	18.0	
		Week 110	Sparsentan	119	87 (73.1)	-0.01 (7.21)	-20.5	-2.86	-0.41	4.50	16.4	0.05 [-0.28, 0.37]
			Irbesartan	107	63 (58.9)	-0.36 (7.71)	-18.5	-5.13	0.00	4.84	15.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Randomization strata												
eGFR Low and UP High	KDQOL-SF12: PCS	Baseline	Sparsentan	71	64 (90.1)	51.45 (7.23)	29.7	46.69	53.18	56.41	63.5	
			Irbesartan	74	64 (86.5)	50.34 (7.86)	29.2	44.67	52.50	56.15	60.1	
		Week 24	Sparsentan	71	54 (76.1)	51.20 (7.62)	16.3	47.24	52.97	56.66	60.9	
			Irbesartan	74	44 (59.5)	50.24 (7.51)	33.8	43.77	53.04	56.18	61.9	
		Week 48	Sparsentan	71	53 (74.6)	51.36 (7.35)	25.4	47.92	53.24	57.22	61.9	
			Irbesartan	74	38 (51.4)	49.94 (9.76)	18.0	45.30	52.63	56.48	64.5	
		Week 70	Sparsentan	71	58 (81.7)	50.24 (8.02)	28.0	42.96	52.12	56.40	61.1	
			Irbesartan	74	41 (55.4)	49.86 (8.38)	21.7	47.36	52.11	55.86	59.6	
		Week 94	Sparsentan	71	52 (73.2)	51.03 (7.58)	23.8	46.47	53.04	56.93	59.6	
			Irbesartan	74	38 (51.4)	49.91 (7.97)	20.0	47.59	52.89	54.53	57.8	
		Week 110	Sparsentan	71	53 (74.6)	50.91 (7.25)	32.6	44.40	52.62	56.15	64.2	
			Irbesartan	74	36 (48.6)	49.95 (7.78)	25.4	45.33	52.32	55.47	58.9	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	71	54 (76.1)	-0.38 (6.55)	-13.4	-3.70	-0.27	3.49	20.4	0.01 [-0.39, 0.41]
			Irbesartan	74	44 (59.5)	-0.46 (5.53)	-15.6	-2.69	0.20	3.29	12.3	
		Week 48	Sparsentan	71	53 (74.6)	0.02 (7.21)	-18.7	-3.60	-0.29	3.75	20.6	0.05 [-0.36, 0.47]
			Irbesartan	74	38 (51.4)	-0.47 (11.00)	-35.7	-5.82	0.00	5.13	20.4	
		Week 70	Sparsentan	71	58 (81.7)	-1.13 (6.36)	-20.6	-4.50	-0.08	2.30	15.6	-0.05 [-0.45, 0.35]
			Irbesartan	74	41 (55.4)	-0.78 (8.38)	-28.0	-4.57	-0.29	2.69	17.8	
		Week 94	Sparsentan	71	52 (73.2)	-0.56 (5.87)	-15.2	-3.58	-0.85	3.72	13.7	-0.09 [-0.51, 0.32]
			Irbesartan	74	38 (51.4)	0.06 (7.55)	-20.1	-3.49	0.00	3.53	18.0	
		Week 110	Sparsentan	71	53 (74.6)	-0.91 (7.41)	-17.9	-2.90	-0.74	2.13	16.4	-0.07 [-0.49, 0.36]
			Irbesartan	74	36 (48.6)	-0.43 (7.21)	-18.3	-4.20	-0.94	4.45	15.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR Low and UP Low	KDQOL-SF12: PCS	Baseline	Sparsentan	55	52 (94.5)	49.20 (8.16)	25.8	45.51	50.70	54.97	61.1	
			Irbesartan	55	50 (90.9)	52.29 (4.45)	39.6	50.07	52.68	56.15	62.0	
		Week 24	Sparsentan	55	44 (80.0)	50.64 (7.32)	31.2	44.35	52.97	55.89	64.0	
			Irbesartan	55	39 (70.9)	51.58 (6.48)	32.9	46.99	52.62	56.22	64.3	
		Week 48	Sparsentan	55	43 (78.2)	51.31 (7.15)	36.0	46.31	53.71	55.95	66.0	
			Irbesartan	55	36 (65.5)	52.06 (6.11)	37.7	47.94	53.58	56.61	63.5	
		Week 70	Sparsentan	55	42 (76.4)	50.79 (7.47)	30.4	48.80	53.27	56.15	63.2	
			Irbesartan	55	40 (72.7)	50.11 (7.96)	22.3	46.68	52.04	56.15	60.3	
		Week 94	Sparsentan	55	42 (76.4)	50.49 (7.11)	31.0	46.35	53.18	55.90	61.3	
			Irbesartan	55	40 (72.7)	51.67 (7.11)	34.4	47.90	54.43	56.79	60.8	
		Week 110	Sparsentan	55	38 (69.1)	49.90 (7.40)	34.1	43.40	52.16	54.86	63.2	
			Irbesartan	55	34 (61.8)	50.93 (8.28)	36.1	41.84	54.56	57.79	62.0	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	55	44 (80.0)	1.24 (6.33)	-14.9	-3.17	1.14	4.45	14.7	0.32 [-0.12, 0.75]
			Irbesartan	55	39 (70.9)	-0.73 (6.05)	-20.0	-3.09	0.00	2.22	16.9	
		Week 48	Sparsentan	55	43 (78.2)	1.61 (5.51)	-11.5	-1.54	0.69	6.14	14.8	0.25 [-0.19, 0.70]
			Irbesartan	55	36 (65.5)	0.11 (6.40)	-11.9	-2.78	0.55	2.59	16.0	
		Week 70	Sparsentan	55	42 (76.4)	0.63 (6.88)	-20.4	-2.95	0.96	4.22	21.2	0.32 [-0.11, 0.76]
			Irbesartan	55	40 (72.7)	-1.71 (7.67)	-27.2	-5.77	-0.13	3.52	15.2	
		Week 94	Sparsentan	55	42 (76.4)	1.24 (7.35)	-19.6	-2.77	0.19	6.33	20.7	0.25 [-0.18, 0.69]
			Irbesartan	55	40 (72.7)	-0.48 (6.04)	-13.0	-4.29	0.81	3.69	12.0	
		Week 110	Sparsentan	55	38 (69.1)	0.11 (7.90)	-15.3	-4.31	0.42	5.95	14.2	0.14 [-0.32, 0.60]
			Irbesartan	55	34 (61.8)	-0.98 (7.69)	-17.3	-8.29	-0.01	3.57	15.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP High	KDQOL-SF12: PCS	Baseline	Sparsentan	37	35 (94.6)	52.49 (9.30)	12.4	50.75	54.80	56.71	62.9	
			Irbesartan	36	33 (91.7)	51.69 (7.00)	32.5	48.47	53.46	56.15	64.3	
		Week 24	Sparsentan	37	27 (73.0)	53.52 (8.37)	27.3	50.86	57.20	57.78	61.8	
			Irbesartan	36	26 (72.2)	53.12 (4.22)	43.0	51.40	54.51	56.15	58.9	
		Week 48	Sparsentan	37	34 (91.9)	51.81 (7.99)	29.8	47.31	53.55	57.49	62.1	
			Irbesartan	36	25 (69.4)	51.76 (5.43)	40.3	49.48	53.17	55.32	60.8	
		Week 70	Sparsentan	37	31 (83.8)	52.34 (8.04)	21.9	50.55	55.21	57.20	63.2	
			Irbesartan	36	25 (69.4)	51.72 (7.76)	23.5	51.57	53.47	56.15	59.9	
		Week 94	Sparsentan	37	27 (73.0)	51.28 (8.01)	27.9	45.84	54.59	56.95	61.7	
			Irbesartan	36	25 (69.4)	52.72 (5.44)	39.8	48.24	54.12	56.15	61.3	
		Week 110	Sparsentan	37	26 (70.3)	54.40 (5.75)	34.7	50.91	56.22	58.64	59.4	
			Irbesartan	36	22 (61.1)	51.79 (6.14)	32.1	49.25	52.52	55.09	60.5	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	37	27 (73.0)	-0.24 (7.30)	-24.8	-1.42	1.57	4.02	9.9	-0.25 [-0.79, 0.29]
			Irbesartan	36	26 (72.2)	1.32 (5.10)	-5.9	-1.86	0.00	2.69	13.3	
		Week 48	Sparsentan	37	34 (91.9)	-0.62 (8.07)	-22.3	-3.76	-1.15	3.39	24.7	-0.05 [-0.57, 0.46]
			Irbesartan	36	25 (69.4)	-0.22 (6.59)	-15.8	-3.90	0.00	4.31	13.1	
		Week 70	Sparsentan	37	31 (83.8)	0.42 (9.53)	-30.2	-3.34	1.06	4.13	31.3	0.12 [-0.41, 0.65]
			Irbesartan	36	25 (69.4)	-0.59 (7.05)	-20.4	-2.75	0.67	2.61	11.2	
		Week 94	Sparsentan	37	27 (73.0)	-1.83 (8.09)	-24.1	-5.12	-0.53	2.96	8.2	-0.30 [-0.85, 0.25]
			Irbesartan	36	25 (69.4)	0.44 (6.93)	-13.4	-3.49	0.00	4.04	15.4	
		Week 110	Sparsentan	37	26 (70.3)	1.07 (6.12)	-17.4	-1.94	0.53	5.40	13.3	0.20 [-0.37, 0.77]
			Irbesartan	36	22 (61.1)	-0.21 (6.78)	-18.5	-1.73	-0.65	3.46	13.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP Low	KDQOL-SF12: PCS	Baseline	Sparsentan	39	37 (94.9)	51.70 (8.03)	25.5	46.73	53.46	57.30	62.3	
			Irbesartan	37	36 (97.3)	53.11 (8.14)	21.6	51.72	55.73	56.96	60.8	
		Week 24	Sparsentan	39	34 (87.2)	52.30 (6.02)	39.4	49.19	52.57	56.42	62.9	
			Irbesartan	37	29 (78.4)	52.70 (8.63)	20.8	52.62	54.80	56.71	60.8	
		Week 48	Sparsentan	39	35 (89.7)	51.58 (7.05)	32.1	46.58	54.61	56.45	66.1	
			Irbesartan	37	28 (75.7)	53.40 (7.79)	33.7	52.73	56.28	58.02	63.4	
		Week 70	Sparsentan	39	32 (82.1)	49.36 (7.48)	31.6	44.91	51.47	54.80	66.8	
			Irbesartan	37	29 (78.4)	53.89 (7.61)	30.0	52.29	56.66	58.82	63.0	
		Week 94	Sparsentan	39	34 (87.2)	50.61 (8.28)	30.9	44.79	53.24	56.15	63.5	
			Irbesartan	37	30 (81.1)	52.94 (7.08)	29.2	49.81	54.71	57.22	62.7	
		Week 110	Sparsentan	39	33 (84.6)	48.93 (8.49)	22.8	43.24	50.22	54.84	59.7	
			Irbesartan	37	29 (78.4)	52.87 (6.97)	35.0	48.68	56.15	57.76	62.6	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	39	34 (87.2)	1.07 (6.59)	-8.4	-3.69	-0.79	5.98	14.3	0.21 [-0.29, 0.70]
			Irbesartan	37	29 (78.4)	-0.14 (4.78)	-12.8	-2.16	-0.32	2.42	10.4	
		Week 48	Sparsentan	39	35 (89.7)	0.43 (6.84)	-13.6	-3.28	0.02	4.02	17.5	0.12 [-0.38, 0.62]
			Irbesartan	37	28 (75.7)	-0.42 (7.38)	-20.8	-1.89	0.95	3.14	12.5	
		Week 70	Sparsentan	39	32 (82.1)	-1.64 (8.90)	-25.7	-7.93	-1.60	4.43	15.8	-0.03 [-0.54, 0.47]
			Irbesartan	37	29 (78.4)	-1.36 (6.92)	-25.1	-2.48	0.51	1.89	10.0	
		Week 94	Sparsentan	39	34 (87.2)	-0.37 (8.42)	-18.4	-7.35	0.21	4.04	15.9	0.13 [-0.36, 0.62]
			Irbesartan	37	30 (81.1)	-1.32 (5.52)	-14.7	-4.04	0.33	2.45	6.6	
		Week 110	Sparsentan	39	33 (84.6)	-2.17 (7.84)	-20.5	-6.76	-2.52	1.07	16.1	-0.16 [-0.66, 0.34]
			Irbesartan	37	29 (78.4)	-1.06 (5.45)	-13.7	-4.48	0.00	1.61	8.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 1												
< 60 mL/min/1.73 m**2	KDQOL-SF12: PCS	Baseline	Sparsentan	127	117 (92.1)	50.36 (7.64)	25.8	46.21	52.35	56.15	63.5	
			Irbesartan	129	115 (89.1)	51.35 (6.58)	27.9	48.45	52.89	56.15	62.0	
		Week 24	Sparsentan	127	99 (78.0)	50.77 (7.40)	16.3	45.43	52.77	56.15	64.0	
			Irbesartan	129	85 (65.9)	50.78 (7.10)	31.2	45.08	52.62	56.15	64.3	
		Week 48	Sparsentan	127	97 (76.4)	51.64 (7.08)	25.4	47.92	53.46	56.15	66.0	
			Irbesartan	129	76 (58.9)	51.51 (8.31)	18.0	47.94	54.51	56.84	64.5	
		Week 70	Sparsentan	127	101 (79.5)	50.48 (7.77)	28.0	44.05	52.35	56.42	63.2	
			Irbesartan	129	83 (64.3)	50.13 (7.99)	21.7	47.36	52.22	56.13	60.3	
		Week 94	Sparsentan	127	94 (74.0)	50.53 (7.52)	23.8	44.96	53.04	56.15	61.3	
			Irbesartan	129	79 (61.2)	51.02 (7.65)	20.0	47.89	53.46	56.15	61.3	
		Week 110	Sparsentan	127	93 (73.2)	50.57 (7.34)	32.6	44.05	52.62	55.92	64.2	
			Irbesartan	129	72 (55.8)	50.32 (8.06)	25.4	44.81	51.97	56.40	62.6	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	127	99 (78.0)	0.25 (6.51)	-14.9	-3.48	0.00	3.69	20.4	0.09 [-0.20, 0.38]
			Irbesartan	129	85 (65.9)	-0.30 (5.62)	-20.0	-2.69	0.00	2.96	16.9	
		Week 48	Sparsentan	127	97 (76.4)	1.12 (6.29)	-18.7	-2.83	0.00	4.71	20.6	0.10 [-0.20, 0.40]
			Irbesartan	129	76 (58.9)	0.37 (8.77)	-35.7	-4.23	0.81	3.66	20.4	
		Week 70	Sparsentan	127	101 (79.5)	-0.29 (6.60)	-20.6	-2.95	0.38	2.98	21.2	0.12 [-0.17, 0.41]
			Irbesartan	129	83 (64.3)	-1.12 (7.91)	-28.0	-4.76	-0.26	3.49	17.8	
		Week 94	Sparsentan	127	94 (74.0)	0.14 (6.79)	-19.6	-3.46	-0.14	4.86	20.7	0.02 [-0.28, 0.32]
			Irbesartan	129	79 (61.2)	-0.02 (6.06)	-18.6	-3.47	0.41	3.77	13.6	
		Week 110	Sparsentan	127	93 (73.2)	-0.38 (7.54)	-17.9	-2.90	0.00	4.53	16.4	0.06 [-0.25, 0.37]
			Irbesartan	129	72 (55.8)	-0.82 (7.09)	-18.3	-5.03	-0.29	4.05	15.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	KDQOL-SF12: PCS	Baseline	Sparsentan	49	47 (95.9)	53.00 (6.69)	37.4	48.78	53.79	57.76	61.8	
			Irbesartan	48	44 (91.7)	52.03 (7.49)	29.6	49.15	54.95	56.30	64.3	
		Week 24	Sparsentan	49	39 (79.6)	53.54 (6.86)	27.3	50.55	56.15	57.49	62.9	
			Irbesartan	48	33 (68.8)	53.37 (5.41)	34.9	52.40	54.53	56.15	60.8	
		Week 48	Sparsentan	49	45 (91.8)	51.72 (8.05)	29.8	46.56	53.83	57.49	66.1	
			Irbesartan	48	33 (68.8)	50.68 (6.74)	33.7	45.97	52.37	56.15	58.6	
		Week 70	Sparsentan	49	40 (81.6)	52.29 (7.02)	21.9	50.42	53.41	56.15	66.8	
			Irbesartan	48	32 (66.7)	50.79 (8.76)	23.5	47.65	53.48	57.07	59.6	
		Week 94	Sparsentan	49	41 (83.7)	51.67 (7.62)	27.9	45.88	54.26	57.35	63.5	
			Irbesartan	48	35 (72.9)	50.98 (6.51)	30.4	47.55	52.60	56.15	59.9	
		Week 110	Sparsentan	49	36 (73.5)	52.30 (6.30)	34.7	47.36	53.92	57.83	59.4	
			Irbesartan	48	32 (66.7)	51.75 (6.92)	32.1	47.17	53.34	57.67	60.9	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	49	39 (79.6)	0.64 (6.99)	-24.8	-2.13	0.00	4.30	14.3	0.05 [-0.41, 0.51]
			Irbesartan	48	33 (68.8)	0.30 (6.11)	-15.6	-1.89	0.00	3.24	13.3	
		Week 48	Sparsentan	49	45 (91.8)	-1.08 (7.58)	-22.3	-3.76	-0.88	3.45	17.5	0.10 [-0.35, 0.55]
			Irbesartan	48	33 (68.8)	-1.84 (7.76)	-20.8	-4.32	-1.06	1.61	16.4	
		Week 70	Sparsentan	49	40 (81.6)	-0.20 (7.76)	-30.2	-3.69	-0.31	3.88	15.8	0.36 [-0.11, 0.82]
			Irbesartan	48	32 (66.7)	-2.97 (7.82)	-25.1	-7.96	-1.08	1.61	9.7	
		Week 94	Sparsentan	49	41 (83.7)	-0.79 (8.77)	-24.1	-3.31	0.56	3.49	15.9	0.09 [-0.36, 0.54]
			Irbesartan	48	35 (72.9)	-1.58 (8.56)	-20.1	-6.39	-1.62	3.17	18.0	
		Week 110	Sparsentan	49	36 (73.5)	-0.09 (7.28)	-17.4	-3.89	-0.60	3.85	16.1	0.14 [-0.34, 0.62]
			Irbesartan	48	32 (66.7)	-1.13 (7.54)	-18.5	-5.19	-1.03	3.04	15.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	KDQOL-SF12: PCS	Baseline	Sparsentan	26	24 (92.3)	50.73 (11.70)	12.4	49.48	54.33	56.81	62.9	
			Irbesartan	25	24 (96.0)	52.47 (8.27)	21.6	51.67	55.35	56.15	61.1	
		Week 24	Sparsentan	26	21 (80.8)	52.48 (7.66)	35.4	51.29	56.15	57.49	59.7	
			Irbesartan	25	20 (80.0)	52.72 (8.49)	20.8	51.95	54.58	57.35	59.7	
		Week 48	Sparsentan	26	23 (88.5)	50.41 (6.97)	32.1	46.58	51.29	56.15	58.6	
			Irbesartan	25	18 (72.0)	54.09 (5.97)	40.3	53.17	56.28	58.02	60.8	
		Week 70	Sparsentan	26	22 (84.6)	48.12 (8.65)	31.6	42.16	50.41	56.22	58.1	
			Irbesartan	25	20 (80.0)	55.94 (5.29)	43.3	55.34	57.48	59.28	63.0	
		Week 94	Sparsentan	26	20 (76.9)	50.55 (8.35)	30.9	44.80	53.91	56.15	61.0	
			Irbesartan	25	19 (76.0)	55.52 (4.33)	47.4	51.84	56.44	57.49	62.7	
		Week 110	Sparsentan	26	21 (80.8)	49.45 (9.78)	22.8	46.04	52.38	57.20	59.7	
			Irbesartan	25	17 (68.0)	54.34 (4.69)	43.1	51.02	56.15	56.71	61.3	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	26	21 (80.8)	0.68 (6.68)	-16.1	-2.65	0.98	2.98	14.1	0.15 [-0.47, 0.76]
			Irbesartan	25	20 (80.0)	-0.11 (3.39)	-7.0	-1.42	-0.16	0.96	10.0	
		Week 48	Sparsentan	26	23 (88.5)	0.19 (7.81)	-11.7	-4.37	-0.08	2.28	24.7	0.02 [-0.60, 0.63]
			Irbesartan	25	18 (72.0)	0.07 (6.08)	-11.6	-2.98	1.33	2.42	13.1	
		Week 70	Sparsentan	26	22 (84.6)	-1.89 (11.57)	-25.7	-8.46	-2.63	3.78	31.3	-0.40 [-1.01, 0.21]
			Irbesartan	25	20 (80.0)	1.69 (4.40)	-7.0	-0.57	1.48	3.63	11.2	
		Week 94	Sparsentan	26	20 (76.9)	-0.98 (6.39)	-15.9	-4.89	-0.64	3.17	9.8	-0.31 [-0.94, 0.32]
			Irbesartan	25	19 (76.0)	0.60 (3.20)	-5.5	-2.02	0.81	3.01	6.3	
		Week 110	Sparsentan	26	21 (80.8)	-2.35 (7.32)	-20.5	-5.65	-1.80	2.03	12.2	-0.50 [-1.15, 0.15]
			Irbesartan	25	17 (68.0)	0.62 (3.66)	-5.7	-1.09	0.00	1.61	8.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 2												
< 45 mL/min/1.73 m**2	KDQOL-SF12: PCS	Baseline	Sparsentan	82	73 (89.0)	49.80 (7.82)	29.2	44.56	51.81	55.95	60.8	
			Irbesartan	80	70 (87.5)	50.48 (6.75)	29.2	46.31	52.11	56.06	60.1	
		Week 24	Sparsentan	82	64 (78.0)	50.57 (7.38)	16.3	46.16	52.64	56.15	60.9	
			Irbesartan	80	51 (63.8)	49.80 (6.61)	33.8	43.80	52.09	55.88	61.9	
		Week 48	Sparsentan	82	63 (76.8)	51.48 (7.52)	25.4	46.85	53.71	56.71	61.9	
			Irbesartan	80	45 (56.3)	50.17 (9.31)	18.0	47.10	52.50	55.86	64.5	
		Week 70	Sparsentan	82	65 (79.3)	50.39 (8.09)	28.0	44.11	53.17	56.62	61.1	
			Irbesartan	80	50 (62.5)	48.63 (8.90)	21.7	44.28	51.23	55.28	60.3	
		Week 94	Sparsentan	82	61 (74.4)	49.78 (7.93)	23.8	43.05	52.91	56.15	59.1	
			Irbesartan	80	48 (60.0)	49.65 (7.93)	20.0	46.20	52.23	55.67	58.8	
		Week 110	Sparsentan	82	57 (69.5)	50.75 (6.59)	34.1	47.39	52.50	55.33	63.1	
			Irbesartan	80	44 (55.0)	48.81 (8.17)	25.4	44.43	51.33	55.32	60.0	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	82	64 (78.0)	0.42 (5.94)	-13.4	-3.24	-0.12	3.92	15.5	0.09 [-0.27, 0.46]
			Irbesartan	80	51 (63.8)	-0.13 (5.73)	-15.0	-2.38	0.00	3.57	16.9	
		Week 48	Sparsentan	82	63 (76.8)	1.48 (6.23)	-18.7	-2.43	0.00	4.71	20.6	0.22 [-0.17, 0.60]
			Irbesartan	80	45 (56.3)	-0.30 (10.46)	-35.7	-4.31	-0.27	3.28	20.4	
		Week 70	Sparsentan	82	65 (79.3)	0.11 (6.71)	-20.6	-2.89	0.29	2.98	21.2	0.22 [-0.15, 0.59]
			Irbesartan	80	50 (62.5)	-1.62 (8.97)	-28.0	-5.69	-0.82	3.64	17.8	
		Week 94	Sparsentan	82	61 (74.4)	-0.45 (7.13)	-19.6	-3.24	-1.22	2.69	20.7	0.05 [-0.33, 0.42]
			Irbesartan	80	48 (60.0)	-0.78 (6.99)	-18.6	-4.69	0.29	3.27	13.6	
		Week 110	Sparsentan	82	57 (69.5)	0.22 (7.02)	-17.9	-2.69	0.00	3.91	16.4	0.31 [-0.09, 0.70]
			Irbesartan	80	44 (55.0)	-2.06 (7.86)	-18.3	-7.95	-0.98	1.89	15.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
45 to < 60 mL/min/1.73 m**2	KDQOL-SF12: PCS	Baseline	Sparsentan	45	44 (97.8)	51.30 (7.34)	25.8	46.86	52.52	56.15	63.5	
			Irbesartan	49	45 (91.8)	52.71 (6.14)	27.9	50.34	53.18	56.71	62.0	
		Week 24	Sparsentan	45	35 (77.8)	51.14 (7.54)	31.2	45.43	53.03	56.48	64.0	
			Irbesartan	49	34 (69.4)	52.25 (7.65)	31.2	47.89	54.95	57.03	64.3	
		Week 48	Sparsentan	45	34 (75.6)	51.92 (6.27)	33.2	49.81	53.19	55.09	66.0	
			Irbesartan	49	31 (63.3)	53.46 (6.23)	39.0	49.95	54.80	57.76	63.4	
		Week 70	Sparsentan	45	36 (80.0)	50.65 (7.27)	35.2	43.90	51.99	56.17	63.2	
			Irbesartan	49	33 (67.3)	52.40 (5.78)	34.6	50.07	53.71	56.15	59.3	
		Week 94	Sparsentan	45	33 (73.3)	51.90 (6.58)	34.1	49.92	53.17	56.15	61.3	
			Irbesartan	49	31 (63.3)	53.13 (6.80)	29.2	52.50	54.53	56.96	61.3	
		Week 110	Sparsentan	45	36 (80.0)	50.27 (8.48)	32.6	42.27	54.13	56.15	64.2	
			Irbesartan	49	28 (57.1)	52.67 (7.42)	35.0	46.39	54.66	58.43	62.6	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	45	35 (77.8)	-0.06 (7.53)	-14.9	-4.25	0.27	2.88	20.4	0.08 [-0.40, 0.55]
			Irbesartan	49	34 (69.4)	-0.56 (5.51)	-20.0	-3.09	0.00	2.22	10.1	
		Week 48	Sparsentan	45	34 (75.6)	0.46 (6.45)	-13.9	-3.27	-0.31	4.84	17.0	-0.15 [-0.63, 0.34]
			Irbesartan	49	31 (63.3)	1.34 (5.47)	-11.3	0.00	2.10	4.04	12.5	
		Week 70	Sparsentan	45	36 (80.0)	-1.00 (6.43)	-16.7	-5.16	0.46	3.04	11.0	-0.10 [-0.57, 0.37]
			Irbesartan	49	33 (67.3)	-0.37 (6.02)	-24.4	-2.07	0.00	2.61	9.1	
		Week 94	Sparsentan	45	33 (73.3)	1.24 (6.06)	-12.6	-3.46	1.89	6.13	14.8	0.01 [-0.48, 0.50]
			Irbesartan	49	31 (63.3)	1.17 (4.07)	-7.0	-1.82	1.29	4.70	9.1	
		Week 110	Sparsentan	45	36 (80.0)	-1.33 (8.31)	-17.8	-7.16	0.00	4.97	15.6	-0.35 [-0.84, 0.15]
			Irbesartan	49	28 (57.1)	1.14 (5.23)	-8.9	-2.57	1.75	4.59	11.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	KDQOL-SF12: PCS	Baseline	Sparsentan	49	47 (95.9)	53.00 (6.69)	37.4	48.78	53.79	57.76	61.8	
			Irbesartan	48	44 (91.7)	52.03 (7.49)	29.6	49.15	54.95	56.30	64.3	
		Week 24	Sparsentan	49	39 (79.6)	53.54 (6.86)	27.3	50.55	56.15	57.49	62.9	
			Irbesartan	48	33 (68.8)	53.37 (5.41)	34.9	52.40	54.53	56.15	60.8	
		Week 48	Sparsentan	49	45 (91.8)	51.72 (8.05)	29.8	46.56	53.83	57.49	66.1	
			Irbesartan	48	33 (68.8)	50.68 (6.74)	33.7	45.97	52.37	56.15	58.6	
		Week 70	Sparsentan	49	40 (81.6)	52.29 (7.02)	21.9	50.42	53.41	56.15	66.8	
			Irbesartan	48	32 (66.7)	50.79 (8.76)	23.5	47.65	53.48	57.07	59.6	
		Week 94	Sparsentan	49	41 (83.7)	51.67 (7.62)	27.9	45.88	54.26	57.35	63.5	
			Irbesartan	48	35 (72.9)	50.98 (6.51)	30.4	47.55	52.60	56.15	59.9	
		Week 110	Sparsentan	49	36 (73.5)	52.30 (6.30)	34.7	47.36	53.92	57.83	59.4	
			Irbesartan	48	32 (66.7)	51.75 (6.92)	32.1	47.17	53.34	57.67	60.9	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	49	39 (79.6)	0.64 (6.99)	-24.8	-2.13	0.00	4.30	14.3	0.05 [-0.41, 0.51]
			Irbesartan	48	33 (68.8)	0.30 (6.11)	-15.6	-1.89	0.00	3.24	13.3	
		Week 48	Sparsentan	49	45 (91.8)	-1.08 (7.58)	-22.3	-3.76	-0.88	3.45	17.5	0.10 [-0.35, 0.55]
			Irbesartan	48	33 (68.8)	-1.84 (7.76)	-20.8	-4.32	-1.06	1.61	16.4	
		Week 70	Sparsentan	49	40 (81.6)	-0.20 (7.76)	-30.2	-3.69	-0.31	3.88	15.8	0.36 [-0.11, 0.82]
			Irbesartan	48	32 (66.7)	-2.97 (7.82)	-25.1	-7.96	-1.08	1.61	9.7	
		Week 94	Sparsentan	49	41 (83.7)	-0.79 (8.77)	-24.1	-3.31	0.56	3.49	15.9	0.09 [-0.36, 0.54]
			Irbesartan	48	35 (72.9)	-1.58 (8.56)	-20.1	-6.39	-1.62	3.17	18.0	
		Week 110	Sparsentan	49	36 (73.5)	-0.09 (7.28)	-17.4	-3.89	-0.60	3.85	16.1	0.14 [-0.34, 0.62]
			Irbesartan	48	32 (66.7)	-1.13 (7.54)	-18.5	-5.19	-1.03	3.04	15.0	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	KDQOL-SF12: PCS	Baseline	Sparsentan	26	24 (92.3)	50.73 (11.70)	12.4	49.48	54.33	56.81	62.9	
			Irbesartan	25	24 (96.0)	52.47 (8.27)	21.6	51.67	55.35	56.15	61.1	
		Week 24	Sparsentan	26	21 (80.8)	52.48 (7.66)	35.4	51.29	56.15	57.49	59.7	
			Irbesartan	25	20 (80.0)	52.72 (8.49)	20.8	51.95	54.58	57.35	59.7	
		Week 48	Sparsentan	26	23 (88.5)	50.41 (6.97)	32.1	46.58	51.29	56.15	58.6	
			Irbesartan	25	18 (72.0)	54.09 (5.97)	40.3	53.17	56.28	58.02	60.8	
		Week 70	Sparsentan	26	22 (84.6)	48.12 (8.65)	31.6	42.16	50.41	56.22	58.1	
			Irbesartan	25	20 (80.0)	55.94 (5.29)	43.3	55.34	57.48	59.28	63.0	
		Week 94	Sparsentan	26	20 (76.9)	50.55 (8.35)	30.9	44.80	53.91	56.15	61.0	
			Irbesartan	25	19 (76.0)	55.52 (4.33)	47.4	51.84	56.44	57.49	62.7	
		Week 110	Sparsentan	26	21 (80.8)	49.45 (9.78)	22.8	46.04	52.38	57.20	59.7	
			Irbesartan	25	17 (68.0)	54.34 (4.69)	43.1	51.02	56.15	56.71	61.3	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	26	21 (80.8)	0.68 (6.68)	-16.1	-2.65	0.98	2.98	14.1	0.15 [-0.47, 0.76]
			Irbesartan	25	20 (80.0)	-0.11 (3.39)	-7.0	-1.42	-0.16	0.96	10.0	
		Week 48	Sparsentan	26	23 (88.5)	0.19 (7.81)	-11.7	-4.37	-0.08	2.28	24.7	0.02 [-0.60, 0.63]
			Irbesartan	25	18 (72.0)	0.07 (6.08)	-11.6	-2.98	1.33	2.42	13.1	
		Week 70	Sparsentan	26	22 (84.6)	-1.89 (11.57)	-25.7	-8.46	-2.63	3.78	31.3	-0.40 [-1.01, 0.21]
			Irbesartan	25	20 (80.0)	1.69 (4.40)	-7.0	-0.57	1.48	3.63	11.2	
		Week 94	Sparsentan	26	20 (76.9)	-0.98 (6.39)	-15.9	-4.89	-0.64	3.17	9.8	-0.31 [-0.94, 0.32]
			Irbesartan	25	19 (76.0)	0.60 (3.20)	-5.5	-2.02	0.81	3.01	6.3	
		Week 110	Sparsentan	26	21 (80.8)	-2.35 (7.32)	-20.5	-5.65	-1.80	2.03	12.2	-0.50 [-1.15, 0.15]
			Irbesartan	25	17 (68.0)	0.62 (3.66)	-5.7	-1.09	0.00	1.61	8.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline urine protein excretion												
<= 1.75 g/day	KDQOL-SF12: PCS	Baseline	Sparsentan	98	93 (94.9)	50.35 (8.28)	25.5	46.10	52.40	56.74	62.3	
			Irbesartan	93	83 (89.2)	51.93 (6.71)	21.6	49.79	53.43	56.15	60.8	
		Week 24	Sparsentan	98	81 (82.7)	50.96 (7.37)	27.3	45.00	52.70	56.15	64.0	
			Irbesartan	93	59 (63.4)	52.35 (7.13)	20.8	50.61	54.51	56.71	60.8	
		Week 48	Sparsentan	98	83 (84.7)	51.41 (7.33)	29.8	46.85	53.39	56.15	66.1	
			Irbesartan	93	57 (61.3)	52.48 (6.32)	33.7	49.68	54.55	57.20	63.4	
		Week 70	Sparsentan	98	77 (78.6)	49.52 (8.26)	21.9	44.05	51.63	56.15	66.8	
			Irbesartan	93	62 (66.7)	52.24 (6.82)	30.0	48.45	53.59	57.22	63.0	
		Week 94	Sparsentan	98	79 (80.6)	49.89 (8.21)	27.9	41.68	52.91	56.15	63.5	
			Irbesartan	93	64 (68.8)	51.87 (6.69)	34.4	47.49	54.15	56.69	62.7	
		Week 110	Sparsentan	98	76 (77.6)	49.14 (8.38)	22.8	42.51	51.19	54.98	63.2	
			Irbesartan	93	57 (61.3)	51.27 (8.30)	25.4	44.94	53.68	57.76	62.6	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	98	81 (82.7)	0.82 (7.48)	-24.8	-3.69	0.00	4.90	20.4	0.16 [-0.18, 0.49]
			Irbesartan	93	59 (63.4)	-0.24 (5.70)	-20.0	-2.16	0.00	2.31	16.9	
		Week 48	Sparsentan	98	83 (84.7)	0.88 (6.62)	-22.3	-2.38	0.60	4.84	17.5	0.15 [-0.18, 0.49]
			Irbesartan	93	57 (61.3)	-0.14 (6.55)	-20.8	-2.24	0.29	2.42	16.4	
		Week 70	Sparsentan	98	77 (78.6)	-0.97 (8.31)	-30.2	-4.50	-0.27	3.78	21.2	-0.03 [-0.36, 0.31]
			Irbesartan	93	62 (66.7)	-0.75 (6.36)	-25.1	-3.77	0.14	2.69	15.2	
		Week 94	Sparsentan	98	79 (80.6)	-0.10 (8.37)	-24.1	-4.03	0.19	5.11	20.7	0.06 [-0.27, 0.39]
			Irbesartan	93	64 (68.8)	-0.57 (6.05)	-14.7	-3.75	0.35	2.71	18.0	
		Week 110	Sparsentan	98	76 (77.6)	-1.42 (8.21)	-20.5	-6.74	-0.85	4.22	16.1	-0.04 [-0.38, 0.31]
			Irbesartan	93	57 (61.3)	-1.14 (7.29)	-18.5	-5.71	0.00	2.15	15.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 1.75 g/day	KDQOL-SF12: PCS	Baseline	Sparsentan	104	95 (91.3)	51.77 (7.87)	12.4	48.84	53.50	56.68	63.5	
			Irbesartan	109	100 (91.7)	51.44 (7.29)	27.9	48.39	53.46	56.34	64.3	
		Week 24	Sparsentan	104	78 (75.0)	52.41 (7.32)	16.3	50.30	54.26	57.49	61.8	
			Irbesartan	109	79 (72.5)	51.18 (6.92)	31.2	45.96	53.46	56.15	64.3	
		Week 48	Sparsentan	104	82 (78.8)	51.56 (7.33)	25.4	47.13	53.46	57.22	62.1	
			Irbesartan	109	70 (64.2)	51.00 (8.57)	18.0	46.17	54.55	56.71	64.5	
		Week 70	Sparsentan	104	86 (82.7)	51.57 (7.21)	28.0	47.70	54.10	56.40	63.2	
			Irbesartan	109	73 (67.0)	50.21 (8.91)	21.7	46.63	53.46	56.15	60.3	
		Week 94	Sparsentan	104	76 (73.1)	51.81 (6.87)	23.8	49.11	54.02	56.49	61.7	
			Irbesartan	109	69 (63.3)	51.45 (7.52)	20.0	48.24	53.46	56.15	61.3	
		Week 110	Sparsentan	104	74 (71.2)	52.56 (6.06)	32.6	49.10	53.46	57.20	64.2	
			Irbesartan	109	64 (58.7)	51.25 (6.69)	28.1	48.22	52.78	56.13	62.0	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	104	78 (75.0)	-0.03 (5.59)	-16.1	-2.18	0.14	3.10	15.5	0.00 [-0.31, 0.32]
			Irbesartan	109	79 (72.5)	-0.05 (5.30)	-15.6	-2.69	0.00	3.22	13.3	
		Week 48	Sparsentan	104	82 (78.8)	-0.11 (7.18)	-18.7	-3.58	-0.58	3.45	24.7	0.03 [-0.29, 0.35]
			Irbesartan	109	70 (64.2)	-0.34 (9.35)	-35.7	-5.29	0.18	5.13	20.4	
		Week 70	Sparsentan	104	86 (82.7)	-0.05 (7.11)	-20.6	-2.77	0.17	2.90	31.3	0.18 [-0.13, 0.50]
			Irbesartan	109	73 (67.0)	-1.48 (8.48)	-28.0	-4.57	-0.29	2.61	17.8	
		Week 94	Sparsentan	104	76 (73.1)	-0.41 (6.01)	-20.0	-3.50	-0.52	3.32	13.7	-0.04 [-0.37, 0.28]
			Irbesartan	109	69 (63.3)	-0.12 (6.97)	-20.1	-3.49	0.00	4.04	15.4	
		Week 110	Sparsentan	104	74 (71.2)	0.27 (6.50)	-17.9	-2.69	-0.04	3.64	16.4	0.09 [-0.25, 0.42]
			Irbesartan	109	64 (58.7)	-0.30 (6.41)	-18.3	-3.47	-0.88	4.45	15.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline use of antihypertensives												
Yes	KDQOL-SF12: PCS	Baseline	Sparsentan	90	80 (88.9)	50.28 (8.52)	25.8	46.20	52.90	56.15	62.3	
			Irbesartan	88	77 (87.5)	50.39 (7.25)	27.9	46.31	51.28	55.86	64.3	
		Week 24	Sparsentan	90	68 (75.6)	51.03 (8.35)	16.3	45.53	52.84	57.08	64.0	
			Irbesartan	88	52 (59.1)	50.60 (6.50)	31.2	45.81	52.77	56.01	61.9	
		Week 48	Sparsentan	90	68 (75.6)	50.68 (8.14)	25.4	45.19	53.35	56.15	66.0	
			Irbesartan	88	48 (54.5)	50.84 (7.08)	32.8	46.16	51.91	56.15	64.5	
		Week 70	Sparsentan	90	69 (76.7)	49.51 (8.14)	28.0	42.96	51.57	56.15	63.2	
			Irbesartan	88	51 (58.0)	49.41 (8.02)	26.4	44.28	51.67	55.28	59.6	
		Week 94	Sparsentan	90	66 (73.3)	49.88 (7.62)	23.8	43.05	51.60	56.15	61.3	
			Irbesartan	88	57 (64.8)	50.26 (6.69)	29.2	47.89	52.79	54.53	58.6	
		Week 110	Sparsentan	90	64 (71.1)	50.89 (7.12)	32.6	44.82	52.25	56.22	63.2	
			Irbesartan	88	51 (58.0)	49.37 (8.28)	25.4	43.10	51.26	56.15	61.2	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	90	68 (75.6)	0.38 (7.03)	-16.1	-3.41	-0.64	3.89	20.4	0.03 [-0.33, 0.39]
			Irbesartan	88	52 (59.1)	0.17 (6.38)	-15.0	-2.93	0.00	3.50	16.9	
		Week 48	Sparsentan	90	68 (75.6)	0.56 (7.03)	-15.4	-3.52	-0.03	4.78	20.6	-0.05 [-0.42, 0.32]
			Irbesartan	88	48 (54.5)	0.93 (9.19)	-24.7	-4.07	-0.06	6.95	20.4	
		Week 70	Sparsentan	90	69 (76.7)	-1.09 (6.82)	-20.6	-3.34	0.29	2.69	15.6	0.08 [-0.29, 0.44]
			Irbesartan	88	51 (58.0)	-1.65 (8.27)	-28.0	-5.65	-0.29	2.44	15.2	
		Week 94	Sparsentan	90	66 (73.3)	0.08 (7.73)	-19.6	-3.64	-0.23	4.99	20.7	-0.05 [-0.40, 0.31]
			Irbesartan	88	57 (64.8)	0.42 (7.26)	-18.6	-3.49	1.06	4.87	18.0	
		Week 110	Sparsentan	90	64 (71.1)	0.24 (7.37)	-16.4	-2.82	0.00	4.86	16.4	0.22 [-0.15, 0.59]
			Irbesartan	88	51 (58.0)	-1.45 (8.12)	-18.5	-6.59	-1.01	3.77	15.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	KDQOL-SF12: PCS	Baseline	Sparsentan	112	108 (96.4)	51.65 (7.74)	12.4	47.39	53.45	56.86	63.5	
			Irbesartan	114	106 (93.0)	52.58 (6.73)	21.6	50.34	54.51	56.37	62.0	
		Week 24	Sparsentan	112	91 (81.3)	52.15 (6.54)	27.3	50.15	53.46	56.66	62.0	
			Irbesartan	114	86 (75.4)	52.33 (7.26)	20.8	51.35	54.66	56.22	64.3	
		Week 48	Sparsentan	112	97 (86.6)	52.05 (6.65)	29.8	48.31	53.46	56.44	66.1	
			Irbesartan	114	79 (69.3)	52.16 (7.98)	18.0	49.48	54.80	57.49	63.5	
		Week 70	Sparsentan	112	94 (83.9)	51.41 (7.43)	21.9	46.39	53.27	56.42	66.8	
			Irbesartan	114	84 (73.7)	52.20 (7.93)	21.7	48.73	54.80	57.20	63.0	
		Week 94	Sparsentan	112	89 (79.5)	51.54 (7.58)	27.9	48.14	54.53	56.56	63.5	
			Irbesartan	114	76 (66.7)	52.70 (7.28)	20.0	49.03	54.80	57.36	62.7	
		Week 110	Sparsentan	112	86 (76.8)	50.78 (7.81)	22.8	46.35	53.46	56.42	64.2	
			Irbesartan	114	70 (61.4)	52.64 (6.52)	28.1	49.25	53.91	57.55	62.6	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	112	91 (81.3)	0.42 (6.32)	-24.8	-3.25	0.29	4.08	14.3	0.13 [-0.17, 0.42]
			Irbesartan	114	86 (75.4)	-0.31 (4.84)	-20.0	-2.13	0.00	1.71	10.9	
		Week 48	Sparsentan	112	97 (86.6)	0.27 (6.85)	-22.3	-3.11	-0.08	3.45	24.7	0.17 [-0.12, 0.47]
			Irbesartan	114	79 (69.3)	-0.97 (7.48)	-35.7	-4.22	0.54	2.22	18.9	
		Week 70	Sparsentan	112	94 (83.9)	-0.04 (8.28)	-30.2	-4.04	-0.23	3.73	31.3	0.10 [-0.19, 0.40]
			Irbesartan	114	84 (73.7)	-0.84 (7.14)	-27.2	-3.31	0.00	2.65	17.8	
		Week 94	Sparsentan	112	89 (79.5)	-0.50 (6.97)	-24.1	-3.31	-0.14	3.46	15.9	0.06 [-0.24, 0.37]
			Irbesartan	114	76 (66.7)	-0.91 (5.90)	-20.1	-3.63	0.00	2.57	13.6	
		Week 110	Sparsentan	112	86 (76.8)	-1.20 (7.47)	-20.5	-4.78	-0.63	2.69	16.1	-0.16 [-0.47, 0.16]
			Irbesartan	114	70 (61.4)	-0.15 (5.69)	-13.7	-4.22	0.00	3.46	15.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Time since renal biopsy												
<= 5 years	KDQOL-SF12: PCS	Baseline	Sparsentan	113	105 (92.9)	49.79 (7.95)	25.8	45.62	51.57	56.15	63.5	
			Irbesartan	127	118 (92.9)	51.56 (7.62)	21.6	48.83	53.95	56.42	64.3	
		Week 24	Sparsentan	113	90 (79.6)	51.43 (7.53)	16.3	47.50	53.04	56.48	64.0	
			Irbesartan	127	91 (71.7)	51.22 (7.54)	20.8	46.70	54.36	56.15	59.7	
		Week 48	Sparsentan	113	93 (82.3)	50.51 (7.28)	25.4	46.11	52.88	55.87	66.0	
			Irbesartan	127	86 (67.7)	51.71 (8.36)	18.0	47.21	54.72	57.02	64.5	
		Week 70	Sparsentan	113	91 (80.5)	50.10 (7.78)	28.0	44.11	52.40	56.15	63.2	
			Irbesartan	127	88 (69.3)	51.65 (8.42)	21.7	48.93	54.38	57.20	63.0	
		Week 94	Sparsentan	113	88 (77.9)	50.56 (7.67)	23.8	44.90	53.04	56.15	61.7	
			Irbesartan	127	88 (69.3)	51.87 (7.55)	20.0	49.16	54.15	56.53	62.7	
		Week 110	Sparsentan	113	88 (77.9)	50.96 (6.49)	35.4	46.19	52.37	56.03	64.2	
			Irbesartan	127	80 (63.0)	51.41 (7.84)	25.4	46.22	53.59	57.10	62.6	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	113	90 (79.6)	1.38 (6.75)	-16.1	-2.69	0.75	4.84	20.4	0.27 [-0.02, 0.56]
			Irbesartan	127	91 (71.7)	-0.34 (5.99)	-20.0	-2.77	-0.88	3.22	16.9	
		Week 48	Sparsentan	113	93 (82.3)	0.57 (7.15)	-18.7	-3.28	-0.06	4.84	20.6	0.06 [-0.23, 0.36]
			Irbesartan	127	86 (67.7)	0.06 (8.94)	-35.7	-4.22	0.93	4.27	20.4	
		Week 70	Sparsentan	113	91 (80.5)	-0.08 (7.43)	-25.7	-3.10	0.27	3.78	21.2	0.07 [-0.23, 0.36]
			Irbesartan	127	88 (69.3)	-0.59 (7.85)	-28.0	-3.31	0.00	3.57	17.8	
		Week 94	Sparsentan	113	88 (77.9)	0.66 (7.52)	-19.6	-3.28	0.27	5.05	20.7	0.07 [-0.23, 0.37]
			Irbesartan	127	88 (69.3)	0.16 (6.80)	-20.1	-3.48	0.89	4.27	18.0	
		Week 110	Sparsentan	113	88 (77.9)	0.60 (7.59)	-20.5	-3.17	0.00	5.13	16.4	0.09 [-0.21, 0.40]
			Irbesartan	127	80 (63.0)	-0.10 (7.32)	-18.5	-4.44	-0.01	4.57	15.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 5 years	KDQOL-SF12: PCS	Baseline	Sparsentan	89	83 (93.3)	52.69 (8.01)	12.4	49.93	54.80	57.25	62.3	
			Irbesartan	75	65 (86.7)	51.85 (5.81)	34.9	49.51	53.43	56.11	62.0	
		Week 24	Sparsentan	89	69 (77.5)	51.99 (7.18)	27.3	49.67	53.46	57.20	62.9	
			Irbesartan	75	47 (62.7)	52.58 (5.82)	39.0	47.89	53.46	57.05	64.3	
		Week 48	Sparsentan	89	72 (80.9)	52.75 (7.20)	29.8	50.07	53.89	57.49	66.1	
			Irbesartan	75	41 (54.7)	51.57 (6.00)	37.7	48.01	53.46	56.15	60.8	
		Week 70	Sparsentan	89	72 (80.9)	51.24 (7.76)	21.9	45.42	53.71	56.43	66.8	
			Irbesartan	75	47 (62.7)	50.21 (7.32)	22.3	46.26	52.11	56.13	59.7	
		Week 94	Sparsentan	89	67 (75.3)	51.20 (7.60)	27.9	46.35	53.46	56.95	63.5	
			Irbesartan	75	45 (60.0)	51.23 (6.22)	37.7	47.29	53.17	56.15	61.3	
		Week 110	Sparsentan	89	62 (69.7)	50.64 (8.79)	22.8	43.24	53.18	56.48	63.1	
			Irbesartan	75	41 (54.7)	50.97 (6.75)	36.1	46.91	51.90	56.48	62.0	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	89	69 (77.5)	-0.88 (6.25)	-24.8	-4.03	-0.27	2.69	14.1	-0.21 [-0.58, 0.16]
			Irbesartan	75	47 (62.7)	0.28 (4.25)	-12.7	-0.83	0.56	2.31	10.8	
		Week 48	Sparsentan	89	72 (80.9)	0.16 (6.61)	-22.3	-3.04	-0.29	3.49	24.7	0.16 [-0.22, 0.55]
			Irbesartan	75	41 (54.7)	-0.89 (6.36)	-12.5	-3.45	0.00	1.35	15.6	
		Week 70	Sparsentan	89	72 (80.9)	-0.99 (8.03)	-30.2	-4.89	-0.38	2.46	31.3	0.16 [-0.21, 0.52]
			Irbesartan	75	47 (62.7)	-2.18 (6.96)	-27.2	-4.76	-0.93	1.61	15.7	
		Week 94	Sparsentan	89	67 (75.3)	-1.45 (6.83)	-24.1	-3.53	-1.42	2.69	10.2	-0.02 [-0.40, 0.36]
			Irbesartan	75	45 (60.0)	-1.31 (5.90)	-14.7	-5.11	0.00	1.56	13.6	
		Week 110	Sparsentan	89	62 (69.7)	-2.27 (6.93)	-17.9	-5.45	-1.18	2.13	8.6	-0.06 [-0.46, 0.33]
			Irbesartan	75	41 (54.7)	-1.86 (5.63)	-17.3	-4.65	-0.81	1.61	9.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: History of hypertension												
Yes	KDQOL-SF12: PCS	Baseline	Sparsentan	155	142 (91.6)	50.13 (8.54)	12.4	45.76	52.34	56.15	62.3	
			Irbesartan	161	143 (88.8)	51.59 (6.91)	27.9	48.76	53.24	56.15	64.3	
		Week 24	Sparsentan	155	121 (78.1)	51.12 (7.51)	16.3	46.96	52.77	56.15	64.0	
			Irbesartan	161	106 (65.8)	51.43 (6.90)	31.2	46.58	53.70	56.15	64.3	
		Week 48	Sparsentan	155	124 (80.0)	50.83 (7.21)	25.4	46.57	53.18	56.06	66.0	
			Irbesartan	161	97 (60.2)	51.62 (7.94)	18.0	48.01	54.80	56.71	64.5	
		Week 70	Sparsentan	155	125 (80.6)	50.23 (7.43)	28.0	44.05	52.35	56.15	63.2	
			Irbesartan	161	104 (64.6)	50.18 (8.61)	21.7	46.86	52.35	56.15	63.0	
		Week 94	Sparsentan	155	118 (76.1)	50.36 (7.10)	23.8	44.96	52.56	56.15	61.7	
			Irbesartan	161	103 (64.0)	50.93 (7.33)	20.0	47.89	53.17	56.15	61.3	
		Week 110	Sparsentan	155	113 (72.9)	50.56 (7.52)	22.8	44.33	52.40	56.15	64.2	
			Irbesartan	161	92 (57.1)	50.89 (7.83)	25.4	45.91	52.79	56.68	62.6	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	155	121 (78.1)	0.63 (6.50)	-16.1	-3.24	0.21	4.07	20.4	0.15 [-0.11, 0.41]
			Irbesartan	161	106 (65.8)	-0.28 (5.84)	-20.0	-2.69	0.00	2.42	16.9	
		Week 48	Sparsentan	155	124 (80.0)	0.59 (6.93)	-18.7	-3.56	-0.14	4.12	24.7	0.08 [-0.19, 0.35]
			Irbesartan	161	97 (60.2)	-0.02 (8.54)	-35.7	-3.90	0.08	3.04	20.4	
		Week 70	Sparsentan	155	125 (80.6)	-0.14 (7.13)	-20.4	-3.80	0.08	3.18	31.3	0.21 [-0.05, 0.47]
			Irbesartan	161	104 (64.6)	-1.76 (8.11)	-28.0	-5.77	-0.28	2.43	17.8	
		Week 94	Sparsentan	155	118 (76.1)	-0.03 (7.01)	-20.0	-3.31	-0.23	4.51	20.7	0.07 [-0.20, 0.33]
			Irbesartan	161	103 (64.0)	-0.51 (6.85)	-20.1	-4.03	0.00	3.17	18.0	
		Week 110	Sparsentan	155	113 (72.9)	-0.20 (7.43)	-17.9	-3.20	0.00	4.53	16.4	0.04 [-0.23, 0.32]
			Irbesartan	161	92 (57.1)	-0.50 (7.14)	-18.5	-4.20	-0.01	3.99	15.6	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSHM: KDQOL-SF12: Course of PCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	KDQOL-SF12: PCS	Baseline	Sparsentan	47	46 (97.9)	53.97 (5.64)	37.4	51.80	54.80	57.49	63.5	
			Irbesartan	41	40 (97.6)	51.92 (7.46)	21.6	49.37	54.25	56.26	60.1	
		Week 24	Sparsentan	47	38 (80.9)	53.44 (6.65)	27.3	51.61	56.15	57.49	60.9	
			Irbesartan	41	32 (78.0)	52.50 (7.41)	20.8	51.26	54.58	56.44	59.7	
		Week 48	Sparsentan	47	41 (87.2)	53.48 (7.33)	29.8	50.07	55.09	57.76	66.1	
			Irbesartan	41	30 (73.2)	51.81 (6.77)	37.9	47.87	53.44	56.71	63.5	
		Week 70	Sparsentan	47	38 (80.9)	51.85 (8.79)	21.9	47.79	54.21	56.62	66.8	
			Irbesartan	41	31 (75.6)	54.38 (4.59)	42.8	52.43	55.88	57.22	60.8	
		Week 94	Sparsentan	47	37 (78.7)	52.33 (9.03)	27.9	51.57	55.09	57.49	63.5	
			Irbesartan	41	30 (73.2)	54.14 (5.74)	40.6	52.79	55.79	57.70	62.7	
		Week 110	Sparsentan	47	37 (78.7)	51.62 (7.47)	34.7	49.73	53.50	56.71	59.7	
			Irbesartan	41	29 (70.7)	52.43 (6.13)	39.8	49.31	53.22	56.71	62.0	
	KDQOL-SF12: change from baseline in PCS	Week 24	Sparsentan	47	38 (80.9)	-0.32 (6.99)	-24.8	-3.69	-0.13	2.70	14.3	-0.12 [-0.59, 0.35]
			Irbesartan	41	32 (78.0)	0.36 (3.94)	-8.9	-1.83	0.00	2.03	10.4	
		Week 48	Sparsentan	47	41 (87.2)	-0.22 (6.87)	-22.3	-2.69	-0.04	2.28	15.6	0.11 [-0.36, 0.58]
			Irbesartan	41	30 (73.2)	-0.98 (6.99)	-20.8	-4.66	0.55	2.22	15.6	
		Week 70	Sparsentan	47	38 (80.9)	-1.62 (9.31)	-30.2	-4.04	-0.11	3.17	15.6	-0.33 [-0.81, 0.15]
			Irbesartan	41	31 (75.6)	0.90 (4.88)	-14.2	-1.27	1.06	3.78	15.7	
		Week 94	Sparsentan	47	37 (78.7)	-0.95 (8.16)	-24.1	-3.87	-0.14	3.46	12.9	-0.17 [-0.65, 0.31]
			Irbesartan	41	30 (73.2)	0.26 (5.33)	-14.7	-3.00	1.45	3.53	7.8	
		Week 110	Sparsentan	47	37 (78.7)	-1.77 (7.45)	-20.5	-5.45	-1.34	2.03	14.6	-0.07 [-0.55, 0.42]
			Irbesartan	41	29 (70.7)	-1.31 (5.76)	-13.7	-5.13	-1.06	1.61	11.3	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Sex	Overall	Sparsentan						Interaction:	0.833
Male	Week 24	Sparsentan	139	110 (79.1)	0.65 (0.58)	(-0.49, 1.80)	0.96 (0.84)	(-0.70, 2.61)	0.258
		Irbesartan	143	100 (69.9)	-0.30 (0.61)	(-1.50, 0.90)			
	Week 48	Sparsentan	139	115 (82.7)	0.24 (0.57)	(-0.88, 1.36)	-0.07 (0.85)	(-1.74, 1.60)	0.938
		Irbesartan	143	90 (62.9)	0.30 (0.63)	(-0.93, 1.54)			
	Week 70	Sparsentan	139	117 (84.2)	-0.35 (0.57)	(-1.47, 0.76)	0.31 (0.84)	(-1.34, 1.96)	0.711
		Irbesartan	143	97 (67.8)	-0.66 (0.62)	(-1.88, 0.55)			
	Week 94	Sparsentan	139	108 (77.7)	-0.13 (0.59)	(-1.28, 1.02)	0.00 (0.85)	(-1.67, 1.67)	1.000
		Irbesartan	143	99 (69.2)	-0.13 (0.62)	(-1.34, 1.08)			
	Week 110	Sparsentan	139	104 (74.8)	-0.18 (0.60)	(-1.36, 1.00)	-0.22 (0.88)	(-1.95, 1.52)	0.807
		Irbesartan	143	89 (62.2)	0.03 (0.65)	(-1.24, 1.30)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Female	Week 24	Sparsentan	63	49 (77.8)	-0.17 (0.92)	(-1.99, 1.64)	-0.83 (1.40)	(-3.59, 1.92)	0.552
		Irbesartan	59	38 (64.4)	0.66 (1.05)	(-1.41, 2.73)			
	Week 48	Sparsentan	63	50 (79.4)	-0.35 (0.91)	(-2.14, 1.45)	0.55 (1.39)	(-2.19, 3.30)	0.692
		Irbesartan	59	37 (62.7)	-0.90 (1.05)	(-2.97, 1.17)			
	Week 70	Sparsentan	63	46 (73.0)	-1.13 (0.94)	(-2.98, 0.73)	0.44 (1.41)	(-2.35, 3.22)	0.758
		Irbesartan	59	38 (64.4)	-1.56 (1.05)	(-3.62, 0.50)			
	Week 94	Sparsentan	63	47 (74.6)	-1.16 (0.94)	(-3.01, 0.69)	-0.23 (1.45)	(-3.07, 2.62)	0.874
		Irbesartan	59	34 (57.6)	-0.93 (1.10)	(-3.09, 1.22)			
	Week 110	Sparsentan	63	46 (73.0)	-1.51 (0.95)	(-3.39, 0.37)	0.14 (1.49)	(-2.79, 3.07)	0.924
		Irbesartan	59	32 (54.2)	-1.65 (1.14)	(-3.89, 0.59)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age	Overall	Sparsentan						Interaction:	0.463
<= 45 years	Week 24	Sparsentan	96	72 (75.0)	0.49 (0.71)	(-0.91, 1.88)	0.66 (1.01)	(-1.33, 2.65)	0.514
		Irbesartan	99	70 (70.7)	-0.17 (0.72)	(-1.59, 1.24)			
	Week 48	Sparsentan	96	76 (79.2)	-0.10 (0.69)	(-1.46, 1.26)	0.86 (1.02)	(-1.14, 2.87)	0.398
		Irbesartan	99	62 (62.6)	-0.96 (0.75)	(-2.44, 0.51)			
	Week 70	Sparsentan	96	75 (78.1)	-0.78 (0.70)	(-2.14, 0.59)	-0.09 (1.02)	(-2.10, 1.92)	0.930
		Irbesartan	99	64 (64.6)	-0.69 (0.75)	(-2.16, 0.78)			
	Week 94	Sparsentan	96	70 (72.9)	-0.38 (0.72)	(-1.79, 1.02)	1.06 (1.04)	(-0.98, 3.10)	0.307
		Irbesartan	99	64 (64.6)	-1.44 (0.75)	(-2.92, 0.03)			
	Week 110	Sparsentan	96	70 (72.9)	-0.58 (0.72)	(-2.00, 0.84)	-0.04 (1.07)	(-2.13, 2.05)	0.971
		Irbesartan	99	59 (59.6)	-0.54 (0.78)	(-2.08, 1.00)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 45 years	Week 24	Sparsentan	106	87 (82.1)	0.25 (0.68)	(-1.09, 1.58)	0.13 (1.03)	(-1.89, 2.16)	0.897
		Irbesartan	103	68 (66.0)	0.11 (0.77)	(-1.41, 1.63)			
	Week 48	Sparsentan	106	89 (84.0)	0.13 (0.67)	(-1.19, 1.46)	-0.68 (1.03)	(-2.71, 1.34)	0.506
		Irbesartan	103	65 (63.1)	0.82 (0.78)	(-0.71, 2.34)			
	Week 70	Sparsentan	106	88 (83.0)	-0.46 (0.68)	(-1.80, 0.87)	0.66 (1.02)	(-1.34, 2.66)	0.517
		Irbesartan	103	71 (68.9)	-1.13 (0.76)	(-2.61, 0.36)			
	Week 94	Sparsentan	106	85 (80.2)	-0.58 (0.69)	(-1.94, 0.78)	-1.26 (1.03)	(-3.29, 0.77)	0.223
		Irbesartan	103	69 (67.0)	0.68 (0.77)	(-0.83, 2.19)			
	Week 110	Sparsentan	106	80 (75.5)	-0.72 (0.71)	(-2.12, 0.68)	-0.51 (1.08)	(-2.63, 1.61)	0.637
		Irbesartan	103	62 (60.2)	-0.21 (0.81)	(-1.79, 1.38)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age at IgAN diagnosis	Overall	Sparsentan						Interaction:	0.797
<= 18 years	Week 24	Sparsentan	9	5 (55.6)	5.12 (2.18)	(0.64, 9.61)	4.69 (3.18)	(-1.93, 11.30)	0.156
		Irbesartan	5	5 (100.0)	0.44 (2.23)	(-4.23, 5.10)			
	Week 48	Sparsentan	9	7 (77.8)	2.07 (1.87)	(-1.81, 5.95)	-2.48 (3.30)	(-9.28, 4.32)	0.459
		Irbesartan	5	3 (60.0)	4.55 (2.68)	(-0.95, 10.05)			
	Week 70	Sparsentan	9	7 (77.8)	2.68 (1.89)	(-1.26, 6.61)	2.19 (3.21)	(-4.49, 8.87)	0.503
		Irbesartan	5	4 (80.0)	0.49 (2.50)	(-4.70, 5.68)			
	Week 94	Sparsentan	9	5 (55.6)	-4.53 (2.16)	(-8.98, -0.08)	-5.03 (3.42)	(-12.13, 2.08)	0.157
		Irbesartan	5	4 (80.0)	0.50 (2.55)	(-4.81, 5.81)			
	Week 110	Sparsentan	9	4 (44.4)	-0.07 (2.45)	(-5.09, 4.96)	-0.36 (4.17)	(-8.92, 8.20)	0.932
		Irbesartan	5	2 (40.0)	0.29 (3.36)	(-6.59, 7.18)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 18 to 40 years	Week 24	Sparsentan	102	80 (78.4)	0.28 (0.68)	(-1.04, 1.61)	0.53 (0.98)	(-1.39, 2.45)	0.588
		Irbesartan	109	73 (67.0)	-0.25 (0.71)	(-1.63, 1.14)			
	Week 48	Sparsentan	102	83 (81.4)	0.05 (0.66)	(-1.25, 1.36)	0.85 (0.98)	(-1.06, 2.77)	0.383
		Irbesartan	109	69 (63.3)	-0.80 (0.72)	(-2.21, 0.61)			
	Week 70	Sparsentan	102	80 (78.4)	-1.01 (0.67)	(-2.33, 0.31)	0.05 (0.98)	(-1.88, 1.98)	0.957
		Irbesartan	109	71 (65.1)	-1.06 (0.71)	(-2.46, 0.34)			
	Week 94	Sparsentan	102	76 (74.5)	-0.15 (0.69)	(-1.51, 1.20)	1.32 (1.00)	(-0.64, 3.29)	0.187
		Irbesartan	109	69 (63.3)	-1.47 (0.72)	(-2.89, -0.05)			
	Week 110	Sparsentan	102	73 (71.6)	-0.77 (0.71)	(-2.16, 0.62)	-0.28 (1.03)	(-2.30, 1.74)	0.786
		Irbesartan	109	65 (59.6)	-0.49 (0.75)	(-1.96, 0.98)			
> 40 years	Week 24	Sparsentan	91	74 (81.3)	0.20 (0.76)	(-1.29, 1.69)	0.10 (1.13)	(-2.13, 2.33)	0.929
		Irbesartan	88	60 (68.2)	0.10 (0.84)	(-1.55, 1.75)			
	Week 48	Sparsentan	91	75 (82.4)	-0.13 (0.75)	(-1.60, 1.34)	-0.71 (1.14)	(-2.95, 1.53)	0.533
		Irbesartan	88	55 (62.5)	0.58 (0.86)	(-1.11, 2.27)			
	Week 70	Sparsentan	91	76 (83.5)	-0.44 (0.75)	(-1.91, 1.03)	0.42 (1.13)	(-1.79, 2.64)	0.706
		Irbesartan	88	60 (68.2)	-0.86 (0.84)	(-2.51, 0.79)			
	Week 94	Sparsentan	91	74 (81.3)	-0.51 (0.76)	(-2.00, 0.98)	-1.42 (1.13)	(-3.65, 0.81)	0.212
		Irbesartan	88	60 (68.2)	0.91 (0.84)	(-0.75, 2.56)			
	Week 110	Sparsentan	91	73 (80.2)	-0.40 (0.77)	(-1.91, 1.10)	-0.08 (1.17)	(-2.38, 2.22)	0.945
		Irbesartan	88	54 (61.4)	-0.32 (0.88)	(-2.06, 1.42)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Geographic region	Overall	Sparsentan						Interaction:	0.237
North America	Week 24	Sparsentan	35	23 (65.7)	0.05 (1.21)	(-2.34, 2.44)	0.24 (1.56)	(-2.84, 3.33)	0.878
		Irbesartan	46	37 (80.4)	-0.19 (0.97)	(-2.11, 1.72)			
	Week 48	Sparsentan	35	25 (71.4)	0.79 (1.16)	(-1.50, 3.08)	0.14 (1.54)	(-2.90, 3.19)	0.926
		Irbesartan	46	33 (71.7)	0.64 (1.01)	(-1.34, 2.63)			
	Week 70	Sparsentan	35	23 (65.7)	0.64 (1.19)	(-1.72, 2.99)	-0.24 (1.58)	(-3.36, 2.88)	0.877
		Irbesartan	46	31 (67.4)	0.88 (1.03)	(-1.16, 2.92)			
	Week 94	Sparsentan	35	24 (68.6)	1.63 (1.19)	(-0.72, 3.98)	1.46 (1.60)	(-1.69, 4.62)	0.362
		Irbesartan	46	30 (65.2)	0.16 (1.06)	(-1.92, 2.25)			
	Week 110	Sparsentan	35	21 (60.0)	-0.73 (1.27)	(-3.23, 1.78)	-1.73 (1.66)	(-5.01, 1.55)	0.299
		Irbesartan	46	31 (67.4)	1.01 (1.06)	(-1.09, 3.10)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Europe	Week 24	Sparsentan	98	75 (76.5)	0.95 (0.72)	(-0.45, 2.36)	1.61 (1.06)	(-0.46, 3.69)	0.127
		Irbesartan	115	65 (56.5)	-0.66 (0.77)	(-2.18, 0.86)			
	Week 48	Sparsentan	98	77 (78.6)	0.11 (0.71)	(-1.29, 1.50)	0.62 (1.06)	(-1.46, 2.69)	0.561
		Irbesartan	115	61 (53.0)	-0.51 (0.78)	(-2.05, 1.03)			
	Week 70	Sparsentan	98	76 (77.6)	-0.64 (0.72)	(-2.05, 0.76)	1.78 (1.03)	(-0.25, 3.80)	0.085
		Irbesartan	115	72 (62.6)	-2.42 (0.74)	(-3.87, -0.97)			
	Week 94	Sparsentan	98	71 (72.4)	-0.73 (0.74)	(-2.18, 0.72)	0.28 (1.04)	(-1.77, 2.33)	0.788
		Irbesartan	115	72 (62.6)	-1.01 (0.74)	(-2.45, 0.44)			
	Week 110	Sparsentan	98	68 (69.4)	0.29 (0.76)	(-1.19, 1.78)	1.56 (1.10)	(-0.59, 3.72)	0.155
		Irbesartan	115	61 (53.0)	-1.27 (0.79)	(-2.83, 0.29)			
Asia Pacific	Week 24	Sparsentan	69	61 (88.4)	-0.02 (0.83)	(-1.65, 1.60)	-0.67 (1.36)	(-3.34, 2.00)	0.620
		Irbesartan	41	36 (87.8)	0.65 (1.07)	(-1.46, 2.76)			
	Week 48	Sparsentan	69	63 (91.3)	-0.12 (0.82)	(-1.73, 1.48)	0.31 (1.38)	(-2.39, 3.02)	0.819
		Irbesartan	41	33 (80.5)	-0.44 (1.10)	(-2.61, 1.74)			
	Week 70	Sparsentan	69	64 (92.8)	-0.82 (0.81)	(-2.42, 0.78)	-0.85 (1.40)	(-3.60, 1.89)	0.541
		Irbesartan	41	32 (78.0)	0.03 (1.13)	(-2.19, 2.26)			
	Week 94	Sparsentan	69	60 (87.0)	-0.72 (0.83)	(-2.35, 0.91)	-0.65 (1.42)	(-3.44, 2.15)	0.649
		Irbesartan	41	31 (75.6)	-0.08 (1.15)	(-2.34, 2.19)			
	Week 110	Sparsentan	69	61 (88.4)	-1.35 (0.83)	(-2.98, 0.29)	-0.55 (1.45)	(-3.41, 2.31)	0.704
		Irbesartan	41	29 (70.7)	-0.79 (1.19)	(-3.14, 1.55)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline BMI	Overall	Sparsentan						Interaction:	0.910
< 27 kg/m**2	Week 24	Sparsentan	83	66 (79.5)	0.35 (0.74)	(-1.10, 1.81)	0.64 (1.04)	(-1.40, 2.68)	0.540
		Irbesartan	94	69 (73.4)	-0.28 (0.73)	(-1.71, 1.14)			
	Week 48	Sparsentan	83	68 (81.9)	-0.33 (0.73)	(-1.76, 1.11)	0.83 (1.06)	(-1.25, 2.90)	0.435
		Irbesartan	94	60 (63.8)	-1.15 (0.76)	(-2.65, 0.34)			
	Week 70	Sparsentan	83	66 (79.5)	-1.47 (0.74)	(-2.93, -0.02)	0.03 (1.06)	(-2.06, 2.11)	0.980
		Irbesartan	94	62 (66.0)	-1.50 (0.76)	(-2.99, -0.01)			
	Week 94	Sparsentan	83	64 (77.1)	-1.06 (0.75)	(-2.53, 0.42)	-0.28 (1.06)	(-2.37, 1.81)	0.791
		Irbesartan	94	64 (68.1)	-0.78 (0.75)	(-2.25, 0.70)			
	Week 110	Sparsentan	83	63 (75.9)	-1.39 (0.76)	(-2.88, 0.10)	-0.98 (1.10)	(-3.13, 1.18)	0.373
		Irbesartan	94	57 (60.6)	-0.41 (0.79)	(-1.97, 1.15)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
>= 27 kg/m**2	Week 24	Sparsentan	119	93 (78.2)	0.37 (0.66)	(-0.93, 1.67)	0.13 (1.01)	(-1.86, 2.12)	0.896
		Irbesartan	107	69 (64.5)	0.24 (0.77)	(-1.27, 1.75)			
	Week 48	Sparsentan	119	97 (81.5)	0.30 (0.65)	(-0.97, 1.57)	-0.63 (1.00)	(-2.60, 1.34)	0.531
		Irbesartan	107	67 (62.6)	0.93 (0.77)	(-0.57, 2.43)			
	Week 70	Sparsentan	119	97 (81.5)	0.01 (0.65)	(-1.26, 1.29)	0.31 (0.99)	(-1.63, 2.26)	0.751
		Irbesartan	107	73 (68.2)	-0.30 (0.75)	(-1.77, 1.17)			
	Week 94	Sparsentan	119	91 (76.5)	-0.04 (0.67)	(-1.35, 1.26)	-0.25 (1.02)	(-2.25, 1.75)	0.807
		Irbesartan	107	68 (63.6)	0.20 (0.77)	(-1.30, 1.71)			
	Week 110	Sparsentan	119	87 (73.1)	-0.06 (0.68)	(-1.40, 1.29)	0.05 (1.05)	(-2.02, 2.12)	0.964
		Irbesartan	107	63 (58.9)	-0.10 (0.80)	(-1.68, 1.47)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Randomization strata	Overall	Sparsentan						Interaction:	0.761
eGFR Low and UP High	Week 24	Sparsentan	71	54 (76.1)	-0.08 (0.90)	(-1.84, 1.69)	0.92 (1.34)	(-1.70, 3.55)	0.490
		Irbesartan	74	44 (59.5)	-1.00 (0.99)	(-2.94, 0.95)			
	Week 48	Sparsentan	71	53 (74.6)	0.11 (0.89)	(-1.65, 1.87)	0.53 (1.36)	(-2.15, 3.21)	0.697
		Irbesartan	74	38 (51.4)	-0.42 (1.03)	(-2.44, 1.59)			
	Week 70	Sparsentan	71	58 (81.7)	-1.05 (0.87)	(-2.77, 0.66)	0.11 (1.34)	(-2.52, 2.75)	0.932
		Irbesartan	74	41 (55.4)	-1.17 (1.01)	(-3.16, 0.83)			
	Week 94	Sparsentan	71	52 (73.2)	-0.55 (0.90)	(-2.33, 1.23)	0.07 (1.39)	(-2.66, 2.80)	0.962
		Irbesartan	74	38 (51.4)	-0.62 (1.05)	(-2.68, 1.45)			
	Week 110	Sparsentan	71	53 (74.6)	-0.76 (0.91)	(-2.55, 1.02)	-0.39 (1.42)	(-3.18, 2.40)	0.784
		Irbesartan	74	36 (48.6)	-0.37 (1.09)	(-2.52, 1.77)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
eGFR Low and UP Low	Week 24	Sparsentan	55	44 (80.0)	0.64 (0.92)	(-1.18, 2.46)	0.54 (1.36)	(-2.13, 3.22)	0.688
		Irbesartan	55	39 (70.9)	0.09 (0.98)	(-1.85, 2.03)			
	Week 48	Sparsentan	55	43 (78.2)	0.69 (0.93)	(-1.13, 2.52)	0.22 (1.37)	(-2.48, 2.91)	0.875
		Irbesartan	55	36 (65.5)	0.48 (1.00)	(-1.50, 2.45)			
	Week 70	Sparsentan	55	42 (76.4)	0.46 (0.94)	(-1.39, 2.31)	1.79 (1.35)	(-0.87, 4.46)	0.186
		Irbesartan	55	40 (72.7)	-1.33 (0.97)	(-3.23, 0.57)			
	Week 94	Sparsentan	55	42 (76.4)	0.56 (0.95)	(-1.30, 2.42)	0.56 (1.36)	(-2.12, 3.23)	0.683
		Irbesartan	55	40 (72.7)	0.00 (0.97)	(-1.91, 1.91)			
	Week 110	Sparsentan	55	38 (69.1)	-0.10 (0.99)	(-2.04, 1.85)	0.14 (1.44)	(-2.69, 2.98)	0.920
		Irbesartan	55	34 (61.8)	-0.24 (1.04)	(-2.29, 1.81)			
eGFR High and UP High	Week 24	Sparsentan	37	27 (73.0)	0.69 (1.11)	(-1.50, 2.89)	-0.30 (1.61)	(-3.48, 2.87)	0.851
		Irbesartan	36	26 (72.2)	1.00 (1.16)	(-1.30, 3.29)			
	Week 48	Sparsentan	37	34 (91.9)	-0.54 (1.02)	(-2.56, 1.48)	-0.17 (1.56)	(-3.24, 2.90)	0.912
		Irbesartan	36	25 (69.4)	-0.37 (1.17)	(-2.68, 1.94)			
	Week 70	Sparsentan	37	31 (83.8)	0.43 (1.06)	(-1.66, 2.52)	0.87 (1.58)	(-2.25, 4.00)	0.582
		Irbesartan	36	25 (69.4)	-0.44 (1.18)	(-2.76, 1.88)			
	Week 94	Sparsentan	37	27 (73.0)	-1.00 (1.12)	(-3.20, 1.21)	-0.86 (1.62)	(-4.06, 2.33)	0.594
		Irbesartan	36	25 (69.4)	-0.13 (1.17)	(-2.45, 2.19)			
	Week 110	Sparsentan	37	26 (70.3)	1.40 (1.15)	(-0.87, 3.67)	2.30 (1.69)	(-1.04, 5.64)	0.176
		Irbesartan	36	22 (61.1)	-0.90 (1.24)	(-3.34, 1.54)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
eGFR High and UP Low	Week 24	Sparsentan	39	34 (87.2)	0.76 (1.07)	(-1.36, 2.87)	0.58 (1.58)	(-2.53, 3.68)	0.715
		Irbesartan	37	29 (78.4)	0.18 (1.15)	(-2.09, 2.45)			
	Week 48	Sparsentan	39	35 (89.7)	-0.03 (1.06)	(-2.12, 2.06)	-0.21 (1.58)	(-3.32, 2.91)	0.896
		Irbesartan	37	28 (75.7)	0.18 (1.17)	(-2.12, 2.48)			
	Week 70	Sparsentan	39	32 (82.1)	-1.98 (1.10)	(-4.15, 0.18)	-1.58 (1.60)	(-4.74, 1.58)	0.326
		Irbesartan	37	29 (78.4)	-0.40 (1.16)	(-2.69, 1.88)			
	Week 94	Sparsentan	39	34 (87.2)	-0.97 (1.07)	(-3.09, 1.15)	-0.34 (1.57)	(-3.44, 2.76)	0.831
		Irbesartan	37	30 (81.1)	-0.63 (1.14)	(-2.88, 1.62)			
	Week 110	Sparsentan	39	33 (84.6)	-2.54 (1.09)	(-4.69, -0.39)	-2.15 (1.60)	(-5.30, 0.99)	0.179
		Irbesartan	37	29 (78.4)	-0.39 (1.16)	(-2.67, 1.90)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 1	Overall	Sparsentan						Interaction:	0.107
< 60 mL/min/1.73 m**2	Week 24	Sparsentan	127	99 (78.0)	0.21 (0.63)	(-1.03, 1.45)	0.59 (0.93)	(-1.23, 2.41)	0.524
		Irbesartan	129	85 (65.9)	-0.38 (0.68)	(-1.72, 0.95)			
	Week 48	Sparsentan	127	97 (76.4)	0.75 (0.63)	(-0.49, 1.98)	0.26 (0.94)	(-1.59, 2.12)	0.780
		Irbesartan	129	76 (58.9)	0.48 (0.70)	(-0.89, 1.86)			
	Week 70	Sparsentan	127	101 (79.5)	-0.31 (0.62)	(-1.53, 0.92)	0.95 (0.93)	(-0.88, 2.77)	0.308
		Irbesartan	129	83 (64.3)	-1.25 (0.68)	(-2.60, 0.09)			
	Week 94	Sparsentan	127	94 (74.0)	-0.17 (0.64)	(-1.43, 1.09)	-0.03 (0.95)	(-1.89, 1.84)	0.978
		Irbesartan	129	79 (61.2)	-0.14 (0.70)	(-1.51, 1.23)			
	Week 110	Sparsentan	127	93 (73.2)	-0.30 (0.65)	(-1.58, 0.98)	0.16 (0.98)	(-1.77, 2.09)	0.869
		Irbesartan	129	72 (55.8)	-0.46 (0.73)	(-1.91, 0.98)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
60 to < 90 mL/min/1.73 m**2	Week 24	Sparsentan	49	39 (79.6)	0.83 (1.01)	(-1.17, 2.82)	0.03 (1.50)	(-2.93, 2.99)	0.986
		Irbesartan	48	33 (68.8)	0.80 (1.11)	(-1.38, 2.98)			
	Week 48	Sparsentan	49	45 (91.8)	-0.94 (0.96)	(-2.83, 0.96)	0.69 (1.46)	(-2.19, 3.57)	0.637
		Irbesartan	48	33 (68.8)	-1.63 (1.10)	(-3.78, 0.53)			
	Week 70	Sparsentan	49	40 (81.6)	0.13 (1.00)	(-1.83, 2.10)	2.10 (1.49)	(-0.84, 5.04)	0.161
		Irbesartan	48	32 (66.7)	-1.97 (1.11)	(-4.15, 0.21)			
	Week 94	Sparsentan	49	41 (83.7)	-0.79 (1.00)	(-2.76, 1.18)	1.16 (1.47)	(-1.75, 4.06)	0.434
		Irbesartan	48	35 (72.9)	-1.95 (1.08)	(-4.07, 0.18)			
	Week 110	Sparsentan	49	36 (73.5)	-0.38 (1.06)	(-2.46, 1.70)	0.76 (1.54)	(-2.27, 3.79)	0.622
		Irbesartan	48	32 (66.7)	-1.14 (1.12)	(-3.34, 1.06)			
>= 90 mL/min/1.73 m**2	Week 24	Sparsentan	26	21 (80.8)	0.54 (1.23)	(-1.88, 2.96)	0.38 (1.76)	(-3.09, 3.84)	0.831
		Irbesartan	25	20 (80.0)	0.16 (1.26)	(-2.32, 2.64)			
	Week 48	Sparsentan	26	23 (88.5)	-0.77 (1.18)	(-3.10, 1.56)	-1.55 (1.78)	(-5.06, 1.96)	0.384
		Irbesartan	25	18 (72.0)	0.78 (1.32)	(-1.82, 3.39)			
	Week 70	Sparsentan	26	22 (84.6)	-2.90 (1.21)	(-5.28, -0.52)	-5.39 (1.75)	(-8.85, -1.93)	0.002 *
		Irbesartan	25	20 (80.0)	2.49 (1.26)	(-0.01, 4.98)			
	Week 94	Sparsentan	26	20 (76.9)	-1.18 (1.26)	(-3.66, 1.30)	-2.96 (1.81)	(-6.54, 0.61)	0.103
		Irbesartan	25	19 (76.0)	1.79 (1.30)	(-0.77, 4.34)			
	Week 110	Sparsentan	26	21 (80.8)	-2.55 (1.23)	(-4.97, -0.12)	-3.74 (1.84)	(-7.37, -0.12)	0.043 *
		Irbesartan	25	17 (68.0)	1.19 (1.36)	(-1.50, 3.89)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 2	Overall	Sparsentan						Interaction:	0.053
< 45 mL/min/1.73 m**2	Week 24	Sparsentan	82	64 (78.0)	0.46 (0.82)	(-1.16, 2.08)	0.96 (1.24)	(-1.47, 3.40)	0.436
		Irbesartan	80	51 (63.8)	-0.51 (0.92)	(-2.32, 1.31)			
	Week 48	Sparsentan	82	63 (76.8)	1.14 (0.83)	(-0.48, 2.77)	1.06 (1.26)	(-1.41, 3.53)	0.401
		Irbesartan	80	45 (56.3)	0.09 (0.95)	(-1.78, 1.95)			
	Week 70	Sparsentan	82	65 (79.3)	0.07 (0.82)	(-1.54, 1.69)	2.07 (1.23)	(-0.35, 4.49)	0.094
		Irbesartan	80	50 (62.5)	-2.00 (0.92)	(-3.80, -0.19)			
	Week 94	Sparsentan	82	61 (74.4)	-0.68 (0.84)	(-2.33, 0.97)	0.16 (1.26)	(-2.32, 2.63)	0.900
		Irbesartan	80	48 (60.0)	-0.83 (0.94)	(-2.68, 1.01)			
	Week 110	Sparsentan	82	57 (69.5)	0.40 (0.87)	(-1.31, 2.10)	1.74 (1.31)	(-0.84, 4.33)	0.185
		Irbesartan	80	44 (55.0)	-1.35 (0.98)	(-3.28, 0.59)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
45 to < 60 mL/min/1.73 m**2	Week 24	Sparsentan	45	35 (77.8)	-0.23 (0.96)	(-2.11, 1.66)	-0.02 (1.37)	(-2.72, 2.68)	0.989
		Irbesartan	49	34 (69.4)	-0.21 (0.97)	(-2.13, 1.71)			
	Week 48	Sparsentan	45	34 (75.6)	0.05 (0.96)	(-1.84, 1.93)	-1.16 (1.40)	(-3.91, 1.59)	0.407
		Irbesartan	49	31 (63.3)	1.21 (1.01)	(-0.78, 3.19)			
	Week 70	Sparsentan	45	36 (80.0)	-1.01 (0.94)	(-2.87, 0.85)	-0.94 (1.38)	(-3.65, 1.77)	0.495
		Irbesartan	49	33 (67.3)	-0.07 (0.99)	(-2.03, 1.89)			
	Week 94	Sparsentan	45	33 (73.3)	0.81 (0.98)	(-1.11, 2.73)	-0.21 (1.42)	(-3.00, 2.58)	0.884
		Irbesartan	49	31 (63.3)	1.02 (1.02)	(-0.99, 3.02)			
	Week 110	Sparsentan	45	36 (80.0)	-1.41 (0.95)	(-3.28, 0.46)	-2.45 (1.44)	(-5.28, 0.38)	0.089
		Irbesartan	49	28 (57.1)	1.04 (1.07)	(-1.07, 3.15)			
60 to < 90 mL/min/1.73 m**2	Week 24	Sparsentan	49	39 (79.6)	0.83 (1.01)	(-1.17, 2.82)	0.03 (1.50)	(-2.93, 2.99)	0.986
		Irbesartan	48	33 (68.8)	0.80 (1.11)	(-1.38, 2.98)			
	Week 48	Sparsentan	49	45 (91.8)	-0.94 (0.96)	(-2.83, 0.96)	0.69 (1.46)	(-2.19, 3.57)	0.637
		Irbesartan	48	33 (68.8)	-1.63 (1.10)	(-3.78, 0.53)			
	Week 70	Sparsentan	49	40 (81.6)	0.13 (1.00)	(-1.83, 2.10)	2.10 (1.49)	(-0.84, 5.04)	0.161
		Irbesartan	48	32 (66.7)	-1.97 (1.11)	(-4.15, 0.21)			
	Week 94	Sparsentan	49	41 (83.7)	-0.79 (1.00)	(-2.76, 1.18)	1.16 (1.47)	(-1.75, 4.06)	0.434
		Irbesartan	48	35 (72.9)	-1.95 (1.08)	(-4.07, 0.18)			
	Week 110	Sparsentan	49	36 (73.5)	-0.38 (1.06)	(-2.46, 1.70)	0.76 (1.54)	(-2.27, 3.79)	0.622
		Irbesartan	48	32 (66.7)	-1.14 (1.12)	(-3.34, 1.06)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
>= 90 mL/min/1.73 m**2	Week 24	Sparsentan	26	21 (80.8)	0.54 (1.23)	(-1.88, 2.96)	0.38 (1.76)	(-3.09, 3.84)	0.831
		Irbesartan	25	20 (80.0)	0.16 (1.26)	(-2.32, 2.64)			
	Week 48	Sparsentan	26	23 (88.5)	-0.77 (1.18)	(-3.10, 1.56)	-1.55 (1.78)	(-5.06, 1.96)	0.384
		Irbesartan	25	18 (72.0)	0.78 (1.32)	(-1.82, 3.39)			
	Week 70	Sparsentan	26	22 (84.6)	-2.90 (1.21)	(-5.28, -0.52)	-5.39 (1.75)	(-8.85, -1.93)	0.002 *
		Irbesartan	25	20 (80.0)	2.49 (1.26)	(-0.01, 4.98)			
	Week 94	Sparsentan	26	20 (76.9)	-1.18 (1.26)	(-3.66, 1.30)	-2.96 (1.81)	(-6.54, 0.61)	0.103
		Irbesartan	25	19 (76.0)	1.79 (1.30)	(-0.77, 4.34)			
	Week 110	Sparsentan	26	21 (80.8)	-2.55 (1.23)	(-4.97, -0.12)	-3.74 (1.84)	(-7.37, -0.12)	0.043 *
		Irbesartan	25	17 (68.0)	1.19 (1.36)	(-1.50, 3.89)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline urine protein excretion	Overall	Sparsentan						Interaction:	0.182
<= 1.75 g/day	Week 24	Sparsentan	98	81 (82.7)	0.39 (0.71)	(-1.01, 1.78)	-0.02 (1.09)	(-2.16, 2.13)	0.988
		Irbesartan	93	59 (63.4)	0.40 (0.83)	(-1.22, 2.03)			
	Week 48	Sparsentan	98	83 (84.7)	0.33 (0.70)	(-1.04, 1.71)	0.09 (1.08)	(-2.04, 2.22)	0.932
		Irbesartan	93	57 (61.3)	0.24 (0.83)	(-1.38, 1.86)			
	Week 70	Sparsentan	98	77 (78.6)	-1.07 (0.72)	(-2.49, 0.34)	-0.89 (1.08)	(-3.02, 1.24)	0.412
		Irbesartan	93	62 (66.7)	-0.18 (0.81)	(-1.77, 1.41)			
	Week 94	Sparsentan	98	79 (80.6)	-0.55 (0.72)	(-1.96, 0.86)	-0.31 (1.08)	(-2.43, 1.81)	0.774
		Irbesartan	93	64 (68.8)	-0.24 (0.80)	(-1.81, 1.33)			
	Week 110	Sparsentan	98	76 (77.6)	-1.46 (0.73)	(-2.89, -0.02)	-0.88 (1.12)	(-3.07, 1.32)	0.433
		Irbesartan	93	57 (61.3)	-0.58 (0.84)	(-2.23, 1.08)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 1.75 g/day	Week 24	Sparsentan	104	78 (75.0)	0.41 (0.69)	(-0.93, 1.76)	0.89 (0.97)	(-1.02, 2.80)	0.359
		Irbesartan	109	79 (72.5)	-0.48 (0.69)	(-1.83, 0.87)			
	Week 48	Sparsentan	104	82 (78.8)	-0.20 (0.67)	(-1.51, 1.11)	0.16 (0.98)	(-1.76, 2.08)	0.870
		Irbesartan	109	70 (64.2)	-0.36 (0.71)	(-1.76, 1.04)			
	Week 70	Sparsentan	104	86 (82.7)	-0.11 (0.66)	(-1.41, 1.18)	1.50 (0.97)	(-0.41, 3.40)	0.123
		Irbesartan	109	73 (67.0)	-1.61 (0.71)	(-3.00, -0.22)			
	Week 94	Sparsentan	104	76 (73.1)	-0.29 (0.69)	(-1.65, 1.07)	0.16 (1.00)	(-1.81, 2.13)	0.872
		Irbesartan	109	69 (63.3)	-0.45 (0.73)	(-1.88, 0.97)			
	Week 110	Sparsentan	104	74 (71.2)	0.33 (0.71)	(-1.06, 1.72)	0.69 (1.04)	(-1.34, 2.73)	0.503
		Irbesartan	109	64 (58.7)	-0.36 (0.76)	(-1.84, 1.12)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline use of antihypertensives	Overall	Sparsentan						Interaction:	0.807
Yes	Week 24	Sparsentan	90	68 (75.6)	0.52 (0.77)	(-1.00, 2.03)	0.19 (1.17)	(-2.11, 2.48)	0.874
		Irbesartan	88	52 (59.1)	0.33 (0.88)	(-1.40, 2.06)			
	Week 48	Sparsentan	90	68 (75.6)	0.34 (0.77)	(-1.17, 1.84)	-0.62 (1.18)	(-2.94, 1.70)	0.598
		Irbesartan	88	48 (54.5)	0.96 (0.90)	(-0.80, 2.72)			
	Week 70	Sparsentan	90	69 (76.7)	-0.96 (0.76)	(-2.46, 0.55)	0.08 (1.17)	(-2.21, 2.38)	0.942
		Irbesartan	88	51 (58.0)	-1.04 (0.88)	(-2.77, 0.69)			
	Week 94	Sparsentan	90	66 (73.3)	-0.37 (0.78)	(-1.90, 1.16)	-0.58 (1.15)	(-2.83, 1.68)	0.617
		Irbesartan	88	57 (64.8)	0.20 (0.84)	(-1.45, 1.86)			
	Week 110	Sparsentan	90	64 (71.1)	0.43 (0.80)	(-1.14, 1.99)	1.19 (1.19)	(-1.15, 3.53)	0.319
		Irbesartan	88	51 (58.0)	-0.76 (0.89)	(-2.50, 0.98)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
No	Week 24	Sparsentan	112	91 (81.3)	0.31 (0.64)	(-0.95, 1.57)	0.60 (0.92)	(-1.21, 2.41)	0.517
		Irbesartan	114	86 (75.4)	-0.29 (0.66)	(-1.59, 1.02)			
	Week 48	Sparsentan	112	97 (86.6)	-0.14 (0.62)	(-1.36, 1.09)	0.54 (0.92)	(-1.27, 2.36)	0.556
		Irbesartan	114	79 (69.3)	-0.68 (0.68)	(-2.02, 0.65)			
	Week 70	Sparsentan	112	94 (83.9)	-0.30 (0.63)	(-1.55, 0.94)	0.56 (0.92)	(-1.25, 2.37)	0.545
		Irbesartan	114	84 (73.7)	-0.86 (0.67)	(-2.18, 0.45)			
	Week 94	Sparsentan	112	89 (79.5)	-0.52 (0.65)	(-1.80, 0.75)	0.20 (0.96)	(-1.68, 2.08)	0.836
		Irbesartan	114	76 (66.7)	-0.72 (0.70)	(-2.10, 0.65)			
	Week 110	Sparsentan	112	86 (76.8)	-1.37 (0.66)	(-2.67, -0.07)	-1.27 (0.99)	(-3.21, 0.67)	0.198
		Irbesartan	114	70 (61.4)	-0.09 (0.73)	(-1.53, 1.34)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Time since renal biopsy	Overall	Sparsentan						Interaction:	0.567
<= 5 years	Week 24	Sparsentan	113	90 (79.6)	1.04 (0.67)	(-0.28, 2.37)	1.16 (0.95)	(-0.71, 3.03)	0.223
		Irbesartan	127	91 (71.7)	-0.12 (0.67)	(-1.43, 1.20)			
	Week 48	Sparsentan	113	93 (82.3)	0.03 (0.66)	(-1.27, 1.33)	-0.33 (0.95)	(-2.20, 1.53)	0.725
		Irbesartan	127	86 (67.7)	0.37 (0.68)	(-0.96, 1.70)			
	Week 70	Sparsentan	113	91 (80.5)	-0.27 (0.67)	(-1.58, 1.05)	0.03 (0.95)	(-1.84, 1.89)	0.979
		Irbesartan	127	88 (69.3)	-0.29 (0.68)	(-1.62, 1.04)			
	Week 94	Sparsentan	113	88 (77.9)	0.11 (0.68)	(-1.22, 1.44)	-0.12 (0.96)	(-2.01, 1.76)	0.898
		Irbesartan	127	88 (69.3)	0.24 (0.68)	(-1.10, 1.57)			
	Week 110	Sparsentan	113	88 (77.9)	0.49 (0.68)	(-0.85, 1.83)	0.34 (0.99)	(-1.60, 2.27)	0.733
		Irbesartan	127	80 (63.0)	0.15 (0.71)	(-1.24, 1.55)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 5 years	Week 24	Sparsentan	89	69 (77.5)	-0.58 (0.72)	(-1.99, 0.83)	-0.93 (1.14)	(-3.17, 1.31)	0.413
		Irbesartan	75	47 (62.7)	0.35 (0.88)	(-1.38, 2.08)			
	Week 48	Sparsentan	89	72 (80.9)	-0.04 (0.70)	(-1.42, 1.35)	0.59 (1.15)	(-1.67, 2.86)	0.607
		Irbesartan	75	41 (54.7)	-0.63 (0.91)	(-2.42, 1.16)			
	Week 70	Sparsentan	89	72 (80.9)	-1.09 (0.71)	(-2.49, 0.30)	0.86 (1.13)	(-1.36, 3.08)	0.445
		Irbesartan	75	47 (62.7)	-1.96 (0.87)	(-3.68, -0.24)			
	Week 94	Sparsentan	89	67 (75.3)	-1.30 (0.73)	(-2.73, 0.14)	-0.05 (1.16)	(-2.33, 2.22)	0.962
		Irbesartan	75	45 (60.0)	-1.24 (0.89)	(-3.00, 0.51)			
	Week 110	Sparsentan	89	62 (69.7)	-2.22 (0.76)	(-3.71, -0.73)	-0.95 (1.20)	(-3.32, 1.42)	0.430
		Irbesartan	75	41 (54.7)	-1.27 (0.93)	(-3.11, 0.56)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
History of hypertension	Overall	Sparsentan						Interaction:	0.390
Yes	Week 24	Sparsentan	155	121 (78.1)	0.52 (0.56)	(-0.59, 1.62)	0.58 (0.82)	(-1.04, 2.20)	0.483
		Irbesartan	161	106 (65.8)	-0.06 (0.60)	(-1.24, 1.12)			
	Week 48	Sparsentan	155	124 (80.0)	0.11 (0.55)	(-0.98, 1.20)	-0.23 (0.83)	(-1.86, 1.40)	0.782
		Irbesartan	161	97 (60.2)	0.34 (0.62)	(-0.87, 1.55)			
	Week 70	Sparsentan	155	125 (80.6)	-0.31 (0.56)	(-1.40, 0.78)	1.10 (0.82)	(-0.52, 2.71)	0.183
		Irbesartan	161	104 (64.6)	-1.41 (0.60)	(-2.60, -0.22)			
	Week 94	Sparsentan	155	118 (76.1)	-0.26 (0.57)	(-1.37, 0.85)	0.26 (0.83)	(-1.37, 1.90)	0.754
		Irbesartan	161	103 (64.0)	-0.52 (0.61)	(-1.71, 0.67)			
	Week 110	Sparsentan	155	113 (72.9)	-0.22 (0.58)	(-1.36, 0.92)	-0.04 (0.87)	(-1.74, 1.66)	0.965
		Irbesartan	161	92 (57.1)	-0.18 (0.64)	(-1.44, 1.08)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KPSC_FSCM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in PCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
No	Week 24	Sparsentan	47	38 (80.9)	0.01 (1.04)	(-2.04, 2.06)	-0.17 (1.55)	(-3.22, 2.89)	0.914
		Irbesartan	41	32 (78.0)	0.18 (1.14)	(-2.08, 2.43)			
	Week 48	Sparsentan	47	41 (87.2)	-0.10 (1.01)	(-2.09, 1.89)	1.09 (1.54)	(-1.94, 4.13)	0.478
		Irbesartan	41	30 (73.2)	-1.20 (1.16)	(-3.48, 1.08)			
	Week 70	Sparsentan	47	38 (80.9)	-1.43 (1.04)	(-3.47, 0.62)	-2.25 (1.56)	(-5.32, 0.81)	0.149
		Irbesartan	41	31 (75.6)	0.83 (1.15)	(-1.45, 3.10)			
	Week 94	Sparsentan	47	37 (78.7)	-1.06 (1.06)	(-3.14, 1.02)	-1.48 (1.59)	(-4.60, 1.65)	0.352
		Irbesartan	41	30 (73.2)	0.42 (1.18)	(-1.90, 2.74)			
	Week 110	Sparsentan	47	37 (78.7)	-1.77 (1.06)	(-3.86, 0.33)	-0.77 (1.61)	(-3.95, 2.40)	0.631
		Irbesartan	41	29 (70.7)	-0.99 (1.21)	(-3.37, 1.38)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. PCS = physical component summary.
Source Data: aqs, created on: 05MAR2024

Figure PF2KPSC_FSGM: KDQOL-SF12: Change from baseline in PCS by subgroup
Full Analysis Set

Not done: No significant subgroup found.

_____
Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
PCS = physical component summary.
Reference table: PT2KPSC_FSCM

Table PT2KPSIT_FSTM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sex	Sparsentan						Interaction test:	0.942
Male	Sparsentan	139	22 (15.8)	NE		1.074	(0.569, 2.025)	0.826
	Irbesartan	143	20 (14.0)	117.0	(NE, NE)			
Female	Sparsentan	63	10 (15.9)	NE		1.274	(0.363, 4.476)	0.705
	Irbesartan	59	4 (6.8)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KPSIT_FSTM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.167
<= 45 years	Sparsentan	96	10 (10.4)	NE		0.620	(0.239, 1.608)	0.325
	Irbesartan	99	10 (10.1)	NE				
> 45 years	Sparsentan	106	22 (20.8)	NE		1.367	(0.679, 2.754)	0.381
	Irbesartan	103	14 (13.6)	117.0	(NE, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KPSIT_FSTM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Age at IgAN diagnosis	Sparsentan						Interaction test:	<0.001	#
<= 18 years	Sparsentan	9	1 (11.1)	NE		NE		NE	
	Irbesartan	5	1 (20.0)	NE					
> 18 to 40 years	Sparsentan	102	11 (10.8)	NE		1.184	(0.500, 2.804)	0.701	
	Irbesartan	109	11 (10.1)	NE					
> 40 years	Sparsentan	91	20 (22.0)	NE		1.318	(0.606, 2.867)	0.486	
	Irbesartan	88	12 (13.6)	117.0	(NE, NE)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KPSIT_FSTM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Geographic region	Sparsentan						Interaction test:	<0.001	#
North America	Sparsentan	35	2 (5.7)	NE		0.109	(0.012, 1.024)	0.052	
	Irbesartan	46	9 (19.6)	NE					
Europe	Sparsentan	98	12 (12.2)	NE		1.011	(0.382, 2.673)	0.983	
	Irbesartan	115	9 (7.8)	117.0	(117.0, NE)				
Asia Pacific	Sparsentan	69	18 (26.1)	NE		1.708	(0.656, 4.444)	0.273	
	Irbesartan	41	6 (14.6)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KPSIT_FSTM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.674
< 27 kg/m**2	Sparsentan	83	13 (15.7)	NE		1.035	(0.385, 2.784)	0.945
	Irbesartan	94	8 (8.5)	NE				
>= 27 kg/m**2	Sparsentan	119	19 (16.0)	NE		1.232	(0.604, 2.512)	0.566
	Irbesartan	107	16 (15.0)	117.0	(117.0, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KPSIT_FSTM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Randomization strata	Sparsentan						Interaction test:	<0.001	#
eGFR Low and UP High	Sparsentan	71	8 (11.3)	NE		0.794	(0.304, 2.070)	0.637	
	Irbesartan	74	10 (13.5)	117.0	(NE, NE)				
eGFR Low and UP Low	Sparsentan	55	12 (21.8)	NE		0.947	(0.286, 3.142)	0.929	
	Irbesartan	55	5 (9.1)	NE					
eGFR High and UP High	Sparsentan	37	3 (8.1)	NE		0.134	(0.016, 1.155)	0.067	
	Irbesartan	36	5 (13.9)	NE					
eGFR High and UP Low	Sparsentan	39	9 (23.1)	NE		4.828	(1.153, 20.215)	0.031	*
	Irbesartan	37	4 (10.8)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KPSIT_FSTM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.580
< 60 mL/min/1.73 m**2	Sparsentan	127	21 (16.5)	NE		1.098	(0.546, 2.206)	0.794
	Irbesartan	129	16 (12.4)	117.0	(NE, NE)			
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	7 (14.3)	116.1	(116.1, NE)	2.550	(0.603, 10.780)	0.203
	Irbesartan	48	6 (12.5)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	4 (15.4)	NE		0.916	(0.133, 6.290)	0.929
	Irbesartan	25	2 (8.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KPSIT_FSTM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 2	Sparsentan						Interaction test:	0.730
< 45 mL/min/1.73 m**2	Sparsentan	82	13 (15.9)	NE		0.891	(0.359, 2.207)	0.802
	Irbesartan	80	10 (12.5)	117.0	(NE, NE)			
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	8 (17.8)	NE		1.321	(0.402, 4.336)	0.647
	Irbesartan	49	6 (12.2)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	7 (14.3)	116.1	(116.1, NE)	2.550	(0.603, 10.780)	0.203
	Irbesartan	48	6 (12.5)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	4 (15.4)	NE		0.916	(0.133, 6.290)	0.929
	Irbesartan	25	2 (8.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KPSIT_FSTM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline urine protein excretion	Sparsentan						Interaction test:	0.017	#
<= 1.75 g/day	Sparsentan	98	21 (21.4)	NE		1.976	(0.869, 4.493)	0.104	
	Irbesartan	93	9 (9.7)	NE					
> 1.75 g/day	Sparsentan	104	11 (10.6)	NE		0.493	(0.209, 1.163)	0.106	
	Irbesartan	109	15 (13.8)	117.0	(NE, NE)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KPSIT_FSTM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.393
Yes	Sparsentan	90	14 (15.6)	NE		0.635	(0.282, 1.427)	0.271
	Irbesartan	88	14 (15.9)	NE				
No	Sparsentan	112	18 (16.1)	NE		1.878	(0.818, 4.313)	0.137
	Irbesartan	114	10 (8.8)	117.0	(117.0, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KPSIT_FSTM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Time since renal biopsy	Sparsentan						Interaction test:	0.374
<= 5 years	Sparsentan	113	23 (20.4)	NE		1.284	(0.673, 2.449)	0.448
	Irbesartan	127	18 (14.2)	NE				
> 5 years	Sparsentan	89	9 (10.1)	NE		1.346	(0.397, 4.567)	0.634
	Irbesartan	75	6 (8.0)	117.0	(117.0, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KPSIT_FSTM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
History of hypertension	Sparsentan						Interaction test:	0.034	#
Yes	Sparsentan	155	24 (15.5)	NE		0.730	(0.383, 1.393)	0.340	
	Irbesartan	161	20 (12.4)	117.0	(117.0, NE)				
No	Sparsentan	47	8 (17.0)	NE		4.536	(0.904, 22.756)	0.066	
	Irbesartan	41	4 (9.8)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Figure PF2KPSIT_FSKM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Age at IgAN diagnosis: <= 18 years



Sparsentan	9	8	7	6	5	3
Irbesartan	5	5	4	4	3	2

An increase reflects an improvement of the status of the patient.
Reference table: PT2KPSIT_FSTM

Figure PF2KPSIT_FSKM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Age at IgAN diagnosis: > 18 to 40 years



Sparsentan	102	91	84	77	71	62
Irbesartan	109	90	78	69	67	63

An increase reflects an improvement of the status of the patient.
Reference table: PT2KPSIT_FSTM

Figure PF2KPSIT_FSKM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Age at IgAN diagnosis: > 40 years



Sparsentan	91	81	70	69	64	54
Irbesartan	88	68	61	56	53	40

An increase reflects an improvement of the status of the patient.
Reference table: PT2KPSIT_FSTM

Figure PF2KPSIT_FSKM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Geographic region: North America



Sparsentan	35	30	29	28	26	20
Irbesartan	46	40	31	26	24	23

An increase reflects an improvement of the status of the patient.
Reference table: PT2KPSIT_FSTM

Figure PF2KPSIT_FSKM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Geographic region: Europe



Sparsentan	98	85	75	72	67	56
Irbesartan	115	85	78	74	71	59

An increase reflects an improvement of the status of the patient.
Reference table: PT2KPSIT_FSTM

Figure PF2KPSIT_FSKM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Geographic region: Asia Pacific



Sparsentan	69	65	57	52	47	43
Irbesartan	41	38	34	29	28	23

An increase reflects an improvement of the status of the patient.
Reference table: PT2KPSIT_FSTM

Figure PF2KPSIT_FSKM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Randomization strata: eGFR Low and UP High



Sparsentan	71	61	58	55	50	41
Irbesartan	74	54	47	38	37	30

An increase reflects an improvement of the status of the patient.
Reference table: PT2KPSIT_FSTM

Figure PF2KPSIT_FSKM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Randomization strata: eGFR Low and UP Low



Sparsentan	55	49	40	38	34	28
Irbesartan	55	46	41	38	36	30

An increase reflects an improvement of the status of the patient.
Reference table: PT2KPSIT_FSTM

Figure PF2KPSIT_FSKM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Randomization strata: eGFR High and UP High



Sparsentan	37	34	32	30	27	23
Irbesartan	36	29	24	23	22	20

An increase reflects an improvement of the status of the patient.
Reference table: PT2KPSIT_FSTM

Figure PF2KPSIT_FSKM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Randomization strata: eGFR High and UP Low



Sparsentan	39	36	31	29	29	27
Irbesartan	37	34	31	30	28	25

An increase reflects an improvement of the status of the patient.
Reference table: PT2KPSIT_FSTM

Figure PF2KPSIT_FSKM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline urine protein excretion: <= 1.75 g/day



Sparsentan	98	90	75	72	69	57
Irbesartan	93	74	65	61	57	46

An increase reflects an improvement of the status of the patient.
Reference table: PT2KPSIT_FSTM

Figure PF2KPSIT_FSKM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline urine protein excretion: > 1.75 g/day



Sparsentan	104	90	86	80	71	62
Irbesartan	109	89	78	68	66	59

An increase reflects an improvement of the status of the patient.
Reference table: PT2KPSIT_FSTM

Figure PF2KPSIT_FSKM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
History of hypertension: Yes



Sparsentan	155	136	122	117	108	91
Irbesartan	161	128	112	100	95	79

An increase reflects an improvement of the status of the patient.
Reference table: PT2KPSIT_FSTM

Figure PF2KPSIT_FSKM: KDQOL-SF12: Time to increase in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
History of hypertension: No



Sparsentan	47	44	39	35	32	28
Irbesartan	41	35	31	29	28	26

An increase reflects an improvement of the status of the patient.
Reference table: PT2KPSIT_FSTM

Table PT2KPSDT_FSTM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sex	Sparsentan						Interaction test:	0.797
Male	Sparsentan	139	37 (26.6)	NE		1.142	(0.701, 1.861)	0.594
	Irbesartan	143	29 (20.3)	NE				
Female	Sparsentan	63	21 (33.3)	NE		0.989	(0.512, 1.912)	0.974
	Irbesartan	59	17 (28.8)	116.0	(111.3, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KPSDT_FSTM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.787
<= 45 years	Sparsentan	96	27 (28.1)	115.6	(114.3, NE)	1.055	(0.603, 1.848)	0.850
	Irbesartan	99	23 (23.2)	NE				
> 45 years	Sparsentan	106	31 (29.2)	NE		1.189	(0.691, 2.049)	0.532
	Irbesartan	103	23 (22.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KPSDT_FSTM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age at IgAN diagnosis	Sparsentan						Interaction test:	NE
<= 18 years	Sparsentan	9	2 (22.2) No events in 1 group	NE		NE		NE
	Irbesartan	5	0 (0.0)	NE				
> 18 to 40 years	Sparsentan	102	30 (29.4)	115.6	(114.3, NE)	1.082	(0.632, 1.854)	0.773
	Irbesartan	109	25 (22.9)	NE				
> 40 years	Sparsentan	91	26 (28.6)	NE		1.085	(0.606, 1.942)	0.784
	Irbesartan	88	21 (23.9)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KPSDT_FSTM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Geographic region	Sparsentan						Interaction test:	0.756
North America	Sparsentan	35	10 (28.6)	115.6	(111.6, NE)	0.916	(0.362, 2.317)	0.853
	Irbesartan	46	11 (23.9)	NE				
Europe	Sparsentan	98	26 (26.5)	NE		1.011	(0.585, 1.747)	0.969
	Irbesartan	115	27 (23.5)	NE				
Asia Pacific	Sparsentan	69	22 (31.9)	NE		1.610	(0.706, 3.670)	0.258
	Irbesartan	41	8 (19.5)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KPSDT_FSTM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.510
< 27 kg/m**2	Sparsentan	83	24 (28.9)	NE		1.347	(0.735, 2.469)	0.335
	Irbesartan	94	19 (20.2)	NE				
>= 27 kg/m**2	Sparsentan	119	34 (28.6)	NE		1.025	(0.613, 1.714)	0.925
	Irbesartan	107	26 (24.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KPSDT_FSTM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Randomization strata	Sparsentan						Interaction test:	0.419
eGFR Low and UP High	Sparsentan	71	22 (31.0)	NE		1.457	(0.731, 2.903)	0.285
	Irbesartan	74	13 (17.6)	NE				
eGFR Low and UP Low	Sparsentan	55	9 (16.4)	NE		0.598	(0.257, 1.393)	0.233
	Irbesartan	55	14 (25.5)	NE				
eGFR High and UP High	Sparsentan	37	12 (32.4)	115.0	(113.6, NE)	1.226	(0.496, 3.033)	0.659
	Irbesartan	36	8 (22.2)	NE				
eGFR High and UP Low	Sparsentan	39	15 (38.5)	NE		1.262	(0.578, 2.756)	0.558
	Irbesartan	37	11 (29.7)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KPSDT_FSTM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.040	#
< 60 mL/min/1.73 m**2	Sparsentan	127	31 (24.4)	NE		1.152	(0.676, 1.961)	0.603	
	Irbesartan	129	26 (20.2)	NE					
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	15 (30.6)	NE		0.628	(0.306, 1.289)	0.205	
	Irbesartan	48	17 (35.4)	NE					
>= 90 mL/min/1.73 m**2	Sparsentan	26	12 (46.2)	114.3	(72.1, NE)	3.618	(1.017, 12.874)	0.047	*
	Irbesartan	25	3 (12.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KPSDT_FSTM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eGFR Group 2	Sparsentan						Interaction test:	0.001	#
< 45 mL/min/1.73 m**2	Sparsentan	82	17 (20.7)	NE		0.625	(0.331, 1.179)	0.146	
	Irbesartan	80	22 (27.5)	116.0	(111.7, NE)				
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	14 (31.1)	NE		5.981	(1.744, 20.512)	0.004	*
	Irbesartan	49	4 (8.2)	NE					
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	15 (30.6)	NE		0.628	(0.306, 1.289)	0.205	
	Irbesartan	48	17 (35.4)	NE					
>= 90 mL/min/1.73 m**2	Sparsentan	26	12 (46.2)	114.3	(72.1, NE)	3.618	(1.017, 12.874)	0.047	*
	Irbesartan	25	3 (12.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KPSDT_FSTM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline urine protein excretion	Sparsentan						Interaction test:	0.931
<= 1.75 g/day	Sparsentan	98	29 (29.6)	NE		1.099	(0.631, 1.916)	0.738
	Irbesartan	93	22 (23.7)	NE				
> 1.75 g/day	Sparsentan	104	29 (27.9)	NE		1.154	(0.669, 1.992)	0.606
	Irbesartan	109	24 (22.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KPSDT_FSTM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.545
Yes	Sparsentan	90	24 (26.7)	NE		1.034	(0.573, 1.866)	0.913
	Irbesartan	88	21 (23.9)	NE				
No	Sparsentan	112	34 (30.4)	NE		1.259	(0.751, 2.111)	0.383
	Irbesartan	114	25 (21.9)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KPSDT_FSTM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Time since renal biopsy	Sparsentan						Interaction test:	0.809
<= 5 years	Sparsentan	113	30 (26.5)	NE		1.091	(0.658, 1.810)	0.736
	Irbesartan	127	31 (24.4)	NE				
> 5 years	Sparsentan	89	28 (31.5)	NE		1.203	(0.636, 2.278)	0.570
	Irbesartan	75	15 (20.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KPSDT_FSTM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in PCS by at least 8.4				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
History of hypertension	Sparsentan						Interaction test:	0.592
Yes	Sparsentan	155	41 (26.5)	NE		1.058	(0.678, 1.652)	0.804
	Irbesartan	161	37 (23.0)	NE				
No	Sparsentan	47	17 (36.2)	115.0	(111.6, NE)	1.244	(0.541, 2.858)	0.608
	Irbesartan	41	9 (22.0)	116.0	(116.0, NE)			

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Figure PF2KPSDT_FSKM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline eGFR Group 1: < 60 mL/min/1.73 m**2



Sparsentan	127	108	98	92	81	68
Irbesartan	129	101	87	79	71	60

_____
A decrease reflects a worsening of the status of the patient.
Reference table: PT2KPSDT_FSTM

Figure PF2KPSDT_FSKM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline eGFR Group 1: 60 to < 90 mL/min/1.73 m**2



Sparsentan	49	46	43	36	34	28
Irbesartan	48	41	37	32	26	20

_____
A decrease reflects a worsening of the status of the patient.
Reference table: PT2KPSDT_FSTM

Figure PF2KPSDT_FSKM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline eGFR Group 1: >= 90 mL/min/1.73 m**2



Sparsentan	26	23	23	21	15	13
Irbesartan	25	21	19	17	16	14

_____
A decrease reflects a worsening of the status of the patient.
Reference table: PT2KPSDT_FSTM

Figure PF2KPSDT_FSKM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline eGFR Group 2: < 45 mL/min/1.73 m**2



Sparsentan	82	66	62	59	52	46
Irbesartan	80	63	54	47	40	32

_____
A decrease reflects a worsening of the status of the patient.
Reference table: PT2KPSDT_FSTM

Figure PF2KPSDT_FSKM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline eGFR Group 2: 45 to < 60 mL/min/1.73 m**2



Sparsentan	45	42	36	33	29	22
Irbesartan	49	38	33	32	31	28

A decrease reflects a worsening of the status of the patient.
Reference table: PT2KPSDT_FSTM

Figure PF2KPSDT_FSKM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline eGFR Group 2: 60 to < 90 mL/min/1.73 m**2



Sparsentan	49	46	43	36	34	28
Irbesartan	48	41	37	32	26	20

_____
A decrease reflects a worsening of the status of the patient.
Reference table: PT2KPSDT_FSTM

Figure PF2KPSDT_FSKM: KDQOL-SF12: Time to decrease in PCS by at least 8.4 points by subgroup
Full Analysis Set

Study: PROTECT
Baseline eGFR Group 2: >= 90 mL/min/1.73 m**2



Sparsentan	26	23	23	21	15	13
Irbesartan	25	21	19	17	16	14

A decrease reflects a worsening of the status of the patient.
Reference table: PT2KPSDT_FSTM

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Sex												
Male	KDQOL-SF12: MCS	Baseline	Sparsentan	139	130 (93.5)	50.45 (7.97)	30.1	45.01	51.54	57.06	66.5	
			Irbesartan	143	132 (92.3)	51.61 (8.91)	24.3	48.28	53.36	57.16	66.6	
		Week 24	Sparsentan	139	110 (79.1)	51.41 (8.17)	20.8	47.15	52.23	57.16	68.7	
			Irbesartan	143	100 (69.9)	52.19 (8.39)	24.2	48.37	54.62	57.76	64.2	
		Week 48	Sparsentan	139	115 (82.7)	51.03 (8.39)	27.5	46.56	52.62	57.16	64.2	
			Irbesartan	143	90 (62.9)	51.71 (8.45)	28.5	47.59	54.20	57.16	64.6	
		Week 70	Sparsentan	139	117 (84.2)	50.84 (8.25)	25.4	45.40	52.87	57.16	65.5	
			Irbesartan	143	97 (67.8)	51.19 (8.51)	18.9	46.98	52.54	57.16	63.8	
		Week 94	Sparsentan	139	108 (77.7)	50.37 (8.83)	26.5	43.72	53.62	57.11	66.9	
			Irbesartan	143	99 (69.2)	50.05 (10.02)	21.9	43.32	54.20	57.53	63.4	
		Week 110	Sparsentan	139	104 (74.8)	50.79 (8.39)	20.8	45.43	51.31	57.16	68.0	
			Irbesartan	143	89 (62.2)	49.07 (10.05)	20.0	43.59	50.20	57.16	62.7	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	139	110 (79.1)	0.52 (7.77)	-19.1	-4.29	0.00	4.84	25.3	-0.03 [-0.30, 0.24]
			Irbesartan	143	100 (69.9)	0.77 (6.94)	-15.4	-3.40	0.00	4.39	28.7	
		Week 48	Sparsentan	139	115 (82.7)	0.51 (7.75)	-20.8	-4.67	1.34	5.68	18.7	0.15 [-0.13, 0.43]
			Irbesartan	143	90 (62.9)	-0.56 (6.49)	-17.3	-3.88	0.00	3.11	17.3	
		Week 70	Sparsentan	139	117 (84.2)	0.52 (8.06)	-21.8	-3.95	0.39	5.23	22.1	0.11 [-0.16, 0.38]
			Irbesartan	143	97 (67.8)	-0.29 (6.89)	-27.2	-3.95	-0.10	3.64	17.4	
		Week 94	Sparsentan	139	108 (77.7)	-0.04 (7.60)	-22.4	-4.62	0.81	4.93	16.9	0.15 [-0.12, 0.43]
			Irbesartan	143	99 (69.2)	-1.21 (7.69)	-21.0	-5.33	-0.84	2.72	23.3	
		Week 110	Sparsentan	139	104 (74.8)	0.08 (7.71)	-17.6	-3.95	0.00	4.74	22.2	0.26 [-0.02, 0.55]
			Irbesartan	143	89 (62.2)	-1.97 (8.02)	-29.3	-6.43	-2.20	2.07	19.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Female	KDQOL-SF12: MCS	Baseline	Sparsentan	63	58 (92.1)	50.37 (9.08)	16.2	44.79	52.28	56.44	65.2	
			Irbesartan	59	51 (86.4)	50.92 (7.92)	31.5	45.74	53.14	57.16	61.3	
		Week 24	Sparsentan	63	49 (77.8)	52.81 (7.44)	30.7	48.65	54.20	58.26	63.5	
			Irbesartan	59	38 (64.4)	52.76 (7.73)	32.5	48.87	54.29	57.66	62.6	
		Week 48	Sparsentan	63	50 (79.4)	50.97 (8.73)	27.5	44.18	51.75	59.31	64.7	
			Irbesartan	59	37 (62.7)	47.44 (11.50)	19.6	39.39	50.48	56.11	64.5	
		Week 70	Sparsentan	63	46 (73.0)	50.56 (8.64)	31.6	43.46	52.70	57.56	62.7	
			Irbesartan	59	38 (64.4)	51.06 (6.98)	29.2	48.81	52.32	55.51	62.1	
		Week 94	Sparsentan	63	47 (74.6)	50.54 (10.26)	16.0	45.18	51.83	57.94	64.7	
			Irbesartan	59	34 (57.6)	49.51 (9.42)	28.3	42.22	51.91	57.73	61.5	
		Week 110	Sparsentan	63	46 (73.0)	48.34 (9.73)	20.1	42.30	50.10	56.49	62.5	
			Irbesartan	59	32 (54.2)	50.04 (8.15)	32.4	43.58	52.18	56.91	60.9	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	63	49 (77.8)	2.01 (8.74)	-23.6	-1.40	0.61	7.30	26.4	0.13 [-0.30, 0.55]
			Irbesartan	59	38 (64.4)	1.02 (5.90)	-9.4	-2.96	1.32	3.95	20.2	
		Week 48	Sparsentan	63	50 (79.4)	-0.06 (10.26)	-23.7	-4.74	0.04	4.38	28.1	0.35 [-0.08, 0.77]
			Irbesartan	59	37 (62.7)	-3.51 (9.59)	-33.9	-6.62	-2.56	3.74	11.3	
		Week 70	Sparsentan	63	46 (73.0)	-0.43 (9.51)	-21.3	-5.39	0.04	3.17	26.5	0.07 [-0.36, 0.50]
			Irbesartan	59	38 (64.4)	-1.01 (6.24)	-18.6	-3.56	-0.45	3.80	9.4	
		Week 94	Sparsentan	63	47 (74.6)	-0.19 (9.89)	-28.8	-6.46	0.04	6.28	24.1	0.25 [-0.20, 0.69]
			Irbesartan	59	34 (57.6)	-2.40 (7.47)	-19.0	-6.22	-0.15	2.34	10.7	
		Week 110	Sparsentan	63	46 (73.0)	-2.05 (11.45)	-31.2	-6.43	-2.47	3.42	33.3	-0.04 [-0.49, 0.41]
			Irbesartan	59	32 (54.2)	-1.66 (6.75)	-16.1	-5.31	-0.77	3.79	10.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age												
<= 45 years	KDQOL-SF12: MCS	Baseline	Sparsentan	96	88 (91.7)	48.94 (8.49)	27.8	43.44	50.17	55.34	65.2	
			Irbesartan	99	92 (92.9)	50.34 (9.59)	24.3	44.08	52.45	57.16	64.2	
		Week 24	Sparsentan	96	72 (75.0)	50.21 (8.49)	20.8	45.18	50.62	57.16	63.5	
			Irbesartan	99	70 (70.7)	51.72 (8.88)	24.2	48.30	53.19	57.76	62.7	
		Week 48	Sparsentan	96	76 (79.2)	49.23 (8.82)	27.5	42.71	51.04	56.41	62.5	
			Irbesartan	99	62 (62.6)	49.88 (10.41)	21.5	44.16	51.51	57.16	64.6	
		Week 70	Sparsentan	96	75 (78.1)	49.92 (9.09)	25.4	42.45	52.82	57.16	65.5	
			Irbesartan	99	64 (64.6)	50.60 (8.73)	18.9	46.62	51.89	57.06	63.8	
		Week 94	Sparsentan	96	70 (72.9)	48.47 (9.76)	16.0	41.53	49.49	56.85	66.9	
			Irbesartan	99	64 (64.6)	48.37 (11.25)	21.9	41.83	51.48	57.66	63.4	
		Week 110	Sparsentan	96	70 (72.9)	48.87 (9.14)	20.1	42.67	49.92	56.27	67.0	
			Irbesartan	99	59 (59.6)	49.67 (9.74)	20.0	43.59	50.82	57.16	62.7	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	96	72 (75.0)	0.59 (8.77)	-23.6	-4.30	0.44	5.35	26.4	-0.05 [-0.38, 0.28]
			Irbesartan	99	70 (70.7)	1.01 (7.00)	-14.1	-2.96	0.68	5.23	21.7	
		Week 48	Sparsentan	96	76 (79.2)	0.06 (8.89)	-23.7	-4.74	0.42	5.33	21.1	0.22 [-0.11, 0.56]
			Irbesartan	99	62 (62.6)	-1.78 (7.25)	-23.5	-5.33	-0.35	2.43	13.4	
		Week 70	Sparsentan	96	75 (78.1)	0.77 (8.52)	-21.3	-4.37	0.97	5.22	26.4	0.23 [-0.10, 0.56]
			Irbesartan	99	64 (64.6)	-0.96 (6.15)	-21.2	-5.33	-0.28	4.03	10.4	
		Week 94	Sparsentan	96	70 (72.9)	-0.60 (9.27)	-28.8	-5.53	-0.46	4.94	24.1	0.24 [-0.10, 0.58]
			Irbesartan	99	64 (64.6)	-2.67 (8.05)	-21.0	-6.24	-2.96	2.31	16.1	
		Week 110	Sparsentan	96	70 (72.9)	-0.32 (9.30)	-24.6	-5.16	-0.11	4.18	26.4	0.15 [-0.20, 0.50]
			Irbesartan	99	59 (59.6)	-1.61 (7.75)	-21.2	-7.53	-2.25	3.00	14.2	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 45 years	KDQOL-SF12: MCS	Baseline	Sparsentan	106	100 (94.3)	51.73 (7.95)	16.2	48.28	53.38	57.16	66.5	
			Irbesartan	103	91 (88.3)	52.51 (7.44)	26.4	49.06	53.45	57.16	66.6	
		Week 24	Sparsentan	106	87 (82.1)	53.19 (7.26)	34.3	48.65	54.37	57.47	68.7	
			Irbesartan	103	68 (66.0)	52.98 (7.43)	27.2	49.46	54.62	57.33	64.2	
		Week 48	Sparsentan	106	89 (84.0)	52.54 (7.89)	29.5	49.35	53.51	58.32	64.7	
			Irbesartan	103	65 (63.1)	51.01 (8.79)	19.6	47.58	53.63	57.06	64.5	
		Week 70	Sparsentan	106	88 (83.0)	51.47 (7.61)	27.6	46.05	52.75	57.16	65.4	
			Irbesartan	103	71 (68.9)	51.66 (7.49)	29.2	47.34	52.88	57.16	63.4	
		Week 94	Sparsentan	106	85 (80.2)	52.03 (8.54)	28.0	47.79	54.34	57.73	64.7	
			Irbesartan	103	69 (67.0)	51.34 (8.15)	30.5	45.79	54.37	57.33	61.5	
		Week 110	Sparsentan	106	80 (75.5)	51.06 (8.53)	20.8	46.61	51.76	57.24	68.0	
			Irbesartan	103	62 (60.2)	49.00 (9.46)	23.2	42.38	50.63	57.06	62.7	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	106	87 (82.1)	1.31 (7.50)	-18.1	-2.79	0.37	4.80	25.9	0.09 [-0.22, 0.41]
			Irbesartan	103	68 (66.0)	0.65 (6.32)	-15.4	-3.40	0.00	3.83	28.7	
		Week 48	Sparsentan	106	89 (84.0)	0.58 (8.32)	-20.8	-4.58	1.48	5.23	28.1	0.20 [-0.12, 0.52]
			Irbesartan	103	65 (63.1)	-1.08 (7.97)	-33.9	-3.76	-0.10	4.19	17.3	
		Week 70	Sparsentan	106	88 (83.0)	-0.19 (8.46)	-21.8	-4.78	-0.14	4.18	26.5	-0.02 [-0.33, 0.30]
			Irbesartan	103	71 (68.9)	-0.07 (7.18)	-27.2	-3.03	0.00	3.22	17.4	
		Week 94	Sparsentan	106	85 (80.2)	0.34 (7.49)	-22.4	-4.52	0.99	4.92	16.9	0.11 [-0.21, 0.42]
			Irbesartan	103	69 (67.0)	-0.44 (7.11)	-19.0	-3.64	0.00	2.72	23.3	
		Week 110	Sparsentan	106	80 (75.5)	-0.79 (8.85)	-31.2	-5.10	-1.13	4.33	33.3	0.16 [-0.17, 0.49]
			Irbesartan	103	62 (60.2)	-2.15 (7.67)	-29.3	-4.70	-1.94	2.27	19.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Age at IgAN diagnosis												
<= 18 years	KDQOL-SF12: MCS	Baseline	Sparsentan	9	9 (100.0)	44.94 (11.76)	31.1	35.44	42.40	51.24	62.5	
			Irbesartan	5	5 (100.0)	50.09 (9.56)	34.8	46.63	54.94	56.91	57.2	
		Week 24	Sparsentan	9	5 (55.6)	42.94 (15.49)	20.8	39.14	41.07	51.21	62.5	
			Irbesartan	5	5 (100.0)	47.89 (10.99)	29.7	46.63	50.42	55.54	57.2	
		Week 48	Sparsentan	9	7 (77.8)	46.48 (6.88)	37.2	41.30	44.18	51.24	57.2	
			Irbesartan	5	3 (60.0)	52.01 (4.47)	49.3	49.29	49.58	57.16	57.2	
		Week 70	Sparsentan	9	7 (77.8)	46.88 (7.77)	37.3	39.56	46.14	57.06	57.2	
			Irbesartan	5	4 (80.0)	42.98 (11.96)	28.1	34.69	43.38	51.26	57.1	
		Week 94	Sparsentan	9	5 (55.6)	42.92 (10.92)	32.5	38.00	39.01	44.11	61.0	
			Irbesartan	5	4 (80.0)	39.90 (12.63)	29.6	30.49	36.41	49.32	57.2	
		Week 110	Sparsentan	9	4 (44.4)	48.77 (7.80)	38.4	43.46	49.75	54.08	57.2	
			Irbesartan	5	2 (40.0)	35.53 (12.08)	27.0	26.99	35.53	44.07	44.1	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	9	5 (55.6)	-4.27 (15.99)	-19.1	-11.28	-10.30	-3.26	22.5	-0.18 [-1.42, 1.06]
			Irbesartan	5	5 (100.0)	-2.20 (2.46)	-5.1	-4.51	-1.37	0.00	0.0	
		Week 48	Sparsentan	9	7 (77.8)	1.77 (7.09)	-11.3	0.45	1.73	5.92	12.4	0.95 [-0.47, 2.36]
			Irbesartan	5	3 (60.0)	-4.33 (3.91)	-7.6	-7.62	-5.36	0.00	0.0	
		Week 70	Sparsentan	9	7 (77.8)	2.17 (7.66)	-5.3	-5.11	4.12	5.82	15.6	1.14 [-0.18, 2.45]
			Irbesartan	5	4 (80.0)	-5.41 (3.94)	-9.5	-8.10	-6.02	-2.72	-0.1	
		Week 94	Sparsentan	9	5 (55.6)	0.65 (7.05)	-4.4	-2.95	-1.48	-0.94	13.0	1.29 [-0.16, 2.73]
			Irbesartan	5	4 (80.0)	-8.48 (7.17)	-15.3	-14.38	-9.31	-2.58	0.0	
		Week 110	Sparsentan	9	4 (44.4)	1.97 (12.53)	-11.5	-7.74	0.97	11.67	17.4	1.04 [-0.76, 2.83]
			Irbesartan	5	2 (40.0)	-9.34 (2.16)	-10.9	-10.86	-9.34	-7.81	-7.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 18 to 40 years	KDQOL-SF12: MCS	Baseline	Sparsentan	102	94 (92.2)	50.15 (7.60)	27.8	44.79	51.32	55.70	65.2	
			Irbesartan	109	100 (91.7)	50.61 (9.27)	24.3	45.26	52.05	57.16	64.2	
		Week 24	Sparsentan	102	80 (78.4)	51.03 (7.40)	30.7	46.63	52.03	57.16	63.5	
			Irbesartan	109	73 (67.0)	52.24 (8.33)	24.2	48.87	54.45	57.76	62.7	
		Week 48	Sparsentan	102	83 (81.4)	49.95 (8.73)	27.5	43.09	51.77	57.06	62.5	
			Irbesartan	109	69 (63.3)	49.96 (10.03)	21.5	44.16	52.00	57.16	62.5	
		Week 70	Sparsentan	102	80 (78.4)	50.05 (8.84)	25.4	42.76	52.96	57.11	65.5	
			Irbesartan	109	71 (65.1)	50.93 (8.14)	18.9	46.63	52.09	57.06	62.4	
		Week 94	Sparsentan	102	76 (74.5)	49.28 (9.44)	16.0	43.23	51.75	56.95	66.9	
			Irbesartan	109	69 (63.3)	49.73 (10.62)	21.9	43.13	54.20	57.60	63.4	
		Week 110	Sparsentan	102	73 (71.6)	49.06 (9.09)	20.1	43.65	50.03	56.27	67.0	
			Irbesartan	109	65 (59.6)	50.15 (9.38)	20.0	44.45	51.05	57.16	62.7	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	102	80 (78.4)	0.58 (7.54)	-23.6	-3.61	0.00	4.96	26.4	-0.13 [-0.44, 0.19]
			Irbesartan	109	73 (67.0)	1.51 (7.22)	-14.1	-2.96	0.99	5.33	21.7	
		Week 48	Sparsentan	102	83 (81.4)	-0.19 (9.03)	-23.7	-5.08	0.00	5.23	21.1	0.17 [-0.15, 0.49]
			Irbesartan	109	69 (63.3)	-1.56 (7.07)	-23.5	-3.88	-0.10	2.43	13.4	
		Week 70	Sparsentan	102	80 (78.4)	-0.14 (8.87)	-21.8	-4.71	0.48	4.78	26.4	0.11 [-0.21, 0.43]
			Irbesartan	109	71 (65.1)	-1.02 (6.95)	-27.2	-4.16	-0.64	4.87	10.6	
		Week 94	Sparsentan	102	76 (74.5)	-0.72 (9.56)	-28.8	-6.19	0.52	5.25	24.1	0.09 [-0.23, 0.42]
			Irbesartan	109	69 (63.3)	-1.52 (7.63)	-21.0	-5.31	-0.41	2.96	16.1	
		Week 110	Sparsentan	102	73 (71.6)	-0.64 (9.10)	-24.6	-5.33	-0.99	3.54	26.4	0.06 [-0.27, 0.40]
			Irbesartan	109	65 (59.6)	-1.18 (7.38)	-21.2	-5.58	-1.14	2.75	14.2	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 40 years	KDQOL-SF12: MCS	Baseline	Sparsentan	91	85 (93.4)	51.32 (8.50)	16.2	46.65	53.37	57.16	66.5	
			Irbesartan	88	78 (88.6)	52.53 (7.66)	26.4	48.76	54.19	57.57	66.6	
		Week 24	Sparsentan	91	74 (81.3)	53.31 (7.49)	34.3	49.11	54.94	57.90	68.7	
			Irbesartan	88	60 (68.2)	52.84 (7.82)	27.2	48.57	54.29	57.46	64.2	
		Week 48	Sparsentan	91	75 (82.4)	52.61 (8.04)	29.5	48.77	54.20	58.72	64.7	
			Irbesartan	88	55 (62.5)	51.00 (9.30)	19.6	47.27	54.20	57.06	64.6	
		Week 70	Sparsentan	91	76 (83.5)	51.86 (7.74)	27.6	46.05	53.38	57.33	65.4	
			Irbesartan	88	60 (68.2)	51.96 (7.58)	29.2	47.81	52.75	57.16	63.8	
		Week 94	Sparsentan	91	74 (81.3)	52.10 (8.63)	28.0	47.79	54.27	57.90	64.7	
			Irbesartan	88	60 (68.2)	50.79 (8.43)	28.3	45.09	53.48	57.33	61.5	
		Week 110	Sparsentan	91	73 (80.2)	51.10 (8.67)	20.8	46.05	52.08	57.16	68.0	
			Irbesartan	88	54 (61.4)	48.85 (9.48)	23.2	42.38	50.63	55.94	62.7	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	91	74 (81.3)	1.77 (7.95)	-18.1	-2.72	1.05	5.56	25.9	0.21 [-0.13, 0.55]
			Irbesartan	88	60 (68.2)	0.26 (6.09)	-15.4	-3.40	0.13	3.23	28.7	
		Week 48	Sparsentan	91	75 (82.4)	0.80 (8.21)	-17.5	-4.58	1.89	5.92	28.1	0.23 [-0.12, 0.58]
			Irbesartan	88	55 (62.5)	-1.09 (8.41)	-33.9	-3.95	0.00	4.87	17.3	
		Week 70	Sparsentan	91	76 (83.5)	0.48 (8.19)	-17.1	-4.39	-0.14	5.13	26.5	0.00 [-0.34, 0.34]
			Irbesartan	88	60 (68.2)	0.46 (6.40)	-18.6	-2.63	0.18	3.06	17.4	
		Week 94	Sparsentan	91	74 (81.3)	0.51 (6.99)	-15.5	-4.25	0.96	4.91	16.9	0.21 [-0.13, 0.56]
			Irbesartan	88	60 (68.2)	-1.04 (7.54)	-19.0	-5.75	-0.09	2.46	23.3	
		Week 110	Sparsentan	91	73 (80.2)	-0.65 (8.90)	-31.2	-4.29	-0.72	4.55	33.3	0.21 [-0.14, 0.56]
			Irbesartan	88	54 (61.4)	-2.46 (8.04)	-29.3	-5.43	-2.06	0.87	19.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Geographic region												
North America	KDQOL-SF12: MCS	Baseline	Sparsentan	35	32 (91.4)	49.84 (8.24)	32.9	44.11	51.11	56.51	62.6	
			Irbesartan	46	43 (93.5)	53.85 (6.93)	35.7	48.11	56.91	58.15	64.2	
		Week 24	Sparsentan	35	23 (65.7)	52.94 (6.13)	40.6	49.25	54.20	57.16	68.7	
			Irbesartan	46	37 (80.4)	54.43 (7.66)	24.2	51.25	57.06	58.15	63.2	
		Week 48	Sparsentan	35	25 (71.4)	51.23 (9.62)	30.2	46.56	53.02	57.06	64.2	
			Irbesartan	46	33 (71.7)	50.23 (11.03)	19.6	46.91	54.69	57.16	62.4	
		Week 70	Sparsentan	35	23 (65.7)	50.66 (7.82)	35.5	45.99	52.62	57.16	63.5	
			Irbesartan	46	31 (67.4)	52.86 (6.47)	39.7	48.92	54.37	57.16	62.4	
		Week 94	Sparsentan	35	24 (68.6)	48.95 (10.33)	16.0	42.33	50.58	57.11	62.0	
			Irbesartan	46	30 (65.2)	51.08 (8.68)	31.8	45.91	53.45	57.34	63.4	
		Week 110	Sparsentan	35	21 (60.0)	51.15 (11.11)	20.1	46.13	54.37	57.16	68.0	
			Irbesartan	46	31 (67.4)	50.57 (8.91)	30.5	41.23	52.77	57.49	62.4	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	35	23 (65.7)	1.40 (7.19)	-19.1	-0.99	0.00	5.33	14.0	0.21 [-0.32, 0.73]
			Irbesartan	46	37 (80.4)	0.12 (5.42)	-14.1	-2.54	0.27	2.45	13.0	
		Week 48	Sparsentan	35	25 (71.4)	1.22 (7.98)	-23.4	-1.59	1.14	6.04	16.3	0.51 [-0.02, 1.03]
			Irbesartan	46	33 (71.7)	-2.97 (8.50)	-33.9	-5.33	-0.89	0.53	12.1	
		Week 70	Sparsentan	35	23 (65.7)	-0.11 (8.27)	-16.0	-5.33	-0.10	5.33	22.1	0.18 [-0.36, 0.72]
			Irbesartan	46	31 (67.4)	-1.33 (5.60)	-21.2	-2.96	-0.10	0.69	10.4	
		Week 94	Sparsentan	35	24 (68.6)	-1.97 (9.27)	-28.8	-6.45	0.41	2.80	13.6	0.08 [-0.46, 0.62]
			Irbesartan	46	30 (65.2)	-2.60 (6.61)	-21.0	-5.50	-0.14	0.99	5.9	
		Week 110	Sparsentan	35	21 (60.0)	0.15 (8.19)	-24.6	-2.14	0.42	2.96	15.0	0.41 [-0.15, 0.97]
			Irbesartan	46	31 (67.4)	-3.03 (7.51)	-21.2	-7.59	-2.96	0.59	12.7	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Europe	KDQOL-SF12: MCS	Baseline	Sparsentan	98	89 (90.8)	50.64 (9.24)	16.2	45.43	51.83	57.16	66.5	
			Irbesartan	115	99 (86.1)	50.45 (9.15)	26.4	46.56	52.31	57.16	64.6	
		Week 24	Sparsentan	98	75 (76.5)	50.77 (8.57)	20.8	46.59	50.17	57.24	63.5	
			Irbesartan	115	65 (56.5)	51.60 (8.20)	27.2	47.77	52.71	57.73	62.7	
		Week 48	Sparsentan	98	77 (78.6)	50.28 (8.49)	29.5	43.09	51.65	57.16	64.7	
			Irbesartan	115	61 (53.0)	49.94 (9.29)	28.6	44.56	51.83	57.16	64.5	
		Week 70	Sparsentan	98	76 (77.6)	49.72 (8.14)	27.6	43.53	50.64	56.48	62.7	
			Irbesartan	115	72 (62.6)	49.66 (8.75)	18.9	45.42	51.02	56.31	63.4	
		Week 94	Sparsentan	98	71 (72.4)	50.10 (9.45)	30.9	43.32	52.92	57.73	64.7	
			Irbesartan	115	72 (62.6)	48.37 (10.78)	21.9	41.83	50.72	57.56	61.5	
		Week 110	Sparsentan	98	68 (69.4)	49.54 (8.40)	20.8	45.39	50.11	55.86	62.7	
			Irbesartan	115	61 (53.0)	47.92 (10.58)	20.0	42.26	49.61	57.06	62.7	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	98	75 (76.5)	-0.17 (7.44)	-17.0	-4.54	-0.17	3.27	25.9	-0.22 [-0.55, 0.12]
			Irbesartan	115	65 (56.5)	1.50 (7.91)	-15.4	-4.49	0.00	5.33	28.7	
		Week 48	Sparsentan	98	77 (78.6)	-0.87 (8.46)	-20.8	-5.18	0.00	4.34	28.1	0.04 [-0.30, 0.37]
			Irbesartan	115	61 (53.0)	-1.17 (7.34)	-23.5	-3.95	-0.74	3.45	17.3	
		Week 70	Sparsentan	98	76 (77.6)	-0.75 (7.87)	-21.3	-4.21	-0.16	3.37	26.5	-0.04 [-0.36, 0.28]
			Irbesartan	115	72 (62.6)	-0.46 (7.60)	-27.2	-4.60	-1.06	5.36	17.4	
		Week 94	Sparsentan	98	71 (72.4)	-0.37 (7.97)	-22.4	-5.33	0.00	4.92	15.7	0.12 [-0.21, 0.44]
			Irbesartan	115	72 (62.6)	-1.29 (8.02)	-17.4	-5.34	-1.75	2.72	23.3	
		Week 110	Sparsentan	98	68 (69.4)	-1.01 (9.55)	-31.2	-6.66	-1.39	4.15	33.3	0.04 [-0.31, 0.38]
			Irbesartan	115	61 (53.0)	-1.35 (8.23)	-29.3	-5.43	-0.37	3.48	19.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Asia Pacific	KDQOL-SF12: MCS	Baseline	Sparsentan	69	67 (97.1)	50.42 (7.02)	27.8	45.01	51.25	55.70	64.2	
			Irbesartan	41	41 (100.0)	51.19 (8.65)	24.3	49.04	51.77	57.16	66.6	
		Week 24	Sparsentan	69	61 (88.4)	52.75 (7.72)	30.7	47.94	54.20	57.35	66.8	
			Irbesartan	41	36 (87.8)	51.53 (8.55)	30.8	47.62	52.00	57.24	64.2	
		Week 48	Sparsentan	69	63 (91.3)	51.81 (8.00)	27.5	48.28	52.60	57.33	62.4	
			Irbesartan	41	33 (80.5)	51.66 (8.76)	21.5	47.59	53.02	57.16	64.6	
		Week 70	Sparsentan	69	64 (92.8)	52.03 (8.69)	25.4	46.00	54.32	57.96	65.5	
			Irbesartan	41	32 (78.0)	52.87 (7.46)	33.9	50.83	54.32	58.47	63.8	
		Week 94	Sparsentan	69	60 (87.0)	51.40 (8.60)	26.5	47.75	54.20	57.16	66.9	
			Irbesartan	41	31 (75.6)	52.36 (8.03)	31.9	49.76	54.94	57.97	61.1	
		Week 110	Sparsentan	69	61 (88.4)	50.22 (8.62)	28.3	43.83	50.69	57.16	67.0	
			Irbesartan	41	29 (70.7)	50.96 (7.61)	32.5	47.72	51.14	57.06	62.5	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	69	61 (88.4)	2.23 (9.04)	-23.6	-2.29	1.28	7.00	26.4	0.24 [-0.17, 0.65]
			Irbesartan	41	36 (87.8)	0.36 (5.20)	-9.4	-2.77	0.18	3.36	15.5	
		Week 48	Sparsentan	69	63 (91.3)	1.46 (8.85)	-23.7	-4.61	1.97	7.21	21.1	0.22 [-0.20, 0.64]
			Irbesartan	41	33 (80.5)	-0.35 (7.12)	-18.5	-3.09	0.62	4.92	12.6	
		Week 70	Sparsentan	69	64 (92.8)	1.57 (9.16)	-21.8	-4.39	0.77	7.04	26.4	0.16 [-0.26, 0.59]
			Irbesartan	41	32 (78.0)	0.26 (5.47)	-10.7	-2.19	1.03	3.81	10.4	
		Week 94	Sparsentan	69	60 (87.0)	1.01 (8.32)	-16.8	-4.40	1.11	5.79	24.1	0.24 [-0.19, 0.68]
			Irbesartan	41	31 (75.6)	-0.97 (7.74)	-19.0	-6.26	0.00	4.86	14.5	
		Week 110	Sparsentan	69	61 (88.4)	-0.33 (8.84)	-23.0	-4.08	-0.73	4.55	26.4	0.18 [-0.27, 0.62]
			Irbesartan	41	29 (70.7)	-1.78 (6.72)	-13.3	-6.43	-1.97	0.87	12.9	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline BMI												
< 27 kg/m**2	KDQOL-SF12: MCS	Baseline	Sparsentan	83	75 (90.4)	48.54 (9.00)	16.2	43.23	50.35	54.50	64.6	
			Irbesartan	94	86 (91.5)	51.32 (8.05)	27.9	48.11	52.55	57.16	62.7	
		Week 24	Sparsentan	83	66 (79.5)	50.04 (9.49)	20.8	42.93	50.09	57.16	66.8	
			Irbesartan	94	69 (73.4)	52.06 (8.79)	24.2	48.30	54.45	57.76	62.7	
		Week 48	Sparsentan	83	68 (81.9)	49.31 (9.39)	27.5	42.61	51.33	57.08	64.7	
			Irbesartan	94	60 (63.8)	49.52 (10.04)	19.6	45.36	51.02	57.11	64.5	
		Week 70	Sparsentan	83	66 (79.5)	49.22 (9.62)	25.4	41.23	52.38	57.16	65.4	
			Irbesartan	94	62 (66.0)	50.66 (8.16)	28.1	45.46	52.01	57.06	62.7	
		Week 94	Sparsentan	83	64 (77.1)	48.90 (10.07)	26.5	41.17	51.75	56.03	66.9	
			Irbesartan	94	64 (68.1)	50.22 (10.21)	24.5	43.32	54.55	57.73	63.4	
		Week 110	Sparsentan	83	63 (75.9)	48.51 (8.97)	20.8	41.87	48.69	57.06	65.1	
			Irbesartan	94	57 (60.6)	49.11 (9.46)	23.3	42.61	51.05	57.06	62.7	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	83	66 (79.5)	1.25 (9.82)	-23.6	-4.54	-0.16	7.65	26.4	-0.01 [-0.34, 0.33]
			Irbesartan	94	69 (73.4)	1.29 (6.70)	-14.1	-2.96	0.39	5.23	28.7	
		Week 48	Sparsentan	83	68 (81.9)	1.01 (9.34)	-23.4	-3.96	0.89	6.45	28.1	0.30 [-0.05, 0.65]
			Irbesartan	94	60 (63.8)	-1.64 (8.08)	-33.9	-4.95	-1.67	2.79	17.3	
		Week 70	Sparsentan	83	66 (79.5)	1.02 (10.13)	-21.8	-5.11	0.72	7.45	26.5	0.18 [-0.17, 0.53]
			Irbesartan	94	62 (66.0)	-0.53 (6.64)	-27.2	-4.13	0.00	3.22	16.2	
		Week 94	Sparsentan	83	64 (77.1)	1.17 (9.00)	-22.4	-3.73	1.30	6.97	24.1	0.23 [-0.12, 0.58]
			Irbesartan	94	64 (68.1)	-0.79 (7.82)	-19.0	-4.59	-0.12	4.38	16.1	
		Week 110	Sparsentan	83	63 (75.9)	0.33 (10.27)	-31.2	-5.37	-0.73	5.23	33.3	0.26 [-0.10, 0.62]
			Irbesartan	94	57 (60.6)	-2.12 (8.18)	-29.3	-5.92	-2.14	2.12	19.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 27 kg/m**2	KDQOL-SF12: MCS	Baseline	Sparsentan	119	113 (95.0)	51.68 (7.59)	31.4	47.07	53.19	57.16	66.5	
			Irbesartan	107	96 (89.7)	51.76 (8.86)	24.3	47.57	54.14	57.45	66.6	
		Week 24	Sparsentan	119	93 (78.2)	53.12 (6.40)	37.4	48.65	54.20	57.35	68.7	
			Irbesartan	107	69 (64.5)	52.63 (7.61)	27.2	48.87	54.20	57.59	64.2	
		Week 48	Sparsentan	119	97 (81.5)	52.21 (7.58)	27.5	48.76	53.02	57.56	64.2	
			Irbesartan	107	67 (62.6)	51.30 (9.17)	28.4	47.01	54.20	57.16	64.6	
		Week 70	Sparsentan	119	97 (81.5)	51.81 (7.20)	35.5	46.11	52.82	57.16	65.5	
			Irbesartan	107	73 (68.2)	51.58 (8.05)	18.9	47.34	53.20	57.06	63.8	
		Week 94	Sparsentan	119	91 (76.5)	51.50 (8.53)	16.0	45.97	54.34	57.73	62.7	
			Irbesartan	107	68 (63.6)	50.03 (8.99)	23.6	42.60	51.28	57.33	61.1	
		Week 110	Sparsentan	119	87 (73.1)	51.15 (8.67)	20.1	45.57	51.74	57.16	68.0	
			Irbesartan	107	63 (58.9)	49.82 (9.51)	20.0	44.45	50.82	57.33	62.7	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	119	93 (78.2)	0.79 (6.63)	-18.1	-2.46	1.11	4.59	22.5	0.06 [-0.25, 0.37]
			Irbesartan	107	69 (64.5)	0.38 (6.62)	-15.4	-3.53	0.00	3.48	20.6	
		Week 48	Sparsentan	119	97 (81.5)	-0.13 (7.99)	-23.7	-4.74	0.99	4.59	18.7	0.14 [-0.17, 0.45]
			Irbesartan	107	67 (62.6)	-1.22 (7.20)	-23.5	-3.53	0.00	4.85	12.1	
		Week 70	Sparsentan	119	97 (81.5)	-0.27 (7.14)	-21.3	-3.95	0.01	3.68	22.1	0.03 [-0.28, 0.33]
			Irbesartan	107	73 (68.2)	-0.46 (6.80)	-21.2	-3.70	-0.17	3.87	17.4	
		Week 94	Sparsentan	119	91 (76.5)	-0.97 (7.74)	-28.8	-5.53	-0.17	3.82	14.4	0.15 [-0.16, 0.47]
			Irbesartan	107	68 (63.6)	-2.14 (7.48)	-21.0	-6.09	-1.16	2.31	23.3	
		Week 110	Sparsentan	119	87 (73.1)	-1.23 (8.02)	-24.6	-4.83	-0.72	3.54	22.2	0.07 [-0.26, 0.39]
			Irbesartan	107	63 (58.9)	-1.76 (7.29)	-21.3	-6.43	-1.91	2.75	12.9	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Randomization strata												
eGFR Low and UP High	KDQOL-SF12: MCS	Baseline	Sparsentan	71	64 (90.1)	51.84 (7.80)	31.4	45.00	54.20	57.25	64.6	
			Irbesartan	74	64 (86.5)	50.93 (8.84)	26.4	47.48	53.01	56.83	64.6	
		Week 24	Sparsentan	71	54 (76.1)	52.24 (7.56)	36.1	47.15	54.19	57.34	68.7	
			Irbesartan	74	44 (59.5)	52.68 (8.74)	27.2	49.07	56.15	58.23	62.6	
		Week 48	Sparsentan	71	53 (74.6)	51.84 (7.96)	33.7	46.92	54.20	57.33	64.7	
			Irbesartan	74	38 (51.4)	52.17 (10.94)	19.6	49.29	54.79	59.14	64.6	
		Week 70	Sparsentan	71	58 (81.7)	49.70 (7.77)	32.1	44.19	49.48	55.90	65.4	
			Irbesartan	74	41 (55.4)	52.10 (7.28)	28.1	49.02	54.02	56.94	63.8	
		Week 94	Sparsentan	71	52 (73.2)	52.10 (8.07)	32.1	45.80	54.45	57.92	64.7	
			Irbesartan	74	38 (51.4)	52.03 (9.60)	21.9	49.78	55.35	57.53	63.4	
		Week 110	Sparsentan	71	53 (74.6)	49.93 (7.84)	32.3	46.14	50.20	57.06	62.7	
			Irbesartan	74	36 (48.6)	49.16 (10.26)	23.2	45.33	50.51	57.11	62.7	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	71	54 (76.1)	-0.46 (6.51)	-14.5	-4.09	-0.31	2.55	20.8	-0.16 [-0.56, 0.24]
			Irbesartan	74	44 (59.5)	0.61 (6.76)	-15.4	-2.96	0.34	3.27	28.7	
		Week 48	Sparsentan	71	53 (74.6)	-1.01 (7.52)	-20.8	-5.18	-0.37	4.45	16.3	-0.08 [-0.50, 0.33]
			Irbesartan	74	38 (51.4)	-0.33 (9.00)	-33.9	-3.06	0.08	4.85	17.3	
		Week 70	Sparsentan	71	58 (81.7)	-2.73 (7.25)	-21.8	-7.40	-2.73	2.53	17.0	-0.32 [-0.72, 0.09]
			Irbesartan	74	41 (55.4)	-0.40 (7.55)	-27.2	-3.13	0.00	2.00	17.4	
		Week 94	Sparsentan	71	52 (73.2)	-0.29 (7.81)	-22.4	-5.12	1.41	3.59	13.6	-0.17 [-0.59, 0.25]
			Irbesartan	74	38 (51.4)	0.96 (7.10)	-17.6	-3.38	0.66	4.56	23.3	
		Week 110	Sparsentan	71	53 (74.6)	-2.22 (7.81)	-31.2	-5.37	-1.63	2.57	13.8	-0.14 [-0.57, 0.28]
			Irbesartan	74	36 (48.6)	-1.19 (6.42)	-9.9	-5.31	-2.48	0.35	19.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR Low and UP Low	KDQOL-SF12: MCS	Baseline	Sparsentan	55	52 (94.5)	50.44 (9.63)	16.2	45.35	53.09	57.19	65.2	
			Irbesartan	55	50 (90.9)	52.45 (7.68)	31.9	49.36	52.36	57.73	66.6	
		Week 24	Sparsentan	55	44 (80.0)	52.68 (7.95)	34.3	47.52	54.58	58.08	63.9	
			Irbesartan	55	39 (70.9)	52.60 (8.16)	30.8	47.84	54.37	57.66	64.2	
		Week 48	Sparsentan	55	43 (78.2)	50.18 (8.77)	29.5	42.35	52.05	57.16	63.7	
			Irbesartan	55	36 (65.5)	49.38 (9.46)	29.2	42.71	52.89	57.06	62.5	
		Week 70	Sparsentan	55	42 (76.4)	50.98 (8.48)	27.6	44.95	53.34	57.33	64.2	
			Irbesartan	55	40 (72.7)	50.86 (8.16)	29.2	44.94	52.61	57.06	62.7	
		Week 94	Sparsentan	55	42 (76.4)	50.24 (10.63)	16.0	44.54	54.03	57.16	66.9	
			Irbesartan	55	40 (72.7)	49.10 (10.55)	23.6	40.85	52.13	57.66	61.3	
		Week 110	Sparsentan	55	38 (69.1)	50.54 (11.01)	20.1	43.84	51.04	58.77	68.0	
			Irbesartan	55	34 (61.8)	47.67 (9.60)	23.3	39.15	47.09	56.76	62.5	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	55	44 (80.0)	2.37 (8.05)	-17.0	-2.38	1.14	6.24	25.9	0.29 [-0.14, 0.73]
			Irbesartan	55	39 (70.9)	0.22 (6.50)	-9.4	-5.65	0.00	5.02	20.2	
		Week 48	Sparsentan	55	43 (78.2)	-0.41 (8.87)	-20.3	-5.08	-0.99	5.62	28.1	0.25 [-0.19, 0.69]
			Irbesartan	55	36 (65.5)	-2.53 (8.05)	-23.5	-7.17	-2.92	2.63	12.6	
		Week 70	Sparsentan	55	42 (76.4)	0.92 (8.97)	-21.3	-3.77	0.52	4.63	26.5	0.22 [-0.22, 0.65]
			Irbesartan	55	40 (72.7)	-0.85 (7.20)	-21.2	-3.54	-0.33	3.97	10.6	
		Week 94	Sparsentan	55	42 (76.4)	-0.08 (7.53)	-28.8	-3.72	-0.50	4.38	15.7	0.38 [-0.06, 0.81]
			Irbesartan	55	40 (72.7)	-3.17 (8.84)	-21.0	-7.98	-1.97	2.35	14.5	
		Week 110	Sparsentan	55	38 (69.1)	-0.14 (10.09)	-24.6	-4.74	-1.20	5.43	33.3	0.42 [-0.05, 0.89]
			Irbesartan	55	34 (61.8)	-4.03 (8.31)	-29.3	-6.82	-3.57	1.88	10.5	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP High	KDQOL-SF12: MCS	Baseline	Sparsentan	37	35 (94.6)	48.30 (7.97)	27.8	43.44	49.67	54.20	62.4	
			Irbesartan	36	33 (91.7)	52.02 (8.60)	27.9	46.56	54.45	57.33	64.2	
		Week 24	Sparsentan	37	27 (73.0)	49.15 (8.16)	20.8	46.59	51.83	54.37	57.3	
			Irbesartan	36	26 (72.2)	52.61 (7.05)	36.7	48.43	53.54	57.76	62.5	
		Week 48	Sparsentan	37	34 (91.9)	49.58 (8.82)	27.5	43.09	51.14	57.16	62.5	
			Irbesartan	36	25 (69.4)	49.95 (9.55)	28.4	47.01	51.01	57.06	62.4	
		Week 70	Sparsentan	37	31 (83.8)	49.86 (7.62)	35.9	43.60	51.83	56.60	65.5	
			Irbesartan	36	25 (69.4)	50.60 (8.63)	33.9	46.54	51.94	57.16	63.4	
		Week 94	Sparsentan	37	27 (73.0)	48.32 (7.67)	30.9	44.11	49.52	55.02	60.1	
			Irbesartan	36	25 (69.4)	50.11 (8.59)	24.5	45.91	52.85	57.16	59.5	
		Week 110	Sparsentan	37	26 (70.3)	48.72 (6.67)	28.3	46.08	50.45	53.78	57.3	
			Irbesartan	36	22 (61.1)	51.87 (7.70)	32.5	46.39	53.97	57.33	62.5	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	37	27 (73.0)	0.54 (9.21)	-19.1	-5.23	0.00	5.54	26.4	-0.09 [-0.63, 0.45]
			Irbesartan	36	26 (72.2)	1.26 (6.90)	-13.4	-2.54	0.51	3.77	21.7	
		Week 48	Sparsentan	37	34 (91.9)	1.63 (10.31)	-23.7	-2.43	2.70	7.36	21.1	0.28 [-0.24, 0.80]
			Irbesartan	36	25 (69.4)	-0.82 (6.18)	-15.3	-3.76	0.00	4.94	6.9	
		Week 70	Sparsentan	37	31 (83.8)	2.23 (8.30)	-12.5	-2.96	0.09	5.23	26.4	0.34 [-0.19, 0.88]
			Irbesartan	36	25 (69.4)	-0.31 (5.97)	-10.7	-3.70	-0.10	5.14	8.9	
		Week 94	Sparsentan	37	27 (73.0)	1.18 (10.07)	-14.5	-9.39	3.66	7.97	24.1	0.31 [-0.24, 0.85]
			Irbesartan	36	25 (69.4)	-1.36 (5.87)	-13.5	-5.86	-1.18	1.55	9.9	
		Week 110	Sparsentan	37	26 (70.3)	0.84 (9.62)	-23.0	-5.33	0.95	4.11	26.4	0.12 [-0.45, 0.68]
			Irbesartan	36	22 (61.1)	-0.20 (8.37)	-16.1	-5.58	0.03	5.68	12.9	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
eGFR High and UP Low	KDQOL-SF12: MCS	Baseline	Sparsentan	39	37 (94.9)	49.98 (7.21)	30.1	46.33	50.94	54.63	66.5	
			Irbesartan	37	36 (97.3)	50.30 (9.63)	24.3	45.44	51.94	57.16	62.5	
		Week 24	Sparsentan	39	34 (87.2)	52.25 (8.31)	30.7	48.65	52.32	58.72	66.8	
			Irbesartan	37	29 (78.4)	51.24 (8.65)	24.2	47.77	52.23	57.16	62.5	
		Week 48	Sparsentan	39	35 (89.7)	52.17 (8.55)	27.5	49.43	54.79	58.72	62.5	
			Irbesartan	37	28 (75.7)	50.00 (7.90)	28.6	44.36	51.55	55.51	62.5	
		Week 70	Sparsentan	39	32 (82.1)	53.25 (9.56)	25.4	50.37	57.07	60.07	62.7	
			Irbesartan	37	29 (78.4)	50.72 (8.86)	18.9	47.10	51.67	57.06	61.0	
		Week 94	Sparsentan	39	34 (87.2)	49.77 (10.17)	26.5	42.72	52.56	57.73	63.2	
			Irbesartan	37	30 (81.1)	48.14 (10.12)	24.5	41.17	48.77	57.92	60.1	
		Week 110	Sparsentan	39	33 (84.6)	50.70 (9.43)	30.0	43.83	53.39	58.47	64.0	
			Irbesartan	37	29 (78.4)	49.55 (9.93)	20.0	44.26	51.14	57.16	62.7	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	39	34 (87.2)	1.82 (9.32)	-23.6	-2.72	1.74	7.65	25.3	0.02 [-0.47, 0.52]
			Irbesartan	37	29 (78.4)	1.63 (6.72)	-13.9	-1.32	0.00	4.80	20.6	
		Week 48	Sparsentan	39	35 (89.7)	2.04 (7.66)	-18.6	-0.27	1.97	5.23	19.4	0.58 [0.07, 1.09]
			Irbesartan	37	28 (75.7)	-2.02 (6.08)	-17.3	-5.06	-1.01	0.62	13.4	
		Week 70	Sparsentan	39	32 (82.1)	2.87 (8.78)	-20.3	-3.20	4.13	8.25	17.0	0.43 [-0.08, 0.93]
			Irbesartan	37	29 (78.4)	-0.28 (5.51)	-10.6	-4.26	-0.51	3.87	10.4	
		Week 94	Sparsentan	39	34 (87.2)	-0.78 (8.77)	-16.8	-7.82	-0.46	5.23	16.9	0.22 [-0.27, 0.71]
			Irbesartan	37	30 (81.1)	-2.56 (7.35)	-16.7	-6.03	-3.01	1.58	16.1	
		Week 110	Sparsentan	39	33 (84.6)	0.46 (9.14)	-15.6	-4.40	-1.41	6.06	22.2	0.23 [-0.27, 0.73]
			Irbesartan	37	29 (78.4)	-1.51 (7.67)	-21.3	-6.43	-0.10	3.48	12.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 1												
< 60 mL/min/1.73 m**2	KDQOL-SF12: MCS	Baseline	Sparsentan	127	117 (92.1)	51.41 (8.59)	16.2	46.65	53.71	57.22	65.2	
			Irbesartan	129	115 (89.1)	51.65 (8.12)	26.4	48.11	52.63	57.16	66.6	
		Week 24	Sparsentan	127	99 (78.0)	52.44 (7.68)	34.3	47.15	54.20	57.65	68.7	
			Irbesartan	129	85 (65.9)	52.45 (8.22)	27.2	48.87	54.45	57.76	64.2	
		Week 48	Sparsentan	127	97 (76.4)	50.95 (8.29)	29.5	44.50	52.05	57.33	64.7	
			Irbesartan	129	76 (58.9)	50.21 (9.94)	19.6	43.74	53.32	57.16	64.5	
		Week 70	Sparsentan	127	101 (79.5)	50.33 (7.81)	27.6	44.73	51.83	57.06	65.4	
			Irbesartan	129	83 (64.3)	51.29 (7.70)	28.1	47.34	52.63	57.06	62.7	
		Week 94	Sparsentan	127	94 (74.0)	51.15 (8.72)	28.0	43.45	54.10	57.33	66.9	
			Irbesartan	129	79 (61.2)	50.84 (9.76)	21.9	42.46	54.94	57.73	63.4	
		Week 110	Sparsentan	127	93 (73.2)	50.61 (8.61)	20.8	45.57	50.99	57.16	68.0	
			Irbesartan	129	72 (55.8)	49.07 (9.81)	23.2	42.50	50.51	57.11	62.7	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	127	99 (78.0)	0.66 (7.37)	-17.0	-3.26	0.00	3.97	25.9	0.03 [-0.26, 0.32]
			Irbesartan	129	85 (65.9)	0.48 (6.59)	-15.4	-4.36	0.27	4.26	28.7	
		Week 48	Sparsentan	127	97 (76.4)	-1.12 (8.18)	-20.8	-5.18	-0.99	4.34	28.1	0.09 [-0.21, 0.39]
			Irbesartan	129	76 (58.9)	-1.87 (8.69)	-33.9	-4.71	-0.94	3.28	17.3	
		Week 70	Sparsentan	127	101 (79.5)	-1.34 (7.90)	-21.8	-5.43	-1.80	2.92	26.5	-0.09 [-0.38, 0.20]
			Irbesartan	129	83 (64.3)	-0.61 (7.43)	-27.2	-3.70	-0.10	3.64	17.4	
		Week 94	Sparsentan	127	94 (74.0)	-0.51 (7.32)	-22.4	-5.02	0.03	3.53	15.7	0.05 [-0.25, 0.35]
			Irbesartan	129	79 (61.2)	-0.89 (8.29)	-21.0	-5.31	0.00	4.07	23.3	
		Week 110	Sparsentan	127	93 (73.2)	-1.24 (8.51)	-31.2	-5.16	-1.40	2.96	33.3	0.10 [-0.21, 0.40]
			Irbesartan	129	72 (55.8)	-2.03 (7.83)	-29.3	-5.39	-2.17	2.19	19.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	KDQOL-SF12: MCS	Baseline	Sparsentan	49	47 (95.9)	48.70 (7.66)	30.1	43.44	48.53	54.37	66.5	
			Irbesartan	48	44 (91.7)	51.20 (9.16)	27.9	44.31	54.27	57.45	64.2	
		Week 24	Sparsentan	49	39 (79.6)	50.15 (9.01)	20.8	47.83	51.83	57.16	66.8	
			Irbesartan	48	33 (68.8)	52.74 (8.14)	24.2	49.52	54.96	57.33	62.7	
		Week 48	Sparsentan	49	45 (91.8)	49.59 (9.53)	27.5	43.19	51.73	57.06	63.4	
			Irbesartan	48	33 (68.8)	51.32 (9.72)	28.6	49.58	51.36	57.16	64.6	
		Week 70	Sparsentan	49	40 (81.6)	50.63 (9.37)	25.4	43.53	54.41	57.19	62.7	
			Irbesartan	48	32 (66.7)	51.85 (7.95)	33.9	47.04	52.87	57.25	63.8	
		Week 94	Sparsentan	49	41 (83.7)	48.19 (11.16)	16.0	40.95	50.63	57.06	62.7	
			Irbesartan	48	35 (72.9)	48.50 (9.92)	24.5	42.73	51.83	57.16	60.1	
		Week 110	Sparsentan	49	36 (73.5)	47.61 (9.86)	20.1	41.91	49.71	54.92	62.5	
			Irbesartan	48	32 (66.7)	49.33 (8.52)	30.5	42.65	50.20	57.11	62.5	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	49	39 (79.6)	0.67 (9.04)	-23.6	-3.11	0.37	5.54	25.3	-0.03 [-0.49, 0.44]
			Irbesartan	48	33 (68.8)	0.89 (6.37)	-13.9	-1.98	0.00	2.98	21.7	
		Week 48	Sparsentan	49	45 (91.8)	1.14 (8.19)	-23.7	-1.59	2.04	6.32	15.7	0.15 [-0.30, 0.60]
			Irbesartan	48	33 (68.8)	0.07 (4.90)	-12.1	-3.03	0.59	3.95	6.7	
		Week 70	Sparsentan	49	40 (81.6)	2.33 (7.90)	-17.9	-2.84	2.41	6.54	17.0	0.29 [-0.18, 0.76]
			Irbesartan	48	32 (66.7)	0.35 (5.27)	-9.5	-3.38	-0.05	5.06	8.9	
		Week 94	Sparsentan	49	41 (83.7)	-0.05 (9.62)	-28.8	-5.53	1.14	5.24	16.9	0.34 [-0.12, 0.79]
			Irbesartan	48	35 (72.9)	-2.83 (6.20)	-16.2	-6.22	-3.06	0.59	9.4	
		Week 110	Sparsentan	49	36 (73.5)	-0.70 (9.25)	-24.6	-4.92	-0.11	4.52	18.4	0.20 [-0.27, 0.68]
			Irbesartan	48	32 (66.7)	-2.47 (8.10)	-21.3	-7.25	-2.75	2.31	12.9	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	KDQOL-SF12: MCS	Baseline	Sparsentan	26	24 (92.3)	49.00 (7.58)	27.8	47.06	50.17	53.71	61.5	
			Irbesartan	25	24 (96.0)	50.68 (10.24)	24.3	46.60	53.61	57.51	62.5	
		Week 24	Sparsentan	26	21 (80.8)	52.17 (7.01)	36.1	47.09	52.62	57.16	62.4	
			Irbesartan	25	20 (80.0)	51.21 (8.47)	36.1	46.40	50.33	59.86	62.5	
		Week 48	Sparsentan	26	23 (88.5)	54.06 (6.23)	39.9	50.34	55.02	59.46	62.5	
			Irbesartan	25	18 (72.0)	49.98 (8.15)	28.4	44.16	53.82	54.37	60.0	
		Week 70	Sparsentan	26	22 (84.6)	52.95 (8.73)	31.7	49.11	54.58	60.02	65.5	
			Irbesartan	25	20 (80.0)	49.48 (9.92)	18.9	45.86	51.81	56.81	60.1	
		Week 94	Sparsentan	26	20 (76.9)	51.59 (6.73)	38.5	46.18	51.75	57.16	63.2	
			Irbesartan	25	19 (76.0)	48.65 (10.10)	24.5	43.32	49.52	57.90	60.1	
		Week 110	Sparsentan	26	21 (80.8)	51.71 (7.66)	36.4	47.10	51.66	58.47	64.0	
			Irbesartan	25	17 (68.0)	50.44 (10.78)	20.0	47.77	52.48	57.16	62.7	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	26	21 (80.8)	3.05 (9.49)	-13.0	-2.62	3.65	9.48	26.4	0.09 [-0.52, 0.71]
			Irbesartan	25	20 (80.0)	2.26 (7.48)	-13.4	-2.71	1.88	5.28	20.6	
		Week 48	Sparsentan	26	23 (88.5)	4.94 (9.36)	-14.6	-0.03	3.68	13.74	21.1	0.87 [0.22, 1.51]
			Irbesartan	25	18 (72.0)	-2.25 (6.68)	-15.3	-6.63	-2.47	0.00	13.4	
		Week 70	Sparsentan	26	22 (84.6)	3.77 (10.35)	-20.3	-3.69	4.01	11.62	26.4	0.61 [-0.01, 1.22]
			Irbesartan	25	20 (80.0)	-1.33 (5.58)	-10.6	-5.33	-0.72	1.95	9.2	
		Week 94	Sparsentan	26	20 (76.9)	1.82 (9.99)	-12.7	-6.21	1.87	9.56	24.1	0.40 [-0.23, 1.04]
			Irbesartan	25	19 (76.0)	-1.68 (7.17)	-15.3	-7.82	-0.14	2.79	16.1	
		Week 110	Sparsentan	26	21 (80.8)	2.58 (10.63)	-15.6	-3.98	1.71	7.90	26.4	0.31 [-0.33, 0.95]
			Irbesartan	25	17 (68.0)	-0.19 (6.25)	-11.7	-2.86	0.00	5.16	12.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline eGFR Group 2												
< 45 mL/min/1.73 m**2	KDQOL-SF12: MCS	Baseline	Sparsentan	82	73 (89.0)	50.19 (8.99)	16.2	44.41	52.00	57.16	64.2	
			Irbesartan	80	70 (87.5)	50.90 (8.98)	26.4	47.81	52.12	57.16	66.6	
		Week 24	Sparsentan	82	64 (78.0)	52.42 (8.03)	34.3	47.00	54.29	57.56	68.7	
			Irbesartan	80	51 (63.8)	52.07 (8.95)	27.2	48.87	54.45	58.17	64.2	
		Week 48	Sparsentan	82	63 (76.8)	50.54 (8.10)	29.5	44.50	51.65	57.16	64.2	
			Irbesartan	80	45 (56.3)	49.71 (10.72)	19.6	43.60	51.65	57.41	64.5	
		Week 70	Sparsentan	82	65 (79.3)	49.81 (8.06)	27.6	44.19	49.62	57.06	63.5	
			Irbesartan	80	50 (62.5)	50.06 (7.97)	28.1	44.95	51.92	55.41	62.4	
		Week 94	Sparsentan	82	61 (74.4)	51.27 (8.83)	28.0	46.14	54.20	57.33	66.9	
			Irbesartan	80	48 (60.0)	50.72 (9.57)	21.9	42.89	53.34	57.53	63.4	
		Week 110	Sparsentan	82	57 (69.5)	50.41 (9.02)	20.8	45.22	51.53	57.16	67.0	
			Irbesartan	80	44 (55.0)	48.47 (10.01)	23.2	42.44	50.51	56.91	62.7	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	82	64 (78.0)	1.75 (7.44)	-13.0	-2.78	1.20	4.71	25.9	0.18 [-0.19, 0.55]
			Irbesartan	80	51 (63.8)	0.38 (7.56)	-15.4	-4.80	0.00	4.24	28.7	
		Week 48	Sparsentan	82	63 (76.8)	-0.18 (8.38)	-20.8	-5.16	0.00	4.49	28.1	0.19 [-0.19, 0.58]
			Irbesartan	80	45 (56.3)	-1.96 (10.17)	-33.9	-6.62	-0.11	4.85	17.3	
		Week 70	Sparsentan	82	65 (79.3)	-1.07 (8.21)	-21.8	-5.33	0.01	3.36	26.5	0.03 [-0.34, 0.40]
			Irbesartan	80	50 (62.5)	-1.33 (7.90)	-27.2	-4.16	-1.40	1.83	17.4	
		Week 94	Sparsentan	82	61 (74.4)	0.66 (6.60)	-22.4	-2.96	0.99	3.82	15.7	0.09 [-0.29, 0.47]
			Irbesartan	80	48 (60.0)	0.00 (8.11)	-19.0	-5.01	-0.11	3.86	23.3	
		Week 110	Sparsentan	82	57 (69.5)	-0.65 (8.38)	-17.6	-4.74	-1.40	3.54	33.3	0.05 [-0.34, 0.45]
			Irbesartan	80	44 (55.0)	-1.05 (6.77)	-13.3	-5.39	-2.17	2.87	19.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
45 to < 60 mL/min/1.73 m**2	KDQOL-SF12: MCS	Baseline	Sparsentan	45	44 (97.8)	53.44 (7.56)	33.8	49.54	55.60	57.82	65.2	
			Irbesartan	49	45 (91.8)	52.83 (6.48)	31.9	49.36	54.15	57.09	64.6	
		Week 24	Sparsentan	45	35 (77.8)	52.46 (7.12)	40.6	47.77	53.04	57.90	63.9	
			Irbesartan	49	34 (69.4)	53.03 (7.08)	33.5	48.43	54.62	57.16	63.2	
		Week 48	Sparsentan	45	34 (75.6)	51.69 (8.70)	30.2	42.67	52.61	59.31	64.7	
			Irbesartan	49	31 (63.3)	50.93 (8.81)	29.2	47.58	54.61	57.06	62.4	
		Week 70	Sparsentan	45	36 (80.0)	51.28 (7.36)	35.9	45.95	52.28	56.40	65.4	
			Irbesartan	49	33 (67.3)	53.16 (6.97)	36.7	50.51	55.36	57.16	62.7	
		Week 94	Sparsentan	45	33 (73.3)	50.92 (8.62)	36.0	42.90	52.77	57.16	64.7	
			Irbesartan	49	31 (63.3)	51.03 (10.20)	23.6	41.34	57.06	57.73	61.3	
		Week 110	Sparsentan	45	36 (80.0)	50.92 (8.03)	33.4	46.10	49.91	57.16	68.0	
			Irbesartan	49	28 (57.1)	50.01 (9.60)	23.3	43.42	51.92	57.54	62.5	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	45	35 (77.8)	-1.32 (6.89)	-17.0	-6.52	-0.77	2.37	14.8	-0.33 [-0.80, 0.15]
			Irbesartan	49	34 (69.4)	0.64 (4.88)	-8.6	-2.96	1.38	4.66	8.9	
		Week 48	Sparsentan	45	34 (75.6)	-2.86 (7.62)	-18.6	-5.50	-2.58	2.70	11.8	-0.16 [-0.65, 0.33]
			Irbesartan	49	31 (63.3)	-1.74 (6.08)	-17.3	-3.53	-1.14	2.45	8.2	
		Week 70	Sparsentan	45	36 (80.0)	-1.82 (7.40)	-17.1	-5.61	-2.27	1.45	15.2	-0.33 [-0.80, 0.15]
			Irbesartan	49	33 (67.3)	0.48 (6.62)	-21.2	-2.86	0.42	4.20	10.6	
		Week 94	Sparsentan	45	33 (73.3)	-2.67 (8.17)	-20.7	-8.51	-0.57	2.18	13.6	-0.05 [-0.54, 0.44]
			Irbesartan	49	31 (63.3)	-2.27 (8.50)	-21.0	-7.31	0.00	4.20	10.1	
		Week 110	Sparsentan	45	36 (80.0)	-2.16 (8.73)	-31.2	-6.70	-1.27	2.50	16.0	0.16 [-0.34, 0.65]
			Irbesartan	49	28 (57.1)	-3.56 (9.19)	-29.3	-5.39	-2.37	1.84	10.9	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
60 to < 90 mL/min/1.73 m**2	KDQOL-SF12: MCS	Baseline	Sparsentan	49	47 (95.9)	48.70 (7.66)	30.1	43.44	48.53	54.37	66.5	
			Irbesartan	48	44 (91.7)	51.20 (9.16)	27.9	44.31	54.27	57.45	64.2	
		Week 24	Sparsentan	49	39 (79.6)	50.15 (9.01)	20.8	47.83	51.83	57.16	66.8	
			Irbesartan	48	33 (68.8)	52.74 (8.14)	24.2	49.52	54.96	57.33	62.7	
		Week 48	Sparsentan	49	45 (91.8)	49.59 (9.53)	27.5	43.19	51.73	57.06	63.4	
			Irbesartan	48	33 (68.8)	51.32 (9.72)	28.6	49.58	51.36	57.16	64.6	
		Week 70	Sparsentan	49	40 (81.6)	50.63 (9.37)	25.4	43.53	54.41	57.19	62.7	
			Irbesartan	48	32 (66.7)	51.85 (7.95)	33.9	47.04	52.87	57.25	63.8	
		Week 94	Sparsentan	49	41 (83.7)	48.19 (11.16)	16.0	40.95	50.63	57.06	62.7	
			Irbesartan	48	35 (72.9)	48.50 (9.92)	24.5	42.73	51.83	57.16	60.1	
		Week 110	Sparsentan	49	36 (73.5)	47.61 (9.86)	20.1	41.91	49.71	54.92	62.5	
			Irbesartan	48	32 (66.7)	49.33 (8.52)	30.5	42.65	50.20	57.11	62.5	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	49	39 (79.6)	0.67 (9.04)	-23.6	-3.11	0.37	5.54	25.3	-0.03 [-0.49, 0.44]
			Irbesartan	48	33 (68.8)	0.89 (6.37)	-13.9	-1.98	0.00	2.98	21.7	
		Week 48	Sparsentan	49	45 (91.8)	1.14 (8.19)	-23.7	-1.59	2.04	6.32	15.7	0.15 [-0.30, 0.60]
			Irbesartan	48	33 (68.8)	0.07 (4.90)	-12.1	-3.03	0.59	3.95	6.7	
		Week 70	Sparsentan	49	40 (81.6)	2.33 (7.90)	-17.9	-2.84	2.41	6.54	17.0	0.29 [-0.18, 0.76]
			Irbesartan	48	32 (66.7)	0.35 (5.27)	-9.5	-3.38	-0.05	5.06	8.9	
		Week 94	Sparsentan	49	41 (83.7)	-0.05 (9.62)	-28.8	-5.53	1.14	5.24	16.9	0.34 [-0.12, 0.79]
			Irbesartan	48	35 (72.9)	-2.83 (6.20)	-16.2	-6.22	-3.06	0.59	9.4	
		Week 110	Sparsentan	49	36 (73.5)	-0.70 (9.25)	-24.6	-4.92	-0.11	4.52	18.4	0.20 [-0.27, 0.68]
			Irbesartan	48	32 (66.7)	-2.47 (8.10)	-21.3	-7.25	-2.75	2.31	12.9	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
>= 90 mL/min/1.73 m**2	KDQOL-SF12: MCS	Baseline	Sparsentan	26	24 (92.3)	49.00 (7.58)	27.8	47.06	50.17	53.71	61.5	
			Irbesartan	25	24 (96.0)	50.68 (10.24)	24.3	46.60	53.61	57.51	62.5	
		Week 24	Sparsentan	26	21 (80.8)	52.17 (7.01)	36.1	47.09	52.62	57.16	62.4	
			Irbesartan	25	20 (80.0)	51.21 (8.47)	36.1	46.40	50.33	59.86	62.5	
		Week 48	Sparsentan	26	23 (88.5)	54.06 (6.23)	39.9	50.34	55.02	59.46	62.5	
			Irbesartan	25	18 (72.0)	49.98 (8.15)	28.4	44.16	53.82	54.37	60.0	
		Week 70	Sparsentan	26	22 (84.6)	52.95 (8.73)	31.7	49.11	54.58	60.02	65.5	
			Irbesartan	25	20 (80.0)	49.48 (9.92)	18.9	45.86	51.81	56.81	60.1	
		Week 94	Sparsentan	26	20 (76.9)	51.59 (6.73)	38.5	46.18	51.75	57.16	63.2	
			Irbesartan	25	19 (76.0)	48.65 (10.10)	24.5	43.32	49.52	57.90	60.1	
		Week 110	Sparsentan	26	21 (80.8)	51.71 (7.66)	36.4	47.10	51.66	58.47	64.0	
			Irbesartan	25	17 (68.0)	50.44 (10.78)	20.0	47.77	52.48	57.16	62.7	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	26	21 (80.8)	3.05 (9.49)	-13.0	-2.62	3.65	9.48	26.4	0.09 [-0.52, 0.71]
			Irbesartan	25	20 (80.0)	2.26 (7.48)	-13.4	-2.71	1.88	5.28	20.6	
		Week 48	Sparsentan	26	23 (88.5)	4.94 (9.36)	-14.6	-0.03	3.68	13.74	21.1	0.87 [0.22, 1.51]
			Irbesartan	25	18 (72.0)	-2.25 (6.68)	-15.3	-6.63	-2.47	0.00	13.4	
		Week 70	Sparsentan	26	22 (84.6)	3.77 (10.35)	-20.3	-3.69	4.01	11.62	26.4	0.61 [-0.01, 1.22]
			Irbesartan	25	20 (80.0)	-1.33 (5.58)	-10.6	-5.33	-0.72	1.95	9.2	
		Week 94	Sparsentan	26	20 (76.9)	1.82 (9.99)	-12.7	-6.21	1.87	9.56	24.1	0.40 [-0.23, 1.04]
			Irbesartan	25	19 (76.0)	-1.68 (7.17)	-15.3	-7.82	-0.14	2.79	16.1	
		Week 110	Sparsentan	26	21 (80.8)	2.58 (10.63)	-15.6	-3.98	1.71	7.90	26.4	0.31 [-0.33, 0.95]
			Irbesartan	25	17 (68.0)	-0.19 (6.25)	-11.7	-2.86	0.00	5.16	12.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline urine protein excretion												
<= 1.75 g/day	KDQOL-SF12: MCS	Baseline	Sparsentan	98	93 (94.9)	50.20 (8.75)	16.2	45.91	51.55	56.44	66.5	
			Irbesartan	93	83 (89.2)	50.95 (8.77)	24.3	47.81	52.09	57.16	66.6	
		Week 24	Sparsentan	98	81 (82.7)	51.60 (8.82)	20.8	46.86	52.62	57.90	68.7	
			Irbesartan	93	59 (63.4)	52.10 (8.36)	24.2	47.77	54.20	57.33	64.2	
		Week 48	Sparsentan	98	83 (84.7)	50.58 (9.28)	27.5	44.32	52.05	58.32	64.2	
			Irbesartan	93	57 (61.3)	50.11 (9.11)	19.6	44.56	52.77	57.06	62.5	
		Week 70	Sparsentan	98	77 (78.6)	51.51 (8.58)	25.4	47.07	53.24	57.33	63.5	
			Irbesartan	93	62 (66.7)	50.66 (8.61)	18.9	46.98	52.31	57.06	62.7	
		Week 94	Sparsentan	98	79 (80.6)	49.87 (9.73)	26.5	42.72	51.67	57.73	66.9	
			Irbesartan	93	64 (68.8)	48.76 (10.45)	21.9	41.68	51.80	57.66	61.3	
		Week 110	Sparsentan	98	76 (77.6)	49.82 (9.68)	20.8	43.25	50.09	57.63	68.0	
			Irbesartan	93	57 (61.3)	48.64 (10.10)	20.0	42.62	50.66	57.16	62.7	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	98	81 (82.7)	1.33 (8.38)	-23.6	-2.79	0.87	5.84	25.9	0.08 [-0.25, 0.42]
			Irbesartan	93	59 (63.4)	0.71 (6.13)	-13.9	-3.53	0.00	4.66	20.6	
		Week 48	Sparsentan	98	83 (84.7)	0.37 (9.03)	-23.7	-4.58	0.70	5.23	28.1	0.22 [-0.12, 0.55]
			Irbesartan	93	57 (61.3)	-1.46 (7.61)	-33.9	-3.53	-0.10	2.43	13.4	
		Week 70	Sparsentan	98	77 (78.6)	1.37 (8.93)	-21.3	-3.80	1.81	5.39	26.5	0.29 [-0.04, 0.63]
			Irbesartan	93	62 (66.7)	-0.93 (6.15)	-18.6	-4.26	-0.54	3.87	10.4	
		Week 94	Sparsentan	98	79 (80.6)	-0.35 (8.08)	-20.7	-5.56	-0.17	4.94	16.9	0.24 [-0.09, 0.57]
			Irbesartan	93	64 (68.8)	-2.22 (7.44)	-19.0	-5.49	-2.36	1.94	16.1	
		Week 110	Sparsentan	98	76 (77.6)	-0.36 (9.53)	-23.0	-5.59	-1.81	5.33	33.3	0.20 [-0.14, 0.54]
			Irbesartan	93	57 (61.3)	-2.12 (7.74)	-29.3	-4.85	-0.68	2.75	12.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 1.75 g/day	KDQOL-SF12: MCS	Baseline	Sparsentan	104	95 (91.3)	50.65 (7.88)	27.8	44.79	51.83	57.16	64.6	
			Irbesartan	109	100 (91.7)	51.80 (8.54)	26.4	47.17	54.16	57.33	64.6	
		Week 24	Sparsentan	104	78 (75.0)	52.09 (6.99)	36.1	47.15	54.20	57.16	63.9	
			Irbesartan	109	79 (72.5)	52.53 (8.11)	27.2	48.87	54.45	58.15	62.6	
		Week 48	Sparsentan	104	82 (78.8)	51.45 (7.59)	33.7	46.61	52.61	57.33	64.7	
			Irbesartan	109	70 (64.2)	50.75 (10.02)	21.5	46.91	53.54	57.41	64.6	
		Week 70	Sparsentan	104	86 (82.7)	50.09 (8.11)	32.1	44.07	52.23	57.06	65.5	
			Irbesartan	109	73 (67.0)	51.57 (7.65)	28.1	47.45	52.54	57.06	63.8	
		Week 94	Sparsentan	104	76 (73.1)	51.00 (8.75)	16.0	45.84	54.15	57.16	64.7	
			Irbesartan	109	69 (63.3)	50.98 (9.18)	23.6	46.53	54.79	57.34	63.4	
		Week 110	Sparsentan	104	74 (71.2)	50.27 (7.99)	20.1	46.98	51.46	57.06	65.1	
			Irbesartan	109	64 (58.7)	49.94 (9.10)	23.2	44.26	50.93	57.16	62.7	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	104	78 (75.0)	0.62 (7.80)	-19.1	-3.26	0.00	4.20	26.4	-0.04 [-0.36, 0.27]
			Irbesartan	109	79 (72.5)	0.93 (7.06)	-15.4	-2.96	0.72	4.24	28.7	
		Week 48	Sparsentan	104	82 (78.8)	0.31 (8.12)	-20.8	-4.74	1.06	5.68	21.1	0.21 [-0.11, 0.53]
			Irbesartan	109	70 (64.2)	-1.39 (7.65)	-23.5	-4.01	-0.42	4.19	17.3	
		Week 70	Sparsentan	104	86 (82.7)	-0.75 (7.96)	-21.8	-5.11	-1.13	3.36	26.4	-0.08 [-0.39, 0.23]
			Irbesartan	109	73 (67.0)	-0.12 (7.16)	-27.2	-3.56	0.00	2.96	17.4	
		Week 94	Sparsentan	104	76 (73.1)	0.19 (8.62)	-28.8	-4.77	1.41	5.00	24.1	0.13 [-0.20, 0.45]
			Irbesartan	109	69 (63.3)	-0.85 (7.80)	-21.0	-5.16	0.00	3.66	23.3	
		Week 110	Sparsentan	104	74 (71.2)	-0.80 (8.55)	-31.2	-4.83	0.00	2.96	26.4	0.11 [-0.23, 0.44]
			Irbesartan	109	64 (58.7)	-1.67 (7.68)	-21.2	-6.83	-2.48	2.00	19.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Baseline use of antihypertensives												
Yes	KDQOL-SF12: MCS	Baseline	Sparsentan	90	80 (88.9)	49.67 (9.27)	16.2	43.84	51.69	57.16	65.2	
			Irbesartan	88	77 (87.5)	52.31 (7.80)	27.2	48.59	54.15	57.16	66.6	
		Week 24	Sparsentan	90	68 (75.6)	51.15 (8.01)	20.8	47.00	52.03	57.16	63.9	
			Irbesartan	88	52 (59.1)	53.14 (7.55)	30.8	50.30	55.37	58.16	64.2	
		Week 48	Sparsentan	90	68 (75.6)	51.13 (8.02)	29.5	44.25	52.52	57.25	63.7	
			Irbesartan	88	48 (54.5)	51.39 (8.57)	28.5	49.52	53.32	57.11	64.5	
		Week 70	Sparsentan	90	69 (76.7)	50.28 (8.06)	27.6	45.81	51.83	57.06	64.2	
			Irbesartan	88	51 (58.0)	51.18 (7.52)	29.2	48.30	52.63	56.18	62.1	
		Week 94	Sparsentan	90	66 (73.3)	50.64 (9.29)	16.0	44.60	53.62	57.16	63.2	
			Irbesartan	88	57 (64.8)	51.33 (9.57)	21.9	44.47	56.10	57.73	61.5	
		Week 110	Sparsentan	90	64 (71.1)	49.53 (8.76)	20.1	45.51	50.51	56.26	68.0	
			Irbesartan	88	51 (58.0)	49.59 (9.40)	23.3	42.38	51.05	57.16	62.7	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	90	68 (75.6)	0.98 (7.49)	-18.1	-2.91	0.73	4.82	25.9	0.11 [-0.25, 0.47]
			Irbesartan	88	52 (59.1)	0.21 (6.21)	-15.4	-4.23	0.08	3.32	28.7	
		Week 48	Sparsentan	90	68 (75.6)	0.79 (8.40)	-17.5	-4.16	1.63	5.33	28.1	0.20 [-0.17, 0.57]
			Irbesartan	88	48 (54.5)	-0.87 (7.85)	-23.5	-3.74	0.08	3.82	17.3	
		Week 70	Sparsentan	90	69 (76.7)	0.08 (8.64)	-21.8	-5.11	-0.14	4.63	26.5	0.16 [-0.20, 0.53]
			Irbesartan	88	51 (58.0)	-1.16 (5.77)	-18.6	-4.26	-1.54	2.43	16.2	
		Week 94	Sparsentan	90	66 (73.3)	0.74 (8.16)	-28.8	-4.25	1.21	5.09	15.7	0.23 [-0.13, 0.58]
			Irbesartan	88	57 (64.8)	-0.96 (6.67)	-16.7	-5.31	-0.84	2.72	14.5	
		Week 110	Sparsentan	90	64 (71.1)	-0.39 (8.98)	-24.6	-5.59	0.00	4.37	33.3	0.12 [-0.25, 0.49]
			Irbesartan	88	51 (58.0)	-1.46 (8.50)	-29.3	-5.43	-1.91	3.72	19.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	KDQOL-SF12: MCS	Baseline	Sparsentan	112	108 (96.4)	50.99 (7.51)	27.8	45.98	51.65	56.51	66.5	
			Irbesartan	114	106 (93.0)	50.76 (9.17)	24.3	45.98	52.16	57.16	64.6	
		Week 24	Sparsentan	112	91 (81.3)	52.36 (7.91)	30.7	47.15	54.20	57.65	68.7	
			Irbesartan	114	86 (75.4)	51.86 (8.56)	24.2	47.84	52.47	57.66	63.2	
		Week 48	Sparsentan	112	97 (86.6)	50.93 (8.80)	27.5	46.56	51.73	57.33	64.7	
			Irbesartan	114	79 (69.3)	49.90 (10.18)	19.6	43.89	52.00	57.16	64.6	
		Week 70	Sparsentan	112	94 (83.9)	51.11 (8.56)	25.4	44.26	52.99	57.33	65.5	
			Irbesartan	114	84 (73.7)	51.14 (8.45)	18.9	46.58	52.01	57.16	63.8	
		Week 94	Sparsentan	112	89 (79.5)	50.26 (9.27)	26.5	43.32	51.83	57.16	66.9	
			Irbesartan	114	76 (66.7)	48.84 (9.96)	23.6	41.83	51.20	57.16	63.4	
		Week 110	Sparsentan	112	86 (76.8)	50.42 (8.97)	28.3	43.84	51.59	57.33	67.0	
			Irbesartan	114	70 (61.4)	49.14 (9.74)	20.0	43.59	50.51	57.16	62.7	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	112	91 (81.3)	0.98 (8.54)	-23.6	-4.29	0.00	5.32	26.4	-0.03 [-0.32, 0.26]
			Irbesartan	114	86 (75.4)	1.22 (6.91)	-14.1	-2.96	0.18	5.23	21.7	
		Week 48	Sparsentan	112	97 (86.6)	0.02 (8.70)	-23.7	-5.14	0.39	5.23	21.1	0.22 [-0.08, 0.52]
			Irbesartan	114	79 (69.3)	-1.76 (7.48)	-33.9	-5.33	-0.60	2.79	13.4	
		Week 70	Sparsentan	112	94 (83.9)	0.37 (8.40)	-21.3	-4.06	0.90	4.97	26.4	0.06 [-0.24, 0.35]
			Irbesartan	114	84 (73.7)	-0.09 (7.21)	-27.2	-3.51	0.00	4.48	17.4	
		Week 94	Sparsentan	112	89 (79.5)	-0.70 (8.44)	-22.4	-5.60	-0.11	4.56	24.1	0.15 [-0.16, 0.45]
			Irbesartan	114	76 (66.7)	-1.93 (8.30)	-21.0	-6.19	-0.29	2.54	23.3	
		Week 110	Sparsentan	112	86 (76.8)	-0.71 (9.13)	-31.2	-5.16	-1.11	3.95	26.4	0.18 [-0.14, 0.50]
			Irbesartan	114	70 (61.4)	-2.19 (7.07)	-21.9	-6.84	-2.06	1.63	12.8	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: Time since renal biopsy												
<= 5 years	KDQOL-SF12: MCS	Baseline	Sparsentan	113	105 (92.9)	50.34 (8.81)	16.2	45.01	52.02	57.16	66.5	
			Irbesartan	127	118 (92.9)	51.30 (9.07)	24.3	46.98	53.77	57.32	66.6	
		Week 24	Sparsentan	113	90 (79.6)	52.35 (8.46)	20.8	47.61	54.20	57.90	68.7	
			Irbesartan	127	91 (71.7)	52.57 (8.44)	24.2	48.30	54.45	58.16	64.2	
		Week 48	Sparsentan	113	93 (82.3)	52.25 (7.78)	30.2	48.76	52.64	58.72	64.7	
			Irbesartan	127	86 (67.7)	50.09 (10.19)	19.6	44.56	52.74	57.16	64.6	
		Week 70	Sparsentan	113	91 (80.5)	51.46 (8.27)	31.6	45.81	53.44	57.16	65.5	
			Irbesartan	127	88 (69.3)	51.67 (7.93)	18.9	48.23	52.31	57.16	63.8	
		Week 94	Sparsentan	113	88 (77.9)	50.43 (9.64)	16.0	43.58	53.39	57.16	66.9	
			Irbesartan	127	88 (69.3)	49.44 (10.27)	21.9	42.04	53.48	57.73	63.4	
		Week 110	Sparsentan	113	88 (77.9)	51.07 (8.41)	20.1	46.85	51.81	57.11	68.0	
			Irbesartan	127	80 (63.0)	50.17 (9.91)	20.0	43.10	52.71	57.25	62.7	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	113	90 (79.6)	1.71 (8.68)	-23.6	-2.96	1.86	6.42	26.4	0.05 [-0.25, 0.34]
			Irbesartan	127	91 (71.7)	1.35 (7.06)	-14.1	-2.88	0.72	5.23	28.7	
		Week 48	Sparsentan	113	93 (82.3)	1.79 (8.07)	-18.6	-3.97	2.39	6.48	28.1	0.42 [0.12, 0.71]
			Irbesartan	127	86 (67.7)	-1.56 (8.01)	-33.9	-4.01	-0.35	3.11	17.3	
		Week 70	Sparsentan	113	91 (80.5)	1.05 (9.13)	-20.3	-5.04	0.13	5.66	26.5	0.16 [-0.13, 0.45]
			Irbesartan	127	88 (69.3)	-0.20 (6.09)	-21.2	-3.51	0.00	3.81	16.2	
		Week 94	Sparsentan	113	88 (77.9)	-0.04 (8.74)	-28.8	-5.37	1.02	5.08	24.1	0.26 [-0.04, 0.56]
			Irbesartan	127	88 (69.3)	-2.20 (7.92)	-21.0	-6.19	-2.52	2.35	23.3	
		Week 110	Sparsentan	113	88 (77.9)	0.63 (9.78)	-31.2	-4.02	0.00	5.23	33.3	0.22 [-0.08, 0.53]
			Irbesartan	127	80 (63.0)	-1.40 (8.29)	-29.3	-5.75	-0.91	3.60	19.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
> 5 years	KDQOL-SF12: MCS	Baseline	Sparsentan	89	83 (93.3)	50.53 (7.66)	30.1	44.79	51.40	56.59	64.2	
			Irbesartan	75	65 (86.7)	51.63 (7.83)	26.4	47.72	52.31	57.16	63.0	
		Week 24	Sparsentan	89	69 (77.5)	51.18 (7.24)	34.3	47.15	52.01	57.16	62.7	
			Irbesartan	75	47 (62.7)	51.90 (7.75)	29.7	48.43	53.00	57.16	62.7	
		Week 48	Sparsentan	89	72 (80.9)	49.42 (9.09)	27.5	42.54	51.68	56.53	63.4	
			Irbesartan	75	41 (54.7)	51.24 (8.28)	29.2	47.59	53.45	57.33	61.4	
		Week 70	Sparsentan	89	72 (80.9)	49.87 (8.39)	25.4	43.53	51.74	57.16	61.3	
			Irbesartan	75	47 (62.7)	50.20 (8.37)	28.1	45.46	52.88	57.06	62.7	
		Week 94	Sparsentan	89	67 (75.3)	50.41 (8.79)	26.5	46.14	52.92	57.06	62.7	
			Irbesartan	75	45 (60.0)	50.83 (8.99)	23.6	47.78	52.88	57.33	61.3	
		Week 110	Sparsentan	89	62 (69.7)	48.58 (9.34)	20.8	41.87	49.41	57.16	67.0	
			Irbesartan	75	41 (54.7)	47.70 (8.74)	23.2	44.07	47.72	53.16	62.4	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	89	69 (77.5)	0.03 (7.19)	-19.1	-3.11	0.00	3.27	22.5	0.03 [-0.34, 0.40]
			Irbesartan	75	47 (62.7)	-0.16 (5.71)	-15.4	-4.36	0.00	3.55	20.2	
		Week 48	Sparsentan	89	72 (80.9)	-1.53 (8.87)	-23.7	-5.38	-0.58	3.60	19.4	-0.05 [-0.43, 0.33]
			Irbesartan	75	41 (54.7)	-1.13 (6.75)	-18.5	-3.95	-0.10	3.95	12.6	
		Week 70	Sparsentan	89	72 (80.9)	-0.76 (7.51)	-21.8	-4.17	0.05	3.26	17.0	0.04 [-0.33, 0.40]
			Irbesartan	75	47 (62.7)	-1.03 (7.75)	-27.2	-4.26	-0.57	3.22	17.4	
		Week 94	Sparsentan	89	67 (75.3)	-0.14 (7.82)	-22.4	-4.85	0.00	4.94	13.6	0.00 [-0.37, 0.38]
			Irbesartan	75	45 (60.0)	-0.16 (6.91)	-19.0	-2.85	0.00	4.56	14.5	
		Week 110	Sparsentan	89	62 (69.7)	-2.28 (7.62)	-23.0	-6.34	-1.60	2.71	13.8	0.08 [-0.32, 0.47]
			Irbesartan	75	41 (54.7)	-2.83 (6.32)	-21.9	-6.97	-2.20	1.80	10.9	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
Subgroup: History of hypertension												
Yes	KDQOL-SF12: MCS	Baseline	Sparsentan	155	142 (91.6)	50.36 (8.29)	16.2	44.79	51.80	57.06	65.2	
			Irbesartan	161	143 (88.8)	51.74 (8.63)	26.4	48.02	54.10	57.33	66.6	
		Week 24	Sparsentan	155	121 (78.1)	52.17 (8.07)	20.8	47.83	53.96	57.34	68.7	
			Irbesartan	161	106 (65.8)	52.79 (7.74)	27.2	49.35	54.41	57.76	64.2	
		Week 48	Sparsentan	155	124 (80.0)	51.02 (8.46)	29.5	44.41	52.24	57.33	64.7	
			Irbesartan	161	97 (60.2)	50.67 (9.32)	19.6	47.01	53.45	57.16	64.6	
		Week 70	Sparsentan	155	125 (80.6)	51.10 (7.88)	27.6	45.40	52.87	57.16	65.5	
			Irbesartan	161	104 (64.6)	51.13 (8.18)	18.9	47.81	52.75	57.06	63.8	
		Week 94	Sparsentan	155	118 (76.1)	50.70 (9.17)	16.0	44.47	53.39	57.16	66.9	
			Irbesartan	161	103 (64.0)	50.33 (9.72)	21.9	44.47	54.20	57.60	61.3	
		Week 110	Sparsentan	155	113 (72.9)	50.25 (8.95)	20.1	43.65	51.53	57.16	68.0	
			Irbesartan	161	92 (57.1)	49.54 (9.74)	20.0	44.17	51.43	57.16	62.7	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	155	121 (78.1)	1.46 (7.73)	-17.0	-2.96	0.99	5.28	25.9	0.08 [-0.18, 0.34]
			Irbesartan	161	106 (65.8)	0.87 (6.71)	-15.4	-3.28	0.13	4.24	28.7	
		Week 48	Sparsentan	155	124 (80.0)	0.53 (8.15)	-23.4	-4.62	1.17	5.77	28.1	0.23 [-0.04, 0.50]
			Irbesartan	161	97 (60.2)	-1.31 (7.77)	-33.9	-3.88	-0.10	2.79	17.3	
		Week 70	Sparsentan	155	125 (80.6)	0.71 (7.85)	-17.1	-4.24	0.39	4.97	26.5	0.15 [-0.11, 0.41]
			Irbesartan	161	104 (64.6)	-0.34 (6.51)	-21.2	-3.63	-0.17	3.82	17.4	
		Week 94	Sparsentan	155	118 (76.1)	0.24 (8.19)	-28.8	-5.02	0.96	5.09	16.9	0.17 [-0.09, 0.44]
			Irbesartan	161	103 (64.0)	-1.13 (7.57)	-21.0	-5.33	-0.11	2.79	23.3	
		Week 110	Sparsentan	155	113 (72.9)	-0.42 (8.86)	-31.2	-4.40	0.00	4.55	33.3	0.14 [-0.13, 0.42]
			Irbesartan	161	92 (57.1)	-1.64 (8.20)	-29.3	-6.18	-1.30	3.50	19.1	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSHM: KDQOL-SF12: Course of MCS by subgroup
Full Analysis Set

Subgroup	Parameter	Time	Treatment	N	n (%)	Mean (SD)	Min	Q25	Q50	Q75	Max	Hedge's G [95% CI]
No	KDQOL-SF12: MCS	Baseline	Sparsentan	47	46 (97.9)	50.65 (8.43)	27.8	46.33	51.51	56.59	66.5	
			Irbesartan	41	40 (97.6)	50.28 (8.64)	24.3	45.85	51.25	57.16	62.5	
		Week 24	Sparsentan	47	38 (80.9)	50.79 (7.57)	30.7	46.52	52.54	57.16	62.7	
			Irbesartan	41	32 (78.0)	50.85 (9.52)	24.2	46.40	53.30	57.24	62.6	
		Week 48	Sparsentan	47	41 (87.2)	50.99 (8.59)	27.5	46.89	52.05	57.06	62.5	
			Irbesartan	41	30 (73.2)	49.79 (10.57)	21.5	43.60	50.99	57.56	64.5	
		Week 70	Sparsentan	47	38 (80.9)	49.62 (9.71)	25.4	41.34	52.37	57.16	62.7	
			Irbesartan	41	31 (75.6)	51.23 (7.90)	34.7	45.09	51.94	57.16	63.4	
		Week 94	Sparsentan	47	37 (78.7)	49.54 (9.57)	26.5	42.90	51.83	56.85	62.5	
			Irbesartan	41	30 (73.2)	48.47 (10.26)	30.5	41.07	51.69	57.16	63.4	
		Week 110	Sparsentan	47	37 (78.7)	49.40 (8.68)	28.3	45.81	50.20	54.96	64.0	
			Irbesartan	41	29 (70.7)	48.66 (9.12)	30.5	42.61	48.93	57.06	62.5	
	KDQOL-SF12: change from baseline in MCS	Week 24	Sparsentan	47	38 (80.9)	-0.55 (9.05)	-23.6	-4.31	-0.05	3.86	26.4	-0.16 [-0.63, 0.31]
			Irbesartan	41	32 (78.0)	0.71 (6.55)	-14.1	-2.92	0.08	4.74	15.5	
		Week 48	Sparsentan	47	41 (87.2)	-0.25 (9.78)	-23.7	-4.74	-0.24	5.04	21.1	0.17 [-0.30, 0.65]
			Irbesartan	41	30 (73.2)	-1.78 (7.15)	-17.6	-7.62	-0.30	3.95	12.6	
		Week 70	Sparsentan	47	38 (80.9)	-1.27 (10.24)	-21.8	-5.78	-0.42	3.36	26.4	-0.03 [-0.51, 0.44]
			Irbesartan	41	31 (75.6)	-0.99 (7.41)	-27.2	-5.33	0.00	3.22	10.6	
		Week 94	Sparsentan	47	37 (78.7)	-1.12 (8.78)	-16.8	-7.87	-0.42	4.10	24.1	0.20 [-0.28, 0.68]
			Irbesartan	41	30 (73.2)	-2.81 (7.81)	-19.0	-7.82	-2.85	1.23	14.5	
		Week 110	Sparsentan	47	37 (78.7)	-1.04 (9.67)	-23.0	-5.33	-1.41	2.96	26.4	0.20 [-0.29, 0.68]
			Irbesartan	41	29 (70.7)	-2.65 (5.78)	-16.1	-5.34	-2.25	0.00	10.4	

N = total number of patients in analysis set. n = number of evaluable values. SD = standard deviation. Q = quantile.
95% CI = 95% confidence interval for Hedges G. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Sex	Overall	Sparsentan						Interaction:	0.896
Male	Week 24	Sparsentan	139	110 (79.1)	0.40 (0.66)	(-0.89, 1.69)	-0.44 (0.96)	(-2.32, 1.43)	0.645
		Irbesartan	143	100 (69.9)	0.84 (0.69)	(-0.52, 2.20)			
	Week 48	Sparsentan	139	115 (82.7)	0.20 (0.64)	(-1.06, 1.46)	0.51 (0.96)	(-1.38, 2.40)	0.594
		Irbesartan	143	90 (62.9)	-0.31 (0.71)	(-1.72, 1.09)			
	Week 70	Sparsentan	139	117 (84.2)	0.17 (0.64)	(-1.10, 1.43)	0.49 (0.95)	(-1.37, 2.36)	0.605
		Irbesartan	143	97 (67.8)	-0.33 (0.70)	(-1.70, 1.05)			
	Week 94	Sparsentan	139	108 (77.7)	-0.27 (0.66)	(-1.57, 1.03)	0.84 (0.96)	(-1.05, 2.73)	0.384
		Irbesartan	143	99 (69.2)	-1.11 (0.70)	(-2.47, 0.26)			
	Week 110	Sparsentan	139	104 (74.8)	-0.22 (0.68)	(-1.56, 1.11)	1.78 (1.00)	(-0.17, 3.74)	0.074
		Irbesartan	143	89 (62.2)	-2.01 (0.73)	(-3.44, -0.57)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Female	Week 24	Sparsentan	63	49 (77.8)	1.66 (1.10)	(-0.51, 3.83)	0.32 (1.67)	(-2.96, 3.61)	0.847
		Irbesartan	59	38 (64.4)	1.34 (1.25)	(-1.13, 3.80)			
	Week 48	Sparsentan	63	50 (79.4)	-0.26 (1.09)	(-2.40, 1.88)	3.33 (1.66)	(0.05, 6.60)	0.046 *
		Irbesartan	59	37 (62.7)	-3.58 (1.26)	(-6.06, -1.11)			
	Week 70	Sparsentan	63	46 (73.0)	-0.68 (1.13)	(-2.90, 1.54)	-0.06 (1.69)	(-3.38, 3.25)	0.971
		Irbesartan	59	38 (64.4)	-0.62 (1.25)	(-3.08, 1.85)			
	Week 94	Sparsentan	63	47 (74.6)	-0.57 (1.12)	(-2.78, 1.64)	1.54 (1.73)	(-1.86, 4.94)	0.375
		Irbesartan	59	34 (57.6)	-2.11 (1.31)	(-4.69, 0.47)			
	Week 110	Sparsentan	63	46 (73.0)	-2.42 (1.14)	(-4.66, -0.18)	-1.20 (1.78)	(-4.70, 2.29)	0.499
		Irbesartan	59	32 (54.2)	-1.22 (1.36)	(-3.89, 1.46)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age	Overall	Sparsentan						Interaction:	0.693
<= 45 years	Week 24	Sparsentan	96	72 (75.0)	0.40 (0.88)	(-1.34, 2.14)	-0.73 (1.26)	(-3.21, 1.75)	0.564
		Irbesartan	99	70 (70.7)	1.13 (0.90)	(-0.64, 2.89)			
	Week 48	Sparsentan	96	76 (79.2)	-0.46 (0.86)	(-2.15, 1.23)	0.95 (1.27)	(-1.55, 3.45)	0.454
		Irbesartan	99	62 (62.6)	-1.41 (0.93)	(-3.25, 0.42)			
	Week 70	Sparsentan	96	75 (78.1)	0.53 (0.87)	(-1.18, 2.24)	1.19 (1.28)	(-1.32, 3.69)	0.353
		Irbesartan	99	64 (64.6)	-0.66 (0.93)	(-2.49, 1.18)			
	Week 94	Sparsentan	96	70 (72.9)	-0.74 (0.89)	(-2.50, 1.01)	1.55 (1.29)	(-0.99, 4.10)	0.231
		Irbesartan	99	64 (64.6)	-2.30 (0.94)	(-4.13, -0.46)			
	Week 110	Sparsentan	96	70 (72.9)	-0.93 (0.90)	(-2.70, 0.85)	0.47 (1.33)	(-2.15, 3.08)	0.727
		Irbesartan	99	59 (59.6)	-1.39 (0.97)	(-3.31, 0.52)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 45 years	Week 24	Sparsentan	106	87 (82.1)	1.25 (0.73)	(-0.19, 2.68)	0.35 (1.11)	(-1.82, 2.52)	0.752
		Irbesartan	103	68 (66.0)	0.90 (0.83)	(-0.73, 2.53)			
	Week 48	Sparsentan	106	89 (84.0)	0.60 (0.72)	(-0.81, 2.02)	1.73 (1.11)	(-0.45, 3.90)	0.119
		Irbesartan	103	65 (63.1)	-1.12 (0.84)	(-2.76, 0.52)			
	Week 70	Sparsentan	106	88 (83.0)	-0.49 (0.73)	(-1.92, 0.94)	-0.27 (1.09)	(-2.41, 1.88)	0.808
		Irbesartan	103	71 (68.9)	-0.22 (0.81)	(-1.81, 1.37)			
	Week 94	Sparsentan	106	85 (80.2)	0.06 (0.74)	(-1.40, 1.51)	0.62 (1.11)	(-1.56, 2.79)	0.578
		Irbesartan	103	69 (67.0)	-0.56 (0.82)	(-2.17, 1.05)			
	Week 110	Sparsentan	106	80 (75.5)	-0.76 (0.76)	(-2.26, 0.73)	1.57 (1.15)	(-0.70, 3.84)	0.174
		Irbesartan	103	62 (60.2)	-2.34 (0.87)	(-4.04, -0.64)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Age at IgAN diagnosis	Overall	Sparsentan						Interaction:	0.250
<= 18 years	Week 24	Sparsentan	9	5 (55.6)	-4.46 (3.73)	(-12.23, 3.32)	-4.20 (5.50)	(-15.91, 7.52)	0.457
		Irbesartan	5	5 (100.0)	-0.26 (3.91)	(-8.69, 8.17)			
	Week 48	Sparsentan	9	7 (77.8)	-0.58 (3.20)	(-7.38, 6.23)	1.72 (5.69)	(-10.23, 13.66)	0.766
		Irbesartan	5	3 (60.0)	-2.29 (4.58)	(-11.81, 7.22)			
	Week 70	Sparsentan	9	7 (77.8)	0.21 (3.25)	(-6.74, 7.15)	4.40 (5.56)	(-7.45, 16.26)	0.441
		Irbesartan	5	4 (80.0)	-4.19 (4.32)	(-13.35, 4.96)			
	Week 94	Sparsentan	9	5 (55.6)	-1.46 (3.72)	(-9.21, 6.30)	5.74 (5.97)	(-6.89, 18.37)	0.350
		Irbesartan	5	4 (80.0)	-7.20 (4.43)	(-16.65, 2.25)			
	Week 110	Sparsentan	9	4 (44.4)	0.09 (4.18)	(-8.59, 8.78)	8.33 (7.11)	(-6.44, 23.10)	0.254
		Irbesartan	5	2 (40.0)	-8.24 (5.71)	(-20.03, 3.56)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 18 to 40 years	Week 24	Sparsentan	102	80 (78.4)	0.50 (0.83)	(-1.13, 2.12)	-0.94 (1.20)	(-3.29, 1.41)	0.434
		Irbesartan	109	73 (67.0)	1.44 (0.86)	(-0.26, 3.13)			
	Week 48	Sparsentan	102	83 (81.4)	-0.51 (0.81)	(-2.11, 1.08)	0.86 (1.20)	(-1.49, 3.21)	0.475
		Irbesartan	109	69 (63.3)	-1.37 (0.88)	(-3.09, 0.35)			
	Week 70	Sparsentan	102	80 (78.4)	-0.28 (0.83)	(-1.90, 1.34)	0.46 (1.20)	(-1.91, 2.82)	0.705
		Irbesartan	109	71 (65.1)	-0.73 (0.87)	(-2.45, 0.98)			
	Week 94	Sparsentan	102	76 (74.5)	-0.95 (0.85)	(-2.61, 0.71)	0.45 (1.23)	(-1.96, 2.85)	0.715
		Irbesartan	109	69 (63.3)	-1.40 (0.89)	(-3.14, 0.34)			
	Week 110	Sparsentan	102	73 (71.6)	-1.17 (0.87)	(-2.87, 0.53)	-0.03 (1.26)	(-2.51, 2.45)	0.983
		Irbesartan	109	65 (59.6)	-1.14 (0.92)	(-2.94, 0.66)			
> 40 years	Week 24	Sparsentan	91	74 (81.3)	1.53 (0.80)	(-0.03, 3.10)	0.91 (1.19)	(-1.43, 3.25)	0.445
		Irbesartan	88	60 (68.2)	0.62 (0.88)	(-1.11, 2.36)			
	Week 48	Sparsentan	91	75 (82.4)	0.81 (0.79)	(-0.73, 2.36)	1.85 (1.20)	(-0.51, 4.22)	0.125
		Irbesartan	88	55 (62.5)	-1.04 (0.91)	(-2.83, 0.75)			
	Week 70	Sparsentan	91	76 (83.5)	0.15 (0.79)	(-1.40, 1.69)	-0.04 (1.18)	(-2.36, 2.28)	0.973
		Irbesartan	88	60 (68.2)	0.19 (0.88)	(-1.55, 1.92)			
	Week 94	Sparsentan	91	74 (81.3)	0.35 (0.80)	(-1.21, 1.91)	1.37 (1.19)	(-0.96, 3.71)	0.249
		Irbesartan	88	60 (68.2)	-1.02 (0.88)	(-2.76, 0.71)			
	Week 110	Sparsentan	91	73 (80.2)	-0.62 (0.80)	(-2.19, 0.96)	1.88 (1.23)	(-0.53, 4.30)	0.127
		Irbesartan	88	54 (61.4)	-2.50 (0.93)	(-4.33, -0.67)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Geographic region	Overall	Sparsentan						Interaction:	0.811
North America	Week 24	Sparsentan	35	23 (65.7)	1.40 (1.48)	(-1.52, 4.31)	1.02 (1.90)	(-2.72, 4.76)	0.591
		Irbesartan	46	37 (80.4)	0.37 (1.18)	(-1.95, 2.70)			
	Week 48	Sparsentan	35	25 (71.4)	0.11 (1.43)	(-2.70, 2.92)	2.67 (1.89)	(-1.06, 6.39)	0.160
		Irbesartan	46	33 (71.7)	-2.55 (1.23)	(-4.97, -0.14)			
	Week 70	Sparsentan	35	23 (65.7)	-0.25 (1.47)	(-3.15, 2.66)	1.21 (1.95)	(-2.63, 5.06)	0.535
		Irbesartan	46	31 (67.4)	-1.46 (1.26)	(-3.95, 1.04)			
	Week 94	Sparsentan	35	24 (68.6)	-2.26 (1.46)	(-5.13, 0.62)	-0.18 (1.96)	(-4.04, 3.68)	0.928
		Irbesartan	46	30 (65.2)	-2.08 (1.29)	(-4.62, 0.46)			
	Week 110	Sparsentan	35	21 (60.0)	-0.26 (1.55)	(-3.32, 2.79)	2.40 (2.02)	(-1.58, 6.38)	0.236
		Irbesartan	46	31 (67.4)	-2.66 (1.28)	(-5.19, -0.13)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Europe	Week 24	Sparsentan	98	75 (76.5)	-0.07 (0.83)	(-1.69, 1.55)	-1.37 (1.21)	(-3.76, 1.01)	0.258
		Irbesartan	115	65 (56.5)	1.30 (0.89)	(-0.44, 3.05)			
	Week 48	Sparsentan	98	77 (78.6)	-0.46 (0.81)	(-2.07, 1.14)	1.10 (1.21)	(-1.29, 3.49)	0.366
		Irbesartan	115	61 (53.0)	-1.56 (0.90)	(-3.33, 0.20)			
	Week 70	Sparsentan	98	76 (77.6)	-0.87 (0.82)	(-2.49, 0.74)	-0.19 (1.18)	(-2.51, 2.13)	0.872
		Irbesartan	115	72 (62.6)	-0.68 (0.85)	(-2.35, 0.98)			
	Week 94	Sparsentan	98	71 (72.4)	-0.32 (0.85)	(-1.98, 1.35)	1.48 (1.20)	(-0.88, 3.84)	0.218
		Irbesartan	115	72 (62.6)	-1.80 (0.85)	(-3.46, -0.14)			
	Week 110	Sparsentan	98	68 (69.4)	-0.91 (0.87)	(-2.62, 0.79)	1.06 (1.26)	(-1.42, 3.54)	0.400
		Irbesartan	115	61 (53.0)	-1.98 (0.91)	(-3.77, -0.18)			
Asia Pacific	Week 24	Sparsentan	69	61 (88.4)	1.96 (0.94)	(0.12, 3.81)	1.42 (1.54)	(-1.60, 4.45)	0.355
		Irbesartan	41	36 (87.8)	0.54 (1.22)	(-1.85, 2.93)			
	Week 48	Sparsentan	69	63 (91.3)	1.11 (0.92)	(-0.71, 2.92)	0.93 (1.56)	(-2.14, 4.00)	0.553
		Irbesartan	41	33 (80.5)	0.18 (1.25)	(-2.28, 2.64)			
	Week 70	Sparsentan	69	64 (92.8)	1.25 (0.92)	(-0.55, 3.06)	0.38 (1.58)	(-2.74, 3.50)	0.810
		Irbesartan	41	32 (78.0)	0.87 (1.28)	(-1.65, 3.40)			
	Week 94	Sparsentan	69	60 (87.0)	0.61 (0.94)	(-1.24, 2.45)	0.73 (1.62)	(-2.45, 3.91)	0.653
		Irbesartan	41	31 (75.6)	-0.12 (1.31)	(-2.69, 2.45)			
	Week 110	Sparsentan	69	61 (88.4)	-0.74 (0.94)	(-2.59, 1.11)	0.32 (1.65)	(-2.93, 3.57)	0.848
		Irbesartan	41	29 (70.7)	-1.06 (1.35)	(-3.71, 1.60)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline BMI	Overall	Sparsentan						Interaction:	0.829
< 27 kg/m**2	Week 24	Sparsentan	83	66 (79.5)	0.81 (0.97)	(-1.11, 2.72)	-0.88 (1.37)	(-3.58, 1.81)	0.521
		Irbesartan	94	69 (73.4)	1.69 (0.96)	(-0.20, 3.57)			
	Week 48	Sparsentan	83	68 (81.9)	0.46 (0.96)	(-1.43, 2.35)	1.77 (1.39)	(-0.97, 4.51)	0.204
		Irbesartan	94	60 (63.8)	-1.31 (1.00)	(-3.28, 0.66)			
	Week 70	Sparsentan	83	66 (79.5)	0.25 (0.98)	(-1.66, 2.17)	0.27 (1.40)	(-2.49, 3.02)	0.849
		Irbesartan	94	62 (66.0)	-0.01 (1.00)	(-1.98, 1.95)			
	Week 94	Sparsentan	83	64 (77.1)	0.09 (0.99)	(-1.85, 2.04)	0.48 (1.41)	(-2.28, 3.25)	0.731
		Irbesartan	94	64 (68.1)	-0.39 (0.99)	(-2.35, 1.56)			
	Week 110	Sparsentan	83	63 (75.9)	-0.31 (1.00)	(-2.28, 1.67)	1.43 (1.45)	(-1.43, 4.29)	0.326
		Irbesartan	94	57 (60.6)	-1.74 (1.05)	(-3.79, 0.32)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
>= 27 kg/m**2	Week 24	Sparsentan	119	93 (78.2)	0.81 (0.68)	(-0.52, 2.15)	0.48 (1.04)	(-1.57, 2.53)	0.647
		Irbesartan	107	69 (64.5)	0.33 (0.79)	(-1.22, 1.89)			
	Week 48	Sparsentan	119	97 (81.5)	-0.20 (0.66)	(-1.51, 1.10)	1.01 (1.03)	(-1.03, 3.04)	0.331
		Irbesartan	107	67 (62.6)	-1.21 (0.79)	(-2.77, 0.35)			
	Week 70	Sparsentan	119	97 (81.5)	-0.34 (0.67)	(-1.65, 0.97)	0.33 (1.02)	(-1.67, 2.33)	0.746
		Irbesartan	107	73 (68.2)	-0.67 (0.77)	(-2.18, 0.84)			
	Week 94	Sparsentan	119	91 (76.5)	-0.74 (0.69)	(-2.08, 0.61)	1.40 (1.05)	(-0.66, 3.46)	0.183
		Irbesartan	107	68 (63.6)	-2.13 (0.79)	(-3.69, -0.58)			
	Week 110	Sparsentan	119	87 (73.1)	-1.31 (0.70)	(-2.69, 0.07)	0.66 (1.09)	(-1.47, 2.79)	0.542
		Irbesartan	107	63 (58.9)	-1.97 (0.83)	(-3.60, -0.35)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Randomization strata	Overall	Sparsentan						Interaction:	0.163
eGFR Low and UP High	Week 24	Sparsentan	71	54 (76.1)	-0.26 (0.93)	(-2.09, 1.56)	-0.75 (1.38)	(-3.47, 1.97)	0.586
		Irbesartan	74	44 (59.5)	0.49 (1.03)	(-1.52, 2.51)			
	Week 48	Sparsentan	71	53 (74.6)	-0.79 (0.93)	(-2.62, 1.03)	-0.06 (1.43)	(-2.86, 2.75)	0.968
		Irbesartan	74	38 (51.4)	-0.74 (1.08)	(-2.86, 1.39)			
	Week 70	Sparsentan	71	58 (81.7)	-2.60 (0.90)	(-4.37, -0.83)	-1.69 (1.39)	(-4.42, 1.04)	0.223
		Irbesartan	74	41 (55.4)	-0.91 (1.06)	(-2.98, 1.17)			
	Week 94	Sparsentan	71	52 (73.2)	-0.26 (0.94)	(-2.10, 1.59)	-0.71 (1.44)	(-3.55, 2.13)	0.623
		Irbesartan	74	38 (51.4)	0.46 (1.10)	(-1.70, 2.61)			
	Week 110	Sparsentan	71	53 (74.6)	-2.41 (0.94)	(-4.26, -0.56)	-0.44 (1.47)	(-3.33, 2.46)	0.768
		Irbesartan	74	36 (48.6)	-1.97 (1.13)	(-4.20, 0.26)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
eGFR Low and UP Low	Week 24	Sparsentan	55	44 (80.0)	2.02 (1.12)	(-0.19, 4.22)	1.42 (1.64)	(-1.81, 4.64)	0.388
		Irbesartan	55	39 (70.9)	0.60 (1.20)	(-1.75, 2.95)			
	Week 48	Sparsentan	55	43 (78.2)	-0.62 (1.13)	(-2.84, 1.59)	1.60 (1.66)	(-1.67, 4.87)	0.337
		Irbesartan	55	36 (65.5)	-2.22 (1.22)	(-4.63, 0.18)			
	Week 70	Sparsentan	55	42 (76.4)	0.27 (1.14)	(-1.98, 2.52)	0.61 (1.64)	(-2.61, 3.84)	0.708
		Irbesartan	55	40 (72.7)	-0.34 (1.18)	(-2.66, 1.97)			
	Week 94	Sparsentan	55	42 (76.4)	-0.49 (1.15)	(-2.75, 1.76)	2.22 (1.65)	(-1.02, 5.46)	0.179
		Irbesartan	55	40 (72.7)	-2.71 (1.18)	(-5.03, -0.39)			
	Week 110	Sparsentan	55	38 (69.1)	-0.23 (1.20)	(-2.59, 2.14)	3.50 (1.75)	(0.06, 6.94)	0.046 *
		Irbesartan	55	34 (61.8)	-3.73 (1.27)	(-6.23, -1.24)			
eGFR High and UP High	Week 24	Sparsentan	37	27 (73.0)	0.31 (1.34)	(-2.33, 2.94)	-2.12 (1.93)	(-5.93, 1.70)	0.275
		Irbesartan	36	26 (72.2)	2.42 (1.39)	(-0.32, 5.17)			
	Week 48	Sparsentan	37	34 (91.9)	0.64 (1.22)	(-1.78, 3.05)	0.75 (1.87)	(-2.94, 4.44)	0.688
		Irbesartan	36	25 (69.4)	-0.11 (1.41)	(-2.89, 2.66)			
	Week 70	Sparsentan	37	31 (83.8)	1.18 (1.27)	(-1.32, 3.69)	0.43 (1.91)	(-3.33, 4.19)	0.821
		Irbesartan	36	25 (69.4)	0.75 (1.41)	(-2.03, 3.53)			
	Week 94	Sparsentan	37	27 (73.0)	-0.06 (1.35)	(-2.72, 2.59)	0.19 (1.96)	(-3.68, 4.05)	0.924
		Irbesartan	36	25 (69.4)	-0.25 (1.41)	(-3.03, 2.53)			
	Week 110	Sparsentan	37	26 (70.3)	-0.18 (1.38)	(-2.91, 2.55)	-1.42 (2.05)	(-5.46, 2.61)	0.488
		Irbesartan	36	22 (61.1)	1.24 (1.49)	(-1.70, 4.19)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
eGFR High and UP Low	Week 24	Sparsentan	39	34 (87.2)	1.38 (1.28)	(-1.14, 3.91)	0.18 (1.88)	(-3.51, 3.88)	0.922
		Irbesartan	37	29 (78.4)	1.20 (1.37)	(-1.51, 3.91)			
	Week 48	Sparsentan	39	35 (89.7)	1.85 (1.27)	(-0.65, 4.35)	3.30 (1.87)	(-0.39, 6.99)	0.079
		Irbesartan	37	28 (75.7)	-1.45 (1.38)	(-4.17, 1.26)			
	Week 70	Sparsentan	39	32 (82.1)	2.70 (1.30)	(0.13, 5.27)	3.41 (1.89)	(-0.32, 7.14)	0.073
		Irbesartan	37	29 (78.4)	-0.71 (1.37)	(-3.41, 1.99)			
	Week 94	Sparsentan	39	34 (87.2)	-0.52 (1.28)	(-3.04, 2.01)	2.11 (1.87)	(-1.57, 5.79)	0.259
		Irbesartan	37	30 (81.1)	-2.63 (1.36)	(-5.30, 0.05)			
	Week 110	Sparsentan	39	33 (84.6)	0.27 (1.30)	(-2.29, 2.83)	1.64 (1.89)	(-2.10, 5.37)	0.388
		Irbesartan	37	29 (78.4)	-1.36 (1.38)	(-4.08, 1.35)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 1	Overall	Sparsentan						Interaction:	0.181
< 60 mL/min/1.73 m**2	Week 24	Sparsentan	127	99 (78.0)	0.62 (0.71)	(-0.76, 2.01)	0.10 (1.04)	(-1.94, 2.14)	0.925
		Irbesartan	129	85 (65.9)	0.53 (0.76)	(-0.97, 2.02)			
	Week 48	Sparsentan	127	97 (76.4)	-1.06 (0.71)	(-2.45, 0.33)	0.92 (1.07)	(-1.17, 3.01)	0.389
		Irbesartan	129	76 (58.9)	-1.98 (0.79)	(-3.54, -0.42)			
	Week 70	Sparsentan	127	101 (79.5)	-1.48 (0.70)	(-2.85, -0.10)	-0.74 (1.04)	(-2.79, 1.30)	0.474
		Irbesartan	129	83 (64.3)	-0.73 (0.77)	(-2.24, 0.78)			
	Week 94	Sparsentan	127	94 (74.0)	-0.63 (0.72)	(-2.05, 0.78)	0.23 (1.07)	(-1.86, 2.33)	0.827
		Irbesartan	129	79 (61.2)	-0.87 (0.79)	(-2.41, 0.68)			
	Week 110	Sparsentan	127	93 (73.2)	-1.33 (0.73)	(-2.76, 0.10)	0.96 (1.10)	(-1.20, 3.13)	0.383
		Irbesartan	129	72 (55.8)	-2.30 (0.83)	(-3.92, -0.67)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
60 to < 90 mL/min/1.73 m**2	Week 24	Sparsentan	49	39 (79.6)	0.21 (1.16)	(-2.09, 2.50)	-1.30 (1.73)	(-4.72, 2.12)	0.455
		Irbesartan	48	33 (68.8)	1.51 (1.27)	(-1.00, 4.02)			
	Week 48	Sparsentan	49	45 (91.8)	0.41 (1.11)	(-1.77, 2.59)	-0.25 (1.69)	(-3.57, 3.08)	0.884
		Irbesartan	48	33 (68.8)	0.66 (1.26)	(-1.83, 3.14)			
	Week 70	Sparsentan	49	40 (81.6)	1.47 (1.15)	(-0.80, 3.74)	0.80 (1.73)	(-2.60, 4.20)	0.644
		Irbesartan	48	32 (66.7)	0.67 (1.27)	(-1.84, 3.18)			
	Week 94	Sparsentan	49	41 (83.7)	-0.74 (1.15)	(-3.02, 1.53)	1.70 (1.70)	(-1.66, 5.06)	0.320
		Irbesartan	48	35 (72.9)	-2.45 (1.24)	(-4.89, 0.00)			
	Week 110	Sparsentan	49	36 (73.5)	-1.27 (1.22)	(-3.67, 1.13)	0.25 (1.78)	(-3.26, 3.76)	0.889
		Irbesartan	48	32 (66.7)	-1.52 (1.29)	(-4.06, 1.02)			
>= 90 mL/min/1.73 m**2	Week 24	Sparsentan	26	21 (80.8)	2.82 (1.58)	(-0.30, 5.95)	1.03 (2.26)	(-3.45, 5.50)	0.651
		Irbesartan	25	20 (80.0)	1.80 (1.62)	(-1.40, 5.00)			
	Week 48	Sparsentan	26	23 (88.5)	4.66 (1.53)	(1.64, 7.68)	6.14 (2.27)	(1.65, 10.62)	0.008 *
		Irbesartan	25	18 (72.0)	-1.48 (1.67)	(-4.78, 1.83)			
	Week 70	Sparsentan	26	22 (84.6)	3.70 (1.55)	(0.63, 6.77)	4.59 (2.26)	(0.13, 9.06)	0.044 *
		Irbesartan	25	20 (80.0)	-0.90 (1.63)	(-4.13, 2.33)			
	Week 94	Sparsentan	26	20 (76.9)	2.05 (1.61)	(-1.13, 5.23)	3.57 (2.31)	(-1.01, 8.15)	0.125
		Irbesartan	25	19 (76.0)	-1.52 (1.66)	(-4.80, 1.77)			
	Week 110	Sparsentan	26	21 (80.8)	2.14 (1.59)	(-1.01, 5.30)	2.10 (2.36)	(-2.57, 6.77)	0.375
		Irbesartan	25	17 (68.0)	0.04 (1.74)	(-3.40, 3.48)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline eGFR Group 2	Overall	Sparsentan						Interaction:	0.179
< 45 mL/min/1.73 m**2	Week 24	Sparsentan	82	64 (78.0)	1.61 (0.88)	(-0.13, 3.34)	1.05 (1.33)	(-1.55, 3.66)	0.427
		Irbesartan	80	51 (63.8)	0.55 (0.99)	(-1.39, 2.50)			
	Week 48	Sparsentan	82	63 (76.8)	-0.28 (0.89)	(-2.02, 1.46)	2.03 (1.36)	(-0.64, 4.70)	0.136
		Irbesartan	80	45 (56.3)	-2.31 (1.03)	(-4.34, -0.28)			
	Week 70	Sparsentan	82	65 (79.3)	-1.15 (0.88)	(-2.87, 0.58)	0.23 (1.32)	(-2.38, 2.83)	0.864
		Irbesartan	80	50 (62.5)	-1.37 (0.99)	(-3.32, 0.57)			
	Week 94	Sparsentan	82	61 (74.4)	0.46 (0.90)	(-1.31, 2.23)	0.76 (1.35)	(-1.90, 3.42)	0.576
		Irbesartan	80	48 (60.0)	-0.30 (1.01)	(-2.29, 1.69)			
	Week 110	Sparsentan	82	57 (69.5)	-0.59 (0.93)	(-2.43, 1.24)	1.14 (1.41)	(-1.63, 3.92)	0.419
		Irbesartan	80	44 (55.0)	-1.74 (1.06)	(-3.82, 0.35)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
45 to < 60 mL/min/1.73 m**2	Week 24	Sparsentan	45	35 (77.8)	-1.17 (1.17)	(-3.47, 1.13)	-1.64 (1.67)	(-4.92, 1.65)	0.328
		Irbesartan	49	34 (69.4)	0.47 (1.19)	(-1.87, 2.81)			
	Week 48	Sparsentan	45	34 (75.6)	-2.41 (1.18)	(-4.73, -0.10)	-0.93 (1.71)	(-4.30, 2.44)	0.588
		Irbesartan	49	31 (63.3)	-1.49 (1.24)	(-3.92, 0.95)			
	Week 70	Sparsentan	45	36 (80.0)	-2.09 (1.15)	(-4.36, 0.17)	-2.36 (1.67)	(-5.66, 0.93)	0.159
		Irbesartan	49	33 (67.3)	0.27 (1.21)	(-2.11, 2.65)			
	Week 94	Sparsentan	45	33 (73.3)	-2.62 (1.20)	(-4.98, -0.27)	-0.78 (1.73)	(-4.18, 2.62)	0.651
		Irbesartan	49	31 (63.3)	-1.84 (1.24)	(-4.29, 0.61)			
	Week 110	Sparsentan	45	36 (80.0)	-2.52 (1.16)	(-4.80, -0.24)	0.78 (1.75)	(-2.67, 4.23)	0.656
		Irbesartan	49	28 (57.1)	-3.30 (1.31)	(-5.88, -0.72)			
60 to < 90 mL/min/1.73 m**2	Week 24	Sparsentan	49	39 (79.6)	0.21 (1.16)	(-2.09, 2.50)	-1.30 (1.73)	(-4.72, 2.12)	0.455
		Irbesartan	48	33 (68.8)	1.51 (1.27)	(-1.00, 4.02)			
	Week 48	Sparsentan	49	45 (91.8)	0.41 (1.11)	(-1.77, 2.59)	-0.25 (1.69)	(-3.57, 3.08)	0.884
		Irbesartan	48	33 (68.8)	0.66 (1.26)	(-1.83, 3.14)			
	Week 70	Sparsentan	49	40 (81.6)	1.47 (1.15)	(-0.80, 3.74)	0.80 (1.73)	(-2.60, 4.20)	0.644
		Irbesartan	48	32 (66.7)	0.67 (1.27)	(-1.84, 3.18)			
	Week 94	Sparsentan	49	41 (83.7)	-0.74 (1.15)	(-3.02, 1.53)	1.70 (1.70)	(-1.66, 5.06)	0.320
		Irbesartan	48	35 (72.9)	-2.45 (1.24)	(-4.89, 0.00)			
	Week 110	Sparsentan	49	36 (73.5)	-1.27 (1.22)	(-3.67, 1.13)	0.25 (1.78)	(-3.26, 3.76)	0.889
		Irbesartan	48	32 (66.7)	-1.52 (1.29)	(-4.06, 1.02)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
>= 90 mL/min/1.73 m**2	Week 24	Sparsentan	26	21 (80.8)	2.82 (1.58)	(-0.30, 5.95)	1.03 (2.26)	(-3.45, 5.50)	0.651
		Irbesartan	25	20 (80.0)	1.80 (1.62)	(-1.40, 5.00)			
	Week 48	Sparsentan	26	23 (88.5)	4.66 (1.53)	(1.64, 7.68)	6.14 (2.27)	(1.65, 10.62)	0.008 *
		Irbesartan	25	18 (72.0)	-1.48 (1.67)	(-4.78, 1.83)			
	Week 70	Sparsentan	26	22 (84.6)	3.70 (1.55)	(0.63, 6.77)	4.59 (2.26)	(0.13, 9.06)	0.044 *
		Irbesartan	25	20 (80.0)	-0.90 (1.63)	(-4.13, 2.33)			
	Week 94	Sparsentan	26	20 (76.9)	2.05 (1.61)	(-1.13, 5.23)	3.57 (2.31)	(-1.01, 8.15)	0.125
		Irbesartan	25	19 (76.0)	-1.52 (1.66)	(-4.80, 1.77)			
	Week 110	Sparsentan	26	21 (80.8)	2.14 (1.59)	(-1.01, 5.30)	2.10 (2.36)	(-2.57, 6.77)	0.375
		Irbesartan	25	17 (68.0)	0.04 (1.74)	(-3.40, 3.48)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline urine protein excretion	Overall	Sparsentan						Interaction:	0.440
<= 1.75 g/day	Week 24	Sparsentan	98	81 (82.7)	1.22 (0.82)	(-0.38, 2.83)	0.36 (1.26)	(-2.12, 2.83)	0.776
		Irbesartan	93	59 (63.4)	0.86 (0.96)	(-1.02, 2.74)			
	Week 48	Sparsentan	98	83 (84.7)	0.16 (0.81)	(-1.43, 1.74)	1.27 (1.26)	(-1.20, 3.73)	0.313
		Irbesartan	93	57 (61.3)	-1.11 (0.96)	(-3.00, 0.78)			
	Week 70	Sparsentan	98	77 (78.6)	0.97 (0.83)	(-0.67, 2.61)	1.69 (1.25)	(-0.77, 4.15)	0.178
		Irbesartan	93	62 (66.7)	-0.72 (0.93)	(-2.55, 1.12)			
	Week 94	Sparsentan	98	79 (80.6)	-0.49 (0.83)	(-2.12, 1.13)	1.65 (1.24)	(-0.79, 4.09)	0.185
		Irbesartan	93	64 (68.8)	-2.14 (0.92)	(-3.96, -0.32)			
	Week 110	Sparsentan	98	76 (77.6)	-0.49 (0.84)	(-2.15, 1.17)	1.56 (1.29)	(-0.97, 4.10)	0.227
		Irbesartan	93	57 (61.3)	-2.05 (0.97)	(-3.96, -0.13)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 1.75 g/day	Week 24	Sparsentan	104	78 (75.0)	0.44 (0.79)	(-1.11, 1.99)	-0.56 (1.12)	(-2.75, 1.64)	0.618
		Irbesartan	109	79 (72.5)	1.00 (0.79)	(-0.56, 2.55)			
	Week 48	Sparsentan	104	82 (78.8)	0.07 (0.77)	(-1.44, 1.58)	1.51 (1.13)	(-0.70, 3.72)	0.181
		Irbesartan	109	70 (64.2)	-1.44 (0.82)	(-3.06, 0.17)			
	Week 70	Sparsentan	104	86 (82.7)	-0.97 (0.76)	(-2.46, 0.52)	-0.74 (1.11)	(-2.93, 1.45)	0.507
		Irbesartan	109	73 (67.0)	-0.23 (0.81)	(-1.83, 1.37)			
	Week 94	Sparsentan	104	76 (73.1)	-0.14 (0.80)	(-1.71, 1.42)	0.57 (1.16)	(-1.70, 2.84)	0.624
		Irbesartan	109	69 (63.3)	-0.71 (0.84)	(-2.35, 0.93)			
	Week 110	Sparsentan	104	74 (71.2)	-1.19 (0.81)	(-2.79, 0.41)	0.51 (1.19)	(-1.84, 2.85)	0.671
		Irbesartan	109	64 (58.7)	-1.69 (0.87)	(-3.40, 0.01)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Baseline use of antihypertensives	Overall	Sparsentan						Interaction:	0.536
Yes	Week 24	Sparsentan	90	68 (75.6)	0.44 (0.84)	(-1.21, 2.08)	-0.60 (1.27)	(-3.10, 1.90)	0.637
		Irbesartan	88	52 (59.1)	1.04 (0.95)	(-0.84, 2.91)			
	Week 48	Sparsentan	90	68 (75.6)	0.40 (0.83)	(-1.24, 2.03)	0.92 (1.28)	(-1.60, 3.45)	0.473
		Irbesartan	88	48 (54.5)	-0.53 (0.98)	(-2.44, 1.39)			
	Week 70	Sparsentan	90	69 (76.7)	-0.37 (0.83)	(-2.00, 1.26)	0.69 (1.27)	(-1.81, 3.18)	0.589
		Irbesartan	88	51 (58.0)	-1.05 (0.96)	(-2.94, 0.83)			
	Week 94	Sparsentan	90	66 (73.3)	0.13 (0.85)	(-1.53, 1.79)	0.43 (1.25)	(-2.02, 2.89)	0.730
		Irbesartan	88	57 (64.8)	-0.30 (0.92)	(-2.10, 1.50)			
	Week 110	Sparsentan	90	64 (71.1)	-1.12 (0.86)	(-2.82, 0.57)	0.15 (1.29)	(-2.40, 2.69)	0.910
		Irbesartan	88	51 (58.0)	-1.27 (0.96)	(-3.16, 0.62)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
No	Week 24	Sparsentan	112	91 (81.3)	1.12 (0.77)	(-0.40, 2.64)	0.15 (1.11)	(-2.04, 2.34)	0.893
		Irbesartan	114	86 (75.4)	0.97 (0.80)	(-0.60, 2.54)			
	Week 48	Sparsentan	112	97 (86.6)	-0.13 (0.75)	(-1.61, 1.35)	1.59 (1.11)	(-0.60, 3.77)	0.155
		Irbesartan	114	79 (69.3)	-1.72 (0.82)	(-3.33, -0.11)			
	Week 70	Sparsentan	112	94 (83.9)	0.14 (0.76)	(-1.36, 1.64)	0.20 (1.11)	(-1.99, 2.38)	0.858
		Irbesartan	114	84 (73.7)	-0.06 (0.81)	(-1.65, 1.53)			
	Week 94	Sparsentan	112	89 (79.5)	-0.73 (0.78)	(-2.27, 0.81)	1.47 (1.15)	(-0.79, 3.73)	0.202
		Irbesartan	114	76 (66.7)	-2.20 (0.85)	(-3.86, -0.54)			
	Week 110	Sparsentan	112	86 (76.8)	-0.71 (0.80)	(-2.28, 0.87)	1.54 (1.19)	(-0.80, 3.88)	0.198
		Irbesartan	114	70 (61.4)	-2.24 (0.88)	(-3.98, -0.51)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
Time since renal biopsy	Overall	Sparsentan						Interaction:	0.223
<= 5 years	Week 24	Sparsentan	113	90 (79.6)	1.53 (0.77)	(0.02, 3.05)	0.15 (1.09)	(-1.99, 2.28)	0.894
		Irbesartan	127	91 (71.7)	1.39 (0.77)	(-0.12, 2.89)			
	Week 48	Sparsentan	113	93 (82.3)	1.52 (0.76)	(0.04, 3.01)	2.89 (1.08)	(0.76, 5.02)	0.008 *
		Irbesartan	127	86 (67.7)	-1.37 (0.78)	(-2.89, 0.16)			
	Week 70	Sparsentan	113	91 (80.5)	0.73 (0.76)	(-0.77, 2.23)	0.94 (1.09)	(-1.19, 3.08)	0.386
		Irbesartan	127	88 (69.3)	-0.22 (0.77)	(-1.74, 1.30)			
	Week 94	Sparsentan	113	88 (77.9)	-0.27 (0.78)	(-1.79, 1.25)	1.64 (1.10)	(-0.51, 3.80)	0.135
		Irbesartan	127	88 (69.3)	-1.91 (0.78)	(-3.44, -0.39)			
	Week 110	Sparsentan	113	88 (77.9)	0.27 (0.78)	(-1.27, 1.81)	1.34 (1.13)	(-0.88, 3.55)	0.236
		Irbesartan	127	80 (63.0)	-1.07 (0.81)	(-2.66, 0.53)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
> 5 years	Week 24	Sparsentan	89	69 (77.5)	-0.02 (0.83)	(-1.64, 1.61)	-0.26 (1.31)	(-2.84, 2.32)	0.843
		Irbesartan	75	47 (62.7)	0.24 (1.01)	(-1.75, 2.24)			
	Week 48	Sparsentan	89	72 (80.9)	-1.72 (0.81)	(-3.32, -0.13)	-0.72 (1.34)	(-3.34, 1.91)	0.593
		Irbesartan	75	41 (54.7)	-1.00 (1.06)	(-3.09, 1.08)			
	Week 70	Sparsentan	89	72 (80.9)	-1.05 (0.82)	(-2.65, 0.56)	-0.22 (1.30)	(-2.77, 2.34)	0.868
		Irbesartan	75	47 (62.7)	-0.83 (1.01)	(-2.81, 1.15)			
	Week 94	Sparsentan	89	67 (75.3)	-0.41 (0.84)	(-2.06, 1.24)	-0.11 (1.33)	(-2.72, 2.51)	0.936
		Irbesartan	75	45 (60.0)	-0.30 (1.03)	(-2.33, 1.72)			
	Week 110	Sparsentan	89	62 (69.7)	-2.43 (0.87)	(-4.15, -0.71)	0.71 (1.39)	(-2.02, 3.44)	0.608
		Irbesartan	75	41 (54.7)	-3.14 (1.08)	(-5.26, -1.03)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
History of hypertension	Overall	Sparsentan						Interaction:	0.997
Yes	Week 24	Sparsentan	155	121 (78.1)	1.25 (0.63)	(0.01, 2.49)	-0.01 (0.93)	(-1.83, 1.80)	0.989
		Irbesartan	161	106 (65.8)	1.26 (0.68)	(-0.07, 2.58)			
	Week 48	Sparsentan	155	124 (80.0)	0.28 (0.62)	(-0.94, 1.50)	1.42 (0.93)	(-0.40, 3.25)	0.127
		Irbesartan	161	97 (60.2)	-1.14 (0.69)	(-2.50, 0.22)			
	Week 70	Sparsentan	155	125 (80.6)	0.35 (0.62)	(-0.87, 1.57)	0.67 (0.92)	(-1.14, 2.48)	0.467
		Irbesartan	161	104 (64.6)	-0.32 (0.68)	(-1.65, 1.01)			
	Week 94	Sparsentan	155	118 (76.1)	0.03 (0.64)	(-1.22, 1.28)	0.93 (0.93)	(-0.91, 2.76)	0.322
		Irbesartan	161	103 (64.0)	-0.89 (0.68)	(-2.23, 0.44)			
	Week 110	Sparsentan	155	113 (72.9)	-0.72 (0.65)	(-2.00, 0.57)	0.85 (0.97)	(-1.05, 2.76)	0.380
		Irbesartan	161	92 (57.1)	-1.57 (0.72)	(-2.99, -0.16)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Table PT2KMSC_FSCM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

KDQOL-SF12: change from baseline in MCS					Repeated measures analysis				
					Change from Baseline		Treatment Difference		
Subgroup	Time	Treatment	N	n (%)	LS-Mean (STE)	95% CI	LS-Mean (STE)	95% CI	p-value
No	Week 24	Sparsentan	47	38 (80.9)	-0.60 (1.28)	(-3.12, 1.91)	-0.68 (1.90)	(-4.42, 3.06)	0.722
		Irbesartan	41	32 (78.0)	0.07 (1.40)	(-2.68, 2.83)			
	Week 48	Sparsentan	47	41 (87.2)	-0.62 (1.24)	(-3.05, 1.82)	1.14 (1.89)	(-2.58, 4.86)	0.547
		Irbesartan	41	30 (73.2)	-1.76 (1.42)	(-4.56, 1.05)			
	Week 70	Sparsentan	47	38 (80.9)	-1.42 (1.28)	(-3.93, 1.09)	-0.57 (1.91)	(-4.33, 3.19)	0.766
		Irbesartan	41	31 (75.6)	-0.85 (1.42)	(-3.65, 1.94)			
	Week 94	Sparsentan	47	37 (78.7)	-1.60 (1.30)	(-4.15, 0.96)	1.54 (1.95)	(-2.30, 5.38)	0.429
		Irbesartan	41	30 (73.2)	-3.14 (1.45)	(-5.99, -0.29)			
	Week 110	Sparsentan	47	37 (78.7)	-1.42 (1.30)	(-3.99, 1.14)	1.40 (1.98)	(-2.50, 5.30)	0.480
		Irbesartan	41	29 (70.7)	-2.82 (1.48)	(-5.74, 0.09)			

N = number of patients in analysis set. n (%) = number of non-missing values included in the model. MMRM = Mixed Model Repeated Measures. LS-Mean = Least square mean. STE = Standard error. 95% CI = 95% confidence interval. * = significant treatment effect. # = significant interaction.
A MMRM was applied with fixed factors for treatment, time, interaction treatment-by-time, randomization strata and baseline as covariate. Baseline covariates/factors, which are part of considered subgroup, were excluded from the model. For interaction test, subgroup and interaction subgroup*treatment was added to the model. All observed values are included. A first order regressive covariance structure was used.
A decrease reflects a worsening of the status of the patient. eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day. eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index. MCS = mental component summary.
Source Data: aqs, created on: 05MAR2024

Figure PF2KMSC_FSGM: KDQOL-SF12: Change from baseline in MCS by subgroup
Full Analysis Set

Not done: No significant subgroup found.

Number of available records are presented for key visits up to Week 110 only. LS-Mean = Least square mean. 95% CI = 95% confidence interval. A decrease reflects a worsening of the status of the patient.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
MCS = mental component summary.
Reference table: PT2KMSC_FSCM

Table PT2KMSIT_FSTM: KDQOL-SF12: Time to increase in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Sex	Sparsentan						Interaction test:	0.284	
Male	Sparsentan	139	35 (25.2)	NE		1.622	(0.923, 2.848)	0.093	
	Irbesartan	143	20 (14.0)	NE					
Female	Sparsentan	63	16 (25.4)	NE		3.300	(1.152, 9.451)	0.026	*
	Irbesartan	59	5 (8.5)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KMSIT_FSTM: KDQOL-SF12: Time to increase in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Age	Sparsentan						Interaction test:	0.850	
<= 45 years	Sparsentan	96	28 (29.2)	NE		1.754	(0.940, 3.272)	0.078	
	Irbesartan	99	16 (16.2)	NE					
> 45 years	Sparsentan	106	23 (21.7)	NE		2.516	(1.126, 5.625)	0.025	*
	Irbesartan	103	9 (8.7)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KMSIT_FSTM: KDQOL-SF12: Time to increase in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Age at IgAN diagnosis	Sparsentan						Interaction test:	NE	
<= 18 years	Sparsentan	9	2 (22.2) No events in 1 group	NE		NE		NE	
	Irbesartan	5	0 (0.0)	NE					
> 18 to 40 years	Sparsentan	102	28 (27.5)	NE		1.993	(1.069, 3.716)	0.030	*
	Irbesartan	109	18 (16.5)	NE					
> 40 years	Sparsentan	91	21 (23.1)	NE		3.061	(1.252, 7.484)	0.014	*
	Irbesartan	88	7 (8.0)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KMSIT_FSTM: KDQOL-SF12: Time to increase in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Geographic region	Sparsentan						Interaction test:	0.261	
North America	Sparsentan	35	11 (31.4)	NE		2.323	(0.783, 6.888)	0.129	
	Irbesartan	46	5 (10.9)	NE					
Europe	Sparsentan	98	17 (17.3)	NE		1.347	(0.621, 2.924)	0.451	
	Irbesartan	115	13 (11.3)	NE					
Asia Pacific	Sparsentan	69	23 (33.3)	NE		3.617	(1.446, 9.046)	0.006	*
	Irbesartan	41	7 (17.1)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KMSIT_FSTM: KDQOL-SF12: Time to increase in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.777
< 27 kg/m**2	Sparsentan	83	26 (31.3)	NE		2.147	(0.981, 4.696)	0.056
	Irbesartan	94	9 (9.6)	NE				
>= 27 kg/m**2	Sparsentan	119	25 (21.0)	NE		1.959	(0.995, 3.858)	0.052
	Irbesartan	107	16 (15.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KMSIT_FSTM: KDQOL-SF12: Time to increase in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Randomization strata	Sparsentan						Interaction test:	0.627
eGFR Low and UP High	Sparsentan	71	13 (18.3)	NE		2.675	(0.935, 7.650)	0.066
	Irbesartan	74	6 (8.1)	NE				
eGFR Low and UP Low	Sparsentan	55	13 (23.6)	NE		1.331	(0.513, 3.458)	0.557
	Irbesartan	55	7 (12.7)	NE				
eGFR High and UP High	Sparsentan	37	12 (32.4)	NE		1.680	(0.615, 4.588)	0.311
	Irbesartan	36	6 (16.7)	NE				
eGFR High and UP Low	Sparsentan	39	13 (33.3)	NE		2.498	(0.926, 6.737)	0.071
	Irbesartan	37	6 (16.2)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KMSIT_FSTM: KDQOL-SF12: Time to increase in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.221	
< 60 mL/min/1.73 m**2	Sparsentan	127	25 (19.7)	NE		1.512	(0.789, 2.896)	0.213	
	Irbesartan	129	15 (11.6)	NE					
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	14 (28.6)	NE		1.893	(0.705, 5.082)	0.206	
	Irbesartan	48	6 (12.5)	NE					
>= 90 mL/min/1.73 m**2	Sparsentan	26	12 (46.2)	114.3	(46.1, NE)	13.813	(2.534, 75.308)	0.002	*
	Irbesartan	25	4 (16.0)	115.3	(115.3, NE)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KMSIT_FSTM: KDQOL-SF12: Time to increase in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline eGFR Group 2	Sparsentan						Interaction test:	0.388	
< 45 mL/min/1.73 m**2	Sparsentan	82	17 (20.7)	NE		1.581	(0.709, 3.526)	0.263	
	Irbesartan	80	10 (12.5)	NE					
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	8 (17.8)	NE		1.244	(0.373, 4.147)	0.722	
	Irbesartan	49	5 (10.2)	NE					
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	14 (28.6)	NE		1.893	(0.705, 5.082)	0.206	
	Irbesartan	48	6 (12.5)	NE					
>= 90 mL/min/1.73 m**2	Sparsentan	26	12 (46.2)	114.3	(46.1, NE)	13.813	(2.534, 75.308)	0.002	*
	Irbesartan	25	4 (16.0)	115.3	(115.3, NE)				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KMSIT_FSTM: KDQOL-SF12: Time to increase in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline urine protein excretion	Sparsentan						Interaction test:	0.223	
<= 1.75 g/day	Sparsentan	98	27 (27.6)	NE		2.549	(1.186, 5.479)	0.017	*
	Irbesartan	93	9 (9.7)	NE					
> 1.75 g/day	Sparsentan	104	24 (23.1)	NE		1.620	(0.838, 3.133)	0.151	
	Irbesartan	109	16 (14.7)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KMSIT_FSTM: KDQOL-SF12: Time to increase in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.508	
Yes	Sparsentan	90	21 (23.3)	NE		2.975	(1.168, 7.578)	0.022	*
	Irbesartan	88	6 (6.8)	NE					
No	Sparsentan	112	30 (26.8)	NE		1.903	(1.045, 3.467)	0.035	*
	Irbesartan	114	19 (16.7)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KMSIT_FSTM: KDQOL-SF12: Time to increase in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
Time since renal biopsy	Sparsentan						Interaction test:	0.537	
<= 5 years	Sparsentan	113	35 (31.0)	NE		2.210	(1.234, 3.959)	0.008	*
	Irbesartan	127	18 (14.2)	NE					
> 5 years	Sparsentan	89	16 (18.0)	NE		1.788	(0.714, 4.479)	0.215	
	Irbesartan	75	7 (9.3)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KMSIT_FSTM: KDQOL-SF12: Time to increase in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to increase in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression			
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value	
History of hypertension	Sparsentan						Interaction test:	0.508	
Yes	Sparsentan	155	39 (25.2)	NE		2.171	(1.230, 3.832)	0.007	*
	Irbesartan	161	18 (11.2)	NE					
No	Sparsentan	47	12 (25.5)	NE		1.721	(0.556, 5.322)	0.346	
	Irbesartan	41	7 (17.1)	NE					

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
An increase reflects an improvement of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Figure PF2KMSIT_FSKM: KDQOL-SF12: Time to increase in MCS by at least 9.0 points by subgroup
Full Analysis Set

Not done. No significant subgroups.

_____
An increase reflects an improvement of the status of the patient.
Reference table: PT2KMSIT_FSTM

Table PT2KMSDT_FSTM: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Sex	Sparsentan						Interaction test:	0.441
Male	Sparsentan	139	34 (24.5)	NE		1.018	(0.626, 1.655)	0.943
	Irbesartan	143	33 (23.1)	NE				
Female	Sparsentan	63	23 (36.5)	NE		1.499	(0.776, 2.896)	0.228
	Irbesartan	59	15 (25.4)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KMSDT_FSTM: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age	Sparsentan						Interaction test:	0.440
<= 45 years	Sparsentan	96	26 (27.1)	NE		0.964	(0.554, 1.676)	0.896
	Irbesartan	99	28 (28.3)	116.0	(111.1, NE)			
> 45 years	Sparsentan	106	31 (29.2)	NE		1.372	(0.777, 2.421)	0.275
	Irbesartan	103	20 (19.4)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KMSDT_FSTM: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Age at IgAN diagnosis	Sparsentan						Interaction test:	0.993
<= 18 years	Sparsentan	9	3 (33.3)	NE		2.696	(0.254, 28.581)	0.410
	Irbesartan	5	2 (40.0)	NE				
> 18 to 40 years	Sparsentan	102	30 (29.4)	NE		1.176	(0.697, 1.984)	0.544
	Irbesartan	109	29 (26.6)	116.0	(114.3, NE)			
> 40 years	Sparsentan	91	24 (26.4)	NE		1.130	(0.604, 2.114)	0.702
	Irbesartan	88	17 (19.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KMSDT_FSTM: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Geographic region	Sparsentan						Interaction test:	0.731
North America	Sparsentan	35	9 (25.7)	NE		0.876	(0.347, 2.207)	0.778
	Irbesartan	46	12 (26.1)	NE				
Europe	Sparsentan	98	32 (32.7)	NE		1.441	(0.850, 2.441)	0.175
	Irbesartan	115	26 (22.6)	NE				
Asia Pacific	Sparsentan	69	16 (23.2)	NE		1.010	(0.448, 2.276)	0.981
	Irbesartan	41	10 (24.4)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KMSDT_FSTM: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline BMI	Sparsentan						Interaction test:	0.491
< 27 kg/m**2	Sparsentan	83	26 (31.3)	NE		1.292	(0.731, 2.286)	0.378
	Irbesartan	94	24 (25.5)	NE				
>= 27 kg/m**2	Sparsentan	119	31 (26.1)	NE		1.026	(0.598, 1.760)	0.926
	Irbesartan	107	24 (22.4)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KMSDT_FSTM: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Randomization strata	Sparsentan						Interaction test:	0.543
eGFR Low and UP High	Sparsentan	71	19 (26.8)	NE		1.296	(0.639, 2.629)	0.472
	Irbesartan	74	13 (17.6)	NE				
eGFR Low and UP Low	Sparsentan	55	15 (27.3)	NE		0.886	(0.435, 1.806)	0.739
	Irbesartan	55	16 (29.1)	NE				
eGFR High and UP High	Sparsentan	37	15 (40.5)	114.6	(94.1, NE)	1.726	(0.725, 4.110)	0.217
	Irbesartan	36	9 (25.0)	NE				
eGFR High and UP Low	Sparsentan	39	8 (20.5)	NE		0.739	(0.290, 1.888)	0.528
	Irbesartan	37	10 (27.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KMSDT_FSTM: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 1	Sparsentan						Interaction test:	0.794
< 60 mL/min/1.73 m**2	Sparsentan	127	36 (28.3)	NE		1.189	(0.725, 1.948)	0.493
	Irbesartan	129	30 (23.3)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	14 (28.6)	NE		1.386	(0.601, 3.196)	0.443
	Irbesartan	48	11 (22.9)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	7 (26.9)	NE		0.756	(0.252, 2.266)	0.617
	Irbesartan	25	7 (28.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KMSDT_FSTM: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline eGFR Group 2	Sparsentan						Interaction test:	0.520
< 45 mL/min/1.73 m**2	Sparsentan	82	18 (22.0)	NE		0.797	(0.413, 1.539)	0.500
	Irbesartan	80	18 (22.5)	NE				
45 to < 60 mL/min/1.73 m**2	Sparsentan	45	18 (40.0)	NE		1.828	(0.856, 3.904)	0.119
	Irbesartan	49	12 (24.5)	NE				
60 to < 90 mL/min/1.73 m**2	Sparsentan	49	14 (28.6)	NE		1.386	(0.601, 3.196)	0.443
	Irbesartan	48	11 (22.9)	NE				
>= 90 mL/min/1.73 m**2	Sparsentan	26	7 (26.9)	NE		0.756	(0.252, 2.266)	0.617
	Irbesartan	25	7 (28.0)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KMSDT_FSTM: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline urine protein excretion	Sparsentan						Interaction test:	0.663
<= 1.75 g/day	Sparsentan	98	27 (27.6)	NE		0.979	(0.554, 1.730)	0.942
	Irbesartan	93	22 (23.7)	NE				
> 1.75 g/day	Sparsentan	104	30 (28.8)	NE		1.341	(0.781, 2.303)	0.288
	Irbesartan	109	26 (23.9)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KMSDT_FSTM: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Baseline use of antihypertensives	Sparsentan						Interaction test:	0.738
Yes	Sparsentan	90	26 (28.9)	NE		1.255	(0.694, 2.271)	0.452
	Irbesartan	88	21 (23.9)	NE				
No	Sparsentan	112	31 (27.7)	NE		1.123	(0.664, 1.901)	0.665
	Irbesartan	114	27 (23.7)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KMSDT_FSTM: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
Time since renal biopsy	Sparsentan						Interaction test:	0.386
<= 5 years	Sparsentan	113	28 (24.8)	NE		0.948	(0.567, 1.586)	0.839
	Irbesartan	127	32 (25.2)	NE				
> 5 years	Sparsentan	89	29 (32.6)	NE		1.433	(0.774, 2.655)	0.252
	Irbesartan	75	16 (21.3)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Table PT2KMSDT_FSTM: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points by subgroup
Full Analysis Set

KDQOL-SF12: time to decrease in MCS by at least 9.0				Kaplan-Meier analysis		Cox regression		
Subgroup	Treatment	N	nev (%)	Median time (weeks)	95% CI	Hazard Ratio	95% CI	p-value
History of hypertension	Sparsentan						Interaction test:	0.967
Yes	Sparsentan	155	39 (25.2)	NE		1.133	(0.710, 1.809)	0.600
	Irbesartan	161	34 (21.1)	NE				
No	Sparsentan	47	18 (38.3)	NE		1.055	(0.521, 2.135)	0.882
	Irbesartan	41	14 (34.1)	NE				

N = number of patients in analysis set. nev (%) = number of patients with at least one event. NE = not evaluable.
95% CI = 95% confidence interval (median: Brookmeyer/Crowley hazard ratio: coming from Cox model).
A Cox proportional model was applied with factors treatment, randomization strata and baseline as covariate.
* = significant treatment effect. # = significant interaction. For interaction test, subgroup and interaction subgroup*treatment was added to the model.
A decrease reflects a worsening of the status of the patient. Time is presented in weeks.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aqs_tte, created on: 26MAR2024

Figure PF2KMSDT_FSKM: KDQOL-SF12: Time to decrease in MCS by at least 9.0 points by subgroup
Full Analysis Set

Not done. No significant subgroups.

_____
A decrease reflects a worsening of the status of the patient.
Reference table: PT2KMSDT_FSTM

Table PT2A_SSIM: Incidence of TEAEs during double-blind period by subgroup
Safety Set

TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.396
Male	Double-blind period	Sparsentan	139	128 (92.1)	1.037 [0.961, 1.119]	1.466 [0.655, 3.282]	3.3 [-4.3, 10.8]	0.420
		Irbesartan	143	127 (88.8)				
Female	Double-blind period	Sparsentan	63	59 (93.7)	1.105 [0.974, 1.253]	2.655 [0.771, 9.143]	8.9 [-3.7, 21.5]	0.145
		Irbesartan	59	50 (84.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSIM: Incidence of TEAEs during double-blind period by subgroup
Safety Set

TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.950
<= 45 years	Double-blind period	Sparsentan	96	90 (93.8)	1.055 [0.967, 1.150]	1.875 [0.665, 5.290]	4.9 [-4.0, 13.7]	0.311
		Irbesartan	99	88 (88.9)				
> 45 years	Double-blind period	Sparsentan	106	97 (91.5)	1.059 [0.962, 1.166]	1.695 [0.699, 4.110]	5.1 [-4.3, 14.5]	0.274
		Irbesartan	103	89 (86.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSIM: Incidence of TEAEs during double-blind period by subgroup
Safety Set

TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.943
<= 18 years	Double-blind period	Sparsentan	9	9 (100.0)	1.036 + [0.783, 1.371]	1.727 + [0.030, 99.953]	0.0 [NE, NE]	NE
		Irbesartan	5	5 (100.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	95 (93.1)	1.047 [0.962, 1.139]	1.679 [0.634, 4.447]	4.1 [-4.5, 12.8]	0.342
		Irbesartan	109	97 (89.0)				
> 40 years	Double-blind period	Sparsentan	91	83 (91.2)	1.070 [0.961, 1.192]	1.798 [0.706, 4.578]	6.0 [-4.6, 16.5]	0.250
		Irbesartan	88	75 (85.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSIM: Incidence of TEAEs during double-blind period by subgroup
Safety Set

TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.896
North America	Double-blind period	Sparsentan	35	32 (91.4)	1.026 [0.889, 1.184]	1.301 [0.289, 5.854]	2.3 [-13.1, 17.7]	1.000
		Irbesartan	46	41 (89.1)				
Europe	Double-blind period	Sparsentan	98	90 (91.8)	1.067 [0.971, 1.172]	1.818 [0.743, 4.452]	5.7 [-3.5, 15.0]	0.201
		Irbesartan	115	99 (86.1)				
Asia Pacific	Double-blind period	Sparsentan	69	65 (94.2)	1.044 [0.929, 1.173]	1.757 [0.415, 7.441]	4.0 [-8.6, 16.5]	0.468
		Irbesartan	41	37 (90.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSIM: Incidence of TEAEs during double-blind period by subgroup
Safety Set

TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.865
< 27 kg/m**2	Double-blind period	Sparsentan	83	76 (91.6)	1.050 [0.949, 1.161]	1.589 [0.595, 4.246]	4.3 [-5.8, 14.5]	0.467
		Irbesartan	94	82 (87.2)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	111 (93.3)	1.062 [0.975, 1.156]	1.919 [0.763, 4.827]	5.4 [-3.1, 14.0]	0.176
		Irbesartan	107	94 (87.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSIM: Incidence of TEAEs during double-blind period by subgroup
Safety Set

TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.663
eGFR Low and UP High	Double-blind period	Sparsentan	71	67 (94.4)	1.074 [0.970, 1.190]	2.319 [0.680, 7.905]	6.5 [-4.0, 17.1]	0.246
		Irbesartan	74	65 (87.8)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	49 (89.1)	1.000 [0.877, 1.140]	1.000 [0.302, 3.316]	0.0 [-13.5, 13.5]	1.000
		Irbesartan	55	49 (89.1)				
eGFR High and UP High	Double-blind period	Sparsentan	37	35 (94.6)	1.135 [0.962, 1.339]	3.500 [0.657, 18.648]	11.3 [-5.7, 28.2]	0.152
		Irbesartan	36	30 (83.3)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	36 (92.3)	1.035 [0.896, 1.196]	1.455 [0.303, 6.989]	3.1 [-12.6, 18.8]	0.708
		Irbesartan	37	33 (89.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSIM: Incidence of TEAEs during double-blind period by subgroup
Safety Set

TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.239
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	118 (92.9)	1.061 [0.978, 1.150]	1.856 [0.788, 4.371]	5.3 [-2.7, 13.3]	0.206
		Irbesartan	129	113 (87.6)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	45 (91.8)	0.980 [0.877, 1.095]	0.750 [0.159, 3.544]	-1.9 [-14.3, 10.4]	1.000
		Irbesartan	48	45 (93.8)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	24 (92.3)	1.215 [0.949, 1.554]	3.789 [0.686, 20.946]	16.3 [-7.2, 39.9]	0.140
		Irbesartan	25	19 (76.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSIM: Incidence of TEAEs during double-blind period by subgroup
Safety Set

TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.366
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	75 (91.5)	1.045 [0.940, 1.162]	1.531 [0.552, 4.242]	4.0 [-6.7, 14.6]	0.452
		Irbesartan	80	70 (87.5)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	43 (95.6)	1.089 [0.964, 1.230]	3.000 [0.573, 15.702]	7.8 [-5.3, 20.9]	0.271
		Irbesartan	49	43 (87.8)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	45 (91.8)	0.980 [0.877, 1.095]	0.750 [0.159, 3.544]	-1.9 [-14.3, 10.4]	1.000
		Irbesartan	48	45 (93.8)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	24 (92.3)	1.215 [0.949, 1.554]	3.789 [0.686, 20.946]	16.3 [-7.2, 39.9]	0.140
		Irbesartan	25	19 (76.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSIM: Incidence of TEAEs during double-blind period by subgroup
Safety Set

TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.481
<= 1.75 g/day	Double-blind period	Sparsentan	98	88 (89.8)	1.031 [0.930, 1.143]	1.304 [0.534, 3.180]	2.7 [-7.4, 12.8]	0.652
		Irbesartan	93	81 (87.1)				
> 1.75 g/day	Double-blind period	Sparsentan	104	99 (95.2)	1.081 [0.996, 1.173]	2.681 [0.921, 7.808]	7.1 [-1.2, 15.4]	0.084
		Irbesartan	109	96 (88.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSIM: Incidence of TEAEs during double-blind period by subgroup
Safety Set

TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.481
Yes	Double-blind period	Sparsentan	90	81 (90.0)	1.029 [0.926, 1.142]	1.286 [0.505, 3.273]	2.5 [-7.9, 12.9]	0.641
		Irbesartan	88	77 (87.5)				
No	Double-blind period	Sparsentan	112	106 (94.6)	1.079 [0.994, 1.171]	2.473 [0.915, 6.687]	6.9 [-1.3, 15.1]	0.099
		Irbesartan	114	100 (87.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSIM: Incidence of TEAEs during double-blind period by subgroup
Safety Set

TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.634
<= 5 years	Double-blind period	Sparsentan	113	105 (92.9)	1.044 [0.964, 1.131]	1.626 [0.656, 4.033]	3.9 [-4.1, 12.0]	0.372
		Irbesartan	127	113 (89.0)				
> 5 years	Double-blind period	Sparsentan	89	82 (92.1)	1.080 [0.966, 1.207]	2.013 [0.739, 5.486]	6.8 [-4.2, 17.8]	0.212
		Irbesartan	75	64 (85.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSIM: Incidence of TEAEs during double-blind period by subgroup
Safety Set

TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.039	#
Yes	Double-blind period	Sparsentan	155	145 (93.5)	1.091 [1.012, 1.177]	2.417 [1.110, 5.262]	7.8 [0.6, 15.1]	0.027	*
		Irbesartan	161	138 (85.7)					
No	Double-blind period	Sparsentan	47	42 (89.4)	0.939 [0.833, 1.060]	0.431 [0.079, 2.350]	-5.8 [-19.1, 7.5]	0.442	
		Irbesartan	41	39 (95.1)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AN_SSIM: Incidence of non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.488
Male	Double-blind period	Sparsentan	139	51 (36.7)	0.937 [0.695, 1.263]	0.900 [0.556, 1.457]	-2.5 [-14.5, 9.6]	0.713
		Irbesartan	143	56 (39.2)				
Female	Double-blind period	Sparsentan	63	20 (31.7)	1.171 [0.673, 2.036]	1.250 [0.572, 2.731]	4.6 [-13.2, 22.4]	0.692
		Irbesartan	59	16 (27.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AN_SSIM: Incidence of non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.246
<= 45 years	Double-blind period	Sparsentan	96	39 (40.6)	1.149 [0.802, 1.647]	1.251 [0.701, 2.233]	5.3 [-9.4, 19.9]	0.464
		Irbesartan	99	35 (35.4)				
> 45 years	Double-blind period	Sparsentan	106	32 (30.2)	0.840 [0.570, 1.238]	0.771 [0.433, 1.375]	-5.7 [-19.4, 8.0]	0.462
		Irbesartan	103	37 (35.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AN_SSIM: Incidence of non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.571
<= 18 years	Double-blind period	Sparsentan	9	7 (77.8)	1.296 [0.585, 2.874]	2.333 [0.216, 25.245]	17.8 [-48.6, 84.1]	0.580
		Irbesartan	5	3 (60.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	33 (32.4)	0.860 [0.594, 1.246]	0.793 [0.450, 1.399]	-5.3 [-19.1, 8.5]	0.472
		Irbesartan	109	41 (37.6)				
> 40 years	Double-blind period	Sparsentan	91	31 (34.1)	1.071 [0.704, 1.627]	1.107 [0.593, 2.066]	2.2 [-12.6, 17.1]	0.754
		Irbesartan	88	28 (31.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AN_SSIM: Incidence of non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.825
North America	Double-blind period	Sparsentan	35	12 (34.3)	1.127 [0.598, 2.122]	1.193 [0.466, 3.050]	3.9 [-19.3, 27.0]	0.811
		Irbesartan	46	14 (30.4)				
Europe	Double-blind period	Sparsentan	98	38 (38.8)	0.949 [0.681, 1.322]	0.916 [0.528, 1.589]	-2.1 [-16.2, 12.0]	0.780
		Irbesartan	115	47 (40.9)				
Asia Pacific	Double-blind period	Sparsentan	69	21 (30.4)	1.134 [0.611, 2.106]	1.193 [0.505, 2.821]	3.6 [-15.7, 22.9]	0.829
		Irbesartan	41	11 (26.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AN_SSIM: Incidence of non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.048 #
< 27 kg/m**2	Double-blind period	Sparsentan	83	24 (28.9)	0.715 [0.471, 1.086]	0.599 [0.320, 1.124]	-11.5 [-26.6, 3.5]	0.117
		Irbesartan	94	38 (40.4)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	47 (39.5)	1.243 [0.871, 1.774]	1.402 [0.810, 2.425]	7.7 [-5.6, 21.1]	0.267
		Irbesartan	107	34 (31.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AN_SSIM: Incidence of non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.989
eGFR Low and UP High	Double-blind period	Sparsentan	71	33 (46.5)	0.955 [0.679, 1.345]	0.917 [0.478, 1.760]	-2.2 [-19.8, 15.5]	0.868
		Irbesartan	74	36 (48.6)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	18 (32.7)	1.000 [0.585, 1.709]	1.000 [0.451, 2.218]	0.0 [-19.4, 19.4]	1.000
		Irbesartan	55	18 (32.7)				
eGFR High and UP High	Double-blind period	Sparsentan	37	12 (32.4)	1.061 [0.539, 2.090]	1.091 [0.406, 2.931]	1.9 [-22.2, 25.9]	1.000
		Irbesartan	36	11 (30.6)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	8 (20.5)	1.084 [0.437, 2.691]	1.106 [0.357, 3.430]	1.6 [-18.9, 22.1]	1.000
		Irbesartan	37	7 (18.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AN_SSIM: Incidence of non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.505
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	50 (39.4)	0.996 [0.735, 1.349]	0.993 [0.602, 1.639]	-0.2 [-12.9, 12.6]	1.000
		Irbesartan	129	51 (39.5)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	14 (28.6)	0.807 [0.450, 1.448]	0.729 [0.310, 1.718]	-6.8 [-27.4, 13.7]	0.518
		Irbesartan	48	17 (35.4)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	7 (26.9)	1.683 [0.561, 5.050]	1.934 [0.488, 7.660]	10.9 [-15.3, 37.1]	0.499
		Irbesartan	25	4 (16.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AN_SSIM: Incidence of non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.618
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	35 (42.7)	1.067 [0.739, 1.541]	1.117 [0.597, 2.088]	2.7 [-13.7, 19.1]	0.752
		Irbesartan	80	32 (40.0)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	15 (33.3)	0.860 [0.500, 1.479]	0.789 [0.339, 1.838]	-5.4 [-27.0, 16.1]	0.669
		Irbesartan	49	19 (38.8)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	14 (28.6)	0.807 [0.450, 1.448]	0.729 [0.310, 1.718]	-6.8 [-27.4, 13.7]	0.518
		Irbesartan	48	17 (35.4)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	7 (26.9)	1.683 [0.561, 5.050]	1.934 [0.488, 7.660]	10.9 [-15.3, 37.1]	0.499
		Irbesartan	25	4 (16.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AN_SSIM: Incidence of non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.315
<= 1.75 g/day	Double-blind period	Sparsentan	98	28 (28.6)	1.208 [0.747, 1.954]	1.291 [0.675, 2.470]	4.9 [-8.6, 18.4]	0.511
		Irbesartan	93	22 (23.7)				
> 1.75 g/day	Double-blind period	Sparsentan	104	43 (41.3)	0.901 [0.663, 1.225]	0.832 [0.484, 1.431]	-4.5 [-18.8, 9.7]	0.581
		Irbesartan	109	50 (45.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AN_SSIM: Incidence of non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.043 #
Yes	Double-blind period	Sparsentan	90	40 (44.4)	1.304 [0.899, 1.890]	1.547 [0.844, 2.835]	10.4 [-5.0, 25.7]	0.170
		Irbesartan	88	30 (34.1)				
No	Double-blind period	Sparsentan	112	31 (27.7)	0.751 [0.512, 1.103]	0.656 [0.374, 1.151]	-9.2 [-22.2, 3.8]	0.156
		Irbesartan	114	42 (36.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AN_SSIM: Incidence of non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.242
<= 5 years	Double-blind period	Sparsentan	113	44 (38.9)	1.124 [0.806, 1.567]	1.203 [0.711, 2.035]	4.3 [-8.8, 17.3]	0.505
		Irbesartan	127	44 (34.6)				
> 5 years	Double-blind period	Sparsentan	89	27 (30.3)	0.813 [0.528, 1.249]	0.731 [0.381, 1.401]	-7.0 [-22.8, 8.8]	0.407
		Irbesartan	75	28 (37.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AN_SSIM: Incidence of non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.002	#
Yes	Double-blind period	Sparsentan	155	65 (41.9)	1.228 [0.925, 1.630]	1.392 [0.882, 2.196]	7.8 [-3.5, 19.1]	0.166	
		Irbesartan	161	55 (34.2)					
No	Double-blind period	Sparsentan	47	6 (12.8)	0.308 [0.134, 0.707]	0.207 [0.072, 0.595]	-28.7 [-48.8, -8.6]	0.003	*
		Irbesartan	41	17 (41.5)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AC_SSIM: Incidence of severe TEAEs during double-blind period by subgroup
Safety Set

Severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.298
Male	Double-blind period	Sparsentan	139	19 (13.7)	0.977 [0.546, 1.751]	0.974 [0.495, 1.915]	-0.3 [-9.1, 8.5]	1.000
		Irbesartan	143	20 (14.0)				
Female	Double-blind period	Sparsentan	63	5 (7.9)	0.520 [0.185, 1.463]	0.479 [0.151, 1.523]	-7.3 [-20.3, 5.7]	0.260
		Irbesartan	59	9 (15.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AC_SSIM: Incidence of severe TEAEs during double-blind period by subgroup
Safety Set

Severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.453
<= 45 years	Double-blind period	Sparsentan	96	16 (16.7)	0.971 [0.521, 1.808]	0.965 [0.456, 2.040]	-0.5 [-12.1, 11.0]	1.000
		Irbesartan	99	17 (17.2)				
> 45 years	Double-blind period	Sparsentan	106	8 (7.5)	0.648 [0.276, 1.519]	0.619 [0.242, 1.583]	-4.1 [-13.0, 4.8]	0.354
		Irbesartan	103	12 (11.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AC_SSIM: Incidence of severe TEAEs during double-blind period by subgroup
Safety Set

Severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.958
<= 18 years	Double-blind period	Sparsentan	9	2 (22.2)	1.111 [0.131, 9.416]	1.143 [0.077, 16.947]	2.2 [-57.7, 62.1]	1.000
		Irbesartan	5	1 (20.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	13 (12.7)	0.817 [0.418, 1.597]	0.790 [0.363, 1.722]	-2.9 [-13.2, 7.5]	0.694
		Irbesartan	109	17 (15.6)				
> 40 years	Double-blind period	Sparsentan	91	9 (9.9)	0.791 [0.345, 1.816]	0.768 [0.302, 1.956]	-2.6 [-13.0, 7.7]	0.640
		Irbesartan	88	11 (12.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AC_SSIM: Incidence of severe TEAEs during double-blind period by subgroup
Safety Set

Severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.650
North America	Double-blind period	Sparsentan	35	7 (20.0)	1.314 [0.508, 3.402]	1.393 [0.439, 4.419]	4.8 [-14.6, 24.1]	0.768
		Irbesartan	46	7 (15.2)				
Europe	Double-blind period	Sparsentan	98	12 (12.2)	0.782 [0.397, 1.543]	0.752 [0.343, 1.650]	-3.4 [-13.6, 6.8]	0.555
		Irbesartan	115	18 (15.7)				
Asia Pacific	Double-blind period	Sparsentan	69	5 (7.2)	0.743 [0.211, 2.610]	0.723 [0.183, 2.860]	-2.5 [-15.4, 10.4]	0.725
		Irbesartan	41	4 (9.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AC_SSIM: Incidence of severe TEAEs during double-blind period by subgroup
Safety Set

Severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.688
< 27 kg/m**2	Double-blind period	Sparsentan	83	9 (10.8)	0.728 [0.333, 1.594]	0.695 [0.284, 1.701]	-4.1 [-15.0, 6.9]	0.505
		Irbesartan	94	14 (14.9)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	15 (12.6)	0.899 [0.462, 1.751]	0.885 [0.410, 1.908]	-1.4 [-11.2, 8.4]	0.845
		Irbesartan	107	15 (14.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AC_SSIM: Incidence of severe TEAEs during double-blind period by subgroup
Safety Set

Severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.646
eGFR Low and UP High	Double-blind period	Sparsentan	71	12 (16.9)	1.042 [0.502, 2.165]	1.051 [0.438, 2.523]	0.7 [-12.8, 14.2]	1.000
		Irbesartan	74	12 (16.2)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	4 (7.3)	0.444 [0.145, 1.358]	0.401 [0.116, 1.390]	-9.1 [-22.9, 4.7]	0.237
		Irbesartan	55	9 (16.4)				
eGFR High and UP High	Double-blind period	Sparsentan	37	4 (10.8)	0.973 [0.263, 3.598]	0.970 [0.223, 4.212]	-0.3 [-17.4, 16.8]	1.000
		Irbesartan	36	4 (11.1)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	4 (10.3)	0.949 [0.256, 3.519]	0.943 [0.218, 4.081]	-0.6 [-17.0, 15.9]	1.000
		Irbesartan	37	4 (10.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AC_SSIM: Incidence of severe TEAEs during double-blind period by subgroup
Safety Set

Severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.762
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	16 (12.6)	0.739 [0.407, 1.340]	0.701 [0.349, 1.407]	-4.5 [-13.9, 5.0]	0.380
		Irbesartan	129	22 (17.1)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	6 (12.2)	1.176 [0.384, 3.596]	1.200 [0.340, 4.230]	1.8 [-12.8, 16.5]	1.000
		Irbesartan	48	5 (10.4)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	2 (7.7)	0.962 [0.147, 6.311]	0.958 [0.124, 7.383]	-0.3 [-19.0, 18.4]	1.000
		Irbesartan	25	2 (8.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AC_SSIM: Incidence of severe TEAEs during double-blind period by subgroup
Safety Set

Severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.882
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	12 (14.6)	0.780 [0.390, 1.562]	0.743 [0.324, 1.705]	-4.1 [-16.8, 8.6]	0.532
		Irbesartan	80	15 (18.8)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	4 (8.9)	0.622 [0.195, 1.985]	0.585 [0.159, 2.151]	-5.4 [-20.4, 9.6]	0.528
		Irbesartan	49	7 (14.3)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	6 (12.2)	1.176 [0.384, 3.596]	1.200 [0.340, 4.230]	1.8 [-12.8, 16.5]	1.000
		Irbesartan	48	5 (10.4)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	2 (7.7)	0.962 [0.147, 6.311]	0.958 [0.124, 7.383]	-0.3 [-19.0, 18.4]	1.000
		Irbesartan	25	2 (8.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AC_SSIM: Incidence of severe TEAEs during double-blind period by subgroup
Safety Set

Severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.731
<= 1.75 g/day	Double-blind period	Sparsentan	98	9 (9.2)	0.949 [0.394, 2.286]	0.944 [0.357, 2.492]	-0.5 [-9.8, 8.8]	1.000
		Irbesartan	93	9 (9.7)				
> 1.75 g/day	Double-blind period	Sparsentan	104	15 (14.4)	0.786 [0.426, 1.451]	0.750 [0.361, 1.558]	-3.9 [-14.8, 6.9]	0.465
		Irbesartan	109	20 (18.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AC_SSIM: Incidence of severe TEAEs during double-blind period by subgroup
Safety Set

Severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.911
Yes	Double-blind period	Sparsentan	90	13 (14.4)	0.847 [0.428, 1.676]	0.822 [0.366, 1.845]	-2.6 [-14.4, 9.2]	0.684
		Irbesartan	88	15 (17.0)				
No	Double-blind period	Sparsentan	112	11 (9.8)	0.800 [0.380, 1.685]	0.778 [0.337, 1.796]	-2.5 [-11.5, 6.6]	0.673
		Irbesartan	114	14 (12.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AC_SSIM: Incidence of severe TEAEs during double-blind period by subgroup
Safety Set

Severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.779
<= 5 years	Double-blind period	Sparsentan	113	18 (15.9)	0.843 [0.483, 1.470]	0.813 [0.415, 1.592]	-3.0 [-13.4, 7.5]	0.611
		Irbesartan	127	24 (18.9)				
> 5 years	Double-blind period	Sparsentan	89	6 (6.7)	1.011 [0.321, 3.182]	1.012 [0.296, 3.458]	0.1 [-8.8, 9.0]	1.000
		Irbesartan	75	5 (6.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AC_SSIM: Incidence of severe TEAEs during double-blind period by subgroup
Safety Set

Severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.757
Yes	Double-blind period	Sparsentan	155	20 (12.9)	0.866 [0.499, 1.502]	0.846 [0.446, 1.603]	-2.0 [-10.3, 6.3]	0.629
		Irbesartan	161	24 (14.9)				
No	Double-blind period	Sparsentan	47	4 (8.5)	0.698 [0.201, 2.427]	0.670 [0.167, 2.682]	-3.7 [-18.8, 11.4]	0.728
		Irbesartan	41	5 (12.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AS_SSIM: Incidence of serious TEAEs during double-blind period by subgroup
Safety Set

Serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.635
Male	Double-blind period	Sparsentan	139	48 (34.5)	1.008 [0.730, 1.391]	1.012 [0.619, 1.654]	0.3 [-11.5, 12.1]	1.000
		Irbesartan	143	49 (34.3)				
Female	Double-blind period	Sparsentan	63	27 (42.9)	1.149 [0.743, 1.779]	1.261 [0.610, 2.608]	5.6 [-13.4, 24.6]	0.582
		Irbesartan	59	22 (37.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AS_SSIM: Incidence of serious TEAEs during double-blind period by subgroup
Safety Set

Serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.965
<= 45 years	Double-blind period	Sparsentan	96	42 (43.8)	1.056 [0.762, 1.464]	1.100 [0.624, 1.942]	2.3 [-12.6, 17.2]	0.773
		Irbesartan	99	41 (41.4)				
> 45 years	Double-blind period	Sparsentan	106	33 (31.1)	1.069 [0.707, 1.616]	1.100 [0.609, 1.987]	2.0 [-11.4, 15.4]	0.765
		Irbesartan	103	30 (29.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AS_SSIM: Incidence of serious TEAEs during double-blind period by subgroup
Safety Set

Serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.763
<= 18 years	Double-blind period	Sparsentan	9	6 (66.7)	0.833 [0.441, 1.575]	0.500 [0.037, 6.683]	-13.3 [-75.6, 48.9]	1.000
		Irbesartan	5	4 (80.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	35 (34.3)	1.100 [0.747, 1.620]	1.152 [0.648, 2.049]	3.1 [-10.5, 16.7]	0.661
		Irbesartan	109	34 (31.2)				
> 40 years	Double-blind period	Sparsentan	91	34 (37.4)	0.996 [0.682, 1.455]	0.994 [0.543, 1.821]	-0.1 [-15.4, 15.2]	1.000
		Irbesartan	88	33 (37.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AS_SSIM: Incidence of serious TEAEs during double-blind period by subgroup
Safety Set

Serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.591
North America	Double-blind period	Sparsentan	35	15 (42.9)	1.232 [0.711, 2.136]	1.406 [0.570, 3.471]	8.1 [-15.8, 32.0]	0.496
		Irbesartan	46	16 (34.8)				
Europe	Double-blind period	Sparsentan	98	37 (37.8)	1.113 [0.777, 1.596]	1.182 [0.674, 2.073]	3.8 [-10.0, 17.7]	0.569
		Irbesartan	115	39 (33.9)				
Asia Pacific	Double-blind period	Sparsentan	69	23 (33.3)	0.854 [0.514, 1.419]	0.781 [0.350, 1.743]	-5.7 [-26.3, 14.9]	0.681
		Irbesartan	41	16 (39.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AS_SSIM: Incidence of serious TEAEs during double-blind period by subgroup
Safety Set

Serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.732
< 27 kg/m**2	Double-blind period	Sparsentan	83	31 (37.3)	1.003 [0.684, 1.471]	1.005 [0.546, 1.850]	0.1 [-15.3, 15.5]	1.000
		Irbesartan	94	35 (37.2)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	44 (37.0)	1.099 [0.771, 1.567]	1.157 [0.669, 2.000]	3.3 [-10.0, 16.7]	0.676
		Irbesartan	107	36 (33.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AS_SSIM: Incidence of serious TEAEs during double-blind period by subgroup
Safety Set

Serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.916
eGFR Low and UP High	Double-blind period	Sparsentan	71	29 (40.8)	1.119 [0.742, 1.688]	1.202 [0.615, 2.347]	4.4 [-12.9, 21.6]	0.613
		Irbesartan	74	27 (36.5)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	17 (30.9)	1.063 [0.600, 1.881]	1.090 [0.482, 2.466]	1.8 [-17.1, 20.8]	1.000
		Irbesartan	55	16 (29.1)				
eGFR High and UP High	Double-blind period	Sparsentan	37	14 (37.8)	1.135 [0.611, 2.109]	1.217 [0.466, 3.179]	4.5 [-20.2, 29.2]	0.808
		Irbesartan	36	12 (33.3)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	15 (38.5)	0.889 [0.517, 1.529]	0.820 [0.328, 2.050]	-4.8 [-29.5, 19.9]	0.816
		Irbesartan	37	16 (43.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AS_SSIM: Incidence of serious TEAEs during double-blind period by subgroup
Safety Set

Serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.746
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	47 (37.0)	1.038 [0.750, 1.435]	1.060 [0.637, 1.764]	1.3 [-11.2, 13.9]	0.897
		Irbesartan	129	46 (35.7)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	19 (38.8)	0.980 [0.597, 1.608]	0.967 [0.428, 2.185]	-0.8 [-22.3, 20.7]	1.000
		Irbesartan	48	19 (39.6)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	9 (34.6)	1.442 [0.601, 3.460]	1.676 [0.494, 5.694]	10.6 [-18.1, 39.3]	0.541
		Irbesartan	25	6 (24.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AS_SSIM: Incidence of serious TEAEs during double-blind period by subgroup
Safety Set

Serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.608
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	32 (39.0)	1.201 [0.792, 1.820]	1.329 [0.698, 2.533]	6.5 [-9.4, 22.5]	0.416
		Irbesartan	80	26 (32.5)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	15 (33.3)	0.817 [0.479, 1.392]	0.725 [0.312, 1.682]	-7.5 [-29.1, 14.1]	0.524
		Irbesartan	49	20 (40.8)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	19 (38.8)	0.980 [0.597, 1.608]	0.967 [0.428, 2.185]	-0.8 [-22.3, 20.7]	1.000
		Irbesartan	48	19 (39.6)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	9 (34.6)	1.442 [0.601, 3.460]	1.676 [0.494, 5.694]	10.6 [-18.1, 39.3]	0.541
		Irbesartan	25	6 (24.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AS_SSIM: Incidence of serious TEAEs during double-blind period by subgroup
Safety Set

Serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.945
<= 1.75 g/day	Double-blind period	Sparsentan	98	36 (36.7)	1.068 [0.728, 1.565]	1.107 [0.612, 2.003]	2.3 [-12.3, 17.0]	0.764
		Irbesartan	93	32 (34.4)				
> 1.75 g/day	Double-blind period	Sparsentan	104	39 (37.5)	1.048 [0.736, 1.492]	1.077 [0.617, 1.881]	1.7 [-12.2, 15.6]	0.887
		Irbesartan	109	39 (35.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AS_SSIM: Incidence of serious TEAEs during double-blind period by subgroup
Safety Set

Serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.178
Yes	Double-blind period	Sparsentan	90	30 (33.3)	0.863 [0.582, 1.278]	0.794 [0.430, 1.466]	-5.3 [-20.5, 9.9]	0.533
		Irbesartan	88	34 (38.6)				
No	Double-blind period	Sparsentan	112	45 (40.2)	1.238 [0.874, 1.753]	1.398 [0.811, 2.409]	7.7 [-5.7, 21.1]	0.269
		Irbesartan	114	37 (32.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AS_SSIM: Incidence of serious TEAEs during double-blind period by subgroup
Safety Set

Serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.021	#
<= 5 years	Double-blind period	Sparsentan	113	42 (37.2)	0.858 [0.629, 1.172]	0.774 [0.461, 1.301]	-6.1 [-19.4, 7.1]	0.358	
		Irbesartan	127	55 (43.3)					
> 5 years	Double-blind period	Sparsentan	89	33 (37.1)	1.738 [1.042, 2.900]	2.173 [1.079, 4.377]	15.7 [0.9, 30.6]	0.039	*
		Irbesartan	75	16 (21.3)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AS_SSIM: Incidence of serious TEAEs during double-blind period by subgroup
Safety Set

Serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.405
Yes	Double-blind period	Sparsentan	155	58 (37.4)	1.004 [0.755, 1.336]	1.007 [0.638, 1.588]	0.2 [-11.1, 11.5]	1.000
		Irbesartan	161	60 (37.3)				
No	Double-blind period	Sparsentan	47	17 (36.2)	1.348 [0.716, 2.537]	1.545 [0.621, 3.846]	9.3 [-12.2, 30.9]	0.370
		Irbesartan	41	11 (26.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AT_SSIM: Incidence of TEAEs leading to study drug discontinuation during double-blind period by subgroup
Safety Set

TEAEs leading to study drug discontinuation

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.936
Male	Double-blind period	Sparsentan	139	15 (10.8)	1.187 [0.587, 2.403]	1.210 [0.553, 2.645]	1.7 [-6.0, 9.4]	0.693
		Irbesartan	143	13 (9.1)				
Female	Double-blind period	Sparsentan	63	6 (9.5)	1.124 [0.362, 3.487]	1.137 [0.328, 3.943]	1.0 [-10.7, 12.8]	1.000
		Irbesartan	59	5 (8.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AT_SSIM: Incidence of TEAEs leading to study drug discontinuation during double-blind period by subgroup
Safety Set

TEAEs leading to study drug discontinuation

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.250
<= 45 years	Double-blind period	Sparsentan	96	10 (10.4)	0.859 [0.390, 1.895]	0.843 [0.346, 2.054]	-1.7 [-11.6, 8.2]	0.822
		Irbesartan	99	12 (12.1)				
> 45 years	Double-blind period	Sparsentan	106	11 (10.4)	1.781 [0.684, 4.639]	1.872 [0.666, 5.265]	4.6 [-3.8, 12.9]	0.313
		Irbesartan	103	6 (5.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AT_SSIM: Incidence of TEAEs leading to study drug discontinuation during double-blind period by subgroup
Safety Set

TEAEs leading to study drug discontinuation

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.587
<= 18 years	Double-blind period	Sparsentan	9	2 (22.2)	0.556 [0.109, 2.826]	0.429 [0.040, 4.637]	-17.8 [-84.1, 48.6]	0.580
		Irbesartan	5	2 (40.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	11 (10.8)	1.069 [0.485, 2.357]	1.077 [0.445, 2.604]	0.7 [-8.5, 9.9]	1.000
		Irbesartan	109	11 (10.1)				
> 40 years	Double-blind period	Sparsentan	91	8 (8.8)	1.547 [0.526, 4.548]	1.600 [0.503, 5.094]	3.1 [-5.6, 11.8]	0.567
		Irbesartan	88	5 (5.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AT_SSIM: Incidence of TEAEs leading to study drug discontinuation during double-blind period by subgroup
Safety Set

TEAEs leading to study drug discontinuation

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.691
North America	Double-blind period	Sparsentan	35	4 (11.4)	0.876 [0.268, 2.870]	0.860 [0.223, 3.316]	-1.6 [-18.5, 15.2]	1.000
		Irbesartan	46	6 (13.0)				
Europe	Double-blind period	Sparsentan	98	12 (12.2)	1.565 [0.688, 3.557]	1.643 [0.662, 4.082]	4.4 [-4.7, 13.5]	0.358
		Irbesartan	115	9 (7.8)				
Asia Pacific	Double-blind period	Sparsentan	69	5 (7.2)	0.990 [0.250, 3.929]	0.990 [0.224, 4.376]	-0.1 [-12.1, 11.9]	1.000
		Irbesartan	41	3 (7.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AT_SSIM: Incidence of TEAEs leading to study drug discontinuation during double-blind period by subgroup
Safety Set

TEAEs leading to study drug discontinuation

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.754
< 27 kg/m**2	Double-blind period	Sparsentan	83	8 (9.6)	1.294 [0.490, 3.416]	1.326 [0.459, 3.828]	2.2 [-7.2, 11.6]	0.788
		Irbesartan	94	7 (7.4)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	13 (10.9)	1.063 [0.497, 2.271]	1.070 [0.458, 2.502]	0.6 [-8.3, 9.6]	1.000
		Irbesartan	107	11 (10.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AT_SSIM: Incidence of TEAEs leading to study drug discontinuation during double-blind period by subgroup
Safety Set

TEAEs leading to study drug discontinuation

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.216
eGFR Low and UP High	Double-blind period	Sparsentan	71	9 (12.7)	0.853 [0.376, 1.933]	0.831 [0.322, 2.146]	-2.2 [-14.8, 10.4]	0.811
		Irbesartan	74	11 (14.9)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	7 (12.7)	7.000 [0.891, 55.014]	7.875 [0.935, 66.337]	10.9 [-0.4, 22.2]	0.060
		Irbesartan	55	1 (1.8)				
eGFR High and UP High	Double-blind period	Sparsentan	37	3 (8.1)	0.584 [0.150, 2.265]	0.547 [0.121, 2.481]	-5.8 [-22.8, 11.3]	0.479
		Irbesartan	36	5 (13.9)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	2 (5.1)	1.897 [0.180, 20.054]	1.946 [0.169, 22.413]	2.4 [-8.9, 13.7]	1.000
		Irbesartan	37	1 (2.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AT_SSIM: Incidence of TEAEs leading to study drug discontinuation during double-blind period by subgroup
Safety Set

TEAEs leading to study drug discontinuation

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.749
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	16 (12.6)	1.354 [0.668, 2.747]	1.405 [0.636, 3.104]	3.3 [-5.1, 11.7]	0.429
		Irbesartan	129	12 (9.3)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2)	0.784 [0.224, 2.744]	0.764 [0.192, 3.037]	-2.3 [-15.9, 11.4]	0.740
		Irbesartan	48	5 (10.4)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8)	0.962 [0.064, 14.551]	0.960 [0.057, 16.232]	-0.2 [-14.7, 14.4]	1.000
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AT_SSIM: Incidence of TEAEs leading to study drug discontinuation during double-blind period by subgroup
Safety Set

TEAEs leading to study drug discontinuation

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.774
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	9 (11.0)	1.098 [0.446, 2.703]	1.110 [0.406, 3.036]	1.0 [-9.7, 11.6]	1.000
		Irbesartan	80	8 (10.0)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	7 (15.6)	1.906 [0.597, 6.078]	2.072 [0.564, 7.621]	7.4 [-7.8, 22.6]	0.342
		Irbesartan	49	4 (8.2)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2)	0.784 [0.224, 2.744]	0.764 [0.192, 3.037]	-2.3 [-15.9, 11.4]	0.740
		Irbesartan	48	5 (10.4)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8)	0.962 [0.064, 14.551]	0.960 [0.057, 16.232]	-0.2 [-14.7, 14.4]	1.000
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AT_SSIM: Incidence of TEAEs leading to study drug discontinuation during double-blind period by subgroup
Safety Set

TEAEs leading to study drug discontinuation

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.576
<= 1.75 g/day	Double-blind period	Sparsentan	98	8 (8.2)	1.518 [0.515, 4.474]	1.564 [0.493, 4.967]	2.8 [-5.4, 10.9]	0.569
		Irbesartan	93	5 (5.4)				
> 1.75 g/day	Double-blind period	Sparsentan	104	13 (12.5)	1.048 [0.510, 2.154]	1.055 [0.464, 2.396]	0.6 [-9.2, 10.3]	1.000
		Irbesartan	109	13 (11.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AT_SSIM: Incidence of TEAEs leading to study drug discontinuation during double-blind period by subgroup
Safety Set

TEAEs leading to study drug discontinuation

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.824
Yes	Double-blind period	Sparsentan	90	10 (11.1)	1.086 [0.464, 2.545]	1.097 [0.423, 2.845]	0.9 [-9.3, 11.1]	1.000
		Irbesartan	88	9 (10.2)				
No	Double-blind period	Sparsentan	112	11 (9.8)	1.244 [0.536, 2.886]	1.271 [0.505, 3.196]	1.9 [-6.4, 10.2]	0.646
		Irbesartan	114	9 (7.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AT_SSIM: Incidence of TEAEs leading to study drug discontinuation during double-blind period by subgroup
Safety Set

TEAEs leading to study drug discontinuation

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.347
<= 5 years	Double-blind period	Sparsentan	113	12 (10.6)	1.499 [0.656, 3.424]	1.558 [0.631, 3.848]	3.5 [-4.5, 11.6]	0.367
		Irbesartan	127	9 (7.1)				
> 5 years	Double-blind period	Sparsentan	89	9 (10.1)	0.843 [0.353, 2.014]	0.825 [0.310, 2.198]	-1.9 [-12.8, 9.0]	0.804
		Irbesartan	75	9 (12.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AT_SSIM: Incidence of TEAEs leading to study drug discontinuation during double-blind period by subgroup
Safety Set

TEAEs leading to study drug discontinuation

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.582
Yes	Double-blind period	Sparsentan	155	16 (10.3)	1.278 [0.636, 2.569]	1.310 [0.608, 2.823]	2.2 [-4.8, 9.3]	0.561
		Irbesartan	161	13 (8.1)				
No	Double-blind period	Sparsentan	47	5 (10.6)	0.872 [0.272, 2.801]	0.857 [0.230, 3.199]	-1.6 [-17.2, 14.1]	1.000
		Irbesartan	41	5 (12.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AD_SSIM: Incidence of fatal TEAEs during double-blind period by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AA_SSIM: Incidence of non-disease related TEAEs during double-blind period by subgroup
Safety Set

Non-disease related TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.853
Male	Double-blind period	Sparsentan	139	128 (92.1)	1.071 [0.986, 1.162]	1.892 [0.871, 4.112]	6.1 [-1.9, 14.0]	0.128
		Irbesartan	143	123 (86.0)				
Female	Double-blind period	Sparsentan	63	58 (92.1)	1.086 [0.954, 1.238]	2.088 [0.657, 6.639]	7.3 [-5.7, 20.3]	0.260
		Irbesartan	59	50 (84.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AA_SSIM: Incidence of non-disease related TEAEs during double-blind period by subgroup
Safety Set

Non-disease related TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.814
<= 45 years	Double-blind period	Sparsentan	96	90 (93.8)	1.067 [0.975, 1.167]	2.069 [0.744, 5.757]	5.9 [-3.2, 14.9]	0.216
		Irbesartan	99	87 (87.9)				
> 45 years	Double-blind period	Sparsentan	106	96 (90.6)	1.085 [0.976, 1.205]	1.898 [0.825, 4.367]	7.1 [-3.0, 17.1]	0.151
		Irbesartan	103	86 (83.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AA_SSIM: Incidence of non-disease related TEAEs during double-blind period by subgroup
Safety Set

Non-disease related TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.842
<= 18 years	Double-blind period	Sparsentan	9	9 (100.0)	1.036 + [0.783, 1.371]	1.727 + [0.030, 99.953]	0.0 [NE, NE]	NE
		Irbesartan	5	5 (100.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	95 (93.1)	1.057 [0.970, 1.153]	1.838 [0.703, 4.808]	5.1 [-3.7, 13.8]	0.245
		Irbesartan	109	96 (88.1)				
> 40 years	Double-blind period	Sparsentan	91	82 (90.1)	1.101 [0.977, 1.241]	2.025 [0.843, 4.861]	8.3 [-3.0, 19.5]	0.133
		Irbesartan	88	72 (81.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AA_SSIM: Incidence of non-disease related TEAEs during double-blind period by subgroup
Safety Set

Non-disease related TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.718
North America	Double-blind period	Sparsentan	35	32 (91.4)	1.026 [0.889, 1.184]	1.301 [0.289, 5.854]	2.3 [-13.1, 17.7]	1.000
		Irbesartan	46	41 (89.1)				
Europe	Double-blind period	Sparsentan	98	90 (91.8)	1.100 [0.995, 1.216]	2.227 [0.928, 5.340]	8.4 [-1.3, 18.0]	0.097
		Irbesartan	115	96 (83.5)				
Asia Pacific	Double-blind period	Sparsentan	69	64 (92.8)	1.056 [0.926, 1.205]	1.778 [0.482, 6.557]	4.9 [-8.7, 18.6]	0.496
		Irbesartan	41	36 (87.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AA_SSIM: Incidence of non-disease related TEAEs during double-blind period by subgroup
Safety Set

Non-disease related TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.535
< 27 kg/m**2	Double-blind period	Sparsentan	83	75 (90.4)	1.049 [0.942, 1.167]	1.505 [0.591, 3.833]	4.2 [-6.4, 14.8]	0.487
		Irbesartan	94	81 (86.2)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	111 (93.3)	1.097 [0.999, 1.204]	2.440 [0.999, 5.957]	8.2 [-0.8, 17.2]	0.053
		Irbesartan	107	91 (85.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AA_SSIM: Incidence of non-disease related TEAEs during double-blind period by subgroup
Safety Set

Non-disease related TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.389
eGFR Low and UP High	Double-blind period	Sparsentan	71	67 (94.4)	1.108 [0.992, 1.238]	2.925 [0.885, 9.661]	9.2 [-1.9, 20.3]	0.100
		Irbesartan	74	63 (85.1)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	48 (87.3)	0.980 [0.854, 1.123]	0.840 [0.263, 2.681]	-1.8 [-15.7, 12.1]	1.000
		Irbesartan	55	49 (89.1)				
eGFR High and UP High	Double-blind period	Sparsentan	37	35 (94.6)	1.174 [0.983, 1.403]	4.224 [0.814, 21.923]	14.0 [-3.5, 31.6]	0.085
		Irbesartan	36	29 (80.6)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	36 (92.3)	1.067 [0.913, 1.248]	1.875 [0.415, 8.475]	5.8 [-10.6, 22.3]	0.475
		Irbesartan	37	32 (86.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AA_SSIM: Incidence of non-disease related TEAEs during double-blind period by subgroup
Safety Set

Non-disease related TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.486
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	117 (92.1)	1.071 [0.982, 1.167]	1.897 [0.839, 4.288]	6.1 [-2.3, 14.5]	0.160
		Irbesartan	129	111 (86.0)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	45 (91.8)	1.025 [0.902, 1.165]	1.308 [0.329, 5.198]	2.3 [-11.4, 15.9]	0.740
		Irbesartan	48	43 (89.6)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	24 (92.3)	1.215 [0.949, 1.554]	3.789 [0.686, 20.946]	16.3 [-7.2, 39.9]	0.140
		Irbesartan	25	19 (76.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AA_SSIM: Incidence of non-disease related TEAEs during double-blind period by subgroup
Safety Set

Non-disease related TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.577
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	74 (90.2)	1.046 [0.935, 1.171]	1.475 [0.560, 3.882]	4.0 [-7.2, 15.1]	0.472
		Irbesartan	80	69 (86.3)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	43 (95.6)	1.115 [0.978, 1.270]	3.583 [0.704, 18.252]	9.8 [-3.8, 23.5]	0.162
		Irbesartan	49	42 (85.7)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	45 (91.8)	1.025 [0.902, 1.165]	1.308 [0.329, 5.198]	2.3 [-11.4, 15.9]	0.740
		Irbesartan	48	43 (89.6)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	24 (92.3)	1.215 [0.949, 1.554]	3.789 [0.686, 20.946]	16.3 [-7.2, 39.9]	0.140
		Irbesartan	25	19 (76.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AA_SSIM: Incidence of non-disease related TEAEs during double-blind period by subgroup
Safety Set

Non-disease related TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.644
<= 1.75 g/day	Double-blind period	Sparsentan	98	88 (89.8)	1.057 [0.948, 1.178]	1.559 [0.656, 3.709]	4.8 [-5.6, 15.3]	0.384
		Irbesartan	93	79 (84.9)				
> 1.75 g/day	Double-blind period	Sparsentan	104	98 (94.2)	1.093 [1.000, 1.194]	2.606 [0.970, 7.001]	8.0 [-0.8, 16.8]	0.066
		Irbesartan	109	94 (86.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AA_SSIM: Incidence of non-disease related TEAEs during double-blind period by subgroup
Safety Set

Non-disease related TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.457	
Yes	Double-blind period	Sparsentan	90	80 (88.9)	1.043 [0.931, 1.168]	1.387 [0.574, 3.352]	3.7 [-7.3, 14.6]	0.509	
		Irbesartan	88	75 (85.2)					
No	Double-blind period	Sparsentan	112	106 (94.6)	1.101 [1.010, 1.200]	2.884 [1.085, 7.667]	8.7 [0.2, 17.2]	0.042	*
		Irbesartan	114	98 (86.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AA_SSIM: Incidence of non-disease related TEAEs during double-blind period by subgroup
Safety Set

Non-disease related TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.894
<= 5 years	Double-blind period	Sparsentan	113	105 (92.9)	1.073 [0.985, 1.168]	2.028 [0.840, 4.899]	6.3 [-2.1, 14.7]	0.139
		Irbesartan	127	110 (86.6)				
> 5 years	Double-blind period	Sparsentan	89	81 (91.0)	1.083 [0.962, 1.220]	1.929 [0.743, 5.003]	7.0 [-4.4, 18.4]	0.231
		Irbesartan	75	63 (84.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AA_SSIM: Incidence of non-disease related TEAEs during double-blind period by subgroup
Safety Set

Non-disease related TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.076	
Yes	Double-blind period	Sparsentan	155	144 (92.9)	1.108 [1.022, 1.201]	2.521 [1.199, 5.300]	9.1 [1.4, 16.7]	0.014	*
		Irbesartan	161	135 (83.9)					
No	Double-blind period	Sparsentan	47	42 (89.4)	0.964 [0.846, 1.099]	0.663 [0.148, 2.963]	-3.3 [-17.5, 10.8]	0.719	
		Irbesartan	41	38 (92.7)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAN_SSIM: Incidence of non-disease related non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.982
Male	Double-blind period	Sparsentan	139	128 (92.1)	1.088 [0.999, 1.185]	2.116 [0.984, 4.548]	7.5 [-0.7, 15.6]	0.064
		Irbesartan	143	121 (84.6)				
Female	Double-blind period	Sparsentan	63	58 (92.1)	1.086 [0.954, 1.238]	2.088 [0.657, 6.639]	7.3 [-5.7, 20.3]	0.260
		Irbesartan	59	50 (84.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAN_SSIM: Incidence of non-disease related non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.817
<= 45 years	Double-blind period	Sparsentan	96	90 (93.8)	1.079 [0.984, 1.184]	2.267 [0.825, 6.235]	6.9 [-2.4, 16.1]	0.147
		Irbesartan	99	86 (86.9)				
> 45 years	Double-blind period	Sparsentan	106	96 (90.6)	1.097 [0.985, 1.223]	2.033 [0.890, 4.645]	8.0 [-2.1, 18.2]	0.106
		Irbesartan	103	85 (82.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAN_SSIM: Incidence of non-disease related non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.810
<= 18 years	Double-blind period	Sparsentan	9	9 (100.0)	1.036 + [0.783, 1.371]	1.727 + [0.030, 99.953]	0.0 [NE, NE]	NE
		Irbesartan	5	5 (100.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	95 (93.1)	1.069 [0.977, 1.168]	2.000 [0.773, 5.176]	6.0 [-2.9, 14.9]	0.172
		Irbesartan	109	95 (87.2)				
> 40 years	Double-blind period	Sparsentan	91	82 (90.1)	1.117 [0.988, 1.263]	2.182 [0.916, 5.198]	9.4 [-2.0, 20.8]	0.091
		Irbesartan	88	71 (80.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAN_SSIM: Incidence of non-disease related non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.562	
North America	Double-blind period	Sparsentan	35	32 (91.4)	1.026 [0.889, 1.184]	1.301 [0.289, 5.854]	2.3 [-13.1, 17.7]	1.000	
		Irbesartan	46	41 (89.1)					
Europe	Double-blind period	Sparsentan	98	90 (91.8)	1.124 [1.012, 1.247]	2.513 [1.059, 5.964]	10.1 [0.3, 19.9]	0.044	*
		Irbesartan	115	94 (81.7)					
Asia Pacific	Double-blind period	Sparsentan	69	64 (92.8)	1.056 [0.926, 1.205]	1.778 [0.482, 6.557]	4.9 [-8.7, 18.6]	0.496	
		Irbesartan	41	36 (87.8)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAN_SSIM: Incidence of non-disease related non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.558	
< 27 kg/m**2	Double-blind period	Sparsentan	83	75 (90.4)	1.062 [0.951, 1.185]	1.641 [0.651, 4.133]	5.3 [-5.5, 16.0]	0.364	
		Irbesartan	94	80 (85.1)					
>= 27 kg/m**2	Double-blind period	Sparsentan	119	111 (93.3)	1.109 [1.008, 1.220]	2.621 [1.082, 6.351]	9.2 [0.0, 18.3]	0.034	*
		Irbesartan	107	90 (84.1)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAN_SSIM: Incidence of non-disease related non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.537
eGFR Low and UP High	Double-blind period	Sparsentan	71	67 (94.4)	1.108 [0.992, 1.238]	2.925 [0.885, 9.661]	9.2 [-1.9, 20.3]	0.100
		Irbesartan	74	63 (85.1)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	48 (87.3)	1.000 [0.867, 1.153]	1.000 [0.326, 3.069]	0.0 [-14.3, 14.3]	1.000
		Irbesartan	55	48 (87.3)				
eGFR High and UP High	Double-blind period	Sparsentan	37	35 (94.6)	1.174 [0.983, 1.403]	4.224 [0.814, 21.923]	14.0 [-3.5, 31.6]	0.085
		Irbesartan	36	29 (80.6)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	36 (92.3)	1.102 [0.931, 1.304]	2.323 [0.536, 10.069]	8.5 [-8.6, 25.7]	0.303
		Irbesartan	37	31 (83.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAN_SSIM: Incidence of non-disease related non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.595
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	117 (92.1)	1.080 [0.989, 1.180]	2.021 [0.900, 4.537]	6.9 [-1.6, 15.3]	0.114
		Irbesartan	129	110 (85.3)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	45 (91.8)	1.050 [0.916, 1.202]	1.607 [0.424, 6.096]	4.3 [-9.8, 18.5]	0.524
		Irbesartan	48	42 (87.5)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	24 (92.3)	1.215 [0.949, 1.554]	3.789 [0.686, 20.946]	16.3 [-7.2, 39.9]	0.140
		Irbesartan	25	19 (76.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAN_SSIM: Incidence of non-disease related non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.582
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	74 (90.2)	1.046 [0.935, 1.171]	1.475 [0.560, 3.882]	4.0 [-7.2, 15.1]	0.472
		Irbesartan	80	69 (86.3)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	43 (95.6)	1.142 [0.994, 1.312]	4.195 [0.841, 20.934]	11.9 [-2.2, 26.0]	0.094
		Irbesartan	49	41 (83.7)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	45 (91.8)	1.050 [0.916, 1.202]	1.607 [0.424, 6.096]	4.3 [-9.8, 18.5]	0.524
		Irbesartan	48	42 (87.5)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	24 (92.3)	1.215 [0.949, 1.554]	3.789 [0.686, 20.946]	16.3 [-7.2, 39.9]	0.140
		Irbesartan	25	19 (76.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAN_SSIM: Incidence of non-disease related non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.919
<= 1.75 g/day	Double-blind period	Sparsentan	98	88 (89.8)	1.085 [0.968, 1.216]	1.829 [0.784, 4.266]	7.0 [-3.8, 17.8]	0.206
		Irbesartan	93	77 (82.8)				
> 1.75 g/day	Double-blind period	Sparsentan	104	98 (94.2)	1.093 [1.000, 1.194]	2.606 [0.970, 7.001]	8.0 [-0.8, 16.8]	0.066
		Irbesartan	109	94 (86.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAN_SSIM: Incidence of non-disease related non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.495	
Yes	Double-blind period	Sparsentan	90	80 (88.9)	1.057 [0.941, 1.188]	1.514 [0.634, 3.616]	4.8 [-6.4, 15.9]	0.386	
		Irbesartan	88	74 (84.1)					
No	Double-blind period	Sparsentan	112	106 (94.6)	1.112 [1.018, 1.215]	3.096 [1.173, 8.173]	9.6 [0.9, 18.2]	0.026	*
		Irbesartan	114	97 (85.1)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAN_SSIM: Incidence of non-disease related non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.827
<= 5 years	Double-blind period	Sparsentan	113	105 (92.9)	1.083 [0.992, 1.181]	2.167 [0.904, 5.199]	7.1 [-1.4, 15.6]	0.097
		Irbesartan	127	109 (85.8)				
> 5 years	Double-blind period	Sparsentan	89	81 (91.0)	1.101 [0.974, 1.244]	2.123 [0.829, 5.439]	8.3 [-3.3, 20.0]	0.159
		Irbesartan	75	62 (82.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAN_SSIM: Incidence of non-disease related non-severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related non-severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.052	
Yes	Double-blind period	Sparsentan	155	144 (92.9)	1.125 [1.035, 1.222]	2.756 [1.320, 5.754]	10.3 [2.5, 18.0]	0.006	*
		Irbesartan	161	133 (82.6)					
No	Double-blind period	Sparsentan	47	42 (89.4)	0.964 [0.846, 1.099]	0.663 [0.148, 2.963]	-3.3 [-17.5, 10.8]	0.719	
		Irbesartan	41	38 (92.7)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAC_SSIM: Incidence of non-disease related severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.178
Male	Double-blind period	Sparsentan	139	16 (11.5)	1.097 [0.565, 2.133]	1.110 [0.526, 2.342]	1.0 [-7.0, 9.0]	0.850
		Irbesartan	143	15 (10.5)				
Female	Double-blind period	Sparsentan	63	3 (4.8)	0.401 [0.109, 1.480]	0.371 [0.091, 1.510]	-7.1 [-18.5, 4.3]	0.195
		Irbesartan	59	7 (11.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAC_SSIM: Incidence of non-disease related severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.744
<= 45 years	Double-blind period	Sparsentan	96	11 (11.5)	0.945 [0.438, 2.039]	0.938 [0.393, 2.242]	-0.7 [-10.7, 9.4]	1.000
		Irbesartan	99	12 (12.1)				
> 45 years	Double-blind period	Sparsentan	106	8 (7.5)	0.777 [0.319, 1.892]	0.759 [0.287, 2.007]	-2.2 [-10.7, 6.4]	0.628
		Irbesartan	103	10 (9.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAC_SSIM: Incidence of non-disease related severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.615
<= 18 years	Double-blind period	Sparsentan	9	0 (0.0)	0.200 + [0.010, 4.166]	0.158 + [0.005, 4.691]	-20.0 [-70.6, 30.6]	0.357
		Irbesartan	5	1 (20.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	10 (9.8)	0.971 [0.431, 2.190]	0.968 [0.393, 2.388]	-0.3 [-9.3, 8.7]	1.000
		Irbesartan	109	11 (10.1)				
> 40 years	Double-blind period	Sparsentan	91	9 (9.9)	0.870 [0.371, 2.039]	0.856 [0.330, 2.219]	-1.5 [-11.6, 8.7]	0.811
		Irbesartan	88	10 (11.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAC_SSIM: Incidence of non-disease related severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.663
North America	Double-blind period	Sparsentan	35	6 (17.1)	1.127 [0.415, 3.056]	1.153 [0.350, 3.795]	1.9 [-16.8, 20.7]	1.000
		Irbesartan	46	7 (15.2)				
Europe	Double-blind period	Sparsentan	98	8 (8.2)	0.722 [0.312, 1.670]	0.697 [0.276, 1.759]	-3.1 [-12.0, 5.7]	0.496
		Irbesartan	115	13 (11.3)				
Asia Pacific	Double-blind period	Sparsentan	69	5 (7.2)	1.486 [0.302, 7.311]	1.523 [0.282, 8.235]	2.4 [-8.6, 13.3]	1.000
		Irbesartan	41	2 (4.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAC_SSIM: Incidence of non-disease related severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.836
< 27 kg/m**2	Double-blind period	Sparsentan	83	7 (8.4)	0.793 [0.316, 1.989]	0.774 [0.281, 2.134]	-2.2 [-12.0, 7.6]	0.799
		Irbesartan	94	10 (10.6)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	12 (10.1)	0.899 [0.422, 1.916]	0.888 [0.381, 2.070]	-1.1 [-10.1, 7.8]	0.831
		Irbesartan	107	12 (11.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAC_SSIM: Incidence of non-disease related severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.497
eGFR Low and UP High	Double-blind period	Sparsentan	71	9 (12.7)	1.173 [0.479, 2.870]	1.198 [0.435, 3.300]	1.9 [-10.0, 13.7]	0.800
		Irbesartan	74	8 (10.8)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	3 (5.5)	0.375 [0.105, 1.340]	0.339 [0.085, 1.353]	-9.1 [-22.0, 3.8]	0.202
		Irbesartan	55	8 (14.5)				
eGFR High and UP High	Double-blind period	Sparsentan	37	3 (8.1)	0.973 [0.210, 4.507]	0.971 [0.183, 5.158]	-0.2 [-15.6, 15.1]	1.000
		Irbesartan	36	3 (8.3)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	4 (10.3)	1.265 [0.303, 5.274]	1.295 [0.270, 6.223]	2.1 [-13.4, 17.7]	1.000
		Irbesartan	37	3 (8.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAC_SSIM: Incidence of non-disease related severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.574
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	12 (9.4)	0.717 [0.357, 1.440]	0.687 [0.314, 1.505]	-3.7 [-12.3, 4.8]	0.431
		Irbesartan	129	17 (13.2)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	5 (10.2)	1.633 [0.413, 6.457]	1.705 [0.384, 7.567]	4.0 [-9.0, 16.9]	0.715
		Irbesartan	48	3 (6.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	2 (7.7)	0.962 [0.147, 6.311]	0.958 [0.124, 7.383]	-0.3 [-19.0, 18.4]	1.000
		Irbesartan	25	2 (8.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAC_SSIM: Incidence of non-disease related severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.754
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	8 (9.8)	0.780 [0.325, 1.876]	0.757 [0.282, 2.027]	-2.7 [-13.7, 8.2]	0.624
		Irbesartan	80	10 (12.5)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	4 (8.9)	0.622 [0.195, 1.985]	0.585 [0.159, 2.151]	-5.4 [-20.4, 9.6]	0.528
		Irbesartan	49	7 (14.3)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	5 (10.2)	1.633 [0.413, 6.457]	1.705 [0.384, 7.567]	4.0 [-9.0, 16.9]	0.715
		Irbesartan	48	3 (6.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	2 (7.7)	0.962 [0.147, 6.311]	0.958 [0.124, 7.383]	-0.3 [-19.0, 18.4]	1.000
		Irbesartan	25	2 (8.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAC_SSIM: Incidence of non-disease related severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.558
<= 1.75 g/day	Double-blind period	Sparsentan	98	9 (9.2)	1.068 [0.430, 2.650]	1.074 [0.396, 2.914]	0.6 [-8.5, 9.7]	1.000
		Irbesartan	93	8 (8.6)				
> 1.75 g/day	Double-blind period	Sparsentan	104	10 (9.6)	0.749 [0.348, 1.610]	0.722 [0.305, 1.706]	-3.2 [-12.6, 6.2]	0.520
		Irbesartan	109	14 (12.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAC_SSIM: Incidence of non-disease related severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.806
Yes	Double-blind period	Sparsentan	90	9 (10.0)	0.800 [0.349, 1.836]	0.778 [0.305, 1.980]	-2.5 [-12.9, 7.9]	0.641
		Irbesartan	88	11 (12.5)				
No	Double-blind period	Sparsentan	112	10 (8.9)	0.925 [0.409, 2.092]	0.918 [0.374, 2.256]	-0.7 [-9.2, 7.7]	1.000
		Irbesartan	114	11 (9.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAC_SSIM: Incidence of non-disease related severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.772
<= 5 years	Double-blind period	Sparsentan	113	15 (13.3)	0.887 [0.474, 1.662]	0.870 [0.419, 1.806]	-1.7 [-11.3, 8.0]	0.853
		Irbesartan	127	19 (15.0)				
> 5 years	Double-blind period	Sparsentan	89	4 (4.5)	1.124 [0.260, 4.863]	1.129 [0.245, 5.213]	0.5 [-6.9, 7.9]	1.000
		Irbesartan	75	3 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAC_SSIM: Incidence of non-disease related severe TEAEs during double-blind period by subgroup
Safety Set

Non-disease related severe TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.619
Yes	Double-blind period	Sparsentan	155	17 (11.0)	0.929 [0.502, 1.721]	0.921 [0.459, 1.845]	-0.8 [-8.5, 6.8]	0.861
		Irbesartan	161	19 (11.8)				
No	Double-blind period	Sparsentan	47	2 (4.3)	0.582 [0.102, 3.312]	0.563 [0.089, 3.547]	-3.1 [-15.2, 9.1]	0.661
		Irbesartan	41	3 (7.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAS_SSIM: Incidence of non-disease related serious TEAEs during double-blind period by subgroup
Safety Set

Non-disease related serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.848
Male	Double-blind period	Sparsentan	139	43 (30.9)	1.053 [0.738, 1.503]	1.077 [0.648, 1.792]	1.6 [-9.9, 13.0]	0.796
		Irbesartan	143	42 (29.4)				
Female	Double-blind period	Sparsentan	63	25 (39.7)	1.115 [0.705, 1.764]	1.190 [0.571, 2.480]	4.1 [-14.7, 22.9]	0.710
		Irbesartan	59	21 (35.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAS_SSIM: Incidence of non-disease related serious TEAEs during double-blind period by subgroup
Safety Set

Non-disease related serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.559
<= 45 years	Double-blind period	Sparsentan	96	35 (36.5)	1.003 [0.692, 1.453]	1.004 [0.560, 1.800]	0.1 [-14.4, 14.6]	1.000
		Irbesartan	99	36 (36.4)				
> 45 years	Double-blind period	Sparsentan	106	33 (31.1)	1.188 [0.772, 1.826]	1.272 [0.697, 2.322]	4.9 [-8.3, 18.1]	0.449
		Irbesartan	103	27 (26.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAS_SSIM: Incidence of non-disease related serious TEAEs during double-blind period by subgroup
Safety Set

Non-disease related serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.190
<= 18 years	Double-blind period	Sparsentan	9	3 (33.3)	0.417 [0.150, 1.159]	0.125 [0.009, 1.671]	-46.7 [-100.0, 15.6]	0.266
		Irbesartan	5	4 (80.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	31 (30.4)	1.142 [0.744, 1.753]	1.204 [0.662, 2.192]	3.8 [-9.3, 16.9]	0.546
		Irbesartan	109	29 (26.6)				
> 40 years	Double-blind period	Sparsentan	91	34 (37.4)	1.096 [0.739, 1.625]	1.153 [0.625, 2.127]	3.3 [-11.9, 18.4]	0.755
		Irbesartan	88	30 (34.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAS_SSIM: Incidence of non-disease related serious TEAEs during double-blind period by subgroup
Safety Set

Non-disease related serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.715
North America	Double-blind period	Sparsentan	35	14 (40.0)	1.150 [0.652, 2.027]	1.250 [0.504, 3.101]	5.2 [-18.6, 29.0]	0.650
		Irbesartan	46	16 (34.8)				
Europe	Double-blind period	Sparsentan	98	33 (33.7)	1.173 [0.786, 1.751]	1.262 [0.705, 2.258]	5.0 [-8.5, 18.4]	0.460
		Irbesartan	115	33 (28.7)				
Asia Pacific	Double-blind period	Sparsentan	69	21 (30.4)	0.891 [0.512, 1.552]	0.844 [0.370, 1.924]	-3.7 [-23.8, 16.4]	0.833
		Irbesartan	41	14 (34.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAS_SSIM: Incidence of non-disease related serious TEAEs during double-blind period by subgroup
Safety Set

Non-disease related serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.586
< 27 kg/m**2	Double-blind period	Sparsentan	83	28 (33.7)	0.991 [0.656, 1.497]	0.986 [0.529, 1.840]	-0.3 [-15.4, 14.8]	1.000
		Irbesartan	94	32 (34.0)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	40 (33.6)	1.160 [0.786, 1.713]	1.241 [0.706, 2.184]	4.6 [-8.3, 17.6]	0.476
		Irbesartan	107	31 (29.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAS_SSIM: Incidence of non-disease related serious TEAEs during double-blind period by subgroup
Safety Set

Non-disease related serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.825
eGFR Low and UP High	Double-blind period	Sparsentan	71	26 (36.6)	1.290 [0.803, 2.073]	1.458 [0.725, 2.933]	8.2 [-8.3, 24.8]	0.375
		Irbesartan	74	21 (28.4)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	16 (29.1)	1.000 [0.558, 1.792]	1.000 [0.439, 2.277]	0.0 [-18.8, 18.8]	1.000
		Irbesartan	55	16 (29.1)				
eGFR High and UP High	Double-blind period	Sparsentan	37	11 (29.7)	0.973 [0.484, 1.956]	0.962 [0.354, 2.614]	-0.8 [-24.6, 23.0]	1.000
		Irbesartan	36	11 (30.6)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	15 (38.5)	0.949 [0.544, 1.655]	0.917 [0.365, 2.301]	-2.1 [-26.7, 22.5]	1.000
		Irbesartan	37	15 (40.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAS_SSIM: Incidence of non-disease related serious TEAEs during double-blind period by subgroup
Safety Set

Non-disease related serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.876
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	43 (33.9)	1.092 [0.766, 1.556]	1.139 [0.675, 1.923]	2.9 [-9.4, 15.1]	0.689
		Irbesartan	129	40 (31.0)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	17 (34.7)	0.980 [0.570, 1.684]	0.969 [0.421, 2.231]	-0.7 [-21.8, 20.3]	1.000
		Irbesartan	48	17 (35.4)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	8 (30.8)	1.282 [0.519, 3.169]	1.407 [0.408, 4.860]	6.8 [-21.5, 35.1]	0.755
		Irbesartan	25	6 (24.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAS_SSIM: Incidence of non-disease related serious TEAEs during double-blind period by subgroup
Safety Set

Non-disease related serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.675
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	28 (34.1)	1.301 [0.809, 2.091]	1.457 [0.741, 2.863]	7.9 [-7.4, 23.2]	0.307
		Irbesartan	80	21 (26.3)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	15 (33.3)	0.860 [0.500, 1.479]	0.789 [0.339, 1.838]	-5.4 [-27.0, 16.1]	0.669
		Irbesartan	49	19 (38.8)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	17 (34.7)	0.980 [0.570, 1.684]	0.969 [0.421, 2.231]	-0.7 [-21.8, 20.3]	1.000
		Irbesartan	48	17 (35.4)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	8 (30.8)	1.282 [0.519, 3.169]	1.407 [0.408, 4.860]	6.8 [-21.5, 35.1]	0.755
		Irbesartan	25	6 (24.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAS_SSIM: Incidence of non-disease related serious TEAEs during double-blind period by subgroup
Safety Set

Non-disease related serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.976
<= 1.75 g/day	Double-blind period	Sparsentan	98	35 (35.7)	1.071 [0.724, 1.585]	1.111 [0.612, 2.019]	2.4 [-12.1, 16.9]	0.762
		Irbesartan	93	31 (33.3)				
> 1.75 g/day	Double-blind period	Sparsentan	104	33 (31.7)	1.081 [0.721, 1.621]	1.118 [0.624, 2.004]	2.4 [-10.9, 15.7]	0.767
		Irbesartan	109	32 (29.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAS_SSIM: Incidence of non-disease related serious TEAEs during double-blind period by subgroup
Safety Set

Non-disease related serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.320
Yes	Double-blind period	Sparsentan	90	25 (27.8)	0.905 [0.573, 1.431]	0.869 [0.455, 1.659]	-2.9 [-17.4, 11.6]	0.742
		Irbesartan	88	27 (30.7)				
No	Double-blind period	Sparsentan	112	43 (38.4)	1.216 [0.850, 1.739]	1.350 [0.780, 2.337]	6.8 [-6.5, 20.1]	0.329
		Irbesartan	114	36 (31.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAS_SSIM: Incidence of non-disease related serious TEAEs during double-blind period by subgroup
Safety Set

Non-disease related serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.032	#
<= 5 years	Double-blind period	Sparsentan	113	37 (32.7)	0.866 [0.613, 1.224]	0.801 [0.471, 1.364]	-5.1 [-18.0, 7.9]	0.421	
		Irbesartan	127	48 (37.8)					
> 5 years	Double-blind period	Sparsentan	89	31 (34.8)	1.742 [1.021, 2.972]	2.138 [1.047, 4.367]	14.8 [0.2, 29.5]	0.038	*
		Irbesartan	75	15 (20.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AAS_SSIM: Incidence of non-disease related serious TEAEs during double-blind period by subgroup
Safety Set

Non-disease related serious TEAEs

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.546
Yes	Double-blind period	Sparsentan	155	53 (34.2)	1.039 [0.762, 1.417]	1.059 [0.664, 1.689]	1.3 [-9.8, 12.3]	0.813
		Irbesartan	161	53 (32.9)				
No	Double-blind period	Sparsentan	47	15 (31.9)	1.309 [0.662, 2.587]	1.453 [0.567, 3.721]	7.5 [-13.5, 28.5]	0.484
		Irbesartan	41	10 (24.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Dizziness	Sex	Double-blind period	Sparsentan					Interaction test:	0.558	
	Male	Double-blind period	Sparsentan	139	15 (10.8)	1.929 [0.845, 4.405]	2.041 [0.837, 4.981]	5.2 [-1.9, 12.3]	0.130	
			Irbesartan	143	8 (5.6)					
	Female	Double-blind period	Sparsentan	63	15 (23.8)	2.810 [1.089, 7.249]	3.375 [1.141, 9.980]	15.3 [1.0, 29.7]	0.028	*
			Irbesartan	59	5 (8.5)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Dizziness	Age	Double-blind period	Sparsentan					Interaction test:	0.720	
	<= 45 years	Double-blind period	Sparsentan	96	14 (14.6)	2.063 [0.870, 4.887]	2.244 [0.864, 5.830]	7.5 [-2.2, 17.2]	0.108	
			Irbesartan	99	7 (7.1)					
	> 45 years	Double-blind period	Sparsentan	106	16 (15.1)	2.591 [1.055, 6.362]	2.874 [1.077, 7.667]	9.3 [0.1, 18.4]	0.041	*
			Irbesartan	103	6 (5.8)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
PT: Dizziness	Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.959
	<= 18 years	Double-blind period	Sparsentan	9	1 (11.1)	1.800 + [0.086, 37.493]	1.941 + [0.066, 56.760]	11.1 [-25.0, 47.2]	1.000
			Irbesartan	5	0 (0.0)				
	> 18 to 40 years	Double-blind period	Sparsentan	102	16 (15.7)	2.137 [0.956, 4.778]	2.349 [0.959, 5.755]	8.3 [-1.2, 17.9]	0.081
			Irbesartan	109	8 (7.3)				
	> 40 years	Double-blind period	Sparsentan	91	13 (14.3)	2.514 [0.935, 6.759]	2.767 [0.943, 8.120]	8.6 [-1.2, 18.4]	0.080
			Irbesartan	88	5 (5.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
PT: Dizziness	Geographic region	Double-blind period	Sparsentan					Interaction test:	0.326
	North America	Double-blind period	Sparsentan	35	4 (11.4)	2.629 [0.510, 13.543]	2.839 [0.489, 16.475]	7.1 [-7.5, 21.7]	0.395
			Irbesartan	46	2 (4.3)				
	Europe	Double-blind period	Sparsentan	98	7 (7.1)	4.107 [0.873, 19.316]	4.346 [0.881, 21.431]	5.4 [-1.2, 12.0]	0.084
			Irbesartan	115	2 (1.7)				
	Asia Pacific	Double-blind period	Sparsentan	69	19 (27.5)	1.254 [0.628, 2.507]	1.351 [0.545, 3.353]	5.6 [-12.8, 24.0]	0.652
			Irbesartan	41	9 (22.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Dizziness	Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.964	
	< 27 kg/m**2	Double-blind period	Sparsentan	83	17 (20.5)	2.407 [1.096, 5.286]	2.769 [1.126, 6.807]	12.0 [0.5, 23.5]	0.030	*
			Irbesartan	94	8 (8.5)					
	>= 27 kg/m**2	Double-blind period	Sparsentan	119	13 (10.9)	2.338 [0.862, 6.341]	2.502 [0.861, 7.269]	6.3 [-1.5, 14.0]	0.091	
			Irbesartan	107	5 (4.7)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
PT: Dizziness	Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.650
	eGFR Low and UP High	Double-blind period	Sparsentan	71	8 (11.3)	1.390 [0.508, 3.805]	1.439 [0.473, 4.378]	3.2 [-7.9, 14.2]	0.582
			Irbesartan	74	6 (8.1)				
	eGFR Low and UP Low	Double-blind period	Sparsentan	55	10 (18.2)	2.500 [0.834, 7.493]	2.833 [0.831, 9.663]	10.9 [-3.2, 25.0]	0.151
			Irbesartan	55	4 (7.3)				
	eGFR High and UP High	Double-blind period	Sparsentan	37	4 (10.8)	3.892 [0.457, 33.169]	4.242 [0.451, 39.943]	8.0 [-6.1, 22.1]	0.358
			Irbesartan	36	1 (2.8)				
	eGFR High and UP Low	Double-blind period	Sparsentan	39	8 (20.5)	3.795 [0.861, 16.717]	4.516 [0.891, 22.892]	15.1 [-2.1, 32.4]	0.087
			Irbesartan	37	2 (5.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
PT: Dizziness	Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.608
	< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	19 (15.0)	1.930 [0.934, 3.987]	2.094 [0.932, 4.700]	7.2 [-1.3, 15.7]	0.078
			Irbesartan	129	10 (7.8)				
	60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	6 (12.2)	5.878 [0.735, 47.011]	6.558 [0.759, 56.698]	10.2 [-1.9, 22.3]	0.111
			Irbesartan	48	1 (2.1)				
	>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	5 (19.2)	2.404 [0.513, 11.271]	2.738 [0.479, 15.651]	11.2 [-11.2, 33.7]	0.419
			Irbesartan	25	2 (8.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
PT: Dizziness	Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.733
	< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	10 (12.2)	1.626 [0.620, 4.264]	1.713 [0.592, 4.958]	4.7 [-5.7, 15.1]	0.431
			Irbesartan	80	6 (7.5)				
	45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	9 (20.0)	2.450 [0.811, 7.405]	2.813 [0.800, 9.882]	11.8 [-4.3, 27.9]	0.136
			Irbesartan	49	4 (8.2)				
	60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	6 (12.2)	5.878 [0.735, 47.011]	6.558 [0.759, 56.698]	10.2 [-1.9, 22.3]	0.111
			Irbesartan	48	1 (2.1)				
	>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	5 (19.2)	2.404 [0.513, 11.271]	2.738 [0.479, 15.651]	11.2 [-11.2, 33.7]	0.419
			Irbesartan	25	2 (8.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Dizziness	Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.161	
	<= 1.75 g/day	Double-blind period	Sparsentan	98	19 (19.4)	3.606 [1.404, 9.263]	4.233 [1.510, 11.867]	14.0 [3.9, 24.1]	0.004	*
			Irbesartan	93	5 (5.4)					
	> 1.75 g/day	Double-blind period	Sparsentan	104	11 (10.6)	1.441 [0.604, 3.440]	1.493 [0.576, 3.874]	3.2 [-5.4, 11.9]	0.475	
			Irbesartan	109	8 (7.3)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Dizziness	Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.912	
	Yes	Double-blind period	Sparsentan	90	9 (10.0)	2.200 [0.703, 6.883]	2.333 [0.691, 7.877]	5.5 [-3.2, 14.2]	0.249	
			Irbesartan	88	4 (4.5)					
	No	Double-blind period	Sparsentan	112	21 (18.8)	2.375 [1.138, 4.958]	2.692 [1.174, 6.173]	10.9 [1.2, 20.5]	0.019	*
			Irbesartan	114	9 (7.9)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Dizziness	Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.972	
	<= 5 years	Double-blind period	Sparsentan	113	19 (16.8)	2.373 [1.119, 5.031]	2.650 [1.146, 6.127]	9.7 [0.7, 18.8]	0.026	*
			Irbesartan	127	9 (7.1)					
	> 5 years	Double-blind period	Sparsentan	89	11 (12.4)	2.317 [0.770, 6.978]	2.503 [0.763, 8.217]	7.0 [-2.7, 16.8]	0.174	
			Irbesartan	75	4 (5.3)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Dizziness	History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.397	
	Yes	Double-blind period	Sparsentan	155	21 (13.5)	2.727 [1.245, 5.971]	2.997 [1.285, 6.989]	8.6 [1.6, 15.6]	0.011	*
			Irbesartan	161	8 (5.0)					
	No	Double-blind period	Sparsentan	47	9 (19.1)	1.570 [0.572, 4.310]	1.705 [0.522, 5.574]	7.0 [-10.4, 24.3]	0.401	
			Irbesartan	41	5 (12.2)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Hypotension	Sex	Double-blind period	Sparsentan					Interaction test:	0.904	
	Male	Double-blind period	Sparsentan	139	13 (9.4)	3.344 [1.117, 10.005]	3.585 [1.139, 11.281]	6.6 [0.3, 12.8]	0.024	*
			Irbesartan	143	4 (2.8)					
	Female	Double-blind period	Sparsentan	63	13 (20.6)	3.044 [1.051, 8.811]	3.575 [1.094, 11.684]	13.9 [0.3, 27.4]	0.036	*
			Irbesartan	59	4 (6.8)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Hypotension	Age	Double-blind period	Sparsentan					Interaction test:	0.255	
	<= 45 years	Double-blind period	Sparsentan	96	10 (10.4)	2.063 [0.732, 5.813]	2.186 [0.719, 6.651]	5.4 [-3.1, 13.9]	0.187	
			Irbesartan	99	5 (5.1)					
	> 45 years	Double-blind period	Sparsentan	106	16 (15.1)	5.182 [1.556, 17.257]	5.926 [1.672, 21.008]	12.2 [3.7, 20.7]	0.003	*
			Irbesartan	103	3 (2.9)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Hypotension	Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.656	
	<= 18 years	Double-blind period	Sparsentan	9	2 (22.2)	3.000 + [0.171, 52.527]	3.667 + [0.145, 92.653]	22.2 [-20.5, 64.9]	0.505	
			Irbesartan	5	0 (0.0)					
	> 18 to 40 years	Double-blind period	Sparsentan	102	10 (9.8)	2.137 [0.756, 6.041]	2.261 [0.745, 6.857]	5.2 [-2.7, 13.1]	0.182	
			Irbesartan	109	5 (4.6)					
	> 40 years	Double-blind period	Sparsentan	91	14 (15.4)	4.513 [1.343, 15.164]	5.152 [1.426, 18.612]	12.0 [2.5, 21.4]	0.009	*
			Irbesartan	88	3 (3.4)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Hypotension	Geographic region	Double-blind period	Sparsentan					Interaction test:	0.814	
	North America	Double-blind period	Sparsentan	35	4 (11.4)	2.629 [0.510, 13.543]	2.839 [0.489, 16.475]	7.1 [-7.5, 21.7]	0.395	
			Irbesartan	46	2 (4.3)					
	Europe	Double-blind period	Sparsentan	98	14 (14.3)	4.107 [1.398, 12.070]	4.625 [1.469, 14.560]	10.8 [2.2, 19.4]	0.006	*
			Irbesartan	115	4 (3.5)					
	Asia Pacific	Double-blind period	Sparsentan	69	8 (11.6)	2.377 [0.530, 10.658]	2.557 [0.516, 12.676]	6.7 [-5.3, 18.7]	0.316	
			Irbesartan	41	2 (4.9)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Hypotension	Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.728	
	< 27 kg/m**2	Double-blind period	Sparsentan	83	13 (15.7)	2.945 [1.096, 7.911]	3.306 [1.125, 9.714]	10.3 [0.2, 20.5]	0.027	*
			Irbesartan	94	5 (5.3)					
	>= 27 kg/m**2	Double-blind period	Sparsentan	119	13 (10.9)	3.896 [1.141, 13.303]	4.252 [1.177, 15.356]	8.1 [0.8, 15.4]	0.020	*
			Irbesartan	107	3 (2.8)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
PT: Hypotension	Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.801
	eGFR Low and UP High	Double-blind period	Sparsentan	71	9 (12.7)	2.345 [0.756, 7.273]	2.540 [0.745, 8.660]	7.3 [-3.4, 17.9]	0.153
			Irbesartan	74	4 (5.4)				
	eGFR Low and UP Low	Double-blind period	Sparsentan	55	9 (16.4)	4.500 [1.018, 19.885]	5.185 [1.066, 25.229]	12.7 [-0.0, 25.5]	0.052
			Irbesartan	55	2 (3.6)				
	eGFR High and UP High	Double-blind period	Sparsentan	37	6 (16.2)	5.838 [0.739, 46.111]	6.774 [0.772, 59.419]	13.4 [-2.3, 29.2]	0.107
			Irbesartan	36	1 (2.8)				
	eGFR High and UP Low	Double-blind period	Sparsentan	39	2 (5.1)	1.897 [0.180, 20.054]	1.946 [0.169, 22.413]	2.4 [-8.9, 13.7]	1.000
			Irbesartan	37	1 (2.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Hypotension	Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.531	
	< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	19 (15.0)	3.217 [1.328, 7.790]	3.606 [1.390, 9.358]	10.3 [2.3, 18.3]	0.006	*
			Irbesartan	129	6 (4.7)					
	60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2)	8.820 + [0.488, 159.505]	9.593 + [0.502, 183.220]	8.2 [-1.6, 17.9]	0.117	
			Irbesartan	48	0 (0.0)					
	>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	3 (11.5)	1.442 [0.263, 7.918]	1.500 [0.229, 9.832]	3.5 [-16.6, 23.7]	1.000	
			Irbesartan	25	2 (8.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Hypotension	Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.541	
	< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	9 (11.0)	2.195 [0.704, 6.842]	2.342 [0.691, 7.941]	6.0 [-3.5, 15.5]	0.247	
			Irbesartan	80	4 (5.0)					
	45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	10 (22.2)	5.444 [1.260, 23.520]	6.714 [1.383, 32.597]	18.1 [2.7, 33.6]	0.012	*
			Irbesartan	49	2 (4.1)					
	60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2)	8.820 + [0.488, 159.505]	9.593 + [0.502, 183.220]	8.2 [-1.6, 17.9]	0.117	
			Irbesartan	48	0 (0.0)					
	>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	3 (11.5)	1.442 [0.263, 7.918]	1.500 [0.229, 9.832]	3.5 [-16.6, 23.7]	1.000	
			Irbesartan	25	2 (8.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Hypotension	Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.900	
	<= 1.75 g/day	Double-blind period	Sparsentan	98	11 (11.2)	3.480 [1.002, 12.080]	3.793 [1.023, 14.060]	8.0 [-0.3, 16.3]	0.050	*
			Irbesartan	93	3 (3.2)					
	> 1.75 g/day	Double-blind period	Sparsentan	104	15 (14.4)	3.144 [1.185, 8.343]	3.506 [1.226, 10.027]	9.8 [1.1, 18.6]	0.018	*
			Irbesartan	109	5 (4.6)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Hypotension	Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.525	
	Yes	Double-blind period	Sparsentan	90	7 (7.8)	2.281 [0.609, 8.542]	2.390 [0.598, 9.555]	4.4 [-3.5, 12.2]	0.330	
			Irbesartan	88	3 (3.4)					
	No	Double-blind period	Sparsentan	112	19 (17.0)	3.868 [1.496, 10.001]	4.454 [1.601, 12.391]	12.6 [3.8, 21.4]	0.002	*
			Irbesartan	114	5 (4.4)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Hypotension	Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.572	
	<= 5 years	Double-blind period	Sparsentan	113	14 (12.4)	3.934 [1.333, 11.605]	4.348 [1.388, 13.628]	9.2 [1.6, 16.9]	0.012	*
			Irbesartan	127	4 (3.1)					
	> 5 years	Double-blind period	Sparsentan	89	12 (13.5)	2.528 [0.851, 7.512]	2.766 [0.853, 8.972]	8.1 [-1.8, 18.1]	0.113	
			Irbesartan	75	4 (5.3)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2A_SSSM: Incidence of TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

TEAEs

SOC/PT	Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
PT: Hypotension	History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.053	
	Yes	Double-blind period	Sparsentan	155	21 (13.5)	5.453 [1.915, 15.525]	6.151 [2.060, 18.365]	11.1 [4.5, 17.6]	<0.001	*
			Irbesartan	161	4 (2.5)					
	No	Double-blind period	Sparsentan	47	5 (10.6)	1.090 [0.314, 3.792]	1.101 [0.275, 4.408]	0.9 [-14.1, 15.8]	1.000	
			Irbesartan	41	4 (9.8)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AC_SSSM: Incidence of severe TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

Not done: No significant soc/pts found.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AS_SSSM: Incidence of serious TEAEs during double-blind period by SOC/PT by subgroups
Safety Set

Not done: No significant soc/pts found.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. TEAE = treatment emergent adverse event. SOC = system organ class. PT = preferred term.
Only events are reported which demonstrate with significant treatment effects in main analysis. 95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEF_SSIM: Incidence of AESI abnormal liver function during double-blind period by subgroup
Safety Set

AESI abnormal liver function

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.559
Male	Double-blind period	Sparsentan	139	5 (3.6)	0.857 [0.268, 2.745]	0.852 [0.254, 2.858]	-0.6 [-5.8, 4.6]	1.000
		Irbesartan	143	6 (4.2)				
Female	Double-blind period	Sparsentan	63	0 (0.0)	0.313 + [0.013, 7.523]	0.307 + [0.012, 7.688]	-1.7 [-6.6, 3.2]	0.484
		Irbesartan	59	1 (1.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEF_SSIM: Incidence of AESI abnormal liver function during double-blind period by subgroup
Safety Set

AESI abnormal liver function

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	NE
<= 45 years	Double-blind period	Sparsentan	96	1 (1.0) all n<10				NE
		Irbesartan	99	6 (6.1)				
> 45 years	Double-blind period	Sparsentan	106	4 (3.8) all n<10				NE
		Irbesartan	103	1 (1.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEF_SSIM: Incidence of AESI abnormal liver function during double-blind period by subgroup
Safety Set

AESI abnormal liver function

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	NE
<= 18 years	Double-blind period	Sparsentan	9	0 (0.0) all n<10				NE
		Irbesartan	5	1 (20.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	2 (2.0) all n<10				NE
		Irbesartan	109	5 (4.6)				
> 40 years	Double-blind period	Sparsentan	91	3 (3.3) all n<10				NE
		Irbesartan	88	1 (1.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEF_SSIM: Incidence of AESI abnormal liver function during double-blind period by subgroup
Safety Set

AESI abnormal liver function

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	NE
North America	Double-blind period	Sparsentan	35	2 (5.7) all n<10				NE
		Irbesartan	46	3 (6.5)				
Europe	Double-blind period	Sparsentan	98	3 (3.1) all n<10				NE
		Irbesartan	115	3 (2.6)				
Asia Pacific	Double-blind period	Sparsentan	69	0 (0.0) all n<10				NE
		Irbesartan	41	1 (2.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEF_SSIM: Incidence of AESI abnormal liver function during double-blind period by subgroup
Safety Set

AESI abnormal liver function

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	NE
< 27 kg/m**2	Double-blind period	Sparsentan	83	2 (2.4) all n<10				NE
		Irbesartan	94	4 (4.3)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	3 (2.5) all n<10				NE
		Irbesartan	107	3 (2.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEF_SSIM: Incidence of AESI abnormal liver function during double-blind period by subgroup
Safety Set

AESI abnormal liver function

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	NE
eGFR Low and UP High	Double-blind period	Sparsentan	71	1 (1.4) all n<10				NE
		Irbesartan	74	4 (5.4)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	1 (1.8) all n<10				NE
		Irbesartan	55	0 (0.0)				
eGFR High and UP High	Double-blind period	Sparsentan	37	2 (5.4) all n<10				NE
		Irbesartan	36	3 (8.3)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	1 (2.6) all n<10				NE
		Irbesartan	37	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEF_SSIM: Incidence of AESI abnormal liver function during double-blind period by subgroup
Safety Set

AESI abnormal liver function

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	NE
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	2 (1.6) all n<10				NE
		Irbesartan	129	4 (3.1)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	2 (4.1) all n<10				NE
		Irbesartan	48	2 (4.2)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8) all n<10				NE
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEF_SSIM: Incidence of AESI abnormal liver function during double-blind period by subgroup
Safety Set

AESI abnormal liver function

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	NE
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	2 (2.4) all n<10				NE
		Irbesartan	80	3 (3.8)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	0 (0.0) all n<10				NE
		Irbesartan	49	1 (2.0)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	2 (4.1) all n<10				NE
		Irbesartan	48	2 (4.2)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8) all n<10				NE
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEF_SSIM: Incidence of AESI abnormal liver function during double-blind period by subgroup
Safety Set

AESI abnormal liver function

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	NE
<= 1.75 g/day	Double-blind period	Sparsentan	98	2 (2.0) all n<10				NE
		Irbesartan	93	2 (2.2)				
> 1.75 g/day	Double-blind period	Sparsentan	104	3 (2.9) all n<10				NE
		Irbesartan	109	5 (4.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEF_SSIM: Incidence of AESI abnormal liver function during double-blind period by subgroup
Safety Set

AESI abnormal liver function

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	NE
Yes	Double-blind period	Sparsentan	90	1 (1.1) all n<10				NE
		Irbesartan	88	2 (2.3)				
No	Double-blind period	Sparsentan	112	4 (3.6) all n<10				NE
		Irbesartan	114	5 (4.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEF_SSIM: Incidence of AESI abnormal liver function during double-blind period by subgroup
Safety Set

AESI abnormal liver function

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	NE
<= 5 years	Double-blind period	Sparsentan	113	3 (2.7) all n<10				NE
		Irbesartan	127	4 (3.1)				
> 5 years	Double-blind period	Sparsentan	89	2 (2.2) all n<10				NE
		Irbesartan	75	3 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEF_SSIM: Incidence of AESI abnormal liver function during double-blind period by subgroup
Safety Set

AESI abnormal liver function

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.880
Yes	Double-blind period	Sparsentan	155	4 (2.6)	0.692 [0.199, 2.407]	0.684 [0.189, 2.473]	-1.1 [-5.6, 3.3]	0.750
		Irbesartan	161	6 (3.7)				
No	Double-blind period	Sparsentan	47	1 (2.1)	0.872 [0.056, 13.510]	0.870 [0.053, 14.357]	-0.3 [-8.9, 8.2]	1.000
		Irbesartan	41	1 (2.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEFN_SSIM: Incidence of AESI abnormal liver function during double-blind period – non-severe by subgroup
Safety Set

AESI abnormal liver function - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.559
Male	Double-blind period	Sparsentan	139	5 (3.6)	0.857 [0.268, 2.745]	0.852 [0.254, 2.858]	-0.6 [-5.8, 4.6]	1.000
		Irbesartan	143	6 (4.2)				
Female	Double-blind period	Sparsentan	63	0 (0.0)	0.313 + [0.013, 7.523]	0.307 + [0.012, 7.688]	-1.7 [-6.6, 3.2]	0.484
		Irbesartan	59	1 (1.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEFN_SSIM: Incidence of AESI abnormal liver function during double-blind period – non-severe by subgroup
Safety Set

AESI abnormal liver function - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	NE
<= 45 years	Double-blind period	Sparsentan	96	1 (1.0) all n<10				NE
		Irbesartan	99	6 (6.1)				
> 45 years	Double-blind period	Sparsentan	106	4 (3.8) all n<10				NE
		Irbesartan	103	1 (1.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEFN_SSIM: Incidence of AESI abnormal liver function during double-blind period – non-severe by subgroup
Safety Set

AESI abnormal liver function - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	NE
<= 18 years	Double-blind period	Sparsentan	9	0 (0.0) all n<10				NE
		Irbesartan	5	1 (20.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	2 (2.0) all n<10				NE
		Irbesartan	109	5 (4.6)				
> 40 years	Double-blind period	Sparsentan	91	3 (3.3) all n<10				NE
		Irbesartan	88	1 (1.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEFN_SSIM: Incidence of AESI abnormal liver function during double-blind period – non-severe by subgroup
Safety Set

AESI abnormal liver function - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	NE
North America	Double-blind period	Sparsentan	35	2 (5.7) all n<10				NE
		Irbesartan	46	3 (6.5)				
Europe	Double-blind period	Sparsentan	98	3 (3.1) all n<10				NE
		Irbesartan	115	3 (2.6)				
Asia Pacific	Double-blind period	Sparsentan	69	0 (0.0) all n<10				NE
		Irbesartan	41	1 (2.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEFN_SSIM: Incidence of AESI abnormal liver function during double-blind period – non-severe by subgroup
Safety Set

AESI abnormal liver function - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	NE
< 27 kg/m**2	Double-blind period	Sparsentan	83	2 (2.4) all n<10				NE
		Irbesartan	94	4 (4.3)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	3 (2.5) all n<10				NE
		Irbesartan	107	3 (2.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEFN_SSIM: Incidence of AESI abnormal liver function during double-blind period – non-severe by subgroup
Safety Set

AESI abnormal liver function - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	NE
eGFR Low and UP High	Double-blind period	Sparsentan	71	1 (1.4) all n<10				NE
		Irbesartan	74	4 (5.4)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	1 (1.8) all n<10				NE
		Irbesartan	55	0 (0.0)				
eGFR High and UP High	Double-blind period	Sparsentan	37	2 (5.4) all n<10				NE
		Irbesartan	36	3 (8.3)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	1 (2.6) all n<10				NE
		Irbesartan	37	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEFN_SSIM: Incidence of AESI abnormal liver function during double-blind period – non-severe by subgroup
Safety Set

AESI abnormal liver function - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	NE
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	2 (1.6) all n<10				NE
		Irbesartan	129	4 (3.1)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	2 (4.1) all n<10				NE
		Irbesartan	48	2 (4.2)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8) all n<10				NE
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEFN_SSIM: Incidence of AESI abnormal liver function during double-blind period – non-severe by subgroup
Safety Set

AESI abnormal liver function - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	NE
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	2 (2.4) all n<10				NE
		Irbesartan	80	3 (3.8)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	0 (0.0) all n<10				NE
		Irbesartan	49	1 (2.0)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	2 (4.1) all n<10				NE
		Irbesartan	48	2 (4.2)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8) all n<10				NE
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEFN_SSIM: Incidence of AESI abnormal liver function during double-blind period – non-severe by subgroup
Safety Set

AESI abnormal liver function - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	NE
<= 1.75 g/day	Double-blind period	Sparsentan	98	2 (2.0) all n<10				NE
		Irbesartan	93	2 (2.2)				
> 1.75 g/day	Double-blind period	Sparsentan	104	3 (2.9) all n<10				NE
		Irbesartan	109	5 (4.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEFN_SSIM: Incidence of AESI abnormal liver function during double-blind period – non-severe by subgroup
Safety Set

AESI abnormal liver function - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	NE
Yes	Double-blind period	Sparsentan	90	1 (1.1) all n<10				NE
		Irbesartan	88	2 (2.3)				
No	Double-blind period	Sparsentan	112	4 (3.6) all n<10				NE
		Irbesartan	114	5 (4.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEFN_SSIM: Incidence of AESI abnormal liver function during double-blind period – non-severe by subgroup
Safety Set

AESI abnormal liver function - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	NE
<= 5 years	Double-blind period	Sparsentan	113	3 (2.7) all n<10				NE
		Irbesartan	127	4 (3.1)				
> 5 years	Double-blind period	Sparsentan	89	2 (2.2) all n<10				NE
		Irbesartan	75	3 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEFN_SSIM: Incidence of AESI abnormal liver function during double-blind period – non-severe by subgroup
Safety Set

AESI abnormal liver function - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.880
Yes	Double-blind period	Sparsentan	155	4 (2.6)	0.692 [0.199, 2.407]	0.684 [0.189, 2.473]	-1.1 [-5.6, 3.3]	0.750
		Irbesartan	161	6 (3.7)				
No	Double-blind period	Sparsentan	47	1 (2.1)	0.872 [0.056, 13.510]	0.870 [0.053, 14.357]	-0.3 [-8.9, 8.2]	1.000
		Irbesartan	41	1 (2.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEFC_SSIM: Incidence of AESI abnormal liver function during double-blind period – severe by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEFS_SSIM: Incidence of AESI abnormal liver function during double-blind period – serious by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEV_SSIM: Incidence of AESI COVID-19 during double-blind period by subgroup
Safety Set

AESI COVID-19

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.865
Male	Double-blind period	Sparsentan	139	33 (23.7)	1.171 [0.753, 1.819]	1.224 [0.696, 2.152]	3.5 [-6.9, 13.8]	0.565
		Irbesartan	143	29 (20.3)				
Female	Double-blind period	Sparsentan	63	20 (31.7)	1.102 [0.642, 1.891]	1.149 [0.530, 2.491]	2.9 [-15.0, 20.9]	0.844
		Irbesartan	59	17 (28.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEV_SSIM: Incidence of AESI COVID-19 during double-blind period by subgroup
Safety Set

AESI COVID-19

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.499
<= 45 years	Double-blind period	Sparsentan	96	30 (31.3)	1.289 [0.816, 2.037]	1.420 [0.756, 2.668]	7.0 [-6.6, 20.6]	0.337
		Irbesartan	99	24 (24.2)				
> 45 years	Double-blind period	Sparsentan	106	23 (21.7)	1.016 [0.605, 1.705]	1.020 [0.527, 1.974]	0.3 [-11.8, 12.4]	1.000
		Irbesartan	103	22 (21.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEV_SSIM: Incidence of AESI COVID-19 during double-blind period by subgroup
Safety Set

AESI COVID-19

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.079
<= 18 years	Double-blind period	Sparsentan	9	1 (11.1)	0.185 [0.026, 1.343]	0.083 [0.005, 1.294]	-48.9 [-100.0, 14.3]	0.095
		Irbesartan	5	3 (60.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	29 (28.4)	1.550 [0.938, 2.559]	1.768 [0.924, 3.381]	10.1 [-2.2, 22.4]	0.103
		Irbesartan	109	20 (18.3)				
> 40 years	Double-blind period	Sparsentan	91	23 (25.3)	0.967 [0.588, 1.591]	0.956 [0.489, 1.869]	-0.9 [-14.8, 13.1]	1.000
		Irbesartan	88	23 (26.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEV_SSIM: Incidence of AESI COVID-19 during double-blind period by subgroup
Safety Set

AESI COVID-19

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.238
North America	Double-blind period	Sparsentan	35	10 (28.6)	1.643 [0.724, 3.727]	1.900 [0.660, 5.472]	11.2 [-9.9, 32.2]	0.285
		Irbesartan	46	8 (17.4)				
Europe	Double-blind period	Sparsentan	98	33 (33.7)	1.335 [0.878, 2.032]	1.506 [0.831, 2.726]	8.5 [-4.8, 21.7]	0.226
		Irbesartan	115	29 (25.2)				
Asia Pacific	Double-blind period	Sparsentan	69	10 (14.5)	0.660 [0.293, 1.489]	0.603 [0.222, 1.635]	-7.5 [-24.6, 9.6]	0.434
		Irbesartan	41	9 (22.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEV_SSIM: Incidence of AESI COVID-19 during double-blind period by subgroup
Safety Set

AESI COVID-19

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.327
< 27 kg/m**2	Double-blind period	Sparsentan	83	19 (22.9)	0.936 [0.550, 1.591]	0.916 [0.457, 1.837]	-1.6 [-15.2, 12.1]	0.861
		Irbesartan	94	23 (24.5)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	34 (28.6)	1.329 [0.839, 2.106]	1.461 [0.795, 2.686]	7.1 [-5.1, 19.2]	0.283
		Irbesartan	107	23 (21.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEV_SSIM: Incidence of AESI COVID-19 during double-blind period by subgroup
Safety Set

AESI COVID-19

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.067	
eGFR Low and UP High	Double-blind period	Sparsentan	71	19 (26.8)	2.200 [1.068, 4.535]	2.639 [1.102, 6.317]	14.6 [0.5, 28.7]	0.035	*
		Irbesartan	74	9 (12.2)					
eGFR Low and UP Low	Double-blind period	Sparsentan	55	14 (25.5)	1.077 [0.559, 2.075]	1.103 [0.463, 2.630]	1.8 [-16.1, 19.7]	1.000	
		Irbesartan	55	13 (23.6)					
eGFR High and UP High	Double-blind period	Sparsentan	37	4 (10.8)	0.389 [0.134, 1.129]	0.315 [0.089, 1.120]	-17.0 [-37.4, 3.5]	0.081	
		Irbesartan	36	10 (27.8)					
eGFR High and UP Low	Double-blind period	Sparsentan	39	16 (41.0)	1.084 [0.620, 1.896]	1.143 [0.455, 2.871]	3.2 [-21.4, 27.8]	0.818	
		Irbesartan	37	14 (37.8)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEV_SSIM: Incidence of AESI COVID-19 during double-blind period by subgroup
Safety Set

AESI COVID-19

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.104
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	33 (26.0)	1.397 [0.877, 2.224]	1.536 [0.847, 2.784]	7.4 [-3.6, 18.3]	0.178
		Irbesartan	129	24 (18.6)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	10 (20.4)	0.612 [0.309, 1.212]	0.513 [0.205, 1.284]	-12.9 [-32.5, 6.6]	0.174
		Irbesartan	48	16 (33.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	10 (38.5)	1.603 [0.685, 3.750]	1.979 [0.590, 6.644]	14.5 [-14.6, 43.5]	0.368
		Irbesartan	25	6 (24.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEV_SSIM: Incidence of AESI COVID-19 during double-blind period by subgroup
Safety Set

AESI COVID-19

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.080
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	22 (26.8)	1.951 [1.014, 3.756]	2.300 [1.031, 5.130]	13.1 [-0.4, 26.5]	0.051
		Irbesartan	80	11 (13.8)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	11 (24.4)	0.921 [0.461, 1.843]	0.896 [0.354, 2.270]	-2.1 [-21.8, 17.7]	1.000
		Irbesartan	49	13 (26.5)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	10 (20.4)	0.612 [0.309, 1.212]	0.513 [0.205, 1.284]	-12.9 [-32.5, 6.6]	0.174
		Irbesartan	48	16 (33.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	10 (38.5)	1.603 [0.685, 3.750]	1.979 [0.590, 6.644]	14.5 [-14.6, 43.5]	0.368
		Irbesartan	25	6 (24.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEV_SSIM: Incidence of AESI COVID-19 during double-blind period by subgroup
Safety Set

AESI COVID-19

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.581
<= 1.75 g/day	Double-blind period	Sparsentan	98	31 (31.6)	1.051 [0.687, 1.607]	1.074 [0.581, 1.986]	1.5 [-12.6, 15.7]	0.876
		Irbesartan	93	28 (30.1)				
> 1.75 g/day	Double-blind period	Sparsentan	104	22 (21.2)	1.281 [0.730, 2.247]	1.356 [0.680, 2.706]	4.6 [-6.8, 16.1]	0.483
		Irbesartan	109	18 (16.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEV_SSIM: Incidence of AESI COVID-19 during double-blind period by subgroup
Safety Set

AESI COVID-19

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.709
Yes	Double-blind period	Sparsentan	90	23 (25.6)	1.071 [0.641, 1.789]	1.095 [0.554, 2.165]	1.7 [-12.1, 15.5]	0.863
		Irbesartan	88	21 (23.9)				
No	Double-blind period	Sparsentan	112	30 (26.8)	1.221 [0.769, 1.939]	1.302 [0.708, 2.396]	4.9 [-7.2, 16.9]	0.440
		Irbesartan	114	25 (21.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEV_SSIM: Incidence of AESI COVID-19 during double-blind period by subgroup
Safety Set

AESI COVID-19

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.559
<= 5 years	Double-blind period	Sparsentan	113	32 (28.3)	1.090 [0.720, 1.650]	1.125 [0.636, 1.990]	2.3 [-9.8, 14.4]	0.771
		Irbesartan	127	33 (26.0)				
> 5 years	Double-blind period	Sparsentan	89	21 (23.6)	1.361 [0.733, 2.530]	1.473 [0.680, 3.189]	6.3 [-7.3, 19.8]	0.342
		Irbesartan	75	13 (17.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEV_SSIM: Incidence of AESI COVID-19 during double-blind period by subgroup
Safety Set

AESI COVID-19

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.410
Yes	Double-blind period	Sparsentan	155	39 (25.2)	1.066 [0.723, 1.572]	1.088 [0.651, 1.819]	1.6 [-8.5, 11.7]	0.794
		Irbesartan	161	38 (23.6)				
No	Double-blind period	Sparsentan	47	14 (29.8)	1.527 [0.713, 3.268]	1.750 [0.648, 4.727]	10.3 [-9.8, 30.4]	0.328
		Irbesartan	41	8 (19.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEVN_SSIM: Incidence of AESI COVID-19 during double-blind period – non-severe by subgroup
Safety Set

AESI COVID-19 - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.887
Male	Double-blind period	Sparsentan	139	30 (21.6)	1.102 [0.696, 1.744]	1.130 [0.634, 2.015]	2.0 [-8.1, 12.1]	0.768
		Irbesartan	143	28 (19.6)				
Female	Double-blind period	Sparsentan	63	19 (30.2)	1.047 [0.604, 1.813]	1.067 [0.490, 2.325]	1.3 [-16.5, 19.2]	1.000
		Irbesartan	59	17 (28.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEVN_SSIM: Incidence of AESI COVID-19 during double-blind period – non-severe by subgroup
Safety Set

AESI COVID-19 - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.894
<= 45 years	Double-blind period	Sparsentan	96	26 (27.1)	1.117 [0.692, 1.803]	1.161 [0.610, 2.209]	2.8 [-10.4, 16.1]	0.743
		Irbesartan	99	24 (24.2)				
> 45 years	Double-blind period	Sparsentan	106	23 (21.7)	1.064 [0.629, 1.800]	1.082 [0.556, 2.105]	1.3 [-10.7, 13.3]	0.866
		Irbesartan	103	21 (20.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEVN_SSIM: Incidence of AESI COVID-19 during double-blind period – non-severe by subgroup
Safety Set

AESI COVID-19 - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.154
<= 18 years	Double-blind period	Sparsentan	9	1 (11.1)	0.185 [0.026, 1.343]	0.083 [0.005, 1.294]	-48.9 [-100.0, 14.3]	0.095
		Irbesartan	5	3 (60.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	25 (24.5)	1.336 [0.792, 2.252]	1.445 [0.745, 2.802]	6.2 [-5.9, 18.2]	0.315
		Irbesartan	109	20 (18.3)				
> 40 years	Double-blind period	Sparsentan	91	23 (25.3)	1.011 [0.610, 1.676]	1.015 [0.516, 1.994]	0.3 [-13.6, 14.1]	1.000
		Irbesartan	88	22 (25.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEVN_SSIM: Incidence of AESI COVID-19 during double-blind period – non-severe by subgroup
Safety Set

AESI COVID-19 - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.221
North America	Double-blind period	Sparsentan	35	9 (25.7)	1.479 [0.635, 3.442]	1.644 [0.561, 4.818]	8.3 [-12.3, 29.0]	0.416
		Irbesartan	46	8 (17.4)				
Europe	Double-blind period	Sparsentan	98	31 (31.6)	1.299 [0.842, 2.006]	1.438 [0.787, 2.625]	7.3 [-5.8, 20.3]	0.283
		Irbesartan	115	28 (24.3)				
Asia Pacific	Double-blind period	Sparsentan	69	9 (13.0)	0.594 [0.257, 1.375]	0.533 [0.193, 1.477]	-8.9 [-25.8, 8.0]	0.288
		Irbesartan	41	9 (22.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEVN_SSIM: Incidence of AESI COVID-19 during double-blind period – non-severe by subgroup
Safety Set

AESI COVID-19 - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.333
< 27 kg/m**2	Double-blind period	Sparsentan	83	18 (21.7)	0.886 [0.516, 1.523]	0.855 [0.423, 1.726]	-2.8 [-16.3, 10.8]	0.723
		Irbesartan	94	23 (24.5)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	31 (26.1)	1.267 [0.784, 2.047]	1.361 [0.730, 2.536]	5.5 [-6.4, 17.4]	0.350
		Irbesartan	107	22 (20.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEVN_SSIM: Incidence of AESI COVID-19 during double-blind period – non-severe by subgroup
Safety Set

AESI COVID-19 - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.106
eGFR Low and UP High	Double-blind period	Sparsentan	71	17 (23.9)	1.969 [0.940, 4.124]	2.274 [0.938, 5.508]	11.8 [-2.0, 25.6]	0.083
		Irbesartan	74	9 (12.2)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	13 (23.6)	1.000 [0.511, 1.958]	1.000 [0.415, 2.410]	0.0 [-17.7, 17.7]	1.000
		Irbesartan	55	13 (23.6)				
eGFR High and UP High	Double-blind period	Sparsentan	37	4 (10.8)	0.389 [0.134, 1.129]	0.315 [0.089, 1.120]	-17.0 [-37.4, 3.5]	0.081
		Irbesartan	36	10 (27.8)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	15 (38.5)	1.095 [0.606, 1.977]	1.154 [0.454, 2.935]	3.3 [-21.0, 27.6]	0.815
		Irbesartan	37	13 (35.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEVN_SSIM: Incidence of AESI COVID-19 during double-blind period – non-severe by subgroup
Safety Set

AESI COVID-19 - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.085
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	30 (23.6)	1.325 [0.816, 2.151]	1.425 [0.775, 2.621]	5.8 [-4.9, 16.5]	0.282
		Irbesartan	129	23 (17.8)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	9 (18.4)	0.551 [0.270, 1.124]	0.450 [0.176, 1.152]	-15.0 [-34.2, 4.3]	0.108
		Irbesartan	48	16 (33.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	10 (38.5)	1.603 [0.685, 3.750]	1.979 [0.590, 6.644]	14.5 [-14.6, 43.5]	0.368
		Irbesartan	25	6 (24.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEVN_SSIM: Incidence of AESI COVID-19 during double-blind period – non-severe by subgroup
Safety Set

AESI COVID-19 - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.086
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	20 (24.4)	1.774 [0.909, 3.460]	2.023 [0.899, 4.556]	10.6 [-2.6, 23.8]	0.110
		Irbesartan	80	11 (13.8)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	10 (22.2)	0.907 [0.435, 1.893]	0.881 [0.338, 2.296]	-2.3 [-21.5, 17.0]	0.813
		Irbesartan	49	12 (24.5)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	9 (18.4)	0.551 [0.270, 1.124]	0.450 [0.176, 1.152]	-15.0 [-34.2, 4.3]	0.108
		Irbesartan	48	16 (33.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	10 (38.5)	1.603 [0.685, 3.750]	1.979 [0.590, 6.644]	14.5 [-14.6, 43.5]	0.368
		Irbesartan	25	6 (24.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEVN_SSIM: Incidence of AESI COVID-19 during double-blind period – non-severe by subgroup
Safety Set

AESI COVID-19 - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.719
<= 1.75 g/day	Double-blind period	Sparsentan	98	29 (29.6)	1.019 [0.656, 1.584]	1.027 [0.551, 1.916]	0.6 [-13.4, 14.5]	1.000
		Irbesartan	93	27 (29.0)				
> 1.75 g/day	Double-blind period	Sparsentan	104	20 (19.2)	1.165 [0.654, 2.074]	1.204 [0.596, 2.430]	2.7 [-8.5, 14.0]	0.721
		Irbesartan	109	18 (16.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEVN_SSIM: Incidence of AESI COVID-19 during double-blind period – non-severe by subgroup
Safety Set

AESI COVID-19 - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.952
Yes	Double-blind period	Sparsentan	90	22 (24.4)	1.076 [0.633, 1.826]	1.100 [0.550, 2.199]	1.7 [-11.9, 15.3]	0.861
		Irbesartan	88	20 (22.7)				
No	Double-blind period	Sparsentan	112	27 (24.1)	1.099 [0.682, 1.772]	1.131 [0.608, 2.102]	2.2 [-9.7, 14.0]	0.753
		Irbesartan	114	25 (21.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEVN_SSIM: Incidence of AESI COVID-19 during double-blind period – non-severe by subgroup
Safety Set

AESI COVID-19 - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.374
<= 5 years	Double-blind period	Sparsentan	113	29 (25.7)	0.988 [0.643, 1.518]	0.983 [0.551, 1.755]	-0.3 [-12.2, 11.6]	1.000
		Irbesartan	127	33 (26.0)				
> 5 years	Double-blind period	Sparsentan	89	20 (22.5)	1.404 [0.736, 2.681]	1.522 [0.689, 3.363]	6.5 [-6.8, 19.7]	0.328
		Irbesartan	75	12 (16.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEVN_SSIM: Incidence of AESI COVID-19 during double-blind period – non-severe by subgroup
Safety Set

AESI COVID-19 - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.447
Yes	Double-blind period	Sparsentan	155	36 (23.2)	1.011 [0.676, 1.511]	1.014 [0.601, 1.711]	0.2 [-9.7, 10.2]	1.000
		Irbesartan	161	37 (23.0)				
No	Double-blind period	Sparsentan	47	13 (27.7)	1.418 [0.653, 3.076]	1.577 [0.579, 4.298]	8.1 [-11.8, 28.1]	0.456
		Irbesartan	41	8 (19.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEVC_SSIM: Incidence of AESI COVID-19 during double-blind period – severe by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEVS_SSIM: Incidence of AESI COVID-19 during double-blind period – serious by subgroup
Safety Set

AESI COVID-19 - serious

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.884
Male	Double-blind period	Sparsentan	139	25 (18.0)	1.072 [0.644, 1.783]	1.087 [0.587, 2.014]	1.2 [-8.4, 10.8]	0.875
		Irbesartan	143	24 (16.8)				
Female	Double-blind period	Sparsentan	63	17 (27.0)	1.137 [0.617, 2.097]	1.188 [0.524, 2.692]	3.3 [-13.8, 20.3]	0.835
		Irbesartan	59	14 (23.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEVS_SSIM: Incidence of AESI COVID-19 during double-blind period – serious by subgroup
Safety Set

AESI COVID-19 - serious

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.549
<= 45 years	Double-blind period	Sparsentan	96	24 (25.0)	1.238 [0.734, 2.087]	1.317 [0.671, 2.583]	4.8 [-8.0, 17.6]	0.494
		Irbesartan	99	20 (20.2)				
> 45 years	Double-blind period	Sparsentan	106	18 (17.0)	0.972 [0.536, 1.761]	0.966 [0.471, 1.981]	-0.5 [-11.7, 10.7]	1.000
		Irbesartan	103	18 (17.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEVS_SSIM: Incidence of AESI COVID-19 during double-blind period – serious by subgroup
Safety Set

AESI COVID-19 - serious

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.120
<= 18 years	Double-blind period	Sparsentan	9	1 (11.1)	0.185 [0.026, 1.343]	0.083 [0.005, 1.294]	-48.9 [-100.0, 14.3]	0.095
		Irbesartan	5	3 (60.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	22 (21.6)	1.469 [0.819, 2.637]	1.598 [0.786, 3.251]	6.9 [-4.4, 18.2]	0.213
		Irbesartan	109	16 (14.7)				
> 40 years	Double-blind period	Sparsentan	91	19 (20.9)	0.967 [0.550, 1.700]	0.958 [0.468, 1.962]	-0.7 [-13.8, 12.4]	1.000
		Irbesartan	88	19 (21.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEVS_SSIM: Incidence of AESI COVID-19 during double-blind period – serious by subgroup
Safety Set

AESI COVID-19 - serious

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.106
North America	Double-blind period	Sparsentan	35	10 (28.6)	1.878 [0.794, 4.437]	2.229 [0.750, 6.619]	13.4 [-7.4, 34.1]	0.174
		Irbesartan	46	7 (15.2)				
Europe	Double-blind period	Sparsentan	98	24 (24.5)	1.280 [0.767, 2.136]	1.371 [0.713, 2.637]	5.4 [-6.7, 17.4]	0.404
		Irbesartan	115	22 (19.1)				
Asia Pacific	Double-blind period	Sparsentan	69	8 (11.6)	0.528 [0.221, 1.261]	0.466 [0.164, 1.325]	-10.4 [-27.1, 6.3]	0.177
		Irbesartan	41	9 (22.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEVS_SSIM: Incidence of AESI COVID-19 during double-blind period – serious by subgroup
Safety Set

AESI COVID-19 - serious

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.168
< 27 kg/m**2	Double-blind period	Sparsentan	83	15 (18.1)	0.809 [0.447, 1.464]	0.767 [0.366, 1.608]	-4.3 [-17.2, 8.7]	0.576
		Irbesartan	94	21 (22.3)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	27 (22.7)	1.428 [0.826, 2.470]	1.554 [0.793, 3.045]	6.8 [-4.3, 17.9]	0.240
		Irbesartan	107	17 (15.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEVS_SSIM: Incidence of AESI COVID-19 during double-blind period – serious by subgroup
Safety Set

AESI COVID-19 - serious

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.118
eGFR Low and UP High	Double-blind period	Sparsentan	71	16 (22.5)	2.085 [0.952, 4.564]	2.400 [0.955, 6.029]	11.7 [-1.7, 25.1]	0.074
		Irbesartan	74	8 (10.8)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	11 (20.0)	1.000 [0.474, 2.112]	1.000 [0.393, 2.546]	0.0 [-16.8, 16.8]	1.000
		Irbesartan	55	11 (20.0)				
eGFR High and UP High	Double-blind period	Sparsentan	37	2 (5.4)	0.278 [0.062, 1.250]	0.237 [0.046, 1.229]	-14.0 [-31.6, 3.5]	0.085
		Irbesartan	36	7 (19.4)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	13 (33.3)	1.028 [0.540, 1.955]	1.042 [0.400, 2.714]	0.9 [-22.9, 24.7]	1.000
		Irbesartan	37	12 (32.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEVS_SSIM: Incidence of AESI COVID-19 during double-blind period – serious by subgroup
Safety Set

AESI COVID-19 - serious

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.327
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	27 (21.3)	1.306 [0.780, 2.186]	1.389 [0.738, 2.612]	5.0 [-5.4, 15.3]	0.339
		Irbesartan	129	21 (16.3)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	9 (18.4)	0.678 [0.320, 1.437]	0.606 [0.231, 1.587]	-8.7 [-27.4, 9.9]	0.341
		Irbesartan	48	13 (27.1)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	6 (23.1)	1.442 [0.461, 4.509]	1.575 [0.386, 6.423]	7.1 [-18.5, 32.7]	0.726
		Irbesartan	25	4 (16.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEVS_SSIM: Incidence of AESI COVID-19 during double-blind period – serious by subgroup
Safety Set

AESI COVID-19 - serious

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.195
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	18 (22.0)	1.951 [0.932, 4.083]	2.219 [0.931, 5.288]	10.7 [-1.9, 23.3]	0.091
		Irbesartan	80	9 (11.3)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	9 (20.0)	0.817 [0.381, 1.753]	0.771 [0.290, 2.051]	-4.5 [-23.4, 14.4]	0.630
		Irbesartan	49	12 (24.5)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	9 (18.4)	0.678 [0.320, 1.437]	0.606 [0.231, 1.587]	-8.7 [-27.4, 9.9]	0.341
		Irbesartan	48	13 (27.1)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	6 (23.1)	1.442 [0.461, 4.509]	1.575 [0.386, 6.423]	7.1 [-18.5, 32.7]	0.726
		Irbesartan	25	4 (16.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEVS_SSIM: Incidence of AESI COVID-19 during double-blind period – serious by subgroup
Safety Set

AESI COVID-19 - serious

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.543
<= 1.75 g/day	Double-blind period	Sparsentan	98	25 (25.5)	0.989 [0.610, 1.602]	0.985 [0.514, 1.885]	-0.3 [-13.7, 13.1]	1.000
		Irbesartan	93	24 (25.8)				
> 1.75 g/day	Double-blind period	Sparsentan	104	17 (16.3)	1.273 [0.662, 2.448]	1.326 [0.617, 2.849]	3.5 [-6.9, 13.9]	0.561
		Irbesartan	109	14 (12.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEVS_SSIM: Incidence of AESI COVID-19 during double-blind period – serious by subgroup
Safety Set

AESI COVID-19 - serious

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.429
Yes	Double-blind period	Sparsentan	90	17 (18.9)	0.923 [0.510, 1.673]	0.906 [0.432, 1.897]	-1.6 [-14.4, 11.2]	0.852
		Irbesartan	88	18 (20.5)				
No	Double-blind period	Sparsentan	112	25 (22.3)	1.272 [0.751, 2.155]	1.351 [0.701, 2.603]	4.8 [-6.5, 16.1]	0.407
		Irbesartan	114	20 (17.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEVS_SSIM: Incidence of AESI COVID-19 during double-blind period – serious by subgroup
Safety Set

AESI COVID-19 - serious

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.452
<= 5 years	Double-blind period	Sparsentan	113	24 (21.2)	0.999 [0.613, 1.627]	0.999 [0.537, 1.856]	-0.0 [-11.2, 11.2]	1.000
		Irbesartan	127	27 (21.3)				
> 5 years	Double-blind period	Sparsentan	89	18 (20.2)	1.379 [0.696, 2.734]	1.475 [0.648, 3.358]	5.6 [-7.2, 18.4]	0.414
		Irbesartan	75	11 (14.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEVS_SSIM: Incidence of AESI COVID-19 during double-blind period – serious by subgroup
Safety Set

AESI COVID-19 - serious

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.706
Yes	Double-blind period	Sparsentan	155	33 (21.3)	1.071 [0.694, 1.652]	1.090 [0.632, 1.882]	1.4 [-8.1, 11.0]	0.782
		Irbesartan	161	32 (19.9)				
No	Double-blind period	Sparsentan	47	9 (19.1)	1.309 [0.509, 3.364]	1.382 [0.446, 4.279]	4.5 [-13.4, 22.4]	0.777
		Irbesartan	41	6 (14.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEC_SSIM: Incidence of AESI cardiovascular system during double-blind period by subgroup
Safety Set

AESI cardiovascular system

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.040 #
Male	Double-blind period	Sparsentan	139	39 (28.1)	0.854 [0.599, 1.217]	0.797 [0.479, 1.325]	-4.8 [-16.2, 6.6]	0.438
		Irbesartan	143	47 (32.9)				
Female	Double-blind period	Sparsentan	63	24 (38.1)	1.729 [0.974, 3.069]	2.178 [0.980, 4.839]	16.1 [-1.6, 33.7]	0.076
		Irbesartan	59	13 (22.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEC_SSIM: Incidence of AESI cardiovascular system during double-blind period by subgroup
Safety Set

AESI cardiovascular system

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.165
<= 45 years	Double-blind period	Sparsentan	96	24 (25.0)	0.825 [0.522, 1.304]	0.767 [0.408, 1.440]	-5.3 [-18.9, 8.3]	0.428
		Irbesartan	99	30 (30.3)				
> 45 years	Double-blind period	Sparsentan	106	39 (36.8)	1.263 [0.854, 1.868]	1.416 [0.793, 2.530]	7.7 [-6.0, 21.3]	0.244
		Irbesartan	103	30 (29.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEC_SSIM: Incidence of AESI cardiovascular system during double-blind period by subgroup
Safety Set

AESI cardiovascular system

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.153
<= 18 years	Double-blind period	Sparsentan	9	5 (55.6)	1.389 [0.409, 4.715]	1.875 [0.204, 17.269]	15.6 [-53.8, 84.9]	1.000
		Irbesartan	5	2 (40.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	23 (22.5)	0.745 [0.471, 1.178]	0.671 [0.361, 1.245]	-7.7 [-20.5, 5.1]	0.216
		Irbesartan	109	33 (30.3)				
> 40 years	Double-blind period	Sparsentan	91	35 (38.5)	1.354 [0.888, 2.063]	1.575 [0.841, 2.948]	10.1 [-4.8, 24.9]	0.205
		Irbesartan	88	25 (28.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEC_SSIM: Incidence of AESI cardiovascular system during double-blind period by subgroup
Safety Set

AESI cardiovascular system

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.357
North America	Double-blind period	Sparsentan	35	6 (17.1)	0.607 [0.256, 1.436]	0.525 [0.177, 1.560]	-11.1 [-31.7, 9.4]	0.296
		Irbesartan	46	13 (28.3)				
Europe	Double-blind period	Sparsentan	98	37 (37.8)	1.206 [0.832, 1.748]	1.331 [0.755, 2.348]	6.5 [-7.3, 20.2]	0.385
		Irbesartan	115	36 (31.3)				
Asia Pacific	Double-blind period	Sparsentan	69	20 (29.0)	1.080 [0.578, 2.020]	1.113 [0.469, 2.643]	2.2 [-17.1, 21.4]	1.000
		Irbesartan	41	11 (26.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEC_SSIM: Incidence of AESI cardiovascular system during double-blind period by subgroup
Safety Set

AESI cardiovascular system

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.294
< 27 kg/m**2	Double-blind period	Sparsentan	83	22 (26.5)	0.859 [0.538, 1.373]	0.808 [0.420, 1.556]	-4.3 [-18.8, 10.1]	0.618
		Irbesartan	94	29 (30.9)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	41 (34.5)	1.189 [0.808, 1.750]	1.289 [0.734, 2.264]	5.5 [-7.5, 18.5]	0.394
		Irbesartan	107	31 (29.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEC_SSIM: Incidence of AESI cardiovascular system during double-blind period by subgroup
Safety Set

AESI cardiovascular system

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.980
eGFR Low and UP High	Double-blind period	Sparsentan	71	24 (33.8)	1.137 [0.705, 1.834]	1.207 [0.599, 2.431]	4.1 [-12.5, 20.6]	0.721
		Irbesartan	74	22 (29.7)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	17 (30.9)	1.000 [0.572, 1.749]	1.000 [0.445, 2.245]	0.0 [-19.1, 19.1]	1.000
		Irbesartan	55	17 (30.9)				
eGFR High and UP High	Double-blind period	Sparsentan	37	12 (32.4)	0.973 [0.505, 1.874]	0.960 [0.361, 2.549]	-0.9 [-25.2, 23.4]	1.000
		Irbesartan	36	12 (33.3)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	10 (25.6)	1.054 [0.483, 2.300]	1.073 [0.379, 3.034]	1.3 [-20.8, 23.4]	1.000
		Irbesartan	37	9 (24.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEC_SSIM: Incidence of AESI cardiovascular system during double-blind period by subgroup
Safety Set

AESI cardiovascular system

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.953
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	41 (32.3)	1.068 [0.742, 1.536]	1.100 [0.648, 1.867]	2.1 [-10.1, 14.2]	0.788
		Irbesartan	129	39 (30.2)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	16 (32.7)	0.980 [0.556, 1.727]	0.970 [0.416, 2.261]	-0.7 [-21.5, 20.1]	1.000
		Irbesartan	48	16 (33.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	6 (23.1)	1.154 [0.403, 3.305]	1.200 [0.315, 4.578]	3.1 [-23.4, 29.5]	1.000
		Irbesartan	25	5 (20.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEC_SSIM: Incidence of AESI cardiovascular system during double-blind period by subgroup
Safety Set

AESI cardiovascular system

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.879
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	26 (31.7)	1.208 [0.743, 1.963]	1.304 [0.660, 2.579]	5.5 [-9.7, 20.6]	0.491
		Irbesartan	80	21 (26.3)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	15 (33.3)	0.907 [0.522, 1.577]	0.861 [0.368, 2.013]	-3.4 [-24.8, 18.0]	0.830
		Irbesartan	49	18 (36.7)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	16 (32.7)	0.980 [0.556, 1.727]	0.970 [0.416, 2.261]	-0.7 [-21.5, 20.1]	1.000
		Irbesartan	48	16 (33.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	6 (23.1)	1.154 [0.403, 3.305]	1.200 [0.315, 4.578]	3.1 [-23.4, 29.5]	1.000
		Irbesartan	25	5 (20.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEC_SSIM: Incidence of AESI cardiovascular system during double-blind period by subgroup
Safety Set

AESI cardiovascular system

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.117
<= 1.75 g/day	Double-blind period	Sparsentan	98	31 (31.6)	1.401 [0.871, 2.254]	1.586 [0.831, 3.027]	9.1 [-4.5, 22.6]	0.194
		Irbesartan	93	21 (22.6)				
> 1.75 g/day	Double-blind period	Sparsentan	104	32 (30.8)	0.860 [0.587, 1.261]	0.798 [0.450, 1.413]	-5.0 [-18.6, 8.6]	0.470
		Irbesartan	109	39 (35.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEC_SSIM: Incidence of AESI cardiovascular system during double-blind period by subgroup
Safety Set

AESI cardiovascular system

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.987
Yes	Double-blind period	Sparsentan	90	28 (31.1)	1.053 [0.674, 1.644]	1.077 [0.568, 2.041]	1.6 [-13.1, 16.2]	0.871
		Irbesartan	88	26 (29.5)				
No	Double-blind period	Sparsentan	112	35 (31.3)	1.048 [0.707, 1.553]	1.070 [0.607, 1.884]	1.4 [-11.5, 14.3]	0.885
		Irbesartan	114	34 (29.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEC_SSIM: Incidence of AESI cardiovascular system during double-blind period by subgroup
Safety Set

AESI cardiovascular system

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.728
<= 5 years	Double-blind period	Sparsentan	113	35 (31.0)	1.009 [0.690, 1.474]	1.012 [0.585, 1.753]	0.3 [-12.3, 12.8]	1.000
		Irbesartan	127	39 (30.7)				
> 5 years	Double-blind period	Sparsentan	89	28 (31.5)	1.124 [0.699, 1.807]	1.180 [0.602, 2.316]	3.5 [-11.8, 18.7]	0.732
		Irbesartan	75	21 (28.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEC_SSIM: Incidence of AESI cardiovascular system during double-blind period by subgroup
Safety Set

AESI cardiovascular system

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.276
Yes	Double-blind period	Sparsentan	155	55 (35.5)	1.143 [0.835, 1.563]	1.221 [0.764, 1.951]	4.4 [-6.6, 15.4]	0.474
		Irbesartan	161	50 (31.1)				
No	Double-blind period	Sparsentan	47	8 (17.0)	0.698 [0.304, 1.600]	0.636 [0.224, 1.804]	-7.4 [-26.6, 11.9]	0.436
		Irbesartan	41	10 (24.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AECN_SSIM: Incidence of AESI cardiovascular system during double-blind period – non-severe by subgroup
Safety Set

AESI cardiovascular system - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.075
Male	Double-blind period	Sparsentan	139	39 (28.1)	0.892 [0.622, 1.278]	0.849 [0.509, 1.416]	-3.4 [-14.8, 8.0]	0.603
		Irbesartan	143	45 (31.5)				
Female	Double-blind period	Sparsentan	63	23 (36.5)	1.657 [0.928, 2.959]	2.035 [0.913, 4.534]	14.5 [-3.1, 32.0]	0.112
		Irbesartan	59	13 (22.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AECN_SSIM: Incidence of AESI cardiovascular system during double-blind period – non-severe by subgroup
Safety Set

AESI cardiovascular system - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.200
<= 45 years	Double-blind period	Sparsentan	96	24 (25.0)	0.853 [0.538, 1.355]	0.805 [0.427, 1.515]	-4.3 [-17.8, 9.2]	0.523
		Irbesartan	99	29 (29.3)				
> 45 years	Double-blind period	Sparsentan	106	38 (35.8)	1.273 [0.853, 1.900]	1.426 [0.795, 2.559]	7.7 [-5.9, 21.3]	0.240
		Irbesartan	103	29 (28.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AECN_SSIM: Incidence of AESI cardiovascular system during double-blind period – non-severe by subgroup
Safety Set

AESI cardiovascular system - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.183
<= 18 years	Double-blind period	Sparsentan	9	5 (55.6)	1.389 [0.409, 4.715]	1.875 [0.204, 17.269]	15.6 [-53.8, 84.9]	1.000
		Irbesartan	5	2 (40.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	23 (22.5)	0.768 [0.484, 1.220]	0.701 [0.377, 1.304]	-6.8 [-19.5, 5.9]	0.276
		Irbesartan	109	32 (29.4)				
> 40 years	Double-blind period	Sparsentan	91	34 (37.4)	1.370 [0.889, 2.112]	1.591 [0.845, 2.995]	10.1 [-4.6, 24.8]	0.155
		Irbesartan	88	24 (27.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AECN_SSIM: Incidence of AESI cardiovascular system during double-blind period – non-severe by subgroup
Safety Set

AESI cardiovascular system - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.458
North America	Double-blind period	Sparsentan	35	6 (17.1)	0.657 [0.274, 1.578]	0.586 [0.196, 1.758]	-8.9 [-29.3, 11.4]	0.423
		Irbesartan	46	12 (26.1)				
Europe	Double-blind period	Sparsentan	98	36 (36.7)	1.207 [0.826, 1.764]	1.327 [0.750, 2.350]	6.3 [-7.4, 20.0]	0.382
		Irbesartan	115	35 (30.4)				
Asia Pacific	Double-blind period	Sparsentan	69	20 (29.0)	1.080 [0.578, 2.020]	1.113 [0.469, 2.643]	2.2 [-17.1, 21.4]	1.000
		Irbesartan	41	11 (26.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AECN_SSIM: Incidence of AESI cardiovascular system during double-blind period – non-severe by subgroup
Safety Set

AESI cardiovascular system - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.167
< 27 kg/m**2	Double-blind period	Sparsentan	83	21 (25.3)	0.820 [0.509, 1.322]	0.759 [0.392, 1.470]	-5.5 [-19.9, 8.8]	0.504
		Irbesartan	94	29 (30.9)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	41 (34.5)	1.271 [0.854, 1.892]	1.414 [0.800, 2.499]	7.4 [-5.5, 20.2]	0.252
		Irbesartan	107	29 (27.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AECN_SSIM: Incidence of AESI cardiovascular system during double-blind period – non-severe by subgroup
Safety Set

AESI cardiovascular system - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.989
eGFR Low and UP High	Double-blind period	Sparsentan	71	23 (32.4)	1.142 [0.697, 1.871]	1.209 [0.595, 2.457]	4.0 [-12.3, 20.4]	0.718
		Irbesartan	74	21 (28.4)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	17 (30.9)	1.000 [0.572, 1.749]	1.000 [0.445, 2.245]	0.0 [-19.1, 19.1]	1.000
		Irbesartan	55	17 (30.9)				
eGFR High and UP High	Double-blind period	Sparsentan	37	12 (32.4)	1.061 [0.539, 2.090]	1.091 [0.406, 2.931]	1.9 [-22.2, 25.9]	1.000
		Irbesartan	36	11 (30.6)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	10 (25.6)	1.054 [0.483, 2.300]	1.073 [0.379, 3.034]	1.3 [-20.8, 23.4]	1.000
		Irbesartan	37	9 (24.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AECN_SSIM: Incidence of AESI cardiovascular system during double-blind period – non-severe by subgroup
Safety Set

AESI cardiovascular system - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.937
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	40 (31.5)	1.098 [0.756, 1.596]	1.143 [0.670, 1.951]	2.8 [-9.2, 14.8]	0.683
		Irbesartan	129	37 (28.7)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	16 (32.7)	0.980 [0.556, 1.727]	0.970 [0.416, 2.261]	-0.7 [-21.5, 20.1]	1.000
		Irbesartan	48	16 (33.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	6 (23.1)	1.154 [0.403, 3.305]	1.200 [0.315, 4.578]	3.1 [-23.4, 29.5]	1.000
		Irbesartan	25	5 (20.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AECN_SSIM: Incidence of AESI cardiovascular system during double-blind period – non-severe by subgroup
Safety Set

AESI cardiovascular system - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.820
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	26 (31.7)	1.268 [0.773, 2.080]	1.393 [0.700, 2.770]	6.7 [-8.4, 21.8]	0.386
		Irbesartan	80	20 (25.0)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	14 (31.1)	0.897 [0.502, 1.602]	0.850 [0.359, 2.014]	-3.6 [-24.7, 17.5]	0.827
		Irbesartan	49	17 (34.7)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	16 (32.7)	0.980 [0.556, 1.727]	0.970 [0.416, 2.261]	-0.7 [-21.5, 20.1]	1.000
		Irbesartan	48	16 (33.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	6 (23.1)	1.154 [0.403, 3.305]	1.200 [0.315, 4.578]	3.1 [-23.4, 29.5]	1.000
		Irbesartan	25	5 (20.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AECN_SSIM: Incidence of AESI cardiovascular system during double-blind period – non-severe by subgroup
Safety Set

AESI cardiovascular system - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.088
<= 1.75 g/day	Double-blind period	Sparsentan	98	31 (31.6)	1.471 [0.905, 2.390]	1.689 [0.879, 3.244]	10.1 [-3.4, 23.6]	0.141
		Irbesartan	93	20 (21.5)				
> 1.75 g/day	Double-blind period	Sparsentan	104	31 (29.8)	0.855 [0.578, 1.264]	0.793 [0.446, 1.411]	-5.1 [-18.5, 8.4]	0.466
		Irbesartan	109	38 (34.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AECN_SSIM: Incidence of AESI cardiovascular system during double-blind period – non-severe by subgroup
Safety Set

AESI cardiovascular system - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.943
Yes	Double-blind period	Sparsentan	90	27 (30.0)	1.056 [0.668, 1.669]	1.080 [0.566, 2.061]	1.6 [-12.9, 16.1]	0.870
		Irbesartan	88	25 (28.4)				
No	Double-blind period	Sparsentan	112	35 (31.3)	1.080 [0.725, 1.607]	1.116 [0.632, 1.970]	2.3 [-10.5, 15.1]	0.772
		Irbesartan	114	33 (28.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AECN_SSIM: Incidence of AESI cardiovascular system during double-blind period – non-severe by subgroup
Safety Set

AESI cardiovascular system - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.952
<= 5 years	Double-blind period	Sparsentan	113	35 (31.0)	1.063 [0.722, 1.565]	1.091 [0.628, 1.897]	1.8 [-10.6, 14.3]	0.779
		Irbesartan	127	37 (29.1)				
> 5 years	Double-blind period	Sparsentan	89	27 (30.3)	1.083 [0.670, 1.752]	1.120 [0.569, 2.204]	2.3 [-12.8, 17.5]	0.863
		Irbesartan	75	21 (28.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AECN_SSIM: Incidence of AESI cardiovascular system during double-blind period – non-severe by subgroup
Safety Set

AESI cardiovascular system - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.256
Yes	Double-blind period	Sparsentan	155	54 (34.8)	1.169 [0.848, 1.610]	1.259 [0.785, 2.019]	5.0 [-5.9, 16.0]	0.400
		Irbesartan	161	48 (29.8)				
No	Double-blind period	Sparsentan	47	8 (17.0)	0.698 [0.304, 1.600]	0.636 [0.224, 1.804]	-7.4 [-26.6, 11.9]	0.436
		Irbesartan	41	10 (24.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AECC_SSIM: Incidence of AESI cardiovascular system during double-blind period – severe by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AECS_SSIM: Incidence of AESI cardiovascular system during double-blind period – serious by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEH_SSIM: Incidence of AESI hypotension during double-blind period by subgroup
Safety Set

AESI hypotension

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Sex	Double-blind period	Sparsentan					Interaction test:	0.494	
Male	Double-blind period	Sparsentan	139	34 (24.5)	2.058 [1.207, 3.507]	2.400 [1.269, 4.539]	12.6 [3.0, 22.2]	0.008	*
		Irbesartan	143	17 (11.9)					
Female	Double-blind period	Sparsentan	63	24 (38.1)	2.810 [1.372, 5.755]	3.923 [1.591, 9.671]	24.5 [8.1, 41.0]	0.004	*
		Irbesartan	59	8 (13.6)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEH_SSIM: Incidence of AESI hypotension during double-blind period by subgroup
Safety Set

AESI hypotension

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Age	Double-blind period	Sparsentan					Interaction test:	0.465	
<= 45 years	Double-blind period	Sparsentan	96	27 (28.1)	1.989 [1.112, 3.557]	2.376 [1.157, 4.878]	14.0 [1.6, 26.3]	0.022	*
		Irbesartan	99	14 (14.1)					
> 45 years	Double-blind period	Sparsentan	106	31 (29.2)	2.738 [1.455, 5.153]	3.457 [1.629, 7.336]	18.6 [7.1, 30.0]	<0.001	*
		Irbesartan	103	11 (10.7)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEH_SSIM: Incidence of AESI hypotension during double-blind period by subgroup
Safety Set

AESI hypotension

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.541	
<= 18 years	Double-blind period	Sparsentan	9	3 (33.3)	4.200 + [0.259, 68.038]	5.923 + [0.248, 141.482]	33.3 [-13.0, 79.7]	0.258	
		Irbesartan	5	0 (0.0)					
> 18 to 40 years	Double-blind period	Sparsentan	102	30 (29.4)	1.886 [1.110, 3.205]	2.255 [1.154, 4.407]	13.8 [1.7, 25.9]	0.020	*
		Irbesartan	109	17 (15.6)					
> 40 years	Double-blind period	Sparsentan	91	25 (27.5)	3.022 [1.441, 6.335]	3.788 [1.602, 8.954]	18.4 [6.3, 30.5]	0.002	*
		Irbesartan	88	8 (9.1)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEH_SSIM: Incidence of AESI hypotension during double-blind period by subgroup
Safety Set

AESI hypotension

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.135	
North America	Double-blind period	Sparsentan	35	8 (22.9)	2.629 [0.860, 8.031]	3.111 [0.853, 11.347]	14.2 [-4.5, 32.8]	0.114	
		Irbesartan	46	4 (8.7)					
Europe	Double-blind period	Sparsentan	98	24 (24.5)	3.129 [1.528, 6.410]	3.820 [1.680, 8.687]	16.7 [5.9, 27.4]	0.001	*
		Irbesartan	115	9 (7.8)					
Asia Pacific	Double-blind period	Sparsentan	69	26 (37.7)	1.287 [0.732, 2.264]	1.461 [0.637, 3.353]	8.4 [-11.6, 28.4]	0.412	
		Irbesartan	41	12 (29.3)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEH_SSIM: Incidence of AESI hypotension during double-blind period by subgroup
Safety Set

AESI hypotension								
Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.856
< 27 kg/m**2	Double-blind period	Sparsentan	83	28 (33.7)	2.265 [1.281, 4.004]	2.909 [1.405, 6.022]	18.8 [5.2, 32.4]	0.004 *
		Irbesartan	94	14 (14.9)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	30 (25.2)	2.452 [1.294, 4.649]	2.942 [1.391, 6.219]	14.9 [4.3, 25.5]	0.005 *
		Irbesartan	107	11 (10.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEH_SSIM: Incidence of AESI hypotension during double-blind period by subgroup
Safety Set

AESI hypotension

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.626	
eGFR Low and UP High	Double-blind period	Sparsentan	71	18 (25.4)	1.706 [0.868, 3.352]	1.945 [0.845, 4.480]	10.5 [-3.9, 24.8]	0.147	
		Irbesartan	74	11 (14.9)					
eGFR Low and UP Low	Double-blind period	Sparsentan	55	18 (32.7)	2.250 [1.069, 4.736]	2.858 [1.119, 7.299]	18.2 [0.9, 35.5]	0.042	*
		Irbesartan	55	8 (14.5)					
eGFR High and UP High	Double-blind period	Sparsentan	37	10 (27.0)	3.243 [0.971, 10.831]	4.074 [1.018, 16.305]	18.7 [-1.0, 38.4]	0.064	
		Irbesartan	36	3 (8.3)					
eGFR High and UP Low	Double-blind period	Sparsentan	39	12 (30.8)	3.795 [1.163, 12.381]	5.037 [1.290, 19.671]	22.7 [3.1, 42.2]	0.020	*
		Irbesartan	37	3 (8.1)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEH_SSIM: Incidence of AESI hypotension during double-blind period by subgroup
Safety Set

AESI hypotension

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.448	
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	38 (29.9)	2.031 [1.241, 3.327]	2.472 [1.333, 4.584]	15.2 [4.4, 26.0]	0.004	*
		Irbesartan	129	19 (14.7)					
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	14 (28.6)	4.571 [1.402, 14.903]	6.000 [1.598, 22.525]	22.3 [5.9, 38.8]	0.006	*
		Irbesartan	48	3 (6.3)					
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	6 (23.1)	1.923 [0.539, 6.865]	2.200 [0.485, 9.983]	11.1 [-13.5, 35.6]	0.465	
		Irbesartan	25	3 (12.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEH_SSIM: Incidence of AESI hypotension during double-blind period by subgroup
Safety Set

AESI hypotension

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.577	
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	20 (24.4)	1.774 [0.909, 3.460]	2.023 [0.899, 4.556]	10.6 [-2.6, 23.8]	0.110	
		Irbesartan	80	11 (13.8)					
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	18 (40.0)	2.450 [1.183, 5.073]	3.417 [1.303, 8.960]	23.7 [3.9, 43.5]	0.012	*
		Irbesartan	49	8 (16.3)					
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	14 (28.6)	4.571 [1.402, 14.903]	6.000 [1.598, 22.525]	22.3 [5.9, 38.8]	0.006	*
		Irbesartan	48	3 (6.3)					
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	6 (23.1)	1.923 [0.539, 6.865]	2.200 [0.485, 9.983]	11.1 [-13.5, 35.6]	0.465	
		Irbesartan	25	3 (12.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEH_SSIM: Incidence of AESI hypotension during double-blind period by subgroup
Safety Set

AESI hypotension

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.117	
<= 1.75 g/day	Double-blind period	Sparsentan	98	30 (30.6)	3.559 [1.721, 7.358]	4.688 [2.018, 10.886]	22.0 [10.2, 33.8]	<0.001	*
		Irbesartan	93	8 (8.6)					
> 1.75 g/day	Double-blind period	Sparsentan	104	28 (26.9)	1.726 [1.007, 2.961]	1.994 [1.015, 3.915]	11.3 [-0.5, 23.2]	0.046	*
		Irbesartan	109	17 (15.6)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEH_SSIM: Incidence of AESI hypotension during double-blind period by subgroup
Safety Set

AESI hypotension

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.458	
Yes	Double-blind period	Sparsentan	90	17 (18.9)	1.847 [0.870, 3.920]	2.044 [0.858, 4.871]	8.7 [-2.7, 20.1]	0.137	
		Irbesartan	88	9 (10.2)					
No	Double-blind period	Sparsentan	112	41 (36.6)	2.608 [1.558, 4.368]	3.537 [1.840, 6.799]	22.6 [10.7, 34.4]	<0.001	*
		Irbesartan	114	16 (14.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEH_SSIM: Incidence of AESI hypotension during double-blind period by subgroup
Safety Set

AESI hypotension

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.963	
<= 5 years	Double-blind period	Sparsentan	113	31 (27.4)	2.323 [1.324, 4.074]	2.823 [1.431, 5.567]	15.6 [4.8, 26.4]	0.003	*
		Irbesartan	127	15 (11.8)					
> 5 years	Double-blind period	Sparsentan	89	27 (30.3)	2.275 [1.179, 4.390]	2.831 [1.266, 6.329]	17.0 [3.5, 30.5]	0.014	*
		Irbesartan	75	10 (13.3)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEH_SSIM: Incidence of AESI hypotension during double-blind period by subgroup
Safety Set

AESI hypotension

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.209	
Yes	Double-blind period	Sparsentan	155	42 (27.1)	2.727 [1.602, 4.641]	3.368 [1.801, 6.300]	17.2 [8.1, 26.2]	<0.001	*
		Irbesartan	161	16 (9.9)					
No	Double-blind period	Sparsentan	47	16 (34.0)	1.551 [0.769, 3.126]	1.835 [0.707, 4.766]	12.1 [-8.7, 32.9]	0.243	
		Irbesartan	41	9 (22.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEHN_SSIM: Incidence of AESI hypotension during double-blind period – non-severe by subgroup
Safety Set

AESI hypotension - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Sex	Double-blind period	Sparsentan					Interaction test:	0.557	
Male	Double-blind period	Sparsentan	139	34 (24.5)	2.058 [1.207, 3.507]	2.400 [1.269, 4.539]	12.6 [3.0, 22.2]	0.008	*
		Irbesartan	143	17 (11.9)					
Female	Double-blind period	Sparsentan	63	23 (36.5)	2.692 [1.308, 5.542]	3.666 [1.483, 9.059]	22.9 [6.6, 39.3]	0.004	*
		Irbesartan	59	8 (13.6)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEHN_SSIM: Incidence of AESI hypotension during double-blind period – non-severe by subgroup
Safety Set

AESI hypotension - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Age	Double-blind period	Sparsentan					Interaction test:	0.514	
<= 45 years	Double-blind period	Sparsentan	96	27 (28.1)	1.989 [1.112, 3.557]	2.376 [1.157, 4.878]	14.0 [1.6, 26.3]	0.022	*
		Irbesartan	99	14 (14.1)					
> 45 years	Double-blind period	Sparsentan	106	30 (28.3)	2.650 [1.404, 5.003]	3.301 [1.552, 7.022]	17.6 [6.2, 29.0]	0.002	*
		Irbesartan	103	11 (10.7)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEHN_SSIM: Incidence of AESI hypotension during double-blind period – non-severe by subgroup
Safety Set

AESI hypotension - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.588	
<= 18 years	Double-blind period	Sparsentan	9	3 (33.3)	4.200 + [0.259, 68.038]	5.923 + [0.248, 141.482]	33.3 [-13.0, 79.7]	0.258	
		Irbesartan	5	0 (0.0)					
> 18 to 40 years	Double-blind period	Sparsentan	102	30 (29.4)	1.886 [1.110, 3.205]	2.255 [1.154, 4.407]	13.8 [1.7, 25.9]	0.020	*
		Irbesartan	109	17 (15.6)					
> 40 years	Double-blind period	Sparsentan	91	24 (26.4)	2.901 [1.378, 6.108]	3.582 [1.511, 8.495]	17.3 [5.3, 29.3]	0.003	*
		Irbesartan	88	8 (9.1)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEHN_SSIM: Incidence of AESI hypotension during double-blind period – non-severe by subgroup
Safety Set

AESI hypotension - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.159	
North America	Double-blind period	Sparsentan	35	8 (22.9)	2.629 [0.860, 8.031]	3.111 [0.853, 11.347]	14.2 [-4.5, 32.8]	0.114	
		Irbesartan	46	4 (8.7)					
Europe	Double-blind period	Sparsentan	98	23 (23.5)	2.999 [1.457, 6.173]	3.612 [1.582, 8.245]	15.6 [5.0, 26.3]	0.002	*
		Irbesartan	115	9 (7.8)					
Asia Pacific	Double-blind period	Sparsentan	69	26 (37.7)	1.287 [0.732, 2.264]	1.461 [0.637, 3.353]	8.4 [-11.6, 28.4]	0.412	
		Irbesartan	41	12 (29.3)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEHN_SSIM: Incidence of AESI hypotension during double-blind period – non-severe by subgroup
Safety Set

AESI hypotension - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.792	
< 27 kg/m**2	Double-blind period	Sparsentan	83	27 (32.5)	2.184 [1.230, 3.878]	2.755 [1.327, 5.719]	17.6 [4.1, 31.2]	0.007	*
		Irbesartan	94	14 (14.9)					
>= 27 kg/m**2	Double-blind period	Sparsentan	119	30 (25.2)	2.452 [1.294, 4.649]	2.942 [1.391, 6.219]	14.9 [4.3, 25.5]	0.005	*
		Irbesartan	107	11 (10.3)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEHN_SSIM: Incidence of AESI hypotension during double-blind period – non-severe by subgroup
Safety Set

AESI hypotension - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.570	
eGFR Low and UP High	Double-blind period	Sparsentan	71	17 (23.9)	1.611 [0.812, 3.195]	1.803 [0.778, 4.181]	9.1 [-5.1, 23.3]	0.208	
		Irbesartan	74	11 (14.9)					
eGFR Low and UP Low	Double-blind period	Sparsentan	55	18 (32.7)	2.250 [1.069, 4.736]	2.858 [1.119, 7.299]	18.2 [0.9, 35.5]	0.042	*
		Irbesartan	55	8 (14.5)					
eGFR High and UP High	Double-blind period	Sparsentan	37	10 (27.0)	3.243 [0.971, 10.831]	4.074 [1.018, 16.305]	18.7 [-1.0, 38.4]	0.064	
		Irbesartan	36	3 (8.3)					
eGFR High and UP Low	Double-blind period	Sparsentan	39	12 (30.8)	3.795 [1.163, 12.381]	5.037 [1.290, 19.671]	22.7 [3.1, 42.2]	0.020	*
		Irbesartan	37	3 (8.1)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEHN_SSIM: Incidence of AESI hypotension during double-blind period – non-severe by subgroup
Safety Set

AESI hypotension - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.429	
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	37 (29.1)	1.978 [1.205, 3.248]	2.380 [1.281, 4.422]	14.4 [3.6, 25.2]	0.006	*
		Irbesartan	129	19 (14.7)					
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	14 (28.6)	4.571 [1.402, 14.903]	6.000 [1.598, 22.525]	22.3 [5.9, 38.8]	0.006	*
		Irbesartan	48	3 (6.3)					
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	6 (23.1)	1.923 [0.539, 6.865]	2.200 [0.485, 9.983]	11.1 [-13.5, 35.6]	0.465	
		Irbesartan	25	3 (12.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEHN_SSIM: Incidence of AESI hypotension during double-blind period – non-severe by subgroup
Safety Set

AESI hypotension - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.587	
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	20 (24.4)	1.774 [0.909, 3.460]	2.023 [0.899, 4.556]	10.6 [-2.6, 23.8]	0.110	
		Irbesartan	80	11 (13.8)					
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	17 (37.8)	2.314 [1.108, 4.833]	3.112 [1.182, 8.192]	21.5 [1.8, 41.1]	0.021	*
		Irbesartan	49	8 (16.3)					
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	14 (28.6)	4.571 [1.402, 14.903]	6.000 [1.598, 22.525]	22.3 [5.9, 38.8]	0.006	*
		Irbesartan	48	3 (6.3)					
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	6 (23.1)	1.923 [0.539, 6.865]	2.200 [0.485, 9.983]	11.1 [-13.5, 35.6]	0.465	
		Irbesartan	25	3 (12.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEHN_SSIM: Incidence of AESI hypotension during double-blind period – non-severe by subgroup
Safety Set

AESI hypotension - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.101	
<= 1.75 g/day	Double-blind period	Sparsentan	98	30 (30.6)	3.559 [1.721, 7.358]	4.688 [2.018, 10.886]	22.0 [10.2, 33.8]	<0.001	*
		Irbesartan	93	8 (8.6)					
> 1.75 g/day	Double-blind period	Sparsentan	104	27 (26.0)	1.665 [0.966, 2.868]	1.898 [0.963, 3.739]	10.4 [-1.4, 22.1]	0.065	
		Irbesartan	109	17 (15.6)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEHN_SSIM: Incidence of AESI hypotension during double-blind period – non-severe by subgroup
Safety Set

AESI hypotension - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.387	
Yes	Double-blind period	Sparsentan	90	16 (17.8)	1.738 [0.811, 3.724]	1.898 [0.790, 4.558]	7.6 [-3.7, 18.8]	0.196	
		Irbesartan	88	9 (10.2)					
No	Double-blind period	Sparsentan	112	41 (36.6)	2.608 [1.558, 4.368]	3.537 [1.840, 6.799]	22.6 [10.7, 34.4]	<0.001	*
		Irbesartan	114	16 (14.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEHN_SSIM: Incidence of AESI hypotension during double-blind period – non-severe by subgroup
Safety Set

AESI hypotension - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.895	
<= 5 years	Double-blind period	Sparsentan	113	31 (27.4)	2.323 [1.324, 4.074]	2.823 [1.431, 5.567]	15.6 [4.8, 26.4]	0.003	*
		Irbesartan	127	15 (11.8)					
> 5 years	Double-blind period	Sparsentan	89	26 (29.2)	2.191 [1.131, 4.245]	2.683 [1.196, 6.015]	15.9 [2.5, 29.3]	0.022	*
		Irbesartan	75	10 (13.3)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEHN_SSIM: Incidence of AESI hypotension during double-blind period – non-severe by subgroup
Safety Set

AESI hypotension - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.230	
Yes	Double-blind period	Sparsentan	155	41 (26.5)	2.662 [1.560, 4.540]	3.259 [1.740, 6.106]	16.5 [7.5, 25.5]	<0.001	*
		Irbesartan	161	16 (9.9)					
No	Double-blind period	Sparsentan	47	16 (34.0)	1.551 [0.769, 3.126]	1.835 [0.707, 4.766]	12.1 [-8.7, 32.9]	0.243	
		Irbesartan	41	9 (22.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEHC_SSIM: Incidence of AESI hypotension during double-blind period – severe by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEHS_SSIM: Incidence of AESI hypotension during double-blind period – serious by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEL_SSIM: Incidence of AESI hepatic disorders during double-blind period by subgroup
Safety Set

AESI hepatic disorders

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.130
Male	Double-blind period	Sparsentan	139	17 (12.2)	1.943 [0.897, 4.212]	2.075 [0.892, 4.827]	5.9 [-1.5, 13.4]	0.101
		Irbesartan	143	9 (6.3)				
Female	Double-blind period	Sparsentan	63	1 (1.6)	0.312 [0.033, 2.918]	0.301 [0.030, 2.979]	-3.5 [-11.5, 4.5]	0.353
		Irbesartan	59	3 (5.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEL_SSIM: Incidence of AESI hepatic disorders during double-blind period by subgroup
Safety Set

AESI hepatic disorders

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.106
<= 45 years	Double-blind period	Sparsentan	96	5 (5.2)	0.737 [0.242, 2.241]	0.722 [0.221, 2.359]	-1.9 [-9.6, 5.9]	0.768
		Irbesartan	99	7 (7.1)				
> 45 years	Double-blind period	Sparsentan	106	13 (12.3)	2.526 [0.934, 6.834]	2.740 [0.940, 7.985]	7.4 [-1.0, 15.9]	0.083
		Irbesartan	103	5 (4.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEL_SSIM: Incidence of AESI hepatic disorders during double-blind period by subgroup
Safety Set

AESI hepatic disorders

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.404
<= 18 years	Double-blind period	Sparsentan	9	0 (0.0)	0.200 + [0.010, 4.166]	0.158 + [0.005, 4.691]	-20.0 [-70.6, 30.6]	0.357
		Irbesartan	5	1 (20.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	10 (9.8)	1.781 [0.672, 4.724]	1.866 [0.653, 5.335]	4.3 [-3.8, 12.4]	0.301
		Irbesartan	109	6 (5.5)				
> 40 years	Double-blind period	Sparsentan	91	8 (8.8)	1.547 [0.526, 4.548]	1.600 [0.503, 5.094]	3.1 [-5.6, 11.8]	0.567
		Irbesartan	88	5 (5.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEL_SSIM: Incidence of AESI hepatic disorders during double-blind period by subgroup
Safety Set

AESI hepatic disorders

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.353
North America	Double-blind period	Sparsentan	35	5 (14.3)	1.643 [0.476, 5.672]	1.750 [0.433, 7.067]	5.6 [-11.1, 22.3]	0.490
		Irbesartan	46	4 (8.7)				
Europe	Double-blind period	Sparsentan	98	10 (10.2)	2.347 [0.830, 6.634]	2.500 [0.824, 7.582]	5.9 [-2.1, 13.9]	0.112
		Irbesartan	115	5 (4.3)				
Asia Pacific	Double-blind period	Sparsentan	69	3 (4.3)	0.594 [0.126, 2.808]	0.576 [0.111, 2.996]	-3.0 [-14.2, 8.3]	0.669
		Irbesartan	41	3 (7.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEL_SSIM: Incidence of AESI hepatic disorders during double-blind period by subgroup
Safety Set

AESI hepatic disorders

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.282
< 27 kg/m**2	Double-blind period	Sparsentan	83	6 (7.2)	0.971 [0.340, 2.773]	0.968 [0.312, 3.006]	-0.2 [-9.0, 8.6]	1.000
		Irbesartan	94	7 (7.4)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	12 (10.1)	2.158 [0.786, 5.925]	2.288 [0.779, 6.723]	5.4 [-2.2, 13.0]	0.138
		Irbesartan	107	5 (4.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEL_SSIM: Incidence of AESI hepatic disorders during double-blind period by subgroup
Safety Set

AESI hepatic disorders

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.720
eGFR Low and UP High	Double-blind period	Sparsentan	71	8 (11.3)	1.668 [0.573, 4.856]	1.752 [0.545, 5.637]	4.5 [-6.2, 15.2]	0.394
		Irbesartan	74	5 (6.8)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	2 (3.6)	1.000 [0.146, 6.848]	1.000 [0.136, 7.364]	0.0 [-8.8, 8.8]	1.000
		Irbesartan	55	2 (3.6)				
eGFR High and UP High	Double-blind period	Sparsentan	37	4 (10.8)	0.973 [0.263, 3.598]	0.970 [0.223, 4.212]	-0.3 [-17.4, 16.8]	1.000
		Irbesartan	36	4 (11.1)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	4 (10.3)	3.795 [0.444, 32.404]	4.114 [0.438, 38.653]	7.6 [-5.9, 21.0]	0.359
		Irbesartan	37	1 (2.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEL_SSIM: Incidence of AESI hepatic disorders during double-blind period by subgroup
Safety Set

AESI hepatic disorders

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.219
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	10 (7.9)	1.451 [0.570, 3.694]	1.490 [0.549, 4.044]	2.4 [-4.4, 9.3]	0.463
		Irbesartan	129	7 (5.4)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	7 (14.3)	3.429 [0.750, 15.680]	3.833 [0.754, 19.490]	10.1 [-3.3, 23.5]	0.159
		Irbesartan	48	2 (4.2)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8)	0.321 [0.036, 2.880]	0.293 [0.028, 3.029]	-8.2 [-26.8, 10.5]	0.350
		Irbesartan	25	3 (12.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEL_SSIM: Incidence of AESI hepatic disorders during double-blind period by subgroup
Safety Set

AESI hepatic disorders

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.370
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	8 (9.8)	1.561 [0.533, 4.569]	1.622 [0.507, 5.186]	3.5 [-6.1, 13.1]	0.565
		Irbesartan	80	5 (6.3)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	2 (4.4)	1.089 [0.160, 7.410]	1.093 [0.147, 8.102]	0.4 [-10.0, 10.7]	1.000
		Irbesartan	49	2 (4.1)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	7 (14.3)	3.429 [0.750, 15.680]	3.833 [0.754, 19.490]	10.1 [-3.3, 23.5]	0.159
		Irbesartan	48	2 (4.2)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8)	0.321 [0.036, 2.880]	0.293 [0.028, 3.029]	-8.2 [-26.8, 10.5]	0.350
		Irbesartan	25	3 (12.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEL_SSIM: Incidence of AESI hepatic disorders during double-blind period by subgroup
Safety Set

AESI hepatic disorders

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.540
<= 1.75 g/day	Double-blind period	Sparsentan	98	6 (6.1)	1.139 [0.360, 3.605]	1.148 [0.338, 3.897]	0.7 [-6.9, 8.4]	1.000
		Irbesartan	93	5 (5.4)				
> 1.75 g/day	Double-blind period	Sparsentan	104	12 (11.5)	1.797 [0.736, 4.387]	1.901 [0.718, 5.033]	5.1 [-3.5, 13.7]	0.233
		Irbesartan	109	7 (6.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEL_SSIM: Incidence of AESI hepatic disorders during double-blind period by subgroup
Safety Set

AESI hepatic disorders

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.181
Yes	Double-blind period	Sparsentan	90	9 (10.0)	2.933 [0.821, 10.478]	3.148 [0.823, 12.042]	6.6 [-1.8, 15.0]	0.133
		Irbesartan	88	3 (3.4)				
No	Double-blind period	Sparsentan	112	9 (8.0)	1.018 [0.420, 2.470]	1.019 [0.389, 2.671]	0.1 [-7.8, 8.1]	1.000
		Irbesartan	114	9 (7.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEL_SSIM: Incidence of AESI hepatic disorders during double-blind period by subgroup
Safety Set

AESI hepatic disorders

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.135
<= 5 years	Double-blind period	Sparsentan	113	9 (8.0)	1.012 [0.426, 2.400]	1.013 [0.396, 2.588]	0.1 [-7.6, 7.8]	1.000
		Irbesartan	127	10 (7.9)				
> 5 years	Double-blind period	Sparsentan	89	9 (10.1)	3.792 [0.845, 17.013]	4.106 [0.859, 19.632]	7.4 [-1.0, 15.9]	0.067
		Irbesartan	75	2 (2.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEL_SSIM: Incidence of AESI hepatic disorders during double-blind period by subgroup
Safety Set

AESI hepatic disorders

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.358
Yes	Double-blind period	Sparsentan	155	14 (9.0)	1.818 [0.785, 4.211]	1.899 [0.773, 4.663]	4.1 [-2.2, 10.3]	0.187
		Irbesartan	161	8 (5.0)				
No	Double-blind period	Sparsentan	47	4 (8.5)	0.872 [0.233, 3.269]	0.860 [0.201, 3.683]	-1.2 [-15.6, 13.1]	1.000
		Irbesartan	41	4 (9.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AELN_SSIM: Incidence of AESI hepatic disorders during double-blind period – non-severe by subgroup
Safety Set

AESI hepatic disorders - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.130
Male	Double-blind period	Sparsentan	139	17 (12.2)	1.943 [0.897, 4.212]	2.075 [0.892, 4.827]	5.9 [-1.5, 13.4]	0.101
		Irbesartan	143	9 (6.3)				
Female	Double-blind period	Sparsentan	63	1 (1.6)	0.312 [0.033, 2.918]	0.301 [0.030, 2.979]	-3.5 [-11.5, 4.5]	0.353
		Irbesartan	59	3 (5.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AELN_SSIM: Incidence of AESI hepatic disorders during double-blind period – non-severe by subgroup
Safety Set

AESI hepatic disorders - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.106
<= 45 years	Double-blind period	Sparsentan	96	5 (5.2)	0.737 [0.242, 2.241]	0.722 [0.221, 2.359]	-1.9 [-9.6, 5.9]	0.768
		Irbesartan	99	7 (7.1)				
> 45 years	Double-blind period	Sparsentan	106	13 (12.3)	2.526 [0.934, 6.834]	2.740 [0.940, 7.985]	7.4 [-1.0, 15.9]	0.083
		Irbesartan	103	5 (4.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AELN_SSIM: Incidence of AESI hepatic disorders during double-blind period – non-severe by subgroup
Safety Set

AESI hepatic disorders - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.404
<= 18 years	Double-blind period	Sparsentan	9	0 (0.0)	0.200 + [0.010, 4.166]	0.158 + [0.005, 4.691]	-20.0 [-70.6, 30.6]	0.357
		Irbesartan	5	1 (20.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	10 (9.8)	1.781 [0.672, 4.724]	1.866 [0.653, 5.335]	4.3 [-3.8, 12.4]	0.301
		Irbesartan	109	6 (5.5)				
> 40 years	Double-blind period	Sparsentan	91	8 (8.8)	1.547 [0.526, 4.548]	1.600 [0.503, 5.094]	3.1 [-5.6, 11.8]	0.567
		Irbesartan	88	5 (5.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AELN_SSIM: Incidence of AESI hepatic disorders during double-blind period – non-severe by subgroup
Safety Set

AESI hepatic disorders - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.353
North America	Double-blind period	Sparsentan	35	5 (14.3)	1.643 [0.476, 5.672]	1.750 [0.433, 7.067]	5.6 [-11.1, 22.3]	0.490
		Irbesartan	46	4 (8.7)				
Europe	Double-blind period	Sparsentan	98	10 (10.2)	2.347 [0.830, 6.634]	2.500 [0.824, 7.582]	5.9 [-2.1, 13.9]	0.112
		Irbesartan	115	5 (4.3)				
Asia Pacific	Double-blind period	Sparsentan	69	3 (4.3)	0.594 [0.126, 2.808]	0.576 [0.111, 2.996]	-3.0 [-14.2, 8.3]	0.669
		Irbesartan	41	3 (7.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AELN_SSIM: Incidence of AESI hepatic disorders during double-blind period – non-severe by subgroup
Safety Set

AESI hepatic disorders - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.282
< 27 kg/m**2	Double-blind period	Sparsentan	83	6 (7.2)	0.971 [0.340, 2.773]	0.968 [0.312, 3.006]	-0.2 [-9.0, 8.6]	1.000
		Irbesartan	94	7 (7.4)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	12 (10.1)	2.158 [0.786, 5.925]	2.288 [0.779, 6.723]	5.4 [-2.2, 13.0]	0.138
		Irbesartan	107	5 (4.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AELN_SSIM: Incidence of AESI hepatic disorders during double-blind period – non-severe by subgroup
Safety Set

AESI hepatic disorders - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.720
eGFR Low and UP High	Double-blind period	Sparsentan	71	8 (11.3)	1.668 [0.573, 4.856]	1.752 [0.545, 5.637]	4.5 [-6.2, 15.2]	0.394
		Irbesartan	74	5 (6.8)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	2 (3.6)	1.000 [0.146, 6.848]	1.000 [0.136, 7.364]	0.0 [-8.8, 8.8]	1.000
		Irbesartan	55	2 (3.6)				
eGFR High and UP High	Double-blind period	Sparsentan	37	4 (10.8)	0.973 [0.263, 3.598]	0.970 [0.223, 4.212]	-0.3 [-17.4, 16.8]	1.000
		Irbesartan	36	4 (11.1)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	4 (10.3)	3.795 [0.444, 32.404]	4.114 [0.438, 38.653]	7.6 [-5.9, 21.0]	0.359
		Irbesartan	37	1 (2.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AELN_SSIM: Incidence of AESI hepatic disorders during double-blind period – non-severe by subgroup
Safety Set

AESI hepatic disorders - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.219
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	10 (7.9)	1.451 [0.570, 3.694]	1.490 [0.549, 4.044]	2.4 [-4.4, 9.3]	0.463
		Irbesartan	129	7 (5.4)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	7 (14.3)	3.429 [0.750, 15.680]	3.833 [0.754, 19.490]	10.1 [-3.3, 23.5]	0.159
		Irbesartan	48	2 (4.2)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8)	0.321 [0.036, 2.880]	0.293 [0.028, 3.029]	-8.2 [-26.8, 10.5]	0.350
		Irbesartan	25	3 (12.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AELN_SSIM: Incidence of AESI hepatic disorders during double-blind period – non-severe by subgroup
Safety Set

AESI hepatic disorders - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.370
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	8 (9.8)	1.561 [0.533, 4.569]	1.622 [0.507, 5.186]	3.5 [-6.1, 13.1]	0.565
		Irbesartan	80	5 (6.3)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	2 (4.4)	1.089 [0.160, 7.410]	1.093 [0.147, 8.102]	0.4 [-10.0, 10.7]	1.000
		Irbesartan	49	2 (4.1)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	7 (14.3)	3.429 [0.750, 15.680]	3.833 [0.754, 19.490]	10.1 [-3.3, 23.5]	0.159
		Irbesartan	48	2 (4.2)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8)	0.321 [0.036, 2.880]	0.293 [0.028, 3.029]	-8.2 [-26.8, 10.5]	0.350
		Irbesartan	25	3 (12.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AELN_SSIM: Incidence of AESI hepatic disorders during double-blind period – non-severe by subgroup
Safety Set

AESI hepatic disorders - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.540
<= 1.75 g/day	Double-blind period	Sparsentan	98	6 (6.1)	1.139 [0.360, 3.605]	1.148 [0.338, 3.897]	0.7 [-6.9, 8.4]	1.000
		Irbesartan	93	5 (5.4)				
> 1.75 g/day	Double-blind period	Sparsentan	104	12 (11.5)	1.797 [0.736, 4.387]	1.901 [0.718, 5.033]	5.1 [-3.5, 13.7]	0.233
		Irbesartan	109	7 (6.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AELN_SSIM: Incidence of AESI hepatic disorders during double-blind period – non-severe by subgroup
Safety Set

AESI hepatic disorders - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.181
Yes	Double-blind period	Sparsentan	90	9 (10.0)	2.933 [0.821, 10.478]	3.148 [0.823, 12.042]	6.6 [-1.8, 15.0]	0.133
		Irbesartan	88	3 (3.4)				
No	Double-blind period	Sparsentan	112	9 (8.0)	1.018 [0.420, 2.470]	1.019 [0.389, 2.671]	0.1 [-7.8, 8.1]	1.000
		Irbesartan	114	9 (7.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AELN_SSIM: Incidence of AESI hepatic disorders during double-blind period – non-severe by subgroup
Safety Set

AESI hepatic disorders - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.135
<= 5 years	Double-blind period	Sparsentan	113	9 (8.0)	1.012 [0.426, 2.400]	1.013 [0.396, 2.588]	0.1 [-7.6, 7.8]	1.000
		Irbesartan	127	10 (7.9)				
> 5 years	Double-blind period	Sparsentan	89	9 (10.1)	3.792 [0.845, 17.013]	4.106 [0.859, 19.632]	7.4 [-1.0, 15.9]	0.067
		Irbesartan	75	2 (2.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AELN_SSIM: Incidence of AESI hepatic disorders during double-blind period – non-severe by subgroup
Safety Set

AESI hepatic disorders - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.358
Yes	Double-blind period	Sparsentan	155	14 (9.0)	1.818 [0.785, 4.211]	1.899 [0.773, 4.663]	4.1 [-2.2, 10.3]	0.187
		Irbesartan	161	8 (5.0)				
No	Double-blind period	Sparsentan	47	4 (8.5)	0.872 [0.233, 3.269]	0.860 [0.201, 3.683]	-1.2 [-15.6, 13.1]	1.000
		Irbesartan	41	4 (9.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AELC_SSIM: Incidence of AESI hepatic disorders during double-blind period – severe by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AELS_SSIM: Incidence of AESI hepatic disorders during double-blind period – serious by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEP_SSIM: Incidence of AESI acute pancreatitis during double-blind period by subgroup
Safety Set

AESI acute pancreatitis

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.750
Male	Double-blind period	Sparsentan	139	12 (8.6)	1.029 [0.479, 2.212]	1.031 [0.447, 2.381]	0.2 [-7.0, 7.5]	1.000
		Irbesartan	143	12 (8.4)				
Female	Double-blind period	Sparsentan	63	3 (4.8)	1.405 [0.243, 8.113]	1.425 [0.230, 8.844]	1.4 [-7.3, 10.0]	1.000
		Irbesartan	59	2 (3.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEP_SSIM: Incidence of AESI acute pancreatitis during double-blind period by subgroup
Safety Set

AESI acute pancreatitis

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.484
<= 45 years	Double-blind period	Sparsentan	96	7 (7.3)	1.444 [0.474, 4.393]	1.479 [0.453, 4.830]	2.2 [-5.5, 10.0]	0.564
		Irbesartan	99	5 (5.1)				
> 45 years	Double-blind period	Sparsentan	106	8 (7.5)	0.864 [0.347, 2.152]	0.853 [0.316, 2.303]	-1.2 [-9.6, 7.2]	0.804
		Irbesartan	103	9 (8.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEP_SSIM: Incidence of AESI acute pancreatitis during double-blind period by subgroup
Safety Set

AESI acute pancreatitis

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.563
<= 18 years	Double-blind period	Sparsentan	9	2 (22.2)	3.000 + [0.171, 52.527]	3.667 + [0.145, 92.653]	22.2 [-20.5, 64.9]	0.505
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	8 (7.8)	1.221 [0.459, 3.247]	1.240 [0.433, 3.552]	1.4 [-6.5, 9.3]	0.791
		Irbesartan	109	7 (6.4)				
> 40 years	Double-blind period	Sparsentan	91	5 (5.5)	0.691 [0.228, 2.095]	0.673 [0.205, 2.205]	-2.5 [-10.9, 6.0]	0.562
		Irbesartan	88	7 (8.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEP_SSIM: Incidence of AESI acute pancreatitis during double-blind period by subgroup
Safety Set

AESI acute pancreatitis

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.765
North America	Double-blind period	Sparsentan	35	2 (5.7)	0.657 [0.128, 3.386]	0.636 [0.110, 3.690]	-3.0 [-16.7, 10.7]	0.694
		Irbesartan	46	4 (8.7)				
Europe	Double-blind period	Sparsentan	98	9 (9.2)	1.320 [0.530, 3.291]	1.353 [0.501, 3.651]	2.2 [-6.1, 10.5]	0.617
		Irbesartan	115	8 (7.0)				
Asia Pacific	Double-blind period	Sparsentan	69	4 (5.8)	1.188 [0.228, 6.205]	1.200 [0.210, 6.859]	0.9 [-9.6, 11.5]	1.000
		Irbesartan	41	2 (4.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEP_SSIM: Incidence of AESI acute pancreatitis during double-blind period by subgroup
Safety Set

AESI acute pancreatitis

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.366
< 27 kg/m**2	Double-blind period	Sparsentan	83	8 (9.6)	1.510 [0.546, 4.173]	1.564 [0.520, 4.711]	3.3 [-5.9, 12.4]	0.578
		Irbesartan	94	6 (6.4)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	7 (5.9)	0.787 [0.295, 2.097]	0.773 [0.271, 2.210]	-1.6 [-9.0, 5.8]	0.790
		Irbesartan	107	8 (7.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEP_SSIM: Incidence of AESI acute pancreatitis during double-blind period by subgroup
Safety Set

AESI acute pancreatitis

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.190
eGFR Low and UP High	Double-blind period	Sparsentan	71	8 (11.3)	1.668 [0.573, 4.856]	1.752 [0.545, 5.637]	4.5 [-6.2, 15.2]	0.394
		Irbesartan	74	5 (6.8)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	3 (5.5)	0.600 [0.151, 2.389]	0.577 [0.131, 2.542]	-3.6 [-15.1, 7.9]	0.716
		Irbesartan	55	5 (9.1)				
eGFR High and UP High	Double-blind period	Sparsentan	37	3 (8.1)	6.816 + [0.365, 127.440]	7.406 + [0.369, 148.677]	8.1 [-3.4, 19.6]	0.240
		Irbesartan	36	0 (0.0)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	1 (2.6)	0.237 [0.028, 2.025]	0.217 [0.023, 2.040]	-8.2 [-22.0, 5.6]	0.194
		Irbesartan	37	4 (10.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEP_SSIM: Incidence of AESI acute pancreatitis during double-blind period by subgroup
Safety Set

AESI acute pancreatitis

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.356
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	11 (8.7)	0.931 [0.427, 2.032]	0.925 [0.392, 2.179]	-0.6 [-8.4, 7.1]	1.000
		Irbesartan	129	12 (9.3)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2)	3.918 [0.454, 33.802]	4.178 [0.450, 38.818]	6.1 [-4.6, 16.8]	0.362
		Irbesartan	48	1 (2.1)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.321 + [0.014, 7.528]	0.308 + [0.012, 7.927]	-4.0 [-15.6, 7.6]	0.490
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEP_SSIM: Incidence of AESI acute pancreatitis during double-blind period by subgroup
Safety Set

AESI acute pancreatitis

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.564
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	5 (6.1)	0.976 [0.294, 3.241]	0.974 [0.271, 3.502]	-0.2 [-8.8, 8.5]	1.000
		Irbesartan	80	5 (6.3)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	6 (13.3)	0.933 [0.339, 2.569]	0.923 [0.285, 2.987]	-1.0 [-17.0, 15.1]	1.000
		Irbesartan	49	7 (14.3)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2)	3.918 [0.454, 33.802]	4.178 [0.450, 38.818]	6.1 [-4.6, 16.8]	0.362
		Irbesartan	48	1 (2.1)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.321 + [0.014, 7.528]	0.308 + [0.012, 7.927]	-4.0 [-15.6, 7.6]	0.490
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEP_SSIM: Incidence of AESI acute pancreatitis during double-blind period by subgroup
Safety Set

AESI acute pancreatitis

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.283
<= 1.75 g/day	Double-blind period	Sparsentan	98	5 (5.1)	0.678 [0.223, 2.061]	0.661 [0.202, 2.159]	-2.4 [-10.4, 5.5]	0.560
		Irbesartan	93	7 (7.5)				
> 1.75 g/day	Double-blind period	Sparsentan	104	10 (9.6)	1.497 [0.592, 3.786]	1.550 [0.567, 4.238]	3.2 [-5.0, 11.4]	0.454
		Irbesartan	109	7 (6.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEP_SSIM: Incidence of AESI acute pancreatitis during double-blind period by subgroup
Safety Set

AESI acute pancreatitis

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.896
Yes	Double-blind period	Sparsentan	90	8 (8.9)	1.117 [0.423, 2.950]	1.129 [0.391, 3.258]	0.9 [-8.3, 10.2]	1.000
		Irbesartan	88	7 (8.0)				
No	Double-blind period	Sparsentan	112	7 (6.3)	1.018 [0.369, 2.808]	1.019 [0.345, 3.006]	0.1 [-7.1, 7.3]	1.000
		Irbesartan	114	7 (6.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEP_SSIM: Incidence of AESI acute pancreatitis during double-blind period by subgroup
Safety Set

AESI acute pancreatitis

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.316
<= 5 years	Double-blind period	Sparsentan	113	7 (6.2)	0.787 [0.310, 1.998]	0.773 [0.284, 2.102]	-1.7 [-9.0, 5.6]	0.802
		Irbesartan	127	10 (7.9)				
> 5 years	Double-blind period	Sparsentan	89	8 (9.0)	1.685 [0.528, 5.378]	1.753 [0.506, 6.069]	3.7 [-5.4, 12.7]	0.549
		Irbesartan	75	4 (5.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEP_SSIM: Incidence of AESI acute pancreatitis during double-blind period by subgroup
Safety Set

AESI acute pancreatitis

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.104
Yes	Double-blind period	Sparsentan	155	14 (9.0)	1.454 [0.666, 3.175]	1.499 [0.645, 3.485]	2.8 [-3.7, 9.3]	0.399
		Irbesartan	161	10 (6.2)				
No	Double-blind period	Sparsentan	47	1 (2.1)	0.218 [0.025, 1.874]	0.201 [0.022, 1.877]	-7.6 [-19.9, 4.6]	0.180
		Irbesartan	41	4 (9.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEPN_SSIM: Incidence of AESI acute pancreatitis during double-blind period – non-severe by subgroup
Safety Set

AESI acute pancreatitis - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.750
Male	Double-blind period	Sparsentan	139	12 (8.6)	1.029 [0.479, 2.212]	1.031 [0.447, 2.381]	0.2 [-7.0, 7.5]	1.000
		Irbesartan	143	12 (8.4)				
Female	Double-blind period	Sparsentan	63	3 (4.8)	1.405 [0.243, 8.113]	1.425 [0.230, 8.844]	1.4 [-7.3, 10.0]	1.000
		Irbesartan	59	2 (3.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEPN_SSIM: Incidence of AESI acute pancreatitis during double-blind period – non-severe by subgroup
Safety Set

AESI acute pancreatitis - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.484
<= 45 years	Double-blind period	Sparsentan	96	7 (7.3)	1.444 [0.474, 4.393]	1.479 [0.453, 4.830]	2.2 [-5.5, 10.0]	0.564
		Irbesartan	99	5 (5.1)				
> 45 years	Double-blind period	Sparsentan	106	8 (7.5)	0.864 [0.347, 2.152]	0.853 [0.316, 2.303]	-1.2 [-9.6, 7.2]	0.804
		Irbesartan	103	9 (8.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEPN_SSIM: Incidence of AESI acute pancreatitis during double-blind period – non-severe by subgroup
Safety Set

AESI acute pancreatitis - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.563
<= 18 years	Double-blind period	Sparsentan	9	2 (22.2)	3.000 + [0.171, 52.527]	3.667 + [0.145, 92.653]	22.2 [-20.5, 64.9]	0.505
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	8 (7.8)	1.221 [0.459, 3.247]	1.240 [0.433, 3.552]	1.4 [-6.5, 9.3]	0.791
		Irbesartan	109	7 (6.4)				
> 40 years	Double-blind period	Sparsentan	91	5 (5.5)	0.691 [0.228, 2.095]	0.673 [0.205, 2.205]	-2.5 [-10.9, 6.0]	0.562
		Irbesartan	88	7 (8.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEPN_SSIM: Incidence of AESI acute pancreatitis during double-blind period – non-severe by subgroup
Safety Set

AESI acute pancreatitis - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.765
North America	Double-blind period	Sparsentan	35	2 (5.7)	0.657 [0.128, 3.386]	0.636 [0.110, 3.690]	-3.0 [-16.7, 10.7]	0.694
		Irbesartan	46	4 (8.7)				
Europe	Double-blind period	Sparsentan	98	9 (9.2)	1.320 [0.530, 3.291]	1.353 [0.501, 3.651]	2.2 [-6.1, 10.5]	0.617
		Irbesartan	115	8 (7.0)				
Asia Pacific	Double-blind period	Sparsentan	69	4 (5.8)	1.188 [0.228, 6.205]	1.200 [0.210, 6.859]	0.9 [-9.6, 11.5]	1.000
		Irbesartan	41	2 (4.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEPN_SSIM: Incidence of AESI acute pancreatitis during double-blind period – non-severe by subgroup
Safety Set

AESI acute pancreatitis - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.366
< 27 kg/m**2	Double-blind period	Sparsentan	83	8 (9.6)	1.510 [0.546, 4.173]	1.564 [0.520, 4.711]	3.3 [-5.9, 12.4]	0.578
		Irbesartan	94	6 (6.4)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	7 (5.9)	0.787 [0.295, 2.097]	0.773 [0.271, 2.210]	-1.6 [-9.0, 5.8]	0.790
		Irbesartan	107	8 (7.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEPN_SSIM: Incidence of AESI acute pancreatitis during double-blind period – non-severe by subgroup
Safety Set

AESI acute pancreatitis - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.190
eGFR Low and UP High	Double-blind period	Sparsentan	71	8 (11.3)	1.668 [0.573, 4.856]	1.752 [0.545, 5.637]	4.5 [-6.2, 15.2]	0.394
		Irbesartan	74	5 (6.8)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	3 (5.5)	0.600 [0.151, 2.389]	0.577 [0.131, 2.542]	-3.6 [-15.1, 7.9]	0.716
		Irbesartan	55	5 (9.1)				
eGFR High and UP High	Double-blind period	Sparsentan	37	3 (8.1)	6.816 + [0.365, 127.440]	7.406 + [0.369, 148.677]	8.1 [-3.4, 19.6]	0.240
		Irbesartan	36	0 (0.0)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	1 (2.6)	0.237 [0.028, 2.025]	0.217 [0.023, 2.040]	-8.2 [-22.0, 5.6]	0.194
		Irbesartan	37	4 (10.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEPN_SSIM: Incidence of AESI acute pancreatitis during double-blind period – non-severe by subgroup
Safety Set

AESI acute pancreatitis - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.356
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	11 (8.7)	0.931 [0.427, 2.032]	0.925 [0.392, 2.179]	-0.6 [-8.4, 7.1]	1.000
		Irbesartan	129	12 (9.3)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2)	3.918 [0.454, 33.802]	4.178 [0.450, 38.818]	6.1 [-4.6, 16.8]	0.362
		Irbesartan	48	1 (2.1)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.321 + [0.014, 7.528]	0.308 + [0.012, 7.927]	-4.0 [-15.6, 7.6]	0.490
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEPN_SSIM: Incidence of AESI acute pancreatitis during double-blind period – non-severe by subgroup
Safety Set

AESI acute pancreatitis - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.564
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	5 (6.1)	0.976 [0.294, 3.241]	0.974 [0.271, 3.502]	-0.2 [-8.8, 8.5]	1.000
		Irbesartan	80	5 (6.3)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	6 (13.3)	0.933 [0.339, 2.569]	0.923 [0.285, 2.987]	-1.0 [-17.0, 15.1]	1.000
		Irbesartan	49	7 (14.3)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2)	3.918 [0.454, 33.802]	4.178 [0.450, 38.818]	6.1 [-4.6, 16.8]	0.362
		Irbesartan	48	1 (2.1)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.321 + [0.014, 7.528]	0.308 + [0.012, 7.927]	-4.0 [-15.6, 7.6]	0.490
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEPN_SSIM: Incidence of AESI acute pancreatitis during double-blind period – non-severe by subgroup
Safety Set

AESI acute pancreatitis - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.283
<= 1.75 g/day	Double-blind period	Sparsentan	98	5 (5.1)	0.678 [0.223, 2.061]	0.661 [0.202, 2.159]	-2.4 [-10.4, 5.5]	0.560
		Irbesartan	93	7 (7.5)				
> 1.75 g/day	Double-blind period	Sparsentan	104	10 (9.6)	1.497 [0.592, 3.786]	1.550 [0.567, 4.238]	3.2 [-5.0, 11.4]	0.454
		Irbesartan	109	7 (6.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEPN_SSIM: Incidence of AESI acute pancreatitis during double-blind period – non-severe by subgroup
Safety Set

AESI acute pancreatitis - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.896
Yes	Double-blind period	Sparsentan	90	8 (8.9)	1.117 [0.423, 2.950]	1.129 [0.391, 3.258]	0.9 [-8.3, 10.2]	1.000
		Irbesartan	88	7 (8.0)				
No	Double-blind period	Sparsentan	112	7 (6.3)	1.018 [0.369, 2.808]	1.019 [0.345, 3.006]	0.1 [-7.1, 7.3]	1.000
		Irbesartan	114	7 (6.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEPN_SSIM: Incidence of AESI acute pancreatitis during double-blind period – non-severe by subgroup
Safety Set

AESI acute pancreatitis - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.316
<= 5 years	Double-blind period	Sparsentan	113	7 (6.2)	0.787 [0.310, 1.998]	0.773 [0.284, 2.102]	-1.7 [-9.0, 5.6]	0.802
		Irbesartan	127	10 (7.9)				
> 5 years	Double-blind period	Sparsentan	89	8 (9.0)	1.685 [0.528, 5.378]	1.753 [0.506, 6.069]	3.7 [-5.4, 12.7]	0.549
		Irbesartan	75	4 (5.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEPN_SSIM: Incidence of AESI acute pancreatitis during double-blind period – non-severe by subgroup
Safety Set

AESI acute pancreatitis - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.104
Yes	Double-blind period	Sparsentan	155	14 (9.0)	1.454 [0.666, 3.175]	1.499 [0.645, 3.485]	2.8 [-3.7, 9.3]	0.399
		Irbesartan	161	10 (6.2)				
No	Double-blind period	Sparsentan	47	1 (2.1)	0.218 [0.025, 1.874]	0.201 [0.022, 1.877]	-7.6 [-19.9, 4.6]	0.180
		Irbesartan	41	4 (9.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEPC_SSIM: Incidence of AESI acute pancreatitis during double-blind period – severe by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEPS_SSIM: Incidence of AESI acute pancreatitis during double-blind period – serious by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEO_SSIM: Incidence of AESI fluid retention during double-blind period by subgroup
Safety Set

AESI fluid retention

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.714
Male	Double-blind period	Sparsentan	139	21 (15.1)	1.080 [0.613, 1.903]	1.094 [0.564, 2.123]	1.1 [-7.8, 10.1]	0.866
		Irbesartan	143	20 (14.0)				
Female	Double-blind period	Sparsentan	63	15 (23.8)	1.277 [0.639, 2.552]	1.364 [0.569, 3.271]	5.2 [-10.9, 21.3]	0.515
		Irbesartan	59	11 (18.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEO_SSIM: Incidence of AESI fluid retention during double-blind period by subgroup
Safety Set

AESI fluid retention								
Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.813
<= 45 years	Double-blind period	Sparsentan	96	19 (19.8)	1.225 [0.670, 2.238]	1.280 [0.615, 2.666]	3.6 [-8.2, 15.4]	0.577
		Irbesartan	99	16 (16.2)				
> 45 years	Double-blind period	Sparsentan	106	17 (16.0)	1.101 [0.581, 2.087]	1.121 [0.527, 2.382]	1.5 [-9.2, 12.2]	0.849
		Irbesartan	103	15 (14.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEO_SSIM: Incidence of AESI fluid retention during double-blind period by subgroup
Safety Set

AESI fluid retention

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.958
<= 18 years	Double-blind period	Sparsentan	9	1 (11.1)	1.800 + [0.086, 37.493]	1.941 + [0.066, 56.760]	11.1 [-25.0, 47.2]	1.000
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	17 (16.7)	1.135 [0.607, 2.126]	1.163 [0.553, 2.445]	2.0 [-8.8, 12.8]	0.709
		Irbesartan	109	16 (14.7)				
> 40 years	Double-blind period	Sparsentan	91	18 (19.8)	1.160 [0.625, 2.156]	1.200 [0.562, 2.561]	2.7 [-9.7, 15.2]	0.702
		Irbesartan	88	15 (17.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEO_SSIM: Incidence of AESI fluid retention during double-blind period by subgroup
Safety Set

AESI fluid retention

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.650
North America	Double-blind period	Sparsentan	35	5 (14.3)	2.190 [0.561, 8.553]	2.389 [0.530, 10.764]	7.8 [-8.4, 23.9]	0.282
		Irbesartan	46	3 (6.5)				
Europe	Double-blind period	Sparsentan	98	22 (22.4)	1.122 [0.668, 1.886]	1.158 [0.599, 2.237]	2.4 [-9.5, 14.4]	0.737
		Irbesartan	115	23 (20.0)				
Asia Pacific	Double-blind period	Sparsentan	69	9 (13.0)	1.070 [0.385, 2.974]	1.080 [0.336, 3.475]	0.8 [-13.9, 15.6]	1.000
		Irbesartan	41	5 (12.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEO_SSIM: Incidence of AESI fluid retention during double-blind period by subgroup
Safety Set

AESI fluid retention

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.498
< 27 kg/m**2	Double-blind period	Sparsentan	83	11 (13.3)	0.958 [0.454, 2.022]	0.952 [0.401, 2.257]	-0.6 [-11.8, 10.7]	1.000
		Irbesartan	94	13 (13.8)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	25 (21.0)	1.322 [0.757, 2.310]	1.408 [0.713, 2.781]	5.1 [-5.8, 16.1]	0.392
		Irbesartan	107	17 (15.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEO_SSIM: Incidence of AESI fluid retention during double-blind period by subgroup
Safety Set

AESI fluid retention

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.895
eGFR Low and UP High	Double-blind period	Sparsentan	71	14 (19.7)	1.216 [0.604, 2.446]	1.269 [0.542, 2.971]	3.5 [-10.4, 17.4]	0.667
		Irbesartan	74	12 (16.2)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	11 (20.0)	1.375 [0.599, 3.155]	1.469 [0.541, 3.989]	5.5 [-10.5, 21.4]	0.615
		Irbesartan	55	8 (14.5)				
eGFR High and UP High	Double-blind period	Sparsentan	37	6 (16.2)	0.834 [0.310, 2.243]	0.802 [0.241, 2.668]	-3.2 [-23.5, 17.1]	0.768
		Irbesartan	36	7 (19.4)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	5 (12.8)	1.186 [0.345, 4.079]	1.213 [0.299, 4.916]	2.0 [-15.1, 19.1]	1.000
		Irbesartan	37	4 (10.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEO_SSIM: Incidence of AESI fluid retention during double-blind period by subgroup
Safety Set

AESI fluid retention

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.188
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	24 (18.9)	1.283 [0.740, 2.223]	1.349 [0.698, 2.608]	4.2 [-5.8, 14.1]	0.406
		Irbesartan	129	19 (14.7)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	5 (10.2)	0.544 [0.197, 1.506]	0.492 [0.152, 1.595]	-8.5 [-24.5, 7.4]	0.261
		Irbesartan	48	9 (18.8)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	7 (26.9)	2.244 [0.652, 7.723]	2.702 [0.612, 11.932]	14.9 [-10.3, 40.1]	0.291
		Irbesartan	25	3 (12.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEO_SSIM: Incidence of AESI fluid retention during double-blind period by subgroup
Safety Set

AESI fluid retention

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.265
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	12 (14.6)	1.064 [0.499, 2.271]	1.075 [0.445, 2.601]	0.9 [-11.1, 12.9]	1.000
		Irbesartan	80	11 (13.8)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	12 (26.7)	1.633 [0.735, 3.627]	1.864 [0.682, 5.092]	10.3 [-8.3, 29.0]	0.313
		Irbesartan	49	8 (16.3)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	5 (10.2)	0.544 [0.197, 1.506]	0.492 [0.152, 1.595]	-8.5 [-24.5, 7.4]	0.261
		Irbesartan	48	9 (18.8)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	7 (26.9)	2.244 [0.652, 7.723]	2.702 [0.612, 11.932]	14.9 [-10.3, 40.1]	0.291
		Irbesartan	25	3 (12.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEO_SSIM: Incidence of AESI fluid retention during double-blind period by subgroup
Safety Set

AESI fluid retention

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.593
<= 1.75 g/day	Double-blind period	Sparsentan	98	15 (15.3)	1.017 [0.520, 1.989]	1.020 [0.462, 2.249]	0.3 [-11.0, 11.5]	1.000
		Irbesartan	93	14 (15.1)				
> 1.75 g/day	Double-blind period	Sparsentan	104	21 (20.2)	1.295 [0.725, 2.313]	1.369 [0.677, 2.771]	4.6 [-6.6, 15.8]	0.474
		Irbesartan	109	17 (15.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEO_SSIM: Incidence of AESI fluid retention during double-blind period by subgroup
Safety Set

AESI fluid retention								
Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.180
Yes	Double-blind period	Sparsentan	90	17 (18.9)	0.875 [0.488, 1.570]	0.846 [0.407, 1.759]	-2.7 [-15.6, 10.2]	0.711
		Irbesartan	88	19 (21.6)				
No	Double-blind period	Sparsentan	112	19 (17.0)	1.612 [0.821, 3.162]	1.737 [0.800, 3.771]	6.4 [-3.4, 16.3]	0.179
		Irbesartan	114	12 (10.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEO_SSIM: Incidence of AESI fluid retention during double-blind period by subgroup
Safety Set

AESI fluid retention

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.089
<= 5 years	Double-blind period	Sparsentan	113	24 (21.2)	1.587 [0.900, 2.798]	1.745 [0.883, 3.449]	7.9 [-2.6, 18.3]	0.123
		Irbesartan	127	17 (13.4)				
> 5 years	Double-blind period	Sparsentan	89	12 (13.5)	0.722 [0.356, 1.465]	0.679 [0.293, 1.575]	-5.2 [-17.7, 7.4]	0.397
		Irbesartan	75	14 (18.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEO_SSIM: Incidence of AESI fluid retention during double-blind period by subgroup
Safety Set

AESI fluid retention

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.750
Yes	Double-blind period	Sparsentan	155	31 (20.0)	1.150 [0.725, 1.823]	1.188 [0.674, 2.093]	2.6 [-6.6, 11.8]	0.567
		Irbesartan	161	28 (17.4)				
No	Double-blind period	Sparsentan	47	5 (10.6)	1.454 [0.370, 5.714]	1.508 [0.337, 6.739]	3.3 [-10.8, 17.5]	0.719
		Irbesartan	41	3 (7.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEON_SSIM: Incidence of AESI fluid retention during double-blind period – non-severe by subgroup
Safety Set

AESI fluid retention - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.800
Male	Double-blind period	Sparsentan	139	21 (15.1)	1.137 [0.640, 2.021]	1.161 [0.594, 2.269]	1.8 [-7.0, 10.7]	0.734
		Irbesartan	143	19 (13.3)				
Female	Double-blind period	Sparsentan	63	15 (23.8)	1.277 [0.639, 2.552]	1.364 [0.569, 3.271]	5.2 [-10.9, 21.3]	0.515
		Irbesartan	59	11 (18.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEON_SSIM: Incidence of AESI fluid retention during double-blind period – non-severe by subgroup
Safety Set

AESI fluid retention - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.706
<= 45 years	Double-blind period	Sparsentan	96	19 (19.8)	1.306 [0.706, 2.419]	1.382 [0.656, 2.909]	4.6 [-7.0, 16.3]	0.452
		Irbesartan	99	15 (15.2)				
> 45 years	Double-blind period	Sparsentan	106	17 (16.0)	1.101 [0.581, 2.087]	1.121 [0.527, 2.382]	1.5 [-9.2, 12.2]	0.849
		Irbesartan	103	15 (14.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEON_SSIM: Incidence of AESI fluid retention during double-blind period – non-severe by subgroup
Safety Set

AESI fluid retention - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.961
<= 18 years	Double-blind period	Sparsentan	9	1 (11.1)	1.800 + [0.086, 37.493]	1.941 + [0.066, 56.760]	11.1 [-25.0, 47.2]	1.000
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	17 (16.7)	1.211 [0.639, 2.296]	1.253 [0.590, 2.663]	2.9 [-7.7, 13.6]	0.571
		Irbesartan	109	15 (13.8)				
> 40 years	Double-blind period	Sparsentan	91	18 (19.8)	1.160 [0.625, 2.156]	1.200 [0.562, 2.561]	2.7 [-9.7, 15.2]	0.702
		Irbesartan	88	15 (17.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEON_SSIM: Incidence of AESI fluid retention during double-blind period – non-severe by subgroup
Safety Set

AESI fluid retention - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.433
North America	Double-blind period	Sparsentan	35	5 (14.3)	3.286 [0.677, 15.949]	3.667 [0.667, 20.156]	9.9 [-5.6, 25.5]	0.230
		Irbesartan	46	2 (4.3)				
Europe	Double-blind period	Sparsentan	98	22 (22.4)	1.122 [0.668, 1.886]	1.158 [0.599, 2.237]	2.4 [-9.5, 14.4]	0.737
		Irbesartan	115	23 (20.0)				
Asia Pacific	Double-blind period	Sparsentan	69	9 (13.0)	1.070 [0.385, 2.974]	1.080 [0.336, 3.475]	0.8 [-13.9, 15.6]	1.000
		Irbesartan	41	5 (12.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEON_SSIM: Incidence of AESI fluid retention during double-blind period – non-severe by subgroup
Safety Set

AESI fluid retention - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.616
< 27 kg/m**2	Double-blind period	Sparsentan	83	11 (13.3)	1.038 [0.484, 2.227]	1.044 [0.434, 2.510]	0.5 [-10.6, 11.6]	1.000
		Irbesartan	94	12 (12.8)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	25 (21.0)	1.322 [0.757, 2.310]	1.408 [0.713, 2.781]	5.1 [-5.8, 16.1]	0.392
		Irbesartan	107	17 (15.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEON_SSIM: Incidence of AESI fluid retention during double-blind period – non-severe by subgroup
Safety Set

AESI fluid retention - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.874
eGFR Low and UP High	Double-blind period	Sparsentan	71	14 (19.7)	1.327 [0.646, 2.724]	1.407 [0.591, 3.348]	4.9 [-8.8, 18.5]	0.512
		Irbesartan	74	11 (14.9)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	11 (20.0)	1.375 [0.599, 3.155]	1.469 [0.541, 3.989]	5.5 [-10.5, 21.4]	0.615
		Irbesartan	55	8 (14.5)				
eGFR High and UP High	Double-blind period	Sparsentan	37	6 (16.2)	0.834 [0.310, 2.243]	0.802 [0.241, 2.668]	-3.2 [-23.5, 17.1]	0.768
		Irbesartan	36	7 (19.4)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	5 (12.8)	1.186 [0.345, 4.079]	1.213 [0.299, 4.916]	2.0 [-15.1, 19.1]	1.000
		Irbesartan	37	4 (10.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEON_SSIM: Incidence of AESI fluid retention during double-blind period – non-severe by subgroup
Safety Set

AESI fluid retention - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.176
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	24 (18.9)	1.354 [0.774, 2.371]	1.437 [0.737, 2.801]	4.9 [-4.9, 14.8]	0.314
		Irbesartan	129	18 (14.0)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	5 (10.2)	0.544 [0.197, 1.506]	0.492 [0.152, 1.595]	-8.5 [-24.5, 7.4]	0.261
		Irbesartan	48	9 (18.8)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	7 (26.9)	2.244 [0.652, 7.723]	2.702 [0.612, 11.932]	14.9 [-10.3, 40.1]	0.291
		Irbesartan	25	3 (12.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEON_SSIM: Incidence of AESI fluid retention during double-blind period – non-severe by subgroup
Safety Set

AESI fluid retention - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.276
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	12 (14.6)	1.171 [0.536, 2.556]	1.200 [0.487, 2.958]	2.1 [-9.6, 13.9]	0.819
		Irbesartan	80	10 (12.5)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	12 (26.7)	1.633 [0.735, 3.627]	1.864 [0.682, 5.092]	10.3 [-8.3, 29.0]	0.313
		Irbesartan	49	8 (16.3)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	5 (10.2)	0.544 [0.197, 1.506]	0.492 [0.152, 1.595]	-8.5 [-24.5, 7.4]	0.261
		Irbesartan	48	9 (18.8)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	7 (26.9)	2.244 [0.652, 7.723]	2.702 [0.612, 11.932]	14.9 [-10.3, 40.1]	0.291
		Irbesartan	25	3 (12.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEON_SSIM: Incidence of AESI fluid retention during double-blind period – non-severe by subgroup
Safety Set

AESI fluid retention - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.508
<= 1.75 g/day	Double-blind period	Sparsentan	98	15 (15.3)	1.017 [0.520, 1.989]	1.020 [0.462, 2.249]	0.3 [-11.0, 11.5]	1.000
		Irbesartan	93	14 (15.1)				
> 1.75 g/day	Double-blind period	Sparsentan	104	21 (20.2)	1.376 [0.761, 2.487]	1.471 [0.720, 3.005]	5.5 [-5.6, 16.6]	0.366
		Irbesartan	109	16 (14.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEON_SSIM: Incidence of AESI fluid retention during double-blind period – non-severe by subgroup
Safety Set

AESI fluid retention - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.132
Yes	Double-blind period	Sparsentan	90	17 (18.9)	0.875 [0.488, 1.570]	0.846 [0.407, 1.759]	-2.7 [-15.6, 10.2]	0.711
		Irbesartan	88	19 (21.6)				
No	Double-blind period	Sparsentan	112	19 (17.0)	1.758 [0.877, 3.524]	1.913 [0.865, 4.231]	7.3 [-2.4, 17.0]	0.119
		Irbesartan	114	11 (9.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEON_SSIM: Incidence of AESI fluid retention during double-blind period – non-severe by subgroup
Safety Set

AESI fluid retention - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.069
<= 5 years	Double-blind period	Sparsentan	113	24 (21.2)	1.686 [0.944, 3.010]	1.871 [0.937, 3.735]	8.6 [-1.7, 19.0]	0.084
		Irbesartan	127	16 (12.6)				
> 5 years	Double-blind period	Sparsentan	89	12 (13.5)	0.722 [0.356, 1.465]	0.679 [0.293, 1.575]	-5.2 [-17.7, 7.4]	0.397
		Irbesartan	75	14 (18.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEON_SSIM: Incidence of AESI fluid retention during double-blind period – non-severe by subgroup
Safety Set

AESI fluid retention - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.788
Yes	Double-blind period	Sparsentan	155	31 (20.0)	1.193 [0.748, 1.901]	1.241 [0.701, 2.196]	3.2 [-5.9, 12.4]	0.471
		Irbesartan	161	27 (16.8)				
No	Double-blind period	Sparsentan	47	5 (10.6)	1.454 [0.370, 5.714]	1.508 [0.337, 6.739]	3.3 [-10.8, 17.5]	0.719
		Irbesartan	41	3 (7.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEOC_SSIM: Incidence of AESI fluid retention during double-blind period – severe by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEOS_SSIM: Incidence of AESI fluid retention during double-blind period – serious by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEA_SSIM: Incidence of AESI anemia during double-blind period by subgroup
Safety Set

AESI anemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.580
Male	Double-blind period	Sparsentan	139	15 (10.8)	1.715 [0.776, 3.788]	1.801 [0.761, 4.264]	4.5 [-2.7, 11.7]	0.204
		Irbesartan	143	9 (6.3)				
Female	Double-blind period	Sparsentan	63	6 (9.5)	2.810 [0.590, 13.376]	3.000 [0.581, 15.495]	6.1 [-4.1, 16.4]	0.275
		Irbesartan	59	2 (3.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEA_SSIM: Incidence of AESI anemia during double-blind period by subgroup
Safety Set

AESI anemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Age	Double-blind period	Sparsentan					Interaction test:	0.074	
<= 45 years	Double-blind period	Sparsentan	96	8 (8.3)	1.031 [0.403, 2.637]	1.034 [0.372, 2.876]	0.3 [-8.5, 9.0]	1.000	
		Irbesartan	99	8 (8.1)					
> 45 years	Double-blind period	Sparsentan	106	13 (12.3)	4.211 [1.236, 14.345]	4.659 [1.287, 16.872]	9.4 [1.4, 17.3]	0.017	*
		Irbesartan	103	3 (2.9)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEA_SSIM: Incidence of AESI anemia during double-blind period by subgroup
Safety Set

AESI anemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.735
<= 18 years	Double-blind period	Sparsentan	9	0 (0.0)	0.600 + [0.014, 26.475]	0.579 + [0.010, 33.502]	0.0 [NE, NE]	NE
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	9 (8.8)	1.603 [0.591, 4.345]	1.661 [0.570, 4.845]	3.3 [-4.6, 11.2]	0.426
		Irbesartan	109	6 (5.5)				
> 40 years	Double-blind period	Sparsentan	91	12 (13.2)	2.321 [0.853, 6.317]	2.522 [0.850, 7.483]	7.5 [-2.1, 17.1]	0.125
		Irbesartan	88	5 (5.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEA_SSIM: Incidence of AESI anemia during double-blind period by subgroup
Safety Set

AESI anemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.681
North America	Double-blind period	Sparsentan	35	2 (5.7)	2.629 [0.248, 27.835]	2.727 [0.237, 31.357]	3.5 [-7.7, 14.8]	0.575
		Irbesartan	46	1 (2.2)				
Europe	Double-blind period	Sparsentan	98	9 (9.2)	2.112 [0.732, 6.094]	2.225 [0.720, 6.876]	4.8 [-2.9, 12.6]	0.175
		Irbesartan	115	5 (4.3)				
Asia Pacific	Double-blind period	Sparsentan	69	10 (14.5)	1.188 [0.437, 3.235]	1.220 [0.386, 3.857]	2.3 [-12.7, 17.3]	1.000
		Irbesartan	41	5 (12.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEA_SSIM: Incidence of AESI anemia during double-blind period by subgroup
Safety Set

AESI anemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.737
< 27 kg/m**2	Double-blind period	Sparsentan	83	13 (15.7)	1.840 [0.803, 4.220]	1.996 [0.783, 5.088]	7.2 [-3.6, 17.9]	0.166
		Irbesartan	94	8 (8.5)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	8 (6.7)	2.398 [0.653, 8.807]	2.498 [0.645, 9.672]	3.9 [-2.4, 10.3]	0.222
		Irbesartan	107	3 (2.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEA_SSIM: Incidence of AESI anemia during double-blind period by subgroup
Safety Set

AESI anemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.647
eGFR Low and UP High	Double-blind period	Sparsentan	71	9 (12.7)	1.563 [0.587, 4.167]	1.645 [0.554, 4.887]	4.6 [-6.7, 15.9]	0.422
		Irbesartan	74	6 (8.1)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	5 (9.1)	1.250 [0.354, 4.409]	1.275 [0.324, 5.025]	1.8 [-10.2, 13.9]	1.000
		Irbesartan	55	4 (7.3)				
eGFR High and UP High	Double-blind period	Sparsentan	37	4 (10.8)	3.892 [0.457, 33.169]	4.242 [0.451, 39.943]	8.0 [-6.1, 22.1]	0.358
		Irbesartan	36	1 (2.8)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	3 (7.7)	6.650 + [0.355, 124.506]	7.192 + [0.359, 144.166]	7.7 [-3.3, 18.7]	0.241
		Irbesartan	37	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEA_SSIM: Incidence of AESI anemia during double-blind period by subgroup
Safety Set

AESI anemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.461
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	14 (11.0)	1.580 [0.709, 3.519]	1.652 [0.688, 3.966]	4.0 [-3.7, 11.8]	0.282
		Irbesartan	129	9 (7.0)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	6 (12.2)	5.878 [0.735, 47.011]	6.558 [0.759, 56.698]	10.2 [-1.9, 22.3]	0.111
		Irbesartan	48	1 (2.1)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8)	0.962 [0.064, 14.551]	0.960 [0.057, 16.232]	-0.2 [-14.7, 14.4]	1.000
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEA_SSIM: Incidence of AESI anemia during double-blind period by subgroup
Safety Set

AESI anemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.567
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	10 (12.2)	1.951 [0.698, 5.457]	2.083 [0.679, 6.393]	5.9 [-4.1, 16.0]	0.279
		Irbesartan	80	5 (6.3)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	4 (8.9)	1.089 [0.289, 4.099]	1.098 [0.258, 4.675]	0.7 [-12.7, 14.2]	1.000
		Irbesartan	49	4 (8.2)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	6 (12.2)	5.878 [0.735, 47.011]	6.558 [0.759, 56.698]	10.2 [-1.9, 22.3]	0.111
		Irbesartan	48	1 (2.1)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8)	0.962 [0.064, 14.551]	0.960 [0.057, 16.232]	-0.2 [-14.7, 14.4]	1.000
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEA_SSIM: Incidence of AESI anemia during double-blind period by subgroup
Safety Set

AESI anemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.448
<= 1.75 g/day	Double-blind period	Sparsentan	98	9 (9.2)	2.847 [0.795, 10.193]	3.034 [0.795, 11.575]	6.0 [-1.8, 13.8]	0.135
		Irbesartan	93	3 (3.2)				
> 1.75 g/day	Double-blind period	Sparsentan	104	12 (11.5)	1.572 [0.670, 3.690]	1.647 [0.644, 4.208]	4.2 [-4.6, 13.0]	0.351
		Irbesartan	109	8 (7.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEA_SSIM: Incidence of AESI anemia during double-blind period by subgroup
Safety Set

AESI anemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.480
Yes	Double-blind period	Sparsentan	90	9 (10.0)	1.467 [0.545, 3.948]	1.519 [0.517, 4.461]	3.2 [-6.1, 12.4]	0.591
		Irbesartan	88	6 (6.8)				
No	Double-blind period	Sparsentan	112	12 (10.7)	2.443 [0.890, 6.708]	2.616 [0.890, 7.688]	6.3 [-1.4, 14.1]	0.082
		Irbesartan	114	5 (4.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEA_SSIM: Incidence of AESI anemia during double-blind period by subgroup
Safety Set

AESI anemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.555
<= 5 years	Double-blind period	Sparsentan	113	14 (12.4)	1.748 [0.787, 3.884]	1.854 [0.770, 4.465]	5.3 [-3.1, 13.7]	0.191
		Irbesartan	127	9 (7.1)				
> 5 years	Double-blind period	Sparsentan	89	7 (7.9)	2.949 [0.632, 13.774]	3.116 [0.627, 15.476]	5.2 [-2.7, 13.1]	0.182
		Irbesartan	75	2 (2.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEA_SSIM: Incidence of AESI anemia during double-blind period by subgroup
Safety Set

AESI anemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.661
Yes	Double-blind period	Sparsentan	155	16 (10.3)	2.077 [0.915, 4.715]	2.201 [0.914, 5.303]	5.4 [-1.1, 11.8]	0.090
		Irbesartan	161	8 (5.0)				
No	Double-blind period	Sparsentan	47	5 (10.6)	1.454 [0.370, 5.714]	1.508 [0.337, 6.739]	3.3 [-10.8, 17.5]	0.719
		Irbesartan	41	3 (7.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEAN_SSIM: Incidence of AESI anemia during double-blind period – non-severe by subgroup
Safety Set

AESI anemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.580
Male	Double-blind period	Sparsentan	139	15 (10.8)	1.715 [0.776, 3.788]	1.801 [0.761, 4.264]	4.5 [-2.7, 11.7]	0.204
		Irbesartan	143	9 (6.3)				
Female	Double-blind period	Sparsentan	63	6 (9.5)	2.810 [0.590, 13.376]	3.000 [0.581, 15.495]	6.1 [-4.1, 16.4]	0.275
		Irbesartan	59	2 (3.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEAN_SSIM: Incidence of AESI anemia during double-blind period – non-severe by subgroup
Safety Set

AESI anemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Age	Double-blind period	Sparsentan					Interaction test:	0.074	
<= 45 years	Double-blind period	Sparsentan	96	8 (8.3)	1.031 [0.403, 2.637]	1.034 [0.372, 2.876]	0.3 [-8.5, 9.0]	1.000	
		Irbesartan	99	8 (8.1)					
> 45 years	Double-blind period	Sparsentan	106	13 (12.3)	4.211 [1.236, 14.345]	4.659 [1.287, 16.872]	9.4 [1.4, 17.3]	0.017	*
		Irbesartan	103	3 (2.9)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEAN_SSIM: Incidence of AESI anemia during double-blind period – non-severe by subgroup
Safety Set

AESI anemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.735
<= 18 years	Double-blind period	Sparsentan	9	0 (0.0)	0.600 + [0.014, 26.475]	0.579 + [0.010, 33.502]	0.0 [NE, NE]	NE
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	9 (8.8)	1.603 [0.591, 4.345]	1.661 [0.570, 4.845]	3.3 [-4.6, 11.2]	0.426
		Irbesartan	109	6 (5.5)				
> 40 years	Double-blind period	Sparsentan	91	12 (13.2)	2.321 [0.853, 6.317]	2.522 [0.850, 7.483]	7.5 [-2.1, 17.1]	0.125
		Irbesartan	88	5 (5.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEAN_SSIM: Incidence of AESI anemia during double-blind period – non-severe by subgroup
Safety Set

AESI anemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.681
North America	Double-blind period	Sparsentan	35	2 (5.7)	2.629 [0.248, 27.835]	2.727 [0.237, 31.357]	3.5 [-7.7, 14.8]	0.575
		Irbesartan	46	1 (2.2)				
Europe	Double-blind period	Sparsentan	98	9 (9.2)	2.112 [0.732, 6.094]	2.225 [0.720, 6.876]	4.8 [-2.9, 12.6]	0.175
		Irbesartan	115	5 (4.3)				
Asia Pacific	Double-blind period	Sparsentan	69	10 (14.5)	1.188 [0.437, 3.235]	1.220 [0.386, 3.857]	2.3 [-12.7, 17.3]	1.000
		Irbesartan	41	5 (12.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEAN_SSIM: Incidence of AESI anemia during double-blind period – non-severe by subgroup
Safety Set

AESI anemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.737
< 27 kg/m**2	Double-blind period	Sparsentan	83	13 (15.7)	1.840 [0.803, 4.220]	1.996 [0.783, 5.088]	7.2 [-3.6, 17.9]	0.166
		Irbesartan	94	8 (8.5)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	8 (6.7)	2.398 [0.653, 8.807]	2.498 [0.645, 9.672]	3.9 [-2.4, 10.3]	0.222
		Irbesartan	107	3 (2.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEAN_SSIM: Incidence of AESI anemia during double-blind period – non-severe by subgroup
Safety Set

AESI anemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.647
eGFR Low and UP High	Double-blind period	Sparsentan	71	9 (12.7)	1.563 [0.587, 4.167]	1.645 [0.554, 4.887]	4.6 [-6.7, 15.9]	0.422
		Irbesartan	74	6 (8.1)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	5 (9.1)	1.250 [0.354, 4.409]	1.275 [0.324, 5.025]	1.8 [-10.2, 13.9]	1.000
		Irbesartan	55	4 (7.3)				
eGFR High and UP High	Double-blind period	Sparsentan	37	4 (10.8)	3.892 [0.457, 33.169]	4.242 [0.451, 39.943]	8.0 [-6.1, 22.1]	0.358
		Irbesartan	36	1 (2.8)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	3 (7.7)	6.650 + [0.355, 124.506]	7.192 + [0.359, 144.166]	7.7 [-3.3, 18.7]	0.241
		Irbesartan	37	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEAN_SSIM: Incidence of AESI anemia during double-blind period – non-severe by subgroup
Safety Set

AESI anemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.461
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	14 (11.0)	1.580 [0.709, 3.519]	1.652 [0.688, 3.966]	4.0 [-3.7, 11.8]	0.282
		Irbesartan	129	9 (7.0)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	6 (12.2)	5.878 [0.735, 47.011]	6.558 [0.759, 56.698]	10.2 [-1.9, 22.3]	0.111
		Irbesartan	48	1 (2.1)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8)	0.962 [0.064, 14.551]	0.960 [0.057, 16.232]	-0.2 [-14.7, 14.4]	1.000
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEAN_SSIM: Incidence of AESI anemia during double-blind period – non-severe by subgroup
Safety Set

AESI anemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.567
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	10 (12.2)	1.951 [0.698, 5.457]	2.083 [0.679, 6.393]	5.9 [-4.1, 16.0]	0.279
		Irbesartan	80	5 (6.3)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	4 (8.9)	1.089 [0.289, 4.099]	1.098 [0.258, 4.675]	0.7 [-12.7, 14.2]	1.000
		Irbesartan	49	4 (8.2)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	6 (12.2)	5.878 [0.735, 47.011]	6.558 [0.759, 56.698]	10.2 [-1.9, 22.3]	0.111
		Irbesartan	48	1 (2.1)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8)	0.962 [0.064, 14.551]	0.960 [0.057, 16.232]	-0.2 [-14.7, 14.4]	1.000
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEAN_SSIM: Incidence of AESI anemia during double-blind period – non-severe by subgroup
Safety Set

AESI anemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.448
<= 1.75 g/day	Double-blind period	Sparsentan	98	9 (9.2)	2.847 [0.795, 10.193]	3.034 [0.795, 11.575]	6.0 [-1.8, 13.8]	0.135
		Irbesartan	93	3 (3.2)				
> 1.75 g/day	Double-blind period	Sparsentan	104	12 (11.5)	1.572 [0.670, 3.690]	1.647 [0.644, 4.208]	4.2 [-4.6, 13.0]	0.351
		Irbesartan	109	8 (7.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEAN_SSIM: Incidence of AESI anemia during double-blind period – non-severe by subgroup
Safety Set

AESI anemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.480
Yes	Double-blind period	Sparsentan	90	9 (10.0)	1.467 [0.545, 3.948]	1.519 [0.517, 4.461]	3.2 [-6.1, 12.4]	0.591
		Irbesartan	88	6 (6.8)				
No	Double-blind period	Sparsentan	112	12 (10.7)	2.443 [0.890, 6.708]	2.616 [0.890, 7.688]	6.3 [-1.4, 14.1]	0.082
		Irbesartan	114	5 (4.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEAN_SSIM: Incidence of AESI anemia during double-blind period – non-severe by subgroup
Safety Set

AESI anemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.555
<= 5 years	Double-blind period	Sparsentan	113	14 (12.4)	1.748 [0.787, 3.884]	1.854 [0.770, 4.465]	5.3 [-3.1, 13.7]	0.191
		Irbesartan	127	9 (7.1)				
> 5 years	Double-blind period	Sparsentan	89	7 (7.9)	2.949 [0.632, 13.774]	3.116 [0.627, 15.476]	5.2 [-2.7, 13.1]	0.182
		Irbesartan	75	2 (2.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEAN_SSIM: Incidence of AESI anemia during double-blind period – non-severe by subgroup
Safety Set

AESI anemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.661
Yes	Double-blind period	Sparsentan	155	16 (10.3)	2.077 [0.915, 4.715]	2.201 [0.914, 5.303]	5.4 [-1.1, 11.8]	0.090
		Irbesartan	161	8 (5.0)				
No	Double-blind period	Sparsentan	47	5 (10.6)	1.454 [0.370, 5.714]	1.508 [0.337, 6.739]	3.3 [-10.8, 17.5]	0.719
		Irbesartan	41	3 (7.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEAC_SSIM: Incidence of AESI anemia during double-blind period – severe by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEAS_SSIM: Incidence of AESI anemia during double-blind period – serious by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEU_SSIM: Incidence of AESI hyperkalemia during double-blind period by subgroup
Safety Set

AESI hyperkalemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.452
Male	Double-blind period	Sparsentan	139	26 (18.7)	1.408 [0.817, 2.424]	1.502 [0.789, 2.860]	5.4 [-3.8, 14.7]	0.256
		Irbesartan	143	19 (13.3)				
Female	Double-blind period	Sparsentan	63	8 (12.7)	0.937 [0.376, 2.334]	0.927 [0.324, 2.654]	-0.9 [-14.5, 12.8]	1.000
		Irbesartan	59	8 (13.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEU_SSIM: Incidence of AESI hyperkalemia during double-blind period by subgroup
Safety Set

AESI hyperkalemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.975
<= 45 years	Double-blind period	Sparsentan	96	17 (17.7)	1.252 [0.654, 2.397]	1.307 [0.604, 2.824]	3.6 [-7.7, 14.9]	0.559
		Irbesartan	99	14 (14.1)				
> 45 years	Double-blind period	Sparsentan	106	17 (16.0)	1.271 [0.651, 2.481]	1.322 [0.607, 2.883]	3.4 [-7.0, 13.9]	0.556
		Irbesartan	103	13 (12.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEU_SSIM: Incidence of AESI hyperkalemia during double-blind period by subgroup
Safety Set

AESI hyperkalemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.692
<= 18 years	Double-blind period	Sparsentan	9	1 (11.1)	1.800 + [0.086, 37.493]	1.941 + [0.066, 56.760]	11.1 [-25.0, 47.2]	1.000
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	18 (17.6)	1.069 [0.589, 1.937]	1.083 [0.529, 2.220]	1.1 [-10.0, 12.2]	0.856
		Irbesartan	109	18 (16.5)				
> 40 years	Double-blind period	Sparsentan	91	15 (16.5)	1.612 [0.744, 3.490]	1.732 [0.715, 4.195]	6.3 [-4.8, 17.3]	0.274
		Irbesartan	88	9 (10.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEU_SSIM: Incidence of AESI hyperkalemia during double-blind period by subgroup
Safety Set

AESI hyperkalemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.325
North America	Double-blind period	Sparsentan	35	8 (22.9)	2.629 [0.860, 8.031]	3.111 [0.853, 11.347]	14.2 [-4.5, 32.8]	0.114
		Irbesartan	46	4 (8.7)				
Europe	Double-blind period	Sparsentan	98	14 (14.3)	1.027 [0.528, 1.996]	1.031 [0.476, 2.236]	0.4 [-10.0, 10.7]	1.000
		Irbesartan	115	16 (13.9)				
Asia Pacific	Double-blind period	Sparsentan	69	12 (17.4)	1.019 [0.436, 2.379]	1.023 [0.367, 2.848]	0.3 [-16.2, 16.8]	1.000
		Irbesartan	41	7 (17.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEU_SSIM: Incidence of AESI hyperkalemia during double-blind period by subgroup
Safety Set

AESI hyperkalemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.914
< 27 kg/m**2	Double-blind period	Sparsentan	83	14 (16.9)	1.220 [0.609, 2.443]	1.264 [0.557, 2.871]	3.0 [-8.8, 14.8]	0.676
		Irbesartan	94	13 (13.8)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	20 (16.8)	1.285 [0.683, 2.414]	1.342 [0.641, 2.811]	3.7 [-6.4, 13.9]	0.462
		Irbesartan	107	14 (13.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEU_SSIM: Incidence of AESI hyperkalemia during double-blind period by subgroup
Safety Set

AESI hyperkalemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.288
eGFR Low and UP High	Double-blind period	Sparsentan	71	18 (25.4)	1.251 [0.684, 2.286]	1.336 [0.613, 2.912]	5.1 [-9.9, 20.1]	0.553
		Irbesartan	74	15 (20.3)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	11 (20.0)	1.100 [0.509, 2.377]	1.125 [0.434, 2.914]	1.8 [-14.7, 18.3]	1.000
		Irbesartan	55	10 (18.2)				
eGFR High and UP High	Double-blind period	Sparsentan	37	5 (13.5)	10.711 + [0.614, 186.919]	12.354 + [0.657, 232.145]	13.5 [-0.2, 27.3]	0.054
		Irbesartan	36	0 (0.0)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	0 (0.0)	0.190 + [0.009, 3.831]	0.180 + [0.008, 3.872]	-5.4 [-15.3, 4.5]	0.234
		Irbesartan	37	2 (5.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEU_SSIM: Incidence of AESI hyperkalemia during double-blind period by subgroup
Safety Set

AESI hyperkalemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.920
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	29 (22.8)	1.227 [0.758, 1.988]	1.295 [0.706, 2.375]	4.2 [-6.5, 14.9]	0.443
		Irbesartan	129	24 (18.6)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	5 (10.2)	1.633 [0.413, 6.457]	1.705 [0.384, 7.567]	4.0 [-9.0, 16.9]	0.715
		Irbesartan	48	3 (6.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.963 + [0.020, 46.760]	0.962 + [0.018, 50.349]	0.0 [NE, NE]	NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEU_SSIM: Incidence of AESI hyperkalemia during double-blind period by subgroup
Safety Set

AESI hyperkalemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.915
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	23 (28.0)	1.122 [0.671, 1.876]	1.169 [0.581, 2.352]	3.0 [-11.8, 17.9]	0.723
		Irbesartan	80	20 (25.0)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	6 (13.3)	1.633 [0.493, 5.416]	1.731 [0.455, 6.582]	5.2 [-9.5, 19.8]	0.512
		Irbesartan	49	4 (8.2)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	5 (10.2)	1.633 [0.413, 6.457]	1.705 [0.384, 7.567]	4.0 [-9.0, 16.9]	0.715
		Irbesartan	48	3 (6.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.963 + [0.020, 46.760]	0.962 + [0.018, 50.349]	0.0 [NE, NE]	NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEU_SSIM: Incidence of AESI hyperkalemia during double-blind period by subgroup
Safety Set

AESI hyperkalemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.676
<= 1.75 g/day	Double-blind period	Sparsentan	98	13 (13.3)	1.122 [0.529, 2.377]	1.140 [0.483, 2.690]	1.4 [-9.0, 11.9]	0.829
		Irbesartan	93	11 (11.8)				
> 1.75 g/day	Double-blind period	Sparsentan	104	21 (20.2)	1.376 [0.761, 2.487]	1.471 [0.720, 3.005]	5.5 [-5.6, 16.6]	0.366
		Irbesartan	109	16 (14.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEU_SSIM: Incidence of AESI hyperkalemia during double-blind period by subgroup
Safety Set

AESI hyperkalemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.095
Yes	Double-blind period	Sparsentan	90	21 (23.3)	1.867 [0.957, 3.640]	2.130 [0.959, 4.735]	10.8 [-1.4, 23.1]	0.079
		Irbesartan	88	11 (12.5)				
No	Double-blind period	Sparsentan	112	13 (11.6)	0.827 [0.417, 1.639]	0.804 [0.367, 1.760]	-2.4 [-12.0, 7.2]	0.692
		Irbesartan	114	16 (14.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEU_SSIM: Incidence of AESI hyperkalemia during double-blind period by subgroup
Safety Set

AESI hyperkalemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.419
<= 5 years	Double-blind period	Sparsentan	113	21 (18.6)	1.475 [0.810, 2.685]	1.584 [0.781, 3.210]	6.0 [-4.1, 16.0]	0.215
		Irbesartan	127	16 (12.6)				
> 5 years	Double-blind period	Sparsentan	89	13 (14.6)	0.996 [0.474, 2.091]	0.995 [0.417, 2.373]	-0.1 [-12.1, 12.0]	1.000
		Irbesartan	75	11 (14.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEU_SSIM: Incidence of AESI hyperkalemia during double-blind period by subgroup
Safety Set

AESI hyperkalemia

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.277
Yes	Double-blind period	Sparsentan	155	29 (18.7)	1.434 [0.856, 2.404]	1.534 [0.833, 2.827]	5.7 [-3.0, 14.3]	0.217
		Irbesartan	161	21 (13.0)				
No	Double-blind period	Sparsentan	47	5 (10.6)	0.727 [0.239, 2.207]	0.694 [0.195, 2.470]	-4.0 [-20.2, 12.2]	0.749
		Irbesartan	41	6 (14.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEUN_SSIM: Incidence of AESI hyperkalemia during double-blind period – non-severe by subgroup
Safety Set

AESI hyperkalemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.452
Male	Double-blind period	Sparsentan	139	26 (18.7)	1.408 [0.817, 2.424]	1.502 [0.789, 2.860]	5.4 [-3.8, 14.7]	0.256
		Irbesartan	143	19 (13.3)				
Female	Double-blind period	Sparsentan	63	8 (12.7)	0.937 [0.376, 2.334]	0.927 [0.324, 2.654]	-0.9 [-14.5, 12.8]	1.000
		Irbesartan	59	8 (13.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEUN_SSIM: Incidence of AESI hyperkalemia during double-blind period – non-severe by subgroup
Safety Set

AESI hyperkalemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.975
<= 45 years	Double-blind period	Sparsentan	96	17 (17.7)	1.252 [0.654, 2.397]	1.307 [0.604, 2.824]	3.6 [-7.7, 14.9]	0.559
		Irbesartan	99	14 (14.1)				
> 45 years	Double-blind period	Sparsentan	106	17 (16.0)	1.271 [0.651, 2.481]	1.322 [0.607, 2.883]	3.4 [-7.0, 13.9]	0.556
		Irbesartan	103	13 (12.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEUN_SSIM: Incidence of AESI hyperkalemia during double-blind period – non-severe by subgroup
Safety Set

AESI hyperkalemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.692
<= 18 years	Double-blind period	Sparsentan	9	1 (11.1)	1.800 + [0.086, 37.493]	1.941 + [0.066, 56.760]	11.1 [-25.0, 47.2]	1.000
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	18 (17.6)	1.069 [0.589, 1.937]	1.083 [0.529, 2.220]	1.1 [-10.0, 12.2]	0.856
		Irbesartan	109	18 (16.5)				
> 40 years	Double-blind period	Sparsentan	91	15 (16.5)	1.612 [0.744, 3.490]	1.732 [0.715, 4.195]	6.3 [-4.8, 17.3]	0.274
		Irbesartan	88	9 (10.2)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEUN_SSIM: Incidence of AESI hyperkalemia during double-blind period – non-severe by subgroup
Safety Set

AESI hyperkalemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.325
North America	Double-blind period	Sparsentan	35	8 (22.9)	2.629 [0.860, 8.031]	3.111 [0.853, 11.347]	14.2 [-4.5, 32.8]	0.114
		Irbesartan	46	4 (8.7)				
Europe	Double-blind period	Sparsentan	98	14 (14.3)	1.027 [0.528, 1.996]	1.031 [0.476, 2.236]	0.4 [-10.0, 10.7]	1.000
		Irbesartan	115	16 (13.9)				
Asia Pacific	Double-blind period	Sparsentan	69	12 (17.4)	1.019 [0.436, 2.379]	1.023 [0.367, 2.848]	0.3 [-16.2, 16.8]	1.000
		Irbesartan	41	7 (17.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEUN_SSIM: Incidence of AESI hyperkalemia during double-blind period – non-severe by subgroup
Safety Set

AESI hyperkalemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.914
< 27 kg/m**2	Double-blind period	Sparsentan	83	14 (16.9)	1.220 [0.609, 2.443]	1.264 [0.557, 2.871]	3.0 [-8.8, 14.8]	0.676
		Irbesartan	94	13 (13.8)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	20 (16.8)	1.285 [0.683, 2.414]	1.342 [0.641, 2.811]	3.7 [-6.4, 13.9]	0.462
		Irbesartan	107	14 (13.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEUN_SSIM: Incidence of AESI hyperkalemia during double-blind period – non-severe by subgroup
Safety Set

AESI hyperkalemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.288
eGFR Low and UP High	Double-blind period	Sparsentan	71	18 (25.4)	1.251 [0.684, 2.286]	1.336 [0.613, 2.912]	5.1 [-9.9, 20.1]	0.553
		Irbesartan	74	15 (20.3)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	11 (20.0)	1.100 [0.509, 2.377]	1.125 [0.434, 2.914]	1.8 [-14.7, 18.3]	1.000
		Irbesartan	55	10 (18.2)				
eGFR High and UP High	Double-blind period	Sparsentan	37	5 (13.5)	10.711 + [0.614, 186.919]	12.354 + [0.657, 232.145]	13.5 [-0.2, 27.3]	0.054
		Irbesartan	36	0 (0.0)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	0 (0.0)	0.190 + [0.009, 3.831]	0.180 + [0.008, 3.872]	-5.4 [-15.3, 4.5]	0.234
		Irbesartan	37	2 (5.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEUN_SSIM: Incidence of AESI hyperkalemia during double-blind period – non-severe by subgroup
Safety Set

AESI hyperkalemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.920
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	29 (22.8)	1.227 [0.758, 1.988]	1.295 [0.706, 2.375]	4.2 [-6.5, 14.9]	0.443
		Irbesartan	129	24 (18.6)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	5 (10.2)	1.633 [0.413, 6.457]	1.705 [0.384, 7.567]	4.0 [-9.0, 16.9]	0.715
		Irbesartan	48	3 (6.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.963 + [0.020, 46.760]	0.962 + [0.018, 50.349]	0.0 [NE, NE]	NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEUN_SSIM: Incidence of AESI hyperkalemia during double-blind period – non-severe by subgroup
Safety Set

AESI hyperkalemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.915
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	23 (28.0)	1.122 [0.671, 1.876]	1.169 [0.581, 2.352]	3.0 [-11.8, 17.9]	0.723
		Irbesartan	80	20 (25.0)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	6 (13.3)	1.633 [0.493, 5.416]	1.731 [0.455, 6.582]	5.2 [-9.5, 19.8]	0.512
		Irbesartan	49	4 (8.2)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	5 (10.2)	1.633 [0.413, 6.457]	1.705 [0.384, 7.567]	4.0 [-9.0, 16.9]	0.715
		Irbesartan	48	3 (6.3)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.963 + [0.020, 46.760]	0.962 + [0.018, 50.349]	0.0 [NE, NE]	NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEUN_SSIM: Incidence of AESI hyperkalemia during double-blind period – non-severe by subgroup
Safety Set

AESI hyperkalemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.676
<= 1.75 g/day	Double-blind period	Sparsentan	98	13 (13.3)	1.122 [0.529, 2.377]	1.140 [0.483, 2.690]	1.4 [-9.0, 11.9]	0.829
		Irbesartan	93	11 (11.8)				
> 1.75 g/day	Double-blind period	Sparsentan	104	21 (20.2)	1.376 [0.761, 2.487]	1.471 [0.720, 3.005]	5.5 [-5.6, 16.6]	0.366
		Irbesartan	109	16 (14.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEUN_SSIM: Incidence of AESI hyperkalemia during double-blind period – non-severe by subgroup
Safety Set

AESI hyperkalemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.095
Yes	Double-blind period	Sparsentan	90	21 (23.3)	1.867 [0.957, 3.640]	2.130 [0.959, 4.735]	10.8 [-1.4, 23.1]	0.079
		Irbesartan	88	11 (12.5)				
No	Double-blind period	Sparsentan	112	13 (11.6)	0.827 [0.417, 1.639]	0.804 [0.367, 1.760]	-2.4 [-12.0, 7.2]	0.692
		Irbesartan	114	16 (14.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEUN_SSIM: Incidence of AESI hyperkalemia during double-blind period – non-severe by subgroup
Safety Set

AESI hyperkalemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.419
<= 5 years	Double-blind period	Sparsentan	113	21 (18.6)	1.475 [0.810, 2.685]	1.584 [0.781, 3.210]	6.0 [-4.1, 16.0]	0.215
		Irbesartan	127	16 (12.6)				
> 5 years	Double-blind period	Sparsentan	89	13 (14.6)	0.996 [0.474, 2.091]	0.995 [0.417, 2.373]	-0.1 [-12.1, 12.0]	1.000
		Irbesartan	75	11 (14.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEUN_SSIM: Incidence of AESI hyperkalemia during double-blind period – non-severe by subgroup
Safety Set

AESI hyperkalemia - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.277
Yes	Double-blind period	Sparsentan	155	29 (18.7)	1.434 [0.856, 2.404]	1.534 [0.833, 2.827]	5.7 [-3.0, 14.3]	0.217
		Irbesartan	161	21 (13.0)				
No	Double-blind period	Sparsentan	47	5 (10.6)	0.727 [0.239, 2.207]	0.694 [0.195, 2.470]	-4.0 [-20.2, 12.2]	0.749
		Irbesartan	41	6 (14.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEUC_SSIM: Incidence of AESI hyperkalemia during double-blind period – severe by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEUS_SSIM: Incidence of AESI hyperkalemia during double-blind period – serious by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEY_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period by subgroup
Safety Set

AESI cardiac arrhythmias

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.327
Male	Double-blind period	Sparsentan	139	7 (5.0)	0.450 [0.191, 1.060]	0.421 [0.168, 1.057]	-6.2 [-13.2, 0.9]	0.081
		Irbesartan	143	16 (11.2)				
Female	Double-blind period	Sparsentan	63	5 (7.9)	0.937 [0.286, 3.071]	0.931 [0.255, 3.395]	-0.5 [-11.9, 10.9]	1.000
		Irbesartan	59	5 (8.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEY_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period by subgroup
Safety Set

AESI cardiac arrhythmias

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.423
<= 45 years	Double-blind period	Sparsentan	96	5 (5.2)	0.430 [0.157, 1.174]	0.398 [0.135, 1.178]	-6.9 [-15.8, 1.9]	0.127
		Irbesartan	99	12 (12.1)				
> 45 years	Double-blind period	Sparsentan	106	7 (6.6)	0.756 [0.292, 1.954]	0.738 [0.264, 2.063]	-2.1 [-10.3, 6.0]	0.611
		Irbesartan	103	9 (8.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEY_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period by subgroup
Safety Set

AESI cardiac arrhythmias

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.637
<= 18 years	Double-blind period	Sparsentan	9	1 (11.1)	0.556 [0.044, 7.095]	0.500 [0.024, 10.251]	-8.9 [-65.1, 47.3]	1.000
		Irbesartan	5	1 (20.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	5 (4.9)	0.411 [0.152, 1.112]	0.381 [0.131, 1.109]	-7.0 [-15.4, 1.3]	0.085
		Irbesartan	109	13 (11.9)				
> 40 years	Double-blind period	Sparsentan	91	6 (6.6)	0.829 [0.290, 2.369]	0.817 [0.263, 2.534]	-1.4 [-10.1, 7.4]	0.780
		Irbesartan	88	7 (8.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEY_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period by subgroup
Safety Set

AESI cardiac arrhythmias

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.172
North America	Double-blind period	Sparsentan	35	2 (5.7)	0.438 [0.094, 2.041]	0.404 [0.076, 2.136]	-7.3 [-22.2, 7.6]	0.455
		Irbesartan	46	6 (13.0)				
Europe	Double-blind period	Sparsentan	98	8 (8.2)	1.043 [0.418, 2.600]	1.047 [0.388, 2.826]	0.3 [-7.9, 8.6]	1.000
		Irbesartan	115	9 (7.8)				
Asia Pacific	Double-blind period	Sparsentan	69	2 (2.9)	0.198 [0.042, 0.936]	0.174 [0.033, 0.908]	-11.7 [-25.2, 1.7]	0.050
		Irbesartan	41	6 (14.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEY_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period by subgroup
Safety Set

AESI cardiac arrhythmias

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	0.988
< 27 kg/m**2	Double-blind period	Sparsentan	83	5 (6.0)	0.566 [0.202, 1.590]	0.538 [0.176, 1.645]	-4.6 [-13.8, 4.6]	0.295
		Irbesartan	94	10 (10.6)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	7 (5.9)	0.572 [0.230, 1.423]	0.545 [0.203, 1.462]	-4.4 [-12.4, 3.6]	0.325
		Irbesartan	107	11 (10.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEY_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period by subgroup
Safety Set

AESI cardiac arrhythmias

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.855
eGFR Low and UP High	Double-blind period	Sparsentan	71	5 (7.0)	0.744 [0.248, 2.238]	0.725 [0.219, 2.400]	-2.4 [-12.7, 7.9]	0.765
		Irbesartan	74	7 (9.5)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	3 (5.5)	0.375 [0.105, 1.340]	0.339 [0.085, 1.353]	-9.1 [-22.0, 3.8]	0.202
		Irbesartan	55	8 (14.5)				
eGFR High and UP High	Double-blind period	Sparsentan	37	3 (8.1)	0.730 [0.176, 3.034]	0.706 [0.146, 3.403]	-3.0 [-19.3, 13.3]	0.711
		Irbesartan	36	4 (11.1)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	1 (2.6)	0.474 [0.045, 5.014]	0.461 [0.040, 5.305]	-2.8 [-14.3, 8.6]	0.610
		Irbesartan	37	2 (5.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEY_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period by subgroup
Safety Set

AESI cardiac arrhythmias

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.754
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	7 (5.5)	0.474 [0.200, 1.124]	0.443 [0.174, 1.127]	-6.1 [-13.7, 1.5]	0.117
		Irbesartan	129	15 (11.6)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2)	0.784 [0.224, 2.744]	0.764 [0.192, 3.037]	-2.3 [-15.9, 11.4]	0.740
		Irbesartan	48	5 (10.4)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8)	0.962 [0.064, 14.551]	0.960 [0.057, 16.232]	-0.2 [-14.7, 14.4]	1.000
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEY_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period by subgroup
Safety Set

AESI cardiac arrhythmias

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.595	
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	3 (3.7)	0.293 [0.084, 1.025]	0.266 [0.070, 1.005]	-8.8 [-18.4, 0.7]	0.046	*
		Irbesartan	80	10 (12.5)					
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	4 (8.9)	0.871 [0.249, 3.043]	0.859 [0.216, 3.419]	-1.3 [-15.3, 12.7]	1.000	
		Irbesartan	49	5 (10.2)					
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2)	0.784 [0.224, 2.744]	0.764 [0.192, 3.037]	-2.3 [-15.9, 11.4]	0.740	
		Irbesartan	48	5 (10.4)					
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8)	0.962 [0.064, 14.551]	0.960 [0.057, 16.232]	-0.2 [-14.7, 14.4]	1.000	
		Irbesartan	25	1 (4.0)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEY_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period by subgroup
Safety Set

AESI cardiac arrhythmias

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.457
<= 1.75 g/day	Double-blind period	Sparsentan	98	7 (7.1)	0.738 [0.287, 1.901]	0.718 [0.256, 2.014]	-2.5 [-11.5, 6.4]	0.606
		Irbesartan	93	9 (9.7)				
> 1.75 g/day	Double-blind period	Sparsentan	104	5 (4.8)	0.437 [0.159, 1.197]	0.408 [0.139, 1.202]	-6.2 [-14.3, 1.9]	0.129
		Irbesartan	109	12 (11.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEY_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period by subgroup
Safety Set

AESI cardiac arrhythmias

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.819
Yes	Double-blind period	Sparsentan	90	8 (8.9)	0.602 [0.262, 1.380]	0.563 [0.221, 1.433]	-5.9 [-16.5, 4.7]	0.252
		Irbesartan	88	13 (14.8)				
No	Double-blind period	Sparsentan	112	4 (3.6)	0.509 [0.158, 1.642]	0.491 [0.143, 1.679]	-3.4 [-10.1, 3.3]	0.375
		Irbesartan	114	8 (7.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEY_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period by subgroup
Safety Set

AESI cardiac arrhythmias

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.135	
<= 5 years	Double-blind period	Sparsentan	113	6 (5.3)	0.397 [0.162, 0.971]	0.363 [0.138, 0.955]	-8.1 [-16.1, -0.0]	0.047	*
		Irbesartan	127	17 (13.4)					
> 5 years	Double-blind period	Sparsentan	89	6 (6.7)	1.264 [0.370, 4.313]	1.283 [0.348, 4.728]	1.4 [-7.1, 9.9]	0.756	
		Irbesartan	75	4 (5.3)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEY_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period by subgroup
Safety Set

AESI cardiac arrhythmias

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.401
Yes	Double-blind period	Sparsentan	155	12 (7.7)	0.656 [0.330, 1.306]	0.627 [0.294, 1.340]	-4.1 [-11.2, 3.1]	0.259
		Irbesartan	161	19 (11.8)				
No	Double-blind period	Sparsentan	47	0 (0.0)	0.175 + [0.009, 3.543]	0.166 + [0.008, 3.567]	-4.9 [-13.8, 4.0]	0.214
		Irbesartan	41	2 (4.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEYN_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – non-severe by subgroup
Safety Set

AESI cardiac arrhythmias - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.426
Male	Double-blind period	Sparsentan	139	7 (5.0)	0.514 [0.214, 1.236]	0.489 [0.191, 1.250]	-4.8 [-11.5, 2.0]	0.173
		Irbesartan	143	14 (9.8)				
Female	Double-blind period	Sparsentan	63	5 (7.9)	0.937 [0.286, 3.071]	0.931 [0.255, 3.395]	-0.5 [-11.9, 10.9]	1.000
		Irbesartan	59	5 (8.5)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEYN_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – non-severe by subgroup
Safety Set

AESI cardiac arrhythmias - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.409
<= 45 years	Double-blind period	Sparsentan	96	5 (5.2)	0.469 [0.169, 1.299]	0.440 [0.147, 1.317]	-5.9 [-14.5, 2.7]	0.192
		Irbesartan	99	11 (11.1)				
> 45 years	Double-blind period	Sparsentan	106	7 (6.6)	0.850 [0.320, 2.260]	0.840 [0.293, 2.406]	-1.2 [-9.1, 6.8]	0.794
		Irbesartan	103	8 (7.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEYN_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – non-severe by subgroup
Safety Set

AESI cardiac arrhythmias - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.590
<= 18 years	Double-blind period	Sparsentan	9	1 (11.1)	0.556 [0.044, 7.095]	0.500 [0.024, 10.251]	-8.9 [-65.1, 47.3]	1.000
		Irbesartan	5	1 (20.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	5 (4.9)	0.445 [0.163, 1.220]	0.417 [0.141, 1.228]	-6.1 [-14.3, 2.1]	0.131
		Irbesartan	109	12 (11.0)				
> 40 years	Double-blind period	Sparsentan	91	6 (6.6)	0.967 [0.324, 2.885]	0.965 [0.299, 3.113]	-0.2 [-8.7, 8.2]	1.000
		Irbesartan	88	6 (6.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEYN_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – non-severe by subgroup
Safety Set

AESI cardiac arrhythmias - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	0.195
North America	Double-blind period	Sparsentan	35	2 (5.7)	0.657 [0.128, 3.386]	0.636 [0.110, 3.690]	-3.0 [-16.7, 10.7]	0.694
		Irbesartan	46	4 (8.7)				
Europe	Double-blind period	Sparsentan	98	8 (8.2)	1.043 [0.418, 2.600]	1.047 [0.388, 2.826]	0.3 [-7.9, 8.6]	1.000
		Irbesartan	115	9 (7.8)				
Asia Pacific	Double-blind period	Sparsentan	69	2 (2.9)	0.198 [0.042, 0.936]	0.174 [0.033, 0.908]	-11.7 [-25.2, 1.7]	0.050
		Irbesartan	41	6 (14.6)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEYN_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – non-severe by subgroup
Safety Set

AESI cardiac arrhythmias - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	1.000
< 27 kg/m**2	Double-blind period	Sparsentan	83	5 (6.0)	0.629 [0.220, 1.803]	0.605 [0.194, 1.885]	-3.6 [-12.5, 5.4]	0.418
		Irbesartan	94	9 (9.6)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	7 (5.9)	0.629 [0.248, 1.595]	0.606 [0.222, 1.654]	-3.5 [-11.3, 4.4]	0.450
		Irbesartan	107	10 (9.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEYN_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – non-severe by subgroup
Safety Set

AESI cardiac arrhythmias - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	0.703
eGFR Low and UP High	Double-blind period	Sparsentan	71	5 (7.0)	1.042 [0.315, 3.447]	1.045 [0.289, 3.778]	0.3 [-9.3, 9.9]	1.000
		Irbesartan	74	5 (6.8)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	3 (5.5)	0.375 [0.105, 1.340]	0.339 [0.085, 1.353]	-9.1 [-22.0, 3.8]	0.202
		Irbesartan	55	8 (14.5)				
eGFR High and UP High	Double-blind period	Sparsentan	37	3 (8.1)	0.730 [0.176, 3.034]	0.706 [0.146, 3.403]	-3.0 [-19.3, 13.3]	0.711
		Irbesartan	36	4 (11.1)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	1 (2.6)	0.474 [0.045, 5.014]	0.461 [0.040, 5.305]	-2.8 [-14.3, 8.6]	0.610
		Irbesartan	37	2 (5.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEYN_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – non-severe by subgroup
Safety Set

AESI cardiac arrhythmias - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.858
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	7 (5.5)	0.547 [0.226, 1.326]	0.521 [0.201, 1.351]	-4.6 [-11.9, 2.8]	0.244
		Irbesartan	129	13 (10.1)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2)	0.784 [0.224, 2.744]	0.764 [0.192, 3.037]	-2.3 [-15.9, 11.4]	0.740
		Irbesartan	48	5 (10.4)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8)	0.962 [0.064, 14.551]	0.960 [0.057, 16.232]	-0.2 [-14.7, 14.4]	1.000
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEYN_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – non-severe by subgroup
Safety Set

AESI cardiac arrhythmias - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	0.768
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	3 (3.7)	0.366 [0.101, 1.330]	0.342 [0.087, 1.338]	-6.3 [-15.3, 2.6]	0.129
		Irbesartan	80	8 (10.0)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	4 (8.9)	0.871 [0.249, 3.043]	0.859 [0.216, 3.419]	-1.3 [-15.3, 12.7]	1.000
		Irbesartan	49	5 (10.2)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2)	0.784 [0.224, 2.744]	0.764 [0.192, 3.037]	-2.3 [-15.9, 11.4]	0.740
		Irbesartan	48	5 (10.4)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	1 (3.8)	0.962 [0.064, 14.551]	0.960 [0.057, 16.232]	-0.2 [-14.7, 14.4]	1.000
		Irbesartan	25	1 (4.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEYN_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – non-severe by subgroup
Safety Set

AESI cardiac arrhythmias - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.441
<= 1.75 g/day	Double-blind period	Sparsentan	98	7 (7.1)	0.830 [0.314, 2.199]	0.817 [0.284, 2.351]	-1.5 [-10.2, 7.2]	0.791
		Irbesartan	93	8 (8.6)				
> 1.75 g/day	Double-blind period	Sparsentan	104	5 (4.8)	0.476 [0.171, 1.324]	0.450 [0.151, 1.343]	-5.3 [-13.2, 2.6]	0.195
		Irbesartan	109	11 (10.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEYN_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – non-severe by subgroup
Safety Set

AESI cardiac arrhythmias - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.879
Yes	Double-blind period	Sparsentan	90	8 (8.9)	0.652 [0.280, 1.517]	0.618 [0.240, 1.594]	-4.7 [-15.1, 5.6]	0.351
		Irbesartan	88	12 (13.6)				
No	Double-blind period	Sparsentan	112	4 (3.6)	0.582 [0.175, 1.932]	0.566 [0.161, 1.990]	-2.6 [-9.0, 3.9]	0.539
		Irbesartan	114	7 (6.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEYN_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – non-severe by subgroup
Safety Set

AESI cardiac arrhythmias - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.185
<= 5 years	Double-blind period	Sparsentan	113	6 (5.3)	0.450 [0.181, 1.119]	0.419 [0.157, 1.119]	-6.5 [-14.3, 1.3]	0.108
		Irbesartan	127	15 (11.8)				
> 5 years	Double-blind period	Sparsentan	89	6 (6.7)	1.264 [0.370, 4.313]	1.283 [0.348, 4.728]	1.4 [-7.1, 9.9]	0.756
		Irbesartan	75	4 (5.3)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEYN_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – non-severe by subgroup
Safety Set

AESI cardiac arrhythmias - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.363
Yes	Double-blind period	Sparsentan	155	12 (7.7)	0.733 [0.362, 1.484]	0.711 [0.328, 1.542]	-2.8 [-9.8, 4.2]	0.439
		Irbesartan	161	17 (10.6)				
No	Double-blind period	Sparsentan	47	0 (0.0)	0.175 + [0.009, 3.543]	0.166 + [0.008, 3.567]	-4.9 [-13.8, 4.0]	0.214
		Irbesartan	41	2 (4.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEYC_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – severe by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEYS_SSIM: Incidence of AESI cardiac arrhythmias during double-blind period – serious by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEI_SSIM: Incidence of AESI acute kidney injury during double-blind period by subgroup
Safety Set

AESI acute kidney injury

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.813
Male	Double-blind period	Sparsentan	139	10 (7.2)	2.572 [0.826, 8.008]	2.694 [0.824, 8.802]	4.4 [-1.4, 10.2]	0.105
		Irbesartan	143	4 (2.8)				
Female	Double-blind period	Sparsentan	63	2 (3.2)	1.873 [0.174, 20.118]	1.902 [0.168, 21.541]	1.5 [-5.6, 8.6]	1.000
		Irbesartan	59	1 (1.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEI_SSIM: Incidence of AESI acute kidney injury during double-blind period by subgroup
Safety Set

AESI acute kidney injury

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value	
Age	Double-blind period	Sparsentan					Interaction test:	0.079	
<= 45 years	Double-blind period	Sparsentan	96	10 (10.4)	5.156 [1.160, 22.925]	5.640 [1.202, 26.456]	8.4 [0.7, 16.1]	0.017	*
		Irbesartan	99	2 (2.0)					
> 45 years	Double-blind period	Sparsentan	106	2 (1.9)	0.648 [0.111, 3.798]	0.641 [0.105, 3.917]	-1.0 [-6.1, 4.1]	0.680	
		Irbesartan	103	3 (2.9)					

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEI_SSIM: Incidence of AESI acute kidney injury during double-blind period by subgroup
Safety Set

AESI acute kidney injury

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.971
<= 18 years	Double-blind period	Sparsentan	9	2 (22.2)	3.000 + [0.171, 52.527]	3.667 + [0.145, 92.653]	22.2 [-20.5, 64.9]	0.505
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	8 (7.8)	2.137 [0.664, 6.883]	2.234 [0.652, 7.659]	4.2 [-3.1, 11.4]	0.240
		Irbesartan	109	4 (3.7)				
> 40 years	Double-blind period	Sparsentan	91	2 (2.2)	1.934 [0.179, 20.950]	1.955 [0.174, 21.955]	1.1 [-3.8, 5.9]	1.000
		Irbesartan	88	1 (1.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEI_SSIM: Incidence of AESI acute kidney injury during double-blind period by subgroup
Safety Set

AESI acute kidney injury

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	NE
North America	Double-blind period	Sparsentan	35	3 (8.6) all n<10				NE
		Irbesartan	46	2 (4.3)				
Europe	Double-blind period	Sparsentan	98	7 (7.1) all n<10				NE
		Irbesartan	115	2 (1.7)				
Asia Pacific	Double-blind period	Sparsentan	69	2 (2.9) all n<10				NE
		Irbesartan	41	1 (2.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEI_SSIM: Incidence of AESI acute kidney injury during double-blind period by subgroup
Safety Set

AESI acute kidney injury

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	NE
< 27 kg/m**2	Double-blind period	Sparsentan	83	6 (7.2) all n<10				NE
		Irbesartan	94	2 (2.1)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	6 (5.0) all n<10				NE
		Irbesartan	107	3 (2.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEI_SSIM: Incidence of AESI acute kidney injury during double-blind period by subgroup
Safety Set

AESI acute kidney injury

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	NE
eGFR Low and UP High	Double-blind period	Sparsentan	71	5 (7.0) all n<10				NE
		Irbesartan	74	3 (4.1)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	3 (5.5) all n<10				NE
		Irbesartan	55	1 (1.8)				
eGFR High and UP High	Double-blind period	Sparsentan	37	3 (8.1) all n<10				NE
		Irbesartan	36	1 (2.8)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	1 (2.6) all n<10				NE
		Irbesartan	37	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEI_SSIM: Incidence of AESI acute kidney injury during double-blind period by subgroup
Safety Set

AESI acute kidney injury

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.792
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	8 (6.3)	2.031 [0.627, 6.578]	2.101 [0.616, 7.160]	3.2 [-2.8, 9.2]	0.253
		Irbesartan	129	4 (3.1)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2)	3.918 [0.454, 33.802]	4.178 [0.450, 38.818]	6.1 [-4.6, 16.8]	0.362
		Irbesartan	48	1 (2.1)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.963 + [0.020, 46.760]	0.962 + [0.018, 50.349]	0.0 [NE, NE]	NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEI_SSIM: Incidence of AESI acute kidney injury during double-blind period by subgroup
Safety Set

AESI acute kidney injury

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	NE
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	4 (4.9) all n<10				NE
		Irbesartan	80	3 (3.8)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	4 (8.9) all n<10				NE
		Irbesartan	49	1 (2.0)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	4 (8.2) all n<10				NE
		Irbesartan	48	1 (2.1)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0) all n<10				NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEI_SSIM: Incidence of AESI acute kidney injury during double-blind period by subgroup
Safety Set

AESI acute kidney injury

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	0.300
<= 1.75 g/day	Double-blind period	Sparsentan	98	6 (6.1)	5.694 [0.699, 46.400]	6.000 [0.708, 50.825]	5.0 [-1.2, 11.3]	0.119
		Irbesartan	93	1 (1.1)				
> 1.75 g/day	Double-blind period	Sparsentan	104	6 (5.8)	1.572 [0.457, 5.413]	1.607 [0.440, 5.866]	2.1 [-4.5, 8.7]	0.531
		Irbesartan	109	4 (3.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEI_SSIM: Incidence of AESI acute kidney injury during double-blind period by subgroup
Safety Set

AESI acute kidney injury

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	0.382
Yes	Double-blind period	Sparsentan	90	7 (7.8)	1.711 [0.519, 5.640]	1.771 [0.500, 6.277]	3.2 [-4.9, 11.4]	0.536
		Irbesartan	88	4 (4.5)				
No	Double-blind period	Sparsentan	112	5 (4.5)	5.089 [0.604, 42.874]	5.280 [0.607, 45.936]	3.6 [-1.5, 8.7]	0.118
		Irbesartan	114	1 (0.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEI_SSIM: Incidence of AESI acute kidney injury during double-blind period by subgroup
Safety Set

AESI acute kidney injury

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	0.594
<= 5 years	Double-blind period	Sparsentan	113	8 (7.1)	2.997 [0.815, 11.024]	3.149 [0.815, 12.174]	4.7 [-1.5, 11.0]	0.121
		Irbesartan	127	3 (2.4)				
> 5 years	Double-blind period	Sparsentan	89	4 (4.5)	1.685 [0.317, 8.947]	1.718 [0.306, 9.650]	1.8 [-5.0, 8.7]	0.689
		Irbesartan	75	2 (2.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEI_SSIM: Incidence of AESI acute kidney injury during double-blind period by subgroup
Safety Set

AESI acute kidney injury

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.647
Yes	Double-blind period	Sparsentan	155	10 (6.5)	2.077 [0.727, 5.940]	2.152 [0.718, 6.445]	3.3 [-2.0, 8.7]	0.192
		Irbesartan	161	5 (3.1)				
No	Double-blind period	Sparsentan	47	2 (4.3)	4.375 + [0.216, 88.579]	4.560 + [0.213, 97.787]	4.3 [-3.8, 12.3]	0.497
		Irbesartan	41	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEIN_SSIM: Incidence of AESI acute kidney injury during double-blind period – non-severe by subgroup
Safety Set

AESI acute kidney injury - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Sex	Double-blind period	Sparsentan					Interaction test:	0.670
Male	Double-blind period	Sparsentan	139	7 (5.0)	1.800 [0.539, 6.014]	1.843 [0.527, 6.441]	2.2 [-3.0, 7.5]	0.372
		Irbesartan	143	4 (2.8)				
Female	Double-blind period	Sparsentan	63	1 (1.6)	0.937 [0.060, 14.634]	0.935 [0.057, 15.304]	-0.1 [-6.3, 6.0]	1.000
		Irbesartan	59	1 (1.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEIN_SSIM: Incidence of AESI acute kidney injury during double-blind period – non-severe by subgroup
Safety Set

AESI acute kidney injury - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age	Double-blind period	Sparsentan					Interaction test:	0.045 #
<= 45 years	Double-blind period	Sparsentan	96	8 (8.3)	4.125 [0.899, 18.933]	4.409 [0.912, 21.323]	6.3 [-0.9, 13.5]	0.056
		Irbesartan	99	2 (2.0)				
> 45 years	Double-blind period	Sparsentan	106	0 (0.0)	0.139 + [0.007, 2.655]	0.135 + [0.007, 2.643]	-2.9 [-7.1, 1.3]	0.118
		Irbesartan	103	3 (2.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEIN_SSIM: Incidence of AESI acute kidney injury during double-blind period – non-severe by subgroup
Safety Set

AESI acute kidney injury - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Age at IgAN diagnosis	Double-blind period	Sparsentan					Interaction test:	0.596
<= 18 years	Double-blind period	Sparsentan	9	1 (11.1)	1.800 + [0.086, 37.493]	1.941 + [0.066, 56.760]	11.1 [-25.0, 47.2]	1.000
		Irbesartan	5	0 (0.0)				
> 18 to 40 years	Double-blind period	Sparsentan	102	7 (6.9)	1.870 [0.564, 6.199]	1.934 [0.549, 6.815]	3.2 [-3.8, 10.2]	0.362
		Irbesartan	109	4 (3.7)				
> 40 years	Double-blind period	Sparsentan	91	0 (0.0)	0.322 + [0.013, 7.811]	0.319 + [0.013, 7.930]	-1.1 [-4.5, 2.2]	0.492
		Irbesartan	88	1 (1.1)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEIN_SSIM: Incidence of AESI acute kidney injury during double-blind period – non-severe by subgroup
Safety Set

AESI acute kidney injury - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Geographic region	Double-blind period	Sparsentan					Interaction test:	NE
North America	Double-blind period	Sparsentan	35	3 (8.6) all n<10				NE
		Irbesartan	46	2 (4.3)				
Europe	Double-blind period	Sparsentan	98	4 (4.1) all n<10				NE
		Irbesartan	115	2 (1.7)				
Asia Pacific	Double-blind period	Sparsentan	69	1 (1.4) all n<10				NE
		Irbesartan	41	1 (2.4)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEIN_SSIM: Incidence of AESI acute kidney injury during double-blind period – non-severe by subgroup
Safety Set

AESI acute kidney injury - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline BMI	Double-blind period	Sparsentan					Interaction test:	NE
< 27 kg/m**2	Double-blind period	Sparsentan	83	4 (4.8) all n<10				NE
		Irbesartan	94	2 (2.1)				
>= 27 kg/m**2	Double-blind period	Sparsentan	119	4 (3.4) all n<10				NE
		Irbesartan	107	3 (2.8)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEIN_SSIM: Incidence of AESI acute kidney injury during double-blind period – non-severe by subgroup
Safety Set

AESI acute kidney injury - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Randomization strata	Double-blind period	Sparsentan					Interaction test:	NE
eGFR Low and UP High	Double-blind period	Sparsentan	71	3 (4.2) all n<10				NE
		Irbesartan	74	3 (4.1)				
eGFR Low and UP Low	Double-blind period	Sparsentan	55	3 (5.5) all n<10				NE
		Irbesartan	55	1 (1.8)				
eGFR High and UP High	Double-blind period	Sparsentan	37	1 (2.7) all n<10				NE
		Irbesartan	36	1 (2.8)				
eGFR High and UP Low	Double-blind period	Sparsentan	39	1 (2.6) all n<10				NE
		Irbesartan	37	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEIN_SSIM: Incidence of AESI acute kidney injury during double-blind period – non-severe by subgroup
Safety Set

AESI acute kidney injury - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 1	Double-blind period	Sparsentan					Interaction test:	0.953
< 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	127	6 (4.7)	1.524 [0.440, 5.271]	1.550 [0.427, 5.627]	1.6 [-3.9, 7.2]	0.538
		Irbesartan	129	4 (3.1)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	2 (4.1)	1.959 [0.184, 20.900]	2.000 [0.175, 22.815]	2.0 [-6.9, 10.9]	1.000
		Irbesartan	48	1 (2.1)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0)	0.963 + [0.020, 46.760]	0.962 + [0.018, 50.349]	0.0 [NE, NE]	NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEIN_SSIM: Incidence of AESI acute kidney injury during double-blind period – non-severe by subgroup
Safety Set

AESI acute kidney injury - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline eGFR Group 2	Double-blind period	Sparsentan					Interaction test:	NE
< 45 mL/min/1.73 m**2	Double-blind period	Sparsentan	82	3 (3.7) all n<10				NE
		Irbesartan	80	3 (3.8)				
45 to < 60 mL/min/1.73 m**2	Double-blind period	Sparsentan	45	3 (6.7) all n<10				NE
		Irbesartan	49	1 (2.0)				
60 to < 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	49	2 (4.1) all n<10				NE
		Irbesartan	48	1 (2.1)				
>= 90 mL/min/1.73 m**2	Double-blind period	Sparsentan	26	0 (0.0) all n<10				NE
		Irbesartan	25	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEIN_SSIM: Incidence of AESI acute kidney injury during double-blind period – non-severe by subgroup
Safety Set

AESI acute kidney injury - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline urine protein excretion	Double-blind period	Sparsentan					Interaction test:	NE
<= 1.75 g/day	Double-blind period	Sparsentan	98	6 (6.1) all n<10				NE
		Irbesartan	93	1 (1.1)				
> 1.75 g/day	Double-blind period	Sparsentan	104	2 (1.9) all n<10				NE
		Irbesartan	109	4 (3.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEIN_SSIM: Incidence of AESI acute kidney injury during double-blind period – non-severe by subgroup
Safety Set

AESI acute kidney injury - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Baseline use of antihypertensives	Double-blind period	Sparsentan					Interaction test:	NE
Yes	Double-blind period	Sparsentan	90	4 (4.4) all n<10				NE
		Irbesartan	88	4 (4.5)				
No	Double-blind period	Sparsentan	112	4 (3.6) all n<10				NE
		Irbesartan	114	1 (0.9)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEIN_SSIM: Incidence of AESI acute kidney injury during double-blind period – non-severe by subgroup
Safety Set

AESI acute kidney injury - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
Time since renal biopsy	Double-blind period	Sparsentan					Interaction test:	NE
<= 5 years	Double-blind period	Sparsentan	113	5 (4.4) all n<10				NE
		Irbesartan	127	3 (2.4)				
> 5 years	Double-blind period	Sparsentan	89	3 (3.4) all n<10				NE
		Irbesartan	75	2 (2.7)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEIN_SSIM: Incidence of AESI acute kidney injury during double-blind period – non-severe by subgroup
Safety Set

AESI acute kidney injury - non-severe

Subgroup	Time	Treatment	N	n (%)	RR [95 % CI]	OR [95 % CI]	RD [95 % CI]	p-value
History of hypertension	Double-blind period	Sparsentan					Interaction test:	0.731
Yes	Double-blind period	Sparsentan	155	7 (4.5)	1.454 [0.472, 4.485]	1.476 [0.458, 4.752]	1.4 [-3.4, 6.3]	0.567
		Irbesartan	161	5 (3.1)				
No	Double-blind period	Sparsentan	47	1 (2.1)	2.625 + [0.110, 62.727]	2.677 + [0.106, 67.539]	2.1 [-4.3, 8.5]	1.000
		Irbesartan	41	0 (0.0)				

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEIC_SSIM: Incidence of AESI acute kidney injury during double-blind period – severe by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024

Table PT2AEIS_SSIM: Incidence of AESI acute kidney injury during double-blind period – serious by subgroup
Safety Set

Not done. Less than 10 patients with events in main analysis.

Notes: Due to different lengths of observation periods, incidences between primary and final analysis are not comparable.
N = number of patients in analysis set. n = number of patients with event. AESI = adverse event of special interest.
95% CI = 95% confidence interval (RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. p-value interaction = Cochran's Q. # = significant interaction.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable.
eGFR Low = 30 - < 60 ml/min/1.73m**2, eGFR High >= 60 ml/min/1.73m**2, UP Low = <= 1.75 g/day, UP High = > 1.75 g/day.
eGFR = estimated glomerular filtration rate. UP = urine protein. IgAN = immunoglobulin A nephropathy. BMI = body mass index.
Source Data: aae, created on: 30JAN2024